<SEC-DOCUMENT>0001628280-21-016083.txt : 20210806
<SEC-HEADER>0001628280-21-016083.hdr.sgml : 20210806
<ACCEPTANCE-DATETIME>20210806161121
ACCESSION NUMBER:		0001628280-21-016083
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210806
DATE AS OF CHANGE:		20210806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		211153025

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ameh-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:95c9976f-ff84-4dd6-aeb6-cbf10c7f8b0a,g:1aa3c04f-4646-4116-829c-b4ce4a78f20a,d:1123c47dec074269b382540ae6206c28--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ameh="http://www.apollomed.net/20210630" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ameh-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV8zLTEtMS0xLTA_f1f69469-6eb5-47cc-884d-ea849c2ea910">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV80LTEtMS0xLTA_5059e40d-4b63-406f-a4bf-71470dfbc4f3">2021</ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV81LTEtMS0xLTA_28caa300-c22d-421b-9fba-79554bdb8fe6">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV82LTEtMS0xLTA_4a42b098-5cb5-49b6-81cb-7222d6d54db4">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV83LTEtMS0xLTA_99b995ee-599f-4132-b992-f34fc036d2a2">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i663b801e9e2f4faaa6db3d3affb1f45e_D20210101-20210630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzExNTQ0ODcyMDk0NDMx_f69dfb9e-740f-4b1d-890a-b5aa38e16317">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ameh-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i774336f6b2934a0f91c94085695f17d1_I20210728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c98b023802344859e6d11a8234f1cf2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if83782563ea04b51a3cd25b22894290e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i717e4c08a5f045dbad2f7071e17325fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i433fbe5b9bbf40fab306efc9aee92e57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bf991f15464550976d811de0d62e73_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9a2861a1cd425cbac5b68ba09ac7d9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f37ef4f8e441468877d24814c185a1_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966c0e3cfd7b4121ae382a0aaa9006e5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1686eba6fe45ea8ae559c43929c25a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b10c8aa5ea249a4a41ddbb9cc4eea0a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i034404d6de0e40b4a7e7b9479235c135_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ceb8c42ea441928271a4fe96c772c7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56f9749216e941d6972e946201b43078_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b75704f2b5b46bdb05980233ec4c43a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11a9f1d5e9e54374a1155ab5e469b579_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2445932d5cee413a82029f7fb82d054a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cdf9a72099248dbb61045162c5ad976_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f4308062ec4348a933166fa6f2f686_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9aec26e9304fabb5f23f0a39e18d03_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c3c3a8071974b2ebd2dfc2fc3864f64_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064c3aa533b24d6e9e68036d91b37ce9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd3132fbc4049f99af3739b782bd5e5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdb52ec1c4434204a5ba6722dac7a06c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic275903b015f4a8f987d0517de1d6b23_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e822ece8a3418f958ae5c43e6eb6de_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bf2d3e70c19468bbc98d922ab423bc3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f84a157fed746cf807e86d306825b89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic48ae9c2bd4c4add942fc7d050be7a25_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7c3d0dfa54749a5b3ed5d1271ddff4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01162a4b9b294f918c58c035a6c23ce3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib624e9a32c5b47d4ae32002ccb4e7fda_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f61732e02a249169204410e0423af69_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd96999266142519b4b10cc8506625c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if526e568344046fd872628c73d56c372_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8965f51e39c644189ad1adf884d50c8d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e5ebc9ac3e4cf7ae33e8b75f1f9e16_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37408aff606244098ce0fa1bdfdcacfb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9c4138381c446ffb27c642f7235110c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if42aef36f805415ca26593430dc35d0d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic250c2fb27a24f8f8d50710d9cda482e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i479444d836ce4650a533df644c674a5a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6633894239043beb0507e0d353ae82e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica140c4561ff41ec87f96640e43a80ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c791b64a17e46bcb009aa18c776e397_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic700bd2057234d16a57c7e2195bfc225_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i170a94cec6714d3998abcf063693b6eb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7275ded6bd054db1b521ee6e3aab324f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb568bafdb614780b0b6e325fb8ca3d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3da79ae9a6b41debf540b695fc08b49_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0513fbcf3d407aab4322a16d4bcb1b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8d475aa66074c06ada568ac32d41462_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0587de5d8a7747418d59c5807b78c9aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2980472eb7b9414ba636a7c0026908e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca8ecf06fe9461197b2c72a10f229e4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bab93ced304431f99c5b5869c9a4f50_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff819742d9240a08946f28c513591d3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic342c3c788494bdd9bd051e0e2ea4aa9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438419141df9463190d33a39a16f8e84_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5e51946e0b4b2187d088ed312db6fa_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ce2f5b57784bd082918841fb1016f2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35d7bd9f3262415d9290f44c00268a41_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib70f1135f22a4e66a2932f2d95ad14ed_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae60a583c9a0465886ea5e58639dee38_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800ed291b8df4aa1bc10bb8c331a337f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73ed4c2aa7b04a8fb98de15f2d6201c7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife6556ceee4e4c0fa8fac65b95b81c7b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieab2abffaadf48cc9d3419f9105a0506_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d8b996c11e44099040a2fb9aa1b460_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e01a92ec45487aaeaec0fbbb1e91f8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d6e66a8d9741ee9e3ddbca75ba56a1_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f5c4884b2a4937a0638aaba13197ed_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c4c8fd96fdb461cb92e63360f2be9ab_D19990701-19990701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-07-01</xbrli:startDate><xbrli:endDate>1999-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c0ca208739a43eca6bdd05197aa7a17_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb24ee035e747b28135640c9aa23520_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="idc78d6f0898845efb2fd105feca4a2f2_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071cd8fce44a4d278cb890f2fd12c53e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71623504ed924a538cd451351d50b2da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i241f2dac80774d7382f508fd09e0f8ba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fff49a7a66747b7a57171842d35423d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ameh:plan</xbrli:measure></xbrli:unit><xbrli:context id="i952cacc1a5b04847b6ad828c7370b652_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6f11228e3b4496a5908cf791e2c3d5_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b95c5305c69440b8471686cab8d05a8_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>ameh:clinic</xbrli:measure></xbrli:unit><xbrli:context id="i69897c5a8adf4bfda6e8406ffef233b9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c2a3553336444f8bafa03b845e07bc7_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43a32369dc847e7b58782be85125fa1_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb6b3c6a2494e4bb41a11f504d6faed_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1de45d50eab74b8796ff5445350b8141_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0633663299e44174ba3eb3710cd3e2ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ameh:segment</xbrli:measure></xbrli:unit><xbrli:context id="icddc255662424aa887c3eea17c9feea8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79bc2d0f22014e51b904aed1246e3e16_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f0e73319a641509224036db496b932_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if581aec0ebda442289b0483239719ee4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ce879e744f44499873676c0b759e61_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i185f42a9a8b54e0ca62108c41bd664d8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcdcf6e7ba9c4ef787e0a918d4875119_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c2b9ec1f0794bcba9109e5d8bb3a391_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c7fd29ffb1e402f9a88abab2ffdf543_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b54cb109dc64d6a8a758226a7f16d73_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3515a95fa5423b9f7aae97edc29519_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib589f790bdc2410e999a0e0326ec9f8d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60adfff6acd24500baff0a524b02e5c9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b45c9cc22f407b9e5ae65de8c65877_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbfeb035318646158bca7c726a066225_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471fd709d8b042538ae4ba01794d29fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8a208df3474e8fb273ceaa2c9f7883_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia25a0917754446d9a50268874a89b369_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b597a3a606a4216b96db631cc612d1d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i426466c8cfba4f4ab46a3de7fcb32855_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0678b3587f724407821d7a02905c844a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia75080dfd6264d258c11212217c8b10f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9ec79a20df4253ab7dea22b3b23ee3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34e38dab85924104b5e25338edabc1bd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfc614d6b07f45f7950663dec2648520_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd38b926d5754ba3aa24b67a9981b319_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4efe4431f6694099b8b967669037c803_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2aca92c28e4162bdd408ae26d5ad9d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5cecd31c0dc4fb6a242649aac99e292_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief11bdfc013143bdb2e856c631d0718c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8cf6127a54a494484425f25baddbfc0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i048f53e45f574508978ecfdf4e3d3d22_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id08b33fa7cfd4156a5bacbfe13a639e3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf62c5595329412686bca92c975ba621_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620a3e2dc50c496b98250472c16d6748_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7809f033d5704a408b3a92c0496273c7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3446e8fb9264fa6bceff8cf3d2e166e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i024c1f1b458648a0b9cb88256e9c4a3a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd8f97f0d834086a7e27bc176ab32eb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc8c969a14594d11b493db131e6fc11e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba17faa36f594080b10480edbc5e2578_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dd42db203e84e239ba631310adddf43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42142faaff64fa180f7ffee0c673ac7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc64ef7d67ae4df28598f2989a60b364_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc209d6b1e0486896044884d8a79962_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86a09834f27e46cab5ec171e7d48fd19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ameh:unit</xbrli:measure></xbrli:unit><xbrli:context id="i9b7eb2683f4c475faeaec9c8b1f67839_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f03ca66055944a6b0fb9d49c0ba7b81_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ebc5992e5544fa9612e04b047d6eb0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if30af78cdea54cdbafd288daa6d2c6fe_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i130bee7db4b74cfdac137ec49a5678ab_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib82f85b4c8b24e3eb8d0b090521fffd3_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31665be81e024f77a8eb0c64fdd329d5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e33fda836264739aa7bb8163bc33a5e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dd99b346d847f6afecef6b4ffe3d89_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8330c3700a474f29947f7fde24cb31d0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id890472ab2d0424986384ec74225309a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab2ae2abe941465e94134f35120b632f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i709e028ffa954eac8fe9f174ae35a812_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia462a1dff6eb49f0a14538bf7d4535a8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia873358d93f341de98ab17edbffcde50_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54b9d769c77c4104928dc588fb0c91ca_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044041f8aebc43dea7c8afc0da3d2cae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2589d5bf11b47ddb890e3feeb7d0e43_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42823b74ab154e4cb57ada3938ebe79a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e5c9b3bb5cf4c068e18e1fbe99c4bcf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0fbf27e2a7647899d67e3bd220dbeda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f982d527bd42e7b4fab85539b28ffc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b898d0feaa140ab9e92e780e9feb0ba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib101f9ba2e1e4330b0065d49f9aed221_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0341cbb996e048a6854636392a8e25d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bec418630414a69a769bf4b40f4e7e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i126879ce11594831961b89ab705a48f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93a51086c7d546adab3f7e56b087b382_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9329af8296b449084545734af6bd691_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife67641ec17b442283895740613c5731_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f711e268b9d414f8665d1f912ae7f03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4181eb02bb2f4393a3250731eddb20f1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9343b3aac1264fccba1bf8a8c124302f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b482750d838451c9690b24453bd04a7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009c403c4ff240a19cc16cdbe7834056_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eddafd4ca9e4212901159b5340a98fe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c75381253b47bd8691ab6ed609fbda_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7bc039d7edc42b1b767425117d101c9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c39d18aa59f4fdab441e373be437999_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302d2d42eb894edfa8abcbb27511f099_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if978e802ab374bcb978febf6e68a5f0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d380a7b57e4077a43fd2ca0fe6d807_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="provider"><xbrli:measure>ameh:provider</xbrli:measure></xbrli:unit><xbrli:context id="i1e1b0a8248204e63bc412a37ae8ab329_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2699be005bc448cf854162e6c83dcef3_I20201218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4301c2756dfb415abb72c0f8eb734638_I20201218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54987c743be74a588a51746074a0a1be_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b874970f5404290acf4e877e53cc4d3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e16b9f030248348c4c2fa5de4c74e2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3273b2373fda4cdcb3db5f9523c73062_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd05517d558847b49c015f173be8b91d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7db85519bc746c39bb248797feb58c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739839922e4c4c609f191b0dcbabc14c_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1303e2069e6247dbb7f793e04ef343c5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17796dfb151e489dab379fce67d4e1b8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bca3a4a2ef740ff94ca5e1a3a2ad63e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0899c47275134483b8d984adf3740b3e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32cbe872dd774db5b7d4800706c08caf_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2887d4b59c254ece9c755540893a51fb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29508ad62c9a4ffa96ab856825835cc0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971d5df0b77740f8906d90e5210fbc87_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37ba02674fc4f47a192436d297aff26_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe421e759914ed0b7a4b1765437668b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a037a875d3544e78944fdfbdef2af99_I20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbffb487ac384d7b9e97a9a77c64595e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cd84561b1874a4b9c02a9c4d5aea63c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8abff36813164c6c84417bf95217cc72_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94b60c63c1bc4a058e9a3b6b3cbe98e0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d9d1b124a0e459ca79a0ece66636348_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4a44d05fbf46488b4af77f35c9567d_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eeb59c450004d3e92ae1911c1e1cbeb_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b545869a11420f9ea79a9c44e04340_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70ff4fbd4b12465585f409d00f3b5b5e_I20190423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib451b96ba18f4df7a702b76736baf9a3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0597b46866404e3c9244a5206a042d40_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06dcdcd971e4410ba873f348e8e7adc2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7595906102441585b7663ded30146e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf5836787810470aa58c74049921dc6e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64a97044a35489c8feb4989784095cf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a19122d99d474881d161ebb0dbea6b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8672f34024834923868d11e08668c214_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia760a8cfd561490c90a49b778a9afee7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i554fe9dff9674725962bb4cb2f88b9b2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c5d3001970541c9b1b6bb12adceff18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0536df6fbb684da2b13045d260e8302a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5120ab4996b447e5a3530a8dcd7ceec9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5a95fe077074fdeb9c94b5a02ce35b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb19e6a0df8745acaa9ce709c7fe83bd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6917df2647d94638b04a3554df231459_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9a4d75c299c4d8890a93379fee46e7d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac14ba3f77974628a3f15fb0add7d76e_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i536e73d35938450abf342effa9713c79_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e2323bab9c3467682e9da242c1cd16f_D20190701-20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5691cb4056714c69a234024bd01402c0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie243ca1688274f6687245974580a1e3c_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i212b0ef9733140d5b7611df1f124ec26_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f01cf6f2e04623bfa74a1b1dc2f34b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b65d59e8cee4de190ada04f5c5338aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98420e28f93c487e9091b0de8ef73848_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25dc88dcb88941818003f295e6eaf494_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie19976568f554a309dc818b6740971de_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa899988e7284ac8a1326212ba5333ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92d7c50296e4adb9c6f07c18bd63da6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeafd2d681174371ab57d8e8d2bd170b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd17107a4e4f4d0db7e8fffc934a9f43_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fb36211de84d458695b36c94e44b09_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa02904edf64fd19eb45f52d4bfd62e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf95943f3b45491bb70c64e65514db5b_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99dcab7c36f94052a58f43fb2416b256_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9b7755ce16d436fb858171518d6db85_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9928b035437a466c8063602b61157c72_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3689d97acee409f811f71e5d018b255_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ce176ad8164bbda4a85cdb5c1abe96_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaecc589e663140efa9bdde31ca9fc76e_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fe84306a564af99059a846dc55527f_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61695e4f773245978fcdb79b78a5f4e1_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ad3cbb03fee4c6d849f2b2c7097f926_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30999fd4c670468fa0ac9bc1446026a9_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife4010452d164857b9e426a42b03e2fa_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief20ee6c5c2c4b5f9ca95cdf09203cf9_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25174623ac76453388419ec64c9378b3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ba990e321754287bccd67c80d254cf2_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2864d7724e914818863fb152ae703113_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75bb15e4135844e0b0a19cffc0d0a363_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="financial_ratio"><xbrli:measure>ameh:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="if75078b89e36407a8a184d96312607c7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e7f468af62c460593057d3940ee2131_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00a33c8eaad843f0bed2823a082ba35f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65ada19782cc4566a752ee378270990e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i982a35d5c552427f8707f6f7c52c8456_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fbd15394d2c4d85868b44d4b1890872_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1423c5795a1b4d749457b1fe689f6082_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dac28efd63c445d90c56c1473b525a9_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7340fb66912c49d688f6edcdd3993379_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b4dbef7f2e489f89f33ea163fc5c46_D20200703-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-03</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife40aedab12e4720ba1ac1505ee27d57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d1b698d8e0c455ba42b48cbac36f252_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7fb86722c074f2eafdd868708d994e2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f73410dbab04d0b9949a4de8859b032_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96f1aad698b48e38639c8ec1d301f92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63d7d91e880042f0a4f362f355b812b5_D20200727-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd4cea3e6d54191b5d35c584c4abfc5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3215aa218c043138dfbec866e107ea5_D20200727-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a28537ca584fb4b0ee10b7408d0fbf_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa84fde67bb645cd91b5367196c1f03a_D20230101-20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63fd321ddf634615addc134b27259f9f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i625945a27da84fc6aa443add380d4c00_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144a76c21edf4613a46ce3728e38457d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib533cc59686046eeae2f5f232fac7f9a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i737b37c63ad94a628ff69100f7a2c406_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192b7b8b3d8049bf9d6f9d1c1dc9c763_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib146802ffc804944934f116ce84a41c6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94b5a906722e4e3d8e26a50cae38e0e7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a509d20ed71452e9deba1a12c4e6e19_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i750613cd3f5f46ae8a081a28e372e80b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2155db54a6e94fb3ba14b735aaf78990_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ae2fb1304c141cd8ca7616ff44b486d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bebc359d95142548ffc5a9df83139c8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4e562e2f0f644e696c375ad1dea58ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10f8b79fb1344b7a87ded9035353132_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i320308565cd449e19c679138f90e503b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0408c582d1c8484f98671f80a6529d71_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3bc4e2285e0444884aee89b77334ea4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b0212d54ced47e0b843d969230e7056_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6196e45da98644ffb45f1e5043cc3bb4_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a82fbc742c24e8287ecd7cb5cc7cbbb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5baedd233dd54d5f839fd76b1cae7d1c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a3ac3a0d777469a946e0a10c6595964_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a1a8b237d3a4bf0bf360bf0964d3f6d_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1008be7007d14a7f8231a7aa65e1e551_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5adbba48d4f44cf399a195dcbb2b1cce_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d6dddcc345e4f90952f2a96948a910b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a70b05372d474ebacf388a6848532b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb49c95ec604beba965acb646442a78_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a3b4c371be499a9e024cfd590d0e4a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77783b1764504ea0907a1d3ac4b0ada2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9e1ac26256349d8a8b6660fb3b0cf14_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie69084b20d984611b151ed5ed8994475_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54f87af0d7b41e38ac47a6d994ecf51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f89ff410504d43a409f8a0a4d4dc9b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05b5e17ec6f54ce9b949906a91fbc7d6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12dc265133f44d93bfbea364c99e892e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i663b801e9e2f4faaa6db3d3affb1f45e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d70de54c6ef4853af97ba0be0d711b6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434a1fa4730047f5ba3436f45a45cd10_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c8731f72584484a875a2c7da57e7d4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i155643ff74b34c9b8cc8ec0293852ad6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4833707bf8a34d11992ba230abca2c89_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6a7f97a8e146cd980c88fca3b2ab01_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1f5a0f1507848fe8995404c6c8e603f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if811abb97e1d4b6aac19545793d3feba_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f67bbbdb42498ca966599acb11dff3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i446e0195307d4b82b3e9a4cb39c02c68_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3235fb88c784a87a0e286f32316d340_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec95d5e3a26463e80da6e3b8af4d420_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i408bcca588524bb39b519aeebdc4cac2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9eeadfa628b409395cec8d188e856a9_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ce5a693324465ebfe2a470a3639175_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0a4be6b433c49f6bd902b1cf0e83be9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fab8a89ec0e445ea9f230be250f041a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6655222595b8466db9fa7f8f6e28d701_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e9a46fd55843e19b666e23a93b8077_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i874d478f73294316ad576a40bb59e1ba_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25a8271afdf84b0ba8fed37136cb3814_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89e4b9b73134459ace8ce5c0489bead_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e548a742a8e402cac322c329bba3e8e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic24b4e50300a456398b12c3d4e9c5ad6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a2d42d5c87493e92c0eb8c7fd269db_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ea5c3d23fde4210b75ead61697da1df_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a3adda3f7674cf188378375d6706703_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie006af53fd884424a259b9fa982a4348_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f54f9743af8462db5f026514b1e7f21_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieec217ded7454689910a87b9c2fbed59_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ddd200d6094338a149fcbc196b306b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b8a06109754f1285d0b76fad17c51e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic98de02634744e4eb83e5a16fad56985_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef15142ee464a63a23eb8e6756f0416_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9c0a7c27eb7463185729d7662e9b27f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66379f58d2d94f269eab8ba02e886336_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24dca2e9c9d84a809178fcf0be16e039_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d33951a6dc47ab94b24b9ea268e74c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bba769854d545f5b616e3e0f528bbb8_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d16dbc5ae1849d0ac736d665bd1ea4f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eea3af5cbd2450785901edf939f6913_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47874f0012974d65ab80752547b88e0a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc948505e8f40a58d9ef50d08c16138_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e531b4a2b3848308af8e4c062dc3ae9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1a2f4f2d93b403298227a14e3ea027f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7b855636fc848dbb30121df166e6660_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i561f53dbd6ec40abbfe2adb13955f8b5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7235acd9aa184415ae42f56c42c67220_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88f4defee8d42ec9fb95d874467a531_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48119f8925ce4b7fa46fa0bc444edaf0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3340686a998b49ce95642072d397de0e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64f0216262ee437f994ada0f2b06c020_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e93a59c26d54a048d85bd6ba5ea6cab_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002d7abe90a74c1f87d36f02f9911e16_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib518c264f77248c2961f26353ebe9258_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b03e8cafdca4ef3b5ae3b6f88c8d2ef_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied858eeea01d43f0ab1bd6a8e9d390cf_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5093b44a796548d5a32e7a485043d5ca_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7f32e9378184e58bc262fb167c76e2b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9c44ce4c45c45128c3cb4190f57ff3e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i646e9e6069754dd7973d990412c1ad05_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6396fb99dba4c38bbcd4ff6c21c04cb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e1d1a632d943cd8f9bc6caab027705_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if186b20296204ef3ad7eef32555753af_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0163830e210412f9315ea00b043a5fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae403e37990e47ed849d50e7b275152a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id613d04fbab14d078323ed4a8af18081_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09d5b85850142b5ba448c3c23a85993_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4bfb2672b04d938b81043fab621f6f_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6eb80252b8d41968ceed50dd21e9d24_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6017f3dab4824927a649da5bf8db28a2_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6670c16ced04552b621f7bdec168bce_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cf2fcb06956482fa26b7e68b4e24699_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3629ab6d4d2d4265be7f841a30358d25_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481dd6af2bdd4cf09e6db33df73fe757_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07412c61c634f9ab38ea2cc8e9bb8d9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785190d436454824afe1c0c04e317050_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie215578f33b740438664f8f4e662aaf5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95fb39ce145c4439b0424fb05b3ed94e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if63a149dde3b4d70ac4a2c1ebf3233dd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9654cd90ba324591bbfdc696ed176e15_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605e900922024071b01391ab39f722ff_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55490cf44eb04081807b779af67ab181_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a89c6eeac245a88286608dbe3adbcb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a76c5ebb0ec466fb2566e77ead1ee3f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46d8ce11bc946359432bb84ee798ea2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4196d26cb6024d61bcd2b84921ae5be6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if70bdfc17f4843378fe0e472c8f0af69_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0c32e700994ca0b101674055e539a9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9955d34b683e4071859b13221b7991a2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f45e79358241e4bc75610a691f200c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab736275bf9d4781ab26f264e447d2b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ad5bba1b2945d5aca93409af485c52_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d0522994fa4c0e8e71d2a65df6059b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0014be1c64d54d3b9a57ae96f20be2db_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81cd6e624ce543c1b130425e84f9df76_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb713daf92854f7dbdd3bde3a5d23576_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8efdd516ad464b9cae1cee095ce35994_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife0aa2938ef848b2a9705be0c7e31425_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib82e7ef87abf4a5ca9af04095e4d8100_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c51e142647147e3a11ac050a6f7d7f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e3ea018e65d4409898ec845c882ed39_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c8b5b78dbb848798300feff662c4c35_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89350f0ae8aa4d629dde6b21abd22cb6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c51ebc726a488fbd985b493d51b309_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4db1a9674a54a7ebe6ebf2c416564b2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88ec600700d74563b50882f619542a97_I20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b60bfd8fde493d8a88c8fd34276c56_D20210715-20210715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-15</xbrli:startDate><xbrli:endDate>2021-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d3f4fbb7de478bbc51935ca41ab818_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:SunClinicalLaboratoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b89d29a2264160815b2599c489d073_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:SunClinicalLaboratoriesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="location"><xbrli:measure>ameh:location</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMy0xLTEtMA_6366d7b1-1d44-47df-9924-2597b54deede id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMy0xLTEtMA_f03eecc3-ad45-423f-ae4b-83573a07eaf6 id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMS0xLTEtMA_bdc9231e-d10b-4879-961f-7bf270c932ce id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMS0xLTEtMA_6fb4196b-8ede-4315-ad4b-455a523a32b8" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i1123c47dec074269b382540ae6206c28_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDkx_3c17b9cb-b9c0-4751-b9f4-efb4e11366e3">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6NjgwMjUxOGRhNjY5NGIxZGE0NDQzZDE2Yjg3YjIxMzAvdGFibGVyYW5nZTo2ODAyNTE4ZGE2Njk0YjFkYTQ0NDNkMTZiODdiMjEzMF8wLTAtMS0xLTA_148de52b-f826-47df-907b-20a33e9cee5a">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8xMjQ_28c508ee-cee7-4b8a-9cda-ff50f071211a">June 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjU5MmQ2YWZhMzYyNGI5M2I2MTM0ZTdkZjJlNzkzOGYvdGFibGVyYW5nZTpiNTkyZDZhZmEzNjI0YjkzYjYxMzRlN2RmMmU3OTM4Zl8wLTAtMS0xLTA_7e9c6740-ee54-4406-9dea-8edebc8dc2c9">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from &#160;___&#160;to ___.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk0_0383245a-7b24-48b3-b634-af325f3118aa">001-37392</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk1_73775f4a-248b-4ade-904b-cb6dd502fea8">Apollo Medical Holdings, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6OWIwNWZkMmMwNjJlNGQyNGJiNGU4ZTQwNjExODJjMmYvdGFibGVyYW5nZTo5YjA1ZmQyYzA2MmU0ZDI0YmI0ZThlNDA2MTE4MmMyZl8wLTAtMS0xLTA_633fa788-2a80-4bff-baa2-065a86f6579b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6OWIwNWZkMmMwNjJlNGQyNGJiNGU4ZTQwNjExODJjMmYvdGFibGVyYW5nZTo5YjA1ZmQyYzA2MmU0ZDI0YmI0ZThlNDA2MTE4MmMyZl8wLTEtMS0xLTA_1e93a638-689d-45f2-b3a6-8b484d7cf1a9">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDg3_25027b6f-5966-4a49-864d-e6067df313b2">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDky_25d58653-dd91-4a19-a621-facb3aaaf86c" continuedAt="id9a228d5e96c46e7be71c24220cc7689">2</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="id9a228d5e96c46e7be71c24220cc7689" continuedAt="i9411cf4236d24586bcdc04e83097d05f">nd</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i9411cf4236d24586bcdc04e83097d05f"> Floor</ix:continuation>, <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk2_6a699f9e-5871-44d6-a7ef-4a48f2f554ba">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk3_89826c18-460a-4a07-9c7d-99d436f42622">California</ix:nonNumeric> <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk5_1576b4a0-4e0e-48e7-b562-56070108aa58">91801</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk4_62a9a182-5a06-43b3-8287-91ba1da17aaf">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDg4_113ea4ec-1f38-4e49-90df-806a893b4c98">282-0288</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6ZWQ2YjFlM2FiYTcyNGIyNTg3MTNhMTA1ODkxMDVlMzcvdGFibGVyYW5nZTplZDZiMWUzYWJhNzI0YjI1ODcxM2ExMDU4OTEwNWUzN18xLTAtMS0xLTEyMjIx_4eb10af3-27f1-49f0-9ce4-2d2855d5ebfa">Common Stock, $0.001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6ZWQ2YjFlM2FiYTcyNGIyNTg3MTNhMTA1ODkxMDVlMzcvdGFibGVyYW5nZTplZDZiMWUzYWJhNzI0YjI1ODcxM2ExMDU4OTEwNWUzN18xLTItMS0xLTEyMjI4_663d2020-351d-4569-be6e-90f4a9c76ec7">AMEH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDg5_50416566-7781-4fe0-860b-1b3a9f1adbfa">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDkw_71c0e9f3-2b3b-4742-a76d-c1d9fa647172">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjE3MjliODVkZjQ0NDA0Yzg2ZGNjYTJiNTYwYTc0OWIvdGFibGVyYW5nZTpiMTcyOWI4NWRmNDQ0MDRjODZkY2NhMmI1NjBhNzQ5Yl8wLTItMS0xLTA_03fd4741-b25a-429e-96f3-d3557419fef7">Accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjE3MjliODVkZjQ0NDA0Yzg2ZGNjYTJiNTYwYTc0OWIvdGFibGVyYW5nZTpiMTcyOWI4NWRmNDQ0MDRjODZkY2NhMmI1NjBhNzQ5Yl8xLTMtMS0xLTA_e7a0ef0d-68b5-46ae-83df-a3f79c42979b">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjE3MjliODVkZjQ0NDA0Yzg2ZGNjYTJiNTYwYTc0OWIvdGFibGVyYW5nZTpiMTcyOWI4NWRmNDQ0MDRjODZkY2NhMmI1NjBhNzQ5Yl8yLTMtMS0xLTA_b2a86f71-4123-484a-b6b1-ec8059f4cd87">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8xMTU0NDg3MjA5Mzc3OA_ac6faa19-e2a7-4ec1-84bd-abdd05a210f5">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; No</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July&#160;28, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i774336f6b2934a0f91c94085695f17d1_I20210728" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8xOTg5_346c8536-6500-4235-bfb0-d2ed77a27fba">55,340,095</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q FILING</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAGE</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_13">Introductory Note</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_13">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_13">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_16">PART I</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_19">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_22">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_22">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_22">, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_25">Consolidated Statements of Income for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_25">and Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_25">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_25">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_25">, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">Consolidated Statements of Mezzanine and Stockholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_118">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28"> Equity for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">and Six </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">June </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">, 2021 and 2020</a></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_28">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31">Six</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31">Ju</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31">ne</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31">0</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31">, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_31">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_34">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_34">13</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_118">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_118">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_118">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_166">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_166">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_166">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_169">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_169">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_169">62</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_172">PART II</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_172">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_175">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_175">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_175">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_178">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_178">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_178">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_181">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_181">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_181">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_184">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_184">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_184">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_187">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_187">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_187">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_190">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_190">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_190">64</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_193">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_193">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i1123c47dec074269b382540ae6206c28_193">65</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glossary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care IPA, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIPBP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Hospitalists, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians of California, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bay Area Hospitalist Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDSC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concourse Diagnostic Surgery Center, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CQMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Quality Management Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">College Street Investment LP, a California limited partnership</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Department of Managed Healthcare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Medical Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC International Cancer Center, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">independent practice association</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maverick Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MPP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Property Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMIOC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern California Heart Centers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care Acquisition Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable interest entity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL Partners, LLC</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="i1123c47dec074269b382540ae6206c28_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTORY NOTE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;) and &#8220;ApolloMed&#8221; refers to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Quarterly Report on Form 10-Q describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the Next Generation Accountable Care Organization (&#8220;NGACO&#8221;) Model.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names and trademarks of the Company and its subsidiaries referred to herein and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, statements about the Company&#8217;s guidance for the year ending December 31, 2021, any statements about our business (including the impact of the COVID-19 pandemic on our business), financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, such as our projected capitation from CMS for the year ending December 31, 2021, or otherwise, and our future liquidity, including cash flows and any payments under the $545.0 million loan we made to our VIE, AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;); any statements of any plans, strategies, and objectives of management for future operations, such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; any statements regarding the outlook on our NGACO Model or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, for the year ended&#160;December 31, 2020, filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;15, 2021, including the risk factors discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item IA thereof. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes and results to differ materially from those indicated by such statements.</span></div><div id="i1123c47dec074269b382540ae6206c28_16"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i1123c47dec074269b382540ae6206c28_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNS0xLTEtMS0w_548d9c81-7e22-4f86-be53-ebb2d6418970">177,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNS0zLTEtMS0w_5a0f3568-33af-4ef5-9781-820fec721964">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNy0xLTEtMS0w_82681861-cf37-4eef-875a-b3bd80a8559b">187,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNy0zLTEtMS0w_f9acb4b2-e391-4a54-9ea1-38d88840fc91">67,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOC0xLTEtMS0w_f08bff0d-b017-43de-9a11-aa956641a45e">16,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOC0zLTEtMS0w_334b074e-e24a-41bf-92fe-a6e37b37cafe">7,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOS0xLTEtMS0w_d8b61090-db7c-4cfc-a4a8-30e285a87f82">68,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOS0zLTEtMS0w_b4afa814-0ede-481d-9695-539655002aff">49,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTAtMS0xLTEtMA_92451e91-3ac2-442c-9acb-f8dfa4495d20">4,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTAtMy0xLTEtMA_e4e14ef0-7d82-4da9-9f43-2056f2a868ea">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTEtMS0xLTEtMA_b1a46170-72ec-4a6b-9a6d-91870f49326d">12,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTEtMy0xLTEtMA_6d40b41c-602e-4122-a92f-126a30e65f4b">16,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTMtMS0xLTEtODYzNA_e507a451-764f-4afb-bdbf-a8239b7d1366">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTMtMy0xLTEtODY0Nw_0aa9295a-91f8-422e-b74f-3a0ad57c82a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTUtMS0xLTEtMA_c02a6d3a-e4cf-4ce7-adb2-6bb543e98f6c">470,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTUtMy0xLTEtMA_1fa53abd-a2de-40c9-a166-59a64a38de65">338,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTgtMS0xLTEtMA_21f1459e-0b60-4fde-93ce-9b765e13cb6b">40,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTgtMy0xLTEtMA_50179cdc-6f4e-4127-b308-53706fe189a2">29,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTktMS0xLTEtMA_2c70d84d-11c3-4ab1-bd17-e9622ed07faa">80,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTktMy0xLTEtMA_92e03032-ce76-4ce6-b24b-ab5911a45b40">86,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjAtMS0xLTEtMA_06b29a50-d9f1-47ff-87a0-0f42be418110">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjAtMy0xLTEtMA_5fb3cc72-a7ec-4fbe-a440-6dcac7e23dea">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjEtMS0xLTEtMA_7adeb708-f0da-4cf7-9e42-85db4f93121f">594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjEtMy0xLTEtMA_7da3a54e-31e6-4e94-acda-dbbfbe2a0cbd">480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivables &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjItMS0xLTEtMA_f6180041-4bd0-409b-b689-3dc332b0aa2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjItMy0xLTEtMA_f13bb349-dd5c-44c5-8b97-a6801117f4c2">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjMtMS0xLTEtMA_1c9f05ee-dd45-4465-b8df-c9f3e759a762">37,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjMtMy0xLTEtMA_99ff97c9-dd40-4bcf-8ba2-f4885cef704e">43,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjQtMS0xLTEtMA_78499f85-fb32-4319-85aa-caca74548075">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjQtMy0xLTEtMA_f56ca2c1-abcd-4b19-b687-138cf6b5b769">37,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjUtMS0xLTEtMA_cb455a13-dfb3-495d-83b2-72495a49d600">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjUtMy0xLTEtMA_55b80b90-2e3e-4d9a-a6ce-c63180b769c6">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjYtMS0xLTEtMA_25b24159-c7c9-4b27-bfbf-0755ff8c8418">16,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjYtMy0xLTEtMA_a8fb83e9-62bb-41be-8543-a50b3ec469ce">18,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjctMS0xLTEtMA_815ae5ba-9de3-45a6-b509-bdf0dd907f80">8,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjctMy0xLTEtMA_4678a7d8-09ae-478e-8f9e-d3b640000e0f">18,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjktMS0xLTEtMA_8c201a52-5197-47d3-84f9-0b2788de9841">423,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjktMy0xLTEtMA_0db04a7e-9e67-4746-8f42-6b8d861f420e">478,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMS0xLTEtMA_6fb4196b-8ede-4315-ad4b-455a523a32b8">894,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMy0xLTEtMA_6366d7b1-1d44-47df-9924-2597b54deede">817,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzctMS0xLTEtMA_c90f7883-73a3-4225-b3cc-975e7dd049a6">53,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzctMy0xLTEtMA_71d8ed30-df7e-47db-aa85-40f5eb65ae80">36,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzgtMS0xLTEtMA_6cc89552-178f-4906-bce5-8580eda2e39b">9,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzgtMy0xLTEtMA_d1fd1146-5ddf-4f68-a3de-94080d10e5b5">9,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzktMS0xLTEtMA_a384b30a-eb41-42f7-a0c0-39f51f0d5ca6">59,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzktMy0xLTEtMA_035c6bef-d1ee-4619-a065-59607501d7c4">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDAtMS0xLTEtMA_8731a99c-aa6f-4b9e-80b1-50b36c495012">2,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDAtMy0xLTEtMA_28733d0f-df06-440b-9d04-0fce6ffaab40">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDEtMS0xLTEtMA_26d85f1a-3846-4fbe-b652-596759175352">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDEtMy0xLTEtMA_28ea79d1-42d0-4b98-8b88-7a8f6195dd73">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDItMS0xLTEtMA_18a86b63-28c2-49a1-b28c-78bbde98434b">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDItMy0xLTEtMA_c1a23be6-0d98-4c2a-a57d-3a8e44231bdf">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDMtMS0xLTEtMA_7c831f80-37a8-4d25-ac25-13231488d6df">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDMtMy0xLTEtMA_9a445112-0e01-418f-a383-df111762d511">3,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDQtMS0xLTEtMA_f3e28f03-1ba1-43ea-a3e8-dbbba55773c6">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDQtMy0xLTEtMA_411b6bbd-fc37-404c-8969-edde11ba5fe4">10,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDUtMS0xLTEtMA_621d9c18-8694-40f6-940f-978a07961c6d">128,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDUtMy0xLTEtMA_9d3dc996-72fd-483a-8081-051927e83ff0">114,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDgtMS0xLTEtMA_0d92aa79-9b6d-4b4e-a44e-4731efe23250">21,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDgtMy0xLTEtMA_a0431a96-4f85-4ed3-8b69-cb36ad176950">10,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDktMS0xLTEtMA_34f5ecf4-b0d0-4526-afed-cb1b32bbe9c1">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDktMy0xLTEtMA_068e0f61-e41c-4220-b8a2-5a2c9cc2485d">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMS0xLTEtMA_4a9e7d8e-3c13-42e1-b7ff-121e527ef8f3">14,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMy0xLTEtMA_91c16957-9078-4505-8db3-348163ca6451">15,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMS0xLTEtMTA5NzM_2bd9044b-2d52-4876-a94d-4de5128f49cb">182,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMy0xLTEtMTA5NzM_6c956ae9-6c7f-4c5e-ac42-040743bdb7b4">230,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMS0xLTEtMTA1MjQ_76436b13-6675-4d61-b199-c13dd8f5269c">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMy0xLTEtMTA1MjA_a86205ff-becf-416e-bf65-6b150d24cda8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTMtMS0xLTEtMA_18c09a0a-d6fb-453c-9700-bace388925e1">219,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTMtMy0xLTEtMA_ec94903d-93f5-415e-bc03-102c513de2f9">257,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMS0xLTEtMA_bdc9231e-d10b-4879-961f-7bf270c932ce">347,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMy0xLTEtMA_f03eecc3-ad45-423f-ae4b-83573a07eaf6">372,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTctMS0xLTEtMA_c4ee347c-9853-4ada-9a1d-a47f3c1fc056"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTctMy0xLTEtMA_c7abccac-461b-4792-a6e8-13e36a59b386"></ix:nonFraction>Mezzanine equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjAtMS0xLTEtMA_9bfec5e9-bad7-44d0-9306-aa654b7cd0c0">141,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjAtMy0xLTEtMA_f94d5c79-349b-4757-9ee1-0f83aa549abd">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if83782563ea04b51a3cd25b22894290e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzMw_3ba38bb4-f984-49de-9ec6-faa3910762ea"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzMw_d6cdaad5-c44f-406c-95a0-1e16e06b2712">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="if83782563ea04b51a3cd25b22894290e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzU0_2b7d757d-cefd-4f62-a570-df94c85e5b33"><ix:nonFraction unitRef="shares" contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzU0_86090fd7-9f44-46e4-afd7-5bbe02f76d5e">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE0Nw_87179e3a-b7a4-4639-9903-584c5e6cebdd"><ix:nonFraction unitRef="shares" contextRef="if83782563ea04b51a3cd25b22894290e_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE0Nw_f97912c9-c389-4cde-97de-a525b986e292">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="if83782563ea04b51a3cd25b22894290e_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE2MQ_49db5ff0-3245-48ee-b01f-5ff7fdc29b73"><ix:nonFraction unitRef="shares" contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE2MQ_b0d631e9-adbd-401b-b39e-c0c323b3b2c8">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMS0xLTEtMA_d8fa4499-5596-4994-88d9-95611340b005">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83782563ea04b51a3cd25b22894290e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMy0xLTEtMA_59c2c047-857c-42c6-ae90-decd948cce0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzMw_7fbdb19c-225c-4375-a2f1-c25012a030bb"><ix:nonFraction unitRef="usdPerShare" contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzMw_ccf8f446-66ed-4741-8526-d25768ec02d5">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzU0_0d1fa869-0201-45cc-a0d3-4567092f90c5"><ix:nonFraction unitRef="shares" contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzU0_e630fbac-5f6f-4621-94df-ef48edba9b40">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE0Nw_0c7e61c9-fcf3-4311-902e-14c8b22afcff"><ix:nonFraction unitRef="shares" contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE0Nw_d871c12a-596d-480b-8db2-fb724aa25299">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE2MQ_0a33380e-c799-415f-ade2-ce7c72c51805"><ix:nonFraction unitRef="shares" contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE2MQ_b107cc57-3afd-4152-9ea0-78e74d60633a">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMS0xLTEtMA_b45afbde-c1ac-4157-8a7b-664788e4cb1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMy0xLTEtMA_32001eec-a394-4c47-b2d6-f25c444c54ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzE4_11448a03-5986-4b89-8e13-6a7059b936fb"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzE4_7183e944-47fd-4661-9fb1-01bce25d59b2">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzQy_31a45033-e48c-4b53-940d-df5551a0d4f1"><ix:nonFraction unitRef="shares" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzQy_771dcc41-09b6-4538-9512-95306fe9b8c0">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzY0_69bcfa03-402a-47b4-aa29-a28df66ede00">44,246,796</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5Xzcx_cfd6222c-a9ff-4167-914d-68a1193a6a71">42,249,137</ix:nonFraction> shares outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzEwNA_bcb9ad1f-12b9-4249-bce1-c0caa1cf0c0d">10,885,732</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzExMQ_949d66ab-4144-43f6-98b2-84d23ffcb162">12,323,164</ix:nonFraction> treasury shares, as of June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMS0xLTEtMA_0bc43b44-ffef-4309-b067-914dd6e40225">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMy0xLTEtMA_fb40068c-03de-4989-99b9-9d649161b2a2">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjYtMS0xLTEtMA_9d0a10b9-d9c6-477f-8176-23efa6045176">305,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjYtMy0xLTEtMA_b64d2b4a-0028-4c8b-bb56-f2c7d187677f">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retained earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjctMS0xLTEtMA_e811a3d2-b68e-4b40-95b4-526315bd8d2a">95,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjctMy0xLTEtMA_c5571c7e-82c7-44fe-82eb-8521e28b5fd9">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjgtMS0xLTEtMA_5fc5c16d-71fa-49e3-b370-b589a9c87ac4">401,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjgtMy0xLTEtMA_aaeff108-4bdc-494b-ac9a-d9764e386c1f">330,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzAtMS0xLTEtMA_fd66742a-9ce3-4ad2-847f-24bc6aaf9008">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzAtMy0xLTEtMA_1e7e2550-13db-4d3a-b631-da9993a47729">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzItMS0xLTEtMA_b872d3c2-e739-4591-b83a-f58dca40435f">404,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzItMy0xLTEtMA_1f0d83fe-5c02-416a-ae46-ea5124db3755">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzQtMS0xLTEtMA_b4adb6b4-5b6d-4c64-8eda-0990a555ca8c">894,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzQtMy0xLTEtMA_874ce90e-51c5-4bf4-b66d-3f49628ab6eb">817,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95" footnoteRole="http://www.xbrl.org/2003/role/footnote">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNDcy_dc7f2171-93ae-47a6-b083-8722c3cb695d">1,347.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNDc5_5f3154b9-2747-42f3-8579-4447f15ba64b">801.3</ix:nonFraction>&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNjYz_521b827c-a8f1-4185-8291-7c6cd30dbcc6">107.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNjcw_d2fe661a-8109-46dd-9515-e532f5023879">111.3</ix:nonFraction>&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</ix:footnote></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9a2861a1cd425cbac5b68ba09ac7d9_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy0xLTEtMS0w_f3f8763e-44ae-465b-be18-64a9c08c2e74">144,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f37ef4f8e441468877d24814c185a1_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy0zLTEtMS0w_c29c9825-466b-4413-bb7b-f342c4d97b54">140,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966c0e3cfd7b4121ae382a0aaa9006e5_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy01LTEtMS04Mw_90856575-3fe1-4acf-bf53-586430875a79">289,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1686eba6fe45ea8ae559c43929c25a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy03LTEtMS04Mw_31e0b71d-0ebd-4816-b1d9-63a54098814d">281,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b10c8aa5ea249a4a41ddbb9cc4eea0a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC0xLTEtMS0w_7ff2e8ee-d026-4044-91d2-b29473c103c0">16,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034404d6de0e40b4a7e7b9479235c135_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC0zLTEtMS0w_c13ca8e9-1f21-4112-b187-0bbb2585d54e">12,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ceb8c42ea441928271a4fe96c772c7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC01LTEtMS04Mw_f0832c3d-3bbf-46c2-889e-41fa374b7b06">34,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f9749216e941d6972e946201b43078_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC03LTEtMS04Mw_ae143ea3-48ae-47a5-82a4-a854d31c46c8">23,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b75704f2b5b46bdb05980233ec4c43a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS0xLTEtMS0w_e5c12daa-bdd1-4e8a-b96e-f75ced8c5d26">8,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11a9f1d5e9e54374a1155ab5e469b579_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS0zLTEtMS0w_cd038c3d-4a84-4272-bcbb-6add6e4781e4">8,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2445932d5cee413a82029f7fb82d054a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS01LTEtMS04Mw_5a9d14a2-ffd2-43f0-8738-633843826699">16,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cdf9a72099248dbb61045162c5ad976_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS03LTEtMS04Mw_2811f526-72a8-488c-bc9c-6891c7930cfe">17,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f4308062ec4348a933166fa6f2f686_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi0xLTEtMS0w_6487ccb9-e854-4b91-b22a-1bfc3154af64">4,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9aec26e9304fabb5f23f0a39e18d03_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi0zLTEtMS0w_3b099bea-ac29-4d83-9bd9-9844483480fa">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c3c3a8071974b2ebd2dfc2fc3864f64_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi01LTEtMS04Mw_0f190711-ca18-4443-9a82-a21eafd11c46">7,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064c3aa533b24d6e9e68036d91b37ce9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi03LTEtMS04Mw_71ccdc90-63e1-4f8b-b213-aa33974cd990">5,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd3132fbc4049f99af3739b782bd5e5_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy0xLTEtMS0w_3fa22814-061a-44eb-8e2f-54dc3222fcd8">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdb52ec1c4434204a5ba6722dac7a06c_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy0zLTEtMS0w_d249bc91-35f0-480d-8c0f-1386975843bf">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic275903b015f4a8f987d0517de1d6b23_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy01LTEtMS04Mw_76d611da-56a2-4739-bc2f-49429836a653">3,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16e822ece8a3418f958ae5c43e6eb6de_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy03LTEtMS04Mw_306e544f-656c-470e-9def-a8511e29a905">2,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS0xLTEtMS0w_3b4ce25f-0134-4ffc-a09e-5496b29aac39">175,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS0zLTEtMS0w_a19e4840-f75b-4497-9b3f-83832b22f945">165,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS01LTEtMS04Nw_1b13ede7-187b-492c-bea6-8da666dbc747">351,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS03LTEtMS04Nw_2261d3d4-a0b5-4b40-a6a1-a374feb9fcee">330,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItMS0xLTEtMA_a9757487-8268-455f-8020-738bb12d43ac">136,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItMy0xLTEtMA_b4eb38ed-d72c-4493-bd64-4c6e000ac023">136,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItNS0xLTEtOTE_eaa320ee-8fe9-4986-8d00-34fb0b49bf1a">276,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItNy0xLTEtOTE_9253562d-c91b-461f-a36a-3bb90665e963">280,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtMS0xLTEtMA_68cf0fcc-e99a-4fdc-bf5d-42bb9a29fd34">14,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtMy0xLTEtMA_8beea8e4-1168-4928-a9f0-bb1640c28f31">11,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtNS0xLTEtOTE_d9879c29-1131-4bb5-9253-e70334d11bfa">23,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtNy0xLTEtOTE_2728c94a-1565-424c-91fe-1ceff0942bee">23,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtMS0xLTEtMA_9e6653ac-efae-43aa-b9b6-3f5578bcebed">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtMy0xLTEtMA_041e9c78-7159-4c88-82fd-5c1210f90f87">4,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtNS0xLTEtOTE_00c9a3c7-8fb9-456e-aaf2-eb1a70009c88">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtNy0xLTEtOTE_d4c59c9f-3efe-4714-82c0-2e74b4c83ce0">9,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtMS0xLTEtMA_25472490-9810-4681-bb29-d51bddb18413">154,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtMy0xLTEtMA_1b0f4d1d-8b32-42d5-9b6c-0325dbe44617">152,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtNS0xLTEtOTc_731d0452-1338-4f08-87f3-b8e99b3b8846">308,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtNy0xLTEtOTc_a496f260-edc3-43b2-b921-61f3fbe50373">313,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtMS0xLTEtMA_4d0ca82f-c397-425a-94c9-e9747286f18d">20,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtMy0xLTEtMA_2736f07c-8d4d-4e2a-8654-3f5e1ca7e4a6">12,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtNS0xLTEtMTAy_79be457e-e1c7-445d-99c2-020d7ac5f808">42,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtNy0xLTEtMTAy_134a5df8-0831-4601-b096-f41fc0317fd5">17,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtMS0xLTEtMA_fc464a13-8502-4238-8f15-32d68d72e763">3,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtMy0xLTEtMA_ed2e76ed-e6ba-47c9-9bc3-989ec79fe9cf">834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtNS0xLTEtMTA3_590ba9dd-292b-4fed-9683-2fabd39e5a0a">3,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtNy0xLTEtMTA3_ad342e02-ff5c-4abe-a2b3-31aedbc8d166">2,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtMS0xLTEtMA_f074610c-a90b-4999-956b-b30136014f95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtMy0xLTEtMA_254c2e61-dcb1-4eae-910b-86edd7586f70">99,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtNS0xLTEtNDg0MQ_e34722ef-8d5e-4be6-8086-41f409917c7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtNy0xLTEtMTgxOQ_60317a8d-e4fa-4688-8622-87a5af0004b3">99,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtMS0xLTEtMA_3a53886e-a8cc-4be7-a373-bf4b14b19311">1,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtMy0xLTEtMA_fc47f45d-059f-4fc4-800f-670a676b0f26">2,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtNS0xLTEtMTEx_1799aee4-e03e-4dda-99a4-896759feb18e">3,376</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtNy0xLTEtMTEx_bef6e16b-4500-40e8-b392-78d8a62d6d5a">5,541</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtMS0xLTEtMA_e1fbc64f-42fa-497c-be92-8469e62dca7e">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtMy0xLTEtMA_23995244-d593-4ae9-a47e-1296584044fe">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtNS0xLTEtMTEx_a14a4bbf-9a55-4530-93f9-6bf6620ddee7">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtNy0xLTEtMTEx_79ed51db-22f7-41dc-bb9e-5de9b8142b42">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctMS0xLTEtMA_06cb8c47-2af3-4d7c-a217-ef1f93b0d5a8">67,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctMy0xLTEtMA_8dc7d189-a4d0-4217-8763-e9fb9c0e7567">1,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctNS0xLTEtMTEx_1eab15ff-4cca-40db-8c40-bca7005b7045">69,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctNy0xLTEtMTEx_c028d698-ca18-4dab-81f5-2d2f66dd6a2f">1,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktMS0xLTEtMA_43127f2b-dcc8-47c6-bafa-418bad240d82">63,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktMy0xLTEtMA_6d0a8fdc-a1d6-451d-b810-97a2e8a586d6">99,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktNS0xLTEtMTE2_69c4ac5e-894a-40d9-a50d-91ad674c591f">62,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktNy0xLTEtMTE2_569d6b0b-321a-49cf-a760-8b682ccd8551">100,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtMS0xLTEtMA_a332a0f6-98e6-4450-b32c-b6412a28ddcb">84,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtMy0xLTEtMA_b7a7b3bc-7dce-432e-977f-2bfedbd1b984">112,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtNS0xLTEtMTIx_c5c7695e-75e4-41a9-8fef-c25adefccfdf">105,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtNy0xLTEtMTIx_b2f30287-2aac-4aa6-af38-b75011ad2e7b">117,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtMS0xLTEtMA_02dc410d-d495-4dab-a46b-9b32f3133aaa">24,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtMy0xLTEtMA_0b73a85a-11eb-45bb-9e27-2d84bc945283">31,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtNS0xLTEtMTI2_7f351759-9539-4ccd-b650-70ff46950a1b">31,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtNy0xLTEtMTI2_f39b9a4f-eace-4355-868b-d3f5680a76c9">33,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtMS0xLTEtMA_1f1c93c6-4d86-4e29-a5b7-bd497d3ef521">59,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtMy0xLTEtMA_f4ad5444-e427-4c4f-ac16-0c3127a857ce">81,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtNS0xLTEtMTMz_75adb937-de27-4562-a7c2-1c358346c4f6">73,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtNy0xLTEtMTMz_e1421424-0194-4458-8ae1-c912b1e6d8ba">83,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctMS0xLTEtMA_dc1e7041-0229-46bd-8c5e-4670dcb0e6d2">46,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctMy0xLTEtMA_414ad43b-55ac-43f2-9426-62a567071a4a">73,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctNS0xLTEtMTM3_022681ae-232f-45b9-ae44-31947809c7a6">48,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctNy0xLTEtMTM3_1a9be0d2-a15d-4ccc-9363-8ac51bb081a4">72,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktMS0xLTEtMA_ec239ad9-a172-425c-97a8-179599caa459">12,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktMy0xLTEtMA_2476d85c-b55e-4b2f-8685-524b22caad2f">7,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktNS0xLTEtMTQy_5c556cdc-cc90-4ca7-a348-0b1f8747c736">25,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktNy0xLTEtMTQy_d75d1d96-fbc8-40a5-9299-d92d4d211e66">11,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtMS0xLTEtMA_ec20610c-aef8-4039-b7bd-86f9b4b998be">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtMy0xLTEtMA_9e429622-8d34-4514-a782-172347aea1d5">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtNS0xLTEtMTQ2_5ac7513b-605d-4053-bf93-9da9a2b51864">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtNy0xLTEtMTQ2_3b7a156e-a7e6-4531-8096-98fd3fe5b5c5">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtMS0xLTEtMA_54183e0d-5cd4-4b49-9ed3-c562a0b2782d">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtMy0xLTEtMA_23e1116d-91db-4a05-b311-0de3b146b48a">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtNS0xLTEtMTQ2_dd1a0d34-81d1-4c58-aac3-3aebba051241">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtNy0xLTEtMTQ2_620dd866-4e6c-4d44-aaad-185a27c95e68">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.559%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Mezzanine</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Equity&#160;&#8211;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest&#160;in&#160;APC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Retained</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Earnings</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Common&#160;Stock&#160;Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Paid-in&#160;Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf2d3e70c19468bbc98d922ab423bc3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0xLTEtMS0w_0a4bc8a9-39df-4791-bdb0-5ec56026032d">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f84a157fed746cf807e86d306825b89_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0zLTEtMS0w_a62104ac-74ed-48a0-9e46-62cd70a0a9cb">42,249,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f84a157fed746cf807e86d306825b89_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy01LTEtMS0w_aa7ef3c4-438b-4f32-ace0-7111e7f786c7">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic48ae9c2bd4c4add942fc7d050be7a25_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy03LTEtMS0w_ba9d22d2-7d7d-43b7-8189-1ed8542f75fe">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7c3d0dfa54749a5b3ed5d1271ddff4c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy05LTEtMS0w_b075d3bd-a7bb-4ad9-bef9-46ee76464dcb">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01162a4b9b294f918c58c035a6c23ce3_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0xMS0xLTEtMA_421ead13-1941-4220-bc4e-bf18579b9979">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0xMy0xLTEtMA_c012b2b2-0c11-4ae5-a479-fe7ca19b0e29">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib624e9a32c5b47d4ae32002ccb4e7fda_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC0xLTEtMS0w_a1fd46cb-5ff9-4e41-9623-d2be8d02393c">760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f61732e02a249169204410e0423af69_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC05LTEtMS0w_cb1c2795-e563-4aa1-a7c4-be5caa4c642a">13,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC0xMS0xLTEtMA_f9171cbb-b5f3-495d-80f5-c5815daed672">547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC0xMy0xLTEtMA_711273b3-e052-4459-901e-44ffd6679695">13,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib624e9a32c5b47d4ae32002ccb4e7fda_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNS0xLTEtMS0w_1303c810-73d3-46a3-bc93-463e10ad4e5c">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNS0xMS0xLTEtMA_2b5a619c-0f83-4f7c-9ce4-3a67dce46343">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNS0xMy0xLTEtMA_baea8953-dc7f-4799-a1f8-7fd4c439a8de">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Issuance of treasury shares to APC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNi0zLTEtMS0w_017eae9b-474d-4146-9682-e0ac1526b99f">34,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNi03LTEtMS0w_c9ca5913-8677-4254-b68e-2ff2021eb04c">342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNi0xMy0xLTEtMA_86490b37-52e0-48e8-8e38-bb7819447999">342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNy0zLTEtMS0w_5052a1e7-3ac2-439f-b91a-006f0bc15067">5,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNy03LTEtMS0w_6ddb9262-8d2f-4066-ac23-7f0a66b98052">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNy0xMy0xLTEtMA_5519debd-307a-46f8-92f0-67c08ff09340">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOC0zLTEtMS0w_988dc6c7-5636-43ab-bacf-0385090c609a">7,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOC0xMy0xLTEtMA_0a7a9f64-9c34-42be-8614-3ec4362c6f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOS0xMS0xLTEtMA_9854197d-385a-4ba7-add1-2358c6a30bce">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOS0xMy0xLTEtMA_bee51826-cc49-4df5-9bd8-539515452ea3">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtMy0xLTEtMA_62521f20-40d8-4813-9dee-46ad4de70ac8">421,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtNS0xLTEtMA_3e0758d5-001d-4da1-adbe-4ca9e57fcfb8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtNy0xLTEtMA_284918c2-fbca-45ec-9163-7d79e0f48951">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtMTMtMS0xLTA_d9e541dd-fcf7-47b3-a42e-3d4c64e60f8e">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTEtNy0xLTEtMA_6b067ec7-6488-4e48-9388-d027a9af5f17">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTEtMTMtMS0xLTA_5b04656d-2b8b-4cd7-9fc1-717c4f176c6c">1,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8965f51e39c644189ad1adf884d50c8d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMS0xLTEtMA_7f4eb4de-e56d-44f4-8898-65036e5ddebc">114,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6e5ebc9ac3e4cf7ae33e8b75f1f9e16_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMy0xLTEtMA_270c6e36-a7c2-4fdf-9185-d945f3ea5272">42,638,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e5ebc9ac3e4cf7ae33e8b75f1f9e16_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItNS0xLTEtMA_4ebabb2f-8585-44fe-8c20-38fe15de9a16">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37408aff606244098ce0fa1bdfdcacfb_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItNy0xLTEtMA_23f6fd6f-3c44-453e-9e89-b966305d18b7">266,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9c4138381c446ffb27c642f7235110c_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItOS0xLTEtMA_c1573849-f9f4-461c-bc02-bdf0e66037f7">82,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42aef36f805415ca26593430dc35d0d_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMTEtMS0xLTA_4736e78e-1d54-49e5-906e-e2a0962c18e0">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic250c2fb27a24f8f8d50710d9cda482e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMTMtMS0xLTA_7847463d-22cc-4c2f-94e2-9abbaca96d15">349,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtMS0xLTEtMTgw_99a4e607-9c97-4b07-9d8b-f3b0034f2b5e">46,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479444d836ce4650a533df644c674a5a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtOS0xLTEtMTgw_7063639e-13f4-4ad8-b16c-7c8b7efe075a">12,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtMTEtMS0xLTE4MA_c58d7050-20d2-46d9-bb3c-f89efc5bce2f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtMTMtMS0xLTE4MA_7046ca69-e920-4405-a4c8-a4a409708f3c">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sale of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTQtMS0xLTEtMTgw_528374ba-a7d9-4c18-8ffd-7bdfaa0d480a">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTQtMTEtMS0xLTE4MA_80c5b44d-094d-4149-9ed0-489aaa6994c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTQtMTMtMS0xLTE4MA_d6c4df55-9147-4606-9ae4-9c2f18e12dc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTUtMy0xLTEtMTgw_e1cf980e-305d-41bf-96f9-19a4d2a1c7f8">22,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTUtMTMtMS0xLTE4MA_2a5cfbd6-1fd9-437a-adaa-d57707eec3be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTYtMy0xLTEtMTgw_43a4f4c8-f3c1-44f0-b0ca-aed9dc00cae6">53,504</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTYtNy0xLTEtMTgw_33b0badb-3508-4b23-a075-270532c253eb">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTYtMTMtMS0xLTE4MA_fe70571e-d7c8-4624-96fc-88c36d5e24d7">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTctNy0xLTEtMTgw_eb086179-be79-4721-80c1-4b5e6c72a8eb">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTctMTMtMS0xLTE4MA_3c80a447-24eb-436c-9817-2685e7371161">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTgtMy0xLTEtMTgw_e9104e4e-8ca7-4db4-9546-eef048d86274">5,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTgtNy0xLTEtMTgw_dff112a7-50c9-47cc-8676-2128e0f2d177">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTgtMTMtMS0xLTE4MA_6f6d0f8f-ea5f-47bc-9c8b-efb25400ce06">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repurchase of treasury shares by noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMy0xLTEtOTQ2Mg_f5ee13f6-d1ae-4f0b-b357-aa3aa8c72754">100,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktNy0xLTEtOTQ2Mg_1e5292c9-d938-4618-8c00-32900f2ec23b">2,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMTUtMS0xLTk0NjI_87769669-0e40-41f3-8266-bc37e9932c9c">2,450</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sale of shares by noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMy0xLTEtOTQ2Mg_3098c45a-e304-45f6-bd6f-251282d05132">1,638,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNS0xLTEtOTQ2Mg_dfd9cb6f-c3f0-43d3-ab4a-284583c3702c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNy0xLTEtOTQ2Mg_cad0f2eb-c795-4b8a-aa2b-09874f94173a">40,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMTUtMS0xLTk0NjI_3565858d-dc2f-4e48-96b5-410ec5c7cb4f">40,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Investment in noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjEtMTMtMS0xLTk0NjI_0ff60ca0-3024-4130-9094-ec1cdb1c70fb">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjEtMTUtMS0xLTk0NjI_e16ba309-0f8b-4095-bd78-ed00f2f8a7d0">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMS0xLTEtMTgw_7202d946-5516-4501-977b-256fed16714c">20,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMTEtMS0xLTE4MA_18b8bcf1-8686-4340-99a1-d2538d26c86b">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMTMtMS0xLTE4MA_ff5514f9-1d3d-4371-b8f4-ca72e2118f8b">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica140c4561ff41ec87f96640e43a80ef_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMS0xLTEtMTgw_c47508a9-b9d7-4124-b1b7-f0f72f4bbb73">141,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c791b64a17e46bcb009aa18c776e397_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMy0xLTEtMTgw_80eef65e-60fa-4e05-b346-3925e3224a31">44,246,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c791b64a17e46bcb009aa18c776e397_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNS0xLTEtMTgw_70712fcb-b7a5-4eb1-bc33-ec44accc37a2">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic700bd2057234d16a57c7e2195bfc225_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNy0xLTEtMTgw_c12a68bd-e6e9-443d-836f-36ef6939bbd3">305,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i170a94cec6714d3998abcf063693b6eb_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtOS0xLTEtMTgw_0032c399-6fd1-47eb-b67e-e6dfd04646da">95,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7275ded6bd054db1b521ee6e3aab324f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMTEtMS0xLTE4MA_9919d90f-c479-4441-86ab-afe0f03a445f">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMTMtMS0xLTE4MA_6012858d-5ca8-4f01-a7e6-3b4e64d037b0">404,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.559%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Mezzanine</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Equity&#160;&#8211;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest&#160;in&#160;APC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Retained</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Earnings</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Common&#160;Stock&#160;Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Paid-in&#160;Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb568bafdb614780b0b6e325fb8ca3d3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0xLTEtMS0w_edb5c4fd-4606-4cdd-b0c8-6ee603ab4c2a">168,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3da79ae9a6b41debf540b695fc08b49_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0zLTEtMS0w_dc2ad2cb-6c66-4125-818d-d796adb85c8e">35,908,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3da79ae9a6b41debf540b695fc08b49_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy01LTEtMS0w_b9d2ded1-6dea-4092-a5ad-82bb1ad7779a">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b0513fbcf3d407aab4322a16d4bcb1b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy03LTEtMS0w_d0e3235d-44ef-4e51-a8f7-121c76dea4e0">159,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8d475aa66074c06ada568ac32d41462_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy05LTEtMS0w_dc26156f-2832-457b-831a-ec89bc2ec3ed">31,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0587de5d8a7747418d59c5807b78c9aa_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0xMS0xLTEtMA_f1d88fa0-78ea-42bf-93f1-a374dd18208a">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0xMy0xLTEtMA_7f2ccdd3-651e-441e-bfc0-6412583fd5c7">192,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC0xLTEtMS0w_61f4d0c0-70f2-4ed4-bc96-c373ba3407af">1,160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca8ecf06fe9461197b2c72a10f229e4_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC05LTEtMS0w_fa8fe814-b8be-42aa-868c-88a32d22f426">4,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bab93ced304431f99c5b5869c9a4f50_D20200101-20200331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC0xMS0xLTEtMA_d25ce297-46d5-4550-b6d0-c5b84ea16637">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC0xMy0xLTEtMA_50b3ce78-c312-44fc-9d64-f4ccc5fc5abe">4,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNS0xLTEtMS0w_4a2264b4-7476-4f8a-a368-c9db3742e8b4">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNS0xMy0xLTEtMA_206192b7-1d83-4d32-9b1a-bafe54ba7923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic342c3c788494bdd9bd051e0e2ea4aa9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNi0zLTEtMS0w_bfa067f8-9a95-45e4-bc13-519835c12894">16,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i438419141df9463190d33a39a16f8e84_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNi03LTEtMS0w_f0ad5720-5352-4c76-8812-39a7bdc0a795">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNi0xMy0xLTEtMA_588dc48b-1135-4356-a7ee-9b43c18ff5a0">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic342c3c788494bdd9bd051e0e2ea4aa9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNy0zLTEtMS0w_81ba8a8c-a386-4ffa-9028-2d046d28c29b">151,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438419141df9463190d33a39a16f8e84_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNy03LTEtMS0w_3b2ca0d1-cce3-4124-8e33-c27fe4b49e55">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNy0xMy0xLTEtMA_7c4f1843-de7f-419a-91b2-f3a8acee9cf6">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438419141df9463190d33a39a16f8e84_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOC03LTEtMS0w_fa6a2963-bdb4-48ed-9b9f-27ed03ad8090">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOC0xMy0xLTEtMA_45693e12-4244-4f53-bf0b-06a584079a8c">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOS0xLTEtMS0w_0469aab5-6e7f-429b-ab01-39595cdd8dd2">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOS0xMy0xLTEtMA_95c5eaa7-da35-457c-b40e-53e44354c6de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5e51946e0b4b2187d088ed312db6fa_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMS0xLTEtMA_86d765a7-7703-46bb-b2f6-9bced853f81e">157,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81ce2f5b57784bd082918841fb1016f2_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMy0xLTEtMA_de7644eb-b4c4-4f60-b535-f5e1b7e665f0">36,042,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ce2f5b57784bd082918841fb1016f2_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtNS0xLTEtMA_e3242c1e-a202-4e8c-8b42-2e2a5adfcfa3">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d7bd9f3262415d9290f44c00268a41_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtNy0xLTEtMA_e54f4de9-cfb3-441e-b27d-c63788e36091">161,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib70f1135f22a4e66a2932f2d95ad14ed_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtOS0xLTEtMA_66051c4e-4e5d-426f-966f-ddd1a92f2045">35,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae60a583c9a0465886ea5e58639dee38_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMTEtMS0xLTA_90285fff-663b-4ab1-beba-38e1f07aeaba">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800ed291b8df4aa1bc10bb8c331a337f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMTMtMS0xLTA_294ac49e-7023-4e73-86fb-17bb940aa785">197,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtMS0xLTEtMjAw_d3494297-1f42-4ca5-9e75-e7de21214b71">73,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73ed4c2aa7b04a8fb98de15f2d6201c7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtOS0xLTEtMjAw_dfc1bd55-24dd-4074-9449-c002863c3d42">7,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtMTEtMS0xLTIwMA_3a169782-4319-456d-8a2d-78063c417b0c">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtMTMtMS0xLTIwMA_c30da769-7439-4977-b010-4eac00513790">7,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTItMS0xLTEtMjAw_52d1f9fe-b780-4806-aa33-9642ad716305">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTItMTEtMS0xLTIwMA_8e58bc15-c8c8-467b-8478-2133dcb5e2bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTItMTMtMS0xLTIwMA_967d4239-3799-4446-b107-e1976b505f72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6556ceee4e4c0fa8fac65b95b81c7b_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTMtMy0xLTEtMjAw_9a8a6c2f-da88-4993-84ae-237869800a0c">24,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTMtMTMtMS0xLTIwMA_d56b5e02-da2a-40e1-b5be-b3a7fcc3128c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife6556ceee4e4c0fa8fac65b95b81c7b_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTQtMy0xLTEtMjAw_c4c26375-67d3-4ada-a56e-a62a8b04e570">242,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTQtNy0xLTEtMjAw_787bfac1-859d-4aef-b331-768c0168dedf">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTQtMTMtMS0xLTIwMA_e1e5c9bd-0b3b-42e2-9d6c-f6d7496fa8ad">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTUtNy0xLTEtMjAw_ac745d9b-1321-4730-acb4-33528055589c">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTUtMTMtMS0xLTIwMA_5eac1b2a-1260-4eab-a420-d1c317cec648">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtNy0xLTEtMjk4_7cc3fbbd-3f5a-4f12-ad0e-c9da3005337a">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMTMtMS0xLTI5OA_ed953784-66f6-426c-9a9d-cdf0fa011ed6">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTctMS0xLTEtMjk4_d31b822a-235a-4751-a536-882f880d63ab">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTctMTEtMS0xLTI5OA_ffe1aa1d-a58a-40dc-83d2-333e52728444">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTctMTMtMS0xLTI5OA_ecefe555-1d63-4624-bf5e-ddf8360ac27c">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieab2abffaadf48cc9d3419f9105a0506_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMS0xLTEtMjAw_3a72a3e8-4723-4298-aa9d-5e0941a990ad">210,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1d8b996c11e44099040a2fb9aa1b460_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMy0xLTEtMjAw_e4057fd6-8bbd-4139-b2b4-430b836e60e3">36,309,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d8b996c11e44099040a2fb9aa1b460_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtNS0xLTEtMjAw_0fdecfac-53db-48a2-bc72-35dec3e9fea5">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21e01a92ec45487aaeaec0fbbb1e91f8_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtNy0xLTEtMjAw_15799546-4bbe-4950-b622-958f04d500f5">163,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d6e66a8d9741ee9e3ddbca75ba56a1_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtOS0xLTEtMjAw_f34f8620-6984-4a8a-9175-6b85020aba42">43,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f5c4884b2a4937a0638aaba13197ed_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMTEtMS0xLTIwMA_65bdd5bf-96a8-492b-b80f-f50c9834185f">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMTMtMS0xLTIwMA_f7b7157b-560b-494b-9c8d-c8aa9e83cd98">207,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMy0xLTEtMS0w_3acc5cb5-b9e4-4815-b242-42fa9d8e43d5">73,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMy0zLTEtMS0w_7a7dce8d-4d43-437d-9cf1-4bfcc903eada">83,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNS0xLTEtMS0w_e01566c8-25a8-4a51-b53f-7fa3dc742613">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNS0zLTEtMS0w_13dcf6e0-d56a-4c0b-931b-82effd00fbf2">9,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNy0xLTEtMS0w_251e1036-8b08-436f-9b53-b5001b3d26f9">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNy0zLTEtMS0w_18ad0af7-19c1-42e4-b311-8dfa0d4dc8e2">658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfOS0xLTEtMS0w_dbfc7300-2d69-4022-922f-0d8679a8bcfe">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfOS0zLTEtMS0w_e000e595-1bd9-4b2a-981d-e9e22d708533">1,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized (gain) loss from investment in equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTAtMS0xLTEtMA_909b6c46-6e05-42ad-8cfb-87a4edede754">83,769</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTAtMy0xLTEtMA_d3b8b127-9355-42f6-b127-dc20ad75ecdb">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss (income) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTEtMS0xLTEtMA_8ddda8ae-62ec-43e5-a5d3-8d75b5f83bfb">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTEtMy0xLTEtMA_1a36c380-a766-4ec3-98f7-69694aec7dc0">2,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTItMS0xLTEtMA_d91bec42-8fc2-4bde-a8d5-ebb1056d057e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTItMy0xLTEtMA_e5db6abc-de28-4d69-81c5-c766d03d3ca1">99,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of beneficial interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMS0xLTEtMA_a3a891c0-d896-4c85-a45b-8c0a599e6116">15,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMy0xLTEtMA_dc18a27e-3fcd-4b6a-8ca2-2a04af2867bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLossOnDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMS0xLTEtMTA5MTU_947ab69c-5b4c-4f30-b3ea-6e246159632c">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLossOnDerivative" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMy0xLTEtMTA5MTk_ab8046dd-9dc5-486b-8c25-100dff75845d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTQtMS0xLTEtMA_f1140ace-127c-4888-a2d9-6f6efa9b7cef">10,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTQtMy0xLTEtMA_9276ec96-4d7c-4569-b4be-c0422ea09361">4,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTUtMS0xLTEtMTA2MTE_cadad31c-2ee3-4704-9c74-6a7cacdb38d1">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromOtherOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTUtMy0xLTEtMTA2NDM_f8252b4c-2a58-459b-8ed9-753280cfeaf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of business combinations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTYtMS0xLTEtMA_543c838b-73f5-4b20-89bd-20388cf4a1c6">9,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTYtMy0xLTEtMA_5ef1b321-12bf-491a-8e3a-ffcb31275916">6,284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTctMS0xLTEtMA_ad44eaf5-8b92-4352-9e28-a9d011861a58">19,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTctMy0xLTEtMA_63287e60-6a8b-4930-9349-731dd7b90500">11,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTgtMS0xLTEtMA_e0c0a118-5bd0-4d73-bb40-3ecee7d68291">266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTgtMy0xLTEtMA_893b46f3-bd6e-4853-a9ac-2a28e975ca3e">966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTktMS0xLTEtMA_398b0469-f029-4821-9d27-8a7ab50ddb19">4,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTktMy0xLTEtMA_eb04ee26-e4ce-41a0-9134-b08db066e368">873</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjAtMS0xLTEtMA_a2546543-eede-4be0-bbbe-f79d97037168">1,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjAtMy0xLTEtMA_2e9bf9c9-1d76-4b95-a649-a4af2bb95682">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjEtMS0xLTEtMA_3c0b1666-79ee-488d-8fe7-13ecdcbf96f2">426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjEtMy0xLTEtMA_22d666d4-efc0-4c3b-a10f-bd9ec4bfa886">5,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjItMS0xLTEtMA_73132955-89b8-4ca1-b21a-ca6cfbec45d5">16,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjItMy0xLTEtMA_07bf11ff-9ae0-4ecc-927e-1eec99f622aa">3,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjMtMS0xLTEtMA_d22b93ac-3d4c-4afd-8377-6a52d29f4aa3">550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjMtMy0xLTEtMA_e81dd7b4-d2a3-458e-a14d-3c08b34d356f">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjQtMS0xLTEtMA_571f6f53-85d3-43e2-b1b0-752f84978c83">8,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjQtMy0xLTEtMA_bce3ae1d-fb21-42d9-999d-77c8fe63152d">11,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjUtMS0xLTEtMA_4a08b22b-177e-4791-8cd2-0043807e62a5">2,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjUtMy0xLTEtMA_87f3e28d-0fc7-45ec-bdae-870e0d00245e">37,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjYtMS0xLTEtMA_153ae532-f2fb-4670-8d9c-3ecefb57e6f4">1,698</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjYtMy0xLTEtMA_04c41fb4-ee9a-462c-aa42-c961bbf480a6">1,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjctMS0xLTEtMA_ded3d085-75a4-4cd6-959c-c85755969295">31,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjctMy0xLTEtMA_810d85c8-83b3-4f95-abc5-7d690c215a20">12,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from repayment of loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzEtMS0xLTEtMA_a08817a8-7dbf-4f28-8f57-baba755e61d6">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzEtMy0xLTEtMA_08f70dfb-ee3e-447d-b3f3-f5e2de61c00c">16,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for business acquisition, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMS0xLTEtMTA2ODU_f384ee77-4445-4a0c-8bc2-b904e2765aa1">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMy0xLTEtMTA2ODg_3fdc0119-4a41-41b8-bee7-ac2c59a491bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment for investment purchase</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PrepaymentForInvestmentPurchase" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzgtMS0xLTEtMTI1MTk_4ba6fa7f-098e-4b11-ae12-86c550a66515">4,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" sign="-" xsi:nil="true" name="ameh:PrepaymentForInvestmentPurchase" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzgtMy0xLTEtMTI2Mzg_7d8f47b4-0fef-4ffd-ba9b-81f0aa6e4ca9"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzQtMS0xLTEtMA_7e9a46a5-673b-419f-88b5-46169a2b8f29">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzQtMy0xLTEtMA_45b8b209-6729-40f3-9fa0-40bc6087dbd5">1,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of investment &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzUtMS0xLTEtMA_f7bc4d42-3d0d-4314-8194-050eabe441d4">1,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzUtMy0xLTEtMA_439eb6a2-6a18-4cc9-9a15-d2815ecee1eb">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzYtMS0xLTEtMA_e96942ae-6113-444d-9241-cf09baacc6b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzYtMy0xLTEtMA_cea497c1-7cda-474f-8690-cc9117bf1448">52,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMS0xLTEtMA_72c4b59a-7dcd-4e13-98e2-2e512601ac66">7,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMy0xLTEtMA_91e522bf-ea21-49d1-bb96-d6963ee13cab">451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received from consolidation of VIE</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMS0xLTEtMTA5OTg_9ea419ae-fe5e-4a86-8304-31882e27c5f4">3,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMy0xLTEtMTA5OTg_9a125d1b-e505-42c6-9eb9-7efa124ab272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMS0xLTEtMTA5OTg_d946e293-1e19-442b-a338-eecc9cefc1af">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMy0xLTEtMTA5OTg_3f860055-ab32-48b7-804c-9ad371bf7e2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzktMS0xLTEtMA_b188ab0b-2453-41aa-8f69-5b0faa87bd1f">9,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzktMy0xLTEtMA_01dfbd35-0e8d-4d3f-b9c4-51db27e35dba">67,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMS0xLTEtMA_f5e8fa0e-fd0f-4463-9ccc-dddc6305a1da">21,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMy0xLTEtMA_d6053657-c2fc-4bf0-a402-47aad6d9ab9e">30,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMS0xLTEtMA_5c5913e0-e40a-4f31-924c-c4c489b8b63c">238,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMy0xLTEtMA_33f074f3-e401-4f33-abef-b2b523e2e43f">2,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDUtMS0xLTEtMA_3f95fb2f-9679-42ae-9106-76ae19bdafe2">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDUtMy0xLTEtMA_12135d4b-e1e9-4a7a-ba40-f57ba32d812e">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDYtMS0xLTEtMA_54bc1d3f-569e-453e-a922-775a8964e3dd">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDYtMy0xLTEtMA_11896429-5eac-40ea-aa9d-1340215467cf">2,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDctMS0xLTEtMA_36e0a431-0aea-4a12-b747-7d652c95f9ea">2,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDctMy0xLTEtMA_61076e3a-d86c-4f79-be49-f722da62d8cf">788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDgtMS0xLTEtMA_dce25412-fcfd-4944-bbf3-08728f3bd103">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDgtMy0xLTEtMA_dfacf1bd-1628-4e2b-b475-55b8c539cfda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDktMS0xLTEtMA_8c2c8c3a-a825-471b-bfb1-0946c30d581c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:ProceedsFromSaleOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDktMy0xLTEtMA_c9ce9126-e9a9-4f34-832e-2ef6fd7fd1a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on revolver</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMS0xLTEtMTA3MjM_1db1ebd7-1cc2-4cee-b1e3-55c65b235ea5">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMy0xLTEtMTA3Mzg_d94e4c92-82c2-4144-99e6-0739a7d4ccc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTktMS0xLTEtMTA3MzA_357cbc0e-1b66-49b9-be8f-10965a29ded2">40,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMy0xLTEtMTEwMDk_2a9d47e6-97d4-4866-acee-f6b61a807643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjAtMS0xLTEtMTA3MzM_486a9fa6-44ea-42eb-81bc-b1aeb1c79e4b">727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjAtMy0xLTEtMTA3NDI_f84b55ba-fe49-4c23-a0a5-0281a4d1188d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTItMS0xLTEtMA_8cad8db5-4daf-4627-a210-af123472fe08">38,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTItMy0xLTEtMA_688099bf-2a76-4316-991c-06f6a074404b">30,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTQtMS0xLTEtMA_f0e7c266-0990-4ca7-b261-6fc97187ec07">16,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTQtMy0xLTEtMA_615a0c20-060d-4bf3-88bc-48cc80f665a9">49,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTYtMS0xLTEtMA_e1ac51ec-0f8b-4e3d-a259-4b33014345ab">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTYtMy0xLTEtMA_6094348e-371e-4fb4-a40d-8b0de0b126ae">104,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMS0xLTEtMA_ff723c3a-2398-4ced-b8aa-3e8ede219623">177,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMy0xLTEtMA_b21d084a-68d3-4c8d-888d-821d85522731">153,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjEtMS0xLTEtMA_70793129-8953-410f-9425-07c781831ba3">23,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjEtMy0xLTEtMA_8efe962e-dc08-4d9a-b594-d9a2056b4ef5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjItMS0xLTEtMA_8b51a526-02b1-4fdd-a748-d4f92f2ee4e1">2,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjItMy0xLTEtMA_7c21e19f-67b8-4227-9d12-617ea1951fe8">2,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend declared included in dividend payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjUtMS0xLTEtMA_f22bf4aa-d1a7-4b16-bbe2-db97c96119f4">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjUtMy0xLTEtMA_9df24991-751e-4059-88e4-667c23e5c9ff">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares received from sale of equity investment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjYtMS0xLTEtMA_a12eb6e6-12de-47c1-9023-4fb541af66d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjYtMy0xLTEtMA_44e8456e-b13a-4177-b830-c34fdea9b748">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of Restricted Stock Awards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="ameh:CancellationOfRestrictedStockAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNzYtMS0xLTEtMTA3NTc_f936577f-19cb-4313-b397-4d06447da04b">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="ameh:CancellationOfRestrictedStockAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNzYtMy0xLTEtMTA3NjA_3d18c3da-c5bd-4af7-8d68-09122214e90a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfMi0xLTEtMS0w_218e0669-0029-4b86-8832-a9cb13572c6d"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfMi0xLTEtMS0w_6146e4be-03de-4f06-b288-40552a5af601">177,287</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfMi0zLTEtMS0w_cd34e5a8-d0df-4175-a056-dd100ed2ed89">152,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNC0xLTEtMS0w_0cabb233-3a35-4706-9f1f-d5ca8ceec703">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNC0zLTEtMS0w_e6370609-df30-4037-a474-1a1287e90d39">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNS0xLTEtMS0w_81331724-34fe-47e4-9311-0306a038fda5">177,287</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNS0zLTEtMS0w_a4bdc986-f0df-44a6-89ff-77d777c4c610">153,187</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMi0xLTEtMS0w_b59302cb-5d9a-4dff-868a-da9cea8575f2">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMi0zLTEtMS0w_e9151c8d-feba-4f77-8f51-ef9690e27a47">103,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMy0xLTEtMS0w_dd53b18e-5cd0-4140-b453-2f50ba749f96">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMy0zLTEtMS0w_6b9382c6-f3ac-4b59-b675-35367d1f4722">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNC0xLTEtMS0w_2fdb32a7-5c6c-491a-814a-4ee3cbe64746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNC0zLTEtMS0w_c16188c8-0a4b-426a-a70a-744ffa659a2b">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNS0xLTEtMS0w_8d545e96-eb55-4e02-8af3-4d2c654468d1">193,970</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNS0zLTEtMS0w_a5ccdfc4-0131-4238-9e3f-63a9301eae15">104,010</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div id="i1123c47dec074269b382540ae6206c28_37"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTQzMDM_06e549b1-d49e-40b2-8e70-e19fc3938cf1" continuedAt="ie770d30e6e7f4e48bbe1d52e275ef59d" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="ie770d30e6e7f4e48bbe1d52e275ef59d" continuedAt="i00856854242f4bfe89da30e9ac1182f0"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) on December 8, 2017 (&#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of <ix:nonNumeric contextRef="i8c4c8fd96fdb461cb92e63360f2be9ab_D19990701-19990701" format="ixt-sec:duryear" name="ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNDEwOQ_e334b0db-5951-438b-bd2b-5729574a41f0">30</ix:nonNumeric> years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i00856854242f4bfe89da30e9ac1182f0" continuedAt="i37cfcd29ebcb4955a9accdff65a88cea"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. In accordance with relevant accounting guidance, AP-AMH is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $<ix:nonFraction unitRef="usd" contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNTM4MA_63e3ed79-6c99-426f-9a27-13ab584fc583">545.0</ix:nonFraction> million pursuant to a <ix:nonNumeric contextRef="i9bb24ee035e747b28135640c9aa23520_D20190901-20190930" format="ixt-sec:duryear" name="ameh:FinanceReceivableTermOfReceivable" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNTM5Nw_25ab36e5-2980-407f-bdff-bcd13120c6fc">10</ix:nonNumeric>-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930" decimals="2" name="ameh:FinanceReceivableStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNTQ4Ng_c15bcf5d-951f-44f1-8f10-c2cee2d9ad3b">10</ix:nonFraction>% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930" decimals="4" name="ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjIwMQ_25956609-34f3-480c-8a3c-756125e82545">10.75</ix:nonFraction>% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="idc78d6f0898845efb2fd105feca4a2f2_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjI0OA_bc4de0c5-4690-4259-9d1c-30ed00b71030">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock for aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjMyMQ_979defa5-f107-4d62-9a33-3ada3cca1048">545.0</ix:nonFraction> million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends (&#8220;Series A Dividends&#8221;) that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased <ix:nonFraction unitRef="shares" contextRef="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjkxMA_400e0b01-3dc8-44de-98f2-e40899d0e311">15,015,015</ix:nonFraction> shares of ApolloMed&#8217;s common stock for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjk3NQ_837553c0-8a3a-45dd-8d7d-271e14a8caba">300.0</ix:nonFraction> million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of <ix:nonFraction unitRef="number" contextRef="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930" decimals="4" name="ameh:StockIssuedDuringPeriodProxyVotesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNzE3OQ_144c2279-0d6d-45f3-8e10-098120ba897b">9.99</ix:nonFraction>% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term &#8220;Excluded Assets.&#8221; Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was <ix:nonFraction unitRef="number" contextRef="i071cd8fce44a4d278cb890f2fd12c53e_I20210630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfODg4Mw_b65d6914-e5c4-433e-953f-945d0932c7a6">19.77</ix:nonFraction>% at June&#160;30, 2021 and <ix:nonFraction unitRef="number" contextRef="i71623504ed924a538cd451351d50b2da_I20201231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfODg5Ng_4b31535e-cad1-4673-9f57-0f032b98064d">22.58</ix:nonFraction>% at December&#160;31, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of June&#160;30, 2021, APC owned <ix:nonFraction unitRef="number" contextRef="i241f2dac80774d7382f508fd09e0f8ba_I20210630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfOTM4Mw_aa2fb011-5db9-4490-9c76-b8937f87a724">45.01</ix:nonFraction>% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i37cfcd29ebcb4955a9accdff65a88cea" continuedAt="i5e0cea6954074dcb9bdba43c5f0fc051"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a <ix:nonFraction unitRef="number" contextRef="i7fff49a7a66747b7a57171842d35423d_I20210630" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTA4MTI_964cc53e-f6f5-4d0b-804f-d4a68e708ec6">100</ix:nonFraction>% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through <ix:nonFraction unitRef="plan" contextRef="i952cacc1a5b04847b6ad828c7370b652_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFederallyQualifiedHealthPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTIwNzA_8cca190d-4d97-4968-aa9b-7f884c91ad6a">three</ix:nonFraction> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising <ix:nonFraction unitRef="number" contextRef="idc6f11228e3b4496a5908cf791e2c3d5_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTIzNDA_90887e1a-175d-4663-ae6b-af381e4a1a4a">75</ix:nonFraction>%) for&#160;$<ix:nonFraction unitRef="usd" contextRef="i2b95c5305c69440b8471686cab8d05a8_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTIzNDg_b69e859b-fc06-4103-aee3-1be4cbeff06d">7.3</ix:nonFraction> million&#160;in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of <ix:nonFraction unitRef="clinic" contextRef="i69897c5a8adf4bfda6e8406ffef233b9_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFamilyPracticeClinics" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI0MjE_184deeee-4aee-4596-9729-e91dad972e0b">three</ix:nonFraction> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased <ix:nonFraction unitRef="number" contextRef="i2c2a3553336444f8bafa03b845e07bc7_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI2Njg_473700d0-4ee5-40fa-9b98-7fdf97a28ea0">100</ix:nonFraction>% of the shares of capital stock of AMG for $<ix:nonFraction unitRef="usd" contextRef="if43a32369dc847e7b58782be85125fa1_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI3MTM_a93ee23f-2bb1-4013-979e-95bf3e2a9e56">1.2</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="i4bb6b3c6a2494e4bb41a11f504d6faed_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI3Mjg_0869d3a5-04e9-4ea9-8bdc-c75d623b734b">0.4</ix:nonFraction> million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i1de45d50eab74b8796ff5445350b8141_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI4MzY_9c1c37f8-c903-4b5f-a0ff-4180bce94908">100</ix:nonFraction>% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a <ix:nonFraction unitRef="number" contextRef="i0633663299e44174ba3eb3710cd3e2ac_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjU5NzA2OTc4MzM4Mg_0e7912dc-11c4-4027-8e76-6ad398ea2dbf">50</ix:nonFraction>% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants or vacant land with plans to lease the building in the future. MPP, AMG Properties, and ZLL are <ix:nonFraction unitRef="number" contextRef="i1de45d50eab74b8796ff5445350b8141_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTMwNTQ_9c1c37f8-c903-4b5f-a0ff-4180bce94908">100</ix:nonFraction>% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation, it was concluded that Tag 8 is a VIE and is consolidated by APC because APC has the ability to direct the activities that most significantly affect Tag 8&#8217;s economic performance. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the definitive proxy statement that ApolloMed filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 31, 2019 (the &#8220;2019 Proxy Statement&#8221;), and consequently will not affect net income attributable to ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5e0cea6954074dcb9bdba43c5f0fc051">APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model of CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDA_c6b0baef-128f-4502-8dc7-e49e0863e565" continuedAt="i83ec27e67c35464096791e5711e07d27" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i83ec27e67c35464096791e5711e07d27" continuedAt="ib5f28d25317a4d21b9bbcc6510d7bcb5"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODY_bb55ab81-3ca2-4c68-bd70-a3a737c84a3d" continuedAt="i4c0910ee81c74654a2b293c3cbcc2d09" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4c0910ee81c74654a2b293c3cbcc2d09">The accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2021, and for the three and six months ended June&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</ix:continuation> Operating results for the three and six months ended June&#160;30, 2021, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or any future periods.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODA_e2c39ca5-868d-40c7-b23d-b341c44518be" continuedAt="i3bb5b8b6d16a4bf38af8c4091b50959d" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3bb5b8b6d16a4bf38af8c4091b50959d">The consolidated balance sheets as of June&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of income for the three and six months ended June&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIE, AP-AMH; AMM&#8217;s consolidated VIE, SCHC; NMM&#8217;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#8217;s consolidated VIE, APC; APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties and ZLL, APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</ix:continuation> </span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDM_15a71991-2509-42f9-8a3f-ca428f673458" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzM_f25f7ced-a474-4f10-b81c-2f7ba4e6f036" continuedAt="i0a598857a8cb490890d46930d510c6b1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ib5f28d25317a4d21b9bbcc6510d7bcb5" continuedAt="ie974425e6c2945319038393103b089a7"><ix:continuation id="i0a598857a8cb490890d46930d510c6b1" continuedAt="i77e478ab32834034b45b74a006b4c616"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i77e478ab32834034b45b74a006b4c616">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 15 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</ix:continuation><br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNzI_e6ea7c45-c4e9-4157-bbf2-e7156cd1bbd2" continuedAt="i8312d38bc81e41afb4d05d7bd62952af" escape="true">Business Combinations</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8312d38bc81e41afb4d05d7bd62952af">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.</ix:continuation></span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzc_6cf6bfb9-9f80-4ad6-b7e9-9ee0e3e0086f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2MQ_76ef5360-4b9b-4490-96db-de11db5d6f21"><ix:nonFraction unitRef="segment" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2MQ_86163511-7490-48ba-a8b8-5be2b700e4a2">one</ix:nonFraction></ix:nonFraction> reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in <ix:nonFraction unitRef="segment" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2NQ_76ef5360-4b9b-4490-96db-de11db5d6f21"><ix:nonFraction unitRef="segment" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2NQ_86163511-7490-48ba-a8b8-5be2b700e4a2">one</ix:nonFraction></ix:nonFraction> reportable segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDk_c8ef222c-d5d6-45f2-beb9-c76b514a2ba0" continuedAt="iecc70450ee0c417193a5aa83c7ef94ff" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iecc70450ee0c417193a5aa83c7ef94ff">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.</ix:continuation> As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc3OQ_457b6d24-4378-441c-90c6-42a8b3c94d1d">268.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc4Nw_4427c9e8-c106-47fa-b83b-af64db339643">294.9</ix:nonFraction> million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNTU_954e2545-7981-4d36-ad5b-b21870df0136" continuedAt="i9634ed9952ee42d0b8dd75da8b398ddf" escape="true">Restricted Cash</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ie974425e6c2945319038393103b089a7" continuedAt="i3e80f0482bd7435e94e954c5d752cdcb"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9634ed9952ee42d0b8dd75da8b398ddf">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</ix:continuation></span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDY_213928f7-b9df-487d-b702-c9e3fe30c01f" continuedAt="ie4dd9cbc47a54eecb4a19b1d00e93055" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consisted of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from <ix:nonNumeric contextRef="icddc255662424aa887c3eea17c9feea8_D20210101-20210630" format="ixt-sec:durwordsen" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODE_74222511-f532-443b-9673-4e8c0a132e23">four months</ix:nonNumeric> to <ix:nonNumeric contextRef="i79bc2d0f22014e51b904aed1246e3e16_D20210101-20210630" format="ixt-sec:durmonth" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfOTE3Nw_ef45a689-f5c7-4690-bb31-263cde93bdf4">24</ix:nonNumeric> months. As of June&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i48f0e73319a641509224036db496b932_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNTU1Ng_7196b991-17c9-4868-bc1e-befc33d28664">67.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if581aec0ebda442289b0483239719ee4_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNTU2NA_f818580d-f5dc-4fcb-8675-068c31d33c20">67.6</ix:nonFraction> million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie4dd9cbc47a54eecb4a19b1d00e93055">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy where quoted market prices from reputable third-party brokers are available in an active market. Equity securities held by the Company are primarily comprised of common stock of a payer partner that completed its initial public offering in June 2021. The shares were acquired as a result of UCAP selling its</ix:continuation> <ix:nonFraction unitRef="number" contextRef="if5ce879e744f44499873676c0b759e61_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMDM0MA_d18ef0c7-cb43-4928-b8c0-eee330e9c73a">48.9</ix:nonFraction>% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. As of June&#160;30, 2021, equity securities amounted to $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMzg0NA_89f337fb-4fd5-46d1-ae15-356e18c5d659">119.9</ix:nonFraction> million. As of December&#160;31, 2020, prior to our payer partner&#8217;s IPO, the related investment balance was included in investment in privately held entities at its cost basis of $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzg0ODI5MDc2MzMyMw_89345883-c1c6-4782-a270-c80269df2b03">36.2</ix:nonFraction> million in the accompanying consolidated balance sheets. For the three and six months ended June&#160;30, 2021, the Company recognized unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMzk1Mg_f09e157d-524c-4058-9162-1f100d5fcc79"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMzk1Mg_f20702d3-04ed-4c72-a285-3b28f498251b">83.8</ix:nonFraction></ix:nonFraction> million in other income in the accompanying consolidated income statements.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODk_15c01850-0953-4f19-ad0d-d84d43811650" continuedAt="i5e4ef89a4c71495dba69e02b75af4020" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivables</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivables and loan receivables &#8211; related parties consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:durmonth" name="ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA2NzM_2c41942a-2e68-45cc-aad1-d34b0156253c">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5e4ef89a4c71495dba69e02b75af4020">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.</ix:continuation> </span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwOTc_22e35549-ebe1-41e6-8b0c-993b33aed622" continuedAt="ic3a80a1cae274282b01ffd5f44e2359c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i3e80f0482bd7435e94e954c5d752cdcb" continuedAt="ic2fcd684b9a345d6b07d10617e23c46c"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3a80a1cae274282b01ffd5f44e2359c">The consolidated statements of income present disaggregated revenue by service type.</ix:continuation> <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNjA_48b39d7e-033f-4c9d-9ccf-2f91e7f6ea04" continuedAt="ia8c406b85d0c4922bc6fe686aa8730b4" escape="true">The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ia8c406b85d0c4922bc6fe686aa8730b4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185f42a9a8b54e0ca62108c41bd664d8_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy0xLTEtMS0w_5bdb3956-aae2-49d1-94e1-7c9e434ee520">33,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcdcf6e7ba9c4ef787e0a918d4875119_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy0zLTEtMS0w_976291a8-70e9-49fc-9db5-a486b96fc67a">25,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c2b9ec1f0794bcba9109e5d8bb3a391_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy01LTEtMS0zMDk4_e73ead9f-1e95-42fb-9771-64f39f2d7502">65,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7fd29ffb1e402f9a88abab2ffdf543_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy03LTEtMS0zMDk4_e830072a-c3f3-4718-bb40-e39d1c95047d">50,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b54cb109dc64d6a8a758226a7f16d73_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC0xLTEtMS0w_6eb42b69-75ae-40f0-8b0c-5863b231abd9">64,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e3515a95fa5423b9f7aae97edc29519_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC0zLTEtMS0w_670c9269-8f9b-4772-a16f-d38bd11e2e57">62,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib589f790bdc2410e999a0e0326ec9f8d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC01LTEtMS0zMDk4_b0ab19db-90f1-473e-b9a3-df047d889948">128,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60adfff6acd24500baff0a524b02e5c9_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC03LTEtMS0zMDk4_a15643e9-dd98-41a3-a493-f4fa1f6860cf">126,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b45c9cc22f407b9e5ae65de8c65877_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS0xLTEtMS0w_f77f9bf4-7b4a-459c-9e79-2229f63367ea">68,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbfeb035318646158bca7c726a066225_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS0zLTEtMS0w_d94a8f74-0279-4704-a594-50c65cec9533">68,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471fd709d8b042538ae4ba01794d29fd_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS01LTEtMS0zMDk4_46aef247-5ba7-40be-a026-5511ccb7d7c7">138,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba8a208df3474e8fb273ceaa2c9f7883_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS03LTEtMS0zMDk4_e3d0a379-212c-4f7c-b4e5-99088b302600">134,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia25a0917754446d9a50268874a89b369_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi0xLTEtMS0w_46b3380a-dd39-4816-babe-d1a861d62880">9,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b597a3a606a4216b96db631cc612d1d_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi0zLTEtMS0w_48a3734e-335d-4e64-aa09-b854004db07a">9,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i426466c8cfba4f4ab46a3de7fcb32855_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi01LTEtMS0zMDk4_050035d6-a41f-4543-91df-c319ba691116">19,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0678b3587f724407821d7a02905c844a_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi03LTEtMS0zMDk4_2599ad87-f37b-480b-8b96-7e18f7c4dd8e">18,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy0xLTEtMS0w_7f1ac074-db77-4c3d-a67d-657a5d2a42a6">175,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy0zLTEtMS0w_09feb1b0-8307-4bfc-a4d0-daaf861d93cc">165,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy01LTEtMS0zMDk4_ee75a5f4-0199-4fb1-8cb5-5afae62364c9">351,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy03LTEtMS0zMDk4_cbd5b9bb-2e08-4020-8ec4-69d8f89d4ffa">330,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwOTk_a9ec22a0-1275-4225-aff9-748afdabe578" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia75080dfd6264d258c11212217c8b10f_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy0xLTEtMS0w_1099a19c-4e6b-4631-a9b9-707d71466bc1">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e9ec79a20df4253ab7dea22b3b23ee3_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy0zLTEtMS0w_3a5201d2-288c-46a7-a010-f54102b4bbe8">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34e38dab85924104b5e25338edabc1bd_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy01LTEtMS0zMTI1_a86b96eb-9459-42b7-aa91-ab9d4a66499e">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfc614d6b07f45f7950663dec2648520_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy03LTEtMS0zMTI1_1b57da1c-915e-427b-83ce-063fdac80a6a">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd38b926d5754ba3aa24b67a9981b319_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC0xLTEtMS0w_067e9995-1a2e-45e3-9d14-c3fcf9da54d2">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4efe4431f6694099b8b967669037c803_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC0zLTEtMS0w_56fee66a-2af1-4d89-9c56-ab6768840f58">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c2aca92c28e4162bdd408ae26d5ad9d_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC01LTEtMS0zMTI1_028e8100-2eb7-4e6b-b8cd-984a32e0c6ca">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5cecd31c0dc4fb6a242649aac99e292_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC03LTEtMS0zMTI1_4c6e6028-84b3-4aae-9980-0afc5ec207ae">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief11bdfc013143bdb2e856c631d0718c_D20210401-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS0xLTEtMS0w_32bc18e7-3925-4c6d-a793-c26a32321490">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id8cf6127a54a494484425f25baddbfc0_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS0zLTEtMS0w_2695b55b-e576-4e2d-b57c-67abfeab7337">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i048f53e45f574508978ecfdf4e3d3d22_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS01LTEtMS0zMTI1_c6997b5c-1162-47bb-ad5f-686f533a39f4">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id08b33fa7cfd4156a5bacbfe13a639e3_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS03LTEtMS0zMTI1_42c7eb2d-a10c-4ee3-ad1f-511e0f66ecf6">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icf62c5595329412686bca92c975ba621_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNi0zLTEtMS0w_581413c0-5bb2-466e-99b2-85e60e5a15a6">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i620a3e2dc50c496b98250472c16d6748_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNi03LTEtMS0zMTI1_67730ad0-2040-41a7-b934-3e75460c6403">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7809f033d5704a408b3a92c0496273c7_D20200401-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNy0zLTEtMS00MjA_6689f635-3407-4b0a-8940-68ae2af72bbd">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3446e8fb9264fa6bceff8cf3d2e166e_D20200101-20200630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNy03LTEtMS0zMTI1_e41d4850-469c-4bcd-9425-bafc340cdf2b">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i024c1f1b458648a0b9cb88256e9c4a3a_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfMy0xLTEtMS0w_c2949b23-e4a5-4a21-80bc-a4a1aa00927c">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5dd8f97f0d834086a7e27bc176ab32eb_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNC0xLTEtMS0w_51c5865e-be01-4f2d-86f3-6a211edd5004">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc8c969a14594d11b493db131e6fc11e_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNC0zLTEtMS0w_b50f75ab-ccd6-45c7-bfa6-84bf960c8bb4">43.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba17faa36f594080b10480edbc5e2578_D20210101-20210630" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNS0xLTEtMS0w_aa12b5f0-b37b-400c-bb5f-ad1b4b588d20">34.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3dd42db203e84e239ba631310adddf43_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNS0zLTEtMS0w_55830ad3-923c-40e5-ae8f-e54418d15697">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDc_f116ee6e-986f-41e2-8c45-5c905ed1cac3" continuedAt="i458087705a5f453a8f59859b28aba831" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ic2fcd684b9a345d6b07d10617e23c46c" continuedAt="i4ed10ddeeecb429e9572ef42fc38ac54"><ix:continuation id="i458087705a5f453a8f59859b28aba831"><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div></ix:continuation><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMjg_aa1513a8-c5a3-4245-90da-28472e4795ec" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy0xLTEtMS0w_d722f565-ee0d-456c-92c1-2f3fed37a3d9">107,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy0zLTEtMS0w_082714a3-1065-4b74-8fab-5900cee92260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy01LTEtMS0w_e5921e4e-a1e1-4304-b498-6f373e37969e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy03LTEtMS0w_988400fe-8011-4047-a238-e2a33995418e">107,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC0xLTEtMS0w_a9a7df9a-1aff-4a81-a726-7908dbd283bd">67,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC0zLTEtMS0w_feb93043-06d9-4f2a-9cc8-64b7a88c438e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC01LTEtMS0w_de803773-bde7-4238-ad3a-e558df677bdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC03LTEtMS0w_fd074e25-8d53-491a-a856-f89d9cf871de">67,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS0xLTEtMS0w_c29f9f22-da8d-47e9-99eb-f8f42f2cbe12">120,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS0zLTEtMS0w_0aee3c4d-9208-4ff2-a483-9c6123249015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS01LTEtMS0w_47527104-65e2-4923-ba04-f1f6117f4017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS03LTEtMS0w_2e805502-4090-4b95-88d4-5310d640d96a">120,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy0xLTEtMS0w_f3e22b41-999d-45a1-a339-4201d849b238">294,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy0zLTEtMS0w_473977a4-3443-48f2-be66-8cbb6b8c2377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy01LTEtMS0w_1384889c-e69d-4319-a6ff-bbeb0c3b1f14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy03LTEtMS0w_124ecbf4-0db9-4a05-9413-113a361de137">294,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS0xLTEtMS0xMjE2MA_5bb190a8-8e43-4553-96fb-7401987b10eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS0zLTEtMS0xMjE2MA_3f336934-8f1a-4b1b-aea1-024180e67b2d">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS01LTEtMS0xMjE2MA_ca92de20-c0a2-4830-becf-a20270150052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS03LTEtMS0xMjE2MA_4242bf83-a7a3-43f7-a151-9f92fcfad3d3">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtMS0xLTEtMTIxNzE_38866b6f-3985-40b7-b329-6afb09a8cfb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtMy0xLTEtMTIxNzE_e6d17c93-955f-4d0b-a429-1c4074739a53">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtNS0xLTEtMTIxNzE_2a86f88e-aa85-4b2d-b0ca-4bfd12eaa04f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtNy0xLTEtMTIxNzE_5bfe14c3-63ea-4e96-a2b4-7b6c1aa6b4ce">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy0xLTEtMS0w_69b1c03b-9ef0-496e-a6f5-e7934e559890">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy0zLTEtMS0w_0078fb40-d67a-4071-9b4b-8fd40beefcc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy01LTEtMS0w_bb8dd26f-387f-4398-b61b-0acab0bf1339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy03LTEtMS0w_2e1c890a-ab2f-47a9-8728-02b5bcde4b62">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC0xLTEtMS0w_8b166b79-ab5f-4a1f-a05c-0f40f4e0f3d0">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC0zLTEtMS0w_b68d82f1-6adb-4ebe-9d94-a6d816031b84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC01LTEtMS0w_b850d911-d26b-4459-b799-ee9d55bf7350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC03LTEtMS0w_47e32476-e3e2-4b9f-8279-607756acf330">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS0xLTEtMS0w_34ef54ac-9ca7-4efc-b6f7-550c11efe605">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS0zLTEtMS0w_0a4b0a23-27b8-4c15-acb8-fd19cf68aa6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS01LTEtMS0w_d785716a-4c1e-4f80-bfd3-7a3bd9cc7f6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS03LTEtMS0w_5b0047b8-fd67-4a54-b7ea-b60c594f6630">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy0xLTEtMS0w_2436785e-6786-4c4b-85c0-37184cc1cc29">183,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy0zLTEtMS0w_eedd200c-4938-4a79-99bd-9a35b0cc55cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy01LTEtMS0w_ee01c7a1-db8e-4e06-8a14-baa89c132855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy03LTEtMS0w_ff315bb4-a20a-4f7c-9116-a53a6613a9ba">183,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2021.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwOTE_4464bb93-a1d6-403c-a648-3d598b837e14" continuedAt="i1b3b9de306e641199b9104bce22a7e66" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1b3b9de306e641199b9104bce22a7e66">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</ix:continuation> The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_3f99c666-45df-4335-b64c-6a20badce5a0"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_a1b828d5-09d7-466d-b93c-d9410295b3db"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_b9f6a409-d6c9-4295-a240-0f21c595ec32"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_efad7904-5b4e-44db-bbb4-29abf2369cba">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2021 and 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i4ed10ddeeecb429e9572ef42fc38ac54" continuedAt="i5f0d71ce89294d3a916636cae83c4df3"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNjE_8e6c16e8-ff64-4e80-bbbb-01627503dae2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s <ix:nonFraction unitRef="unit" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTc2NjU_5663b87a-0aa1-4f37-9c0a-eec9c92375e6">three</ix:nonFraction> reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_16a70ed7-5cfb-4f7c-a821-1b9e1a60314a"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_38bdd138-4559-4031-b5f7-981c7ec0f29b"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_6ac1c92c-eb16-428f-bc8f-4762da010d74"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_f6e91783-2f75-43ce-b18f-23fef4b8a1d1">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2021 and 2020. Goodwill as of June&#160;30, 2021 and December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMjE3NQ_90a26465-e5e0-4af0-9015-8ea55015c631"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMjE3NQ_e2cd088e-8cb7-497a-b208-aa5020daccf5">239.1</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTM_75ae68b7-f572-4478-9a62-fd94ba8f87a5" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Cost Method </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDY_3a64d746-2461-4ce8-8790-314c2c1955c3" continuedAt="i45ef4bb5503b4d78b59a97f396abb6f5" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i5f0d71ce89294d3a916636cae83c4df3" continuedAt="i31a7d8c2a6ad4609a3ed1d2270312a8e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i45ef4bb5503b4d78b59a97f396abb6f5">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</ix:continuation></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="ameh:FiduciaryCashAndPayablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODM_d0dd61c2-ca6d-443f-be99-751e74f555b1" continuedAt="i956026d918fd4521bf8ef6d820d2e308" escape="true">Fiduciary Cash and Payable</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i956026d918fd4521bf8ef6d820d2e308">APC, Alpha Care, and Accountable Health Care collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of</ix:continuation> $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjg4NA_f94bc676-9578-4494-80e8-b74a0059a98f">9.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjg4OA_527aeb42-f05e-40fd-9261-4a1efa7730bc">9.6</ix:nonFraction> million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNjU5NzA2OTgzNDAzOQ_2a3ba9fd-91e3-4b37-9bcd-e6dd4fed940a" continuedAt="ie889610c971246bb83ecb1018499ce62" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 8 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie889610c971246bb83ecb1018499ce62">The estimated fair value of the derivative instrument was determined using Level 2 inputs. The fair value of the derivative instrument as of June&#160;30, 2021 and December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9b7eb2683f4c475faeaec9c8b1f67839_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNjgyNw_43c5a994-d30b-4550-a7d2-9193beb2650a">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5f03ca66055944a6b0fb9d49c0ba7b81_I20201231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNjYzMg_62485515-11d9-4e78-a42a-1aff8665bb86">0</ix:nonFraction>, respectively, and is presented within other long-term liabilities in the accompanying consolidated balance sheets.</ix:continuation>  </span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNTk_05170899-8ee5-4f11-aa58-b52aa275e6ad" continuedAt="id84bec32ef1d4fc09434b75ff3e71b34" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i31a7d8c2a6ad4609a3ed1d2270312a8e" continuedAt="i89c9d89aae00427793aab865cb0a01b1"><ix:continuation id="id84bec32ef1d4fc09434b75ff3e71b34" continuedAt="i67280aa4eda7456d8a27febe85caf6d9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of <ix:nonNumeric contextRef="i73ebc5992e5544fa9612e04b047d6eb0_D20210101-20210630" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDI_f17818f6-ae42-42cb-9967-f2e487dfd516">one year</ix:nonNumeric> or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i89c9d89aae00427793aab865cb0a01b1" continuedAt="i3ac465898a79435d9351fc981d1d675b"><ix:continuation id="i67280aa4eda7456d8a27febe85caf6d9" continuedAt="i3da14381ef794f10afb9bf6e4c4c5184"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like payments, called All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 7), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within <ix:nonNumeric contextRef="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzQwNTM_dc97f467-9417-44c6-ae9b-b79f48857b74">30</ix:nonNumeric> days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within <ix:nonNumeric contextRef="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzQzMTM_3838e485-4381-420e-a1be-4d0cb8bd7c6a">30</ix:nonNumeric> days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within <ix:nonNumeric contextRef="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzQ0MzY_3838e485-4381-420e-a1be-4d0cb8bd7c6a">30</ix:nonNumeric> days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenueMonthlyAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjY5Mw_b9054372-bb41-427c-9fa3-07d1f46f2eee">8.0</ix:nonFraction> million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjY5OA_bf8b1959-dda7-46ba-968b-a8f1ed27511d">24.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjcwMg_9ae0f0dd-c398-4ce3-8654-bddb6a03db92">48.1</ix:nonFraction> million in total AIPBP payments for the three and six months ended June&#160;30, 2021, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenueRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjcwNg_1f7e584c-5be8-47ae-a04e-ffb8c16e8094">14.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenueRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjcxMA_30cce759-7b86-4e36-9f76-c25638d43dd7">31.2</ix:nonFraction> million has been recognized as revenue for the three months and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i3ac465898a79435d9351fc981d1d675b" continuedAt="i951bfe64bee84dfda63a54ff3e14eb0d"><ix:continuation id="i3da14381ef794f10afb9bf6e4c4c5184" continuedAt="i25e0e8c0f75540269d6537b7ff95d7d7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., <ix:nonNumeric contextRef="i2445932d5cee413a82029f7fb82d054a_D20210101-20210630" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTU_f6f72bd8-2694-4f8c-bed4-275f6d476bbd">10 years</ix:nonNumeric>), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i951bfe64bee84dfda63a54ff3e14eb0d" continuedAt="id6cb957db96a447f86da47bac5d10a57"><ix:continuation id="i25e0e8c0f75540269d6537b7ff95d7d7" continuedAt="idab63aa0055c4063b8136189346efa52"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idab63aa0055c4063b8136189346efa52">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</ix:continuation> The Company&#8217;s contract liability balance was $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5Mzk0OQ_fadddf52-44e6-4f02-a7d7-f6b641e9d708">29.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5Mzk1Nw_12127c86-5e52-4d50-bdd9-96ac3bc999e5">13.0</ix:nonFraction> million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="if30af78cdea54cdbafd288daa6d2c6fe_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjg3OQ_bf3a45df-85f2-4d2f-8b1f-ec9655cafe61">0.4</ix:nonFraction> million of the Company&#8217;s contract liability accrued in 2020 has been recognized as revenue.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzA_f6543227-9de7-4d52-8418-c7db7747b117" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNzA_5de2cb26-219f-493c-876c-ff930ee5fdc8" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDc_c58f6ca4-a502-40e7-9ec8-93d3636c7463" continuedAt="iaa7cd7c7cfe54c77b408e95cbf773363" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="id6cb957db96a447f86da47bac5d10a57" continuedAt="i1a4a727c164c47b99469590084a66462"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa7cd7c7cfe54c77b408e95cbf773363">outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</ix:continuation></span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="ameh:MinorityInterestPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzY_b81921ba-77c5-4cf6-9a01-eb39a4cfa0a5" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="ameh:TemporaryEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTY_57e28bd1-0cfc-4de0-9166-d14709507d93" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2021 and December&#160;31, 2020, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDE_0e32f905-9597-4a45-ab30-7eccfba95ccb" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12 month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="ameh:BeneficialInterestPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzE_8a63d483-260e-4667-8890-e799e607c4bd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a <ix:nonFraction unitRef="number" contextRef="i130bee7db4b74cfdac137ec49a5678ab_I20200430" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNDk4ODE_b48ff815-ea25-41f8-8c98-bb50c12921a0">100</ix:nonFraction>% owned subsidiary of APC, sold its <ix:nonFraction unitRef="number" contextRef="if5ce879e744f44499873676c0b759e61_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNTU1NA_d18ef0c7-cb43-4928-b8c0-eee330e9c73a">48.9</ix:nonFraction>% ownership interest in UCI pursuant to the terms of the stock purchase agreement, APC received a beneficial interest in the equity method investment sold. The estimated fair value of such interest in April 2020, was&#160;$<ix:nonFraction unitRef="usd" contextRef="ib82f85b4c8b24e3eb8d0b090521fffd3_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTAxNDI_1f76b63d-df65-4d1a-af06-7a90b20a336c">15.7</ix:nonFraction> million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $<ix:nonFraction unitRef="usd" contextRef="if5ce879e744f44499873676c0b759e61_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTA0NTQ_242a10bc-2feb-47cc-a772-ea688499d7f5">15.6</ix:nonFraction>&#160;million and preferred shares with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="if5ce879e744f44499873676c0b759e61_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTA1MTA_55c6bcff-1757-4728-a77f-8ff55f45bdc2">6.4</ix:nonFraction>&#160;million, total estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="if5ce879e744f44499873676c0b759e61_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTA1NDQ_3777c347-550f-4c31-ad11-a0b2bfdc5ef9">22.0</ix:nonFraction>&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free Treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020 was assessed and beneficial interest was concluded to not be collectible. For the three and six months ended June&#160;30, 2021, the $<ix:nonFraction unitRef="usd" contextRef="i31665be81e024f77a8eb0c64fdd329d5_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNzczNw_8c116896-594c-4a95-b0c0-5d265edcddb7"><ix:nonFraction unitRef="usd" contextRef="i9e33fda836264739aa7bb8163bc33a5e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNzczNw_c8f116a2-e747-4330-bb93-8b53326985f6">15.7</ix:nonFraction></ix:nonFraction> million was written off and expensed in other income in the accompanying consolidated statements of income.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTc_121aee19-6820-4b4b-9be9-6ffb651f90bd" continuedAt="iad70799059ce4519aa6c059139a1615e" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i1a4a727c164c47b99469590084a66462"><ix:continuation id="iad70799059ce4519aa6c059139a1615e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div></ix:continuation></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_49"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfNDk1_02481a69-a114-41b5-92b6-8ef2170c7e02" continuedAt="iac7a2a83e8e94b62824d182618b8ea25" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="iac7a2a83e8e94b62824d182618b8ea25"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfNDk3_6bb0b80d-4a99-41dd-8173-d7bc203c29cc" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82dd99b346d847f6afecef6b4ffe3d89_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi0xLTEtMS0wL3RleHRyZWdpb246ZjRlYWFhNjM1Mjg0NDBkMDgwZWQxZTQ4OGVhZmNjOGFfNA_221aab28-2d71-4459-adf7-ca5ffc834895">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i8330c3700a474f29947f7fde24cb31d0_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi0xLTEtMS0wL3RleHRyZWdpb246ZjRlYWFhNjM1Mjg0NDBkMDgwZWQxZTQ4OGVhZmNjOGFfNw_39ed9166-452d-4017-8f9c-1452c2c32a58">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id890472ab2d0424986384ec74225309a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi0zLTEtMS0w_bd2f8914-231c-428d-9e2a-9435a4f40e14">143,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id890472ab2d0424986384ec74225309a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi01LTEtMS0w_25d7f74e-fb19-4935-bf03-428f40907f33">79,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id890472ab2d0424986384ec74225309a_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi03LTEtMS0w_42759973-5004-4b94-b34d-9d370b704fe7">64,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iab2ae2abe941465e94134f35120b632f_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy0xLTEtMS0w_0cbaed3b-a05f-4951-80e0-31eb18dbc952">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709e028ffa954eac8fe9f174ae35a812_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy0zLTEtMS0w_349feed7-7769-4bdf-91d3-45903b8b2af8">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i709e028ffa954eac8fe9f174ae35a812_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy01LTEtMS0w_5f157d7f-8db1-4ef1-9144-d31327c33ad1">12,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i709e028ffa954eac8fe9f174ae35a812_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy03LTEtMS0w_1b83480f-4650-4ebc-a93f-ef056c6adf22">10,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia462a1dff6eb49f0a14538bf7d4535a8_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC0xLTEtMS0w_5e260a17-1dbb-4e6b-be5b-bc6066e075e2">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC0zLTEtMS0w_2e5954a7-1d24-4d95-b564-916e0a57d20e">7,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC01LTEtMS0w_63ca57ed-ee2b-4562-a120-e0f971293973">3,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC03LTEtMS0w_ee925d04-143d-455e-9789-7b5ff13cf223">3,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia873358d93f341de98ab17edbffcde50_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS0xLTEtMS0w_0aeb7585-a518-4c7e-947f-e5c517693d15">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS0zLTEtMS0w_00b64e2c-4759-41b9-b486-6cdceaba9575">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS01LTEtMS0w_68377c2b-9dfc-4386-8c91-8c2512f83fa4">1,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS03LTEtMS0w_fd5c0867-5827-4ee3-80f8-226560afe9ba">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54b9d769c77c4104928dc588fb0c91ca_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi0xLTEtMS0w_32139b8b-325f-4990-bdea-50274bee625b">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi0zLTEtMS0w_b83ebd0c-7559-477c-b899-d7a0ec05080a">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi01LTEtMS0w_621e6716-983b-4c39-84e8-9d6ee23e375a">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi03LTEtMS0w_be15b9a4-a4b5-4ea4-a75f-42aa4f0f0520">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNy0zLTEtMS0w_382ad1e6-ffd7-4096-add3-9883420104b3">177,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNy01LTEtMS0w_5653ab70-a862-4b70-8eb4-8602b5eaab47">97,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNy03LTEtMS0w_473605cd-2f6b-48b3-b3c3-667593ab98f0">80,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i044041f8aebc43dea7c8afc0da3d2cae_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi0xLTEtMS0wL3RleHRyZWdpb246YTYxOTc1ODk5YjdjNDFlNGFkYWZjYzhmNGE1NDExMzNfNA_82ac0614-305f-4b46-8ea4-2153434dc75b">11</ix:nonNumeric>-<ix:nonNumeric contextRef="id2589d5bf11b47ddb890e3feeb7d0e43_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi0xLTEtMS0wL3RleHRyZWdpb246YTYxOTc1ODk5YjdjNDFlNGFkYWZjYzhmNGE1NDExMzNfNw_38580672-a52d-45f5-acd4-22a01fd56874">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42823b74ab154e4cb57ada3938ebe79a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi0zLTEtMS0w_ad31f0c5-641d-4a50-bb98-2c8c9ef548c6">143,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42823b74ab154e4cb57ada3938ebe79a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi01LTEtMS0w_8976d71b-7dc5-4017-8c94-abfe88dec73c">73,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42823b74ab154e4cb57ada3938ebe79a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi03LTEtMS0w_a4e7b5f9-2c53-47a8-b98f-b84d8c711dba">70,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3e5c9b3bb5cf4c068e18e1fbe99c4bcf_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy0xLTEtMS0w_2f9eda15-ed49-4d91-9bba-3018b6b28506">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy0zLTEtMS0w_62181fec-6c16-457a-a612-4c9050fa6f6e">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy01LTEtMS0w_3268d44c-1413-4bad-b2a6-71bb5c372620">11,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy03LTEtMS0w_10aa0e8b-ad09-4d88-a3a2-50f2fb317cc0">11,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if0fbf27e2a7647899d67e3bd220dbeda_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC0xLTEtMS0w_632d9016-6cb2-4b71-a332-cc400c2b88ad">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f982d527bd42e7b4fab85539b28ffc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC0zLTEtMS0w_ea41725f-e72e-429f-bafc-2fea261c85ff">6,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73f982d527bd42e7b4fab85539b28ffc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC01LTEtMS0w_fccb1d01-e57a-4eb8-a7a0-515c2afc8f30">3,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f982d527bd42e7b4fab85539b28ffc_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC03LTEtMS0w_9de0eb3f-efd3-4da4-aeef-fab759c4dd6f">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1b898d0feaa140ab9e92e780e9feb0ba_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS0xLTEtMS0w_27eb454c-5522-4ca5-9598-87b573e56c8e">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib101f9ba2e1e4330b0065d49f9aed221_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS0zLTEtMS0w_a7f120ea-1048-4528-a1f0-2973c15e21a9">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib101f9ba2e1e4330b0065d49f9aed221_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS01LTEtMS0w_86bf53a2-393e-4a72-8cb8-40a35e8f40e6">1,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib101f9ba2e1e4330b0065d49f9aed221_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS03LTEtMS0w_1c2668f2-d6d2-498e-8ff6-7dffb799a51a">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0341cbb996e048a6854636392a8e25d5_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi0xLTEtMS0w_ebc57e58-dcfa-4837-8f58-ff0d756d12ef">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bec418630414a69a769bf4b40f4e7e5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi0zLTEtMS0w_08853971-a3c4-4b09-b351-3ec1af82a584">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bec418630414a69a769bf4b40f4e7e5_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi01LTEtMS0w_35463434-84d3-4baf-9376-6b2583f1ec42">156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bec418630414a69a769bf4b40f4e7e5_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi03LTEtMS0w_425db7bd-56f6-44a8-82e6-fb74572ae0ef">855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNy0zLTEtMS0w_613b93d9-e722-4841-b68c-51e5231d7147">176,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNy01LTEtMS0w_cb17002d-de63-4f3c-942f-af2b5328f632">89,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNy03LTEtMS0w_d4961326-feb9-40f9-9d10-78864eef6446">86,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMzM2_484a77c4-26e4-459c-aeb1-8602888ed603">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMzQz_8a5414bb-5cd9-42c4-9dbb-605f046328f6">4.1</ix:nonFraction> million for the three months ended June&#160;30, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMTA5OTUxMTYyODM4MQ_6cf743d7-5151-4cf7-b750-69baa701b931">7.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMTA5OTUxMTYyODM4NQ_c4c96d78-3849-46fb-8166-b9d533afa718">8.2</ix:nonFraction>&#160;million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfNDk5_6526b45e-fba3-4220-96b5-7c0b37b5a2d5" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfMi0xLTEtMS0w_d38fe9e5-2a73-4cbd-8114-8f3730920edd">7,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfMy0xLTEtMS0w_51e243d7-d377-47b9-97ab-19319165fd43">12,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNC0xLTEtMS0w_b6aa85a2-f25b-49c2-8991-f7cec3b60c64">10,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNS0xLTEtMS0w_71542780-8674-4130-bada-846b92692d08">9,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNi0xLTEtMS0w_3029e876-e514-4535-9b39-476e2a9b155b">8,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNy0xLTEtMS0w_c21862ec-cdbd-4380-8dca-5ac8de783dd1">30,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfOS0xLTEtMS0w_e3540a3a-c8c7-485d-8750-552f16ef0a83">80,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="ameh:EquityMethodAndOtherEquityInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI4OQ_4408244d-8a55-4305-b417-8eb78cdc8dc1" continuedAt="ic4a0f5b324264b0f81a2cf28c8732016" escape="true">Investments in Other Entities &#8212; Equity Method</ix:nonNumeric></span></div><ix:continuation id="ic4a0f5b324264b0f81a2cf28c8732016" continuedAt="idbe78ac4485d4874a73998623e6af294"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI5NA_7409cf09-5d20-4cc5-b65a-7c5d63166648" continuedAt="i38c55710af6342d487a87e1660558bb2" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contribution</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity Consolidated</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126879ce11594831961b89ab705a48f0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS0xLTEtMS0w_0a2651f3-8148-4f59-a993-51efcaba40b8">13,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS01LTEtMS0w_2fcc530d-012e-46c3-b355-336b09ac5fd5">4,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS03LTEtMS0w_b177c304-9217-49ce-9cf4-45ed64a34354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS04LTEtMS0xMDk0MQ_5660ae44-1b92-4ccf-a616-02662ef538a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93a51086c7d546adab3f7e56b087b382_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS0xMS0xLTEtMA_0cfa5d33-6364-46dd-8ee3-5eb987187717">8,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9329af8296b449084545734af6bd691_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xLTEtMS0yOTM5_1b58ee81-6be5-4d9a-8590-23043fd91d35">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi01LTEtMS0yOTM5_52397d9f-5bfb-4f14-9a1a-beebe6c0e7ab">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi03LTEtMS0yOTM5_5f03bce6-ce9e-4acb-83b0-23985cc43952">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi04LTEtMS0xMDk0MQ_d19edfbb-7197-4403-9843-4efb9697ca2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife67641ec17b442283895740613c5731_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xMS0xLTEtMjkzOQ_a973d93d-6d27-491a-82d7-84f66918b870">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f711e268b9d414f8665d1f912ae7f03_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xLTEtMS0w_d2aed3d3-fdfc-4a85-b312-8c502ad877f2">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi01LTEtMS0w_21351e9c-4200-45b4-869c-dab3b4498886">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi03LTEtMS0w_b84ba69d-0d7b-4c4b-bd69-2adbe82030f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMy04LTEtMS0xMDk0MQ_87938fb5-39e4-41d1-a0cc-bfbf27aa44d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4181eb02bb2f4393a3250731eddb20f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xMS0xLTEtMA_45bd9979-7c81-4f14-8dca-8d9526ac671e">2,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9343b3aac1264fccba1bf8a8c124302f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS0xLTEtMS0w_6ac9f71e-9b22-4e46-8935-287f7f640b6a">17,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS01LTEtMS0w_56ae6ff9-ceac-4cc8-bb65-3d05602b269a">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS03LTEtMS0w_77eb73cc-9baf-49a2-ba0f-b31de3a16296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNC04LTEtMS0xMDk0MQ_367de8ed-72d5-46b8-a564-e8f189461181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009c403c4ff240a19cc16cdbe7834056_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS0xMS0xLTEtMA_5cc10bbf-5f6e-4946-8b78-c07dda92baf2">17,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eddafd4ca9e4212901159b5340a98fe_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy0xLTEtMS0w_121551ad-600f-48b1-becb-d8cd168c0d02">2,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8c75381253b47bd8691ab6ed609fbda_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy01LTEtMS0w_b1dc5345-f664-467a-806f-8ada6da6db61">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy03LTEtMS0w_319791a8-8cf4-42a3-8aa3-7c98340e9d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS04LTEtMS0xMDk0MQ_21c3ad4a-cfb6-454f-a1e1-daddb04def82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7bc039d7edc42b1b767425117d101c9_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy0xMS0xLTEtMA_78953149-73cc-43df-830d-785f0d21231b">2,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c39d18aa59f4fdab441e373be437999_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC0xLTEtMS0w_a3d000bd-5747-4a0c-a4b7-f2ce47828f73">4,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC01LTEtMS0w_176df6d0-f634-40c8-b9ef-20174d35d470">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC03LTEtMS0w_9031b4da-8875-4235-bed9-59dbd59e345e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNi04LTEtMS0xMDk0MQ_e28a4e38-3ec9-41c0-986a-0e9894c6da59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i302d2d42eb894edfa8abcbb27511f099_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC0xMS0xLTEtMA_18de79d9-051a-4709-af27-e7a091b11860">4,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if978e802ab374bcb978febf6e68a5f0a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS0xLTEtMS0w_f724add6-bf6d-4529-981d-78ece5883f22">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS01LTEtMS0w_cf1ad796-6c7f-4900-b2b0-0cca56adb90a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS03LTEtMS0w_590cf21e-aaa8-4ae4-8e89-b418261815ec">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy04LTEtMS0xMDk0MQ_cd4579de-c3aa-4468-99be-ad7bb8818ba3">3,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d380a7b57e4077a43fd2ca0fe6d807_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS0xMS0xLTEtMA_2d70a510-54ef-4c8f-b1e7-cc8745c982df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtMS0xLTEtMA_29177d7e-c4ec-41a1-a301-b341535a0110">43,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtNS0xLTEtMA_42b2b42e-5ee6-4835-92c9-90bd4f16c6ab">3,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtNy0xLTEtMA_1cd14739-816d-4b13-837c-30d6b350892d">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsConsolidated" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC04LTEtMS0xMDk1OQ_14972e3b-46c8-49a6-9dbe-5d7b0e50b553">3,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtMTEtMS0xLTA_94ffe4b7-da31-481a-a02d-a0b5662bcb67">37,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties through its network of approximately <ix:nonFraction unitRef="provider" contextRef="i93a51086c7d546adab3f7e56b087b382_I20210630" decimals="-2" format="ixt:numdotdecimal" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzk0_b85aa28e-8260-4a19-95f4-eb1a88d8bfeb">2,400</ix:nonFraction> independently contracted primary care physicians and specialist providers. LMA&#8217;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="i1e1b0a8248204e63bc412a37ae8ab329_I20121231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzEx_504f6788-fa58-4541-9f6b-adf51781f605">5.0</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i1e1b0a8248204e63bc412a37ae8ab329_I20121231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzIw_51aae810-5fa0-4aa5-992b-60b2c64034bc">25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. On December 18, 2020, the Company exercised its option to convert the promissory note totaling $<ix:nonFraction unitRef="usd" contextRef="i2699be005bc448cf854162e6c83dcef3_I20201218" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODU4_802a118f-488c-4b78-84bf-10c6d5031ec7">6.4</ix:nonFraction>&#160;million due from Dr. Arteaga into an additional <ix:nonFraction unitRef="number" contextRef="i2699be005bc448cf854162e6c83dcef3_I20201218" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTAx_1a692d52-7ba7-4173-b7f1-be3d6e596d73">21.25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. As a result, APC-LSMA&#8217;s interest in LMA&#8217;s IPA line of business increased to <ix:nonFraction unitRef="number" contextRef="i4301c2756dfb415abb72c0f8eb734638_I20201218" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTAyMA_096c6739-08b3-46dd-aa6f-e18872c6026c">46.25</ix:nonFraction>%. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i54987c743be74a588a51746074a0a1be_D20210401-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTI2NQ_0d645c07-23b2-41b7-860b-de76efff1e57">3.6</ix:nonFraction> million and income of $<ix:nonFraction unitRef="usd" contextRef="i7b874970f5404290acf4e877e53cc4d3_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTI3Mg_b7134f3c-7165-4667-8de8-60d3853e0611">0.2</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and June&#160;30, 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i85e16b9f030248348c4c2fa5de4c74e2_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTI1OQ_524199e5-c368-4510-97b3-3f2671da834b">4.3</ix:nonFraction> million and a $<ix:nonFraction unitRef="usd" contextRef="i3273b2373fda4cdcb3db5f9523c73062_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTI4MQ_8830ea42-c28b-4223-9d78-dfa585468924">0.4</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i93a51086c7d546adab3f7e56b087b382_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTQzMw_16045acf-34b5-462a-9c10-8dece09a32d7">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i126879ce11594831961b89ab705a48f0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTQ0MA_c3aff98f-297d-41ad-aee7-d24a5650e8d5">13.0</ix:nonFraction> million at June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="idbe78ac4485d4874a73998623e6af294" continuedAt="i9cb2a40d81fe4c539607220e29259109"><ix:continuation id="i38c55710af6342d487a87e1660558bb2" continuedAt="i4c0e0b67440b4460ad16c4fc02a9ce2d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the six months ended June&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMy0xLTEtMS0w_60c82293-8157-4d52-822d-3b68ff66c821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMy0zLTEtMS0w_48af263c-01a2-41e0-ae74-cf5cbd11c430">9,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNC0xLTEtMS0w_8d96a73e-e385-400c-9231-58e4cec0325b">694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNC0zLTEtMS0w_d429fb5e-34ff-40d1-a79d-af5f90dfa8ee">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNS0xLTEtMS0w_1a8b2a05-4619-422f-bdb4-9078652db32b">6,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNS0zLTEtMS0w_7ffe05da-e8cb-4c9d-b835-e63399513945">3,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNi0xLTEtMS0w_48193a4a-4933-4413-b01a-0013f647ada6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNi0zLTEtMS0w_dd542fdd-30e9-4cb2-ace9-ff0278a77691">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNy0xLTEtMS0w_b74a22a9-02b9-4e4e-9ea1-5cb0dc6eaba3">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNy0zLTEtMS0w_9b5cf51f-77ff-4976-9e95-cb4cf3937700">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfOS0xLTEtMS0w_76c01268-7ebe-4830-8110-7fea8b22dbb5">9,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfOS0zLTEtMS0w_72fc3100-e1dc-486b-acc1-018daaa88a8f">17,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTItMS0xLTEtMA_dd034919-bc3f-4f45-8a5a-dcc912497dee">23,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTItMy0xLTEtMA_733855ec-2118-4c90-a9c4-52dbe79af2d9">21,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTMtMS0xLTEtMA_ea7318e3-2167-4a02-bcdc-2150ee587f95">13,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTMtMy0xLTEtMA_2088cec2-a04a-4e75-8904-75b0649179a6">4,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd05517d558847b49c015f173be8b91d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTUtMS0xLTEtMA_4eb9c32c-f4e6-4bc7-8c36-e1654fe3ae6d">9,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db85519bc746c39bb248797feb58c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTUtMy0xLTEtMA_d482b597-acd3-4120-8a1b-7155a451b67c">17,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfMy0xLTEtMS0w_dda287b3-c70d-41fb-8c18-2f52edb4831a">95,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfMy0zLTEtMS0w_ec8e77d1-2a0f-448c-9777-9dcf4dd42f4f">92,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNC0xLTEtMS0w_c2ca2241-a135-43c0-8f1e-df037f797d07">104,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNC0zLTEtMS0w_550465fd-fc0b-43a9-b513-71926a537de1">93,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNi0xLTEtMS0w_d191a2ae-ca9f-4f3f-b46f-6d40fb2ed6ae">9,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNi0zLTEtMS0w_2af86831-28bd-4093-9358-d78e6b7963d2">1,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at its facilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="i739839922e4c4c609f191b0dcbabc14c_I20150731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjE3Mg_7cad56ef-1cd2-471d-9c9a-234f6cde07dd">1.2</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i739839922e4c4c609f191b0dcbabc14c_I20150731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjE4MQ_291edf46-14a3-4ad3-ac1c-70ac23ebf9ce">40</ix:nonFraction>% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $<ix:nonFraction unitRef="usd" contextRef="i1303e2069e6247dbb7f793e04ef343c5_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjQzOA_2383fd02-8595-4c4f-8a90-874cf8c5a0c5">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i17796dfb151e489dab379fce67d4e1b8_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjQ0NQ_270a0307-6a93-4276-b872-e3c1c43f4e1c">0.4</ix:nonFraction> million, for the three months ended June&#160;30, 2021 and 2020, respectively, and fees of approximately $<ix:nonFraction unitRef="usd" contextRef="i6bca3a4a2ef740ff94ca5e1a3a2ad63e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTc0NA_a9b23bcf-7ed0-4bc2-a01b-45269a0a6841">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0899c47275134483b8d984adf3740b3e_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTc0OA_22e1dc61-189b-4330-99eb-753f74e0499b">1.0</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="i32cbe872dd774db5b7d4800706c08caf_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc3MQ_6ca0ea01-64b5-415e-9b61-1fbeda2be93d">16,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2887d4b59c254ece9c755540893a51fb_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc3OA_bdb431ab-832d-40de-8a7a-8ace87d617ec">10,200</ix:nonFraction>, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i29508ad62c9a4ffa96ab856825835cc0_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjA0Mg_87475955-6d42-4248-887f-f4683db3740b">30,000</ix:nonFraction> and income of $<ix:nonFraction unitRef="usd" contextRef="i971d5df0b77740f8906d90e5210fbc87_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjA0Ng_601d0306-c5e0-42be-8f6e-814bfee2301f">0.1</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $<ix:nonFraction unitRef="usd" contextRef="if37ba02674fc4f47a192436d297aff26_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjg4Mg_02cc362c-3442-4830-ba98-3ab5cf501ad7">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iefe421e759914ed0b7a4b1765437668b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjg4OQ_9b9d0861-2f1e-4bf3-aaad-60d8cfce1111">1.4</ix:nonFraction> million at June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i9cb2a40d81fe4c539607220e29259109" continuedAt="i7d2fd0d536044c7f8bc07c59f01609f0"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA entered into a share purchase agreement whereby APC-LSMA acquired a <ix:nonFraction unitRef="number" contextRef="i0a037a875d3544e78944fdfbdef2af99_I20160531" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzA3NQ_6de2aa58-3bd6-4e0b-bbd1-42cf61c5f9ad">40</ix:nonFraction>% ownership interest in DMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#8217;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="idbffb487ac384d7b9e97a9a77c64595e_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzM2MA_fd79e39e-a70a-4f17-8933-de8a454a432f">0.2</ix:nonFraction>&#160;million and a loss of $<ix:nonFraction unitRef="usd" contextRef="i3cd84561b1874a4b9c02a9c4d5aea63c_D20200401-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzM2Nw_a9a2ed92-47ee-4b40-9085-f5feefcb8111">0.1</ix:nonFraction> million, respectively, in the consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recognized income from investment of $<ix:nonFraction unitRef="usd" contextRef="i8abff36813164c6c84417bf95217cc72_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjIwOQ_4c9338d1-dd37-4684-a71a-2c99c2650eff">0.2</ix:nonFraction> million and a loss of $<ix:nonFraction unitRef="usd" contextRef="i94b60c63c1bc4a058e9a3b6b3cbe98e0_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjIxMw_da6ba07d-647b-4e0d-b8b8-eb3bba9841e7">0.1</ix:nonFraction> million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i4181eb02bb2f4393a3250731eddb20f1_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzUxNQ_717babc9-0ba8-408a-8ace-1f6060558e39">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1f711e268b9d414f8665d1f912ae7f03_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzUyMg_32331f35-df6c-472d-8755-e616980398fe">2.6</ix:nonFraction> million as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC, and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owned <ix:nonFraction unitRef="number" contextRef="i1d9d1b124a0e459ca79a0ece66636348_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzkwNA_8e8a4ae0-fa06-4338-980a-a14e7b4bb720">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i3b4a44d05fbf46488b4af77f35c9567d_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzkwOA_61cd0bfe-624c-4e2d-8287-0d7c27204b83">25</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i8eeb59c450004d3e92ae1911c1e1cbeb_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzkxNg_cda63c6d-6e68-4b9c-ad4d-cf835a05bf0a">25</ix:nonFraction>%, respectively, of member units based on initial capital contributions of $<ix:nonFraction unitRef="usd" contextRef="i1d9d1b124a0e459ca79a0ece66636348_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzk5Mg_8ce50ad9-9538-4b9c-97b1-4c4d2695c151">16.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3b4a44d05fbf46488b4af77f35c9567d_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzk5Ng_54a6fdf7-00a8-434f-9f20-c7b76000449a">8.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i8eeb59c450004d3e92ae1911c1e1cbeb_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDAwNA_905b78e7-b74b-4d1c-97e1-ce95f666450f">8.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $<ix:nonFraction unitRef="usd" contextRef="i75b545869a11420f9ea79a9c44e04340_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDI1OQ_2a5b1afe-2de4-4eb2-bcb2-86c32eec648b">33.3</ix:nonFraction> million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s <ix:nonFraction unitRef="number" contextRef="i70ff4fbd4b12465585f409d00f3b5b5e_I20190423" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDM2Mw_a60be28c-3fcd-4633-930d-30b8093d4c81">25</ix:nonFraction>% membership interest in 531 W. College, LLC for approximately $<ix:nonFraction unitRef="usd" contextRef="i70ff4fbd4b12465585f409d00f3b5b5e_I20190423" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDQyNw_a35aca8c-29bd-454c-8af6-a2ed64ecda82">8.3</ix:nonFraction> million. Subsequently, APC has a <ix:nonFraction unitRef="number" contextRef="ib451b96ba18f4df7a702b76736baf9a3_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDQ1NQ_851a294b-e8cc-455a-af0a-3ea0cd209fbb">50</ix:nonFraction>% ownership in 531 W. College LLC with a total investment balance of approximately $<ix:nonFraction unitRef="usd" contextRef="i0597b46866404e3c9244a5206a042d40_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDUzOQ_d49836f8-35af-49ce-aa99-f8f313767348">16.1</ix:nonFraction>&#160;million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i06dcdcd971e4410ba873f348e8e7adc2_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDgxNA_6e8438ce-f166-44b8-8af8-1f1e6b5c1b4c">9,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="icc7595906102441585b7663ded30146e_D20200401-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDgyMQ_b5ea93e0-5981-42f7-8bb1-30e68b132bdf">0.1</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recorded a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="ibf5836787810470aa58c74049921dc6e_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTA5OTUxMTYzODYyOA_44fa09c2-2fb8-4355-b68b-26d92d59f6b3">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib64a97044a35489c8feb4989784095cf_D20200101-20200630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTA5OTUxMTYzODYzMg_928ab686-6c88-4c66-8da4-96c1125a17ea">0.2</ix:nonFraction> million in the accompanying consolidated statements of income, respectively. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i009c403c4ff240a19cc16cdbe7834056_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDk4Mg_fdd81ba3-ad40-4e3d-90d8-8c9eab274cd4">17.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9343b3aac1264fccba1bf8a8c124302f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc0ODc3OTA4MDc1Mw_6cd09e92-232a-4038-a15e-70ea72a0c282">17.2</ix:nonFraction> million at June&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><ix:continuation id="i4c0e0b67440b4460ad16c4fc02a9ce2d" continuedAt="iab6cacc4bf374436aaaa26f61bf9afa2"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the six months ended June&#160;30, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMy0xLTEtMS0w_554995f7-23a8-41bb-a71c-b3be0406d32a">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMy0zLTEtMS0w_dd1e9a76-20c6-40d9-8173-b127e5a6b764">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNC0xLTEtMS0w_7638a922-1c0b-4666-b402-6407d5043b8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNC0zLTEtMS0w_15d5ea9d-0b0c-458b-9d6d-ed279ede636d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNS0xLTEtMS0w_e0d0186c-157b-44f6-9ec3-e8d7ea206698">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNS0zLTEtMS0w_d13144b8-3922-4fa9-889e-2a58f14ddb80">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNi0xLTEtMS0w_75c534f8-f48f-4cf5-98f9-7d09da16663c">33,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNi0zLTEtMS0w_8bfc2bb2-3fce-403b-bdf2-c0f2b18725c0">33,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfOC0xLTEtMS0w_02b105e9-33b7-4f8a-9b5d-f9d21867f9c6">34,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfOC0zLTEtMS0w_3a9636a4-c3bc-492b-b1b7-fcac6d18eaea">34,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTItMS0xLTEtMA_9c0f9523-04e4-4947-ae97-8f99985297b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTItMy0xLTEtMA_c75982ca-2e5c-48c4-b81d-81c788ce3842">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTMtMS0xLTEtMA_fccc57b1-eb23-4ac0-956b-1d474740b28c">34,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTMtMy0xLTEtMA_789ee816-35e7-4742-94b1-7cf49917231a">34,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTUtMS0xLTEtMA_e5d9c235-7677-4ee2-a4b0-18c770dc465d">34,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTUtMy0xLTEtMA_4e99ac65-36b4-40c3-affe-c1fdd69a4e4b">34,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i7d2fd0d536044c7f8bc07c59f01609f0"><ix:continuation id="iab6cacc4bf374436aaaa26f61bf9afa2"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMi0xLTEtMS0w_09640d07-4fb8-4ce1-9d27-1674c9297c99">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMi0zLTEtMS0w_d576de28-2a73-4bf8-926c-1d212eb7a86d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMy0xLTEtMS0w_c36bb3bc-23b0-43a6-9983-e7aed69a51b8">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMy0zLTEtMS0w_ec3c9c4f-14d3-41ed-9e02-f3d3b614431d">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNC0xLTEtMS0w_12627633-f8e4-42db-8392-20a0c1d953af">228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNC0zLTEtMS0w_3fbd5c91-0a62-4fdd-9b8a-a5ed6667cbe1">579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNi0xLTEtMS0w_0d901955-a8cb-45dd-aaf9-e71b085761a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNi0zLTEtMS0w_4dc7a921-c185-4684-866b-edc03ce2d8fe">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfOC0xLTEtMS0w_ecb86fe4-675f-40eb-b8e3-9946a0c77449">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfOC0zLTEtMS0w_8e4201fa-36d9-4ba2-bff5-9efa3b8c81e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMTAtMS0xLTEtMA_8f88c604-01d0-4066-b117-3af55e4e55d9">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMTAtMy0xLTEtMA_71154277-ddc3-4299-b60d-ae7c94d5d98c">558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>One MSO LLC - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="ia760a8cfd561490c90a49b778a9afee7_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNTMyNQ_10693254-b525-4825-a9cb-7f4a5b1f3429">50</ix:nonFraction>% membership interest in One MSO LLC (&#8220;One MSO&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i0eddafd4ca9e4212901159b5340a98fe_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNTM3OQ_854f09d4-765e-4ed8-a00c-2b4ae9850453">2.4</ix:nonFraction> million. One MSO owns an office building in Monterey Park, California that is currently being leased to tenants, including NMM. For the three months ended June&#160;30, 2021, One MSO recognized income of $<ix:nonFraction unitRef="usd" contextRef="i554fe9dff9674725962bb4cb2f88b9b2_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNTkzMQ_eb0c0b04-1d96-4dc0-917a-6f033bedf678">0.1</ix:nonFraction> million in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021, One MSO recognized income of $<ix:nonFraction unitRef="usd" contextRef="ia8c75381253b47bd8691ab6ed609fbda_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTA5OTUxMTYzOTAwOQ_f7551e32-9cb4-444c-9e88-7312fc9bdb44">0.2</ix:nonFraction>&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="ib7bc039d7edc42b1b767425117d101c9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjA3Nw_491a4791-43bb-4872-9773-b796cd7fec4f">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0eddafd4ca9e4212901159b5340a98fe_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjA4NA_854f09d4-765e-4ed8-a00c-2b4ae9850453">2.4</ix:nonFraction> million at June&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC - Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i9c5d3001970541c9b1b6bb12adceff18_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjI5Ng_20ab9cd6-0243-488e-a45b-616873f7d795">50</ix:nonFraction>% membership interest in Tag 6 for $<ix:nonFraction unitRef="usd" contextRef="i0536df6fbb684da2b13045d260e8302a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjM3Mg_e697380a-8122-40e7-99ae-c6dc27229538">4.5</ix:nonFraction> million and a <ix:nonFraction unitRef="number" contextRef="i5120ab4996b447e5a3530a8dcd7ceec9_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjU5NzA2OTc4OTcwOQ_7355cb3d-76a4-4ed0-a0fe-ade0b1bce098">50</ix:nonFraction>% membership interest in Tag 8 for $<ix:nonFraction unitRef="usd" contextRef="if5a95fe077074fdeb9c94b5a02ce35b2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjQ1Nw_c0228109-121e-4724-a55f-606d48252b2c">2.1</ix:nonFraction> million. The Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. For the three and six months ended June&#160;30, 2021, Tag 6 recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="ibb19e6a0df8745acaa9ce709c7fe83bd_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ0Mzk3ODg_02242d94-668f-40c1-80c7-7fcb127ca0f3"><ix:nonFraction unitRef="usd" contextRef="i6917df2647d94638b04a3554df231459_D20210401-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ0Mzk3ODg_35eb8380-6f2a-42cd-a145-40f4c579ccff">0.2</ix:nonFraction></ix:nonFraction> million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the Tag 6 investment of $<ix:nonFraction unitRef="usd" contextRef="ie9a4d75c299c4d8890a93379fee46e7d_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzI3Nw_4ca9a415-ce26-45ad-9e70-c37ce9bc90ec">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0536df6fbb684da2b13045d260e8302a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc0ODc3OTA5MzcyNQ_63c80b8c-d56d-4cc3-a8ef-3081832ee3dc">4.5</ix:nonFraction>&#160;million at June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased <ix:nonFraction unitRef="shares" contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzQ1MQ_f5904b75-ff0d-4ec3-8707-96c936f87143">270,000</ix:nonFraction> membership interests of MediPortal LLC, a New York limited liability company, for $<ix:nonFraction unitRef="usd" contextRef="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzUzNg_d36911fe-0b47-4b58-bea9-f15dd11f8766">0.4</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzU0Mg_94a6a18f-053c-4c64-961e-fb9c62341391">1.50</ix:nonFraction> per membership interest, which represented an approximately <ix:nonFraction unitRef="number" contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531" decimals="3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzYwNQ_3d237356-b7e1-44b0-bdbf-0a7fa13eeb8f">2.8</ix:nonFraction>% ownership interest. In connection with the initial purchase, APC received a <ix:nonNumeric contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI5Ng_ea30cb0b-e501-4d66-aaea-1e2294f39881">five-year</ix:nonNumeric> warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzcyNg_987447d7-e3f8-48a5-91af-fd4884f57786">270,000</ix:nonFraction> membership interests. A <ix:nonNumeric contextRef="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI4Ng_f93840b6-eb52-4d4d-90e7-738e7415815b">five-year</ix:nonNumeric> option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzc5NA_53609916-2a85-4011-b0e7-2e012630b57a">380,000</ix:nonFraction> membership interests and a <ix:nonNumeric contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI5Mw_d5490eec-0b7a-4096-a3a3-2f097f6db5de">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzg1Mg_5c96bca3-f169-464a-942a-db065a9138b7">480,000</ix:nonFraction> membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase <ix:nonFraction unitRef="number" contextRef="i536e73d35938450abf342effa9713c79_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODQ2MQ_85ec3b57-7ed0-4891-8082-df3d09799df7">50</ix:nonFraction>% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed <ix:nonNumeric contextRef="i8e2323bab9c3467682e9da242c1cd16f_D20190701-20190701" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODU1NQ_ee28a208-6924-4316-bd94-449f20e12b50">five years</ix:nonNumeric>. As a result of this transaction NMM invested $<ix:nonFraction unitRef="usd" contextRef="i536e73d35938450abf342effa9713c79_I20190701" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODYwNA_b7d6925c-2f7b-4219-858a-ba996197cbe4">0.5</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i536e73d35938450abf342effa9713c79_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODYxMw_38d41c2d-f538-45cf-84e8-635953a0b0e0">10</ix:nonFraction>% interest. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i5691cb4056714c69a234024bd01402c0_I20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODY2MA_46197a88-d154-4145-b794-29b7259e6805">0.5</ix:nonFraction> million is included in investment in privately held entities in the accompanying consolidated balance sheets as of June&#160;30, 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="ameh:LoanReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfMTI3NQ_d27527e9-a444-4697-9417-6a6b245206a7" continuedAt="i9e9a1b0bee1e47469b5b58b030e2e4ff" escape="true">Loan Receivable and Loan Receivable &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="i9e9a1b0bee1e47469b5b58b030e2e4ff"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 totaling $<ix:nonFraction unitRef="usd" contextRef="idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfMTU5_d0bfce48-9c23-4070-8723-dc5311ee3ef1">0.5</ix:nonFraction>&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of <ix:nonFraction unitRef="number" contextRef="idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfMjUw_c9527381-381e-4ad0-9294-ab5e15d15a24">5</ix:nonFraction>% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC (the &#8220;AHMC Note&#8221;) for a principal amount of $<ix:nonFraction unitRef="usd" contextRef="ie243ca1688274f6687245974580a1e3c_I20201031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfNDc4_23f6076f-89ee-4c38-8f77-4273559d33a1">4.0</ix:nonFraction>&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is <ix:nonFraction unitRef="number" contextRef="ie243ca1688274f6687245974580a1e3c_I20201031" decimals="INF" name="ameh:FinanceReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfNTkw_56621a22-a30a-4210-b8d0-a890a31f09c8">3.75</ix:nonFraction>% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of June&#160;30, 2021, the total principal of $<ix:nonFraction unitRef="usd" contextRef="i212b0ef9733140d5b7611df1f124ec26_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfNzg0_e5289296-669c-4aa9-b458-621dc04697ec">4.0</ix:nonFraction>&#160;million remains outstanding. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_67"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RleHRyZWdpb246MThiMmVmZjQ4NWExNDNkNDlmNjhmODE1YzQzNThjMGVfMTQz_55422a86-2997-4259-90e2-6154becdc89d" continuedAt="i2d4c850ccf1940a68450319a88c9d8d5" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i2d4c850ccf1940a68450319a88c9d8d5"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RleHRyZWdpb246MThiMmVmZjQ4NWExNDNkNDlmNjhmODE1YzQzNThjMGVfMTQ2_cd574581-2536-4b69-8b84-8fce01ea53e1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMS0xLTEtMS0w_f4ef969d-ade8-4134-9e3b-775c75491d1e">11,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMS0zLTEtMS0w_6aef4056-8557-4381-bb5a-f880873386e6">9,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMi0xLTEtMS0w_09de157c-2b51-4785-bfdb-e9674278fe69">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMi0zLTEtMS0w_b2980a9c-1088-4c9f-b93e-086ff5fea75e">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMy0xLTEtMS0w_356140eb-f5d9-465a-ac37-5e26e94d1fd4">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMy0zLTEtMS0w_66d3e272-54f6-43bd-9571-7938b732778b">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNC0xLTEtMS0w_e3289567-4ecf-4fb4-8351-2aadada098cf">962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNC0zLTEtMS0w_baa0705c-8f53-417a-8364-bd7cc2664f84">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNS0xLTEtMS0w_f11e4739-12c6-41f5-9729-d93dc54aea06">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNS0zLTEtMS0w_08ec3810-193b-4eb6-a58d-1e14308d0b8c">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNi0xLTEtMS0w_55041409-9bd9-4140-910c-e5df0487caf6">29,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNi0zLTEtMS0w_5e0ff64e-b6e9-4d5d-b1f0-859369802af6">12,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNy0xLTEtMS0w_dc98052f-4137-4cf6-bf64-7c42f1beb79e">6,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNy0zLTEtMS0w_524b46fb-67ba-455e-a618-bede00501b29">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfOC0xLTEtMS0w_72cfade9-69cb-4fa7-a291-c199eb26c344">53,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfOC0zLTEtMS0w_08316ff9-8d77-49cc-893c-d00848aab0cb">36,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_70"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RleHRyZWdpb246ZmM5YzEwYzlmNDY0NDFlNzhjZDJjOWM0MmUwYzY0ODJfMTA4_3bc9432a-8630-4703-ae68-b65ac7286739" continuedAt="ic118732433f0479f90500bdae2b3d0ad" escape="true">Medical Liabilities</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic118732433f0479f90500bdae2b3d0ad" continuedAt="i50e5d2b639f9477fb6f810b8d990f7c4"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RleHRyZWdpb246ZmM5YzEwYzlmNDY0NDFlNzhjZDJjOWM0MmUwYzY0ODJfMTEx_10c1ccad-9bef-4d8c-8808-e751fac147b3" continuedAt="if59db062f121422b8fe1d75ec6c9152d" escape="true">The Company&#8217;s medical liabilities consisted of the following (in thousands):</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><ix:continuation id="i50e5d2b639f9477fb6f810b8d990f7c4"><ix:continuation id="if59db062f121422b8fe1d75ec6c9152d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMS0xLTEtMS0w_342bfe4e-8413-43b4-9390-d32863d1e567">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMS0zLTEtMS0w_ca586009-e08c-4de6-b5d9-72da0cc03c94">58,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMy0xLTEtMS0w_571e2112-6ca3-408c-b075-1f87fb1a9ab1">158,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMy0zLTEtMS0w_f419b2b2-bc6a-419e-92d7-a41a51e45b8e">165,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNC0xLTEtMS0w_3d536833-5b5e-4c9d-896a-49c94e0b2967">1,293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNC0zLTEtMS0w_7378b602-c7cd-4bad-9dc6-7016b9923792">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNS0xLTEtMS0w_499b05e0-b1aa-414c-931b-57e8c05f2768">157,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNS0zLTEtMS0w_ae8a5124-8a19-4562-a64b-740fb93cb23a">165,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNy0xLTEtMS0w_0ccb6d2a-41c5-4f8d-b5b0-f91554adaf52">103,302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNy0zLTEtMS0w_0326d7df-3859-40b1-9989-d16600fd9635">97,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOC0xLTEtMS0w_37db14e7-166e-470e-8e4e-a77ef1405859">45,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOC0zLTEtMS0w_9fd48fac-d424-4a77-aa1d-f673f6fc7c16">57,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOS0xLTEtMS0w_16c54efb-03c5-40be-88b8-0862f1cf0e31">148,432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOS0zLTEtMS0w_8438ebaa-9c28-4849-885a-45eb4bbe8283">154,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTAtMS0xLTEtMA_1195844d-62c9-43e1-8878-54567c650955">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTAtMy0xLTEtMA_77dc34a7-a435-4b7d-96b9-f3dc1bd3a925">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTItMS0xLTEtMA_e35d1838-347b-496d-b092-e00ad8c500d1">59,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTItMy0xLTEtMA_59eea286-c5de-4e63-87d9-158d74480c5d">70,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div id="i1123c47dec074269b382540ae6206c28_73"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDM_f454b9ab-48f0-4ddb-9d2c-c19da402d062" continuedAt="ic29119764c464c828f7ecd2cf3072b96" escape="true">Credit Facility, Bank Loan and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="ic29119764c464c828f7ecd2cf3072b96" continuedAt="ib53557f547f54f27bd65809eaabe1796"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA4OTk_538edce9-13bb-488f-ba6a-f8644742838d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f01cf6f2e04623bfa74a1b1dc2f34b_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMi0xLTEtMS0w_78c6ead2-85ce-439a-b4af-cbbc73e9404d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b65d59e8cee4de190ada04f5c5338aa_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMi0zLTEtMS0w_e3f2eda3-dd08-4c1b-aa38-47e98f74f100">178,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98420e28f93c487e9091b0de8ef73848_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMy0xLTEtMS0w_23116e57-a3d9-475b-9686-2bfe3ac0d209">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25dc88dcb88941818003f295e6eaf494_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMy0zLTEtMS0w_01486cc3-1767-413c-b1f4-8297e8798899">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19976568f554a309dc818b6740971de_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNC0xLTEtMS0w_216a7ff9-5066-4844-b1a9-6ccbe031115e">7,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa899988e7284ac8a1326212ba5333ff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNC0zLTEtMS0w_1981d838-4e71-460a-b2ae-890bd801a4e7">7,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92d7c50296e4adb9c6f07c18bd63da6_I20210630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0xLTEtMS03OTAy_ce81ea9b-b289-44f1-9e49-f350a66ef053">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeafd2d681174371ab57d8e8d2bd170b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0zLTEtMS03Nzky_babc427c-7c78-4936-a84a-077595613ae2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0xLTEtMS0w_794c82c8-be50-4e76-bb0a-6a10b3f42519">187,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0zLTEtMS0w_c81e22c9-981c-4438-9804-2c5544ac2922">245,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNy0xLTEtMS0w_90d2e029-1e56-45dc-b66b-80e17615dd3b">205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNy0zLTEtMS0w_c9cc1bde-bf69-4ccb-b424-c689b873aef9">10,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfOC0xLTEtMS0w_e251f3c3-576b-4dbe-9d04-b5afe535cbc3">4,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfOC0zLTEtMS0w_83f13b56-60cb-4f0a-8d35-bba62cdff075">4,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMTAtMS0xLTEtMA_e093f289-69a4-4156-b6da-b5a5414ec124">182,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMTAtMy0xLTEtMA_0d81fdb6-b352-4e31-ae63-7cbf4da04bc4">230,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDU_486d2ded-c438-483c-b5d6-5f8dfddf3de6" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfMS0xLTEtMS0w_46fedbe8-6c7f-42a8-8f04-4650abf5fdfa">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfMi0xLTEtMS0w_189469f8-f14f-469e-be22-af3b7b3751f1">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfMy0xLTEtMS0w_5e9faa3c-6e76-47cf-8fb8-02a6d701902d">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfNC0xLTEtMS0w_5dbc214a-af36-41ff-9073-27cbc9413cdc">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfNS0xLTEtMS0w_86974d73-3610-4ff3-842f-2d306a7aef52">186,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfNy0xLTEtMS0w_44094640-35c6-479b-ab12-74a5ee20ced6">187,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ib53557f547f54f27bd65809eaabe1796" continuedAt="ieb365eb889dc4bbd9f117f733637b907"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the &#8220;Credit Facility&#8221;) with Truist Bank (f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders. The Credit Agreement provided a <ix:nonNumeric contextRef="ifd17107a4e4f4d0db7e8fffc934a9f43_D20190901-20190930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDY_0d1c2006-86e3-4e3a-a605-1c313579ae85">five-year</ix:nonNumeric> revolving credit facility to the Company of $<ix:nonFraction unitRef="usd" contextRef="id5fb36211de84d458695b36c94e44b09_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTU1MA_1999af79-890e-4e0e-9a42-4037120068c9">100.0</ix:nonFraction> million, which includes a letter of credit subfacility of up to $<ix:nonFraction unitRef="usd" contextRef="iaaa02904edf64fd19eb45f52d4bfd62e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTYyNw_e72a3414-f28e-491c-af38-360c4315d00d">25.0</ix:nonFraction> million. The Credit Agreement also provided a term loan of $<ix:nonFraction unitRef="usd" contextRef="idf95943f3b45491bb70c64e65514db5b_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY4NQ_3ea4a04a-5220-49d9-a4a5-1784ef948039">190.0</ix:nonFraction> million. Amounts borrowed under the Credit Agreement bore interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between <ix:nonFraction unitRef="number" contextRef="i99dcab7c36f94052a58f43fb2416b256_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5MTM_4e9ea5a6-562d-44f3-94de-5125c9ffae06">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ia9b7755ce16d436fb858171518d6db85_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5MjY_2f17548f-eaf2-4297-9246-8937a8ff1f6a">3.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between <ix:nonFraction unitRef="number" contextRef="i9928b035437a466c8063602b61157c72_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5NjU_74929f38-2185-41bb-9c36-c475d9544fec">1.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie3689d97acee409f811f71e5d018b255_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5Nzg_b5e96d2d-90a1-4376-bb28-4eeda38e934b">2.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement and, together with the Company, granted the Lenders a security interest in all of its assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Wells Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a <ix:nonNumeric contextRef="i37ce176ad8164bbda4a85cdb5c1abe96_D20210616-20210616" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjU5NzA2OTgyMjE2Mw_f1a262f7-f86e-44fb-9e45-e7be20f89860">five-year</ix:nonNumeric> revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $<ix:nonFraction unitRef="usd" contextRef="iaecc589e663140efa9bdde31ca9fc76e_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjIzNQ_029e6bf4-443d-4a57-a104-0a5e80bc38aa">400.0</ix:nonFraction> million, which includes a letter of credit sub-facility of up to $<ix:nonFraction unitRef="usd" contextRef="ic3fe84306a564af99059a846dc55527f_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjI3Mw_17a8c2a3-dce3-4bee-b746-ebc7925fec93">25.0</ix:nonFraction> million and a swingline loan sub-facility of $<ix:nonFraction unitRef="usd" contextRef="i61695e4f773245978fcdb79b78a5f4e1_I20210616" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjI4Ng_40e5e136-3ccd-4888-94cf-8a5367f76dd4">25.0</ix:nonFraction> million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts borrowed under the Amended Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters LIBOR01screen page, adjusted for any reserve requirement in effect, plus a spread of from <ix:nonFraction unitRef="number" contextRef="i4ad3cbb03fee4c6d849f2b2c7097f926_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMwNg_fa95f176-36bb-4b0a-acb0-c5eba2ee9eb0">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i30999fd4c670468fa0ac9bc1446026a9_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMxMw_61d0ea5f-0636-4c74-8de6-b1d2f8de57e3">2.5</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of <ix:nonFraction unitRef="number" contextRef="ife4010452d164857b9e426a42b03e2fa_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMxOQ_e91f66c7-819e-40b3-a3bd-1696f135e3ae">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ief20ee6c5c2c4b5f9ca95cdf09203cf9_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMyNg_ed8bc075-35be-480d-9700-bd748aa945ea">1.5</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of June&#160;30, 2021, the interest rate on Amended Credit Facility was <ix:nonFraction unitRef="number" contextRef="i25174623ac76453388419ec64c9378b3_I20210630" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfOTg5NTYwNDcwNTUwNw_4e47a3b1-cde8-4356-8b23-3d2fc9d42475">1.65</ix:nonFraction>%.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $<ix:nonFraction unitRef="usd" contextRef="i7ba990e321754287bccd67c80d254cf2_D20210616-20210616" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMzMg_db86506d-c6f0-4e64-9306-6b53be42cea1">50,000</ix:nonFraction> and an annual facility fee of <ix:nonFraction unitRef="number" contextRef="ife4010452d164857b9e426a42b03e2fa_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM0MQ_8e420527-b10d-4419-87de-9c20cd9f22d5">0.175</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ief20ee6c5c2c4b5f9ca95cdf09203cf9_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM0OQ_b4135bfa-385a-4a76-ac0d-2183ae62aa91">0.35</ix:nonFraction>% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to <ix:nonFraction unitRef="number" contextRef="i2864d7724e914818863fb152ae703113_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM1Ng_c9987859-4f04-4bf3-8f11-aa67230a0357">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i75bb15e4135844e0b0a19cffc0d0a363_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM2Mw_f7ca4477-9e1d-4617-93a5-bd5ea381d56d">2.5</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="if75078b89e36407a8a184d96312607c7_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="ameh:DebtInstrumentNumberOfKeyFinancialRatios" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNDkxMQ_e86e00bc-a46b-44c5-8757-2853863b998b">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="if75078b89e36407a8a184d96312607c7_I20210630" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTA2MQ_f4e04dcc-3c89-4adf-9c33-799e03c01f98">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter.  The Company must maintain a minimum consolidated interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i5e7f468af62c460593057d3940ee2131_D20210101-20210630" decimals="INF" name="ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTM0Nw_9031d6e7-e57a-4d14-86c3-e21d543f12d9">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i00a33c8eaad843f0bed2823a082ba35f_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTYxNg_043fe7d6-f1e7-4dc5-ba3f-2dedbd0825f1">6.5</ix:nonFraction> million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i25174623ac76453388419ec64c9378b3_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyNTI5Nw_e3a3e5de-69fb-4a33-9191-d816e9ea0f09">0.7</ix:nonFraction>&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ieb365eb889dc4bbd9f117f733637b907" continuedAt="i5f6f5bc21ad045c187fd24a389bd03f1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At June&#160;30, 2021 and December&#160;31, 2020, the unamortized deferred financing cost was $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTk0OA_91d15889-659c-44ce-861d-27eedda53856">4.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTk1NQ_f51d90e3-d27f-4e3a-a703-045fde68a4e1">4.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i65ada19782cc4566a752ee378270990e_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjA3OA_6775acb7-08b2-4b64-9a2b-0a555a38fe2f"><ix:nonFraction unitRef="number" contextRef="i982a35d5c552427f8707f6f7c52c8456_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjA3OA_680543cc-c7df-4e4b-b320-1993e2eaa6ec"><ix:nonFraction unitRef="number" contextRef="i3fbd15394d2c4d85868b44d4b1890872_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjA3OA_b4e58102-0d9f-41fb-a657-df47ad639acc">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="i1423c5795a1b4d749457b1fe689f6082_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjM3OQ_e7968fac-118f-4e2b-b7d4-101c428bada7">6.4</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i5dac28efd63c445d90c56c1473b525a9_D20200703-20200703" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjQxNQ_5a184d45-7f7f-420a-93ad-9df0eba134ab">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i7340fb66912c49d688f6edcdd3993379_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjc0NA_2ed946de-c102-4566-9b87-5c0e73c0a7b5">6.2</ix:nonFraction> million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i89b4dbef7f2e489f89f33ea163fc5c46_D20200703-20200703" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjkwNw_757c3179-9682-434a-8dce-44142012efab">1.25</ix:nonFraction> to 1. <br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="ife40aedab12e4720ba1ac1505ee27d57_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzA5OQ_36ac2dff-aa56-4467-8dfa-480527c262f6">0.7</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i6d1b698d8e0c455ba42b48cbac36f252_D20200805-20200805" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzEzNQ_a8c85ac9-2f0c-4f70-b3cb-2ba2ef7ab2c0">0.30</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="id7fb86722c074f2eafdd868708d994e2_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzQ3NA_5a658109-a771-4496-8ae9-a0876f503ba1">0.7</ix:nonFraction> million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i7f73410dbab04d0b9949a4de8859b032_D20200805-20200805" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzY0OA_1be08bb8-b0e2-4e3d-a562-1aae730cd21e">1.25</ix:nonFraction> to 1.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $<ix:nonFraction unitRef="usd" contextRef="id96f1aad698b48e38639c8ec1d301f92_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzgxNg_e64d085d-a784-4f79-8080-9dda8c18a347">0.7</ix:nonFraction>&#160;million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i63d7d91e880042f0a4f362f355b812b5_D20200727-20201231" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzg1Mg_f5ddbb7c-ac2f-4d15-a967-f95cda721851">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i7cd4cea3e6d54191b5d35c584c4abfc5_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODE4MQ_a44386ee-b0a0-4046-a6e4-a9ae6eee3fdc">0.6</ix:nonFraction> million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="ib3215aa218c043138dfbec866e107ea5_D20200727-20201231" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODM0NA_4fb41228-0007-41e9-9538-d7fc824b9cd6">1.25</ix:nonFraction> to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $<ix:nonFraction unitRef="usd" contextRef="ie5a28537ca584fb4b0ee10b7408d0fbf_I20210430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTA5Njg1OA_d9214a3b-e8ed-469e-85d5-a49a308ff657">10.7</ix:nonFraction> million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be <ix:nonFraction unitRef="number" contextRef="iaa84fde67bb645cd91b5367196c1f03a_D20230101-20231231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjU5NzA2OTgyMjEzOQ_623d357a-0189-4d0f-9944-c9ab40555ad4">2.0</ix:nonFraction>% per annum in excess of the LIBOR rate. As of June&#160;30, 2021, the balance outstanding was $<ix:nonFraction unitRef="usd" contextRef="i63fd321ddf634615addc134b27259f9f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyNTEwOA_412a39ae-27da-426b-bc94-2ec73a1e7a78">0.1</ix:nonFraction>&#160;million. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i63fd321ddf634615addc134b27259f9f_I20210630" decimals="INF" name="ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjU5NzA2OTgyMjE0NQ_644e6f2e-af90-4bf5-b66b-7a77c96312fa">1.25</ix:nonFraction> to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2021 and 2020, was <ix:nonFraction unitRef="number" contextRef="i5e7f468af62c460593057d3940ee2131_D20210101-20210630" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODQ4Nw_d44221f2-b306-411a-8a9d-dd43431678a8">2.31</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i625945a27da84fc6aa443add380d4c00_D20200101-20200630" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODQ5NA_b64cf31b-b1a0-4f42-a8e7-82a14a570e31">3.93</ix:nonFraction>%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2021 and 2020, of $<ix:nonFraction unitRef="usd" contextRef="i144a76c21edf4613a46ce3728e38457d_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODgxNQ_e068b819-7f62-4b3a-8148-a55a21678c50">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e7f468af62c460593057d3940ee2131_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODkyNA_fe77fba9-31b0-4046-929d-a09eba27ae46">0.3</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ib533cc59686046eeae2f5f232fac7f9a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODkyMA_1f6b1b52-e45f-4d20-bfe2-a03215706ee9">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i625945a27da84fc6aa443add380d4c00_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODkzMg_d7c6dfc0-5119-419b-9450-133370ff67b9">0.7</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i5f6f5bc21ad045c187fd24a389bd03f1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to decrease loan availability to $<ix:nonFraction unitRef="usd" contextRef="i737b37c63ad94a628ff69100f7a2c406_I20190910" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODg3NA_89ffb8f4-9691-4ccd-8e4d-d387cb924d85">4.1</ix:nonFraction> million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#8217;s board members, totaling $<ix:nonFraction unitRef="usd" contextRef="i192b7b8b3d8049bf9d6f9d1c1dc9c763_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfOTg1OQ_ea5da6aa-037f-48ea-8bb9-9255644bdb1d">14.8</ix:nonFraction>&#160;million for the benefit of CMS. In August 2020, the irrevocable standby letter of credit was  released by CMS. As of June&#160;30, 2021, there were <ix:nonFraction unitRef="usd" contextRef="ib146802ffc804944934f116ce84a41c6_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LettersOfCreditOutstandingAmount" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEzMDQzNQ_981d320f-3e56-411e-9f10-19f405ce5321">no</ix:nonFraction> outstanding letters of credit and the Company had $<ix:nonFraction unitRef="usd" contextRef="i94b5a906722e4e3d8e26a50cae38e0e7_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEzMDQ1MQ_6e6d5f75-125d-4fd1-a6ae-dc0116055997">25.0</ix:nonFraction>&#160;million available under the Amended Credit Facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i8a509d20ed71452e9deba1a12c4e6e19_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTAxNjA_564a7e3a-d29c-429c-a881-3f0a7cf499b7">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i750613cd3f5f46ae8a081a28e372e80b_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDc_c52cc0e9-1c7f-4402-a030-694afa8e77ab">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i2155db54a6e94fb3ba14b735aaf78990_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA1OTc_f32fa53e-49ad-4cb2-b19d-9918ec830e42">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i4ae2fb1304c141cd8ca7616ff44b486d_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MTE_321ffc6f-c552-4f92-a2da-1048d6838fff">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_79"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTc4OQ_aeb12d88-ea12-4b31-8ce1-dc84f5d40a94" continuedAt="icacefba83da74fe3b6a32d8e78db3aa0" escape="true">Mezzanine and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="icacefba83da74fe3b6a32d8e78db3aa0" continuedAt="ib4114266fb654b8b87ebb5e64acdb30e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares are not redeemable, and it is not probable that the shares will become redeemable as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringPeriodSharesMerger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY4Mw_43658e34-d836-4b34-beb7-6a81652297c0">143,052</ix:nonFraction> holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned <ix:nonFraction unitRef="shares" contextRef="i3bebc359d95142548ffc5a9df83139c8_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY5MQ_73848690-c100-4a04-b097-38842a3613e1">10,885,732</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if4e562e2f0f644e696c375ad1dea58ee_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY4Nw_8aecc3be-ee1a-4d39-9920-376a65c081ff">12,323,164</ix:nonFraction> shares of ApolloMed&#8217;s common stock as of June&#160;30, 2021 and December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. During the six months ended June&#160;30, 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTYxMg_675bd86a-3590-42fd-9107-dfad589ea977">34,158</ix:nonFraction> shares of common stock to APC as a result of APC exercising its warrants. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2021 and 2020, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="ia10f8b79fb1344b7a87ded9035353132_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTg5ODU_232a8de4-7231-4cde-8828-dfd5a5cfe8dd">19.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i320308565cd449e19c679138f90e503b_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTg5OTQ_03896de5-5c50-41a8-96c9-b556ab6f6b1d">19.6</ix:nonFraction>&#160;million, respectively. During the six months ended June&#160;30, 2021 and 2020, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i0408c582d1c8484f98671f80a6529d71_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY5Ng_63c233e2-8769-453d-a37e-604e9adc0f62">19.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3bc4e2285e0444884aee89b77334ea4_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTcwMQ_c588a0fc-9e37-4b81-923d-b256a551401c">29.6</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib4114266fb654b8b87ebb5e64acdb30e">During the three months ended June&#160;30, 2021 and 2020, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i5b0212d54ced47e0b843d969230e7056_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTkwMTI_1b904a13-41a1-4262-badd-520af5d90a45">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6196e45da98644ffb45f1e5043cc3bb4_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTkwMjg_01fb767d-589e-42a3-b815-e33f7522402d">0.6</ix:nonFraction>&#160;million, respectively. During the six months ended June&#160;30, 2021 and 2020, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i8a82fbc742c24e8287ecd7cb5cc7cbbb_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTcwOA_97498ea5-e679-4863-b78b-9a41591ccf6a">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5baedd233dd54d5f839fd76b1cae7d1c_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTcxMg_ebbbc221-1416-4aeb-8862-e094165063e8">0.6</ix:nonFraction> million, respectively.</ix:continuation></span></div><div><span><br/></span></div><div id="i1123c47dec074269b382540ae6206c28_106"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzU_a577a821-507d-44a7-98a7-f39ca02ad93a" continuedAt="idc87b810dad2460bb56344daecc0c861" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="idc87b810dad2460bb56344daecc0c861" continuedAt="i2798d5ba65d6472bb2b3c56722da5af3"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzY_0cfc0bc4-7783-4579-936a-d137bac2812e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and six months ended June&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3ac3a0d777469a946e0a10c6595964_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzEtMS0xLTEtMA_4df1b13e-1fc6-4ca1-b1b3-e3e898c5ae50">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a1a8b237d3a4bf0bf360bf0964d3f6d_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzEtMy0xLTEtMA_e4a0f9a2-fb94-456d-98a2-7230552fd8fa">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1008be7007d14a7f8231a7aa65e1e551_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItNS0xLTEtMzI3OA_04376fd3-4fdd-48bd-a1b8-20328b9777c1">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5adbba48d4f44cf399a195dcbb2b1cce_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItNy0xLTEtMzI5MA_bd9a4054-edfc-4906-8560-5201ae3e4be0">972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d6dddcc345e4f90952f2a96948a910b_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItMS0xLTEtMA_634262b6-f707-417b-8c8b-a67e620b58ca">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a70b05372d474ebacf388a6848532b_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItMy0xLTEtMA_e6a3b747-e00f-4a62-a00f-5317404c6f7a">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb49c95ec604beba965acb646442a78_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzMtNS0xLTEtMzI4Mg_1163750e-9a05-41f0-88e5-2ff8e87333ab">1,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a3b4c371be499a9e024cfd590d0e4a_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzMtNy0xLTEtMzI5NA_d5e80398-fc16-454d-85a7-ddcc78eb911f">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzQtMS0xLTEtMA_ef98fbc2-dba9-4a91-89ba-c838a5bea9ca">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzQtMy0xLTEtMA_4454b3ee-b756-49f7-a671-89892cb9e005">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzUtNS0xLTEtMzI4Ng_4197684a-7e70-4b2c-afbf-892ef4917f60">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzUtNy0xLTEtMzI5OA_3c378dc5-6732-4950-b2ec-9997ed55982d">1,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2021, was $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NjI_1ee8859d-6313-401f-a958-363978f600f5">8.0</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzc_386f30c8-f98c-4ea9-a178-afa4f68b33f2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtMS0xLTEtMA_4f17f1dd-48bb-4bd3-afd2-5fffc3a38038">725,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtMy0xLTEtMA_87aa4ad3-39f1-45ab-b7d9-cf8a3eaf6746">13.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i77783b1764504ea0907a1d3ac4b0ada2_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtNS0xLTEtMA_68c3b0c8-6cb1-4450-bb81-82a44ad33e5e">3.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtNy0xLTEtMA_f76b1ad6-df46-4600-8f2a-628be9f0ab16">3,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzItMS0xLTEtMA_70dca5ea-84f0-496c-b379-83cc71f125e1">24,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzItMy0xLTEtMA_76ad2d26-de66-4c26-843f-d9136aa68032">23.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzMtMS0xLTEtMA_12a59199-46e5-406f-bcc8-325b5996a2d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzMtMy0xLTEtMA_2732eab0-eb1d-43ac-9e9c-bf60405bc42a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzQtMS0xLTEtMA_c3ca51a5-4bfe-4b16-963c-1a300049c2e5">9,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzQtMy0xLTEtMA_b0cabd8e-e742-4b45-8c38-bad880c19deb">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtMS0xLTEtMA_1cc7fbb4-69ef-492b-88e7-05e2deb721b9">740,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtMy0xLTEtMA_a77b61c8-37b0-4bf5-8ba8-9582be88a13c">13.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtNS0xLTEtMA_655faac2-c169-4ded-8590-489b4d9fbc14">3.35</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtNy0xLTEtMA_9be8dde8-a829-432b-9bfb-d11ff3fed0fa">36,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtMS0xLTEtMA_f911cd72-3d76-4a68-927c-61c6d71d87df">529,638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtMy0xLTEtMA_9fd5559b-05c3-4e23-9534-3d56803618d6">8.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtNS0xLTEtMA_23d12d55-9b07-470f-a7c3-fa7cdc11f42d">2.14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtNy0xLTEtMA_1d6ffa9a-9622-4ebd-8874-66286c9de2bb">27,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzYzMg_12a59199-46e5-406f-bcc8-325b5996a2d5">no</ix:nonFraction> stock options were exercised. During the six months ended June&#160;30, 2020, options were exercised for <ix:nonFraction unitRef="shares" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzcyNg_bd648b63-f22a-42ca-9a3f-e0d2d3f64df8">120,000</ix:nonFraction> shares of the Company's common stock, resulting in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ic9e1ac26256349d8a8b6660fb3b0cf14_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzgwNg_d6c92065-c348-476a-af7e-7c01f1bc0de7">0.3</ix:nonFraction> million.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzg_f4fccfaf-5309-4ae3-b1b8-2aaadc9d73d8" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzg2MQ_4956ec50-6d85-4410-83bf-c3d36ba7974d">24,437</ix:nonFraction> stock options with a vesting period of <ix:nonNumeric contextRef="ic54f87af0d7b41e38ac47a6d994ecf51_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzkwMw_cc211d95-271b-4238-bc0b-de3bc0387d12">two years</ix:nonNumeric> to certain ApolloMed executives with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3f89ff410504d43a409f8a0a4d4dc9b_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NTQ_16d26415-d375-4e4d-b0f2-6cba49994590">23.24</ix:nonFraction>, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzEtMS0xLTEtMA_0e3e1bec-e675-4d1f-ac01-c5f63642331a">3.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzItMS0xLTEtMA_ef11b862-5af7-4b3e-87d9-e1ab5d3c80b0">81.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzMtMS0xLTEtMA_57b4fce6-cf01-4cb4-847b-e37b07a9d0a3">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3f89ff410504d43a409f8a0a4d4dc9b_I20210630" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzQtMS0xLTEtMA_f9149c83-d06b-4189-83c3-aa4cfd6621b6">12.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzUtMS0xLTEtMA_7bac343b-6549-4313-af38-98eb6a16f9d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzYtMS0xLTEtMA_dd16f7c5-dafb-43b9-aed8-a440f0df33d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i2798d5ba65d6472bb2b3c56722da5af3" continuedAt="ie8be0873e63048a5ad70b0039bad3fb9"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the six months ended June&#160;30, 2021, the Company granted restricted stock awards totaling <ix:nonFraction unitRef="shares" contextRef="i05b5e17ec6f54ce9b949906a91fbc7d6_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzk4OTU2MDQ2NTI3Nzg_d8b2c4e9-30ae-444c-a029-16eb57ad3a4e">150,130</ix:nonFraction> shares with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i05b5e17ec6f54ce9b949906a91fbc7d6_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzk4OTU2MDQ2NTI3ODU_42929246-131e-4bff-a959-4e33b23e8117">24.16</ix:nonFraction>. The grant date fair value of the restricted stock was $<ix:nonFraction unitRef="usd" contextRef="i12dc265133f44d93bfbea364c99e892e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzk4OTU2MDQ2NTI3OTI_02976472-1ab5-4646-867a-3e77cdc2de35">3.6</ix:nonFraction>&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzExNTQ0ODcyMDk0NDMx_f69dfb9e-740f-4b1d-890a-b5aa38e16317">one</span> to <ix:nonNumeric contextRef="i5d70de54c6ef4853af97ba0be0d711b6_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwODI_9b8bf42f-2c70-4766-9237-2a204f1ae4d7">three years</ix:nonNumeric>. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwODM_f69cd960-987d-490b-992c-41dea5ce3b27" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtMS0xLTEtMA_61321177-2fda-4ccb-b439-b47f47ec74bd">1,878,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtMy0xLTEtMA_c320f09f-b521-4a50-9f80-99e96ebec2dc">10.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i77783b1764504ea0907a1d3ac4b0ada2_D20200101-20201231" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtNS0xLTEtMA_3d5392d8-2bb2-481c-83cb-45a4b1857ebe">1.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtNy0xLTEtMA_ab5f26ab-60a7-4017-9c64-34993a70f872">14,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="ameh:NumberOfWarrantsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzItMS0xLTEtMA_7813d389-e684-4cb9-b8e6-706ff1ba2f86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzItMy0xLTEtMA_0edc28e7-08f4-4542-bf84-c500f56e338b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzItNy0xLTEtMA_e17d9ad7-148e-4637-80c3-e12522b42c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:NumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzMtMS0xLTEtMA_13fa9510-d1c2-4f31-9646-dcf5ca0fbc0b">474,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzMtMy0xLTEtMA_3413229a-491e-4d07-9406-de15109d1066">10.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzMtNy0xLTEtMA_f7be38c0-9d02-49da-acd0-e005dbe52f52">8,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightCancelledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzQtMS0xLTEtMA_e5afccd9-cee0-47a5-8643-d6aa88859055">17,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzQtMy0xLTEtMA_2c5860d8-b2d9-4877-a9df-8d398f22d752">9.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzQtNy0xLTEtMA_ef8c3042-9156-4c30-b922-d94b6c4a3b75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtMS0xLTEtMA_81103bdf-de1b-4fe2-b02b-1743169f9f06">1,385,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtMy0xLTEtMA_ff01143a-d664-4191-8970-471de6d25109">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtNS0xLTEtMA_5bc226a4-44db-4dc2-842b-97a919c33065">1.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtNy0xLTEtMA_765944c5-6e86-4247-88ae-d045c9cc4f22">72,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i434a1fa4730047f5ba3436f45a45cd10_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtMC0xLTEtMA_72af1f0e-0d56-4f3d-a104-759b13915086">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89c8731f72584484a875a2c7da57e7d4_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtMi0xLTEtMA_9fb0c4fe-4282-48d9-9a5b-9a612ebb7998">710,756</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i89c8731f72584484a875a2c7da57e7d4_D20210101-20210630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtNC0xLTEtMA_b86edbb8-45a5-4dd0-82ca-ed6cffbee69f">1.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i434a1fa4730047f5ba3436f45a45cd10_I20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtNi0xLTEtMA_e19184b7-cd6e-4dbc-92cc-754add327a07">710,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i434a1fa4730047f5ba3436f45a45cd10_I20210630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtOC0xLTEtMA_cbd590e9-3334-454e-98af-181f24eebad5">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i155643ff74b34c9b8cc8ec0293852ad6_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItMC0xLTEtMA_6c7b8ae6-5cab-48ad-b8f9-cc4a8c921299">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4833707bf8a34d11992ba230abca2c89_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItMi0xLTEtMA_83adc71c-4a90-4a1c-9b07-6329ea918c83">675,061</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4833707bf8a34d11992ba230abca2c89_D20210101-20210630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItNC0xLTEtMA_515a5819-6bc6-46f8-99a3-40ab45465bc7">1.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i155643ff74b34c9b8cc8ec0293852ad6_I20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItNi0xLTEtMA_8becc912-ce66-4b06-8090-f1d9e32ee534">675,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i155643ff74b34c9b8cc8ec0293852ad6_I20210630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItOC0xLTEtMA_a7697400-4914-41df-91e4-25eb5c666309">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  <ix:nonFraction unitRef="usdPerShare" contextRef="i2a6a7f97a8e146cd980c88fca3b2ab01_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM1MTVmMDIzNTIyYjRhNjRiNGJhMDhlYzFlMTBlNmY0XzEwOTk1MTE2Mjc4NDY_97a02b5d-19ad-4be9-b32a-9f3aa15ddc52">10.00</ix:nonFraction> &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="ia1f5a0f1507848fe8995404c6c8e603f_I20210630" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM1MTVmMDIzNTIyYjRhNjRiNGJhMDhlYzFlMTBlNmY0XzEwOTk1MTE2Mjc4Mzc_cf2978d7-5125-4900-bb35-a29fc83f9b33">11.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if811abb97e1d4b6aac19545793d3feba_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtMi0xLTEtMA_e6de2ba5-dc0b-4d04-9aa6-27f142b54fb8">1,385,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if811abb97e1d4b6aac19545793d3feba_D20210101-20210630" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtNC0xLTEtMA_f268e74f-328a-4eb9-80ea-ee3d8aa1cfee">1.44</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1f67bbbdb42498ca966599acb11dff3_I20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtNi0xLTEtMA_1afa6390-f201-4b84-8cda-9cb6b7fbb946">1,385,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1f67bbbdb42498ca966599acb11dff3_I20210630" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtOC0xLTEtMA_fb033c87-d629-410e-b095-852eaf72cd62">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie8be0873e63048a5ad70b0039bad3fb9">During the six months ended June&#160;30, 2021 and 2020, common stock warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MjI_0e42bdfa-6ee3-44fc-898b-88c579fafbb9">474,506</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MjY_27f5b116-ee39-469a-82a7-e58f2126e8c8">273,900</ix:nonFraction> shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MzA_18163a09-b6ad-4959-af17-8037ffe3de94">4.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MzQ_a15ffc45-66b6-420f-b9e5-8b2389a16662">2.6</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i446e0195307d4b82b3e9a4cb39c02c68_D20210101-20210630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NDY_703e082c-0eec-42c0-870b-df7ba1b92055"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3235fb88c784a87a0e286f32316d340_D20200101-20200630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NDY_cc7a82a8-0379-4ae8-b981-ed6931bde682">9.00</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="icec95d5e3a26463e80da6e3b8af4d420_D20200101-20200630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NTA_c4dfc018-5080-4509-86d8-04b121eda52c"><ix:nonFraction unitRef="usdPerShare" contextRef="i408bcca588524bb39b519aeebdc4cac2_D20210101-20210630" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NTA_f6f5576d-d296-49a7-a457-5faa792e191b">11.00</ix:nonFraction></ix:nonFraction> per share for the exercises during the six months ended June&#160;30, 2021 and 2020, respectively.</ix:continuation> </span></div><div id="i1123c47dec074269b382540ae6206c28_85"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMzgzMw_3d5b63d5-2d64-441e-8a11-c4f9868380eb" continuedAt="ifdb3554b1e1347a4821f97a43d12909b" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ifdb3554b1e1347a4821f97a43d12909b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS. The guarantee generally must be in an amount equal to <ix:nonFraction unitRef="number" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="ameh:PercentageOfFinancialGuaranteeBenchmarkAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMTc2NQ_b3d697e3-7c15-4b10-93d9-495b10b7d9ba">2</ix:nonFraction>% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. In August 2020, $<ix:nonFraction unitRef="usd" contextRef="id9eeadfa628b409395cec8d188e856a9_I20200831" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMTg1Mg_e10004af-a72b-433a-8aef-d71d7532d2c8">14.8</ix:nonFraction>&#160;million of the irrevocable standby letters of credit were released by CMS and $<ix:nonFraction unitRef="usd" contextRef="ia8ce5a693324465ebfe2a470a3639175_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMTkyNQ_eb4c0dc1-ac13-4b44-b36f-9ce8eef86baa">0</ix:nonFraction> million remains outstanding as of June&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $<ix:nonFraction unitRef="usd" contextRef="ie0a4be6b433c49f6bd902b1cf0e83be9_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMjA2NQ_25baeb61-7064-435a-b94d-d9d289ca875f">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5fab8a89ec0e445ea9f230be250f041a_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMjA3Mg_877af320-7f70-418f-9c08-63a59ef79ac2">3.8</ix:nonFraction> million, respectively, for the benefit of certain health plans (see Note 8). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_88"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzkxMg_41b8b311-3085-4bfa-b9ea-ea59add0a1e6" continuedAt="ib7f9dc61450d48a4a0f374569adf18ef" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7f9dc61450d48a4a0f374569adf18ef" continuedAt="ie81334d3523749de88c329cebc88352d">During the three and six months ended June&#160;30, 2021 and 2020, NMM earned approximately $<ix:nonFraction unitRef="usd" contextRef="i6655222595b8466db9fa7f8f6e28d701_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTAw_3107723b-e773-434b-9e6f-b9fff32cd21c">4.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i92e9a46fd55843e19b666e23a93b8077_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA3_203dbdcf-851e-432e-8ed1-af13a08e2ef0">4.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i874d478f73294316ad576a40bb59e1ba_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTcyOQ_5fc4f93c-af64-46a7-be35-3bfd448a48f5">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i25a8271afdf84b0ba8fed37136cb3814_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTczNw_1daa0923-dff3-48da-b2d2-8e1cc3ec7e53">8.4</ix:nonFraction> million, respectively, in management fees from LMA, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="id89e4b9b73134459ace8ce5c0489bead_I20210630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjEw_8165251b-315b-4078-b0fa-bcdafedfb6b6"><ix:nonFraction unitRef="number" contextRef="i5e548a742a8e402cac322c329bba3e8e_I20200630" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjEw_e6ac47cf-5d29-4933-9b66-62e2baed0e90">46.25</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 4).</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="ie81334d3523749de88c329cebc88352d" continuedAt="i6f25094682344f9a87fcfb181387fb37"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ic24b4e50300a456398b12c3d4e9c5ad6_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzU2_341da55f-9a8f-407a-b695-f4de77b52fcc">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i49a2d42d5c87493e92c0eb8c7fd269db_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzYz_748891d6-96de-4032-8e76-ac2e9b31c964">0.4</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i6ea5c3d23fde4210b75ead61697da1df_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc1NA_ad786499-c9ca-4a7d-90d7-f586e7534ac4">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7a3adda3f7674cf188378375d6706703_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc2Mg_53f81f26-8f8c-4009-a957-e81e62a6b894">1.0</ix:nonFraction> million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="ie006af53fd884424a259b9fa982a4348_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNDY5_6ac63e97-cb4f-4c4e-9b69-d4ba9eb4cf6d"><ix:nonFraction unitRef="number" contextRef="i7f54f9743af8462db5f026514b1e7f21_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNDY5_b54ccbe6-f5e2-4015-bbd1-9ef7577a54bb">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 4).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ieec217ded7454689910a87b9c2fbed59_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNTg1_0fe38f4c-1983-4765-9a7e-d17efbc8d1cc">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i53ddd200d6094338a149fcbc196b306b_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNTky_f1b7eff7-19a0-4546-be6f-0f97b9ff3a5b">0.9</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i22b8a06109754f1285d0b76fad17c51e_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgwNw_cfc19127-99bc-4768-b984-0dfa3399d041">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic98de02634744e4eb83e5a16fad56985_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgxNQ_34079042-34c0-4695-abf0-56b140c0dfe3">2.6</ix:nonFraction> million, respectively, to DMG for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="idef15142ee464a63a23eb8e6756f0416_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNjk2_9fb3374c-abea-4161-a31b-81168fb8885c"><ix:nonFraction unitRef="number" contextRef="id9c0a7c27eb7463185729d7662e9b27f_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNjk2_bec2d7df-b8b8-409a-9965-41cd4479b497">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 4).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i66379f58d2d94f269eab8ba02e886336_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfODEy_bba3e899-c839-493d-a1b9-fad0d5946e79">30,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i24dca2e9c9d84a809178fcf0be16e039_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfODE5_7eeab4a5-7b74-4008-9c1b-d8fba7941c5e">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i07d33951a6dc47ab94b24b9ea268e74c_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc4MA_d1ca2572-9a36-4974-b8c8-c287d6848511">51,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i8bba769854d545f5b616e3e0f528bbb8_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc4OA_f8758e23-8414-4209-ae29-a4adfa759402">0.1</ix:nonFraction> million to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i4d16dbc5ae1849d0ac736d665bd1ea4f_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA2MQ_4bb954bc-597a-4410-b1a4-0a97f667f8cc">19,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6eea3af5cbd2450785901edf939f6913_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA2OA_a890186c-985b-421f-86eb-03c892447005">25,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i47874f0012974d65ab80752547b88e0a_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgzNA_bc084923-ade2-47d8-ade8-bcebf8592671">52,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iecc948505e8f40a58d9ef50d08c16138_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgzNw_dd88f478-983f-436d-ad0d-2fc9f01e09ab">76,000</ix:nonFraction>, respectively, to Fresenius Medical Care (&#8220;Fresenius&#8221;) and their subsidiaries for services as a provider. During the three and six months ended June&#160;30, 2021 and 2020, APAACO paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3e531b4a2b3848308af8e4c062dc3ae9_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTI0MQ_65abe391-2f1c-4ba6-87ad-620ebb918876">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if1a2f4f2d93b403298227a14e3ea027f_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTI0OA_bfff0dc3-fe63-4af6-ba9c-3a0b061030ab">0.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ie7b855636fc848dbb30121df166e6660_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg3MQ_17671918-29b6-44a3-afa0-359eefafc1c2">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i561f53dbd6ec40abbfe2adb13955f8b5_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg3OQ_f90aca69-d2e1-4958-9379-c2a7e973fd6f">0.3</ix:nonFraction> million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i7235acd9aa184415ae42f56c42c67220_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTQ1Mw_45c736bf-5a1e-47fa-9bc0-78697bc41a46">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib88f4defee8d42ec9fb95d874467a531_D20210101-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTQ2MA_9029e6e0-bcf3-4eb6-b3dc-a8218460d41e">0</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i48119f8925ce4b7fa46fa0bc444edaf0_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg5MQ_0aa5bdaf-dd6c-441c-8086-bea54b04c3c3">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3340686a998b49ce95642072d397de0e_D20200101-20200630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg5OQ_75ead3c9-d94d-4f3e-808b-3c0d5537d12c">0</ix:nonFraction>, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shared a common board member with the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2021 and 2020, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i64f0216262ee437f994ada0f2b06c020_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY3OQ_495ba60a-2f6b-4ac1-823e-1adaf9f9666f">8.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e93a59c26d54a048d85bd6ba5ea6cab_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY4Ng_875eeda5-d725-466b-8c52-162ff6931a32">9.0</ix:nonFraction> million to shareholders, respectively, which included approximately $<ix:nonFraction unitRef="usd" contextRef="i002d7abe90a74c1f87d36f02f9911e16_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjQyMA_ea943ecf-c212-4431-8cb5-d557b546220b">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib518c264f77248c2961f26353ebe9258_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjQyNQ_a10e75ae-cfe3-4795-956d-95cbd8413b4f">3.0</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2021 and 2020, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i3b03e8cafdca4ef3b5ae3b6f88c8d2ef_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTkzNw_ae7562fb-4fa5-46f6-98f8-fdb57197d4a9">15.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ied858eeea01d43f0ab1bd6a8e9d390cf_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTk0NA_fa4e7b53-5bdb-4e22-84bd-73bd9c3742c2">16.3</ix:nonFraction> million to shareholders, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i5093b44a796548d5a32e7a485043d5ca_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTk5NA_6808228f-85de-40af-865b-a55631c402cb">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic7f32e9378184e58bc262fb167c76e2b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjAwMg_a6376c5a-8f95-472d-8870-100aa5d7edd0">4.8</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="if9c44ce4c45c45128c3cb4190f57ff3e_D20210401-20210630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTg5Nw_0097e9bf-fa6b-4dc2-8f67-30f2e4c3cb45">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i646e9e6069754dd7973d990412c1ad05_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTkwNA_a8729672-c368-473b-bdf1-b9c125c870f3">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia6396fb99dba4c38bbcd4ff6c21c04cb_D20200401-20200630" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjAxMw_ad79ce40-35a2-42fc-b469-2e78035262dd">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i55e1d1a632d943cd8f9bc6caab027705_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjAyMQ_c2cf0ff3-b434-4c82-a4bb-176cfc6d1d04">0.2</ix:nonFraction> million, respectively, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2021 and 2020, SCHC paid approximately $<ix:nonFraction unitRef="usd" contextRef="if186b20296204ef3ad7eef32555753af_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjExOA_aa0fac5e-391f-437b-90b2-779d0a979112">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0163830e210412f9315ea00b043a5fd_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjEyNQ_6d8d99c2-0141-43e8-9b9c-b5e0c041c2bc">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iae403e37990e47ed849d50e7b275152a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE1NA_6ae013fe-386e-4ae9-9739-d1c1f7438510">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id613d04fbab14d078323ed4a8af18081_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE2Mg_9033d8ee-2157-450f-ade9-36f8010df2fd">0.2</ix:nonFraction> million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six ended June&#160;30, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ie09d5b85850142b5ba448c3c23a85993_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjI4Ng_3da9a6bb-1db8-4c22-a23c-1c832575110b">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0b4bfb2672b04d938b81043fab621f6f_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjI5Mw_9ce6f186-c4d2-4317-8962-7bd60f2c2061">0.4</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia6eb80252b8d41968ceed50dd21e9d24_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE4Ng_ffff1094-efbd-4648-a623-d7712c742c77">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6017f3dab4824927a649da5bf8db28a2_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE5NA_6f4767e6-0ad5-478f-a43b-cb10031e8fe1">0.7</ix:nonFraction> million, respectively, to One MSO, Inc. (&#8220;One MSO&#8221;) for an office lease, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="ib6670c16ced04552b621f7bdec168bce_I20210630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjQxNw_b19f06f8-6588-4042-951a-564a939af652"><ix:nonFraction unitRef="number" contextRef="i7cf2fcb06956482fa26b7e68b4e24699_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjQxNw_d920f039-8905-4fed-916b-48383e2f7350">50</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 4).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare Inc. (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzkxNQ_112e9bb8-fc89-4eda-830b-b9653d29e9c2" continuedAt="iad1df0eede7a471f93382129c4eb7dcb" escape="true">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="iad1df0eede7a471f93382129c4eb7dcb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3629ab6d4d2d4265be7f841a30358d25_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi0xLTEtMS0w_bed17f58-780e-4ddd-a0cb-c93ec7d709dc">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481dd6af2bdd4cf09e6db33df73fe757_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi0zLTEtMS0w_8f6d6b04-e134-4117-a3c9-a75865ee9dff">6,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07412c61c634f9ab38ea2cc8e9bb8d9_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi01LTEtMS0w_e779954e-20e5-443a-bfaf-9fec3a97ff27">25,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785190d436454824afe1c0c04e317050_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi03LTEtMS0w_5494164e-4880-4503-899e-82635f81d8e1">18,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie215578f33b740438664f8f4e662aaf5_D20210401-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy0xLTEtMS0w_5b9b8010-6e3c-4e35-8fed-b05db5c3745c">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95fb39ce145c4439b0424fb05b3ed94e_D20200401-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy0zLTEtMS0w_31f8e8b1-b27e-4772-84a0-970967876d33">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if63a149dde3b4d70ac4a2c1ebf3233dd_D20210101-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy01LTEtMS0w_693b8f43-1d96-44de-a50b-185382cb51f7">108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9654cd90ba324591bbfdc696ed176e15_D20200101-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy03LTEtMS0w_51221f99-ceb1-4647-bb8c-30c6c24a758a">321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i605e900922024071b01391ab39f722ff_D20210401-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC0xLTEtMS0w_506d670f-83a2-4a1f-a97f-9d0684001dd0">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55490cf44eb04081807b779af67ab181_D20200401-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC0zLTEtMS0w_c5f3c6c3-b152-4f01-b7d4-44f71b860693">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1a89c6eeac245a88286608dbe3adbcb_D20210101-20210630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC01LTEtMS0w_21fc2d72-b140-4191-8117-8e60d2771766">152</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a76c5ebb0ec466fb2566e77ead1ee3f_D20200101-20200630" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC03LTEtMS0w_3f21a529-00d4-4e16-a9bf-f672401a5571">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi0xLTEtMS0w_5ace83f0-d29a-4220-b2a5-0ffc22458145">12,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi0zLTEtMS0w_5ce19922-cda3-4e34-bf2f-e6df90d230ce">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi01LTEtMS0w_f2b08c95-3dd1-4ecc-9954-33eb73f057cb">25,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi03LTEtMS0w_76d6222a-468d-4d45-8d34-0f752b030121">17,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i3629ab6d4d2d4265be7f841a30358d25_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzEyNA_abc35f77-066a-4946-97b2-5eb38d33bad2">14.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic07412c61c634f9ab38ea2cc8e9bb8d9_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzEzMQ_ab62ea5e-ef91-4c2f-8181-7067cb09dad7">10.2</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i481dd6af2bdd4cf09e6db33df73fe757_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY0OTI2NzQ0NjI1Mw_7f0dba28-9721-4ab2-85fa-5a8c127bcef5">31.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i785190d436454824afe1c0c04e317050_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY0OTI2NzQ0NjI1Nw_0bf6a6b0-432b-48c1-a53d-8166577fcb9d">21.0</ix:nonFraction>&#160;million. $<ix:nonFraction unitRef="usd" contextRef="ib46d8ce11bc946359432bb84ee798ea2_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzE1OQ_8a0ad7bb-c225-4926-8bf4-6047b0802f77">63.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4196d26cb6024d61bcd2b84921ae5be6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzE2Ng_74dd7e76-86b4-4659-a939-39cf75d65ef2">45.3</ix:nonFraction> million remained outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i6f25094682344f9a87fcfb181387fb37"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="if70bdfc17f4843378fe0e472c8f0af69_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzI4Mw_831192bf-858d-4316-8500-4a0f88bba582">44,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifc0c32e700994ca0b101674055e539a9_D20210101-20210630" decimals="-3" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzI5MA_302e6a7f-4350-4bb1-a091-deb607804c0c">0</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i9955d34b683e4071859b13221b7991a2_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjMwMQ_31237967-0ebd-4487-a655-451f16f150e9">44,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if2f45e79358241e4bc75610a691f200c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjMwOQ_4b399fa0-9388-4418-916c-de921d83bb71">27,000</ix:nonFraction>, respectively, to an ApolloMed board member for consulting services. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company&#8217;s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable and line of credits from related parties, see Notes 4, 5, and 8, respectively.</span></div></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_94"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85NC9mcmFnOjE3MWU1OTUyNDM3MjQxZmRhZjBmY2JhZTQ3NTBkZjYxL3RleHRyZWdpb246MTcxZTU5NTI0MzcyNDFmZGFmMGZjYmFlNDc1MGRmNjFfMjQ4Ng_da46f367-d46f-481e-a1ab-aeda48f2de7b" continuedAt="ibf6b770bcce14d53b1ef03408b210050" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ibf6b770bcce14d53b1ef03408b210050"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the six months ended June&#160;30, 2021 and June&#160;30, 2020, was <ix:nonFraction unitRef="number" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85NC9mcmFnOjE3MWU1OTUyNDM3MjQxZmRhZjBmY2JhZTQ3NTBkZjYxL3RleHRyZWdpb246MTcxZTU5NTI0MzcyNDFmZGFmMGZjYmFlNDc1MGRmNjFfMTY0OTI2NzQ0MTkxOTg_a0352966-0761-48d3-b0eb-2ffff598d9ff">30.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85NC9mcmFnOjE3MWU1OTUyNDM3MjQxZmRhZjBmY2JhZTQ3NTBkZjYxL3RleHRyZWdpb246MTcxZTU5NTI0MzcyNDFmZGFmMGZjYmFlNDc1MGRmNjFfMTY0OTI2NzQ0MTkyMDI_1414f947-515a-4725-9e1e-13488494e938">28.5</ix:nonFraction>%, respectively. The tax rate for the six months ended June&#160;30, 2021 differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2016 through December&#160;31, 2020, and for the years ended December 31, 2017 through December&#160;31, 2020, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_97"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfMTEyNw_aa372ed2-cb05-4ed7-aef8-693f644793ba" continuedAt="ibb707e7ab71a442ebc39a1a00db2f77c" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="ibb707e7ab71a442ebc39a1a00db2f77c" continuedAt="i902d848b28984fdb8295221f7e60cf0a"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, APC held <ix:nonFraction unitRef="shares" contextRef="i0408c582d1c8484f98671f80a6529d71_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfNzI3_8cb735ae-0fc7-461e-aeca-9ebaa6c68d0f">10,885,732</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iab736275bf9d4781ab26f264e447d2b9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfNzM0_e4c2ce10-761f-4aa9-aae8-b59ffe90ab54">12,323,164</ix:nonFraction> shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i902d848b28984fdb8295221f7e60cf0a"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfMTEyMg_673e74ce-07c8-47f7-a08e-88d8289c888b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMS0yLTEtMS0w_bfe1fda5-6529-4eaf-b951-3d6120db2594">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMS00LTEtMS0w_674f79d8-3ae8-4be2-a58b-89c8a15166ef">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMi0yLTEtMS0w_8ab70872-57a6-4e20-8136-9db504f350d6">0.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMi00LTEtMS0w_a6581ae8-5c8c-42f3-9f0d-890afcd9a2cf">0.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMy0yLTEtMS0w_548c67e4-79cb-459c-b7f1-6284ca300543">44,165,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMy00LTEtMS0w_5eaef521-e1ec-48e1-a446-f56f10012f32">36,071,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfNC0yLTEtMS0w_147215dd-1146-4031-8ecc-4a3957043be6">45,828,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfNC00LTEtMS0w_48309598-6a79-4886-be48-d63981f00d2d">37,285,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMi0yLTEtMS0w_3c490f4c-127e-4b8d-87a2-009a7764e267">0.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMi00LTEtMS0w_9238accd-b3b6-4e24-939b-dd25ee1ef101">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMy0yLTEtMS0w_dfa2b83c-1f00-4f83-9e85-08ce492aeb38">0.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMy00LTEtMS0w_dfc0299e-acab-4993-a2f7-dadcaebfec2c">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNC0yLTEtMS0w_b862a31f-2fc1-4c72-97bd-7811dfc43bee">43,255,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNC00LTEtMS0w_471810b4-319a-4a96-acd5-ae34dd1cf841">36,040,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNS0yLTEtMS0w_fc05a589-e2b9-46a6-a3d0-209f30ff06b9">44,746,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNS00LTEtMS0w_48481688-8dcc-4853-8659-969c546dda1a">37,296,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfMTEyNA_c564d3d4-0f76-4ca4-a5e7-e9f02214e8b1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMS0yLTEtMS0w_c41fe26f-abe3-409a-bb7d-149ba06bfb8e">44,165,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMS00LTEtMS0w_d976ba20-7be5-45ff-83d5-2bc2b5a1c199">36,071,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3ad5bba1b2945d5aca93409af485c52_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMy0yLTEtMS0w_2b52a4b4-66c7-4136-8969-8c70eb29c232">466,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7d0522994fa4c0e8e71d2a65df6059b_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMy00LTEtMS0w_283a25e0-7ff3-4934-a044-7a43ac32208b">169,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0014be1c64d54d3b9a57ae96f20be2db_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNC0yLTEtMS0w_d0f3c0f3-f606-4d09-aabe-a4aa497f8dff">992,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81cd6e624ce543c1b130425e84f9df76_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNC00LTEtMS0w_9f8ff432-6c8a-4654-88f8-14348efd716b">1,041,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb713daf92854f7dbdd3bde3a5d23576_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNS0yLTEtMS0w_5c9bd39e-16fb-4a8a-afc6-abe1174c9a74">204,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8efdd516ad464b9cae1cee095ce35994_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNS00LTEtMS0w_8788980c-eca3-4a84-938f-729fb01eac57">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNi0yLTEtMS0w_824a63e6-2a33-47db-a4e3-c6c381c6d2eb">45,828,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNi00LTEtMS0w_27696a75-dfc6-457e-96f0-c7190d1471b8">37,285,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfMi0yLTEtMS0w_2d91ee07-2368-4088-ab52-469e24f9fdb5">43,255,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfMi00LTEtMS0w_17e10ade-7df2-4a7c-87d4-43ec70243b7c">36,040,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife0aa2938ef848b2a9705be0c7e31425_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNC0yLTEtMS0w_e8f0cbee-ccb5-4856-aec3-6a02d5129f05">409,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib82e7ef87abf4a5ca9af04095e4d8100_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNC00LTEtMS0w_58543671-50c0-4e4b-9669-6110161df897">173,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c51e142647147e3a11ac050a6f7d7f0_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNS0yLTEtMS0w_8647f6d0-bd0f-4b5f-a025-520efbffca07">911,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e3ea018e65d4409898ec845c882ed39_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNS00LTEtMS0w_9787975a-4c69-4911-b74a-f7360bc6406b">1,076,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c8b5b78dbb848798300feff662c4c35_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNi0yLTEtMS0w_4b10c7f4-b45e-4233-8983-9cb85430d77e">170,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89350f0ae8aa4d629dde6b21abd22cb6_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNi00LTEtMS0w_0ca3bf3f-8a5c-4f33-83ea-3580d647a68d">5,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNy0yLTEtMS0w_2f695886-223e-41c2-9b47-555a656edd6f">44,746,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNy00LTEtMS0w_8f1a4d39-56df-40a5-8629-6fb83811e719">37,296,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i1123c47dec074269b382540ae6206c28_100"></div><div style="margin-top:10pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90ZXh0cmVnaW9uOjQxOGEyMWRhYjQ2NTRmOTM5YzhiY2RmNmUwYTc0OTRiXzE5MTU_b0f1f90c-fbe7-4231-b53e-a40a47bc98aa" continuedAt="i7ee010d048b843819b2eb33c0ca613d9" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><ix:continuation id="i7ee010d048b843819b2eb33c0ca613d9" continuedAt="i46bc7cef872a4d35b32111ada317e4ca"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90ZXh0cmVnaW9uOjQxOGEyMWRhYjQ2NTRmOTM5YzhiY2RmNmUwYTc0OTRiXzE5MTI_e69f2e01-f163-4fe9-b0c4-fe5ca46b2096" continuedAt="i06f2792953d24535b5731f04e78af745" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQtMS0xLTEtMA_7d7b0579-813b-4e67-9941-a05ccdaa921d">105,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQtMy0xLTEtMA_27771166-fc08-4b5f-b801-5fa16e57e3bc">126,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzYtMS0xLTEtMA_21258628-c04b-419f-832d-7fd97be0b8ab">187,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzYtMy0xLTEtMA_0843247d-2ca8-4959-9b80-8833660ff50e">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzctMS0xLTEtMA_091c2fde-33c2-497f-bf94-58cddc023b51">14,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzctMy0xLTEtMA_fdc92cba-d30c-4c37-ad10-135b35b2df6f">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzgtMS0xLTEtMA_e3269307-5514-4341-b1a7-037cf5b7670a">66,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzgtMy0xLTEtMA_6b82882c-52e8-458c-bf96-ea8f4f141291">46,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzktMS0xLTEtMA_9c5ebdb1-1ccc-49ba-90a4-f82aaa11fb46">1,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzktMy0xLTEtMA_601812b9-edfe-4a24-9043-36d8c252c336">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEwLTEtMS0xLTA_eedb4351-17ae-4047-80c7-d2a796555539">10,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEwLTMtMS0xLTA_ceda0a1f-cc54-4017-8f28-b943f5cd4d77">14,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTEtMS0xLTEwODY0_ba41db3d-86e6-4f3a-b2c5-73ea86c1a6d6">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTMtMS0xLTEwODY3_279dd922-9998-4248-9038-2a522da224c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueFromAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE0LTEtMS0xLTEyNjA5_b7a0e06f-a79b-45e8-b5ab-f69f03919bbf">16,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DueFromAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE0LTMtMS0xLTEyNjA5_fd4d24b7-1b77-48d2-97bc-da6fd34df474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTEtMS0xLTA_d81d2539-887f-4b37-99ac-e211767d4c1d">406,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTMtMS0xLTA_a0a314ca-93e3-4ba1-ab37-a1ec79dfaf68">261,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE2LTEtMS0xLTA_25944d36-fa4d-499a-ad2e-b822294eba6d">38,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE2LTMtMS0xLTA_fc8f26b3-ead0-4b3b-8ce7-7fe36878e8a5">27,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE3LTEtMS0xLTA_de47c03d-4e04-4464-a9d2-87709eef2a3b">64,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE3LTMtMS0xLTA_ad8f0c81-14bc-4c09-b79d-c3cfd54a293d">69,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE4LTEtMS0xLTA_a9ad470b-2ecf-46c9-880a-16cda05d5d6a">109,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE4LTMtMS0xLTA_c8b1ec6e-f643-48b1-b143-78d1bbe321c7">109,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE5LTEtMS0xLTA_6d341bae-5951-43a6-8d15-517b74c4bf1f">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE5LTMtMS0xLTA_bc83cf42-341d-427e-9e6c-a37a330ef1da">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIwLTEtMS0xLTA_ca6f07c0-38a9-4340-9278-ebed20ecd5d4">683,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIwLTMtMS0xLTA_992f6478-57ae-4126-93e7-56c392bb54bb">225,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIxLTEtMS0xLTA_92d2a9d0-c305-4455-8260-52deb5f0f634">37,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIxLTMtMS0xLTA_2f47a2b6-01e9-4e36-b9cc-39cd1b2608c6">43,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIyLTEtMS0xLTA_e1c1d978-5dfc-46d8-835b-3a716412e740">405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIyLTMtMS0xLTA_91091314-67c4-44a1-aaf6-5ac8ca8fcee4">36,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIzLTEtMS0xLTA_c005b688-cb76-4c18-aeca-b6ab8a53c5ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIzLTMtMS0xLTA_a4149ac9-6711-4cf7-9b78-bbc46358d8d9">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI0LTEtMS0xLTA_86a544a9-69b1-4755-a89a-409b7d4b1e5e">5,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI0LTMtMS0xLTA_6f68f411-c64b-4240-8515-15b51aed03ba">6,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI1LTEtMS0xLTA_0408debb-d9b5-49b7-b873-cb0c20122106">1,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI1LTMtMS0xLTA_fce35c94-2d5b-4e8c-963c-2ab1a2cc7d0f">17,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI3LTEtMS0xLTA_4b3e1918-ea30-4502-a39e-303b3f2a473b">941,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI3LTMtMS0xLTA_4a7b7af8-9b8b-4f90-9f10-00a4cdb4962a">539,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI5LTEtMS0xLTA_f4762602-91f9-487a-a241-bccf46714652">1,347,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI5LTMtMS0xLTA_a2070f10-3468-4151-aad6-e5e5981e5296">801,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMyLTEtMS0xLTA_429e39f7-38f7-40fa-a015-c5a0757e5d5d">14,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMyLTMtMS0xLTA_cc1c5549-bc0b-48f4-8d97-fcdc746d5b7f">12,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMzLTEtMS0xLTA_c8d76729-b60f-4920-954e-1f65411034cc">9,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMzLTMtMS0xLTA_93c4cf8e-ff12-4a5e-b7a4-1cfa2339fa0f">9,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i46bc7cef872a4d35b32111ada317e4ca"><div><ix:continuation id="i06f2792953d24535b5731f04e78af745"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM0LTEtMS0xLTA_0b77dddf-2ab9-4152-ae94-ebff87fa3de6">46,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM0LTMtMS0xLTA_cc6eca3b-b480-4464-953e-8770c360b153">37,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM1LTEtMS0xLTA_fb4919b8-d6d5-469d-8936-a8d224f58811">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM1LTMtMS0xLTA_45e8bf04-f9cd-4c68-ba60-b195543d09a1">4,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM2LTEtMS0xLTA_ef74a73b-0874-4161-8086-42b60b5d16bf">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM2LTMtMS0xLTA_c89d214f-5887-42f4-8352-1816cdc9b6b9">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM3LTEtMS0xLTA_abdcc33d-aa15-497e-ae62-88b6f55d2adb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM3LTMtMS0xLTA_5c617867-3f76-4d75-84e7-3ad728cc7347">22,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM4LTEtMS0xLTA_682a92e7-0005-48bf-b70d-a38f24dffc8a">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM4LTMtMS0xLTA_90dcda14-f764-457f-bc86-9bdc13b58435">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM5LTEtMS0xLTA_fd60f228-90d4-4802-9cc4-75ce413f7e85">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM5LTMtMS0xLTA_e3a54bc6-102d-4d0f-92de-c19b79506139">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQwLTEtMS0xLTA_cbd1a820-d368-4307-a0d2-3e35a532fa7a">1,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQwLTMtMS0xLTA_4ebb5deb-1df9-4128-a729-6995ccb438ea">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQyLTEtMS0xLTA_74fbd93e-e57e-423b-aed6-5bb805353167">73,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQyLTMtMS0xLTA_777af49a-6118-4a5a-a38f-50b0a3f49579">89,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ1LTEtMS0xLTA_33615a36-142d-408c-b811-1713e2ab3803">7,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ1LTMtMS0xLTA_f90118a1-787a-40d1-86d0-18f9ba169e70">7,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ2LTEtMS0xLTA_a91765bf-2ce6-4f6a-afaa-e7357a5af002">20,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ2LTMtMS0xLTA_278325ee-eb8a-4783-a878-025fb3708673">9,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ3LTEtMS0xLTA_a1955e70-ab89-4181-8b5f-d338763953d0">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ3LTMtMS0xLTA_8c51cab9-3038-4d6d-aa04-53e7c47bad86">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ4LTEtMS0xLTA_0e05c0b1-26c4-4605-9564-f487143c281f">4,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ4LTMtMS0xLTA_6d36e539-46f6-4673-946a-41f50f328cc8">5,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTEtMS0xLTEwODgx_68b9588b-8e65-41ed-a364-c28995076dbf">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTMtMS0xLTEwODkw_1b091ea6-a025-4145-96c4-68e601a30361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTEtMS0xLTA_efad1489-9b34-4353-9a69-45fd35b65f10">33,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTMtMS0xLTA_2776a8d6-2a60-419c-b60b-9ccf01de587a">22,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUyLTEtMS0xLTA_4b663f1b-97b7-4131-86b4-ac0362d52d75">107,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf991f15464550976d811de0d62e73_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUyLTMtMS0xLTA_183bda3d-1461-45fa-b892-86efcd0e89bc">111,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of the Company&#8217;s other consolidated VIEs were not considered significant.</span></div></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_103"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNjM_e6946198-ee22-4c1d-a063-2ddd5f0ce85e" continuedAt="ibf83bb34db124e09be7571090225f4f4" escape="true"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNzQ_ad97f98b-52b7-4edf-897f-a63aa4a1e23a" continuedAt="i2153261e748f4f40a899c137c4fdbddc" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ibf83bb34db124e09be7571090225f4f4" continuedAt="i25d5c5f8c5cf4bb88f616ef0d45be34b"><ix:continuation id="i2153261e748f4f40a899c137c4fdbddc" continuedAt="i5505aa8871034cb0982b0292e40ac6ce"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of <ix:nonNumeric contextRef="i64c51ebc726a488fbd985b493d51b309_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTc_2d57f2a0-4522-44f4-aa51-d5dd74152f9e"><ix:nonNumeric contextRef="i64c51ebc726a488fbd985b493d51b309_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTc_b55c7a28-f093-4cd4-8117-62caafaffb43">one month</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="ib4db1a9674a54a7ebe6ebf2c416564b2_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTM_8e8f39cd-fc5c-4021-8ac9-416d4894bfad"><ix:nonNumeric contextRef="ib4db1a9674a54a7ebe6ebf2c416564b2_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTM_c44fe732-aac7-46e4-b2fc-1ba1ccd0ac22">five years</ix:nonNumeric></ix:nonNumeric>, some of which may include options to extend the leases for up to <ix:nonNumeric contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzI0OA_022737a9-f368-409e-bb0f-d4bdb96b3260"><ix:nonNumeric contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzI0OA_c173aa78-3aa6-4ad6-af79-2ba93393854b">10</ix:nonNumeric></ix:nonNumeric> years, and some of which may include options to terminate the leases within <ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:durwordsen" name="ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzMyNw_6902406d-a152-44cb-8298-563308e233d9"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" format="ixt-sec:durwordsen" name="ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzMyNw_b72922d5-5e07-4435-aa11-4cea95fbc69b">one year</ix:nonNumeric></ix:nonNumeric>. As of June&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4ODM_1c472579-67fa-42e7-893d-c99370917c1f">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4NzU_996ab2b6-21a6-49b5-92ef-a7b37dc0c695">0.4</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases were $<ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4ODg_c12c8e8b-c5f4-4d48-b1f2-83536cd3c027">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4Nzk_7689223e-f4ba-4b69-8da1-1f4babac8812">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNTg_fe69591a-9e53-4a16-a9f9-4dd6187bc915" continuedAt="i492cbbd90bf843f3b61aee9a7ebcec99" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzMtMS0xLTEtMA_eb28a7ca-e506-44a0-a6b3-b3176cee842b">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzMtMy0xLTEtMA_076b1a6d-9795-46ce-847b-b23664c4290e">1,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzYtMS0xLTEtMA_caa0a5e6-e668-4caa-b86e-dff958dba2af">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzYtMy0xLTEtMA_cceac0f5-7bbd-4a04-bcaa-3148ba978d72">35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzctMS0xLTEtMA_a92592d9-c303-4603-b93e-b176f3f96faa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzctMy0xLTEtMA_7ae3d8e7-1602-44c2-968c-7def4af312b2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzktMS0xLTEtMA_97199767-8ea9-4686-ab71-22247dd6d1f8">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzktMy0xLTEtMA_9f64c6b5-5ecf-43b3-89fb-d21be0e6f1d8">226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzExLTEtMS0xLTA_32767a93-4c30-466c-980c-e8899e02db38">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzExLTMtMS0xLTA_0edc8c54-7a50-4cdc-993e-7b9806e0ef00">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzQtMS0xLTEtMA_8447755f-9da5-4a8f-926e-63b7072fce64">2,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzQtMy0xLTEtMA_eb71a0cc-ff5b-4b70-b7e3-7de8c572dd14">3,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzctMS0xLTEtMA_7b44c892-7ef8-4843-8be2-0c19a43efc51">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzctMy0xLTEtMA_fb8c99d5-f16f-4229-aa85-ab055c7b4fc8">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzgtMS0xLTEtMA_1ded3ad8-3d04-4c11-a9b3-79da6ded5a50">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzgtMy0xLTEtMA_fd32fa91-b4cb-4a3b-8e3c-04a19ee8b288">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEwLTEtMS0xLTA_d7b080d5-b669-493b-83b9-2783aa9b1784">473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEwLTMtMS0xLTA_1009f6ec-7c92-4a0d-bc0c-5fb596084d16">360</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEyLTEtMS0xLTA_d824380e-2697-4e3f-b214-a50518af96bd">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEyLTMtMS0xLTA_24c41176-d80e-44f4-8a84-2161bc9a0141">3,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i25d5c5f8c5cf4bb88f616ef0d45be34b" continuedAt="i9f5e2b0bb20a46bda8600bacbbcd9c7e"><ix:continuation id="i5505aa8871034cb0982b0292e40ac6ce" continuedAt="i74d0789ff8e54262b41482390d73a13c"><ix:continuation id="i492cbbd90bf843f3b61aee9a7ebcec99"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzYtMS0xLTEtMA_080449ca-1799-4e72-bb36-044fdd31869f">1,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzYtMy0xLTEtMA_0eb4f2a7-594c-4c14-91d2-51b8065d43c1">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzctMS0xLTEtMA_001497c8-93f3-4678-b8a4-31b458fbf9fd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzctMy0xLTEtMA_abfd6a10-e056-4b67-b8f5-6945fa22dc67">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzgtMS0xLTEtMA_eccbc902-c7ff-4249-8c25-b9ab3244ac17">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzgtMy0xLTEtMA_12935600-e854-4b68-b576-1fac36d780ec">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzExLTEtMS0xLTA_b39ebbcd-10dd-40b6-abed-371e2604d590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzExLTMtMS0xLTA_521a57f0-fc7b-4625-9432-91e6df44e1f4">2,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIwLTEtMS0xLTA_5436b99c-f492-4be6-8b88-4491fe0218e9">3,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIwLTMtMS0xLTA_b946f3b7-2b9a-4df4-9a5f-d23855fdef14">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIxLTEtMS0xLTA_01757519-0055-4d31-934d-8e68260756ff">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIxLTMtMS0xLTA_cfd53e5d-4d5a-4e2f-acb3-a90994488f3f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIyLTEtMS0xLTA_4f8454da-a1c2-44c0-9217-74a717628106">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIyLTMtMS0xLTA_519abb0e-b0b2-4da7-ba2e-ef3056f819a3">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzI1LTEtMS0xLTA_79740da6-2588-49bf-976c-18ff1d6dc7f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzI1LTMtMS0xLTA_be27a734-838e-4c87-a5d5-50b0648fd65a">7,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMyLTEtMS0xLTA_1007e807-61b8-49d6-b5e5-253bae5f6b1a">6.56</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMyLTMtMS0xLTA_9a0d58dd-6d7a-428f-b369-b448f0e93f45">7.06</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMzLTEtMS0xLTA_993e1a95-6274-4282-a52e-de0607b6d98e">3.17</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMzLTMtMS0xLTA_e2e07c56-a751-4604-937e-a5ef2933d697">4.17</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM3LTEtMS0xLTA_a9fc02e3-625c-45a8-896c-9bf299b68dbc">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM3LTMtMS0xLTA_046e00c2-f994-4b37-b48f-7fcc68302f5a">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM4LTEtMS0xLTA_428b66bf-c10e-4c15-b342-71bb2e205cdb">3.00</ix:nonFraction> %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM4LTMtMS0xLTA_6198a85f-9cad-4034-9386-a9e9bc6dd452">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><ix:continuation id="i9f5e2b0bb20a46bda8600bacbbcd9c7e"><ix:continuation id="i74d0789ff8e54262b41482390d73a13c"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNjE_4a6021a8-a84e-4dc8-b49c-b81edb7b8d43" escape="true"><ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNjI_64b9ac54-a947-4c2e-ab4d-8bfd3f6e9f20" escape="true"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEtMS0xLTEtMA_5bd7a93f-8281-42be-8e93-17765bcf6aa8">2,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEtMy0xLTEtMA_5b43ce0b-360c-4f6b-abf1-7deba2c8bee8">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzItMS0xLTEtMA_46e09581-d661-4f07-b121-c1b890f53d86">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzItMy0xLTEtMA_9b05e6ed-0b39-4e5e-9b8b-b8de528120b5">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzMtMS0xLTEtMA_0e0e34e0-1088-408c-83fb-44987a0fc1d9">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzMtMy0xLTEtMA_0b192a4d-7009-4b28-8596-cf9f7485a942">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzQtMS0xLTEtMA_f3c963b5-af94-45c1-9af4-c0ec41f5c9d5">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzQtMy0xLTEtMA_a966c0ba-c404-45f5-800c-06d9cbfa87df">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzUtMS0xLTEtMA_74870707-216d-4a8e-9200-9b0648f2a6e7">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzUtMy0xLTEtMA_3058422f-bc36-4793-9093-6c58add67f0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzYtMS0xLTEtMA_5d288292-6ef1-44c5-8013-8b70c1feb159">6,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:zerodash" name="ameh:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzYtMy0xLTEtMA_e89d0ced-1ce1-4937-b1c1-63b0d1ad3dad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzgtMS0xLTEtMA_869b2c5a-bd60-4314-bff7-59ad43de3429">21,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzgtMy0xLTEtMA_f79681a3-b74e-4012-93fc-6fb7f9550652">377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzktMS0xLTEtMA_922cb837-5ee9-454b-8b9a-e8bb7463e0f2">3,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzktMy0xLTEtMA_03914fbd-bcce-41d6-8f5f-d5670a5f5ce8">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEwLTEtMS0xLTA_8e4592e3-b0ff-4009-8176-f6e49479f987">17,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEwLTMtMS0xLTA_daa21059-e8fb-4998-84b1-0d888d885bad">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzExLTEtMS0xLTA_1e9507f2-f286-4b95-b78e-40314611b06e">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzExLTMtMS0xLTA_8864100a-65c5-4b6c-aa43-c57af0abe3e7">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEyLTEtMS0xLTA_d8d65091-703f-4180-b849-ce02488bb21c">14,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEyLTMtMS0xLTA_647e023d-27b2-4952-8d3d-1f742434e48f">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.</span></div></ix:continuation></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_112"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2Xzc3Mg_f2ee8cc9-a6da-4788-aaa4-2f9ba88159fa" continuedAt="i086966885ed54441bb1b9e6128590b3d" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i086966885ed54441bb1b9e6128590b3d"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Access Primary Care Medical Group</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 15, 2021, a physician-owned designated shareholder professional corporation affiliated with the Company entered into a definitive agreement to acquire <ix:nonFraction unitRef="number" contextRef="i88ec600700d74563b50882f619542a97_I20210715" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3NzAwMDI_99d18650-a29a-4372-9da2-6455a33db1ec">80</ix:nonFraction>% of the fully diluted capitalization of Access Primary Care Medical Group (&#8220;APCMG&#8221;). <ix:nonFraction unitRef="number" contextRef="i84b60bfd8fde493d8a88c8fd34276c56_D20210715-20210715" decimals="2" name="ameh:BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3NzAwMTk_dfb11725-37d4-4c28-8245-b312f539b965">50</ix:nonFraction>% will be paid out in cash to APCMG within 10 business days of the transaction and the remaining <ix:nonFraction unitRef="number" contextRef="i84b60bfd8fde493d8a88c8fd34276c56_D20210715-20210715" decimals="2" name="ameh:BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3NzAwMjY_5f871d61-d83d-4163-b598-cdf716ad92fa">50</ix:nonFraction>% will be paid out in cash upon APCMG&#8217;s achievement of certain financial milestones related to fiscal year 2022. APCMG is a primary care physicians' group focused on providing high-quality care to senior patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sun Clinical Laboratories <br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2021,  the Company entered into a definitive agreement with Sun Clinical Laboratories ("Sun Labs"), under which the Company will purchase a <ix:nonFraction unitRef="number" contextRef="id1d3f4fbb7de478bbc51935ca41ab818_I20210930" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3ODc5MDI_850485f9-be14-43c4-a901-d4acd13cfb1d">49</ix:nonFraction>% interest in Sun Labs for $<ix:nonFraction unitRef="usd" contextRef="i57b89d29a2264160815b2599c489d073_D20210701-20210930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3ODYyMDk_53048dbb-0954-4e96-a3a0-0a11dc471841">4.0</ix:nonFraction>&#160;million. Sun Labs is a CLIA-certified full-service lab that operates <ix:nonFraction unitRef="location" contextRef="id1d3f4fbb7de478bbc51935ca41ab818_I20210930" decimals="INF" name="ameh:NumberOfLocations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3ODYyMjM_f60a238a-df92-42d6-9e50-c6a4d34d5a39">19</ix:nonFraction> locations across the San Gabriel Valley in southern California.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The transaction is expected to close by the end of the third quarter of 2021.</span></div></ix:continuation><div id="i1123c47dec074269b382540ae6206c28_118"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on March&#160;15, 2021.</span></div><div id="i1123c47dec074269b382540ae6206c28_121"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, together with our affiliated physician-owned medical groups and consolidated entities, are a leading physician-centric, technology-enabled healthcare management company. Leveraging our proprietary population health management and healthcare delivery platform, we operate an integrated, value-based healthcare model. We aim to empower the healthcare providers in our network to deliver the highest quality of care to our patients in a cost-effective manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, our subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). Network Medical Management, Inc. (&#8220;NMM&#8221;) and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under brands including (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc., and (iii) Accountable Health Care IPA. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;), and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). Our NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services program, which allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward under an attribution-based risk-sharing model.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, together with our affiliated physician-owned medical groups and consolidated entities, provide coordinated outcomes-based medical care primarily serving patients in California. The majority of our patients are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#8220;HMOs&#8221;). However, a small portion of our revenue comes from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. Our physician network consists of primary care physicians, specialist physicians and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) and the following subsidiaries: NMM, AMM, and APAACO and their consolidated entities, including consolidated VIEs.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Led by a management team with several decades of experience, we are focused on physicians providing high-quality medical care, population health management, and care coordination for patients. As a result, we are well positioned to take advantage of the shift in the U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our NGACO model and a network of IPAs with more than 2,000 primary care physicians, 7,000 specialist physicians, 10 dual physicians, and 400 physician and specialist extenders, we are currently responsible for coordinating care for approximately 1.1 million patients in California.</span></div><div id="i1123c47dec074269b382540ae6206c28_124"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent and Other Developments</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Access Primary Care Medical Group</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2021, the Company entered into a definitive agreement to acquire 80% of the fully diluted capitalization of Access Primary Care Medical Group (&#8220;APCMG&#8221;). 50% will be paid out in cash to APCMG within 10 business days of the transaction and the remaining 50% will be paid out in cash upon APCMG&#8217;s achievement of certain financial milestones related to fiscal year 2022. APCMG is a primary care physicians' group focused on providing high-quality care to senior patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sun Clinical Laboratories </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2021,  the Company entered into a definitive agreement with Sun Clinical Laboratories ("Sun Labs"), under which the Company will purchase a 49% interest in Sun Labs for $4.0&#160;million. Sun Labs is a CLIA-certified full-service lab that operates 19 locations across the San Gabriel Valley in southern California.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The transaction is expected to close by the end of the third quarter of 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Coalition of Asian-American IPA</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2021, the Company entered into an agreement to purchase a 30% interest CAIPA MSO. CAIPA MSO provides management, consulting, administrative, and other support services to professional healthcare service providers, including to Chinese American IPA d/b/a Coalition of Asian-American IPA ("CAIPA"), a leading independent practice association providing medical services to approximately 0.5&#160;million members in the greater New York City area. The transaction is expected to close by the end of the third quarter of 2021.</span></div><div id="i1123c47dec074269b382540ae6206c28_127"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Measures and Indicators</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Revenues</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO AIPBP revenue, management fee income, and FFS revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest expenses are the patient care cost paid to contracted physicians and the cost of providing management and administrative support services to our affiliated physician groups. These management services include utilization and case management, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.</span></div><div id="i1123c47dec074269b382540ae6206c28_130"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,638&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,082&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,968)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,491)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,938)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,471)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,085)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,658&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Percentage change of over 500%</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,010&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,274&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,454)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,812)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,647)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,376)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,541)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,256)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,713)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,713&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Percentage change of over 500%</span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the three months ended June&#160;30, 2021, was $12.7 million, as compared to $7.0 million for the same period in 2020, an increase of $5.6 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the six months ended June&#160;30, 2021, was $25.8 million, as compared to $11.1 million for the same period in 2020, an increase of $14.7 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and 2020, we managed a total of 12 and 13 groups of affiliated physicians, respectively, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.1 million and 1.1 million, respectively. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the three months ended June&#160;30, 2021, was $175.6 million, as compared to $165.2 million for the three months ended June&#160;30, 2020, an increase of $10.5 million, or 6%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $3.6 million driven by membership growth at APC and ACMG, which contributed additional capitation revenue of approximately $13.1&#160;million, offset with a decrease in capitation revenue at APA ACO and AHC of $6.5 million and $2.9 million, respectively. The decrease in revenue at APA ACO was due to timing of claims expenditures incurred and the decrease at AHC was a result of membership reductions. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Risk pool settlement and incentive revenue increased by $4.2 million primarily due to reduced utilization at ApolloMed&#8217;s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, as these revenues from ApolloMed's partner hospitals reflect a 15-18 month lag.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (iii) Fee for service increased by approximately $2.4 million due to increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the six months ended June&#160;30, 2021, was $351.7 million, as compared to $330.3 million for the six months ended June&#160;30, 2020, an increase of $21.4 million, or 6%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $7.9 million driven by membership growth at APC and ACMG and higher average capitation rate at APC, which contributed additional capitation revenue of approximately $25.7&#160;million, offset with a decrease in capitation revenue at APA ACO and AHC of $11.2 million and $6.6 million, respectively. The decrease in revenue at APA ACO was due to timing of claims expenditures incurred and the decrease at AHC was a result of membership reductions. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Risk pool settlement and incentive revenue increased by $11.0 million primarily due to reduced utilization at ApolloMed&#8217;s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, as these revenues from ApolloMed's partner hospitals reflect a 15-18 month lag. In addition, the Company received a $4.5 million settlement related to prior year risk pool. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Fee for service increased by approximately $2.0 million due to increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services, excluding depreciation and amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the three months ended June&#160;30, 2021, were $136.2 million, as compared to $136.1 million for the same period in 2020, an increase of $0.1 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the six months ended June&#160;30, 2021, were $276.8 million, as compared to $280.3 million for the same period in 2020, a decrease of $3.5 million. The overall decrease was primarily due to a reduction of claims expenditures incurred at APA ACO.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended June&#160;30, 2021, were $14.2 million, as compared to $11.6 million for the same period in 2020, an increase of $2.6 million, or 23%. The increase was primarily due to costs incurred as a result of the execution of the Amended Credit Facility agreement. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the six months ended June&#160;30, 2021, were $23.7 million, as compared to $23.4 million for the same period in 2020, an increase of $0.3 million, or 1%. The increase is primarily due to costs incurred as a result of the execution of the Amended Credit Facility agreement. This is partially offset by a reduction in consulting and professional costs as a result of efficiencies gained from our continued development of our in-house technology platform of approximately $1.0 million and the elimination of rent expense for properties leased by MPP, ZLL, and AMG Properties as a result of the Company's acquisition of these entities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the three months ended June&#160;30, 2021 were $4.2 million, as compared to $4.6 million for the same period in 2020. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the six months ended June&#160;30, 2021 were $8.4 million, as compared to $9.3 million for the same period in 2020. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Loss) Income from Equity Method Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from equity method investments for the three months ended June&#160;30, 2021, was $3.1 million, as compared to income from equity method investments of $0.8 million for the same period in 2020, a decrease of $4.0 million. The decrease was primarily due to our investment in LMA. The Company incurred a loss of $3.8 million from LMA as a result of increased claims expense.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from equity method investments for the six months ended June&#160;30, 2021, was $3.8 million, as compared to income from equity method investments of $2.9 million for the same period in 2020, a decrease of $6.7 million. The decrease was partially due to the sale of UCI in April 2020. For the six months ended June 30, 2020, UCI contributed equity earnings of $3.6 million. The additional decrease is from our investment in LMA. For the six months ended June&#160;30, 2021, the Company incurred a loss of $3.9 million from LMA as a result of increased claims expense.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended June&#160;30, 2021, was $1.9 million, as compared to $2.7 million for the same period in 2020, a decrease of $0.8 million.  Interest expense for the six months ended June&#160;30, 2021, was $3.4 million, as compared to $5.5 million for the same period in 2020, a decrease of $2.2 million. Interest expense reflected was primarily for interest incurred on our Credit Facility. The decrease in interest expense for the three and six months ended June&#160;30, 2021 was primarily due to the Company refinancing their Credit Facility to the Amended Credit Facility in June 2021 and lower interest rates for the three and six months ended June 30, 2021 as compared to the same periods in 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three and six months ended June&#160;30, 2021, was $0.6 million and $0.9 million, respectively, as compared to $0.9 million and $1.8 million, respectively, for the three and six months ended June&#160;30, 2020. Interest income reflects interest earned on cash held in money market and certificate of deposit accounts and the interest from notes receivable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the three months ended June&#160;30, 2021, was $67.9 million, as compared to $1.3 million for the same period in 2020, an increase of $66.6 million. Other income for the six months ended June&#160;30, 2021, was $69.2 million, as compared to $1.4 million for the same period in 2020, an increase of $67.8 million. The increase in other income was primarily due to an unrealized gain of $83.8 million as a result of a 1-to-3 conversion of a payer partner&#8217;s preferred shares to common stock as a result of the payer partner becoming a public company. The increase was partially offset by a $15.7 million write-off of the Company&#8217;s beneficial interest receivable. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Tax</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $24.9 million for the three months ended June&#160;30, 2021, as compared to $31.9 million for the same period in 2020. The decrease in tax expense was due to a decrease in pre-tax income for the three months ended June&#160;30, 2021, period as compared to the same period in 2020, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $31.7 million for the six months ended June&#160;30, 2021, as compared to $33.5 million for the same period in 2020. The decrease in tax expense was due to decrease in pre-tax income for the six months ended June&#160;30, 2021, period as compared to the same period in 2020, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests for the three months ended June&#160;30, 2021 and June&#160;30, 2020, was $46.9 million and $74.0 million, respectively, a decrease of $27.1 million. The decrease was primarily driven by the sale of UCI in April 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests for the six months ended June&#160;30, 2021 and June 30,2020, was $48.2 million and $72.9 million, respectively, a decrease of $24.7 million. The decrease was primarily driven by the sale of UCI in April 2020.</span></div><div id="i1123c47dec074269b382540ae6206c28_136"></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Guidance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;ApolloMed is raising its full-year 2021 guidance, previously disclosed on March 10, 2021, and subsequently reiterated on May 5, 2021,  as a result of our continued organic growth and encouraging results in the first half of the year. Net income and EBITDA include the impact of APC's investment in a payer partner, which completed an initial public offering to become a publicly traded company in June 2021. As APC's investment is an excluded asset solely for the benefit of APC and its shareholders, any gains or losses as a result of this investment do not affect the net income attributable to ApolloMed and adjusted EBITDA attributable to ApolloMed. The revised net income and EBITDA guidance ranges assumes a share price of $8.49 on close of August 3, 2021. These assumptions are based on the Company&#8217;s existing business, current view of existing market conditions and assumptions for the year ending December&#160;31, 2021. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Guidance Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Guidance Range</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(as of March 10, 2021)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(as of August 5, 2021)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to ApolloMed</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See &#8220;Guidance Reconciliation of Net Income to EBITDA and adjusted EBITDA&#8221; and &#8220;Use of Non-GAAP Financial Measures&#8221; for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See &#8220;Forward-Looking Statements&#8221; within this Quarterly Report on Form 10-Q.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Guidance Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Guidance Range</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(as of March 10, 2021)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(as of August 5, 2021)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in payer partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider bonus payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,500&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Non-GAAP Financial Measures</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with GAAP is net (loss) income. These measures are not in accordance with, or an alternative to, U.S. generally accepted accounting principles (&#8220;GAAP&#8221;), and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations,&#160;for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income from equity method investments, provider bonuses, impairment of intangibles, provision of doubtful accounts, and other income earned that is not related to the Company&#8217;s normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company&#8217;s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div id="i1123c47dec074269b382540ae6206c28_139"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investment in marketable securities at June&#160;30, 2021, totaled $364.5 million as compared to $261.2 million at December&#160;31, 2020. Working capital totaled $342.5 million at June&#160;30, 2021, as compared to $223.6 million at December&#160;31, 2020, an increase of $118.9 million, or 53%.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups and fee-for-service reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and restricted cash decreased by $16.7 million from $194.0 million at December&#160;31, 2020, to $177.3 million at June&#160;30, 2021. Cash provided by operating activities for the six months ended June&#160;30, 2021, was $31.3 million, as compared to cash provided by operating activities of $12.6 million for the six months ended June&#160;30, 2020. The increase in cash provided by operating activities was primarily driven by increase in earnings adjusted for non-cash items of approximately $44.6 million for the six months ended June 30, 2021 compared to the six months ended June 30, 2020. This was offset with increased cash usage related to our working capital accounts of $25.9 million for the six months ended June 30, 2021 as compared to the six months ended June 30, 2020, including $8.3 million in receivables, net &#8211; related parties and payments for income taxes, accounts payable and accrued expenses of $19.7 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities during the six months ended June&#160;30, 2021, was $9.8 million, primarily due to purchases of property and equipment of $7.4 million, prepayment for investment purchase of $4.5 million, funding for an equity method investment of $1.7 million, and purchase of marketable securities of $0.7 million. The cash used in investing activities was partially offset by cash received from consolidation of Tag 8 of $3.3 million and proceeds from sale of marketable securities of $1.1 million. This is compared to cash provided by investing activities of $67.2 million for the six months ended June&#160;30, 2020 due to the proceeds received related to the sale of UCI totaling $52.7 million and proceeds from loan receivable repayment of $16.5 million. The proceeds were offset with cash used to purchase marketable securities of $1.1 million, funding for an equity method investment of $0.5 million, and capital expenditures (mainly purchases of property and equipment) of $0.5 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the six months ended June&#160;30, 2021, was $38.2 million as compared to cash used in financing activities of $30.5 million for the six months ended June&#160;30, 2020. Cash used for the six months ended June&#160;30, 2021 was primarily due to repayment of long-term debt of $238.2 million, dividend payment of $21.1 million, and repurchase of shares of $3.0 million. The cash used in financing activities was partially offset by a drawdown of $180.0 million on the Amended Credit Facility, proceeds from sale of shares of $40.1 million, and proceeds from the exercise of options and warrants of $4.8 million. This is compared to cash used in the six months period ended June&#160;30, 2020 of $30.5 million due to dividend payment of $30.2 million, repayment of long-term debt totaling $2.4 million and repurchase of shares of $0.8 million, offset with proceeds from exercise of stock options and warrants of $2.9 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excluded Assets</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement, which clarified the term &#8220;Excluded Assets&#8221;. &#8220;Excluded Assets&#8221; means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, Excluded Assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Excluded Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,923&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,087&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i1123c47dec074269b382540ae6206c28_148"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,705&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the &#8220;Credit Facility&#8221;) with Truist Bank (f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders. The Credit Agreement provided a five-year revolving credit facility to the Company of $100.0 million, which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provided a term loan of $190.0 million. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Well Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a five-year revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenant Ratios </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Requirement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated leverage ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 3.75 to 1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated interest coverage ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 3.25 to 1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.17</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) All covenant ratio titles utilize terms as defined in the respective debt agreements. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this Quarterly Report on Form 10-Q for additional information. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2021 and 2020, were 2.31% and 3.93%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2021 and 2020, of $0.4 million and $0.3 million, respectively, and $0.3 million and $0.7 million, respectively. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase, APC assumed $6.4&#160;million, $0.7&#160;million, and $0.7&#160;million of existing loans held by MPP, AMG Properties, and ZLL, respectively. Refer to Note 8 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;) that allows Tag 8 to borrow up to $10.7 million. Tag 8 is a VIE consolidated by the Company. Refer to Note 8 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221; to our consolidated financial statements under Item 1 in this quarterly report on Form 10-Q for additional information.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to decrease loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit. The amendment also reclassified, as a permitted lien, the security interest in all of APC&#8217;s assets granted in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Loans</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of AMH, MMG, AKM Medical Group, Inc. (&#8220;AKM&#8221;), SCHC, and Bay Area Hospitalist Associates (&#8220;BAHA&#8221;) has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitment to each such affiliated entity in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM&#8217;s obligation to make any advances automatically terminates upon the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).  </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intercompany Credit Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest<br/>Rate<br/>per Annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During&#160;Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,679&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div id="i1123c47dec074269b382540ae6206c28_154"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions and estimates that affect the amounts of revenue, expenses, income, assets, and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions, and estimates. In addition, judgments, assumptions, and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions, and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions.&#160;We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 thereto. Please also refer to the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div id="i1123c47dec074269b382540ae6206c28_157"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to the accompanying consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.</span></div><div id="i1123c47dec074269b382540ae6206c28_160"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had no off-balance sheet arrangements that are or have been reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.</span></div><div id="i1123c47dec074269b382540ae6206c28_163"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation and changing prices have had de minimis effect on our continuing operations over our two most recent fiscal years.</span></div><div id="i1123c47dec074269b382540ae6206c28_166"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of June&#160;30, 2021, we had $180.0&#160;million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Credit Agreement bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR. In addition, as of June&#160;30, 2021, Tag 8, a VIE consolidated by the Company, had $0.1&#160;million in outstanding borrowings for the Construction Loan.  Interest rate on the &#8220;Construction Loan&#8221; is equal to an index rate determined by the bank. Furthermore, as of June&#160;30, 2021, APC had $7.5 million in outstanding borrowings for real estate loans related to ZLL, MPP, and AMG Properties (&#8220;Real Estate Loans&#8221;). Each agreement bears interest that is subject to change from time to time based on changes in an independent index, which is the daily Wall Street Journal Prime Rate, as quoted in the &#8220;Money Rates&#8221; column of The Wall Street Journal (Western edition) as determined by the Lender (the &#8220;Index&#8221;). On the dates of the agreement, the Index is 3.250% per annum. Under no circumstances will the interest rate on this loan be less than 3.500% per annum or more than the maximum rate allowed by applicable law. The Company has entered into interest rate swap agreements for certain of these agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loan, and Real Estate Loans would have increased or decreased our interest expense for the three months ended June&#160;30, 2021, by $1.9 million.</span></div><div id="i1123c47dec074269b382540ae6206c28_169"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of June&#160;30, 2021, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under Exchange Act) during our second fiscal quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i1123c47dec074269b382540ae6206c28_172"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="i1123c47dec074269b382540ae6206c28_175"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we from time to time become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services that are provided by our affiliated hospitalists. Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services, which may not come to light until a substantial period of time has passed following contract implementation. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding which management expects to, individually or in the aggregate, have a material adverse effect on us or our business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div id="i1123c47dec074269b382540ae6206c28_178"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition, and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as&#160;risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on March&#160;15, 2021. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows, or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, &#8220;Financial Statements&#8221; and Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company&#8217;s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div id="i1123c47dec074269b382540ae6206c28_181"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None for the three months ended June&#160;30, 2021.</span></div><div id="i1123c47dec074269b382540ae6206c28_184"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None </span></div><div id="i1123c47dec074269b382540ae6206c28_187"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i1123c47dec074269b382540ae6206c28_190"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (the &#8220;Merger Agreement&#8221;) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017, that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp., and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock purchase agreement dated March 15, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">(incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 16, 2015)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm">Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-1.htm">Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-3.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-4.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series A Warrant&#8221;) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-6.htm">Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series B Warrant&#8221;) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-8.htm">Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020003626/ameh-20191231xexx410.htm">Description of Registered Securities</a></span></div><div style="text-align:justify"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex102021063010-q.htm">Amended and Restated Credit Agreement dated as of June 16, 2021, by and among Apollo Medical Holdings, Inc., as Borrower, the Lenders from time to time party thereto, and Truist Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex31120210630110-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex3122021063010-q.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3132021063010-q.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322021063010-q.htm">Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The schedules and exhibits thereof have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i1123c47dec074269b382540ae6206c28_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 6, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kenneth Sim</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth Sim, M.D.<br/>Executive Chairman &amp; Co-Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 6, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Lam</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.<br/>Co-Chief Executive Officer &amp; President<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: August 6, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Eric Chin</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Chin<br/>Chief Financial Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>ex102021063010-q.htm
<DESCRIPTION>EX-10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id55ab9f14ecd402db5a3e5a411c9a975_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Execution Version</font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deal CUSIP&#58; 03768KAA9</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revolver CUSIP&#58; 03768KAB7</font></div><div style="margin-bottom:18pt;text-align:right"><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CREDIT AGREEMENT   </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">dated as of June 16, 2021</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">among</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Borrower</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE LENDERS FROM TIME TO TIME PARTY HERETO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRUIST BANK</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Administrative Agent </font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRUIST SECURITIES, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JPMORGAN CHASE BANK, N.A.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MUFG UNION BANK, N.A.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PREFERRED BANK</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ROYAL BANK OF CANADA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIFTH THIRD BANK, NATIONAL ASSOCIATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as Joint Lead Arrangers</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1.5pt double #000000;padding:0 1pt"><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-indent:36pt"><font><br></font></div></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="id55ab9f14ecd402db5a3e5a411c9a975_79"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:12pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Page</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article I DEFINITIONS&#59; CONSTRUCTION</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Definitions</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Classifications of Loans and Borrowings</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounting Terms and Determination</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">44</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Terms Generally</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Divisions</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 1.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LIBOR</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article II AMOUNT AND TERMS OF THE COMMITMENTS</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">46</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General Description of Facilities</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revolving Loans</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">46</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Procedure for Revolving Borrowings</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Swingline Commitment.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Reserved&#93;.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Funding of Borrowings.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest Elections.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">49</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Optional Reduction and Termination of Commitments.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Repayment of Loans.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Evidence of Indebtedness.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Optional Prepayments</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mandatory Prepayments.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest on Loans.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fees.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computation of Interest and Fees.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inability to Determine Interest Rates.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">54</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.17</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Illegality</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Increased Costs.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Funding Indemnity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">57</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Taxes.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">57</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payments Generally&#59; Pro Rata Treatment&#59; Sharing of Set-offs.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Letters of Credit.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">62</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.23</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Increase of Commitments&#59; Additional Lenders.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">67</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mitigation of Obligations</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">71</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.25</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement of Lenders</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">71</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 2.26</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Defaulting Lenders.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">71</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article III CONDITIONS PRECEDENT TO LOANS AND LETTERS OF CREDIT</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">74</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Conditions to Effectiveness</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">74</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Conditions to Each Credit Event</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Delivery of Documents</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">78</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 3.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Effect of Amendment and Restatement</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">78</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article IV REPRESENTATIONS AND WARRANTIES</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">78</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existence&#59; Power</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Organizational Power&#59; Authorization</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Governmental Approvals&#59; No Conflicts</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial Statements</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Litigation and Environmental Matters.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">79</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance with Laws and Agreements</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investment Company Act</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Taxes</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Margin Regulations</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ERISA</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">80</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ownership of Property&#59; Insurance.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">81</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Disclosure.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Labor Relations</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsidiaries</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Solvency</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">83</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deposit and Disbursement Accounts</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">83</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.17</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collateral Documents.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">83</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Associated Practice Documents&#59; APC 2019 Transaction Documents</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">84</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Material Agreements</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">84</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sanctions and Anti-Corruption Laws.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">84</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Affected Financial Institutions</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">84</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Healthcare Matters</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">84</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 4.23</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Use of Proceeds</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">84</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article V AFFIRMATIVE COVENANTS</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">85</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Financial Statements and Other Information</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">85</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notices of Material Events.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">86</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existence&#59; Conduct of Business</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance with Laws</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payment of Obligations</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Books and Records</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Visitation and Inspection&#59; Lender Meetings</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">89</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Maintenance of Properties&#59; Insurance</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Use of Proceeds&#59; Margin Regulations</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">90</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Casualty and Condemnation</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash Management</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional Subsidiaries and Collateral.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">91</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additional Real Estate&#59; Leased Locations.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">92</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Further Assurances</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">92</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Healthcare Matters</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">93</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Associated Practice Documents</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">93</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 5.17</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Post-Closing Obligations</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">93</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article VI FINANCIAL COVENANTS</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">93</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consolidated Total Net Leverage Ratio</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">93</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 6.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Consolidated Interest Coverage Ratio</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">94</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article VII NEGATIVE COVENANTS</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">94</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indebtedness and Preferred Equity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">94</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Liens&#59; Negative Pledge</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">97</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fundamental Changes.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">98</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments, Loans</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">99</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted Payments</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sale of Assets</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Transactions with Affiliates</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">103</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restrictive Agreements</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sale and Leaseback Transactions</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Hedging Transactions</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amendment to Material Documents</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Associated Practice Documents</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounting Changes</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sanctions and Anti-Corruption Laws</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 7.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lease Obligations</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article VIII EVENTS OF DEFAULT</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">106</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Events of Default</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">106</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 8.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Application of Proceeds from Collateral</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">109</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article IX THE ADMINISTRATIVE AGENT</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">110</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Appointment of the Administrative Agent.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">110</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nature of Duties of the Administrative Agent</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">111</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lack of Reliance on the Administrative Agent</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">112</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain Rights of the Administrative Agent</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">112</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Reliance by the Administrative Agent</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">112</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Administrative Agent in its Individual Capacity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Successor Administrative Agent.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Withholding Tax</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">114</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Administrative Agent May File Proofs of Claim.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">114</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Authorization to Execute Other Loan Documents</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">115</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collateral and Guaranty Matters</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">115</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No Other Duties&#59; Designation of Additional Agents</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">115</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Right to Realize on Collateral and Enforce Guarantee</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">115</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Secured Bank Product Obligations and Hedging Obligations</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">116</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 9.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Erroneous Payments</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">116</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Article X MISCELLANEOUS</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">118</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notices.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">118</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Waiver&#59; Amendments.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">122</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expenses&#59; Indemnification.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">124</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Successors and Assigns.</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">125</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Governing Law&#59; Jurisdiction&#59; Consent to Service of Process.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">129</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WAIVER OF JURY TRIAL</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">130</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Right of Set-off</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">130</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Counterparts&#59; Integration</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">131</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Survival</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">131</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Severability</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">131</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Confidentiality</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">132</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest Rate Limitation</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">132</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Waiver of Effect of Corporate Seal</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Patriot Act</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No Advisory or Fiduciary Responsibility</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Location of Closing</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.17</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Independence of Covenants</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Acknowledgement and Consent to Bail-In of Affected Financial Institutions</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">133</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Certain ERISA Matters.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">134</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Acknowledgement Regarding Any Supported QFCs</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">135</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Section 10.21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Electronic Signatures</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">136</font></div></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#91;Omitted Schedules and Exhibits&#93;</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedules</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"><tr><td style="width:1.0%"></td><td style="width:28.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule I</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Applicable Margin and Applicable Percentage</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule II</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commitment Amounts</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 1.1(a)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Associated Practices</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 1.1(b)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Associated Practice Documents</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 2.22</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Letters of Credit</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 4.5</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Environmental Matters</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 4.14</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsidiaries</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 4.16</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deposit and Disbursement Accounts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 4.19</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Material Agreements</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 5.17</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Post-Closing Obligations</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 7.1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Indebtedness</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 7.2</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Liens</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 7.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Investments</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Schedule 7.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 20.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Existing Transactions with Affiliates</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibits</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.628%"><tr><td style="width:1.0%"></td><td style="width:28.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:65.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit A</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Assignment and Acceptance</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 2.3</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Notice of Revolving Borrowing</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 2.4</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Notice of Swingline Borrowing</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 2.7</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Notice of Conversion&#47;Continuation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibits 2.20A &#8211; D</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tax Certificates</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 3.1(b)(ii)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Secretary&#8217;s Certificate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 3.1(b)(v)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Officer&#8217;s Certificate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 5.1(c)</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">_</font></td><td colspan="3" style="padding:2px 1pt 2px 19.47pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Form of Compliance Certificate</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">v</font></div></div></div><div id="id55ab9f14ecd402db5a3e5a411c9a975_94"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CREDIT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> AMENDED AND RESTATED CREDIT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of June 16, 2021, by and among </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), those several banks and other financial institutions and lenders from time to time party hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRUIST BANK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in its capacity as administrative agent for the Lenders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as issuing bank (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Issuing&#160;Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and as swingline lender (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Swingline Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">W I T N E S S E T H&#58;</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Borrower, certain of the Lenders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Truist Bank, successor by merger to SunTrust Bank, as administrative agent, are parties to that certain Credit Agreement, dated as of September 11, 2019 (as amended, restated, supplemented or otherwise modified from time to time prior to the date hereof, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Borrower has requested that the Existing Lenders and the Administrative Agent amend and restate the Existing Credit Agreement and the Lenders establish a $400,000,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">revolving credit facility in favor of the Borrower&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, subject to the terms and conditions of this Agreement, the Existing Lenders and the Administrative Agent are willing to amend and restate the Existing Credit Agreement, and the Lenders, the Issuing Banks and the Swingline Lender, to the extent of their respective Commitments as defined herein, are willing severally to establish the requested revolving credit facility (including letters of credit and swingline subfacilities) in favor of the Borrower on the terms and conditions of this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in consideration of the premises and the mutual covenants herein contained, the Borrower, the Lenders, the Administrative Agent, the Issuing Bank and the Swingline Lender agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>DEFINITIONS&#59; CONSTRUCTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition to the other terms defined herein, the following terms used herein shall have the meanings herein specified (to be equally applicable to both the singular and plural forms of the terms defined)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) any Investment by the Borrower or any of its Subsidiaries in any other Person organized in the United States (with substantially all of the assets of such Person and its Subsidiaries located in the United States), pursuant to which such Person shall become a Subsidiary of the Borrower or any of its Subsidiaries or shall be merged with the Borrower or any of its Subsidiaries or (b) any acquisition by the Borrower or any of its Subsidiaries of the assets of any Person (other than a Subsidiary of the Borrower) that constitute all or substantially all of the assets of such Person or a division or business unit of such Person, whether through purchase, merger or other business combination or transaction (and all or substantially all of such assets, division or business unit are located in the United States).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Adjusted LIBO Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Interest Period for a Eurodollar Loan, (i) the rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> equal to the London interbank offered rate for deposits in Dollars appearing on Reuters screen page LIBOR 01 (or on any successor or substitute page of such service or any successor to such service, or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) at approximately 11&#58;00 A.M. (London time) two (2) Business Days prior to the first day of such Interest Period, with a maturity comparable to such Interest Period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if such rate is less than zero, such rate shall be deemed to be zero), divided by (ii) a percentage equal to 100% </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the then stated maximum rate of all reserve requirements (including any marginal, emergency, supplemental, special or other reserves and without benefit of credits for proration, exceptions or offsets that may be available from time to time) expressed as a decimal (rounded upward to the next 1&#47;100th of 1%) applicable to any member bank of the Federal Reserve System in respect of Eurocurrency liabilities as defined in Regulation D (or any successor category of liabilities under Regulation D)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if the rate referred to in clause (i) above is not available at any such time for any reason, then the rate referred to in clause (i) shall instead be the interest rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as determined by the Administrative Agent, to be the arithmetic average of the rates </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> at which deposits in Dollars in an amount equal to the amount of such Eurodollar Loan are offered by major banks in the London interbank market to the Administrative Agent at approximately 11&#58;00 A.M. (London time), two (2) Business Days prior to the first day of such Interest Period. For purposes of this Agreement, the Adjusted LIBO Rate will not be less than zero percent (0%).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Truist Bank, in its capacity as administrative agent under any of the Loan Documents, or any successor administrative agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Questionnaire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Lender, an administrative questionnaire in the form provided by the Administrative Agent and submitted to the Administrative Agent duly completed by such Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Administrative Services Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Administrative Services Agreement, dated as of May 10, 2019 and effective as of the Original Closing Date, between NMM and AP-AMH.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affected Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) any EEA Financial Institution or (b) any UK Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, another Person that directly, or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with, the specified Person. For the purposes of this definition, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ability to exercise voting power, by control or otherwise. The terms &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; have meanings correlative thereto.  Associated Practices shall be deemed not to be an Affiliate of any Loan Party or any Subsidiary thereof.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Aggregate Revolving Commitment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the aggregate principal amount of the Aggregate Revolving Commitments from time to time.  On the Closing Date, the Aggregate Revolving Commitment Amount is $400,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Aggregate Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, all Revolving Commitments of all Lenders at any time outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Alpha Care</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Alpha Care Medical Group, Inc., a California professional corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all laws, rules and regulations of any jurisdiction applicable to the Borrower and&#47;or its Subsidiaries concerning or relating to bribery or corruption.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Allied Physicians of California, a Professional Medical Corporation, a California professional medical corporation, doing business as Allied Pacific IPA. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC 2019 Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the AP-AMH Loan Documents, the Tradename Licensing Agreement, the Administrative Services Agreement, and all other agreements or instruments executed in connection with the APC 2019 Transactions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC 2019 Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, each of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the execution and delivery of and performance under (1) the AP-AMH Loan Documents (including the funding of the AP-AMH Loan thereunder), (2) the Tradename Licensing Agreement and (3) the Administrative Services Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the consummation of the acquisition by AP-AMH of the Series A Preferred Stock for consideration in an amount equal to $545,000,000 pursuant to the Series A Preferred SPA&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the consummation of the acquisition by APC of 15,000,000 shares of common Capital Stock of the Borrower for consideration in an amount equal to $300,000,000 as set forth in that certain Stock Purchase Agreement, dated May 10, 2019 and effective as of the Original Closing Date, by and between APC and the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC Approved Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (i) any Permitted Investment, (ii) any dividend or distribution to the holders of the common Capital Stock of APC, (iii) any repurchase of common Capital Stock of APC from the holders thereof, (iv) the payment of any Taxes relating to or arising from any of the Excluded Assets or APC 2019 Transactions, or (v) the funding of any losses, deficits or working capital support on account of the Excluded Assets in an amount not to exceed $125,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC Excluded Asset Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning in the defined term &#8220;APC Excluded Assets&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC Excluded Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the &#8220;Excluded Assets&#8221; as defined in the Certificate of Determination (as in effect on the Closing Date)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the net cash proceeds that were received by APC in connection with the APC 2019 Transactions (including, for the avoidance of doubt, cash proceeds from the sale or assignment of Capital Stock of the Borrower by APC following the Original Closing Date) shall be included in &#8220;APC Excluded Assets&#8221; so long as held by APC and deposited in a segregated identifiable deposit account (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC Excluded Asset Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC Non-Recourse Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Indebtedness incurred by APC for which the holder of such Indebtedness has no recourse, directly or indirectly, to the Borrower, APC or any of their respective Subsidiaries or to any property (except as provided in the last sentence of this definition) of the Borrower, APC or any of their respective Subsidiaries in respect of all or any portion of such Indebtedness, and for which none of the Borrower, APC or any of their respective Subsidiaries are directly or indirectly liable for such Indebtedness.  Notwithstanding the foregoing, Indebtedness of APC shall be &#8220;APC Non-Recourse Indebtedness&#8221; if the holder of such Indebtedness has recourse that is limited solely to one or more of the APC Excluded Assets in which a Lien has been granted therein by APC pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">7.2(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC Performance Incentive Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the portion of APC&#8217;s net income from healthcare services in excess of the &#8220;Series A Preferred Dividend&#8221;, if any, that APC&#8217;s shareholders are entitled to retain pursuant to the Certificate of Determination.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">APC Shareholder Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Special Purpose Shareholder Agreement of Allied Physicians of California, a Professional Medical Corporation dated as of May 10, 2019 as in effect as of the Original Closing Date.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Lending Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for each Lender and for each Type of Loan, the &#8220;Lending Office&#8221; of such Lender (or an Affiliate of such Lender) designated for such Type of Loan in the Administrative Questionnaire submitted by such Lender or such other office of such Lender (or such Affiliate of such Lender) as such Lender may from time to time specify to the Administrative Agent and the Borrower as the office by which its Loans of such Type are to be made and maintained.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date, with respect to interest on all Loans outstanding on such date, or the letter of credit fee, as the case may be, the percentage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> determined by reference to the applicable Consolidated Total Net Leverage Ratio in effect on such date as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that a change in the Applicable Margin resulting from a change in the Consolidated Total Net Leverage Ratio shall be effective on the second Business Day after which the Borrower delivers each of the financial statements required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the Compliance Certificate required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if at any time the Borrower shall have failed to deliver such financial statements and such Compliance Certificate when so required, the Applicable Margin shall be at Pricing Level VI as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> until such time as such financial statements and Compliance Certificate are delivered, at which time the Applicable Margin shall be determined as provided above. Notwithstanding the foregoing, (A) the Applicable Margin from the Closing Date until the date by which the financial statements and Compliance Certificate for the Fiscal Quarter ending June 30, 2021 are required to be delivered shall be at Pricing Level II as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (B) Pricing Level I as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be eligible to apply as the Applicable Margin at any time until the date by which the financial statements and Compliance Certificate for the Fiscal Quarter ending September 30, 2021 are required to be delivered. In the event that any financial statement or Compliance Certificate delivered hereunder is shown to be inaccurate (regardless of whether this Agreement or the Commitments are in effect or any Loans are outstanding when such inaccuracy is discovered), and such inaccuracy, if corrected, would have led to the application of a higher Applicable Margin based upon the pricing grid set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Accurate Applicable Margin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for any period that such financial statement or Compliance Certificate covered, then (i) the Borrower shall immediately deliver to the Administrative Agent a correct financial statement or Compliance Certificate, as the case may be, for such period, (ii) the Applicable Margin shall be adjusted such that after giving effect to the corrected financial statement or Compliance Certificate, as the case may be, the Applicable Margin shall be reset to the Accurate Applicable Margin based upon the pricing grid set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule&#160;I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for such period and (iii) the Borrower shall immediately pay to the Administrative Agent, for the account of the Lenders, the accrued additional interest and fees owing as a result of such Accurate Applicable Margin for such period. The provisions of this definition shall not limit the rights of the Administrative Agent and the Lenders with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date, with respect to the Commitment Fee as of such date, the percentage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> determined by reference to the Consolidated Total Net Leverage Ratio in effect on such date as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that a change in the Applicable Percentage resulting from a change in the Consolidated Total Net Leverage Ratio shall be effective on the second Business Day after which the Borrower delivers each of the financial statements required by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the Compliance Certificate required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(c)&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that if at any time the Borrower shall have failed to deliver such financial statements and such Compliance Certificate when so required, the Applicable Percentage shall be at Pricing Level VI as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> until such time as such financial statements and Compliance Certificate are delivered, at which time the Applicable Percentage shall be determined as provided above. Notwithstanding the foregoing, (A) the Applicable Percentage from the Closing Date until the date by which the financial statements and Compliance Certificate for the Fiscal Quarter ending June 30, 2021 are required to be delivered shall be at Pricing Level II as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (B) Pricing Level I as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not be eligible to apply as the Applicable Percentage at any time until the date by which the financial statements and Compliance Certificate for the Fiscal Quarter ending September 30, 2021 are required to be delivered. In the event that any financial statement or Compliance Certificate delivered hereunder is shown to be inaccurate (regardless of whether this Agreement or the Commitments are in effect or any Loans are outstanding when such inaccuracy is discovered), and such inaccuracy, if corrected, would have led to the application of a higher Applicable Percentage based upon the pricing grid set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Accurate Applicable Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) for any period that such financial statement or Compliance Certificate covered, then (i) the Borrower shall immediately deliver to the Administrative Agent a correct financial statement or Compliance Certificate, as the case may be, for such period, (ii) the Applicable Percentage shall be adjusted such that after giving effect to the corrected financial statement or Compliance Certificate, as the case may be, the Applicable Percentage shall be reset to the Accurate Applicable Percentage based upon the pricing grid set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for such period and (iii) the Borrower shall immediately pay to the Administrative Agent, for the account of the Lenders, the accrued additional Commitment Fee owing as a result of such Accurate Applicable Percentage for such period. The provisions of this definition shall not limit the rights of the Administrative Agent and the Lenders with respect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (i) AP-AMH or (ii) another entity with an executive officer of the Borrower serving as a &#8220;nominee shareholder&#8221; (including where the officer as a licensed physician, rather than the Borrower, serves as the shareholder of such entity on behalf of the Borrower or a Subsidiary of the Borrower in order to achieve certain corporate, regulatory and&#47;or accounting treatment) and where such officer derives no direct financial benefit from such status.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Person (other than a natural Person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AP-AMH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean AP-AMH Medical Corporation, a California professional medical corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AP-AMH Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain $545,000,000 loan made on the Original Closing Date by the Borrower to AP-AMH.  For the avoidance of doubt, as of the Closing Date, the full original principal amount of the AP-AMH Loan remains outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">AP-AMH Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) that certain Loan Agreement, dated as of the Original Closing Date, by and between the Borrower and AP-AMH, as amended from time to time in accordance with the terms hereof and (b) that certain Security Agreement, dated as of the Original Closing Date, by AP-AMH in favor of the Borrower, as amended from time to time in accordance with the terms hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Arrangers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means an assignment and acceptance entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4(b))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and accepted by the Administrative Agent, in substantially the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto or any other form approved by the Administrative Agent. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Associated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean each professional entity or other Person (other than any Loan Party or Subsidiary thereof) that is (i)&#160;party to a Management Services Agreement with a Loan Party or (ii)&#160;an entity with an executive officer of the Borrower serving as a &#8220;nominee shareholder&#8221; (where the officer as a licensed physician, rather than the Borrower, serves as the shareholder of such entity on behalf of the Borrower, a Subsidiary of the Borrower or APC in order to achieve certain corporate, regulatory and&#47;or accounting treatment) and where such officer derives no direct financial benefit from such status.  Each Associated Practice that exists as of the Closing Date is described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Associated Practice Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, the Management Services Agreements, the Administrative Services Agreement and the Transfer Restriction Agreements,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in each case as the same may now or hereafter be in existence and be amended, restated, supplemented or otherwise modified from time to time to the extent not prohibited by this Agreement.  Each Associated Practice Document that exists as of the Closing Date is described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 1.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Availability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the period from the Closing Date to but excluding the Revolving Commitment Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Available Tenor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, as of any date of determination and with respect to the then-current Benchmark, as applicable, any tenor for such Benchmark or payment period for interest calculated with reference to such Benchmark, as applicable, that is or may be used for determining the length of an Interest Period pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of &#8220;Interest Period&#8221; pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.16(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bail-In Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bail-In Legislation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014&#47;59&#47;EU of the European Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bank Product Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; mean, collectively, all obligations and other liabilities of any Loan Party to any Bank Product Provider arising with respect to any Bank Products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bank Product Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person that, at the time it provides any Bank Product to any Loan Party, (i) is a Lender or an Affiliate of a Lender and (ii) except when the Bank Product Provider is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Truist Bank and its Affiliates, has provided prior written notice to the Administrative Agent which has been acknowledged by the Borrower of (x) the existence of such Bank Product, (y) the maximum dollar amount of obligations arising thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bank Product Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and (z) the methodology to be used by such parties in determining the obligations under such Bank Product from time to time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the term &#8220;Bank Product Provider&#8221; shall include any Person that is the Administrative Agent, an Affiliate of the Administrative Agent, a Lender or an Affiliate of a Lender as of the Closing Date or as of the date that such Person provides any Bank Product to any Loan Party, but subsequently ceases to be the Administrative Agent, an Affiliate of the Administrative Agent, a Lender or an Affiliate of a Lender, as the case may be. In no event shall any Bank Product Provider acting in such capacity be deemed a Lender for purposes hereof to the extent of and as to Bank Products except that each reference to the term &#8220;Lender&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be deemed to include such Bank Product Provider and in no event shall the approval of any such person in its capacity as Bank Product Provider be required in connection with the release or termination of any security interest or Lien of the Administrative Agent. The Bank Product Amount may be changed from time to time upon written notice to the Administrative Agent by the applicable Bank Product Provider. No Bank Product Amount may be established at any time that a Default or Event of Default exists.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Bank Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of the following services provided to any Loan Party by any Bank Product Provider&#58; (a) any treasury or other cash management services, including deposit accounts, automated clearing house (ACH) origination and other funds transfer, depository (including cash vault and check deposit), zero balance accounts and sweeps, return items processing, controlled disbursement accounts, positive pay, lockboxes and lockbox accounts, account reconciliation and information reporting, payables outsourcing, payroll processing, trade finance services, investment accounts and securities accounts, and (b) card services, including credit cards (including purchasing cards and commercial cards), prepaid cards, including payroll, stored value and gift cards, merchant services processing, and debit card services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Base Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means for any day a rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> equal to the highest of (i) the rate of interest which the Administrative Agent announces from time to time as its prime lending rate, as in effect from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Prime Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) the Federal Funds Rate, as in effect from time to time, plus 0.50%, (iii) the Adjusted LIBO Rate determined on a daily basis for an Interest Period of one (1) month, plus 1.00% (any changes in such rates to be effective as of the date of any change in such rate), and (iv) zero percent (0.00%). The Administrative Agent&#8217;s prime lending rate is a reference rate and does not necessarily represent the lowest or best rate actually charged to any customer. The Administrative Agent may make commercial loans or other loans at rates of interest at, above, or below the Administrative Agent&#8217;s prime lending rate. Any change in the Base Rate due to a change in the Prime Rate, the Federal Funds Rate, or the Adjusted LIBO Rate will be effective from and including the effective date of such change in the Prime Rate, the Federal Funds Rate, or the Adjusted LIBO Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, initially, the Adjusted LIBO Rate&#59; provided that if a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date have occurred with respect to Adjusted LIBO Rate or the then-current Benchmark, then &#8220;Benchmark&#8221; means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to clause (b) or clause (c) of Section 2.16.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for any Available Tenor, the first alternative set forth in the order below that can be determined by the Administrative Agent for the applicable Benchmark Replacement Date&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;the sum of&#58; (a) Term SOFR and (b) the related Benchmark Replacement Adjustment&#59;</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2) the sum of&#58; (a) Daily Simple SOFR and (b) the related Benchmark Replacement Adjustment&#59;</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3) the sum of&#58; (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower as the replacement for the then-current Benchmark for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as a replacement for the then-current Benchmark for U.S. dollar-denominated syndicated credit facilities at such time and (b) the related Benchmark Replacement Adjustment&#59;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in the case of clause (1), such Unadjusted Benchmark Replacement is displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion&#59; provided further that, notwithstanding anything to the contrary in this Agreement or in any other Loan Document, upon the occurrence of a Term SOFR Transition Event, and the delivery of a Term SOFR Notice, on the applicable Benchmark Replacement Date the &#8220;Benchmark Replacement&#8221; shall revert to and shall be deemed to be the sum of (a) Term SOFR and (b) the related Benchmark Replacement Adjustment, as set forth in clause (1) of this definition (subject to the first proviso above).   If the Benchmark Replacement as determined pursuant to clause (1), (2) or (3) above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this Agreement and the other Loan Documents.</font></div><div style="margin-bottom:12pt;margin-top:0.1pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement for any applicable Interest Period and Available Tenor for any setting of such Unadjusted Benchmark Replacement&#58;</font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;for purposes of clauses (1) and (2) of the definition of &#8220;Benchmark Replacement,&#8221; the first alternative set forth in the order below that can be determined by the Administrative Agent&#58;</font></div><div style="margin-top:0.1pt;text-indent:72pt"><font><br></font></div><div style="margin-top:0.1pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) as of the Reference Time such Benchmark Replacement is first set for such Interest Period that has been selected or recommended by the Relevant Governmental Body for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for the applicable Corresponding Tenor&#59;</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="margin-top:0.1pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the spread adjustment (which may be a positive or negative value or zero) as of the Reference Time such Benchmark Replacement is first set for such Interest Period that would apply to the fallback rate for a derivative transaction referencing the ISDA Definitions to be effective upon an index cessation event with respect to such Benchmark for the applicable Corresponding Tenor&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;for purposes of clause (3) of the definition of &#8220;Benchmark Replacement,&#8221; the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower for the applicable Corresponding Tenor giving due consideration to (i) any selection </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or recommendation of a  spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body on the applicable Benchmark Replacement Date or (ii) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for U.S. dollar-denominated syndicated credit facilities at such time&#59;</font></div><div style="margin-top:0.1pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;margin-top:0.1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in the case of clause (1) above, such adjustment is displayed on a screen or other information service that publishes such Benchmark Replacement Adjustment from time to time as selected by the Administrative Agent in its reasonable discretion.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement Conforming Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#8220;Base Rate,&#8221; the definition of &#8220;Business Day&#8221;, the definition of &#8220;Interest Period,&#8221; timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation notices, length of lookback periods, the applicability of breakage provisions, and other technical, administrative, or operational matters) that the Administrative Agent decides in its reasonable discretion may be appropriate to reflect the adoption and implementation of such Benchmark Replacement and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of such Benchmark Replacement exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement and the other Loan Documents).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Replacement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the earliest to occur of the following events with respect to the then-current Benchmark&#58; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;in the case of clause (1) or (2) of the definition of &#8220;Benchmark Transition Event,&#8221; the later of (a) the date of the public statement or publication of information referenced therein and (b) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof)&#59; </font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;in the case of clause (3) of the definition of &#8220;Benchmark Transition Event,&#8221; the date of the public statement or publication of information referenced therein&#59; or</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;in the case of a Term SOFR Transition Event, the date that is thirty (30) days after the date a Term SOFR Notice is provided to the Lenders and the Borrower pursuant to Section 2.16(c)&#59; or</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;in the case of an Early Opt-in Election, the sixth (6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) Business Day after the date notice of such Early Opt-in Election is provided to the Lenders, so long as the Administrative Agent has not received, by 5&#58;00 p.m. (New York City time) on the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) Business Day after the date notice of such Early Opt-In Election is provided </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to the Lenders, written notice of objection to such Early Opt-in Election from Lenders comprising the Required Lenders. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, (i) if the event giving rise to the Benchmark Replacement Date occurs on the same day as, but earlier than, the Reference Time in respect of any determination, the Benchmark Replacement Date will be deemed to have occurred prior to the Reference Time for such determination and (ii) the &#8220;Benchmark Replacement Date&#8221; will be deemed to have occurred in the case of clause (1) or (2) with respect to any Benchmark upon the occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof). </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Transition Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of one or more of the following events with respect to the then-current Benchmark&#58; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof)&#59;  </font></div><div style="padding-left:90pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the U.S. Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such component), or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark (or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof)&#59; or</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are no longer representative.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the avoidance of doubt, a &#8220;Benchmark Transition Event&#8221; will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof). </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benchmark Unavailability Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, the period (if any) (x) beginning at the time that a Benchmark Replacement Date pursuant to clauses (1) or (2) of that definition has occurred if, at such time, no Benchmark Replacement has replaced the then-current Benchmark  for all purposes hereunder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and under any Loan Document in accordance with Section 2.16 and (y) ending at the time that a Benchmark Replacement has replaced the then-current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 2.16.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Beneficial Ownership Regulation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means 31 C.F.R. &#167; 1010.230.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of (a) an &#8220;employee benefit plan&#8221; (as defined in ERISA) that is subject to Title I of ERISA, (b) a &#8220;plan&#8221; as defined in and subject to Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such &#8220;employee benefit plan&#8221; or &#8220;plan&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the introductory paragraph hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a borrowing consisting of (i) any Loans of the same Type and Class made, converted or continued on the same date and, in the case of Eurodollar Loans, as to which a single Interest Period is in effect or (ii) a Swingline Loan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any day other than (i) a Saturday, Sunday or other day on which commercial banks in Charlotte, North Carolina or New York are authorized or required by law to close and (ii) if such day relates to a Borrowing of, a payment or prepayment of principal or interest on, a conversion of or into, or an Interest Period for, a Eurodollar Loan or a notice with respect to any of the foregoing, any such day that is also a day on which dealings in Dollar deposits are not conducted by and between banks in the London interbank market.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Expenditures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for any period, without duplication, (i) the additions to property, plant and equipment and other capital expenditures of the Borrower and its Subsidiaries that are (or would be) set forth on a consolidated statement of cash flows of the Borrower for such period prepared in accordance with GAAP and (ii) Capital Lease Obligations incurred by the Borrower and its Subsidiaries during such period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Lease Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean all obligations of such Person to pay rent or other amounts under any lease (or other arrangement conveying the right to use) of real or personal property, or a combination thereof, which obligations are required to be classified and accounted for as capital leases on a balance sheet of such Person under GAAP, and the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all shares, options, warrants, general or limited partnership interests, membership interests or other equivalents (regardless of how designated) of or in a corporation, partnership, limited liability company or equivalent entity whether voting or nonvoting, including common stock, preferred stock or any other &#8220;equity security&#8221; (as such term is defined in Rule 3a11-1 of the General Rules and Regulations promulgated by the Securities and Exchange Commission under the Exchange Act).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Collateralize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, to pledge and deposit with or deliver to the Administrative Agent, for the benefit of an Issuing Bank or Swingline Lender (as applicable) and the Lenders, as collateral for L&#47;C Obligations, Obligations in respect of Swingline Loans, or obligations of Lenders to fund participations in respect of either thereof (as the context may require), cash or deposit account </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">balances or, if the applicable Issuing Bank or Swingline Lender benefitting from such collateral shall agree in its sole discretion, other credit support, in each case pursuant to documentation in form and substance satisfactory to (a) the Administrative Agent and (b) the applicable Issuing Bank or the Swingline Lender (as applicable). &#8220;Cash Collateral&#8221; shall have a meaning correlative to the foregoing and shall include the proceeds of such cash collateral and other credit support. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Certificate of Determination of Preferences of Series A Preferred Stock of Allied Physicians of California, a Professional Medical Corporation dated as of May 10, 2019 as in effect as of the Original Closing Date.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the occurrence of one or more of the following events&#58; (i) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person (other than APC) or &#8220;group&#8221; (within the meaning of the Exchange Act and the rules of the Securities and Exchange Commission thereunder as in effect on the date hereof) of 35% or more of the outstanding shares of the Capital Stock of the Borrower entitled to vote generally for the election of members of the board of directors of the Borrower, (ii) during any period of 24 consecutive months, a majority of the members of the board of directors or other equivalent governing body of the Borrower cease to be composed of individuals who are Continuing Directors or (iii) the Borrower ceases to own, directly or indirectly, and control 100% (other than directors&#8217; qualifying shares) of the Capital Stock of each Subsidiary Loan Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence, after the Closing Date, of any of the following&#58; (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in any law, rule, regulation or treaty, or in the administration, interpretation, implementation or application thereof by any Governmental Authority, or (iii) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) of any Governmental Authority&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law&#8221;, regardless of the date enacted, adopted, implemented or issued.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Class</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are Revolving Loans, Swingline Loans or Incremental Term Loans and when used in reference to any Commitment, refers to whether such Commitment is a Revolving Commitment, a Swingline Commitment or an Incremental Term Loan Commitment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the date on which the conditions precedent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been satisfied or waived in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">CMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the U.S. Centers for Medicare &#38; Medicaid Services.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Internal Revenue Code of 1986, as amended and in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all tangible and intangible property, real and personal, of any Loan Party that is or purports to be the subject of a Lien to the Administrative Agent to secure the whole or any part of the Obligations or any Guarantee thereof, and shall include, without limitation, all casualty insurance proceeds and condemnation awards with respect to any of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (a) each Original Closing Date Collateral Assignment and (b) any other collateral assignment of Associated Practice Documents, (c) any collateral assignment of a seller&#8217;s representations, warranties, covenants and indemnities as required in connection with any Permitted Acquisition or other Acquisition and (d) any collateral assignment of loan documents and other agreements as may be required in connection with any Future Approved Entity Investment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Collateral Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, the Guaranty and Security Agreement, any Real Estate Documents, the Control Account Agreements, the Collateral Assignments, the Perfection Certificate, all Copyright Security Agreements, all Patent Security Agreements, all Trademark Security Agreements and all other instruments and agreements now or hereafter securing or perfecting the Liens securing the whole or any part of the Obligations or any Guarantee thereof, all UCC financing statements, fixture filings and stock powers, and all other documents, instruments, agreements and certificates executed and delivered by any Loan Party to the Administrative Agent and the Lenders in connection with the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a Revolving Commitment, a Swingline Commitment or an Incremental Commitment or any combination thereof (as the context shall permit or require).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commodity Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Commodity Exchange Act (7 U.S.C. &#167; 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.), as amended and in effect from time to time, and any successor statute.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a certificate from the principal executive officer or the principal financial officer of the Borrower in the form of, and containing the certifications set forth in, the certificate attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 5.1(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated EBITDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for the Borrower and its Subsidiaries for any period, determined on a consolidated basis (including, for the avoidance of doubt, all Associated Practices in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), an amount equal to the sum of&#58;  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Consolidated Net Income for such period, </font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;to the extent reducing Consolidated Net Income for such period, and without duplication, </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;Consolidated Interest Expense, </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;income tax expense determined on a consolidated basis in accordance with GAAP, </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;depreciation and amortization determined on a consolidated basis in accordance with GAAP, </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">transaction costs and expenses incurred in connection with the Related Transactions and any Permitted Acquisition or Future Approved Entity Investment permitted hereunder that was consummated during such period, </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unusual, one-time or non-recurring charges and expenses, including restructuring charges, integration costs, retention, recruiting and relocation expenses and expenses arising from severance of employees or management and other non-recurring </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses not otherwise added back to Consolidated EBITDA, in each case incurred during such period, as certified by a Responsible Officer of the Borrower and acceptable to the Administrative Agent in its sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the aggregate amount added back pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for any period shall not exceed fifteen percent (15%) of Consolidated EBITDA for such period (calculated before giving effect to such add-back)&#59; and </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(F)&#160;&#160;&#160;&#160;all other non-cash charges acceptable to the Administrative Agent in its sole discretion determined on a consolidated basis in accordance with GAAP, in each case for such period,</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">less</font></div><div style="margin-bottom:11pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;to the extent increasing Consolidated Net Income for such period, and without duplication, </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;unusual, one-time or non-recurring gains, </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;non-cash gains, excluding any non-cash gains that represent the reversal of any accrual of, or cash reserve for, anticipated cash items in any prior period (other than any such accruals or cash reserves that have been added back to Consolidated Net Income in calculating Consolidated EBITDA in accordance with this definition)&#59; </font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;any Consolidated EBITDA representing the net income of any Person (other than the Borrower and its Subsidiaries) that is required to be consolidated in the financial statements of the Borrower and its Subsidiaries multiplied by the percentage of such Person&#8217;s Capital Stock that is owned by a third party that is wholly unaffiliated with the Borrower and its Subsidiaries&#59; and</font></div><div style="margin-bottom:11pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;any Consolidated EBITDA representing any net income that is attributable to the owners of APC&#8217;s Capital Stock pursuant to the APC Performance Incentive Plan&#59;</font></div><div style="margin-bottom:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that for purposes of calculating compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the extent that during such period an Acquisition was consummated (including any Acquisition by an Associated Practice, Permitted Acquisition by a Loan Party or other Acquisition approved in writing by the Required Lenders), or any sale, transfer or other disposition of any Person, business, property or assets (which shall be deemed to include any Associated Practice that ceased to be an Associated Practice during such period) occurred, Consolidated EBITDA shall be calculated on a Pro Forma Basis with respect to such Person, Associated Practice, business, property or assets so acquired or disposed of&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that no payments or other amounts received by the Borrower or any Subsidiary from CMS pursuant to the &#8220;NextGen ACO shared savings program&#8221; shall be treated as unusual, one-time or non-recurring income or gains for purposes of calculating Consolidated EBITDA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Interest Coverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date, the ratio of (i) Consolidated EBITDA for the four consecutive Fiscal Quarters ending on or immediately prior to such date for which financial statements are required to have been delivered under this Agreement to (ii) Consolidated Interest Expense for the four consecutive Fiscal Quarters ending on or immediately prior to such date for which financial statements are required to have been delivered under this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Interest Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for the Borrower and its Subsidiaries for any period, determined on a consolidated basis in accordance with GAAP, the sum of (i) total interest expense, including, without limitation, the interest component of any payments in respect of Capital Lease Obligations, capitalized or expensed during such period (whether or not actually paid during such period) plus (ii) the net amount payable or expensed or deducted in calculating Consolidated Net Income (or minus the net amount receivable) with respect to Hedging Transactions during such period (whether or not actually paid or received during such period).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Lease Expense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for the Borrower and its Subsidiaries for any period, the aggregate amount of fixed and contingent rentals expensed with respect to leases of real and personal property (excluding Capital Lease Obligations) for such period determined on a consolidated basis in accordance with GAAP.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Net Income</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for the Borrower and its Subsidiaries for any period, the net income (or loss) of the Borrower and its Subsidiaries for such period determined on a consolidated basis in accordance with GAAP (including, for the avoidance of doubt, all Associated Practices in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), but excluding therefrom (to the extent otherwise included therein)&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any extraordinary gains or losses (as determined by reference to GAAP immediately prior to giving effect to FASB&#8217;s Accounting Standards Update No. 2015-01)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any gains attributable to write-ups of assets or the sale of assets (other than the sale of inventory in the ordinary course of business)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;other than with respect to any Associated Practice, the net income of any Person (other than a Subsidiary) in which the Borrower or any of its Subsidiaries has a joint interest with a third party or a minority interest, except to the extent such net income is actually paid in cash to the Borrower or any of its Subsidiaries by dividend or other distribution during such period&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;the income of any Subsidiary that is not a Loan Party to the extent that the declaration or payment of dividends or similar distributions by such Subsidiary of that income is not at the time permitted by operation of the terms of its charter or any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to such Subsidiary&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any income (or loss) of any Person accrued prior to the date it becomes a Subsidiary or is merged into or consolidated with the Borrower or any Subsidiary or the date that such Person&#8217;s assets are acquired by the Borrower or any Subsidiary</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any payments or other amounts received by the Borrower or any Subsidiary from CMS pursuant to the &#8220;NextGen ACO shared savings program&#8221; shall be treated as income for purposes of calculating Consolidated Net Income.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Total Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the consolidated total assets of the Borrower and its Subsidiaries determined in accordance with GAAP as of the date of the financial statements most recently delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Total Net Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date, (i) all Indebtedness of the Borrower and its Subsidiaries measured on a consolidated basis (including, for the avoidance of doubt, all Associated Practices in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) as of such date, but excluding Indebtedness of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">type described in subsection (xi) of the definition thereof </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">minus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ii) the amount of Qualified Cash as of such date in an amount not to exceed $50,000,000. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated Total Net Leverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, as of any date, the ratio of (i) Consolidated Total Net Debt as of such date to (ii) Consolidated EBITDA for the four consecutive Fiscal Quarters ending on or immediately prior to such date for which financial statements are required to have been delivered under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Continuing Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any period, any individuals (A) who were members of the board of directors or other equivalent governing body of the Borrower on the first day of such period, (B) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (A) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body, or (C) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (A) and (B) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Contractual Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean any provision of any security issued by such Person or of any agreement, instrument or undertaking under which such Person is obligated or by which it or any of the property in which it has an interest is bound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Control Account Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any tri-party agreement by and among a Loan Party, the Administrative Agent and a depositary bank or securities intermediary at which such Loan Party maintains a Controlled Account, in each case in form and substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Copyright</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning assigned to such term in the Guaranty and Security Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Copyright Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Copyright Security Agreement executed by a Loan Party owning registered Copyrights or applications for Copyrights in favor of the Administrative Agent for the benefit of the Secured Parties, including on the Original Closing Date and at any time thereafter (in each case as amended, restated, reaffirmed (including pursuant to the Reaffirmation Agreement), supplemented or otherwise modified from time to time).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Corresponding Tenor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; with respect to any Available Tenor shall mean, as applicable, either a tenor (including overnight) or an interest payment period having approximately the same length (disregarding business day adjustment) as such Available Tenor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Covenant Holiday</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Daily Simple SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for any day, SOFR, with the conventions for this rate (which will include a lookback) ) being established by the Administrative Agent in accordance with the conventions for this rate selected or recommended by the Relevant Governmental Body for determining &#8220;Daily Simple SOFR&#8221; for business loans&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> if the Administrative Agent decides that any such convention is not administratively feasible for the Administrative Agent, then the Administrative Agent may establish another convention in its reasonable discretion.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Debtor Relief Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Bankruptcy Code of the United States of America, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any condition or event that, with the giving of notice or the lapse of time or both, would constitute an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.13(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defaulting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(c),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> any Lender that (a) has failed to (i) fund all or any portion of its Loans within two (2) Business Days of the date such Loans were required to be funded hereunder unless such Lender notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender&#8217;s determination that one or more conditions precedent to funding (each of which conditions precedent, together with any applicable default, shall be specifically identified in such writing) has not been satisfied, or (ii) pay to the Administrative Agent, any Issuing Bank, any Swingline Lender or any other Lender any other amount required to be paid by it hereunder (including in respect of its participation in Letters of Credit or Swingline Loans) within two (2) Business Days of the date when due, (b) has notified the Borrower, the Administrative Agent or any Issuing Bank or Swingline Lender in writing that it does not intend to comply with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender&#8217;s obligation to fund a Loan hereunder and states that such position is based on such Lender&#8217;s determination that a condition precedent to funding (which condition precedent, together with any applicable default, shall be specifically identified in such writing or public statement) cannot be satisfied), (c) has failed, within three (3) Business Days after written request by the Administrative Agent or the Borrower, to confirm in writing to the Administrative Agent and the Borrower that it will comply with its prospective funding obligations hereunder (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon receipt of such written confirmation by the Administrative Agent and the Borrower), or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver, custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or federal regulatory authority acting in such a capacity or (iii) become the subject of a Bail-in Action&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under clauses (a)&#160;through (d) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> upon delivery of written notice of such determination to the Borrower, each Issuing Bank, each Swingline Lender and each Lender. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Dollar(s)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and the sign &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean lawful money of the United States.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Domestic Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean each Subsidiary of the Borrower that is organized under the laws of the United States or any state or district thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Early Opt-in Election</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, if the then-current Benchmark is the Adjusted LIBO Rate, the occurrence of&#58; </font></div><div style="margin-bottom:11pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;a notification by the Administrative Agent to (or the request by the Borrower to the Administrative Agent to notify) each of the other parties hereto that at least five currently outstanding U.S. dollar-denominated syndicated credit facilities at such time contain (as a result of amendment or as originally executed) a SOFR-based rate (including SOFR, a term SOFR or any other rate based upon SOFR) as a benchmark rate (and such syndicated credit facilities are identified in such notice and are publicly available for review), and</font></div><div style="margin-bottom:11pt;padding-left:90pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;the joint election by the Administrative Agent and the Borrower to trigger a fallback from the Adjusted LIBO Rate and the provision by the Administrative Agent of written notice of such election to the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EEA Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clause (a) or (b) of this definition and is subject to consolidated supervision with its parent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EEA Member Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any of the member states of the European Union, Iceland, Liechtenstein and Norway.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EEA Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Person that meets the requirements to be an assignee under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (subject to such consents, if any, as may be required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)(iii)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean each environmental indemnity made by each Loan Party with Real Estate required to be pledged as Collateral in favor of the Administrative Agent for the benefit of the Secured Parties, in each case in form and substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all applicable laws, rules, regulations, codes, ordinances, orders, decrees, judgments, injunctions, notices or binding agreements issued, promulgated or entered into by or with any Governmental Authority relating in any way to the environment, preservation or reclamation of natural resources, the management, Release or threatened Release of any Hazardous Material or to health and safety matters concerning exposure to Hazardous Materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Environmental Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any liability, contingent or otherwise (including any liability for damages, costs of environmental investigation and remediation, costs of administrative oversight, fines, natural resource damages, penalties or indemnities), of the Borrower or any of its Subsidiaries directly or indirectly resulting from or based upon (i) any actual or alleged violation of any Environmental Law, (ii) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (iii) any actual or alleged exposure to any Hazardous Materials, (iv) the Release or threatened Release of any Hazardous Materials or (v) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended and in effect from time to time, and any successor statute thereto and the regulations promulgated and rulings issued thereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any person that for purposes of Title I or Title IV of ERISA or Section 412 of the Code would be deemed at any relevant time to be a &#8220;single employer&#8221; or otherwise aggregated with the Borrower or any of its Subsidiaries under Section 414(b), (c), (m) or (o) of the Code or Section 4001 of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ERISA Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (i) any &#8220;reportable event&#8221; as defined in Section 4043 of ERISA with respect to a Plan (other than an event as to which the PBGC has waived under subsection .22, .23, .25, .27 or .28 of PBGC Regulation Section 4043 the requirement of Section 4043(a) of ERISA that it be notified of such event)&#59; (ii) any failure to make a required contribution to any Plan that would result in the imposition of a lien or other encumbrance or the provision of security under Section 430 of the Code or Section 303 or 4068 of ERISA, or the arising of such a lien or encumbrance, there being or arising any &#8220;unpaid minimum required contribution&#8221; or &#8220;accumulated funding deficiency&#8221; (as defined or otherwise set forth in Section 4971 of the Code or Part 3 of Subtitle B of Title 1 of ERISA), whether or not waived, or any filing of any request for or receipt of a minimum funding waiver under Section 412 of the Code or Section 302 of ERISA with respect to any Plan or Multiemployer Plan, or that such filing may be made, or any determination that any Plan is, or is expected to be, in at-risk status under Title IV of ERISA&#59; (iii) any incurrence by the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of any liability under Title IV of ERISA with respect to any Plan or Multiemployer Plan (other than for premiums due and not delinquent under Section 4007 of ERISA)&#59; (iv) any institution of proceedings, or the occurrence of an event or condition which would reasonably be expected to constitute grounds for the institution of proceedings by the PBGC, under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Plan&#59; (v) any incurrence by the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of any liability with respect to the withdrawal or partial withdrawal from any Plan or Multiemployer Plan, or the receipt by the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of any notice that a Multiemployer Plan is in endangered or critical status under Section 305 of ERISA&#59; (vi) any receipt by the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of any notice, or any receipt by any Multiemployer Plan from the Borrower, any of its Subsidiaries or any of their respective ERISA Affiliates of any notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent or in reorganization, within the meaning of Title IV of ERISA&#59; (vii) engaging in a non-exempt prohibited transaction within the meaning of Section 4975 of the Code or Section 406 of ERISA&#59; or (viii) any filing of a notice of intent to terminate any Plan if such termination would require material additional contributions in order to be considered a standard termination within the meaning of Section 4041(b) of ERISA, any filing under Section 4041(c) of ERISA of a notice of intent to terminate any Plan, or the termination of any Plan under Section 4041(c) of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.15(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Deficiency Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Impacted Class</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Return Deficiency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Subrogation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to it in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.15(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">EU Bail-In Legislation Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Eurodollar</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, when used in reference to any Loan or Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, bears interest at a rate determined by reference to the Adjusted LIBO Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Securities Exchange Act of 1934, as amended and in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (a) any zero-balance accounts, (b) any payroll, withholding tax and other fiduciary or escrow accounts, in each case solely to the extent such accounts contain only amounts designated for payment of payroll, withholding tax and other fiduciary or escrow liabilities, (c) refund accounts, solely to the extent such accounts contain amounts designated for refunds to patients, Governmental Authorities or Third Party Payors&#59; (d) third party administrator accounts, solely to the extent such accounts contain amounts related to the administration of payment and collections for physicians (other than management fees relating to such administration)&#59; (e) accounts containing payments from CMS that have not yet been applied to claims&#59; (f) any accounts owned exclusively by Excluded Subsidiaries&#59; and (g) any other accounts as long as the aggregate monthly average daily balance for all such Loan Parties in all such other accounts does not exceed $500,000 at any time. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively&#58; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any fee-owned real property which has a fair market value of less than $7,500,000 and any leasehold real property&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;commercial tort claims reasonably expected to result in recovery of less than $1,000,000 individually&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any governmental or regulatory licenses, to the extent that, and for so long as, the grant (or perfection) of a security interest therein, or the assignment thereof, is prohibited or restricted thereby or under applicable law or would require a governmental consent that has not been obtained after the Borrower&#8217;s use of commercially reasonable efforts to obtain such consent (in each case, after giving effect to the applicable anti-assignment provisions of the Uniform Commercial Code or similar applicable laws that would have a similar effect)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that nothing in this clause (iii) shall prohibit the pledge or grant of security in the proceeds of such licenses&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any particular asset (including the Capital Stock of any direct Subsidiary held by the Borrower or any Guarantor) or right under contract to the extent that, and for so long as, the pledge thereof or a security interest therein (A) is prohibited or restricted by applicable law, including any regulation applicable to the Loan Parties&#8217; line of business, or (B) would violate the terms of any agreement (including, without limitation, any purchase money security interest or similar arrangement permitted by the loan documentation) that is legally binding on the Borrower or any Guarantor or any Regulated Entity (in each case, after giving effect to the applicable anti-assignment provisions of the Uniform Commercial Code or similar applicable laws that would have a similar effect)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that nothing in this clause (iv) shall prohibit the pledge or grant of security in the proceeds of such assets or rights to such proceeds&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any margin stock&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;any intent-to-use trademark application prior to the filing of a &#8220;Statement of Use&#8221;, &#8220;Amendment to Allege Use&#8221; or similar filing with respect thereto, solely to the extent, if any, that, and solely during the period, if any, in which the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark application under applicable law&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;any motor vehicles, aircraft and other similar assets subject to certificates of title or ownership (except to the extent a security interest therein can be perfected by the filing of a UCC financing statement)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;any Excluded Accounts&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;any other assets if, and for so long as, in the reasonable judgment of the Administrative Agent (in consultation with the Borrower), the cost or burden of creating or perfecting a pledge or security interest in such assets is excessive in relation of the benefits afforded to the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any&#58; (a)&#160;Subsidiary of the Borrower with respect to which the provision of a guaranty by such Subsidiary would result in material adverse tax consequences, as reasonably determined by the Borrower in consultation with the Administrative Agent&#59; (b) Subsidiary of the Borrower that is a captive insurance subsidiary&#59; (c) not-for-profit Subsidiary of the Borrower&#59; (d) Subsidiary of the Borrower that is a special purpose entity&#59; (e) Subsidiary of the Borrower that is prohibited by applicable laws or contractual obligation (other than with any Affiliate of any Loan Party) from guaranteeing the Obligations or with respect to which any consent, approval, license or authorization from any Governmental Authority would be required for the provision of any such guarantee in each case so long as the Administrative Agent shall have received a certification from a Responsible Officer of the Borrower as to the existence of such applicable law or required consent, approval, license or authorization upon the Administrative Agent&#8217;s request for such a certificate, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (i) in the case of such guarantee being prohibited due to a contractual obligation, such contractual obligation shall have been in place on the Closing Date or, if later, at the time such Subsidiary became a Subsidiary, and shall not have been created or amended in contemplation of or in connection with such Person becoming a Subsidiary, and (ii) to the extent any such prohibition is capable of being overcome or eliminated, the Loan Parties shall use commercially reasonable efforts for a period not to exceed ninety (90) days to overcome or eliminate any such prohibition and each such Subsidiary shall cease to be an Excluded Subsidiary if such prohibition shall cease to exist or apply&#59; and (f) any Immaterial Subsidiary.  For the avoidance of doubt, it is understood and agreed that APA ACO, Inc. shall be deemed to be an Excluded Subsidiary pursuant to clause (e) of the foregoing definition for so long as the Borrower, in consultation with its healthcare counsel, reasonably determines there to be prohibition under applicable law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Collateral shall include a pledge of 100% of the Capital Stock of APA ACO, Inc. so long as such pledge does not result in an &#8220;assignment&#8221; or &#8220;change in control&#8221; (in each case as such term is defined by CMS) under the Next Generation ACO Model Participation Agreement dated December 15, 2016 and is not otherwise &#8220;Excluded Property&#8221; pursuant to clause (iv) of the definition thereof (and it being understood and agreed that the Administrative Agent shall receive CMS&#8217; consent prior to exercising any remedies with respect to the pledge described in this proviso).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Swap Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Guarantor, any Swap Obligation if, and to the extent that, all or a portion of the Guarantee of such Guarantor of, or the grant by such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Guarantor of a security interest to secure, such Swap Obligation (or any Guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof) by virtue of such Guarantor&#8217;s failure for any reason to constitute an &#8220;eligible contract participant&#8221; as defined in the Commodity Exchange Act at the time the Guarantee of such Guarantor becomes effective with respect to such related Swap Obligation. If a Swap Obligation arises under a master agreement governing more than one swap, such exclusion shall apply only to the portion of such Swap Obligation that is attributable to swaps for which such Guarantee or security interest is or becomes illegal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Excluded Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment to a Recipient, (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i) imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Borrower under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or (ii) such Lender changes its lending office, except in each case to the extent that, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, amounts with respect to such Taxes were payable either to such Lender's assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (c) Taxes attributable to such Recipient&#8217;s failure to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (d) any U.S. federal withholding Taxes imposed under FATCA.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Credit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the recitals hereto.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the recitals hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Letters of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the letters of credit issued and outstanding under the Existing Credit Agreement as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 2.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (as of the Closing Date).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Federal Reserve Bank of New York&#8217;s Website</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the website of the Federal Reserve Bank of New York at http&#58;&#47;&#47;www.newyorkfed.org, or any successor source.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Federal Funds Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for any day, the rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (rounded upwards, if necessary, to the next 1&#47;100 of 1%) equal to the weighted average of the rates on overnight Federal funds transactions with member banks of the Federal Reserve System, as published by the Federal Reserve Bank of New York on the next succeeding Business Day or, if such rate is not so published for any Business Day, the Federal Funds Rate for such day shall be the average (rounded upwards, if necessary, to the next 1&#47;100 of 1%) of the quotations for such day on such transactions received by the Administrative Agent from three Federal funds brokers of recognized standing selected by the Administrative Agent. For purposes of this Agreement, the Federal Funds Rate shall not be less than zero percent (0%).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fee Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain fee letter, dated as of May 10, 2021 executed by Truist Securities, Inc. and consented to by the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any fiscal quarter of the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Fiscal Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any fiscal year of the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Flood Insurance Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (i) the National Flood Insurance Reform Act of 1994 (which comprehensively revised the National Flood Insurance Act of 1968 and the Flood Disaster Protection Act of 1973), as now or hereafter in effect or any successor statute thereto, (ii) the Flood Insurance Reform Act of 2004, as now or hereafter in effect or any successor statute thereto and (iii) the Biggert &#8211;Waters Flood Insurance Reform Act of 2012, as now or hereafter in effect or any successor statute thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Floor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the benchmark rate floor, if any, provided in this Agreement initially (as of the execution of this Agreement, the modification amendment, or renewal of this Agreement or otherwise) with respect to the Adjusted LIBO Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a Lender that is not a U.S. Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean each Subsidiary of the Borrower that is organized under the laws of a jurisdiction other than one of the fifty states of the United States or the District of Columbia.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Future Approved Entity Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any secured loan made by the Borrower to an Approved Entity after the Original Closing Date with terms and structure substantially similar to the AP-AMH Loan (other than the total debt amount, loan term and interest rate)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that it is understood and agreed that the underlying use of proceeds and collateral securing any such loan may differ from the use of proceeds and collateral securing the AP-AMH Loan made on the Original Closing Date so long as the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to any such Future Approved Entity Investment are satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean generally accepted accounting principles in the United States applied on a consistent basis and subject to the terms of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the government of the United States or any other nation, or any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank), it being understood and agreed that the foregoing definition shall include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">any agency, branch or other governmental body charged with the responsibility and&#47;or vested with the authority to administer and&#47;or enforce any Healthcare Laws, including any Medicare or Medicaid contractors, intermediaries or carriers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Governmental Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any permit, license, authorization, certification, registration, approval, plan, directive, consent order or consent decree of or from any Governmental Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of or by any Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">guaranto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">r&#8221;) shall mean any obligation, contingent or otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">primary obligor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in any manner, whether directly or indirectly and including any obligation, direct or indirect, of the guarantor (i)&#160;to purchase or pay (or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (ii) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (iv) as an account party in respect of any letter of credit or letter of guaranty issued in support of such Indebtedness or obligation&#59; provided that the term &#8220;Guarantee&#8221; shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the primary obligation in respect of which such Guarantee is made or, if not so stated or determinable, the maximum reasonably anticipated liability in respect thereof (assuming such Person is required to perform thereunder) as determined by such Person in good faith. The term &#8220;Guarantee&#8221; used as a verb has a corresponding meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean each of the Subsidiary Loan Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Guaranty and Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Guaranty and Security Agreement, dated as of the Original Closing Date, made by the Loan Parties in favor of the Administrative Agent for the benefit of the Secured Parties, as amended, restated, reaffirmed (including pursuant to the Reaffirmation Agreement), supplemented or otherwise modified from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hazardous Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Healthcare Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all applicable federal and state healthcare Laws relating to the provision of clinical care or management, leasing, or provision of goods and services to medical clinics or medical practices that provide medical services, including, without limitation, (a) all fraud and abuse Laws (including, without limitation, the following statutes, as amended, modified or supplemented from time to time and any successor statutes thereto and regulations promulgated from time to time thereunder&#58; (i) the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b))&#59; (ii) the civil False Claims Act (31 U.S.C. &#167; 3729 et seq.)&#59; Sections 1320a-7,1320a-7a and 1320a-7b of Title 42 of the United States Code&#59; (iii) the Emergency Medical Treatment and Labor Act (42 U.S.C. &#167; 1395dd), Sections 1320a-7 and 1320a-71 of Title 42 of the United States Code&#59; and (iv) the Ethics in Patient Referrals Act (42 U.S.C. &#167; 1395nn),&#59; (b) the Health Insurance Portability and Accountability Act of 1996, as amended by the HITECH Act, and as otherwise may be amended from time to time&#59; (c) (i) Medicare and the regulations promulgated thereunder, (ii) Medicaid and the regulations promulgated thereunder, (iii) TRICARE (10 U.S.C. Section 1071 et seq.) or (iv) other analogous state or federal programs&#59; (d) the Health Information Technology for Economic and Clinical Health Act provisions of the American Recovery and Reinvestment Act of 2009, Pub. Law No. 111-5 and its implementing regulations 42 C.F.R. &#167;&#167; 412, 413, 422 and 495&#59; (e) quality, safety and accreditation standards and requirements of all applicable state laws or regulatory bodies&#59; (f) requirements of Law relating to the ownership or operation of a healthcare facility or business, or assets used in connection therewith and restrictions on the corporate practice of medicine, corporate practice of nursing, professional fee-splitting, office-based medical procedures, anesthesia requirements and the provision of management or administrative services to medical practices&#59; (g) requirements of Law relating to the billing or submission of claims, collection of accounts, underwriting the cost of, or provision of management or administrative services in connection with, any and all of the foregoing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Healthcare Permits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means all material and applicable healthcare related licenses, permits, approvals, registrations, certifications, accreditations, contracts, consents, qualifications and authorizations necessary for the lawful conduct of each of the Borrower&#8217;s, its Subsidiaries&#8217; and the Associated Practices&#8217; respective businesses pursuant to all applicable Healthcare Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hedge Termination Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, in respect of any one or more Hedging Transactions, after taking into account the effect of any legally enforceable netting agreement relating to such Hedging Transactions, (a) for any date on or after the date such Hedging Transactions have been closed out and termination value(s) determined in accordance therewith, such termination value(s) and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for such Hedging Transactions, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Hedging Transactions (which may include a Lender or any Affiliate of a Lender).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean any and all obligations of such Person, whether absolute or contingent and howsoever and whensoever created, arising, evidenced or acquired under (i) any and all Hedging Transactions, (ii) any and all cancellations, buy backs, reversals, terminations or assignments of any Hedging Transactions and (iii) any and all renewals, extensions and modifications of any Hedging Transactions and any and all substitutions for any Hedging Transactions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Hedging Transaction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean (a) any transaction (including an agreement with respect to any such transaction) now existing or hereafter entered into by such Person that is a rate swap transaction, swap option, basis swap, forward rate transaction, commodity swap, commodity option, equity or equity index swap or option, bond option, interest rate option, foreign exchange transaction, cap transaction, floor transaction, collar transaction, currency swap transaction, cross-currency rate swap transaction, currency option, spot transaction, credit protection transaction, credit swap, credit default swap, credit default option, total return swap, credit spread transaction, repurchase transaction, reverse repurchase transaction, buy&#47;sell-back transaction, securities lending transaction, or any other similar transaction (including any option with respect to any of these transactions) or any combination thereof, whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a &#8220;Master Agreement&#8221;), including any such obligations or liabilities under any Master Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">HIPAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, (a) the Health Insurance Portability and Accountability Act of 1996, 42 U.S.C. &#167;&#167; 1320d-1320d-8, as amended by the HITECH Act, and any regulations adopted thereunder&#59; and (b) the Health Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009 in each case with respect to the laws described in clauses (a) and (b) of this definition, as the same may be amended, modified or supplemented from time to time, any successor statutes thereto, any and all rules or regulations promulgated from time to time thereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Historical Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean copies of (a) the internally prepared quarterly financial statements of the Borrower and its Subsidiaries on a consolidated basis for the Fiscal Quarter ended March 31, 2021 and (b) the audited consolidated financial statements for the Borrower and its Subsidiaries for the Fiscal Year ended December 31, 2020.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Immaterial Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, on any date of determination, any Subsidiary of the Borrower that, together with its Subsidiaries, (i) generated less than 5.0% of revenue of the Borrower and its Subsidiaries for the most recent four (4) consecutive Fiscal Quarter period for which financial statements have been delivered (or are required to have been delivered) pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (ii) has total assets (including Capital Stock in other Subsidiaries and excluding investments that are eliminated in consolidation) of less than 5.0% of Consolidated Total Assets as reflected in the financial statements most recently delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  For the avoidance of doubt, as of the Closing Date, Allied Physicians ACO, LLC, APCN-ACO, Inc., 99 Medical Equipment, Healthcare Supplies &#38; Wheelchair Center, ApolloMed Accountable Care Organization, Inc., Apollo Medical Management, Inc., ApolloMed Laboratories, Inc., ApolloMed Imaging, Inc., Apollo Care Connect, Inc., Pulmonary Critical Care Management, Inc., Verdugo Medical Management, Inc., Apollo Palliative Services LLC, Best Choice Hospice Care, LLC, Holistic Care Home Health Agency, Inc., Allied Pacific Hospice LLC, Concourse Diagnostic and Surgery Center, LLC, AP Healthcare System, Apollo-Sun Labs Management, LLC and  Sun Clinical Laboratories shall each be an Immaterial Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that each of the foregoing shall at all times be subject to the thresholds in the foregoing definition and the thresholds and covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Increasing Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Revolving Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Term Loan Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean, without duplication, (i) all obligations of such Person for borrowed money, (ii) all obligations of such Person evidenced by bonds, debentures, notes or other similar instruments, (iii) all obligations of such Person in respect of the deferred purchase price of property or services (other than trade payables and management fees incurred in the ordinary course of business&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, trade payables and management fees overdue by more than 120 days shall be included in this definition except to the extent that any of such trade payables are being disputed in good faith and by appropriate measures), (iv) all obligations of such Person under any conditional sale or other title retention agreement(s) relating to property acquired by such Person, (v) all Capital Lease Obligations of such Person, (vi) all obligations, contingent or otherwise, of such Person in respect of letters of credit, acceptances or similar extensions of credit, (vii) all Guarantees of such Person of the type of Indebtedness described in clauses (i) through (vi) above, (viii) all Indebtedness of a third party secured by any Lien on property owned by such Person, whether or not such Indebtedness has been assumed by such Person, (ix)&#160;all obligations of such Person, contingent or otherwise, to purchase, redeem, retire or otherwise acquire for value any Capital Stock of such Person, (x) all Off-Balance Sheet Liabilities and (xi) all net Hedging Obligations.  For all purposes hereof, the Indebtedness of any Person shall include the Indebtedness of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company or the foreign equivalent thereof) in which such Person is a general partner or a joint venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of any net obligation under any Hedging Transaction on any date shall be deemed to be the Swap Termination Value thereof as of such date. The amount of Indebtedness of any Person for purposes of clause (viii) that is expressly made nonrecourse or limited-recourse (limited solely to the assets securing such Indebtedness) to such Person shall be deemed to be equal to the lesser of (a) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">aggregate unpaid amount of such Indebtedness and (b) the fair market value of the property encumbered thereby as determined by such Person in good faith&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that none of the following shall constitute Indebtedness of any Person&#58; (x)&#160;obligations or liabilities of any Person for unissued equity shares, deferred revenue, deferred or subordinated management fees, deferred taxes or other similar accrued or deferred expenses (other than deferred purchase price payments of any kind as set forth above), in each case arising in the ordinary course of business, (y)&#160;&#8220;incurred but not reported&#8221; liabilities and (z)&#160;obligations or liabilities of any Person to CMS owed in the ordinary course of business, but any such obligations or liabilities under this clause (z) shall constitute Indebtedness if overdue by more than 10 Business Days (other than to the extent contested in good faith).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnified Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean with respect to any Eurodollar Borrowing, a period of one, three or six months (in each case, to the extent available)&#59; provided that&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;the initial Interest Period for such Borrowing shall commence on the date of such Borrowing (including the date of any conversion from a Borrowing of another Type), and each Interest Period occurring thereafter in respect of such Borrowing shall commence on the day on which the next preceding Interest Period expires&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;if any Interest Period would otherwise end on a day other than a Business Day, such Interest Period shall be extended to the next succeeding Business Day, unless such Business Day falls in another calendar month, in which case such Interest Period would end on the immediately preceding Business Day&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;any Interest Period which begins on the last Business Day of a calendar month or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period shall end on the last Business Day of such calendar month&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;each principal installment of the Incremental Term Loans shall have an Interest Period ending on each installment payment date and the remaining principal balance (if any) of the Incremental Term Loans shall have an Interest Period determined as set forth above&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;no Interest Period may extend beyond the Revolving Commitment Termination Date, unless on the Revolving Commitment Termination Date the aggregate outstanding principal amount of Incremental Term Loans is equal to or greater than the aggregate principal amount of Eurodollar Loans with Interest Periods expiring after such date, and no Interest Period may extend beyond the Maturity Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investment Consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (A) the aggregate purchase consideration for an Acquisition and all other payments (but excluding any related acquisition fees, costs and expenses incurred in connection with any Acquisition), directly or indirectly, by any Person in exchange for, or as part of, or in connection with, an Acquisition, whether paid in cash or cash equivalents or by exchange of equity interests or of any property or by the assumption of Indebtedness of the target, business unit or asset group acquired or proposed to be acquired in any such Acquisition or otherwise and whether payable prior to, as of the consummation of, or after any such Acquisition, including any earn-outs and deferred payment obligations (whether contingent or otherwise), (B) the aggregate amount of all loans made by the Borrower to an Approved Entity in the case of any Future Approved Entity Investment and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C) the aggregate amount of all loans made by the Borrower to any Subsidiary or Associated Practice to fund Permitted Acquisitions or other Investments&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that Investment Consideration shall not include (a) any consideration or payment paid by the Borrower or any of its Subsidiaries (i) with the net cash proceeds from any substantially concurrent issuance of Capital Stock of the Borrower to its shareholders and&#47;or (ii) in the form of Capital Stock of the Borrower and (b) cash and cash equivalents acquired by the Borrower or any of its Subsidiaries as part of the applicable Investment. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">IRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the United States Internal Revenue Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ISDA Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the 2006 ISDA Definitions, published by the International Swaps and Derivatives Association, Inc., or any successor thereto, as amended or supplemented from time to time, or any successor definitional booklet for interest rate derivatives published from time to time by the International Swaps and Derivatives Association, Inc. or such successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Issuing Banks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Truist Bank in its capacity as the issuer of Letters of Credit pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> together with any other Lender as the Borrower may from time to time select as an Issuing Bank hereunder pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such Lender has agreed to be an Issuing Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Knowledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of Borrower shall mean the actual knowledge of any of the Borrower&#8217;s Responsible Officers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LC Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that portion of the Aggregate Revolving Commitments that may be used by the Borrower for the issuance of Letters of Credit in an aggregate face amount not to exceed $25,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LC Disbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a payment made by any Issuing Bank pursuant to a Letter of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LC Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all applications, agreements and instruments relating to the Letters of Credit but excluding the Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LC Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, the sum of (i) the aggregate undrawn amount of all outstanding Letters of Credit at such time, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ii) the aggregate amount of all LC Disbursements that have not been reimbursed by or on behalf of the Borrower at such time. The LC Exposure of any Lender shall be its Pro Rata Share (based on such Revolving Lender&#8217;s Revolving Commitment or Revolving Credit Exposure, as applicable)  of the total LC Exposure at such time. Unless otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit in effect at such time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that with respect to any Letter of Credit that, by its terms or any document related thereto, provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum stated amount is in effect at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lender-Related Hedge Provider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any Person that, at the time it enters into a Hedging Transaction with any Loan Party, (i) is a Lender or an Affiliate of a Lender and (ii) except when the Lender-Related Hedge Provider is Truist Bank or any of its Affiliates, has provided prior written notice to the Administrative Agent which has been acknowledged by the Borrower of (x) the existence of such Hedging Transaction and (y) the methodology to be used by such parties in determining the obligations </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">under such Hedging Transaction from time to time. In no event shall any Lender-Related Hedge Provider acting in such capacity be deemed a Lender for purposes hereof to the extent of and as to Hedging Obligations except that each reference to the term &#8220;Lender&#8221; in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be deemed to include such Lender-Related Hedge Provider. In no event shall the approval of any such Person in its capacity as Lender-Related Hedge Provider be required in connection with the release or termination of any security interest or Lien of the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in the introductory paragraph hereof and shall include, where appropriate, the Swingline Lender, each Increasing Lender and each Additional Lender that joins this Agreement pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Letter of Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any stand-by letter of credit issued pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> by any Issuing Bank for the account of the Borrower or any Subsidiary Loan Party (which may be for the benefit of any Subsidiary or Associated Practice) pursuant to the LC Commitment and any Existing Letter of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any mortgage, pledge, security interest, lien (statutory or otherwise), charge, encumbrance, hypothecation, assignment, deposit arrangement, or other arrangement having the practical effect of any of the foregoing or any preference, priority or other security agreement or preferential arrangement of any kind or nature whatsoever (including any conditional sale or other title retention agreement and any capital lease having the same economic effect as any of the foregoing).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, this Agreement, the Collateral Documents, the Reaffirmation Agreement, the LC Documents, the Fee Letter, all Notices of Revolving Borrowing, all Notices of Swingline Borrowing, all Notices of Conversion&#47;Continuation, all Compliance Certificates, any promissory notes issued hereunder and any and all other instruments, agreements, documents and writings executed in connection with any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loan Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Borrower and the Subsidiary Loan Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all Revolving Loans, Swingline Loans and Incremental Term Loans in the aggregate or any of them, as the context shall require, and shall include, where appropriate, any loan made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Management Services Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, each management services agreement between an Associated Practice and a Loan Party, and any other similar services agreements, including administrative services agreements, between the Borrower or its Subsidiaries and Associated Practices pursuant to which the Borrower or such Subsidiaries provide non-clinical management services to such Associated Practices, which such agreements shall be in form and substance reasonably satisfactory to Administrative Agent.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Adverse Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any event, act, condition or occurrence of whatever nature (including any adverse determination in any litigation, arbitration, or governmental investigation or proceeding), whether singularly or in conjunction with any other event or events, act or acts, condition or conditions, occurrence or occurrences whether or not related, resulting in a material adverse change in, or a material adverse effect on, (i) the business, results of operations, financial condition, assets, liabilities or prospects of the Borrower and its Subsidiaries taken as a whole, (ii) the ability of the Loan Parties to perform any of their respective obligations under the Loan Documents, (iii) the rights and remedies of the Administrative Agent, the Issuing Banks, the Swingline Lender or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lenders under any of the Loan Documents or (iv)&#160;the legality, validity or enforceability of any of the Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (i) all agreements, indentures or notes governing the terms of any Material Indebtedness, (ii) the APC 2019 Transaction Documents, (iii) the NMM-APC Management Services Agreement and (iv) each other agreement, document, contract, indenture and instrument pursuant to which (A) any Loan Party or any of its Subsidiaries are obligated to make payments in any twelve month period of $5,000,000 or more, (B) any Loan Party or any of its Subsidiaries expects to receive revenue in any twelve month period of $5,000,000 or more and (C) a default, breach or termination thereof could reasonably be expected to result in a Material Adverse Effect.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Associated Practice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (i) any Associated Practice and (ii) any ambulatory surgery center (including, for the avoidance of doubt, Concourse Diagnostic and Surgery Center, LLC), in each case of the foregoing clauses (i) and (ii), solely to the extent that the accounts of any such Person would be required to be consolidated with those of the Borrower in the Borrower&#8217;s consolidated financial statements if such financial statements were prepared in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Material Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Indebtedness (other than the Commitments, the Loans and the Letters of Credit) of the Borrower or any of its Subsidiaries individually or in an aggregate committed or outstanding principal amount exceeding the Threshold Amount. For purposes of determining the amount of attributed Indebtedness from Hedging Obligations, the &#8220;principal amount&#8221; of any Hedging Obligations at any time shall be the Net Mark-to-Market Exposure of such Hedging Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, as relates to any Incremental Term Loans, (i) the maturity date specified therefor in the applicable incremental agreement and (ii) the date on which the principal amount of all outstanding Incremental Term Loans have been declared or automatically have become due and payable (whether by acceleration or otherwise).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Moody&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Moody&#8217;s Investors Service, Inc.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Mortgaged Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, the Real Estate subject to the Mortgages, including, but not limited to, any Real Estate for which a Mortgage is required to be delivered after the date hereof pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Mortgages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, each mortgage, deed of trust, trust deed, security deed, debenture, deed of immovable hypothec, deed to secure debt or other real estate security documents delivered by any Loan Party to the Administrative Agent from time to time, all in form and substance satisfactory to the Administrative Agent, as the same may be amended, amended and restated, extended, supplemented, substituted or otherwise modified from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Multiemployer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any &#8220;multiemployer plan&#8221; as defined in Section 4001(a)(3) of ERISA, which is contributed to by (or to which there is or may be an obligation to contribute of) the Borrower, any of its Subsidiaries or an ERISA Affiliate, and each such plan for the five-year period immediately following the latest date on which the Borrower, any of its Subsidiaries or an ERISA Affiliate contributed to or had an obligation to contribute to such plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Net Mark-to-Market Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean, as of any date of determination with respect to any Hedging Obligation, the excess (if any) of all unrealized losses over all unrealized profits of such Person arising from such Hedging Obligation. &#8220;Unrealized losses&#8221; shall mean the fair market </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">value of the cost to such Person of replacing the Hedging Transaction giving rise to such Hedging Obligation as of the date of determination (assuming such Hedging Transaction were to be terminated as of that date), and &#8220;unrealized profits&#8221; shall mean the fair market value of the gain to such Person of replacing such Hedging Transaction as of the date of determination (assuming such Hedging Transaction were to be terminated as of that date).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">NMM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Network Medical Management, Inc., a California corporation.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Defaulting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, a Lender that is not a Defaulting Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Non-U.S. Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any plan, fund (including, without limitation, any superannuation fund) or other similar program established, contributed to (regardless of whether through direct contributions or through employee withholding) or maintained outside the United States by the Borrower or one or more of its Subsidiaries primarily for the benefit of employees of the Borrower or such Subsidiaries residing outside the United States, which plan, fund or other similar program provides, or results in, retirement income, a deferral of income in contemplation of retirement, or payments to be made upon termination of employment, and which plan is not subject to ERISA or the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a Notice of Revolving Borrowing, a Notice of Swingline Borrowing, or the initial notice of borrowing to be delivered on or prior to the Closing Date in connection with all Revolving Loans to be funded on the Closing Date, as the context may require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Conversion&#47;Continuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Revolving Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Swingline Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) all amounts owing by the Loan Parties to the Administrative Agent, the Issuing Banks, any Lender (including the Swingline Lender) or the Arrangers pursuant to or in connection with this Agreement or any other Loan Document or otherwise with respect to any Commitment, Loan or Letter of Credit including, without limitation, all principal, interest (including any interest accruing after the filing of any petition in bankruptcy or the commencement of any insolvency, reorganization or like proceeding relating to the Borrower, whether or not a claim for post-filing or post-petition interest is allowed in such proceeding), reimbursement obligations, obligations pursuant to the Administrative Agent&#8217;s Erroneous Payment Subrogation Rights, fees, expenses, indemnification and reimbursement payments, costs and expenses (including all fees and expenses of counsel to the Administrative Agent, the Issuing Banks and any Lender (including the Swingline Lender) incurred pursuant to this Agreement or any other Loan Document), whether direct or indirect, absolute or contingent, liquidated or unliquidated, now existing or hereafter arising hereunder or thereunder, (b) all Hedging Obligations owed by any Loan Party to any Lender-Related Hedge Provider, and (c) all Bank Product Obligations, together with all renewals, extensions, modifications or refinancings of any of the foregoing&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that with respect to any Guarantor, the Obligations shall not include any Excluded Swap Obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Off-Balance Sheet Liabilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Person shall mean (i) any repurchase obligation or liability of such Person with respect to accounts or notes receivable sold by such Person, (ii) any liability of such Person under any sale and leaseback transactions that do not create a liability on the balance sheet of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Person, (iii) any Synthetic Lease Obligation or (iv) any obligation arising with respect to any other transaction which is the functional equivalent of or takes the place of borrowing but which does not constitute a liability on the balance sheet of such Person other than, in the case of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, any operating lease, including, for the avoidance of doubt, any other lease referred to in the proviso of the definition of &#8220;Capital Lease Obligations&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Original Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean September 11, 2019.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Original Closing Date Collateral Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (a) each collateral assignment of Associated Practice Documents made on the Original Closing Date by the applicable Loan Party in favor of the Administrative Agent pursuant to which such Loan Party collaterally assigned in favor of the Administrative Agent, on behalf of the Secured Parties, all of its rights under the applicable Associated Practice Documents and (b) a collateral assignment made on the Original Closing Date by the Borrower in favor of the Administrative Agent pursuant to which the Borrower collaterally assigned in favor of the Administrative Agent, on behalf of the Secured Parties, all of its rights under the applicable AP-AMH Loan Documents, (c) a collateral assignment of the Tradename Licensing Agreement made on the Original Closing Date by the Borrower in favor of the Administrative Agent pursuant to which the Borrower collaterally assigned in favor of the Administrative Agent, on behalf of the Secured Parties, all of its rights under the Tradename Licensing Agreement, in each case in form an substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">OSHA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Occupational Safety and Health Act of 1970, as amended and in effect from time to time, and any successor statute thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any and all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made hereunder or under any other Loan Document or from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Parent Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to a Lender, the &#8220;bank holding company&#8221; as defined in Regulation Y, if any, of such Lender, and&#47;or any Person owning, beneficially or of record, directly or indirectly, a majority of the shares of such Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning assigned to such term in the Guaranty and Security Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patent Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Patent Security Agreement executed by a Loan Party owning Patents or licenses of Patents in favor of the Administrative Agent for the benefit of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Secured Parties, including on the Original Closing Date and thereafter (in each case as amended, restated, reaffirmed (including pursuant to the Reaffirmation Agreement), supplemented or otherwise modified from time to time).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, Pub. L. 107-56.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the office of the Administrative Agent located at 303 Peachtree Street, N.E., Atlanta, Georgia 30308, or such other location as to which the Administrative Agent shall have given written notice to the Borrower and the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PBGC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the U.S. Pension Benefit Guaranty Corporation referred to and defined in ERISA, and any successor entity performing similar functions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Perfection Certificate, dated as of the Closing Date, which is executed and delivered by the Loan Parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Acquisition by a Loan Party that occurs when the following conditions have been satisfied&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;before and after giving effect to such Acquisition, no Default or Event of Default has occurred and is continuing or would result therefrom, and all representations and warranties of each Loan Party set forth in the Loan Documents shall be and remain true and correct in all material respects&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;before and after giving effect to such Acquisition, on a Pro Forma Basis, the Borrower is in compliance with each of the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (taking into account the Covenant Holiday, if applicable), measuring Consolidated Total Net Debt for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the date of such Acquisition and otherwise recomputing the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Acquisition had occurred, and, solely in the case of any such Acquisition in which the Investment Consideration is greater than $25,000,000, the Borrower shall have delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer certifying to the foregoing at least 5 days prior to the date of the consummation of such Acquisition&#59;  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;at least 5 days prior to the date of the consummation of any such Acquisition in which the Investment Consideration is greater than $40,000,000, the Borrower shall have delivered to the Administrative Agent notice of such Acquisition, together with historical financial information and analysis with respect to the Person whose stock or assets are being acquired and copies of the acquisition agreement and related documents (including financial information and analysis, environmental assessments and reports, opinions, certificates and lien searches) and information reasonably requested by the Administrative Agent&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;such Acquisition is consensual and approved by the board of directors (or the equivalent thereof) of the Person whose stock or assets are being acquired&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;the Person or assets being acquired is in the same type of business conducted by the Borrower and its Subsidiaries on the date hereof or any business reasonably related thereto&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;such Acquisition is consummated in compliance with all Requirements of Law, and all consents and approvals from any Governmental Authority or other Person required in connection with such Acquisition have been obtained&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;before and after giving effect to such Acquisition and any Indebtedness incurred in connection therewith, each Loan Party is Solvent&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;the Borrower shall have executed and delivered, or caused its Subsidiaries to execute and deliver, all guarantees, Collateral Documents and other related documents required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;solely with respect to any such Acquisition in which the Investment Consideration is greater than $25,000,000, the Borrower has delivered to the Administrative Agent a certificate executed by a Responsible Officer certifying that each of the conditions set forth above has been satisfied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Encumbrances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Liens imposed by law for taxes not yet due or which are being contested in good faith by appropriate proceedings diligently conducted and with respect to which adequate reserves are being maintained in accordance with GAAP&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;statutory Liens of landlords, carriers, warehousemen, mechanics, materialmen and other Liens imposed by law in the ordinary course of business for amounts not yet due or which are being contested in good faith by appropriate proceedings diligently conducted and with respect to which adequate reserves are being maintained in accordance with GAAP&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;pledges and deposits made in the ordinary course of business in compliance with workers&#8217; compensation, unemployment insurance and other social security laws or regulations&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;deposits to secure the performance of bids, trade contracts, leases, statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;judgment and attachment liens not giving rise to an Event of Default or Liens created by or existing from any litigation or legal proceeding that are currently being contested in good faith by appropriate proceedings diligently conducted and with respect to which adequate reserves are being maintained in accordance with GAAP&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;customary rights of set-off, revocation, refund or chargeback under deposit agreements or under the Uniform Commercial Code or common law of banks or other financial institutions where the Borrower or any of its Subsidiaries maintains deposits (other than deposits intended as cash collateral) in the ordinary course of business&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary course of business that do not secure any monetary obligations and do not materially detract from the value of the affected property or materially interfere with the ordinary conduct of business of the Borrower and its Subsidiaries taken as a whole&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;(x) Liens solely on any cash earnest money deposits made by the Borrower or any of its Subsidiaries and (y) restrictions on transfers of assets that are subject to sale or transfer pursuant to purchase and sale arrangements, in each case, in connection with any letter of intent or purchase and sale agreement permitted hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;in the case of any non-wholly owned Subsidiary or joint venture, any put and call arrangements or restrictions on disposition related to its Capital Stock set forth in its organizational documents or any related joint venture or similar agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;licenses and sublicenses of intellectual property granted by the Borrower or any of its Subsidiaries in the ordinary course of business and not interfering in any material respect with the ordinary conduct of business of the Borrower or any of its Subsidiaries or pursuant to the Tradename Licensing Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;leases or subleases granted in the ordinary course of business to others not interfering in any material respect with the business of the Borrower or any of its Subsidiaries and any interest or title of a lessor under any lease not in violation of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;Liens arising from the rights of lessors under leases (including financing statements regarding property subject to lease) not in violation of the requirements of this Agreement, provided that such Liens are only in respect of the property subject to, and secure only, the obligations under the respective lease (and any other lease with the same or an affiliated lessor)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;purported Liens evidenced by the filing of precautionary Uniform Commercial Code financing statements relating solely to operating leases of personal property entered into in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;Liens (i) in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods or (ii) on specific items of inventory or other goods and proceeds thereof of any Person securing such Person&#8217;s obligations in respect of bankers&#8217; acceptances or letters of credit issued or created for the account of such person to facilitate the purchase, shipment or storage of such inventory or goods in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xv)&#160;&#160;&#160;&#160;Liens on insurance premium refunds and insurance proceeds granted in favor of insurance companies (or their financing affiliates) in connection with the financing of insurance premiums&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xvi)&#160;&#160;&#160;&#160;rights of consignors of goods, whether or not perfected by the filing of a financing statement under the Uniform Commercial Code&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xvii)&#160;&#160;&#160;&#160;Liens in favor of CMS on moneys paid by CMS pursuant to contractual arrangements between such Persons&#59;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">provided that the term &#8220;Permitted Encumbrances&#8221; shall not include any Lien securing Indebtedness.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;direct obligations of, or obligations the principal of and interest on which are unconditionally guaranteed by, the United States (or by any agency thereof to the extent such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">obligations are backed by the full faith and credit of the United States), in each case maturing within one year from the date of acquisition thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;commercial paper having the highest rating, at the time of acquisition thereof, of S&#38;P or Moody&#8217;s and in either case maturing within six months from the date of acquisition thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;certificates of deposit, bankers&#8217; acceptances and time deposits maturing within 180 days of the date of acquisition thereof issued or guaranteed by or placed with, and money market deposit accounts issued or offered by, any domestic office of any commercial bank organized under the laws of the United States or any state thereof which has a combined capital and surplus and undivided profits of not less than $500,000,000&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;fully collateralized repurchase agreements with a term of not more than 30 days for securities described in clause (i) above and entered into with a financial institution satisfying the criteria described in clause (iii) above&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;mutual funds investing solely in any one or more of the Permitted Investments described in clauses (i) through (iv) above&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;any similar investments approved in good faith by the board of directors of the Borrower as constituting cash equivalents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Permitted Third Party Bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Lender with whom any Loan Party maintains a Controlled Account and with whom a Control Account Agreement has been executed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any natural Person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Shareholder Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Physician Shareholder Agreement, dated as of May 10, 2019 and effective as of the Original Closing Date, granted and delivered by Thomas Lam, M.D., in his capacity as the sole shareholder of AP-AMH, in favor of NMM and the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any &#8220;employee benefit plan&#8221; as defined in Section 3 of ERISA (other than a Multiemployer Plan) maintained or contributed to by the Borrower or any ERISA Affiliate or to which the Borrower or any ERISA Affiliate has or may have an obligation to contribute, and each such plan that is subject to Title IV of ERISA for the five-year period immediately following the latest date on which the Borrower or any ERISA Affiliate maintained, contributed to or had an obligation to contribute to (or is deemed under Section 4069 of ERISA to have maintained or contributed to or to have had an obligation to contribute to, or otherwise to have liability with respect to) such plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Platform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Debt Domain, Intralinks, Syndtrak or a substantially similar electronic transmission system.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Forma Basis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, (i) with respect to any Person, business, property or asset acquired in a Permitted Acquisition or other Acquisition permitted hereunder or otherwise approved in writing by the Required Lenders, the inclusion as &#8220;Consolidated EBITDA&#8221; of the Consolidated EBITDA for such Person, business, property or asset as if such Acquisition had been consummated on the first day of the applicable period, based on historical results accounted for in accordance with GAAP, and (ii) with respect to any Person, business, property or asset sold, transferred or otherwise disposed of (including any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">prior Associated Practice that ceased to be an Associated Practice during the applicable period), the exclusion from &#8220;Consolidated EBITDA&#8221; of the portion of Consolidated EBITDA for such Person, business, property or asset so disposed of during such period as if such disposition had been consummated on the first day of the applicable period, in accordance with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (i) with respect to any Class of Commitment or Loan of any Lender at any time, a percentage, the numerator of which shall be such Lender&#8217;s Commitment of such Class (or if such Commitment has been terminated or expired or the Loans have been declared to be due and payable, such Lender&#8217;s Revolving Credit Exposure or Incremental Term Loan, as applicable), and the denominator of which shall be the sum of all Commitments of such Class of all Lenders (or if such Commitments have been terminated or expired or the Loans have been declared to be due and payable, all Revolving Credit Exposure or Incremental Term Loans, as applicable, of all Lenders) and (ii) with respect to all Classes of Commitments and Loans of any Lender at any time, the numerator of which shall be the sum of such Lender&#8217;s Revolving Commitment (or if such Revolving Commitment has been terminated or expired or the Loans have been declared to be due and payable, such Lender&#8217;s Revolving Credit Exposure) and Incremental Term Loan and the denominator of which shall be the sum of all Lenders&#8217; Revolving Commitments (or if such Revolving Commitments have been terminated or expired or the Loans have been declared to be due and payable, all Revolving Credit Exposure of all Lenders funded under such Commitments) and Incremental Term Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">PTE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Qualified Cash</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the aggregate amount of the Loan Parties&#8217; unrestricted cash or cash equivalents in Controlled Accounts in which the Administrative Agent has a first priority perfected Lien&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that all cash that is (i) reserved to satisfy the &#8220;incurred but not reported&#8221; liabilities and (ii) held in an Excluded Account shall be deemed not to be Qualified Cash.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reaffirmation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1(b)(xiii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Real Estate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all real property owned or leased by the Borrower and its Subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Real Estate Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (i) Mortgages covering all Real Estate owned by the Loan Parties, duly executed by each applicable Loan Party, together with (A) title insurance policies, current as-built ALTA&#47;ACSM Land Title surveys certified to the Administrative Agent, zoning letters, building permits and certificates of occupancy, in each case relating to such Real Estate and satisfactory in form and substance to the Administrative Agent, (B) (x) Life of Loan&#8221; Federal Emergency Management Agency Standard Flood Hazard determinations, (y) notices, in the form required under the Flood Insurance Laws, about special flood hazard area status and flood disaster assistance duly executed by each Loan Party, and (z) if any improved real property encumbered by any Mortgage is located in a special flood hazard area, a policy of flood insurance that is on terms satisfactory to the Administrative Agent, (C) evidence that counterparts of such Mortgages have been recorded in all places to the extent necessary or desirable, in the judgment of the Administrative Agent, to create a valid and enforceable first priority Lien (subject to Permitted Encumbrances) on such Real Estate in favor of the Administrative Agent for the benefit of the Secured Parties (or in favor of such other trustee as may be required or desired under local law), (D) an opinion of counsel in each state in which such Real Estate is located in form and substance and from counsel satisfactory to the Administrative Agent, (E) a duly executed Environmental Indemnity with respect thereto, (F) Phase I Environmental Site Assessment Reports, consistent with American Society of Testing and Materials (ASTM) Standard E 1527-05, and applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">state requirements, on all of the owned Real Estate, dated no more than six (6) months prior to the Closing Date (or date of the applicable Mortgage if provided post-closing), prepared by environmental engineers satisfactory to the Administrative Agent, all in form and substance satisfactory to the Administrative Agent, and such environmental review and audit reports, including Phase II reports, with respect to the Real Estate of any Loan Party as the Administrative Agent shall have requested, in each case together with letters executed by the environmental firms preparing such environmental reports, in form and substance satisfactory to the Administrative Agent, authorizing the Administrative Agent and the Lenders to rely on such reports, and the Administrative Agent shall be satisfied with the contents of all such environmental reports and (G) such other reports, documents, instruments and agreements as the Administrative Agent shall request, each in form and substance satisfactory to Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, as applicable, (a) the Administrative Agent, (b) any Lender and (c) the Issuing Banks.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reference Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; with respect to any setting of the then-current Benchmark means (1) if such Benchmark is the Adjusted LIBO Rate, 11&#58;00 a.m. (London time) on the day that is two London banking days preceding the date of such setting, and (2) if such Benchmark is not the Adjusted LIBO Rate, the time determined by the Administrative Agent in its reasonable discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulated Entities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, collectively, (a) APA ACO, Inc. and (b) any Subsidiary with a health care service plan license issued by the California Department of Managed Health Care for the provision of, or the arranging, payment, or reimbursement for the provision of, health care services to subscribers or enrollees of another full service or specialized health care service plan under a contract or other arrangement whereby the person assumes both professional and institutional risk but does not directly market, solicit, or sell health care service plan contracts. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulation D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation D of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to time, and any successor regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulation T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation T of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to time, and any successor regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulation U</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation U of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to time, and any successor regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulation X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation X of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to time, and any successor regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Regulation Y</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Regulation Y of the Board of Governors of the Federal Reserve System, as the same may be in effect from time to time, and any successor regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any specified Person, such Person&#8217;s Affiliates and the respective managers, administrators, trustees, partners, directors, officers, employees, agents, advisors or other representatives of such Person and such Person&#8217;s Affiliates.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Related Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Loan Documents and all other agreements or instruments executed in connection with the Related Transactions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Related Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the amendment and restatement of the Existing Credit Agreement (resulting from the execution and delivery of this Agreement), the making of the initial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revolving Loans on the Closing Date (and the repayment in full of all outstanding &#8220;Term Loans&#8221; (as such term is defined in the Existing Credit Agreement) with proceeds of such Revolving Loans), and the payment of all fees, costs and expenses in connection with the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any release, spill, emission, leaking, dumping, injection, pouring, deposit, disposal, discharge, dispersal, leaching or migration into the environment (including ambient air, surface water, groundwater, land surface or subsurface strata) or within any building, structure, facility or fixture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Relevant Governmental Body</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Federal Reserve Board and&#47;or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and&#47;or the Federal Reserve Bank of New York or any successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, Lenders holding more than 50% of the aggregate outstanding Revolving Commitments and Incremental Term Loans at such time or, if the Lenders have no Commitments outstanding, then Lenders holding more than 50% of the aggregate outstanding Revolving Credit Exposure and Incremental Term Loans of the Lenders at such time&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that to the extent that any Lender is a Defaulting Lender, such Defaulting Lender and all of its Revolving Commitments, Revolving Credit Exposure and Incremental Term Loans shall be excluded for purposes of determining Required Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Required Revolving Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, Lenders holding more than 50% of the aggregate outstanding Revolving Commitments at such time or, if the Lenders have no Revolving Commitments outstanding, then Lenders holding more than 50% of the aggregate Revolving Credit Exposure&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that to the extent that any Lender is a Defaulting Lender, such Defaulting Lender and all of its Revolving Commitments and Revolving Credit Exposure shall be excluded for purposes of determining Required Revolving Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Requirement of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; for any Person shall mean the articles or certificate of incorporation, bylaws, partnership certificate and agreement, or limited liability company certificate of organization and agreement, as the case may be, and other organizational and governing documents of such Person, and any law, treaty, rule or regulation, or determination of a Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject, including all Healthcare Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Responsible Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (x) with respect to certifying compliance with the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, any of the chief financial officer, the treasurer or the vice president of finance of the Borrower and (y) with respect to all other provisions, any of the executive chairman, the president, the chief executive officer, the chief operating officer, the chief financial officer, the treasurer or the vice president of finance of the Borrower or such other representative of the Borrower as may be designated in writing by any one of the foregoing with the consent of the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for any Person, </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;any dividend or other distribution, direct or indirect, on account of any shares of any class of Capital Stock of such Person&#59; </font></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of any shares of any class of Capital Stock of such Person now or hereafter outstanding&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:11pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any payment made to retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Capital Stock of such Person now or hereafter outstanding&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any payment on account of Indebtedness that is subordinated to the Obligations. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Revolving Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Lender, the commitment of such Lender to make Revolving Loans to the Borrower and to acquire participations in Letters of Credit and Swingline Loans in an aggregate principal amount not exceeding the amount set forth with respect to such Lender on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as such schedule may be amended pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or, in the case of a Person becoming a Lender after the Closing Date, the amount of the assigned &#8220;Revolving Commitment&#8221; as provided in the Assignment and Acceptance executed by such Person as an assignee, or the joinder executed by such Person, in each case as such commitment may subsequently be increased or decreased pursuant to the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Revolving Commitment Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the earliest of (i) June 16, 2026</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ii) the date on which the Revolving Commitments are terminated pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and (iii) the date on which all amounts outstanding under this Agreement have been declared or have automatically become due and payable (whether by acceleration or otherwise).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Revolving Credit Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Lender at any time, the sum of the outstanding principal amount of such Lender&#8217;s Revolving Loans, LC Exposure and Swingline Exposure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Revolving Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a loan made by a Lender (other than the Swingline Lender) to the Borrower under its Revolving Commitment, which may either be a Base Rate Loan or a Eurodollar Loan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">S&#38;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Standard &#38; Poor&#8217;s Rating Agency Group.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctioned Country</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, a country, region or territory that is, or whose government is, the subject or target of any Sanctions including, without limitation, Crimea, Cuba, Iran, North Korea and Syria.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctioned Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, at any time, (a) any Person that is the subject or target of any Sanctions, (b) any Person located, organized, operating or resident in a Sanctioned Country or (c) any Person owned or controlled by any such Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sanctions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those administered by OFAC or the U.S. Department of State, (b) the United Nations Security Council, the European Union or Her Majesty&#8217;s Treasury of the United Kingdom or (c) any other relevant sanctions authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Screen Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the rate specified in clause (i) of the definition of Adjusted LIBO Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Dividend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the dividends to be issued by APC to AP-AMH on account of the Series A Preferred Stock pursuant to the Certificate of Determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred SPA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Series A Preferred Stock Purchase Agreement dated as of May 10, 2019 and effective as of the Original Closing Date, by and between APC and AP-AMH.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the 1,000,000 shares of Series A Preferred Capital Stock issued by APC and purchased by AP-AMH in connection with the Series A Preferred SPA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Secured Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Administrative Agent, the Lenders, the Issuing Banks, the Lender-Related Hedge Providers and the Bank Product Providers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; with respect to any Business Day, a rate per annum equal to the secured overnight financing rate published for such day by the Federal Reserve Bank of New York, as the administrator of the benchmark, (or a successor administrator) on the Federal Reserve Bank of New York&#8217;s Website at approximately 8&#58;00 a.m. (New York City time) on the immediately succeeding Business Day.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person on a particular date, that on such date (a) the fair value of the property of such Person is greater than the total amount of liabilities, including subordinated and contingent liabilities, of such Person&#59; (b) the present fair saleable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts and liabilities, including subordinated and contingent liabilities as they become absolute and matured&#59; (c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person&#8217;s ability to pay as such debts and liabilities mature&#59; and (d) such Person is not engaged in a business or transaction, and is not about to engage in a business or transaction, for which such Person&#8217;s property would constitute an unreasonably small capital. The amount of contingent liabilities (such as litigation, guaranties and pension plan liabilities) at any time shall be computed as the amount that, in light of all the facts and circumstances existing at the time, represents the amount that would reasonably be expected to become an actual or matured liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at any date, any corporation, partnership, joint venture, limited liability company, association or other entity the accounts of which would be consolidated with those of the parent in the parent&#8217;s consolidated financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation, partnership, joint venture, limited liability company, association or other entity (i) of which securities or other ownership interests representing more than 50% of the equity or more than 50% of the ordinary voting power or, in the case of a partnership, more than 50% of the general partnership interests are, as of such date, owned, controlled or held, or (ii) that is, as of such date, otherwise controlled, by the parent or one or more subsidiaries of the parent or by the parent and one or more subsidiaries of the parent.   Unless otherwise indicated, all references to &#8220;Subsidiary&#8221; hereunder shall mean a Subsidiary of the Borrower.  Notwithstanding anything to the contrary contained herein, the Associated Practices will be deemed not to be Subsidiaries of the Borrower (except as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 1.3(b))</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Subsidiary Loan Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Subsidiary that executes or becomes a party to the Guaranty and Security Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Swap Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Guarantor, any obligation to pay or perform under any agreement, contract or transaction that constitutes a &#8220;swap&#8221; within the meaning of section 1a(47) of the Commodity Exchange Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Swap Termination Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, in respect of any one or more Hedging Transactions, after taking into account the effect of any legally enforceable netting agreement relating to such Hedging Transactions, (a) for any date on or after the date such Hedging Transactions have been closed out and termination value(s) determined in accordance therewith, such termination value(s), and (b) for any date prior to the date referenced in clause (a), the amount(s) determined as the mark-to-market value(s) for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such Hedging Transactions, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Hedging Transactions (which may include a Lender or any Affiliate of a Lender).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Swingline Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the commitment of the Swingline Lender to make Swingline Loans in an aggregate principal amount at any time outstanding not to exceed $25,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Swingline Exposure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to each Lender, the principal amount of the Swingline Loans in which such Lender is legally obligated either to make a Base Rate Loan or to purchase a participation in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which shall equal such Lender&#8217;s Pro Rata Share of all outstanding Swingline Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Swingline Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean Truist Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Swingline Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a loan made to the Borrower by the Swingline Lender under the Swingline Commitment. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Synthetic Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean a lease transaction under which the parties intend that (i) the lease will be treated as an &#8220;operating lease&#8221; by the lessee pursuant to Accounting Standards Codification Sections 840-10 and 840-20, as amended, and Accounting Standards Codification Section 842 and (ii) the lessee will be entitled to various tax and other benefits ordinarily available to owners (as opposed to lessees) of like property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Synthetic Lease Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any Person, the sum of (i) all remaining rental obligations of such Person as lessee under Synthetic Leases which are attributable to principal and, without duplication, (ii) all rental and purchase price payment obligations of such Person under such Synthetic Leases assuming such Person exercises the option to purchase the lease property at the end of the lease term.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any and all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees, or charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, for the applicable Corresponding Tenor as of the applicable Reference Time, the forward-looking term rate based on SOFR that has been selected or recommended by the Relevant Governmental Body.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means a notification by the Administrative Agent to the Lenders and the Borrower of the occurrence of a Term SOFR Transition Event. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Term SOFR Transition Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the determination by the Administrative Agent that (a) Term SOFR has been recommended for use by the Relevant Governmental Body, (b) the administration of Term SOFR is administratively feasible for the Administrative Agent and (c) a Benchmark Transition Event has previously occurred resulting in a Benchmark Replacement in accordance with Section 2.16 that is not Term SOFR.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Payor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means Medicare, Medicaid, TRICARE, state government insurers, public or private insurers (including Blue Cross and&#47;or Blue Shield) and any other Person which presently or in the future maintains a healthcare payment or reimbursement program.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Third Party Payor Programs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean all payment or reimbursement programs, sponsored or maintained by any Third Party Payor, in which the Loan Parties or any of their respective Subsidiaries or any Associated Practice participates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Threshold Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean $10,000,000.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning assigned to such term in the Guaranty and Security Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trademark Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Trademark Security Agreement executed by a Loan Party owning registered Trademarks or applications for Trademarks in favor of the Administrative Agent for the benefit of the Secured Parties, including on the Original Closing Date and thereafter (in each case as amended, restated, reaffirmed (including pursuant to the Reaffirmation Agreement), supplemented or otherwise modified from time to time).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Tradename Licensing Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean that certain Tradename Licensing Agreement dated as of May 20, 2019, between the Borrower and AP-AMH.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer Restriction Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean each physician shareholder agreement (including, for the avoidance of doubt, the Physician Shareholder Agreement), membership interest transfer restriction agreement, stock transfer restriction agreement, continuity agreement or other similar agreement between the applicable Loan Party, the applicable Associated Practice and the applicable equity holder(s) of such Associated Practice, in each case, in form and substance reasonably satisfactory to Administrative Agent or similar provisions in any Management Services Agreement, in each case except for such changes required by any change in law (including Healthcare Laws and state corporate laws), in each case, as the same may be amended, restated, supplemented or otherwise modified from time to time in accordance with the terms hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Type</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;, when used in reference to a Loan or a Borrowing, refers to whether the rate of interest on such Loan, or on the Loans comprising such Borrowing, is determined by reference to the Adjusted LIBO Rate or the Base Rate.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Financial Institution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.</font></div><div style="margin-bottom:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UK Resolution Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Unadjusted Benchmark Replacement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Benchmark Replacement excluding the Benchmark Replacement Adjustment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Unfunded Pension Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of any Plan shall mean the amount, if any, by which the value of the accumulated plan benefits under the Plan, determined on a plan termination basis in accordance with actuarial assumptions at such time consistent with those prescribed by the PBGC for purposes of Section 4044 of ERISA, exceeds the fair market value of all Plan assets allocable to such liabilities under Title IV of ERISA (excluding any accrued but unpaid contributions).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Uniform Commercial Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">UCC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Uniform Commercial Code as in effect from time to time in the State of New York.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221; shall mean the United States of America. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean any Person that is a &#8220;United States person&#8221; as defined in Section 7701(a)(30) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Tax Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall have the meaning set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20(g)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withdrawal Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Withholding Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the Borrower, any other Loan Party or the Administrative Agent, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Write-Down and Conversion Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Classifications of Loans and Borrowings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For purposes of this Agreement, Loans may be classified and referred to by Class (e.g. &#8220;Revolving Loan&#8221; or &#8220;Incremental Term Loan&#8221;) or by Type (e.g. &#8220;Eurodollar Loan&#8221; or &#8220;Base Rate Loan&#8221;) or by Class and Type (e.g. &#8220;Revolving Eurodollar Loan&#8221;). Borrowings also may be classified and referred to by Class (e.g. &#8220;Revolving Borrowing&#8221;) or by Type (e.g. &#8220;Eurodollar Borrowing&#8221;) or by Class and Type (e.g. &#8220;Revolving Eurodollar Borrowing&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Terms and Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Unless otherwise defined or specified herein, all accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be made, and all financial statements required to be delivered hereunder shall be prepared, in accordance with GAAP as in effect from time to time, applied on a basis consistent with the most recent audited consolidated financial statements of the Borrower delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (or, if no such financial statements have been delivered, on a basis consistent with the audited consolidated financial statements of the Borrower last publicly filed)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if the Borrower notifies the Administrative Agent that the Borrower wishes to amend any covenant in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to eliminate the effect of any change in GAAP on the operation of such covenant (or if the Administrative Agent notifies the Borrower that the Required Lenders wish to amend </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for such purpose), then the Borrower&#8217;s compliance with such covenant shall be determined on the basis of GAAP in effect immediately before the relevant change in GAAP became effective, until either such notice is withdrawn or such covenant is amended in a manner satisfactory to the Borrower and the Required Lenders. Notwithstanding any other provision contained herein, (i) all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">herein shall be made, without giving effect to any election under Accounting Standards Codification Section 825-10 (or any other Financial Accounting Standard having a similar result or effect including ASU 2015-03, and any other related treatment for debt discounts and premiums, such as original issue discount) to value any Indebtedness or other liabilities of any Loan Party or any Subsidiary of any Loan Party at &#8220;fair value&#8221;, as defined therein and (ii) for purposes of this Agreement, any lease that was accounted for by any Person as an operating lease as of December 31, 2018 and any lease entered into after December 31, 2018 that would have been accounted for as an operating lease if such lease had been in effect on December 31, 2018 shall be accounted for as an operating lease consistent with GAAP as in effect on December 31, 2018.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in this Agreement or any other Loan Document, the consolidated financial results or performance of the Borrower and its Subsidiaries shall include the financial results or performance of the Associated Practices to the extent required under GAAP. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Terms Generally</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation&#8221;. The words &#8220;other&#8221; and &#8220;otherwise&#8221; shall not be construed ejusdem generis with any foregoing words where a wider construction is possible. The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;. In the computation of periods of time from a specified date to a later specified date, the word &#8220;from&#8221; means &#8220;from and including&#8221; and the word &#8220;to&#8221; means &#8220;to but excluding&#8221;. Unless the context requires otherwise (i) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as it was originally executed or as it may from time to time be amended, restated, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (ii) any reference herein to any Person shall be construed to include such Person&#8217;s successors and permitted assigns, (iii) the words &#8220;hereof&#8221;, &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import shall be construed to refer to this Agreement as a whole and not to any particular provision hereof, (iv) all references to Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles, Sections, Exhibits and Schedules to this Agreement, (v) any definition of or reference to any law shall include all statutory and regulatory provisions consolidating, amending, or interpreting any such law and any reference to or definition of any law or regulation, unless otherwise specified, shall refer to such law or regulation as amended, modified or supplemented from time to time, (vi) the words &#8220;asset&#8221; and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights and (vii) all references to a specific time shall be construed to refer to the time in the city and state of the Administrative Agent&#8217;s principal office, unless otherwise indicated. Unless otherwise expressly provided herein, all references to dollar amounts shall mean Dollars. In determining whether any individual event, act, condition or occurrence of the foregoing types could reasonably be expected to result in a Material Adverse Effect, notwithstanding that a particular event, act, condition or occurrence does not itself have such effect, a Material Adverse Effect shall be deemed to have occurred if the cumulative effect of such event, act, condition or occurrence and all other such events, acts, conditions or occurrences of the foregoing types which have occurred could reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 1.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Divisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For all purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction&#8217;s laws)&#58; (a) if any asset, right, obligation or liability of any Person becomes the asset, right, obligation or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person, and (b) if any new Person comes into existence, such new Person shall be deemed to have been organized on the first date of its existence by the holders of its equity interests at such time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 1.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">LIBOR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The London interbank offered rate (&#8220;LIBOR&#8221;) is intended to represent the rate at which contributing banks could obtain short-term borrowings from one another in the London interbank market. On March 5, 2021, the Financial Conduct Authority (&#34;FCA&#34;), the regulatory supervisor of LIBOR's administrator, announced in a public statement the future cessation of the 35 LIBOR benchmark settings currently published by ICE Benchmark administration. This public statement constitutes a Benchmark Transition Event. To the extent the Revolving Commitment Termination Date and&#47;or Maturity Date goes beyond the cessation dates indicated in the FCA&#8217;s announcement, an alternate rate of interest will be determined at the appropriate time in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.16(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for any applicable tenors of USD LIBOR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, Section 2.16(b) and (c) provide the mechanism for determining an alternative rate of interest. The Administrative Agent will promptly notify the Borrower, pursuant to Section 2.16(e), of any change to the reference rates upon which the interest rates on Eurodollar Loans are based. However, the Administrative Agent does not warrant or accept any responsibility for, and shall not have any liability with respect to, the administration, submission or any other matter related to LIBOR or other rates in the definition of &#8220;Adjusted LIBO Rate&#8221; or with respect to any alternative or successor rate thereto, or replacement rate thereof (including, without limitation, (i) any such alternative, successor or replacement rate implemented pursuant to Section 2.16(b) or (c), whether upon the occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, and (ii) the implementation of any Benchmark Replacement Conforming Changes pursuant to Section 2.16(d)), including without limitation, whether the composition or characteristics of any such alternative, successor or replacement reference rate will be similar to, or produce the same value or economic equivalence of, the Adjusted LIBO Rate or have the same volume or liquidity as did LIBOR prior to its discontinuance or unavailability.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>AMOUNT AND TERMS OF THE COMMITMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">General Description of Facilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to and upon the terms and conditions herein set forth, (i) the Lenders hereby establish in favor of the Borrower a revolving credit facility pursuant to which each Lender severally agrees (to the extent of such Lender&#8217;s Revolving Commitment) to make Revolving Loans to the Borrower in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; (ii) each Issuing Bank may issue Letters of Credit in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; (iii) the Swingline Lender may make Swingline Loans in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and (iv) each Lender agrees to purchase a participation interest in the Letters of Credit and the Swingline Loans pursuant to the terms and conditions hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that in no event shall the aggregate principal amount of all outstanding Revolving Loans, Swingline Loans and outstanding LC Exposure exceed the Aggregate Revolving Commitment Amount in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Revolving Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Subject to the terms and conditions set forth herein, each Lender severally agrees to make Revolving Loans, ratably in proportion to its Pro Rata Share of the Aggregate Revolving Commitments, to the Borrower, from time to time during the Availability Period, in an aggregate principal amount outstanding at any time that will not result in (a) such Lender&#8217;s Revolving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Credit Exposure exceeding such Lender&#8217;s Revolving Commitment or (b) the aggregate Revolving Credit Exposures of all Lenders exceeding the Aggregate Revolving Commitment Amount. During the Availability Period, the Borrower shall be entitled to borrow, prepay and reborrow Revolving Loans in accordance with the terms and conditions of this Agreement&#59; provided that the Borrower may not borrow or reborrow should there exist a Default or Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Procedure for Revolving Borrowings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall give the Administrative Agent written notice (or telephonic notice promptly confirmed in writing) of each Revolving Borrowing, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Revolving Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (x) prior to 12&#58;00 p.m. one (1) Business Day prior to the requested date of each Base Rate Borrowing (other than with respect to the Closing Date, for which such request shall be required to be provided no later than 12&#58;00 p.m. on the Closing Date) and (y) prior to 11&#58;00 a.m. three (3) Business Days prior to the requested date of each Eurodollar Borrowing (other than with respect to the Closing Date, for which such request shall be provided prior to 5&#58;00 p.m. three (3) Business Days prior to the Closing Date). Each Notice of Revolving Borrowing shall be irrevocable and shall specify (i) the aggregate principal amount of such Borrowing, (ii) the date of such Borrowing (which shall be a Business Day), (iii) the Type of such Revolving Loan comprising such Borrowing and (iv) in the case of a Eurodollar Borrowing, the duration of the initial Interest Period applicable thereto (subject to the provisions of the definition of Interest Period). Each Revolving Borrowing shall consist entirely of Base Rate Loans or Eurodollar Loans, as the Borrower may request. The aggregate principal amount of each Eurodollar Borrowing shall not be less than $2,000,000 or a larger multiple of $500,000, and the aggregate principal amount of each Base Rate Borrowing shall not be less than $1,000,000 or a larger multiple of $100,000&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that Base Rate Loans made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.22(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> may be made in lesser amounts as provided therein. At no time shall the total number of Eurodollar Borrowings outstanding at any time exceed four (4). Promptly following the receipt of a Notice of Revolving Borrowing in accordance herewith, the Administrative Agent shall advise each Lender of the details thereof and the amount of such Lender&#8217;s Revolving Loan to be made as part of the requested Revolving Borrowing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Swingline Commitment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions set forth herein, the Swingline Lender may, in its sole discretion, make Swingline Loans to the Borrower, from time to time during the Availability Period, in an aggregate principal amount outstanding at any time not to exceed the lesser of (i) the Swingline Commitment then in effect and (ii) the difference between the Aggregate Revolving Commitment Amount and the aggregate Revolving Credit Exposures of all Lenders&#59; provided that the Swingline Lender shall not be required to make a Swingline Loan to refinance an outstanding Swingline Loan. The Borrower shall be entitled to borrow, repay and reborrow Swingline Loans in accordance with the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower shall give the Administrative Agent written notice (or telephonic notice promptly confirmed in writing) of each Swingline Borrowing, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Swingline Borrowing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), prior to 10&#58;00 a.m. on the requested date of each Swingline Borrowing. Each Notice of Swingline Borrowing shall be irrevocable and shall specify (i) the principal amount of such Swingline Borrowing, (ii) the date of such Swingline Borrowing (which shall be a Business Day) and (iii) the account of the Borrower to which the proceeds of such Swingline Borrowing should be credited. The Administrative Agent will promptly advise the Swingline Lender of each Notice of Swingline Borrowing. The aggregate principal amount of each Swingline Loan shall not be less than $100,000 or a larger multiple of $50,000, or such other minimum amounts agreed to by the Swingline Lender and the Borrower. The Swingline Lender will make the proceeds of each Swingline </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loan available to the Borrower in Dollars in immediately available funds at the account specified by the Borrower in the applicable Notice of Swingline Borrowing not later than 1&#58;00 p.m. on the requested date of such Swingline Borrowing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Swingline Lender, at any time and from time to time in its sole discretion, may, but in no event no less frequently than once each calendar week shall, on behalf of the Borrower (which hereby irrevocably authorizes and directs the Swingline Lender to act on its behalf), give a Notice of Revolving Borrowing to the Administrative Agent requesting the Lenders (including the Swingline Lender) to make Base Rate Loans in an amount equal to the unpaid principal amount of any Swingline Loan. Each Lender will make the proceeds of its Base Rate Loan included in such Borrowing available to the Administrative Agent for the account of the Swingline Lender in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which will be used solely for the repayment of such Swingline Loan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;If for any reason a Base Rate Borrowing may not be (as determined in the sole discretion of the Administrative Agent), or is not, made in accordance with the foregoing provisions, then each Lender (other than the Swingline Lender) shall purchase an undivided participating interest in such Swingline Loan in an amount equal to its Pro Rata Share thereof on the date that such Base Rate Borrowing should have occurred. On the date of such required purchase, each Lender shall promptly transfer, in immediately available funds, the amount of its participating interest to the Administrative Agent for the account of the Swingline Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Each Lender&#8217;s obligation to make a Base Rate Loan pursuant to subsection (c) of this Section or to purchase participating interests pursuant to subsection (d) of this Section shall be absolute and unconditional and shall not be affected by any circumstance, including, without limitation, (i) any set-off, counterclaim, recoupment, defense or other right that such Lender or any other Person may have or claim against the Swingline Lender, the Borrower or any other Person for any reason whatsoever, (ii) the existence of a Default or an Event of Default or the termination of any Lender&#8217;s Revolving Commitment, (iii) the existence (or alleged existence) of any event or condition which has had or could reasonably be expected to have a Material Adverse Effect, (iv) any breach of this Agreement or any other Loan Document by any Loan Party, the Administrative Agent or any Lender or (v) any other circumstance, happening or event whatsoever, whether or not similar to any of the foregoing. If such amount is not in fact made available to the Swingline Lender by any Lender, the Swingline Lender shall be entitled to recover such amount on demand from such Lender, together with accrued interest thereon for each day from the date of demand thereof (x) at the Federal Funds Rate until the second Business Day after such demand and (y) at the Base Rate at all times thereafter. Until such time as such Lender makes its required payment, the Swingline Lender shall be deemed to continue to have outstanding Swingline Loans in the amount of the unpaid participation for all purposes of the Loan Documents. In addition, such Lender shall be deemed to have assigned any and all payments made of principal and interest on its Loans and any other amounts due to it hereunder to the Swingline Lender to fund the amount of such Lender&#8217;s participation interest in such Swingline Loans that such Lender failed to fund pursuant to this Section, until such amount has been purchased in full.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">&#91;Reserved&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Funding of Borrowings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Lender will make available each Loan to be made by it hereunder on the proposed date thereof by wire transfer in immediately available funds by 11&#58;00 a.m. to the Administrative Agent at the Payment Office&#59; provided that the Swingline Loans will be made as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Administrative Agent will make such Loans available to the Borrower by promptly crediting the amounts that it receives, in like funds by the close of business on such proposed date, to an account maintained by the Borrower with the Administrative Agent or, at the Borrower&#8217;s option, by effecting a wire transfer of such amounts to an account designated by the Borrower to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Unless the Administrative Agent shall have been notified by any Lender prior to 5&#58;00 p.m. one (1) Business Day prior to the date of a Borrowing in which such Lender is to participate that such Lender will not make available to the Administrative Agent such Lender&#8217;s share of such Borrowing, the Administrative Agent may assume that such Lender has made such amount available to the Administrative Agent on such date, and the Administrative Agent, in reliance on such assumption, may make available to the Borrower on such date a corresponding amount. If such corresponding amount is not in fact made available to the Administrative Agent by such Lender on the date of such Borrowing, the Administrative Agent shall be entitled to recover such corresponding amount on demand from such Lender together with interest (x) at the Federal Funds Rate until the second Business Day after such demand and (y) at the Base Rate at all times thereafter. If such Lender does not pay such corresponding amount forthwith upon the Administrative Agent&#8217;s demand therefor, the Administrative Agent shall promptly notify the Borrower, and the Borrower shall immediately pay such corresponding amount to the Administrative Agent together with interest at the rate specified for such Borrowing. Nothing in this subsection shall be deemed to relieve any Lender from its obligation to fund its Pro Rata Share of any Borrowing hereunder or to prejudice any rights which the Borrower may have against any Lender as a result of any default by such Lender hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;All Revolving Borrowings shall be made by the Lenders on the basis of their respective Pro Rata Shares. No Lender shall be responsible for any default by any other Lender in its obligations hereunder, and each Lender shall be obligated to make its Loans provided to be made by it hereunder, regardless of the failure of any other Lender to make its Loans hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Interest Elections.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Borrowing initially shall be of the Type specified in the applicable Notice of Borrowing. Thereafter, the Borrower may elect to convert such Borrowing into a different Type or to continue such Borrowing, all as provided in this Section. The Borrower may elect different options with respect to different portions of the affected Borrowing, in which case each such portion shall be allocated ratably among the Lenders holding Loans comprising such Borrowing, and the Loans comprising each such portion shall be considered a separate Borrowing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To make an election pursuant to this Section, the Borrower shall give the Administrative Agent written notice (or telephonic notice promptly confirmed in writing) of each Borrowing that is to be converted or continued, as the case may be, substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> attached hereto (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Conversion&#47;Continuation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (x) prior to 10&#58;00 a.m. one (1) Business Day prior to the requested date of a conversion into a Base Rate Borrowing and (y) prior to 11&#58;00 a.m. three (3) Business Days prior to a continuation of or conversion into a Eurodollar Borrowing. Each such Notice of Conversion&#47;Continuation shall be irrevocable and shall specify (i) the Borrowing to which such Notice of Conversion&#47;Continuation applies and, if different options are being elected with respect to different portions thereof, the portions thereof that are to be allocated to each resulting Borrowing (in which case the information to be specified pursuant to clauses (iii) and (iv) shall be specified for each resulting Borrowing), (ii) the effective date of the election made pursuant to such Notice of Conversion&#47;Continuation, which shall be a Business Day, (iii) whether the resulting Borrowing is to be a Base Rate Borrowing or a Eurodollar Borrowing, and (iv) if the resulting Borrowing is to be a Eurodollar </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Borrowing, the Interest Period applicable thereto after giving effect to such election, which shall be a period contemplated by the definition of &#8220;Interest Period&#8221;. If any such Notice of Conversion&#47; Continuation requests a Eurodollar Borrowing but does not specify an Interest Period, the Borrower shall be deemed to have selected an Interest Period of one month. The principal amount of any resulting Borrowing shall satisfy the minimum borrowing amount for Eurodollar Borrowings and Base Rate Borrowings set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If, on the expiration of any Interest Period in respect of any Eurodollar Borrowing, the Borrower shall have failed to deliver a Notice of Conversion&#47;Continuation, then, unless such Borrowing is repaid as provided herein, the Borrower shall be deemed to have elected to convert such Borrowing to a Base Rate Borrowing. No Borrowing may be converted into, or continued as, a Eurodollar Borrowing if a Default or an Event of Default exists, unless the Administrative Agent and each of the Lenders shall have otherwise consented in writing. No conversion of any Eurodollar Loan shall be permitted except on the last day of the Interest Period in respect thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Upon receipt of any Notice of Conversion&#47;Continuation, the Administrative Agent shall promptly notify each Lender of the details thereof and of such Lender&#8217;s portion of each resulting Borrowing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Optional Reduction and Termination of Commitments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Unless previously terminated, all Revolving Commitments, Swingline Commitments and LC Commitments shall terminate on the Revolving Commitment Termination Date. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Upon at least three (3) Business Days&#8217; prior written notice (or telephonic notice promptly confirmed in writing) to the Administrative Agent (which notice shall be irrevocable), the Borrower may reduce the Aggregate Revolving Commitments in part or terminate the Aggregate Revolving Commitments in whole&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) any partial reduction shall apply to reduce proportionately and permanently the Revolving Commitment of each Lender, (ii)&#160;any partial reduction pursuant to this Section shall be in an amount of at least $5,000,000 and any larger multiple of $1,000,000, and (iii) no such reduction shall be permitted which would reduce the Aggregate Revolving Commitment Amount to an amount less than the aggregate outstanding Revolving Credit Exposure of all Lenders. Any such reduction in the Aggregate Revolving Commitment Amount below the principal amount of the Swingline Commitment and the LC Commitment shall result in a dollar-for-dollar reduction in the Swingline Commitment and the LC Commitment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;With the written approval of the Administrative Agent, the Borrower may terminate (on a non-ratable basis) the unused amount of the Revolving Commitment of a Defaulting Lender, and in such event the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> will apply to all amounts thereafter paid by the Borrower for the account of any such Defaulting Lender under this Agreement (whether on account of principal, interest, fees, indemnity or other amounts)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such termination will not be deemed to be a waiver or release of any claim that the Borrower, the Administrative Agent, the Issuing Banks, the Swingline Lender or any other Lender may have against such Defaulting Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Repayment of Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The outstanding principal amount of all Revolving Loans and Swingline Loans shall be due and payable (together with accrued and unpaid interest thereon) on the Revolving Commitment Termination Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">50</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Evidence of Indebtedness.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Lender shall maintain in accordance with its usual practice appropriate records evidencing the Indebtedness of the Borrower to such Lender resulting from each Loan made by such Lender from time to time, including the amounts of principal and interest payable thereon and paid to such Lender from time to time under this Agreement. The Administrative Agent shall maintain appropriate records in which shall be recorded (i) the Revolving Commitment and the Incremental Term Loan Commitment of each Lender, (ii) the amount of each Loan made hereunder by each Lender, the Class and Type thereof and, in the case of each Eurodollar Loan, the Interest Period applicable thereto, (iii) the date of any continuation of any Loan pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (iv) the date of any conversion of all or a portion of any Loan to another Type pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (v) the date and amount of any principal or interest due and payable or to become due and payable from the Borrower to each Lender hereunder in respect of the Loans and (vi) both the date and amount of any sum received by the Administrative Agent hereunder from the Borrower in respect of the Loans and each Lender&#8217;s Pro Rata Share thereof. The entries made in such records shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">prima facie</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> evidence of the existence and amounts of the obligations of the Borrower therein recorded&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the failure or delay of any Lender or the Administrative Agent in maintaining or making entries into any such record or any error therein shall not in any manner affect the obligation of the Borrower to repay the Loans (both principal and unpaid accrued interest) of such Lender in accordance with the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This Agreement evidences the obligation of the Borrower to repay the Loans and is being executed as a &#8220;noteless&#8221; credit agreement. However, at the request of any Lender (including the Swingline Lender) at any time, the Borrower agrees that it will prepare, execute and deliver to such Lender a promissory note payable to the order of such Lender (or, if requested by such Lender, to such Lender and its registered assigns) and in a form approved by the Administrative Agent. Thereafter, the Loans evidenced by such promissory note and interest thereon shall at all times (including after assignment permitted hereunder) be represented by one or more promissory notes in such form payable to the order of the payee named therein (or, if such promissory note is a registered note, to such payee and its registered assigns).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Optional Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall have the right at any time and from time to time to prepay any Borrowing, in whole or in part, without premium or penalty, by giving written notice (or telephonic notice promptly confirmed in writing) to the Administrative Agent no later than (i) in the case of any prepayment of any Eurodollar Borrowing, 11&#58;00 a.m. not less than three (3) Business Days prior to the date of such prepayment, (ii) in the case of any prepayment of any Base Rate Borrowing, not less than one (1) Business Day prior to the date of such prepayment, and (iii) in the case of any prepayment of any Swingline Borrowing, prior to 11&#58;00 a.m. on the date of such prepayment. Each such notice shall be irrevocable and shall specify the proposed date of such prepayment and the principal amount of each Borrowing or portion thereof to be prepaid. Upon receipt of any such notice, the Administrative Agent shall promptly notify each affected Lender of the contents thereof and of such Lender&#8217;s Pro Rata Share of any such prepayment. If such notice is given, the aggregate amount specified in such notice shall be due and payable on the date designated in such notice, together with accrued interest to such date on the amount so prepaid in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.13(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if a Eurodollar Borrowing is prepaid on a date other than the last day of an Interest Period applicable thereto, the Borrower shall also pay all amounts required pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each partial prepayment of any Loan shall be in an amount that would be permitted in the case of an advance of a Revolving Borrowing of the same Type pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or, in the case of a Swingline Loan, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each prepayment of a Borrowing shall be applied ratably to the Loans comprising such Borrowing and, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">51</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the case of a prepayment of an Incremental Term Loan Borrowing, to principal installments as may be directed by the Borrower (and in the absence of any such direction, in the inverse order of maturity).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Mandatory Prepayments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#91;Reserved&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#91;Reserved&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#91;Reserved&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#91;Reserved&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If at any time the aggregate Revolving Credit Exposure of all Lenders exceeds the Aggregate Revolving Commitment Amount, as reduced pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or otherwise, the Borrower shall immediately repay the Swingline Loans and the Revolving Loans in an amount equal to such excess, together with all accrued and unpaid interest on such excess amount and any amounts due under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each prepayment shall be applied as follows&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the Swingline Loans to the full extent thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the Base Rate Loans to the full extent thereof&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the Eurodollar Loans to the full extent thereof. If, after giving effect to prepayment of all Swingline Loans and Revolving Loans, the aggregate Revolving Credit Exposure of all Lenders exceeds the Aggregate Revolving Commitment Amount, the Borrower shall Cash Collateralize its reimbursement obligations with respect to all Letters of Credit in an amount equal to such excess plus any accrued and unpaid fees thereon. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Interest on Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower shall pay interest on (i) each Base Rate Loan at the Base Rate plus the Applicable Margin in effect from time to time and (ii) each Eurodollar Loan at the Adjusted LIBO Rate for the applicable Interest Period in effect for such Loan plus the Applicable Margin in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower shall pay interest on each Swingline Loan at the Base Rate plus the Applicable Margin in effect from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding subsections (a) and (b) of this Section, at the request of the Required Lenders if an Event of Default has occurred and is continuing, and automatically after acceleration or with respect to any Event of Default due to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 8.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Borrower shall pay interest (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with respect to all Eurodollar Loans at the rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> equal to 200 basis points above the otherwise applicable interest rate for such Eurodollar Loans for the then-current Interest Period until the last day of such Interest Period, and thereafter, and with respect to all Base Rate Loans and all other Obligations hereunder (other than Loans), at the rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> equal to 200 basis points above the otherwise applicable interest rate for Base Rate Loans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Interest on the principal amount of all Loans shall accrue from and including the date such Loans are made to but excluding the date of any repayment thereof. Interest on all outstanding Base Rate Loans and Swingline Loans shall be payable quarterly in arrears on the last Business Day of each March, June, September and December and on the Revolving Commitment Termination Date or the Maturity Date, as the case may be. Interest on all outstanding Eurodollar Loans shall be payable on the last day of each Interest Period applicable thereto, and, in the case of any Eurodollar Loans having an Interest Period in excess of three months, on each day which occurs every three months after the initial </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">52</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date of such Interest Period, and on the Revolving Commitment Termination Date or the Maturity Date, as the case may be. Interest on any Loan which is converted into a Loan of another Type or which is repaid or prepaid shall be payable on the date of such conversion or on the date of any such repayment or prepayment (on the amount repaid or prepaid) thereof. All Default Interest shall be payable on demand.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Administrative Agent shall determine each interest rate applicable to the Loans hereunder and shall promptly notify the Borrower and the Lenders of such rate in writing (or by telephone, promptly confirmed in writing). Any such determination shall be conclusive and binding for all purposes, absent manifest error.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower shall pay to the Administrative Agent for its own account fees in the amounts and at the times previously agreed upon in writing by the Borrower and the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower agrees to pay to the Administrative Agent for the account of each Lender a commitment fee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Commitment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which shall accrue at the Applicable Percentage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (determined daily in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) on the daily amount of the unused Revolving Commitment of such Lender during the Availability Period.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of computing the Commitment Fee, the Revolving Commitment of each Lender shall be deemed used to the extent of the outstanding Revolving Loans and LC Exposure, but not Swingline Exposure, of such Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Borrower agrees to pay (i) to the Administrative Agent, for the account of each Lender, a letter of credit fee with respect to its participation in each Letter of Credit, which shall accrue at a rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> equal to the Applicable Margin for Eurodollar Loans then in effect on the average daily amount of such Lender&#8217;s LC Exposure attributable to such Letter of Credit during the period from and including the date of issuance of such Letter of Credit to but excluding the date on which such Letter of Credit expires or is drawn in full (including, without limitation, any LC Exposure that remains outstanding after the Revolving Commitment Termination Date) and (ii) to each Issuing Bank for its own account a fronting fee, which shall accrue at the rate set forth in the Fee Letter on the average daily amount of the LC Exposure (excluding any portion thereof attributable to unreimbursed LC Disbursements) during the Availability Period (or until the date that such Letter of Credit is irrevocably cancelled, whichever is later), as well as such Issuing Bank&#8217;s standard fees with respect to issuance, amendment, renewal or extension of any Letter of Credit or processing of drawings thereunder. Notwithstanding the foregoing, if the interest rate on the Loans is increased to the rate for Default Interest pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (as a result of an election by the Required Lenders or otherwise in accordance with the terms thereof), the rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> used to calculate the letter of credit fee pursuant to clause (i) above shall automatically be increased by 200 basis points.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Borrower shall pay on the Closing Date to the Administrative Agent and its affiliates all fees in the Fee Letter that are due and payable on the Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Accrued fees under subsections (b) and (c) of this Section shall be payable quarterly in arrears on the last day of each March, June, September and December, commencing with the first payment due (on a prorated basis) on June 30, 2021, and on the Revolving Commitment Termination Date (and, if later, the date the Loans and LC Exposure shall be repaid in their entirety)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any such fees accruing after the Revolving Commitment Termination Date shall be payable on demand.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Computation of Interest and Fees.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">53</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest hereunder based on the Administrative Agent&#8217;s prime lending rate shall be computed on the basis of a year of 365 days (or 366 days in a leap year) and paid for the actual number of days elapsed (including the first day but excluding the last day). All other interest and all fees hereunder shall be computed on the basis of a year of 360 days and paid for the actual number of days elapsed (including the first day but excluding the last day). Each determination by the Administrative Agent of an interest rate or fee hereunder shall be made in good faith and, except for manifest error, shall be final, conclusive and binding for all purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Inability to Determine Interest Rates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If, prior to the commencement of any Interest Period for any Eurodollar Borrowing&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Administrative Agent shall have determined (which determination shall be conclusive and binding upon the Borrower) that, by reason of circumstances affecting the relevant interbank market, adequate and reasonable means do not exist for ascertaining the Adjusted LIBO Rate (including, without limitation, because the Screen Rate is not available or published on a current basis) for such Interest Period, or </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Administrative Agent shall have received notice from the Required Lenders that the Adjusted LIBO Rate for such Interest Period will not adequately and fairly reflect the cost to such Lenders of making, funding or maintaining their Eurodollar Loans for such Interest Period,</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then the Administrative Agent shall give written notice thereof (or telephonic notice, promptly confirmed in writing) to the Borrower and to the Lenders as soon as practicable thereafter.  Until the Administrative Agent shall notify the Borrower and the Lenders that the circumstances giving rise to such notice no longer exist, (i)&#160;the obligations of the Lenders to make Eurodollar Revolving Loans or to continue or convert outstanding Loans as or into Eurodollar Loans shall be suspended and (ii) all such affected Loans shall be converted into Base Rate Loans on the last day of the then current Interest Period applicable thereto unless the Borrower prepays such Loans in accordance with this Agreement.  Unless the Borrower notifies the Administrative Agent at least one (1) Business Day before the date of any Eurodollar Borrowing for which a Notice of Revolving Borrowing has previously been given that it elects not to borrow, continue or convert to a Eurodollar Borrowing on such date, then such Revolving Borrowing shall be made as, continued as or converted into a Base Rate Borrowing.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein or in any other Loan Document, if a Benchmark Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with clause (1) or (2) of the definition of &#8220;Benchmark Replacement&#8221; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with clause (3) of the definition of &#8220;Benchmark Replacement&#8221; for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark setting at or after 5&#58;00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">54</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such Benchmark Replacement is provided to the Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein or in any other Loan Document and subject to the proviso below in this paragraph, if a Term SOFR Transition Event and its related Benchmark Replacement Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then the applicable Benchmark Replacement will replace the then-current Benchmark for all purposes hereunder or under any Loan Document in respect of such Benchmark setting and subsequent  Benchmark settings, without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document&#59; provided that this clause (c) shall not be effective unless the Administrative Agent has delivered to the Lenders and the Borrower a Term SOFR Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;In connection with the implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to this Agreement or any other Loan Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Administrative Agent will promptly notify the Borrower and the Lenders of (i) any occurrence of a Benchmark Transition Event, a Term SOFR Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date, (ii) the implementation of any Benchmark Replacement, (iii) the effectiveness of any Benchmark Replacement Conforming Changes, (iv) the removal or reinstatement of any tenor of a Benchmark pursuant to clause (f) below and (v) the commencement or conclusion of any Benchmark  Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this Section 2.16, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement or any other Loan Document, except, in each case, as expressly required pursuant to this Section 2.16.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary herein or in any other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including Term SOFR or the Adjusted LIBO Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is or will be no longer representative, then the Administrative Agent may modify the definition of &#8220;Interest Period&#8221; for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A) is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is or will no longer be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent may modify the definition of &#8220;Interest Period&#8221; for all Benchmark settings at or after such time to reinstate such previously removed tenor.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">55</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Upon the Borrower&#8217;s receipt of notice of the commencement of a Benchmark Unavailability Period, the Borrower may revoke any request for a Eurodollar Borrowing of, conversion to or continuation of Eurodollar Loans to be made, converted or continued during any Benchmark Unavailability Period and, failing that, the Borrower will be deemed to have converted any such request into a request for a Borrowing of or conversion to Base Rate Loans. During any Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of Base Rate based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of Base Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Illegality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any Change in Law shall make it unlawful or impossible for any Lender to perform any of its obligations hereunder or to make, maintain or fund any Eurodollar Loan and such Lender shall so notify the Administrative Agent, the Administrative Agent shall promptly give notice thereof to the Borrower and the other Lenders, whereupon until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such suspension no longer exist, the obligation of such Lender to make Eurodollar Revolving Loans, or to continue or convert outstanding Loans as or into Eurodollar Loans, shall be suspended. In the case of the making of a Eurodollar Borrowing, such Lender&#8217;s Revolving Loan shall be made as a Base Rate Loan as part of the same Revolving Borrowing for the same Interest Period and, if the affected Eurodollar Loan is then outstanding, such Loan shall be converted to a Base Rate Loan either (i) on the last day of the then current Interest Period applicable to such Eurodollar Loan if such Lender may lawfully continue to maintain such Loan to such date or (ii) immediately if such Lender shall determine that it may not lawfully continue to maintain such Eurodollar Loan to such date. Notwithstanding the foregoing, the affected Lender shall, prior to giving such notice to the Administrative Agent, use reasonable efforts to designate a different Applicable Lending Office if such designation would avoid the need for giving such notice and if such designation would not otherwise be disadvantageous to such Lender in the good faith exercise of its discretion. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Increased Costs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If any Change in Law shall&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;impose, modify or deem applicable any reserve, special deposit or similar requirement that is not otherwise included in the determination of the Adjusted LIBO Rate hereunder against assets of, deposits with or for the account of, or credit extended by, any Lender (except any such reserve requirement reflected in the Adjusted LIBO Rate) or any Issuing Bank&#59; or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;subject any Recipient to any Taxes (other than (A) Indemnified Taxes and (B) Taxes described in clauses (b) through (d) of the definition of Excluded Taxes&#59; or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;impose on any Lender, any Issuing Bank or the eurodollar interbank market any other condition affecting this Agreement or any Eurodollar Loans made by such Lender or any Letter of Credit or any participation therein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and the result of any of the foregoing is to increase the cost to such Lender of making, converting into, continuing or maintaining a Eurodollar Loan or to increase the cost to such Lender or such Issuing Bank of participating in or issuing any Letter of Credit or to reduce the amount received or receivable by such Lender or such Issuing Bank hereunder (whether of principal, interest or any other amount),</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then, from time to time, such Lender or such Issuing Bank may provide the Borrower (with a copy thereof to the Administrative Agent) with written notice and demand (including the calculation of all applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">56</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">amounts) with respect to such increased costs or reduced amounts, and within five (5) Business Days after receipt of such notice and demand and calculation, the Borrower shall pay to such Lender or such Issuing Bank, as the case may be, such additional amounts as will compensate such Lender or such Issuing Bank for any such increased costs incurred or reduction suffered.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If any Lender or any Issuing Bank shall have determined that on or after the Closing Date any Change in Law regarding capital or liquidity ratios or requirements has or would have the effect of reducing the rate of return on such Lender&#8217;s or such Issuing Bank&#8217;s capital (or on the capital of the Parent Company of such Lender or such Issuing Bank) as a consequence of its obligations hereunder or under or in respect of any Letter of Credit to a level below that which such Lender, such Issuing Bank or such Parent Company could have achieved but for such Change in Law (taking into consideration such Lender&#8217;s or such Issuing Bank&#8217;s policies or the policies of such Parent Company with respect to capital adequacy and liquidity), then, from time to time, such Lender or such Issuing Bank may provide the Borrower (with a copy thereof to the Administrative Agent) with written notice and demand (including the calculation of all applicable amounts) with respect to such reduced amounts, and within five (5) Business Days after receipt of such notice and demand and calculation the Borrower shall pay to such Lender or such Issuing Bank, as the case may be, such additional amounts as will compensate such Lender, such Issuing Bank or such Parent Company for any such reduction suffered.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;A certificate of such Lender or such Issuing Bank setting forth the amount or amounts necessary to compensate such Lender, such Issuing Bank or the Parent Company of such Lender or such Issuing Bank, as the case may be, specified in subsection (a) or (b) of this Section shall be delivered to the Borrower (with a copy to the Administrative Agent) and shall be conclusive, absent manifest error.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Failure or delay on the part of any Lender or any Issuing Bank to demand compensation pursuant to this Section shall not constitute a waiver of such Lender&#8217;s or such Issuing Bank&#8217;s right to demand such compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Funding Indemnity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In the event of (a) the payment of any principal of a Eurodollar Loan other than on the last day of the Interest Period applicable thereto (including as a result of an Event of Default), (b) the conversion or continuation of a Eurodollar Loan other than on the last day of the Interest Period applicable thereto, or (c) the failure by the Borrower to borrow, prepay, convert or continue any Eurodollar Loan on the date specified in any applicable notice (regardless of whether such notice is withdrawn or revoked), then, in any such event, the Borrower shall compensate each Lender, within five (5) Business Days after written demand from such Lender, for any loss, cost or expense attributable to such event. In the case of a Eurodollar Loan, such loss, cost or expense shall be deemed to include an amount determined by such Lender to be the excess, if any, of (A) the amount of interest that would have accrued on the principal amount of such Eurodollar Loan if such event had not occurred at the Adjusted LIBO Rate applicable to such Eurodollar Loan for the period from the date of such event to the last day of the then current Interest Period therefor (or, in the case of a failure to borrow, convert or continue, for the period that would have been the Interest Period for such Eurodollar Loan) over (B) the amount of interest that would accrue on the principal amount of such Eurodollar Loan for the same period if the Adjusted LIBO Rate were set on the date such Eurodollar Loan was prepaid or converted or the date on which the Borrower failed to borrow, convert or continue such Eurodollar Loan. A certificate as to any additional amount payable under this Section submitted to the Borrower by any Lender (with a copy to the Administrative Agent) shall be conclusive, absent manifest error.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Taxes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">57</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. For purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the term &#8220;Lender&#8221; includes Issuing Bank and the term &#8220;applicable law&#8221; includes FATCA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payments Free of Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any and all payments by or on account of any obligation of any Loan Party under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable law. If any applicable law (as determined in the good faith discretion of an applicable Withholding Agent) requires the deduction or withholding of any Tax from any such payment by a Withholding Agent, then the applicable Withholding Agent shall be entitled to make such deduction or withholding and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified Tax, then the sum payable by the applicable Loan Party shall be increased as necessary so that after such deduction or withholding has been made (including such deductions and withholdings applicable to additional sums payable under this Section) the applicable Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Other Taxes by the Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by the Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification by the Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Lender shall severally indemnify the Administrative Agent, within 10 days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Borrower to do so), (ii) any Taxes attributable to such Lender&#8217;s failure to comply with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> relating to the maintenance of a Participant Register and (iii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this paragraph (e).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Evidence of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As soon as practicable after any payment of Taxes by the Borrower or any other Loan Party to a Governmental Authority pursuant to this Section 2.20, the Borrower or other Loan Party shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">58</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Status of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Borrower and the Administrative Agent, at the time or times reasonably requested by the Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by the Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20(g)(ii)(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(ii)(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(ii)(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> below) shall not be required if in the Lender&#8217;s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Without limiting the generality of the foregoing,</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;any Lender that is a U.S. Person shall deliver to the Borrower and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed originals of IRS Form W-9 certifying that such Lender is exempt from U.S. federal backup withholding tax&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), whichever of the following is applicable&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect to payments of interest under any Loan Document, executed originals of IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;interest&#8221; article of such tax treaty and (y) with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN or IRS Form W-8BEN-E establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the &#8220;business profits&#8221; or &#8220;other income&#8221; article of such tax treaty&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;executed originals of IRS Form W-8ECI&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">59</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 2.20A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the effect that such Foreign Lender is not a &#8220;bank&#8221; within the meaning of Section 881(c)(3)(A) of the Code, a &#8220;10 percent shareholder&#8221; of the Borrower within the meaning of Section 881(c)(3)(B) of the Code, or a &#8220;controlled foreign corporation&#8221; described in Section 881(c)(3)(C) of the Code (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Tax Compliance Certificate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) and (y) executed originals of IRS Form W-8BEN or IRS Form W-8BEN-E&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;to the extent a Foreign Lender is not the beneficial owner, executed originals of IRS Form W-8IMY, accompanied by IRS Form W-8ECI, IRS Form W-8BEN or IRS Form W-8BEN-E, a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 2.20B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 2.20C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, IRS Form W-9, and&#47;or other certification documents from each beneficial owner, as applicable&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide a U.S. Tax Compliance Certificate substantially in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;2.20D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on behalf of each such direct and indirect partner&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Borrower or the Administrative Agent), executed originals of any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in U.S. federal withholding Tax, duly completed, together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower or the Administrative Agent to determine the withholding or deduction required to be made&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;if a payment made to a Lender under any Loan Document would be subject to U.S. federal withholding Tax imposed by FATCA if such Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Borrower and the Administrative Agent at the time or times prescribed by law and at such time or times reasonably requested by the Borrower or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Borrower or the Administrative Agent as may be necessary for the Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender&#8217;s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this clause (D), &#8220;FATCA&#8221; shall include any amendments made to FATCA after the Closing Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">60</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify the Borrower and the Administrative Agent in writing of its legal inability to do so.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Treatment of Certain Refunds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (including by the payment of additional amounts pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this paragraph (h) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this paragraph (h), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this paragraph (h) the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This paragraph shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each party&#8217;s obligations under this Section 2.20 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all obligations under any Loan Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Payments Generally&#59; Pro Rata Treatment&#59; Sharing of Set-offs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower shall make each payment required to be made by it hereunder (whether of principal, interest, fees or reimbursement of LC Disbursements, or of amounts payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or otherwise) prior to 12&#58;00 noon on the date when due, in immediately available funds, free and clear of any defenses, rights of set-off, counterclaim, or withholding or deduction of taxes. Any amounts received after such time on any date may, in the discretion of the Administrative Agent, be deemed to have been received on the next succeeding Business Day for purposes of calculating interest thereon. All such payments shall be made to the Administrative Agent at the Payment Office, except payments to be made directly to the applicable Issuing Bank or the Swingline Lender as expressly provided herein and except that payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be made directly to the Persons entitled thereto. The Administrative Agent shall distribute any such payments received by it for the account of any other Person to the appropriate recipient promptly following receipt thereof. If any payment hereunder shall be due on a day that is not a Business Day, the date for payment shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall be made payable for the period of such extension. All payments hereunder shall be made in Dollars.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If at any time insufficient funds are received by and available to the Administrative Agent to pay fully all amounts of principal, unreimbursed LC Disbursements, interest and fees then due hereunder, such funds shall be applied as follows&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to all fees and reimbursable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">61</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses of the Administrative Agent then due and payable pursuant to any of the Loan Documents&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to all reimbursable expenses of the Lenders and all fees and reimbursable expenses of the Issuing Banks then due and payable pursuant to any of the Loan Documents, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the Lenders and the Issuing Banks based on their respective </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shares of such fees and expenses&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to all interest and fees then due and payable hereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the Lenders based on their respective </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shares of such interest and fees&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to all principal of the Loans and unreimbursed LC Disbursements then due and payable hereunder, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the parties entitled thereto based on their respective </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shares of such principal and unreimbursed LC Disbursements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;If any Lender shall, by exercising any right of set-off or counterclaim or otherwise, obtain payment in respect of any principal of or interest on any of its Loans or participations in LC Disbursements or Swingline Loans that would result in such Lender receiving payment of a greater proportion of the aggregate amount of its Revolving Credit Exposure, Incremental Term Loans and accrued interest and fees thereon than the proportion received by any other Lender with respect to its Revolving Credit Exposure or Incremental Term Loans, then the Lender receiving such greater proportion shall purchase (for cash at face value) participations in the Revolving Credit Exposure and Incremental Term Loans of other Lenders to the extent necessary so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Revolving Credit Exposure and Incremental Term Loans&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i)&#160;if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest, and (ii) the provisions of this subsection shall not be construed to apply to any payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender) or any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Revolving Credit Exposure or Incremental Term Loans to any assignee or participant, other than to the Borrower or any Subsidiary or Affiliate thereof (as to which the provisions of this subsection shall apply). The Borrower consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against the Borrower rights of set-off and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Borrower in the amount of such participation.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Unless the Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the Issuing Banks hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the Issuing Banks, as the case may be, the amount or amounts due. In such event, if the Borrower has not in fact made such payment, then each of the Lenders or the Issuing Banks, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or such Issuing Bank with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;During the Availability Period, each Issuing Bank, in reliance upon the agreements of the other Lenders pursuant to subsections (d) and (e) of this Section, may, in its sole discretion, issue, at the request of the Borrower, Letters of Credit for the account of the Borrower or any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">62</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsidiary Loan Party (which may be for the benefit of any Subsidiary or Associated Practice) (as specified by the Borrower in the request for such Letter of Credit) on the terms and conditions hereinafter set forth&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) each Letter of Credit shall expire on the earlier of (A) the date one year after the date of issuance of such Letter of Credit (or, in the case of any renewal or extension thereof, one year after such renewal or extension) and (B) the date that is five (5) Business Days prior to the Revolving Commitment Termination Date&#59; (ii) each Letter of Credit shall be in a stated amount to be mutually agreed between the Borrower and the applicable Issuing Bank&#59; and (iii) the Borrower may not request any Letter of Credit if, after giving effect to such issuance, (A) the aggregate LC Exposure would exceed the LC Commitment or (B) the aggregate Revolving Credit Exposure of all Lenders would exceed the Aggregate Revolving Commitment Amount and (iv) the Borrower shall not request, and no Issuing Bank shall have an obligation to issue, any Letter of Credit the proceeds of which would be made available to any Person (AA) to fund any activity or business of or with any Sanctioned Person or in any Sanctioned Countries, that, at the time of such funding, is the subject of any Sanctions or (BB) in any manner that would result in a violation of any Sanctions by any party to this Agreement.  The Borrower hereby acknowledges and agrees that the Existing Letters of Credit are deemed to be issued by the applicable Issuing Bank, as an Issuing Bank hereunder, for the account of the Borrower.  Each Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the applicable Issuing Bank without recourse a participation in each Letter of Credit equal to such Lender&#8217;s Pro Rata Share of the aggregate amount available to be drawn under such Letter of Credit (i) on the Closing Date with respect to all Existing Letters of Credit and (ii) on the date of issuance with respect to all other Letters of Credit.  Each issuance of a Letter of Credit shall be deemed to utilize the Revolving Commitment of each Lender by an amount equal to the amount of such participation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To request the issuance of a Letter of Credit (or any amendment, renewal or extension of an outstanding Letter of Credit), the Borrower shall give the applicable Issuing Bank and the Administrative Agent irrevocable written notice at least three (3) Business Days prior to the requested date of such issuance specifying the date (which shall be a Business Day) such Letter of Credit is to be issued (or amended, renewed or extended, as the case may be), the expiration date of such Letter of Credit, the amount of such Letter of Credit, the name and address of the beneficiary thereof, whether such Letter of Credit shall be issued on the account of the Borrower or a Subsidiary, and such other information as shall be necessary to prepare, amend, renew or extend such Letter of Credit. In addition to the satisfaction of the conditions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the issuance of such Letter of Credit (or any amendment which increases the amount of such Letter of Credit) will be subject to the further conditions that such Letter of Credit shall be in such form and contain such terms as the applicable Issuing Bank shall approve and that the Borrower and&#47;or the applicable Subsidiary shall have executed and delivered any additional applications, agreements and instruments relating to such Letter of Credit as the applicable Issuing Bank shall reasonably require&#59; provided that in the event of any conflict between such applications, agreements or instruments and this Agreement, the terms of this Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;At least two (2) Business Days prior to the issuance of any Letter of Credit, the applicable Issuing Bank will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has received such notice, and, if not, the applicable Issuing Bank will provide the Administrative Agent with a copy thereof. Unless the applicable Issuing Bank has received notice from the Administrative Agent, on or before the Business Day immediately preceding the date the applicable Issuing Bank is to issue the requested Letter of Credit, directing the applicable Issuing Bank not to issue the Letter of Credit because such issuance is not then permitted hereunder because of the limitations set forth in subsection (a) of this Section or that one or more conditions specified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are not then satisfied, then, subject to the terms and conditions hereof, the applicable Issuing Bank shall, on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">63</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">requested date, issue such Letter of Credit in accordance with such Issuing Bank&#8217;s usual and customary business practices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each Issuing Bank shall examine all documents purporting to represent a demand for payment under a Letter of Credit promptly following its receipt thereof. Each Issuing Bank shall notify the Borrower and the Administrative Agent of such demand for payment and whether such Issuing Bank has made or will make a LC Disbursement thereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any failure to give or delay in giving such notice shall not relieve the Borrower of its obligation to reimburse such Issuing Bank and the Lenders with respect to such LC Disbursement. The Borrower shall be irrevocably and unconditionally obligated to reimburse the applicable Issuing Bank for any LC Disbursements paid by such Issuing Bank in respect of such drawing, without presentment, demand or other formalities of any kind. Unless the Borrower shall have notified the applicable Issuing Bank and the Administrative Agent prior to 11&#58;00 a.m. on the Business Day immediately prior to the date on which such drawing is honored that the Borrower intends to reimburse such Issuing Bank for the amount of such drawing in funds other than from the proceeds of Revolving Loans, the Borrower shall be deemed to have timely given a Notice of Revolving Borrowing to the Administrative Agent requesting the Lenders to make a Base Rate Borrowing on the date on which such drawing is honored in an exact amount due to such Issuing Bank&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that for purposes solely of such Borrowing, the conditions precedent set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> hereof shall not be applicable. The Administrative Agent shall notify the Lenders of such Borrowing in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and each Lender shall make the proceeds of its Base Rate Loan included in such Borrowing available to the Administrative Agent for the account of the applicable Issuing Bank in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The proceeds of such Borrowing shall be applied directly by the Administrative Agent to reimburse the applicable Issuing Bank for such LC Disbursement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;If for any reason a Base Rate Borrowing may not be (as determined in the sole discretion of the Administrative Agent), or is not, made in accordance with the foregoing provisions, then each Lender (other than the applicable Issuing Bank) shall be obligated to fund the participation that such Lender purchased pursuant to subsection (a) of this Section in an amount equal to its Pro Rata Share of such LC Disbursement on and as of the date which such Base Rate Borrowing should have occurred. Each Lender&#8217;s obligation to fund its participation shall be absolute and unconditional and shall not be affected by any circumstance, including, without limitation, (i) any set-off, counterclaim, recoupment, defense or other right that such Lender or any other Person may have against the applicable Issuing Bank or any other Person for any reason whatsoever, (ii) the existence of a Default or an Event of Default or the termination of the Aggregate Revolving Commitments, (iii) any adverse change in the condition (financial or otherwise) of the Borrower or any of its Subsidiaries, (iv) any breach of this Agreement by the Borrower or any other Lender, (v) any amendment, renewal or extension of any Letter of Credit or (vi) any other circumstance, happening or event whatsoever, whether or not similar to any of the foregoing. On the date that such participation is required to be funded, each Lender shall promptly transfer, in immediately available funds, the amount of its participation to the Administrative Agent for the account of the applicable Issuing Bank. Whenever, at any time after the applicable Issuing Bank has received from any such Lender the funds for its participation in a LC Disbursement, such Issuing Bank (or the Administrative Agent on its behalf) receives any payment on account thereof, the Administrative Agent or such Issuing Bank, as the case may be, will distribute to such Lender its Pro Rata Share of such payment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if such payment is required to be returned for any reason to the Borrower or to a trustee, receiver, liquidator, custodian or similar official in any bankruptcy proceeding, such Lender will return to the Administrative Agent or such Issuing Bank any portion thereof previously distributed by the Administrative Agent or such Issuing Bank to it.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">64</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;To the extent that any Lender shall fail to pay any amount required to be paid pursuant to subsection (d) or (e) of this Section on the due date therefor, such Lender shall pay interest to the applicable Issuing Bank (through the Administrative Agent) on such amount from such due date to the date such payment is made at a rate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> equal to the Federal Funds Rate&#59; provided that if such Lender shall fail to make such payment to the applicable Issuing Bank within three (3) Business Days of such due date, then, retroactively to the due date, such Lender shall be obligated to pay interest on such amount at the Base Rate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;If any Event of Default shall occur and be continuing, on the Business Day that the Borrower receives notice from the Administrative Agent or the Required Lenders demanding that its reimbursement obligations with respect to the Letters of Credit be Cash Collateralized pursuant to this subsection, the Borrower shall deposit in an account with the Administrative Agent, in the name of the Administrative Agent and for the benefit of the Issuing Banks (as applicable) and the Lenders, an amount in cash equal to 105% of the aggregate LC Exposure of all Lenders as of such date plus any accrued and unpaid fees thereon&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such obligation to Cash Collateralize the reimbursement obligations of the Borrower with respect to the Letters of Credit shall become effective immediately, and such deposit shall become immediately due and payable, without demand or notice of any kind, upon the occurrence of any Event of Default with respect to the Borrower described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.1(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Such deposit shall be held by the Administrative Agent as collateral for the payment and performance of the obligations of the Borrower under this Agreement. The Administrative Agent shall have exclusive dominion and control, including the exclusive right of withdrawal, over such account. The Borrower agrees to execute any documents and&#47;or certificates to effectuate the intent of this subsection. Other than any interest earned on the investment of such deposits, which investments shall be made at the option and sole discretion of the Administrative Agent and at the Borrower&#8217;s risk and expense, such deposits shall not bear interest. Interest and profits, if any, on such investments shall accumulate in such account. Moneys in such account shall be applied by the Administrative Agent to reimburse each Issuing Bank for LC Disbursements for which it had not been reimbursed and, to the extent not so applied, shall be held for the satisfaction of the reimbursement obligations of the Borrower for the LC Exposure at such time or, if the maturity of the Loans has been accelerated, with the consent of the Required Lenders, be applied to satisfy other obligations of the Borrower under this Agreement and the other Loan Documents. If the Borrower is required to Cash Collateralize its reimbursement obligations with respect to the Letters of Credit as a result of the occurrence of an Event of Default, such cash collateral so posted (to the extent not so applied as aforesaid) shall be returned to the Borrower within three (3) Business Days after all Events of Default have been cured or waived.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Upon the request of any Lender, but no more frequently than quarterly, each Issuing Bank shall deliver (through the Administrative Agent) to each Lender and the Borrower a report describing the aggregate Letters of Credit then outstanding. Upon the request of any Lender from time to time, each Issuing Bank shall deliver to such Lender any other information reasonably requested by such Lender with respect to each Letter of Credit then outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Borrower&#8217;s obligation to reimburse LC Disbursements hereunder shall be absolute, unconditional and irrevocable and shall be performed strictly in accordance with the terms of this Agreement under all circumstances whatsoever and irrespective of any of the following circumstances&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;any lack of validity or enforceability of any Letter of Credit or this Agreement&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">65</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the existence of any claim, set-off, defense or other right which the Borrower or any Subsidiary or Affiliate of the Borrower may have at any time against a beneficiary or any transferee of any Letter of Credit (or any Persons or entities for whom any such beneficiary or transferee may be acting), any Lender (including any Issuing Bank) or any other Person, whether in connection with this Agreement or the Letter of Credit or any document related hereto or thereto or any unrelated transaction&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any draft or other document presented under a Letter of Credit proving to be forged, fraudulent or invalid in any respect or any statement therein being untrue or inaccurate in any respect&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;payment by the applicable Issuing Bank under a Letter of Credit against presentation of a draft or other document to such Issuing Bank that does not comply with the terms of such Letter of Credit&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any other event or circumstance whatsoever, whether or not similar to any of the foregoing, that might, but for the provisions of this Section, constitute a legal or equitable discharge of, or provide a right of set-off against, the Borrower&#8217;s obligations hereunder&#59; or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;the existence of a Default or an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Neither the Administrative Agent, any Issuing Bank, any Lender nor any Related Party of any of the foregoing shall have any liability or responsibility by reason of or in connection with the issuance or transfer of any Letter of Credit or any payment or failure to make any payment thereunder (irrespective of any of the circumstances referred to above), or any error, omission, interruption, loss or delay in transmission or delivery of any draft, notice or other communication under or relating to any Letter of Credit (including any document required to make a drawing thereunder), any error in interpretation of technical terms or any consequence arising from causes beyond the control of the Issuing Banks&#59; provided that the foregoing shall not be construed to excuse any Issuing Banks from liability to the Borrower to the extent of any actual direct damages (as opposed to special, indirect (including claims for lost profits or other consequential damages), or punitive damages, claims in respect of which are hereby waived by the Borrower to the extent permitted by applicable law) suffered by the Borrower that are caused by such Issuing Bank&#8217;s failure to exercise due care when determining whether drafts or other documents presented under a Letter of Credit comply with the terms thereof. The parties hereto expressly agree that, in the absence of gross negligence or willful misconduct on the part of any Issuing Bank (as finally determined by a court of competent jurisdiction), such Issuing Bank shall be deemed to have exercised due care in each such determination. In furtherance of the foregoing and without limiting the generality thereof, the parties agree that, with respect to documents presented that appear on their face to be in substantial compliance with the terms of a Letter of Credit, each Issuing Bank may, in its sole discretion, either accept and make payment upon such documents without responsibility for further investigation, regardless of any notice or information to the contrary, or refuse to accept and make payment upon such documents if such documents are not in strict compliance with the terms of such Letter of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Unless otherwise expressly agreed by the applicable Issuing Bank and the Borrower when a Letter of Credit is issued and subject to applicable laws, (i) each standby Letter of Credit shall be governed by the &#8220;International Standby Practices 1998&#8221; (ISP98) (or such later revision as may be published by the Institute of International Banking Law &#38; Practice on any date any Letter of Credit may be issued), (ii) each documentary Letter of Credit shall be governed by the Uniform Customs and Practices for Documentary Credits (2007 Revision), International Chamber of Commerce Publication </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">66</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No. 600 (or such later revision as may be published by the International Chamber of Commerce on any date any Letter of Credit may be issued) and (iii) the Borrower shall specify the foregoing in each letter of credit application submitted for the issuance of a Letter of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Any Issuing Bank may resign as an &#8220;Issuing Bank&#8221; hereunder upon 30 days&#8217; prior written notice to the Administrative Agent, the Lenders and the Borrower&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that on or prior to the expiration of such 30-day period with respect to such resignation, the relevant Issuing Bank shall have identified a successor Issuing Bank reasonably acceptable to the Borrower willing to accept its appointment as successor Issuing Bank, and the effectiveness of such resignation shall be conditioned upon such successor assuming the rights and duties of the resigning Issuing Bank.  In the event of any such resignation as Issuing Bank, the Borrower shall be entitled to appoint from among the Lenders a successor Issuing Bank hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, however, that no failure by the Borrower to appoint any such successor shall affect the resignation of the resigning Issuing Bank except as expressly provided above.  The Borrower may terminate the appointment of any Issuing Bank as an &#8220;Issuing Bank&#8221; hereunder by providing a written notice thereof to such Issuing Bank, with a copy to the Administrative Agent.  Any such termination shall become effective upon the earlier of (i) such Issuing Bank acknowledging receipt of such notice and (ii) the third Business Day following the date of the delivery thereof&#59; provided that no such termination shall become effective until and unless the LC Exposure attributable to Letters of Credit issued by such Issuing Bank (or its Affiliates) shall have been reduced to zero.  At the time any such resignation or termination shall become effective, the Borrower shall pay all unpaid fees accrued for the account of the resigning or terminated Issuing Bank pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.14(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding the effectiveness of any such resignation or termination, the resigning or terminated Issuing Bank shall remain a party hereto and shall continue to have all the rights of an Issuing Bank under this Agreement with respect to Letters of Credit issued by it prior to such resignation or termination, but shall not be required to issue any additional Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Notwithstanding that a Letter of Credit issued or outstanding hereunder is in support of any obligations of, or is for the account of, a Subsidiary, the Borrower shall be obligated to reimburse the applicable Issuing Bank hereunder for all LC Disbursements and to otherwise perform all obligations hereunder in respect of such Letter of Credit as if it has been issued for the account of the Borrower.  The Borrower hereby acknowledges that the issuance of Letters of Credit for the account of Subsidiaries inures to the benefit of the Borrower, and that the Borrower&#8217;s business derives substantial benefits from the businesses of such Subsidiaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Increase of Commitments&#59; Additional Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;From time to time after the Closing Date and in accordance with this Section, the Borrower and one or more Increasing Lenders or Additional Lenders (each as defined below) may enter into an agreement to increase the aggregate Revolving Commitments (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Revolving Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and&#47;or establish term loan commitments hereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Term Loan Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;&#59; and together with any Incremental Revolving Commitments, each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) so long as the following conditions are satisfied&#58;  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the aggregate principal amount of all such Incremental Commitments made pursuant to this Section shall not exceed the sum of (I) $125,000,000 and (II) an unlimited amount so long as the Consolidated Total Net Leverage Ratio is less than 2.90&#58;1.00 calculated on a pro forma basis after giving effect to the incurrence of such Incremental Commitments (and assuming the aggregate amount of such Incremental Commitments, including all Incremental Revolving </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">67</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commitments, have been fully funded) and the use of the proceeds thereof (the principal amount of each such Incremental Commitment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Commitment Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Borrower shall execute and deliver such documents and instruments and take such other actions as may be reasonably required by the Administrative Agent in connection with and at the time of any such proposed increase&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;at the time of and immediately after giving effect to any such proposed increase, no Default or Event of Default shall exist, all representations and warranties of each Loan Party set forth in the Loan Documents shall be true and correct in all material respects (other than those representations and warranties that are expressly qualified by a Material Adverse Effect or other materiality, in which case such representations and warranties shall be true and correct in all respects), and, since December 31, 2020, there shall have been no change which has had or could reasonably be expected to have a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;(x) any incremental term loans made pursuant to this Section (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Incremental Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall have a Maturity Date, an amortization schedule, and interest rates, interest margins, rate floors, upfront fees, funding discounts, original issue discounts and premiums (including prepayment premiums) as determined by the Borrower and the lenders providing such Incremental Term Loans&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Maturity Date shall be no earlier than 180 days after the Revolving Commitment Termination Date, and (y) any Incremental Revolving Commitments provided pursuant to this Section shall have terms that are identical to the existing Revolving Commitments (except for the amount thereof) and the Revolving Loans&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;the Borrower and its Subsidiaries shall be in pro forma compliance with each of the financial covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered, calculated as if all such Incremental Term Loans had been made and all such Incremental Revolving Commitments had been established (and fully funded) as of the first day of the relevant period for testing compliance&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;if the Initial Yield applicable to any such Incremental Term Loans exceeds by more than 0.50% </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">per annum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the sum of the Applicable Margin then in effect for existing Revolving Loans </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> one-fourth of the Up Front Fees paid in respect of the existing Revolving Loans (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Existing Yield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), then the Applicable Margin of all existing Revolving Loans shall increase by an amount equal to the difference between the Initial Yield and the Existing Yield&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;any collateral securing any such Incremental Commitments (and Incremental Term Loans) shall also secure all other Obligations on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pari passu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> basis&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;all other terms and conditions with respect to any such Incremental Commitments (and Incremental Term Loans) shall be reasonably satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower shall provide at least 30 days&#8217; written notice to the Administrative Agent (who shall promptly provide a copy of such notice to each Lender) of any proposal to establish an Incremental Commitment. The Borrower may also, but is not required to, specify any fees offered to those Lenders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Increasing Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that agree to increase the principal amount of their Revolving Commitments and&#47;or establish Incremental Term Loan Commitments, which fees may be variable based upon the amount by which any such Lender is willing to increase the principal amount of its Revolving Commitment and&#47;or provide Incremental Term Loan Commitments, as applicable. Each Increasing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">68</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lender shall as soon as practicable, and in any case within 15 days following receipt of such notice, specify in a written notice to the Borrower and the Administrative Agent the amount of such proposed Incremental Commitment that it is willing to provide. No Lender (or any successor thereto) shall have any obligation, express or implied, to offer to increase the aggregate principal amount of its Revolving Commitment and&#47;or establish an Incremental Term Loan Commitment, and any decision by a Lender to increase its Revolving Commitment and&#47;or establish an Incremental Term Loan Commitment shall be made in its sole discretion independently from any other Lender. Only the consent of each Increasing Lender shall be required for an increase in the aggregate principal amount of the Revolving Commitments and&#47;or the Incremental Term Loan Commitments, as applicable, pursuant to this Section. No Lender which declines to increase the principal amount of its Revolving Commitment and&#47;or establish Incremental Term Loan Commitments may be replaced with respect to its existing Revolving Commitment (and&#47;or its existing Incremental Term Loans, if any), as a result thereof without such Lender&#8217;s consent. If any Lender shall fail to notify the Borrower and the Administrative Agent in writing about whether it will increase its Revolving Commitment and&#47;or establish an Incremental Term Loan Commitment within 15 days after receipt of such notice, such Lender shall be deemed to have declined the request. The Borrower may in its sole discretion accept some or all of the offered amounts, reject the offered amounts entirely (in which case the proposed Incremental Commitment shall be deemed withdrawn and of no force or effect) or designate new lenders that are acceptable to the Administrative Agent (such approval not to be unreasonably withheld) and otherwise permitted under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as additional Lenders hereunder in accordance with this Section (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which Additional Lenders may assume all or a portion of such Incremental Commitment. The Borrower and the Administrative Agent shall have discretion jointly to adjust the allocation of such Incremental Revolving Commitments and&#47;or such Incremental Term Loans among the Increasing Lenders and the Additional Lenders. The sum of the increase in the Revolving Commitments and the amount of Incremental Term Loan Commitments established (or increased, as the case may be) by the Increasing Lenders plus the Revolving Commitments and the Incremental Term Loan Commitments of the Additional Lenders shall not in the aggregate exceed the unsubscribed amount of the Incremental Commitment Amount. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Subject to subsections (a) and (b) of this Section, any increase requested by the Borrower shall be effective upon delivery to the Administrative Agent of each of the following documents&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;an originally executed copy of an instrument of joinder, in form and substance reasonably acceptable to the Administrative Agent, executed by the Borrower, by each Additional Lender and by each Increasing Lender, setting forth the new Revolving Commitments and&#47;or new Incremental Term Loan Commitments, as applicable, of such Lenders and setting forth the agreement of each Additional Lender to become a party to this Agreement and to be bound by all of the terms and provisions hereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;such evidence of appropriate corporate authorization on the part of the Borrower with respect to such Incremental Commitment and such opinions of counsel for the Borrower with respect to such Incremental Commitment as the Administrative Agent may reasonably request&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;a certificate of the Borrower signed by a Responsible Officer, in form and substance reasonably acceptable to the Administrative Agent, certifying that each of the conditions in subsection (a) of this Section has been satisfied and each of the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> have been satisfied&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">69</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;to the extent requested by any Additional Lender or any Increasing Lender, executed promissory notes evidencing such Incremental Revolving Commitments and&#47;or such Incremental Term Loans, issued by the Borrower in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;2.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any other certificates or documents that the Administrative Agent shall reasonably request, in form and substance reasonably satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the effectiveness of any such Incremental Commitment, the Commitments and Pro Rata Share of each Lender will be adjusted to give effect to the Incremental Revolving Commitments and&#47;or the Incremental Term Loans, as applicable, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall automatically be deemed amended accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;All terms (including, without limitation, maturity, amortization, pricing, prepayment, etc.) of any Incremental Term Loans shall be as set forth in a separate incremental agreement among the Borrower, the Lenders providing such Incremental Term Loans and the Administrative Agent, the execution and delivery of which incremental agreement shall be a condition to the effectiveness of the Incremental Term Loans.  If the Borrower incurs Incremental Revolving Commitments under this Section, the Borrower shall, after such time, repay and incur Revolving Loans ratably as between the Incremental Revolving Commitments and the Revolving Commitments outstanding immediately prior to such incurrence.  Notwithstanding anything to the contrary in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Administrative Agent is expressly permitted to amend the Loan Documents to the extent necessary to give effect to any increase pursuant to this Section and mechanical changes necessary or advisable in connection therewith (including amendments to implement the requirements in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.23(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, amendments to ensure </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> allocations of Eurodollar Loans and Base Rate Loans between Loans incurred pursuant to this Section and Loans outstanding immediately prior to any such incurrence and amendments to implement ratable participation in Letters of Credit).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;For purposes of this Section, the following terms shall have the meanings specified below&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Yield</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to Incremental Term Loans, the amount (as determined by the Administrative Agent) equal to the sum of (A) the margin above the Adjusted LIBO Rate on such Incremental Term Loans (including as margin the effect of any &#8220;LIBO rate floor&#8221; applicable on the date of the calculation), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (B) (x) the amount of any Up-Front Fees on such Incremental Term Loans (including any fee or discount received by the Lenders in connection with the initial extension thereof), divided by (y) the lesser of (I) the Weighted Average Life to Maturity of such Incremental Term Loans and (II)&#160;four.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Up-Front Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean the amount of any fees or discounts received by the Lenders in connection with the making of Loans or extensions of credit, expressed as a percentage of such Loan or extension of credit. For the avoidance of doubt, &#8220;Up-Front Fees&#8221; shall not include any arrangement fee paid to the arranger(s) thereof.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Weighted Average Life to Maturity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; shall mean, when applied to any Indebtedness at any date, the number of years obtained by dividing (i) the sum of the products obtained by multiplying (x) the amount of each then remaining installment, sinking fund, serial maturity or other required payments of principal, including payment at final maturity, in respect thereof, by (y) the number of years (calculated to the nearest one-twelfth) that will elapse between </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">70</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such date and the making of such payment by (ii) the then outstanding principal amount of such Indebtedness.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Mitigation of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any Lender requests compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the sole judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as the case may be, in the future and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all costs and expenses incurred by any Lender in connection with such designation or assignment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.25&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Replacement of Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If (a) any Lender requests compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, (b) any Lender is a Defaulting Lender, or (c) in connection with any proposed amendment, modification, termination, waiver or consent with respect to any of the provisions hereof as contemplated by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the consent of Required Lenders shall have been obtained but the consent of one or more of such other Lenders (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">NonConsenting Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) whose consent is required shall not have been obtained, then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.4(b</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)), all of its interests, rights (other than its existing rights to payments pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as applicable) and obligations under this Agreement to an assignee that shall assume such obligations (which assignee may be another Lender) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Replacement Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) the Borrower shall have received the prior written consent of the Administrative Agent, which consent shall not be unreasonably withheld, (ii) such Lender shall have received payment of an amount equal to the outstanding principal amount of all Loans owed to it, accrued interest thereon, accrued fees and all other amounts payable to it hereunder from the assignee (in the case of such outstanding principal and accrued interest) and from the Borrower (in the case of all other amounts), (iii) in the case of a claim for compensation under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or payments required to be made pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such assignment will result in a reduction in such compensation or payments, and (iv) in the case of a NonConsenting Lender, each Replacement Lender shall consent, at the time of such assignment, to each matter in respect of which such terminated Lender was a NonConsenting Lender.  A Lender shall not be required to make any such assignment and delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 2.26&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Defaulting Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Cash Collateral</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;At any time that there shall exist a Defaulting Lender, within one Business Day following the written request of the Administrative Agent or the applicable Issuing Bank (with a copy to the Administrative Agent) the Borrower shall Cash Collateralize such Issuing Bank&#8217;s LC Exposure with respect to such Defaulting Lender (determined after giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and any Cash Collateral provided by such Defaulting Lender) in an amount not less than 105% of such Issuing Bank&#8217;s LC Exposure with respect to such Defaulting Lender.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">71</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The Borrower, and to the extent provided by any Defaulting Lender, such Defaulting Lender, hereby grants to the Administrative Agent, for the benefit of each Issuing Bank, and agrees to maintain, a first priority security interest in all such Cash Collateral as security for the Defaulting Lenders&#8217; obligation to fund participations in respect of Letters of Credit, to be applied pursuant to clause (iii) below. If at any time the Administrative Agent determines that Cash Collateral is subject to any right or claim of any Person other than the Administrative Agent and the applicable Issuing Bank as herein provided, or that the total amount of such Cash Collateral is less than the minimum amount required pursuant to clause (i) above, the Borrower will, promptly upon demand by the Administrative Agent, pay or provide to the Administrative Agent additional Cash Collateral in an amount sufficient to eliminate such deficiency (after giving effect to any Cash Collateral provided by the Defaulting Lender).</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained in this Agreement, Cash Collateral provided under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in respect of Letters of Credit shall be applied to the satisfaction of the Defaulting Lender&#8217;s obligation to fund participations in respect of Letters of Credit or LC Disbursements (including, as to Cash Collateral provided by a Defaulting Lender, any interest accrued on such obligation) for which the Cash Collateral was so provided, prior to any other application of such property as may otherwise be provided for herein.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Cash Collateral (or the appropriate portion thereof) provided to reduce any Issuing Bank&#8217;s LC Exposure shall no longer be required to be held as Cash Collateral pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> following (A) the elimination of the applicable LC Exposure (including by the termination of Defaulting Lender status of the applicable Lender), or (ii) the determination by the Administrative Agent and such Issuing Bank that there exists excess Cash Collateral&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> the Person providing Cash Collateral and the applicable Issuing Bank may agree that Cash Collateral shall be held to support future anticipated LC Exposure or other obligations and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> further that to the extent that such Cash Collateral was provided by the Borrower, such Cash Collateral shall remain subject to the security interest granted pursuant to the Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defaulting Lender Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as such Lender is no longer a Defaulting Lender, to the extent permitted by applicable law&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Such Defaulting Lender&#8217;s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in the definition of Required Lenders and in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of such Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or otherwise) or received by the Administrative Agent from a Defaulting Lender pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be applied at such time or times as may be determined by the Administrative Agent as follows&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the payment of any amounts owing by such Defaulting Lender to the Administrative Agent hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the payment on a pro rata basis of any amounts owing by such Defaulting Lender to the Issuing Banks or Swingline Lender hereunder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to Cash Collateralize each Issuing Bank&#8217;s LC Exposure with respect to such Defaulting Lender in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">72</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent&#59; fifth, if so determined by the Administrative Agent and the Borrower, to be held in a deposit account and released pro rata in order to (x) satisfy such Defaulting Lender&#8217;s potential future funding obligations with respect to Loans under this Agreement and (y) Cash Collateralize the Issuing Banks&#8217; future LC Exposure with respect to such Defaulting Lender with respect to future Letters of Credit issued under this Agreement, in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">sixth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the payment of any amounts owing to the Lenders, the Issuing Banks or Swingline Lender as a result of any judgment of a court of competent jurisdiction obtained by any Lender, any Issuing Bank or Swingline Lender against such Defaulting Lender as a result of such Defaulting Lender&#8217;s breach of its obligations under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">seventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against such Defaulting Lender as a result of such Defaulting Lender's breach of its obligations under this Agreement&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">eighth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to such Defaulting Lender or as otherwise directed by a court of competent jurisdiction&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if (x) such payment is a payment of the principal amount of any Loans or LC Disbursements in respect of which such Defaulting Lender has not fully funded its appropriate share, and (y) such Loans were made or the related Letters of Credit were issued at a time when the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> were satisfied or waived, such payment shall be applied solely to pay the Loans of, and LC Disbursements owed to, all Non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or LC Disbursements owed to, such Defaulting Lender until such time as all Loans and funded and unfunded participations in L&#47;C Obligations and Swingline Loans are held by the Lenders pro rata in accordance with the Commitments under the applicable Facility without giving effect to sub-section (iv) below. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be deemed paid to and redirected by such Defaulting Lender, and each Lender irrevocably consents hereto.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;(A) No Defaulting Lender shall be entitled to receive any Commitment Fee pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.14(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for any period during which that Lender is a Defaulting Lender (and the Borrower shall not be required to pay any such fee that otherwise would have been required to have been paid to that Defaulting Lender).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;Each Defaulting Lender shall be entitled to receive letter of credit fees pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.14(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> for any period during which that Lender is a Defaulting Lender only to the extent allocable to that portion of its LC Exposure for which it has provided Cash Collateral pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;With respect to any letter of credit fee not required to be paid to any Defaulting Lender pursuant to clause (A) or (B) above, the Borrower shall (x) pay to each Non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect to such Defaulting Lender&#8217;s participation in Letters of Credit or Swingline Loans that has been reallocated to such Non-Defaulting Lender pursuant to clause (iv) below, (y) pay to each Issuing Bank and Swingline Lender, as applicable, the amount of any such fee otherwise payable to such Defaulting Lender to the extent allocable to such Issuing Bank&#8217;s LC Exposure or Swingline Lender&#8217;s Swingline Exposure with respect to such Defaulting Lender, and (z) not be required to pay the remaining amount of any such fee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">73</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;All or any part of such Defaulting Lender&#8217;s participation in Letters of Credit and Swingline Loans shall be reallocated among the Non-Defaulting Lenders in accordance with their respective Pro Rata Shares of the Revolving Commitments (calculated without regard to such Defaulting Lender&#8217;s Revolving Commitment) but only to the extent that (x) the conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> are satisfied at the time of such reallocation (and, unless the Borrower shall have otherwise notified the Administrative Agent at such time, the Borrower shall be deemed to have represented and warranted that such conditions are satisfied at such time), and (y) such reallocation does not cause the aggregate Revolving Credit Exposure of any Non-Defaulting Lender to exceed such Non-Defaulting Lender&#8217;s Revolving Commitment. Subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, no reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a Defaulting Lender arising from that Lender having become a Defaulting Lender, including any claim of a Non-Defaulting Lender as a result of such Non-Defaulting Lender&#8217;s increased exposure following such reallocation.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;If the reallocation described in clause (iv) above cannot, or can only partially, be effected, the Borrower shall, without prejudice to any right or remedy available to it hereunder or under law, (x) first, prepay Swingline Loans in an amount equal to the Swingline Lender&#8217;s Swingline Exposure with respect to such Defaulting Lender and (y)&#160;second, Cash Collateralize the Issuing Banks&#8217; LC Exposure with respect to such Defaulting Lender in accordance with the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Defaulting Lender Cure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If the Borrower, the Administrative Agent, Swingline Lender and the Issuing Banks agree in writing that a Lender is no longer a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase at par that portion of outstanding Loans of the other Lenders or take such other actions as the Administrative Agent may determine to be necessary to cause the Loans and funded and unfunded participations in Letters of Credit and Swingline Loans to be held pro rata by the Lenders in accordance with the applicable Commitments (without giving effect to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b)(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, whereupon such Lender will cease to be a Defaulting Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender&#8217;s having been a Defaulting Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">New Swingline Loans&#47;Letters of Credit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> So long as any Lender is a Defaulting Lender, (i) the Swingline Lender shall not be required to fund any Swingline Loans unless it is satisfied that it will have no Swingline Exposure after giving effect to such Swingline Loan and (ii) no Issuing Bank shall be required to issue, extend, renew or increase any Letter of Credit unless it is satisfied that it will have no LC Exposure after giving effect thereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>CONDITIONS PRECEDENT TO LOANS AND LETTERS OF CREDIT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conditions to Effectiveness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The obligations of the Lenders (including the Swingline Lender) to make Loans and the obligation of the Issuing Banks to issue any Letters of Credit </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">74</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereunder shall not become effective until the date on which each of the following conditions is satisfied (or waived in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Administrative Agent shall have received payment of all fees, expenses and other amounts due and payable on or prior to the Closing Date, including, without limitation, all fees payable pursuant to the Fee Letter and reimbursement or payment of all out-of-pocket expenses of the Administrative Agent, Truist Securities, Inc. and their Affiliates (including reasonable fees, charges and disbursements of counsel to the Administrative Agent) required to be reimbursed or paid by the Borrower hereunder, under any other Loan Document and under any agreement with the Administrative Agent or the Arrangers.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Administrative Agent (or its counsel) shall have received the following, each to be in form and substance satisfactory to the Administrative Agent&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a counterpart of this Agreement signed by or on behalf of each party hereto or written evidence satisfactory to the Administrative Agent (which may include facsimile transmission of a signed signature page of this Agreement) that such party has signed a counterpart of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;a certificate of the Secretary or Assistant Secretary of each Loan Party in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 3.1(b)(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, attaching and certifying copies of its bylaws, or partnership agreement or limited liability company agreement, and of the resolutions of its board of directors or other equivalent governing body, or comparable organizational documents and authorizations, authorizing the execution, delivery and performance of the Loan Documents to which it is a party and certifying the name, title and true signature of each officer of such Loan Party executing the Loan Documents to which it is a party&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;certified copies of the articles or certificate of incorporation (subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), certificate of organization or limited partnership, or other registered organizational documents of each Loan Party, together with certificates of good standing or existence, as may be available from the Secretary of State of the jurisdiction of organization of such Loan Party (and each other jurisdiction where such Loan Party is required to be qualified to do business as a foreign corporation solely to the extent that the failure to be so qualified as a foreign corporation in such other jurisdiction could result in a Material Adverse Effect)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;a favorable written opinion of (A) Tin Kin Lee Law Offices, counsel to the Loan Parties, addressed to the Administrative Agent, each Issuing Bank and each of the Lenders, and covering such matters relating to the Loan Parties, the Loan Documents and the transactions contemplated therein as the Administrative Agent shall reasonably request (which opinions will expressly permit reliance by permitted successors and assigns of the Administrative Agent, the Issuing Banks and the Lenders) and (B) Bryan Cave LLP, addressed to the Administrative Agent, each Issuing Bank and each of the Lenders, and covering certain matters relating to the Investment Company Act of 1940&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;a certificate in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 3.1(b)(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, dated the Closing Date and signed by a Responsible Officer, certifying that after giving effect to the funding of the initial Revolving Borrowing, (x) no Default or Event of Default exists, (y) all representations and warranties of each Loan Party set forth in the Loan Documents are true and correct and (z) since the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">75</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">date of the financial statements of the Borrower described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 4.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, there shall have been no change which has had or could reasonably be expected to have a Material Adverse Effect&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;a duly executed Notice of Borrowing for the initial Revolving Borrowing, together with a report setting forth the sources and uses of the proceeds thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;certified copies of all consents, approvals, authorizations, registrations and filings and orders required or advisable to be made or obtained under any Requirement of Law, or by any Contractual Obligation of any Loan Party in connection with the execution, delivery, performance, validity and enforceability of the Loan Documents and (to the extent applicable) APC 2019 Transaction Documents or any of the transactions contemplated thereby, and such consents, approvals, authorizations, registrations, filings and orders shall be in full force and effect and all applicable waiting periods shall have expired, and no investigation or inquiry by any governmental authority regarding the Commitments or any transaction being financed with the proceeds thereof shall be ongoing&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;copies of the Historical Financial Statements&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;financial projections of the Borrower and its Subsidiaries (to be made on a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> basis after giving effect to the consummation of the Related Transactions) for the Fiscal Year ending December 31, 2022 and for each Fiscal Year ending thereafter through the Fiscal Year ending December 31, 2025&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;a certificate, dated the Closing Date and signed by the chief financial officer of each Loan Party, confirming that each Loan Party is Solvent before and after giving effect to the funding of the initial Revolving Borrowing and the consummation of the transactions contemplated to occur on the Closing Date&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160; (A) copies of favorable UCC, tax, judgment and fixture lien search reports in all necessary or appropriate jurisdictions and under all legal and trade names of the Loan Parties and their Subsidiaries and the Material Associated Practices, as requested by the Administrative Agent, indicating that there are no prior Liens on any of the Collateral other than Permitted Encumbrances and Liens to be released on the Closing Date and (B) a Perfection Certificate, duly completed and executed by the Borrower&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiii)&#160;&#160;&#160;&#160;a counterpart of the Reaffirmation Agreement and Master Amendment dated the Closing Date, duly executed by each Loan Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Reaffirmation Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xiv)&#160;&#160;&#160;&#160;at least five (5) days prior to the date of this Agreement, all documentation and other information required by bank regulatory authorities or reasonably requested by the Administrative Agent or any Lender under or in respect of applicable &#8220;know your customer&#8221; and anti-money laundering legal requirements including the Patriot Act and, if the Borrower qualifies as a &#8220;legal entity customer&#8221; under the Beneficial Ownership Regulation, a Beneficial Ownership Certification in relation to Borrower&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xv)&#160;&#160;&#160;&#160;certified copies of all Material Agreements (including, for the avoidance of doubt, the Associated Practice Documents)&#59; and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">76</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xvi)&#160;&#160;&#160;&#160;subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, certificates of insurance, in form and detail acceptable to the Administrative Agent, describing the types and amounts of insurance (property and liability) maintained by any of the Loan Parties, in each case naming the Administrative Agent as loss payee or additional insured, as the case may be, together with a lender&#8217;s loss payable endorsement in form and substance satisfactory to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Without limiting the generality of the provisions of this Section, for purposes of determining compliance with the conditions specified in this Section, each Lender that has signed this Agreement shall be deemed to have consented to, approved of, accepted or been satisfied with each document or other matter required thereunder to be consented to, approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Conditions to Each Credit Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The obligation of each Lender to make a Loan on the occasion of any Borrowing and of each Issuing Bank to issue, amend, renew or extend any Letter of Credit is subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the satisfaction of the following conditions&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;at the time of and immediately after giving effect to such Borrowing or the issuance, amendment, renewal or extension of such Letter of Credit, as applicable, no Default or Event of Default shall exist&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;at the time of and immediately after giving effect to such Borrowing or the issuance, amendment, renewal or extension of such Letter of Credit, as applicable, all representations and warranties of each Loan Party set forth in the Loan Documents shall be true and correct in all material respects (other than those representations and warranties that are expressly qualified by a Material Adverse Effect or other materiality, in which case such representations and warranties shall be true and correct in all respects)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;since the date of the most recent financial statements delivered by the Borrower pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, there shall have been no change which has had or could reasonably be expected to have a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Borrower shall have delivered the required Notice of Borrowing together with a report setting forth the sources and uses of the proceeds hereof (if applicable)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the Borrower shall be in compliance on a pro forma basis with each of the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, measuring Consolidated Total Net Debt for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the date of any such Borrowing (or issuance, amendment, renewal or extension, as the case may be) and otherwise recomputing the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Borrowing (or issuance, amendment, renewal or extension, as the case may be) had occurred&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the Administrative Agent shall have received such other documents, certificates, information or legal opinions as the Administrative Agent or the Required Lenders may reasonably request, all in form and substance reasonably satisfactory to the Administrative Agent or the Required Lenders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">77</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Borrowing and each issuance, amendment, renewal or extension of any Letter of Credit shall be deemed to constitute a representation and warranty by the Borrower on the date thereof as to the matters specified in subsections (a), (b) and (c) of this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Delivery of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All of the Loan Documents, certificates, legal opinions and other documents and papers referred to in this Article, unless otherwise specified, shall be delivered to the Administrative Agent for the account of each of the Lenders and in sufficient counterparts or copies for each of the Lenders and shall be in form and substance satisfactory in all respects to the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Effect of Amendment and Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The parties hereto agree that, upon this Agreement becoming effective pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the following shall be deemed to occur or exist automatically, without further action by any party hereto or otherwise&#58; (i) the Existing Credit Agreement shall be deemed to be amended and restated in its entirety pursuant to this Agreement&#59; (ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A) all outstanding &#8220;Revolving Loans&#8221; (as such term is defined in the Existing Credit Agreement), if any, shall be repaid in full, (B) each outstanding &#8220;Letter of Credit&#8221; (as such term is defined in the Existing Credit Agreement), if any, shall be deemed to be a Letter of Credit issued and outstanding hereunder and (C) all outstanding &#8220;Term Loans&#8221; (as such term is defined in the Existing Credit Agreement) shall be repaid in full with proceeds of a Revolving Loan to be made on the Closing Date&#59; (iii) all terms and conditions of the Existing Credit Agreement and any other &#8220;Loan Document&#8221; as defined therein, as amended and restated by this Agreement and the other Loan Documents being executed and delivered on the Closing Date, shall be and remain in full force and effect, as so amended and restated, and shall constitute the legal, valid, binding and enforceable obligations of the Loan Parties to the Lenders and the Administrative Agent&#59; and (iv) all indemnification obligations of the Loan Parties under the Existing Credit Agreement and any other &#8220;Loan Document&#8221; as defined therein shall survive the execution and delivery of this Agreement and shall continue in full force and effect for the benefit of the Lenders, the Administrative Agent, and any other Person indemnified under the Existing Credit Agreement or such other Loan Document at any time prior to the Closing Date.  This Agreement shall not in any way release or impair the rights, duties, Obligations or Liens created pursuant to the Existing Credit Agreement or any other &#8220;Loan Document&#8221; as defined therein or affect the relative priorities of such Liens, in each case to the extent in force and effect thereunder as of the Closing Date, except as modified hereby or by documents, instruments and agreements executed and delivered in connection herewith, and all of such rights, duties, Obligations and Liens are assumed, ratified and affirmed by the Borrower.  The execution, delivery and effectiveness of this Agreement shall not operate as a waiver of any right, power or remedy of the Existing Lenders or the Administrative Agent under the Existing Credit Agreement, nor constitute a waiver of any covenant, agreement or obligation under the Existing Credit Agreement, except to the extent that any such covenant, agreement or obligation is no longer set forth herein or is modified hereby. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Borrower represents and warrants, both before and after giving effect to the Related Transactions, to the Administrative Agent, each Lender and each Issuing Bank as follows (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, however, that any representation and warranty made with respect to any Associated Practice by the Borrower pursuant to this Article IV shall be deemed to be made subject to the Knowledge of the Borrower and it being further acknowledged and agreed that each such representation and warranty is made (i) only to the extent that there is an express reference to an Associated Practice in such representation and warranty and (ii) by the Borrower and not any Associated Practice)&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">78</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Existence&#59; Power</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower, each of its Subsidiaries and each Associated Practice (i) is duly organized, validly existing and in good standing as a corporation, partnership or limited liability company under the laws of the jurisdiction of its organization, (ii) has all requisite power and authority to carry on its business as now conducted and (iii) is duly qualified to do business, and is in good standing, in each jurisdiction where such qualification is required, except where a failure to be so qualified could not reasonably be expected to result in a Material Adverse Effect.  The Borrower and each of its Subsidiaries has all requisite power and authority to execute, deliver and perform its obligations under the Loan Documents to which it is a party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Organizational Power&#59; Authorization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The execution, delivery and performance by each Loan Party of the Loan Documents and the other Related Transaction Documents to which it is a party are within such Loan Party&#8217;s organizational powers and have been duly authorized by all necessary organizational and, if required, shareholder, partner or member action. This Agreement has been duly executed and delivered by the Borrower and constitutes, and each other Loan Document and Related Transaction Document to which any Loan Party is a party, when executed and delivered by such Loan Party, will constitute, valid and binding obligations of the Borrower or such Loan Party (as the case may be), enforceable against it in accordance with their respective terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors&#8217; rights generally and by general principles of equity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Governmental Approvals&#59; No Conflicts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The execution, delivery and performance by each Loan Party of the Loan Documents and the other Related Transaction Documents to which it is a party (a) do not require any consent or approval of, registration or filing with, or any action by, any Governmental Authority, except those as have been obtained or made and are in full force and effect and except for filings necessary to perfect or maintain perfection of the Liens created under the Loan Documents, (b) will not violate any Requirement of Law applicable to the Borrower or any of its Subsidiaries or any judgment, order or ruling of any Governmental Authority, (c) will not violate or result in a default under any Contractual Obligation of the Borrower or any of its Subsidiaries or any of its assets or give rise to a right thereunder to require any payment to be made by the Borrower or any of its Subsidiaries and (d) will not result in the creation or imposition of any Lien on any asset of the Borrower or any of its Subsidiaries, except Liens (if any) created under the Loan Documents.  Each of the Borrower&#8217;s, its Subsidiaries&#8217; and Associated Practices&#8217; employees and contractors providing professional medical services to patients is, and has at all times been, while servicing in such capacity under employment of or contract with the Borrower, any other Loan Party or any Associated Practices, (i) duly licensed and certified (as and where required) by each regulatory body having jurisdiction over services rendered by such Person and (ii) eligible (as and where required) to participate in Third Party Payor Programs, except to the extent that such failure to be licensed, certified or eligible, as the case may be, would not reasonably be expected to have a Material Adverse Effect, either individually or in the aggregate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower has furnished the Historical Financial Statements to the Administrative Agent. The Historical Financial Statements fairly present the consolidated financial condition of the Borrower and its Subsidiaries as of such dates and the consolidated results of operations for such periods in conformity with GAAP consistently applied, subject to year-end audit adjustments and the absence of footnotes in the case of the quarterly statements. Since December 31, 2020, there have been no changes with respect to the Borrower and its Subsidiaries which have had or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Litigation and Environmental Matters.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">79</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;No litigation, investigation or proceeding of or before any arbitrators or Governmental Authorities is pending against or, to the Knowledge of the Borrower, threatened against or affecting the Borrower, any of its Subsidiaries or any Associated Practice (i) as to which there is a reasonable possibility of an adverse determination that could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect or (ii) which in any manner draws into question the validity or enforceability of this Agreement or any other Loan Document or Related Transaction Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except for the matters set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, none of the Borrower, any of its Subsidiaries or any Associated Practice (i) has failed to comply with any Environmental Law or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law, (ii) has become subject to any Environmental Liability, (iii) has received notice of any claim with respect to any Environmental Liability or (iv) knows of any basis for any Environmental Liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Compliance with Laws and Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower, each of its Subsidiaries and each Associated Practice is in compliance with (a) all Requirements of Law and all judgments, decrees and orders of any Governmental Authority and (b) all indentures, agreements or other instruments binding upon it or its properties, except where non-compliance, either individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Investment Company Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Borrower nor any of its Subsidiaries is (a) an &#8220;investment company&#8221; or is &#8220;controlled&#8221; by an &#8220;investment company&#8221;, as such terms are defined in, or subject to regulation under, the Investment Company Act of 1940, as amended and in effect from time to time, or (b) other than in the case of any Regulated Entity, otherwise subject to any other regulatory scheme limiting its ability to borrow  money or requiring any approval or consent from, or registration or filing with, any Governmental Authority in connection therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower, its Subsidiaries, the Associated Practices and each other Person for whose taxes the Borrower, any of its Subsidiaries or any Associated Practice could become liable have timely filed or caused to be filed all Federal income tax returns and all other material tax returns that are required to be filed by them, and have paid all taxes shown to be due and payable on such returns or on any assessments made against it or its property and all other taxes, fees or other charges imposed on it or any of its property by any Governmental Authority, except where the same are currently being contested in good faith by appropriate proceedings and for which the Borrower, such Subsidiary or such Associated Practice, as the case may be, has set aside on its books adequate reserves in accordance with GAAP. The charges, accruals and reserves on the books of the Borrower, its Subsidiaries and the Associated Practices in respect of such taxes are adequate, and no tax liabilities that could be materially in excess of the amount so provided are anticipated.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Margin Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. None of the proceeds of any of the Loans or Letters of Credit will be used, directly or indirectly, for &#8220;purchasing&#8221; or &#8220;carrying&#8221; any &#8220;margin stock&#8221; within the respective meanings of each of such terms under Regulation U or for any purpose that violates the provisions of Regulation T, Regulation U or Regulation X. Neither the Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying &#8220;margin stock&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Plan is in substantial compliance in form and operation with its terms and with ERISA and the Code (including, without limitation, the Code provisions compliance with which is necessary for any intended favorable tax treatment) and all other applicable laws and regulations. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">80</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Plan (and each related trust, if any) which is intended to be qualified under Section 401(a) of the Code has received a favorable determination letter from the IRS to the effect that it meets the requirements of Sections 401(a) and 501(a) of the Code covering all applicable tax law changes, or is comprised of a master or prototype plan that has received a favorable opinion letter from the IRS, and nothing has occurred since the date of such determination that would adversely affect such determination (or, in the case of a Plan with no determination, nothing has occurred that would adversely affect the issuance of a favorable determination letter or otherwise adversely affect such qualification). No ERISA Event has occurred or is reasonably expected to occur. There exists no Unfunded Pension Liability with respect to any Plan. None of the Borrower, any of its Subsidiaries or any ERISA Affiliate is making or accruing an obligation to make contributions, or has, within any of the five calendar years immediately preceding the date this assurance is given or deemed given, made or accrued an obligation to make, contributions to any Multiemployer Plan. There are no actions, suits or claims pending against or involving a Plan (other than routine claims for benefits) or, to the Knowledge of the Borrower, any of its Subsidiaries or any ERISA Affiliate, threatened, which would reasonably be expected to be asserted successfully against any Plan and, if so asserted successfully, would reasonably be expected either singly or in the aggregate to result in liability to the Borrower or any of its Subsidiaries. The Borrower, each of its Subsidiaries and each ERISA Affiliate have made all contributions to or under each Plan and Multiemployer Plan required by law within the applicable time limits prescribed thereby, by the terms of such Plan or Multiemployer Plan, respectively, or by any contract or agreement requiring contributions to a Plan or Multiemployer Plan. No Plan which is subject to Section 412 of the Code or Section 302 of ERISA has applied for or received an extension of any amortization period within the meaning of Section 412 of the Code or Section 303 or 304 of ERISA. None of the Borrower, any of its Subsidiaries or any ERISA Affiliate have ceased operations at a facility so as to become subject to the provisions of Section 4068(a) of ERISA, withdrawn as a substantial employer so as to become subject to the provisions of Section 4063 of ERISA or ceased making contributions to any Plan subject to Section 4064(a) of ERISA to which it made contributions. Each Non-U.S. Plan has been maintained in compliance with its terms and with the requirements of any and all applicable laws, statutes, rules, regulations and orders and has been maintained, where required, in good standing with applicable regulatory authorities, except as would not reasonably be expected to result in liability to the Borrower or any of its Subsidiaries. All contributions required to be made with respect to a Non-U.S. Plan have been timely made. Neither the Borrower nor any of its Subsidiaries has incurred any obligation in connection with the termination of, or withdrawal from, any Non-U.S. Plan. The present value of the accrued benefit liabilities (whether or not vested) under each Non-U.S. Plan, determined as of the end of the Borrower&#8217;s most recently ended fiscal year on the basis of reasonable actuarial assumptions, did not exceed the current value of the assets of such Non-U.S. Plan allocable to such benefit liabilities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Ownership of Property&#59; Insurance.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each of the Borrower and its Subsidiaries has good title to, or valid leasehold interests in, all of its real and personal property material to the operation of its business, including all such properties reflected in the most recent audited Historical Financial Statements or purported to have been acquired by the Borrower or any of its Subsidiaries after said date (except as sold or otherwise disposed of in the ordinary course of business), in each case free and clear of Liens prohibited by this Agreement. All leases that individually or in the aggregate are material to the business or operations of the Borrower and its Subsidiaries are valid and subsisting and are in full force.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each of the Borrower, its Subsidiaries and the Associated Practices, as the case may be, owns, or is licensed or otherwise has the right to use, all patents, trademarks, service marks, trade names, copyrights and other intellectual property material to its business, and the use thereof by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">81</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Borrower, its Subsidiaries  and the Associated Practices, as the case may be, does not infringe in any material respect on the rights of any other Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The properties of the Borrower and its Subsidiaries are insured with financially sound and reputable insurance companies which are not Affiliates of the Borrower, in such amounts with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where the Borrower or any applicable Subsidiary operates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of the Closing Date, neither the Borrower nor any of its Subsidiaries owns any Real Estate. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Disclosure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower has disclosed to the Lenders all agreements, instruments, and corporate or other restrictions to which the Borrower, each of its Subsidiaries and each Associated Practice is subject, and all other matters known to any of them, that, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. Neither the lender presentation nor any of the reports (including, without limitation, all reports that the Borrower is required to file with the Securities and Exchange Commission), financial statements, certificates or other information furnished by or on behalf of the Borrower to the Administrative Agent or any Lender in connection with the negotiation or syndication of this Agreement or any other Loan Document or delivered hereunder or thereunder (as modified or supplemented by any other information so furnished) contains any material misstatement of fact or omits to state any material fact necessary to make the statements therein, taken as a whole in light of the circumstances under which they were made, not misleading&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, with respect to projected financial information, the Borrower represents only that such information was prepared in good faith based upon assumptions believed to be reasonable at the time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As of the Closing Date, the information included in the Beneficial Ownership Certification is true and correct in all respects.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Labor Relations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. There are no strikes, lockouts or other material labor disputes or grievances against the Borrower, any of its Subsidiaries or any Associated Practice, or, to the Borrower&#8217;s Knowledge, threatened against or affecting the Borrower, any of its Subsidiaries or any Associated Practice, and no significant unfair labor practice charges or grievances are pending against the Borrower, any of its Subsidiaries or any Associated Practice, or, to the Borrower&#8217;s Knowledge, threatened against any of them before any Governmental Authority. All payments due from the Borrower, any of its Subsidiaries or any Associated Practice pursuant to the provisions of any collective bargaining agreement have been paid or accrued as a liability on the books of the Borrower, any such Subsidiary or any such Associated Practice, except where the failure to do so could not reasonably be expected to have a Material Adverse Effect. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sets forth the name of, the ownership interest of the applicable Loan Party in, the jurisdiction of incorporation or organization of, and the type of each Subsidiary of the Borrower and the other Loan Parties and identifies each Subsidiary that is a Subsidiary Loan Party, in each case as of the Closing Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">82</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Solvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. After giving effect to the execution and delivery of the Loan Documents and the other Related Transaction Documents, the making of the Loans under this Agreement and the consummation of the other Related Transactions, each Loan Party is Solvent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Deposit and Disbursement Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> lists all banks and other financial institutions at which any Loan Party maintains deposit accounts, lockbox accounts, disbursement accounts, investment accounts or other similar accounts as of the Closing Date, and such Schedule correctly identifies the name, address and telephone number of each financial institution, the name in which the account is held, the type of the account, and the complete account number therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Collateral Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Guaranty and Security Agreement (including as reaffirmed by the Reaffirmation Agreement) is effective to create in favor of the Administrative Agent for the ratable benefit of the Secured Parties a legal, valid and enforceable security interest in the Collateral (as defined therein), and the Liens created under the Guaranty and Security Agreement constitute fully perfected Liens (to the extent that such Liens may be perfected by the filing of a UCC financing statement in the offices specified on Schedule 3 to the Guaranty and Security Agreement) on, and security interest in, all right, title and interest of the grantors thereunder in such Collateral, in each case prior and superior in right to any other Person, other than with respect to Liens expressly permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> which are prior as a matter of law. When the certificates evidencing all Capital Stock pledged pursuant to the Guaranty and Security Agreement are delivered to the Administrative Agent, together with appropriate stock powers or other similar instruments of transfer duly executed in blank, the Liens in such Capital Stock shall be fully perfected first priority security interests, perfected by &#8220;control&#8221; as defined in the UCC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;When, if applicable, the Patent Security Agreements and the Trademark Security Agreements are filed in the United States Patent and Trademark Office and the Copyright Security Agreements are filed in the United States Copyright Office, the Liens created by Guaranty and Security Agreement shall constitute fully perfected Liens on, and security interest in, all right, title and interest of the Loan Parties in the Patents, Trademarks and Copyrights, if any, in which a security interest may be perfected by filing, recording or registering a security agreement, financing statement or analogous document in the United States Patent and Trademark Office or the United States Copyright Office, as applicable, in each case prior and superior in right to any other Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each Mortgage, when duly executed and delivered by the relevant Loan Party, will be effective to create in favor of the Administrative Agent for the ratable benefit of the Secured Parties a legal, valid and enforceable Lien on all of such Loan Party&#8217;s right, title and interest in and to the Real Estate of such Loan Party covered thereby and the proceeds thereof, and when such Mortgage is filed in the real estate records where the respective Mortgaged Property is located, such Mortgage shall constitute a fully perfected Lien on, and security interest in, all right, title and interest of such Loan Party in such Real Estate and the proceeds thereof, in each case prior and superior in right to any other Person, other than with respect to Liens expressly permitted by Section 7.2 which are prior as a matter of law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;No Mortgage encumbers improved real property that is located in an area that has been identified by the Secretary of Housing and Urban Development as an area having special flood hazards and in which flood insurance has been made available under the National Flood Insurance Act of 1968, except to the extent that the applicable Loan Party maintains flood insurance with respect to such improved real property in compliance with the requirements of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">83</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Associated Practice Documents&#59; APC 2019 Transaction Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Associated Practice Documents and APC 2019 Transaction Documents remain in full force and effect and no default or event of default has occurred thereunder.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Material Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. As of the Closing Date, all Material Agreements of the Borrower and its Subsidiaries are described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and each such Material Agreement is in full force and effect. The Borrower does not have any Knowledge of any pending amendments or threatened termination of any of the Material Agreements. As of the Closing Date, the Borrower has delivered to the Administrative Agent a true, complete and correct copy of each Material Agreement (including all schedules, exhibits, amendments, supplements, modifications, assignments and all other documents delivered pursuant thereto or in connection therewith).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Sanctions and Anti-Corruption Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;None of the Borrower or any of its Subsidiaries or any of their respective directors, officers, employees, agents or affiliates is a Sanctioned Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Borrower, its Subsidiaries and their respective directors, officers and employees and, to the Knowledge of the Borrower, the agents of the Borrower and its Subsidiaries, are in compliance with applicable Anti-Corruption Laws and applicable Sanctions. The Borrower and its Subsidiaries have instituted and maintain policies and procedures designed to promote and achieve continued compliance therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Affected Financial Institutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Neither the Borrower nor any Subsidiary is an Affected Financial Institution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Healthcare Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Except as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 4.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower, each of its Subsidiaries and each Associated Practice is in compliance with the requirements of all applicable Healthcare Laws, except in such instances in which the failure to comply therewith could not reasonably be expected to have a Material Adverse Effect. To the Knowledge of the Borrower, there is no action pending against, received by or threatened against the Borrower, its Subsidiaries or any Associated Practice which relates in any way to a violation of any Healthcare Law, except for such violations which could not reasonably be expected to have a Material Adverse Effect.  As of the Closing Date, none of the Borrower, its Subsidiaries or any Associated Practice is a party to any corporate integrity agreements or has any ongoing reporting obligations pursuant to any settlement agreement entered into with any Governmental Authority. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To the Knowledge of the Borrower, all Persons employed by or engaged as an independent contractor by the Borrower, its Subsidiaries and any Associated Practice possesses all licenses, permits and authorizations that are required by any Governmental Authority or Requirement of Law to permit such Person to provide the services they provide for such Loan Party, its Subsidiaries and each Associated Practice except to the extent the failure to do so could not reasonably be expected to have a Material Adverse Effect.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 4.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each Borrowing and each request for a Letter of Credit hereunder will be used solely for the purposes permitted hereunder.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">84</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>AFFIRMATIVE COVENANTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until the Commitments have expired or been terminated and all Obligations have been paid in full and all Letters of Credit shall have expired or terminated, in each case without any pending draw, or all such Letters of Credit shall have been cash collateralized to the satisfaction of each Issuing Bank, and all LC Disbursements shall have been reimbursed, the Borrower covenants and agrees with the Lenders that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Statements and Other Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will deliver to the Administrative Agent and each Lender&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;as soon as available and in any event within 90 days after the end of each Fiscal Year of the Borrower, a copy of the annual audited report for such Fiscal Year for the Borrower, containing a consolidated balance sheet of the Borrower as of the end of such Fiscal Year and the related consolidated statements of income, stockholders&#8217; equity and cash flows (together with all footnotes thereto) of the Borrower for such Fiscal Year, setting forth in each case in comparative form the figures for the previous Fiscal Year, all in reasonable detail and together with a report by BDO USA, LLP or other independent public accountants of nationally recognized standing (without a &#8220;going concern&#8221; qualification, exception or explanation and without any qualification or exception as to the scope of such audit) stating that such financial statements present fairly in all material respects the financial condition and the results of operations of the Borrower for such Fiscal Year on a consolidated basis in accordance with GAAP and that the examination by such accountants in connection with such consolidated financial statements has been made in accordance with generally accepted auditing standards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;as soon as available and in any event within 45 days after the end of each Fiscal Quarter of the Borrower (other than the fourth Fiscal Quarter of each Fiscal Year), an unaudited consolidated balance sheet of the Borrower as of the end of such Fiscal Quarter and the related unaudited consolidated statements of income and cash flows of the Borrower for such Fiscal Quarter and the then elapsed portion of such Fiscal Year, setting forth in each case in comparative form the figures for the corresponding Fiscal Quarter and the corresponding portion of the Borrower&#8217;s previous Fiscal Year&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;concurrently with the delivery of the financial statements referred to in subsections (a) and (b) of this Section, a Compliance Certificate signed by the principal executive officer or the principal financial officer of the Borrower (i) certifying as to whether there exists a Default or Event of Default on the date of such certificate and, if a Default or an Event of Default then exists, specifying the details thereof and the action which the Borrower has taken or proposes to take with respect thereto, (ii) setting forth in reasonable detail calculations demonstrating compliance with the financial covenants set forth in Article VI, (iii) specifying any change in the identity of the Subsidiaries as of the end of such Fiscal Year or Fiscal Quarter from the Subsidiaries identified to the Lenders on the Closing Date or as of the most recent Fiscal Year or Fiscal Quarter, as the case may be, (iv) setting forth the balance of funds then on deposit in APC Excluded Asset Account, together with a summary statement from the Borrower of the amount and use of any funds withdrawn from the APC Excluded Asset Account following the delivery of the prior Compliance Certificate (or, in the case of the first Compliance Certificate delivered after the Closing Date, since the Closing Date) and (v) stating whether any change in GAAP or the application thereof has occurred since the date of the mostly recently delivered audited financial statements of the Borrower and its Subsidiaries, and, if any change has occurred, specifying the effect of such change on the financial statements accompanying such Compliance Certificate&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">85</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;as soon as available and in any event within 30 days after the end of the calendar year, forecasts and a pro forma budget for the succeeding Fiscal Year, containing an income statement, balance sheet and statement of cash flow&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;promptly after the same become publicly available, copies of all periodic and other reports, proxy statements and other materials filed with the Securities and Exchange Commission, or any Governmental Authority succeeding to any or all functions of said Commission, or with any national securities exchange, or distributed by the Borrower to its shareholders generally, as the case may be&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;promptly following any request therefor, (i) such other information regarding the results of operations, business affairs and financial condition of the Borrower or any of its Subsidiaries as the Administrative Agent or any Lender may reasonably request and (ii) information and documentation reasonably requested by the Administrative Agent or any Lender for purposes of compliance with applicable &#8220;know your customer&#8221; requirements under the Patriot Act or other applicable anti-money laundering laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">So long as the Borrower is required to file periodic reports under Section 13(a) or Section 15(d) of the Exchange Act, the Borrower may satisfy its obligation to deliver the financial statements and periodic and other reports, proxy statements and other materials referred to in clauses (a), (b) and (e) above by delivering a notice of filing of such financial statements and periodic and other reports, proxy statements and other materials by electronic mail to such e-mail addresses as the Administrative Agent shall have provided to the Borrower from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Borrower hereby acknowledges that (a) the Administrative Agent and&#47;or the Arrangers will make available to the Lenders and each Issuing Bank materials and&#47;or information provided by or on behalf of the Borrower hereunder (collectively, &#8220;Borrower Materials&#8221;) by posting the Borrower Materials on the Platform and (b) certain of the Lenders (each, a &#8220;Public Lender&#8221;) may have personnel who do not wish to receive material non-public information with respect to the Borrower or its Affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons&#8217; securities. The Borrower hereby agrees that it will use commercially reasonable efforts to identify that portion of the Borrower Materials that may be distributed to Public Lenders and that (w) all such Borrower Materials shall be clearly and conspicuously marked &#8220;PUBLIC&#8221; which, at a minimum, shall mean that the word &#8220;PUBLIC&#8221; shall appear prominently on the first page thereof&#59; (x) by marking Borrower Materials &#8220;PUBLIC&#8221;, the Borrower shall be deemed to have authorized the Administrative Agent, the Arrangers, the Issuing Banks and the Lenders to treat such Borrower Materials as not containing any material non-public information (although it may be sensitive and proprietary) with respect to the Borrower or its securities for purposes of United States Federal and state securities laws (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that to the extent such Borrower Materials constitute confidential information, they shall be treated as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#59; (y) all Borrower Materials marked &#8220;PUBLIC&#8221; are permitted to be made available through a portion of the Platform designated &#8220;Public Side Information&#8221;&#59; and (z) the Administrative Agent and the Arrangers shall be entitled to treat any Borrower Materials that are not marked &#8220;PUBLIC&#8221; as being suitable only for posting on a portion of the Platform not designated &#8220;Public Side Information&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Notices of Material Events.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">86</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower will furnish to the Administrative Agent and each Lender prompt (and, in any event, not later than three (3) Business Days after a Responsible Officer becomes aware thereof, other than in the case of clause (iv) below) written notice of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the occurrence of any Default or Event of Default&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the filing or commencement of, or any material development in, any action, suit or proceeding by or before any arbitrator or Governmental Authority against or, to the Knowledge of the Borrower, affecting the Borrower, any of its Subsidiaries or, to the Knowledge of the Borrower, any Associated Practice that could reasonably be expected to result in a Material Adverse Effect (including, without limitation, any of the foregoing that (x) seeks injunctive or similar relief or (y) alleges potential or actual violations of any Healthcare Law by the Borrower, any of its Subsidiaries or, to the Knowledge of the Borrower, any Associated Practice and, in either case)&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the occurrence of any event or any other development by which the Borrower, any of its Subsidiaries or, to the Knowledge of the Borrower, any Associated Practice (A)&#160;fails to comply with any Environmental Law or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law, (B) becomes subject to any Environmental Liability, (C) receives notice of any claim with respect to any Environmental Liability, or (D) becomes aware of any basis for any Environmental Liability, in each case which, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;promptly and in any event within 15 days after the Borrower, any of its Subsidiaries, any Associated Practice or any ERISA Affiliate (A) knows or has reason to know that any ERISA Event has occurred, a certificate of the chief financial officer of the Borrower describing such ERISA Event and the action, if any, proposed to be taken with respect to such ERISA Event and a copy of any notice filed with the PBGC or the IRS pertaining to such ERISA Event and any notices received by the Borrower, such Subsidiary or such ERISA Affiliate from the PBGC or any other governmental agency with respect thereto, and (B) becoming aware (1) that there has been an increase in Unfunded Pension Liabilities (not taking into account Plans with negative Unfunded Pension Liabilities) since the date the representations hereunder are given or deemed given, or from any prior notice, as applicable, (2) of the existence of any Withdrawal Liability, (3) of the adoption of, or the commencement of contributions to, any Plan subject to Section 412 of the Code by the Borrower, any of its Subsidiaries or any ERISA Affiliate, or (4) of the adoption of any amendment to a Plan subject to Section 412 of the Code which results in a material increase in contribution obligations of the Borrower, any of its Subsidiaries or any ERISA Affiliate, a detailed written description thereof from the chief financial officer of the Borrower&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;any breach or non-performance of, or any default under, any Associated Practice Document by any Loan Party or, any of its respective Subsidiaries or to Borrower&#8217;s Knowledge, any Associated Practices, or any violation of, or non-compliance with, any Requirement of Law, which would reasonably be expected to result, either individually or in the aggregate, in a Material Adverse Effect, including a description of such breach, non-performance, default, violation or non-compliance and the steps, if any, such Loan Party, such Subsidiary or such Associated Practice has taken, is taking or proposes to take in respect thereof&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">87</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;the occurrence of any default or event of default, or the receipt by the Borrower or any of its Subsidiaries of any written notice of an alleged default or event of default, with respect to any Material Indebtedness of the Borrower or any of its Subsidiaries&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;any material amendment or modification to any Material Agreement (together with a copy thereof), and prompt notice of any termination, expiration or loss of any Material Agreement that, individually or in the aggregate, could reasonably be expected to result in a reduction in revenue or Consolidated EBITDA of the Loan Parties of 10% or more on a consolidated basis from the prior Fiscal Year&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;any change in the information provided in the Beneficial Ownership Certification that would result in a change to the list of beneficial owners identified in parts (c) and (d) of such certification&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;(A) receipt by the Borrower, any of its Subsidiaries or, to the Knowledge of the Borrower, any Associated Practice of any notification, through letter or otherwise, of a potential investigation relating to submission of claims to Third Party Payor Programs by the Borrower, any of its Subsidiaries or any Associated Practice (other than any additional data requests and audits, inspections and investigations, that, in each case, are in the ordinary course of business and would not reasonably be expected to have a Material Adverse Effect)&#59; (B) the voluntary disclosure by the Borrower, any of its Subsidiaries or, to the Knowledge of the Borrower, any Associated Practice to the Office of the Inspector General of the United States Department of Health and Human Services, a Medicare fiscal intermediary, any Governmental Authority or any state&#8217;s Medicaid program of a potential material overpayment matter involving the submission of claims to such payor&#59; or (C) receipt by the Borrower, any of its Subsidiaries or, to the Knowledge of the Borrower, any Associated Practice of any notice from a Governmental Authority that the Borrower, any of its Subsidiaries or any Associated Practice is subject to a civil or criminal investigation, inquiry or audit involving and&#47;or related to its compliance with Healthcare Laws which, if adversely determined, would reasonably be expected to have a Material Adverse Effect&#59; and  </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;receipt by the Borrower, any of its Subsidiaries or, to the Knowledge of the Borrower, any Associated Practice from any Governmental Authority of the imposition of any forfeiture or the designation of a hearing that could result in the expiration, termination, revocation, impairment or suspension of any Healthcare Permit that would reasonably be expected to have a Material Adverse Effect&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xi)&#160;&#160;&#160;&#160;any material defaults or termination received from any Material Associated Practice, or given by any Loan Party to any Associated Practice, under any Associated Practice Document&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(xii)&#160;&#160;&#160;&#160;any other development that results in, or could reasonably be expected to result in, a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower will furnish to the Administrative Agent and each Lender the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;promptly and in any event at least 30 days prior thereto, notice of any change (i) in any Loan Party&#8217;s legal name, (ii) in any Loan Party&#8217;s chief executive office, its principal place of business, any office in which it maintains books or records or any office or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">88</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">facility at which Collateral owned by it is located (including the establishment of any such new office or facility), (iii) in any Loan Party&#8217;s identity or legal structure, (iv) in any Loan Party&#8217;s federal taxpayer identification number or organizational number or (v) in any Loan Party&#8217;s jurisdiction of organization&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;as soon as available and in any event within 30 days after receipt thereof, a copy of any environmental report or site assessment obtained by or for the Borrower or any of its Subsidiaries after the Closing Date on any Real Estate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each notice or other document delivered under this Section shall be accompanied by a written statement of a Responsible Officer setting forth the details of the event or development requiring such notice or other document and any action taken or proposed to be taken with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Existence&#59; Conduct of Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will, and will cause each of its Subsidiaries to, do or cause to be done all things necessary to preserve, renew and maintain in full force and effect its legal existence and its respective rights, licenses, permits, privileges, franchises, patents, copyrights, trademarks and trade names material to the conduct of its business&#59; provided that nothing in this Section shall prohibit any merger, consolidation, liquidation or dissolution permitted under Section 7.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Compliance with Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will, and will cause each of its Subsidiaries  to (and, to the extent permitted by applicable law, cause the Material Associated Practices to), comply with all laws, rules, regulations and requirements of any Governmental Authority applicable to its business and properties, including, without limitation, all Healthcare Laws, Environmental Laws, ERISA and OSHA, except where the failure to do so, either individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect. The Borrower will maintain in effect and enforce policies and procedures designed to promote and achieve compliance by the Borrower, its Subsidiaries, the Material Associated Practices and their respective directors, officers, employees and agents with applicable Anti-Corruption Laws and applicable Sanctions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Payment of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will, and will cause each of its Subsidiaries to, pay and discharge at or before maturity all of its obligations and liabilities (including, without limitation, all taxes, assessments and other governmental charges, levies and all other claims that could result in a statutory Lien) before the same shall become delinquent or in default, except where (a) the validity or amount thereof is being contested in good faith by appropriate proceedings and the Borrower or such Subsidiary has set aside on its books adequate reserves with respect thereto in accordance with GAAP or (b) the failure to make any such payment could not reasonably be expected to result in a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Books and Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will, and will cause each of its Subsidiaries to (and, to the extent permitted by applicable law, cause the Material Associated Practices to), keep proper books of record and account in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities to the extent necessary to prepare the consolidated financial statements of the Borrower in conformity with GAAP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Visitation and Inspection&#59; Lender Meetings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower will, and will cause each of its Subsidiaries to (and, to the extent permitted by applicable law, cause the Material Associated Practices to), permit any representative of the Administrative Agent or any Lender to visit and inspect its properties (excluding the APC Excluded </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">89</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets), to examine its books and records and to make copies and take extracts therefrom, and to discuss its affairs, finances and accounts with any of its officers and with its independent certified public accountants, all at such reasonable times and as often as the Administrative Agent or any Lender may reasonably request after reasonable prior notice to the Borrower&#59; provided that if an Event of Default has occurred and is continuing, no prior notice shall be required. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower will participate in annual meetings with the Administrative Agent and the Lenders to be held at the Borrower&#8217;s corporate offices (or at such other location as may be agreed to by the Borrower and the Administrative Agent, including via conference call) at such time as may be reasonably agreed to by the Borrower and the Administrative Agent.  The Borrower will provide reasonable advance notice and an invitation to the Administrative Agent and the Lenders to each earnings call, if any.  It is understood and agreed that the Borrower&#8217;s establishment of earnings calls on an annual or more frequent basis to which the Administrative Agent and the Lenders are invited shall relinquish its obligations to participate in annual meetings with the Administrative Agent and the Lenders.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Maintenance of Properties&#59; Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will, and will cause each of its Subsidiaries to (and, to the extent permitted by applicable law, cause the Material Associated Practices to), (a) keep and maintain all property material to the conduct of its business in good working order and condition, ordinary wear and tear excepted, (b) maintain with financially sound and reputable insurance companies which are not Affiliates of the Borrower (i) insurance with respect to its properties and business, and the properties and business of its Subsidiaries and the Associated Practices, against loss or damage of the kinds customarily insured against by companies in the same or similar businesses operating in the same or similar locations (including, in any event, flood insurance as described in the definition of and required by the Real Estate Documents) and (ii) all insurance required to be maintained pursuant to the Collateral Documents, and will, upon request of the Administrative Agent, furnish to each Lender at reasonable intervals a certificate of a Responsible Officer setting forth the nature and extent of all insurance maintained by the Borrower, its Subsidiaries and the Material Associated Practices in accordance with this Section (and if requested by the Administrative Agent or any Lender a copy of any policy referenced therein if not already delivered), and (c) solely with respect to any such insurance held by the Borrower and&#47; its Subsidiaries, at all times shall name the Administrative Agent as additional insured on all liability policies of the Borrower and its Subsidiaries and as lender loss payee (pursuant to a loss payee endorsement approved by the Administrative Agent) on all casualty and property insurance policies of the Borrower and its Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that (except with respect to third-party liability insurance) this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall not apply to any APC Excluded Assets. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Proceeds&#59; Margin Regulations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower will use the proceeds of all Revolving Loans funded on the Closing Date to (i) refinance certain Indebtedness of the Borrower and its Subsidiaries, (which shall include, for the avoidance of doubt, the repayment in full of the &#8220;Term Loan&#8221; (as defined in the Existing Credit Agreement) outstanding immediately before giving effect to this Agreement, together with all accrued interest thereon), (ii) pay transaction costs and expenses arising in connection with this Agreement and (iii) provide for working capital, capital expenditures and other general corporate purposes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that it is understood and agreed that no greater than $180,000,000 in Revolving Loans shall be borrowed on the Closing Date (exclusive of any LC Exposure incurred on the Closing Date due to the roll-over of the Existing Letters of Credit).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower will use the proceeds of the Loans after the Closing Date to (i) finance future Permitted Acquisitions and Investments (in each case, solely to the extent permitted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">90</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereunder) and (ii) provide for working capital needs, capital expenditures, and for other general corporate purposes.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;All Letters of Credit will be used for general corporate purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained herein, no part of the proceeds of any Loan will be used, whether directly or indirectly, for any purpose that would violate any rule or regulation of the Board of Governors of the Federal Reserve System, including Regulation T, Regulation U or Regulation X.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Casualty and Condemnation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower (a) will furnish to the Administrative Agent and the Lenders prompt written notice of any casualty or other insured damage to any material portion of any Collateral or the commencement of any action or proceeding for the taking of any material portion of any Collateral or any part thereof or interest therein under power of eminent domain or by condemnation or similar proceeding and (b) will ensure that the net cash proceeds of any such event (whether in the form of insurance proceeds, condemnation awards or otherwise) are collected and applied in accordance with the applicable provisions of this Agreement and the Collateral Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Cash Management</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall, and shall cause its Subsidiaries to maintain all cash management and treasury business with Truist Bank or a Permitted Third Party Bank, including, without limitation, all deposit accounts, disbursement accounts, investment accounts and lockbox accounts (other than Excluded Accounts) (each such deposit account, disbursement account, investment account and lockbox account, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Controlled Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;)&#59; each Controlled Account shall be a cash collateral account, with all cash, checks and other similar items of payment in such account securing payment of the Obligations, and in which the Borrower and each of the Subsidiary Loan Parties shall have granted a first priority Lien to the Administrative Agent, on behalf of the Secured Parties, perfected either automatically under the UCC (with respect to Controlled Accounts at Truist Bank) or subject to Control Account Agreements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Subsidiaries and Collateral.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the event that, subsequent to the Closing Date, any Person becomes a Subsidiary (other than an Excluded Subsidiary), whether pursuant to formation, Acquisition or otherwise, (x) the Borrower shall promptly notify the Administrative Agent and the Lenders thereof and (y) within 30 days after such Person becomes a Subsidiary, the Borrower shall cause such Subsidiary (i) to become a new Guarantor and to grant Liens in favor of the Administrative Agent in all of its personal property by executing and delivering to the Administrative Agent a supplement to the Guaranty and Security Agreement in form and substance reasonably satisfactory to the Administrative Agent, executing and delivering a Copyright Security Agreement, Patent Security Agreement and Trademark Security Agreement, as applicable, and authorizing and delivering, at the request of the Administrative Agent, such UCC financing statements or similar instruments required by the Administrative Agent to perfect the Liens in favor of the Administrative Agent and granted under any of the Loan Documents, (ii) to grant Liens in favor of the Administrative Agent in all fee ownership interests in all Real Estate with a fair market value in excess of $7,500,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">by executing and delivering to the Administrative Agent such Real Estate Documents as the Administrative Agent shall require, and (iii) to deliver all such other documentation (including, without limitation, certified organizational documents, resolutions, lien searches, title insurance policies, surveys, environmental reports and legal opinions) and to take all such other actions as such Subsidiary would have been required to deliver and take pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> if </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">91</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">such Subsidiary had been a Loan Party on the Closing Date or that such Subsidiary would be required to deliver pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to any Real Estate.  In addition, within 45 days after the date any Person becomes a Subsidiary, the Borrower shall, or shall cause the applicable Loan Party to (i) pledge all of the Capital Stock of such Subsidiary to the Administrative Agent as security for the Obligations by executing and delivering a supplement to the Guaranty and Security Agreement in form and substance satisfactory to the Administrative Agent, and (ii) deliver the original certificates evidencing such pledged Capital Stock to the Administrative Agent, together with appropriate powers executed in blank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;If, at any time and from time to time after the Closing Date, Subsidiaries that are not Guarantors solely because they do not meet the thresholds set forth in the definition of &#8220;Immaterial Subsidiary&#8221; comprise in the aggregate more than 5.0% of Consolidated Total Assets or more than 5.0% of Consolidated EBITDA, in each case, as of the end of the most recently ended Fiscal Quarter for which financial statements have been delivered (or were required to be delivered) pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then the Borrower shall, not later than five (5) Business Days after the date by which financial statements for such Fiscal Quarter are required to be delivered pursuant to this Agreement (or such longer period as the Administrative Agent may agree in its reasonable discretion), (i) designate in writing to the Administrative Agent one or more of such Subsidiaries as no longer being an &#8220;Immaterial Subsidiary&#8221; (to the extent that, as a result of such designation, the remaining Immaterial Subsidiaries constitute less than each of the thresholds set forth in this subsection (d) in the aggregate) and (ii) comply with the provisions of subsection (a) of this Section applicable to each such Subsidiary (subject to the time periods set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> which shall run from the date that any Subsidiary is so designated as no longer being an Immaterial Subsidiary hereunder).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Borrower agrees that, following the delivery of any Collateral Documents required to be executed and delivered by this Section, the Administrative Agent shall have a valid and enforceable, first priority perfected Lien on the property required to be pledged pursuant to subsections (a) and (b) of this Section (to the extent that such Lien can be perfected by execution, delivery and&#47;or recording of the Collateral Documents or UCC financing statements, or possession of such Collateral), free and clear of all Liens other than Liens expressly permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All actions to be taken pursuant to this Section shall be at the expense of the Borrower or the applicable Loan Party, and shall be taken to the reasonable satisfaction of the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Additional Real Estate&#59; Leased Locations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To the extent otherwise permitted hereunder, if any Loan Party proposes to acquire a fee ownership interest in Real Estate after the Closing Date having a fair market value in excess of $7,500,000 as of the date of the acquisition thereof, it shall at the time of such acquisition provide to the Administrative Agent Real Estate Documents in regard to such Real Estate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Borrower will, and will cause each other Loan Party to, execute any and all further documents, financing statements, agreements and instruments, and take all such further actions (including the filing and recording of financing statements, fixture filings, Mortgages and other documents), which may be required under any applicable law, or which the Administrative Agent or the Required Lenders may reasonably request, to effectuate the transactions contemplated by the Loan Documents or to grant, preserve, protect or perfect the Liens created by the Collateral Documents or the validity or priority of any such Lien, all at the expense of the Loan Parties. The Borrower also agrees to provide to the Administrative Agent, from time to time upon request, evidence reasonably satisfactory </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">92</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to the Administrative Agent as to the perfection and priority of the Liens created or intended to be created by the Collateral Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Healthcare Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will, and will cause each of its Subsidiaries  to (and, to the extent permitted by applicable law, cause the Associated Practices to), (i) comply in all material respects with all applicable Healthcare Laws relating to the operation of its business, (ii) obtain, maintain and timely renew all material Healthcare Permits required in the proper conduct of its business, (iii) keep and maintain all records required to be maintained by any Governmental Authority or under any Healthcare Law, and (iv) maintain a corporate and health care regulatory compliance program that addresses the requirements of Healthcare Laws, except where the failure to comply, obtain, keep and maintain could not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Associated Practice Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower will, and will cause each of its Subsidiaries to, enforce all of its rights under each Associated Practice Document, in each case, where the failure to do so could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, subject to limitations, in the reasonable judgment of Borrower, in consultation with its healthcare counsel, under applicable laws&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any management fees payable under any Associated Practice Document may be subordinated and&#47;or the payment of such management fees may be deferred, in each case, to the extent that the Borrower in good faith deems it advisable in order to satisfy any regulation by any Governmental Authority having jurisdiction over the parties to such Associated Practice Document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower will, and will cause each of its Subsidiaries to, deliver and collaterally assign to the Administrative Agent each Associated Practice Document entered into after the Closing Date, for the benefit of the Secured Parties, pursuant to a Collateral Assignment, subject to any limitations under applicable law, to be delivered to the Administrative Agent within 21 days after the applicable Associated Practice Document is entered into.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 5.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Closing Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower shall satisfy the requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 5.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and deliver to the Administrative Agent satisfactory evidence of the same, on or before the date specified for such requirement (or such later date as may be agreed in writing to by the Administrative Agent in its sole discretion).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>FINANCIAL COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until the Commitments have expired or been terminated and all Obligations have been paid in full and all Letters of Credit shall have expired or terminated, in each case without any pending draw, or all such Letters of Credit shall have been cash collateralized to the satisfaction of each Issuing Bank, and all LC Disbursements shall have been reimbursed, the Borrower covenants and agrees with the Lenders that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Total Net Leverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will maintain, as of the end of each Fiscal Quarter, commencing with the Fiscal Quarter ending on June 30, 2021, a Consolidated Total Net Leverage Ratio of not greater than 3.75&#58;1.00&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that for any Fiscal Quarter during which a Loan Party has consummated a Permitted Acquisition or Future Approved Entity Investment permitted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">93</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">hereunder in which the Investment Consideration payable in connection with such Permitted Acquisition or Future Approved Entity Investment was greater than $75,000,000 (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Trigger Quarter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the Consolidated Total Net Leverage Ratio for such Trigger Quarter and the next succeeding three Fiscal Quarters shall be increased by 0.25&#58;1.00 to 4.00&#58;1.00 (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Covenant Holiday</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). For the avoidance of doubt, the Consolidated Total Net Leverage Ratio shall revert to 3.75&#58;1.00 commencing with the fourth Fiscal Quarter ending after any such initial Trigger Quarter.  After the completion of any Covenant Holiday, no subsequent new Trigger Quarter shall be permitted to occur for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> unless and until the Borrower shall demonstrate compliance with the Consolidated Total Net Leverage Ratio (absent any Covenant Holiday) as of the end of at least one Fiscal Quarter after any such Covenant Holiday&#8217;s completion.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Consolidated Interest Coverage Ratio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Borrower will maintain, as of the end of each Fiscal Quarter, commencing with the Fiscal Quarter ending on June 30, 2021, a Consolidated Interest Coverage Ratio of not less than 3.25&#58;1.00.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>NEGATIVE COVENANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Until the Commitments have expired or been terminated and all Obligations have been paid in full and all Letters of Credit shall have expired or terminated, in each case without any pending draw, or all such Letters of Credit shall have been cash collateralized to the satisfaction of each Issuing Bank, and all LC Disbursements shall have been reimbursed, the Borrower covenants and agrees with the Lenders that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Indebtedness and Preferred Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to and, to the extent permitted by applicable law, the Borrower will use commercially reasonable efforts to cause the Material Associated Practices not to, create, incur, assume or suffer to exist any Indebtedness, except&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Indebtedness created pursuant to the Loan Documents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Indebtedness existing on the Closing Date and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and extensions, renewals and replacements of any such Indebtedness that do not increase the outstanding principal amount thereof (immediately prior to giving effect to such extension, renewal or replacement) or shorten the maturity or the weighted average life thereof&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Indebtedness of the Borrower, any of its Subsidiaries or any Material Associated Practice incurred to finance the acquisition, construction or improvement of any fixed or capital assets, including Capital Lease Obligations, and any Indebtedness assumed in connection with the acquisition of any such assets or secured by a Lien on any such assets prior to the acquisition thereof (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such Indebtedness is incurred prior to or within 90 days after such acquisition or the completion of such construction or improvements), and extensions, renewals or replacements of any such Indebtedness that do not increase the outstanding principal amount thereof (immediately prior to giving effect to such extension, renewal or replacement) or shorten the maturity or the weighted average life thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the aggregate principal amount of such Indebtedness does not exceed $35,000,000 at any time outstanding&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">94</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Indebtedness of the Borrower owing to any Subsidiary and of any Subsidiary owing to the Borrower or any other Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any such Indebtedness that is owed by or to a Subsidiary that is not a Subsidiary Loan Party shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Guarantees by the Borrower of Indebtedness of any Subsidiary and by any Subsidiary of Indebtedness of the Borrower or any other Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that Guarantees by any Loan Party of Indebtedness of any Subsidiary that is not a Subsidiary Loan Party shall be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Indebtedness of any Person which becomes a Subsidiary or Material Associated Practice after the date of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) such Indebtedness exists at the time that such Person becomes a Subsidiary and is not created in contemplation of or in connection with such Person becoming a Subsidiary, and (ii) the aggregate principal amount of such Indebtedness permitted hereunder shall not exceed $30,000,000 at any time outstanding&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Indebtedness consisting of Investments to the extent permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Indebtedness of any Associated Practice to a Loan Party or a Material Associated Practice&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Hedging Obligations permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;unsecured Indebtedness arising from agreements of the Borrower, any of its Subsidiaries or any Material Associated Practice providing for indemnification, adjustment of purchase price, working capital adjustments or other deferred purchase price consideration (including earn-out obligations), in each case, whether or not evidenced by a note and&#47;or whether contingent or otherwise, and incurred or assumed in connection with any Permitted Acquisition or any Investment permitted under this Agreement (any such obligations, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Deferred Acquisition Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) so long as the aggregate amount of such Indebtedness does not at any time exceed $40,000,000&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Indebtedness incurred in favor of insurance companies (or their financing affiliates) in connection with the financing of insurance premiums in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Indebtedness in respect of netting services, overdraft protections and otherwise in connection with deposit accounts to the extent incurred in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;obligations in respect of surety, stay, customs and appeal bonds, bid or performance bonds and performance and completion guaranties and obligations of a like nature (including letters of credit-related thereto), worker&#8217;s compensation claims, health, disability or other employee benefits or property, casualty or liability insurance or self-insurance obligations, trade contracts, governmental contracts and leases, in each case incurred in the ordinary course of business and not in connection with the borrowing of money&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;to the extent constituting Indebtedness, deposits and advance payments received from customers in the ordinary course of business consistent with past practices&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;to the extent constituting Indebtedness, bonus or other deferred compensation arrangements with respect to officers, directors, employees or consultants of the Borrower, any of its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">95</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsidiaries or any Material Associated Practice solely in their capacities as such that is paid in the ordinary course of business and consistent with past practices&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;non-cash accruals of interest, accretion or amortization of original issue discount and&#47;or pay-in-kind interest with respect to Indebtedness otherwise permitted under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;Indebtedness of any Regulated Entity owing to any Loan Party&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;so long as no Event of Default has occurred and is continuing at the time of the incurrence thereof, APC Non-Recourse Indebtedness&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;Indebtedness pursuant to the AP-AMH Loan Documents&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;other unsecured Indebtedness of the Borrower, any of its Subsidiaries or any Material Associated Practice in an aggregate principal amount not to exceed $20,000,000 at any time outstanding&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;other unsecured Indebtedness of any Loan Party (not including, for the avoidance of doubt, APC, any other Associated Practice, or any Subsidiary that is not a Loan Party) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (i) before and after giving effect to the incurrence of any such unsecured Indebtedness, no Default or Event of Default has occurred and is continuing, (ii) the Borrower shall have delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer demonstrating that after giving effect to the proposed incurrence and&#47;or funding, the Consolidated Total Net Leverage Ratio is less than 3.50&#58;1.00, measuring Consolidated Total Net Debt for purposes of Section 6.1 as of the date of such incurrence and otherwise recomputing such covenants as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Indebtedness had been incurred, (iii) the maturity date of such unsecured Indebtedness is no earlier than 180 days after the Revolving Commitment Termination Date and (iv) the restrictions and covenants set forth in any documentation evidencing such unsecured Indebtedness are not more restrictive than those in effect under this Agreement as of the Closing Date&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;other Indebtedness incurred by APC (or any special purpose vehicle owned by APC) to finance the acquisition, construction or improvement of Real Estate </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (i) the Borrower shall have delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer demonstrating that after giving effect to the proposed incurrence, the Consolidated Total Net Leverage Ratio is less than 1.75&#58;1.00, measuring Consolidated Total Net Debt for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the date of such incurrence and otherwise recomputing such covenants as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Indebtedness had been incurred, (ii) such Real Estate constitutes APC Excluded Assets and the Investment in such Real Estate is made solely using APC Excluded Assets, (iii) before and after giving effect to the incurrence of any such unsecured Indebtedness, no Default or Event of Default has occurred and is continuing and (iv) the Indebtedness incurred does not exceed the cost of acquiring, constructing or improving the applicable Real Estate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Borrower will not, and will not permit any Subsidiary to, issue any preferred stock or other preferred equity interest that (i) matures or is mandatorily redeemable pursuant to a sinking fund obligation or otherwise, (ii) is or may become redeemable or repurchaseable by the Borrower or such Subsidiary at the option of the holder thereof, in whole or in part, or (iii) is convertible or exchangeable at the option of the holder thereof for Indebtedness or preferred stock or any other preferred equity interest described in this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">96</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">paragraph, on or prior to, in the case of clause (i), (ii) or (iii), the first anniversary of the Revolving Commitment Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Liens&#59; Negative Pledge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Borrower will not, and will not permit any of its Subsidiaries to and, to the extent permitted by applicable law, the Borrower will use commercially reasonable efforts to cause the Material Associated Practices not to, create, incur, assume or suffer to exist any Lien on any of its assets or property now owned or hereafter acquired, except&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Liens securing the Obligations&#59; provided that no Liens may secure Hedging Obligations or Bank Product Obligations without securing all other Obligations on a basis at least pari passu with such Hedging Obligations or Bank Product Obligations and subject to the priority of payments set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Permitted Encumbrances&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Liens on any property or asset of the Borrower, any of its Subsidiaries or any Material Associated Practice existing on the date hereof and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such Liens shall not apply to any other property or asset of such Person&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;purchase money Liens upon or in any fixed or capital assets to secure the purchase price or the cost of construction or improvement of such fixed or capital assets or to secure Indebtedness incurred solely for the purpose of financing the acquisition, construction or improvement of such fixed or capital assets (including Liens securing any Capital Lease Obligations)&#59; provided that (i) such Lien secures Indebtedness permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), (ii)&#160;such Lien attaches to such asset concurrently or within 90 days after the acquisition or the completion of the construction or improvements thereof, (iii) such Lien does not extend to any other asset, and (iv) the Indebtedness secured thereby does not exceed the cost of acquiring, constructing or improving such fixed or capital assets&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;any Lien (x) existing on any asset of any Person at the time such Person becomes a Subsidiary of the Borrower, (y) existing on any asset of any Person at the time such Person is merged with or into the Borrower or any of its Subsidiaries, or (z) existing on any asset prior to the acquisition thereof by the Borrower, any of its Subsidiaries or any Material Associated Practice, as the case may be&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) any such Lien was not created in the contemplation of any of the foregoing and (ii) any such Lien secures only those obligations which it secures on the date that such Person becomes a Subsidiary or Material Associated Practice, as the case may be, or the date of such merger or the date of such acquisition&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;extensions, renewals, or replacements of any Lien referred to in subsections (b) through (e) of this Section&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the principal amount of the Indebtedness secured thereby is not increased and that any such extension, renewal or replacement is limited to the assets originally encumbered thereby&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;Liens granted by any Material Associated Practice in favor of any Loan Party securing such Material Associated Practice&#8217;s obligations to such Loan Party pursuant to any Associated Practice Documents&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;Liens granted by APC on APC Excluded Assets to secure APC Non-Recourse Indebtedness&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">97</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Liens granted pursuant to the AP-AMH Loan Documents&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;other Liens not specifically listed above securing other obligations in an aggregate amount not to exceed $20,000,000 at any time outstanding&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Liens to secure Indebtedness incurred by APC solely for the purpose of financing the acquisition, construction or improvement of Real Estate&#59; provided that (i) such Liens only secure Indebtedness permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(v</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), (ii)&#160;such Lien attaches to such Real Estate concurrently or within 90 days after the acquisition or the completion of the construction or improvements thereof and (iii) such Lien does not extend to any other asset. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that notwithstanding anything to the contrary contained herein, at no time shall any Lien in favor of any Person (other than the Lien in favor of the Administrative Agent created under the Loan Documents) be permitted on any Collateral consisting of the Borrower&#8217;s interests and rights under (A) the AP-AMH Loan Documents or (B) any other similarly structured Investment by any Loan Party (including any Future Approved Entity Investment) permitted hereunder. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary contained herein, at no time shall any Lien in favor of any Person be permitted on any Real Estate (other than with respect to Liens (1) of the type set forth in clauses (i), (ii), (v) and (vii) of the definition of &#8220;Permitted Encumbrance&#8221;, (2) on any APC Excluded Assets and (3) securing the Obligations).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Fundamental Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower will not, and will not permit any of its Subsidiaries to, merge into or consolidate into any other Person, or permit any other Person to merge into or consolidate with it, or sell, lease, transfer or otherwise dispose of (in a single transaction or a series of transactions) all or substantially all of its assets (in each case, whether now owned or hereafter acquired) or all or substantially all of the stock of any of its Subsidiaries (in each case, whether now owned or hereafter acquired) or liquidate or dissolve&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that if, at the time thereof and immediately after giving effect thereto, no Default or Event of Default shall have occurred and be continuing&#58; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Borrower or any Subsidiary may merge with a Person if the Borrower (or such Subsidiary if the Borrower is not a party to such merger) is the surviving Person, </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;any Subsidiary may merge into another Subsidiary, provided that if any party to such merger is a Subsidiary Loan Party, a Subsidiary Loan Party shall be the surviving Person, </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any Subsidiary may sell, transfer, lease or otherwise dispose of all or substantially all of its assets to the Borrower or to a Subsidiary Loan Party, and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;any Subsidiary (other than a Subsidiary Loan Party) may liquidate or dissolve if the Borrower determines in good faith that such liquidation or dissolution is in the best interests of the Borrower and is not materially disadvantageous to the Lenders&#59; </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that any such merger involving a Person that is not a wholly owned Subsidiary immediately prior to such merger shall not be permitted unless also permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">98</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower will not, and will not permit any of its Subsidiaries to, engage in any business other than businesses of the type conducted by the Borrower and its Subsidiaries on the date hereof and businesses reasonably related or ancillary thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Investments, Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to and, to the extent permitted by applicable law, the Borrower will use commercially reasonable efforts to cause the Material Associated Practices not to, purchase, hold or acquire (including pursuant to any merger with any Person that was not a wholly owned Subsidiary prior to such merger) any Capital Stock, evidence of Indebtedness or other securities (including any option, warrant, or other right to acquire any of the foregoing) of, make or permit to exist any capital contributions, loans or advances to, Guarantee any obligations of, or make or permit to exist any investment or any other interest in, any other Person, or purchase or otherwise acquire (in one transaction or a series of transactions) all or substantially all of the assets of a Person, or any assets of any other Person that constitute a business unit or division of any other Person, or create or form any Subsidiary (all of the foregoing being collectively called &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), except&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Investments (other than Permitted Investments) existing on the date hereof and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (including Investments in Subsidiaries)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Permitted Investments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Guarantees by the Borrower and its Subsidiaries constituting Indebtedness permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (other than APC Non-Recourse Indebtedness and Indebtedness permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the aggregate principal amount of Indebtedness of Subsidiaries that are not Subsidiary Loan Parties that is Guaranteed by any Loan Party shall be subject to the limitation set forth in subsection (d) of this Section&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Investments made by the Borrower in or to any Subsidiary and by any Subsidiary to the Borrower or in or to another Subsidiary&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the aggregate amount of Investments by the Loan Parties in or to, and Guarantees by the Loan Parties of Indebtedness of, any Subsidiary that is not a Subsidiary Loan Party (including all such Investments and Guarantees existing on the Closing Date) shall not exceed $20,000,000 at any time outstanding&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;loans or advances to employees, officers or directors of the Borrower or any of its Subsidiaries in the ordinary course of business for travel, relocation and related expenses&#59; provided that the aggregate amount of all such loans and advances does not exceed $2,500,000 at any time outstanding&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Hedging Transactions permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;loans to Associated Practices pursuant to any Associated Practice Documents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;the AP-AMH Loan Documents&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Permitted Acquisitions&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;Future Approved Entity Investments in an aggregate amount not to exceed $150,000,000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (i) the Approved Entity substantially concurrently uses all of the proceeds of the Future Approved Entity Investment to acquire Capital Stock in or all or substantially all of the assets of APC or another Material Associated Practice pursuant to which the net economic benefit of such acquisition is wholly transferred to such Approved Entity through such Approved Entity&#8217;s ownership of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">99</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Capital Stock in or assets of APC or such other Material Associated Practice, (ii) the Administrative Agent receives collateral security in respect of such Investment that is substantially similar (and no less favorable to the Administrative Agent, including, for the avoidance of doubt, a Collateral Assignment and designation as an &#8220;additional secured party&#8221;) to the AP-AMH Loan, (iii) before and after giving effect to any such Future Approved Entity Investment, no Default or Event of Default has occurred and is continuing and (iv) the Borrower shall have delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer at least 5 days prior to the date of the consummation of such Future Approved Entity Investment demonstrating that on a Pro Forma Basis after giving effect to any such Future Approved Entity Investment, the Borrower is in compliance with each of the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, measuring Consolidated Total Net Debt for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the date of such Future Approved Entity Investment and otherwise recomputing the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Future Approved Entity Investment had occurred&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;Investments from the Borrower to AP-AMH to fund loans or capital contributions by AP-AMH to APC pursuant to Section 1.2(c) of the APC Shareholder Agreement so long as the aggregate amount funded does not exceed $15,000,000 at any time outstanding&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, notwithstanding the foregoing cap, additional Investments may be made under this clause (k) so long</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) before and after giving effect to any such Investment, no Default or Event of Default has occurred and is continuing and (ii) the Borrower has delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer demonstrating that the Consolidated Total Net Leverage Ratio is less than 2.00&#58;1.00, measuring Consolidated Total Net Debt for purposes thereof as of the date of any such Investment and otherwise recomputing such calculation of the Consolidated Total Net Leverage Ratio in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Investment had occurred&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;Investments by (x) any Loan Party in or to one or more Associated Practices and (y) an Associated Practice in or to one or more other Associated Practices in an aggregate amount (collectively between clauses (x) and (y)) not to exceed $40,000,000 (exclusive of other Investments permitted in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) at any time outstanding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (i) before and after giving effect to any such Investment, no Default or Event of Default has occurred and is continuing and (ii) the Borrower shall have delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer at least 5 days prior to the date of the consummation of such Investment demonstrating that on a Pro Forma Basis after giving effect to any such Investment, the Borrower is in compliance with each of the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, measuring Consolidated Total Net Debt for purposes of Section 6.1 as of the date of such Investment and otherwise recomputing such covenants as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Investment had occurred)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the extent the proceeds of an Investment permitted pursuant to clause (x) immediately above are used substantially concurrently to make an Investment under clause (y) immediately above, such Investments will be deemed to be a single Investment for purposes of the $40,000,000 limitation under this clause (l)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;Investments by a Material Associated Practice in or to another Material Associated Practice&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;Investments by APC using any of the APC Excluded Assets (including to fund the purchase of assets that, upon the consummation of such purchase, become APC Excluded Assets)&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">100</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;the purchase by AP-AMH of Series A Preferred Stock of APC on the Original Closing Date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;the purchase by APC on the Original Closing Date of common Capital Stock of the Borrower in connection with the APC 2019 Transactions&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;the acquisition by APC of Capital Stock of the Borrower using excess revenue not required to be distributed to the holders of its Series A Preferred Stock pursuant to the Certificate of Determination&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;the acquisition by APC of Capital Stock of the Borrower without consideration (to include, for example, receipt of Capital Stock of the Borrower as a result of a stock split)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;Investments by APC or a Material Associated Practice in the Borrower in connection with a Future Approved Entity Investment&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;other Investments which do not exceed $20,000,000 in the aggregate amount at any time outstanding&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(u)&#160;&#160;&#160;&#160;Investments by a Loan Party in the Capital Stock of a Person that does not result in such Person becoming a &#8220;Subsidiary&#8221; of any Loan Party </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (i) before and after giving effect to any such Investment, no Default or Event of Default has occurred and is continuing and (ii) the aggregate amount of such Investments does not to exceed $20,000,000 at any time outstanding&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;Investments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (i) the Borrower shall have delivered to the Administrative Agent a Compliance Certificate signed by a Responsible Officer demonstrating that after giving effect to the proposed Investment on a Pro Forma Basis, the Consolidated Total Net Leverage Ratio is less than 1.75&#58;1.00, measuring Consolidated Total Net Debt for purposes of Section 6.1 as of the date of such Investment and otherwise recomputing such covenants as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Investment had occurred and (ii) before and after giving effect to any such Investment no Default or Event of Default has occurred and is continuing&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(w)&#160;&#160;&#160;&#160;Guarantees by APC of Indebtedness incurred by a special purpose vehicle owned by APC under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.1(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(x)&#160;&#160;&#160;&#160;a one-time Investment by the Borrower in a minority share of the outstanding Capital Stock of an independent practice association based in the State of New York</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (i) the Borrower shall have delivered to the Administrative Agent (prior to the consummation of such Investment) a Compliance Certificate signed by a Responsible Officer demonstrating that after giving effect to such proposed Investment on a Pro Forma Basis, the Consolidated Total Net Leverage Ratio is less than 2.50&#58;1.00, measuring Consolidated Total Net Debt for purposes of Section 6.1 as of the date of such Investment and otherwise recomputing such covenants as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Investment had occurred, (ii) before and after giving effect to such Investment no Default or Event of Default has occurred and is continuing and (iii) the Borrower uses commercially reasonable efforts (which shall include the Borrower&#8217;s pursuit of any amendments to the shareholder&#8217;s agreement of the target, as the case may require) to cause the Capital Stock acquired to be pledged in favor of the Administrative Agent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">101</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For purposes of determining the amount of any Investment outstanding for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, such amount shall be deemed to be the amount of such Investment when made, purchased or acquired less any amount realized in respect of such Investment upon the sale, collection or return of capital (not to exceed the original amount invested).  For the avoidance of doubt, any deferral of or subordination of management fees payable under any Associated Practice Document that is in good faith deemed advisable by the Borrower in order to satisfy any regulation by any Governmental Authority having jurisdiction over the parties to such Associated Practice Documents shall not constitute an Investment.  Notwithstanding anything to the contrary in this Credit Agreement, the exercise by any Loan Party of its rights under any Transfer Restriction Agreement shall not constitute an Investment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Restricted Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment, except&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;dividends payable by the Borrower solely in interests of any class of its common equity&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any Subsidiary of the Borrower may declare and pay dividends or make other distributions to the Borrower or any Guarantor&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Restricted Payments made by any Subsidiary to the Borrower or to another Subsidiary, on at least a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> basis with any other shareholders if such Subsidiary is not wholly owned by the Borrower and other wholly owned Subsidiaries of the Borrower&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Restricted Payments in an amount not to exceed $20,000,000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) before and after giving effect to any such Restricted Payment, no Default or Event of Default has occurred and is continuing and (ii) the Borrower shall have delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer demonstrating that on a pro forma basis after giving effect to any such Restricted Payment, the Borrower is in compliance with each of the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, measuring Consolidated Total Net Debt for purposes of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the date of any such Restricted Payment and otherwise recomputing the covenants set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article&#160;VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Restricted Payment had occurred&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;other Restricted Payments </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">so long as</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) before and after giving effect to any such Restricted Payment, no Default or Event of Default has occurred and is continuing and (ii) the Borrower has delivered to the Administrative Agent a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro forma </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Compliance Certificate signed by a Responsible Officer demonstrating that the Consolidated Total Net Leverage Ratio is less than 1.50&#58;1.00, measuring Consolidated Total Net Debt for purposes thereof as of the date of any such Restricted Payment and otherwise recomputing such calculation of the Consolidated Total Net Leverage Ratio in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as of the last day of the most recently ended Fiscal Quarter for which financial statements are required to have been delivered pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as if such Restricted Payment had occurred. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Sale of Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The Borrower will not, and will not permit any of its Subsidiaries to, convey, sell, lease, assign, transfer or otherwise dispose of any of its assets, business or property or, in the case of any Subsidiary, any shares of such Subsidiary&#8217;s Capital Stock, in each case whether now owned or hereafter acquired, to any Person other than a Loan Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(or to qualify directors if required by applicable law), except&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">102</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the sale or other disposition for fair market value of obsolete or worn out property or other property not necessary for operations disposed of in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the sale of inventory and Permitted Investments in the ordinary course of business&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the disposition of equipment or real property to the extent that (i) such property is exchanged for credit against the purchase price of similar replacement property or (ii) the proceeds of such disposition are reasonably promptly applied to the purchase price of such replacement property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the non-exclusive license or sublicense of intellectual property in the ordinary course of business and not interfering in any material respect with the ordinary conduct of business of the Loan Parties or pursuant to the Tradename Licensing Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;the disposition of cash or cash equivalents in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;the termination or assignment of leased office locations in the ordinary course of business&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the disposition of accounts receivable in the ordinary course of business in connection with the collection or compromise thereof&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;the sale or other disposition of such assets in an aggregate amount based on the fair market value of such assets not to exceed $15,000,000 in any Fiscal Year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Transactions with Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, sell, lease or otherwise transfer any property or assets to, or purchase, lease or otherwise acquire any property or assets from, or otherwise engage in any other transactions with, any of its Affiliates, except&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;in the ordinary course of business at prices and on terms and conditions not less favorable to the Borrower or such Subsidiary than could be obtained on an arm&#8217;s-length basis from unrelated third parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;transactions between or among the Borrower and any Subsidiary Loan Party not involving any other Affiliates&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any transactions approved or permitted by the Borrower&#8217;s &#8220;Related Party Transaction Policy&#8221; so long as such transaction is at prices and on terms and conditions not less favorable to the Borrower or such Subsidiary than could be obtained on an arm&#8217;s-length basis from unrelated third parties&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;any transactions existing as of the date hereof and set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;cash or equity compensation payable to directors and officers of the Borrower or any of its Subsidiaries in the ordinary course of business or as otherwise approved by the Borrower&#8217;s board of directors&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;any Restricted Payment permitted by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">103</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Restrictive Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur or permit to exist any agreement that prohibits, restricts or imposes any condition upon (a) the ability of the Borrower or any of its Subsidiaries to create, incur or permit any Lien upon any of its assets or properties, whether now owned or hereafter acquired, or (b) the ability of any of its Subsidiaries to pay dividends or other distributions with respect to its Capital Stock, to make or repay loans or advances to the Borrower or any other Subsidiary thereof, to Guarantee Indebtedness of the Borrower or any other Subsidiary thereof or to transfer any of its property or assets to the Borrower or any other Subsidiary thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that (i) the foregoing shall not apply to restrictions or conditions imposed by law or by this Agreement or any other Loan Document, (ii) the foregoing shall not apply to customary restrictions and conditions contained in agreements relating to the sale of a Subsidiary pending such sale, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> such restrictions and conditions apply only to the Subsidiary that is sold and such sale is permitted hereunder, (iii) clause (a) shall not apply to restrictions or conditions imposed by any agreement relating to secured Indebtedness permitted by this Agreement if such restrictions and conditions apply only to the property or assets securing such Indebtedness and (iv)&#160;clause (a) shall not apply to customary provisions in leases restricting the assignment thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Sale and Leaseback Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, enter into any arrangement, directly or indirectly, whereby it shall sell or transfer any property, real or personal, used or useful in its business, whether now owned or hereinafter acquired, and thereafter rent or lease such property or other property that it intends to use for substantially the same purpose or purposes as the property sold or transferred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Hedging Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, enter into any Hedging Transaction, other than Hedging Transactions entered into in the ordinary course of business to hedge or mitigate risks to which the Borrower or any of its Subsidiaries is exposed in the conduct of its business or the management of its liabilities. Solely for the avoidance of doubt, the Borrower acknowledges that a Hedging Transaction entered into for speculative purposes or of a speculative nature (which shall be deemed to include any Hedging Transaction under which the Borrower or any of its Subsidiaries is or may become obliged to make any payment (i) in connection with the purchase by any third party of any Capital Stock or any Indebtedness or (ii) as a result of changes in the market value of any Capital Stock or any Indebtedness) is not a Hedging Transaction entered into in the ordinary course of business to hedge or mitigate risks.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Amendment to Material Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, amend, modify or waive any of its rights under (a) its certificate of incorporation, bylaws or other organizational documents, (b) any Material Agreements (other than (i) subject to the last sentence of this Section 7.11, the AP-AMH Loan Documents or any other similar documents in connection with a Future Approved Entity Investment and (ii) any agreements between a Regulated Entity and any Third Party Payor) or (c) any Associated Practice Documents between APC and a Loan Party or Alpha Care and a Loan Party (other than as may be required by applicable law) or (d) any other Associated Practice Documents that account for in excess of 10% of the total revenue of the Borrower and its Subsidiaries (other than as may be required by applicable law), in each case if the effect of such amendment, modification or waiver would have an adverse effect in any material respect on the Lenders, the Administrative Agent, the Borrower or any of its Subsidiaries&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that any management fees payable under any Associated Practice Document may be subordinated and&#47;or the payment of such management fees may be deferred, in each case, to the extent deemed by the Borrower in good faith to be advisable in order to satisfy any regulation by any Governmental Authority having jurisdiction over the parties to such Associated Practice Document. The Borrower will not, and will not permit any of its Subsidiaries to, amend, modify or waive any of its rights under the AP-AMH Loan </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">104</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Documents or any other similar documents in connection with a Future Approved Entity Investment other than to (A) increase the interest rate on any such loan or (B) extend the maturity date of any such loan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Associated Practice Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">The Borrower will not, and will not permit any of its Subsidiaries to, enter into any Management Services Agreement with any Associated Practice after the Closing Date unless&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Borrower shall have given Administrative Agent at least five (5) Business Days&#8217; prior written notice (or such lesser notice as Administrative Agent may agree in its sole discretion) of any Loan Party entering into such Management Services Agreement and Borrower shall have delivered to Administrative Agent a copy of the draft Management Services Agreement prior to its execution and delivery&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the form of such Management Services Agreement shall be substantially similar to a form approved by Administrative Agent, which, in each case, shall provide that such Management Services Agreement is freely assignable or collaterally assignable to the Administrative Agent by such Loan Party, without any further consent of, or notice to, any other Person (including, without limitation, the Associated Practice party thereto)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;such fully executed Management Services Agreement is delivered and collaterally assigned to Administrative Agent pursuant to a Collateral Assignment within fifteen (15) days following the execution of such Management Services Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in this Agreement, the Borrower and each other Loan Party shall be permitted to make such changes to the structure, contractual agreements, and other aspects of its relationship with any Associated Practice as it may deem in good faith in consultation with its healthcare counsel to be necessary to comply with applicable Requirements of Law or the Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Accounting Changes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, make any significant change in accounting treatment or reporting practices, except as required by GAAP, or change the fiscal year of the Borrower or of any of its Subsidiaries, except to change the fiscal year of a Subsidiary to conform its fiscal year to that of the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Sanctions and Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any Subsidiary to, request any Loan or Letter of Credit or, directly or indirectly, use the proceeds of any Loan or any Letter of Credit, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other Person (i) to fund any activities or business of or with any Person, or in any country or territory, that, at the time of such funding, is, or whose government is, the subject of Sanctions, (ii) in any other manner that would result in a violation of Sanctions by any Person (including any Person participating in the Loans or Letters of Credit, whether as an Arranger, the Administrative Agent, any Lender (including a Swingline Lender), any Issuing Bank, underwriter, advisor, investor or otherwise), or (iii) in furtherance of an offer, payment , promise to pay or authorization of the payment or giving of money or anything else of value to any Person in violation of applicable Anti-Corruption Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 7.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Lease Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower will not, and will not permit any of its Subsidiaries to, create or suffer to exist any obligations for the payment under operating leases or agreements to lease (but excluding any obligations under leases required to be classified as capital leases under GAAP having a term of five years or more) which would cause the present value of the direct or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">105</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contingent liabilities of the Borrower and its Subsidiaries under such leases or agreements to lease, on a consolidated basis, to exceed $15,000,000 in the aggregate in any Fiscal Year.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>EVENTS OF DEFAULT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Events of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If any of the following events (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) shall occur&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Borrower shall fail to pay any principal of any Loan or of any reimbursement obligation in respect of any LC Disbursement, when and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment or otherwise&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Borrower shall fail to pay any interest on any Loan or any fee or any other amount (other than an amount payable under subsection (a) of this Section or an amount related to a Bank Product Obligation) payable under this Agreement or any other Loan Document, when and as the same shall become due and payable, and such failure shall continue unremedied for a period of five (5) Business Days&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;any representation or warranty made or deemed made by or on behalf of the Borrower or any of its Subsidiaries in or in connection with this Agreement or any other Loan Document (including the Schedules attached hereto and thereto), or in any amendments or modifications hereof or waivers hereunder, or in any certificate, report, financial statement or other document submitted to the Administrative Agent or the Lenders by any Loan Party or any representative of any Loan Party pursuant to or in connection with this Agreement or any other Loan Document shall prove to be incorrect in any material respect (other than any representation or warranty that is expressly qualified by a Material Adverse Effect or other materiality, in which case such representation or warranty shall prove to be incorrect in any respect) when made or deemed made or submitted&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Borrower shall fail to observe or perform any covenant or agreement contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline"> 5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (with respect to the Borrower&#8217;s legal existence) or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article VI </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;any Loan Party shall fail to observe or perform any covenant or agreement contained in this Agreement (other than those referred to in subsections (a), (b) and (d) of this Section) or any other Loan Document or related to any Bank Product Obligation, and such failure shall remain unremedied for 30 days after the earlier of (i) any officer of the Borrower becomes aware of such failure, or (ii) notice thereof shall have been given to the Borrower by the Administrative Agent or any Lender&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;(i) the Borrower or any of its Subsidiaries (whether as primary obligor or as guarantor or other surety) shall fail to pay any principal of, or premium or interest on, any Material Indebtedness (other than any Hedging Obligation) that is outstanding, when and as the same shall become due and payable (whether at scheduled maturity, required prepayment, acceleration, demand or otherwise), and such failure shall continue after the applicable grace period, if any, specified in the agreement or instrument evidencing or governing such Indebtedness&#59; or any other event shall occur or condition shall exist under any agreement or instrument relating to any Material Indebtedness and shall continue after the applicable grace period, if any, specified in such agreement or instrument, if the effect of such event or condition is to accelerate, or permit the acceleration of, the maturity of such Indebtedness&#59; or any Material Indebtedness shall be declared to be due and payable, or required to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">106</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">prepaid or redeemed (other than by a regularly scheduled required prepayment or redemption), purchased or defeased, or any offer to prepay, redeem, purchase or defease such Indebtedness shall be required to be made, in each case prior to the stated maturity thereof or (ii) there occurs under any Hedging Transaction an Early Termination Date (as defined in such Hedge Transaction) resulting from (A) any event of default under such Hedging Transaction as to which the Borrower or any of its Subsidiaries is the Defaulting Party (as defined in such Hedging Transaction) and the Hedge Termination Value owed by the Borrower or such Subsidiary as a result thereof is greater than the Threshold Amount or (B) any Termination Event (as so defined) under such Hedging Transaction as to which the Borrower or any Subsidiary is an Affected Party (as so defined) and the Hedge Termination Value owed by the Borrower or such Subsidiary as a result thereof is greater than the Threshold Amount and is not paid&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the Borrower or any of its Subsidiaries shall (i) commence a voluntary case or other proceeding or file any petition seeking liquidation, reorganization or other relief under any federal, state or foreign bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a custodian, trustee, receiver, liquidator or other similar official of it or any substantial part of its property, (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or petition described in subsection (i) of this Section, (iii) apply for or consent to the appointment of a custodian, trustee, receiver, liquidator or other similar official for the Borrower or any such Subsidiary or for a substantial part of its assets, (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of creditors, or (vi) take any action for the purpose of effecting any of the foregoing&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;an involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking (i) liquidation, reorganization or other relief in respect of the Borrower or any of its Subsidiaries or its debts, or any substantial part of its assets, under any federal, state or foreign bankruptcy, insolvency or other similar law now or hereafter in effect or (ii) the appointment of a custodian, trustee, receiver, liquidator or other similar official for the Borrower or any of its Subsidiaries or for a substantial part of its assets, and in any such case, such proceeding or petition shall remain undismissed for a period of 60 days or an order or decree approving or ordering any of the foregoing shall be entered&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Borrower or any of its Subsidiaries shall become unable to pay, shall admit in writing its inability to pay, or shall fail to pay, its debts as they become due&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;(i) an ERISA Event shall have occurred that, in the opinion of the Required Lenders, when taken together with other ERISA Events that have occurred, could reasonably be expected to result in liability to the Borrower and its Subsidiaries in an aggregate amount exceeding $10,000,000, (ii) there is or arises an Unfunded Pension Liability (not taking into account Plans with negative Unfunded Pension Liability) in an aggregate amount exceeding $10,000,000, or (iii) there is or arises any potential Withdrawal Liability in an aggregate amount exceeding $10,000,000&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;any judgment, order for the payment of money, writ, warrant of attachment or similar process involving an amount in excess of $10,000,000 in the aggregate shall be rendered against the Borrower or any of its Subsidiaries, and either (i) enforcement proceedings shall have been commenced by any creditor upon such judgment or order or (ii) there shall be a period of 45 consecutive days during which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">107</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(l)&#160;&#160;&#160;&#160;any non-monetary judgment or order shall be rendered against the Borrower or any of its Subsidiaries that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect, and there shall be a period of 30 consecutive days during which a stay of enforcement of such judgment or order, by reason of a pending appeal or otherwise, shall not be in effect&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(m)&#160;&#160;&#160;&#160;a Change in Control shall occur or exist&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(n)&#160;&#160;&#160;&#160;any provision of the Guaranty and Security Agreement or any other Loan Document shall for any reason cease to be valid and binding on, or enforceable against, any Loan Party, or any Loan Party shall so state in writing, or any Loan Party shall seek to terminate its obligation under the Guaranty and Security Agreement or any other Loan Document (other than the release of any guaranty or collateral to the extent permitted pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(o)&#160;&#160;&#160;&#160;any Lien purported to be created under any Collateral Document shall fail or cease to be, or shall be asserted by any Loan Party not to be, a valid and perfected Lien on any Collateral, with the priority required by the applicable Collateral Documents&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(p)&#160;&#160;&#160;&#160;there shall occur (i) any revocation, suspension, termination, rescission, non-renewal or forfeiture or any similar final administrative action with respect to one or more Healthcare Permits or Third Party Payor Programs that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect or (ii) the Borrower or any of its Subsidiaries shall be named in any action, fully or partially unsealed, in which the United States has affirmatively intervened, alleging violation of the federal False Claims Act or any other applicable law and, in connection with such action, the Borrower shall have offered, agreed or paid to, or received a final judgment requiring payment to, any Governmental Authority for payment of any fine, penalty or overpayment in excess of $25,000,000&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(q)&#160;&#160;&#160;&#160;the occurrence of an &#8220;Event of Default&#8221; (as defined in the AP-AMH Loan Documents)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(r)&#160;&#160;&#160;&#160;(i) APC shall fail to make any dividend in cash in respect of the Series A Preferred Stock issued to AP-AMH on the Original Closing Date for any period of two consecutive fiscal quarters or (ii) AP-AMH shall fail to pay any cash interest payment to the Borrower, and such failure under either of clauses (i) or (ii) shall continue unremedied for a period of five (5) Business Days&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(s)&#160;&#160;&#160;&#160;any modification to the Certificate of Determination or APC Shareholder Agreement is effected that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred Dividend by APC to AP-AMH&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(t)&#160;&#160;&#160;&#160;APC shall use all or any portion of the consideration received by APC from AP-AMH in connection with the APC 2019 Transactions on account of AP-AMH&#8217;s purchase of the Series A Preferred Stock (including the cash and Capital Stock of the Borrower and&#47;or any proceeds from the sale or other disposition of such Capital Stock) for any purpose other than an APC Approved Use (each such other purpose, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Other APC Use</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), unless not less than 50.01% of all holders of common stock of APC at such time approve such Other APC Use&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the amount of &#8220;consideration received&#8221; by APC for purposes of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be deemed to be $545,000,000 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">less</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> any amounts used to pay off any existing Indebtedness of APC on the Original Closing Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that notwithstanding the foregoing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (t)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, APC may use up to $50,000,000 after the Closing Date in the aggregate of such consideration for any Other APC Use without any requirement to obtain such approval of the holders of common stock of APC (it being understood and agreed that any use that occurred prior to the Closing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">108</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date that was permitted under the Existing Credit Agreement shall not reduce such $50,000,000 threshold)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">then, and in every such event (other than an event with respect to the Borrower described in subsection (g) or (h) of this Section) and at any time thereafter during the continuance of such event, the Administrative Agent may, and upon the written request of the Required Lenders shall, by notice to the Borrower, take any or all of the following actions, at the same or different times&#58; (i) terminate the Commitments, whereupon the Commitment of each Lender shall terminate immediately, (ii) declare the principal of and any accrued interest on the Loans, and all other Obligations owing hereunder, to be, whereupon the same shall become, due and payable immediately, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower, (iii) exercise all remedies contained in any other Loan Document, and (iv) exercise any other remedies available at law or in equity&#59; provided that, if an Event of Default specified in either subsection (g) or (h) shall occur, the Commitments shall automatically terminate and the principal of the Loans then outstanding, together with accrued interest thereon, and all fees and all other Obligations shall automatically become due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Application of Proceeds from Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All proceeds from each sale of, or other realization upon, all or any part of the Collateral by any Secured Party after an Event of Default arises shall be applied as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the reimbursable expenses of the Administrative Agent incurred in connection with such sale or other realization upon the Collateral, until the same shall have been paid in full&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">second</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the fees, all amounts owed pursuant to Erroneous Payment Subrogation Rights, and other reimbursable expenses of the Administrative Agent, the Swingline Lender and the Issuing Banks then due and payable pursuant to any of the Loan Documents, until the same shall have been paid in full&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to all reimbursable expenses, if any, of the Lenders then due and payable pursuant to any of the Loan Documents, until the same shall have been paid in full&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">fourth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the fees and interest then due and payable under the terms of this Agreement, until the same shall have been paid in full&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">fifth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the aggregate outstanding principal amount of the Loans, the LC Exposure, the Bank Product Obligations and the Net Mark-to-Market Exposure of the Hedging Obligations that constitute Obligations, until the same shall have been paid in full, allocated </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> among the Secured Parties based on their respective </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shares of the aggregate amount of such Loans, LC Exposure, Bank Product Obligations and Net Mark-to-Market Exposure of such Hedging Obligations&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">sixth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to additional cash collateral for the aggregate amount of all outstanding Letters of Credit until the aggregate amount of all cash collateral held by the Administrative Agent pursuant to this Agreement is at least 105% of the LC Exposure after giving effect to the foregoing clause fifth&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">109</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">seventh</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the extent any proceeds remain, to the Borrower or as otherwise provided by a court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All amounts allocated pursuant to the foregoing clauses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">third</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> through </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">fifth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the Lenders as a result of amounts owed to the Lenders under the Loan Documents shall be allocated among, and distributed to, the Lenders </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> based on their respective Pro Rata Shares&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that all amounts allocated to that portion of the LC Exposure comprised of the aggregate undrawn amount of all outstanding Letters of Credit pursuant to clauses </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">fifth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">sixth</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be distributed to the Administrative Agent, rather than to the Lenders, and held by the Administrative Agent in an account in the name of the Administrative Agent for the benefit of the Issuing Banks and the Lenders as cash collateral for the LC Exposure, such account to be administered in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.22(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All cash collateral for LC Exposure shall be applied to satisfy drawings under the Letters of Credit as they occur&#59; if any amount remains on deposit on cash collateral after all letters of credit have either been fully drawn or expired, such remaining amount shall be applied to other Obligations, if any, in the order set forth above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, (a) no amount received from any Guarantor (including any proceeds of any sale of, or other realization upon, all or any part of the Collateral owned by such Guarantor) shall be applied to any Excluded Swap Obligation of such Guarantor and (b) Bank Product Obligations and Hedging Obligations shall be excluded from the application described above if the Administrative Agent has not received written notice thereof, together with such supporting documentation as the Administrative Agent may request, from the Bank Product Provider or the Lender-Related Hedge Provider, as the case may be. Each Bank Product Provider or Lender-Related Hedge Provider that has given the notice contemplated by the preceding sentence shall, by such notice, be deemed to have acknowledged and accepted the appointment of the Administrative Agent pursuant to the terms of Article IX hereof for itself and its Affiliates as if a &#8220;Lender&#8221; party hereto.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>THE ADMINISTRATIVE AGENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Appointment of the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Lender irrevocably appoints Truist Bank as the Administrative Agent and authorizes it to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent under this Agreement and the other Loan Documents, together with all such actions and powers that are reasonably incidental thereto. The Administrative Agent may perform any of its duties hereunder or under the other Loan Documents by or through any one or more sub-agents or attorneys-in-fact appointed by the Administrative Agent. The Administrative Agent and any such sub-agent or attorney-in-fact may perform any and all of its duties and exercise its rights and powers through their respective Related Parties. The exculpatory provisions set forth in this Article shall apply to any such sub-agent, attorney-in-fact or Related Party and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Each Issuing Bank shall act on behalf of the Lenders with respect to any Letters of Credit issued by it and the documents associated therewith until such time and except for so long as the Administrative Agent may agree at the request of the Required Lenders to act for such Issuing Bank with respect thereto&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such Issuing Bank shall have all the benefits and immunities (i) provided to the Administrative Agent in this Article with respect to any acts taken or omissions suffered by such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">110</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Issuing Bank in connection with Letters of Credit issued by it or proposed to be issued by it and the application and agreements for letters of credit pertaining to the Letters of Credit as fully as if the term &#8220;Administrative Agent&#8221; as used in this Article included such Issuing Bank with respect to such acts or omissions and (ii) as additionally provided in this Agreement with respect to such Issuing Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;It is understood and agreed that the use of the term &#8220;agent&#8221; herein or in any other Loan Document (or any similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable law. Instead such term is used as a matter of market custom and is intended to create or reflect only an administrative relationship between contracting parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Nature of Duties of the Administrative Agent </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrative Agent shall not have any duties or obligations except those expressly set forth in this Agreement and the other Loan Documents. Without limiting the generality of the foregoing, (a) the Administrative Agent shall not be subject to any fiduciary or other implied duties, regardless of whether a Default or an Event of Default has occurred and is continuing, (b) the Administrative Agent shall not have any duty to take any discretionary action or exercise any discretionary powers, except those discretionary rights and powers expressly contemplated by the Loan Documents that the Administrative Agent is required to exercise in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be necessary under the circumstances as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2), provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law&#59; and (c) except as expressly set forth in the Loan Documents, the Administrative Agent shall not have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of its Subsidiaries that is communicated to or obtained by the Administrative Agent or any of its Affiliates in any capacity. The Administrative Agent shall not be liable for any action taken or not taken by it, its sub-agents or its attorneys-in-fact with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary under the circumstances as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction in a final non-appealable judgment. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents or attorneys-in-fact except to the extent that a court of competent jurisdiction determines in a final and non-appelable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents. The Administrative Agent shall not be deemed to have knowledge of any Default or Event of Default unless and until written notice thereof (which notice shall include an express reference to such event being a &#8220;Default&#8221; or &#8220;Event of Default&#8221; hereunder) is given to the Administrative Agent by the Borrower or any Lender, and the Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with any Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements, or other terms and conditions set forth in any Loan Document, (iv) the validity, enforceability, effectiveness or genuineness of any Loan Document or any other agreement, instrument or document, or (v) the satisfaction of any condition set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or elsewhere in any Loan Document, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent. The Administrative Agent may consult with legal counsel (including counsel for the Borrower) concerning all matters pertaining to such duties.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">111</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Lack of Reliance on the Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the Lenders, the Swingline Lender and the Issuing Banks acknowledges that it has, independently and without reliance upon the Administrative Agent, any Issuing Bank or any other Lender and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each of the Lenders, the Swingline Lender and the Issuing Banks also acknowledges that it will, independently and without reliance upon the Administrative Agent, any Issuing Bank or any other Lender and based on such documents and information as it has deemed appropriate, continue to make its own credit analysis, appraisals and decisions in taking or not taking any action under or based on this Agreement, any related agreement or any document furnished hereunder or thereunder, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of the Loan Parties. Each Lender represents and warrants to the Administrative Agent that (i) the Loan Documents set forth the terms of a commercial lending facility and (ii) it is engaged in making, acquiring or holding commercial loans in the ordinary course and is entering into this Agreement as a Lender for the purpose of making, acquiring or holding commercial loans and providing other facilities set forth herein as may be applicable to such Lender, and not for the purpose of purchasing, acquiring or holding any other type of financial instrument, and each Lender agrees not to assert a claim in contravention of the foregoing.  Each Lender represents and warrants to the Administrative Agent that it is sophisticated with respect to decisions to make, acquire and&#47;or hold commercial loans and to provide other facilities set forth herein, as may be applicable to such Lender, and either it, or the Person exercising discretion in making its decision to make, acquire and&#47;or hold such commercial loans or to provide such other facilities, is experienced in making, acquiring or holding such commercial loans or providing such other facilities.  Each of the Lenders acknowledges and agrees that outside legal counsel to the Administrative Agent in connection with the preparation, negotiation, execution, delivery and administration (including any amendments, waivers and consents) of this Agreement and the other Loan Documents is acting solely as counsel to the Administrative Agent and is not acting as counsel to any Lender (other than the Administrative Agent and its Affiliates) in connection with this Agreement, the other Loan Documents or any of the transactions contemplated hereby or thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Certain Rights of the Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. If the Administrative Agent shall request instructions from the Required Lenders with respect to any action or actions (including the failure to act) in connection with this Agreement, the Administrative Agent shall be entitled to refrain from such act or taking such act unless and until it shall have received instructions from such Lenders, and the Administrative Agent shall not incur liability to any Person by reason of so refraining. Without limiting the foregoing, no Lender shall have any right of action whatsoever against the Administrative Agent as a result of the Administrative Agent acting or refraining from acting hereunder in accordance with the instructions of the Required Lenders where required by the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Reliance by the Administrative Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, posting or other distribution) believed by it to be genuine and to have been signed, sent or made by the proper Person. The Administrative Agent may also rely upon any statement made to it orally or by telephone and believed by it to be made by the proper Person and shall not incur any liability for relying thereon. The Administrative Agent may consult with legal counsel (including counsel for the Borrower), independent public accountants and other experts selected by it and shall not be liable for any action taken or not taken by it in accordance with the advice of such counsel, accountants or experts.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">112</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">The Administrative Agent in its Individual Capacity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The bank serving as the Administrative Agent shall have the same rights and powers under this Agreement and any other Loan Document in its capacity as a Lender as any other Lender and may exercise or refrain from exercising the same as though it were not the Administrative Agent&#59; and the terms &#8220;Lenders&#8221;, &#8220;Required Lenders&#8221;, &#8220;Required Revolving Lenders&#8221;, or any similar terms shall, unless the context clearly otherwise indicates, include the Administrative Agent in its individual capacity. The bank acting as the Administrative Agent and its Affiliates may accept deposits from, lend money to, and generally engage in any kind of business with the Borrower or any Subsidiary or Affiliate of the Borrower as if it were not the Administrative Agent hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Successor Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Administrative Agent may resign at any time by giving notice thereof to the Lenders and the Borrower. Upon any such resignation, the Required Lenders shall have the right to appoint a successor Administrative Agent, subject to approval by the Borrower provided that no Default or Event of Default shall exist at such time. If no successor Administrative Agent shall have been so appointed, and shall have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of resignation, then the retiring Administrative Agent may, on behalf of the Lenders, appoint a successor Administrative Agent which shall be a commercial bank organized under the laws of the United States or any state thereof or a bank which maintains an office in the United States.  Any resignation by the Administrative Agent pursuant to this Section shall also constitute its resignation as an Issuing Bank and Swingline Lender. Upon the acceptance of a successor&#8217;s appointment as Administrative Agent hereunder&#58; (i)&#160;such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring Issuing Bank and Swingline Lender&#59; (ii)&#160;the retiring Issuing Bank and Swingline Lender shall be discharged from all of their respective duties and obligations hereunder or under the other Loan Documents&#59; and (iii)&#160;the successor Issuing Lender shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangement satisfactory to the retiring Issuing Bank to effectively assume the obligations of the retiring Issuing Bank with respect to such Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Upon the acceptance of its appointment as the Administrative Agent hereunder by a successor, such successor Administrative Agent shall thereupon succeed to and become vested with all the rights, powers, privileges and duties of the retiring Administrative Agent, and the retiring Administrative Agent shall be discharged from its duties and obligations under this Agreement and the other Loan Documents. If, within 45 days after written notice is given of the retiring Administrative Agent&#8217;s resignation under this Section, no successor Administrative Agent shall have been appointed and shall have accepted such appointment, then on such 45th day (i) the retiring Administrative Agent&#8217;s resignation shall become effective, (ii) the retiring Administrative Agent shall thereupon be discharged from its duties and obligations under the Loan Documents and (iii) the Required Lenders shall thereafter perform all duties of the retiring Administrative Agent under the Loan Documents until such time as the Required Lenders appoint a successor Administrative Agent as provided above. After any retiring Administrative Agent&#8217;s resignation hereunder, the provisions of this Article shall continue in effect for the benefit of such retiring Administrative Agent and its representatives and agents in respect of any actions taken or not taken by any of them while it was serving as the Administrative Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In addition to the foregoing, if a Lender becomes, and during the period it remains, a Defaulting Lender, and if any Default has arisen from a failure of the Borrower to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, then the Issuing Banks and the Swingline Lender may, upon prior written notice to the Borrower and the Administrative Agent, resign as an Issuing Bank or as Swingline Lender, as the case </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">113</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">may be, effective at the close of business Charlotte, North Carolina time on a date specified in such notice (which date may not be less than five (5) Business Days after the date of such notice).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Withholding Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. To the extent required by any applicable law, the Administrative Agent may withhold from any interest payment to any Lender an amount equivalent to any applicable withholding tax. If the IRS or any authority of the United States or any other jurisdiction asserts a claim that the Administrative Agent did not properly withhold tax from amounts paid to or for the account of any Lender (because the appropriate form was not delivered or was not properly executed, or because such Lender failed to notify the Administrative Agent of a change in circumstances that rendered the exemption from, or reduction of, withholding tax ineffective, or for any other reason), such Lender shall indemnify the Administrative Agent (to the extent that the Administrative Agent has not already been reimbursed by the Borrower and without limiting the obligation of the Borrower to do so) fully for all amounts paid, directly or indirectly, by the Administrative Agent as tax or otherwise, including penalties and interest, together with all expenses incurred, including legal expenses, allocated staff costs and any out of pocket expenses.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">The Administrative Agent May File Proofs of Claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan or any Revolving Credit Exposure shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans or Revolving Credit Exposure and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders, the Issuing Banks and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders, the Issuing Banks and the Administrative Agent and its agents and counsel and all other amounts due the Lenders, the Issuing Banks and the Administrative Agent under Section 10.3) allowed in such judicial proceeding&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender and each Issuing Bank to make such payments to the Administrative Agent and, if the Administrative Agent shall consent to the making of such payments directly to the Lenders and the Issuing Banks, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender or any Issuing Bank any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">114</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Authorization to Execute Other Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each Lender hereby authorizes the Administrative Agent to execute on behalf of all Lenders all Loan Documents (including, without limitation, the Collateral Documents and any subordination agreements) other than this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Collateral and Guaranty Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Lenders irrevocably authorize the Administrative Agent, at its option and in its discretion&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;to release any Lien on any property granted to or held by the Administrative Agent under any Loan Document (i) upon the termination of all Revolving Commitments, the Cash Collateralization of all reimbursement obligations with respect to Letters of Credit in an amount equal to 105% of the aggregate LC Exposure of all Lenders, and the payment in full of all Obligations (other than contingent indemnification obligations and such Cash Collateralized reimbursement obligations), (ii) that is sold or to be sold as part of or in connection with any sale permitted hereunder or under any other Loan Document, or (iii) if approved, authorized or ratified in writing in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to release any Loan Party from its obligations under the applicable Collateral Documents if such Person ceases to be a Subsidiary as a result of a transaction permitted hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent&#8217;s authority to release its interest in particular types or items of property, or to release any Loan Party from its obligations under the applicable Collateral Documents pursuant to this Section. In each case as specified in this Section, the Administrative Agent is authorized, at the Borrower&#8217;s expense, to execute and deliver to the applicable Loan Party such documents as such Loan Party may reasonably request to evidence the release of such item of Collateral from the Liens granted under the applicable Collateral Documents, or to release such Loan Party from its obligations under the applicable Collateral Documents, in each case in accordance with the terms of the Loan Documents and this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">No Other Duties&#59; Designation of Additional Agents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. None of the Lenders or other Persons identified on the facing page or signature pages of this Agreement as a &#8220;co-syndication agent&#8221;, &#8220;joint lead arranger&#8221; or &#8220;joint bookrunner&#8221; shall have any right, power, obligation, liability, responsibility or duty under this Agreement other than those applicable to all Lenders as such.  Without limiting the foregoing, none of the Lenders or other Persons so identified shall have or be deemed to have any fiduciary relationship with any Lender.  Each Lender acknowledges that it has not relied, and will not rely, on any of the Lenders or other Persons so identified in deciding to enter into this Agreement or in taking or not taking action hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Right to Realize on Collateral and Enforce Guarantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Anything contained in any of the Loan Documents to the contrary notwithstanding, the Borrower, the Administrative Agent and each Lender hereby agree that (i) no Lender shall have any right individually to realize upon any of the Collateral or to enforce the Collateral Documents, it being understood and agreed that all powers, rights and remedies hereunder and under the Collateral Documents may be exercised solely by the Administrative Agent, and (ii) in the event of a foreclosure by the Administrative Agent on any of the Collateral pursuant to a public or private sale or other disposition, the Administrative Agent or any Lender may be the purchaser or licensor of any or all of such Collateral at any such sale or other disposition and the Administrative Agent, as agent for and representative of the Lenders (but not any Lender or Lenders in its or their respective individual capacities unless the Required Lenders shall otherwise agree in writing), shall be entitled, for the purpose of bidding and making settlement or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">115</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">payment of the purchase price for all or any portion of the Collateral sold at any such public sale, to use and apply any of the Obligations as a credit on account of the purchase price for any collateral payable by the Administrative Agent at such sale or other disposition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Secured Bank Product Obligations and Hedging Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No Bank Product Provider or Lender-Related Hedge Provider that obtains the benefits of Section 8.2, the Collateral Documents or any Collateral by virtue of the provisions hereof or of any other Loan Document shall have any right to notice of any action or to consent to, direct or object to any action hereunder or under any other Loan Document or otherwise in respect of the Collateral (including the release or impairment of any Collateral) other than in its capacity as a Lender and, in such case, only to the extent expressly provided in the Loan Documents. Notwithstanding any other provision of this Article to the contrary, the Administrative Agent shall not be required to verify the payment of, or that other satisfactory arrangements have been made with respect to, Bank Product Obligations and Hedging Obligations unless the Administrative Agent has received written notice of such Obligations, together with such supporting documentation as the Administrative Agent may request, from the applicable Bank Product Provider or Lender-Related Hedge Provider, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 9.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Erroneous Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;. If the Administrative Agent notifies&#160;a Lender, Issuing Bank or Secured Party, or any Person who has received funds on behalf of a Lender, Issuing Bank or Secured Party such Lender or Issuing Bank (any such Lender, Issuing Bank, Secured Party or other recipient, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Payment Recipient</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) that the Administrative Agent has determined&#160;in its sole discretion (whether or not after receipt of any notice under immediately succeeding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) that any funds received by such Payment Recipient from the Administrative Agent or any of its Affiliates were erroneously transmitted to, or otherwise erroneously or mistakenly received by, such Payment Recipient (whether or not known to such Lender, Issuing Bank, Secured Party or other Payment Recipient on its behalf)  (any such funds, whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise, individually and collectively, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and demands the return of such Erroneous Payment (or a portion thereof), such Erroneous Payment shall at all times remain the property of the Administrative Agent and shall be segregated by the Payment Recipient and held in trust for the benefit of the Administrative Agent, and such Lender, Issuing Bank or Secured Party shall (or, with respect to any Payment Recipient who received such funds on its behalf, shall cause such Payment Recipient to) promptly, but in no event later than two Business Days thereafter, return to the Administrative Agent the amount of any such Erroneous Payment (or portion thereof) as to which such a demand was made, in same day funds (in the currency so received), together with interest thereon in respect of each day from and including the date such Erroneous Payment (or portion thereof) was received by such Payment Recipient to the date such amount is repaid to the Administrative Agent in same day funds at the greater of the Federal Funds Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect. A notice of the Administrative Agent to any Payment Recipient under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall be conclusive, absent manifest error.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Without limiting immediately preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, each Lender, Issuing Bank or Secured Party, or any Person who has received funds on behalf of a Lender, Issuing Bank or Secured Party such Lender or Issuing Bank, hereby further agrees that if it&#160;receives a payment, prepayment or repayment (whether received as a payment, prepayment or repayment of principal, interest, fees, distribution or otherwise) from the Administrative Agent (or any of its Affiliates) (x) that is in a different amount than, or on a different date from, that specified in a notice of payment, prepayment or repayment sent by the Administrative Agent (or any of its Affiliates) with respect to such payment, prepayment or repayment, (y) that was not preceded or accompanied by a notice of payment, prepayment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">116</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">or repayment sent by the Administrative Agent (or any of its Affiliates), or (z) that such Lender, Issuing Bank or Secured Party, or other such recipient, otherwise becomes aware was transmitted, or received, in error or by mistake (in whole or in part) in each case&#58; </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;(A) in the case of immediately preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clauses (x)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(y)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, an error shall be presumed to have been made (absent written confirmation from the Administrative Agent to the contrary) or (B) an error has been made (in the case of immediately preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (z)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), in each case, with respect to such payment, prepayment or repayment&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;such Lender, Issuing Bank or Secured Party shall (and shall cause any other recipient that receives funds on its respective behalf to) promptly (and, in all events, within one Business Day of its knowledge of such error) notify the Administrative Agent of its receipt of such payment, prepayment or repayment, the details thereof (in reasonable detail) and that it is so notifying the Administrative Agent pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.15(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Each Lender, Issuing Bank or Secured Party hereby authorizes the Administrative Agent to set off, net and apply any and all amounts at any time owing to such Lender, Issuing Bank or Secured Party under any Loan Document, or otherwise payable or distributable by the Administrative Agent to such Lender, Issuing Bank or Secured Party from any source, against any amount due to the Administrative Agent under immediately preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or under the indemnification provisions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;In the event that an Erroneous Payment (or portion thereof) is not recovered by the Administrative Agent for any reason, after demand therefor by the Administrative Agent in accordance with immediately preceding </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">clause (a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, from any Lender or Issuing Bank that has received such Erroneous Payment (or portion thereof) (and&#47;or from any Payment Recipient who received such Erroneous Payment (or portion thereof) on its respective behalf)  (such unrecovered amount, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Return Deficiency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), upon the Administrative Agent&#8217;s notice to such Lender or Issuing Lender at any time, (i) such Lender or Issuing Bank shall be deemed to have assigned its Loans (but not its Commitments) of the relevant Class with respect to which such Erroneous Payment was made (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Impacted Class</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in an amount equal to the Erroneous Payment Return Deficiency (or such lesser amount as the Administrative Agent may specify) (such assignment of the Loans (but not Commitments) of the Erroneous Payment  Impacted Class, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Deficiency Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) at par plus any accrued and unpaid interest (with the assignment fee to be waived by the Administrative Agent in such instance), and is hereby (together with the Borrower) deemed to execute and deliver an Assignment and Assumption (or, to the extent applicable, an agreement incorporating an Assignment and Assumption by reference pursuant to a Platform as to which the Administrative Agent and such parties are participants) with respect to such Erroneous Payment Deficiency Assignment, and such Lender or Issuing Bank shall deliver any promissory notes evidencing such Loans to the Borrower or the Administrative Agent, (ii) the Administrative Agent as the assignee Lender shall be deemed to acquire the Erroneous Payment Deficiency Assignment, (iii) upon such deemed acquisition, the Administrative Agent as the assignee Lender shall become a Lender or Issuing Bank, as applicable, hereunder with respect to such Erroneous Payment Deficiency Assignment and the assigning Lender or assigning Issuing Bank shall cease to be a Lender or Issuing Bank, as applicable, hereunder with respect to such Erroneous Payment Deficiency Assignment, excluding, for the avoidance of doubt, its obligations under the indemnification provisions of this Agreement and its applicable Commitments which shall survive as to such assigning Lender or assigning Issuing Bank, and (iv) the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">117</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Administrative Agent may reflect in the Register its ownership interest in the Loans subject to the Erroneous Payment Deficiency Assignment. The Administrative Agent may, in its discretion, sell any Loans acquired pursuant to an Erroneous Payment Deficiency Assignment and upon receipt of the proceeds of such sale, the Erroneous Payment Return Deficiency owing by the applicable Lender or Issuing Bank shall be reduced by the net proceeds of the sale of such Loan (or portion thereof), and the Administrative Agent shall retain all other rights, remedies and claims against such Lender or Issuing Bank (and&#47;or against any recipient that receives funds on its respective behalf). For the avoidance of doubt, no Erroneous Payment Deficiency Assignment will reduce the Commitments of any Lender or Issuing Bank and such Commitments shall remain available in accordance with the terms of this Agreement.  In addition, each party hereto agrees that, except to the extent that the Administrative Agent has sold a Loan (or portion thereof) acquired pursuant to an Erroneous Payment Deficiency Assignment, and irrespective of whether the Administrative Agent may be equitably subrogated, the Administrative Agent shall be contractually subrogated to all the rights and interests of the applicable Lender, Issuing Bank or Secured Party under the Loan Documents with respect to each Erroneous Payment Return Deficiency (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Erroneous Payment Subrogation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The parties hereto agree that an Erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Obligations owed by the Borrower or any other Loan Party, except, in each case, to the extent such Erroneous Payment is, and solely with respect to the amount of such Erroneous Payment that is, comprised of funds received by the Administrative Agent from the Borrower or any other Loan Party for the purpose of making such Erroneous Payment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;To the extent permitted by applicable law, no Payment Recipient shall assert any right or claim to an Erroneous Payment, and hereby waives, and is deemed to waive, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the Administrative Agent for the return of any Erroneous Payment received, including without limitation waiver of any defense based on &#8220;discharge for value&#8221; or any similar doctrine.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each party&#8217;s obligations, agreements and waivers under this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 9.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall survive the resignation or replacement of the Administrative Agent, any transfer of rights or obligations by, or the replacement of, a Lender or Issuing Bank,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the termination of the Commitments and&#47;or the repayment, satisfaction or discharge of all Obligations (or any portion thereof) under any Loan Document.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline"><br><br>MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Notices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Written Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Except in the case of notices and other communications expressly permitted to be given by telephone, all notices and other communications to any party herein to be effective shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile, as follows&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.467%"><tr><td style="width:1.0%"></td><td style="width:39.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the Borrower&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1668 S. Garfield Avenue, 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Floor</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alhambra, CA 91801</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">118</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.467%"><tr><td style="width:1.0%"></td><td style="width:39.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Eric Chin, CFO</font></div><div style="margin-bottom:0.12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58;  eric.chin&#64;nmm.cc</font></div><div style="margin-bottom:0.12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telephone Number&#58;  626-943-6008</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With a copy to (for information purposes only)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Tin Kin Lee Law Offices<br>1811 Fair Oaks Ave.<br>South Pasadena, California 91030<br>Attention&#58;  Tin Kin Lee, Esq.<br>Email&#58;  tlee&#64;tinkinlee.com<br>Facsimile Number&#58; 626-229-9820</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the Administrative Agent&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3333 Peachtree Road</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Atlanta, GA 30326</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Portfolio Manager &#8211; ApolloMed</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Facsimile Number&#58; 404-926-5173</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With copies to (for information purposes only)&#58;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3333 Peachtree Road</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Atlanta, GA 30326</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Ron Caldwell &#8211; ApolloMed </font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58;  Ron.Caldwell&#64;Truist.com</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Facsimile Number&#58; 404-926-5248</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Truist Bank</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agency Services</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">303 Peachtree Street, N.E. &#47; 25th Floor</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Atlanta, Georgia 30308</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Agency Services Manager</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Facsimile Number&#58; (404) 221-2001</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alston &#38; Bird LLP</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1201 West Peachtree Street</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Atlanta, Georgia  30309</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Adam R. Monich, Esq.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Email&#58; adam.monich&#64;alston.com</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the Issuing Banks&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Truist Bank</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attn&#58; Standby Letter of Credit Dept.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">303 Peachtree Street NE</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> FL, Mail Code 803-05-25-60</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Atlanta, GA 30308</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Telephone&#58; 800-951-7847</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Preferred Bank</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">601 South Figueroa Street, 47th Floor</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Los Angeles, CA&#160; 90017&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">213-891-1188</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the Swingline Lender&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Truist Bank</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">119</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.467%"><tr><td style="width:1.0%"></td><td style="width:39.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agency Services</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">303 Peachtree Street, N.E. &#47; 25th Floor</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Atlanta, Georgia 30308</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attention&#58; Agency Services Manager</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Facsimile Number&#58; (404) 221-2001</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To any other Lender&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the address set forth in the Administrative Questionnaire or the Assignment and Acceptance executed by such Lender</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:40.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any party hereto may change its address or facsimile number for notices and other communications hereunder by notice to the other parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Any agreement of the Administrative Agent, any Issuing Bank or any Lender herein to receive certain notices by telephone or facsimile is solely for the convenience and at the request of the Borrower. The Administrative Agent, each Issuing Bank and each Lender shall be entitled to rely on the authority of any Person purporting to be a Person authorized by the Borrower to give such notice and the Administrative Agent, the Issuing Banks and the Lenders shall not have any liability to the Borrower or other Person on account of any action taken or not taken by the Administrative Agent, any Issuing Bank or any Lender in reliance upon such telephonic or facsimile notice. The obligation of the Borrower to repay the Loans and all other Obligations hereunder shall not be affected in any way or to any extent by any failure of the Administrative Agent, any Issuing Bank or any Lender to receive written confirmation of any telephonic or facsimile notice or the receipt by the Administrative Agent, any Issuing Bank or any Lender of a confirmation which is at variance with the terms understood by the Administrative Agent, such Issuing Bank and such Lender to be contained in any such telephonic or facsimile notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Electronic Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Notices and other communications to the Lenders and the Issuing Banks hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the foregoing shall not apply to notices to any Lender or any Issuing Bank if such Lender or such Issuing Bank, as applicable, has notified the Administrative Agent that it is incapable of receiving, or is unwilling to receive, notices by electronic communication. The Administrative Agent or the Borrower may, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that approval of such procedures may be limited to particular notices or communications.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;Unless the Administrative Agent otherwise prescribes, (A) notices and other communications sent to an e-mail address shall be deemed received upon the sender&#8217;s receipt of an acknowledgement from the intended recipient (such as by the &#8220;return receipt requested&#8221; function, as available, return e-mail or other written acknowledgement) and (B) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (A) of notification that such notice or communication is available and identifying the website address therefor&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, in the case of clauses (A) and (B) above, if such notice or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">120</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next Business Day for the recipient.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Borrower agrees that the Administrative Agent may, but shall not be obligated to, make Communications (as defined below) available to the Issuing Banks and the other Lenders by posting the Communications on Debt Domain, Intralinks, Syndtrak, ClearPar or a substantially similar electronic system.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;THE PLATFORM IS PROVIDED &#8220;AS IS&#8221; AND &#8220;AS AVAILABLE.&#8221; NEITHER THE ADMINISTRATIVE AGENT NOR ANY OF ITS RELATED PARTIES WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS IN THE COMMUNICATIONS (AS DEFINED BELOW) AND FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY THE ADMINISTRATIVE AGENT OR ANY OF ITS RELATED PARTIES IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Administrative Agent or any of its Related Parties have any liability to any Loan Party or any of their respective Subsidiaries, any Lender, any Issuing Bank or any other Person or entity for losses, claims, damages, liabilities or expenses of any kind, including, without limitation, direct or indirect, special, incidental or consequential damages, losses or expenses, whether or not based on strict liability (whether in tort, contract or otherwise), arising out of any Loan Party&#8217;s or the Administrative Agent&#8217;s transmission of Borrower Materials through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and non-appealable judgment to have resulted from the gross negligence or willful misconduct of the Administrative Agent or such Related Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> , </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that in no event shall the Administrative Agent or any Related Party have any liability to any Loan Party or any of their respective Subsidiaries, any Lender, any Issuing Bank or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed to direct or actual damages) arising out of any Loan Party&#8217;s or the Administrative Agent&#8217;s transmission of Communications. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Communications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means, collectively, any notice, demand, communication, information, document or other material provided by or on behalf of any Loan Party pursuant to any Loan Document or the transactions contemplated therein which is distributed by the Administrative Agent, any Lender or any Issuing Bank by means of electronic communications pursuant to this Section, including through the Platform.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Telephonic Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Unless otherwise expressly provided herein, all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile or electronic mail as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;if to the Borrower, the Administrative Agent or an Issuing Bank, to the address, facsimile number, electronic mail address or telephone number specified for such Person in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.1(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or to such other address, facsimile number, electronic mail address or telephone </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">121</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">number as shall be designated by such party in a notice to the other parties hereto, as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.1(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;if to any other Lender, to the address, facsimile number, electronic mail address or telephone number specified in its Administrative Questionnaire.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;All such notices and other communications sent to any party hereto in accordance with the provisions of this Agreement are made upon the earlier to occur of (i) actual receipt by the relevant party hereto and (ii) (A) if delivered by hand or by courier, when signed for by or on behalf of the relevant party hereto&#59; (B) if delivered by mail, four (4) Business Days after deposit in the mails, postage prepaid&#59; (C) if delivered by facsimile, when sent and receipt has been confirmed by telephone&#59; and (D) if delivered by electronic mail, to the extent provided in clause (b) above and effective as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in such clause&#59; provided that notices and other communications to the Administrative Agent and an Issuing Bank pursuant to Article II shall not be effective until actually received by such Person. In no event shall a voice mail message be effective as a notice, communication or confirmation hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Loan Documents may be transmitted and&#47;or signed by facsimile or other electronic communication. The effectiveness of any such documents and signatures shall, subject to applicable Law, have the same force and effect as manually signed originals and shall be binding on all Loan Parties, the Agents and the Lenders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Waiver&#59; Amendments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;No failure or delay by the Administrative Agent, any Issuing Bank or any Lender in exercising any right or power hereunder or under any other Loan Document, and no course of dealing between the Borrower and the Administrative Agent or any Lender, shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power hereunder or thereunder. The rights and remedies of the Administrative Agent, the Issuing Banks and the Lenders hereunder and under the other Loan Documents are cumulative and are not exclusive of any rights or remedies provided by law. No waiver of any provision of this Agreement or of any other Loan Document or consent to any departure by the Borrower therefrom shall in any event be effective unless the same shall be permitted by subsection (b) of this Section, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. Without limiting the generality of the foregoing, the making of a Loan or the issuance of a Letter of Credit shall not be construed as a waiver of any Default or Event of Default, regardless of whether the Administrative Agent, any Lender or any Issuing Bank may have had notice or knowledge of such Default or Event of Default at the time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except as otherwise provided in this Agreement, including, without limitation, as provided in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to the implementation of a Benchmark Replacement Rate or Benchmark Conforming Changes (as set forth therein), no amendment or waiver of any provision of this Agreement or of the other Loan Documents (other than the Fee Letter), nor consent to any departure by the Borrower therefrom, shall in any event be effective unless the same shall be in writing and signed by the Borrower and the Required Lenders, or the Borrower and the Administrative Agent with the consent of the Required Lenders, and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given&#59; provided that, subject to Section 2.16(b), in addition to the consent of the Required Lenders, no amendment, waiver or consent shall&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">122</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;increase the Commitment of any Lender without the written consent of such Lender&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;reduce the principal amount of any Loan or LC Disbursement or reduce the rate of interest thereon (it being agreed that the waiver of the Default Interest rate (or the imposition thereof) shall only require the consent of the Required Lenders), or reduce any fees or other amounts payable hereunder, without the written consent of each Lender affected thereby&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;postpone the date fixed for any payment (other than any mandatory prepayment) of any principal of, or interest on, any Loan or LC Disbursement or any fees or other amounts hereunder or reduce the amount of, waive or excuse any such payment, or postpone the scheduled date for the termination or reduction of any Commitment, without the written consent of each Lender affected thereby&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;alter, change or have the effect of changing the priority or pro rata treatment or the order of application of any payments (including, without limitation, any repayments or prepayments) under this Agreement (including, without limitation, pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.21(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) or under any other Loan Documents, Liens, proceeds of Collateral or reductions in Commitments (including as a result in whole or in part of allowing the issuance or incurrence, pursuant to this Agreement or otherwise, of new loans or other indebtedness having any priority over any of the Obligations in respect of payments, Liens, Collateral or proceeds of Collateral, in exchange for any Obligations or otherwise), without the written consent of each Lender&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;change any of the provisions of this subsection (b) or the definition of &#8220;Required Lenders&#8221; or &#8220;Required Revolving Lenders&#8221; or any other provision hereof specifying the number or percentage of Lenders which are required to waive, amend or modify any rights hereunder or make any determination or grant any consent hereunder, without the consent of each Lender&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;release all or substantially all of the guarantors, or limit the liability of such guarantors, under any guaranty agreement guaranteeing any of the Obligations, without the written consent of each Lender&#59; </font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;release all or substantially all Collateral securing any of the Obligations, without the written consent of each Lender&#59; or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;subordinate the payment priority of the Obligations or subordinate the Liens granted to the Administrative Agent (for the benefit of the Secured Parties) in the Collateral, without the written consent of each Lender</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, that no such amendment, waiver or consent shall amend, modify or otherwise affect the rights, duties or obligations of the Administrative Agent, the Swingline Lender or any Issuing Bank without the prior written consent of such Person.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder, except that the Commitment of such Lender may not be increased or extended, and amounts payable to such Lender hereunder may not be permanently reduced, without the consent of such Lender (other than reductions in fees and interest in which such reduction does not disproportionately affect such Lender). Notwithstanding anything </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">123</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contained herein to the contrary, this Agreement may be amended and restated without the consent of any Lender (but with the consent of the Borrower and the Administrative Agent) if, upon giving effect to such amendment and restatement, such Lender shall no longer be a party to this Agreement (as so amended and restated), the Commitments of such Lender shall have terminated (but such Lender shall continue to be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), such Lender shall have no other commitment or other obligation hereunder and such Lender shall have been paid in full all principal, interest and other amounts owing to it or accrued for its account under this Agreement.  Notwithstanding anything herein or otherwise to the contrary, any Event of Default occurring hereunder shall continue to exist (and shall be deemed to be continuing) until such time as such Event of Default is waived in writing in accordance with the terms of this Section notwithstanding (i) any attempted cure or other action taken by the Borrower or any other Person subsequent to the occurrence of such Event of Default or (ii) any action taken or omitted to be taken by the Administrative Agent or any Lender prior to or subsequent to the occurrence of such Event of Default (other than the granting of a waiver in writing in accordance with the terms of this Section).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary herein, the Administrative Agent may, with the consent of the Borrower only, amend, modify or supplement any Loan Document to cure any obvious ambiguity, omission, mistake, defect or inconsistency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Expenses&#59; Indemnification.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Borrower shall pay (i) all reasonable, out-of-pocket costs and expenses of the Administrative Agent and its Affiliates, including the reasonable fees, charges and disbursements of counsel for the Administrative Agent and its Affiliates, in connection with the syndication of the credit facilities provided for herein, the preparation and administration of the Loan Documents and any amendments, modifications or waivers thereof (whether or not the transactions contemplated in this Agreement or any other Loan Document shall be consummated), including the reasonable fees, charges and disbursements of counsel for the Administrative Agent and its Affiliates, (ii) all reasonable out-of-pocket expenses incurred by any Issuing Bank in connection with the issuance, amendment, renewal or extension of any Letter of Credit or any demand for payment thereunder and (iii) all out-of-pocket costs and expenses (including, without limitation, the reasonable fees, charges and disbursements of outside counsel and the allocated cost of inside counsel) incurred by the Administrative Agent, any Issuing Bank or any Lender in connection with the enforcement or protection of its rights in connection with this Agreement, including its rights under this Section, or in connection with the Loans made or any Letters of Credit issued hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower shall indemnify the Administrative Agent (and any sub-agent thereof), each Lender and each Issuing Bank, and each Related Party of any of the foregoing Persons (each such Person being called an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee), and shall indemnify and hold harmless each Indemnitee from all fees and time charges and disbursements for attorneys who may be employees of any Indemnitee, incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Borrower or any other Loan Party arising out of, in connection with, or as a result of (i) the execution, delivery of this Agreement, any other Loan Document, any APC 2019 Transaction Document, any Associated Practice Documents or any agreement or instrument contemplated hereby or by any of the foregoing, the performance by the parties hereto, any Loan Party or any other Person of their respective obligations hereunder or under any of the foregoing or the consummation of the transactions </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">124</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">contemplated hereby or thereby, (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by any Issuing Bank to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged presence or Release of Hazardous Materials on or from any property owned or operated by the Borrower or any of its Subsidiaries, or any Environmental Liability related in any way to the Borrower or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower or any other Loan Party, and regardless of whether any Indemnitee is a party thereto&#59; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and non-appealable judgment to have resulted from (x) the gross negligence or willful misconduct of such Indemnitee, (y) a claim brought by the Borrower or any other Loan Party against an Indemnitee for a breach in bad faith of such Indemnitee&#8217;s obligations hereunder or under any other Loan Document or (z) disputes solely among Indemnitees, other than any claims arising out of or resulting from any act or omission on the part of the Borrower or its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Borrower shall pay, and hold the Administrative Agent, each Issuing Bank and each of the Lenders harmless from and against, any and all present and future stamp, documentary, and other similar taxes with respect to this Agreement and any other Loan Documents, any collateral described therein or any payments due thereunder, and save the Administrative Agent, each Issuing Bank and each Lender harmless from and against any and all liabilities with respect to or resulting from any delay or omission to pay such taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;To the extent that the Borrower fails to pay any amount required to be paid to the Administrative Agent, any Issuing Bank or the Swingline Lender under subsection (a), (b) or (c) hereof, each Lender severally agrees to pay to the Administrative Agent, the applicable Issuing Bank or the Swingline Lender, as the case may be, such Lender&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> share (in accordance with its respective Revolving Commitment (or Revolving Credit Exposure, as applicable) and Incremental Term Loan determined as of the time that the unreimbursed expense or indemnity payment is sought) of such unpaid amount&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that the unreimbursed expense or indemnified payment, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent, the applicable Issuing Bank or the Swingline Lender in its capacity as such.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;To the extent permitted by applicable law, the Borrower shall not assert, and hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to actual or direct damages) arising out of, in connection with or as a result of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated therein, any Loan or any Letter of Credit or the use of proceeds thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that nothing in this clause (e) shall relieve the Borrower of any obligation it may have to indemnify any Indemnitee against special, indirect, consequential or punitive damages asserted against such Indemnitee by a third party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;All amounts due under this Section shall be payable promptly after written demand therefor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Successors and Assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">125</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that the Borrower may not assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and each Lender, and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection (d) of this Section or (iii) by way of pledge or assignment of a security interest subject to the restrictions of subsection (f) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in subsection (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any Lender may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitments, Loans and other Revolving Credit Exposure at the time owing to it)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that any such assignment shall be subject to the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;Minimum Amounts.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;in the case of an assignment of the entire remaining amount of the assigning Lender&#8217;s Commitments, Loans and other Revolving Credit Exposure at the time owing to it or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;in any case not described in subsection (b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans and Revolving Credit Exposure outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the Loans and Revolving Credit Exposure of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Acceptance with respect to such assignment is delivered to the Administrative Agent or, if &#8220;Trade Date&#8221; is specified in the Assignment and Acceptance, as of the Trade Date) shall not be less than $1,000,000 with respect to Incremental Term Loans and $5,000,000 with respect to Revolving Loans and in minimum increments of $1,000,000, unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed).</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Proportionate Amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender&#8217;s rights and obligations under this Agreement with respect to the Loans, other Revolving Credit Exposure or the Commitments assigned, except that this subsection (b)(ii) shall not prohibit any Lender from assigning all or a portion of its rights and obligations among separate Commitments on a non-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> basis.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Required Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No consent shall be required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">126</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (x) an Event of Default has occurred and is continuing at the time of such assignment or (y) such assignment is to a Lender, an Affiliate of such Lender or an Approved Fund of such Lender&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(B)&#160;&#160;&#160;&#160;the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required unless such assignment is of an Incremental Term Loan to a Lender, an Affiliate of such Lender or an Approved Fund of such Lender&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;the consent of each Issuing Bank (such consent not to be unreasonably withheld or delayed) shall be required for any assignment that increases the obligation of the assignee to participate in exposure under one or more Letters of Credit (whether or not then outstanding), and the consent of the Swingline Lender (such consent not to be unreasonably withheld or delayed) shall be required for any assignment in respect of the Revolving Commitments.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The parties to each assignment shall deliver to the Administrative Agent (A) a duly executed Assignment and Acceptance, (B) a processing and recordation fee of $3,500, (C) an Administrative Questionnaire unless the assignee is already a Lender and (D) the documents required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20(e).</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Assignment to the certain Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No such assignment shall be made to (A) the Borrower or any of the Borrower&#8217;s Affiliates or Subsidiaries or (B) to any Defaulting Lender or any of its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this clause (B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">No Assignment to Natural Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. No such assignment shall be made to a natural person.</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Certain Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#160;&#160;&#160;&#160;In connection with any  assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent, each Issuing Bank, the Swingline Lender and each other Lender hereunder (and interest accrued thereon), and (y) acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit and Swingline Loans. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">127</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to acceptance and recording thereof by the Administrative Agent pursuant to subsection (c) of this Section, from and after the effective date specified in each Assignment and Acceptance, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Acceptance, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Acceptance, be released from its obligations under this Agreement (and, in the case of an Assignment and Acceptance covering all of the assigning Lender&#8217;s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with respect to facts and circumstances occurring prior to the effective date of such assignment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that, except to the extent otherwise expressly agreed by the affected parties, no assignment by a Defaulting Lender will constitute a waiver or release of any claim of any party hereunder arising from such Lender&#8217;s having been a Defaulting Lender. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this subsection shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with subsection (d) of this Section. If the consent of the Borrower to an assignment is required hereunder (including a consent to an assignment which does not meet the minimum assignment thresholds specified above), the Borrower shall be deemed to have given its consent unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after notice thereof has actually been delivered by the assigning Lender (through the Administrative Agent) to the Borrower.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at one of its offices in Charlotte, North Carolina a copy of each Assignment and Acceptance delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amount of the Loans and Revolving Credit Exposure owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Information contained in the Register with respect to any Lender shall be available for inspection by such Lender at any reasonable time and from time to time upon reasonable prior notice&#59; information contained in the Register shall also be available for inspection by the Borrower at any reasonable time and from time to time upon reasonable prior notice. In establishing and maintaining the Register, the Administrative Agent shall serve as the Borrower&#8217;s agent solely for tax purposes and solely with respect to the actions described in this Section, and the Borrower hereby agrees that, to the extent Truist Bank serves in such capacity, Truist Bank and its officers, directors, employees, agents, sub-agents and affiliates shall constitute &#8220;Indemnitees&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Any Lender may at any time, without the consent of, or notice to, the Borrower, the Administrative Agent, the Swingline Lender or any Issuing Bank, sell participations to any Person (other than a natural person, the Borrower, or any of the Borrower&#8217;s Affiliates or Subsidiaries) (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in all or a portion of such Lender&#8217;s rights and&#47;or obligations under this Agreement (including all or a portion of its Commitment and&#47;or the Loans owing to it)&#59; provided that (i) such Lender&#8217;s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent, the Issuing Banks, the Swingline Lender and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender&#8217;s rights and obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement&#59; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">128</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">modification or waiver with respect to the following to the extent affecting such Participant&#58; (i) increase the Commitment of such Lender&#59; (ii) reduce the principal amount of any Loan or LC Disbursement or reduce the rate of interest thereon, or reduce any fees payable hereunder&#59; (iii) postpone the date fixed for any payment of any principal of, or interest on, any Loan or LC Disbursement or any fees hereunder or reduce the amount of, waive or excuse any such payment, or postpone the scheduled date for the termination or reduction of any Commitment&#59; (iv) change </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.21(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">c</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) in a manner that would alter the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">pro rata</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sharing of payments required thereby&#59; (v) change any of the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> or the definition of &#8220;Required Lenders&#8221; or &#8220;Required Revolving Lenders&#8221; or any other provision hereof specifying the number or percentage of Lenders which are required to waive, amend or modify any rights hereunder or make any determination or grant any consent hereunder&#59; (vi) release all or substantially all of the guarantors, or limit the liability of such guarantors, under any guaranty agreement guaranteeing any of the Obligations&#59; or (vii) release all or substantially all collateral (if any) securing any of the Obligations. Subject to subsection (e) of this Section, the Borrower agrees that each Participant shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (b)&#160;of this Section&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that such Participant agrees to be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as though it were a Lender. To the extent permitted by law, each Participant also shall be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as though it were a Lender&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that such Participant agrees to be subject to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as though it were a Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register in the United States on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#8217;s interest in the Loans or other obligations under the Loan Documents (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Participant Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). The entries in the Participant Register shall be conclusive, absent manifest error, and such Lender shall treat each person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. The Borrower and the Administrative Agent shall have inspection rights to such Participant Register (upon reasonable prior notice to the applicable Lender) solely for purposes of demonstrating that such Loans or other obligations under the Loan Documents are in &#8220;registered form&#8221; for purposes of the Code. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;A Participant shall not be entitled to receive any greater payment under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant, unless the sale of the participation to such Participant is made with the Borrower&#8217;s prior written consent. A Participant shall not be entitled to the benefits of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> unless the Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to comply with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.20(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as though it were a Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including, without limitation, any pledge or assignment to secure obligations to a Federal Reserve Bank&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Governing Law&#59; Jurisdiction&#59; Consent to Service of Process.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;This Agreement and the other Loan Documents and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement or any other Loan Document (except, as to any other Loan Document, as expressly set </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">129</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">forth therein) and the transactions contemplated hereby and thereby shall be construed in accordance with and be governed by the law (without giving effect to the conflict of law principles thereof) of the State of New York.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Borrower hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the United States District Court for the Southern District of New York, and of the Supreme Court of the State of New York sitting in New York County, Borough of Manhattan, and of any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or any other Loan Document or the transactions contemplated hereby or thereby, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such District Court or New York state court or, to the extent permitted by applicable law, such appellate court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or any other Loan Document shall affect any right that the Administrative Agent, any Issuing Bank or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Loan Document against the Borrower or its properties in the courts of any jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Borrower irrevocably and unconditionally waives any objection which it may now or hereafter have to the laying of venue of any such suit, action or proceeding described in subsection (b) of this Section and brought in any court referred to in subsection (b) of this Section. Each of the parties hereto irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Each party to this Agreement irrevocably consents to the service of process in the manner provided for notices in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Nothing in this Agreement or in any other Loan Document will affect the right of any party hereto to serve process in any other manner permitted by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">WAIVER OF JURY TRIAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  EACH PARTY HERETO IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Right of Set-off</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In addition to any rights now or hereafter granted under applicable law and not by way of limitation of any such rights, each Lender and each Issuing Bank shall have the right, at any time or from time to time upon the occurrence and during the continuance of an Event of Default, without prior notice to the Borrower, any such notice being expressly waived by the Borrower to the extent permitted by applicable law, to set off and apply against all deposits (general or special, time or demand, provisional or final) of the Borrower at any time held or other obligations at any time owing by such Lender and such Issuing Bank to or for the credit or the account of the Borrower </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">130</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">against any and all Obligations held by such Lender or such Issuing Bank, as the case may be, irrespective of whether such Lender or such Issuing Bank shall have made demand hereunder and although such Obligations may be unmatured&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> that in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.26(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent, the Issuing Banks, and the Lenders, and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. Each Lender and each Issuing Bank agrees promptly to notify the Administrative Agent and the Borrower after any such set-off and any application made by such Lender or such Issuing Bank, as the case may be&#59; provided that the failure to give such notice shall not affect the validity of such set-off and application. Each Lender and each Issuing Bank agrees to apply all amounts collected from any such set-off to the Obligations before applying such amounts to any other Indebtedness or other obligations owed by the Borrower and any of its Subsidiaries to such Lender or such Issuing Bank.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Counterparts&#59; Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts, and all of said counterparts taken together shall be deemed to constitute one and the same instrument. This Agreement, the Fee Letter, the other Loan Documents, and any separate letter agreements relating to any fees payable to the Administrative Agent and its Affiliates constitute the entire agreement among the parties hereto and thereto and their affiliates regarding the subject matters hereof and thereof and supersede all prior agreements and understandings, oral or written, regarding such subject matters. Delivery of an executed counterpart to this Agreement or any other Loan Document by facsimile transmission or by electronic mail in pdf format shall be as effective as delivery of a manually executed counterpart hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All covenants, agreements, representations and warranties made by the Borrower herein and in the certificates, reports, notices or other instruments delivered in connection with or pursuant to this Agreement shall be considered to have been relied upon by the other parties hereto and shall survive the execution and delivery of this Agreement and the other Loan Documents and the making of any Loans and issuance of any Letters of Credit, regardless of any investigation made by any such other party or on its behalf and notwithstanding that the Administrative Agent, any Issuing Bank or any Lender may have had notice or knowledge of any Default or incorrect representation or warranty at the time any credit is extended hereunder, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any fee or any other amount payable under this Agreement is outstanding and unpaid or any Letter of Credit is outstanding and so long as the Commitments have not expired or terminated. The provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Sections 2.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">2.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">10.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and the last sentence of the definition of Applicable Margin shall survive and remain in full force and effect regardless of the consummation of the transactions contemplated hereby, the repayment of the Loans, the expiration or termination of the Letters of Credit and the Commitments or the termination of this Agreement or any provision hereof. All representations and warranties made herein, in the Loan Documents in the certificates, reports, notices, and other documents delivered pursuant to this Agreement shall survive the execution and delivery of this Agreement and the other Loan Documents, and the making of the Loans and the issuance of the Letters of Credit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Any provision of this Agreement or any other Loan Document held to be illegal, invalid or unenforceable in any jurisdiction, shall, as to such jurisdiction, be ineffective to the extent of such illegality, invalidity or unenforceability without affecting the legality, validity or enforceability of the remaining provisions hereof or thereof&#59; and the illegality, invalidity or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">131</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">unenforceability of a particular provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Each of the Administrative Agent, the Issuing Banks and the Lenders agrees to maintain the confidentiality of any information received from the Borrower, any of its Subsidiaries or any Associated Practice relating to the Borrower, any of its Subsidiaries or any Associated Practice or any of their respective businesses, other than any such information that is available to the Administrative Agent, any Issuing Bank or any Lender on a non-confidential basis prior to disclosure by the Borrower, any of its Subsidiaries or any Associated Practice, except that such information may be disclosed (i) to any Related Party of the Administrative Agent, any Issuing Bank or any such Lender including, without limitation, accountants, legal counsel and other advisors, (ii) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (iii) to the extent requested by any regulatory agency or authority purporting to have jurisdiction over it (including any self-regulatory authority such as the National Association of Insurance Commissioners), (iv) to the extent that such information becomes publicly available other than as a result of a breach of this Section, or which becomes available to the Administrative Agent, any Issuing Bank, any Lender or any Related Party of any of the foregoing on a non-confidential basis from a source other than the Borrower, any of its Subsidiaries or any Associated Practice, (v) in connection with the exercise of any remedy hereunder or under any other Loan Documents or any suit, action or proceeding relating to this Agreement or any other Loan Documents or the enforcement of rights hereunder or thereunder, (vi) subject to execution by such Person of an agreement containing provisions substantially the same as those of this Section, to (A) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement, and, in each case, their respective financing sources, or (B) any actual or prospective party (or its Related Parties) to any swap or derivative or other transaction under which payments are to be made by reference to the Borrower and its obligations, this Agreement or payments hereunder, (vii) to any rating agency, (viii) to the CUSIP Service Bureau or any similar organization, or (ix) with the written consent of the Borrower. Any Person required to maintain the confidentiality of any information as provided for in this Section shall exercise the same degree of care to maintain the confidentiality of such information as such Person would accord its own confidential information. In the event of any conflict between the terms of this Section and those of any other Contractual Obligation entered into with any Loan Party (whether or not a Loan Document), the terms of this Section shall govern.  Each Arranger may, at its own expense, place customary tombstone announcements and advertisements or otherwise publicize their engagement hereunder (which may include the reproduction of any Loan Party&#8217;s name and logo and other publicly available information) in financial and other newspapers and journals and marketing materials describing its services hereunder.  Further, each Arranger may provide to market data collectors, such as league table, or other service providers to the lending industry, information regarding the closing date, size, type, purpose of, and parties to, the credit facilities established hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Interest Rate Limitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything herein to the contrary, if at any time the interest rate applicable to any Loan, together with all fees, charges and other amounts which may be treated as interest on such Loan under applicable law (collectively, the &#8220;Charges&#8221;), shall exceed the maximum lawful rate of interest (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) which may be contracted for, charged, taken, received or reserved by a Lender holding such Loan in accordance with applicable law, the rate of interest payable in respect of such Loan hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent lawful, the interest and Charges that would have been payable in respect of such Loan but were not payable as a result of the operation of this Section shall be cumulated and the interest and Charges payable to such Lender in respect of other Loans or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">132</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">interest thereon at the Federal Funds Rate to the date of repayment (to the extent permitted by applicable law), shall have been received by such Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Waiver of Effect of Corporate Seal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Borrower represents and warrants that neither it nor any other Loan Party is required to affix its corporate seal to this Agreement or any other Loan Document pursuant to any Requirement of Law, agrees that this Agreement is delivered by the Borrower under seal and waives any shortening of the statute of limitations that may result from not affixing the corporate seal to this Agreement or such other Loan Documents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Administrative Agent and each Lender hereby notifies the Loan Parties that, pursuant to (a) the requirements of the Patriot Act, it is required to obtain, verify and record information that identifies each Loan Party, which information includes the name and address of such Loan Party and other information that will allow such Lender or the Administrative Agent, as applicable, to identify such Loan Party in accordance with the Patriot Act and (b) the Beneficial Ownership Regulation, it is required to obtain a Beneficial Ownership Certificate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">No Advisory or Fiduciary Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), the Borrower and each other Loan Party acknowledges and agrees and acknowledges its Affiliates&#8217; understanding that (i) (A) the services regarding this Agreement provided by the Administrative Agent and&#47;or the Lenders are arm&#8217;s-length commercial transactions between the Borrower, each other Loan Party and their respective Affiliates, on the one hand, and the Administrative Agent and the Lenders, on the other hand, (B) each of the Borrower and the other Loan Parties have consulted their own legal, accounting, regulatory and tax advisors to the extent they have deemed appropriate, and (C) the Borrower and each other Loan Party is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents&#59; (ii) (A) each of the Administrative Agent and the Lenders is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Borrower, any other Loan Party or any of their respective Affiliates, or any other Person, and (B) neither the Administrative Agent nor any Lender has any obligation to the Borrower, any other Loan Party or any of their Affiliates with respect to the transaction contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents&#59; and (iii) the Administrative Agent, the Lenders and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower, the other Loan Parties and their respective Affiliates, and each of the Administrative Agent and the Lenders has no obligation to disclose any of such interests to the Borrower, any other Loan Party or any of their respective Affiliates. To the fullest extent permitted by law, each of the Borrower and the other Loan Parties hereby waives and releases any claims that it may have against the Administrative Agent or any Lender with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Location of Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each Lender and each Issuing Bank acknowledges and agrees that it has delivered, with the intent to be bound, its executed counterparts of this Agreement to the Administrative Agent, c&#47;o Alston &#38; Bird LLP, 90 Park Avenue, New York, NY 10016. The Borrower acknowledges and agrees that it has delivered, with the intent to be bound, its executed counterparts of this Agreement and each other Loan Document, together with all other documents, instruments, opinions, certificates and other items required under </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, to the Administrative Agent, c&#47;o Alston &#38; Bird LLP, 90 Park Avenue, New York, NY 10016. All parties agree that the closing of the transactions contemplated by this Agreement has occurred in New York.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">133</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Independence of Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All covenants hereunder shall be given independent effect so that if a particular action or condition is not permitted by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within the limitations of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken or condition exists.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Acknowledgement and Consent to Bail-In of Affected Financial Institutions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the effects of any Bail-in Action on any such liability, including, if applicable (i) a reduction in full or in part or cancellation of any such liability, (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document or (iii) the variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of the applicable Resolution Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Certain ERISA Matters.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Loan Party, that at least one of the following is and will be true&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;such Lender is not using &#8220;plan assets&#8221; (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Benefit Plans with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments or this Agreement,</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">134</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;(A) such Lender is an investment fund managed by a &#8220;Qualified Professional Asset Manager&#8221; (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Letters of Credit, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement, or</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or (2) a Lender has provided another representation, warranty and covenant in accordance with sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Loan Party, that the Administrative Agent is not a fiduciary with respect to the assets of such Lender involved in such Lender&#8217;s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any Loan Document or any documents related hereto or thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Acknowledgement Regarding Any Supported QFCs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Hedging Obligations or any other agreement or instrument that is a QFC (such support, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">QFC Credit Support</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and each such QFC a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Supported QFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Special Resolution Regimes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in respect of such Supported QFC and QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and&#47;or of the United States or any other state of the United States)&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In the event a Covered Entity that is party to a Supported QFC (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC or such QFC Credit Support) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">135</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;As used in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 10.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the following terms have the following meanings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BHC Act Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; of a party means an &#8220;affiliate&#8221; (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; means any of the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:85.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;252.82(b)&#59;</font></div><div style="margin-bottom:12pt;padding-left:85.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;47.3(b)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:85.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;382.2(b).</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Default Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167;252.81, 47.2 or 382.1, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">QFC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; has the meaning assigned to the term &#8220;qualified financial contract&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Section 10.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Electronic Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The words &#8220;execution,&#8221; &#8220;execute,&#8221; &#8220;signed,&#8221; &#8220;signature,&#8221; and words of like import in or related to this Agreement or any other document to be signed in connection with this Agreement and the transactions contemplated hereby shall be deemed to include electronic signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">that notwithstanding anything contained herein to the contrary the Administrative Agent is under no obligation to agree to accept electronic signatures in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#91;Remainder of page intentionally blank&#59; signature pages follow.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">136</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first above written.</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Thomas S. Lam&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Thomas S. Lam, M.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; President and Co-CEO</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Eric Chin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Eric Chin</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Chief Financial Officer</font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:252pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">137</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRUIST BANK</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as the Administrative Agent, as an Issuing Bank, as the Swingline Lender and as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ron Caldwell&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Ron Caldwell</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Managing Director</font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">138</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">JPMORGAN CHASE BANK, N.A.</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David Hyman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; David Hyman</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Executive Director</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">139</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FIFTH THIRD BANK, NATIONAL ASSOCIATION</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Thomas Avery&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Thomas Avery</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Executive Director</font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">140</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MUFG UNION BANK, N.A.</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Erik Siegfried&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Erik Siegfried</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Vice President</font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">141</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PREFERRED BANK</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Frank Phalen&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Frank Phalen</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; First Vice President</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">142</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ROYAL BANK OF CANADA</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Mustafa Topiwalla&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Mustafa Topiwalla</font></div><div style="padding-left:234pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">143</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CITY NATIONAL BANK</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Breck Fleming&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Breck Fleming</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Senior VP</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">144</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BANK OF THE WEST</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Shikha Rehman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Shikha Rehman</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Director</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">145</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">THE TORONTO-DOMINION BANK, NEW YORK BRANCH</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Maria Macchiaroli&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Maria Macchiaroli</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Authorized Signatory</font></div><div><font><br></font></div><div style="padding-left:234pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">146</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WELLS FARGO BANK, NATIONAL ASSOCIATION</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">as a Lender</font></div><div style="padding-left:234pt"><font><br></font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jonathan Antonio&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58; Jonathan Antonio</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President</font></div><div style="padding-left:252pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">147</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31120210630110-q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie0b8acf53e8940948a2b3817c6be12c1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth Sim, M.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth Sim</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman and Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex3122021063010-q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8f2ade53cba14adc822116fddbc2bcb3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.2</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>5
<FILENAME>ex3132021063010-q.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2ee2e671cd7a43b685c24f62694312c9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.3</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eric Chin</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>ex322021063010-q.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7af087f4d0464629b453a7c659ab5c84_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth Sim, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth Sim</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman and Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended June&#160;30, 2021 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 6, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eric Chin</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ameh-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:95c9976f-ff84-4dd6-aeb6-cbf10c7f8b0a,g:1aa3c04f-4646-4116-829c-b4ce4a78f20a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ameh="http://www.apollomed.net/20210630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.apollomed.net/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>2110103 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>2311302 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>2412406 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>2412406 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails">
        <link:definition>2414408 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethod" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod">
        <link:definition>2115104 - Disclosure - Investments in Other Entities &#8212; Equity Method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables">
        <link:definition>2316303 - Disclosure - Investments in Other Entities &#8212; Equity Method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
        <link:definition>2417409 - Disclosure - Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
        <link:definition>2418410 - Disclosure - Investments in Other Entities &#8212; Equity Method - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>2419411 - Disclosure - Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedParties" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties">
        <link:definition>2120105 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
        <link:definition>2421412 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>2122106 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2323304 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>2424413 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>2125107 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>2326305 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails">
        <link:definition>2427414 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit">
        <link:definition>2128108 - Disclosure - Credit Facility, Bank Loan and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables">
        <link:definition>2329306 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails">
        <link:definition>2430415 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>2431416 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails">
        <link:definition>2432417 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>2133109 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails">
        <link:definition>2434418 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>2135110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2436419 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>2137111 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>2338307 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2439420 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
        <link:definition>2440421 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>2141112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2442422 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>2143113 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>2344308 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>2445423 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails">
        <link:definition>2446424 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
        <link:definition>2447425 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>2148114 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>2349309 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails">
        <link:definition>2450426 - Disclosure - Variable Interest Entities (VIEs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>2151115 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>2352310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>2453427 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2454428 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails">
        <link:definition>2455429 - Disclosure - Leases - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails">
        <link:definition>2456430 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2456430 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.apollomed.net/role/StockBasedCompensation">
        <link:definition>2157116 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.apollomed.net/role/StockBasedCompensationTables">
        <link:definition>2358311 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2459431 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2460432 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2461433 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
        <link:definition>2462434 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWarrantDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails">
        <link:definition>2463435 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWarrantsDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails">
        <link:definition>2464436 - Disclosure - Stock-Based Compensation - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.apollomed.net/role/SubsequentEvents">
        <link:definition>2165117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>2466437 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ameh_ContractTypeAxis" abstract="true" name="ContractTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_FulgentGeneticsIncMember" abstract="true" name="FulgentGeneticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AchievaMedInc.Member" abstract="true" name="AchievaMedInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationPreferredShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessLineItems" abstract="true" name="DescriptionOfBusinessLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_Tag8MedicalInvestmentGroupLLCMember" abstract="true" name="Tag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_AssetAcquisitionPercentageOfSharesAcquired" abstract="false" name="AssetAcquisitionPercentageOfSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_BeneficialInterestPolicyTextBlock" abstract="false" name="BeneficialInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ZLLPartnersLLCMember" abstract="true" name="ZLLPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfLocations" abstract="false" name="NumberOfLocations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_EarningsPerShareTable" abstract="true" name="EarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CollegeStreetInvestmentLpMember" abstract="true" name="CollegeStreetInvestmentLpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodProxyVotesPercentage" abstract="false" name="StockIssuedDuringPeriodProxyVotesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageDisposed" abstract="false" name="EquityMethodInvestmentOwnershipPercentageDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationCash" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsConsolidated" abstract="false" name="EquityMethodInvestmentsConsolidated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountableHealthCareIPAMember" abstract="true" name="AccountableHealthCareIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AlphaCareMedicalGroupInc.Member" abstract="true" name="AlphaCareMedicalGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicalCareCostsAbstract" abstract="true" name="MedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_UniversalCareAcquisitionPartnersLlcMember" abstract="true" name="UniversalCareAcquisitionPartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareholdersAndOfficersMember" abstract="true" name="ShareholdersAndOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_ApcLsmaMember" abstract="true" name="ApcLsmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_FinanceReceivableInterestRateStatedPercentage" abstract="false" name="FinanceReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PaymentConsultingFees" abstract="false" name="PaymentConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PayorGMember" abstract="true" name="PayorGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MediPortalLLCMember" abstract="true" name="MediPortalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" abstract="false" name="FinanceReceivableModificationsSubsequentDefaultInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_AMGPropertiesLLCMember" abstract="true" name="AMGPropertiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NumberOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_FinanceReceivableStatedInterestRate" abstract="false" name="FinanceReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_AccountsPayableAndAccruedExpensesMember" abstract="true" name="AccountsPayableAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" abstract="true" name="MPPAMGPropertiesAndZLLAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" abstract="true" name="OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeOneMember" abstract="true" name="WarrantExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" abstract="false" name="PercentageOfFinancialGuaranteeBenchmarkAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_DiagnosticMedicalGroupMember" abstract="true" name="DiagnosticMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_Pacific6EnterprisesMember" abstract="true" name="Pacific6EnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfEmployees" abstract="false" name="NumberOfEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_NumenLLCMember" abstract="true" name="NumenLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Dr.ArteagaMember" abstract="true" name="Dr.ArteagaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableTermOfReceivable" abstract="false" name="FinanceReceivableTermOfReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_AmgIncMember" abstract="true" name="AmgIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockAwardsAndUnitsMember" abstract="true" name="StockAwardsAndUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentOfRevenue" abstract="false" name="PaymentOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SunClinicalLaboratoriesMember" abstract="true" name="SunClinicalLaboratoriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ApcStockOptionMember" abstract="true" name="ApcStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeTwoMember" abstract="true" name="WarrantExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessTable" abstract="true" name="DescriptionOfBusinessTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" abstract="true" name="ConcourseDiagnosticSurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_AccessPrimaryCareMedicalGroupMember" abstract="true" name="AccessPrimaryCareMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOLLCMember" abstract="true" name="OneMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOInc.Member" abstract="true" name="OneMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CancellationOfRestrictedStockAwards" abstract="false" name="CancellationOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PayorFMember" abstract="true" name="PayorFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PerMemberPerMonthManagedCareContractMember" abstract="true" name="PerMemberPerMonthManagedCareContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AdvanceDiagnosticSurgeryCenterMember" abstract="true" name="AdvanceDiagnosticSurgeryCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_APCAndAPCLSMAMember" abstract="true" name="APCAndAPCLSMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ProceedsFromSaleOfNoncontrollingInterest" abstract="false" name="ProceedsFromSaleOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_TemporaryEquityPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ConstructionLoanMember" abstract="true" name="ConstructionLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" abstract="true" name="Tag8MedicalInvestmentGroupLLCRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfFamilyPracticeClinics" abstract="false" name="NumberOfFamilyPracticeClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" abstract="false" name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementIncMember" abstract="true" name="NetworkMedicalManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_Dr.JayMember" abstract="true" name="Dr.JayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentOfRevenueMonthlyAmount" abstract="false" name="PaymentOfRevenueMonthlyAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ApaacoMember" abstract="true" name="ApaacoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" abstract="false" name="BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" abstract="false" name="ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_PaymentOfRevenueRevenueRecognized" abstract="false" name="PaymentOfRevenueRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ContractTypeDomain" abstract="true" name="ContractTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" abstract="false" name="AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ApaAcoIncMember" abstract="true" name="ApaAcoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantDebtCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_FiduciaryCashAndPayablePolicyTextBlock" abstract="false" name="FiduciaryCashAndPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_AggregateintrinsicvalueAbstract" abstract="true" name="AggregateintrinsicvalueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightCancelledInPeriod" abstract="false" name="ClassOfWarrantOrRightCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantCashFlowCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" abstract="true" name="WeightedaverageremainingcontractualtermyearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueTable" abstract="true" name="AccountsReceivableAndNetRevenueTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CriticalQualityManagementCorpMember" abstract="true" name="CriticalQualityManagementCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" abstract="true" name="LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_FreseniusMember" abstract="true" name="FreseniusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_APAMHMedicalCorporationMember" abstract="true" name="APAMHMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicalPropertyPartnersLLCMember" abstract="true" name="MedicalPropertyPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorEMember" abstract="true" name="PayorEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" abstract="false" name="InsuranceServicesRevenueCapitationAndClaimsPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PrepaymentForInvestmentPurchase" abstract="false" name="PrepaymentForInvestmentPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CMSMember" abstract="true" name="CMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SCHCMember" abstract="true" name="SCHCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeThreeMember" abstract="true" name="WarrantExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WeightedAverageExercisePriceWarrantsRollForward" abstract="true" name="WeightedAverageExercisePriceWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_MinorityInterestPolicyPolicyTextBlock" abstract="false" name="MinorityInterestPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_SubcontractorIPAPayable" abstract="false" name="SubcontractorIPAPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" abstract="false" name="EquityMethodAndOtherEquityInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_EarningsPerShareLineItems" abstract="true" name="EarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" abstract="false" name="WarrantIssuedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AncillaryServiceContractMember" abstract="true" name="AncillaryServiceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueLineItems" abstract="true" name="AccountsReceivableAndNetRevenueLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_MaverickMedicalGroupIncMember" abstract="true" name="MaverickMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" abstract="false" name="ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_ApcShareholdersMember" abstract="true" name="ApcShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" abstract="false" name="BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentMadeToRelatedParty" abstract="false" name="PaymentMadeToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LmaMember" abstract="true" name="LmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SharesWarrantsRollForward" abstract="true" name="SharesWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_UniversalCareIncMember" abstract="true" name="UniversalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" abstract="false" name="EquityMethodInvestmentWriteOffOfAdditionalProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsContribution" abstract="false" name="EquityMethodInvestmentsContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ameh-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:95c9976f-ff84-4dd6-aeb6-cbf10c7f8b0a,g:1aa3c04f-4646-4116-829c-b4ce4a78f20a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_770a51f6-16ba-4d28-ba57-b424cd91ae31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_75421ed1-c085-4898-8207-0f087d3039af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_770a51f6-16ba-4d28-ba57-b424cd91ae31" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_75421ed1-c085-4898-8207-0f087d3039af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_18e4c3aa-fd8a-4091-9755-5dc7287fea21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_770a51f6-16ba-4d28-ba57-b424cd91ae31" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_18e4c3aa-fd8a-4091-9755-5dc7287fea21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b9d3fde-6b98-4dd7-9f7e-64850bf462be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_770a51f6-16ba-4d28-ba57-b424cd91ae31" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1b9d3fde-6b98-4dd7-9f7e-64850bf462be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_69d68cae-382b-41ea-aa2b-2aa729027209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_770a51f6-16ba-4d28-ba57-b424cd91ae31" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_69d68cae-382b-41ea-aa2b-2aa729027209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5585d71b-0314-4d96-9aa4-45c977cd4c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_770a51f6-16ba-4d28-ba57-b424cd91ae31" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5585d71b-0314-4d96-9aa4-45c977cd4c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5d793495-44cb-46ad-aa78-944c41e314e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5d793495-44cb-46ad-aa78-944c41e314e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_7d869ab4-7c1a-494e-a97f-e1901bf9dfe7" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_7d869ab4-7c1a-494e-a97f-e1901bf9dfe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b45081c5-28de-4a42-8d6b-345a3f8c5726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b45081c5-28de-4a42-8d6b-345a3f8c5726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_1c26ad0b-64b3-41df-a16f-7634c54c8afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_1c26ad0b-64b3-41df-a16f-7634c54c8afe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_6781d7f0-201e-4d8b-ab9e-230429af779c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_us-gaap_DividendsPayableCurrent_6781d7f0-201e-4d8b-ab9e-230429af779c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f4146799-6d43-45cb-858d-dde1e6e00d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f4146799-6d43-45cb-858d-dde1e6e00d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57073ea4-be9d-4b2b-b34e-b2bb2ad93c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57073ea4-be9d-4b2b-b34e-b2bb2ad93c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_848642d6-fd99-4750-a028-f8ab0f3df66a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_97cbe86e-8cc1-410e-af6d-0684122ba573" xlink:to="loc_us-gaap_LongTermDebtCurrent_848642d6-fd99-4750-a028-f8ab0f3df66a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9ed6a738-a579-4d3f-8c45-fdf9bd7e84ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c6087622-885c-4a05-9060-a4b606b7c278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9ed6a738-a579-4d3f-8c45-fdf9bd7e84ee" xlink:to="loc_us-gaap_StockholdersEquity_c6087622-885c-4a05-9060-a4b606b7c278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c27449e6-ce67-4216-b52a-35011e442b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9ed6a738-a579-4d3f-8c45-fdf9bd7e84ee" xlink:to="loc_us-gaap_MinorityInterest_c27449e6-ce67-4216-b52a-35011e442b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_df07a335-7a75-4f4c-b705-3bc4a144b1da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_024194fa-5ab2-4cc5-afc8-6b51b6d42264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df07a335-7a75-4f4c-b705-3bc4a144b1da" xlink:to="loc_us-gaap_CommonStockValue_024194fa-5ab2-4cc5-afc8-6b51b6d42264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1346f6d8-b1ac-4f9a-9cbd-6d3945751907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df07a335-7a75-4f4c-b705-3bc4a144b1da" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1346f6d8-b1ac-4f9a-9cbd-6d3945751907" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aad5aba3-ce98-40fc-8068-af5dfa56d547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df07a335-7a75-4f4c-b705-3bc4a144b1da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aad5aba3-ce98-40fc-8068-af5dfa56d547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5526c6c1-a52e-4537-8e48-cac1eedd96e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_df07a335-7a75-4f4c-b705-3bc4a144b1da" xlink:to="loc_us-gaap_PreferredStockValue_5526c6c1-a52e-4537-8e48-cac1eedd96e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f4b19fe-1753-42b1-af05-6ef63c571846" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f9f2edd6-4a3e-4dc7-86a5-b95b0d976ff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f4b19fe-1753-42b1-af05-6ef63c571846" xlink:to="loc_us-gaap_Liabilities_f9f2edd6-4a3e-4dc7-86a5-b95b0d976ff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_9ebcbc12-970e-4bc3-a8a4-ed3ea0b4707f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f4b19fe-1753-42b1-af05-6ef63c571846" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_9ebcbc12-970e-4bc3-a8a4-ed3ea0b4707f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b0a1f79a-5ffd-4fa8-95e0-c0967323c341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f4b19fe-1753-42b1-af05-6ef63c571846" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b0a1f79a-5ffd-4fa8-95e0-c0967323c341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49cf3eea-3389-4eb0-839e-547089c25599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6f4b19fe-1753-42b1-af05-6ef63c571846" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49cf3eea-3389-4eb0-839e-547089c25599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_84748770-1be9-434c-a6cc-ec611c43e09f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2f0fe56d-4f68-4a8c-a92c-029a8140d961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_84748770-1be9-434c-a6cc-ec611c43e09f" xlink:to="loc_us-gaap_LiabilitiesCurrent_2f0fe56d-4f68-4a8c-a92c-029a8140d961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_95d52455-684d-4ea4-9b4e-1f4602a79121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_84748770-1be9-434c-a6cc-ec611c43e09f" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_95d52455-684d-4ea4-9b4e-1f4602a79121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9fa2e2a7-56ee-4806-9809-706d23c11f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_073a4fab-8af1-4d83-872a-f1ade190e2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9fa2e2a7-56ee-4806-9809-706d23c11f68" xlink:to="loc_us-gaap_AssetsCurrent_073a4fab-8af1-4d83-872a-f1ade190e2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_80a5b70e-cc62-4d26-a9af-6598e6b602ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9fa2e2a7-56ee-4806-9809-706d23c11f68" xlink:to="loc_us-gaap_AssetsNoncurrent_80a5b70e-cc62-4d26-a9af-6598e6b602ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_afcf434d-0328-4837-a5a0-cb8d3f2632e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_afcf434d-0328-4837-a5a0-cb8d3f2632e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e2993eb-6c72-4a0a-87ff-b1855dd217ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9e2993eb-6c72-4a0a-87ff-b1855dd217ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_15d118b4-7262-4a24-bb57-6eeec8398529" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_Goodwill_15d118b4-7262-4a24-bb57-6eeec8398529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_a879acb8-c01d-4134-9c7b-4f1c2c8b9f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_a879acb8-c01d-4134-9c7b-4f1c2c8b9f5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_71e6efc6-06a7-4887-a4e3-750a2b6f8b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_71e6efc6-06a7-4887-a4e3-750a2b6f8b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6d2305ab-c951-40c3-a4c4-9a23d5e856a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_EquityMethodInvestments_6d2305ab-c951-40c3-a4c4-9a23d5e856a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_03e107e5-1a6f-4ad1-9ee0-b01304a2fcff" xlink:href="ameh-20210630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_03e107e5-1a6f-4ad1-9ee0-b01304a2fcff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_de1cd548-9c70-4fa0-92c8-6c52497180ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_de1cd548-9c70-4fa0-92c8-6c52497180ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_82defcbd-aa38-437d-bfdc-737bd46deb25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_82defcbd-aa38-437d-bfdc-737bd46deb25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_032f6747-6349-431f-b90d-968f64f1da22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_8013dfb1-43e9-45a3-b277-1a36c52e4d58" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_032f6747-6349-431f-b90d-968f64f1da22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6cec261a-f40e-4ade-9e01-9cef54c3664b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7196852b-0627-49f5-acb9-b9e4d386dc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6cec261a-f40e-4ade-9e01-9cef54c3664b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7196852b-0627-49f5-acb9-b9e4d386dc0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d9ef1a41-7579-49f6-a596-b6789440a1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6cec261a-f40e-4ade-9e01-9cef54c3664b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d9ef1a41-7579-49f6-a596-b6789440a1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7d131c0e-149f-4ea9-a3d5-344de2038cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6cec261a-f40e-4ade-9e01-9cef54c3664b" xlink:to="loc_us-gaap_InterestExpense_7d131c0e-149f-4ea9-a3d5-344de2038cbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_c8a0ad16-cb74-4132-8fd9-7f705b4ef378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6cec261a-f40e-4ade-9e01-9cef54c3664b" xlink:to="loc_us-gaap_GainLossOnInvestments_c8a0ad16-cb74-4132-8fd9-7f705b4ef378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cf13c495-eb50-4bf8-a266-f31fd0734a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6cec261a-f40e-4ade-9e01-9cef54c3664b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cf13c495-eb50-4bf8-a266-f31fd0734a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ef95559-5944-467c-99f6-4586a73954cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8584485b-f17c-42fe-bcf0-08bf1107cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1ef95559-5944-467c-99f6-4586a73954cd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_8584485b-f17c-42fe-bcf0-08bf1107cdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d6617e16-636e-4ee0-a859-12f7c0174076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1ef95559-5944-467c-99f6-4586a73954cd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d6617e16-636e-4ee0-a859-12f7c0174076" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5a35fcbc-9239-48d0-b563-c8faed9f76a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a8cce25c-a75e-4fd4-834f-b792690d765a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5a35fcbc-9239-48d0-b563-c8faed9f76a4" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_a8cce25c-a75e-4fd4-834f-b792690d765a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_aebe3511-ec39-4249-b9d6-d9977482efe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5a35fcbc-9239-48d0-b563-c8faed9f76a4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_aebe3511-ec39-4249-b9d6-d9977482efe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_ba26a259-ca30-4148-871e-ace692b57365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_5a35fcbc-9239-48d0-b563-c8faed9f76a4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_ba26a259-ca30-4148-871e-ace692b57365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_98fd359b-df41-4b76-a588-86630c39a0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e0f6dfdf-b83c-4f13-82c6-a6883bf44f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98fd359b-df41-4b76-a588-86630c39a0cb" xlink:to="loc_us-gaap_ProfitLoss_e0f6dfdf-b83c-4f13-82c6-a6883bf44f4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a696b52-e7c6-4df0-a17a-f29a9a21d216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98fd359b-df41-4b76-a588-86630c39a0cb" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a696b52-e7c6-4df0-a17a-f29a9a21d216" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fc105b5f-68d2-4ea6-b9ad-b5ad1491fd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a00be07-179e-4eac-bb22-c133029853d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fc105b5f-68d2-4ea6-b9ad-b5ad1491fd43" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2a00be07-179e-4eac-bb22-c133029853d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_80bc0075-1093-4565-8d0b-63699c0e03a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fc105b5f-68d2-4ea6-b9ad-b5ad1491fd43" xlink:to="loc_us-gaap_CostsAndExpenses_80bc0075-1093-4565-8d0b-63699c0e03a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_020a9d32-fcb7-459d-b2d4-9f3718a01ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bdb6ec2a-69a8-4ee2-91b4-118c1da98025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_020a9d32-fcb7-459d-b2d4-9f3718a01ef8" xlink:to="loc_us-gaap_OperatingIncomeLoss_bdb6ec2a-69a8-4ee2-91b4-118c1da98025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3ae5d7df-6f6c-4a42-8fb2-2b1ec7efa38d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_020a9d32-fcb7-459d-b2d4-9f3718a01ef8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3ae5d7df-6f6c-4a42-8fb2-2b1ec7efa38d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f443a476-7494-49fd-a146-4179f76517a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4c71bc1-ace2-4038-9dec-7b08d9b5b766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f443a476-7494-49fd-a146-4179f76517a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4c71bc1-ace2-4038-9dec-7b08d9b5b766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87bb322b-d7b1-4c72-8d4a-220d2c908e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f443a476-7494-49fd-a146-4179f76517a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87bb322b-d7b1-4c72-8d4a-220d2c908e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f8a6b1f-d612-4346-bdcb-abc506380a10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f443a476-7494-49fd-a146-4179f76517a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f8a6b1f-d612-4346-bdcb-abc506380a10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_4aa0d5d0-6d01-40bf-a34d-6eb2364eeb00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_4aa0d5d0-6d01-40bf-a34d-6eb2364eeb00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_906ef31c-5006-4bd7-b236-de485a7db188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_906ef31c-5006-4bd7-b236-de485a7db188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bd9517a2-18c0-42a4-b232-f4598f1e576c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bd9517a2-18c0-42a4-b232-f4598f1e576c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrepaymentForInvestmentPurchase_2496376a-142d-4757-aa2a-3d46c96848da" xlink:href="ameh-20210630.xsd#ameh_PrepaymentForInvestmentPurchase"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_ameh_PrepaymentForInvestmentPurchase_2496376a-142d-4757-aa2a-3d46c96848da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_397292a9-6c0e-4cc7-b6b7-d61372689af6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_397292a9-6c0e-4cc7-b6b7-d61372689af6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_6b3b9b79-2d26-4315-8ced-e86e9e214ed1" xlink:href="ameh-20210630.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_6b3b9b79-2d26-4315-8ced-e86e9e214ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_ede61f12-5ccb-43e4-92b0-cfc58080cc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_ede61f12-5ccb-43e4-92b0-cfc58080cc8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_eccf6b9c-2b3c-4789-8d6c-d4c79c30bd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_eccf6b9c-2b3c-4789-8d6c-d4c79c30bd5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_74a14b49-35ac-41f7-8807-4f9f065b80c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d5c31089-a36c-491a-a94e-e4ce17474d85" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_74a14b49-35ac-41f7-8807-4f9f065b80c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8b003ef0-3ad4-4155-b76b-b064818c77fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8b003ef0-3ad4-4155-b76b-b064818c77fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_7a1d5723-36df-49ec-ba62-2e38a952b976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_7a1d5723-36df-49ec-ba62-2e38a952b976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_936a2f34-887a-4ad6-a98d-a8937954d89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_936a2f34-887a-4ad6-a98d-a8937954d89b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_6e4cf213-213b-4e80-88c8-d879a2a72b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_6e4cf213-213b-4e80-88c8-d879a2a72b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2d89cf8d-9ddf-4448-b43f-39f961d051b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2d89cf8d-9ddf-4448-b43f-39f961d051b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_886b289b-5532-4fd6-94cd-a3455843d460" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_PaymentsOfDividends_886b289b-5532-4fd6-94cd-a3455843d460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_c6390970-a7c0-439b-a580-9af8ff650eb2" xlink:href="ameh-20210630.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_c6390970-a7c0-439b-a580-9af8ff650eb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8c27f00d-1c1a-4952-9f9e-e5f80847430a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8c27f00d-1c1a-4952-9f9e-e5f80847430a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_bcba0dd7-3e93-47ba-8c2b-f0718d87be80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_bcba0dd7-3e93-47ba-8c2b-f0718d87be80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_bda846bf-2ca5-43dd-aa43-941406ffdc88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_910dd497-e8de-4ab0-8341-3e6c6db017f6" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_bda846bf-2ca5-43dd-aa43-941406ffdc88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_4e789b16-b4c3-424c-942c-88d55c4e9235" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_4e789b16-b4c3-424c-942c-88d55c4e9235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6433511b-3e4a-4f40-8c95-da9d06df0786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_6433511b-3e4a-4f40-8c95-da9d06df0786" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_afdfc3e9-a98d-4965-bddc-561f38213566" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_afdfc3e9-a98d-4965-bddc-561f38213566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b4e8163a-b97e-4523-9f55-44b06ad0debf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b4e8163a-b97e-4523-9f55-44b06ad0debf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_d7247498-b12f-40b0-8e81-e1130022d0b8" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_d7247498-b12f-40b0-8e81-e1130022d0b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_f96937d4-7639-4978-82d4-9383fd160f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_f96937d4-7639-4978-82d4-9383fd160f9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_da97a029-4258-4432-86f5-bbba46b52ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_da97a029-4258-4432-86f5-bbba46b52ab2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7e68d1a0-b75d-4f9f-aee9-90192e5d7ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7e68d1a0-b75d-4f9f-aee9-90192e5d7ba4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c1dc1c51-9e41-48d0-a5b9-2569029fa2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c1dc1c51-9e41-48d0-a5b9-2569029fa2d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_4091273d-d1a2-4539-9f3b-23538945df18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_4091273d-d1a2-4539-9f3b-23538945df18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6b3b2655-aaed-421e-9122-4866a2be17ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_AssetImpairmentCharges_6b3b2655-aaed-421e-9122-4866a2be17ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2786fc28-0f3b-430d-b4ee-876315d13515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_2786fc28-0f3b-430d-b4ee-876315d13515" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_9b8da5fc-457d-4914-a069-9e51ebbbc57d" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_9b8da5fc-457d-4914-a069-9e51ebbbc57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4fddf38c-e658-479a-ad7f-f60291ab7f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4fddf38c-e658-479a-ad7f-f60291ab7f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3fa7615a-22ad-488d-b1e0-4bcfd8836e61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_ProfitLoss_3fa7615a-22ad-488d-b1e0-4bcfd8836e61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ebeb4229-df18-4eda-af77-aceaeb651d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ebeb4229-df18-4eda-af77-aceaeb651d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_89cb5e5e-4c55-4f7f-83a8-eb405867c2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_89cb5e5e-4c55-4f7f-83a8-eb405867c2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_61ecb352-a5de-42e2-ba49-56e6b50ef2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_61ecb352-a5de-42e2-ba49-56e6b50ef2f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c5d59cea-fe14-497d-bf5e-9a07b8385655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c5d59cea-fe14-497d-bf5e-9a07b8385655" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_01023b9d-b557-45c9-bce0-3b75b7bc88ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_01023b9d-b557-45c9-bce0-3b75b7bc88ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b8c7a6fc-8b6e-4978-bbf5-e24cf2614082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b8c7a6fc-8b6e-4978-bbf5-e24cf2614082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_61fb5be4-3248-4022-abad-18358c379d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4fe4a0cb-865c-43ef-b0a0-3ba42fddd574" xlink:to="loc_us-gaap_ShareBasedCompensation_61fb5be4-3248-4022-abad-18358c379d33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac3af20c-8690-4be3-ab36-b18f044f9fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_a53bfc5f-d90f-4c2a-ad7c-e42b1eede595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac3af20c-8690-4be3-ab36-b18f044f9fa5" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_a53bfc5f-d90f-4c2a-ad7c-e42b1eede595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61048f9e-83c7-4007-8ea9-45eb43912b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac3af20c-8690-4be3-ab36-b18f044f9fa5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61048f9e-83c7-4007-8ea9-45eb43912b29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_cd80f659-2ec8-47fc-add9-1ad60b8cec5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac3af20c-8690-4be3-ab36-b18f044f9fa5" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_cd80f659-2ec8-47fc-add9-1ad60b8cec5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e250a584-0804-44eb-aac3-b0176c3b9582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dfa1fc5b-d349-4170-b6ec-05ea5ed5e45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e250a584-0804-44eb-aac3-b0176c3b9582" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_dfa1fc5b-d349-4170-b6ec-05ea5ed5e45a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_57c46278-e1c9-4a51-956a-746d1bc062e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e250a584-0804-44eb-aac3-b0176c3b9582" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_57c46278-e1c9-4a51-956a-746d1bc062e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_2c749fa2-8965-48ec-8fb7-11940af154c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e250a584-0804-44eb-aac3-b0176c3b9582" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_2c749fa2-8965-48ec-8fb7-11940af154c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5ff9a88b-7b92-494a-8bcc-c37173e50585" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_f5e8981f-e22f-448e-ae1f-9b325de37251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_5ff9a88b-7b92-494a-8bcc-c37173e50585" xlink:to="loc_us-gaap_DerivativeLiabilities_f5e8981f-e22f-448e-ae1f-9b325de37251" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_59fd848c-ccaa-4142-8153-c8c8a423e6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ec6cc5a9-f8c4-423d-94d0-5674ebf6fa60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_59fd848c-ccaa-4142-8153-c8c8a423e6d0" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_ec6cc5a9-f8c4-423d-94d0-5674ebf6fa60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a94f3e0-c582-4361-8fde-4d47fcb7b34d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_59fd848c-ccaa-4142-8153-c8c8a423e6d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0a94f3e0-c582-4361-8fde-4d47fcb7b34d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_281f433d-2e49-4bd7-b119-dec0c7ddcfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93a01de-5921-4f37-a7cf-0030b8c4072f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_281f433d-2e49-4bd7-b119-dec0c7ddcfbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93a01de-5921-4f37-a7cf-0030b8c4072f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d39d589d-b279-4ce2-97b8-911b528ee497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_281f433d-2e49-4bd7-b119-dec0c7ddcfbd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d39d589d-b279-4ce2-97b8-911b528ee497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a5ca99e5-148d-4e4e-8301-56ed9b4e4414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_953571f6-baf9-4d6b-89e9-1f2dacf250d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a5ca99e5-148d-4e4e-8301-56ed9b4e4414" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_953571f6-baf9-4d6b-89e9-1f2dacf250d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2488e150-0fc2-4da3-a56b-1089364707b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0b9dfda4-92ca-40b3-8552-268390781887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2488e150-0fc2-4da3-a56b-1089364707b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0b9dfda4-92ca-40b3-8552-268390781887" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3df8c841-c29d-45da-8b5a-a48c103d0b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9da58882-fa95-43fa-9839-6f0280419a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3df8c841-c29d-45da-8b5a-a48c103d0b7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9da58882-fa95-43fa-9839-6f0280419a22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2c07a752-9173-4231-8437-4e9ec09d08d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3df8c841-c29d-45da-8b5a-a48c103d0b7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2c07a752-9173-4231-8437-4e9ec09d08d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a4b0aecb-e8f9-44e3-845a-2309207ccf15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3df8c841-c29d-45da-8b5a-a48c103d0b7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a4b0aecb-e8f9-44e3-845a-2309207ccf15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cebbda1b-35a6-4e0f-ab66-97256be89c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3df8c841-c29d-45da-8b5a-a48c103d0b7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cebbda1b-35a6-4e0f-ab66-97256be89c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_23591f3b-906c-4d87-afcd-cbe6e09b9dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3df8c841-c29d-45da-8b5a-a48c103d0b7d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_23591f3b-906c-4d87-afcd-cbe6e09b9dc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_219f55e9-5c89-4532-884b-3312f64a71e1" xlink:href="ameh-20210630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3df8c841-c29d-45da-8b5a-a48c103d0b7d" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_219f55e9-5c89-4532-884b-3312f64a71e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_595b4f9e-59d8-420c-ac63-240c66b111e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_595b4f9e-59d8-420c-ac63-240c66b111e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_42f7f083-ec6d-48d4-85c6-80b998bd5de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_42f7f083-ec6d-48d4-85c6-80b998bd5de4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_80744fbe-6bbe-4cf0-b158-a4c4578d741e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:to="loc_us-gaap_RestrictedCashCurrent_80744fbe-6bbe-4cf0-b158-a4c4578d741e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_9fd20473-63c1-474a-88a6-f39bf36bfa71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_9fd20473-63c1-474a-88a6-f39bf36bfa71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_864b10e2-6c0b-40d1-b120-2b303a19c5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:to="loc_us-gaap_OtherAssetsCurrent_864b10e2-6c0b-40d1-b120-2b303a19c5a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_df122afb-9666-4bb8-8853-d12b2b2c58b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:to="loc_us-gaap_OtherAssets_df122afb-9666-4bb8-8853-d12b2b2c58b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d7bc2808-f69d-42a4-a126-90c51403a868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6d10725f-62a5-4f2b-ae4d-3876ffdc1abb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d7bc2808-f69d-42a4-a126-90c51403a868" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_89e6bcef-e207-4500-9a97-4cf73f30b45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:to="loc_us-gaap_AccountsPayableCurrent_89e6bcef-e207-4500-9a97-4cf73f30b45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_70f37495-4c2e-4520-afd0-6fac911f34c5" xlink:href="ameh-20210630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_70f37495-4c2e-4520-afd0-6fac911f34c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_998cefea-6dc7-4b15-b3a2-39f8b6b2d92e" xlink:href="ameh-20210630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:to="loc_ameh_SubcontractorIPAPayable_998cefea-6dc7-4b15-b3a2-39f8b6b2d92e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8bb076dc-a1a1-4319-924f-b3f11da54eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8bb076dc-a1a1-4319-924f-b3f11da54eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_f0bcf91a-2df9-4b13-b087-5b898c617071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_f0bcf91a-2df9-4b13-b087-5b898c617071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2db8eeb6-1257-430f-a2cb-ccf104a4ca9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2db8eeb6-1257-430f-a2cb-ccf104a4ca9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e4966d36-203c-4926-b1a9-4667780af2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_5c769834-e8f9-425e-beac-0fbce56df6ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e4966d36-203c-4926-b1a9-4667780af2ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_03128020-62d3-4d0a-ac85-96fe1813c9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_49333e83-f6f0-48e5-9e16-a2a3c661b98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_03128020-62d3-4d0a-ac85-96fe1813c9c3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_49333e83-f6f0-48e5-9e16-a2a3c661b98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_300d2f99-a5bd-41f8-bf1a-2c5d9465b684" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_03128020-62d3-4d0a-ac85-96fe1813c9c3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_300d2f99-a5bd-41f8-bf1a-2c5d9465b684" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6726f136-3955-426a-82e0-7c5f7ecf6a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_0a6a9a32-f0d7-41b3-90ff-465cfe6b4c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6726f136-3955-426a-82e0-7c5f7ecf6a71" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_0a6a9a32-f0d7-41b3-90ff-465cfe6b4c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_3b01af19-5e10-49eb-9105-c43e4c66a9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6726f136-3955-426a-82e0-7c5f7ecf6a71" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_3b01af19-5e10-49eb-9105-c43e4c66a9f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_cec18ada-7072-40c2-905d-fc918324d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a93adb28-292d-4d11-8086-d2facd3d0942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_cec18ada-7072-40c2-905d-fc918324d7cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a93adb28-292d-4d11-8086-d2facd3d0942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f30cd612-c307-401f-b68a-062a405e2619" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_cec18ada-7072-40c2-905d-fc918324d7cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f30cd612-c307-401f-b68a-062a405e2619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1c775864-69df-4864-853b-1bee1d1b9dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_cec18ada-7072-40c2-905d-fc918324d7cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1c775864-69df-4864-853b-1bee1d1b9dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0d2327cf-252f-43c9-98b4-831664ec0423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_cec18ada-7072-40c2-905d-fc918324d7cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0d2327cf-252f-43c9-98b4-831664ec0423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_22acb015-e137-4ccd-84bf-5f33b509e58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_cec18ada-7072-40c2-905d-fc918324d7cc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_22acb015-e137-4ccd-84bf-5f33b509e58e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_06707c6c-20fb-4a27-a8d3-1cc165cb35dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_ff8c434a-4b40-4c85-a6e7-49a1b03008c5" xlink:href="ameh-20210630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_06707c6c-20fb-4a27-a8d3-1cc165cb35dd" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_ff8c434a-4b40-4c85-a6e7-49a1b03008c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_3d217cd5-5a21-4068-b84c-4edf5222004a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_06707c6c-20fb-4a27-a8d3-1cc165cb35dd" xlink:to="loc_us-gaap_ManagementFeeExpense_3d217cd5-5a21-4068-b84c-4edf5222004a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7ee35de4-b661-4991-a8b2-e5ce497b3dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1c87a7e7-7288-47c6-866e-fe85513940ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7ee35de4-b661-4991-a8b2-e5ce497b3dd9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1c87a7e7-7288-47c6-866e-fe85513940ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e9566a5b-be0b-4d7b-a764-39ececa2d3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7ee35de4-b661-4991-a8b2-e5ce497b3dd9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e9566a5b-be0b-4d7b-a764-39ececa2d3d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_87330e05-72d7-45f1-b860-52811c568c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_87330e05-72d7-45f1-b860-52811c568c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f7716f4f-1fb5-4c4a-8e99-43a8dd76cb31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f7716f4f-1fb5-4c4a-8e99-43a8dd76cb31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_d1f004e9-0a4e-440b-8453-c54449620c75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_d1f004e9-0a4e-440b-8453-c54449620c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_6d1806e1-2405-4f58-93aa-0486a4cf5945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_6d1806e1-2405-4f58-93aa-0486a4cf5945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_7ad386c3-6193-4e57-bf70-c026aad76abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_7ad386c3-6193-4e57-bf70-c026aad76abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc2896e2-bfe5-450e-87ff-2c501784ae49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dc2896e2-bfe5-450e-87ff-2c501784ae49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_c623ce3c-0727-44ca-a457-88779e45630f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_c623ce3c-0727-44ca-a457-88779e45630f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_913d07f3-3709-45a4-b1f2-121aea5ee188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6152631b-8707-41a5-ac93-ffa6c1e3582c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_913d07f3-3709-45a4-b1f2-121aea5ee188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0cf3b575-8152-4bbf-afa0-5d9cd09b6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0cf3b575-8152-4bbf-afa0-5d9cd09b6e2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_0561d2fb-c44a-417b-8e91-1aac227aeb42" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_0561d2fb-c44a-417b-8e91-1aac227aeb42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_44bb1507-d22c-4c55-8f2a-9730d6cd06f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_LongTermDebtCurrent_44bb1507-d22c-4c55-8f2a-9730d6cd06f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2050d199-7c00-4877-aba5-076309e27730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2050d199-7c00-4877-aba5-076309e27730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_97469401-7259-44fb-8766-1951f88e7134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_TaxesPayableCurrent_97469401-7259-44fb-8766-1951f88e7134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_fa8ef6fd-6371-411b-bcfe-41367294989e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_DueToAffiliateCurrent_fa8ef6fd-6371-411b-bcfe-41367294989e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_a55ef907-a4ac-42d0-898a-96c82240104e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_DividendsPayableCurrent_a55ef907-a4ac-42d0-898a-96c82240104e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f7803c46-a3ae-44ce-bb9c-585f3cdd84f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f7803c46-a3ae-44ce-bb9c-585f3cdd84f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a9100d6b-5f53-408a-8e62-8b49f69a489a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_506d5e5c-e5a4-4323-8386-8323dc322f38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a9100d6b-5f53-408a-8e62-8b49f69a489a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf2a37c8-e279-4fef-b6fd-4e3d0829cfda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bf2a37c8-e279-4fef-b6fd-4e3d0829cfda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_438513e4-52a5-4842-a392-318d0439b6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_438513e4-52a5-4842-a392-318d0439b6e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a147bd4b-4ad9-45cc-8e08-eb11a4088895" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_Goodwill_a147bd4b-4ad9-45cc-8e08-eb11a4088895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_df5dcf01-7576-449a-b257-42e6c266ac80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_df5dcf01-7576-449a-b257-42e6c266ac80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_901078b5-4b0a-477b-9012-80c48f6581b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_OtherLongTermInvestments_901078b5-4b0a-477b-9012-80c48f6581b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_44c9d7f0-5ba3-4b60-b78b-7e6b88f8f956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_44c9d7f0-5ba3-4b60-b78b-7e6b88f8f956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0f138585-8944-4e08-8860-83b07687f7de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_EquityMethodInvestments_0f138585-8944-4e08-8860-83b07687f7de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_fbe72aeb-9a6b-4f66-9ab0-4fb9be2ff52d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_fbe72aeb-9a6b-4f66-9ab0-4fb9be2ff52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5be3173b-b08a-4849-924c-d43a1f2ba8bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5be3173b-b08a-4849-924c-d43a1f2ba8bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e8762f76-17e1-4b52-aa4f-637c3bd0606f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_e6283054-1991-4504-b08e-a584b8d09627" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e8762f76-17e1-4b52-aa4f-637c3bd0606f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1cebd204-1819-4232-9af1-96572d30f95f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_bfee4cb1-e89d-4637-b5e1-55e732da976c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1cebd204-1819-4232-9af1-96572d30f95f" xlink:to="loc_us-gaap_OperatingLeaseCost_bfee4cb1-e89d-4637-b5e1-55e732da976c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3f1ee094-ccf8-4edc-822f-fb0001e11353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1cebd204-1819-4232-9af1-96572d30f95f" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_3f1ee094-ccf8-4edc-822f-fb0001e11353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_495e075f-0f96-4c22-ad56-09271f450e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1cebd204-1819-4232-9af1-96572d30f95f" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_495e075f-0f96-4c22-ad56-09271f450e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_3c3a17c4-f3c9-4089-bfc3-e56c972f98cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_1cebd204-1819-4232-9af1-96572d30f95f" xlink:to="loc_us-gaap_SubleaseIncome_3c3a17c4-f3c9-4089-bfc3-e56c972f98cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65ba33ca-8147-47d5-a0b1-1f800b0c6273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb30de7c-54d0-4977-8b37-3e88471ce7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65ba33ca-8147-47d5-a0b1-1f800b0c6273" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_eb30de7c-54d0-4977-8b37-3e88471ce7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bf066847-7a28-435b-a8ea-f7a074435ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65ba33ca-8147-47d5-a0b1-1f800b0c6273" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bf066847-7a28-435b-a8ea-f7a074435ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2266b2b2-fc94-4903-ae9a-842c2a25c73a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65ba33ca-8147-47d5-a0b1-1f800b0c6273" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2266b2b2-fc94-4903-ae9a-842c2a25c73a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_962bfe90-d334-4991-bbcb-49305a355f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65ba33ca-8147-47d5-a0b1-1f800b0c6273" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_962bfe90-d334-4991-bbcb-49305a355f9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b219b522-1391-460f-aeae-8b2d74620969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65ba33ca-8147-47d5-a0b1-1f800b0c6273" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b219b522-1391-460f-aeae-8b2d74620969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9bec21bd-b2cd-48d3-94a8-5bb71267159b" xlink:href="ameh-20210630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_65ba33ca-8147-47d5-a0b1-1f800b0c6273" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_9bec21bd-b2cd-48d3-94a8-5bb71267159b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0e88e46c-5adc-4805-b606-9933a153acc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b93af5b0-dc0d-48f3-95f8-965cf0d2e6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0e88e46c-5adc-4805-b606-9933a153acc8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b93af5b0-dc0d-48f3-95f8-965cf0d2e6d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_13a48888-afdd-4c9c-b97a-6852eebc2764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0e88e46c-5adc-4805-b606-9933a153acc8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_13a48888-afdd-4c9c-b97a-6852eebc2764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0526e6ea-1421-49de-ac57-db302d71454b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a38cee53-2aad-4c5a-a934-5ac6b912df94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0526e6ea-1421-49de-ac57-db302d71454b" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a38cee53-2aad-4c5a-a934-5ac6b912df94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6d3bac68-48c3-416d-8202-4fd72f3ac9ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0526e6ea-1421-49de-ac57-db302d71454b" xlink:to="loc_us-gaap_FinanceLeaseLiability_6d3bac68-48c3-416d-8202-4fd72f3ac9ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_77c9cd4c-edbf-4040-9174-3848da03b14d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_492cac16-b03b-4742-bd25-177d667355a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_77c9cd4c-edbf-4040-9174-3848da03b14d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_492cac16-b03b-4742-bd25-177d667355a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d3018e91-c312-46e0-81d4-01f8e03411d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_77c9cd4c-edbf-4040-9174-3848da03b14d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_d3018e91-c312-46e0-81d4-01f8e03411d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17234f52-73f8-4a9e-93ee-794be128974c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c5cf8716-05ab-430a-b2ee-6104416dbe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17234f52-73f8-4a9e-93ee-794be128974c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c5cf8716-05ab-430a-b2ee-6104416dbe0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7f4a11c5-de2e-4e86-a758-5f77e100842d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17234f52-73f8-4a9e-93ee-794be128974c" xlink:to="loc_us-gaap_OperatingLeaseLiability_7f4a11c5-de2e-4e86-a758-5f77e100842d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f468a41c-eb92-45ed-9f2b-c4676def9322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_7c7532b9-4860-4769-8a2b-1fd2cf9aae09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f468a41c-eb92-45ed-9f2b-c4676def9322" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_7c7532b9-4860-4769-8a2b-1fd2cf9aae09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_798e9bf4-1018-4898-be00-33779b9fbff2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f468a41c-eb92-45ed-9f2b-c4676def9322" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_798e9bf4-1018-4898-be00-33779b9fbff2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ea5b5d5e-dc60-4bd2-92c1-568b55281b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f468a41c-eb92-45ed-9f2b-c4676def9322" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_ea5b5d5e-dc60-4bd2-92c1-568b55281b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_725e0348-0ff5-45ed-b1c4-559294af0a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f468a41c-eb92-45ed-9f2b-c4676def9322" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_725e0348-0ff5-45ed-b1c4-559294af0a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c477ae69-3af1-47ec-b3da-11ace673a461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f468a41c-eb92-45ed-9f2b-c4676def9322" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_c477ae69-3af1-47ec-b3da-11ace673a461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_a94462fc-541a-4fd8-a3c4-7532aab3c024" xlink:href="ameh-20210630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_f468a41c-eb92-45ed-9f2b-c4676def9322" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_a94462fc-541a-4fd8-a3c4-7532aab3c024" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ameh-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:95c9976f-ff84-4dd6-aeb6-cbf10c7f8b0a,g:1aa3c04f-4646-4116-829c-b4ce4a78f20a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="ibda71cc2c291481d9488bf31ebe28d4f_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:to="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66e6bb10-439e-4d4d-b9af-77b7322a5382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66e6bb10-439e-4d4d-b9af-77b7322a5382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_808cce4c-ed03-4c30-b037-2bb5ffe0bb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_808cce4c-ed03-4c30-b037-2bb5ffe0bb0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_11394c5b-d9ae-43cf-88ec-b895fde42b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_11394c5b-d9ae-43cf-88ec-b895fde42b7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_ff0ce005-7c42-42f0-b164-912d714a9681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_ff0ce005-7c42-42f0-b164-912d714a9681" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_666ef49b-ab20-4132-856d-35e836c04485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_666ef49b-ab20-4132-856d-35e836c04485" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_03752fd9-d28d-4af9-87dc-84b18fbdfe83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_03752fd9-d28d-4af9-87dc-84b18fbdfe83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_633cbb0d-458b-4021-9ea5-e7d87105d791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_AssetsCurrent_633cbb0d-458b-4021-9ea5-e7d87105d791" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74eeb132-8a7c-4ecb-ab0e-17ee9c662d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74eeb132-8a7c-4ecb-ab0e-17ee9c662d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_652c7569-b334-4fde-bc28-a1813bd5bd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_652c7569-b334-4fde-bc28-a1813bd5bd05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7a0e5c97-af84-4aa5-9ff1-5aa86a07a2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_Goodwill_7a0e5c97-af84-4aa5-9ff1-5aa86a07a2fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_0dce0bb5-78d0-4ce6-bb5c-a8be053918c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_0dce0bb5-78d0-4ce6-bb5c-a8be053918c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ce523449-837f-4964-a2fe-0db808a915a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ce523449-837f-4964-a2fe-0db808a915a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_117646cc-f65e-432a-b466-cf1cdc56e0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_EquityMethodInvestments_117646cc-f65e-432a-b466-cf1cdc56e0af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_50be13ae-0d53-416b-bdfb-cfee4e179bf7" xlink:href="ameh-20210630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_50be13ae-0d53-416b-bdfb-cfee4e179bf7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_729108a9-07e7-442d-80b2-94ce1f190c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_729108a9-07e7-442d-80b2-94ce1f190c44" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c587d27e-dba2-4a79-8417-fd7de9bba2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c587d27e-dba2-4a79-8417-fd7de9bba2b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_376cc2f3-b723-4804-bb5d-fb2040171d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_376cc2f3-b723-4804-bb5d-fb2040171d81" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_732cdbb5-ff39-410a-a97f-a8e21d0318b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_AssetsNoncurrent_732cdbb5-ff39-410a-a97f-a8e21d0318b6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_39064507-05a8-44d6-a4d3-e8f7bebdd099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:to="loc_us-gaap_Assets_39064507-05a8-44d6-a4d3-e8f7bebdd099" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8fe1db08-8136-4717-89c7-a3cbcf0c8ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8fe1db08-8136-4717-89c7-a3cbcf0c8ff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_30663837-5a73-4778-8b4a-47e554efd06b" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_30663837-5a73-4778-8b4a-47e554efd06b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9c9f47ed-682e-4453-9033-3c334be3c07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9c9f47ed-682e-4453-9033-3c334be3c07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b6c4f024-4013-40ba-b4c8-0f028c8a0dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b6c4f024-4013-40ba-b4c8-0f028c8a0dfe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_8a55e7c5-c7f5-47e7-84dc-b2f68986c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_DividendsPayableCurrent_8a55e7c5-c7f5-47e7-84dc-b2f68986c81b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_28eff579-9750-49f0-a4b9-b6a5bd8af69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_28eff579-9750-49f0-a4b9-b6a5bd8af69c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e64fa37-112d-4096-b1fa-b9432619bb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e64fa37-112d-4096-b1fa-b9432619bb3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_600bbf07-cc50-4838-b32b-9b3e2bce85dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_LongTermDebtCurrent_600bbf07-cc50-4838-b32b-9b3e2bce85dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c6ab171a-94b5-467b-b819-abd505fde3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_LiabilitiesCurrent_c6ab171a-94b5-467b-b819-abd505fde3e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c6ec7400-97b7-4f8f-a031-eb413300b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c6ec7400-97b7-4f8f-a031-eb413300b9a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_15b0e8a0-0684-4812-8075-1a4f501ccba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_15b0e8a0-0684-4812-8075-1a4f501ccba2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2df030b-6d89-4c8d-83f7-9b4a0ac31ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2df030b-6d89-4c8d-83f7-9b4a0ac31ceb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_71e13abf-c812-4eea-a866-848a1e549c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_71e13abf-c812-4eea-a866-848a1e549c6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2d498d60-dff5-473d-840c-0e053908e8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2d498d60-dff5-473d-840c-0e053908e8dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_13acd607-bd7a-49ce-98fa-2cba6688fe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_13acd607-bd7a-49ce-98fa-2cba6688fe7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7c1ef098-fd85-48cc-ae54-6f2df1732cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_Liabilities_7c1ef098-fd85-48cc-ae54-6f2df1732cda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f9d4ea5a-b2b5-4f8a-bac6-6129bddc4bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f9d4ea5a-b2b5-4f8a-bac6-6129bddc4bed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_2371d93b-8a62-4ea7-b07b-1b07bea60d4c" xlink:href="ameh-20210630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_ameh_MezzanineEquityAbstract_2371d93b-8a62-4ea7-b07b-1b07bea60d4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_de3db126-3843-46ac-beee-7cb8b393c7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_2371d93b-8a62-4ea7-b07b-1b07bea60d4c" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_de3db126-3843-46ac-beee-7cb8b393c7e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a818f389-93c9-42ac-b846-3a5f18140f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_PreferredStockValue_a818f389-93c9-42ac-b846-3a5f18140f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fb0c88ee-fc2b-4cb7-a7ae-e85e0a4a2bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_CommonStockValue_fb0c88ee-fc2b-4cb7-a7ae-e85e0a4a2bf7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_349616fb-8967-41a5-95b4-0ecc2ab6ad32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_349616fb-8967-41a5-95b4-0ecc2ab6ad32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dda99143-80df-4606-9bc6-289bb627f793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dda99143-80df-4606-9bc6-289bb627f793" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_701f1e98-c621-45bb-aded-ca0a0195ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_StockholdersEquity_701f1e98-c621-45bb-aded-ca0a0195ff2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ea98d705-a1c6-49ee-acf6-47d52808faa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_MinorityInterest_ea98d705-a1c6-49ee-acf6-47d52808faa9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11dbe545-4485-44ee-a80a-e26e31f8caf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11dbe545-4485-44ee-a80a-e26e31f8caf4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a672d0e5-3fab-49cf-a33e-6ed270572b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a672d0e5-3fab-49cf-a33e-6ed270572b50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4c85a119-9dfa-4092-9b4a-454eef234538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:to="loc_us-gaap_StatementTable_4c85a119-9dfa-4092-9b4a-454eef234538" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6eeb1159-2ee0-46bf-ba13-da55b870c7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4c85a119-9dfa-4092-9b4a-454eef234538" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6eeb1159-2ee0-46bf-ba13-da55b870c7ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6eeb1159-2ee0-46bf-ba13-da55b870c7ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6eeb1159-2ee0-46bf-ba13-da55b870c7ef" xlink:to="loc_us-gaap_ClassOfStockDomain_6eeb1159-2ee0-46bf-ba13-da55b870c7ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6eeb1159-2ee0-46bf-ba13-da55b870c7ef" xlink:to="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_40061c22-5dec-4071-92e4-f7d420fda9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_40061c22-5dec-4071-92e4-f7d420fda9ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_a47d5e41-827c-4d78-b214-66539601d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_a47d5e41-827c-4d78-b214-66539601d64a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i116a53c7b64a4e65800be626a2e7b225_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34a8e184-0a5b-456c-8ff6-8589fb23b9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34a8e184-0a5b-456c-8ff6-8589fb23b9bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4b7fa0eb-6879-4894-b36f-5a69d52deae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4b7fa0eb-6879-4894-b36f-5a69d52deae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_55f6ac03-0586-4586-a3e6-ca874394bcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_55f6ac03-0586-4586-a3e6-ca874394bcd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7b8d4149-5489-4a1e-8027-04b256629400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7b8d4149-5489-4a1e-8027-04b256629400" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9974c147-da2e-422e-ac1a-84e69119c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9974c147-da2e-422e-ac1a-84e69119c5c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9c3f9eee-c07d-41d6-bd38-47f9537fe149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9c3f9eee-c07d-41d6-bd38-47f9537fe149" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_751bc0a9-9fe0-4afb-9397-9ff2d5529fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_751bc0a9-9fe0-4afb-9397-9ff2d5529fa0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_064e75f0-0df9-4c28-9bfb-80f0eb3970f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_064e75f0-0df9-4c28-9bfb-80f0eb3970f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0e438085-1d94-41fa-b001-4f5a6d52d160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_Assets_0e438085-1d94-41fa-b001-4f5a6d52d160" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ddfbc29a-d8ef-4e2c-97f5-6160943426f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_Liabilities_ddfbc29a-d8ef-4e2c-97f5-6160943426f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77b8faa9-8bc4-41f3-9010-c80288f82cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77b8faa9-8bc4-41f3-9010-c80288f82cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_77b8faa9-8bc4-41f3-9010-c80288f82cb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77b8faa9-8bc4-41f3-9010-c80288f82cb4" xlink:to="loc_us-gaap_ClassOfStockDomain_77b8faa9-8bc4-41f3-9010-c80288f82cb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77b8faa9-8bc4-41f3-9010-c80288f82cb4" xlink:to="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_264c6222-acbd-4738-ad9d-cee39a2d8aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_264c6222-acbd-4738-ad9d-cee39a2d8aa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6e5911bd-1ea1-4096-947f-d788b9d859fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6e5911bd-1ea1-4096-947f-d788b9d859fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e0cf4761-ab36-4257-9c52-66ae3099c8fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e0cf4761-ab36-4257-9c52-66ae3099c8fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e0cf4761-ab36-4257-9c52-66ae3099c8fa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e0cf4761-ab36-4257-9c52-66ae3099c8fa" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e0cf4761-ab36-4257-9c52-66ae3099c8fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3e60a098-603a-4ab5-8968-15736991aa24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e0cf4761-ab36-4257-9c52-66ae3099c8fa" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3e60a098-603a-4ab5-8968-15736991aa24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_185d88f7-82b8-4837-a989-7d822c88ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3e60a098-603a-4ab5-8968-15736991aa24" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_185d88f7-82b8-4837-a989-7d822c88ea09" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="i190057fc54f7405e93892292c29019d5_CONSOLIDATEDSTATEMENTSOFINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6923159a-f511-4acc-b232-b343cd63d1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_RevenuesAbstract_6923159a-f511-4acc-b232-b343cd63d1d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3d6e7f9d-3278-4bc3-bdd1-154327e5ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_6923159a-f511-4acc-b232-b343cd63d1d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3d6e7f9d-3278-4bc3-bdd1-154327e5ce3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_cd5f63b4-0193-4d42-a2e0-43eaf726d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_cd5f63b4-0193-4d42-a2e0-43eaf726d3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_38a1a5bd-aeb6-464e-beb4-de1e10b09fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_38a1a5bd-aeb6-464e-beb4-de1e10b09fe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1fdb0c5f-0b74-4aa6-921d-b48a2ecca83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1fdb0c5f-0b74-4aa6-921d-b48a2ecca83e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c7cb64b1-5f2a-4b99-8376-c474a86bb7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_CostsAndExpenses_c7cb64b1-5f2a-4b99-8376-c474a86bb7c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cbe83635-3ae9-4ca9-8c6b-a60c459735c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_OperatingIncomeLoss_cbe83635-3ae9-4ca9-8c6b-a60c459735c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa1b22cc-c5b0-4738-af44-f4ae9be6507c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa1b22cc-c5b0-4738-af44-f4ae9be6507c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_b66a5f01-53c2-4abe-aef5-3cebe2d20dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_GainLossOnInvestments_b66a5f01-53c2-4abe-aef5-3cebe2d20dc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3a9bec16-3f53-4156-8c23-28d30a9ef33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_InterestExpense_3a9bec16-3f53-4156-8c23-28d30a9ef33c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6d33bdef-4a46-4d0d-bd2e-5aca760a4c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6d33bdef-4a46-4d0d-bd2e-5aca760a4c90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d5dcd125-c008-4d54-a8c6-50c539ad4158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d5dcd125-c008-4d54-a8c6-50c539ad4158" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_384b8f38-a553-47cc-95b4-ebb112197774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_384b8f38-a553-47cc-95b4-ebb112197774" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2be07e26-c602-414d-9553-569eb2b4a217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2be07e26-c602-414d-9553-569eb2b4a217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_679fd038-6787-42a1-9885-bf795962c89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_679fd038-6787-42a1-9885-bf795962c89e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_12fcdfde-a94f-4190-973e-a3374662830f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_ProfitLoss_12fcdfde-a94f-4190-973e-a3374662830f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b801dc7b-69d5-44f6-9b48-8683414b9226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b801dc7b-69d5-44f6-9b48-8683414b9226" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b42a0fd-cc9c-4a1e-8908-2bf50fed5450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_NetIncomeLoss_0b42a0fd-cc9c-4a1e-8908-2bf50fed5450" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_28fbf8b9-e835-441d-9f34-d64d4b3f772c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_EarningsPerShareBasic_28fbf8b9-e835-441d-9f34-d64d4b3f772c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_81561671-363d-4279-801c-2e94a03d903e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_EarningsPerShareDiluted_81561671-363d-4279-801c-2e94a03d903e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2c12db00-54f9-42a9-88b8-5977985e4da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_StatementTable_2c12db00-54f9-42a9-88b8-5977985e4da8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2c12db00-54f9-42a9-88b8-5977985e4da8" xlink:to="loc_srt_ProductOrServiceAxis_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b" xlink:to="loc_srt_ProductsAndServicesDomain_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b" xlink:to="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_98d91185-6442-4a27-b3b5-34e624f40ace" xlink:href="ameh-20210630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_98d91185-6442-4a27-b3b5-34e624f40ace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_60717725-639d-4504-a465-d5fa42180986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_HealthCareOtherMember_60717725-639d-4504-a465-d5fa42180986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_ba609458-8bbf-4be3-a6a5-02e735bf5218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_ManagementServiceMember_ba609458-8bbf-4be3-a6a5-02e735bf5218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_8422c750-5396-4342-aeb5-c2eda0bf5db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_8422c750-5396-4342-aeb5-c2eda0bf5db1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_eadd055f-a717-46a7-a229-33434d1234a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_eadd055f-a717-46a7-a229-33434d1234a3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended" id="i6bac63c35804427b982b38bf74ebedd8_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0f77c435-9d54-4b83-b0a0-403c64134a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0f77c435-9d54-4b83-b0a0-403c64134a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_550f250b-0cae-49d7-be31-b98b77901554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_550f250b-0cae-49d7-be31-b98b77901554" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_be88b851-84d4-45e7-ad6b-b3546254dbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_SharesOutstanding_be88b851-84d4-45e7-ad6b-b3546254dbe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4c9bca05-4156-45bc-ac6b-eb8b25eda763" xlink:href="ameh-20210630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4c9bca05-4156-45bc-ac6b-eb8b25eda763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8c3abcdc-fbda-4dc9-a42d-d0775af44ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8c3abcdc-fbda-4dc9-a42d-d0775af44ca7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_09dbe12c-d519-4103-86bd-50a0d241228d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_09dbe12c-d519-4103-86bd-50a0d241228d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_eb9c5ff6-fee8-440b-a77f-b667b6c05eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_eb9c5ff6-fee8-440b-a77f-b667b6c05eb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2992cc42-a155-4c58-b299-a42305e190ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2992cc42-a155-4c58-b299-a42305e190ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_6ed27216-9845-46aa-a274-0e8797ba0c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_6ed27216-9845-46aa-a274-0e8797ba0c5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_62f26956-8d07-45ab-8cd8-e75f63eebaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_62f26956-8d07-45ab-8cd8-e75f63eebaa6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3004cc37-16ed-4d9e-8157-9d396295e3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3004cc37-16ed-4d9e-8157-9d396295e3f5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_6096481a-f5a3-439d-aa05-c3c4c3a59c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_6096481a-f5a3-439d-aa05-c3c4c3a59c01" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_3c9905bb-0abe-4d35-ae6b-d17c9f97a7b6" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_3c9905bb-0abe-4d35-ae6b-d17c9f97a7b6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_1614725b-9460-4aa1-85e4-6ce4a4a6882f" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_1614725b-9460-4aa1-85e4-6ce4a4a6882f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d0952052-dd74-4e83-8d05-333216aaeaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d0952052-dd74-4e83-8d05-333216aaeaf5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_319c6f92-799b-4fa8-bb18-cb403760e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_319c6f92-799b-4fa8-bb18-cb403760e6c3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6720e0e0-10c8-40d7-b82a-048888e37e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6720e0e0-10c8-40d7-b82a-048888e37e7f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_613fdfc2-f239-4190-8c57-7d7c456330c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_613fdfc2-f239-4190-8c57-7d7c456330c7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a2ea644b-5ac5-46d2-981f-22a0200f6340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a2ea644b-5ac5-46d2-981f-22a0200f6340" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ceee48a7-e342-4f91-85e7-fc51a5095f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a2df6c6d-4680-4a1e-a760-675773c31422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0f77c435-9d54-4b83-b0a0-403c64134a5b" xlink:to="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ab779c88-4193-45b2-a1d8-33aca553716b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ab779c88-4193-45b2-a1d8-33aca553716b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ab779c88-4193-45b2-a1d8-33aca553716b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ab779c88-4193-45b2-a1d8-33aca553716b" xlink:to="loc_us-gaap_EquityComponentDomain_ab779c88-4193-45b2-a1d8-33aca553716b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ab779c88-4193-45b2-a1d8-33aca553716b" xlink:to="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9aa10a18-b6e9-4c2a-b64d-c26b718a683b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_CommonStockMember_9aa10a18-b6e9-4c2a-b64d-c26b718a683b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1b3b80d5-09b1-4e61-b5b4-3d27258b8900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1b3b80d5-09b1-4e61-b5b4-3d27258b8900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cee1c256-a1b6-429a-9809-6ce7512432fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_RetainedEarningsMember_cee1c256-a1b6-429a-9809-6ce7512432fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c388db2d-6fbe-4103-a7ad-3df0b7454bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c388db2d-6fbe-4103-a7ad-3df0b7454bf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ec88c889-0d62-41a1-80f1-aa895548c3a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:to="loc_dei_LegalEntityAxis_ec88c889-0d62-41a1-80f1-aa895548c3a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ec88c889-0d62-41a1-80f1-aa895548c3a7_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ec88c889-0d62-41a1-80f1-aa895548c3a7" xlink:to="loc_dei_EntityDomain_ec88c889-0d62-41a1-80f1-aa895548c3a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a3315695-348a-4414-8118-0ec693ad7bf7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ec88c889-0d62-41a1-80f1-aa895548c3a7" xlink:to="loc_dei_EntityDomain_a3315695-348a-4414-8118-0ec693ad7bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_2496dba4-18a9-4ba2-8295-a90130198d5a" xlink:href="ameh-20210630.xsd#ameh_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a3315695-348a-4414-8118-0ec693ad7bf7" xlink:to="loc_ameh_MezzanineMember_2496dba4-18a9-4ba2-8295-a90130198d5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="i33fa93e9f0004032b3e4b41a20fff550_DescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:href="ameh-20210630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07074a70-9920-462c-82d0-b8c131180b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07074a70-9920-462c-82d0-b8c131180b51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1b1a9e3a-304b-4529-ac91-ce145e5f3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1b1a9e3a-304b-4529-ac91-ce145e5f3c88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66270700-0533-4da3-ab7f-83df747c15af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66270700-0533-4da3-ab7f-83df747c15af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_ad90167a-8b19-4823-9fcc-314d73347e13" xlink:href="ameh-20210630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_ad90167a-8b19-4823-9fcc-314d73347e13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_dca9f143-98ca-49d5-b2b1-74f8e815fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_NotesReceivableNet_dca9f143-98ca-49d5-b2b1-74f8e815fed7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_3314dacc-036a-4277-8f84-2809fc3323dc" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_3314dacc-036a-4277-8f84-2809fc3323dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_0d742164-2429-49db-94fd-b22470c8a6b0" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_0d742164-2429-49db-94fd-b22470c8a6b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_b3ac3a9f-9bf4-43d0-ba51-f3851c13300d" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_b3ac3a9f-9bf4-43d0-ba51-f3851c13300d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_888ac045-3843-42a2-938e-02d2c7c9225a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_888ac045-3843-42a2-938e-02d2c7c9225a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82db9085-ddee-4ef0-8d2a-b7d71046d92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82db9085-ddee-4ef0-8d2a-b7d71046d92d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_51514e32-f69f-45b1-9d88-c0df444eb80d" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_51514e32-f69f-45b1-9d88-c0df444eb80d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6a5c6bf7-2fb1-4df6-ac08-450793bdb3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6a5c6bf7-2fb1-4df6-ac08-450793bdb3e2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_6bfcf00e-38dc-41b6-9eaf-fa49abb9fd69" xlink:href="ameh-20210630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_6bfcf00e-38dc-41b6-9eaf-fa49abb9fd69" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_31f3e6e2-af65-49ea-90b8-bc4e9588489b" xlink:href="ameh-20210630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_31f3e6e2-af65-49ea-90b8-bc4e9588489b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b51d0af8-e9b1-40de-9bb8-116bfe3673d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b51d0af8-e9b1-40de-9bb8-116bfe3673d5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a51a1d34-58d2-4079-a912-64139267051a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a51a1d34-58d2-4079-a912-64139267051a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0968d37c-1c63-4c6a-bad1-b1e975f760e7" xlink:href="ameh-20210630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0968d37c-1c63-4c6a-bad1-b1e975f760e7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:href="ameh-20210630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_80f3aeca-95fd-4a98-b1b6-202c3bdb1263" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_dei_LegalEntityAxis_80f3aeca-95fd-4a98-b1b6-202c3bdb1263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_80f3aeca-95fd-4a98-b1b6-202c3bdb1263_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_80f3aeca-95fd-4a98-b1b6-202c3bdb1263" xlink:to="loc_dei_EntityDomain_80f3aeca-95fd-4a98-b1b6-202c3bdb1263_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_80f3aeca-95fd-4a98-b1b6-202c3bdb1263" xlink:to="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_86577791-2b3d-4917-a3b3-72e672fd4970" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_86577791-2b3d-4917-a3b3-72e672fd4970" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_e7559171-505c-4f81-80c5-b13964931bb5" xlink:href="ameh-20210630.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_ApcLsmaMember_e7559171-505c-4f81-80c5-b13964931bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_1ecb4b77-f4a3-453b-b73b-4684789902e0" xlink:href="ameh-20210630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_AccountableHealthCareIPAMember_1ecb4b77-f4a3-453b-b73b-4684789902e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_cbf86a29-000a-41cc-976a-c8f4e28e5718" xlink:href="ameh-20210630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_APCAndAPCLSMAMember_cbf86a29-000a-41cc-976a-c8f4e28e5718" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_6a9f9107-b21f-40f6-95c5-55be5e54963d" xlink:href="ameh-20210630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_AmgIncMember_6a9f9107-b21f-40f6-95c5-55be5e54963d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_srt_CounterpartyNameAxis_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f3782b47-53d0-4f53-955d-2a7aab5a6167" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f3782b47-53d0-4f53-955d-2a7aab5a6167" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_31654ffb-82a6-4fc9-9276-d8b9aaa29f3a" xlink:href="ameh-20210630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:to="loc_ameh_APAMHMedicalCorporationMember_31654ffb-82a6-4fc9-9276-d8b9aaa29f3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_571c08e7-49d4-4781-89bd-d2d12c977d85" xlink:href="ameh-20210630.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:to="loc_ameh_Dr.JayMember_571c08e7-49d4-4781-89bd-d2d12c977d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e61f22c4-c3d6-4c55-84b7-70d3494c183a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e61f22c4-c3d6-4c55-84b7-70d3494c183a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e61f22c4-c3d6-4c55-84b7-70d3494c183a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e61f22c4-c3d6-4c55-84b7-70d3494c183a" xlink:to="loc_us-gaap_RelatedPartyDomain_e61f22c4-c3d6-4c55-84b7-70d3494c183a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8a570962-2da6-4338-8a9b-1bb98df2745d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e61f22c4-c3d6-4c55-84b7-70d3494c183a" xlink:to="loc_us-gaap_RelatedPartyDomain_8a570962-2da6-4338-8a9b-1bb98df2745d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_855f68c6-ae51-4bbb-a827-b29c7885adcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8a570962-2da6-4338-8a9b-1bb98df2745d" xlink:to="loc_srt_AffiliatedEntityMember_855f68c6-ae51-4bbb-a827-b29c7885adcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ab000fef-45a7-45df-ac58-02e4306ecf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ab000fef-45a7-45df-ac58-02e4306ecf8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ab000fef-45a7-45df-ac58-02e4306ecf8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab000fef-45a7-45df-ac58-02e4306ecf8c" xlink:to="loc_us-gaap_ClassOfStockDomain_ab000fef-45a7-45df-ac58-02e4306ecf8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f687f701-76e5-436f-ad92-ef6cc5800d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab000fef-45a7-45df-ac58-02e4306ecf8c" xlink:to="loc_us-gaap_ClassOfStockDomain_f687f701-76e5-436f-ad92-ef6cc5800d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9f8a7688-0865-4ad5-9564-98f8ca5cdd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f687f701-76e5-436f-ad92-ef6cc5800d0f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9f8a7688-0865-4ad5-9564-98f8ca5cdd7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3dec4f-147d-4334-abbe-86de80d25748" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3dec4f-147d-4334-abbe-86de80d25748" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ff3dec4f-147d-4334-abbe-86de80d25748_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3dec4f-147d-4334-abbe-86de80d25748" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ff3dec4f-147d-4334-abbe-86de80d25748_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3dec4f-147d-4334-abbe-86de80d25748" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_38ddb925-f1ee-48b1-94d8-96db6363823e" xlink:href="ameh-20210630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_38ddb925-f1ee-48b1-94d8-96db6363823e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_477b836b-c4a2-48a3-a9be-8ea9dff844fb" xlink:href="ameh-20210630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_477b836b-c4a2-48a3-a9be-8ea9dff844fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3d88b836-0d4c-4005-bd16-543ce2dd3126" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_srt_OwnershipAxis_3d88b836-0d4c-4005-bd16-543ce2dd3126" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3d88b836-0d4c-4005-bd16-543ce2dd3126_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3d88b836-0d4c-4005-bd16-543ce2dd3126" xlink:to="loc_srt_OwnershipDomain_3d88b836-0d4c-4005-bd16-543ce2dd3126_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a1a6ea06-2e08-4394-b858-f029de1e0e03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3d88b836-0d4c-4005-bd16-543ce2dd3126" xlink:to="loc_srt_OwnershipDomain_a1a6ea06-2e08-4394-b858-f029de1e0e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_51a790a0-aa2b-4878-a4cf-0f7cd49a7aff" xlink:href="ameh-20210630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_a1a6ea06-2e08-4394-b858-f029de1e0e03" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_51a790a0-aa2b-4878-a4cf-0f7cd49a7aff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00278247-adf7-4382-af4c-55205ef275fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00278247-adf7-4382-af4c-55205ef275fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00278247-adf7-4382-af4c-55205ef275fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00278247-adf7-4382-af4c-55205ef275fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_00278247-adf7-4382-af4c-55205ef275fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00278247-adf7-4382-af4c-55205ef275fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_4cc89750-b43b-4ea1-a2e3-fa776d8bb177" xlink:href="ameh-20210630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:to="loc_ameh_AccountableHealthCareIPAMember_4cc89750-b43b-4ea1-a2e3-fa776d8bb177" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_7994de55-b213-4b13-91af-0b0c13a1401e" xlink:href="ameh-20210630.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:to="loc_ameh_AmgIncMember_7994de55-b213-4b13-91af-0b0c13a1401e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SunClinicalLaboratoriesMember_d345631c-70a7-4c09-91b4-2c78205b27fe" xlink:href="ameh-20210630.xsd#ameh_SunClinicalLaboratoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:to="loc_ameh_SunClinicalLaboratoriesMember_d345631c-70a7-4c09-91b4-2c78205b27fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_0ec15e5f-ae7c-47ba-8182-22d73756547a" xlink:href="ameh-20210630.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_0ec15e5f-ae7c-47ba-8182-22d73756547a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_940fadfd-2123-4602-98d7-bf038beafa26" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_940fadfd-2123-4602-98d7-bf038beafa26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ica658a261e114e43ae803635fb6a3141_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:href="ameh-20210630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f572929f-8bf0-413e-abcd-11c21018791d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f572929f-8bf0-413e-abcd-11c21018791d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b69e2859-b721-407b-b5d8-fccce960ce5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_NumberOfReportableSegments_b69e2859-b721-407b-b5d8-fccce960ce5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_cf9385c1-99b9-4204-b2ee-a279b7c7cd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_CashUninsuredAmount_cf9385c1-99b9-4204-b2ee-a279b7c7cd2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_f53da2de-21a8-4a1a-b0e3-90c63507670c" xlink:href="ameh-20210630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_f53da2de-21a8-4a1a-b0e3-90c63507670c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1fcc6ee-2409-410a-89d3-4b498e2ea090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1fcc6ee-2409-410a-89d3-4b498e2ea090" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_d02f5fe1-c1b0-4c5a-a214-cf84c8f0d227" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_d02f5fe1-c1b0-4c5a-a214-cf84c8f0d227" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8b8a429a-2d30-4ff5-abc2-8660141167ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8b8a429a-2d30-4ff5-abc2-8660141167ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_41722de2-da07-4efd-a120-da3aaf736016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_41722de2-da07-4efd-a120-da3aaf736016" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bdfdbf07-85df-4dbd-bdc9-3dd2746ea3bb" xlink:href="ameh-20210630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bdfdbf07-85df-4dbd-bdc9-3dd2746ea3bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1311be7-c402-4af3-9a3b-d2a5b7ee9574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1311be7-c402-4af3-9a3b-d2a5b7ee9574" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7a9b3b95-281a-4c9a-97b4-8ef4f4e12cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7a9b3b95-281a-4c9a-97b4-8ef4f4e12cd0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_a672a3d8-fa64-4680-a754-ba3af032fa2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_NumberOfReportingUnits_a672a3d8-fa64-4680-a754-ba3af032fa2b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_bc07b064-dd78-48ee-afb1-d168835223b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_bc07b064-dd78-48ee-afb1-d168835223b8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e5696bee-452e-489f-8386-81f472d19e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e5696bee-452e-489f-8386-81f472d19e7d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1de4183c-1d9c-4543-bc65-28b0bda94f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_Goodwill_1de4183c-1d9c-4543-bc65-28b0bda94f09" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_633a2d77-bec7-488b-93f2-d49d33344bba" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_633a2d77-bec7-488b-93f2-d49d33344bba" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fdc3a8a4-e991-42ce-9324-356f9417f1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fdc3a8a4-e991-42ce-9324-356f9417f1f5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_6a8b1cf6-e717-439c-89ec-c3705a81aa25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_6a8b1cf6-e717-439c-89ec-c3705a81aa25" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_301b5a24-ddce-423d-967d-cf0c9714f744" xlink:href="ameh-20210630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_301b5a24-ddce-423d-967d-cf0c9714f744" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_97aedf6b-1e74-46f4-bfb8-9ac96dbd0553" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_97aedf6b-1e74-46f4-bfb8-9ac96dbd0553" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_b14f4edf-8804-4570-a112-b195254490e4" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_PaymentOfRevenue_b14f4edf-8804-4570-a112-b195254490e4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized_81804918-9170-4310-9ad7-8ead43711617" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_PaymentOfRevenueRevenueRecognized_81804918-9170-4310-9ad7-8ead43711617" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6362f51f-8fd9-44c6-b705-d4a951652e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6362f51f-8fd9-44c6-b705-d4a951652e48" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e2bdc7a4-9767-4a73-9ef0-8965295d1982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e2bdc7a4-9767-4a73-9ef0-8965295d1982" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_159631e5-e72d-4470-b377-64e3a151e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_159631e5-e72d-4470-b377-64e3a151e6af" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_374af527-6213-48ba-b585-b25cc53c3944" xlink:href="ameh-20210630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_374af527-6213-48ba-b585-b25cc53c3944" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_77296a14-b0ce-43a0-bfdf-84f941b056b0" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_77296a14-b0ce-43a0-bfdf-84f941b056b0" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_0e9a7178-3b2a-4276-ad20-9d8567deca94" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_0e9a7178-3b2a-4276-ad20-9d8567deca94" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_3eb0fd70-dfd0-4f75-aee7-7979367d375c" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_3eb0fd70-dfd0-4f75-aee7-7979367d375c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_9a0c7f5e-9805-496c-b3f3-bd81bff48a7f" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_9a0c7f5e-9805-496c-b3f3-bd81bff48a7f" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:href="ameh-20210630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41380629-6cf9-41f6-a2c6-534cd6ab344b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_RangeAxis_41380629-6cf9-41f6-a2c6-534cd6ab344b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41380629-6cf9-41f6-a2c6-534cd6ab344b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_41380629-6cf9-41f6-a2c6-534cd6ab344b" xlink:to="loc_srt_RangeMember_41380629-6cf9-41f6-a2c6-534cd6ab344b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_41380629-6cf9-41f6-a2c6-534cd6ab344b" xlink:to="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c9cbccc-68c0-4937-a6dd-44ade151db3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:to="loc_srt_MinimumMember_2c9cbccc-68c0-4937-a6dd-44ade151db3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d8face71-45b6-4718-a526-3d92513bf9b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:to="loc_srt_MaximumMember_d8face71-45b6-4718-a526-3d92513bf9b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dc4396c-db44-4bd1-9f51-3e86d3a9c064" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_CounterpartyNameAxis_0dc4396c-db44-4bd1-9f51-3e86d3a9c064" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dc4396c-db44-4bd1-9f51-3e86d3a9c064_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0dc4396c-db44-4bd1-9f51-3e86d3a9c064" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dc4396c-db44-4bd1-9f51-3e86d3a9c064_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d50ef6ba-0a1f-4066-a72a-919cd483dfd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0dc4396c-db44-4bd1-9f51-3e86d3a9c064" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d50ef6ba-0a1f-4066-a72a-919cd483dfd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_afd95c7b-d76a-480d-9ac0-c831f60d8fa7" xlink:href="ameh-20210630.xsd#ameh_CMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d50ef6ba-0a1f-4066-a72a-919cd483dfd9" xlink:to="loc_ameh_CMSMember_afd95c7b-d76a-480d-9ac0-c831f60d8fa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0e1c531-ef56-45c3-a0ae-4465b6ddba43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_ProductOrServiceAxis_c0e1c531-ef56-45c3-a0ae-4465b6ddba43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0e1c531-ef56-45c3-a0ae-4465b6ddba43_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c0e1c531-ef56-45c3-a0ae-4465b6ddba43" xlink:to="loc_srt_ProductsAndServicesDomain_c0e1c531-ef56-45c3-a0ae-4465b6ddba43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c0e1c531-ef56-45c3-a0ae-4465b6ddba43" xlink:to="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_fd795c52-bda7-4e65-a1e5-7848c64deac6" xlink:href="ameh-20210630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_fd795c52-bda7-4e65-a1e5-7848c64deac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_8882facf-39dd-49b9-9219-3c13bee17487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:to="loc_us-gaap_ManagementServiceMember_8882facf-39dd-49b9-9219-3c13bee17487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9a8b4433-19ce-4ce0-9149-430d530dd3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9a8b4433-19ce-4ce0-9149-430d530dd3cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_9a8b4433-19ce-4ce0-9149-430d530dd3cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9a8b4433-19ce-4ce0-9149-430d530dd3cb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_9a8b4433-19ce-4ce0-9149-430d530dd3cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9a8b4433-19ce-4ce0-9149-430d530dd3cb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_a1bebdd0-b453-41f2-a9e4-48629a983a27" xlink:href="ameh-20210630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_a1bebdd0-b453-41f2-a9e4-48629a983a27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f4f8454f-4e27-4ad4-a95a-0304f3875de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f4f8454f-4e27-4ad4-a95a-0304f3875de2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_79670913-f77f-4b65-839f-4acef1520060" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_OwnershipAxis_79670913-f77f-4b65-839f-4acef1520060" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_79670913-f77f-4b65-839f-4acef1520060_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_79670913-f77f-4b65-839f-4acef1520060" xlink:to="loc_srt_OwnershipDomain_79670913-f77f-4b65-839f-4acef1520060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d306c93b-efef-46a2-a5fd-af6c628c5de7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_79670913-f77f-4b65-839f-4acef1520060" xlink:to="loc_srt_OwnershipDomain_d306c93b-efef-46a2-a5fd-af6c628c5de7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2861acf0-aa9b-424b-a86b-718081c19e61" xlink:href="ameh-20210630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_d306c93b-efef-46a2-a5fd-af6c628c5de7" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2861acf0-aa9b-424b-a86b-718081c19e61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_dei_LegalEntityAxis_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e" xlink:to="loc_dei_EntityDomain_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e" xlink:to="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dc8b7fd4-0ed5-4e22-b394-689f4f87315e" xlink:href="ameh-20210630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dc8b7fd4-0ed5-4e22-b394-689f4f87315e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_eb7a325d-e9ca-4d0c-846d-ad7a7c56e234" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_eb7a325d-e9ca-4d0c-846d-ad7a7c56e234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_662f32b6-adb8-4030-9992-86b97860e732" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_662f32b6-adb8-4030-9992-86b97860e732" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_662f32b6-adb8-4030-9992-86b97860e732_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_662f32b6-adb8-4030-9992-86b97860e732" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_662f32b6-adb8-4030-9992-86b97860e732_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c71ec60-998d-4240-ba0c-d0c5960599b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_662f32b6-adb8-4030-9992-86b97860e732" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c71ec60-998d-4240-ba0c-d0c5960599b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_e31ca37f-7441-4aac-97b4-0cdf02ebd9b5" xlink:href="ameh-20210630.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c71ec60-998d-4240-ba0c-d0c5960599b3" xlink:to="loc_ameh_UniversalCareIncMember_e31ca37f-7441-4aac-97b4-0cdf02ebd9b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c2ea2aa2-bbe9-4f0d-983f-5590186e01aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c2ea2aa2-bbe9-4f0d-983f-5590186e01aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f613eaf1-e404-4c10-87b9-0811aeee024c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c2ea2aa2-bbe9-4f0d-983f-5590186e01aa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f613eaf1-e404-4c10-87b9-0811aeee024c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4224ad43-0afe-4ebe-bcfd-72d78cc51deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4224ad43-0afe-4ebe-bcfd-72d78cc51deb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4224ad43-0afe-4ebe-bcfd-72d78cc51deb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4224ad43-0afe-4ebe-bcfd-72d78cc51deb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4224ad43-0afe-4ebe-bcfd-72d78cc51deb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_24b8a17b-501c-438e-aea2-0f666bfc4ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4224ad43-0afe-4ebe-bcfd-72d78cc51deb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_24b8a17b-501c-438e-aea2-0f666bfc4ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b837016f-a420-406c-9c73-9228986e4261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_24b8a17b-501c-438e-aea2-0f666bfc4ca6" xlink:to="loc_us-gaap_InterestRateSwapMember_b837016f-a420-406c-9c73-9228986e4261" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4ddf2611-3016-4c01-9568-294e743ca786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4ddf2611-3016-4c01-9568-294e743ca786" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4ddf2611-3016-4c01-9568-294e743ca786_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4ddf2611-3016-4c01-9568-294e743ca786" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4ddf2611-3016-4c01-9568-294e743ca786_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8165cb68-7ce6-4313-b267-7faf31974440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4ddf2611-3016-4c01-9568-294e743ca786" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8165cb68-7ce6-4313-b267-7faf31974440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_de124be1-f4c6-4ddd-a99e-d0a55100946d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8165cb68-7ce6-4313-b267-7faf31974440" xlink:to="loc_us-gaap_CashFlowHedgingMember_de124be1-f4c6-4ddd-a99e-d0a55100946d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c12f1625-d9e4-4857-a4b6-5bed2745def8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_HedgingDesignationAxis_c12f1625-d9e4-4857-a4b6-5bed2745def8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c12f1625-d9e4-4857-a4b6-5bed2745def8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c12f1625-d9e4-4857-a4b6-5bed2745def8" xlink:to="loc_us-gaap_HedgingDesignationDomain_c12f1625-d9e4-4857-a4b6-5bed2745def8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cc2f9f83-dc7a-4f29-82f6-f40870e4158a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c12f1625-d9e4-4857-a4b6-5bed2745def8" xlink:to="loc_us-gaap_HedgingDesignationDomain_cc2f9f83-dc7a-4f29-82f6-f40870e4158a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_75cdfc15-9f14-4634-8e4b-c3a482a791c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_cc2f9f83-dc7a-4f29-82f6-f40870e4158a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_75cdfc15-9f14-4634-8e4b-c3a482a791c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended" id="ic9074519d4044ad595a4465dea6c801d_BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_edb2f9ec-5a1e-43a1-9749-1faf9b323d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87371ad-e1ec-472d-a2dd-e7262891bff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_edb2f9ec-5a1e-43a1-9749-1faf9b323d7a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87371ad-e1ec-472d-a2dd-e7262891bff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_10384d46-768f-40f6-a621-e42367562d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_edb2f9ec-5a1e-43a1-9749-1faf9b323d7a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_10384d46-768f-40f6-a621-e42367562d94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c67571b4-c43d-473d-b253-4c2220c9d53e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_10384d46-768f-40f6-a621-e42367562d94" xlink:to="loc_srt_MajorCustomersAxis_c67571b4-c43d-473d-b253-4c2220c9d53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c67571b4-c43d-473d-b253-4c2220c9d53e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c67571b4-c43d-473d-b253-4c2220c9d53e" xlink:to="loc_srt_NameOfMajorCustomerDomain_c67571b4-c43d-473d-b253-4c2220c9d53e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c67571b4-c43d-473d-b253-4c2220c9d53e" xlink:to="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_b0abb69e-7cad-4d73-b702-000f28721e5b" xlink:href="ameh-20210630.xsd#ameh_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_CommercialMember_b0abb69e-7cad-4d73-b702-000f28721e5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_6d6bc88d-ed7f-450e-9a79-176cc9312723" xlink:href="ameh-20210630.xsd#ameh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_MedicareMember_6d6bc88d-ed7f-450e-9a79-176cc9312723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_34cbb5db-81bf-4983-85bf-38faf8ee40d1" xlink:href="ameh-20210630.xsd#ameh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_MedicaidMember_34cbb5db-81bf-4983-85bf-38faf8ee40d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_79a0a5a2-15ee-40e6-ad67-a36fcc16f85d" xlink:href="ameh-20210630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_OtherThirdPartiesMember_79a0a5a2-15ee-40e6-ad67-a36fcc16f85d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended" id="id06d3da9e2c74085993a277cdbdacf4a_BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_c06e9a6f-5cc9-4571-b4dc-7dce757dce5f" xlink:href="ameh-20210630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_680132d0-a736-4cf2-aff2-a5ce2f2fe6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_c06e9a6f-5cc9-4571-b4dc-7dce757dce5f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_680132d0-a736-4cf2-aff2-a5ce2f2fe6fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:href="ameh-20210630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_c06e9a6f-5cc9-4571-b4dc-7dce757dce5f" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56861e11-cb02-4032-8c37-7895048bb4db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56861e11-cb02-4032-8c37-7895048bb4db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56861e11-cb02-4032-8c37-7895048bb4db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56861e11-cb02-4032-8c37-7895048bb4db" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_56861e11-cb02-4032-8c37-7895048bb4db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56861e11-cb02-4032-8c37-7895048bb4db" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b276c655-4d68-4d76-8083-7517d9c8b2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:to="loc_us-gaap_SalesRevenueNetMember_b276c655-4d68-4d76-8083-7517d9c8b2d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2aa4021a-5c36-497b-bf37-978329ccde1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:to="loc_us-gaap_AccountsReceivableMember_2aa4021a-5c36-497b-bf37-978329ccde1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_65d594f4-c1a2-404b-b920-c6f3dd96f92c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:to="loc_srt_MajorCustomersAxis_65d594f4-c1a2-404b-b920-c6f3dd96f92c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_65d594f4-c1a2-404b-b920-c6f3dd96f92c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_65d594f4-c1a2-404b-b920-c6f3dd96f92c" xlink:to="loc_srt_NameOfMajorCustomerDomain_65d594f4-c1a2-404b-b920-c6f3dd96f92c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_65d594f4-c1a2-404b-b920-c6f3dd96f92c" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_47a24435-45f2-4af2-a5f6-7185d6c2b374" xlink:href="ameh-20210630.xsd#ameh_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorAMember_47a24435-45f2-4af2-a5f6-7185d6c2b374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_2090ddd0-5a43-481d-aeb3-093eeb1136a1" xlink:href="ameh-20210630.xsd#ameh_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorBMember_2090ddd0-5a43-481d-aeb3-093eeb1136a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_d23101a4-b218-4e48-9563-7b2479db1371" xlink:href="ameh-20210630.xsd#ameh_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorCMember_d23101a4-b218-4e48-9563-7b2479db1371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_c2f77a4a-a1c4-4b6b-b278-c9cdad227aad" xlink:href="ameh-20210630.xsd#ameh_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorDMember_c2f77a4a-a1c4-4b6b-b278-c9cdad227aad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_f61f26f9-e43d-4136-941c-ce611d77b566" xlink:href="ameh-20210630.xsd#ameh_PayorEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorEMember_f61f26f9-e43d-4136-941c-ce611d77b566" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_1adb0153-fd6d-440e-af9e-9d49bf96e7cc" xlink:href="ameh-20210630.xsd#ameh_PayorFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorFMember_1adb0153-fd6d-440e-af9e-9d49bf96e7cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_2d505bde-88a3-44b3-9ff3-3cddb0edde1f" xlink:href="ameh-20210630.xsd#ameh_PayorGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorGMember_2d505bde-88a3-44b3-9ff3-3cddb0edde1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4975afe4-5c7f-46e0-a2f3-69f3b6016f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4975afe4-5c7f-46e0-a2f3-69f3b6016f7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_84728f82-1cec-4cb0-90dd-e060f2d3ab4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4975afe4-5c7f-46e0-a2f3-69f3b6016f7c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_84728f82-1cec-4cb0-90dd-e060f2d3ab4b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended" id="i271e29dbb93e4c7c920e189c76b1f324_BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4f78788-6d33-4566-9972-1950d8822455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4f78788-6d33-4566-9972-1950d8822455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f96dd83-188d-4542-9ae8-9f5c9bfa7a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f96dd83-188d-4542-9ae8-9f5c9bfa7a09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7a2f0a60-fb5c-4125-8fbf-f63f0ca0c79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7a2f0a60-fb5c-4125-8fbf-f63f0ca0c79c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5a238cb7-db67-4ba8-b74a-ac431c4fdd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5a238cb7-db67-4ba8-b74a-ac431c4fdd61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_91213c88-71fa-4a70-933e-0b819bf1d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:to="loc_us-gaap_DerivativeLiabilities_91213c88-71fa-4a70-933e-0b819bf1d0da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7884b913-b3dc-4dd4-82c0-5e5a7ec0495e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7884b913-b3dc-4dd4-82c0-5e5a7ec0495e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1feba034-d99e-4af5-8c93-9985da53db63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1feba034-d99e-4af5-8c93-9985da53db63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11de1487-a2bb-40b9-a65f-4b62b61f61a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1feba034-d99e-4af5-8c93-9985da53db63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11de1487-a2bb-40b9-a65f-4b62b61f61a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11de1487-a2bb-40b9-a65f-4b62b61f61a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11de1487-a2bb-40b9-a65f-4b62b61f61a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_11de1487-a2bb-40b9-a65f-4b62b61f61a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11de1487-a2bb-40b9-a65f-4b62b61f61a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c53cebbd-f96e-441c-b91a-64a3a0399681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c53cebbd-f96e-441c-b91a-64a3a0399681" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f0d1af7a-75ec-4d25-82a4-5429220b93a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f0d1af7a-75ec-4d25-82a4-5429220b93a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7eb58d8e-3173-4664-bc83-8c9065448351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7eb58d8e-3173-4664-bc83-8c9065448351" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i4627554168f34a3b9b4bb520490cd792_IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2916e768-d8fe-40b6-9c0b-49fd60263f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2916e768-d8fe-40b6-9c0b-49fd60263f08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e555e1cf-915a-474b-be52-492952d7c637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e555e1cf-915a-474b-be52-492952d7c637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ffca9fb0-de70-475d-be09-ceb32767ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ffca9fb0-de70-475d-be09-ceb32767ea73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60b579ea-e006-4ace-b139-2759ad12334c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60b579ea-e006-4ace-b139-2759ad12334c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6d718ee6-bc01-482c-a312-04d51b2740f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6d718ee6-bc01-482c-a312-04d51b2740f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90052e10-36ce-4d57-9b9d-99384b10a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90052e10-36ce-4d57-9b9d-99384b10a3a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_1fd89b68-63d1-4270-93a7-b0f7c88e71b2" xlink:href="ameh-20210630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_NetworkRelationshipsMember_1fd89b68-63d1-4270-93a7-b0f7c88e71b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_8cc73e8c-5f75-4e3f-a53c-00de468c72ae" xlink:href="ameh-20210630.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_ManagementContractsMember_8cc73e8c-5f75-4e3f-a53c-00de468c72ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_21d09550-c3ed-4c51-97fc-f18609a913cd" xlink:href="ameh-20210630.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_MemberRelationshipsMember_21d09550-c3ed-4c51-97fc-f18609a913cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_296feb9f-9a17-4265-bec4-620be9f84515" xlink:href="ameh-20210630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_PatientManagementPlatformMember_296feb9f-9a17-4265-bec4-620be9f84515" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_edf8feff-e381-469a-96d5-8700b606fc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_edf8feff-e381-469a-96d5-8700b606fc3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:to="loc_srt_RangeAxis_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33" xlink:to="loc_srt_RangeMember_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33" xlink:to="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3295f18-dec0-42bc-a398-2d86c3a0108d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:to="loc_srt_MinimumMember_c3295f18-dec0-42bc-a398-2d86c3a0108d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cfe0fa5-8f93-4b67-9a64-4abd17429d93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:to="loc_srt_MaximumMember_6cfe0fa5-8f93-4b67-9a64-4abd17429d93" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended" id="i3bf7897d65f24c4cb950f41e170ba436_InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1c24c0bf-0643-4543-9406-2d2d6e341129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1c24c0bf-0643-4543-9406-2d2d6e341129" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6ebf6faa-72ee-49ed-ab19-73c8249b67a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_us-gaap_EquityMethodInvestments_6ebf6faa-72ee-49ed-ab19-73c8249b67a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_27a7e6a4-9df0-42d4-880a-57fa6065aa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_27a7e6a4-9df0-42d4-880a-57fa6065aa20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_35b198f7-f3f3-4f89-b469-14752774ff25" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_35b198f7-f3f3-4f89-b469-14752774ff25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated_f13c418a-6c38-4a16-9e55-7f2b2d27429c" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_ameh_EquityMethodInvestmentsConsolidated_f13c418a-6c38-4a16-9e55-7f2b2d27429c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2738d2cd-47a5-4397-8ebd-9a3df8ef1076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f4b5c65f-1488-4760-a3cf-512755d64b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1c24c0bf-0643-4543-9406-2d2d6e341129" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f4b5c65f-1488-4760-a3cf-512755d64b65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_60585b81-9323-43f1-a925-b387cd31e422" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f4b5c65f-1488-4760-a3cf-512755d64b65" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_60585b81-9323-43f1-a925-b387cd31e422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_60585b81-9323-43f1-a925-b387cd31e422_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_60585b81-9323-43f1-a925-b387cd31e422" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_60585b81-9323-43f1-a925-b387cd31e422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_60585b81-9323-43f1-a925-b387cd31e422" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_571cf82c-e65b-424f-af6d-0cbbbcf08cff" xlink:href="ameh-20210630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_571cf82c-e65b-424f-af6d-0cbbbcf08cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9e6f2bf7-cdc6-4797-988b-700e56d007e9" xlink:href="ameh-20210630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9e6f2bf7-cdc6-4797-988b-700e56d007e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_16d4b19a-f1f4-4339-b8f8-d9d89c57c4fa" xlink:href="ameh-20210630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_16d4b19a-f1f4-4339-b8f8-d9d89c57c4fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_8c864103-9b2b-4df2-ad5b-664167403c29" xlink:href="ameh-20210630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_8c864103-9b2b-4df2-ad5b-664167403c29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_34f2160a-1223-40e3-a2db-988b539a0d66" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_OneMSOLLCMember_34f2160a-1223-40e3-a2db-988b539a0d66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_478b901a-320d-4ba7-b030-18f69acb7625" xlink:href="ameh-20210630.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_478b901a-320d-4ba7-b030-18f69acb7625" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_8b9c55bf-467e-49ac-ac81-5e40098d4e25" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_8b9c55bf-467e-49ac-ac81-5e40098d4e25" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended" id="id2504a6776144671940c34ba27fe1660_InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_c82fc379-a9e2-4d91-8cc3-c412d4f74542" xlink:href="ameh-20210630.xsd#ameh_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_NumberOfEmployees_c82fc379-a9e2-4d91-8cc3-c412d4f74542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_87e0da4f-2eac-4548-8bcc-62d7202f9eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_87e0da4f-2eac-4548-8bcc-62d7202f9eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d0b8aefe-4ec0-4443-a809-8ffc66c4a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d0b8aefe-4ec0-4443-a809-8ffc66c4a6ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_8d434e58-7847-4f10-a43c-846e2ee8fbca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_NotesReceivableNet_8d434e58-7847-4f10-a43c-846e2ee8fbca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_eff0605d-3b60-4571-955c-68c4de40fcde" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_eff0605d-3b60-4571-955c-68c4de40fcde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b754c6a9-64f7-4f71-b512-c3b03a7e85e2" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b754c6a9-64f7-4f71-b512-c3b03a7e85e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_caeabafa-e35f-4320-b4d0-c2a7843dec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_caeabafa-e35f-4320-b4d0-c2a7843dec03" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a9ee28f0-716d-4b16-a18c-7e53da761016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_EquityMethodInvestments_a9ee28f0-716d-4b16-a18c-7e53da761016" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_245b4fef-b980-4981-9fa4-3640938835fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_PaymentsForFees_245b4fef-b980-4981-9fa4-3640938835fd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_3e920a79-4247-4600-9982-41f6e1526a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_MembersCapital_3e920a79-4247-4600-9982-41f6e1526a65" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_9e787972-9586-4932-a5ee-27f00726f3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_9e787972-9586-4932-a5ee-27f00726f3e7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_8c2a36ca-20c0-4869-812a-2a759987fb63" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_8c2a36ca-20c0-4869-812a-2a759987fb63" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a6ca9396-188b-4a54-8526-550edd6624c2" xlink:href="ameh-20210630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a6ca9396-188b-4a54-8526-550edd6624c2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_508939c8-65d1-4253-96fb-962f65f2c8ad" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_508939c8-65d1-4253-96fb-962f65f2c8ad" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0ca4213f-49ba-421f-b11f-cac8fa42937f" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0ca4213f-49ba-421f-b11f-cac8fa42937f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_30cecdf1-67ac-40c4-8d73-78ec3e093dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_30cecdf1-67ac-40c4-8d73-78ec3e093dd3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c5dc3b40-0557-4c1f-b799-d6e449d4170c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c5dc3b40-0557-4c1f-b799-d6e449d4170c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_da74bdc7-7ef5-4e8a-a898-15a30ac1e23a" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_da74bdc7-7ef5-4e8a-a898-15a30ac1e23a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_84cbbf66-927c-4d0c-b78d-7d3d1d73b6ac" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_84cbbf66-927c-4d0c-b78d-7d3d1d73b6ac" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_00cec657-6021-4d15-bd6a-39689f95c456" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_00cec657-6021-4d15-bd6a-39689f95c456" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_e4ddc36a-8a28-460d-8ed5-541ea50c4ec8" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_e4ddc36a-8a28-460d-8ed5-541ea50c4ec8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_c3aea224-228f-40d3-801b-b2999a277835" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_c3aea224-228f-40d3-801b-b2999a277835" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c030868a-e1f6-4014-bc16-641dce1ddd3d" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c030868a-e1f6-4014-bc16-641dce1ddd3d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_aef5f700-4672-44b9-8a5e-cc2495ed716a" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_aef5f700-4672-44b9-8a5e-cc2495ed716a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bddf5e4-4bab-4ce8-893b-c96b0460dd17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bddf5e4-4bab-4ce8-893b-c96b0460dd17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0bddf5e4-4bab-4ce8-893b-c96b0460dd17_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bddf5e4-4bab-4ce8-893b-c96b0460dd17" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0bddf5e4-4bab-4ce8-893b-c96b0460dd17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bddf5e4-4bab-4ce8-893b-c96b0460dd17" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_e03dfad8-8472-4e7b-b180-d1fc681b4cb3" xlink:href="ameh-20210630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_e03dfad8-8472-4e7b-b180-d1fc681b4cb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_c4cdb2e4-4bbd-4570-a751-61fc8187ec09" xlink:href="ameh-20210630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_c4cdb2e4-4bbd-4570-a751-61fc8187ec09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_51037b22-c864-42c9-9c54-5bd5b38c74c0" xlink:href="ameh-20210630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_51037b22-c864-42c9-9c54-5bd5b38c74c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_0a7831fa-78e9-4950-b29b-a2971f51108a" xlink:href="ameh-20210630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_0a7831fa-78e9-4950-b29b-a2971f51108a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_188b8fe0-e9ac-40a6-8a8a-43b2c807c1b9" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_OneMSOLLCMember_188b8fe0-e9ac-40a6-8a8a-43b2c807c1b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e4fccc2c-3010-4c86-92f3-15f03c4d6f1c" xlink:href="ameh-20210630.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e4fccc2c-3010-4c86-92f3-15f03c4d6f1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_9c82d8b8-c9ff-4085-b787-3d2109a636d1" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_9c82d8b8-c9ff-4085-b787-3d2109a636d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fd88bfd3-7907-4944-b932-71ab3b738f0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_dei_LegalEntityAxis_fd88bfd3-7907-4944-b932-71ab3b738f0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fd88bfd3-7907-4944-b932-71ab3b738f0c_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_fd88bfd3-7907-4944-b932-71ab3b738f0c" xlink:to="loc_dei_EntityDomain_fd88bfd3-7907-4944-b932-71ab3b738f0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_fd88bfd3-7907-4944-b932-71ab3b738f0c" xlink:to="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:href="ameh-20210630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:to="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_8bde67a2-334c-41ae-86a0-9cd503a15d7e" xlink:href="ameh-20210630.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:to="loc_ameh_ApcLsmaMember_8bde67a2-334c-41ae-86a0-9cd503a15d7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_18277533-112f-4565-b5a9-9d312c41d933" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_18277533-112f-4565-b5a9-9d312c41d933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_002782e8-541c-434e-a593-58a836fd0509" xlink:href="ameh-20210630.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_002782e8-541c-434e-a593-58a836fd0509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_2f28eb50-a98f-4d99-b6d9-a3c95b6dffa3" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_2f28eb50-a98f-4d99-b6d9-a3c95b6dffa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_bde0269e-0fdc-4e91-b907-64a66633d843" xlink:href="ameh-20210630.xsd#ameh_ContractTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_ameh_ContractTypeAxis_bde0269e-0fdc-4e91-b907-64a66633d843" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_bde0269e-0fdc-4e91-b907-64a66633d843_default" xlink:href="ameh-20210630.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ContractTypeAxis_bde0269e-0fdc-4e91-b907-64a66633d843" xlink:to="loc_ameh_ContractTypeDomain_bde0269e-0fdc-4e91-b907-64a66633d843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_040e8886-4e4a-41fc-b043-e91c497e332d" xlink:href="ameh-20210630.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ContractTypeAxis_bde0269e-0fdc-4e91-b907-64a66633d843" xlink:to="loc_ameh_ContractTypeDomain_040e8886-4e4a-41fc-b043-e91c497e332d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_250f8369-4f33-4885-acf0-71079a6aca3e" xlink:href="ameh-20210630.xsd#ameh_AncillaryServiceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ContractTypeDomain_040e8886-4e4a-41fc-b043-e91c497e332d" xlink:to="loc_ameh_AncillaryServiceContractMember_250f8369-4f33-4885-acf0-71079a6aca3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2649bd54-94fa-4b52-87bd-ae82cf13a899" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_srt_CounterpartyNameAxis_2649bd54-94fa-4b52-87bd-ae82cf13a899" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2649bd54-94fa-4b52-87bd-ae82cf13a899_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2649bd54-94fa-4b52-87bd-ae82cf13a899" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2649bd54-94fa-4b52-87bd-ae82cf13a899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5f37fc7-81ca-406b-86a9-689f4d53577e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2649bd54-94fa-4b52-87bd-ae82cf13a899" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5f37fc7-81ca-406b-86a9-689f4d53577e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a6bef693-5235-436d-9f0e-f11a7a3b623f" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5f37fc7-81ca-406b-86a9-689f4d53577e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a6bef693-5235-436d-9f0e-f11a7a3b623f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6e518845-9c32-4aeb-b0bc-99d56c4eaa84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_srt_OwnershipAxis_6e518845-9c32-4aeb-b0bc-99d56c4eaa84" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6e518845-9c32-4aeb-b0bc-99d56c4eaa84_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6e518845-9c32-4aeb-b0bc-99d56c4eaa84" xlink:to="loc_srt_OwnershipDomain_6e518845-9c32-4aeb-b0bc-99d56c4eaa84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6e518845-9c32-4aeb-b0bc-99d56c4eaa84" xlink:to="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_e7d68971-6a0c-4c6e-bdf9-3ea9503ec79b" xlink:href="ameh-20210630.xsd#ameh_MediPortalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:to="loc_ameh_MediPortalLLCMember_e7d68971-6a0c-4c6e-bdf9-3ea9503ec79b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_fc55a5ff-7f17-44b9-837e-b4ee7cdde4c3" xlink:href="ameh-20210630.xsd#ameh_AchievaMedInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:to="loc_ameh_AchievaMedInc.Member_fc55a5ff-7f17-44b9-837e-b4ee7cdde4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7de56c11-b589-4f93-b0b6-2f086c887344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7de56c11-b589-4f93-b0b6-2f086c887344" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_7de56c11-b589-4f93-b0b6-2f086c887344_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7de56c11-b589-4f93-b0b6-2f086c887344" xlink:to="loc_us-gaap_ReceivableTypeDomain_7de56c11-b589-4f93-b0b6-2f086c887344_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_262dcb1d-293f-4e69-914a-c614ffe0bdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7de56c11-b589-4f93-b0b6-2f086c887344" xlink:to="loc_us-gaap_ReceivableTypeDomain_262dcb1d-293f-4e69-914a-c614ffe0bdd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_60a7bbdc-73f5-4385-a6c3-0bbd378c5acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_262dcb1d-293f-4e69-914a-c614ffe0bdd9" xlink:to="loc_us-gaap_NotesReceivableMember_60a7bbdc-73f5-4385-a6c3-0bbd378c5acf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64bd769e-42c0-423b-b1bc-788c165bd2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64bd769e-42c0-423b-b1bc-788c165bd2f9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_64bd769e-42c0-423b-b1bc-788c165bd2f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64bd769e-42c0-423b-b1bc-788c165bd2f9" xlink:to="loc_us-gaap_RelatedPartyDomain_64bd769e-42c0-423b-b1bc-788c165bd2f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0b7a572b-5773-469b-b14e-84333e4b98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64bd769e-42c0-423b-b1bc-788c165bd2f9" xlink:to="loc_us-gaap_RelatedPartyDomain_0b7a572b-5773-469b-b14e-84333e4b98b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_c19338f7-e693-46c3-81b2-59152a4b2ed6" xlink:href="ameh-20210630.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0b7a572b-5773-469b-b14e-84333e4b98b7" xlink:to="loc_ameh_Dr.ArteagaMember_c19338f7-e693-46c3-81b2-59152a4b2ed6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended" id="i7acc78936c0246a9be1711c716d8fb0b_InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:to="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72c0c02e-0a2e-4222-937d-4aa6f1f31f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72c0c02e-0a2e-4222-937d-4aa6f1f31f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_29521598-339f-4d45-9901-f6a752adea26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_RestrictedCashCurrent_29521598-339f-4d45-9901-f6a752adea26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d410c962-fcdb-438c-a9cd-381d817d79d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d410c962-fcdb-438c-a9cd-381d817d79d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_69cd6762-ce4e-4b88-8952-f2de17d0281b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_OtherAssetsCurrent_69cd6762-ce4e-4b88-8952-f2de17d0281b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_90e4e4c8-cfea-4889-bb7c-b273cc03c3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_OtherAssets_90e4e4c8-cfea-4889-bb7c-b273cc03c3c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9b3ccd2c-6fa5-4fbc-92e6-e420f8f09e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9b3ccd2c-6fa5-4fbc-92e6-e420f8f09e25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_01548393-5de3-4af3-b143-e3cb3d98428f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_01548393-5de3-4af3-b143-e3cb3d98428f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_75ea16d0-05a5-4c40-9908-1fb5819e9067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_Assets_75ea16d0-05a5-4c40-9908-1fb5819e9067" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dcd5ec97-17ab-4c8a-af31-99b54d14a674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:to="loc_us-gaap_LiabilitiesCurrent_dcd5ec97-17ab-4c8a-af31-99b54d14a674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8d1391c-7555-4ba2-ae25-eb7a4c60b292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8d1391c-7555-4ba2-ae25-eb7a4c60b292" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b1a2bffd-0eba-42f2-807c-5988b80766e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b1a2bffd-0eba-42f2-807c-5988b80766e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:to="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6941ba0f-bd7a-4d6b-8a3d-c98eb36be287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6941ba0f-bd7a-4d6b-8a3d-c98eb36be287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2c7e5e3a-234a-41e5-9297-3d43dceee98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_CostsAndExpenses_2c7e5e3a-234a-41e5-9297-3d43dceee98f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_627b5d69-ca6a-4dd2-a25f-b9051e3e44e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_OperatingIncomeLoss_627b5d69-ca6a-4dd2-a25f-b9051e3e44e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f70eb5ea-3a63-4ca6-bf66-a4ec05d9b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f70eb5ea-3a63-4ca6-bf66-a4ec05d9b2ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ae292c0-1a5e-4dbc-90eb-40528c409427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ae292c0-1a5e-4dbc-90eb-40528c409427" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_58cbc499-1ee4-47ed-ae84-89c4694e9ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_ProfitLoss_58cbc499-1ee4-47ed-ae84-89c4694e9ae9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_698a14d0-ec90-4e6a-89f7-618e1fa70a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_698a14d0-ec90-4e6a-89f7-618e1fa70a97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d02c06a0-e697-42e5-b33b-0a263901d3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_698a14d0-ec90-4e6a-89f7-618e1fa70a97" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d02c06a0-e697-42e5-b33b-0a263901d3cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_d02c06a0-e697-42e5-b33b-0a263901d3cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d02c06a0-e697-42e5-b33b-0a263901d3cf" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_d02c06a0-e697-42e5-b33b-0a263901d3cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d02c06a0-e697-42e5-b33b-0a263901d3cf" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_51de91a6-222c-4cd1-8015-a5758fdd7fcf" xlink:href="ameh-20210630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_51de91a6-222c-4cd1-8015-a5758fdd7fcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_3842c655-66cf-4187-9583-9552e22cc267" xlink:href="ameh-20210630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_3842c655-66cf-4187-9583-9552e22cc267" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended" id="i288a986e4be8490dba1cf526b14a4ec3_LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_393a0af0-23cb-49ba-9bcc-939791d85fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_us-gaap_NotesReceivableNet_393a0af0-23cb-49ba-9bcc-939791d85fdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_670c2394-2924-4a83-ba39-29d591916c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_670c2394-2924-4a83-ba39-29d591916c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_2376dcc2-f81b-467a-ab87-696eb81aa1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_us-gaap_NotesReceivableGross_2376dcc2-f81b-467a-ab87-696eb81aa1b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_535fa3fc-b2f6-4e5f-8e22-fa7179854fde" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_535fa3fc-b2f6-4e5f-8e22-fa7179854fde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_53ac7930-91c9-40ba-a657-53cfa0d83085" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_53ac7930-91c9-40ba-a657-53cfa0d83085" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1" xlink:to="loc_us-gaap_ReceivableTypeDomain_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_3c1d32cf-e538-4e7c-a7e0-fbc06aca8f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1" xlink:to="loc_us-gaap_ReceivableTypeDomain_3c1d32cf-e538-4e7c-a7e0-fbc06aca8f38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_dda460f2-e31a-4eaf-a3d4-48fe2e8f9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_3c1d32cf-e538-4e7c-a7e0-fbc06aca8f38" xlink:to="loc_us-gaap_NotesReceivableMember_dda460f2-e31a-4eaf-a3d4-48fe2e8f9b56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4451924b-61c4-4809-a7d4-2faf60db5d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4451924b-61c4-4809-a7d4-2faf60db5d93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4451924b-61c4-4809-a7d4-2faf60db5d93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4451924b-61c4-4809-a7d4-2faf60db5d93" xlink:to="loc_us-gaap_RelatedPartyDomain_4451924b-61c4-4809-a7d4-2faf60db5d93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4451924b-61c4-4809-a7d4-2faf60db5d93" xlink:to="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_560038ca-90a9-4b96-ac6a-fcee8e950fe8" xlink:href="ameh-20210630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:to="loc_ameh_Pacific6EnterprisesMember_560038ca-90a9-4b96-ac6a-fcee8e950fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_a0450cd5-b235-4542-b3de-612ef53ed419" xlink:href="ameh-20210630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:to="loc_ameh_AHMCMember_a0450cd5-b235-4542-b3de-612ef53ed419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_85f63b16-babd-4176-b542-b319c12a14ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:to="loc_dei_LegalEntityAxis_85f63b16-babd-4176-b542-b319c12a14ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_85f63b16-babd-4176-b542-b319c12a14ae_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_85f63b16-babd-4176-b542-b319c12a14ae" xlink:to="loc_dei_EntityDomain_85f63b16-babd-4176-b542-b319c12a14ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_85f63b16-babd-4176-b542-b319c12a14ae" xlink:to="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_e5360072-0dc4-4e5b-bdaf-b877e91bbd25" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:to="loc_ameh_NetworkMedicalManagementMember_e5360072-0dc4-4e5b-bdaf-b877e91bbd25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_be9ae247-3b7d-47b6-b682-2bb8537e431f" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_be9ae247-3b7d-47b6-b682-2bb8537e431f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended" id="i2209293ae2a1408ea8f17d5b727952be_CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0284b8cb-880c-43e2-b627-fc7e213c3fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0284b8cb-880c-43e2-b627-fc7e213c3fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a84a88f1-b524-4b8c-a410-e151f0e7c790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_LongTermDebtCurrent_a84a88f1-b524-4b8c-a410-e151f0e7c790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_185fd45f-4007-4d98-b823-707098fb4873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_185fd45f-4007-4d98-b823-707098fb4873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cb0a7ba3-bbd1-4ba7-8831-f158d1d84320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cb0a7ba3-bbd1-4ba7-8831-f158d1d84320" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4026c8e5-72e2-463c-95a1-ca872c29d018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:to="loc_us-gaap_CreditFacilityAxis_4026c8e5-72e2-463c-95a1-ca872c29d018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4026c8e5-72e2-463c-95a1-ca872c29d018_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4026c8e5-72e2-463c-95a1-ca872c29d018" xlink:to="loc_us-gaap_CreditFacilityDomain_4026c8e5-72e2-463c-95a1-ca872c29d018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4026c8e5-72e2-463c-95a1-ca872c29d018" xlink:to="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_7fa00106-7ddf-4fa0-b76b-34b6bc5aec78" xlink:href="ameh-20210630.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:to="loc_ameh_TermLoanAMember_7fa00106-7ddf-4fa0-b76b-34b6bc5aec78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f351fc0f-19f0-4eb7-b211-61ea781a9789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f351fc0f-19f0-4eb7-b211-61ea781a9789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b839ba5d-7611-47eb-97d7-e5db21b62582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b839ba5d-7611-47eb-97d7-e5db21b62582" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b839ba5d-7611-47eb-97d7-e5db21b62582_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b839ba5d-7611-47eb-97d7-e5db21b62582" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b839ba5d-7611-47eb-97d7-e5db21b62582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b839ba5d-7611-47eb-97d7-e5db21b62582" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_3389df10-e0e7-461a-af6c-5d270411ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:to="loc_us-gaap_RealEstateLoanMember_3389df10-e0e7-461a-af6c-5d270411ccb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_6a4b9049-fefd-4e2d-a26e-49beb8c647f7" xlink:href="ameh-20210630.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:to="loc_ameh_ConstructionLoanMember_6a4b9049-fefd-4e2d-a26e-49beb8c647f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended" id="ib86debe42e1c4c3eb70b6363cfa072a9_CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e04c846b-ca55-4c30-be29-c683c5e6cc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentTerm_e04c846b-ca55-4c30-be29-c683c5e6cc31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23a3975f-bf46-4e22-a7a4-48d64e271867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23a3975f-bf46-4e22-a7a4-48d64e271867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d07ebdb5-e095-4e0b-932c-0670fa3b6671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d07ebdb5-e095-4e0b-932c-0670fa3b6671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_64155ad9-08f3-4d50-b6da-60f5e6a6f9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_64155ad9-08f3-4d50-b6da-60f5e6a6f9f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_6176bb37-9d8f-4cb6-9c16-3dd9ec3546de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_6176bb37-9d8f-4cb6-9c16-3dd9ec3546de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_72a68501-b592-426a-b4b7-a8bc3e8ab226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_72a68501-b592-426a-b4b7-a8bc3e8ab226" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_022e93c4-d0ea-4724-9231-91132e6a1dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCredit_022e93c4-d0ea-4724-9231-91132e6a1dbd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_898bcc82-1839-49dd-8684-06cabb9ec5d6" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_898bcc82-1839-49dd-8684-06cabb9ec5d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_624f3f43-802c-4e22-94e3-d14e49134207" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_624f3f43-802c-4e22-94e3-d14e49134207" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1d20b7a4-c8a2-43f8-864b-f57ab22e1b1f" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1d20b7a4-c8a2-43f8-864b-f57ab22e1b1f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_9eea0d44-34a9-4d63-91d4-47a938c39a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_9eea0d44-34a9-4d63-91d4-47a938c39a64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1bb55599-479d-4b3d-8f8b-b9077e31ba2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1bb55599-479d-4b3d-8f8b-b9077e31ba2e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_b982bb0e-683a-4448-ad07-d106a7301784" xlink:href="ameh-20210630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_b982bb0e-683a-4448-ad07-d106a7301784" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a8d3c8a2-26c1-4967-9f69-62368fe8e7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a8d3c8a2-26c1-4967-9f69-62368fe8e7c2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_506b862e-2777-4154-a002-2a97c11f38c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LongTermDebt_506b862e-2777-4154-a002-2a97c11f38c5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_061c3977-5536-4b4c-ae83-89eef5de3b6b" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_061c3977-5536-4b4c-ae83-89eef5de3b6b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_7f0a6831-cc8f-4f9c-9a80-b8d78e9ad4aa" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_7f0a6831-cc8f-4f9c-9a80-b8d78e9ad4aa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64901c71-a23e-4010-8c5f-fc67724728b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64901c71-a23e-4010-8c5f-fc67724728b7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f88b25fa-640c-4c38-aba3-52a61ae7335a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_InterestExpense_f88b25fa-640c-4c38-aba3-52a61ae7335a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_830be1cd-621d-467b-b671-d5933f8cc32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_830be1cd-621d-467b-b671-d5933f8cc32c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_d641bc07-369e-47a8-acc2-73cc410536af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_d641bc07-369e-47a8-acc2-73cc410536af" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6452fd52-9874-48a7-b593-9bcb57605b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6452fd52-9874-48a7-b593-9bcb57605b59" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_dafd4486-d9e1-4f6d-a0b0-1a304738810c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_CreditFacilityAxis_dafd4486-d9e1-4f6d-a0b0-1a304738810c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dafd4486-d9e1-4f6d-a0b0-1a304738810c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_dafd4486-d9e1-4f6d-a0b0-1a304738810c" xlink:to="loc_us-gaap_CreditFacilityDomain_dafd4486-d9e1-4f6d-a0b0-1a304738810c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_dafd4486-d9e1-4f6d-a0b0-1a304738810c" xlink:to="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_eb74adf6-1032-4d9d-ba28-0943b9b4029c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_eb74adf6-1032-4d9d-ba28-0943b9b4029c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c6b5c69b-7d68-4f1a-b4de-11f2adfa3751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_LineOfCreditMember_c6b5c69b-7d68-4f1a-b4de-11f2adfa3751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_6e167616-8dd1-42e3-a8a2-83b5bc12d193" xlink:href="ameh-20210630.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_ameh_TermLoanAMember_6e167616-8dd1-42e3-a8a2-83b5bc12d193" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c947c727-5072-400e-bc06-d4184b4ddb81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_LetterOfCreditMember_c947c727-5072-400e-bc06-d4184b4ddb81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_b9280a53-36a0-4123-bf42-dbbfa8d15475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_BridgeLoanMember_b9280a53-36a0-4123-bf42-dbbfa8d15475" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_a0f97de2-4594-47fc-b08f-f668208ad907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_a0f97de2-4594-47fc-b08f-f668208ad907" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7b103882-3c01-4e7f-a21b-9a640c4015b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_DebtInstrumentAxis_7b103882-3c01-4e7f-a21b-9a640c4015b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b103882-3c01-4e7f-a21b-9a640c4015b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7b103882-3c01-4e7f-a21b-9a640c4015b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b103882-3c01-4e7f-a21b-9a640c4015b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7b103882-3c01-4e7f-a21b-9a640c4015b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_20115f55-4037-439c-9c85-69c31edd6c24" xlink:href="ameh-20210630.xsd#ameh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_CreditAgreementMember_20115f55-4037-439c-9c85-69c31edd6c24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_de805744-b543-4bb9-8a9e-aaaa01ddb3cb" xlink:href="ameh-20210630.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_AmendedCreditAgreementMember_de805744-b543-4bb9-8a9e-aaaa01ddb3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_60c31d96-a4ac-4eb4-8746-1a111bc9ec66" xlink:href="ameh-20210630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_60c31d96-a4ac-4eb4-8746-1a111bc9ec66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_63315cbb-3bc1-4db1-8b5f-50910795ad87" xlink:href="ameh-20210630.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_ConstructionLoanMember_63315cbb-3bc1-4db1-8b5f-50910795ad87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4516e3d4-3fe1-44d4-9594-f3cb34e1207f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4516e3d4-3fe1-44d4-9594-f3cb34e1207f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4516e3d4-3fe1-44d4-9594-f3cb34e1207f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4516e3d4-3fe1-44d4-9594-f3cb34e1207f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4516e3d4-3fe1-44d4-9594-f3cb34e1207f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d2983820-a675-4aa1-a08d-35faa8844dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4516e3d4-3fe1-44d4-9594-f3cb34e1207f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d2983820-a675-4aa1-a08d-35faa8844dc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_340ad5fc-7666-4582-894a-ccd6ea6e5274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d2983820-a675-4aa1-a08d-35faa8844dc2" xlink:to="loc_us-gaap_LineOfCreditMember_340ad5fc-7666-4582-894a-ccd6ea6e5274" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_49c907f5-f259-415b-9771-2fffd33428c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_srt_RangeAxis_49c907f5-f259-415b-9771-2fffd33428c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49c907f5-f259-415b-9771-2fffd33428c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_49c907f5-f259-415b-9771-2fffd33428c6" xlink:to="loc_srt_RangeMember_49c907f5-f259-415b-9771-2fffd33428c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_49c907f5-f259-415b-9771-2fffd33428c6" xlink:to="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a13d12a7-1a3e-4632-8d80-4e34979a722c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:to="loc_srt_MinimumMember_a13d12a7-1a3e-4632-8d80-4e34979a722c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5522fd12-8b7d-465c-913c-2829208b225b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:to="loc_srt_MaximumMember_5522fd12-8b7d-465c-913c-2829208b225b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d24788dc-687d-45db-9e3b-72e4be18e8f7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_dei_LegalEntityAxis_d24788dc-687d-45db-9e3b-72e4be18e8f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d24788dc-687d-45db-9e3b-72e4be18e8f7_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d24788dc-687d-45db-9e3b-72e4be18e8f7" xlink:to="loc_dei_EntityDomain_d24788dc-687d-45db-9e3b-72e4be18e8f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d24788dc-687d-45db-9e3b-72e4be18e8f7" xlink:to="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_aba8fb86-56b6-43fa-8e0b-5ff7f1bc4185" xlink:href="ameh-20210630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_aba8fb86-56b6-43fa-8e0b-5ff7f1bc4185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_cdf84801-b996-42b6-8f6d-7435261cc69d" xlink:href="ameh-20210630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_AMGPropertiesLLCMember_cdf84801-b996-42b6-8f6d-7435261cc69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_7bccc65c-7826-4f17-a023-c8326f448c92" xlink:href="ameh-20210630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_ZLLPartnersLLCMember_7bccc65c-7826-4f17-a023-c8326f448c92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_b106ed16-b0fc-4b61-9bea-9d69122f1d48" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_b106ed16-b0fc-4b61-9bea-9d69122f1d48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ff9fa2f6-2cf2-4b3d-af25-afba09a9cf73" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ff9fa2f6-2cf2-4b3d-af25-afba09a9cf73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_4def2ee2-1974-45f7-9a44-fe082f391989" xlink:href="ameh-20210630.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_ApaacoMember_4def2ee2-1974-45f7-9a44-fe082f391989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_9ba1d1b3-bc1e-40ec-992d-a4135cc3fa47" xlink:href="ameh-20210630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_9ba1d1b3-bc1e-40ec-992d-a4135cc3fa47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_VariableRateAxis_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e" xlink:to="loc_us-gaap_VariableRateDomain_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e" xlink:to="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b879e6cf-4e0e-4a48-99ab-c9db6a4746d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b879e6cf-4e0e-4a48-99ab-c9db6a4746d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_c0aa7c7d-e457-49d9-83ee-3ab01fc97e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:to="loc_us-gaap_PrimeRateMember_c0aa7c7d-e457-49d9-83ee-3ab01fc97e24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_51a1e6e9-075d-4e38-9da4-3f484016cc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_51a1e6e9-075d-4e38-9da4-3f484016cc14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_03bbc9ab-a65d-45da-b4b2-346ae1a1589c" xlink:href="ameh-20210630.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_51a1e6e9-075d-4e38-9da4-3f484016cc14" xlink:to="loc_ameh_PreferredBankMember_03bbc9ab-a65d-45da-b4b2-346ae1a1589c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c6e630a3-be13-4d0c-8a60-bf127357b923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c6e630a3-be13-4d0c-8a60-bf127357b923" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c6e630a3-be13-4d0c-8a60-bf127357b923_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c6e630a3-be13-4d0c-8a60-bf127357b923" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c6e630a3-be13-4d0c-8a60-bf127357b923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c6e630a3-be13-4d0c-8a60-bf127357b923" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_9b83516c-e94c-42b6-9018-58ce5ed93aca" xlink:href="ameh-20210630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:to="loc_ameh_AMGPropertiesLLCMember_9b83516c-e94c-42b6-9018-58ce5ed93aca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_d54e16ef-7830-4ce1-bd89-51adfe2f13f8" xlink:href="ameh-20210630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_d54e16ef-7830-4ce1-bd89-51adfe2f13f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_0162f02d-e9ed-49d5-b68b-5310d775a73c" xlink:href="ameh-20210630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:to="loc_ameh_ZLLPartnersLLCMember_0162f02d-e9ed-49d5-b68b-5310d775a73c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a8123f7c-8390-474e-8200-72821ce991d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_srt_StatementScenarioAxis_a8123f7c-8390-474e-8200-72821ce991d6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a8123f7c-8390-474e-8200-72821ce991d6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a8123f7c-8390-474e-8200-72821ce991d6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a8123f7c-8390-474e-8200-72821ce991d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_329763bd-0163-49e6-8448-a668286ad515" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a8123f7c-8390-474e-8200-72821ce991d6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_329763bd-0163-49e6-8448-a668286ad515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b556d44e-ab2a-41c6-a402-4ff5f07d1974" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_329763bd-0163-49e6-8448-a668286ad515" xlink:to="loc_srt_ScenarioForecastMember_b556d44e-ab2a-41c6-a402-4ff5f07d1974" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="id3cdb092daf1444c8b90200cb34b8714_MezzanineandStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_a53b108d-7676-4fda-ad11-5f625a0045af" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_a53b108d-7676-4fda-ad11-5f625a0045af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_70a179a9-04b5-4845-a2c4-1d377987db92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_us-gaap_TreasuryStockCommonShares_70a179a9-04b5-4845-a2c4-1d377987db92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_ed66df8d-b34d-4934-ab1c-f09718eb94e8" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_ed66df8d-b34d-4934-ab1c-f09718eb94e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_143018bf-0ea3-4eda-ac14-97b345f944d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_us-gaap_Dividends_143018bf-0ea3-4eda-ac14-97b345f944d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6ce8fd8-5e48-4588-a1aa-5ff3b41a1d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6ce8fd8-5e48-4588-a1aa-5ff3b41a1d55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ecb3fb90-364d-436d-a7f2-ea7314402964" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6ce8fd8-5e48-4588-a1aa-5ff3b41a1d55" xlink:to="loc_dei_LegalEntityAxis_ecb3fb90-364d-436d-a7f2-ea7314402964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ecb3fb90-364d-436d-a7f2-ea7314402964_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ecb3fb90-364d-436d-a7f2-ea7314402964" xlink:to="loc_dei_EntityDomain_ecb3fb90-364d-436d-a7f2-ea7314402964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ecb3fb90-364d-436d-a7f2-ea7314402964" xlink:to="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_42f251d2-cd36-448f-9fd2-f32a6300f43c" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_42f251d2-cd36-448f-9fd2-f32a6300f43c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_74da0b39-4a88-46ac-adca-9f8a5590be43" xlink:href="ameh-20210630.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:to="loc_ameh_CDSCMember_74da0b39-4a88-46ac-adca-9f8a5590be43" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="id42f54c4f90742868e3478e47cdc28ca_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:href="ameh-20210630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_069db0b4-f381-4cbc-9744-acd18f94a834" xlink:href="ameh-20210630.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_069db0b4-f381-4cbc-9744-acd18f94a834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3eea8f89-a147-424a-955c-03ecf40abeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3eea8f89-a147-424a-955c-03ecf40abeb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_9e4ff3ff-68f4-49d1-aeee-c4302d3e9ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_us-gaap_LineOfCredit_9e4ff3ff-68f4-49d1-aeee-c4302d3e9ad2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_1f9531c8-bdbb-4cd3-8ef8-5c64a2c71cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_1f9531c8-bdbb-4cd3-8ef8-5c64a2c71cb2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:href="ameh-20210630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_98ac9004-1745-4111-88a8-a6cb8575e7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_us-gaap_CreditFacilityAxis_98ac9004-1745-4111-88a8-a6cb8575e7f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_98ac9004-1745-4111-88a8-a6cb8575e7f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_98ac9004-1745-4111-88a8-a6cb8575e7f9" xlink:to="loc_us-gaap_CreditFacilityDomain_98ac9004-1745-4111-88a8-a6cb8575e7f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_876275f0-0df6-4e65-892e-da3448d9aa50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_98ac9004-1745-4111-88a8-a6cb8575e7f9" xlink:to="loc_us-gaap_CreditFacilityDomain_876275f0-0df6-4e65-892e-da3448d9aa50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_dece6273-9f9e-46f8-8d2b-5678ba972a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_876275f0-0df6-4e65-892e-da3448d9aa50" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_dece6273-9f9e-46f8-8d2b-5678ba972a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9a570577-8b38-42ff-a475-5a63ce7c4f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9a570577-8b38-42ff-a475-5a63ce7c4f4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_9a570577-8b38-42ff-a475-5a63ce7c4f4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9a570577-8b38-42ff-a475-5a63ce7c4f4a" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_9a570577-8b38-42ff-a475-5a63ce7c4f4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b020937b-2826-4584-8278-a97ec9bb605f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9a570577-8b38-42ff-a475-5a63ce7c4f4a" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b020937b-2826-4584-8278-a97ec9bb605f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_2153a2a9-75f9-4832-89bf-060f5f444bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b020937b-2826-4584-8278-a97ec9bb605f" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_2153a2a9-75f9-4832-89bf-060f5f444bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_dei_LegalEntityAxis_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef" xlink:to="loc_dei_EntityDomain_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef" xlink:to="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_7cca2bd9-5bad-4d77-a9e8-0fecbc8500f5" xlink:href="ameh-20210630.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:to="loc_ameh_ApaacoMember_7cca2bd9-5bad-4d77-a9e8-0fecbc8500f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d636092d-8934-4a82-bde6-30193fdec50e" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d636092d-8934-4a82-bde6-30193fdec50e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_0299155c-b26a-40b4-9497-11ac568fef4b" xlink:href="ameh-20210630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_0299155c-b26a-40b4-9497-11ac568fef4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_26aee619-5a8d-499f-be62-1860ec2f7287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_26aee619-5a8d-499f-be62-1860ec2f7287" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_26aee619-5a8d-499f-be62-1860ec2f7287_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_26aee619-5a8d-499f-be62-1860ec2f7287" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_26aee619-5a8d-499f-be62-1860ec2f7287_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_bdc5da56-2470-4fd9-b77a-f1f44661b4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_26aee619-5a8d-499f-be62-1860ec2f7287" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_bdc5da56-2470-4fd9-b77a-f1f44661b4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_6dae130a-6a04-4e23-b766-bccd881852a6" xlink:href="ameh-20210630.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_bdc5da56-2470-4fd9-b77a-f1f44661b4cb" xlink:to="loc_ameh_PreferredBankMember_6dae130a-6a04-4e23-b766-bccd881852a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="i5b333739b58d42e08b429bcdc3c5fa43_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_246e5094-450e-4c63-9516-f176524ae044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_RevenueFromRelatedParties_246e5094-450e-4c63-9516-f176524ae044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a87d3421-a947-4fb2-a5f7-054c1e9f8137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a87d3421-a947-4fb2-a5f7-054c1e9f8137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_c6a226e1-9106-46b6-90eb-6c29a6413488" xlink:href="ameh-20210630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_ameh_PaymentMadeToRelatedParty_c6a226e1-9106-46b6-90eb-6c29a6413488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3ff578ab-8f98-4d9d-ab00-62316df7d167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3ff578ab-8f98-4d9d-ab00-62316df7d167" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_4d4ae3c5-bb9c-44ce-8e74-712ba7484dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_4d4ae3c5-bb9c-44ce-8e74-712ba7484dff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_e5d10b94-758a-4b8b-a67f-c16d569274f3" xlink:href="ameh-20210630.xsd#ameh_PaymentConsultingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_ameh_PaymentConsultingFees_e5d10b94-758a-4b8b-a67f-c16d569274f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f9719d71-e274-408f-a3bc-da128ed351c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f9719d71-e274-408f-a3bc-da128ed351c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f9719d71-e274-408f-a3bc-da128ed351c3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f9719d71-e274-408f-a3bc-da128ed351c3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f9719d71-e274-408f-a3bc-da128ed351c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f9719d71-e274-408f-a3bc-da128ed351c3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_3a11c93a-a430-4df7-b534-fe3edd1b02a5" xlink:href="ameh-20210630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_LmaMember_3a11c93a-a430-4df7-b534-fe3edd1b02a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_4f992db8-7a88-46de-8dfa-80a60b9ae9f0" xlink:href="ameh-20210630.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_PmiocMember_4f992db8-7a88-46de-8dfa-80a60b9ae9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_0518b331-79e0-4764-b8f3-0b962ad7d618" xlink:href="ameh-20210630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_DmgMember_0518b331-79e0-4764-b8f3-0b962ad7d618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_b693a0dd-bd1c-44d3-be0a-cfda1c0ad8bb" xlink:href="ameh-20210630.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_OneMSOInc.Member_b693a0dd-bd1c-44d3-be0a-cfda1c0ad8bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5af33fac-472b-4c00-93bf-9a4cb7334474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5af33fac-472b-4c00-93bf-9a4cb7334474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5af33fac-472b-4c00-93bf-9a4cb7334474_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5af33fac-472b-4c00-93bf-9a4cb7334474" xlink:to="loc_us-gaap_RelatedPartyDomain_5af33fac-472b-4c00-93bf-9a4cb7334474_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5af33fac-472b-4c00-93bf-9a4cb7334474" xlink:to="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_58b674a2-49b2-42dc-b7f5-41c9c401a51f" xlink:href="ameh-20210630.xsd#ameh_ApcShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_ApcShareholdersMember_58b674a2-49b2-42dc-b7f5-41c9c401a51f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_327121c6-f2b2-4b67-8efb-b30dd3c3668a" xlink:href="ameh-20210630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_327121c6-f2b2-4b67-8efb-b30dd3c3668a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_a83d133c-75a3-4c14-a4d7-2f9fdb63f2ff" xlink:href="ameh-20210630.xsd#ameh_FreseniusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_FreseniusMember_a83d133c-75a3-4c14-a4d7-2f9fdb63f2ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_db2712bb-0992-4e21-8b01-8720cfbf761e" xlink:href="ameh-20210630.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_FulgentGeneticsIncMember_db2712bb-0992-4e21-8b01-8720cfbf761e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_be61d7fa-7668-47f8-a6a3-b160d7d895d8" xlink:href="ameh-20210630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_ShareholdersAndOfficersMember_be61d7fa-7668-47f8-a6a3-b160d7d895d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_bd8c93ed-daac-4f6d-8374-95cc0d3ef0f8" xlink:href="ameh-20210630.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_bd8c93ed-daac-4f6d-8374-95cc0d3ef0f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_f59eefab-2057-42ae-8f9b-b51b9dc0ecb3" xlink:href="ameh-20210630.xsd#ameh_NumenLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_NumenLLCMember_f59eefab-2057-42ae-8f9b-b51b9dc0ecb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_506c372f-fd30-4e64-808b-36381f43359e" xlink:href="ameh-20210630.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_OneMSOInc.Member_506c372f-fd30-4e64-808b-36381f43359e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_4e0d71e0-ade3-4e15-8c58-47e71a6edd5f" xlink:href="ameh-20210630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_AHMCMember_4e0d71e0-ade3-4e15-8c58-47e71a6edd5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2cc374f3-4182-4393-a170-5812d0b0eeb7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_dei_LegalEntityAxis_2cc374f3-4182-4393-a170-5812d0b0eeb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2cc374f3-4182-4393-a170-5812d0b0eeb7_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2cc374f3-4182-4393-a170-5812d0b0eeb7" xlink:to="loc_dei_EntityDomain_2cc374f3-4182-4393-a170-5812d0b0eeb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2cc374f3-4182-4393-a170-5812d0b0eeb7" xlink:to="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_9a0257fc-cba1-49ac-a7ad-ff6227963b9a" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_NetworkMedicalManagementMember_9a0257fc-cba1-49ac-a7ad-ff6227963b9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8ce364f3-e83d-4aaf-8750-5792ae8bafe8" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8ce364f3-e83d-4aaf-8750-5792ae8bafe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_129ffee0-03fb-428b-bd1b-f2ae2c8fe32a" xlink:href="ameh-20210630.xsd#ameh_ApaAcoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_ApaAcoIncMember_129ffee0-03fb-428b-bd1b-f2ae2c8fe32a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_86eb300a-28a1-4ff3-9446-f4c4d5b60fcd" xlink:href="ameh-20210630.xsd#ameh_SCHCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_SCHCMember_86eb300a-28a1-4ff3-9446-f4c4d5b60fcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_5033b7ee-c586-4432-a285-2d49491fe85b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_srt_ConsolidatedEntitiesAxis_5033b7ee-c586-4432-a285-2d49491fe85b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5033b7ee-c586-4432-a285-2d49491fe85b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5033b7ee-c586-4432-a285-2d49491fe85b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5033b7ee-c586-4432-a285-2d49491fe85b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5033b7ee-c586-4432-a285-2d49491fe85b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_a2f88d4e-0c64-4946-a560-dc4d72c48b2c" xlink:href="ameh-20210630.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:to="loc_ameh_LmaMember_a2f88d4e-0c64-4946-a560-dc4d72c48b2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_3c87385d-73ba-4d41-b7b6-75a4b9898a24" xlink:href="ameh-20210630.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:to="loc_ameh_PmiocMember_3c87385d-73ba-4d41-b7b6-75a4b9898a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_f1b7597a-2a28-41e4-9d49-cd931110083e" xlink:href="ameh-20210630.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:to="loc_ameh_DmgMember_f1b7597a-2a28-41e4-9d49-cd931110083e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5911ea87-cf34-47eb-9d5d-1233a5fee59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5911ea87-cf34-47eb-9d5d-1233a5fee59f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5911ea87-cf34-47eb-9d5d-1233a5fee59f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5911ea87-cf34-47eb-9d5d-1233a5fee59f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5911ea87-cf34-47eb-9d5d-1233a5fee59f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14542d46-8090-4a60-9502-407a5fc949ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5911ea87-cf34-47eb-9d5d-1233a5fee59f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14542d46-8090-4a60-9502-407a5fc949ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_310644a6-7533-4a9f-8a65-47a236f10e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14542d46-8090-4a60-9502-407a5fc949ea" xlink:to="loc_us-gaap_ServiceMember_310644a6-7533-4a9f-8a65-47a236f10e2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_99b6670c-0f79-4799-8b57-7f7028811d9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_srt_TitleOfIndividualAxis_99b6670c-0f79-4799-8b57-7f7028811d9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99b6670c-0f79-4799-8b57-7f7028811d9d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_99b6670c-0f79-4799-8b57-7f7028811d9d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_99b6670c-0f79-4799-8b57-7f7028811d9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08127068-232a-48a6-a80a-cb1c767c6ed7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_99b6670c-0f79-4799-8b57-7f7028811d9d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08127068-232a-48a6-a80a-cb1c767c6ed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_9bf9e814-5667-4cc7-8b55-56804ae1e64e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08127068-232a-48a6-a80a-cb1c767c6ed7" xlink:to="loc_srt_DirectorMember_9bf9e814-5667-4cc7-8b55-56804ae1e64e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended" id="ia532a20c4a1f42919e68888f2e9678e9_RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_7e1c0d35-822b-4575-a493-62bae79ee1e0" xlink:href="ameh-20210630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_7e1c0d35-822b-4575-a493-62bae79ee1e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_24b2bc53-0d15-44b6-a99e-7d7db44cadb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:to="loc_us-gaap_ManagementFeeExpense_24b2bc53-0d15-44b6-a99e-7d7db44cadb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_06a63e9f-6732-403c-883f-f535699d33e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_06a63e9f-6732-403c-883f-f535699d33e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_981c93fc-74cf-4799-9e99-2a05c9dcab9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_981c93fc-74cf-4799-9e99-2a05c9dcab9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_873c5539-cc3a-4591-a9a1-8b684e0ad8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_981c93fc-74cf-4799-9e99-2a05c9dcab9d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_873c5539-cc3a-4591-a9a1-8b684e0ad8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_873c5539-cc3a-4591-a9a1-8b684e0ad8c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_873c5539-cc3a-4591-a9a1-8b684e0ad8c2" xlink:to="loc_us-gaap_RelatedPartyDomain_873c5539-cc3a-4591-a9a1-8b684e0ad8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_873c5539-cc3a-4591-a9a1-8b684e0ad8c2" xlink:to="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_02944372-8b7c-4307-adb1-b154b2b3bce7" xlink:href="ameh-20210630.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:to="loc_ameh_AHMCMember_02944372-8b7c-4307-adb1-b154b2b3bce7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_70ad737f-f2b2-4123-86b3-592c4647ad0a" xlink:href="ameh-20210630.xsd#ameh_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:to="loc_ameh_HSMSOMember_70ad737f-f2b2-4123-86b3-592c4647ad0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_75c0756b-ff7b-4164-aa72-5b38e35e070b" xlink:href="ameh-20210630.xsd#ameh_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:to="loc_ameh_AurionMember_75c0756b-ff7b-4164-aa72-5b38e35e070b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended" id="iab099973ccd144fd8c3a0421087583db_EarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_dd465c91-7a99-43d7-bc72-0f490b6c1a65" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb53cc14-dfeb-4179-983a-9ca0869cad6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_dd465c91-7a99-43d7-bc72-0f490b6c1a65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb53cc14-dfeb-4179-983a-9ca0869cad6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_f78ce5d8-cfea-4302-a929-78863c881fed" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_dd465c91-7a99-43d7-bc72-0f490b6c1a65" xlink:to="loc_ameh_EarningsPerShareTable_f78ce5d8-cfea-4302-a929-78863c881fed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_369adf7c-9f4c-436c-a94a-ab1945eed8b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_f78ce5d8-cfea-4302-a929-78863c881fed" xlink:to="loc_dei_LegalEntityAxis_369adf7c-9f4c-436c-a94a-ab1945eed8b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_369adf7c-9f4c-436c-a94a-ab1945eed8b5_default" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_369adf7c-9f4c-436c-a94a-ab1945eed8b5" xlink:to="loc_dei_EntityDomain_369adf7c-9f4c-436c-a94a-ab1945eed8b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1fff638d-2c5d-4794-ae84-f0db21e281c9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_369adf7c-9f4c-436c-a94a-ab1945eed8b5" xlink:to="loc_dei_EntityDomain_1fff638d-2c5d-4794-ae84-f0db21e281c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6d962039-3b39-433e-827f-93779b030251" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1fff638d-2c5d-4794-ae84-f0db21e281c9" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6d962039-3b39-433e-827f-93779b030251" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended" id="i5f70fc7092d2465db7fe4ebaacd6e369_EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cded29f9-ff57-4d11-8381-da8a43adc26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cded29f9-ff57-4d11-8381-da8a43adc26c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8727a961-d274-41e5-8df3-452cd09818ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8727a961-d274-41e5-8df3-452cd09818ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33ea62f7-6889-428e-af8a-1d64f377c574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33ea62f7-6889-428e-af8a-1d64f377c574" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:to="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_24674026-6852-4aef-bc3f-7b66827bff75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_24674026-6852-4aef-bc3f-7b66827bff75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_24674026-6852-4aef-bc3f-7b66827bff75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_24674026-6852-4aef-bc3f-7b66827bff75" xlink:to="loc_us-gaap_EquityComponentDomain_24674026-6852-4aef-bc3f-7b66827bff75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b2078b7-2715-4371-a557-bd5b8980ab9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_24674026-6852-4aef-bc3f-7b66827bff75" xlink:to="loc_us-gaap_EquityComponentDomain_6b2078b7-2715-4371-a557-bd5b8980ab9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c049da1d-2a38-4d24-b6bf-3fce8af47040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6b2078b7-2715-4371-a557-bd5b8980ab9e" xlink:to="loc_us-gaap_WarrantMember_c049da1d-2a38-4d24-b6bf-3fce8af47040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b3978b7-57e6-4c6a-bc14-ad84790198e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b3978b7-57e6-4c6a-bc14-ad84790198e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5b3978b7-57e6-4c6a-bc14-ad84790198e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b3978b7-57e6-4c6a-bc14-ad84790198e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5b3978b7-57e6-4c6a-bc14-ad84790198e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b3978b7-57e6-4c6a-bc14-ad84790198e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_197a28a1-c915-4321-8c31-83eab6670756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:to="loc_us-gaap_EmployeeStockOptionMember_197a28a1-c915-4321-8c31-83eab6670756" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9b3c7d55-c496-4fab-a902-406ba11b19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:to="loc_us-gaap_RestrictedStockMember_9b3c7d55-c496-4fab-a902-406ba11b19b8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended" id="i4fa35ee0bbd14ef49c107c9032eae01a_VariableInterestEntitiesVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3a87010-1677-4538-a23e-452ca97254e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3a87010-1677-4538-a23e-452ca97254e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b0357787-c832-435c-9de7-9154a45ab807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b0357787-c832-435c-9de7-9154a45ab807" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f08bc3c7-727d-4fdd-b6fc-04843be22b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f08bc3c7-727d-4fdd-b6fc-04843be22b48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f2eb0d05-01cb-4676-b809-f21b230f1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f2eb0d05-01cb-4676-b809-f21b230f1ddf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ed7d4b88-06c1-4ad6-b7eb-89e29413be18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ed7d4b88-06c1-4ad6-b7eb-89e29413be18" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f6722efc-73f0-47e9-adef-fbeb53569d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f6722efc-73f0-47e9-adef-fbeb53569d97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_966052f3-329c-4693-95be-5a0ce086be99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_966052f3-329c-4693-95be-5a0ce086be99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_95155e20-aa34-4dbd-9756-8901b5033e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_95155e20-aa34-4dbd-9756-8901b5033e5e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_55b38eff-8137-4087-9947-63935ef06b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_AssetsCurrent_55b38eff-8137-4087-9947-63935ef06b62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3c6dfd5-7e9c-4b2a-a2f0-a7772bacd91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e3c6dfd5-7e9c-4b2a-a2f0-a7772bacd91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2af5a5bd-7100-4331-ad50-705d329eaea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2af5a5bd-7100-4331-ad50-705d329eaea9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5e7e814d-861d-4774-968c-0ef297260eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_Goodwill_5e7e814d-861d-4774-968c-0ef297260eab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_eb773d4a-7334-4834-9f91-f09a7df85408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_eb773d4a-7334-4834-9f91-f09a7df85408" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_4308a43d-0eaa-4f1d-811b-997b680d0d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_OtherLongTermInvestments_4308a43d-0eaa-4f1d-811b-997b680d0d1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d1d6c188-4af6-433f-8cc6-82e4f91ba97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_EquityMethodInvestments_d1d6c188-4af6-433f-8cc6-82e4f91ba97d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_b04ac3c6-8700-4dc5-9ef5-356f8fb4a338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_b04ac3c6-8700-4dc5-9ef5-356f8fb4a338" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e83a5067-b2d2-42d6-ba24-92e288d01f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e83a5067-b2d2-42d6-ba24-92e288d01f79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d54e2265-9904-4ee6-9744-5954898562b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d54e2265-9904-4ee6-9744-5954898562b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_42ff094a-3825-4de9-9559-fccadb2b19eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_42ff094a-3825-4de9-9559-fccadb2b19eb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_7bb4f13b-775a-432b-aad2-b8d893d5d2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_AssetsNoncurrent_7bb4f13b-775a-432b-aad2-b8d893d5d2ab" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_35d80d8e-dfcb-4bb7-8d88-d46a465e1fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:to="loc_us-gaap_Assets_35d80d8e-dfcb-4bb7-8d88-d46a465e1fa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21246058-90b7-404d-bbcb-70cddd4e5f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21246058-90b7-404d-bbcb-70cddd4e5f92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_94fa1ac8-83b1-4a58-88ce-29122112eeb7" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_94fa1ac8-83b1-4a58-88ce-29122112eeb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d099e8b9-6c09-44a1-b575-d6abad203078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d099e8b9-6c09-44a1-b575-d6abad203078" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_c3a991c4-ff40-4135-b40b-916e5da022e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_TaxesPayableCurrent_c3a991c4-ff40-4135-b40b-916e5da022e6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_b9415527-b55b-4ce2-ad00-7d51c283fd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_DividendsPayableCurrent_b9415527-b55b-4ce2-ad00-7d51c283fd5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_60f8cfa3-6878-4d6a-9cba-7e9bb4d8d406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_DueToAffiliateCurrent_60f8cfa3-6878-4d6a-9cba-7e9bb4d8d406" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_19315c3d-9198-48d5-b7b5-075bf07ea6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_LongTermDebtCurrent_19315c3d-9198-48d5-b7b5-075bf07ea6a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a3912fe5-ab01-4a90-bc58-ae2e742a1c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a3912fe5-ab01-4a90-bc58-ae2e742a1c15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_74870cf8-83ae-499a-988f-92140ea88bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_74870cf8-83ae-499a-988f-92140ea88bc8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c20e25e9-746e-413a-8b20-a6761240c744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_LiabilitiesCurrent_c20e25e9-746e-413a-8b20-a6761240c744" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_577a64d4-424f-47e2-8683-c91b2582f3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_577a64d4-424f-47e2-8683-c91b2582f3e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_03239b50-72e5-413b-a81a-da21745a288f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_03239b50-72e5-413b-a81a-da21745a288f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8862171a-735d-4e97-b7ac-4add48eb0b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8862171a-735d-4e97-b7ac-4add48eb0b55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e4dccef-7fb6-4602-aae9-05a01eb3bc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e4dccef-7fb6-4602-aae9-05a01eb3bc44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a291596d-3c6d-4762-85e0-627168577d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a291596d-3c6d-4762-85e0-627168577d35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_6e83e688-a3f0-4b6a-b583-cba48e1b9db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_6e83e688-a3f0-4b6a-b583-cba48e1b9db1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ff002940-eb26-4c91-b5b9-15bd176688fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_Liabilities_ff002940-eb26-4c91-b5b9-15bd176688fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c4fd71b9-2e80-4a12-8028-8b6a43b2e3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c4fd71b9-2e80-4a12-8028-8b6a43b2e3ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_47c44f0e-127b-4f57-887b-bbf848c0913a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c4fd71b9-2e80-4a12-8028-8b6a43b2e3ec" xlink:to="loc_srt_ConsolidatedEntitiesAxis_47c44f0e-127b-4f57-887b-bbf848c0913a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_47c44f0e-127b-4f57-887b-bbf848c0913a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_47c44f0e-127b-4f57-887b-bbf848c0913a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_47c44f0e-127b-4f57-887b-bbf848c0913a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5270ff85-d000-4373-b494-d8a073df034f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_47c44f0e-127b-4f57-887b-bbf848c0913a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5270ff85-d000-4373-b494-d8a073df034f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_cdecb675-8c00-4af5-a228-a07c57345946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5270ff85-d000-4373-b494-d8a073df034f" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_cdecb675-8c00-4af5-a228-a07c57345946" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="ib56ec3f26fd34b55be6f9081df092d44_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f48ebbe1-647c-4c7f-b960-43a91bba98cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f48ebbe1-647c-4c7f-b960-43a91bba98cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_4a2c923f-5a32-4e11-a57a-16622bd5cc48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_4a2c923f-5a32-4e11-a57a-16622bd5cc48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8a49d9a1-f341-4014-985e-39b5bfc05261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8a49d9a1-f341-4014-985e-39b5bfc05261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_41663e1a-cef8-4615-8684-b4f320a890c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_41663e1a-cef8-4615-8684-b4f320a890c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_67a05d79-5dc5-446f-98b8-168f29853cac" xlink:href="ameh-20210630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_67a05d79-5dc5-446f-98b8-168f29853cac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_1318db1f-e198-4538-b228-40c02ac48489" xlink:href="ameh-20210630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_1318db1f-e198-4538-b228-40c02ac48489" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_7ff4547a-4456-4faa-ac59-7ca81a5f9b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_7ff4547a-4456-4faa-ac59-7ca81a5f9b46" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_899d5436-eb40-4448-9023-beeb4cdf497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_899d5436-eb40-4448-9023-beeb4cdf497a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d09730a6-82a8-4092-a684-49205600f778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d09730a6-82a8-4092-a684-49205600f778" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7146b2e-0d55-4867-9b89-db15505ed158" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d09730a6-82a8-4092-a684-49205600f778" xlink:to="loc_srt_RangeAxis_d7146b2e-0d55-4867-9b89-db15505ed158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7146b2e-0d55-4867-9b89-db15505ed158_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d7146b2e-0d55-4867-9b89-db15505ed158" xlink:to="loc_srt_RangeMember_d7146b2e-0d55-4867-9b89-db15505ed158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d7146b2e-0d55-4867-9b89-db15505ed158" xlink:to="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e9f566f0-57d4-460d-abf5-c7dea3eeac59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:to="loc_srt_MinimumMember_e9f566f0-57d4-460d-abf5-c7dea3eeac59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44c05b1d-a29d-4396-ad0d-5c0c1b35474f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:to="loc_srt_MaximumMember_44c05b1d-a29d-4396-ad0d-5c0c1b35474f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="if234b8341a77484a963f216ed5b440ba_StockBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1690af9-4fc0-432d-90be-5bff8e3e715c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ba573b5-d236-4ee7-8c0d-b3e2b4fb57cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1690af9-4fc0-432d-90be-5bff8e3e715c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ba573b5-d236-4ee7-8c0d-b3e2b4fb57cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_356a8986-b675-4bcc-b994-964dceb24afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1690af9-4fc0-432d-90be-5bff8e3e715c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_356a8986-b675-4bcc-b994-964dceb24afe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b6650a3-9ce5-425c-8a2d-17d276144453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_356a8986-b675-4bcc-b994-964dceb24afe" xlink:to="loc_us-gaap_AwardTypeAxis_7b6650a3-9ce5-425c-8a2d-17d276144453" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b6650a3-9ce5-425c-8a2d-17d276144453_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7b6650a3-9ce5-425c-8a2d-17d276144453" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b6650a3-9ce5-425c-8a2d-17d276144453_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7b6650a3-9ce5-425c-8a2d-17d276144453" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9fe140e6-b336-4b58-ac35-0f67378cfb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9fe140e6-b336-4b58-ac35-0f67378cfb9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_330f2d69-4601-46fd-bcb1-76f0b1ca2bda" xlink:href="ameh-20210630.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:to="loc_ameh_StockAwardsAndUnitsMember_330f2d69-4601-46fd-bcb1-76f0b1ca2bda" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i415e7fd4d20c4f49a7a1023a442768ee_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3e538137-0c97-4a60-8596-0cd8d4b3c99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3e538137-0c97-4a60-8596-0cd8d4b3c99b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc7c5f6d-8e89-41b3-a94d-c41eea61d577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc7c5f6d-8e89-41b3-a94d-c41eea61d577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27b27483-c726-4ce0-bebf-c48fdf7018ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27b27483-c726-4ce0-bebf-c48fdf7018ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_48262957-68fa-4fa5-b6e3-af803b98649a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_48262957-68fa-4fa5-b6e3-af803b98649a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d88fcbff-116c-4e8e-92a2-ec18cbf319aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d88fcbff-116c-4e8e-92a2-ec18cbf319aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9294d0c-c38a-476f-a4d9-1d3f0a8da1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9294d0c-c38a-476f-a4d9-1d3f0a8da1a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_532b9b9b-04d8-4099-b50d-bbaf06d2a0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_532b9b9b-04d8-4099-b50d-bbaf06d2a0cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dbfcf39e-36e3-4773-8e67-783cecb40a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dbfcf39e-36e3-4773-8e67-783cecb40a35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_93ba8c65-4351-4f58-8242-5bfd9ee005e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_93ba8c65-4351-4f58-8242-5bfd9ee005e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_cb5d6176-ac68-47c8-b527-06d3b75d8d0f" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_cb5d6176-ac68-47c8-b527-06d3b75d8d0f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_2105ba8b-a8e0-4787-92d3-ba5eda0a44d3" xlink:href="ameh-20210630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_2105ba8b-a8e0-4787-92d3-ba5eda0a44d3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_b7fc5fa0-e1e0-4ca6-abc2-e4a1aef0c2e3" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_b7fc5fa0-e1e0-4ca6-abc2-e4a1aef0c2e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd3a906f-1a83-4d39-9b0a-cb0ec843c893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:to="loc_us-gaap_AwardTypeAxis_cd3a906f-1a83-4d39-9b0a-cb0ec843c893" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd3a906f-1a83-4d39-9b0a-cb0ec843c893_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cd3a906f-1a83-4d39-9b0a-cb0ec843c893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd3a906f-1a83-4d39-9b0a-cb0ec843c893_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cd3a906f-1a83-4d39-9b0a-cb0ec843c893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9833f267-acfd-4f10-8135-4ff5e9b934ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9833f267-acfd-4f10-8135-4ff5e9b934ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_02549b9a-0e0f-4db2-8d27-6fdc11e76c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:to="loc_us-gaap_RestrictedStockMember_02549b9a-0e0f-4db2-8d27-6fdc11e76c10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2483df56-f957-4017-975c-63bfa083e45b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:to="loc_srt_TitleOfIndividualAxis_2483df56-f957-4017-975c-63bfa083e45b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2483df56-f957-4017-975c-63bfa083e45b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2483df56-f957-4017-975c-63bfa083e45b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2483df56-f957-4017-975c-63bfa083e45b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2483df56-f957-4017-975c-63bfa083e45b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_68286dd5-4939-4e10-981b-c2e9a32808ec" xlink:href="ameh-20210630.xsd#ameh_ApcStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:to="loc_ameh_ApcStockOptionMember_68286dd5-4939-4e10-981b-c2e9a32808ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_a23dcd93-c393-4b67-8409-1584ea9b6660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:to="loc_srt_DirectorMember_a23dcd93-c393-4b67-8409-1584ea9b6660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78fafe88-18f0-4d23-960b-5d970325dc3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:to="loc_srt_RangeAxis_78fafe88-18f0-4d23-960b-5d970325dc3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_78fafe88-18f0-4d23-960b-5d970325dc3b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_78fafe88-18f0-4d23-960b-5d970325dc3b" xlink:to="loc_srt_RangeMember_78fafe88-18f0-4d23-960b-5d970325dc3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_78fafe88-18f0-4d23-960b-5d970325dc3b" xlink:to="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7904f6a2-538b-4423-a6c5-04b74ac864e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:to="loc_srt_MinimumMember_7904f6a2-538b-4423-a6c5-04b74ac864e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60013524-f2b5-481a-9a2f-caf99511dc53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:to="loc_srt_MaximumMember_60013524-f2b5-481a-9a2f-caf99511dc53" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended" id="ic8223953929d4cc59178fb4114122d82_StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50ebef94-2490-400b-aedd-eee548cab3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50ebef94-2490-400b-aedd-eee548cab3ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9467e204-14d7-4a0b-887c-b5c72504e080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9467e204-14d7-4a0b-887c-b5c72504e080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_84357307-0c18-4f11-8b1f-2d769d19f6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_84357307-0c18-4f11-8b1f-2d769d19f6a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_656fce0b-7f80-484c-844c-a863e1dba98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_SharePrice_656fce0b-7f80-484c-844c-a863e1dba98d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f592f319-f771-4daa-a41b-4907c531a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f592f319-f771-4daa-a41b-4907c531a0d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_3ac5753f-49ab-42b5-942e-9bc93819d8c8" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_3ac5753f-49ab-42b5-942e-9bc93819d8c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b414d95-17d5-4e73-a0a1-6e1bc6a1429a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b414d95-17d5-4e73-a0a1-6e1bc6a1429a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_178f1dbc-2e19-4baf-b80e-ac4aa540cae9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b414d95-17d5-4e73-a0a1-6e1bc6a1429a" xlink:to="loc_srt_TitleOfIndividualAxis_178f1dbc-2e19-4baf-b80e-ac4aa540cae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_178f1dbc-2e19-4baf-b80e-ac4aa540cae9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_178f1dbc-2e19-4baf-b80e-ac4aa540cae9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_178f1dbc-2e19-4baf-b80e-ac4aa540cae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c25afa29-d344-4ac1-8527-447280f454f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_178f1dbc-2e19-4baf-b80e-ac4aa540cae9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c25afa29-d344-4ac1-8527-447280f454f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_a8344e1e-7596-4791-947c-db5fcbf33b86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c25afa29-d344-4ac1-8527-447280f454f1" xlink:to="loc_srt_DirectorMember_a8344e1e-7596-4791-947c-db5fcbf33b86" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended" id="i3ceb71540d1b40d8b3fb9628a21b08cb_StockBasedCompensationWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6dfcec2a-bc9e-4352-af0f-75ff5f7a77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6dfcec2a-bc9e-4352-af0f-75ff5f7a77e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_3d2ad9fd-1e69-49c3-913f-2bd566e04153" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_3d2ad9fd-1e69-49c3-913f-2bd566e04153" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_534ca46d-ef2f-4a0a-b29e-6fa1cbda5673" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_534ca46d-ef2f-4a0a-b29e-6fa1cbda5673" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_3f49f5d0-9097-4fa5-b5cb-404a75d927ab" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_3f49f5d0-9097-4fa5-b5cb-404a75d927ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_7360f877-104b-425c-80af-acc648d0f417" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_7360f877-104b-425c-80af-acc648d0f417" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe4debc3-df5d-4763-8a28-5aacd0fb232b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe4debc3-df5d-4763-8a28-5aacd0fb232b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_fe4debc3-df5d-4763-8a28-5aacd0fb232b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe4debc3-df5d-4763-8a28-5aacd0fb232b" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_fe4debc3-df5d-4763-8a28-5aacd0fb232b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe4debc3-df5d-4763-8a28-5aacd0fb232b" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_69795559-cf7e-4209-b004-e2ee035e48c8" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_69795559-cf7e-4209-b004-e2ee035e48c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_be913565-e8d3-4f86-a3e1-05dbe0b83d8a" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_be913565-e8d3-4f86-a3e1-05dbe0b83d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_ae6d78e5-2770-47b4-a74e-97798a8fe095" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_ae6d78e5-2770-47b4-a74e-97798a8fe095" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6f354f7-4429-4332-a1a5-d566c3e0ec39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:to="loc_srt_RangeAxis_a6f354f7-4429-4332-a1a5-d566c3e0ec39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6f354f7-4429-4332-a1a5-d566c3e0ec39_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a6f354f7-4429-4332-a1a5-d566c3e0ec39" xlink:to="loc_srt_RangeMember_a6f354f7-4429-4332-a1a5-d566c3e0ec39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a6f354f7-4429-4332-a1a5-d566c3e0ec39" xlink:to="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62475e5a-1906-4737-8721-bab234932551" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:to="loc_srt_MinimumMember_62475e5a-1906-4737-8721-bab234932551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7afdaf1a-2695-46de-be93-4939490a412b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:to="loc_srt_MaximumMember_7afdaf1a-2695-46de-be93-4939490a412b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended" id="i30b605a044b9424ea78393a2311cb20f_SubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays_9e55ad36-cd2d-473a-9651-b4bd3c240f6f" xlink:href="ameh-20210630.xsd#ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays_9e55ad36-cd2d-473a-9651-b4bd3c240f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones_e66c3572-0287-45f3-b0d2-71fd1af8fe1e" xlink:href="ameh-20210630.xsd#ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones_e66c3572-0287-45f3-b0d2-71fd1af8fe1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a744a899-f871-4d65-9e06-556e5a7e7797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a744a899-f871-4d65-9e06-556e5a7e7797" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_34feb3e3-01d4-4e2d-a5ac-8ff5cb7cd3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_34feb3e3-01d4-4e2d-a5ac-8ff5cb7cd3a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfLocations_dba331d2-7370-43d5-bf59-92f497e7357f" xlink:href="ameh-20210630.xsd#ameh_NumberOfLocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_ameh_NumberOfLocations_dba331d2-7370-43d5-bf59-92f497e7357f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6e59a1d7-760e-4e72-8ffa-db496a01f0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6e59a1d7-760e-4e72-8ffa-db496a01f0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6e59a1d7-760e-4e72-8ffa-db496a01f0ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6e59a1d7-760e-4e72-8ffa-db496a01f0ad" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6e59a1d7-760e-4e72-8ffa-db496a01f0ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fb31814f-5a6c-4839-b9c3-94a4642b4f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6e59a1d7-760e-4e72-8ffa-db496a01f0ad" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fb31814f-5a6c-4839-b9c3-94a4642b4f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_67022587-9154-4e17-a62c-64db792d3c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fb31814f-5a6c-4839-b9c3-94a4642b4f7d" xlink:to="loc_us-gaap_SubsequentEventMember_67022587-9154-4e17-a62c-64db792d3c81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5c07af6-74e8-4577-80f3-03b3ff4f4409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5c07af6-74e8-4577-80f3-03b3ff4f4409" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5c07af6-74e8-4577-80f3-03b3ff4f4409_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5c07af6-74e8-4577-80f3-03b3ff4f4409" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5c07af6-74e8-4577-80f3-03b3ff4f4409_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5c07af6-74e8-4577-80f3-03b3ff4f4409" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_d4c7528e-7571-494d-99b0-7461d25eab8e" xlink:href="ameh-20210630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_d4c7528e-7571-494d-99b0-7461d25eab8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SunClinicalLaboratoriesMember_db99632a-f43c-4b85-8db7-aaee8bcb078d" xlink:href="ameh-20210630.xsd#ameh_SunClinicalLaboratoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:to="loc_ameh_SunClinicalLaboratoriesMember_db99632a-f43c-4b85-8db7-aaee8bcb078d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_17d3618d-7ccb-4836-90fb-f9482bcc2afb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:to="loc_srt_StatementScenarioAxis_17d3618d-7ccb-4836-90fb-f9482bcc2afb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_17d3618d-7ccb-4836-90fb-f9482bcc2afb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_17d3618d-7ccb-4836-90fb-f9482bcc2afb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_17d3618d-7ccb-4836-90fb-f9482bcc2afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_79433ddb-715f-43f5-b5fc-66dafc7709dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_17d3618d-7ccb-4836-90fb-f9482bcc2afb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_79433ddb-715f-43f5-b5fc-66dafc7709dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5d2707ab-1d7e-45d6-ae4b-2a3482903e3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_79433ddb-715f-43f5-b5fc-66dafc7709dd" xlink:to="loc_srt_ScenarioForecastMember_5d2707ab-1d7e-45d6-ae4b-2a3482903e3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ameh-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:95c9976f-ff84-4dd6-aeb6-cbf10c7f8b0a,g:1aa3c04f-4646-4116-829c-b4ce4a78f20a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_df93d8dc-96cd-4116-b53d-8cea14cd7853_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_b04cca8b-6e56-4cc6-987c-39eb353968c5_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivables</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b2558949-54d5-4708-9ba7-605caf4298b5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_e3d6c837-80da-4c6e-bc7d-bd8b6965d924_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_8058cac6-ca63-4f0d-a5e3-28ea1c156721_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_229e24d9-65c5-4049-a9cf-05171944064a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_57fee8de-31fd-4f1a-8373-578dca924c39_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicaidMember_5222dcd9-65d0-433b-bc3f-68e83816f554_terseLabel_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ameh_MedicaidMember_label_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ameh_MedicaidMember_documentation_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember" xlink:href="ameh-20210630.xsd#ameh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_946ca5f0-2242-4866-8685-5abf9876cc5e_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - related party</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC - Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:href="ameh-20210630.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a41c0aa4-4d4c-40cd-ac8d-d025722acc4b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_10a6b39d-c498-4f4d-a3ee-63156db350c1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_78895256-80dd-4ed3-a752-6dc2870ee839_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2da6a3b1-241b-4bb5-9088-2632a8d06ad6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_8b2019ea-6621-41f8-9b58-4df6e17cc3f5_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_0d1fe723-2b77-45cc-a927-dd397de8c446_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc.</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_b104f885-610c-4fa2-a039-c4663616e476_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6ca20c84-4738-41c0-85cb-6f513ac25651_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_30be05bc-2ce6-45aa-91c5-8e5a30754883_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_8ec0b173-d98d-4464-834f-f13af0dd709d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_681db976-cbdd-4937-89eb-bbb67d06fdd3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_85bad966-6dc7-4b76-8116-d984b883ea2d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5b44b1dc-eccf-46d2-bd75-94e084736f89_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommercialMember_69bef628-98c0-47a4-bce2-d190098ccace_terseLabel_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_ameh_CommercialMember_label_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_ameh_CommercialMember_documentation_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember" xlink:href="ameh-20210630.xsd#ameh_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_cc127250-1ff4-4dfa-97ef-532ddf31a3eb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_b8168ed9-131f-4215-a8ee-fc692add7cc0_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_30f13178-02b2-44a4-aeb7-d9e45cda6b5d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_48d29d65-52cc-4dcd-adef-7c687b7a9966_terseLabel_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_label_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" xlink:href="ameh-20210630.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_23622a5e-2e9d-4344-b25e-3b12c928d15e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_667857ca-3ac7-484e-836f-8ef325738e8f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_f0e2f42b-f479-4185-be77-2694faf6c0d1_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CDSCMember_66f607af-6d7f-47d7-b315-2ff437b976ad_terseLabel_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_ameh_CDSCMember_label_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_ameh_CDSCMember_documentation_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember" xlink:href="ameh-20210630.xsd#ameh_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CDSCMember" xlink:to="lab_ameh_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2eaa58b3-10ed-41d5-8c08-9b7aa709f7df_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_dc906068-d867-47f3-a5cf-401814a8d97d_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_f5290320-d929-43a8-92fe-d391e8b0514c_terseLabel_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy [Policy Text Block]</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:href="ameh-20210630.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_20f7eb8b-8d6f-4386-ada1-6a7bc77b09b7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_59403dc6-941a-4b74-aa00-889ded14f011_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares not included in the calculation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_cca136cf-4356-4c16-8bf8-a0918b616eda_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract liability recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a748a95b-c9fe-468a-b1f6-583d39b2a8ad_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AncillaryServiceContractMember_a8244455-66e2-4a41-8598-e036ea2cfb91_terseLabel_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract</link:label>
    <link:label id="lab_ameh_AncillaryServiceContractMember_label_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember" xlink:href="ameh-20210630.xsd#ameh_AncillaryServiceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AncillaryServiceContractMember" xlink:to="lab_ameh_AncillaryServiceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1386b915-cf4b-4b89-a053-c4904868d745_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8ed41f76-233f-4d97-af16-7f0cfe4cf470_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_9735f541-aff2-486d-bee1-7095e567ca83_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow hedges:</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_a2f591d7-eea1-4a8c-9c60-3c8ab1afaf9c_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:to="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0287facc-4ce4-4795-9904-290454a3c86b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock to be recognized straight-line</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96b00bf9-4eca-497e-b46a-bf2b2ac17a53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_feb65e26-b0cb-43db-9078-2c9736b6b86f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_025a56eb-8a75-479d-b2da-a1549d7ac3da_terseLabel_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related parties</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_label_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made To Related Party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_documentation_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty" xlink:href="ameh-20210630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e8031cf0-4d47-44f7-ad0d-086021073039_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d72c7a77-cf23-4220-a83b-6ae4bff3b98c_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_3c6ada0f-d9da-43db-8169-65d7925b516f_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a7971ede-f2e9-473f-8871-93b84641b860_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_273d3c95-78bb-4cc0-a702-f30394a96fa2_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_f237b4cd-ece7-4577-b6fb-c0df768433a9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SubcontractorIPAPayable_01695582-eee0-48f2-9322-0552c536b1b1_verboseLabel_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_label_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_documentation_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable" xlink:href="ameh-20210630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIPAPayable" xlink:to="lab_ameh_SubcontractorIPAPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9c55cd63-a3cf-4faf-83e9-d216026ef89a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_f18e5722-398e-49d3-829b-1a9d046a4631_terseLabel_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_label_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_documentation_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards" xlink:href="ameh-20210630.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CancellationOfRestrictedStockAwards" xlink:to="lab_ameh_CancellationOfRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_342ae676-1c70-412d-b7e6-019ac21b38ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_10f78180-2cff-4f08-ac20-077e3d6b9294_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorEMember_6ca6e4d3-df04-4a5b-b61c-227085d64c04_terseLabel_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:label id="lab_ameh_PayorEMember_label_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember" xlink:href="ameh-20210630.xsd#ameh_PayorEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorEMember" xlink:to="lab_ameh_PayorEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_f67b60ff-9ee8-4039-9f75-3f02e9c31ee1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3c07a8d1-e89f-493e-92db-1d0d624b7591_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_350ef7c7-1f3b-4ec4-94e7-70ec0ffa69dd_terseLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash consideration entitled to be received</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:href="ameh-20210630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:to="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_a2fb5acb-e5fd-452a-966c-4b17c50e1237_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f8908081-315b-4d62-afe7-3048b208deb2_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b4009093-f37a-4ee1-865c-7d6c672d7046_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_80f32ef4-5f97-44c8-8cd2-bc481f9b4283_terseLabel_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities, maturity period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="ameh-20210630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PmiocMember_29588b4e-4fd9-479f-9ec7-e1c100d98aaa_terseLabel_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_ameh_PmiocMember_label_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember" xlink:href="ameh-20210630.xsd#ameh_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0dc4038f-afc3-4e02-a83c-0676357ccb02_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_b90ffdaa-23c2-4304-883d-263615bdf2c1_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool surplus or deficits, settlement period after risk pool performance year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="ameh-20210630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_8319b699-8cb3-43f6-87f0-f943431ad08f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_36fe56cd-8dc0-42d2-84b8-90cf53107726_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_18e7cd9b-05df-41ad-8f76-35612f32c55b_terseLabel_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember" xlink:href="ameh-20210630.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmendedCreditAgreementMember" xlink:to="lab_ameh_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_eaac0f78-f00c-4ad3-8332-634ffe98852d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4237fb9a-9d91-45f7-81e5-e38295882718_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_a50f1157-f1ab-4a2f-8587-97e2fbc8a9a7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8e5dbaf0-76f3-43d1-9302-a4c4de67ade7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_b039aa00-4642-4845-a894-66b15f5cf7bb_verboseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_1066181e-7c87-4cb2-8c45-4fd6df8ca923_terseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dec60cf5-f4c3-48ad-bded-62081df6198a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_31c30f99-0220-4bde-b59c-b46a4006cbba_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash - noncurrent</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_f4600f32-095e-4f6b-89a2-151ce30002c0_terseLabel_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_label_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC [Member]</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_documentation_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember" xlink:href="ameh-20210630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AMGPropertiesLLCMember" xlink:to="lab_ameh_AMGPropertiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_adade25d-8695-480a-9b3e-897e64095635_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_c194af6a-a7cb-4ba7-9086-f4ef98e7adb3_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities - Equity Method and Investments in Other Entities - Cost Method</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_cd7695af-ea02-49ee-9125-c7648ac75fe3_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_144d90cd-00e5-46af-bf5e-e7fb740fbacc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fbe3f313-a1b0-4063-9202-e678906dcfce_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f0dcba38-dfc8-4838-be0b-d75a54cf2357_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_39b06f45-e52e-4a88-b176-e7207f198c8e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcShareholdersMember_08493c19-49b8-41d2-9250-9edfee09f1ba_terseLabel_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders</link:label>
    <link:label id="lab_ameh_ApcShareholdersMember_label_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember" xlink:href="ameh-20210630.xsd#ameh_ApcShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_46fd5fde-aac6-4b24-bbae-2a33fb1e4c90_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_82c61774-d4ca-4bbf-8e40-36aeafff8b1c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f169b5b8-2d7c-442f-82f1-4c77e3a23e42_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_be3a08ed-3539-4642-839b-9ffa1b10fcb0_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fa12e956-6de4-4100-bdd7-09e948ea4532_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d045dd20-4802-438f-959a-feee05ef80ef_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price adjustment from Merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_dd09aac0-a7a2-4677-8108-a8618e08a24d_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorAMember_cd3249ee-792c-4b44-8fb2-1172215fbe82_terseLabel_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_ameh_PayorAMember_label_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_ameh_PayorAMember_documentation_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember" xlink:href="ameh-20210630.xsd#ameh_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorAMember" xlink:to="lab_ameh_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_3f8677d2-0075-4d84-b1b7-c7abf05b22a2_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f47ff172-122b-4797-b1e9-271d077ef4df_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_766543bd-69f1-4590-bf92-f3bb24740a21_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenue_6d813c5a-b255-4c7b-96d1-b6a0d30386fb_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_label_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenue" xlink:to="lab_ameh_PaymentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_850ea3a7-80dc-431b-966b-d59fbac44d62_terseLabel_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_label_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp [Member]</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_documentation_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Critical Quality Management Corp Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember" xlink:href="ameh-20210630.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CriticalQualityManagementCorpMember" xlink:to="lab_ameh_CriticalQualityManagementCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_0c79f959-445a-4541-89b3-03aeabb2e736_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfEmployees_efe5aac2-1876-4d2d-876f-09e647210fc0_terseLabel_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_label_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_documentation_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees" xlink:href="ameh-20210630.xsd#ameh_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfEmployees" xlink:to="lab_ameh_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_7e5dc073-9dd9-4d2d-99aa-842253f281f3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_8cc53327-6df0-49a6-8968-8dae20f6eb07_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_229c0d0d-c2c9-4c2c-be1c-466d8417211e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_a0590e8a-110a-4385-9f3c-0c34e716b5d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_d2635628-ce9d-4cda-8677-149b74fd5822_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares by noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_1251eb51-d3c2-4d2d-ba61-0a2fa423b419_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_55d55173-6359-4ea2-bc2f-00d74abfad27_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_fa2eb9cc-cb6a-4fc0-9e8a-b5ca2fb4bec5_negatedLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_bf7de392-80d6-4269-a2a9-8a7406d01617_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_c1abf911-6abf-4055-8d2f-d2e4e88c009e_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_18baccaf-7e31-4440-868f-fd8660d53b67_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_06b50419-0b17-4bbb-8f14-4574490fae01_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_6612553f-e14b-4810-a48a-5e52b23123d2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_563c5ba8-b067-49f3-89c7-42fc4ed0a67b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e12e669-f404-4926-8e68-9e6e3a3f70aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1fe9f40c-ddcd-4e82-8f17-c6a83d0e48c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_530306ea-8583-410a-9cd9-3cb58253e041_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SharesWarrantsRollForward_5f154eb7-90d1-43ff-a7d7-029dbb197989_terseLabel_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_label_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward" xlink:href="ameh-20210630.xsd#ameh_SharesWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesWarrantsRollForward" xlink:to="lab_ameh_SharesWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f0c655b0-1764-4e28-8210-99ad07b7e560_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_5af14c41-0905-44f3-a377-8f84a85cd2b1_terseLabel_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_label_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable And Accrued Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:href="ameh-20210630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:to="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6ef36aef-2284-4e1c-b8dc-d5c08d56f354_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,246,796 and 42,249,137 shares outstanding, excluding 10,885,732 and 12,323,164 treasury shares, as of June&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_22414d01-bc41-4719-9ec4-b75556a055d7_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeDomain_525ce79b-157a-47cd-80ec-cbf41ee9081e_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:label id="lab_ameh_ContractTypeDomain_label_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain" xlink:href="ameh-20210630.xsd#ameh_ContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeDomain" xlink:to="lab_ameh_ContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_2f172f79-5efc-4f9c-bea2-5b897d54238c_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaacoMember_0bb103de-4882-49e0-a12d-c0e0d4cc1ddc_terseLabel_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO</link:label>
    <link:label id="lab_ameh_ApaacoMember_label_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember" xlink:href="ameh-20210630.xsd#ameh_ApaacoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaacoMember" xlink:to="lab_ameh_ApaacoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_152a17aa-abd1-4165-8f9a-f1521f926942_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_174d178b-a243-408e-af7f-63cdda06353f_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_fbbf8fac-45d7-404e-a6c0-51b36806ddb9_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_f580f80d-6822-4c80-96b5-a8c5818617e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Income Contract</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_53f05878-0629-4a6c-b056-dc8228a85fa9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the six months ended June 30, 2021)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6d02c628-6ceb-4003-807d-1a34e0554ee4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_3309a06f-0b23-4bb7-b57c-82d07f764907_terseLabel_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group</link:label>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_label_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember" xlink:href="ameh-20210630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DiagnosticMedicalGroupMember" xlink:to="lab_ameh_DiagnosticMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_0f0c0f83-63cd-46d8-b357-b524083e5c90_terseLabel_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:href="ameh-20210630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_df2a0abd-705a-4570-9799-827f11648c16_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_2f976932-4185-4b55-83f8-417d43967702_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_9b3b1b8b-af30-4f14-ba38-5c4cc992901c_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ab2165f8-1b9d-4191-a0b4-5ec13e6ef40e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_687f2aef-fea6-422d-9400-0c5efe804227_terseLabel_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_label_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc. [Member]</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_documentation_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember" xlink:href="ameh-20210630.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FulgentGeneticsIncMember" xlink:to="lab_ameh_FulgentGeneticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_6ebfda52-31d6-4335-8638-292869e5df3c_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherThirdPartiesMember_dc6f17c0-36d2-4dff-94a1-6db39325bc4d_terseLabel_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_label_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember" xlink:href="ameh-20210630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_fe3f63b0-5c7d-40fe-b34a-2698d858f69a_terseLabel_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_label_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_documentation_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember" xlink:href="ameh-20210630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APAMHMedicalCorporationMember" xlink:to="lab_ameh_APAMHMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_affca224-ae1d-4478-b061-b25b3072f269_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_98e62bc6-08e7-4283-b771-2aae7810b8d8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_485e4610-9e09-4ef1-b557-49afba9c7d7f_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_0dab9356-b640-46b1-b874-5ac561cc73d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby letters of credit assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_a076b6e3-3233-43af-8825-7e4341224ff5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_98c7bebd-10c9-464b-9a83-d41a5fd54bfd_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_577bf40a-8f67-4e5e-9fad-696ab7fd50bc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b764491-5193-452a-875f-14e70e9be761_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaAcoIncMember_e200050e-6d25-41f4-b77d-e9b674c426b2_terseLabel_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APA ACO Inc</link:label>
    <link:label id="lab_ameh_ApaAcoIncMember_label_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APA ACO Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember" xlink:href="ameh-20210630.xsd#ameh_ApaAcoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaAcoIncMember" xlink:to="lab_ameh_ApaAcoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5fc29f87-8689-4692-bb1a-62231af18aae_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fc42b4ea-3592-4328-8d6c-1a9c7dab5505_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f486d712-c522-4530-a917-d54a6e5049f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_5c532d47-a53e-4862-ac23-580a254d6328_terseLabel_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC</link:label>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:href="ameh-20210630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_f1352a14-bdfa-4cc6-b0c5-7c24dfc4968c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_5f97e6b6-b4d4-4f39-b7f4-3dcf4e6d6fa6_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_00747c09-07a8-4100-a92f-f9eb9cc12f3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_554da684-8f0e-4c7f-ac58-1915b658cc1d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d23ff57-ed09-4475-a360-57b08cd9aebc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_2f67ca5a-988e-4597-aa5d-e85d17bbc8f5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6e2b1cb6-59d5-403e-a575-1770b68a0bc7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_e5776fb8-1b35-4f3c-8209-421783a52054_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" xlink:href="ameh-20210630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_ed1bb241-d9b9-4b41-b90d-d2af2820be7e_terseLabel_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMPM Managed Care Contract</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_label_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_documentation_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:href="ameh-20210630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:to="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_b55fff80-8d6b-41a8-aa5a-1ab1adf7a84d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_5cd9ab39-8287-4615-9969-ef5ef4b3f31c_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_2a0cd5bb-7626-4ba2-a25c-8eb94eb6b789_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_6ca41988-a8dc-4131-b903-d7d9e3890054_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_98cbb3e9-2d8b-4181-9e4e-11109a90424d_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants received (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_19346413-1ab9-40f4-b44a-a39f28eaee8e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on revolver</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_b11342d1-4a40-444f-9fab-59e606db1ba1_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loan</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0754979d-a6c4-4876-8c29-7f0231664492_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5567fe4f-91d7-42b3-b988-db396e947c0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_0ab5d1d4-9895-4ebb-bf21-39b9c353571c_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock, within five years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_673f6574-a04d-4df2-b81c-f17307df977c_terseLabel_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed term of amended and restated management and administrative services agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_label_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_documentation_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:href="ameh-20210630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkRelationshipsMember_9cec2b9d-2e7c-498d-97c8-99785a83b00f_terseLabel_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_label_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember" xlink:href="ameh-20210630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_dd43aa2c-bafa-4b4e-9522-b85e3f23f692_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_60ce4c71-73d6-46c0-b0e3-52bd0a030ab5_terseLabel_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_label_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember" xlink:href="ameh-20210630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ZLLPartnersLLCMember" xlink:to="lab_ameh_ZLLPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_9bfe40a8-76bc-4c16-aadd-867f5afd35d0_terseLabel_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_label_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:href="ameh-20210630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:to="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_97cacfbf-7b44-4473-91fd-851d7bc5ca12_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, preferred shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_205a76fc-de92-47f0-8114-d1fb7d309baf_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_24d92462-6ce3-4645-98ab-485a517cdb64_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75b499df-a694-4721-9760-2cedbb5c25f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_0ae1dd0d-6ad1-416e-a027-f6cfc6306d35_negatedLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, cancelled in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dfd17bdd-b828-4130-8f57-b1cb25c02df6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_bfd5f0d4-bbac-4280-b656-e6f5b7e8117a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3222474c-9f66-4fd9-9622-7cfe46f9dadb_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity, parent</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4d0a7212-2e26-48c4-afd3-2149d7d77cef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88033dcd-d7b2-4cb4-82d1-9f2429e198ac_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_df68e249-48c5-400c-86ba-cacdae0e56c5_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership upon conversion of finance receivable</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_f73541c5-e0bc-42d2-b1b0-cd5781f567c8_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments:</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e6468131-1c79-4a91-ba3c-6af99d14d5e7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_a70c8e98-cfd5-4b53-8971-6a571d8333a3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_a6c998ec-ce0f-41c6-8832-b31470a02127_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_cf5e93ef-3b11-4b95-827c-1074292d64ad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9dd7c862-ab6c-41a0-bc96-21d8ae4461c0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8904d8f5-2146-4cac-95c2-46160cff8cdb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_458b6644-97c2-49ec-a1be-9832d65ced4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_cc19be4a-82dc-4fab-a1c5-c336314f85c6_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_fb3f49b8-72af-4501-9931-44a9e1182e47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, principal sum</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_bd7b9cc3-1031-4586-aba1-90d45e1f5b3b_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to purchase membership interests</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20210630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_fda81a05-0936-4df3-9bd3-17379216fba6_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_31757bdc-8ce7-452a-9498-7ee835c32fd6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_268498d2-21ff-425f-97d7-a4189d4f9e54_terseLabel_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center</link:label>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_label_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:href="ameh-20210630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOInc.Member_bd18c31e-4959-487d-b9d9-757a269c586b_terseLabel_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc.</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_label_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member" xlink:href="ameh-20210630.xsd#ameh_OneMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOInc.Member" xlink:to="lab_ameh_OneMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_e506fc72-5018-4d2a-a747-e591d4d710a9_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_06f935a8-dfc7-4c36-b61e-41d3e552c818_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_c7730d71-4325-4fa5-a378-8aa45667df01_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_dc41375c-dc0a-4e42-ba4d-7ae47f2b11b9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_209b010a-6311-4440-82f3-beb200de0b04_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_7cb1154e-e9dc-4406-8ac5-477b930ac382_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_f1c25ee1-e7fe-49d2-82e3-fdeee4d92a19_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_130c1a57-4779-4928-b314-36b4daaf2343_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_ba1d81cb-f288-4426-84ea-85875578f151_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_d08e7b8f-7f1f-4e2d-b3ef-ae243542a33d_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable" xlink:href="ameh-20210630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_133bec14-daba-42e8-bcb9-2358a9b88733_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:to="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_286faa9c-3dd0-44fa-8e7e-e2034d3b3639_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8353f698-971c-4e84-a3c3-9a255be01f1e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_885bf47f-5d30-4654-8371-96396779b895_terseLabel_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC &#8211; Risk pool, capitation, claims payment</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_label_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_documentation_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:href="ameh-20210630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:to="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_e13c2549-0fbd-4f76-93fc-036cbda616d6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0970f795-4bdd-4930-acb2-3121af91e9d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_597383e9-076b-4b22-a667-906f33340511_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_bf5559d7-5c17-43aa-af6c-059ec28a93af_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3f92407e-4917-4e21-b584-55f1f3eec731_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_c583705d-d094-45bb-a8da-3e47449fb6f2_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, debt coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_9eb8dac5-dba2-41dc-989d-fc630b68efd0_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentConsultingFees_69e93e02-ecd9-4560-96a6-f9eb9dbcff76_terseLabel_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services paid</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_label_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_documentation_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees" xlink:href="ameh-20210630.xsd#ameh_PaymentConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentConsultingFees" xlink:to="lab_ameh_PaymentConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8eb96179-ca14-473e-8c12-36fa80bafa58_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6b7d9f5e-ffd4-4f43-b8aa-a870f0a2f097_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_4b149d1f-aaa1-427a-aca3-c9eb1e9b1543_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables-Related Parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4bb36975-30e2-4f0e-adf9-14562687bc4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f96dfe9f-4630-40c2-ad39-de4cc8c65cb9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_78cf8abd-7393-45d9-bae5-030b0fe5374f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c977882a-867e-41ae-9de2-8e8a4f7aabd4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_b25520f8-8ed3-4a44-b2cc-b5d48b479f85_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount invested for interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_d425f756-0e29-4150-ba54-5780cf38fe63_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_76803646-44de-4667-a575-b24c6a24ad96_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_696ea3f8-015c-4f6d-a653-7f73dbb96ce8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_90a88cf6-976c-4836-a107-2fc1700a3a0c_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_311da4a4-fe68-4435-a3e2-8cef63c40eec_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_2f2f024a-d250-4599-822a-9eef0ee0d3ba_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4fb5a2f9-20ff-454c-bedd-862eda355566_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5047cdc9-2806-4ab4-92e1-194268045a21_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_5f88af74-0620-4ffb-a4d1-94bab53b93f2_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9c7ff574-a2fa-45d5-9211-bd6dd3f4bc85_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_88923345-199c-4642-8d94-09344d16a21b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_96b533af-fae9-4c67-9b34-14a2f4bdf8a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_b11e2ddd-40dc-4e03-a0e9-e610e4c5f6c7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_297b1bee-6eb4-41c7-af12-13b6d0e177ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_3fd7a4ee-e3cc-4322-a213-d6ce2667f63e_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20210630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d7b2cdf0-6357-4c50-9bd8-e721b76a6bd1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_511f5996-7f31-499f-9d3a-efa91a616225_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_1dcc15ec-002d-46a5-b61c-798eba093690_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Sales by NCI (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_846c6c97-23d7-48d7-94b4-b6f888c8004e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_1e72028a-8621-48b3-a764-753ee23c57e1_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_1b1181d8-1f26-41c7-996a-f8e83e124e05_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_712b6dca-c686-4c90-a010-c82e591bcdf7_verboseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="ameh-20210630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_dafd48b4-2eaf-468f-b9ee-7213197eb0c2_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_12ba5be7-7e4d-4430-af87-65d5865285ba_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_df860358-9ead-4854-9f87-8bbe027b07c3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3ae91dff-695b-4a74-b13b-90680d25371a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_1e8d1a58-31b0-4bba-ba3e-ffd221412399_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_94c23f76-07d2-4ffc-98b3-36efd149538d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_f0bafabe-f3ce-4d51-a058-cac61dc30f17_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5745c6bf-359d-455e-ba79-85e114cd240e_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c64f2dee-2fe7-43b1-8d47-fea65caa016b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_16b6638f-0ce1-4fc8-9a22-fbb882ee788c_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20210630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_28d91fda-e63b-4d53-bb31-de64ef3563da_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_d56ba00e-32de-47f6-838f-e20360313920_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="ameh-20210630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_3ea5419c-eb24-4891-b13d-192fda585934_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_21db5036-c9ac-4cf5-973c-bbfa48f9a875_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_label_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:href="ameh-20210630.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:to="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_55a7a4c2-211a-40df-bfed-ed32f43bc48c_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9f4d37c8-12c7-469c-b9b0-af0f4b1d08ee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_13981369-d6c9-4192-9a1b-2d6c1baae7d1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_033ce585-6796-4c1e-8672-1563684c7c75_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_f84f8584-326a-4212-8d97-922221bfe081_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_92964f9d-aedb-49f0-a0a9-797a3245f74d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_83fc21be-4639-4190-8c65-265b9ca4263a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5bba2449-efb5-40a2-9670-978648befa9f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ed8c0c06-3426-4b01-9933-8535aa7873d1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_0e6c6fdb-adc8-4f69-bf78-479637e07c75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_b97b958b-3878-40d1-9a01-eef930627e50_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_da334c93-cce4-4aca-8a2a-853268966bed_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_cfc35883-80cc-43a5-b609-cd554322f684_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_29c41c12-688b-430a-b73a-05bf6b124b34_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on loan receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.ArteagaMember_ef40e58c-d71d-4232-91d5-1fd6fb0df873_verboseLabel_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_label_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_documentation_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember" xlink:href="ameh-20210630.xsd#ameh_Dr.ArteagaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.ArteagaMember" xlink:to="lab_ameh_Dr.ArteagaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_14927572-a33a-4d83-a306-9fad2225ead6_verboseLabel_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities &#8212; Equity Method</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:href="ameh-20210630.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:to="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_611a14ec-5792-4d9a-b19e-0b1506fb704b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_43a4ae1c-62ef-4fae-939e-7b554b1e3fe8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e7471fe-5a26-46bd-bb57-d63080f6b22a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_0166e4c7-e22b-4f9c-bb71-1ac38b007bd1_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_ad482f4d-db1b-457f-90e3-8ab44f3565f2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_9ca213b4-ca38-479f-87ad-3c51cc8067f8_verboseLabel_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember" xlink:href="ameh-20210630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthCareCapitationRevenueMember" xlink:to="lab_ameh_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_79370996-440e-4ced-b25b-7ad8ddd7044a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareIncMember_c28765a0-ac18-4f20-8b1c-011156d3e4b3_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc</link:label>
    <link:label id="lab_ameh_UniversalCareIncMember_label_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember" xlink:href="ameh-20210630.xsd#ameh_UniversalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_8c5c2313-dac1-4f0a-b6e9-c2ad81274fc8_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_f20c85ce-8534-44da-b90d-b2118422c177_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_992d3d67-7256-4d4b-a5f1-c279eb83a7c9_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated rate of note of loan receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableStatedInterestRate" xlink:to="lab_ameh_FinanceReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_b69a880a-81d5-4bfb-8d40-6129964c462d_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_00db5013-2a2c-446b-9009-d6d22ca03b7e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_b797d0f3-96b2-43ed-8037-beceb28658cd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_91e265ca-777c-4d3e-9a96-6cb87a6552e3_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_fd39c079-4d75-4b1f-8dfd-0febc624aceb_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gain) loss from investment in equity securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5ef49332-d401-45a5-9b00-fa8e015aa7e5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_11b0b4bd-d17c-4768-a0f3-ad389e119d13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_f8fdf8f6-1390-4d04-aa1b-719a8302e7b7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_75e69345-68e6-4595-99c3-40733677722d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1bc4671d-e1ad-41b8-a7da-9403b9f4635a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (income) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_4a88665f-44a5-4b9e-b274-5b3a501f0017_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_081c95f2-c544-405f-8012-ab46007b2812_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PreferredBankMember_ec110dca-6e3b-4c58-9063-2d89dc1b582f_terseLabel_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_ameh_PreferredBankMember_label_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember" xlink:href="ameh-20210630.xsd#ameh_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PreferredBankMember" xlink:to="lab_ameh_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.JayMember_143aa438-53dc-46d4-b6e4-7ad041d11591_terseLabel_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay</link:label>
    <link:label id="lab_ameh_Dr.JayMember_label_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:label id="lab_ameh_Dr.JayMember_documentation_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember" xlink:href="ameh-20210630.xsd#ameh_Dr.JayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.JayMember" xlink:to="lab_ameh_Dr.JayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_642d1d09-1464-4ffe-b39f-90c92d547163_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a284b2b6-09da-44e7-9dd3-21b7b6c211f1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_4a2a99b9-f3de-4901-b077-ef1743a0eefa_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:href="ameh-20210630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_fbec9eca-fc1f-4196-9014-ad3d3d6af72c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmgIncMember_95c059e3-9aed-4277-a4e6-1ce6a1b38edf_terseLabel_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc</link:label>
    <link:label id="lab_ameh_AmgIncMember_label_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember" xlink:href="ameh-20210630.xsd#ameh_AmgIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e3d12af8-46a7-4fec-abad-7297eb7a081c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_508db0d8-9611-4c81-8a7c-f20c58be7045_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_384c7bb5-01ce-40c8-90ca-aed20f6cae00_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared included in dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_6fb275b2-2c29-42ea-98da-1b5b29a5654b_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized risk pool revenue</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_0d6b37a7-2ae1-48eb-b33e-4997b1344135_totalLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts, net</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_1503d49b-ed66-4a9d-913e-c605c944397a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_88045617-136b-4d8e-a682-33bff8ecf73c_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_ac5d388f-ebe1-4c7c-ba4e-ca1d1d82516a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of main reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_678f4f31-aa73-4682-b286-405ad8a6ad97_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ec86c9fc-5ea7-4fa4-82b1-0e5889d60389_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_0dac7845-35d3-48b1-8dcf-1124bf253502_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MemberRelationshipsMember_816fa6ed-0bd9-4c60-ad36-34a73f955df4_terseLabel_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_label_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember" xlink:href="ameh-20210630.xsd#ameh_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_8910c3b3-4e81-45fd-b010-a9c24fe1a2b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_1fcd7d7f-e03c-4685-b788-d7b9d3e2ef8e_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c957f32c-2cde-4eb4-829e-a880909e471e_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_2b3caab9-87aa-4bac-bb6c-88e8a1a1aa6c_verboseLabel_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Receivables &#8211; Related Parties, and Loan Receivables</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_label_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables And Related parties Receivables Policy Text Block [Policy Text Block]</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:href="ameh-20210630.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:to="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f36b80d7-d65b-403a-9508-eaea1d3c1f43_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_652501fe-0c6d-4d7b-ac36-ac372165c358_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, cash flow coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_59eefb38-63fe-49f6-af35-cd37451be40b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ddba729c-9b2b-45ec-9cab-4a79cf1b4256_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_df6d695a-cd6f-4601-8503-40438160134e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_35f8894f-0dac-4bc8-940e-c7f714f6d3b5_terseLabel_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders and Officers</link:label>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_label_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders And Officers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember" xlink:href="ameh-20210630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareholdersAndOfficersMember" xlink:to="lab_ameh_ShareholdersAndOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_67faab96-ab6d-47a6-9764-7791af829651_verboseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_label_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember" xlink:href="ameh-20210630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountableHealthCareIPAMember" xlink:to="lab_ameh_AccountableHealthCareIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_f3260df5-ab16-4ca0-9d0f-835c8f3ce95b_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from consolidation of VIE</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_label_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_documentation_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:href="ameh-20210630.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:to="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones_fda69feb-9060-40cf-b876-6b5b32671062_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, percentage paid out in cash upon achievement of financial milestones</link:label>
    <link:label id="lab_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones_label_en-US" xlink:label="lab_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Percentage Paid Out in Cash Upon Achievement of Financial Milestones</link:label>
    <link:label id="lab_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Percentage Paid Out in Cash Upon Achievement of Financial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" xlink:href="ameh-20210630.xsd#ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" xlink:to="lab_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_ab6cce34-1c6f-4267-81a5-b051ce9523f6_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received, revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Revenue Recognized</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueRevenueRecognized" xlink:to="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cdf0d5f4-c991-4271-a5a4-919ec1799fca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8f98a451-5df4-4a35-a962-f192461c6a73_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10d607e3-36dd-4e85-a68d-18c708f1da66_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bfcf499b-9ba2-4c11-a1ae-98b0e9eb482b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_96cb4548-2766-4745-9a97-49a0b44740f5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_24093f34-f269-4a70-abe4-37f2df77806e_verboseLabel_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="ameh-20210630.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_0aa8e42d-f084-4693-ac88-a4ae95b4fff2_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementMember" xlink:to="lab_ameh_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_33e8cfae-7524-484e-b3d9-7ba86cd4fd72_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ef3e634e-1cf1-4058-824d-81ca390aecf5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_a62d8dd7-783e-42ac-a9ef-9be022630b19_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0283493d-e36d-4fbb-b9f0-6d5f47a170df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_df0e18cd-ae46-45af-8f40-6889581e28b0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4962a57d-d53c-46ac-90df-22742fad76a1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_677b2a78-a65d-46e9-8af9-20f4677d79b9_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_798e2e2e-d062-4931-97b0-6fdd9ef20490_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_62cf3e00-98d1-4e18-8ecb-20fc0527374f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d7205f54-8c5c-49eb-930b-4b78a082ead9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_74db78e1-8541-4108-bb9c-ba2161354f01_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_e845f0f0-8cf5-4e69-bf31-6dc4c93126d7_verboseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_aef61586-4c64-4d6f-81ac-77ef987db051_terseLabel_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:href="ameh-20210630.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_d25f30de-b88a-4f1b-9e14-40d9445b2fad_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_d52f0d9c-0c5b-443d-837b-48e9126e5416_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_fef30211-a1d0-4cc6-8f91-0b34af4f00d4_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareTable_ce959099-9bac-498d-a084-ee87e9400667_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_label_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareTable" xlink:to="lab_ameh_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_145aa94e-fe4e-479b-82aa-ef5d5cfb10d8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_57020f06-37ab-4da4-b67f-2d2e422ee504_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_449fa3cb-2c06-4377-b5a8-10b6ee341ab5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8f9ab4fb-9f5a-4916-ba15-a9818bd82612_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d5b05f0e-162c-4096-b23f-2e73dc2efb14_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_3b148850-b1ff-4dce-9ff4-03505b2f6de3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_875a7fc9-ff4e-4c34-b69b-58d3a0a5e205_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b8562cc2-eb41-4b69-a832-c6d566f5f5d3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d5f8bc43-c0a2-4c15-8293-24e443f499f3_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_44c033ab-a267-471e-be95-61d567891dc9_terseLabel_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General amount of guarantee (as a percent)</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_label_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Financial Guarantee Benchmark Amount</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_documentation_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of financial guarantee on benchmark Medicare expenditure amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:href="ameh-20210630.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:to="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_96d9ea85-ee00-4fd2-9a49-db4d8facf316_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_491830a5-5aec-4d03-9b6a-3904721a5a9f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_5029e19f-69a7-4da0-90c4-c2d499f0435a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ed8b1515-2bc0-4271-b99c-1ff6f922334d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_783d29d9-d2d3-461e-b195-e3a24a56c899_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_6cd1c8ae-a000-4601-8060-80e223104f15_terseLabel_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20210630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c8340033-44be-4a30-b145-10b113025a06_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_09d6c0cb-3e58-4fce-80fd-b97e87536853_terseLabel_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_label_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_documentation_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember" xlink:href="ameh-20210630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Pacific6EnterprisesMember" xlink:to="lab_ameh_Pacific6EnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7ecb1e3e-b18f-4c98-9816-e832a6e93f2c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_03b15153-a07f-405d-a36a-a4c0324f42e3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_a14d4451-1362-41b8-8b0a-de76a7763cba_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e54bdb2-c075-4597-ad32-1fbd2b5b8df2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_0c911703-e9cc-4c30-859b-127a52ea191c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5ce0ddf1-1bb6-4395-bab0-7154c54b655a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_6e626cc4-dec7-4480-9ef8-2572588c1b25_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_f0b715a8-b2ba-43cf-886e-54ede926e96c_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_bce22e78-33cb-43b3-b227-820f0e8e3395_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ba327838-8492-4d9b-a3ee-ce27ad8829e8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b339c917-3af0-4d87-8120-e5b364d44ab2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_f1411288-b06d-4da1-a1d3-3c41eb1a8a8c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivables &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5d88d261-2899-42c6-bc2a-fb28ec6f86ca_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_c5091c7b-ac08-4e54-828e-f693dbc66018_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_e82cbc84-96fa-491c-879b-65f9f660f21a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_27e87940-84aa-40f8-98ca-1b0ae3761f93_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, amount</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_c2d999b0-bcfb-49e5-a787-43b5a4fca7f8_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_65c799ec-f3ff-4d73-bc9b-d46f237e06d2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the six months ended June 30, 2021)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8f3f41c3-20aa-42b4-ad01-3f3340c4be2f_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_97940fb3-72e5-4e43-a29a-a8f8af79bf36_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_695b346a-0e8c-48eb-b0f5-1659f6002aed_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fab333df-ca39-4d1a-b6f1-90a950da8fef_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_1b408e01-3dce-4637-a2a6-8e5a16eef7ea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_e35b3351-f350-4c37-97f7-38b0bca18dc3_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b74b47cb-fdfa-4365-85ad-016ce1f2a068_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_de29e67d-fe9e-4209-ac88-ce742cb3217a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_befdaf92-bf92-4dd3-a2c1-7abc149a43ba_terseLabel_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract" xlink:href="ameh-20210630.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalCareCostsAbstract" xlink:to="lab_ameh_MedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d8901976-ff82-4bf8-b572-9c89b8a62a80_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_2e0e55a3-5c88-4c88-ae1a-8ecb4f691b22_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_b2da6a55-87fa-4090-a6ac-b442afabecc5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_32248d22-8e21-4658-b3ec-9173826e0194_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_e01cc658-8099-4847-9330-05d7c60f6a55_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_4dd77dd7-f8e9-4b6a-847a-56b52f2a74d5_terseLabel_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_label_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group [Member]</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_documentation_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:href="ameh-20210630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:to="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_665f9e73-02a9-49f6-b5e2-a0b4b13d75b1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_16f88e9c-cc27-480b-a8f1-3a6b71623ec6_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_ead79511-fbe9-443e-8096-fab8c856132c_verboseLabel_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="ameh-20210630.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_9aadd920-daf0-4d3a-ad89-18bd8bf1d5de_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c4f452d-381c-4590-ab40-9772644a994e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_22079eb2-8350-40d4-88ef-b1f194d73677_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward" xlink:to="lab_ameh_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_44c09ea4-271c-4b7e-a52d-1e8c6ccfcdd6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_b878829d-cedf-4eb6-9cb6-867c8fd5fd63_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_67766d28-e9da-4f41-b034-592e7af30005_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_092e4665-0ba8-469b-84f8-b3192689ebc8_terseLabel_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="ameh-20210630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_ccc418ba-69f1-4a07-8d06-9f33a10c929c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CreditAgreementMember_a2f842ce-2986-46c6-9c8b-f62783317e9e_terseLabel_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_label_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember" xlink:href="ameh-20210630.xsd#ameh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CreditAgreementMember" xlink:to="lab_ameh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_cacae437-95e3-4b89-afa0-396275c5d620_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_a7306a3a-c7b7-4fee-989d-504421bc2c2a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_c8578d57-ddc5-4e2d-aeac-3cc89e122cf5_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_71ccc218-108d-4d14-8751-32d2a2cd7572_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names/trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ae0eaa9d-65f3-413e-a6a8-2ebabd6c46b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_47d1d4ee-3149-4d86-badb-2aa77b4ba00c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_530f3142-623f-4bd9-8ce0-ad58782bb760_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c3d2eb44-bc9f-4a3c-9dd8-38b17163a1ab_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0fb537ac-7fea-4649-904b-f747e54cd514_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a3c07660-5388-49d3-87fb-ee2bba715028_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_19c1b711-3bf7-4ef1-9af0-c62415c3e499_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0ba22d83-7910-42c7-a68a-aede66c23388_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_03f0c0f2-45e8-4ba5-95f1-f68e5f52938d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_793781e7-3a9f-4e6e-a0ee-8f725b9569b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_41b87663-012c-4a48-ac07-56a9284317ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_24fff348-5431-4ee6-8fe2-aa09b070e1e4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_46ad9f66-e9b2-4a12-af44-7bb73c66bd39_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Commitments of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_4a801d8d-4abf-41e0-a1eb-799b055b78e3_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_60d1770d-1018-4646-9f11-406cd8e5761b_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercisable</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2e4e5367-6309-40a0-ba19-03db062d1f2a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e684691c-4d7a-4f59-b739-6c0a7a184cd7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_da9dfead-69f4-464f-b039-0c47616c6422_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_7c584eb1-e878-4735-946b-8becd9923895_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in privately held entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3d2cd7b5-1cd7-46ac-8525-080ecd10f8e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_4dc03a0c-ca82-474d-9a9b-e3f3c182ab5b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_2b6bf8be-4894-4d5e-aa53-e60cce81a1ee_terseLabel_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_label_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units [Member]</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_documentation_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember" xlink:href="ameh-20210630.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockAwardsAndUnitsMember" xlink:to="lab_ameh_StockAwardsAndUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_90f4b2bb-09fb-4237-8fd9-5e78dae2ed30_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the six months ended June 30, 2021)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_b4b376f6-2a6a-44c7-a730-fc875814f70d_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsContribution" xlink:to="lab_ameh_EquityMethodInvestmentsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c305028-1a41-42fc-97b0-ab6f7a207afc_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_71cdc456-733e-4faf-b877-10f50767739e_terseLabel_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc</link:label>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:href="ameh-20210630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DmgMember_d91c24a3-541a-4960-86dd-6fe6f9e24d27_terseLabel_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG</link:label>
    <link:label id="lab_ameh_DmgMember_label_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember" xlink:href="ameh-20210630.xsd#ameh_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_f5303cfe-b316-4725-ba18-6a9c4b9e81ec_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual agent fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_d91d783a-4307-4f3b-84ff-f4cc1b23ff20_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_66a304e0-ee1a-46da-a934-7c7aa3793b9d_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_178bf814-d16a-4539-85a1-ea99435e3ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_2edde973-d57a-4857-9dde-da0053ffda7e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required annual facility fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_c96138f5-6147-4bb9-b108-3946fa05f584_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_ae238f41-92d8-43ac-ab61-a27910a49892_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests acquired (in dollars per share)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_a7c68df8-0797-41ff-8470-e46313d17b62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_4bd4beae-e713-45b7-8a9f-49c37b1d53b9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_94e7312b-5f4f-4ad6-bbb9-d445a6fedb86_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_06c53c6a-177c-4092-a8e9-d293fba2201d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_c947466e-75c2-455f-9810-b8600e7c4a8f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c6a93f7f-c0f3-4a68-8bb3-f9d569b50f46_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_55c44a6d-ee44-43c6-b1d4-8140e205eef0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a7e6683c-386f-4953-8023-5b8a97721644_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4a8c785c-72bb-4cc6-beab-8a0ed7412d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f888f993-8f01-4a30-a10e-028d0577c162_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d6e33cb-39d8-420d-a9dd-f8162332f51a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6e4a643b-0f23-4d8f-af75-b237b847abf8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_817bc82d-4b08-48dd-977f-da60b12d161a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_abee1130-25ae-4de8-bdce-ac58dd64160c_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MediPortalLLCMember_26cbbca6-85af-419d-9ce9-eef61bd08e08_terseLabel_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC</link:label>
    <link:label id="lab_ameh_MediPortalLLCMember_label_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember" xlink:href="ameh-20210630.xsd#ameh_MediPortalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MediPortalLLCMember" xlink:to="lab_ameh_MediPortalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_59a2c76c-04e9-43da-8f9c-9915380b6fac_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_78f83494-0bbe-4108-ab8b-b2f14cee632e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_ebe45f80-c94c-4a86-a702-29b4eeaf1cde_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1baf0e51-0ea3-454a-8bd8-838b5d3a3170_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_c781c74e-6f7a-440b-9c5f-aa9d2c1092f4_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e3aa5c24-666e-44ca-995d-e20d351839cc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_e518af17-e176-460b-a976-0abcca63ee09_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0ea52796-dfb6-4a1e-ba0c-538cdf832404_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_51772ea0-5b28-4439-a6e8-d23eacc3665f_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, conversion of finance receivable, ownership percentage increase</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ManagementContractsMember_35b09c9a-1add-4fe3-862d-b6c6120417de_verboseLabel_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_label_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_documentation_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember" xlink:href="ameh-20210630.xsd#ameh_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_593f6215-efaf-4e7d-a905-fafb9aa9f9d1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_9bc96616-432c-4f8f-82cf-e92e096f0bb9_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_22035cf5-e227-4b48-b6a4-44cf2f5b33c3_terseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA Line of Business</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_270babaa-fed7-4be0-b692-7904272d83eb_verboseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:href="ameh-20210630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f7753998-ff8f-43b3-949f-5399e8b2a40e_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_84b415bd-0403-46c0-82b3-5920bcfe9e41_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_73d5e2cd-63f9-463c-9792-80fe8d916809_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_a47adfff-f1ad-4e7c-a777-6b3da77fc824_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_b52868ac-2845-4ed1-b46c-4e1920120483_negatedTerseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Consolidated</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Consolidated</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsConsolidated" xlink:to="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_09c12146-5094-4319-b7dc-32af2bae5818_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_146af252-aa73-4d4d-b137-ac6af3f5abc3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLossOnDerivative_89a7d481-b69a-4752-82d1-1b4b3b766e57_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLossOnDerivative_label_en-US" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HSMSOMember_f378ae8b-d7eb-4a78-98f4-650e5d78d11e_verboseLabel_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HSMSOMember_label_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_ameh_HSMSOMember_documentation_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember" xlink:href="ameh-20210630.xsd#ameh_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HSMSOMember" xlink:to="lab_ameh_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_c417ea69-c95e-4ac2-8bb0-e3413653d9af_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Each Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_7701f62a-5944-4753-8fb2-35ffa1c30927_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:href="ameh-20210630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AurionMember_9eca5d0f-795f-4571-b68c-873786f50271_verboseLabel_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_ameh_AurionMember_label_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_ameh_AurionMember_documentation_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember" xlink:href="ameh-20210630.xsd#ameh_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AurionMember" xlink:to="lab_ameh_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_942d1f97-c144-4e1f-8819-9889edb6ec24_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_c178252b-1eee-499e-9bdc-036a5848291a_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of family practice clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_label_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Family Practice Clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_documentation_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Family Practice Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics" xlink:href="ameh-20210630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFamilyPracticeClinics" xlink:to="lab_ameh_NumberOfFamilyPracticeClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_42ade3a2-ff58-4923-bee2-299df402ba7a_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d37ce06e-874a-4ba3-be5b-fa7f7924a8bf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfLocations_ee23a786-7da2-47c4-8b16-ca608aa52ca5_terseLabel_en-US" xlink:label="lab_ameh_NumberOfLocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of locations</link:label>
    <link:label id="lab_ameh_NumberOfLocations_label_en-US" xlink:label="lab_ameh_NumberOfLocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Locations</link:label>
    <link:label id="lab_ameh_NumberOfLocations_documentation_en-US" xlink:label="lab_ameh_NumberOfLocations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Locations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfLocations" xlink:href="ameh-20210630.xsd#ameh_NumberOfLocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfLocations" xlink:to="lab_ameh_NumberOfLocations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c6df13dd-ca65-4742-a162-d547f6dac1e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_e8cd13e7-1fd8-49f7-8fca-2b6cc02fc078_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_a2e1abb6-1d9a-429a-be51-c0206279ea46_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2f103e01-1ceb-499d-a8ed-c4a7e42e6e27_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineEquityAbstract_b74b26dc-23f1-4aa9-b865-7a9faab95627_verboseLabel_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_ameh_MezzanineEquityAbstract_label_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract" xlink:href="ameh-20210630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_1065810d-8e0a-4ee2-839a-657dfca652cc_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateLoanMember_9d3f1418-6752-417e-a11a-c2677c496f0d_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan</link:label>
    <link:label id="lab_us-gaap_RealEstateLoanMember_label_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateLoanMember" xlink:to="lab_us-gaap_RealEstateLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_5471634e-524f-49c5-bc27-6d2ad9308b7b_terseLabel_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc</link:label>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" xlink:href="ameh-20210630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c9352898-990c-4810-bfac-d6a46c36bfb5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_355faf2b-b94b-40f7-b341-d4acbc8326b2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_0d63826c-bb9e-441b-b64a-47c50b28a6e0_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated interest coverage ratio (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_98b2683e-951b-4b44-bec0-0296cc2cc2bf_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorCMember_855f4118-4f3a-4aaa-82df-6aaf8309104c_terseLabel_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_ameh_PayorCMember_label_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_ameh_PayorCMember_documentation_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember" xlink:href="ameh-20210630.xsd#ameh_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorCMember" xlink:to="lab_ameh_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f775ce55-703e-46f9-90be-fbd5937395c7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_c7ea97c0-3689-4328-a7ed-2a716c5f6370_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_9a81d1ac-9952-4981-ac5c-392e42b91043_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:href="ameh-20210630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2a6abe5a-fc6c-49fb-b4df-aed51e9b52f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_5199b7f0-4cac-43b8-9142-14db04412536_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcStockOptionMember_85912e66-51a4-4222-947d-667e4c3cdf74_terseLabel_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option</link:label>
    <link:label id="lab_ameh_ApcStockOptionMember_label_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember" xlink:href="ameh-20210630.xsd#ameh_ApcStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcStockOptionMember" xlink:to="lab_ameh_ApcStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_ca8ce79d-3cc7-403c-8256-1d98c7109c1d_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_93021170-5c09-48df-85e4-94febb3e42c3_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e015b784-b5ad-41e6-9dd7-c4674cce86a7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_5b6ac052-ed18-482d-b32f-81c538f17521_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_262c3779-78c0-4879-aa1e-f85f8c15ab52_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_868ccbfd-d1d5-4060-bfcb-f0523f49d0f3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_12615345-2a26-4eb3-98a9-4550a464deab_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of noncontrolling interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:href="ameh-20210630.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:to="lab_ameh_ProceedsFromSaleOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_6d2e2204-51e3-4b82-baf0-92db9f8a7465_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6f28027f-a278-48c2-84e7-4bb9f02ff3d3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_d6d26909-6f7b-4ffe-b124-4beda4a2bebb_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AHMCMember_3d181ce7-6637-4c39-a36b-90bd61e9f7f3_terseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_d5e91b0a-acb6-420b-a218-ddd0c69a0890_verboseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_label_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember" xlink:href="ameh-20210630.xsd#ameh_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AHMCMember" xlink:to="lab_ameh_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0c98e5ac-c145-4cf4-9f91-c5a456566b8a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_407e994d-6e4d-46b2-819d-746ff849cfe0_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_53481a59-2597-413b-890f-63dc13859387_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_e58951ed-9afc-4f2a-8362-f39eae783414_verboseLabel_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities:</link:label>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_label_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="ameh-20210630.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays_3b726c79-0ecc-456d-b46a-341478b9c2b3_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, percentage paid In cash within ten business days</link:label>
    <link:label id="lab_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays_label_en-US" xlink:label="lab_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Percentage Paid In Cash Within Ten Business Days</link:label>
    <link:label id="lab_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Percentage Paid In Cash Within Ten Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" xlink:href="ameh-20210630.xsd#ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" xlink:to="lab_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a622e0e3-f5b3-4761-b6b9-331ee88c4900_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_51ae4c15-e0d5-44e7-a54c-520c1c6d497d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_23838138-50c2-4e9a-be08-626ea782520e_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_label_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableTermOfReceivable" xlink:to="lab_ameh_FinanceReceivableTermOfReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_d02dc91d-3bfe-4b4b-95e7-98b93b4bd314_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FreseniusMember_486bfec1-71eb-48f4-a834-8ddb6e5f8104_terseLabel_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:label id="lab_ameh_FreseniusMember_label_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius [Member]</link:label>
    <link:label id="lab_ameh_FreseniusMember_documentation_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember" xlink:href="ameh-20210630.xsd#ameh_FreseniusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FreseniusMember" xlink:to="lab_ameh_FreseniusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_d453b109-3907-4fae-90d3-107514267e67_terseLabel_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC - related party</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_label_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC - Related Party [Member]</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_documentation_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC - Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:to="lab_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_e71484d3-d4ac-4c73-8329-3ebe2554023c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5f7b859a-f660-43c1-99fa-947d7be80202_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_03e25883-6afa-437f-8707-4ea02a902819_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscriptions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d0fc75d7-5347-44a0-8b16-0ef25d860a99_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c8594f7c-8bd7-4746-9244-91937b5acffc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Bank Loan and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_12d6edf8-d3f4-431e-bffb-6c8c23da3294_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f28fff40-c58f-4c27-9333-b8f96b0247f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a4461c31-57f7-4c82-b68c-12ad2171b091_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_ee1e3859-94c8-46d4-a4b2-62d541b8646f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_c1973219-922d-49ed-8808-5770622d57ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_02b67189-d00c-4cb2-81b2-ab8e0806491d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased by related party</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_8cddc087-2d6b-4efd-b4f5-7034764b581c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_f416ecaa-dca6-4de4-837a-8fe735bd4790_terseLabel_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc.</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_label_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_documentation_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:href="ameh-20210630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:to="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_6f5c9b9d-0b56-4c53-a760-ecad72c11cc6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_f6aaa162-2cf3-4402-aa16-30cd27891ab9_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_b215963c-a1f9-4b4f-a2db-671da6ddf3fc_terseLabel_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_label_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member]</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_documentation_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember" xlink:href="ameh-20210630.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CollegeStreetInvestmentLpMember" xlink:to="lab_ameh_CollegeStreetInvestmentLpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_9f344e20-f67e-46f2-86a1-c17ec0e082c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_cdb3e1af-1ce5-41b1-8493-fef84d0cf82a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_27b361e3-1aa1-4b75-9cd7-57f67036b676_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_26ba35d2-dd23-4e60-bd83-8842b75ec29e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_f106c173-22f2-4941-ba68-852f79419644_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_33a9da3b-34d7-499b-baf1-d13b33dbbee7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_48035e41-ebf4-48ee-a3ad-265ee0c33e3f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_0eedcaf3-48b1-4262-9231-5019fbfe1be4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash - current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_d15a7a97-8e72-48b0-9320-70e217f20933_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related investment balance</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCMember_7190a3e4-5c08-4868-ab32-47a7ebc9620e_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC - related party</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCMember" xlink:to="lab_ameh_OneMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b8911e40-6949-4982-a25e-97095ac27424_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_1398eadc-e6ef-460d-adab-246aebb7fd16_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_85c14bb8-c965-43da-9c73-db80298ef27d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_76116759-e29d-4a98-b20c-afb2f3d04f33_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_ffde1968-7e09-4384-9231-55bcdfc372bd_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9e3d8528-910d-458b-a04c-5aa3f6b2c173_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_84cdd667-84bc-4125-83a1-d32b7ba668a4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI, unrealized gain</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c5f6a10d-7d18-4e49-9040-fa5f875a1354_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_5246529a-1061-4992-a312-8fb5554a7090_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4f955678-28e7-40ef-8d96-04d6369e12ac_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_078b9487-e3a6-4eac-a864-2167e7b5c84a_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, fair value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_44cb337c-f462-4af6-b44e-fe8e1499aed4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_e71cde6e-3283-49cc-ad63-7be86206459a_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f774eb48-006a-4a2c-b2d6-30a6309370e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_e8f3be77-2ddf-4253-b5eb-1796b140db66_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableTextBlock_9a109d68-f8f2-4e74-8e4c-55c7e8e8e6d5_verboseLabel_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable and Loan Receivable &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_label_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock" xlink:href="ameh-20210630.xsd#ameh_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b1adfd7d-3156-4450-8b38-1919a04442e3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_a0ff98fd-93cc-40a6-8d8c-7ec8ede69edb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_1984a898-9da6-40bc-a1cb-2dfe88437cb8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumenLLCMember_777961e0-01d4-4304-b762-9953b8424fc9_terseLabel_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC</link:label>
    <link:label id="lab_ameh_NumenLLCMember_label_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember" xlink:href="ameh-20210630.xsd#ameh_NumenLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumenLLCMember" xlink:to="lab_ameh_NumenLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_c9d33e1e-dd90-46f0-a2f3-90e7dab71ca2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_847ba751-a794-4ee3-b4c0-beb90f984ea0_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:href="ameh-20210630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_db6719c7-82bb-4952-b3d7-cdc914395840_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SCHCMember_70b3b536-5f08-4248-b3ba-3401cd8a73dd_terseLabel_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:label id="lab_ameh_SCHCMember_label_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:label id="lab_ameh_SCHCMember_documentation_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember" xlink:href="ameh-20210630.xsd#ameh_SCHCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SCHCMember" xlink:to="lab_ameh_SCHCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_70ae1ba5-2cba-47db-96da-0bb5bbda8709_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LmaMember_8b67aa3b-3bff-4402-91cb-4691629ff7e8_terseLabel_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA</link:label>
    <link:label id="lab_ameh_LmaMember_label_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember" xlink:href="ameh-20210630.xsd#ameh_LmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LmaMember" xlink:to="lab_ameh_LmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fd2a9330-72de-4200-bf78-e2206b109df8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_38c2305f-712d-452c-a765-42091e234373_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_dc037d90-d5fb-4ff3-888b-0a3444c04841_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_9205bba6-6e4b-42b1-9f05-1e2cc967826d_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related party</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_619cacd4-fae8-49d0-8e50-3c546ebcc4f5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d9b5e971-d920-4873-8f96-656298d1a91d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bbb5f284-08da-4e1c-a1bf-7aad3021bb83_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_38250987-ed36-4708-abdb-e58f53329b0c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_bc0e3bc6-a813-4d27-a658-c0f77313464b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f017030d-160b-4762-b984-f8ee1f9686c4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed46c490-99e2-4dcd-a049-2dad8197554c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f49e8728-91e3-4422-b9a4-1735fa476165_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareMember_364817b5-3b1c-482e-8466-43aadcfdd648_terseLabel_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ameh_MedicareMember_label_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ameh_MedicareMember_documentation_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember" xlink:href="ameh-20210630.xsd#ameh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_957f0ac4-224b-4d69-82bf-354c6248a98f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_394c8581-5475-43a3-9486-ccbe366ed9b8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of beneficial interest</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CMSMember_9f2e6c70-a7f2-415c-99aa-47c85d19012a_terseLabel_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS</link:label>
    <link:label id="lab_ameh_CMSMember_label_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:label id="lab_ameh_CMSMember_documentation_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember" xlink:href="ameh-20210630.xsd#ameh_CMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CMSMember" xlink:to="lab_ameh_CMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ec943a7d-d9ed-46e7-8cf4-9bd6aa14f742_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_7c053541-0488-4ba7-b301-65d45e62be76_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_062ae77a-2f3d-4ea4-9676-332ed54ff7dc_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_3e8ba6c4-7da8-4480-bde4-0d35b4f43d67_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_8b8c8330-6b1e-4b71-a1a2-542e53142c74_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received, monthly</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:to="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_86818ba9-baeb-43a9-b683-882903813841_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1fccfd8f-8355-4dc3-b005-b3d90363cdfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4d097658-dd6e-4b06-9fe6-1055d2b4bdf2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_6fc4e77e-0f73-4b42-8e90-19085b22d4da_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8f0fa519-4a06-4210-8e38-210f4b17bd7d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AchievaMedInc.Member_16f36edd-c1dd-4c4c-9df5-f2e79cf3ab89_terseLabel_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc.</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_label_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_documentation_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member" xlink:href="ameh-20210630.xsd#ameh_AchievaMedInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AchievaMedInc.Member" xlink:to="lab_ameh_AchievaMedInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2a285e91-6298-4afb-bc9c-18dcab927a6d_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_9355bb6f-5168-430e-9a9e-49c03481fc69_terseLabel_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_label_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:href="ameh-20210630.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_d778bfee-7637-4f6c-aae9-7991c88875cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ac2f5bad-b105-4d7b-9215-458d4c2a22ae_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_c59ac6da-5c5c-4bcc-a053-d79664f811c0_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, interest rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:to="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_db7316d0-f2ed-456c-8f30-2fe3bff9cccf_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_31e9987a-9674-4d60-a31f-3cbbd4f38d8a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_aa010e89-d9b1-475f-af12-341e14fb6176_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_54554b14-117e-4798-b63d-7f228e205dd3_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Secured Promissory Note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ae7855de-fb1f-487b-a85e-1f0ed5a6011f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7b43a963-e1af-4d7a-9d19-7d82a66c25a5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorDMember_32288084-fc31-4432-b000-9bb53def2dea_terseLabel_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_ameh_PayorDMember_label_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember" xlink:href="ameh-20210630.xsd#ameh_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_671ec847-0ecc-4410-bba1-4a9cf24514c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_26ba9b16-4a1f-4fde-b2c9-22038ad5905b_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_02f1422d-adc0-4ceb-909f-d70c0e43e08a_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC</link:label>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_label_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:href="ameh-20210630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_59bd7c63-bc5d-4a43-aca2-0945d2c57797_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9aac0c7-954a-4919-b822-6e8df589eafd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_31dafec5-378c-4a95-8949-45e1b2ef2fbf_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:href="ameh-20210630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c83f461d-254d-4601-9be8-e682b81949a0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_86040993-9fd4-4ef4-a0d6-9c80ff736b40_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_f4dd4037-00e2-4110-8d86-4820de62d273_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:href="ameh-20210630.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_8eb8e7a1-4eba-4163-92e4-28bad3009144_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_da850511-7b1e-498f-8b26-ff8db99fa3db_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_9af2312c-bbaf-4073-9041-15e6c2a1b5bd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_fa1c972b-4fd4-4285-a306-4953093865af_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ca7e1b6-1b96-48d2-8e90-4999d0aaf43d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a2c6dcd2-a457-44fb-a9ef-dcda2483452d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_232c377c-854b-4368-a358-44a0720303fb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f2cb14d-6fca-41f4-be5e-31e8c265e15c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1490335a-805c-41e0-b165-71c25b633f73_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_ddc86710-ab6d-42dd-8932-f4a6b04a4a4a_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0d277156-756a-4651-b7e9-1ad6c2a3cebb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f17712e-0619-408f-9be6-3baf6c865978_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5d55001e-0f0d-44bc-86d2-e30dae00c244_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_0f333efa-4c0e-4d56-9a93-ea7cbde36c7b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_9349dfb7-16ec-48f5-a684-8c4a667a261c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_611d4e3e-b7e7-40ad-ab8e-3dc7bf934dac_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1add7c73-9263-4fa4-bc45-3eee94d47d3d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_47f49f47-bfca-4342-a24d-44ec9b833db1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_236bbf1f-cc17-4bad-9dff-94e297a8dbbf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_36430b41-924f-440e-8f0b-6f1879b05339_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_20f8f47c-d8ff-4ba3-bff4-df9b5bdd3326_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_de63a031-b6f9-40c9-a8a5-5c6273960628_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_58339041-ad59-44ba-959e-eb14754e0c0a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_aa6d3671-dbc4-43e5-89ee-0074d20bcc69_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:href="ameh-20210630.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PrepaymentForInvestmentPurchase_af6abda7-7e90-4110-9f78-a09abb80f449_negatedLabel_en-US" xlink:label="lab_ameh_PrepaymentForInvestmentPurchase" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_ameh_PrepaymentForInvestmentPurchase_label_en-US" xlink:label="lab_ameh_PrepaymentForInvestmentPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment for Investment Purchase</link:label>
    <link:label id="lab_ameh_PrepaymentForInvestmentPurchase_documentation_en-US" xlink:label="lab_ameh_PrepaymentForInvestmentPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment for Investment Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrepaymentForInvestmentPurchase" xlink:href="ameh-20210630.xsd#ameh_PrepaymentForInvestmentPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PrepaymentForInvestmentPurchase" xlink:to="lab_ameh_PrepaymentForInvestmentPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ddfd5c37-6a87-4cfc-9921-79b4af669910_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_d04fd683-be22-468e-9b05-2c65c1f27bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_38f30644-1f40-437a-a9d7-7796556fabfd_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareLineItems_01d96ad8-a870-47e0-a039-ab71f8e1a31a_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareLineItems" xlink:to="lab_ameh_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_1a7373a6-4975-4c35-a22e-ed8a8d9c701e_terseLabel_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, percentage of shares acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_label_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_documentation_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:href="ameh-20210630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:to="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ea610c7e-62b9-4176-bd56-a08134804774_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_42654a48-1952-44ba-8bf1-4d046bab2f00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_46016c50-37da-49e0-b17c-8854c37f2ac0_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20210630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a6aae224-32b1-459c-a375-51f924aeaeeb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e133f688-352b-4755-be65-c5b3801c4aeb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_89cfd25b-84fb-44a7-a363-84a674c2c8f4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_2b68241e-9a30-4dd8-89a2-ac5473f2e8ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_3a4675ab-b5ae-460e-aa71-7cf778fdf813_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due to affiliate</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3eadcb1a-74c8-4700-b3a4-e3afeb596fa9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_6597fa50-5a22-4b64-970a-88e5ff6fe7a6_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due from affiliate</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliateCurrent" xlink:to="lab_us-gaap_DueFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_165fe0ab-61f1-43dc-adcc-e2ded6ca8dd0_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_ce6a5d12-326c-4ff3-b2d4-f6881f6da80f_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, cash held in escrow</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_073c6ce1-28a9-4e7d-9301-9b1c8b98d0b4_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a5cb46c7-e600-488b-bebc-97dd464ac3cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d78b096a-703e-4dce-a1da-cd0a4dfef1ea_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f66c0cf3-4304-4894-98da-b2b95aa33646_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_60cc1a3f-f042-4eb2-b32a-580cdd347f40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_c5de8533-2fd2-49bb-816c-77418dfbe6f3_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_4f81cac4-be49-427c-943f-09de0d2abc18_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="ameh-20210630.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_798f786e-a39f-4f9a-bfbc-e73faca1ac3f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cbbf9f3b-504c-4736-9060-17ab8d6cf785_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_7f2e7852-ef52-4f86-aaf0-944126aef0a7_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_4c251e60-d939-4eed-bf83-0acf465becaf_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board members</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_049e5fd9-48ed-4972-a949-ca7cca8fc3d6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_fb4c3e86-03ba-48ab-903d-98f7420d4008_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorBMember_143b0ed0-d3c8-4c1d-9196-e8152ac92852_terseLabel_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_ameh_PayorBMember_label_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_ameh_PayorBMember_documentation_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember" xlink:href="ameh-20210630.xsd#ameh_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorBMember" xlink:to="lab_ameh_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_0ec36db0-b9df-4d6f-b6f1-4c26487443da_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_1354a7f0-a92f-4bcb-9bf2-f0031c33f2e9_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period value of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_67ad529b-b05d-4b58-bd80-013611d54e09_negatedLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised" xlink:href="ameh-20210630.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_42e00d2a-fccf-4b4d-8501-db2691125342_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_4f18b46c-82f7-4ad1-9f19-69511b9ca693_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_119775aa-4951-44f1-aee9-ac9676ce1713_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_c1924adb-c78f-4948-b57a-393a3ed8c6a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ad599aac-b2d2-4d56-9db4-fd717dd8cb42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4a5e1a4a-d937-4f59-8303-978505c4102e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_95aac5d3-74de-423b-9602-88166e32a4cc_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_61329cb0-c72c-4196-a458-301563c4f1a0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_c6b9542e-289a-4aa8-8103-34dbd9a4f522_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_ab0228c9-1384-488c-84d9-7243407ac9bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_7ccfb9ff-9301-4a5e-bc1a-ffad53719c2d_verboseLabel_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:href="ameh-20210630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_875f3064-4d90-44c9-ae18-fe302b8d4f59_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f4ca2fba-9dd0-47f0-8d2e-08a71c89d899_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6ff2cb23-b915-4cac-8f19-39b8451efa74_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_5faa50f9-9934-43d5-a6bd-1f5c5c79eed4_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_31b92262-1c7e-4944-acbc-21d52396a81a_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_6c9c5521-6f2a-46b3-ac92-416a901fc9fe_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_84d04c50-0b36-428e-be1b-60608c0674b4_terseLabel_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_label_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition [Member]</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:href="ameh-20210630.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:to="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cb5a1dfa-1977-42c3-9a20-bc6ab16baa2d_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9ae4d078-7220-4d2c-8996-973dd93ad0ed_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_de42a21a-f401-4d69-8251-6c5cb22be3ed_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_9f07e7ef-5547-42d8-bf57-cb8cb49b7a5b_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_e4192f60-ead9-46d6-8f8d-e096a54f2791_verboseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_56be06db-d0f7-47ca-9eb8-7e952e44dae7_terseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College LLC</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:href="ameh-20210630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_9287db39-9811-4bb1-81ee-9e3deb3f27bb_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_c6a76436-97c3-4966-98fa-5b782178940d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_582e07fe-bb4a-451e-9b37-d3fbdf3d4961_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_af2aad12-d939-40bb-acfd-5ef353064d4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_95264dcc-68c5-49dd-b7b2-5cfc0b165a71_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_e516a47e-fe91-4b69-8df0-45a0fab2bd04_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_0bace57a-13bd-49ff-b9d0-bd2e3bc9bea9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4c646ea6-7244-49bc-9620-2d4e44984794_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_c983f5da-a483-48cb-8945-c33943774a77_terseLabel_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC and APC-LSMA</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_label_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_documentation_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember" xlink:href="ameh-20210630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APCAndAPCLSMAMember" xlink:to="lab_ameh_APCAndAPCLSMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_e1cd4651-d4ab-4d3e-973f-b01a948a103e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities, Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b56648ac-ffef-4333-b22f-ad7a430e133f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (excluding the six months ended June 30, 2021)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_5a521958-12f9-4164-9d9f-2c1e5f833ea3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7bc54018-41bc-4fa3-9a3d-96d222d76f44_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e3f0d4c9-95fb-4cd6-98ca-81e10c18339f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_77f756fa-9a9d-4dd6-9849-d7dc967bc9e0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_d8792515-9e60-47a5-8a92-97644c3e979e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_bcea812a-db75-4a12-99b5-6787366491fa_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of additional proceeds</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Write-off of Additional Proceeds</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Write-off of Additional Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:to="lab_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_af64ff41-6348-448a-bc76-f7368c5df696_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_a28e27c5-1d5f-4544-b94f-1eac99b50fd9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of real estate</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:to="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_5253c799-86e0-4289-b816-e2a437c679df_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_fa5ae022-ca62-413c-922e-86a31a060629_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_a4a6d7d8-4101-474a-aa9b-d0d178887985_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares received from sale of equity investment</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_1c9da60f-7d79-40f0-a098-b58a2bef245b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_90a83977-f1bc-4f64-b787-13d9a0cf1911_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5def4b2e-1d95-4593-898e-17d0c2ef72ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_42d12e7b-df30-459a-b8fb-ae4182ef0dc8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_3d6612cc-eadc-4120-9011-6c44074248b8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_01e70ee0-c8ca-448d-ac2e-614239ff7b1c_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4a37c567-3eda-4eac-bd3c-728570fba3a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_f154b8ec-9ce9-4b82-beb8-da74869096d1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise&#160;Price&#160;Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PatientManagementPlatformMember_cc7a10f8-6ea4-4caf-bb7f-7f3e7cb32941_terseLabel_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_label_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember" xlink:href="ameh-20210630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_223f9e73-6901-42b3-9d94-93a361a7e0ed_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorFMember_76852f10-9a50-4146-bb73-ff7ca11592a4_terseLabel_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F</link:label>
    <link:label id="lab_ameh_PayorFMember_label_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:label id="lab_ameh_PayorFMember_documentation_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember" xlink:href="ameh-20210630.xsd#ameh_PayorFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorFMember" xlink:to="lab_ameh_PayorFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_28452d49-777d-4156-a6cc-6741ec99a094_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_9fd918ee-8a8a-4ea6-a8ee-60d98eb74395_terseLabel_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest</link:label>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_label_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest [Policy Text Block]</link:label>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BeneficialInterestPolicyTextBlock" xlink:href="ameh-20210630.xsd#ameh_BeneficialInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BeneficialInterestPolicyTextBlock" xlink:to="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c872a281-9dad-4ef5-9b2c-2dcf87035337_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0bb5ebea-43be-44dc-a10c-13c1fc69bb98_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_b07234cf-175d-4e4e-a62a-63063b08b3a3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5f33be28-1cb5-439b-b895-3605a0663b9a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_d52b6deb-6b26-485b-a675-5c8957833ce6_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_b711f933-5049-4835-bb21-7ddbdfc4524d_terseLabel_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of payment upon termination of agreement</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_label_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_documentation_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:href="ameh-20210630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:to="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineMember_3338d8c8-df75-4627-a7a6-bc943e0f5379_terseLabel_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine</link:label>
    <link:label id="lab_ameh_MezzanineMember_label_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember" xlink:href="ameh-20210630.xsd#ameh_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineMember" xlink:to="lab_ameh_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_72cee146-436a-4906-a67e-0a6dce38ed2e_terseLabel_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" xlink:href="ameh-20210630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_905d1975-e248-4094-bc11-c1cc1735f538_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_9c9fc591-302f-41e0-b722-1ce452b70946_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_64e1c4fc-7a6e-4b4c-b140-df9dadc26191_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorGMember_ff168850-720f-4750-aa2e-e414586fadcd_terseLabel_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G</link:label>
    <link:label id="lab_ameh_PayorGMember_label_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G [Member]</link:label>
    <link:label id="lab_ameh_PayorGMember_documentation_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember" xlink:href="ameh-20210630.xsd#ameh_PayorGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorGMember" xlink:to="lab_ameh_PayorGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_1e6783b2-65c7-454a-860d-8d6151d7f867_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e039351a-eb53-4aac-9e4e-9328150029da_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_886b07f9-aa65-49a7-ad16-213d7865cb33_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bcdd4130-47f0-44ab-a4cf-1f916b5de9a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2aa20876-8449-4fa6-9dca-bf94f18170f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_ded036d9-4a5e-45c0-b243-c013f4462626_negatedLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_75757e7c-a681-4a0a-9b98-817479bd230d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TermLoanAMember_c6f2d8b9-8f4a-484f-8e50-ce900af1b2cd_terseLabel_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_ameh_TermLoanAMember_label_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_ameh_TermLoanAMember_documentation_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember" xlink:href="ameh-20210630.xsd#ameh_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TermLoanAMember" xlink:to="lab_ameh_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_71af718e-e99f-4078-acc3-6db91e6fa0db_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_a8389721-26ce-4bbc-9f1a-01a21324f0a4_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ee482f42-22fc-4d2e-be6f-15f53f1c23d3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_83b90d90-0cc7-449b-8303-2a9942fb37ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9d79a633-2557-40e0-9f10-1c31c44958c1_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b1ff5136-ba67-4eaa-9fed-923c2d8968df_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_921549db-2973-49d3-afcb-2452019fcb25_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a956e84f-96a4-4ad8-a48f-a97fd068397c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9fdd6d68-495b-4ea1-b551-0084c2602bbe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_9eb75f47-664e-4212-8781-cdf319b05144_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proxy votes</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:to="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcLsmaMember_eade0373-0d77-4d5e-9a47-a4089fb53e74_terseLabel_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA</link:label>
    <link:label id="lab_ameh_ApcLsmaMember_label_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember" xlink:href="ameh-20210630.xsd#ameh_ApcLsmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_52d0f0f9-7866-43ad-9018-a905082bf3a9_terseLabel_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_ce834426-7aa0-4a8e-83ff-090a2f48f394_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b3a30c97-0959-44fb-ad30-b32e681ccffa_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_71058a49-a344-4a4c-bb67-7625ff8abbe7_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f95e0538-6b48-4bc5-8694-8251ca237baa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_6869816d-910e-4c1e-90f2-8f1b48b4e72b_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase additional membership interests (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_b85b6130-4c17-477d-99c9-69c135d916d9_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_b7e048f4-f8f5-4d76-b5e6-e2d414fdc2e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_b10571e4-3fad-491d-931d-c6de112e1f56_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_9d3a1b0d-e5cd-4433-b15f-a11beca749ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investment &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_d30cb0e5-3136-4dda-9aa7-bef296ed939a_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_label_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable [Policy Text Block]</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:href="ameh-20210630.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:to="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c1fca1a4-fbcf-4e3f-86d9-220f3af2a45c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fd533a44-69c0-472e-ba5e-241b80d5facd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_f475fd4a-c8e7-4811-bdaa-6b71fd43c125_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_b55737ce-9ce8-42a1-8302-cccb11a293cd_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted" xlink:href="ameh-20210630.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConstructionLoanMember_953b90ac-248b-4b2e-a0ed-bc5c18bb4728_terseLabel_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_label_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan [Member]</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_documentation_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember" xlink:href="ameh-20210630.xsd#ameh_ConstructionLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConstructionLoanMember" xlink:to="lab_ameh_ConstructionLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_bc18d211-cf57-4682-a539-274b153e1070_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_c7a98c4f-759f-482a-9afa-9646ba2b573b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_e323551c-bf67-4cf3-9d3a-31db62c4d1ee_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_9f073ed9-9b7c-463b-bcd0-4e6eea4d469b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_81b7a772-1db5-4246-b6fa-c5708b955a7e_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_c041fe67-5f64-4b27-ab21-1c37047bb2ae_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_331931df-7574-42c6-95bd-268a11931973_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_14be64a0-7bb5-4b84-ad0b-aac5b8db682a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_7ee6961f-cb8c-4bfa-bc93-84c7ccc90bf1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_65acb8d9-92c1-4883-bb0a-5f75b3536b99_terseLabel_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ameh-20210630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SunClinicalLaboratoriesMember_2c00870a-b69e-4991-bb19-6de49a5d8bd7_terseLabel_en-US" xlink:label="lab_ameh_SunClinicalLaboratoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Clinical Laboratories</link:label>
    <link:label id="lab_ameh_SunClinicalLaboratoriesMember_label_en-US" xlink:label="lab_ameh_SunClinicalLaboratoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Clinical Laboratories [Member]</link:label>
    <link:label id="lab_ameh_SunClinicalLaboratoriesMember_documentation_en-US" xlink:label="lab_ameh_SunClinicalLaboratoriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sun Clinical Laboratories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SunClinicalLaboratoriesMember" xlink:href="ameh-20210630.xsd#ameh_SunClinicalLaboratoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SunClinicalLaboratoriesMember" xlink:to="lab_ameh_SunClinicalLaboratoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9f9ea6e6-fd40-4ccc-b948-5468dd408801_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, finance</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_3f6d02bc-fcf3-4c94-a0eb-100028657f4e_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amount</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7c627468-19b2-4770-aeee-65dd160eb802_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MembersCapital_d9c84c33-ec80-4036-b871-ff1b7b71cef1_terseLabel_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial capital contributions</link:label>
    <link:label id="lab_us-gaap_MembersCapital_label_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members' Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersCapital" xlink:to="lab_us-gaap_MembersCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_525dd5ac-5624-45d5-8a62-69364e5dff6b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_02531778-158d-44ee-a60f-ba63756843e9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_660e0e28-887d-4e54-9670-416d5a8c4c61_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_ca0c275b-c19a-44cd-b39b-010d55344323_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio (not greater than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_c300e7e9-4ca5-435f-a7a4-3484a7c8adbe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_4837acc1-ae13-429d-af31-82934fe41ab8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_210a5201-3ab0-4f5a-b64d-ba50afb9a771_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_69fa5f20-e222-4583-9523-46eddaf2a245_terseLabel_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="ameh-20210630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_80be6819-6c9a-45d8-8ce1-9d0f21a6e4ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_b6cbfa24-c2ff-4519-868a-c4f45f749a15_terseLabel_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_label_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:href="ameh-20210630.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:to="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeAxis_69a6062b-841c-43a6-9d7f-38d7bbfd8d5a_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:label id="lab_ameh_ContractTypeAxis_label_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis" xlink:href="ameh-20210630.xsd#ameh_ContractTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeAxis" xlink:to="lab_ameh_ContractTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2f49be3a-ec36-4624-8e1e-7c0ce7320a2b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_634da68e-3f5e-419b-a52e-51ed4223ed51_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_4c6df66e-bfbe-4259-b768-e29a30fbf98c_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" xlink:href="ameh-20210630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ameh-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:95c9976f-ff84-4dd6-aeb6-cbf10c7f8b0a,g:1aa3c04f-4646-4116-829c-b4ce4a78f20a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20210630.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_cf3756f5-6093-45ff-8c0c-3a0c666429c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_DocumentType_cf3756f5-6093-45ff-8c0c-3a0c666429c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c2ffcc5b-a8eb-4774-aadf-a89ef8690fe8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_DocumentQuarterlyReport_c2ffcc5b-a8eb-4774-aadf-a89ef8690fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_29840d03-962a-4f79-8bab-cb6e01000cd6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_DocumentPeriodEndDate_29840d03-962a-4f79-8bab-cb6e01000cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_1cbd7f69-1191-4ebd-a380-697838fb1326" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_DocumentTransitionReport_1cbd7f69-1191-4ebd-a380-697838fb1326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_795c97a4-9f55-42d9-95fa-6cf28fdbfb74" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityFileNumber_795c97a4-9f55-42d9-95fa-6cf28fdbfb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_72f6428b-50c6-490f-9c5c-bac5a8c827b3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityRegistrantName_72f6428b-50c6-490f-9c5c-bac5a8c827b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_c49db773-24c3-4d0c-947b-b58ab13ebc0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityIncorporationStateCountryCode_c49db773-24c3-4d0c-947b-b58ab13ebc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6c09957e-624f-4421-b40c-433af14ab7e6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityTaxIdentificationNumber_6c09957e-624f-4421-b40c-433af14ab7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7cc5b9ff-caae-4cf7-8169-9d1cc6b579cd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityAddressAddressLine1_7cc5b9ff-caae-4cf7-8169-9d1cc6b579cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_4611a30a-4861-494a-9eca-85f3168542d4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityAddressAddressLine2_4611a30a-4861-494a-9eca-85f3168542d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dd02bf8e-2184-4625-b647-b9d98a16f0ce" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityAddressCityOrTown_dd02bf8e-2184-4625-b647-b9d98a16f0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ba4f6d6c-b7bb-4468-a15f-079561b6bf14" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityAddressStateOrProvince_ba4f6d6c-b7bb-4468-a15f-079561b6bf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_de5f45b9-e3a2-4c95-b0f0-954cf88216df" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityAddressPostalZipCode_de5f45b9-e3a2-4c95-b0f0-954cf88216df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5147535e-d35d-40ec-96fe-daddd501aa29" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_CityAreaCode_5147535e-d35d-40ec-96fe-daddd501aa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_95e9a292-c875-47f4-b1e4-3d3277bdb177" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_LocalPhoneNumber_95e9a292-c875-47f4-b1e4-3d3277bdb177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f318ed47-8079-4984-a6cc-77b63343f376" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_Security12bTitle_f318ed47-8079-4984-a6cc-77b63343f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_09afecfe-f650-486b-9454-ee6383674f6c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_TradingSymbol_09afecfe-f650-486b-9454-ee6383674f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_925a0263-ad8c-45fd-a96c-4777e53daa38" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityCurrentReportingStatus_925a0263-ad8c-45fd-a96c-4777e53daa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_63aa9b1c-68ef-47ee-9d27-aea1d27eaf6e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityInteractiveDataCurrent_63aa9b1c-68ef-47ee-9d27-aea1d27eaf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e29d8679-8805-4805-87ca-45bebe003761" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityFilerCategory_e29d8679-8805-4805-87ca-45bebe003761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b7f7df09-e059-4243-84e3-ced58f0baa0d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntitySmallBusiness_b7f7df09-e059-4243-84e3-ced58f0baa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d8c0bd67-15d7-403c-86f7-ea4be121d1e0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityEmergingGrowthCompany_d8c0bd67-15d7-403c-86f7-ea4be121d1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d2d64ef7-a0ec-4416-b054-65b631a05521" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityShellCompany_d2d64ef7-a0ec-4416-b054-65b631a05521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_31f478de-9701-46f0-8af3-d2a086a23208" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_31f478de-9701-46f0-8af3-d2a086a23208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_cfa5295f-d073-4b46-b567-8d17522be489" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_AmendmentFlag_cfa5295f-d073-4b46-b567-8d17522be489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c0b6cc40-917f-4f13-bea9-3d66291ee62e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_DocumentFiscalYearFocus_c0b6cc40-917f-4f13-bea9-3d66291ee62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_724c52c2-9a42-47b6-b82d-bb4871f75bf7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_DocumentFiscalPeriodFocus_724c52c2-9a42-47b6-b82d-bb4871f75bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7be1cae2-74a1-423e-b939-bd868068a461" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_EntityCentralIndexKey_7be1cae2-74a1-423e-b939-bd868068a461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_afa98ee3-ef03-4082-a455-612aba3c2909" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_199fb135-3820-43cc-8e51-567b4eb2f647" xlink:to="loc_dei_CurrentFiscalYearEndDate_afa98ee3-ef03-4082-a455-612aba3c2909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f452d1b0-9f5e-401e-bbaa-2f51e6204bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4c85a119-9dfa-4092-9b4a-454eef234538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f452d1b0-9f5e-401e-bbaa-2f51e6204bd6" xlink:to="loc_us-gaap_StatementTable_4c85a119-9dfa-4092-9b4a-454eef234538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6eeb1159-2ee0-46bf-ba13-da55b870c7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4c85a119-9dfa-4092-9b4a-454eef234538" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6eeb1159-2ee0-46bf-ba13-da55b870c7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6eeb1159-2ee0-46bf-ba13-da55b870c7ef" xlink:to="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_40061c22-5dec-4071-92e4-f7d420fda9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_40061c22-5dec-4071-92e4-f7d420fda9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_a47d5e41-827c-4d78-b214-66539601d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d969bb91-edaa-46ed-b871-cbdb4fdc82fc" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_a47d5e41-827c-4d78-b214-66539601d64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4c85a119-9dfa-4092-9b4a-454eef234538" xlink:to="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:to="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66e6bb10-439e-4d4d-b9af-77b7322a5382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_66e6bb10-439e-4d4d-b9af-77b7322a5382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_808cce4c-ed03-4c30-b037-2bb5ffe0bb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_808cce4c-ed03-4c30-b037-2bb5ffe0bb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_11394c5b-d9ae-43cf-88ec-b895fde42b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_11394c5b-d9ae-43cf-88ec-b895fde42b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_ff0ce005-7c42-42f0-b164-912d714a9681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_ff0ce005-7c42-42f0-b164-912d714a9681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_666ef49b-ab20-4132-856d-35e836c04485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_666ef49b-ab20-4132-856d-35e836c04485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_03752fd9-d28d-4af9-87dc-84b18fbdfe83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_03752fd9-d28d-4af9-87dc-84b18fbdfe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_633cbb0d-458b-4021-9ea5-e7d87105d791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_27ad5726-5a2b-4666-96a6-86d01452e89f" xlink:to="loc_us-gaap_AssetsCurrent_633cbb0d-458b-4021-9ea5-e7d87105d791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74eeb132-8a7c-4ecb-ab0e-17ee9c662d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_74eeb132-8a7c-4ecb-ab0e-17ee9c662d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_652c7569-b334-4fde-bc28-a1813bd5bd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_652c7569-b334-4fde-bc28-a1813bd5bd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7a0e5c97-af84-4aa5-9ff1-5aa86a07a2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_Goodwill_7a0e5c97-af84-4aa5-9ff1-5aa86a07a2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_0dce0bb5-78d0-4ce6-bb5c-a8be053918c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_0dce0bb5-78d0-4ce6-bb5c-a8be053918c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ce523449-837f-4964-a2fe-0db808a915a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_ce523449-837f-4964-a2fe-0db808a915a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_117646cc-f65e-432a-b466-cf1cdc56e0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_EquityMethodInvestments_117646cc-f65e-432a-b466-cf1cdc56e0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_50be13ae-0d53-416b-bdfb-cfee4e179bf7" xlink:href="ameh-20210630.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_50be13ae-0d53-416b-bdfb-cfee4e179bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_729108a9-07e7-442d-80b2-94ce1f190c44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_729108a9-07e7-442d-80b2-94ce1f190c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c587d27e-dba2-4a79-8417-fd7de9bba2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c587d27e-dba2-4a79-8417-fd7de9bba2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_376cc2f3-b723-4804-bb5d-fb2040171d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_376cc2f3-b723-4804-bb5d-fb2040171d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_732cdbb5-ff39-410a-a97f-a8e21d0318b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_bad5afc1-1acf-43e1-bf1e-f7362907903c" xlink:to="loc_us-gaap_AssetsNoncurrent_732cdbb5-ff39-410a-a97f-a8e21d0318b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_39064507-05a8-44d6-a4d3-e8f7bebdd099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23a062f4-895d-433b-b704-388ee24160dc" xlink:to="loc_us-gaap_Assets_39064507-05a8-44d6-a4d3-e8f7bebdd099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6403881-488f-4be4-8b4a-8f4922e65d3b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8fe1db08-8136-4717-89c7-a3cbcf0c8ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8fe1db08-8136-4717-89c7-a3cbcf0c8ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_30663837-5a73-4778-8b4a-47e554efd06b" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_30663837-5a73-4778-8b4a-47e554efd06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9c9f47ed-682e-4453-9033-3c334be3c07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9c9f47ed-682e-4453-9033-3c334be3c07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b6c4f024-4013-40ba-b4c8-0f028c8a0dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b6c4f024-4013-40ba-b4c8-0f028c8a0dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_8a55e7c5-c7f5-47e7-84dc-b2f68986c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_DividendsPayableCurrent_8a55e7c5-c7f5-47e7-84dc-b2f68986c81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_28eff579-9750-49f0-a4b9-b6a5bd8af69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_28eff579-9750-49f0-a4b9-b6a5bd8af69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e64fa37-112d-4096-b1fa-b9432619bb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5e64fa37-112d-4096-b1fa-b9432619bb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_600bbf07-cc50-4838-b32b-9b3e2bce85dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_LongTermDebtCurrent_600bbf07-cc50-4838-b32b-9b3e2bce85dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c6ab171a-94b5-467b-b819-abd505fde3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4799ecb6-7249-43e9-ac36-64c13c8d0172" xlink:to="loc_us-gaap_LiabilitiesCurrent_c6ab171a-94b5-467b-b819-abd505fde3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c6ec7400-97b7-4f8f-a031-eb413300b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c6ec7400-97b7-4f8f-a031-eb413300b9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_15b0e8a0-0684-4812-8075-1a4f501ccba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_15b0e8a0-0684-4812-8075-1a4f501ccba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2df030b-6d89-4c8d-83f7-9b4a0ac31ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a2df030b-6d89-4c8d-83f7-9b4a0ac31ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_71e13abf-c812-4eea-a866-848a1e549c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_71e13abf-c812-4eea-a866-848a1e549c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2d498d60-dff5-473d-840c-0e053908e8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2d498d60-dff5-473d-840c-0e053908e8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_13acd607-bd7a-49ce-98fa-2cba6688fe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_a3cea889-000e-401c-bcb8-f10f896d00eb" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_13acd607-bd7a-49ce-98fa-2cba6688fe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7c1ef098-fd85-48cc-ae54-6f2df1732cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_Liabilities_7c1ef098-fd85-48cc-ae54-6f2df1732cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f9d4ea5a-b2b5-4f8a-bac6-6129bddc4bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f9d4ea5a-b2b5-4f8a-bac6-6129bddc4bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_2371d93b-8a62-4ea7-b07b-1b07bea60d4c" xlink:href="ameh-20210630.xsd#ameh_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_ameh_MezzanineEquityAbstract_2371d93b-8a62-4ea7-b07b-1b07bea60d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_de3db126-3843-46ac-beee-7cb8b393c7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_2371d93b-8a62-4ea7-b07b-1b07bea60d4c" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_de3db126-3843-46ac-beee-7cb8b393c7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a818f389-93c9-42ac-b846-3a5f18140f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_PreferredStockValue_a818f389-93c9-42ac-b846-3a5f18140f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_fb0c88ee-fc2b-4cb7-a7ae-e85e0a4a2bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_CommonStockValue_fb0c88ee-fc2b-4cb7-a7ae-e85e0a4a2bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_349616fb-8967-41a5-95b4-0ecc2ab6ad32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_349616fb-8967-41a5-95b4-0ecc2ab6ad32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dda99143-80df-4606-9bc6-289bb627f793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dda99143-80df-4606-9bc6-289bb627f793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_701f1e98-c621-45bb-aded-ca0a0195ff2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_StockholdersEquity_701f1e98-c621-45bb-aded-ca0a0195ff2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ea98d705-a1c6-49ee-acf6-47d52808faa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_MinorityInterest_ea98d705-a1c6-49ee-acf6-47d52808faa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11dbe545-4485-44ee-a80a-e26e31f8caf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_aa072a91-ab17-467a-af1e-9b7b7af16b4a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11dbe545-4485-44ee-a80a-e26e31f8caf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a672d0e5-3fab-49cf-a33e-6ed270572b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8339632d-6278-4132-8926-0b315acc306c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_a672d0e5-3fab-49cf-a33e-6ed270572b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a9f9c6a9-823c-4403-912c-07956ff42a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a9f9c6a9-823c-4403-912c-07956ff42a2b" xlink:to="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_77b8faa9-8bc4-41f3-9010-c80288f82cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:to="loc_us-gaap_StatementClassOfStockAxis_77b8faa9-8bc4-41f3-9010-c80288f82cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_77b8faa9-8bc4-41f3-9010-c80288f82cb4" xlink:to="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_264c6222-acbd-4738-ad9d-cee39a2d8aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_264c6222-acbd-4738-ad9d-cee39a2d8aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_6e5911bd-1ea1-4096-947f-d788b9d859fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_05d3bfd0-f6fd-43b0-a9a3-305dbc466519" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_6e5911bd-1ea1-4096-947f-d788b9d859fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e0cf4761-ab36-4257-9c52-66ae3099c8fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e0cf4761-ab36-4257-9c52-66ae3099c8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3e60a098-603a-4ab5-8968-15736991aa24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e0cf4761-ab36-4257-9c52-66ae3099c8fa" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3e60a098-603a-4ab5-8968-15736991aa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_185d88f7-82b8-4837-a989-7d822c88ea09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3e60a098-603a-4ab5-8968-15736991aa24" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_185d88f7-82b8-4837-a989-7d822c88ea09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_efc83fc1-b126-472b-a483-89b21ea04488" xlink:to="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34a8e184-0a5b-456c-8ff6-8589fb23b9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_34a8e184-0a5b-456c-8ff6-8589fb23b9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4b7fa0eb-6879-4894-b36f-5a69d52deae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4b7fa0eb-6879-4894-b36f-5a69d52deae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_55f6ac03-0586-4586-a3e6-ca874394bcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_55f6ac03-0586-4586-a3e6-ca874394bcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7b8d4149-5489-4a1e-8027-04b256629400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7b8d4149-5489-4a1e-8027-04b256629400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9974c147-da2e-422e-ac1a-84e69119c5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9974c147-da2e-422e-ac1a-84e69119c5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9c3f9eee-c07d-41d6-bd38-47f9537fe149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9c3f9eee-c07d-41d6-bd38-47f9537fe149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_751bc0a9-9fe0-4afb-9397-9ff2d5529fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_751bc0a9-9fe0-4afb-9397-9ff2d5529fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_064e75f0-0df9-4c28-9bfb-80f0eb3970f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_064e75f0-0df9-4c28-9bfb-80f0eb3970f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0e438085-1d94-41fa-b001-4f5a6d52d160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_Assets_0e438085-1d94-41fa-b001-4f5a6d52d160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ddfbc29a-d8ef-4e2c-97f5-6160943426f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e9aa97ee-c415-4dfb-814c-81af7346f99a" xlink:to="loc_us-gaap_Liabilities_ddfbc29a-d8ef-4e2c-97f5-6160943426f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b28b564d-db1f-4eca-868a-86eaf57f9ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2c12db00-54f9-42a9-88b8-5977985e4da8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b28b564d-db1f-4eca-868a-86eaf57f9ac3" xlink:to="loc_us-gaap_StatementTable_2c12db00-54f9-42a9-88b8-5977985e4da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2c12db00-54f9-42a9-88b8-5977985e4da8" xlink:to="loc_srt_ProductOrServiceAxis_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_914b84ac-81d0-4c9c-ab1a-0a5617fbbf2b" xlink:to="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_98d91185-6442-4a27-b3b5-34e624f40ace" xlink:href="ameh-20210630.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_98d91185-6442-4a27-b3b5-34e624f40ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_60717725-639d-4504-a465-d5fa42180986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_HealthCareOtherMember_60717725-639d-4504-a465-d5fa42180986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_ba609458-8bbf-4be3-a6a5-02e735bf5218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_ManagementServiceMember_ba609458-8bbf-4be3-a6a5-02e735bf5218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_8422c750-5396-4342-aeb5-c2eda0bf5db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_8422c750-5396-4342-aeb5-c2eda0bf5db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_eadd055f-a717-46a7-a229-33434d1234a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9685419-469d-4bc8-a3c1-aaada5311586" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_eadd055f-a717-46a7-a229-33434d1234a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2c12db00-54f9-42a9-88b8-5977985e4da8" xlink:to="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_6923159a-f511-4acc-b232-b343cd63d1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_RevenuesAbstract_6923159a-f511-4acc-b232-b343cd63d1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3d6e7f9d-3278-4bc3-bdd1-154327e5ce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_6923159a-f511-4acc-b232-b343cd63d1d8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3d6e7f9d-3278-4bc3-bdd1-154327e5ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_cd5f63b4-0193-4d42-a2e0-43eaf726d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_cd5f63b4-0193-4d42-a2e0-43eaf726d3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_38a1a5bd-aeb6-464e-beb4-de1e10b09fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_38a1a5bd-aeb6-464e-beb4-de1e10b09fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1fdb0c5f-0b74-4aa6-921d-b48a2ecca83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_1fdb0c5f-0b74-4aa6-921d-b48a2ecca83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c7cb64b1-5f2a-4b99-8376-c474a86bb7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_14cbeb71-ab67-498d-bf69-c4a84c9ef33a" xlink:to="loc_us-gaap_CostsAndExpenses_c7cb64b1-5f2a-4b99-8376-c474a86bb7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cbe83635-3ae9-4ca9-8c6b-a60c459735c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_OperatingIncomeLoss_cbe83635-3ae9-4ca9-8c6b-a60c459735c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa1b22cc-c5b0-4738-af44-f4ae9be6507c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_fa1b22cc-c5b0-4738-af44-f4ae9be6507c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_b66a5f01-53c2-4abe-aef5-3cebe2d20dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_GainLossOnInvestments_b66a5f01-53c2-4abe-aef5-3cebe2d20dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3a9bec16-3f53-4156-8c23-28d30a9ef33c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_InterestExpense_3a9bec16-3f53-4156-8c23-28d30a9ef33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6d33bdef-4a46-4d0d-bd2e-5aca760a4c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6d33bdef-4a46-4d0d-bd2e-5aca760a4c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d5dcd125-c008-4d54-a8c6-50c539ad4158" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d5dcd125-c008-4d54-a8c6-50c539ad4158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_384b8f38-a553-47cc-95b4-ebb112197774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_58029f40-5e00-4106-b053-6f8c72760fe6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_384b8f38-a553-47cc-95b4-ebb112197774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2be07e26-c602-414d-9553-569eb2b4a217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2be07e26-c602-414d-9553-569eb2b4a217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_679fd038-6787-42a1-9885-bf795962c89e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_679fd038-6787-42a1-9885-bf795962c89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_12fcdfde-a94f-4190-973e-a3374662830f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_ProfitLoss_12fcdfde-a94f-4190-973e-a3374662830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b801dc7b-69d5-44f6-9b48-8683414b9226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b801dc7b-69d5-44f6-9b48-8683414b9226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b42a0fd-cc9c-4a1e-8908-2bf50fed5450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_NetIncomeLoss_0b42a0fd-cc9c-4a1e-8908-2bf50fed5450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_28fbf8b9-e835-441d-9f34-d64d4b3f772c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_EarningsPerShareBasic_28fbf8b9-e835-441d-9f34-d64d4b3f772c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_81561671-363d-4279-801c-2e94a03d903e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e48bec1-1dff-4ed4-b6dc-bf24b8c06196" xlink:to="loc_us-gaap_EarningsPerShareDiluted_81561671-363d-4279-801c-2e94a03d903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2be74021-0da4-444a-a060-076d403cb29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2be74021-0da4-444a-a060-076d403cb29d" xlink:to="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ab779c88-4193-45b2-a1d8-33aca553716b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ab779c88-4193-45b2-a1d8-33aca553716b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ab779c88-4193-45b2-a1d8-33aca553716b" xlink:to="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9aa10a18-b6e9-4c2a-b64d-c26b718a683b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_CommonStockMember_9aa10a18-b6e9-4c2a-b64d-c26b718a683b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1b3b80d5-09b1-4e61-b5b4-3d27258b8900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1b3b80d5-09b1-4e61-b5b4-3d27258b8900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_cee1c256-a1b6-429a-9809-6ce7512432fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_RetainedEarningsMember_cee1c256-a1b6-429a-9809-6ce7512432fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_c388db2d-6fbe-4103-a7ad-3df0b7454bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d22a0c00-83fb-4854-a338-a682e02db870" xlink:to="loc_us-gaap_NoncontrollingInterestMember_c388db2d-6fbe-4103-a7ad-3df0b7454bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ec88c889-0d62-41a1-80f1-aa895548c3a7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:to="loc_dei_LegalEntityAxis_ec88c889-0d62-41a1-80f1-aa895548c3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a3315695-348a-4414-8118-0ec693ad7bf7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ec88c889-0d62-41a1-80f1-aa895548c3a7" xlink:to="loc_dei_EntityDomain_a3315695-348a-4414-8118-0ec693ad7bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_2496dba4-18a9-4ba2-8295-a90130198d5a" xlink:href="ameh-20210630.xsd#ameh_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a3315695-348a-4414-8118-0ec693ad7bf7" xlink:to="loc_ameh_MezzanineMember_2496dba4-18a9-4ba2-8295-a90130198d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0f77c435-9d54-4b83-b0a0-403c64134a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b27f073e-5833-4c45-abba-5a5386a7d99b" xlink:to="loc_us-gaap_StatementLineItems_0f77c435-9d54-4b83-b0a0-403c64134a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0f77c435-9d54-4b83-b0a0-403c64134a5b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_550f250b-0cae-49d7-be31-b98b77901554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_550f250b-0cae-49d7-be31-b98b77901554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_be88b851-84d4-45e7-ad6b-b3546254dbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_SharesOutstanding_be88b851-84d4-45e7-ad6b-b3546254dbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4c9bca05-4156-45bc-ac6b-eb8b25eda763" xlink:href="ameh-20210630.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_4c9bca05-4156-45bc-ac6b-eb8b25eda763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8c3abcdc-fbda-4dc9-a42d-d0775af44ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8c3abcdc-fbda-4dc9-a42d-d0775af44ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_09dbe12c-d519-4103-86bd-50a0d241228d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_09dbe12c-d519-4103-86bd-50a0d241228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_eb9c5ff6-fee8-440b-a77f-b667b6c05eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_eb9c5ff6-fee8-440b-a77f-b667b6c05eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2992cc42-a155-4c58-b299-a42305e190ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2992cc42-a155-4c58-b299-a42305e190ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_6ed27216-9845-46aa-a274-0e8797ba0c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_6ed27216-9845-46aa-a274-0e8797ba0c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_62f26956-8d07-45ab-8cd8-e75f63eebaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_62f26956-8d07-45ab-8cd8-e75f63eebaa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3004cc37-16ed-4d9e-8157-9d396295e3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_3004cc37-16ed-4d9e-8157-9d396295e3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_6096481a-f5a3-439d-aa05-c3c4c3a59c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_6096481a-f5a3-439d-aa05-c3c4c3a59c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_3c9905bb-0abe-4d35-ae6b-d17c9f97a7b6" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_3c9905bb-0abe-4d35-ae6b-d17c9f97a7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_1614725b-9460-4aa1-85e4-6ce4a4a6882f" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_1614725b-9460-4aa1-85e4-6ce4a4a6882f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d0952052-dd74-4e83-8d05-333216aaeaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d0952052-dd74-4e83-8d05-333216aaeaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_319c6f92-799b-4fa8-bb18-cb403760e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_319c6f92-799b-4fa8-bb18-cb403760e6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6720e0e0-10c8-40d7-b82a-048888e37e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_6720e0e0-10c8-40d7-b82a-048888e37e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_613fdfc2-f239-4190-8c57-7d7c456330c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_613fdfc2-f239-4190-8c57-7d7c456330c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a2ea644b-5ac5-46d2-981f-22a0200f6340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_a2ea644b-5ac5-46d2-981f-22a0200f6340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ceee48a7-e342-4f91-85e7-fc51a5095f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ceee48a7-e342-4f91-85e7-fc51a5095f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a2df6c6d-4680-4a1e-a760-675773c31422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_28a5d129-83be-42d5-9df4-1a9f39663b80" xlink:to="loc_us-gaap_SharesOutstanding_a2df6c6d-4680-4a1e-a760-675773c31422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f6b536d-d942-42c6-aebf-5617cd2073cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f6b536d-d942-42c6-aebf-5617cd2073cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9c00d213-24b5-42e0-abba-19f2f4893834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f6b536d-d942-42c6-aebf-5617cd2073cc" xlink:to="loc_us-gaap_ProfitLoss_9c00d213-24b5-42e0-abba-19f2f4893834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f6b536d-d942-42c6-aebf-5617cd2073cc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c80d3e8b-bf61-4c4d-a6eb-fab868fd54c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c80d3e8b-bf61-4c4d-a6eb-fab868fd54c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1595803b-196a-4fc9-b644-799cad2c9daa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1595803b-196a-4fc9-b644-799cad2c9daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f70a0dbe-2c76-4ae5-a574-3e29dad5abbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_ShareBasedCompensation_f70a0dbe-2c76-4ae5-a574-3e29dad5abbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_97a931fb-e587-4c80-846e-2561f70e5d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_97a931fb-e587-4c80-846e-2561f70e5d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c564430-9d31-4d47-8942-4d19ef83fdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1c564430-9d31-4d47-8942-4d19ef83fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_11f5882c-0c13-489e-853e-ebc92bcc167a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_11f5882c-0c13-489e-853e-ebc92bcc167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_7f1d73ab-3b95-4269-ae48-0eb8cb8bd532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_AssetImpairmentCharges_7f1d73ab-3b95-4269-ae48-0eb8cb8bd532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_a1b53434-0286-40f0-aaf8-4f0537180136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_a1b53434-0286-40f0-aaf8-4f0537180136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_aa64e27a-a18b-43f8-aaa3-3b5d24e02dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_aa64e27a-a18b-43f8-aaa3-3b5d24e02dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_34c06abe-5ee6-480e-9a5c-d21d5be5e81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_34c06abe-5ee6-480e-9a5c-d21d5be5e81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4c0b9e67-dd37-419e-834f-25d9ad85b806" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bdc30ff9-ec54-4ad4-9d32-13e2690a30c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_bdc30ff9-ec54-4ad4-9d32-13e2690a30c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_26059fd8-f35f-4062-b4fc-c3ea64f06f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_26059fd8-f35f-4062-b4fc-c3ea64f06f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f7284849-0e87-42be-a16c-4c659594e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_f7284849-0e87-42be-a16c-4c659594e4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_74f9b004-640d-4c71-9074-4699337d973d" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_74f9b004-640d-4c71-9074-4699337d973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_c0dec616-3a51-4143-b279-9f59e2eea2db" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_c0dec616-3a51-4143-b279-9f59e2eea2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_24df9253-d658-4bce-8723-0bae491d1a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_24df9253-d658-4bce-8723-0bae491d1a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_233a7874-dc9f-4d55-960e-fcec8ca0dea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_233a7874-dc9f-4d55-960e-fcec8ca0dea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_7cbb67b8-4a30-493c-8aee-021f22948739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_7cbb67b8-4a30-493c-8aee-021f22948739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_43c2e697-590c-4d64-a04e-52f1bad5a136" xlink:href="ameh-20210630.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_43c2e697-590c-4d64-a04e-52f1bad5a136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7cd991dd-a059-4c4d-bb0d-b226ac621732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7cd991dd-a059-4c4d-bb0d-b226ac621732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_07ccb81a-6e40-49f8-81f6-1d81fd2d5f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fc86b374-deab-4cf6-9091-aaf2d0dd7ee7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_07ccb81a-6e40-49f8-81f6-1d81fd2d5f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bc2b638-302a-462f-9dff-22a87289ff28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1f6b536d-d942-42c6-aebf-5617cd2073cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8bc2b638-302a-462f-9dff-22a87289ff28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_a686626b-5419-4a21-9506-3d99497f4ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_a686626b-5419-4a21-9506-3d99497f4ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2774f131-2042-41bd-bd3d-ccb76e88f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2774f131-2042-41bd-bd3d-ccb76e88f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrepaymentForInvestmentPurchase_0760dd81-8179-4842-9c4a-035f5f370f37" xlink:href="ameh-20210630.xsd#ameh_PrepaymentForInvestmentPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_ameh_PrepaymentForInvestmentPurchase_0760dd81-8179-4842-9c4a-035f5f370f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d761adc6-1b7b-4419-b643-30ee04e8a1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d761adc6-1b7b-4419-b643-30ee04e8a1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_100a3dcd-0538-42fb-90a6-232403a5a7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_100a3dcd-0538-42fb-90a6-232403a5a7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_95891f38-38b9-4558-92a7-61049c4fd2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_95891f38-38b9-4558-92a7-61049c4fd2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9bede4ec-c01f-471c-a14f-82e045079290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9bede4ec-c01f-471c-a14f-82e045079290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_ba799655-b1ed-4bc9-a998-51fec39ffcba" xlink:href="ameh-20210630.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_ba799655-b1ed-4bc9-a998-51fec39ffcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5482a286-9f07-48d2-b793-230808a700b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5482a286-9f07-48d2-b793-230808a700b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6188a5bc-a734-4299-a82d-a26daa0e3bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_91c20b85-6bc4-4c04-871c-bb2c388c5b88" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6188a5bc-a734-4299-a82d-a26daa0e3bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_72a36f1d-65fe-4748-b502-73e7ae4f07a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_PaymentsOfDividends_72a36f1d-65fe-4748-b502-73e7ae4f07a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9c1729cd-00b5-4c45-916c-8106a74fccfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9c1729cd-00b5-4c45-916c-8106a74fccfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0c729cdb-aa38-494a-8ed9-2f8c370f28b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0c729cdb-aa38-494a-8ed9-2f8c370f28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_d04fb613-ab2f-43f2-8fca-91a1c69696c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_d04fb613-ab2f-43f2-8fca-91a1c69696c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af10c24c-7df6-49d5-b6f6-4438799ffb39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_af10c24c-7df6-49d5-b6f6-4438799ffb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0b1a378d-26ee-4bde-8e1c-5e505105e8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_0b1a378d-26ee-4bde-8e1c-5e505105e8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_2f89710c-dffd-45d2-9a13-a372a386cc76" xlink:href="ameh-20210630.xsd#ameh_ProceedsFromSaleOfNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_ameh_ProceedsFromSaleOfNoncontrollingInterest_2f89710c-dffd-45d2-9a13-a372a386cc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1c660202-ac43-4e87-b5a5-63d72b3fe7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1c660202-ac43-4e87-b5a5-63d72b3fe7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_131bb5c5-a027-4266-8b6e-c2e68678aeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_131bb5c5-a027-4266-8b6e-c2e68678aeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_895fa3d2-0f40-43fa-b6ee-78bd6a38b16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_895fa3d2-0f40-43fa-b6ee-78bd6a38b16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a8fcf09-4692-42e0-bc2f-ac59edee0cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60aca660-4a9b-4315-89cc-e5b5bf82c3b0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0a8fcf09-4692-42e0-bc2f-ac59edee0cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d54f171b-233d-4f20-8c39-e0fba54ba97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d54f171b-233d-4f20-8c39-e0fba54ba97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62b7b755-2968-4c4e-8fb2-3df3e4b5908b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_62b7b755-2968-4c4e-8fb2-3df3e4b5908b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8a7fd7a-e6e5-4a8b-a172-97e0f0675b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8a7fd7a-e6e5-4a8b-a172-97e0f0675b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ec30e2a-1bf0-4225-a243-b6b56416f6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ec30e2a-1bf0-4225-a243-b6b56416f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_0362d5f5-943d-4969-91fa-ba14d502fa03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ec30e2a-1bf0-4225-a243-b6b56416f6c2" xlink:to="loc_us-gaap_IncomeTaxesPaid_0362d5f5-943d-4969-91fa-ba14d502fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fc7ce29f-a4dd-4d1f-8dae-03340d3afbcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0ec30e2a-1bf0-4225-a243-b6b56416f6c2" xlink:to="loc_us-gaap_InterestPaidNet_fc7ce29f-a4dd-4d1f-8dae-03340d3afbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7e4b34b8-83bd-4d82-82c7-fe6f36311dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7e4b34b8-83bd-4d82-82c7-fe6f36311dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_d0948d42-1de8-42d2-b075-053b0492b86e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7e4b34b8-83bd-4d82-82c7-fe6f36311dd8" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_d0948d42-1de8-42d2-b075-053b0492b86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_a63e1435-fd04-4ae5-9434-37334f377b66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7e4b34b8-83bd-4d82-82c7-fe6f36311dd8" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_a63e1435-fd04-4ae5-9434-37334f377b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards_c5eab0d5-4a14-4290-9de4-f45571653b44" xlink:href="ameh-20210630.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7e4b34b8-83bd-4d82-82c7-fe6f36311dd8" xlink:to="loc_ameh_CancellationOfRestrictedStockAwards_c5eab0d5-4a14-4290-9de4-f45571653b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_1867a254-f85f-4564-8011-1c85961c7d2a" xlink:href="ameh-20210630.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_125537be-3b16-4447-8ca1-2f3dcdf5e44d" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_1867a254-f85f-4564-8011-1c85961c7d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c96dd761-ad44-4488-a40b-7886865f07ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_1867a254-f85f-4564-8011-1c85961c7d2a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c96dd761-ad44-4488-a40b-7886865f07ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_e2a93a9b-5b8c-4447-b7df-4e8193aa24d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_1867a254-f85f-4564-8011-1c85961c7d2a" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_e2a93a9b-5b8c-4447-b7df-4e8193aa24d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_0875aade-2e84-44f2-b477-d848a715d94d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_1867a254-f85f-4564-8011-1c85961c7d2a" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_0875aade-2e84-44f2-b477-d848a715d94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49803ccb-f64e-4abb-9944-3a2382021c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_1867a254-f85f-4564-8011-1c85961c7d2a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49803ccb-f64e-4abb-9944-3a2382021c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20210630.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_570cdbe6-f466-4e37-b907-d56f4c041470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_e64c9117-bf4e-41fe-96e5-0a3778570e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_570cdbe6-f466-4e37-b907-d56f4c041470" xlink:to="loc_us-gaap_NatureOfOperations_e64c9117-bf4e-41fe-96e5-0a3778570e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646e440e-0846-4fa4-8f62-57070051c698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:href="ameh-20210630.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_646e440e-0846-4fa4-8f62-57070051c698" xlink:to="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_80f3aeca-95fd-4a98-b1b6-202c3bdb1263" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_dei_LegalEntityAxis_80f3aeca-95fd-4a98-b1b6-202c3bdb1263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_80f3aeca-95fd-4a98-b1b6-202c3bdb1263" xlink:to="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_86577791-2b3d-4917-a3b3-72e672fd4970" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_86577791-2b3d-4917-a3b3-72e672fd4970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_e7559171-505c-4f81-80c5-b13964931bb5" xlink:href="ameh-20210630.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_ApcLsmaMember_e7559171-505c-4f81-80c5-b13964931bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_1ecb4b77-f4a3-453b-b73b-4684789902e0" xlink:href="ameh-20210630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_AccountableHealthCareIPAMember_1ecb4b77-f4a3-453b-b73b-4684789902e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_cbf86a29-000a-41cc-976a-c8f4e28e5718" xlink:href="ameh-20210630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_APCAndAPCLSMAMember_cbf86a29-000a-41cc-976a-c8f4e28e5718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_6a9f9107-b21f-40f6-95c5-55be5e54963d" xlink:href="ameh-20210630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b89d42e4-691c-44c5-a807-669a3013395d" xlink:to="loc_ameh_AmgIncMember_6a9f9107-b21f-40f6-95c5-55be5e54963d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_srt_CounterpartyNameAxis_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ccc76cf9-b4f9-441d-8cfd-c2d95f83aa73" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f3782b47-53d0-4f53-955d-2a7aab5a6167" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f3782b47-53d0-4f53-955d-2a7aab5a6167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_31654ffb-82a6-4fc9-9276-d8b9aaa29f3a" xlink:href="ameh-20210630.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:to="loc_ameh_APAMHMedicalCorporationMember_31654ffb-82a6-4fc9-9276-d8b9aaa29f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_571c08e7-49d4-4781-89bd-d2d12c977d85" xlink:href="ameh-20210630.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4c4d00af-b6d1-4ce2-ac3f-74a310a0aadc" xlink:to="loc_ameh_Dr.JayMember_571c08e7-49d4-4781-89bd-d2d12c977d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e61f22c4-c3d6-4c55-84b7-70d3494c183a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e61f22c4-c3d6-4c55-84b7-70d3494c183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8a570962-2da6-4338-8a9b-1bb98df2745d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e61f22c4-c3d6-4c55-84b7-70d3494c183a" xlink:to="loc_us-gaap_RelatedPartyDomain_8a570962-2da6-4338-8a9b-1bb98df2745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_855f68c6-ae51-4bbb-a827-b29c7885adcb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8a570962-2da6-4338-8a9b-1bb98df2745d" xlink:to="loc_srt_AffiliatedEntityMember_855f68c6-ae51-4bbb-a827-b29c7885adcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ab000fef-45a7-45df-ac58-02e4306ecf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ab000fef-45a7-45df-ac58-02e4306ecf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f687f701-76e5-436f-ad92-ef6cc5800d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ab000fef-45a7-45df-ac58-02e4306ecf8c" xlink:to="loc_us-gaap_ClassOfStockDomain_f687f701-76e5-436f-ad92-ef6cc5800d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9f8a7688-0865-4ad5-9564-98f8ca5cdd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f687f701-76e5-436f-ad92-ef6cc5800d0f" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9f8a7688-0865-4ad5-9564-98f8ca5cdd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3dec4f-147d-4334-abbe-86de80d25748" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3dec4f-147d-4334-abbe-86de80d25748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ff3dec4f-147d-4334-abbe-86de80d25748" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_38ddb925-f1ee-48b1-94d8-96db6363823e" xlink:href="ameh-20210630.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_38ddb925-f1ee-48b1-94d8-96db6363823e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_477b836b-c4a2-48a3-a9be-8ea9dff844fb" xlink:href="ameh-20210630.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9daf7e94-cb07-42e4-9c3c-dabb5d17d3d7" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_477b836b-c4a2-48a3-a9be-8ea9dff844fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3d88b836-0d4c-4005-bd16-543ce2dd3126" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_srt_OwnershipAxis_3d88b836-0d4c-4005-bd16-543ce2dd3126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a1a6ea06-2e08-4394-b858-f029de1e0e03" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3d88b836-0d4c-4005-bd16-543ce2dd3126" xlink:to="loc_srt_OwnershipDomain_a1a6ea06-2e08-4394-b858-f029de1e0e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_51a790a0-aa2b-4878-a4cf-0f7cd49a7aff" xlink:href="ameh-20210630.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_a1a6ea06-2e08-4394-b858-f029de1e0e03" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_51a790a0-aa2b-4878-a4cf-0f7cd49a7aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_00278247-adf7-4382-af4c-55205ef275fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_00278247-adf7-4382-af4c-55205ef275fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_00278247-adf7-4382-af4c-55205ef275fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_4cc89750-b43b-4ea1-a2e3-fa776d8bb177" xlink:href="ameh-20210630.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:to="loc_ameh_AccountableHealthCareIPAMember_4cc89750-b43b-4ea1-a2e3-fa776d8bb177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_7994de55-b213-4b13-91af-0b0c13a1401e" xlink:href="ameh-20210630.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:to="loc_ameh_AmgIncMember_7994de55-b213-4b13-91af-0b0c13a1401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SunClinicalLaboratoriesMember_d345631c-70a7-4c09-91b4-2c78205b27fe" xlink:href="ameh-20210630.xsd#ameh_SunClinicalLaboratoriesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0cdc0ce-9f13-433e-a843-7c57e0a481ec" xlink:to="loc_ameh_SunClinicalLaboratoriesMember_d345631c-70a7-4c09-91b4-2c78205b27fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2696d9ba-d8b7-4b9e-8acd-c12724ef98fd" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_0ec15e5f-ae7c-47ba-8182-22d73756547a" xlink:href="ameh-20210630.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_0ec15e5f-ae7c-47ba-8182-22d73756547a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_940fadfd-2123-4602-98d7-bf038beafa26" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b5c45483-2614-45e3-b40f-b65a24625107" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_940fadfd-2123-4602-98d7-bf038beafa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:href="ameh-20210630.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_246a8b2d-08c0-4bb4-9c59-d82852f8f2f5" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07074a70-9920-462c-82d0-b8c131180b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_07074a70-9920-462c-82d0-b8c131180b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1b1a9e3a-304b-4529-ac91-ce145e5f3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1b1a9e3a-304b-4529-ac91-ce145e5f3c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66270700-0533-4da3-ab7f-83df747c15af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_66270700-0533-4da3-ab7f-83df747c15af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_ad90167a-8b19-4823-9fcc-314d73347e13" xlink:href="ameh-20210630.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_ad90167a-8b19-4823-9fcc-314d73347e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_dca9f143-98ca-49d5-b2b1-74f8e815fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_NotesReceivableNet_dca9f143-98ca-49d5-b2b1-74f8e815fed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_3314dacc-036a-4277-8f84-2809fc3323dc" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_3314dacc-036a-4277-8f84-2809fc3323dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_0d742164-2429-49db-94fd-b22470c8a6b0" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_0d742164-2429-49db-94fd-b22470c8a6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_b3ac3a9f-9bf4-43d0-ba51-f3851c13300d" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_b3ac3a9f-9bf4-43d0-ba51-f3851c13300d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_888ac045-3843-42a2-938e-02d2c7c9225a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_888ac045-3843-42a2-938e-02d2c7c9225a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82db9085-ddee-4ef0-8d2a-b7d71046d92d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_82db9085-ddee-4ef0-8d2a-b7d71046d92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_51514e32-f69f-45b1-9d88-c0df444eb80d" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_51514e32-f69f-45b1-9d88-c0df444eb80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6a5c6bf7-2fb1-4df6-ac08-450793bdb3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6a5c6bf7-2fb1-4df6-ac08-450793bdb3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_6bfcf00e-38dc-41b6-9eaf-fa49abb9fd69" xlink:href="ameh-20210630.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_6bfcf00e-38dc-41b6-9eaf-fa49abb9fd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_31f3e6e2-af65-49ea-90b8-bc4e9588489b" xlink:href="ameh-20210630.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_31f3e6e2-af65-49ea-90b8-bc4e9588489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b51d0af8-e9b1-40de-9bb8-116bfe3673d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b51d0af8-e9b1-40de-9bb8-116bfe3673d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a51a1d34-58d2-4079-a912-64139267051a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a51a1d34-58d2-4079-a912-64139267051a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0968d37c-1c63-4c6a-bad1-b1e975f760e7" xlink:href="ameh-20210630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_76212d99-26b1-4c25-be4d-5ebc203d6f49" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0968d37c-1c63-4c6a-bad1-b1e975f760e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_94d6a872-51d4-4079-8f1d-4e0768030ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2cac0ad1-d8de-4e24-a8c7-e4d4c9829554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_94d6a872-51d4-4079-8f1d-4e0768030ea0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_2cac0ad1-d8de-4e24-a8c7-e4d4c9829554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2e3d01ae-4338-4505-8af0-c8db372fff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2e3d01ae-4338-4505-8af0-c8db372fff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7f262d36-f048-4da2-ba20-0f017f2cc403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7f262d36-f048-4da2-ba20-0f017f2cc403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_21d9be21-f480-4606-898d-c570d0919db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_UseOfEstimates_21d9be21-f480-4606-898d-c570d0919db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_5a5ff7c5-93c6-4322-8813-9eaeb15a9b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_5a5ff7c5-93c6-4322-8813-9eaeb15a9b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_96ae9444-6678-426f-a6a2-0d2809179376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_96ae9444-6678-426f-a6a2-0d2809179376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0d593ed5-c5d0-4d0f-8605-a4f5146d9705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0d593ed5-c5d0-4d0f-8605-a4f5146d9705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_788ab04c-12cd-46c2-8d7e-b0c202378248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_788ab04c-12cd-46c2-8d7e-b0c202378248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d483886c-a06a-4dd5-8a21-8f5ad06be74a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_d483886c-a06a-4dd5-8a21-8f5ad06be74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_5b0ebb98-a8d1-4aa3-a321-4adb56f0c11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_5b0ebb98-a8d1-4aa3-a321-4adb56f0c11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_64baf182-5d74-4b6e-a20d-520d17f9c6a1" xlink:href="ameh-20210630.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_64baf182-5d74-4b6e-a20d-520d17f9c6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_00f05bc2-ea41-4478-9bde-7890e7c8f26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_00f05bc2-ea41-4478-9bde-7890e7c8f26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1e7cfb4e-f18e-4998-b043-93696b0c65ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_1e7cfb4e-f18e-4998-b043-93696b0c65ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5a55c445-6c07-4a56-8ce5-d1d8a7fc0cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5a55c445-6c07-4a56-8ce5-d1d8a7fc0cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b3960ba3-748e-4092-8bec-44d1b1b25573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b3960ba3-748e-4092-8bec-44d1b1b25573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_b66f10d4-4164-49a7-972d-044741e444b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_b66f10d4-4164-49a7-972d-044741e444b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_ac77bc2b-52e8-4d0f-bc5c-d3c48074a7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_ac77bc2b-52e8-4d0f-bc5c-d3c48074a7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_dcf168b0-5d96-42af-a412-e0d3cda7b21d" xlink:href="ameh-20210630.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_dcf168b0-5d96-42af-a412-e0d3cda7b21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_cfd5789a-f11b-43ef-b83f-9b7da63b4922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_cfd5789a-f11b-43ef-b83f-9b7da63b4922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_604444ad-547b-45e5-847b-dc1aca0ad29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_604444ad-547b-45e5-847b-dc1aca0ad29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_59d40963-0aa7-442e-b980-d14e4fa060d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_59d40963-0aa7-442e-b980-d14e4fa060d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cc7eb25d-40b7-4be7-ab8c-71a234ff05d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_cc7eb25d-40b7-4be7-ab8c-71a234ff05d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_b78aacb9-0b06-4c3e-8139-9bc62c8bc6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_b78aacb9-0b06-4c3e-8139-9bc62c8bc6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock_03050272-9d39-4497-b502-3394e940fcd9" xlink:href="ameh-20210630.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_ameh_MinorityInterestPolicyPolicyTextBlock_03050272-9d39-4497-b502-3394e940fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock_c19a1e1e-dcc6-4101-bc19-21670ddb9c4f" xlink:href="ameh-20210630.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_ameh_TemporaryEquityPolicyTextBlock_c19a1e1e-dcc6-4101-bc19-21670ddb9c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_786c6f37-0e75-4cc2-b187-e35d18091e08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_786c6f37-0e75-4cc2-b187-e35d18091e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BeneficialInterestPolicyTextBlock_51acdc3d-90ec-45de-a432-c29974382968" xlink:href="ameh-20210630.xsd#ameh_BeneficialInterestPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_ameh_BeneficialInterestPolicyTextBlock_51acdc3d-90ec-45de-a432-c29974382968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_be6950d2-66d5-4534-90ae-ba20261cb2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_56c1e4e1-8714-4924-982f-6c3ec38c08c5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_be6950d2-66d5-4534-90ae-ba20261cb2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c1402a20-a0d5-4ad2-99d6-f9014e929893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_58c26ce2-9510-4f66-ac9b-ae666fd9e5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1402a20-a0d5-4ad2-99d6-f9014e929893" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_58c26ce2-9510-4f66-ac9b-ae666fd9e5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_71acc624-0a36-408d-b378-f88492eb3440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1402a20-a0d5-4ad2-99d6-f9014e929893" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_71acc624-0a36-408d-b378-f88492eb3440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_380926f7-2618-4b46-be09-dd99e94b6b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1402a20-a0d5-4ad2-99d6-f9014e929893" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_380926f7-2618-4b46-be09-dd99e94b6b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_25764c7c-a13f-4b73-add7-22d59e86c037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:href="ameh-20210630.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_25764c7c-a13f-4b73-add7-22d59e86c037" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41380629-6cf9-41f6-a2c6-534cd6ab344b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_RangeAxis_41380629-6cf9-41f6-a2c6-534cd6ab344b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_41380629-6cf9-41f6-a2c6-534cd6ab344b" xlink:to="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2c9cbccc-68c0-4937-a6dd-44ade151db3d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:to="loc_srt_MinimumMember_2c9cbccc-68c0-4937-a6dd-44ade151db3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d8face71-45b6-4718-a526-3d92513bf9b6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_217ecec0-f591-4c43-9855-638fc1766585" xlink:to="loc_srt_MaximumMember_d8face71-45b6-4718-a526-3d92513bf9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dc4396c-db44-4bd1-9f51-3e86d3a9c064" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_CounterpartyNameAxis_0dc4396c-db44-4bd1-9f51-3e86d3a9c064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d50ef6ba-0a1f-4066-a72a-919cd483dfd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0dc4396c-db44-4bd1-9f51-3e86d3a9c064" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d50ef6ba-0a1f-4066-a72a-919cd483dfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_afd95c7b-d76a-480d-9ac0-c831f60d8fa7" xlink:href="ameh-20210630.xsd#ameh_CMSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d50ef6ba-0a1f-4066-a72a-919cd483dfd9" xlink:to="loc_ameh_CMSMember_afd95c7b-d76a-480d-9ac0-c831f60d8fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c0e1c531-ef56-45c3-a0ae-4465b6ddba43" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_ProductOrServiceAxis_c0e1c531-ef56-45c3-a0ae-4465b6ddba43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c0e1c531-ef56-45c3-a0ae-4465b6ddba43" xlink:to="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_fd795c52-bda7-4e65-a1e5-7848c64deac6" xlink:href="ameh-20210630.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_fd795c52-bda7-4e65-a1e5-7848c64deac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_8882facf-39dd-49b9-9219-3c13bee17487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5f6d1b15-d297-4e24-8406-8edd09946c6d" xlink:to="loc_us-gaap_ManagementServiceMember_8882facf-39dd-49b9-9219-3c13bee17487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9a8b4433-19ce-4ce0-9149-430d530dd3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9a8b4433-19ce-4ce0-9149-430d530dd3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9a8b4433-19ce-4ce0-9149-430d530dd3cb" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_a1bebdd0-b453-41f2-a9e4-48629a983a27" xlink:href="ameh-20210630.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_a1bebdd0-b453-41f2-a9e4-48629a983a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f4f8454f-4e27-4ad4-a95a-0304f3875de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_cf118bcd-b411-4276-b2d2-25711a48f839" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_f4f8454f-4e27-4ad4-a95a-0304f3875de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_79670913-f77f-4b65-839f-4acef1520060" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_OwnershipAxis_79670913-f77f-4b65-839f-4acef1520060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d306c93b-efef-46a2-a5fd-af6c628c5de7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_79670913-f77f-4b65-839f-4acef1520060" xlink:to="loc_srt_OwnershipDomain_d306c93b-efef-46a2-a5fd-af6c628c5de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2861acf0-aa9b-424b-a86b-718081c19e61" xlink:href="ameh-20210630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_d306c93b-efef-46a2-a5fd-af6c628c5de7" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2861acf0-aa9b-424b-a86b-718081c19e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_dei_LegalEntityAxis_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9ef0ecb4-bfbb-4f69-9c74-9c50303d5b5e" xlink:to="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dc8b7fd4-0ed5-4e22-b394-689f4f87315e" xlink:href="ameh-20210630.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_dc8b7fd4-0ed5-4e22-b394-689f4f87315e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_eb7a325d-e9ca-4d0c-846d-ad7a7c56e234" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_50ff9d7e-d877-481f-a984-76be9c167024" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_eb7a325d-e9ca-4d0c-846d-ad7a7c56e234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_662f32b6-adb8-4030-9992-86b97860e732" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_662f32b6-adb8-4030-9992-86b97860e732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8c71ec60-998d-4240-ba0c-d0c5960599b3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_662f32b6-adb8-4030-9992-86b97860e732" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8c71ec60-998d-4240-ba0c-d0c5960599b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_e31ca37f-7441-4aac-97b4-0cdf02ebd9b5" xlink:href="ameh-20210630.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8c71ec60-998d-4240-ba0c-d0c5960599b3" xlink:to="loc_ameh_UniversalCareIncMember_e31ca37f-7441-4aac-97b4-0cdf02ebd9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c2ea2aa2-bbe9-4f0d-983f-5590186e01aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e04a3e4b-eed7-43ef-99c9-15bfdddbe28d" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c2ea2aa2-bbe9-4f0d-983f-5590186e01aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f613eaf1-e404-4c10-87b9-0811aeee024c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c2ea2aa2-bbe9-4f0d-983f-5590186e01aa" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f613eaf1-e404-4c10-87b9-0811aeee024c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4224ad43-0afe-4ebe-bcfd-72d78cc51deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4224ad43-0afe-4ebe-bcfd-72d78cc51deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_24b8a17b-501c-438e-aea2-0f666bfc4ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4224ad43-0afe-4ebe-bcfd-72d78cc51deb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_24b8a17b-501c-438e-aea2-0f666bfc4ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_b837016f-a420-406c-9c73-9228986e4261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_24b8a17b-501c-438e-aea2-0f666bfc4ca6" xlink:to="loc_us-gaap_InterestRateSwapMember_b837016f-a420-406c-9c73-9228986e4261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4ddf2611-3016-4c01-9568-294e743ca786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4ddf2611-3016-4c01-9568-294e743ca786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8165cb68-7ce6-4313-b267-7faf31974440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4ddf2611-3016-4c01-9568-294e743ca786" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8165cb68-7ce6-4313-b267-7faf31974440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_de124be1-f4c6-4ddd-a99e-d0a55100946d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8165cb68-7ce6-4313-b267-7faf31974440" xlink:to="loc_us-gaap_CashFlowHedgingMember_de124be1-f4c6-4ddd-a99e-d0a55100946d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c12f1625-d9e4-4857-a4b6-5bed2745def8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_us-gaap_HedgingDesignationAxis_c12f1625-d9e4-4857-a4b6-5bed2745def8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_cc2f9f83-dc7a-4f29-82f6-f40870e4158a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c12f1625-d9e4-4857-a4b6-5bed2745def8" xlink:to="loc_us-gaap_HedgingDesignationDomain_cc2f9f83-dc7a-4f29-82f6-f40870e4158a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_75cdfc15-9f14-4634-8e4b-c3a482a791c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_cc2f9f83-dc7a-4f29-82f6-f40870e4158a" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_75cdfc15-9f14-4634-8e4b-c3a482a791c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:href="ameh-20210630.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_aa4d9b30-6639-4f3e-8034-148abae2b09b" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f572929f-8bf0-413e-abcd-11c21018791d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f572929f-8bf0-413e-abcd-11c21018791d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b69e2859-b721-407b-b5d8-fccce960ce5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_NumberOfReportableSegments_b69e2859-b721-407b-b5d8-fccce960ce5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_cf9385c1-99b9-4204-b2ee-a279b7c7cd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_CashUninsuredAmount_cf9385c1-99b9-4204-b2ee-a279b7c7cd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_f53da2de-21a8-4a1a-b0e3-90c63507670c" xlink:href="ameh-20210630.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_f53da2de-21a8-4a1a-b0e3-90c63507670c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1fcc6ee-2409-410a-89d3-4b498e2ea090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1fcc6ee-2409-410a-89d3-4b498e2ea090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_d02f5fe1-c1b0-4c5a-a214-cf84c8f0d227" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_d02f5fe1-c1b0-4c5a-a214-cf84c8f0d227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_8b8a429a-2d30-4ff5-abc2-8660141167ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_8b8a429a-2d30-4ff5-abc2-8660141167ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_41722de2-da07-4efd-a120-da3aaf736016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGain_41722de2-da07-4efd-a120-da3aaf736016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bdfdbf07-85df-4dbd-bdc9-3dd2746ea3bb" xlink:href="ameh-20210630.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_bdfdbf07-85df-4dbd-bdc9-3dd2746ea3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1311be7-c402-4af3-9a3b-d2a5b7ee9574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a1311be7-c402-4af3-9a3b-d2a5b7ee9574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7a9b3b95-281a-4c9a-97b4-8ef4f4e12cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_7a9b3b95-281a-4c9a-97b4-8ef4f4e12cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_a672a3d8-fa64-4680-a754-ba3af032fa2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_NumberOfReportingUnits_a672a3d8-fa64-4680-a754-ba3af032fa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_bc07b064-dd78-48ee-afb1-d168835223b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_bc07b064-dd78-48ee-afb1-d168835223b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e5696bee-452e-489f-8386-81f472d19e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_e5696bee-452e-489f-8386-81f472d19e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1de4183c-1d9c-4543-bc65-28b0bda94f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_Goodwill_1de4183c-1d9c-4543-bc65-28b0bda94f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_633a2d77-bec7-488b-93f2-d49d33344bba" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_633a2d77-bec7-488b-93f2-d49d33344bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fdc3a8a4-e991-42ce-9324-356f9417f1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_fdc3a8a4-e991-42ce-9324-356f9417f1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_6a8b1cf6-e717-439c-89ec-c3705a81aa25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_6a8b1cf6-e717-439c-89ec-c3705a81aa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_301b5a24-ddce-423d-967d-cf0c9714f744" xlink:href="ameh-20210630.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_301b5a24-ddce-423d-967d-cf0c9714f744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_97aedf6b-1e74-46f4-bfb8-9ac96dbd0553" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_97aedf6b-1e74-46f4-bfb8-9ac96dbd0553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_b14f4edf-8804-4570-a112-b195254490e4" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_PaymentOfRevenue_b14f4edf-8804-4570-a112-b195254490e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized_81804918-9170-4310-9ad7-8ead43711617" xlink:href="ameh-20210630.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_PaymentOfRevenueRevenueRecognized_81804918-9170-4310-9ad7-8ead43711617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6362f51f-8fd9-44c6-b705-d4a951652e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6362f51f-8fd9-44c6-b705-d4a951652e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e2bdc7a4-9767-4a73-9ef0-8965295d1982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e2bdc7a4-9767-4a73-9ef0-8965295d1982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_159631e5-e72d-4470-b377-64e3a151e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_159631e5-e72d-4470-b377-64e3a151e6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_374af527-6213-48ba-b585-b25cc53c3944" xlink:href="ameh-20210630.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_374af527-6213-48ba-b585-b25cc53c3944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_77296a14-b0ce-43a0-bfdf-84f941b056b0" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_77296a14-b0ce-43a0-bfdf-84f941b056b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_0e9a7178-3b2a-4276-ad20-9d8567deca94" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_0e9a7178-3b2a-4276-ad20-9d8567deca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_3eb0fd70-dfd0-4f75-aee7-7979367d375c" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_3eb0fd70-dfd0-4f75-aee7-7979367d375c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_9a0c7f5e-9805-496c-b3f3-bd81bff48a7f" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_61ff1ef1-9efd-4033-b76c-9081eecef6df" xlink:to="loc_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds_9a0c7f5e-9805-496c-b3f3-bd81bff48a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ec672aeb-6fbe-4117-ba84-9cb2619a79f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_10384d46-768f-40f6-a621-e42367562d94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ec672aeb-6fbe-4117-ba84-9cb2619a79f4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_10384d46-768f-40f6-a621-e42367562d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c67571b4-c43d-473d-b253-4c2220c9d53e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_10384d46-768f-40f6-a621-e42367562d94" xlink:to="loc_srt_MajorCustomersAxis_c67571b4-c43d-473d-b253-4c2220c9d53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c67571b4-c43d-473d-b253-4c2220c9d53e" xlink:to="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_b0abb69e-7cad-4d73-b702-000f28721e5b" xlink:href="ameh-20210630.xsd#ameh_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_CommercialMember_b0abb69e-7cad-4d73-b702-000f28721e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_6d6bc88d-ed7f-450e-9a79-176cc9312723" xlink:href="ameh-20210630.xsd#ameh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_MedicareMember_6d6bc88d-ed7f-450e-9a79-176cc9312723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_34cbb5db-81bf-4983-85bf-38faf8ee40d1" xlink:href="ameh-20210630.xsd#ameh_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_MedicaidMember_34cbb5db-81bf-4983-85bf-38faf8ee40d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_79a0a5a2-15ee-40e6-ad67-a36fcc16f85d" xlink:href="ameh-20210630.xsd#ameh_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f7379d7a-3074-455e-8c2c-1344f3d16473" xlink:to="loc_ameh_OtherThirdPartiesMember_79a0a5a2-15ee-40e6-ad67-a36fcc16f85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_edb2f9ec-5a1e-43a1-9749-1faf9b323d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_10384d46-768f-40f6-a621-e42367562d94" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_edb2f9ec-5a1e-43a1-9749-1faf9b323d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87371ad-e1ec-472d-a2dd-e7262891bff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_edb2f9ec-5a1e-43a1-9749-1faf9b323d7a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c87371ad-e1ec-472d-a2dd-e7262891bff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a07d1bca-8f8d-466c-bd59-ba2e8fdee95a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:href="ameh-20210630.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a07d1bca-8f8d-466c-bd59-ba2e8fdee95a" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56861e11-cb02-4032-8c37-7895048bb4db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56861e11-cb02-4032-8c37-7895048bb4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_56861e11-cb02-4032-8c37-7895048bb4db" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_b276c655-4d68-4d76-8083-7517d9c8b2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:to="loc_us-gaap_SalesRevenueNetMember_b276c655-4d68-4d76-8083-7517d9c8b2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_2aa4021a-5c36-497b-bf37-978329ccde1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ee8dccd1-7100-43d8-ac4c-d164e26611d4" xlink:to="loc_us-gaap_AccountsReceivableMember_2aa4021a-5c36-497b-bf37-978329ccde1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_65d594f4-c1a2-404b-b920-c6f3dd96f92c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:to="loc_srt_MajorCustomersAxis_65d594f4-c1a2-404b-b920-c6f3dd96f92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_65d594f4-c1a2-404b-b920-c6f3dd96f92c" xlink:to="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_47a24435-45f2-4af2-a5f6-7185d6c2b374" xlink:href="ameh-20210630.xsd#ameh_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorAMember_47a24435-45f2-4af2-a5f6-7185d6c2b374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_2090ddd0-5a43-481d-aeb3-093eeb1136a1" xlink:href="ameh-20210630.xsd#ameh_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorBMember_2090ddd0-5a43-481d-aeb3-093eeb1136a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_d23101a4-b218-4e48-9563-7b2479db1371" xlink:href="ameh-20210630.xsd#ameh_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorCMember_d23101a4-b218-4e48-9563-7b2479db1371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_c2f77a4a-a1c4-4b6b-b278-c9cdad227aad" xlink:href="ameh-20210630.xsd#ameh_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorDMember_c2f77a4a-a1c4-4b6b-b278-c9cdad227aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_f61f26f9-e43d-4136-941c-ce611d77b566" xlink:href="ameh-20210630.xsd#ameh_PayorEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorEMember_f61f26f9-e43d-4136-941c-ce611d77b566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_1adb0153-fd6d-440e-af9e-9d49bf96e7cc" xlink:href="ameh-20210630.xsd#ameh_PayorFMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorFMember_1adb0153-fd6d-440e-af9e-9d49bf96e7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_2d505bde-88a3-44b3-9ff3-3cddb0edde1f" xlink:href="ameh-20210630.xsd#ameh_PayorGMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1b67629a-98a0-4374-b0ee-9e4af5e1fc30" xlink:to="loc_ameh_PayorGMember_2d505bde-88a3-44b3-9ff3-3cddb0edde1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4975afe4-5c7f-46e0-a2f3-69f3b6016f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_50a6898d-bb90-487e-a9a2-d60dd3f7a9d4" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4975afe4-5c7f-46e0-a2f3-69f3b6016f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_84728f82-1cec-4cb0-90dd-e060f2d3ab4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4975afe4-5c7f-46e0-a2f3-69f3b6016f7c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_84728f82-1cec-4cb0-90dd-e060f2d3ab4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_c06e9a6f-5cc9-4571-b4dc-7dce757dce5f" xlink:href="ameh-20210630.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_09d0801e-7982-45d4-ae8b-46b25a07909d" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueLineItems_c06e9a6f-5cc9-4571-b4dc-7dce757dce5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_680132d0-a736-4cf2-aff2-a5ce2f2fe6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_c06e9a6f-5cc9-4571-b4dc-7dce757dce5f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_680132d0-a736-4cf2-aff2-a5ce2f2fe6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fab8e785-8864-4281-83b7-4bb3105a0b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1feba034-d99e-4af5-8c93-9985da53db63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fab8e785-8864-4281-83b7-4bb3105a0b01" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1feba034-d99e-4af5-8c93-9985da53db63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11de1487-a2bb-40b9-a65f-4b62b61f61a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1feba034-d99e-4af5-8c93-9985da53db63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11de1487-a2bb-40b9-a65f-4b62b61f61a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_11de1487-a2bb-40b9-a65f-4b62b61f61a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c53cebbd-f96e-441c-b91a-64a3a0399681" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c53cebbd-f96e-441c-b91a-64a3a0399681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f0d1af7a-75ec-4d25-82a4-5429220b93a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f0d1af7a-75ec-4d25-82a4-5429220b93a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7eb58d8e-3173-4664-bc83-8c9065448351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d30007c7-d179-49ce-ad3a-02cb218c7647" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7eb58d8e-3173-4664-bc83-8c9065448351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1feba034-d99e-4af5-8c93-9985da53db63" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4f78788-6d33-4566-9972-1950d8822455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4f78788-6d33-4566-9972-1950d8822455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f96dd83-188d-4542-9ae8-9f5c9bfa7a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f96dd83-188d-4542-9ae8-9f5c9bfa7a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7a2f0a60-fb5c-4125-8fbf-f63f0ca0c79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7a2f0a60-fb5c-4125-8fbf-f63f0ca0c79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5a238cb7-db67-4ba8-b74a-ac431c4fdd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1b6f10b6-1957-4647-913a-9fef1d371b34" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5a238cb7-db67-4ba8-b74a-ac431c4fdd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4274a4df-fabe-4032-b461-8384b37881b0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_91213c88-71fa-4a70-933e-0b819bf1d0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:to="loc_us-gaap_DerivativeLiabilities_91213c88-71fa-4a70-933e-0b819bf1d0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7884b913-b3dc-4dd4-82c0-5e5a7ec0495e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_3823dc61-61fa-4701-9c9a-cf080b59ab22" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_7884b913-b3dc-4dd4-82c0-5e5a7ec0495e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b6888b9-5fbf-486d-a9f9-2da53ebc8a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8ad9fad3-446f-4d2a-8a43-79e404325dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4b6888b9-5fbf-486d-a9f9-2da53ebc8a6c" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8ad9fad3-446f-4d2a-8a43-79e404325dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d849c21-669a-439f-abf7-56f27faad186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_aa2a2c67-19cb-4aa9-8438-74c22e3eb902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d849c21-669a-439f-abf7-56f27faad186" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_aa2a2c67-19cb-4aa9-8438-74c22e3eb902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c470f175-59b1-401f-9b1f-2d7165828d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d849c21-669a-439f-abf7-56f27faad186" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c470f175-59b1-401f-9b1f-2d7165828d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f25ce161-c0cd-4ad8-aafc-b1bae55d061d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f25ce161-c0cd-4ad8-aafc-b1bae55d061d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d7c4b8a2-606a-4f1d-98d8-ee3d82347f4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_1fd89b68-63d1-4270-93a7-b0f7c88e71b2" xlink:href="ameh-20210630.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_NetworkRelationshipsMember_1fd89b68-63d1-4270-93a7-b0f7c88e71b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_8cc73e8c-5f75-4e3f-a53c-00de468c72ae" xlink:href="ameh-20210630.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_ManagementContractsMember_8cc73e8c-5f75-4e3f-a53c-00de468c72ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_21d09550-c3ed-4c51-97fc-f18609a913cd" xlink:href="ameh-20210630.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_MemberRelationshipsMember_21d09550-c3ed-4c51-97fc-f18609a913cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_296feb9f-9a17-4265-bec4-620be9f84515" xlink:href="ameh-20210630.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_ameh_PatientManagementPlatformMember_296feb9f-9a17-4265-bec4-620be9f84515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_edf8feff-e381-469a-96d5-8700b606fc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_100a331f-ee8e-47f2-961b-1e0963248d66" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_edf8feff-e381-469a-96d5-8700b606fc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:to="loc_srt_RangeAxis_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f5e867a0-07e7-4c5c-b364-3b5cfc2e0e33" xlink:to="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3295f18-dec0-42bc-a398-2d86c3a0108d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:to="loc_srt_MinimumMember_c3295f18-dec0-42bc-a398-2d86c3a0108d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6cfe0fa5-8f93-4b67-9a64-4abd17429d93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6e4647f-5bab-4988-accf-e957ee71bbff" xlink:to="loc_srt_MaximumMember_6cfe0fa5-8f93-4b67-9a64-4abd17429d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aa6f0c1e-8764-42b6-b104-a3d0431894ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2916e768-d8fe-40b6-9c0b-49fd60263f08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2916e768-d8fe-40b6-9c0b-49fd60263f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e555e1cf-915a-474b-be52-492952d7c637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e555e1cf-915a-474b-be52-492952d7c637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ffca9fb0-de70-475d-be09-ceb32767ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ffca9fb0-de70-475d-be09-ceb32767ea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60b579ea-e006-4ace-b139-2759ad12334c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_60b579ea-e006-4ace-b139-2759ad12334c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6d718ee6-bc01-482c-a312-04d51b2740f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6d718ee6-bc01-482c-a312-04d51b2740f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90052e10-36ce-4d57-9b9d-99384b10a3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f98b80d7-4ee2-402d-8e82-00a2a6db7b79" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_90052e10-36ce-4d57-9b9d-99384b10a3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bb930d45-c99b-422f-8bed-46a6489bbae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9cc98845-ff3e-4f51-81db-f3f1446f82e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bb930d45-c99b-422f-8bed-46a6489bbae9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9cc98845-ff3e-4f51-81db-f3f1446f82e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_cc568a0b-5da6-42a8-9d26-bed673cc80c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_cc568a0b-5da6-42a8-9d26-bed673cc80c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b8cc5bda-2c45-4624-9212-62b6b9a50789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b8cc5bda-2c45-4624-9212-62b6b9a50789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6ad42109-8829-4268-8993-d14351ed3c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6ad42109-8829-4268-8993-d14351ed3c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e8d218cc-f79b-42f5-a42d-3ad0e5c49083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e8d218cc-f79b-42f5-a42d-3ad0e5c49083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_392331ec-8f46-4718-8d11-2a4eb1526989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_392331ec-8f46-4718-8d11-2a4eb1526989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_8a2f4731-54d8-48a4-973b-2eed8acdb1a4" xlink:href="ameh-20210630.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_8a2f4731-54d8-48a4-973b-2eed8acdb1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30f3a737-7111-4fa3-a3ca-8ae5fafe7c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00691125-adae-4759-9bd6-5a24fc951283" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_30f3a737-7111-4fa3-a3ca-8ae5fafe7c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_41bd475e-99a5-49e1-8bd1-9ff03cbbcc64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_f6fe16bc-1113-4fe8-9e3e-a54be5c3f9f9" xlink:href="ameh-20210630.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_41bd475e-99a5-49e1-8bd1-9ff03cbbcc64" xlink:to="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_f6fe16bc-1113-4fe8-9e3e-a54be5c3f9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e5c846a3-ddc2-42c9-975f-432e4c281c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_148d8be4-ba25-4298-a9fe-10eb6edfe20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e5c846a3-ddc2-42c9-975f-432e4c281c7a" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_148d8be4-ba25-4298-a9fe-10eb6edfe20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_77c24f27-b626-44f4-a213-8958227b1498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f4b5c65f-1488-4760-a3cf-512755d64b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_77c24f27-b626-44f4-a213-8958227b1498" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f4b5c65f-1488-4760-a3cf-512755d64b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_60585b81-9323-43f1-a925-b387cd31e422" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f4b5c65f-1488-4760-a3cf-512755d64b65" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_60585b81-9323-43f1-a925-b387cd31e422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_60585b81-9323-43f1-a925-b387cd31e422" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_571cf82c-e65b-424f-af6d-0cbbbcf08cff" xlink:href="ameh-20210630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_571cf82c-e65b-424f-af6d-0cbbbcf08cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9e6f2bf7-cdc6-4797-988b-700e56d007e9" xlink:href="ameh-20210630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9e6f2bf7-cdc6-4797-988b-700e56d007e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_16d4b19a-f1f4-4339-b8f8-d9d89c57c4fa" xlink:href="ameh-20210630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_16d4b19a-f1f4-4339-b8f8-d9d89c57c4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_8c864103-9b2b-4df2-ad5b-664167403c29" xlink:href="ameh-20210630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_8c864103-9b2b-4df2-ad5b-664167403c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_34f2160a-1223-40e3-a2db-988b539a0d66" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_OneMSOLLCMember_34f2160a-1223-40e3-a2db-988b539a0d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_478b901a-320d-4ba7-b030-18f69acb7625" xlink:href="ameh-20210630.xsd#ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember_478b901a-320d-4ba7-b030-18f69acb7625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_8b9c55bf-467e-49ac-ac81-5e40098d4e25" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_7e066fa6-f69f-465e-a22a-0d44c51de215" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember_8b9c55bf-467e-49ac-ac81-5e40098d4e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1c24c0bf-0643-4543-9406-2d2d6e341129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f4b5c65f-1488-4760-a3cf-512755d64b65" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1c24c0bf-0643-4543-9406-2d2d6e341129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1c24c0bf-0643-4543-9406-2d2d6e341129" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_6ebf6faa-72ee-49ed-ab19-73c8249b67a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_us-gaap_EquityMethodInvestments_6ebf6faa-72ee-49ed-ab19-73c8249b67a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_27a7e6a4-9df0-42d4-880a-57fa6065aa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_27a7e6a4-9df0-42d4-880a-57fa6065aa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_35b198f7-f3f3-4f89-b469-14752774ff25" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_35b198f7-f3f3-4f89-b469-14752774ff25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated_f13c418a-6c38-4a16-9e55-7f2b2d27429c" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_ameh_EquityMethodInvestmentsConsolidated_f13c418a-6c38-4a16-9e55-7f2b2d27429c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2738d2cd-47a5-4397-8ebd-9a3df8ef1076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_dbca0fb4-831d-4e15-81f5-7ac8567444d7" xlink:to="loc_us-gaap_EquityMethodInvestments_2738d2cd-47a5-4397-8ebd-9a3df8ef1076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d4a618c2-6a51-430e-8363-a3be92a9e75a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_d4a618c2-6a51-430e-8363-a3be92a9e75a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bddf5e4-4bab-4ce8-893b-c96b0460dd17" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bddf5e4-4bab-4ce8-893b-c96b0460dd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0bddf5e4-4bab-4ce8-893b-c96b0460dd17" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_e03dfad8-8472-4e7b-b180-d1fc681b4cb3" xlink:href="ameh-20210630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_e03dfad8-8472-4e7b-b180-d1fc681b4cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_c4cdb2e4-4bbd-4570-a751-61fc8187ec09" xlink:href="ameh-20210630.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_c4cdb2e4-4bbd-4570-a751-61fc8187ec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_51037b22-c864-42c9-9c54-5bd5b38c74c0" xlink:href="ameh-20210630.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_51037b22-c864-42c9-9c54-5bd5b38c74c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_0a7831fa-78e9-4950-b29b-a2971f51108a" xlink:href="ameh-20210630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_0a7831fa-78e9-4950-b29b-a2971f51108a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_188b8fe0-e9ac-40a6-8a8a-43b2c807c1b9" xlink:href="ameh-20210630.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_OneMSOLLCMember_188b8fe0-e9ac-40a6-8a8a-43b2c807c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e4fccc2c-3010-4c86-92f3-15f03c4d6f1c" xlink:href="ameh-20210630.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_e4fccc2c-3010-4c86-92f3-15f03c4d6f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_9c82d8b8-c9ff-4085-b787-3d2109a636d1" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e04e4b10-2efb-42cb-ba2e-def2bf09b478" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_9c82d8b8-c9ff-4085-b787-3d2109a636d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_fd88bfd3-7907-4944-b932-71ab3b738f0c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_dei_LegalEntityAxis_fd88bfd3-7907-4944-b932-71ab3b738f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_fd88bfd3-7907-4944-b932-71ab3b738f0c" xlink:to="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:href="ameh-20210630.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:to="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_8bde67a2-334c-41ae-86a0-9cd503a15d7e" xlink:href="ameh-20210630.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:to="loc_ameh_ApcLsmaMember_8bde67a2-334c-41ae-86a0-9cd503a15d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_18277533-112f-4565-b5a9-9d312c41d933" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_APCAndAPCLSMAMember_6e82b407-2359-4541-a564-187595b20f40" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_18277533-112f-4565-b5a9-9d312c41d933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_002782e8-541c-434e-a593-58a836fd0509" xlink:href="ameh-20210630.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_002782e8-541c-434e-a593-58a836fd0509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_2f28eb50-a98f-4d99-b6d9-a3c95b6dffa3" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_734bab0f-6118-4560-afef-5b3d76642691" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_2f28eb50-a98f-4d99-b6d9-a3c95b6dffa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_bde0269e-0fdc-4e91-b907-64a66633d843" xlink:href="ameh-20210630.xsd#ameh_ContractTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_ameh_ContractTypeAxis_bde0269e-0fdc-4e91-b907-64a66633d843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_040e8886-4e4a-41fc-b043-e91c497e332d" xlink:href="ameh-20210630.xsd#ameh_ContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeAxis_bde0269e-0fdc-4e91-b907-64a66633d843" xlink:to="loc_ameh_ContractTypeDomain_040e8886-4e4a-41fc-b043-e91c497e332d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_250f8369-4f33-4885-acf0-71079a6aca3e" xlink:href="ameh-20210630.xsd#ameh_AncillaryServiceContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeDomain_040e8886-4e4a-41fc-b043-e91c497e332d" xlink:to="loc_ameh_AncillaryServiceContractMember_250f8369-4f33-4885-acf0-71079a6aca3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2649bd54-94fa-4b52-87bd-ae82cf13a899" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_srt_CounterpartyNameAxis_2649bd54-94fa-4b52-87bd-ae82cf13a899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5f37fc7-81ca-406b-86a9-689f4d53577e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2649bd54-94fa-4b52-87bd-ae82cf13a899" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5f37fc7-81ca-406b-86a9-689f4d53577e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a6bef693-5235-436d-9f0e-f11a7a3b623f" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5f37fc7-81ca-406b-86a9-689f4d53577e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a6bef693-5235-436d-9f0e-f11a7a3b623f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6e518845-9c32-4aeb-b0bc-99d56c4eaa84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_srt_OwnershipAxis_6e518845-9c32-4aeb-b0bc-99d56c4eaa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6e518845-9c32-4aeb-b0bc-99d56c4eaa84" xlink:to="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_e7d68971-6a0c-4c6e-bdf9-3ea9503ec79b" xlink:href="ameh-20210630.xsd#ameh_MediPortalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:to="loc_ameh_MediPortalLLCMember_e7d68971-6a0c-4c6e-bdf9-3ea9503ec79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_fc55a5ff-7f17-44b9-837e-b4ee7cdde4c3" xlink:href="ameh-20210630.xsd#ameh_AchievaMedInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_15af0f01-b12a-44cc-a5dc-1b856603b6fe" xlink:to="loc_ameh_AchievaMedInc.Member_fc55a5ff-7f17-44b9-837e-b4ee7cdde4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7de56c11-b589-4f93-b0b6-2f086c887344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7de56c11-b589-4f93-b0b6-2f086c887344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_262dcb1d-293f-4e69-914a-c614ffe0bdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7de56c11-b589-4f93-b0b6-2f086c887344" xlink:to="loc_us-gaap_ReceivableTypeDomain_262dcb1d-293f-4e69-914a-c614ffe0bdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_60a7bbdc-73f5-4385-a6c3-0bbd378c5acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_262dcb1d-293f-4e69-914a-c614ffe0bdd9" xlink:to="loc_us-gaap_NotesReceivableMember_60a7bbdc-73f5-4385-a6c3-0bbd378c5acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64bd769e-42c0-423b-b1bc-788c165bd2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64bd769e-42c0-423b-b1bc-788c165bd2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0b7a572b-5773-469b-b14e-84333e4b98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_64bd769e-42c0-423b-b1bc-788c165bd2f9" xlink:to="loc_us-gaap_RelatedPartyDomain_0b7a572b-5773-469b-b14e-84333e4b98b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_c19338f7-e693-46c3-81b2-59152a4b2ed6" xlink:href="ameh-20210630.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0b7a572b-5773-469b-b14e-84333e4b98b7" xlink:to="loc_ameh_Dr.ArteagaMember_c19338f7-e693-46c3-81b2-59152a4b2ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1b5f34ac-947b-414c-9961-0725116843e5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_c82fc379-a9e2-4d91-8cc3-c412d4f74542" xlink:href="ameh-20210630.xsd#ameh_NumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_NumberOfEmployees_c82fc379-a9e2-4d91-8cc3-c412d4f74542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_87e0da4f-2eac-4548-8bcc-62d7202f9eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_87e0da4f-2eac-4548-8bcc-62d7202f9eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d0b8aefe-4ec0-4443-a809-8ffc66c4a6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_d0b8aefe-4ec0-4443-a809-8ffc66c4a6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_8d434e58-7847-4f10-a43c-846e2ee8fbca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_NotesReceivableNet_8d434e58-7847-4f10-a43c-846e2ee8fbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_eff0605d-3b60-4571-955c-68c4de40fcde" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_eff0605d-3b60-4571-955c-68c4de40fcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b754c6a9-64f7-4f71-b512-c3b03a7e85e2" xlink:href="ameh-20210630.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b754c6a9-64f7-4f71-b512-c3b03a7e85e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_caeabafa-e35f-4320-b4d0-c2a7843dec03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_caeabafa-e35f-4320-b4d0-c2a7843dec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a9ee28f0-716d-4b16-a18c-7e53da761016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_EquityMethodInvestments_a9ee28f0-716d-4b16-a18c-7e53da761016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_245b4fef-b980-4981-9fa4-3640938835fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_PaymentsForFees_245b4fef-b980-4981-9fa4-3640938835fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_3e920a79-4247-4600-9982-41f6e1526a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_MembersCapital_3e920a79-4247-4600-9982-41f6e1526a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_9e787972-9586-4932-a5ee-27f00726f3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_9e787972-9586-4932-a5ee-27f00726f3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_8c2a36ca-20c0-4869-812a-2a759987fb63" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_8c2a36ca-20c0-4869-812a-2a759987fb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a6ca9396-188b-4a54-8526-550edd6624c2" xlink:href="ameh-20210630.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_a6ca9396-188b-4a54-8526-550edd6624c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_508939c8-65d1-4253-96fb-962f65f2c8ad" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_508939c8-65d1-4253-96fb-962f65f2c8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0ca4213f-49ba-421f-b11f-cac8fa42937f" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_0ca4213f-49ba-421f-b11f-cac8fa42937f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_30cecdf1-67ac-40c4-8d73-78ec3e093dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_30cecdf1-67ac-40c4-8d73-78ec3e093dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c5dc3b40-0557-4c1f-b799-d6e449d4170c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c5dc3b40-0557-4c1f-b799-d6e449d4170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_da74bdc7-7ef5-4e8a-a898-15a30ac1e23a" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_da74bdc7-7ef5-4e8a-a898-15a30ac1e23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_84cbbf66-927c-4d0c-b78d-7d3d1d73b6ac" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_84cbbf66-927c-4d0c-b78d-7d3d1d73b6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_00cec657-6021-4d15-bd6a-39689f95c456" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_00cec657-6021-4d15-bd6a-39689f95c456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_e4ddc36a-8a28-460d-8ed5-541ea50c4ec8" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_e4ddc36a-8a28-460d-8ed5-541ea50c4ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_c3aea224-228f-40d3-801b-b2999a277835" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_c3aea224-228f-40d3-801b-b2999a277835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c030868a-e1f6-4014-bc16-641dce1ddd3d" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c030868a-e1f6-4014-bc16-641dce1ddd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_aef5f700-4672-44b9-8a5e-cc2495ed716a" xlink:href="ameh-20210630.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a6cf6876-f43c-4529-8ecc-0e23c3f70f4b" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_aef5f700-4672-44b9-8a5e-cc2495ed716a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cd106118-599e-465c-8a54-65a779471e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_698a14d0-ec90-4e6a-89f7-618e1fa70a97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cd106118-599e-465c-8a54-65a779471e68" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_698a14d0-ec90-4e6a-89f7-618e1fa70a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d02c06a0-e697-42e5-b33b-0a263901d3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_698a14d0-ec90-4e6a-89f7-618e1fa70a97" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d02c06a0-e697-42e5-b33b-0a263901d3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_d02c06a0-e697-42e5-b33b-0a263901d3cf" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_51de91a6-222c-4cd1-8015-a5758fdd7fcf" xlink:href="ameh-20210630.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_51de91a6-222c-4cd1-8015-a5758fdd7fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_3842c655-66cf-4187-9583-9552e22cc267" xlink:href="ameh-20210630.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_dc7b702c-6646-4a2a-8d6f-4aae943c7cc3" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_3842c655-66cf-4187-9583-9552e22cc267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_698a14d0-ec90-4e6a-89f7-618e1fa70a97" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:to="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72c0c02e-0a2e-4222-937d-4aa6f1f31f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_72c0c02e-0a2e-4222-937d-4aa6f1f31f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_29521598-339f-4d45-9901-f6a752adea26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_RestrictedCashCurrent_29521598-339f-4d45-9901-f6a752adea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d410c962-fcdb-438c-a9cd-381d817d79d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d410c962-fcdb-438c-a9cd-381d817d79d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_69cd6762-ce4e-4b88-8952-f2de17d0281b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_OtherAssetsCurrent_69cd6762-ce4e-4b88-8952-f2de17d0281b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_90e4e4c8-cfea-4889-bb7c-b273cc03c3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_OtherAssets_90e4e4c8-cfea-4889-bb7c-b273cc03c3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9b3ccd2c-6fa5-4fbc-92e6-e420f8f09e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_9b3ccd2c-6fa5-4fbc-92e6-e420f8f09e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_01548393-5de3-4af3-b143-e3cb3d98428f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_01548393-5de3-4af3-b143-e3cb3d98428f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_75ea16d0-05a5-4c40-9908-1fb5819e9067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_22dc4862-c5cb-416e-9e8f-4319024cdc4a" xlink:to="loc_us-gaap_Assets_75ea16d0-05a5-4c40-9908-1fb5819e9067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dcd5ec97-17ab-4c8a-af31-99b54d14a674" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:to="loc_us-gaap_LiabilitiesCurrent_dcd5ec97-17ab-4c8a-af31-99b54d14a674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8d1391c-7555-4ba2-ae25-eb7a4c60b292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8d1391c-7555-4ba2-ae25-eb7a4c60b292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b1a2bffd-0eba-42f2-807c-5988b80766e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dec662-220e-4909-b04e-10ddef9db181" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b1a2bffd-0eba-42f2-807c-5988b80766e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_87bf5bac-d0f5-49a6-98a7-1124212e5960" xlink:to="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6941ba0f-bd7a-4d6b-8a3d-c98eb36be287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6941ba0f-bd7a-4d6b-8a3d-c98eb36be287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2c7e5e3a-234a-41e5-9297-3d43dceee98f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_CostsAndExpenses_2c7e5e3a-234a-41e5-9297-3d43dceee98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_627b5d69-ca6a-4dd2-a25f-b9051e3e44e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_OperatingIncomeLoss_627b5d69-ca6a-4dd2-a25f-b9051e3e44e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f70eb5ea-3a63-4ca6-bf66-a4ec05d9b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f70eb5ea-3a63-4ca6-bf66-a4ec05d9b2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ae292c0-1a5e-4dbc-90eb-40528c409427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ae292c0-1a5e-4dbc-90eb-40528c409427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_58cbc499-1ee4-47ed-ae84-89c4694e9ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_22aa568a-8044-413f-8361-1545e49ad9e0" xlink:to="loc_us-gaap_ProfitLoss_58cbc499-1ee4-47ed-ae84-89c4694e9ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20210630.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_637fd9a5-ff0b-4531-9cfa-9c0bb1b2c071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock_1b7d6af9-95ec-481e-8128-e6e33d3bd74c" xlink:href="ameh-20210630.xsd#ameh_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_637fd9a5-ff0b-4531-9cfa-9c0bb1b2c071" xlink:to="loc_ameh_LoanReceivableTextBlock_1b7d6af9-95ec-481e-8128-e6e33d3bd74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_ce18c163-3f8c-4a56-ada1-3a46327c86b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_ce18c163-3f8c-4a56-ada1-3a46327c86b4" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_3c1d32cf-e538-4e7c-a7e0-fbc06aca8f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_8cfc8723-8bb7-46bf-a8dc-f1d84621ede1" xlink:to="loc_us-gaap_ReceivableTypeDomain_3c1d32cf-e538-4e7c-a7e0-fbc06aca8f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_dda460f2-e31a-4eaf-a3d4-48fe2e8f9b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_3c1d32cf-e538-4e7c-a7e0-fbc06aca8f38" xlink:to="loc_us-gaap_NotesReceivableMember_dda460f2-e31a-4eaf-a3d4-48fe2e8f9b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4451924b-61c4-4809-a7d4-2faf60db5d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4451924b-61c4-4809-a7d4-2faf60db5d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4451924b-61c4-4809-a7d4-2faf60db5d93" xlink:to="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_560038ca-90a9-4b96-ac6a-fcee8e950fe8" xlink:href="ameh-20210630.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:to="loc_ameh_Pacific6EnterprisesMember_560038ca-90a9-4b96-ac6a-fcee8e950fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_a0450cd5-b235-4542-b3de-612ef53ed419" xlink:href="ameh-20210630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_bfbacf5e-dd79-4624-8f7e-221d30423c22" xlink:to="loc_ameh_AHMCMember_a0450cd5-b235-4542-b3de-612ef53ed419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_85f63b16-babd-4176-b542-b319c12a14ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:to="loc_dei_LegalEntityAxis_85f63b16-babd-4176-b542-b319c12a14ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_85f63b16-babd-4176-b542-b319c12a14ae" xlink:to="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_e5360072-0dc4-4e5b-bdaf-b877e91bbd25" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:to="loc_ameh_NetworkMedicalManagementMember_e5360072-0dc4-4e5b-bdaf-b877e91bbd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_be9ae247-3b7d-47b6-b682-2bb8537e431f" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4391ec13-8ed5-4008-b53d-25332885f99f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_be9ae247-3b7d-47b6-b682-2bb8537e431f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_6c1fa773-8469-4a05-803c-4bcf3133fe6a" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_393a0af0-23cb-49ba-9bcc-939791d85fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_us-gaap_NotesReceivableNet_393a0af0-23cb-49ba-9bcc-939791d85fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_670c2394-2924-4a83-ba39-29d591916c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_670c2394-2924-4a83-ba39-29d591916c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_2376dcc2-f81b-467a-ab87-696eb81aa1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_us-gaap_NotesReceivableGross_2376dcc2-f81b-467a-ab87-696eb81aa1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_535fa3fc-b2f6-4e5f-8e22-fa7179854fde" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_535fa3fc-b2f6-4e5f-8e22-fa7179854fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_53ac7930-91c9-40ba-a657-53cfa0d83085" xlink:href="ameh-20210630.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_665bd5c5-cc1a-426d-8558-5f14bda051b1" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_53ac7930-91c9-40ba-a657-53cfa0d83085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20210630.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_92bf7ef1-250a-46a7-b383-7bf364c21b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6aba34dd-decc-445b-9461-3da41676f76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_92bf7ef1-250a-46a7-b383-7bf364c21b84" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6aba34dd-decc-445b-9461-3da41676f76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f107f0ab-b086-4fa0-bf0e-df021c63edf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4eb0eb6e-b15f-4b5b-9ac7-f0944a9b53e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f107f0ab-b086-4fa0-bf0e-df021c63edf2" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4eb0eb6e-b15f-4b5b-9ac7-f0944a9b53e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c616b375-cfa2-4008-9df4-8ff697e0b943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_us-gaap_AccountsPayableCurrent_c616b375-cfa2-4008-9df4-8ff697e0b943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_9d564e0b-993c-46ae-8600-543229dcf474" xlink:href="ameh-20210630.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_9d564e0b-993c-46ae-8600-543229dcf474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_47689a57-260a-4f67-98a3-33273c19a231" xlink:href="ameh-20210630.xsd#ameh_SubcontractorIPAPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_ameh_SubcontractorIPAPayable_47689a57-260a-4f67-98a3-33273c19a231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_abaddc02-f631-40a8-ade3-6a49512dfa52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_abaddc02-f631-40a8-ade3-6a49512dfa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_974e40b9-2df7-43bf-b4a0-16d731183995" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_974e40b9-2df7-43bf-b4a0-16d731183995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fe4331c3-ec4e-4295-be9a-226466ca8560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fe4331c3-ec4e-4295-be9a-226466ca8560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5463287d-2e75-459b-a444-cc85531b9cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5463287d-2e75-459b-a444-cc85531b9cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f42f6343-4d26-45ad-81d0-08136c172a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a8542bca-6c65-4084-a348-6d5a829cf065" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_f42f6343-4d26-45ad-81d0-08136c172a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20210630.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1b4bd8d8-40c3-4cb1-ab46-caece23cf79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_2e9963dd-9e81-4cb2-aaea-8901c676ba55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_1b4bd8d8-40c3-4cb1-ab46-caece23cf79f" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_2e9963dd-9e81-4cb2-aaea-8901c676ba55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_650d003e-4d88-4367-8283-9c6c217102bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_40b3464d-3922-445b-9244-7930a44e6b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_650d003e-4d88-4367-8283-9c6c217102bc" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_40b3464d-3922-445b-9244-7930a44e6b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_4c732663-9aaa-4ab4-b217-f51ff35526cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_32cc9fc0-0c1a-420f-afba-2b3ff4083d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_4c732663-9aaa-4ab4-b217-f51ff35526cf" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_32cc9fc0-0c1a-420f-afba-2b3ff4083d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5de20a61-1ba1-4244-83cb-cb47b566c2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_32cc9fc0-0c1a-420f-afba-2b3ff4083d76" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5de20a61-1ba1-4244-83cb-cb47b566c2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract_65024bbc-0c2e-4fbb-8222-79792f7b38c2" xlink:href="ameh-20210630.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_32cc9fc0-0c1a-420f-afba-2b3ff4083d76" xlink:to="loc_ameh_MedicalCareCostsAbstract_65024bbc-0c2e-4fbb-8222-79792f7b38c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_59a3dde7-0176-4992-ae34-ae16d2c0838c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_65024bbc-0c2e-4fbb-8222-79792f7b38c2" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_59a3dde7-0176-4992-ae34-ae16d2c0838c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ac6ae0c1-0612-41ef-8494-559f86a29609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_65024bbc-0c2e-4fbb-8222-79792f7b38c2" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ac6ae0c1-0612-41ef-8494-559f86a29609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_070cdc61-43c9-4693-bc94-00febc3bd9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_65024bbc-0c2e-4fbb-8222-79792f7b38c2" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_070cdc61-43c9-4693-bc94-00febc3bd9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract_deb52f37-d7e0-45c4-bbc3-46001995f7a8" xlink:href="ameh-20210630.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_32cc9fc0-0c1a-420f-afba-2b3ff4083d76" xlink:to="loc_ameh_PaymentsForMedicalCareCostsAbstract_deb52f37-d7e0-45c4-bbc3-46001995f7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_71b6e1a7-ca4d-4d7b-ac14-c18ca543ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_deb52f37-d7e0-45c4-bbc3-46001995f7a8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_71b6e1a7-ca4d-4d7b-ac14-c18ca543ed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_c3c6af98-fdaa-4fa1-8da1-57ff61605f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_deb52f37-d7e0-45c4-bbc3-46001995f7a8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_c3c6af98-fdaa-4fa1-8da1-57ff61605f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_037b8f9d-2d91-4df5-b60d-db952fa52f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_deb52f37-d7e0-45c4-bbc3-46001995f7a8" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_037b8f9d-2d91-4df5-b60d-db952fa52f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_3dba92f5-c693-4f24-b348-43416418a501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_32cc9fc0-0c1a-420f-afba-2b3ff4083d76" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_3dba92f5-c693-4f24-b348-43416418a501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2d8538d4-453c-4e46-8dcc-8665df2e6751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_32cc9fc0-0c1a-420f-afba-2b3ff4083d76" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2d8538d4-453c-4e46-8dcc-8665df2e6751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e720938f-b59a-4e8b-b251-2474b60c6b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_32e5b3b4-5747-41b9-a94c-b32837342fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e720938f-b59a-4e8b-b251-2474b60c6b0a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_32e5b3b4-5747-41b9-a94c-b32837342fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3ff33335-70f2-4bac-835d-cb14385a4c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_6a8ac446-9663-4888-ab6c-1ad282372ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3ff33335-70f2-4bac-835d-cb14385a4c25" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_6a8ac446-9663-4888-ab6c-1ad282372ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ae8917ba-2067-4d7e-92bf-02acda577303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3ff33335-70f2-4bac-835d-cb14385a4c25" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ae8917ba-2067-4d7e-92bf-02acda577303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_938a0a31-33e8-432a-9716-aa13c13faaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_938a0a31-33e8-432a-9716-aa13c13faaec" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4026c8e5-72e2-463c-95a1-ca872c29d018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:to="loc_us-gaap_CreditFacilityAxis_4026c8e5-72e2-463c-95a1-ca872c29d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4026c8e5-72e2-463c-95a1-ca872c29d018" xlink:to="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_7fa00106-7ddf-4fa0-b76b-34b6bc5aec78" xlink:href="ameh-20210630.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:to="loc_ameh_TermLoanAMember_7fa00106-7ddf-4fa0-b76b-34b6bc5aec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f351fc0f-19f0-4eb7-b211-61ea781a9789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_76ed75f6-f4dd-448a-a186-b9fa902592ba" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f351fc0f-19f0-4eb7-b211-61ea781a9789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_b839ba5d-7611-47eb-97d7-e5db21b62582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_b839ba5d-7611-47eb-97d7-e5db21b62582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_b839ba5d-7611-47eb-97d7-e5db21b62582" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_3389df10-e0e7-461a-af6c-5d270411ccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:to="loc_us-gaap_RealEstateLoanMember_3389df10-e0e7-461a-af6c-5d270411ccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_6a4b9049-fefd-4e2d-a26e-49beb8c647f7" xlink:href="ameh-20210630.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0e02f48f-09ae-4184-bec3-362439b65f5f" xlink:to="loc_ameh_ConstructionLoanMember_6a4b9049-fefd-4e2d-a26e-49beb8c647f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_f758fbf3-f63f-4925-b50e-a5b3f594f078" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0284b8cb-880c-43e2-b627-fc7e213c3fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0284b8cb-880c-43e2-b627-fc7e213c3fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a84a88f1-b524-4b8c-a410-e151f0e7c790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_LongTermDebtCurrent_a84a88f1-b524-4b8c-a410-e151f0e7c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_185fd45f-4007-4d98-b823-707098fb4873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_185fd45f-4007-4d98-b823-707098fb4873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cb0a7ba3-bbd1-4ba7-8831-f158d1d84320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_005dc880-3dfa-4ca8-81a3-1a66e982eaa2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cb0a7ba3-bbd1-4ba7-8831-f158d1d84320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cd720783-cbf5-45b6-81e0-af525384f002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_135b83d6-ab58-4077-93b6-afcd6cd0f1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd720783-cbf5-45b6-81e0-af525384f002" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_135b83d6-ab58-4077-93b6-afcd6cd0f1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fec67bbc-c7d3-48f3-b02a-daf171364490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd720783-cbf5-45b6-81e0-af525384f002" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_fec67bbc-c7d3-48f3-b02a-daf171364490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_58d9dade-3dc7-40e1-9ce4-3e9d0d0b9b81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd720783-cbf5-45b6-81e0-af525384f002" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_58d9dade-3dc7-40e1-9ce4-3e9d0d0b9b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d0ea97bd-e80a-4c81-b345-4b23d0d0fb94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd720783-cbf5-45b6-81e0-af525384f002" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d0ea97bd-e80a-4c81-b345-4b23d0d0fb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f97bfb5e-b24e-4123-9919-ab1a16069525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd720783-cbf5-45b6-81e0-af525384f002" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f97bfb5e-b24e-4123-9919-ab1a16069525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_485dee51-2fa6-4eb8-aed1-ab18c80fca94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd720783-cbf5-45b6-81e0-af525384f002" xlink:to="loc_us-gaap_LineOfCredit_485dee51-2fa6-4eb8-aed1-ab18c80fca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_58544571-6141-4773-991e-d92f8c7b3ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_58544571-6141-4773-991e-d92f8c7b3ca8" xlink:to="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_dafd4486-d9e1-4f6d-a0b0-1a304738810c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_CreditFacilityAxis_dafd4486-d9e1-4f6d-a0b0-1a304738810c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_dafd4486-d9e1-4f6d-a0b0-1a304738810c" xlink:to="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_eb74adf6-1032-4d9d-ba28-0943b9b4029c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_eb74adf6-1032-4d9d-ba28-0943b9b4029c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_c6b5c69b-7d68-4f1a-b4de-11f2adfa3751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_LineOfCreditMember_c6b5c69b-7d68-4f1a-b4de-11f2adfa3751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_6e167616-8dd1-42e3-a8a2-83b5bc12d193" xlink:href="ameh-20210630.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_ameh_TermLoanAMember_6e167616-8dd1-42e3-a8a2-83b5bc12d193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c947c727-5072-400e-bc06-d4184b4ddb81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_LetterOfCreditMember_c947c727-5072-400e-bc06-d4184b4ddb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_b9280a53-36a0-4123-bf42-dbbfa8d15475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_BridgeLoanMember_b9280a53-36a0-4123-bf42-dbbfa8d15475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_a0f97de2-4594-47fc-b08f-f668208ad907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_40202153-1b3d-42d4-8ea8-e90347acc9be" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_a0f97de2-4594-47fc-b08f-f668208ad907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7b103882-3c01-4e7f-a21b-9a640c4015b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_DebtInstrumentAxis_7b103882-3c01-4e7f-a21b-9a640c4015b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7b103882-3c01-4e7f-a21b-9a640c4015b7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_20115f55-4037-439c-9c85-69c31edd6c24" xlink:href="ameh-20210630.xsd#ameh_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_CreditAgreementMember_20115f55-4037-439c-9c85-69c31edd6c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_de805744-b543-4bb9-8a9e-aaaa01ddb3cb" xlink:href="ameh-20210630.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_AmendedCreditAgreementMember_de805744-b543-4bb9-8a9e-aaaa01ddb3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_60c31d96-a4ac-4eb4-8746-1a111bc9ec66" xlink:href="ameh-20210630.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_60c31d96-a4ac-4eb4-8746-1a111bc9ec66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_63315cbb-3bc1-4db1-8b5f-50910795ad87" xlink:href="ameh-20210630.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3bcb29fd-c1d8-4582-9e2e-d2ecc9b41d98" xlink:to="loc_ameh_ConstructionLoanMember_63315cbb-3bc1-4db1-8b5f-50910795ad87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_4516e3d4-3fe1-44d4-9594-f3cb34e1207f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_4516e3d4-3fe1-44d4-9594-f3cb34e1207f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d2983820-a675-4aa1-a08d-35faa8844dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_4516e3d4-3fe1-44d4-9594-f3cb34e1207f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d2983820-a675-4aa1-a08d-35faa8844dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_340ad5fc-7666-4582-894a-ccd6ea6e5274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d2983820-a675-4aa1-a08d-35faa8844dc2" xlink:to="loc_us-gaap_LineOfCreditMember_340ad5fc-7666-4582-894a-ccd6ea6e5274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_49c907f5-f259-415b-9771-2fffd33428c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_srt_RangeAxis_49c907f5-f259-415b-9771-2fffd33428c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_49c907f5-f259-415b-9771-2fffd33428c6" xlink:to="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a13d12a7-1a3e-4632-8d80-4e34979a722c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:to="loc_srt_MinimumMember_a13d12a7-1a3e-4632-8d80-4e34979a722c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5522fd12-8b7d-465c-913c-2829208b225b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_442c95ce-5272-48e1-a981-ac0955a8c04c" xlink:to="loc_srt_MaximumMember_5522fd12-8b7d-465c-913c-2829208b225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d24788dc-687d-45db-9e3b-72e4be18e8f7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_dei_LegalEntityAxis_d24788dc-687d-45db-9e3b-72e4be18e8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d24788dc-687d-45db-9e3b-72e4be18e8f7" xlink:to="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_aba8fb86-56b6-43fa-8e0b-5ff7f1bc4185" xlink:href="ameh-20210630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_aba8fb86-56b6-43fa-8e0b-5ff7f1bc4185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_cdf84801-b996-42b6-8f6d-7435261cc69d" xlink:href="ameh-20210630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_AMGPropertiesLLCMember_cdf84801-b996-42b6-8f6d-7435261cc69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_7bccc65c-7826-4f17-a023-c8326f448c92" xlink:href="ameh-20210630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_ZLLPartnersLLCMember_7bccc65c-7826-4f17-a023-c8326f448c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_b106ed16-b0fc-4b61-9bea-9d69122f1d48" xlink:href="ameh-20210630.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_b106ed16-b0fc-4b61-9bea-9d69122f1d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ff9fa2f6-2cf2-4b3d-af25-afba09a9cf73" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ff9fa2f6-2cf2-4b3d-af25-afba09a9cf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_4def2ee2-1974-45f7-9a44-fe082f391989" xlink:href="ameh-20210630.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_ApaacoMember_4def2ee2-1974-45f7-9a44-fe082f391989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_9ba1d1b3-bc1e-40ec-992d-a4135cc3fa47" xlink:href="ameh-20210630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_754a8b6a-a5ef-4019-ae96-93ab4421bd00" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_9ba1d1b3-bc1e-40ec-992d-a4135cc3fa47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_VariableRateAxis_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c8c96f64-5009-4fbe-a4ff-74e6eefa6f1e" xlink:to="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b879e6cf-4e0e-4a48-99ab-c9db6a4746d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_b879e6cf-4e0e-4a48-99ab-c9db6a4746d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_c0aa7c7d-e457-49d9-83ee-3ab01fc97e24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_adb3df2a-a506-4e97-96c5-b933155b1fc9" xlink:to="loc_us-gaap_PrimeRateMember_c0aa7c7d-e457-49d9-83ee-3ab01fc97e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_51a1e6e9-075d-4e38-9da4-3f484016cc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_647a6b7c-97f5-493a-ac5f-d4f6e9ac0aac" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_51a1e6e9-075d-4e38-9da4-3f484016cc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_03bbc9ab-a65d-45da-b4b2-346ae1a1589c" xlink:href="ameh-20210630.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_51a1e6e9-075d-4e38-9da4-3f484016cc14" xlink:to="loc_ameh_PreferredBankMember_03bbc9ab-a65d-45da-b4b2-346ae1a1589c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c6e630a3-be13-4d0c-8a60-bf127357b923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c6e630a3-be13-4d0c-8a60-bf127357b923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c6e630a3-be13-4d0c-8a60-bf127357b923" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_9b83516c-e94c-42b6-9018-58ce5ed93aca" xlink:href="ameh-20210630.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:to="loc_ameh_AMGPropertiesLLCMember_9b83516c-e94c-42b6-9018-58ce5ed93aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_d54e16ef-7830-4ce1-bd89-51adfe2f13f8" xlink:href="ameh-20210630.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_d54e16ef-7830-4ce1-bd89-51adfe2f13f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_0162f02d-e9ed-49d5-b68b-5310d775a73c" xlink:href="ameh-20210630.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_d8d42aef-6866-42e9-a7ce-d54e7a4ef081" xlink:to="loc_ameh_ZLLPartnersLLCMember_0162f02d-e9ed-49d5-b68b-5310d775a73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a8123f7c-8390-474e-8200-72821ce991d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_srt_StatementScenarioAxis_a8123f7c-8390-474e-8200-72821ce991d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_329763bd-0163-49e6-8448-a668286ad515" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a8123f7c-8390-474e-8200-72821ce991d6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_329763bd-0163-49e6-8448-a668286ad515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_b556d44e-ab2a-41c6-a402-4ff5f07d1974" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_329763bd-0163-49e6-8448-a668286ad515" xlink:to="loc_srt_ScenarioForecastMember_b556d44e-ab2a-41c6-a402-4ff5f07d1974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b73813d-a53f-4fee-91b3-68fbcfa51f8b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e04c846b-ca55-4c30-be29-c683c5e6cc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentTerm_e04c846b-ca55-4c30-be29-c683c5e6cc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23a3975f-bf46-4e22-a7a4-48d64e271867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_23a3975f-bf46-4e22-a7a4-48d64e271867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d07ebdb5-e095-4e0b-932c-0670fa3b6671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d07ebdb5-e095-4e0b-932c-0670fa3b6671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_64155ad9-08f3-4d50-b6da-60f5e6a6f9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_64155ad9-08f3-4d50-b6da-60f5e6a6f9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_6176bb37-9d8f-4cb6-9c16-3dd9ec3546de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_6176bb37-9d8f-4cb6-9c16-3dd9ec3546de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_72a68501-b592-426a-b4b7-a8bc3e8ab226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_72a68501-b592-426a-b4b7-a8bc3e8ab226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_022e93c4-d0ea-4724-9231-91132e6a1dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCredit_022e93c4-d0ea-4724-9231-91132e6a1dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_898bcc82-1839-49dd-8684-06cabb9ec5d6" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_898bcc82-1839-49dd-8684-06cabb9ec5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_624f3f43-802c-4e22-94e3-d14e49134207" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_624f3f43-802c-4e22-94e3-d14e49134207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1d20b7a4-c8a2-43f8-864b-f57ab22e1b1f" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_1d20b7a4-c8a2-43f8-864b-f57ab22e1b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_9eea0d44-34a9-4d63-91d4-47a938c39a64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_9eea0d44-34a9-4d63-91d4-47a938c39a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1bb55599-479d-4b3d-8f8b-b9077e31ba2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1bb55599-479d-4b3d-8f8b-b9077e31ba2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_b982bb0e-683a-4448-ad07-d106a7301784" xlink:href="ameh-20210630.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_b982bb0e-683a-4448-ad07-d106a7301784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a8d3c8a2-26c1-4967-9f69-62368fe8e7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a8d3c8a2-26c1-4967-9f69-62368fe8e7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_506b862e-2777-4154-a002-2a97c11f38c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LongTermDebt_506b862e-2777-4154-a002-2a97c11f38c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_061c3977-5536-4b4c-ae83-89eef5de3b6b" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_061c3977-5536-4b4c-ae83-89eef5de3b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_7f0a6831-cc8f-4f9c-9a80-b8d78e9ad4aa" xlink:href="ameh-20210630.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_7f0a6831-cc8f-4f9c-9a80-b8d78e9ad4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64901c71-a23e-4010-8c5f-fc67724728b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_64901c71-a23e-4010-8c5f-fc67724728b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f88b25fa-640c-4c38-aba3-52a61ae7335a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_InterestExpense_f88b25fa-640c-4c38-aba3-52a61ae7335a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_830be1cd-621d-467b-b671-d5933f8cc32c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_830be1cd-621d-467b-b671-d5933f8cc32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_d641bc07-369e-47a8-acc2-73cc410536af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_d641bc07-369e-47a8-acc2-73cc410536af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6452fd52-9874-48a7-b593-9bcb57605b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_74f3e995-e009-4ac9-a153-88b341961b6e" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6452fd52-9874-48a7-b593-9bcb57605b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20210630.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9030b377-dee9-4dd3-a073-5c0873f76ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8c167f03-951d-4d1c-bd38-3a064f30eb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9030b377-dee9-4dd3-a073-5c0873f76ebb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_8c167f03-951d-4d1c-bd38-3a064f30eb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a0ebcfa3-f7b7-4c51-b2f1-767b648e7c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a6ce8fd8-5e48-4588-a1aa-5ff3b41a1d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a0ebcfa3-f7b7-4c51-b2f1-767b648e7c5b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a6ce8fd8-5e48-4588-a1aa-5ff3b41a1d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ecb3fb90-364d-436d-a7f2-ea7314402964" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6ce8fd8-5e48-4588-a1aa-5ff3b41a1d55" xlink:to="loc_dei_LegalEntityAxis_ecb3fb90-364d-436d-a7f2-ea7314402964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ecb3fb90-364d-436d-a7f2-ea7314402964" xlink:to="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_42f251d2-cd36-448f-9fd2-f32a6300f43c" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_42f251d2-cd36-448f-9fd2-f32a6300f43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_74da0b39-4a88-46ac-adca-9f8a5590be43" xlink:href="ameh-20210630.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_36d647a7-d6b8-4a6d-8aaa-44ab11ac99b2" xlink:to="loc_ameh_CDSCMember_74da0b39-4a88-46ac-adca-9f8a5590be43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a6ce8fd8-5e48-4588-a1aa-5ff3b41a1d55" xlink:to="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_a53b108d-7676-4fda-ad11-5f625a0045af" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_a53b108d-7676-4fda-ad11-5f625a0045af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_70a179a9-04b5-4845-a2c4-1d377987db92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_us-gaap_TreasuryStockCommonShares_70a179a9-04b5-4845-a2c4-1d377987db92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_ed66df8d-b34d-4934-ab1c-f09718eb94e8" xlink:href="ameh-20210630.xsd#ameh_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesWarrantsExercised_ed66df8d-b34d-4934-ab1c-f09718eb94e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_143018bf-0ea3-4eda-ac14-97b345f944d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f7c28a43-0dbb-4ed2-9805-7ca88fda8889" xlink:to="loc_us-gaap_Dividends_143018bf-0ea3-4eda-ac14-97b345f944d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3fc04cae-ba31-43c2-8000-9331cfd69ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3dc866b6-4135-4bb7-b7cb-f9c7143ec49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3fc04cae-ba31-43c2-8000-9331cfd69ce0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3dc866b6-4135-4bb7-b7cb-f9c7143ec49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d94592c-e2e8-4adb-93e1-3992bf4360f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:href="ameh-20210630.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3d94592c-e2e8-4adb-93e1-3992bf4360f7" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_98ac9004-1745-4111-88a8-a6cb8575e7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_us-gaap_CreditFacilityAxis_98ac9004-1745-4111-88a8-a6cb8575e7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_876275f0-0df6-4e65-892e-da3448d9aa50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_98ac9004-1745-4111-88a8-a6cb8575e7f9" xlink:to="loc_us-gaap_CreditFacilityDomain_876275f0-0df6-4e65-892e-da3448d9aa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_dece6273-9f9e-46f8-8d2b-5678ba972a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_876275f0-0df6-4e65-892e-da3448d9aa50" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_dece6273-9f9e-46f8-8d2b-5678ba972a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9a570577-8b38-42ff-a475-5a63ce7c4f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9a570577-8b38-42ff-a475-5a63ce7c4f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b020937b-2826-4584-8278-a97ec9bb605f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_9a570577-8b38-42ff-a475-5a63ce7c4f4a" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b020937b-2826-4584-8278-a97ec9bb605f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_2153a2a9-75f9-4832-89bf-060f5f444bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b020937b-2826-4584-8278-a97ec9bb605f" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_2153a2a9-75f9-4832-89bf-060f5f444bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_dei_LegalEntityAxis_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_21ebf6de-3c26-4a94-ad9d-1aa2bb2b1cef" xlink:to="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_7cca2bd9-5bad-4d77-a9e8-0fecbc8500f5" xlink:href="ameh-20210630.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:to="loc_ameh_ApaacoMember_7cca2bd9-5bad-4d77-a9e8-0fecbc8500f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d636092d-8934-4a82-bde6-30193fdec50e" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_d636092d-8934-4a82-bde6-30193fdec50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_0299155c-b26a-40b4-9497-11ac568fef4b" xlink:href="ameh-20210630.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4ac2b41a-49c2-4b01-9d5b-02dea3982ec0" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_0299155c-b26a-40b4-9497-11ac568fef4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_26aee619-5a8d-499f-be62-1860ec2f7287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_26aee619-5a8d-499f-be62-1860ec2f7287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_bdc5da56-2470-4fd9-b77a-f1f44661b4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_26aee619-5a8d-499f-be62-1860ec2f7287" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_bdc5da56-2470-4fd9-b77a-f1f44661b4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_6dae130a-6a04-4e23-b766-bccd881852a6" xlink:href="ameh-20210630.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_bdc5da56-2470-4fd9-b77a-f1f44661b4cb" xlink:to="loc_ameh_PreferredBankMember_6dae130a-6a04-4e23-b766-bccd881852a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:href="ameh-20210630.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_e3e8cbc2-6bcd-49f9-aea5-a011b7197e66" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_069db0b4-f381-4cbc-9744-acd18f94a834" xlink:href="ameh-20210630.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_069db0b4-f381-4cbc-9744-acd18f94a834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3eea8f89-a147-424a-955c-03ecf40abeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3eea8f89-a147-424a-955c-03ecf40abeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_9e4ff3ff-68f4-49d1-aeee-c4302d3e9ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_us-gaap_LineOfCredit_9e4ff3ff-68f4-49d1-aeee-c4302d3e9ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_1f9531c8-bdbb-4cd3-8ef8-5c64a2c71cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_ba281bdd-8128-4350-b2ca-90787583b8c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_1f9531c8-bdbb-4cd3-8ef8-5c64a2c71cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20210630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_97b77c68-4fdb-4077-821f-db9c3ee15b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_800eaa97-fa4e-46b9-9c4c-9b72cc0f81b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_97b77c68-4fdb-4077-821f-db9c3ee15b32" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_800eaa97-fa4e-46b9-9c4c-9b72cc0f81b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_66c6912c-b172-4c2a-8d25-05985a3d8421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_7898b20c-63c6-4c02-b178-1e6607a63960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_66c6912c-b172-4c2a-8d25-05985a3d8421" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_7898b20c-63c6-4c02-b178-1e6607a63960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9bee66f4-ef75-4082-952d-634b6d9c2651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9bee66f4-ef75-4082-952d-634b6d9c2651" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f9719d71-e274-408f-a3bc-da128ed351c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f9719d71-e274-408f-a3bc-da128ed351c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f9719d71-e274-408f-a3bc-da128ed351c3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_3a11c93a-a430-4df7-b534-fe3edd1b02a5" xlink:href="ameh-20210630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_LmaMember_3a11c93a-a430-4df7-b534-fe3edd1b02a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_4f992db8-7a88-46de-8dfa-80a60b9ae9f0" xlink:href="ameh-20210630.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_PmiocMember_4f992db8-7a88-46de-8dfa-80a60b9ae9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_0518b331-79e0-4764-b8f3-0b962ad7d618" xlink:href="ameh-20210630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_DmgMember_0518b331-79e0-4764-b8f3-0b962ad7d618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_b693a0dd-bd1c-44d3-be0a-cfda1c0ad8bb" xlink:href="ameh-20210630.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_88ec989d-ef9d-40f0-8392-464f6cf187b7" xlink:to="loc_ameh_OneMSOInc.Member_b693a0dd-bd1c-44d3-be0a-cfda1c0ad8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5af33fac-472b-4c00-93bf-9a4cb7334474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5af33fac-472b-4c00-93bf-9a4cb7334474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5af33fac-472b-4c00-93bf-9a4cb7334474" xlink:to="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_58b674a2-49b2-42dc-b7f5-41c9c401a51f" xlink:href="ameh-20210630.xsd#ameh_ApcShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_ApcShareholdersMember_58b674a2-49b2-42dc-b7f5-41c9c401a51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_327121c6-f2b2-4b67-8efb-b30dd3c3668a" xlink:href="ameh-20210630.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_327121c6-f2b2-4b67-8efb-b30dd3c3668a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_a83d133c-75a3-4c14-a4d7-2f9fdb63f2ff" xlink:href="ameh-20210630.xsd#ameh_FreseniusMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_FreseniusMember_a83d133c-75a3-4c14-a4d7-2f9fdb63f2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_db2712bb-0992-4e21-8b01-8720cfbf761e" xlink:href="ameh-20210630.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_FulgentGeneticsIncMember_db2712bb-0992-4e21-8b01-8720cfbf761e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_be61d7fa-7668-47f8-a6a3-b160d7d895d8" xlink:href="ameh-20210630.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_ShareholdersAndOfficersMember_be61d7fa-7668-47f8-a6a3-b160d7d895d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_bd8c93ed-daac-4f6d-8374-95cc0d3ef0f8" xlink:href="ameh-20210630.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_bd8c93ed-daac-4f6d-8374-95cc0d3ef0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_f59eefab-2057-42ae-8f9b-b51b9dc0ecb3" xlink:href="ameh-20210630.xsd#ameh_NumenLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_NumenLLCMember_f59eefab-2057-42ae-8f9b-b51b9dc0ecb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_506c372f-fd30-4e64-808b-36381f43359e" xlink:href="ameh-20210630.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_OneMSOInc.Member_506c372f-fd30-4e64-808b-36381f43359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_4e0d71e0-ade3-4e15-8c58-47e71a6edd5f" xlink:href="ameh-20210630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7cb14a33-e3e7-4833-8121-138bd220a3ac" xlink:to="loc_ameh_AHMCMember_4e0d71e0-ade3-4e15-8c58-47e71a6edd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2cc374f3-4182-4393-a170-5812d0b0eeb7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_dei_LegalEntityAxis_2cc374f3-4182-4393-a170-5812d0b0eeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2cc374f3-4182-4393-a170-5812d0b0eeb7" xlink:to="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_9a0257fc-cba1-49ac-a7ad-ff6227963b9a" xlink:href="ameh-20210630.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_NetworkMedicalManagementMember_9a0257fc-cba1-49ac-a7ad-ff6227963b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8ce364f3-e83d-4aaf-8750-5792ae8bafe8" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_8ce364f3-e83d-4aaf-8750-5792ae8bafe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_129ffee0-03fb-428b-bd1b-f2ae2c8fe32a" xlink:href="ameh-20210630.xsd#ameh_ApaAcoIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_ApaAcoIncMember_129ffee0-03fb-428b-bd1b-f2ae2c8fe32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_86eb300a-28a1-4ff3-9446-f4c4d5b60fcd" xlink:href="ameh-20210630.xsd#ameh_SCHCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_091f6a52-cbab-449e-b232-2705f6aef324" xlink:to="loc_ameh_SCHCMember_86eb300a-28a1-4ff3-9446-f4c4d5b60fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_5033b7ee-c586-4432-a285-2d49491fe85b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_srt_ConsolidatedEntitiesAxis_5033b7ee-c586-4432-a285-2d49491fe85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_5033b7ee-c586-4432-a285-2d49491fe85b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_a2f88d4e-0c64-4946-a560-dc4d72c48b2c" xlink:href="ameh-20210630.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:to="loc_ameh_LmaMember_a2f88d4e-0c64-4946-a560-dc4d72c48b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_3c87385d-73ba-4d41-b7b6-75a4b9898a24" xlink:href="ameh-20210630.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:to="loc_ameh_PmiocMember_3c87385d-73ba-4d41-b7b6-75a4b9898a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_f1b7597a-2a28-41e4-9d49-cd931110083e" xlink:href="ameh-20210630.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8847eae8-e129-4c39-be67-19406e1f4dbf" xlink:to="loc_ameh_DmgMember_f1b7597a-2a28-41e4-9d49-cd931110083e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_5911ea87-cf34-47eb-9d5d-1233a5fee59f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_5911ea87-cf34-47eb-9d5d-1233a5fee59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14542d46-8090-4a60-9502-407a5fc949ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_5911ea87-cf34-47eb-9d5d-1233a5fee59f" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14542d46-8090-4a60-9502-407a5fc949ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_310644a6-7533-4a9f-8a65-47a236f10e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14542d46-8090-4a60-9502-407a5fc949ea" xlink:to="loc_us-gaap_ServiceMember_310644a6-7533-4a9f-8a65-47a236f10e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_99b6670c-0f79-4799-8b57-7f7028811d9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_srt_TitleOfIndividualAxis_99b6670c-0f79-4799-8b57-7f7028811d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08127068-232a-48a6-a80a-cb1c767c6ed7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_99b6670c-0f79-4799-8b57-7f7028811d9d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08127068-232a-48a6-a80a-cb1c767c6ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_9bf9e814-5667-4cc7-8b55-56804ae1e64e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_08127068-232a-48a6-a80a-cb1c767c6ed7" xlink:to="loc_srt_DirectorMember_9bf9e814-5667-4cc7-8b55-56804ae1e64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b04d6b82-f664-45ae-bd28-2f7e4deedf41" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_246e5094-450e-4c63-9516-f176524ae044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_RevenueFromRelatedParties_246e5094-450e-4c63-9516-f176524ae044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a87d3421-a947-4fb2-a5f7-054c1e9f8137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a87d3421-a947-4fb2-a5f7-054c1e9f8137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_c6a226e1-9106-46b6-90eb-6c29a6413488" xlink:href="ameh-20210630.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_ameh_PaymentMadeToRelatedParty_c6a226e1-9106-46b6-90eb-6c29a6413488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3ff578ab-8f98-4d9d-ab00-62316df7d167" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_3ff578ab-8f98-4d9d-ab00-62316df7d167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_4d4ae3c5-bb9c-44ce-8e74-712ba7484dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_4d4ae3c5-bb9c-44ce-8e74-712ba7484dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_e5d10b94-758a-4b8b-a67f-c16d569274f3" xlink:href="ameh-20210630.xsd#ameh_PaymentConsultingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_17206f14-672a-429d-b4bd-cb6bd7336cee" xlink:to="loc_ameh_PaymentConsultingFees_e5d10b94-758a-4b8b-a67f-c16d569274f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_5623765f-96e8-4e5e-bbd8-930f1c2dcf0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_981c93fc-74cf-4799-9e99-2a05c9dcab9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_5623765f-96e8-4e5e-bbd8-930f1c2dcf0a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_981c93fc-74cf-4799-9e99-2a05c9dcab9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_873c5539-cc3a-4591-a9a1-8b684e0ad8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_981c93fc-74cf-4799-9e99-2a05c9dcab9d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_873c5539-cc3a-4591-a9a1-8b684e0ad8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_873c5539-cc3a-4591-a9a1-8b684e0ad8c2" xlink:to="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_02944372-8b7c-4307-adb1-b154b2b3bce7" xlink:href="ameh-20210630.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:to="loc_ameh_AHMCMember_02944372-8b7c-4307-adb1-b154b2b3bce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_70ad737f-f2b2-4123-86b3-592c4647ad0a" xlink:href="ameh-20210630.xsd#ameh_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:to="loc_ameh_HSMSOMember_70ad737f-f2b2-4123-86b3-592c4647ad0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_75c0756b-ff7b-4164-aa72-5b38e35e070b" xlink:href="ameh-20210630.xsd#ameh_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1c5a2ed3-d7be-4d9d-9176-cfaf5609da83" xlink:to="loc_ameh_AurionMember_75c0756b-ff7b-4164-aa72-5b38e35e070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_981c93fc-74cf-4799-9e99-2a05c9dcab9d" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_7e1c0d35-822b-4575-a493-62bae79ee1e0" xlink:href="ameh-20210630.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_7e1c0d35-822b-4575-a493-62bae79ee1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_24b2bc53-0d15-44b6-a99e-7d7db44cadb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:to="loc_us-gaap_ManagementFeeExpense_24b2bc53-0d15-44b6-a99e-7d7db44cadb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_06a63e9f-6732-403c-883f-f535699d33e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_64ce6736-dfaf-49c6-a64b-d1eb83df7dbf" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_06a63e9f-6732-403c-883f-f535699d33e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20210630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9ae9cf9a-9c57-43d2-a8bc-13407baed64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c04ba866-4f76-406c-b9df-9157f0ed9948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9ae9cf9a-9c57-43d2-a8bc-13407baed64b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c04ba866-4f76-406c-b9df-9157f0ed9948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a186ca60-b5d3-4f75-aa4c-18661e011a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_080ed199-c2fe-443e-b49b-24f3c7e1ef68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a186ca60-b5d3-4f75-aa4c-18661e011a3d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_080ed199-c2fe-443e-b49b-24f3c7e1ef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cef6a4f4-3df0-4f20-ac64-d0307164f0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ae81e03e-9fa8-4975-8d0d-3c61c1241c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cef6a4f4-3df0-4f20-ac64-d0307164f0f8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ae81e03e-9fa8-4975-8d0d-3c61c1241c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9ebbe117-b94a-4ac3-a20b-016dd8db5d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4dd13817-c7b3-497e-8585-1cb4009fc9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9ebbe117-b94a-4ac3-a20b-016dd8db5d9d" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4dd13817-c7b3-497e-8585-1cb4009fc9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3c2ff56b-899f-465b-bf53-548be2c3ce8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9ebbe117-b94a-4ac3-a20b-016dd8db5d9d" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_3c2ff56b-899f-465b-bf53-548be2c3ce8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_97398ee2-3e0e-4f4f-ad3e-0f69d126baee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_f78ce5d8-cfea-4302-a929-78863c881fed" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_97398ee2-3e0e-4f4f-ad3e-0f69d126baee" xlink:to="loc_ameh_EarningsPerShareTable_f78ce5d8-cfea-4302-a929-78863c881fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_369adf7c-9f4c-436c-a94a-ab1945eed8b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_f78ce5d8-cfea-4302-a929-78863c881fed" xlink:to="loc_dei_LegalEntityAxis_369adf7c-9f4c-436c-a94a-ab1945eed8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1fff638d-2c5d-4794-ae84-f0db21e281c9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_369adf7c-9f4c-436c-a94a-ab1945eed8b5" xlink:to="loc_dei_EntityDomain_1fff638d-2c5d-4794-ae84-f0db21e281c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6d962039-3b39-433e-827f-93779b030251" xlink:href="ameh-20210630.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1fff638d-2c5d-4794-ae84-f0db21e281c9" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6d962039-3b39-433e-827f-93779b030251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_dd465c91-7a99-43d7-bc72-0f490b6c1a65" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_f78ce5d8-cfea-4302-a929-78863c881fed" xlink:to="loc_ameh_EarningsPerShareLineItems_dd465c91-7a99-43d7-bc72-0f490b6c1a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb53cc14-dfeb-4179-983a-9ca0869cad6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_dd465c91-7a99-43d7-bc72-0f490b6c1a65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_cb53cc14-dfeb-4179-983a-9ca0869cad6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fe9ad144-f684-480c-adad-7b836bdef9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_fff93e39-4d3e-49bd-a4f1-90987ced2fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fe9ad144-f684-480c-adad-7b836bdef9f5" xlink:to="loc_us-gaap_EarningsPerShareBasic_fff93e39-4d3e-49bd-a4f1-90987ced2fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b78114b2-9fa3-4103-9224-fecfafbb89b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fe9ad144-f684-480c-adad-7b836bdef9f5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b78114b2-9fa3-4103-9224-fecfafbb89b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2fa2a841-2d91-49d0-967f-34b1b78b74e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fe9ad144-f684-480c-adad-7b836bdef9f5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2fa2a841-2d91-49d0-967f-34b1b78b74e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39458658-0110-4939-9b4e-d5053a24ae4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fe9ad144-f684-480c-adad-7b836bdef9f5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_39458658-0110-4939-9b4e-d5053a24ae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b12574e8-53c0-4858-9504-5f34dc039e34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b12574e8-53c0-4858-9504-5f34dc039e34" xlink:to="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_24674026-6852-4aef-bc3f-7b66827bff75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_24674026-6852-4aef-bc3f-7b66827bff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b2078b7-2715-4371-a557-bd5b8980ab9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_24674026-6852-4aef-bc3f-7b66827bff75" xlink:to="loc_us-gaap_EquityComponentDomain_6b2078b7-2715-4371-a557-bd5b8980ab9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c049da1d-2a38-4d24-b6bf-3fce8af47040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6b2078b7-2715-4371-a557-bd5b8980ab9e" xlink:to="loc_us-gaap_WarrantMember_c049da1d-2a38-4d24-b6bf-3fce8af47040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b3978b7-57e6-4c6a-bc14-ad84790198e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b3978b7-57e6-4c6a-bc14-ad84790198e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b3978b7-57e6-4c6a-bc14-ad84790198e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_197a28a1-c915-4321-8c31-83eab6670756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:to="loc_us-gaap_EmployeeStockOptionMember_197a28a1-c915-4321-8c31-83eab6670756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_9b3c7d55-c496-4fab-a902-406ba11b19b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4bd468a4-e54e-48e4-8f4a-204d61740408" xlink:to="loc_us-gaap_RestrictedStockMember_9b3c7d55-c496-4fab-a902-406ba11b19b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:href="ameh-20210630.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_620b9db0-a2e1-4646-8776-2913877fb302" xlink:to="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cded29f9-ff57-4d11-8381-da8a43adc26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cded29f9-ff57-4d11-8381-da8a43adc26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8727a961-d274-41e5-8df3-452cd09818ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8727a961-d274-41e5-8df3-452cd09818ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33ea62f7-6889-428e-af8a-1d64f377c574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_c99c11dd-f4ed-45b8-8252-a7173a1a1a75" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_33ea62f7-6889-428e-af8a-1d64f377c574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20210630.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a8f952a-877d-4722-94a1-6dd4e1f1e0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_78c47a09-a4a5-4a8f-80bc-acabba2491c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a8f952a-877d-4722-94a1-6dd4e1f1e0be" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_78c47a09-a4a5-4a8f-80bc-acabba2491c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e3d5d00-af7d-45dc-99bc-843583defbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_c70f4805-a0fb-4ca3-a379-9f0ffd572092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8e3d5d00-af7d-45dc-99bc-843583defbba" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_c70f4805-a0fb-4ca3-a379-9f0ffd572092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb2dba3b-2adb-4161-a4d7-9dabdc0219d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c4fd71b9-2e80-4a12-8028-8b6a43b2e3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fb2dba3b-2adb-4161-a4d7-9dabdc0219d3" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c4fd71b9-2e80-4a12-8028-8b6a43b2e3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_47c44f0e-127b-4f57-887b-bbf848c0913a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c4fd71b9-2e80-4a12-8028-8b6a43b2e3ec" xlink:to="loc_srt_ConsolidatedEntitiesAxis_47c44f0e-127b-4f57-887b-bbf848c0913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_5270ff85-d000-4373-b494-d8a073df034f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_47c44f0e-127b-4f57-887b-bbf848c0913a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_5270ff85-d000-4373-b494-d8a073df034f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_cdecb675-8c00-4af5-a228-a07c57345946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_5270ff85-d000-4373-b494-d8a073df034f" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_cdecb675-8c00-4af5-a228-a07c57345946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_c4fd71b9-2e80-4a12-8028-8b6a43b2e3ec" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:to="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3a87010-1677-4538-a23e-452ca97254e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c3a87010-1677-4538-a23e-452ca97254e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_b0357787-c832-435c-9de7-9154a45ab807" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_b0357787-c832-435c-9de7-9154a45ab807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f08bc3c7-727d-4fdd-b6fc-04843be22b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f08bc3c7-727d-4fdd-b6fc-04843be22b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f2eb0d05-01cb-4676-b809-f21b230f1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_f2eb0d05-01cb-4676-b809-f21b230f1ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ed7d4b88-06c1-4ad6-b7eb-89e29413be18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ed7d4b88-06c1-4ad6-b7eb-89e29413be18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f6722efc-73f0-47e9-adef-fbeb53569d97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f6722efc-73f0-47e9-adef-fbeb53569d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_966052f3-329c-4693-95be-5a0ce086be99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_966052f3-329c-4693-95be-5a0ce086be99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliateCurrent_95155e20-aa34-4dbd-9756-8901b5033e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliateCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_DueFromAffiliateCurrent_95155e20-aa34-4dbd-9756-8901b5033e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_55b38eff-8137-4087-9947-63935ef06b62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_08c67d0c-86cf-44c8-b91d-300d8996ab36" xlink:to="loc_us-gaap_AssetsCurrent_55b38eff-8137-4087-9947-63935ef06b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e3c6dfd5-7e9c-4b2a-a2f0-a7772bacd91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e3c6dfd5-7e9c-4b2a-a2f0-a7772bacd91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2af5a5bd-7100-4331-ad50-705d329eaea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2af5a5bd-7100-4331-ad50-705d329eaea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5e7e814d-861d-4774-968c-0ef297260eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_Goodwill_5e7e814d-861d-4774-968c-0ef297260eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_eb773d4a-7334-4834-9f91-f09a7df85408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_eb773d4a-7334-4834-9f91-f09a7df85408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_4308a43d-0eaa-4f1d-811b-997b680d0d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_OtherLongTermInvestments_4308a43d-0eaa-4f1d-811b-997b680d0d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d1d6c188-4af6-433f-8cc6-82e4f91ba97d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_EquityMethodInvestments_d1d6c188-4af6-433f-8cc6-82e4f91ba97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_b04ac3c6-8700-4dc5-9ef5-356f8fb4a338" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_b04ac3c6-8700-4dc5-9ef5-356f8fb4a338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e83a5067-b2d2-42d6-ba24-92e288d01f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e83a5067-b2d2-42d6-ba24-92e288d01f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d54e2265-9904-4ee6-9744-5954898562b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d54e2265-9904-4ee6-9744-5954898562b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_42ff094a-3825-4de9-9559-fccadb2b19eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_42ff094a-3825-4de9-9559-fccadb2b19eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_7bb4f13b-775a-432b-aad2-b8d893d5d2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_5f03cbe1-18bb-4a84-b93a-61118bc6c762" xlink:to="loc_us-gaap_AssetsNoncurrent_7bb4f13b-775a-432b-aad2-b8d893d5d2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_35d80d8e-dfcb-4bb7-8d88-d46a465e1fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_67038dcd-1b85-45cd-8790-ea9a6673badc" xlink:to="loc_us-gaap_Assets_35d80d8e-dfcb-4bb7-8d88-d46a465e1fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21246058-90b7-404d-bbcb-70cddd4e5f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21246058-90b7-404d-bbcb-70cddd4e5f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_94fa1ac8-83b1-4a58-88ce-29122112eeb7" xlink:href="ameh-20210630.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_94fa1ac8-83b1-4a58-88ce-29122112eeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d099e8b9-6c09-44a1-b575-d6abad203078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d099e8b9-6c09-44a1-b575-d6abad203078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_c3a991c4-ff40-4135-b40b-916e5da022e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_TaxesPayableCurrent_c3a991c4-ff40-4135-b40b-916e5da022e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_b9415527-b55b-4ce2-ad00-7d51c283fd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_DividendsPayableCurrent_b9415527-b55b-4ce2-ad00-7d51c283fd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_60f8cfa3-6878-4d6a-9cba-7e9bb4d8d406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_DueToAffiliateCurrent_60f8cfa3-6878-4d6a-9cba-7e9bb4d8d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_19315c3d-9198-48d5-b7b5-075bf07ea6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_LongTermDebtCurrent_19315c3d-9198-48d5-b7b5-075bf07ea6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_a3912fe5-ab01-4a90-bc58-ae2e742a1c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_a3912fe5-ab01-4a90-bc58-ae2e742a1c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_74870cf8-83ae-499a-988f-92140ea88bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_74870cf8-83ae-499a-988f-92140ea88bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c20e25e9-746e-413a-8b20-a6761240c744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_53861db2-ca73-4a0d-a312-5f1b1b8d1015" xlink:to="loc_us-gaap_LiabilitiesCurrent_c20e25e9-746e-413a-8b20-a6761240c744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_577a64d4-424f-47e2-8683-c91b2582f3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_577a64d4-424f-47e2-8683-c91b2582f3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_03239b50-72e5-413b-a81a-da21745a288f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_03239b50-72e5-413b-a81a-da21745a288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8862171a-735d-4e97-b7ac-4add48eb0b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8862171a-735d-4e97-b7ac-4add48eb0b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e4dccef-7fb6-4602-aae9-05a01eb3bc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e4dccef-7fb6-4602-aae9-05a01eb3bc44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a291596d-3c6d-4762-85e0-627168577d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a291596d-3c6d-4762-85e0-627168577d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_6e83e688-a3f0-4b6a-b583-cba48e1b9db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_6b54eed5-f135-4641-bedc-dfc6c5f784e1" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_6e83e688-a3f0-4b6a-b583-cba48e1b9db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ff002940-eb26-4c91-b5b9-15bd176688fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_49566333-a4da-43ef-9d06-d0c5e3894978" xlink:to="loc_us-gaap_Liabilities_ff002940-eb26-4c91-b5b9-15bd176688fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20210630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2f9bab34-055c-49be-aaa6-c3d0728963ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_dea075d4-3d36-43a6-918b-40f0c9191c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f9bab34-055c-49be-aaa6-c3d0728963ed" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_dea075d4-3d36-43a6-918b-40f0c9191c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ea1d2485-875c-426f-861e-de7f7ba44de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2f9bab34-055c-49be-aaa6-c3d0728963ed" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ea1d2485-875c-426f-861e-de7f7ba44de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a66940c3-a500-475b-9ab1-09971971b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e2ab3e3a-58c7-4da6-920e-6c720e6ba510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a66940c3-a500-475b-9ab1-09971971b4b8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e2ab3e3a-58c7-4da6-920e-6c720e6ba510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8669045e-fa64-44aa-a031-5d5f53c75722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a66940c3-a500-475b-9ab1-09971971b4b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8669045e-fa64-44aa-a031-5d5f53c75722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_b97e2319-a1a4-4f48-8e64-24881ea455d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a66940c3-a500-475b-9ab1-09971971b4b8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_b97e2319-a1a4-4f48-8e64-24881ea455d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f45780bf-9216-4c58-a1c4-d60e643e11a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d09730a6-82a8-4092-a684-49205600f778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f45780bf-9216-4c58-a1c4-d60e643e11a2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d09730a6-82a8-4092-a684-49205600f778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7146b2e-0d55-4867-9b89-db15505ed158" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d09730a6-82a8-4092-a684-49205600f778" xlink:to="loc_srt_RangeAxis_d7146b2e-0d55-4867-9b89-db15505ed158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d7146b2e-0d55-4867-9b89-db15505ed158" xlink:to="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e9f566f0-57d4-460d-abf5-c7dea3eeac59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:to="loc_srt_MinimumMember_e9f566f0-57d4-460d-abf5-c7dea3eeac59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_44c05b1d-a29d-4396-ad0d-5c0c1b35474f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c16f66d9-6c5b-4b3d-ab2b-028cbfb9354a" xlink:to="loc_srt_MaximumMember_44c05b1d-a29d-4396-ad0d-5c0c1b35474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d09730a6-82a8-4092-a684-49205600f778" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f48ebbe1-647c-4c7f-b960-43a91bba98cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f48ebbe1-647c-4c7f-b960-43a91bba98cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_4a2c923f-5a32-4e11-a57a-16622bd5cc48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_4a2c923f-5a32-4e11-a57a-16622bd5cc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8a49d9a1-f341-4014-985e-39b5bfc05261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8a49d9a1-f341-4014-985e-39b5bfc05261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_41663e1a-cef8-4615-8684-b4f320a890c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_41663e1a-cef8-4615-8684-b4f320a890c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_67a05d79-5dc5-446f-98b8-168f29853cac" xlink:href="ameh-20210630.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_67a05d79-5dc5-446f-98b8-168f29853cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_1318db1f-e198-4538-b228-40c02ac48489" xlink:href="ameh-20210630.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_1318db1f-e198-4538-b228-40c02ac48489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_7ff4547a-4456-4faa-ac59-7ca81a5f9b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_7ff4547a-4456-4faa-ac59-7ca81a5f9b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_899d5436-eb40-4448-9023-beeb4cdf497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_05396c38-c432-4bcb-a001-67e8d48f71e2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_899d5436-eb40-4448-9023-beeb4cdf497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1f137d83-1c11-4087-a514-4a5099392bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ef03ecbd-bff5-45bb-920c-d5bc07f13820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f137d83-1c11-4087-a514-4a5099392bc6" xlink:to="loc_us-gaap_OperatingLeaseCost_ef03ecbd-bff5-45bb-920c-d5bc07f13820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ef8c8990-4ff9-46e0-9139-735cb26d14cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f137d83-1c11-4087-a514-4a5099392bc6" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ef8c8990-4ff9-46e0-9139-735cb26d14cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_4f018f61-c3ad-4935-ab60-df1fe5311fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f137d83-1c11-4087-a514-4a5099392bc6" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_4f018f61-c3ad-4935-ab60-df1fe5311fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_70884bec-4120-46b7-a60b-767ff3e54853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f137d83-1c11-4087-a514-4a5099392bc6" xlink:to="loc_us-gaap_SubleaseIncome_70884bec-4120-46b7-a60b-767ff3e54853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_a95ee264-c8b8-4e27-bc95-12289cbd75e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f137d83-1c11-4087-a514-4a5099392bc6" xlink:to="loc_us-gaap_LeaseCost_a95ee264-c8b8-4e27-bc95-12289cbd75e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_355ef60f-62cb-47e5-84c9-14ca54283c86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_af6d5456-4014-4d37-82e7-defdd050f58b" xlink:href="ameh-20210630.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_355ef60f-62cb-47e5-84c9-14ca54283c86" xlink:to="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_af6d5456-4014-4d37-82e7-defdd050f58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3b2e428b-16e8-4642-8db7-e82f7209d646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_af6d5456-4014-4d37-82e7-defdd050f58b" xlink:to="loc_us-gaap_OperatingLeasePayments_3b2e428b-16e8-4642-8db7-e82f7209d646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_7aaecf10-8861-4d9b-a0a4-4987bf6cb1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_af6d5456-4014-4d37-82e7-defdd050f58b" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_7aaecf10-8861-4d9b-a0a4-4987bf6cb1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_c3e46262-495a-496c-ae5f-04108722a386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_af6d5456-4014-4d37-82e7-defdd050f58b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_c3e46262-495a-496c-ae5f-04108722a386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_4d9bdb6c-5ae2-4244-a253-34e6de4555fd" xlink:href="ameh-20210630.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_355ef60f-62cb-47e5-84c9-14ca54283c86" xlink:to="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_4d9bdb6c-5ae2-4244-a253-34e6de4555fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4b1167ae-7a48-444c-b6b3-e5ff8d578798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_4d9bdb6c-5ae2-4244-a253-34e6de4555fd" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4b1167ae-7a48-444c-b6b3-e5ff8d578798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_7fe9bace-168e-4e08-a17e-9ec21f72d93e" xlink:href="ameh-20210630.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_355ef60f-62cb-47e5-84c9-14ca54283c86" xlink:to="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_7fe9bace-168e-4e08-a17e-9ec21f72d93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cebe0414-ea07-427e-b7c5-49db4508be91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_7fe9bace-168e-4e08-a17e-9ec21f72d93e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cebe0414-ea07-427e-b7c5-49db4508be91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_e917d3cc-47d7-4fde-992c-f3c60deb916e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_7fe9bace-168e-4e08-a17e-9ec21f72d93e" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_e917d3cc-47d7-4fde-992c-f3c60deb916e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_72e882fd-522b-44d5-ab08-1e89be1672e9" xlink:href="ameh-20210630.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_355ef60f-62cb-47e5-84c9-14ca54283c86" xlink:to="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_72e882fd-522b-44d5-ab08-1e89be1672e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_561d6460-3d47-4ea1-8be0-0f76783fe9d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_72e882fd-522b-44d5-ab08-1e89be1672e9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_561d6460-3d47-4ea1-8be0-0f76783fe9d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_7a131fbe-8542-40ff-8c89-5511786105fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_72e882fd-522b-44d5-ab08-1e89be1672e9" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_7a131fbe-8542-40ff-8c89-5511786105fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0193f5e9-f7f6-4c08-bf3e-94bfe3b7fcda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0193f5e9-f7f6-4c08-bf3e-94bfe3b7fcda" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d01af244-c9f2-428b-a602-1303ed091a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d01af244-c9f2-428b-a602-1303ed091a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_554834bd-eb25-45bc-b854-04414cc2f355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_554834bd-eb25-45bc-b854-04414cc2f355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_757b37d1-84c0-478f-a92e-aeee9b9d0ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_757b37d1-84c0-478f-a92e-aeee9b9d0ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_43de7114-3a4f-4ed5-988b-687081516196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_43de7114-3a4f-4ed5-988b-687081516196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4570344c-1cfc-4f13-bf2f-e2d70aec69c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4570344c-1cfc-4f13-bf2f-e2d70aec69c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_0bcb8e1d-62cf-4021-8d2b-9366e3e24717" xlink:href="ameh-20210630.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_0bcb8e1d-62cf-4021-8d2b-9366e3e24717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ef61fd9-85d5-4ed1-9762-43972a1cba3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ef61fd9-85d5-4ed1-9762-43972a1cba3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95266d85-fe20-4692-b8bd-ecd22cd10323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_95266d85-fe20-4692-b8bd-ecd22cd10323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_740d3650-a01e-42d0-8b5c-29ccacb008e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_OperatingLeaseLiability_740d3650-a01e-42d0-8b5c-29ccacb008e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_00d903e1-53e9-4e9e-bc66-91436de442f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_00d903e1-53e9-4e9e-bc66-91436de442f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0aeb369-4145-4c64-a2a9-7392c082c903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_399288ec-e802-421a-ac09-60d08b3bee8c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0aeb369-4145-4c64-a2a9-7392c082c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0193f5e9-f7f6-4c08-bf3e-94bfe3b7fcda" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_7611562a-4878-43f6-adbc-b3141f98326c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_7611562a-4878-43f6-adbc-b3141f98326c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7d9b4493-796e-472b-9fc3-426ef3c96967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7d9b4493-796e-472b-9fc3-426ef3c96967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f9149bab-b40b-4ff8-ab6c-db48069dd53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f9149bab-b40b-4ff8-ab6c-db48069dd53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4e2f4fe0-910f-4845-be7d-962587cfc811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4e2f4fe0-910f-4845-be7d-962587cfc811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a75caa1c-2db5-49b1-9a0d-039745b5a960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_a75caa1c-2db5-49b1-9a0d-039745b5a960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_7a1e449a-fc1e-4c46-b445-c0f8e0ee1ac4" xlink:href="ameh-20210630.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_7a1e449a-fc1e-4c46-b445-c0f8e0ee1ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_642aea16-8a2d-4664-b905-e096a067b673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_642aea16-8a2d-4664-b905-e096a067b673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_499d0a79-3b74-4e5c-87b4-327c9994d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_499d0a79-3b74-4e5c-87b4-327c9994d76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_51f05529-8035-4b47-864f-3137344db9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiability_51f05529-8035-4b47-864f-3137344db9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_9cef53ae-d078-4521-ae9a-1dd13e973589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_9cef53ae-d078-4521-ae9a-1dd13e973589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0b1d8903-0bd6-4416-b631-a4ba3c0b443b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_63845b2c-8cba-43df-a082-69ebf7f37b1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_0b1d8903-0bd6-4416-b631-a4ba3c0b443b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20210630.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4dba79f3-8c19-4a88-be43-2e887462e1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fb9c472b-b147-4275-9858-85bf3373843d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4dba79f3-8c19-4a88-be43-2e887462e1e8" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_fb9c472b-b147-4275-9858-85bf3373843d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f56ca5eb-a6de-4ffe-97a0-92a5f273ab4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6876bf9a-876d-47b9-852b-21c9ae4b64b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f56ca5eb-a6de-4ffe-97a0-92a5f273ab4a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6876bf9a-876d-47b9-852b-21c9ae4b64b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d10378d6-684d-4095-b6d1-861b4f03d47b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f56ca5eb-a6de-4ffe-97a0-92a5f273ab4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d10378d6-684d-4095-b6d1-861b4f03d47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3978cbf1-1314-403f-8f39-628507172212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f56ca5eb-a6de-4ffe-97a0-92a5f273ab4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3978cbf1-1314-403f-8f39-628507172212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9436292e-6b3f-4e7d-b3b6-b983c2aaaa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f56ca5eb-a6de-4ffe-97a0-92a5f273ab4a" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9436292e-6b3f-4e7d-b3b6-b983c2aaaa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe4c0fd4-dbee-4e0d-af48-db1b0ec8f851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_356a8986-b675-4bcc-b994-964dceb24afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fe4c0fd4-dbee-4e0d-af48-db1b0ec8f851" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_356a8986-b675-4bcc-b994-964dceb24afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b6650a3-9ce5-425c-8a2d-17d276144453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_356a8986-b675-4bcc-b994-964dceb24afe" xlink:to="loc_us-gaap_AwardTypeAxis_7b6650a3-9ce5-425c-8a2d-17d276144453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7b6650a3-9ce5-425c-8a2d-17d276144453" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9fe140e6-b336-4b58-ac35-0f67378cfb9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9fe140e6-b336-4b58-ac35-0f67378cfb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_330f2d69-4601-46fd-bcb1-76f0b1ca2bda" xlink:href="ameh-20210630.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b20a68f4-dbd6-4b00-80e7-f2843e4e9aa8" xlink:to="loc_ameh_StockAwardsAndUnitsMember_330f2d69-4601-46fd-bcb1-76f0b1ca2bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1690af9-4fc0-432d-90be-5bff8e3e715c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_356a8986-b675-4bcc-b994-964dceb24afe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1690af9-4fc0-432d-90be-5bff8e3e715c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ba573b5-d236-4ee7-8c0d-b3e2b4fb57cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1690af9-4fc0-432d-90be-5bff8e3e715c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0ba573b5-d236-4ee7-8c0d-b3e2b4fb57cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb18887f-e532-4f5e-a1d7-66e25245ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fb18887f-e532-4f5e-a1d7-66e25245ad5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd3a906f-1a83-4d39-9b0a-cb0ec843c893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:to="loc_us-gaap_AwardTypeAxis_cd3a906f-1a83-4d39-9b0a-cb0ec843c893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cd3a906f-1a83-4d39-9b0a-cb0ec843c893" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9833f267-acfd-4f10-8135-4ff5e9b934ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9833f267-acfd-4f10-8135-4ff5e9b934ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_02549b9a-0e0f-4db2-8d27-6fdc11e76c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e73bc1-336d-4073-b764-1d48f7245e74" xlink:to="loc_us-gaap_RestrictedStockMember_02549b9a-0e0f-4db2-8d27-6fdc11e76c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2483df56-f957-4017-975c-63bfa083e45b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:to="loc_srt_TitleOfIndividualAxis_2483df56-f957-4017-975c-63bfa083e45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2483df56-f957-4017-975c-63bfa083e45b" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_68286dd5-4939-4e10-981b-c2e9a32808ec" xlink:href="ameh-20210630.xsd#ameh_ApcStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:to="loc_ameh_ApcStockOptionMember_68286dd5-4939-4e10-981b-c2e9a32808ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_a23dcd93-c393-4b67-8409-1584ea9b6660" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e148e1eb-4016-440b-9a60-0c5af3122cdf" xlink:to="loc_srt_DirectorMember_a23dcd93-c393-4b67-8409-1584ea9b6660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_78fafe88-18f0-4d23-960b-5d970325dc3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:to="loc_srt_RangeAxis_78fafe88-18f0-4d23-960b-5d970325dc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_78fafe88-18f0-4d23-960b-5d970325dc3b" xlink:to="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7904f6a2-538b-4423-a6c5-04b74ac864e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:to="loc_srt_MinimumMember_7904f6a2-538b-4423-a6c5-04b74ac864e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60013524-f2b5-481a-9a2f-caf99511dc53" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8f473a3e-abe5-4365-8a0a-422c455e18fd" xlink:to="loc_srt_MaximumMember_60013524-f2b5-481a-9a2f-caf99511dc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f7e2da3-166c-47dd-9ba1-fe919381d157" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3e538137-0c97-4a60-8596-0cd8d4b3c99b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3e538137-0c97-4a60-8596-0cd8d4b3c99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc7c5f6d-8e89-41b3-a94d-c41eea61d577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fc7c5f6d-8e89-41b3-a94d-c41eea61d577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27b27483-c726-4ce0-bebf-c48fdf7018ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27b27483-c726-4ce0-bebf-c48fdf7018ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_48262957-68fa-4fa5-b6e3-af803b98649a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_48262957-68fa-4fa5-b6e3-af803b98649a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d88fcbff-116c-4e8e-92a2-ec18cbf319aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d88fcbff-116c-4e8e-92a2-ec18cbf319aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9294d0c-c38a-476f-a4d9-1d3f0a8da1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f9294d0c-c38a-476f-a4d9-1d3f0a8da1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_532b9b9b-04d8-4099-b50d-bbaf06d2a0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_532b9b9b-04d8-4099-b50d-bbaf06d2a0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dbfcf39e-36e3-4773-8e67-783cecb40a35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dbfcf39e-36e3-4773-8e67-783cecb40a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_93ba8c65-4351-4f58-8242-5bfd9ee005e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_93ba8c65-4351-4f58-8242-5bfd9ee005e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_cb5d6176-ac68-47c8-b527-06d3b75d8d0f" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_cb5d6176-ac68-47c8-b527-06d3b75d8d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_2105ba8b-a8e0-4787-92d3-ba5eda0a44d3" xlink:href="ameh-20210630.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_2105ba8b-a8e0-4787-92d3-ba5eda0a44d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_b7fc5fa0-e1e0-4ca6-abc2-e4a1aef0c2e3" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d77d31b5-424e-4c28-bd53-75b40b0b0fef" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_b7fc5fa0-e1e0-4ca6-abc2-e4a1aef0c2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51773fd5-d055-41ed-8c09-97876cebc968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a49b12d9-4eec-4d73-9a1b-5baf5ce2291d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51773fd5-d055-41ed-8c09-97876cebc968" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a49b12d9-4eec-4d73-9a1b-5baf5ce2291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2b2fd52-2449-43e4-9f65-0a5c3fc246c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a49b12d9-4eec-4d73-9a1b-5baf5ce2291d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2b2fd52-2449-43e4-9f65-0a5c3fc246c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d269f5b9-b543-4562-9c04-0c2f403fde2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a49b12d9-4eec-4d73-9a1b-5baf5ce2291d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d269f5b9-b543-4562-9c04-0c2f403fde2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_afe788f7-8cc4-4a87-96c7-9747ed671e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a49b12d9-4eec-4d73-9a1b-5baf5ce2291d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_afe788f7-8cc4-4a87-96c7-9747ed671e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39159d05-5ad9-4158-8fa8-487baae2208f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a49b12d9-4eec-4d73-9a1b-5baf5ce2291d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_39159d05-5ad9-4158-8fa8-487baae2208f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a82ae0be-0be4-4928-88c2-790fd6a08d60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a49b12d9-4eec-4d73-9a1b-5baf5ce2291d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a82ae0be-0be4-4928-88c2-790fd6a08d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bcf41605-9bb4-4e7a-b203-6bc887c0706a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51773fd5-d055-41ed-8c09-97876cebc968" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bcf41605-9bb4-4e7a-b203-6bc887c0706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bd060482-eb22-4968-9bee-fa04e723773f" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51773fd5-d055-41ed-8c09-97876cebc968" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bd060482-eb22-4968-9bee-fa04e723773f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4920305c-2952-44ae-97a2-a1e7d32927c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bd060482-eb22-4968-9bee-fa04e723773f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4920305c-2952-44ae-97a2-a1e7d32927c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_315c6ec6-5f5f-4fe7-8a95-9a92617bdeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bd060482-eb22-4968-9bee-fa04e723773f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_315c6ec6-5f5f-4fe7-8a95-9a92617bdeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_df2cbeb1-d013-47b7-926c-1a25ef6f9bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bd060482-eb22-4968-9bee-fa04e723773f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_df2cbeb1-d013-47b7-926c-1a25ef6f9bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6434544b-2abc-47fc-8fcb-e27192c83053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bd060482-eb22-4968-9bee-fa04e723773f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6434544b-2abc-47fc-8fcb-e27192c83053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_86ac8e91-77c9-4c66-9426-f2ff7243de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_bd060482-eb22-4968-9bee-fa04e723773f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_86ac8e91-77c9-4c66-9426-f2ff7243de1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c3ce3a00-9fb4-4fd4-9184-65bbe0b46a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51773fd5-d055-41ed-8c09-97876cebc968" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c3ce3a00-9fb4-4fd4-9184-65bbe0b46a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3e54dac1-b044-4b72-929f-d963c0a4ddab" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51773fd5-d055-41ed-8c09-97876cebc968" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3e54dac1-b044-4b72-929f-d963c0a4ddab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60fe29a2-931b-4d63-8447-6ef36a372ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3e54dac1-b044-4b72-929f-d963c0a4ddab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60fe29a2-931b-4d63-8447-6ef36a372ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ace31a70-d5f8-4596-8cdf-89ff48f9b005" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3e54dac1-b044-4b72-929f-d963c0a4ddab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ace31a70-d5f8-4596-8cdf-89ff48f9b005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_100ca236-ed39-4015-88d9-e73b97475b49" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51773fd5-d055-41ed-8c09-97876cebc968" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_100ca236-ed39-4015-88d9-e73b97475b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2522a7e1-850b-4141-9ac6-b5aab9c6dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_100ca236-ed39-4015-88d9-e73b97475b49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2522a7e1-850b-4141-9ac6-b5aab9c6dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5df4fe09-3583-4ac7-8ca0-275e34ece381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_100ca236-ed39-4015-88d9-e73b97475b49" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_5df4fe09-3583-4ac7-8ca0-275e34ece381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99b29e2e-5ba2-4276-b155-135caff6193b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b414d95-17d5-4e73-a0a1-6e1bc6a1429a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99b29e2e-5ba2-4276-b155-135caff6193b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b414d95-17d5-4e73-a0a1-6e1bc6a1429a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_178f1dbc-2e19-4baf-b80e-ac4aa540cae9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b414d95-17d5-4e73-a0a1-6e1bc6a1429a" xlink:to="loc_srt_TitleOfIndividualAxis_178f1dbc-2e19-4baf-b80e-ac4aa540cae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c25afa29-d344-4ac1-8527-447280f454f1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_178f1dbc-2e19-4baf-b80e-ac4aa540cae9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c25afa29-d344-4ac1-8527-447280f454f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_a8344e1e-7596-4791-947c-db5fcbf33b86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c25afa29-d344-4ac1-8527-447280f454f1" xlink:to="loc_srt_DirectorMember_a8344e1e-7596-4791-947c-db5fcbf33b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7b414d95-17d5-4e73-a0a1-6e1bc6a1429a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50ebef94-2490-400b-aedd-eee548cab3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50ebef94-2490-400b-aedd-eee548cab3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9467e204-14d7-4a0b-887c-b5c72504e080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9467e204-14d7-4a0b-887c-b5c72504e080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_84357307-0c18-4f11-8b1f-2d769d19f6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_84357307-0c18-4f11-8b1f-2d769d19f6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_656fce0b-7f80-484c-844c-a863e1dba98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_SharePrice_656fce0b-7f80-484c-844c-a863e1dba98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f592f319-f771-4daa-a41b-4907c531a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f592f319-f771-4daa-a41b-4907c531a0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_3ac5753f-49ab-42b5-942e-9bc93819d8c8" xlink:href="ameh-20210630.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_33f8971b-ef72-4aac-8a97-4ea85f7cd4bb" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_3ac5753f-49ab-42b5-942e-9bc93819d8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationSummaryofWarrantDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12012472-5d8e-4572-9de5-f610aab0fa62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward_cd09810d-3184-441d-88a2-8d676750b264" xlink:href="ameh-20210630.xsd#ameh_SharesWarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12012472-5d8e-4572-9de5-f610aab0fa62" xlink:to="loc_ameh_SharesWarrantsRollForward_cd09810d-3184-441d-88a2-8d676750b264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4c9af607-2ddc-41c9-b151-f359dbe37ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_cd09810d-3184-441d-88a2-8d676750b264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_4c9af607-2ddc-41c9-b151-f359dbe37ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted_03d2cf5a-b1d9-4443-a751-4afa8e21f781" xlink:href="ameh-20210630.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_cd09810d-3184-441d-88a2-8d676750b264" xlink:to="loc_ameh_NumberOfWarrantsGranted_03d2cf5a-b1d9-4443-a751-4afa8e21f781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised_0cde26e0-d115-43ec-bb30-a676e97aadb2" xlink:href="ameh-20210630.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_cd09810d-3184-441d-88a2-8d676750b264" xlink:to="loc_ameh_NumberOfWarrantsExercised_0cde26e0-d115-43ec-bb30-a676e97aadb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_a5a32565-df57-459d-a319-7af2deae7c88" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_cd09810d-3184-441d-88a2-8d676750b264" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_a5a32565-df57-459d-a319-7af2deae7c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7c412755-770e-458e-b21d-4a6c996c99b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_cd09810d-3184-441d-88a2-8d676750b264" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7c412755-770e-458e-b21d-4a6c996c99b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_194078d1-2ded-4af1-91e5-4f330b0aeb13" xlink:href="ameh-20210630.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12012472-5d8e-4572-9de5-f610aab0fa62" xlink:to="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_194078d1-2ded-4af1-91e5-4f330b0aeb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_57df9027-c7f8-404f-b240-2b0287a17bd0" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_194078d1-2ded-4af1-91e5-4f330b0aeb13" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_57df9027-c7f8-404f-b240-2b0287a17bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_96fa28ed-4438-4359-9f29-8fbbef0700ec" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_194078d1-2ded-4af1-91e5-4f330b0aeb13" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_96fa28ed-4438-4359-9f29-8fbbef0700ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_56621461-d865-4e26-9b1a-2c481da67559" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_194078d1-2ded-4af1-91e5-4f330b0aeb13" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_56621461-d865-4e26-9b1a-2c481da67559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_ecafd460-e80e-4750-9a33-f69dd103e905" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_194078d1-2ded-4af1-91e5-4f330b0aeb13" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_ecafd460-e80e-4750-9a33-f69dd103e905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_b3b77be6-294e-46a4-8c0a-f03e97e6d9a3" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_194078d1-2ded-4af1-91e5-4f330b0aeb13" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_b3b77be6-294e-46a4-8c0a-f03e97e6d9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_74d00b54-e8d9-41a5-a3ec-3d62136c8326" xlink:href="ameh-20210630.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12012472-5d8e-4572-9de5-f610aab0fa62" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_74d00b54-e8d9-41a5-a3ec-3d62136c8326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_de666b7a-4ebf-4796-a6cc-18e783a2c34b" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_74d00b54-e8d9-41a5-a3ec-3d62136c8326" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_de666b7a-4ebf-4796-a6cc-18e783a2c34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_ba49a5b2-e30f-4aa1-ad44-491b527e4135" xlink:href="ameh-20210630.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12012472-5d8e-4572-9de5-f610aab0fa62" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_ba49a5b2-e30f-4aa1-ad44-491b527e4135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e03b0b10-2b27-466c-b19c-27fa392c0623" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_ba49a5b2-e30f-4aa1-ad44-491b527e4135" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_e03b0b10-2b27-466c-b19c-27fa392c0623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_333c7e47-1468-42a9-8477-58b0ae5305cc" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_ba49a5b2-e30f-4aa1-ad44-491b527e4135" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_333c7e47-1468-42a9-8477-58b0ae5305cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_32ebc09f-ee0c-49e3-bdb3-e8ddbe3adf63" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_ba49a5b2-e30f-4aa1-ad44-491b527e4135" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_32ebc09f-ee0c-49e3-bdb3-e8ddbe3adf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_a04efd80-e6b5-4993-a9bd-b8fa0109e342" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_ba49a5b2-e30f-4aa1-ad44-491b527e4135" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_a04efd80-e6b5-4993-a9bd-b8fa0109e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_468d9214-85a1-4468-986d-a0ea58025081" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_ba49a5b2-e30f-4aa1-ad44-491b527e4135" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_468d9214-85a1-4468-986d-a0ea58025081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c354478c-980f-498f-b783-35a8dc4e1021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c354478c-980f-498f-b783-35a8dc4e1021" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe4debc3-df5d-4763-8a28-5aacd0fb232b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe4debc3-df5d-4763-8a28-5aacd0fb232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fe4debc3-df5d-4763-8a28-5aacd0fb232b" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_69795559-cf7e-4209-b004-e2ee035e48c8" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_69795559-cf7e-4209-b004-e2ee035e48c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_be913565-e8d3-4f86-a3e1-05dbe0b83d8a" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_be913565-e8d3-4f86-a3e1-05dbe0b83d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_ae6d78e5-2770-47b4-a74e-97798a8fe095" xlink:href="ameh-20210630.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_42b0dae2-4452-4965-81fc-d06e3f4a5f55" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_ae6d78e5-2770-47b4-a74e-97798a8fe095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6f354f7-4429-4332-a1a5-d566c3e0ec39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:to="loc_srt_RangeAxis_a6f354f7-4429-4332-a1a5-d566c3e0ec39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a6f354f7-4429-4332-a1a5-d566c3e0ec39" xlink:to="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_62475e5a-1906-4737-8721-bab234932551" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:to="loc_srt_MinimumMember_62475e5a-1906-4737-8721-bab234932551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7afdaf1a-2695-46de-be93-4939490a412b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_671b558c-42d2-427f-a90a-5fee93b40a4e" xlink:to="loc_srt_MaximumMember_7afdaf1a-2695-46de-be93-4939490a412b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_bde21c59-d62e-4212-a33f-165fe3775fdc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6dfcec2a-bc9e-4352-af0f-75ff5f7a77e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6dfcec2a-bc9e-4352-af0f-75ff5f7a77e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_3d2ad9fd-1e69-49c3-913f-2bd566e04153" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_3d2ad9fd-1e69-49c3-913f-2bd566e04153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_534ca46d-ef2f-4a0a-b29e-6fa1cbda5673" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_534ca46d-ef2f-4a0a-b29e-6fa1cbda5673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_3f49f5d0-9097-4fa5-b5cb-404a75d927ab" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_3f49f5d0-9097-4fa5-b5cb-404a75d927ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_7360f877-104b-425c-80af-acc648d0f417" xlink:href="ameh-20210630.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_3bb3e2ef-69f0-4993-965c-84f5475832f0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_7360f877-104b-425c-80af-acc648d0f417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEvents" xlink:type="simple" xlink:href="ameh-20210630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_34aeb13f-67f6-4e35-bf01-6bc64c9ccba3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_b83837ad-f484-4bb9-a7fa-bfcce544855b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_34aeb13f-67f6-4e35-bf01-6bc64c9ccba3" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_b83837ad-f484-4bb9-a7fa-bfcce544855b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20210630.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8558c527-9c3e-4043-9b55-5ddab1e67e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8558c527-9c3e-4043-9b55-5ddab1e67e50" xlink:to="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6e59a1d7-760e-4e72-8ffa-db496a01f0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6e59a1d7-760e-4e72-8ffa-db496a01f0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fb31814f-5a6c-4839-b9c3-94a4642b4f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6e59a1d7-760e-4e72-8ffa-db496a01f0ad" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fb31814f-5a6c-4839-b9c3-94a4642b4f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_67022587-9154-4e17-a62c-64db792d3c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_fb31814f-5a6c-4839-b9c3-94a4642b4f7d" xlink:to="loc_us-gaap_SubsequentEventMember_67022587-9154-4e17-a62c-64db792d3c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5c07af6-74e8-4577-80f3-03b3ff4f4409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5c07af6-74e8-4577-80f3-03b3ff4f4409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5c07af6-74e8-4577-80f3-03b3ff4f4409" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_d4c7528e-7571-494d-99b0-7461d25eab8e" xlink:href="ameh-20210630.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_d4c7528e-7571-494d-99b0-7461d25eab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SunClinicalLaboratoriesMember_db99632a-f43c-4b85-8db7-aaee8bcb078d" xlink:href="ameh-20210630.xsd#ameh_SunClinicalLaboratoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_96acfa50-3a48-4ce6-9b1b-aaf36feb01d9" xlink:to="loc_ameh_SunClinicalLaboratoriesMember_db99632a-f43c-4b85-8db7-aaee8bcb078d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_17d3618d-7ccb-4836-90fb-f9482bcc2afb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:to="loc_srt_StatementScenarioAxis_17d3618d-7ccb-4836-90fb-f9482bcc2afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_79433ddb-715f-43f5-b5fc-66dafc7709dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_17d3618d-7ccb-4836-90fb-f9482bcc2afb" xlink:to="loc_srt_ScenarioUnspecifiedDomain_79433ddb-715f-43f5-b5fc-66dafc7709dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5d2707ab-1d7e-45d6-ae4b-2a3482903e3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_79433ddb-715f-43f5-b5fc-66dafc7709dd" xlink:to="loc_srt_ScenarioForecastMember_5d2707ab-1d7e-45d6-ae4b-2a3482903e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_f219674f-5a19-47b2-8167-0a352202ca74" xlink:to="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays_9e55ad36-cd2d-473a-9651-b4bd3c240f6f" xlink:href="ameh-20210630.xsd#ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays_9e55ad36-cd2d-473a-9651-b4bd3c240f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones_e66c3572-0287-45f3-b0d2-71fd1af8fe1e" xlink:href="ameh-20210630.xsd#ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones_e66c3572-0287-45f3-b0d2-71fd1af8fe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a744a899-f871-4d65-9e06-556e5a7e7797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_a744a899-f871-4d65-9e06-556e5a7e7797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_34feb3e3-01d4-4e2d-a5ac-8ff5cb7cd3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_34feb3e3-01d4-4e2d-a5ac-8ff5cb7cd3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfLocations_dba331d2-7370-43d5-bf59-92f497e7357f" xlink:href="ameh-20210630.xsd#ameh_NumberOfLocations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_0c3f14b3-2280-4a40-9758-7fe7ff93704e" xlink:to="loc_ameh_NumberOfLocations_dba331d2-7370-43d5-bf59-92f497e7357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>ameh-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ameh="http://www.apollomed.net/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ameh-20210630.xsd" xlink:type="simple"/>
    <context id="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i774336f6b2934a0f91c94085695f17d1_I20210728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-07-28</instant>
        </period>
    </context>
    <context id="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5c98b023802344859e6d11a8234f1cf2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if83782563ea04b51a3cd25b22894290e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i717e4c08a5f045dbad2f7071e17325fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i433fbe5b9bbf40fab306efc9aee92e57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i34bf991f15464550976d811de0d62e73_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb9a2861a1cd425cbac5b68ba09ac7d9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1f37ef4f8e441468877d24814c185a1_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i966c0e3cfd7b4121ae382a0aaa9006e5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee1686eba6fe45ea8ae559c43929c25a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6b10c8aa5ea249a4a41ddbb9cc4eea0a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i034404d6de0e40b4a7e7b9479235c135_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i24ceb8c42ea441928271a4fe96c772c7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i56f9749216e941d6972e946201b43078_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0b75704f2b5b46bdb05980233ec4c43a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i11a9f1d5e9e54374a1155ab5e469b579_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2445932d5cee413a82029f7fb82d054a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1cdf9a72099248dbb61045162c5ad976_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i19f4308062ec4348a933166fa6f2f686_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3a9aec26e9304fabb5f23f0a39e18d03_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6c3c3a8071974b2ebd2dfc2fc3864f64_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i064c3aa533b24d6e9e68036d91b37ce9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5cd3132fbc4049f99af3739b782bd5e5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icdb52ec1c4434204a5ba6722dac7a06c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic275903b015f4a8f987d0517de1d6b23_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i16e822ece8a3418f958ae5c43e6eb6de_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4bf2d3e70c19468bbc98d922ab423bc3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f84a157fed746cf807e86d306825b89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic48ae9c2bd4c4add942fc7d050be7a25_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7c3d0dfa54749a5b3ed5d1271ddff4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01162a4b9b294f918c58c035a6c23ce3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib624e9a32c5b47d4ae32002ccb4e7fda_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f61732e02a249169204410e0423af69_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibcd96999266142519b4b10cc8506625c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if526e568344046fd872628c73d56c372_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8965f51e39c644189ad1adf884d50c8d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id6e5ebc9ac3e4cf7ae33e8b75f1f9e16_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i37408aff606244098ce0fa1bdfdcacfb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic9c4138381c446ffb27c642f7235110c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if42aef36f805415ca26593430dc35d0d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic250c2fb27a24f8f8d50710d9cda482e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i479444d836ce4650a533df644c674a5a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie6633894239043beb0507e0d353ae82e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica140c4561ff41ec87f96640e43a80ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8c791b64a17e46bcb009aa18c776e397_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic700bd2057234d16a57c7e2195bfc225_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i170a94cec6714d3998abcf063693b6eb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7275ded6bd054db1b521ee6e3aab324f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifb568bafdb614780b0b6e325fb8ca3d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id3da79ae9a6b41debf540b695fc08b49_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b0513fbcf3d407aab4322a16d4bcb1b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if8d475aa66074c06ada568ac32d41462_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0587de5d8a7747418d59c5807b78c9aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2980472eb7b9414ba636a7c0026908e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1ca8ecf06fe9461197b2c72a10f229e4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3bab93ced304431f99c5b5869c9a4f50_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ff819742d9240a08946f28c513591d3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic342c3c788494bdd9bd051e0e2ea4aa9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i438419141df9463190d33a39a16f8e84_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iec5e51946e0b4b2187d088ed312db6fa_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i81ce2f5b57784bd082918841fb1016f2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i35d7bd9f3262415d9290f44c00268a41_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib70f1135f22a4e66a2932f2d95ad14ed_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iae60a583c9a0465886ea5e58639dee38_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i800ed291b8df4aa1bc10bb8c331a337f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i73ed4c2aa7b04a8fb98de15f2d6201c7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ife6556ceee4e4c0fa8fac65b95b81c7b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieab2abffaadf48cc9d3419f9105a0506_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie1d8b996c11e44099040a2fb9aa1b460_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i21e01a92ec45487aaeaec0fbbb1e91f8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if9d6e66a8d9741ee9e3ddbca75ba56a1_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i73f5c4884b2a4937a0638aaba13197ed_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i763c2ef5c52c4947b684f5eeda8ff491_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8c4c8fd96fdb461cb92e63360f2be9ab_D19990701-19990701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-07-01</startDate>
            <endDate>1999-07-01</endDate>
        </period>
    </context>
    <context id="i7c0ca208739a43eca6bdd05197aa7a17_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9bb24ee035e747b28135640c9aa23520_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idc78d6f0898845efb2fd105feca4a2f2_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i071cd8fce44a4d278cb890f2fd12c53e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i71623504ed924a538cd451351d50b2da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i241f2dac80774d7382f508fd09e0f8ba_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7fff49a7a66747b7a57171842d35423d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i952cacc1a5b04847b6ad828c7370b652_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc6f11228e3b4496a5908cf791e2c3d5_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i2b95c5305c69440b8471686cab8d05a8_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i69897c5a8adf4bfda6e8406ffef233b9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2c2a3553336444f8bafa03b845e07bc7_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="if43a32369dc847e7b58782be85125fa1_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4bb6b3c6a2494e4bb41a11f504d6faed_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1de45d50eab74b8796ff5445350b8141_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0633663299e44174ba3eb3710cd3e2ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icddc255662424aa887c3eea17c9feea8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i79bc2d0f22014e51b904aed1246e3e16_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i48f0e73319a641509224036db496b932_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if581aec0ebda442289b0483239719ee4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5ce879e744f44499873676c0b759e61_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i185f42a9a8b54e0ca62108c41bd664d8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifcdcf6e7ba9c4ef787e0a918d4875119_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7c2b9ec1f0794bcba9109e5d8bb3a391_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8c7fd29ffb1e402f9a88abab2ffdf543_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1b54cb109dc64d6a8a758226a7f16d73_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e3515a95fa5423b9f7aae97edc29519_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib589f790bdc2410e999a0e0326ec9f8d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i60adfff6acd24500baff0a524b02e5c9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie9b45c9cc22f407b9e5ae65de8c65877_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifbfeb035318646158bca7c726a066225_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i471fd709d8b042538ae4ba01794d29fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iba8a208df3474e8fb273ceaa2c9f7883_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia25a0917754446d9a50268874a89b369_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4b597a3a606a4216b96db631cc612d1d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i426466c8cfba4f4ab46a3de7fcb32855_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0678b3587f724407821d7a02905c844a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia75080dfd6264d258c11212217c8b10f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e9ec79a20df4253ab7dea22b3b23ee3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i34e38dab85924104b5e25338edabc1bd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idfc614d6b07f45f7950663dec2648520_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icd38b926d5754ba3aa24b67a9981b319_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4efe4431f6694099b8b967669037c803_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8c2aca92c28e4162bdd408ae26d5ad9d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie5cecd31c0dc4fb6a242649aac99e292_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ief11bdfc013143bdb2e856c631d0718c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id8cf6127a54a494484425f25baddbfc0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i048f53e45f574508978ecfdf4e3d3d22_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id08b33fa7cfd4156a5bacbfe13a639e3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icf62c5595329412686bca92c975ba621_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i620a3e2dc50c496b98250472c16d6748_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7809f033d5704a408b3a92c0496273c7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib3446e8fb9264fa6bceff8cf3d2e166e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i024c1f1b458648a0b9cb88256e9c4a3a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dd8f97f0d834086a7e27bc176ab32eb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifc8c969a14594d11b493db131e6fc11e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba17faa36f594080b10480edbc5e2578_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3dd42db203e84e239ba631310adddf43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib42142faaff64fa180f7ffee0c673ac7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibc64ef7d67ae4df28598f2989a60b364_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9cc209d6b1e0486896044884d8a79962_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86a09834f27e46cab5ec171e7d48fd19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b7eb2683f4c475faeaec9c8b1f67839_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5f03ca66055944a6b0fb9d49c0ba7b81_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73ebc5992e5544fa9612e04b047d6eb0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if30af78cdea54cdbafd288daa6d2c6fe_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i130bee7db4b74cfdac137ec49a5678ab_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ib82f85b4c8b24e3eb8d0b090521fffd3_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i31665be81e024f77a8eb0c64fdd329d5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e33fda836264739aa7bb8163bc33a5e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i82dd99b346d847f6afecef6b4ffe3d89_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8330c3700a474f29947f7fde24cb31d0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id890472ab2d0424986384ec74225309a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iab2ae2abe941465e94134f35120b632f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i709e028ffa954eac8fe9f174ae35a812_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia462a1dff6eb49f0a14538bf7d4535a8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia873358d93f341de98ab17edbffcde50_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i54b9d769c77c4104928dc588fb0c91ca_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i044041f8aebc43dea7c8afc0da3d2cae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2589d5bf11b47ddb890e3feeb7d0e43_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42823b74ab154e4cb57ada3938ebe79a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e5c9b3bb5cf4c068e18e1fbe99c4bcf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if0fbf27e2a7647899d67e3bd220dbeda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i73f982d527bd42e7b4fab85539b28ffc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b898d0feaa140ab9e92e780e9feb0ba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib101f9ba2e1e4330b0065d49f9aed221_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0341cbb996e048a6854636392a8e25d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8bec418630414a69a769bf4b40f4e7e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i126879ce11594831961b89ab705a48f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i93a51086c7d546adab3f7e56b087b382_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib9329af8296b449084545734af6bd691_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ife67641ec17b442283895740613c5731_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1f711e268b9d414f8665d1f912ae7f03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4181eb02bb2f4393a3250731eddb20f1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9343b3aac1264fccba1bf8a8c124302f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b482750d838451c9690b24453bd04a7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i009c403c4ff240a19cc16cdbe7834056_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0eddafd4ca9e4212901159b5340a98fe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8c75381253b47bd8691ab6ed609fbda_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib7bc039d7edc42b1b767425117d101c9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8c39d18aa59f4fdab441e373be437999_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i302d2d42eb894edfa8abcbb27511f099_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if978e802ab374bcb978febf6e68a5f0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62d380a7b57e4077a43fd2ca0fe6d807_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1e1b0a8248204e63bc412a37ae8ab329_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="i2699be005bc448cf854162e6c83dcef3_I20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-18</instant>
        </period>
    </context>
    <context id="i4301c2756dfb415abb72c0f8eb734638_I20201218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-18</instant>
        </period>
    </context>
    <context id="i54987c743be74a588a51746074a0a1be_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b874970f5404290acf4e877e53cc4d3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i85e16b9f030248348c4c2fa5de4c74e2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3273b2373fda4cdcb3db5f9523c73062_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifd05517d558847b49c015f173be8b91d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id7db85519bc746c39bb248797feb58c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i739839922e4c4c609f191b0dcbabc14c_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="i1303e2069e6247dbb7f793e04ef343c5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i17796dfb151e489dab379fce67d4e1b8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6bca3a4a2ef740ff94ca5e1a3a2ad63e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0899c47275134483b8d984adf3740b3e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i32cbe872dd774db5b7d4800706c08caf_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2887d4b59c254ece9c755540893a51fb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i29508ad62c9a4ffa96ab856825835cc0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i971d5df0b77740f8906d90e5210fbc87_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if37ba02674fc4f47a192436d297aff26_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iefe421e759914ed0b7a4b1765437668b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a037a875d3544e78944fdfbdef2af99_I20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="idbffb487ac384d7b9e97a9a77c64595e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3cd84561b1874a4b9c02a9c4d5aea63c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8abff36813164c6c84417bf95217cc72_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i94b60c63c1bc4a058e9a3b6b3cbe98e0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1d9d1b124a0e459ca79a0ece66636348_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i3b4a44d05fbf46488b4af77f35c9567d_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i8eeb59c450004d3e92ae1911c1e1cbeb_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i75b545869a11420f9ea79a9c44e04340_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i70ff4fbd4b12465585f409d00f3b5b5e_I20190423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="ib451b96ba18f4df7a702b76736baf9a3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0597b46866404e3c9244a5206a042d40_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i06dcdcd971e4410ba873f348e8e7adc2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc7595906102441585b7663ded30146e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibf5836787810470aa58c74049921dc6e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib64a97044a35489c8feb4989784095cf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic1a19122d99d474881d161ebb0dbea6b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8672f34024834923868d11e08668c214_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia760a8cfd561490c90a49b778a9afee7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i554fe9dff9674725962bb4cb2f88b9b2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9c5d3001970541c9b1b6bb12adceff18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0536df6fbb684da2b13045d260e8302a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5120ab4996b447e5a3530a8dcd7ceec9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5a95fe077074fdeb9c94b5a02ce35b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb19e6a0df8745acaa9ce709c7fe83bd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6917df2647d94638b04a3554df231459_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie9a4d75c299c4d8890a93379fee46e7d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iac14ba3f77974628a3f15fb0add7d76e_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i536e73d35938450abf342effa9713c79_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="i8e2323bab9c3467682e9da242c1cd16f_D20190701-20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="i5691cb4056714c69a234024bd01402c0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="ie243ca1688274f6687245974580a1e3c_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i212b0ef9733140d5b7611df1f124ec26_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i87f01cf6f2e04623bfa74a1b1dc2f34b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1b65d59e8cee4de190ada04f5c5338aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98420e28f93c487e9091b0de8ef73848_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i25dc88dcb88941818003f295e6eaf494_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie19976568f554a309dc818b6740971de_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaa899988e7284ac8a1326212ba5333ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id92d7c50296e4adb9c6f07c18bd63da6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibeafd2d681174371ab57d8e8d2bd170b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd17107a4e4f4d0db7e8fffc934a9f43_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id5fb36211de84d458695b36c94e44b09_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="iaaa02904edf64fd19eb45f52d4bfd62e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="idf95943f3b45491bb70c64e65514db5b_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i99dcab7c36f94052a58f43fb2416b256_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia9b7755ce16d436fb858171518d6db85_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9928b035437a466c8063602b61157c72_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie3689d97acee409f811f71e5d018b255_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i37ce176ad8164bbda4a85cdb5c1abe96_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="iaecc589e663140efa9bdde31ca9fc76e_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="ic3fe84306a564af99059a846dc55527f_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i61695e4f773245978fcdb79b78a5f4e1_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i4ad3cbb03fee4c6d849f2b2c7097f926_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i30999fd4c670468fa0ac9bc1446026a9_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ife4010452d164857b9e426a42b03e2fa_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ief20ee6c5c2c4b5f9ca95cdf09203cf9_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i25174623ac76453388419ec64c9378b3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7ba990e321754287bccd67c80d254cf2_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i2864d7724e914818863fb152ae703113_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i75bb15e4135844e0b0a19cffc0d0a363_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="if75078b89e36407a8a184d96312607c7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e7f468af62c460593057d3940ee2131_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i00a33c8eaad843f0bed2823a082ba35f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i65ada19782cc4566a752ee378270990e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i982a35d5c552427f8707f6f7c52c8456_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3fbd15394d2c4d85868b44d4b1890872_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1423c5795a1b4d749457b1fe689f6082_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5dac28efd63c445d90c56c1473b525a9_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i7340fb66912c49d688f6edcdd3993379_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i89b4dbef7f2e489f89f33ea163fc5c46_D20200703-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-03</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ife40aedab12e4720ba1ac1505ee27d57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d1b698d8e0c455ba42b48cbac36f252_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="id7fb86722c074f2eafdd868708d994e2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7f73410dbab04d0b9949a4de8859b032_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="id96f1aad698b48e38639c8ec1d301f92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i63d7d91e880042f0a4f362f355b812b5_D20200727-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cd4cea3e6d54191b5d35c584c4abfc5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib3215aa218c043138dfbec866e107ea5_D20200727-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5a28537ca584fb4b0ee10b7408d0fbf_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="iaa84fde67bb645cd91b5367196c1f03a_D20230101-20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="i63fd321ddf634615addc134b27259f9f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i625945a27da84fc6aa443add380d4c00_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i144a76c21edf4613a46ce3728e38457d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib533cc59686046eeae2f5f232fac7f9a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i737b37c63ad94a628ff69100f7a2c406_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i192b7b8b3d8049bf9d6f9d1c1dc9c763_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib146802ffc804944934f116ce84a41c6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i94b5a906722e4e3d8e26a50cae38e0e7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8a509d20ed71452e9deba1a12c4e6e19_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i750613cd3f5f46ae8a081a28e372e80b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2155db54a6e94fb3ba14b735aaf78990_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4ae2fb1304c141cd8ca7616ff44b486d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bebc359d95142548ffc5a9df83139c8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if4e562e2f0f644e696c375ad1dea58ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia10f8b79fb1344b7a87ded9035353132_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i320308565cd449e19c679138f90e503b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0408c582d1c8484f98671f80a6529d71_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3bc4e2285e0444884aee89b77334ea4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5b0212d54ced47e0b843d969230e7056_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6196e45da98644ffb45f1e5043cc3bb4_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8a82fbc742c24e8287ecd7cb5cc7cbbb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5baedd233dd54d5f839fd76b1cae7d1c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2a3ac3a0d777469a946e0a10c6595964_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9a1a8b237d3a4bf0bf360bf0964d3f6d_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1008be7007d14a7f8231a7aa65e1e551_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5adbba48d4f44cf399a195dcbb2b1cce_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2d6dddcc345e4f90952f2a96948a910b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i71a70b05372d474ebacf388a6848532b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3cb49c95ec604beba965acb646442a78_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i92a3b4c371be499a9e024cfd590d0e4a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i77783b1764504ea0907a1d3ac4b0ada2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic9e1ac26256349d8a8b6660fb3b0cf14_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie69084b20d984611b151ed5ed8994475_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic54f87af0d7b41e38ac47a6d994ecf51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3f89ff410504d43a409f8a0a4d4dc9b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i05b5e17ec6f54ce9b949906a91fbc7d6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i12dc265133f44d93bfbea364c99e892e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i663b801e9e2f4faaa6db3d3affb1f45e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5d70de54c6ef4853af97ba0be0d711b6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i434a1fa4730047f5ba3436f45a45cd10_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i89c8731f72584484a875a2c7da57e7d4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i155643ff74b34c9b8cc8ec0293852ad6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4833707bf8a34d11992ba230abca2c89_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2a6a7f97a8e146cd980c88fca3b2ab01_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia1f5a0f1507848fe8995404c6c8e603f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if811abb97e1d4b6aac19545793d3feba_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie1f67bbbdb42498ca966599acb11dff3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i446e0195307d4b82b3e9a4cb39c02c68_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib3235fb88c784a87a0e286f32316d340_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icec95d5e3a26463e80da6e3b8af4d420_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i408bcca588524bb39b519aeebdc4cac2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9eeadfa628b409395cec8d188e856a9_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ia8ce5a693324465ebfe2a470a3639175_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie0a4be6b433c49f6bd902b1cf0e83be9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5fab8a89ec0e445ea9f230be250f041a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6655222595b8466db9fa7f8f6e28d701_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i92e9a46fd55843e19b666e23a93b8077_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i874d478f73294316ad576a40bb59e1ba_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i25a8271afdf84b0ba8fed37136cb3814_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id89e4b9b73134459ace8ce5c0489bead_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e548a742a8e402cac322c329bba3e8e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic24b4e50300a456398b12c3d4e9c5ad6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i49a2d42d5c87493e92c0eb8c7fd269db_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6ea5c3d23fde4210b75ead61697da1df_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7a3adda3f7674cf188378375d6706703_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie006af53fd884424a259b9fa982a4348_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i7f54f9743af8462db5f026514b1e7f21_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ieec217ded7454689910a87b9c2fbed59_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i53ddd200d6094338a149fcbc196b306b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i22b8a06109754f1285d0b76fad17c51e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic98de02634744e4eb83e5a16fad56985_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idef15142ee464a63a23eb8e6756f0416_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id9c0a7c27eb7463185729d7662e9b27f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i66379f58d2d94f269eab8ba02e886336_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i24dca2e9c9d84a809178fcf0be16e039_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i07d33951a6dc47ab94b24b9ea268e74c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8bba769854d545f5b616e3e0f528bbb8_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4d16dbc5ae1849d0ac736d665bd1ea4f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6eea3af5cbd2450785901edf939f6913_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47874f0012974d65ab80752547b88e0a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iecc948505e8f40a58d9ef50d08c16138_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3e531b4a2b3848308af8e4c062dc3ae9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if1a2f4f2d93b403298227a14e3ea027f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie7b855636fc848dbb30121df166e6660_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i561f53dbd6ec40abbfe2adb13955f8b5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7235acd9aa184415ae42f56c42c67220_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib88f4defee8d42ec9fb95d874467a531_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i48119f8925ce4b7fa46fa0bc444edaf0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3340686a998b49ce95642072d397de0e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i64f0216262ee437f994ada0f2b06c020_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6e93a59c26d54a048d85bd6ba5ea6cab_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i002d7abe90a74c1f87d36f02f9911e16_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib518c264f77248c2961f26353ebe9258_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3b03e8cafdca4ef3b5ae3b6f88c8d2ef_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ied858eeea01d43f0ab1bd6a8e9d390cf_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5093b44a796548d5a32e7a485043d5ca_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic7f32e9378184e58bc262fb167c76e2b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if9c44ce4c45c45128c3cb4190f57ff3e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i646e9e6069754dd7973d990412c1ad05_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6396fb99dba4c38bbcd4ff6c21c04cb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i55e1d1a632d943cd8f9bc6caab027705_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if186b20296204ef3ad7eef32555753af_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0163830e210412f9315ea00b043a5fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae403e37990e47ed849d50e7b275152a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id613d04fbab14d078323ed4a8af18081_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie09d5b85850142b5ba448c3c23a85993_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0b4bfb2672b04d938b81043fab621f6f_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6eb80252b8d41968ceed50dd21e9d24_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6017f3dab4824927a649da5bf8db28a2_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib6670c16ced04552b621f7bdec168bce_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7cf2fcb06956482fa26b7e68b4e24699_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3629ab6d4d2d4265be7f841a30358d25_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i481dd6af2bdd4cf09e6db33df73fe757_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic07412c61c634f9ab38ea2cc8e9bb8d9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i785190d436454824afe1c0c04e317050_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie215578f33b740438664f8f4e662aaf5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i95fb39ce145c4439b0424fb05b3ed94e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if63a149dde3b4d70ac4a2c1ebf3233dd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9654cd90ba324591bbfdc696ed176e15_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i605e900922024071b01391ab39f722ff_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55490cf44eb04081807b779af67ab181_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie1a89c6eeac245a88286608dbe3adbcb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a76c5ebb0ec466fb2566e77ead1ee3f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib46d8ce11bc946359432bb84ee798ea2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4196d26cb6024d61bcd2b84921ae5be6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if70bdfc17f4843378fe0e472c8f0af69_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifc0c32e700994ca0b101674055e539a9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9955d34b683e4071859b13221b7991a2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if2f45e79358241e4bc75610a691f200c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iab736275bf9d4781ab26f264e447d2b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3ad5bba1b2945d5aca93409af485c52_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic7d0522994fa4c0e8e71d2a65df6059b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0014be1c64d54d3b9a57ae96f20be2db_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i81cd6e624ce543c1b130425e84f9df76_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icb713daf92854f7dbdd3bde3a5d23576_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8efdd516ad464b9cae1cee095ce35994_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ife0aa2938ef848b2a9705be0c7e31425_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib82e7ef87abf4a5ca9af04095e4d8100_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c51e142647147e3a11ac050a6f7d7f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4e3ea018e65d4409898ec845c882ed39_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4c8b5b78dbb848798300feff662c4c35_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i89350f0ae8aa4d629dde6b21abd22cb6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i64c51ebc726a488fbd985b493d51b309_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib4db1a9674a54a7ebe6ebf2c416564b2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i88ec600700d74563b50882f619542a97_I20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="i84b60bfd8fde493d8a88c8fd34276c56_D20210715-20210715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-15</startDate>
            <endDate>2021-07-15</endDate>
        </period>
    </context>
    <context id="id1d3f4fbb7de478bbc51935ca41ab818_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:SunClinicalLaboratoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57b89d29a2264160815b2599c489d073_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:SunClinicalLaboratoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>ameh:plan</measure>
    </unit>
    <unit id="clinic">
        <measure>ameh:clinic</measure>
    </unit>
    <unit id="segment">
        <measure>ameh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>ameh:unit</measure>
    </unit>
    <unit id="provider">
        <measure>ameh:provider</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>ameh:financial_ratio</measure>
    </unit>
    <unit id="location">
        <measure>ameh:location</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV8zLTEtMS0xLTA_f1f69469-6eb5-47cc-884d-ea849c2ea910">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV80LTEtMS0xLTA_5059e40d-4b63-406f-a4bf-71470dfbc4f3">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV81LTEtMS0xLTA_28caa300-c22d-421b-9fba-79554bdb8fe6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV82LTEtMS0xLTA_4a42b098-5cb5-49b6-81cb-7222d6d54db4">0001083446</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80L2ZyYWc6ZGJkZTRlYzM4MjIzNDZlNjg3ZTdhNzY2ODQ4ODZiZDgvdGFibGU6YjI5YWJiODJjYjhiNDIyMWFkYzE2NTk4MTkyMTBjZTkvdGFibGVyYW5nZTpiMjlhYmI4MmNiOGI0MjIxYWRjMTY1OTgxOTIxMGNlOV83LTEtMS0xLTA_99b995ee-599f-4132-b992-f34fc036d2a2">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i663b801e9e2f4faaa6db3d3affb1f45e_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzExNTQ0ODcyMDk0NDMx_f69dfb9e-740f-4b1d-890a-b5aa38e16317">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDkx_3c17b9cb-b9c0-4751-b9f4-efb4e11366e3">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6NjgwMjUxOGRhNjY5NGIxZGE0NDQzZDE2Yjg3YjIxMzAvdGFibGVyYW5nZTo2ODAyNTE4ZGE2Njk0YjFkYTQ0NDNkMTZiODdiMjEzMF8wLTAtMS0xLTA_148de52b-f826-47df-907b-20a33e9cee5a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8xMjQ_28c508ee-cee7-4b8a-9cda-ff50f071211a">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjU5MmQ2YWZhMzYyNGI5M2I2MTM0ZTdkZjJlNzkzOGYvdGFibGVyYW5nZTpiNTkyZDZhZmEzNjI0YjkzYjYxMzRlN2RmMmU3OTM4Zl8wLTAtMS0xLTA_7e9c6740-ee54-4406-9dea-8edebc8dc2c9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk0_0383245a-7b24-48b3-b634-af325f3118aa">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk1_73775f4a-248b-4ade-904b-cb6dd502fea8">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6OWIwNWZkMmMwNjJlNGQyNGJiNGU4ZTQwNjExODJjMmYvdGFibGVyYW5nZTo5YjA1ZmQyYzA2MmU0ZDI0YmI0ZThlNDA2MTE4MmMyZl8wLTAtMS0xLTA_633fa788-2a80-4bff-baa2-065a86f6579b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6OWIwNWZkMmMwNjJlNGQyNGJiNGU4ZTQwNjExODJjMmYvdGFibGVyYW5nZTo5YjA1ZmQyYzA2MmU0ZDI0YmI0ZThlNDA2MTE4MmMyZl8wLTEtMS0xLTA_1e93a638-689d-45f2-b3a6-8b484d7cf1a9">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDg3_25027b6f-5966-4a49-864d-e6067df313b2">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDky_25d58653-dd91-4a19-a621-facb3aaaf86c">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk2_6a699f9e-5871-44d6-a7ef-4a48f2f554ba">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk3_89826c18-460a-4a07-9c7d-99d436f42622">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk5_1576b4a0-4e0e-48e7-b562-56070108aa58">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDk4_62a9a182-5a06-43b3-8287-91ba1da17aaf">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDg4_113ea4ec-1f38-4e49-90df-806a893b4c98">282-0288</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6ZWQ2YjFlM2FiYTcyNGIyNTg3MTNhMTA1ODkxMDVlMzcvdGFibGVyYW5nZTplZDZiMWUzYWJhNzI0YjI1ODcxM2ExMDU4OTEwNWUzN18xLTAtMS0xLTEyMjIx_4eb10af3-27f1-49f0-9ce4-2d2855d5ebfa">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6ZWQ2YjFlM2FiYTcyNGIyNTg3MTNhMTA1ODkxMDVlMzcvdGFibGVyYW5nZTplZDZiMWUzYWJhNzI0YjI1ODcxM2ExMDU4OTEwNWUzN18xLTItMS0xLTEyMjI4_663d2020-351d-4569-be6e-90f4a9c76ec7">AMEH</dei:TradingSymbol>
    <dei:EntityCurrentReportingStatus
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDg5_50416566-7781-4fe0-860b-1b3a9f1adbfa">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8yMDkw_71c0e9f3-2b3b-4742-a76d-c1d9fa647172">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjE3MjliODVkZjQ0NDA0Yzg2ZGNjYTJiNTYwYTc0OWIvdGFibGVyYW5nZTpiMTcyOWI4NWRmNDQ0MDRjODZkY2NhMmI1NjBhNzQ5Yl8wLTItMS0xLTA_03fd4741-b25a-429e-96f3-d3557419fef7">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjE3MjliODVkZjQ0NDA0Yzg2ZGNjYTJiNTYwYTc0OWIvdGFibGVyYW5nZTpiMTcyOWI4NWRmNDQ0MDRjODZkY2NhMmI1NjBhNzQ5Yl8xLTMtMS0xLTA_e7a0ef0d-68b5-46ae-83df-a3f79c42979b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGFibGU6YjE3MjliODVkZjQ0NDA0Yzg2ZGNjYTJiNTYwYTc0OWIvdGFibGVyYW5nZTpiMTcyOWI4NWRmNDQ0MDRjODZkY2NhMmI1NjBhNzQ5Yl8yLTMtMS0xLTA_b2a86f71-4123-484a-b6b1-ec8059f4cd87">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8xMTU0NDg3MjA5Mzc3OA_ac6faa19-e2a7-4ec1-84bd-abdd05a210f5">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i774336f6b2934a0f91c94085695f17d1_I20210728"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xL2ZyYWc6MDA0MGM3MzVlN2E5NGU0NTllNTM3MzViNzM4ZjE4ZDIvdGV4dHJlZ2lvbjowMDQwYzczNWU3YTk0ZTQ1OWU1MzczNWI3MzhmMThkMl8xOTg5_346c8536-6500-4235-bfb0-d2ed77a27fba"
      unitRef="shares">55340095</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNS0xLTEtMS0w_548d9c81-7e22-4f86-be53-ebb2d6418970"
      unitRef="usd">177287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNS0zLTEtMS0w_5a0f3568-33af-4ef5-9781-820fec721964"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNy0xLTEtMS0w_82681861-cf37-4eef-875a-b3bd80a8559b"
      unitRef="usd">187206000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNy0zLTEtMS0w_f9acb4b2-e391-4a54-9ea1-38d88840fc91"
      unitRef="usd">67695000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOC0xLTEtMS0w_f08bff0d-b017-43de-9a11-aa956641a45e"
      unitRef="usd">16540000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOC0zLTEtMS0w_334b074e-e24a-41bf-92fe-a6e37b37cafe"
      unitRef="usd">7058000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOS0xLTEtMS0w_d8b61090-db7c-4cfc-a4a8-30e285a87f82"
      unitRef="usd">68767000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfOS0zLTEtMS0w_b4afa814-0ede-481d-9695-539655002aff"
      unitRef="usd">49260000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTAtMS0xLTEtMA_92451e91-3ac2-442c-9acb-f8dfa4495d20"
      unitRef="usd">4562000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTAtMy0xLTEtMA_e4e14ef0-7d82-4da9-9f43-2056f2a868ea"
      unitRef="usd">4297000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTEtMS0xLTEtMA_b1a46170-72ec-4a6b-9a6d-91870f49326d"
      unitRef="usd">12188000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTEtMy0xLTEtMA_6d40b41c-602e-4122-a92f-126a30e65f4b"
      unitRef="usd">16797000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTMtMS0xLTEtODYzNA_e507a451-764f-4afb-bdbf-a8239b7d1366"
      unitRef="usd">4000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTMtMy0xLTEtODY0Nw_0aa9295a-91f8-422e-b74f-3a0ad57c82a6"
      unitRef="usd">0</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTUtMS0xLTEtMA_c02a6d3a-e4cf-4ce7-adb2-6bb543e98f6c"
      unitRef="usd">470550000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTUtMy0xLTEtMA_1fa53abd-a2de-40c9-a166-59a64a38de65"
      unitRef="usd">338577000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTgtMS0xLTEtMA_21f1459e-0b60-4fde-93ce-9b765e13cb6b"
      unitRef="usd">40738000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTgtMy0xLTEtMA_50179cdc-6f4e-4127-b308-53706fe189a2"
      unitRef="usd">29890000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTktMS0xLTEtMA_2c70d84d-11c3-4ab1-bd17-e9622ed07faa"
      unitRef="usd">80227000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMTktMy0xLTEtMA_92e03032-ce76-4ce6-b24b-ab5911a45b40"
      unitRef="usd">86985000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjAtMS0xLTEtMA_06b29a50-d9f1-47ff-87a0-0f42be418110"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjAtMy0xLTEtMA_5fb3cc72-a7ec-4fbe-a440-6dcac7e23dea"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjEtMS0xLTEtMA_7adeb708-f0da-4cf7-9e42-85db4f93121f"
      unitRef="usd">594000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjEtMy0xLTEtMA_7da3a54e-31e6-4e94-acda-dbbfbe2a0cbd"
      unitRef="usd">480000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjItMS0xLTEtMA_f6180041-4bd0-409b-b689-3dc332b0aa2c"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjItMy0xLTEtMA_f13bb349-dd5c-44c5-8b97-a6801117f4c2"
      unitRef="usd">4145000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjMtMS0xLTEtMA_1c9f05ee-dd45-4465-b8df-c9f3e759a762"
      unitRef="usd">37372000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjMtMy0xLTEtMA_99ff97c9-dd40-4bcf-8ba2-f4885cef704e"
      unitRef="usd">43292000</us-gaap:EquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjQtMS0xLTEtMA_78499f85-fb32-4319-85aa-caca74548075"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjQtMy0xLTEtMA_f56ca2c1-abcd-4b19-b687-138cf6b5b769"
      unitRef="usd">37075000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjUtMS0xLTEtMA_cb455a13-dfb3-495d-83b2-72495a49d600"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjUtMy0xLTEtMA_55b80b90-2e3e-4d9a-a6ce-c63180b769c6"
      unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjYtMS0xLTEtMA_25b24159-c7c9-4b27-bfbf-0755ff8c8418"
      unitRef="usd">16928000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjYtMy0xLTEtMA_a8fb83e9-62bb-41be-8543-a50b3ec469ce"
      unitRef="usd">18574000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjctMS0xLTEtMA_815ae5ba-9de3-45a6-b509-bdf0dd907f80"
      unitRef="usd">8072000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjctMy0xLTEtMA_4678a7d8-09ae-478e-8f9e-d3b640000e0f"
      unitRef="usd">18915000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjktMS0xLTEtMA_8c201a52-5197-47d3-84f9-0b2788de9841"
      unitRef="usd">423880000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMjktMy0xLTEtMA_0db04a7e-9e67-4746-8f42-6b8d861f420e"
      unitRef="usd">478909000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMS0xLTEtMA_6fb4196b-8ede-4315-ad4b-455a523a32b8"
      unitRef="usd">894430000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMy0xLTEtMA_6366d7b1-1d44-47df-9924-2597b54deede"
      unitRef="usd">817486000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzctMS0xLTEtMA_c90f7883-73a3-4225-b3cc-975e7dd049a6"
      unitRef="usd">53792000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzctMy0xLTEtMA_71d8ed30-df7e-47db-aa85-40f5eb65ae80"
      unitRef="usd">36143000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzgtMS0xLTEtMA_6cc89552-178f-4906-bce5-8580eda2e39b"
      unitRef="usd">9092000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzgtMy0xLTEtMA_d1fd1146-5ddf-4f68-a3de-94080d10e5b5"
      unitRef="usd">9642000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzktMS0xLTEtMA_a384b30a-eb41-42f7-a0c0-39f51f0d5ca6"
      unitRef="usd">59307000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzktMy0xLTEtMA_035c6bef-d1ee-4619-a065-59607501d7c4"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDAtMS0xLTEtMA_8731a99c-aa6f-4b9e-80b1-50b36c495012"
      unitRef="usd">2215000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDAtMy0xLTEtMA_28733d0f-df06-440b-9d04-0fce6ffaab40"
      unitRef="usd">4224000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDEtMS0xLTEtMA_26d85f1a-3846-4fbe-b652-596759175352"
      unitRef="usd">536000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDEtMy0xLTEtMA_28ea79d1-42d0-4b98-8b88-7a8f6195dd73"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDItMS0xLTEtMA_18a86b63-28c2-49a1-b28c-78bbde98434b"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDItMy0xLTEtMA_c1a23be6-0d98-4c2a-a57d-3a8e44231bdf"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDMtMS0xLTEtMA_7c831f80-37a8-4d25-ac25-13231488d6df"
      unitRef="usd">2831000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDMtMy0xLTEtMA_9a445112-0e01-418f-a383-df111762d511"
      unitRef="usd">3177000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDQtMS0xLTEtMA_f3e28f03-1ba1-43ea-a3e8-dbbba55773c6"
      unitRef="usd">205000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDQtMy0xLTEtMA_411b6bbd-fc37-404c-8969-edde11ba5fe4"
      unitRef="usd">10889000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDUtMS0xLTEtMA_621d9c18-8694-40f6-940f-978a07961c6d"
      unitRef="usd">128088000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDUtMy0xLTEtMA_9d3dc996-72fd-483a-8081-051927e83ff0"
      unitRef="usd">114992000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDgtMS0xLTEtMA_0d92aa79-9b6d-4b4e-a44e-4731efe23250"
      unitRef="usd">21242000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDgtMy0xLTEtMA_a0431a96-4f85-4ed3-8b69-cb36ad176950"
      unitRef="usd">10959000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDktMS0xLTEtMA_34f5ecf4-b0d0-4526-afed-cb1b32bbe9c1"
      unitRef="usd">249000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNDktMy0xLTEtMA_068e0f61-e41c-4220-b8a2-5a2c9cc2485d"
      unitRef="usd">311000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMS0xLTEtMA_4a9e7d8e-3c13-42e1-b7ff-121e527ef8f3"
      unitRef="usd">14513000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMy0xLTEtMA_91c16957-9078-4505-8db3-348163ca6451"
      unitRef="usd">15865000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMS0xLTEtMTA5NzM_2bd9044b-2d52-4876-a94d-4de5128f49cb"
      unitRef="usd">182705000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMy0xLTEtMTA5NzM_6c956ae9-6c7f-4c5e-ac42-040743bdb7b4"
      unitRef="usd">230211000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMS0xLTEtMTA1MjQ_76436b13-6675-4d61-b199-c13dd8f5269c"
      unitRef="usd">1195000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTAtMy0xLTEtMTA1MjA_a86205ff-becf-416e-bf65-6b150d24cda8"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTMtMS0xLTEtMA_18c09a0a-d6fb-453c-9700-bace388925e1"
      unitRef="usd">219904000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTMtMy0xLTEtMA_ec94903d-93f5-415e-bc03-102c513de2f9"
      unitRef="usd">257346000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMS0xLTEtMA_bdc9231e-d10b-4879-961f-7bf270c932ce"
      unitRef="usd">347992000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMy0xLTEtMA_f03eecc3-ad45-423f-ae4b-83573a07eaf6"
      unitRef="usd">372338000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTctMS0xLTEtMA_c4ee347c-9853-4ada-9a1d-a47f3c1fc056"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTctMy0xLTEtMA_c7abccac-461b-4792-a6e8-13e36a59b386"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjAtMS0xLTEtMA_9bfec5e9-bad7-44d0-9306-aa654b7cd0c0"
      unitRef="usd">141856000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjAtMy0xLTEtMA_f94d5c79-349b-4757-9ee1-0f83aa549abd"
      unitRef="usd">114237000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if83782563ea04b51a3cd25b22894290e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzMw_3ba38bb4-f984-49de-9ec6-faa3910762ea"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzMw_d6cdaad5-c44f-406c-95a0-1e16e06b2712"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if83782563ea04b51a3cd25b22894290e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzU0_2b7d757d-cefd-4f62-a570-df94c85e5b33"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzU0_86090fd7-9f44-46e4-afd7-5bbe02f76d5e"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE0Nw_87179e3a-b7a4-4639-9903-584c5e6cebdd"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if83782563ea04b51a3cd25b22894290e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE0Nw_f97912c9-c389-4cde-97de-a525b986e292"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if83782563ea04b51a3cd25b22894290e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE2MQ_49db5ff0-3245-48ee-b01f-5ff7fdc29b73"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOjVkMGNmMmQ1ZWM4MTRkNjFhMjY2ZjA0NmNhMjlhM2JlXzE2MQ_b0d631e9-adbd-401b-b39e-c0c323b3b2c8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i5c64f14ef0e241418d33b2d1f59c64d1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMS0xLTEtMA_d8fa4499-5596-4994-88d9-95611340b005"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if83782563ea04b51a3cd25b22894290e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjMtMy0xLTEtMA_59c2c047-857c-42c6-ae90-decd948cce0f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzMw_7fbdb19c-225c-4375-a2f1-c25012a030bb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzMw_ccf8f446-66ed-4741-8526-d25768ec02d5"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzU0_0d1fa869-0201-45cc-a0d3-4567092f90c5"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzU0_e630fbac-5f6f-4621-94df-ef48edba9b40"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE0Nw_0c7e61c9-fcf3-4311-902e-14c8b22afcff"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE0Nw_d871c12a-596d-480b-8db2-fb724aa25299"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE2MQ_0a33380e-c799-415f-ade2-ce7c72c51805"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMC0xLTEtMC90ZXh0cmVnaW9uOmM0NTMwNzk2ZDUyMzRmNzI5MDI3NGFlZjY3ZGRiYjYwXzE2MQ_b107cc57-3afd-4152-9ea0-78e74d60633a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i717e4c08a5f045dbad2f7071e17325fb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMS0xLTEtMA_b45afbde-c1ac-4157-8a7b-664788e4cb1e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i433fbe5b9bbf40fab306efc9aee92e57_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjQtMy0xLTEtMA_32001eec-a394-4c47-b2d6-f25c444c54ac"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzE4_11448a03-5986-4b89-8e13-6a7059b936fb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzE4_7183e944-47fd-4661-9fb1-01bce25d59b2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzQy_31a45033-e48c-4b53-940d-df5551a0d4f1"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzQy_771dcc41-09b6-4538-9512-95306fe9b8c0"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzY0_69bcfa03-402a-47b4-aa29-a28df66ede00"
      unitRef="shares">44246796</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5Xzcx_cfd6222c-a9ff-4167-914d-68a1193a6a71"
      unitRef="shares">42249137</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzEwNA_bcb9ad1f-12b9-4249-bce1-c0caa1cf0c0d"
      unitRef="shares">10885732</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMC0xLTEtMC90ZXh0cmVnaW9uOjIwZjU2OTMwNWRiYTQ2ZWE4ZDg4ZDY4NDg5NmIxM2M5XzExMQ_949d66ab-4144-43f6-98b2-84d23ffcb162"
      unitRef="shares">12323164</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMS0xLTEtMA_0bc43b44-ffef-4309-b067-914dd6e40225"
      unitRef="usd">44000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjUtMy0xLTEtMA_fb40068c-03de-4989-99b9-9d649161b2a2"
      unitRef="usd">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjYtMS0xLTEtMA_9d0a10b9-d9c6-477f-8176-23efa6045176"
      unitRef="usd">305736000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjYtMy0xLTEtMA_b64d2b4a-0028-4c8b-bb56-f2c7d187677f"
      unitRef="usd">261011000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjctMS0xLTEtMA_e811a3d2-b68e-4b40-95b4-526315bd8d2a"
      unitRef="usd">95580000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjctMy0xLTEtMA_c5571c7e-82c7-44fe-82eb-8521e28b5fd9"
      unitRef="usd">69771000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjgtMS0xLTEtMA_5fc5c16d-71fa-49e3-b370-b589a9c87ac4"
      unitRef="usd">401360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNjgtMy0xLTEtMA_aaeff108-4bdc-494b-ac9a-d9764e386c1f"
      unitRef="usd">330824000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzAtMS0xLTEtMA_fd66742a-9ce3-4ad2-847f-24bc6aaf9008"
      unitRef="usd">3222000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzAtMy0xLTEtMA_1e7e2550-13db-4d3a-b631-da9993a47729"
      unitRef="usd">87000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzItMS0xLTEtMA_b872d3c2-e739-4591-b83a-f58dca40435f"
      unitRef="usd">404582000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzItMy0xLTEtMA_1f0d83fe-5c02-416a-ae46-ea5124db3755"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzQtMS0xLTEtMA_b4adb6b4-5b6d-4c64-8eda-0990a555ca8c"
      unitRef="usd">894430000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNzQtMy0xLTEtMA_874ce90e-51c5-4bf4-b66d-3f49628ab6eb"
      unitRef="usd">817486000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNDcy_dc7f2171-93ae-47a6-b083-8722c3cb695d"
      unitRef="usd">1347600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNDc5_5f3154b9-2747-42f3-8579-4447f15ba64b"
      unitRef="usd">801300000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNjYz_521b827c-a8f1-4185-8291-7c6cd30dbcc6"
      unitRef="usd">107100000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNjcw_d2fe661a-8109-46dd-9515-e532f5023879"
      unitRef="usd">111300000</us-gaap:Liabilities>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb9a2861a1cd425cbac5b68ba09ac7d9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy0xLTEtMS0w_f3f8763e-44ae-465b-be18-64a9c08c2e74"
      unitRef="usd">144550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1f37ef4f8e441468877d24814c185a1_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy0zLTEtMS0w_c29c9825-466b-4413-bb7b-f342c4d97b54"
      unitRef="usd">140949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i966c0e3cfd7b4121ae382a0aaa9006e5_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy01LTEtMS04Mw_90856575-3fe1-4acf-bf53-586430875a79"
      unitRef="usd">289290000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee1686eba6fe45ea8ae559c43929c25a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMy03LTEtMS04Mw_31e0b71d-0ebd-4816-b1d9-63a54098814d"
      unitRef="usd">281370000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b10c8aa5ea249a4a41ddbb9cc4eea0a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC0xLTEtMS0w_7ff2e8ee-d026-4044-91d2-b29473c103c0"
      unitRef="usd">16214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i034404d6de0e40b4a7e7b9479235c135_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC0zLTEtMS0w_c13ca8e9-1f21-4112-b187-0bbb2585d54e"
      unitRef="usd">12003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24ceb8c42ea441928271a4fe96c772c7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC01LTEtMS04Mw_f0832c3d-3bbf-46c2-889e-41fa374b7b06"
      unitRef="usd">34224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56f9749216e941d6972e946201b43078_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNC03LTEtMS04Mw_ae143ea3-48ae-47a5-82a4-a854d31c46c8"
      unitRef="usd">23239000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b75704f2b5b46bdb05980233ec4c43a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS0xLTEtMS0w_e5c12daa-bdd1-4e8a-b96e-f75ced8c5d26"
      unitRef="usd">8143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11a9f1d5e9e54374a1155ab5e469b579_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS0zLTEtMS0w_cd038c3d-4a84-4272-bcbb-6add6e4781e4"
      unitRef="usd">8690000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2445932d5cee413a82029f7fb82d054a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS01LTEtMS04Mw_5a9d14a2-ffd2-43f0-8738-633843826699"
      unitRef="usd">16693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cdf9a72099248dbb61045162c5ad976_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNS03LTEtMS04Mw_2811f526-72a8-488c-bc9c-6891c7930cfe"
      unitRef="usd">17505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19f4308062ec4348a933166fa6f2f686_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi0xLTEtMS0w_6487ccb9-e854-4b91-b22a-1bfc3154af64"
      unitRef="usd">4621000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a9aec26e9304fabb5f23f0a39e18d03_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi0zLTEtMS0w_3b099bea-ac29-4d83-9bd9-9844483480fa"
      unitRef="usd">2270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c3c3a8071974b2ebd2dfc2fc3864f64_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi01LTEtMS04Mw_0f190711-ca18-4443-9a82-a21eafd11c46"
      unitRef="usd">7707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i064c3aa533b24d6e9e68036d91b37ce9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNi03LTEtMS04Mw_71ccdc90-63e1-4f8b-b213-aa33974cd990"
      unitRef="usd">5697000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cd3132fbc4049f99af3739b782bd5e5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy0xLTEtMS0w_3fa22814-061a-44eb-8e2f-54dc3222fcd8"
      unitRef="usd">2110000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdb52ec1c4434204a5ba6722dac7a06c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy0zLTEtMS0w_d249bc91-35f0-480d-8c0f-1386975843bf"
      unitRef="usd">1257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic275903b015f4a8f987d0517de1d6b23_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy01LTEtMS04Mw_76d611da-56a2-4739-bc2f-49429836a653"
      unitRef="usd">3782000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16e822ece8a3418f958ae5c43e6eb6de_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNy03LTEtMS04Mw_306e544f-656c-470e-9def-a8511e29a905"
      unitRef="usd">2463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS0xLTEtMS0w_3b4ce25f-0134-4ffc-a09e-5496b29aac39"
      unitRef="usd">175638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS0zLTEtMS0w_a19e4840-f75b-4497-9b3f-83832b22f945"
      unitRef="usd">165169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS01LTEtMS04Nw_1b13ede7-187b-492c-bea6-8da666dbc747"
      unitRef="usd">351696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfOS03LTEtMS04Nw_2261d3d4-a0b5-4b40-a6a1-a374feb9fcee"
      unitRef="usd">330274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItMS0xLTEtMA_a9757487-8268-455f-8020-738bb12d43ac"
      unitRef="usd">136214000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItMy0xLTEtMA_b4eb38ed-d72c-4493-bd64-4c6e000ac023"
      unitRef="usd">136079000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItNS0xLTEtOTE_eaa320ee-8fe9-4986-8d00-34fb0b49bf1a"
      unitRef="usd">276829000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTItNy0xLTEtOTE_9253562d-c91b-461f-a36a-3bb90665e963"
      unitRef="usd">280283000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtMS0xLTEtMA_68cf0fcc-e99a-4fdc-bf5d-42bb9a29fd34"
      unitRef="usd">14199000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtMy0xLTEtMA_8beea8e4-1168-4928-a9f0-bb1640c28f31"
      unitRef="usd">11556000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtNS0xLTEtOTE_d9879c29-1131-4bb5-9253-e70334d11bfa"
      unitRef="usd">23663000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTMtNy0xLTEtOTE_2728c94a-1565-424c-91fe-1ceff0942bee"
      unitRef="usd">23390000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtMS0xLTEtMA_9e6653ac-efae-43aa-b9b6-3f5578bcebed"
      unitRef="usd">4237000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtMy0xLTEtMA_041e9c78-7159-4c88-82fd-5c1210f90f87"
      unitRef="usd">4628000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtNS0xLTEtOTE_00c9a3c7-8fb9-456e-aaf2-eb1a70009c88"
      unitRef="usd">8434000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTQtNy0xLTEtOTE_d4c59c9f-3efe-4714-82c0-2e74b4c83ce0"
      unitRef="usd">9330000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtMS0xLTEtMA_25472490-9810-4681-bb29-d51bddb18413"
      unitRef="usd">154650000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtMy0xLTEtMA_1b0f4d1d-8b32-42d5-9b6c-0325dbe44617"
      unitRef="usd">152263000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtNS0xLTEtOTc_731d0452-1338-4f08-87f3-b8e99b3b8846"
      unitRef="usd">308926000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMTgtNy0xLTEtOTc_a496f260-edc3-43b2-b921-61f3fbe50373"
      unitRef="usd">313003000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtMS0xLTEtMA_4d0ca82f-c397-425a-94c9-e9747286f18d"
      unitRef="usd">20988000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtMy0xLTEtMA_2736f07c-8d4d-4e2a-8654-3f5e1ca7e4a6"
      unitRef="usd">12906000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtNS0xLTEtMTAy_79be457e-e1c7-445d-99c2-020d7ac5f808"
      unitRef="usd">42770000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjAtNy0xLTEtMTAy_134a5df8-0831-4601-b096-f41fc0317fd5"
      unitRef="usd">17271000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtMS0xLTEtMA_fc464a13-8502-4238-8f15-32d68d72e763"
      unitRef="usd">-3134000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtMy0xLTEtMA_ed2e76ed-e6ba-47c9-9bc3-989ec79fe9cf"
      unitRef="usd">834000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtNS0xLTEtMTA3_590ba9dd-292b-4fed-9683-2fabd39e5a0a"
      unitRef="usd">-3812000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjMtNy0xLTEtMTA3_ad342e02-ff5c-4abe-a2b3-31aedbc8d166"
      unitRef="usd">2888000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtMS0xLTEtMA_f074610c-a90b-4999-956b-b30136014f95"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtMy0xLTEtMA_254c2e61-dcb1-4eae-910b-86edd7586f70"
      unitRef="usd">99647000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtNS0xLTEtNDg0MQ_e34722ef-8d5e-4be6-8086-41f409917c7b"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjQtNy0xLTEtMTgxOQ_60317a8d-e4fa-4688-8622-87a5af0004b3"
      unitRef="usd">99647000</us-gaap:GainLossOnInvestments>
    <us-gaap:InterestExpense
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtMS0xLTEtMA_3a53886e-a8cc-4be7-a373-bf4b14b19311"
      unitRef="usd">1853000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtMy0xLTEtMA_fc47f45d-059f-4fc4-800f-670a676b0f26"
      unitRef="usd">2673000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtNS0xLTEtMTEx_1799aee4-e03e-4dda-99a4-896759feb18e"
      unitRef="usd">3376000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjUtNy0xLTEtMTEx_bef6e16b-4500-40e8-b392-78d8a62d6d5a"
      unitRef="usd">5541000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtMS0xLTEtMA_e1fbc64f-42fa-497c-be92-8469e62dca7e"
      unitRef="usd">563000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtMy0xLTEtMA_23995244-d593-4ae9-a47e-1296584044fe"
      unitRef="usd">863000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtNS0xLTEtMTEx_a14a4bbf-9a55-4530-93f9-6bf6620ddee7"
      unitRef="usd">912000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjYtNy0xLTEtMTEx_79ed51db-22f7-41dc-bb9e-5de9b8142b42"
      unitRef="usd">1792000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctMS0xLTEtMA_06cb8c47-2af3-4d7c-a217-ef1f93b0d5a8"
      unitRef="usd">67886000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctMy0xLTEtMA_8dc7d189-a4d0-4217-8763-e9fb9c0e7567"
      unitRef="usd">1282000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctNS0xLTEtMTEx_1eab15ff-4cca-40db-8c40-bca7005b7045"
      unitRef="usd">69190000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjctNy0xLTEtMTEx_c028d698-ca18-4dab-81f5-2d2f66dd6a2f"
      unitRef="usd">1384000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktMS0xLTEtMA_43127f2b-dcc8-47c6-bafa-418bad240d82"
      unitRef="usd">63462000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktMy0xLTEtMA_6d0a8fdc-a1d6-451d-b810-97a2e8a586d6"
      unitRef="usd">99953000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktNS0xLTEtMTE2_69c4ac5e-894a-40d9-a50d-91ad674c591f"
      unitRef="usd">62914000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMjktNy0xLTEtMTE2_569d6b0b-321a-49cf-a760-8b682ccd8551"
      unitRef="usd">100170000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtMS0xLTEtMA_a332a0f6-98e6-4450-b32c-b6412a28ddcb"
      unitRef="usd">84450000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtMy0xLTEtMA_b7a7b3bc-7dce-432e-977f-2bfedbd1b984"
      unitRef="usd">112859000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtNS0xLTEtMTIx_c5c7695e-75e4-41a9-8fef-c25adefccfdf"
      unitRef="usd">105684000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzEtNy0xLTEtMTIx_b2f30287-2aac-4aa6-af38-b75011ad2e7b"
      unitRef="usd">117441000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtMS0xLTEtMA_02dc410d-d495-4dab-a46b-9b32f3133aaa"
      unitRef="usd">24920000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtMy0xLTEtMA_0b73a85a-11eb-45bb-9e27-2d84bc945283"
      unitRef="usd">31858000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtNS0xLTEtMTI2_7f351759-9539-4ccd-b650-70ff46950a1b"
      unitRef="usd">31696000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzMtNy0xLTEtMTI2_f39b9a4f-eace-4355-868b-d3f5680a76c9"
      unitRef="usd">33453000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtMS0xLTEtMA_1f1c93c6-4d86-4e29-a5b7-bd497d3ef521"
      unitRef="usd">59530000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtMy0xLTEtMA_f4ad5444-e427-4c4f-ac16-0c3127a857ce"
      unitRef="usd">81001000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtNS0xLTEtMTMz_75adb937-de27-4562-a7c2-1c358346c4f6"
      unitRef="usd">73988000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzUtNy0xLTEtMTMz_e1421424-0194-4458-8ae1-c912b1e6d8ba"
      unitRef="usd">83988000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctMS0xLTEtMA_dc1e7041-0229-46bd-8c5e-4670dcb0e6d2"
      unitRef="usd">46872000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctMy0xLTEtMA_414ad43b-55ac-43f2-9426-62a567071a4a"
      unitRef="usd">73957000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctNS0xLTEtMTM3_022681ae-232f-45b9-ae44-31947809c7a6"
      unitRef="usd">48179000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzctNy0xLTEtMTM3_1a9be0d2-a15d-4ccc-9363-8ac51bb081a4"
      unitRef="usd">72892000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktMS0xLTEtMA_ec239ad9-a172-425c-97a8-179599caa459"
      unitRef="usd">12658000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktMy0xLTEtMA_2476d85c-b55e-4b2f-8685-524b22caad2f"
      unitRef="usd">7044000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktNS0xLTEtMTQy_5c556cdc-cc90-4ca7-a348-0b1f8747c736"
      unitRef="usd">25809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfMzktNy0xLTEtMTQy_d75d1d96-fbc8-40a5-9299-d92d4d211e66"
      unitRef="usd">11096000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtMS0xLTEtMA_ec20610c-aef8-4039-b7bd-86f9b4b998be"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtMy0xLTEtMA_9e429622-8d34-4514-a782-172347aea1d5"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtNS0xLTEtMTQ2_5ac7513b-605d-4053-bf93-9da9a2b51864"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDEtNy0xLTEtMTQ2_3b7a156e-a7e6-4531-8096-98fd3fe5b5c5"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtMS0xLTEtMA_54183e0d-5cd4-4b49-9ed3-c562a0b2782d"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtMy0xLTEtMA_23e1116d-91db-4a05-b311-0de3b146b48a"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtNS0xLTEtMTQ2_dd1a0d34-81d1-4c58-aac3-3aebba051241"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yNS9mcmFnOjk3NGQ1OTgxMjQ2MDRkYzliN2FkZDFlMmI5MGU3N2RhL3RhYmxlOjQyMWQ0OTk4MGE3ZjRhYjQ5MTc0MDFiZDI0MTM2ZDVkL3RhYmxlcmFuZ2U6NDIxZDQ5OTgwYTdmNGFiNDkxNzQwMWJkMjQxMzZkNWRfNDMtNy0xLTEtMTQ2_620dd866-4e6c-4d44-aaad-185a27c95e68"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4bf2d3e70c19468bbc98d922ab423bc3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0xLTEtMS0w_0a4bc8a9-39df-4791-bdb0-5ec56026032d"
      unitRef="usd">114237000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i7f84a157fed746cf807e86d306825b89_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0zLTEtMS0w_a62104ac-74ed-48a0-9e46-62cd70a0a9cb"
      unitRef="shares">42249137</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f84a157fed746cf807e86d306825b89_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy01LTEtMS0w_aa7ef3c4-438b-4f32-ace0-7111e7f786c7"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic48ae9c2bd4c4add942fc7d050be7a25_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy03LTEtMS0w_ba9d22d2-7d7d-43b7-8189-1ed8542f75fe"
      unitRef="usd">261011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7c3d0dfa54749a5b3ed5d1271ddff4c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy05LTEtMS0w_b075d3bd-a7bb-4ad9-bef9-46ee76464dcb"
      unitRef="usd">69771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i01162a4b9b294f918c58c035a6c23ce3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0xMS0xLTEtMA_421ead13-1941-4220-bc4e-bf18579b9979"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMy0xMy0xLTEtMA_c012b2b2-0c11-4ae5-a479-fe7ca19b0e29"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ib624e9a32c5b47d4ae32002ccb4e7fda_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC0xLTEtMS0w_a1fd46cb-5ff9-4e41-9623-d2be8d02393c"
      unitRef="usd">760000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i2f61732e02a249169204410e0423af69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC05LTEtMS0w_cb1c2795-e563-4aa1-a7c4-be5caa4c642a"
      unitRef="usd">13151000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC0xMS0xLTEtMA_f9171cbb-b5f3-495d-80f5-c5815daed672"
      unitRef="usd">547000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNC0xMy0xLTEtMA_711273b3-e052-4459-901e-44ffd6679695"
      unitRef="usd">13698000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ib624e9a32c5b47d4ae32002ccb4e7fda_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNS0xLTEtMS0w_1303c810-73d3-46a3-bc93-463e10ad4e5c"
      unitRef="usd">150000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNS0xMS0xLTEtMA_2b5a619c-0f83-4f7c-9ce4-3a67dce46343"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNS0xMy0xLTEtMA_baea8953-dc7f-4799-a1f8-7fd4c439a8de"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNi0zLTEtMS0w_017eae9b-474d-4146-9682-e0ac1526b99f"
      unitRef="shares">34158</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNi03LTEtMS0w_c9ca5913-8677-4254-b68e-2ff2021eb04c"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNi0xMy0xLTEtMA_86490b37-52e0-48e8-8e38-bb7819447999"
      unitRef="usd">342000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNy0zLTEtMS0w_5052a1e7-3ac2-439f-b91a-006f0bc15067"
      unitRef="shares">5281</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNy03LTEtMS0w_6ddb9262-8d2f-4066-ac23-7f0a66b98052"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfNy0xMy0xLTEtMA_5519debd-307a-46f8-92f0-67c08ff09340"
      unitRef="usd">144000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOC0zLTEtMS0w_988dc6c7-5636-43ab-bacf-0385090c609a"
      unitRef="shares">7689</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOC0xMy0xLTEtMA_0a7a9f64-9c34-42be-8614-3ec4362c6f74"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="idbfe52c73cdc4a6a979d5296a36d7b39_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOS0xMS0xLTEtMA_9854197d-385a-4ba7-add1-2358c6a30bce"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfOS0xMy0xLTEtMA_bee51826-cc49-4df5-9bd8-539515452ea3"
      unitRef="usd">37000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtMy0xLTEtMA_62521f20-40d8-4813-9dee-46ad4de70ac8"
      unitRef="shares">421002</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ibcd96999266142519b4b10cc8506625c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtNS0xLTEtMA_3e0758d5-001d-4da1-adbe-4ca9e57fcfb8"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtNy0xLTEtMA_284918c2-fbca-45ec-9163-7d79e0f48951"
      unitRef="usd">4255000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTAtMTMtMS0xLTA_d9e541dd-fcf7-47b3-a42e-3d4c64e60f8e"
      unitRef="usd">4256000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if526e568344046fd872628c73d56c372_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTEtNy0xLTEtMA_6b067ec7-6488-4e48-9388-d027a9af5f17"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if113145ebc65456db9c0daf8623a90f6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTEtMTMtMS0xLTA_5b04656d-2b8b-4cd7-9fc1-717c4f176c6c"
      unitRef="usd">1346000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8965f51e39c644189ad1adf884d50c8d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMS0xLTEtMA_7f4eb4de-e56d-44f4-8898-65036e5ddebc"
      unitRef="usd">114847000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="id6e5ebc9ac3e4cf7ae33e8b75f1f9e16_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMy0xLTEtMA_270c6e36-a7c2-4fdf-9185-d945f3ea5272"
      unitRef="shares">42638389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6e5ebc9ac3e4cf7ae33e8b75f1f9e16_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItNS0xLTEtMA_4ebabb2f-8585-44fe-8c20-38fe15de9a16"
      unitRef="usd">43000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37408aff606244098ce0fa1bdfdcacfb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItNy0xLTEtMA_23f6fd6f-3c44-453e-9e89-b966305d18b7"
      unitRef="usd">266126000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9c4138381c446ffb27c642f7235110c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItOS0xLTEtMA_c1573849-f9f4-461c-bc02-bdf0e66037f7"
      unitRef="usd">82922000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if42aef36f805415ca26593430dc35d0d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMTEtMS0xLTA_4736e78e-1d54-49e5-906e-e2a0962c18e0"
      unitRef="usd">596000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic250c2fb27a24f8f8d50710d9cda482e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTItMTMtMS0xLTA_7847463d-22cc-4c2f-94e2-9abbaca96d15"
      unitRef="usd">349687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtMS0xLTEtMTgw_99a4e607-9c97-4b07-9d8b-f3b0034f2b5e"
      unitRef="usd">46859000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i479444d836ce4650a533df644c674a5a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtOS0xLTEtMTgw_7063639e-13f4-4ad8-b16c-7c8b7efe075a"
      unitRef="usd">12658000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtMTEtMS0xLTE4MA_c58d7050-20d2-46d9-bb3c-f89efc5bce2f"
      unitRef="usd">13000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTMtMTMtMS0xLTE4MA_7046ca69-e920-4405-a4c8-a4a409708f3c"
      unitRef="usd">12671000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTQtMS0xLTEtMTgw_528374ba-a7d9-4c18-8ffd-7bdfaa0d480a"
      unitRef="usd">-150000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTQtMTEtMS0xLTE4MA_80c5b44d-094d-4149-9ed0-489aaa6994c3"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTQtMTMtMS0xLTE4MA_d6c4df55-9147-4606-9ae4-9c2f18e12dc8"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTUtMy0xLTEtMTgw_e1cf980e-305d-41bf-96f9-19a4d2a1c7f8"
      unitRef="shares">22284</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTUtMTMtMS0xLTE4MA_2a5cfbd6-1fd9-437a-adaa-d57707eec3be"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTYtMy0xLTEtMTgw_43a4f4c8-f3c1-44f0-b0ca-aed9dc00cae6"
      unitRef="shares">53504</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTYtNy0xLTEtMTgw_33b0badb-3508-4b23-a075-270532c253eb"
      unitRef="usd">561000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTYtMTMtMS0xLTE4MA_fe70571e-d7c8-4624-96fc-88c36d5e24d7"
      unitRef="usd">561000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTctNy0xLTEtMTgw_eb086179-be79-4721-80c1-4b5e6c72a8eb"
      unitRef="usd">1556000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTctMTMtMS0xLTE4MA_3c80a447-24eb-436c-9817-2685e7371161"
      unitRef="usd">1556000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTgtMy0xLTEtMTgw_e9104e4e-8ca7-4db4-9546-eef048d86274"
      unitRef="shares">5426</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTgtNy0xLTEtMTgw_dff112a7-50c9-47cc-8676-2128e0f2d177"
      unitRef="usd">189000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTgtMTMtMS0xLTE4MA_6f6d0f8f-ea5f-47bc-9c8b-efb25400ce06"
      unitRef="usd">189000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMy0xLTEtOTQ2Mg_f5ee13f6-d1ae-4f0b-b357-aa3aa8c72754"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktNy0xLTEtOTQ2Mg_1e5292c9-d938-4618-8c00-32900f2ec23b"
      unitRef="usd">2450000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMTUtMS0xLTk0NjI_87769669-0e40-41f3-8266-bc37e9932c9c"
      unitRef="usd">2450000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMy0xLTEtOTQ2Mg_3098c45a-e304-45f6-bd6f-251282d05132"
      unitRef="shares">1638045</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ie6633894239043beb0507e0d353ae82e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNS0xLTEtOTQ2Mg_dfd9cb6f-c3f0-43d3-ab4a-284583c3702c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i34c970c31d5a486ea6f5327ec179becd_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNy0xLTEtOTQ2Mg_cad0f2eb-c795-4b8a-aa2b-09874f94173a"
      unitRef="usd">40132000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMTUtMS0xLTk0NjI_3565858d-dc2f-4e48-96b5-410ec5c7cb4f"
      unitRef="usd">40133000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjEtMTMtMS0xLTk0NjI_0ff60ca0-3024-4130-9094-ec1cdb1c70fb"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjEtMTUtMS0xLTk0NjI_e16ba309-0f8b-4095-bd78-ed00f2f8a7d0"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i144c1256e5ee4fe192f616033e3bc50a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMS0xLTEtMTgw_7202d946-5516-4501-977b-256fed16714c"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2d2ff288f7a44acb8031c34aff98f353_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMTEtMS0xLTE4MA_18b8bcf1-8686-4340-99a1-d2538d26c86b"
      unitRef="usd">1156000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMTktMTMtMS0xLTE4MA_ff5514f9-1d3d-4371-b8f4-ca72e2118f8b"
      unitRef="usd">1156000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica140c4561ff41ec87f96640e43a80ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMS0xLTEtMTgw_c47508a9-b9d7-4124-b1b7-f0f72f4bbb73"
      unitRef="usd">141856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i8c791b64a17e46bcb009aa18c776e397_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMy0xLTEtMTgw_80eef65e-60fa-4e05-b346-3925e3224a31"
      unitRef="shares">44246796</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c791b64a17e46bcb009aa18c776e397_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNS0xLTEtMTgw_70712fcb-b7a5-4eb1-bc33-ec44accc37a2"
      unitRef="usd">44000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic700bd2057234d16a57c7e2195bfc225_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtNy0xLTEtMTgw_c12a68bd-e6e9-443d-836f-36ef6939bbd3"
      unitRef="usd">305736000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i170a94cec6714d3998abcf063693b6eb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtOS0xLTEtMTgw_0032c399-6fd1-47eb-b67e-e6dfd04646da"
      unitRef="usd">95580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7275ded6bd054db1b521ee6e3aab324f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMTEtMS0xLTE4MA_9919d90f-c479-4441-86ab-afe0f03a445f"
      unitRef="usd">3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjRiYjdjYjdmMDA3ZjRhYjc4MzIxNjhlMGM3MjIwODZhL3RhYmxlcmFuZ2U6NGJiN2NiN2YwMDdmNGFiNzgzMjE2OGUwYzcyMjA4NmFfMjAtMTMtMS0xLTE4MA_6012858d-5ca8-4f01-a7e6-3b4e64d037b0"
      unitRef="usd">404582000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb568bafdb614780b0b6e325fb8ca3d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0xLTEtMS0w_edb5c4fd-4606-4cdd-b0c8-6ee603ab4c2a"
      unitRef="usd">168725000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="id3da79ae9a6b41debf540b695fc08b49_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0zLTEtMS0w_dc2ad2cb-6c66-4125-818d-d796adb85c8e"
      unitRef="shares">35908057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3da79ae9a6b41debf540b695fc08b49_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy01LTEtMS0w_b9d2ded1-6dea-4092-a5ad-82bb1ad7779a"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b0513fbcf3d407aab4322a16d4bcb1b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy03LTEtMS0w_d0e3235d-44ef-4e51-a8f7-121c76dea4e0"
      unitRef="usd">159608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8d475aa66074c06ada568ac32d41462_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy05LTEtMS0w_dc26156f-2832-457b-831a-ec89bc2ec3ed"
      unitRef="usd">31905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0587de5d8a7747418d59c5807b78c9aa_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0xMS0xLTEtMA_f1d88fa0-78ea-42bf-93f1-a374dd18208a"
      unitRef="usd">786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMy0xMy0xLTEtMA_7f2ccdd3-651e-441e-bfc0-6412583fd5c7"
      unitRef="usd">192335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC0xLTEtMS0w_61f4d0c0-70f2-4ed4-bc96-c373ba3407af"
      unitRef="usd">-1160000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i1ca8ecf06fe9461197b2c72a10f229e4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC05LTEtMS0w_fa8fe814-b8be-42aa-868c-88a32d22f426"
      unitRef="usd">4052000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i3bab93ced304431f99c5b5869c9a4f50_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC0xMS0xLTEtMA_d25ce297-46d5-4550-b6d0-c5b84ea16637"
      unitRef="usd">95000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNC0xMy0xLTEtMA_50b3ce78-c312-44fc-9d64-f4ccc5fc5abe"
      unitRef="usd">4147000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNS0xLTEtMS0w_4a2264b4-7476-4f8a-a368-c9db3742e8b4"
      unitRef="usd">126000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNS0xMy0xLTEtMA_206192b7-1d83-4d32-9b1a-bafe54ba7923"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic342c3c788494bdd9bd051e0e2ea4aa9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNi0zLTEtMS0w_bfa067f8-9a95-45e4-bc13-519835c12894"
      unitRef="shares">16897</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i438419141df9463190d33a39a16f8e84_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNi03LTEtMS0w_f0ad5720-5352-4c76-8812-39a7bdc0a795"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNi0xMy0xLTEtMA_588dc48b-1135-4356-a7ee-9b43c18ff5a0"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ic342c3c788494bdd9bd051e0e2ea4aa9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNy0zLTEtMS0w_81ba8a8c-a386-4ffa-9028-2d046d28c29b"
      unitRef="shares">151601</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i438419141df9463190d33a39a16f8e84_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNy03LTEtMS0w_3b2ca0d1-cce3-4124-8e33-c27fe4b49e55"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfNy0xMy0xLTEtMA_7c4f1843-de7f-419a-91b2-f3a8acee9cf6"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i438419141df9463190d33a39a16f8e84_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOC03LTEtMS0w_fa6a2963-bdb4-48ed-9b9f-27ed03ad8090"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOC0xMy0xLTEtMA_45693e12-4244-4f53-bf0b-06a584079a8c"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i38873cc86488454aba6e51d3baea46e8_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOS0xLTEtMS0w_0469aab5-6e7f-429b-ab01-39595cdd8dd2"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4ff819742d9240a08946f28c513591d3_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfOS0xMy0xLTEtMA_95c5eaa7-da35-457c-b40e-53e44354c6de"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec5e51946e0b4b2187d088ed312db6fa_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMS0xLTEtMA_86d765a7-7703-46bb-b2f6-9bced853f81e"
      unitRef="usd">157439000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i81ce2f5b57784bd082918841fb1016f2_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMy0xLTEtMA_de7644eb-b4c4-4f60-b535-f5e1b7e665f0"
      unitRef="shares">36042761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81ce2f5b57784bd082918841fb1016f2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtNS0xLTEtMA_e3242c1e-a202-4e8c-8b42-2e2a5adfcfa3"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i35d7bd9f3262415d9290f44c00268a41_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtNy0xLTEtMA_e54f4de9-cfb3-441e-b27d-c63788e36091"
      unitRef="usd">161087000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib70f1135f22a4e66a2932f2d95ad14ed_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtOS0xLTEtMA_66051c4e-4e5d-426f-966f-ddd1a92f2045"
      unitRef="usd">35957000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae60a583c9a0465886ea5e58639dee38_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMTEtMS0xLTA_90285fff-663b-4ab1-beba-38e1f07aeaba"
      unitRef="usd">881000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i800ed291b8df4aa1bc10bb8c331a337f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTAtMTMtMS0xLTA_294ac49e-7023-4e73-86fb-17bb940aa785"
      unitRef="usd">197961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtMS0xLTEtMjAw_d3494297-1f42-4ca5-9e75-e7de21214b71"
      unitRef="usd">73666000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i73ed4c2aa7b04a8fb98de15f2d6201c7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtOS0xLTEtMjAw_dfc1bd55-24dd-4074-9449-c002863c3d42"
      unitRef="usd">7044000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtMTEtMS0xLTIwMA_3a169782-4319-456d-8a2d-78063c417b0c"
      unitRef="usd">291000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTEtMTMtMS0xLTIwMA_c30da769-7439-4977-b010-4eac00513790"
      unitRef="usd">7335000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTItMS0xLTEtMjAw_52d1f9fe-b780-4806-aa33-9642ad716305"
      unitRef="usd">125000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTItMTEtMS0xLTIwMA_8e58bc15-c8c8-467b-8478-2133dcb5e2bc"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTItMTMtMS0xLTIwMA_967d4239-3799-4446-b107-e1976b505f72"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ife6556ceee4e4c0fa8fac65b95b81c7b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTMtMy0xLTEtMjAw_9a8a6c2f-da88-4993-84ae-237869800a0c"
      unitRef="shares">24453</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTMtMTMtMS0xLTIwMA_d56b5e02-da2a-40e1-b5be-b3a7fcc3128c"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ife6556ceee4e4c0fa8fac65b95b81c7b_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTQtMy0xLTEtMjAw_c4c26375-67d3-4ada-a56e-a62a8b04e570"
      unitRef="shares">242299</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTQtNy0xLTEtMjAw_787bfac1-859d-4aef-b331-768c0168dedf"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTQtMTMtMS0xLTIwMA_e1e5c9bd-0b3b-42e2-9d6c-f6d7496fa8ad"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTUtNy0xLTEtMjAw_ac745d9b-1321-4730-acb4-33528055589c"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTUtMTMtMS0xLTIwMA_5eac1b2a-1260-4eab-a420-d1c317cec648"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i4f95cdc1c8254f6095d6128af1b9c6bf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtNy0xLTEtMjk4_7cc3fbbd-3f5a-4f12-ad0e-c9da3005337a"
      unitRef="usd">236000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMTMtMS0xLTI5OA_ed953784-66f6-426c-9a9d-cdf0fa011ed6"
      unitRef="usd">236000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i1b9dd764251d443989a47ee2707efe2c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTctMS0xLTEtMjk4_d31b822a-235a-4751-a536-882f880d63ab"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic37ecbec5e564b55ba5a6c9970b716fe_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTctMTEtMS0xLTI5OA_ffe1aa1d-a58a-40dc-83d2-333e52728444"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTctMTMtMS0xLTI5OA_ecefe555-1d63-4624-bf5e-ddf8360ac27c"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieab2abffaadf48cc9d3419f9105a0506_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMS0xLTEtMjAw_3a72a3e8-4723-4298-aa9d-5e0941a990ad"
      unitRef="usd">210980000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ie1d8b996c11e44099040a2fb9aa1b460_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMy0xLTEtMjAw_e4057fd6-8bbd-4139-b2b4-430b836e60e3"
      unitRef="shares">36309513</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1d8b996c11e44099040a2fb9aa1b460_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtNS0xLTEtMjAw_0fdecfac-53db-48a2-bc72-35dec3e9fea5"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21e01a92ec45487aaeaec0fbbb1e91f8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtNy0xLTEtMjAw_15799546-4bbe-4950-b622-958f04d500f5"
      unitRef="usd">163986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9d6e66a8d9741ee9e3ddbca75ba56a1_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtOS0xLTEtMjAw_f34f8620-6984-4a8a-9175-6b85020aba42"
      unitRef="usd">43001000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i73f5c4884b2a4937a0638aaba13197ed_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMTEtMS0xLTIwMA_65bdd5bf-96a8-492b-b80f-f50c9834185f"
      unitRef="usd">825000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yOC9mcmFnOjRmMjhhYzkyZWZiMDRiZTRiZGU1YTMwNGZjYmJhMzUwL3RhYmxlOjdlZmQ0YWEwMTExYjQ3MGJhZTk5ZmRjYjhhMmExYjMxL3RhYmxlcmFuZ2U6N2VmZDRhYTAxMTFiNDcwYmFlOTlmZGNiOGEyYTFiMzFfMTYtMTMtMS0xLTIwMA_f7b7157b-560b-494b-9c8d-c8aa9e83cd98"
      unitRef="usd">207848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMy0xLTEtMS0w_3acc5cb5-b9e4-4815-b242-42fa9d8e43d5"
      unitRef="usd">73988000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMy0zLTEtMS0w_7a7dce8d-4d43-437d-9cf1-4bfcc903eada"
      unitRef="usd">83988000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNS0xLTEtMS0w_e01566c8-25a8-4a51-b53f-7fa3dc742613"
      unitRef="usd">8434000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNS0zLTEtMS0w_13dcf6e0-d56a-4c0b-931b-82effd00fbf2"
      unitRef="usd">9330000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNy0xLTEtMS0w_251e1036-8b08-436f-9b53-b5001b3d26f9"
      unitRef="usd">741000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNy0zLTEtMS0w_18ad0af7-19c1-42e4-b311-8dfa0d4dc8e2"
      unitRef="usd">658000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfOS0xLTEtMS0w_dbfc7300-2d69-4022-922f-0d8679a8bcfe"
      unitRef="usd">2902000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfOS0zLTEtMS0w_e000e595-1bd9-4b2a-981d-e9e22d708533"
      unitRef="usd">1910000</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTAtMS0xLTEtMA_909b6c46-6e05-42ad-8cfb-87a4edede754"
      unitRef="usd">83769000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTAtMy0xLTEtMA_d3b8b127-9355-42f6-b127-dc20ad75ecdb"
      unitRef="usd">-25000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTEtMS0xLTEtMA_8ddda8ae-62ec-43e5-a5d3-8d75b5f83bfb"
      unitRef="usd">-3812000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTEtMy0xLTEtMA_1a36c380-a766-4ec3-98f7-69694aec7dc0"
      unitRef="usd">2888000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTItMS0xLTEtMA_d91bec42-8fc2-4bde-a8d5-ebb1056d057e"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTItMy0xLTEtMA_e5db6abc-de28-4d69-81c5-c766d03d3ca1"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMS0xLTEtMA_a3a891c0-d896-4c85-a45b-8c0a599e6116"
      unitRef="usd">15723000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMy0xLTEtMA_dc18a27e-3fcd-4b6a-8ca2-2a04af2867bf"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMS0xLTEtMTA5MTU_947ab69c-5b4c-4f30-b3ea-6e246159632c"
      unitRef="usd">1195000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTMtMy0xLTEtMTA5MTk_ab8046dd-9dc5-486b-8c25-100dff75845d"
      unitRef="usd">0</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTQtMS0xLTEtMA_f1140ace-127c-4888-a2d9-6f6efa9b7cef"
      unitRef="usd">10283000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTQtMy0xLTEtMA_9276ec96-4d7c-4569-b4be-c0422ea09361"
      unitRef="usd">-4473000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTUtMS0xLTEtMTA2MTE_cadad31c-2ee3-4704-9c74-6a7cacdb38d1"
      unitRef="usd">189000</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTUtMy0xLTEtMTA2NDM_f8252b4c-2a58-459b-8ed9-753280cfeaf1"
      unitRef="usd">0</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTYtMS0xLTEtMA_543c838b-73f5-4b20-89bd-20388cf4a1c6"
      unitRef="usd">9975000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTYtMy0xLTEtMA_5ef1b321-12bf-491a-8e3a-ffcb31275916"
      unitRef="usd">6284000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTctMS0xLTEtMA_ad44eaf5-8b92-4352-9e28-a9d011861a58"
      unitRef="usd">19508000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTctMy0xLTEtMA_63287e60-6a8b-4930-9349-731dd7b90500"
      unitRef="usd">11191000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTgtMS0xLTEtMA_e0c0a118-5bd0-4d73-bb40-3ecee7d68291"
      unitRef="usd">266000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTgtMy0xLTEtMA_893b46f3-bd6e-4853-a9ac-2a28e975ca3e"
      unitRef="usd">-966000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTktMS0xLTEtMA_398b0469-f029-4821-9d27-8a7ab50ddb19"
      unitRef="usd">-4613000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMTktMy0xLTEtMA_eb04ee26-e4ce-41a0-9134-b08db066e368"
      unitRef="usd">873000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjAtMS0xLTEtMA_a2546543-eede-4be0-bbbe-f79d97037168"
      unitRef="usd">1646000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjAtMy0xLTEtMA_2e9bf9c9-1d76-4b95-a649-a4af2bb95682"
      unitRef="usd">1680000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjEtMS0xLTEtMA_3c0b1666-79ee-488d-8fe7-13ecdcbf96f2"
      unitRef="usd">426000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjEtMy0xLTEtMA_22d666d4-efc0-4c3b-a10f-bd9ec4bfa886"
      unitRef="usd">5095000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjItMS0xLTEtMA_73132955-89b8-4ca1-b21a-ca6cfbec45d5"
      unitRef="usd">16984000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjItMy0xLTEtMA_07bf11ff-9ae0-4ecc-927e-1eec99f622aa"
      unitRef="usd">-3043000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjMtMS0xLTEtMA_d22b93ac-3d4c-4afd-8377-6a52d29f4aa3"
      unitRef="usd">-550000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjMtMy0xLTEtMA_e81dd7b4-d2a3-458e-a14d-3c08b34d356f"
      unitRef="usd">-174000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjQtMS0xLTEtMA_571f6f53-85d3-43e2-b1b0-752f84978c83"
      unitRef="usd">8977000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjQtMy0xLTEtMA_bce3ae1d-fb21-42d9-999d-77c8fe63152d"
      unitRef="usd">11252000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjUtMS0xLTEtMA_4a08b22b-177e-4791-8cd2-0043807e62a5"
      unitRef="usd">-2009000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjUtMy0xLTEtMA_87f3e28d-0fc7-45ec-bdae-870e0d00245e"
      unitRef="usd">37681000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjYtMS0xLTEtMA_153ae532-f2fb-4670-8d9c-3ecefb57e6f4"
      unitRef="usd">-1698000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjYtMy0xLTEtMA_04c41fb4-ee9a-462c-aa42-c961bbf480a6"
      unitRef="usd">-1247000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjctMS0xLTEtMA_ded3d085-75a4-4cd6-959c-c85755969295"
      unitRef="usd">31286000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMjctMy0xLTEtMA_810d85c8-83b3-4f95-abc5-7d690c215a20"
      unitRef="usd">12575000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzEtMS0xLTEtMA_a08817a8-7dbf-4f28-8f57-baba755e61d6"
      unitRef="usd">31000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzEtMy0xLTEtMA_08f70dfb-ee3e-447d-b3f3-f5e2de61c00c"
      unitRef="usd">16500000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMS0xLTEtMTA2ODU_f384ee77-4445-4a0c-8bc2-b904e2765aa1"
      unitRef="usd">117000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMy0xLTEtMTA2ODg_3fdc0119-4a41-41b8-bee7-ac2c59a491bc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <ameh:PrepaymentForInvestmentPurchase
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzgtMS0xLTEtMTI1MTk_4ba6fa7f-098e-4b11-ae12-86c550a66515"
      unitRef="usd">4450000</ameh:PrepaymentForInvestmentPurchase>
    <ameh:PrepaymentForInvestmentPurchase
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzgtMy0xLTEtMTI2Mzg_7d8f47b4-0fef-4ffd-ba9b-81f0aa6e4ca9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzQtMS0xLTEtMA_7e9a46a5-673b-419f-88b5-46169a2b8f29"
      unitRef="usd">670000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzQtMy0xLTEtMA_45b8b209-6729-40f3-9fa0-40bc6087dbd5"
      unitRef="usd">1142000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzUtMS0xLTEtMA_f7bc4d42-3d0d-4314-8194-050eabe441d4"
      unitRef="usd">1660000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzUtMy0xLTEtMA_439eb6a2-6a18-4cc9-9a15-d2815ecee1eb"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzYtMS0xLTEtMA_e96942ae-6113-444d-9241-cf09baacc6b8"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzYtMy0xLTEtMA_cea497c1-7cda-474f-8690-cc9117bf1448"
      unitRef="usd">52743000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMS0xLTEtMA_72c4b59a-7dcd-4e13-98e2-2e512601ac66"
      unitRef="usd">7364000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzctMy0xLTEtMA_91e522bf-ea21-49d1-bb96-d6963ee13cab"
      unitRef="usd">451000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMS0xLTEtMTA5OTg_9ea419ae-fe5e-4a86-8304-31882e27c5f4"
      unitRef="usd">3322000</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMy0xLTEtMTA5OTg_9a125d1b-e505-42c6-9eb9-7efa124ab272"
      unitRef="usd">0</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMS0xLTEtMTA5OTg_d946e293-1e19-442b-a338-eecc9cefc1af"
      unitRef="usd">1106000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMy0xLTEtMTA5OTg_3f860055-ab32-48b7-804c-9ad371bf7e2b"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzktMS0xLTEtMA_b188ab0b-2453-41aa-8f69-5b0faa87bd1f"
      unitRef="usd">-9802000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfMzktMy0xLTEtMA_01dfbd35-0e8d-4d3f-b9c4-51db27e35dba"
      unitRef="usd">67150000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMS0xLTEtMA_f5e8fa0e-fd0f-4463-9ccc-dddc6305a1da"
      unitRef="usd">21110000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDMtMy0xLTEtMA_d6053657-c2fc-4bf0-a402-47aad6d9ab9e"
      unitRef="usd">30187000</us-gaap:PaymentsOfDividends>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMS0xLTEtMA_5c5913e0-e40a-4f31-924c-c4c489b8b63c"
      unitRef="usd">238208000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDQtMy0xLTEtMA_33f074f3-e401-4f33-abef-b2b523e2e43f"
      unitRef="usd">2375000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDUtMS0xLTEtMA_3f95fb2f-9679-42ae-9106-76ae19bdafe2"
      unitRef="usd">54000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDUtMy0xLTEtMA_12135d4b-e1e9-4a7a-ba40-f57ba32d812e"
      unitRef="usd">61000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDYtMS0xLTEtMA_54bc1d3f-569e-453e-a922-775a8964e3dd"
      unitRef="usd">4816000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDYtMy0xLTEtMA_11896429-5eac-40ea-aa9d-1340215467cf"
      unitRef="usd">2863000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDctMS0xLTEtMA_36e0a431-0aea-4a12-b747-7d652c95f9ea"
      unitRef="usd">2981000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDctMy0xLTEtMA_61076e3a-d86c-4f79-be49-f722da62d8cf"
      unitRef="usd">788000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDgtMS0xLTEtMA_dce25412-fcfd-4944-bbf3-08728f3bd103"
      unitRef="usd">75000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDgtMy0xLTEtMA_dfacf1bd-1628-4e2b-b475-55b8c539cfda"
      unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDktMS0xLTEtMA_8c2c8c3a-a825-471b-bfb1-0946c30d581c"
      unitRef="usd">38000</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <ameh:ProceedsFromSaleOfNoncontrollingInterest
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNDktMy0xLTEtMA_c9ce9126-e9a9-4f34-832e-2ef6fd7fd1a2"
      unitRef="usd">0</ameh:ProceedsFromSaleOfNoncontrollingInterest>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMS0xLTEtMTA3MjM_1db1ebd7-1cc2-4cee-b1e3-55c65b235ea5"
      unitRef="usd">180000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMy0xLTEtMTA3Mzg_d94e4c92-82c2-4144-99e6-0739a7d4ccc4"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTktMS0xLTEtMTA3MzA_357cbc0e-1b66-49b9-be8f-10965a29ded2"
      unitRef="usd">40134000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMy0xLTEtMTEwMDk_2a9d47e6-97d4-4866-acee-f6b61a807643"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjAtMS0xLTEtMTA3MzM_486a9fa6-44ea-42eb-81bc-b1aeb1c79e4b"
      unitRef="usd">727000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjAtMy0xLTEtMTA3NDI_f84b55ba-fe49-4c23-a0a5-0281a4d1188d"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTItMS0xLTEtMA_8cad8db5-4daf-4627-a210-af123472fe08"
      unitRef="usd">-38167000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTItMy0xLTEtMA_688099bf-2a76-4316-991c-06f6a074404b"
      unitRef="usd">-30548000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTQtMS0xLTEtMA_f0e7c266-0990-4ca7-b261-6fc97187ec07"
      unitRef="usd">-16683000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTQtMy0xLTEtMA_615a0c20-060d-4bf3-88bc-48cc80f665a9"
      unitRef="usd">49177000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTYtMS0xLTEtMA_e1ac51ec-0f8b-4e3d-a259-4b33014345ab"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTYtMy0xLTEtMA_6094348e-371e-4fb4-a40d-8b0de0b126ae"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMS0xLTEtMA_ff723c3a-2398-4ced-b8aa-3e8ede219623"
      unitRef="usd">177287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNTgtMy0xLTEtMA_b21d084a-68d3-4c8d-888d-821d85522731"
      unitRef="usd">153187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjEtMS0xLTEtMA_70793129-8953-410f-9425-07c781831ba3"
      unitRef="usd">23324000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjEtMy0xLTEtMA_8efe962e-dc08-4d9a-b594-d9a2056b4ef5"
      unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjItMS0xLTEtMA_8b51a526-02b1-4fdd-a748-d4f92f2ee4e1"
      unitRef="usd">2507000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjItMy0xLTEtMA_7c21e19f-67b8-4227-9d12-617ea1951fe8"
      unitRef="usd">2623000</us-gaap:InterestPaidNet>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjUtMS0xLTEtMA_f22bf4aa-d1a7-4b16-bbe2-db97c96119f4"
      unitRef="usd">50000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjUtMy0xLTEtMA_9df24991-751e-4059-88e4-667c23e5c9ff"
      unitRef="usd">160000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjYtMS0xLTEtMA_a12eb6e6-12de-47c1-9023-4fb541af66d7"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNjYtMy0xLTEtMA_44e8456e-b13a-4177-b830-c34fdea9b748"
      unitRef="usd">36179000</us-gaap:ConversionOfStockAmountIssued1>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNzYtMS0xLTEtMTA3NTc_f936577f-19cb-4313-b397-4d06447da04b"
      unitRef="usd">144000</ameh:CancellationOfRestrictedStockAwards>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOmM2NmZkYjNkMDdlNTQwYjViOTc5ZGNjMDczNzg3MjhiL3RhYmxlcmFuZ2U6YzY2ZmRiM2QwN2U1NDBiNWI5NzlkY2MwNzM3ODcyOGJfNzYtMy0xLTEtMTA3NjA_3d18c3da-c5bd-4af7-8d68-09122214e90a"
      unitRef="usd">0</ameh:CancellationOfRestrictedStockAwards>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfMi0xLTEtMS0w_218e0669-0029-4b86-8832-a9cb13572c6d"
      unitRef="usd">177287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfMi0xLTEtMS0w_6146e4be-03de-4f06-b288-40552a5af601"
      unitRef="usd">177287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfMi0zLTEtMS0w_cd34e5a8-d0df-4175-a056-dd100ed2ed89"
      unitRef="usd">152441000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNC0xLTEtMS0w_0cabb233-3a35-4706-9f1f-d5ca8ceec703"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNC0zLTEtMS0w_e6370609-df30-4037-a474-1a1287e90d39"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNS0xLTEtMS0w_81331724-34fe-47e4-9311-0306a038fda5"
      unitRef="usd">177287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjNkYTM2OWFjZDc4MjQ4M2ZhYjMwZjY1MWY5MDQ5YmQwL3RhYmxlcmFuZ2U6M2RhMzY5YWNkNzgyNDgzZmFiMzBmNjUxZjkwNDliZDBfNS0zLTEtMS0w_a4bdc986-f0df-44a6-89ff-77d777c4c610"
      unitRef="usd">153187000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMi0xLTEtMS0w_b59302cb-5d9a-4dff-868a-da9cea8575f2"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMi0zLTEtMS0w_e9151c8d-feba-4f77-8f51-ef9690e27a47"
      unitRef="usd">103189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMy0xLTEtMS0w_dd53b18e-5cd0-4140-b453-2f50ba749f96"
      unitRef="usd">500000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfMy0zLTEtMS0w_6b9382c6-f3ac-4b59-b675-35367d1f4722"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNC0xLTEtMS0w_2fdb32a7-5c6c-491a-814a-4ee3cbe64746"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNC0zLTEtMS0w_c16188c8-0a4b-426a-a70a-744ffa659a2b"
      unitRef="usd">75000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNS0xLTEtMS0w_8d545e96-eb55-4e02-8af3-4d2c654468d1"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zMS9mcmFnOjU2YmVhMjVhNjllNjQxMmFiMmZhNmU1ZjUxMWM1ZTdkL3RhYmxlOjM1ZGFkMjhjYTUwNjQyYmRhZTlkMDM4OGRiYTAwNGZlL3RhYmxlcmFuZ2U6MzVkYWQyOGNhNTA2NDJiZGFlOWQwMzg4ZGJhMDA0ZmVfNS0zLTEtMS0w_a5ccdfc4-0131-4238-9e3f-63a9301eae15"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTQzMDM_06e549b1-d49e-40b2-8e70-e19fc3938cf1">Description of Business&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apollo Medical Holdings, Inc. (&#x201c;ApolloMed&#x201d;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#x201c;NMM&#x201d;) on December 8, 2017 (&#x201c;2017 Merger&#x201d;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headquartered in Alhambra, California, ApolloMed&#x2019;s subsidiaries and VIEs include management services organizations (&#x201c;MSOs&#x201d;), affiliated independent practice associations (&#x201c;IPAs&#x201d;), and a Next Generation Accountable Care Organization (&#x201c;NGACO&#x201d;). NMM and Apollo Medical Management, Inc. (&#x201c;AMM&#x201d;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#x201c;APC&#x201d;), (ii) Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#x201c;Accountable Health Care&#x201d;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). The Company&#x2019;s NGACO operates under the APA ACO, Inc. (&#x201c;APAACO&#x201d;) brand and participates in the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#x2019;s attribution-based risk-sharing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, and hospitalists. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MSOs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPAs and Affiliates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#x201c;HMOs&#x201d;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#x201c;PMPM&#x201d;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AP-AMH was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. In accordance with relevant accounting guidance, AP-AMH is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#x201c;AP-AMH Loan&#x201d;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#x201c;Certificate of Determination&#x201d;), AP-AMH is entitled to receive preferential, cumulative dividends (&#x201c;Series A Dividends&#x201d;) that accrue on a daily basis and that are equal to the sum of (i) APC&#x2019;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#x2019;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;APC purchased 15,015,015 shares of ApolloMed&#x2019;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#x2019;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#x2019;s then outstanding shares will be voted by proxy given to ApolloMed&#x2019;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#x2019;s stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the series of transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term &#x201c;Excluded Assets.&#x201d; Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#x2019;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC&#x2019;s ownership in ApolloMed was 19.77% at June&#160;30, 2021 and 22.58% at December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concourse Diagnostic Surgery Center, LLC (&#x201c;CDSC&#x201d;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of June&#160;30, 2021, APC owned 45.01% of CDSC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA Designated Shareholder Medical Corporation (&#x201c;APC-LSMA&#x201d;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#x2019;s sole &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#x201c;LMA&#x201d;), Pacific Medical Imaging and Oncology Center, Inc. (&#x201c;PMIOC&#x201d;), Diagnostic Medical Group (&#x201c;DMG&#x201d;) and AHMC International Cancer Center, a Medical Corporation (&#x201c;ICC&#x201d;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#x201c;MMG&#x201d;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#x201c;AMG&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#x2019;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#x201c;MPP&#x201d;), AMG Properties, LLC (&#x201c;AMG Properties&#x201d;), and ZLL Partners, LLC (&#x201c;ZLL&#x201d;) and a 50% interest in each of One MSO, LLC (&#x201c;One MSO&#x201d;), Tag-6 Medical Investment Group, LLC (&#x201c;Tag 6&#x201d;), and Tag-8 Medical Investment Group, LLC (&#x201c;Tag 8&#x201d;). These entities own buildings that are currently leased to tenants or vacant land with plans to lease the building in the future. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation, it was concluded that Tag 8 is a VIE and is consolidated by APC because APC has the ability to direct the activities that most significantly affect Tag 8&#x2019;s economic performance. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#x2019;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the definitive proxy statement that ApolloMed filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on July 31, 2019 (the &#x201c;2019 Proxy Statement&#x201d;), and consequently will not affect net income attributable to ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO&lt;/span&gt;&lt;/div&gt;APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model of CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.</us-gaap:NatureOfOperations>
    <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
      contextRef="i8c4c8fd96fdb461cb92e63360f2be9ab_D19990701-19990701"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNDEwOQ_e334b0db-5951-438b-bd2b-5729574a41f0">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>
    <us-gaap:NotesReceivableNet
      contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNTM4MA_63e3ed79-6c99-426f-9a27-13ab584fc583"
      unitRef="usd">545000000.0</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="i9bb24ee035e747b28135640c9aa23520_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNTM5Nw_25ab36e5-2980-407f-bdff-bcd13120c6fc">P10Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableStatedInterestRate
      contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNTQ4Ng_c15bcf5d-951f-44f1-8f10-c2cee2d9ad3b"
      unitRef="number">0.10</ameh:FinanceReceivableStatedInterestRate>
    <ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate
      contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjIwMQ_25956609-34f3-480c-8a3c-756125e82545"
      unitRef="number">0.1075</ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idc78d6f0898845efb2fd105feca4a2f2_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjI0OA_bc4de0c5-4690-4259-9d1c-30ed00b71030"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NotesReceivableNet
      contextRef="i7c0ca208739a43eca6bdd05197aa7a17_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjMyMQ_979defa5-f107-4d62-9a33-3ada3cca1048"
      unitRef="usd">545000000.0</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjkxMA_400e0b01-3dc8-44de-98f2-e40899d0e311"
      unitRef="shares">15015015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjk3NQ_837553c0-8a3a-45dd-8d7d-271e14a8caba"
      unitRef="usd">300000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ameh:StockIssuedDuringPeriodProxyVotesPercentage
      contextRef="i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNzE3OQ_144c2279-0d6d-45f3-8e10-098120ba897b"
      unitRef="number">0.0999</ameh:StockIssuedDuringPeriodProxyVotesPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i071cd8fce44a4d278cb890f2fd12c53e_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfODg4Mw_b65d6914-e5c4-433e-953f-945d0932c7a6"
      unitRef="number">0.1977</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i71623504ed924a538cd451351d50b2da_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfODg5Ng_4b31535e-cad1-4673-9f57-0f032b98064d"
      unitRef="number">0.2258</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i241f2dac80774d7382f508fd09e0f8ba_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfOTM4Mw_aa2fb011-5db9-4490-9c76-b8937f87a724"
      unitRef="number">0.4501</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i7fff49a7a66747b7a57171842d35423d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTA4MTI_964cc53e-f6f5-4d0b-804f-d4a68e708ec6"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:NumberOfFederallyQualifiedHealthPlans
      contextRef="i952cacc1a5b04847b6ad828c7370b652_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTIwNzA_8cca190d-4d97-4968-aa9b-7f884c91ad6a"
      unitRef="plan">3</ameh:NumberOfFederallyQualifiedHealthPlans>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="idc6f11228e3b4496a5908cf791e2c3d5_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTIzNDA_90887e1a-175d-4663-ae6b-af381e4a1a4a"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i2b95c5305c69440b8471686cab8d05a8_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTIzNDg_b69e859b-fc06-4103-aee3-1be4cbeff06d"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfFamilyPracticeClinics
      contextRef="i69897c5a8adf4bfda6e8406ffef233b9_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI0MjE_184deeee-4aee-4596-9729-e91dad972e0b"
      unitRef="clinic">3</ameh:NumberOfFamilyPracticeClinics>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i2c2a3553336444f8bafa03b845e07bc7_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI2Njg_473700d0-4ee5-40fa-9b98-7fdf97a28ea0"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if43a32369dc847e7b58782be85125fa1_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI3MTM_a93ee23f-2bb1-4013-979e-95bf3e2a9e56"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i4bb6b3c6a2494e4bb41a11f504d6faed_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI3Mjg_0869d3a5-04e9-4ea9-8bdc-c75d623b734b"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i1de45d50eab74b8796ff5445350b8141_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTI4MzY_9c1c37f8-c903-4b5f-a0ff-4180bce94908"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i0633663299e44174ba3eb3710cd3e2ac_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfNjU5NzA2OTc4MzM4Mg_0e7912dc-11c4-4027-8e76-6ad398ea2dbf"
      unitRef="number">0.50</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i1de45d50eab74b8796ff5445350b8141_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8zNy9mcmFnOjcyZjlkMzA4M2Y1YzRlMzFhNjU0ZDM0NzE5MDZlMGEyL3RleHRyZWdpb246NzJmOWQzMDgzZjVjNGUzMWE2NTRkMzQ3MTkwNmUwYTJfMTMwNTQ_9c1c37f8-c903-4b5f-a0ff-4180bce94908"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDA_c6b0baef-128f-4502-8dc7-e49e0863e565">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#x2019;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2021, and for the three and six months ended June&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and six months ended June&#160;30, 2021, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or any future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of June&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of income for the three and six months ended June&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIE, AP-AMH; AMM&#x2019;s consolidated VIE, SCHC; NMM&#x2019;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#x2019;s consolidated VIE, APC; APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties and ZLL, APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 15 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $268.2 million and $294.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consisted of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.2 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy where quoted market prices from reputable third-party brokers are available in an active market. Equity securities held by the Company are primarily comprised of common stock of a payer partner that completed its initial public offering in June 2021. The shares were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#x201c;UCI&#x201d;) in April 2020. As of June&#160;30, 2021, equity securities amounted to $119.9 million. As of December&#160;31, 2020, prior to our payer partner&#x2019;s IPO, the related investment balance was included in investment in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. For the three and six months ended June&#160;30, 2021, the Company recognized unrealized gains of $83.8 million in other income in the accompanying consolidated income statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivables and loan receivables &#x2013; related parties consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of June&#160;30, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2021 and 2020. Goodwill as of June&#160;30, 2021 and December&#160;31, 2020 was $239.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Cost Method &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fiduciary Cash and Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, and Accountable Health Care collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $9.1 million and $9.6 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 8 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the derivative instrument was determined using Level 2 inputs. The fair value of the derivative instrument as of June&#160;30, 2021 and December&#160;31, 2020 was $1.2 million and $0, respectively, and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like payments, called All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 7), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $24.3 million and $48.1 million in total AIPBP payments for the three and six months ended June&#160;30, 2021, respectively, of which $14.1 million and $31.2 million has been recognized as revenue for the three months and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#x2019;s contract liability balance was $29.6 million and $13.0 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2021, $0.4 million of the Company&#x2019;s contract liability accrued in 2020 has been recognized as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2021 and December&#160;31, 2020, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12 month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Beneficial Interest&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI pursuant to the terms of the stock purchase agreement, APC received a beneficial interest in the equity method investment sold. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free Treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#x2019;s gross margin for the year ended December 31, 2020 was assessed and beneficial interest was concluded to not be collectible. For the three and six months ended June&#160;30, 2021, the $15.7 million was written off and expensed in other income in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related to the approach for intraperiod tax allocation, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODY_bb55ab81-3ca2-4c68-bd70-a3a737c84a3d">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#x2019;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2021, and for the three and six months ended June&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODA_e2c39ca5-868d-40c7-b23d-b341c44518be">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;The consolidated balance sheets as of June&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of income for the three and six months ended June&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIE, AP-AMH; AMM&#x2019;s consolidated VIE, SCHC; NMM&#x2019;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#x2019;s consolidated VIE, APC; APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties and ZLL, APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDM_15a71991-2509-42f9-8a3f-ca428f673458">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzM_f25f7ced-a474-4f10-b81c-2f7ba4e6f036">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 15 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNzI_e6ea7c45-c4e9-4157-bbf2-e7156cd1bbd2">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzc_6cf6bfb9-9f80-4ad6-b7e9-9ee0e3e0086f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2MQ_76ef5360-4b9b-4490-96db-de11db5d6f21"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2MQ_86163511-7490-48ba-a8b8-5be2b700e4a2"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2NQ_76ef5360-4b9b-4490-96db-de11db5d6f21"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNDU2NQ_86163511-7490-48ba-a8b8-5be2b700e4a2"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDk_c8ef222c-d5d6-45f2-beb9-c76b514a2ba0">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc3OQ_457b6d24-4378-441c-90c6-42a8b3c94d1d"
      unitRef="usd">268200000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc4Nw_4427c9e8-c106-47fa-b83b-af64db339643"
      unitRef="usd">294900000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNTU_954e2545-7981-4d36-ad5b-b21870df0136">Restricted CashRestricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDY_213928f7-b9df-487d-b702-c9e3fe30c01f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consisted of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.2 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy where quoted market prices from reputable third-party brokers are available in an active market. Equity securities held by the Company are primarily comprised of common stock of a payer partner that completed its initial public offering in June 2021. The shares were acquired as a result of UCAP selling its</us-gaap:MarketableSecuritiesPolicy>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="icddc255662424aa887c3eea17c9feea8_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODE_74222511-f532-443b-9673-4e8c0a132e23">P4M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i79bc2d0f22014e51b904aed1246e3e16_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfOTE3Nw_ef45a689-f5c7-4690-bb31-263cde93bdf4">P24M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48f0e73319a641509224036db496b932_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNTU1Ng_7196b991-17c9-4868-bc1e-befc33d28664"
      unitRef="usd">67200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if581aec0ebda442289b0483239719ee4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEyNTU2NA_f818580d-f5dc-4fcb-8675-068c31d33c20"
      unitRef="usd">67600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="if5ce879e744f44499873676c0b759e61_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMDM0MA_d18ef0c7-cb43-4928-b8c0-eee330e9c73a"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMzg0NA_89f337fb-4fd5-46d1-ae15-356e18c5d659"
      unitRef="usd">119900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzg0ODI5MDc2MzMyMw_89345883-c1c6-4782-a270-c80269df2b03"
      unitRef="usd">36200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMzk1Mg_f09e157d-524c-4058-9162-1f100d5fcc79"
      unitRef="usd">83800000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMzk1Mg_f20702d3-04ed-4c72-a285-3b28f498251b"
      unitRef="usd">83800000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODk_15c01850-0953-4f19-ad0d-d84d43811650">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables,  Receivables &#x2013; Related Parties, and Loan Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loan receivables and loan receivables &#x2013; related parties consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model.</ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock>
    <ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA2NzM_2c41942a-2e68-45cc-aad1-d34b0156253c">P18M</ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwOTc_22e35549-ebe1-41e6-8b0c-993b33aed622">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. &lt;/span&gt;&lt;/div&gt;The consolidated statements of income present disaggregated revenue by service type.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNjA_48b39d7e-033f-4c9d-9ccf-2f91e7f6ea04">The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i185f42a9a8b54e0ca62108c41bd664d8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy0xLTEtMS0w_5bdb3956-aae2-49d1-94e1-7c9e434ee520"
      unitRef="usd">33296000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcdcf6e7ba9c4ef787e0a918d4875119_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy0zLTEtMS0w_976291a8-70e9-49fc-9db5-a486b96fc67a"
      unitRef="usd">25479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c2b9ec1f0794bcba9109e5d8bb3a391_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy01LTEtMS0zMDk4_e73ead9f-1e95-42fb-9771-64f39f2d7502"
      unitRef="usd">65562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c7fd29ffb1e402f9a88abab2ffdf543_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfMy03LTEtMS0zMDk4_e830072a-c3f3-4718-bb40-e39d1c95047d"
      unitRef="usd">50192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b54cb109dc64d6a8a758226a7f16d73_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC0xLTEtMS0w_6eb42b69-75ae-40f0-8b0c-5863b231abd9"
      unitRef="usd">64273000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e3515a95fa5423b9f7aae97edc29519_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC0zLTEtMS0w_670c9269-8f9b-4772-a16f-d38bd11e2e57"
      unitRef="usd">62038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib589f790bdc2410e999a0e0326ec9f8d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC01LTEtMS0zMDk4_b0ab19db-90f1-473e-b9a3-df047d889948"
      unitRef="usd">128950000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60adfff6acd24500baff0a524b02e5c9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNC03LTEtMS0zMDk4_a15643e9-dd98-41a3-a493-f4fa1f6860cf"
      unitRef="usd">126918000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9b45c9cc22f407b9e5ae65de8c65877_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS0xLTEtMS0w_f77f9bf4-7b4a-459c-9e79-2229f63367ea"
      unitRef="usd">68482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbfeb035318646158bca7c726a066225_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS0zLTEtMS0w_d94a8f74-0279-4704-a594-50c65cec9533"
      unitRef="usd">68450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i471fd709d8b042538ae4ba01794d29fd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS01LTEtMS0zMDk4_46aef247-5ba7-40be-a026-5511ccb7d7c7"
      unitRef="usd">138146000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba8a208df3474e8fb273ceaa2c9f7883_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNS03LTEtMS0zMDk4_e3d0a379-212c-4f7c-b4e5-99088b302600"
      unitRef="usd">134897000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia25a0917754446d9a50268874a89b369_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi0xLTEtMS0w_46b3380a-dd39-4816-babe-d1a861d62880"
      unitRef="usd">9587000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b597a3a606a4216b96db631cc612d1d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi0zLTEtMS0w_48a3734e-335d-4e64-aa09-b854004db07a"
      unitRef="usd">9202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i426466c8cfba4f4ab46a3de7fcb32855_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi01LTEtMS0zMDk4_050035d6-a41f-4543-91df-c319ba691116"
      unitRef="usd">19038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0678b3587f724407821d7a02905c844a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNi03LTEtMS0zMDk4_2599ad87-f37b-480b-8b96-7e18f7c4dd8e"
      unitRef="usd">18267000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy0xLTEtMS0w_7f1ac074-db77-4c3d-a67d-657a5d2a42a6"
      unitRef="usd">175638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy0zLTEtMS0w_09feb1b0-8307-4bfc-a4d0-daaf861d93cc"
      unitRef="usd">165169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy01LTEtMS0zMDk4_ee75a5f4-0199-4fb1-8cb5-5afae62364c9"
      unitRef="usd">351696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjI1YjlkZWNmYzZlNzQ2ZjFhOTE5MTIxYmQzMGU4YmE4L3RhYmxlcmFuZ2U6MjViOWRlY2ZjNmU3NDZmMWE5MTkxMjFiZDMwZThiYThfNy03LTEtMS0zMDk4_cbd5b9bb-2e08-4020-8ec4-69d8f89d4ffa"
      unitRef="usd">330274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwOTk_a9ec22a0-1275-4225-aff9-748afdabe578">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia75080dfd6264d258c11212217c8b10f_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy0xLTEtMS0w_1099a19c-4e6b-4631-a9b9-707d71466bc1"
      unitRef="number">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4e9ec79a20df4253ab7dea22b3b23ee3_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy0zLTEtMS0w_3a5201d2-288c-46a7-a010-f54102b4bbe8"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i34e38dab85924104b5e25338edabc1bd_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy01LTEtMS0zMTI1_a86b96eb-9459-42b7-aa91-ab9d4a66499e"
      unitRef="number">0.126</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idfc614d6b07f45f7950663dec2648520_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfMy03LTEtMS0zMTI1_1b57da1c-915e-427b-83ce-063fdac80a6a"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icd38b926d5754ba3aa24b67a9981b319_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC0xLTEtMS0w_067e9995-1a2e-45e3-9d14-c3fcf9da54d2"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4efe4431f6694099b8b967669037c803_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC0zLTEtMS0w_56fee66a-2af1-4d89-9c56-ab6768840f58"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8c2aca92c28e4162bdd408ae26d5ad9d_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC01LTEtMS0zMTI1_028e8100-2eb7-4e6b-b8cd-984a32e0c6ca"
      unitRef="number">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie5cecd31c0dc4fb6a242649aac99e292_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNC03LTEtMS0zMTI1_4c6e6028-84b3-4aae-9980-0afc5ec207ae"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ief11bdfc013143bdb2e856c631d0718c_D20210401-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS0xLTEtMS0w_32bc18e7-3925-4c6d-a793-c26a32321490"
      unitRef="number">0.167</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id8cf6127a54a494484425f25baddbfc0_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS0zLTEtMS0w_2695b55b-e576-4e2d-b57c-67abfeab7337"
      unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i048f53e45f574508978ecfdf4e3d3d22_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS01LTEtMS0zMTI1_c6997b5c-1162-47bb-ad5f-686f533a39f4"
      unitRef="number">0.168</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id08b33fa7cfd4156a5bacbfe13a639e3_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNS03LTEtMS0zMTI1_42c7eb2d-a10c-4ee3-ad1f-511e0f66ecf6"
      unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icf62c5595329412686bca92c975ba621_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNi0zLTEtMS0w_581413c0-5bb2-466e-99b2-85e60e5a15a6"
      unitRef="number">0.124</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i620a3e2dc50c496b98250472c16d6748_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNi03LTEtMS0zMTI1_67730ad0-2040-41a7-b934-3e75460c6403"
      unitRef="number">0.129</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7809f033d5704a408b3a92c0496273c7_D20200401-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNy0zLTEtMS00MjA_6689f635-3407-4b0a-8940-68ae2af72bbd"
      unitRef="number">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib3446e8fb9264fa6bceff8cf3d2e166e_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmJkMWY2NTQ4Yjk3NDRkZmNiYzlkN2I5ODBmNGZjZWRmL3RhYmxlcmFuZ2U6YmQxZjY1NDhiOTc0NGRmY2JjOWQ3Yjk4MGY0ZmNlZGZfNy03LTEtMS0zMTI1_e41d4850-469c-4bcd-9425-bafc340cdf2b"
      unitRef="number">0.103</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i024c1f1b458648a0b9cb88256e9c4a3a_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfMy0xLTEtMS0w_c2949b23-e4a5-4a21-80bc-a4a1aa00927c"
      unitRef="number">0.115</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5dd8f97f0d834086a7e27bc176ab32eb_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNC0xLTEtMS0w_51c5865e-be01-4f2d-86f3-6a211edd5004"
      unitRef="number">0.411</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifc8c969a14594d11b493db131e6fc11e_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNC0zLTEtMS0w_b50f75ab-ccd6-45c7-bfa6-84bf960c8bb4"
      unitRef="number">0.439</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iba17faa36f594080b10480edbc5e2578_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNS0xLTEtMS0w_aa12b5f0-b37b-400c-bb5f-ad1b4b588d20"
      unitRef="number">0.344</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3dd42db203e84e239ba631310adddf43_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmYwYjMzMWJlMzI5MzRiNThhOTExZTg2ODkxYWNmMmU2L3RhYmxlcmFuZ2U6ZjBiMzMxYmUzMjkzNGI1OGE5MTFlODY4OTFhY2YyZTZfNS0zLTEtMS0w_55830ad3-923c-40e5-ae8f-e54418d15697"
      unitRef="number">0.365</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDc_f116ee6e-986f-41e2-8c45-5c905ed1cac3">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMjg_aa1513a8-c5a3-4245-90da-28472e4795ec">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of June&#160;30, 2021, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy0xLTEtMS0w_d722f565-ee0d-456c-92c1-2f3fed37a3d9"
      unitRef="usd">107403000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy0zLTEtMS0w_082714a3-1065-4b74-8fab-5900cee92260"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy01LTEtMS0w_e5921e4e-a1e1-4304-b498-6f373e37969e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMy03LTEtMS0w_988400fe-8011-4047-a238-e2a33995418e"
      unitRef="usd">107403000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC0xLTEtMS0w_a9a7df9a-1aff-4a81-a726-7908dbd283bd"
      unitRef="usd">67200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC0zLTEtMS0w_feb93043-06d9-4f2a-9cc8-64b7a88c438e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC01LTEtMS0w_de803773-bde7-4238-ad3a-e558df677bdc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNC03LTEtMS0w_fd074e25-8d53-491a-a856-f89d9cf871de"
      unitRef="usd">67200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS0xLTEtMS0w_c29f9f22-da8d-47e9-99eb-f8f42f2cbe12"
      unitRef="usd">120006000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS0zLTEtMS0w_0aee3c4d-9208-4ff2-a483-9c6123249015"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS01LTEtMS0w_47527104-65e2-4923-ba04-f1f6117f4017"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNS03LTEtMS0w_2e805502-4090-4b95-88d4-5310d640d96a"
      unitRef="usd">120006000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy0xLTEtMS0w_f3e22b41-999d-45a1-a339-4201d849b238"
      unitRef="usd">294609000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy0zLTEtMS0w_473977a4-3443-48f2-be66-8cbb6b8c2377"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy01LTEtMS0w_1384889c-e69d-4319-a6ff-bbeb0c3b1f14"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfNy03LTEtMS0w_124ecbf4-0db9-4a05-9413-113a361de137"
      unitRef="usd">294609000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS0xLTEtMS0xMjE2MA_5bb190a8-8e43-4553-96fb-7401987b10eb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS0zLTEtMS0xMjE2MA_3f336934-8f1a-4b1b-aea1-024180e67b2d"
      unitRef="usd">1195000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS01LTEtMS0xMjE2MA_ca92de20-c0a2-4830-becf-a20270150052"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfOS03LTEtMS0xMjE2MA_4242bf83-a7a3-43f7-a151-9f92fcfad3d3"
      unitRef="usd">1195000</us-gaap:DerivativeLiabilities>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i68feb3803e9d4d8392626ca9c77e1b1f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtMS0xLTEtMTIxNzE_38866b6f-3985-40b7-b329-6afb09a8cfb2"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ib42142faaff64fa180f7ffee0c673ac7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtMy0xLTEtMTIxNzE_e6d17c93-955f-4d0b-a429-1c4074739a53"
      unitRef="usd">1195000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ibc64ef7d67ae4df28598f2989a60b364_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtNS0xLTEtMTIxNzE_2a86f88e-aa85-4b2d-b0ca-4bfd12eaa04f"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOjgxOTMzMjc5M2U2NDQ0OWE4YWZiNGU5NDVmNGIxNjg4L3RhYmxlcmFuZ2U6ODE5MzMyNzkzZTY0NDQ5YThhZmI0ZTk0NWY0YjE2ODhfMTAtNy0xLTEtMTIxNzE_5bfe14c3-63ea-4e96-a2b4-7b6c1aa6b4ce"
      unitRef="usd">1195000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy0xLTEtMS0w_69b1c03b-9ef0-496e-a6f5-e7934e559890"
      unitRef="usd">115769000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy0zLTEtMS0w_0078fb40-d67a-4071-9b4b-8fd40beefcc6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy01LTEtMS0w_bb8dd26f-387f-4398-b61b-0acab0bf1339"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfMy03LTEtMS0w_2e1c890a-ab2f-47a9-8728-02b5bcde4b62"
      unitRef="usd">115769000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC0xLTEtMS0w_8b166b79-ab5f-4a1f-a05c-0f40f4e0f3d0"
      unitRef="usd">67637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC0zLTEtMS0w_b68d82f1-6adb-4ebe-9d94-a6d816031b84"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC01LTEtMS0w_b850d911-d26b-4459-b799-ee9d55bf7350"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNC03LTEtMS0w_47e32476-e3e2-4b9f-8279-607756acf330"
      unitRef="usd">67637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS0xLTEtMS0w_34ef54ac-9ca7-4efc-b6f7-550c11efe605"
      unitRef="usd">58000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS0zLTEtMS0w_0a4b0a23-27b8-4c15-acb8-fd19cf68aa6b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS01LTEtMS0w_d785716a-4c1e-4f80-bfd3-7a3bd9cc7f6e"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNS03LTEtMS0w_5b0047b8-fd67-4a54-b7ea-b60c594f6630"
      unitRef="usd">58000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9cc209d6b1e0486896044884d8a79962_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy0xLTEtMS0w_2436785e-6786-4c4b-85c0-37184cc1cc29"
      unitRef="usd">183464000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1107fb53d2d4763b23b7cc4c7b09fbe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy0zLTEtMS0w_eedd200c-4938-4a79-99bd-9a35b0cc55cd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86a09834f27e46cab5ec171e7d48fd19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy01LTEtMS0w_ee01c7a1-db8e-4e06-8a14-baa89c132855"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RhYmxlOmIwZDIxNzg3ZWQ2ODRmODNhZmVmOTQzOWMxZTNmZDBiL3RhYmxlcmFuZ2U6YjBkMjE3ODdlZDY4NGY4M2FmZWY5NDM5YzFlM2ZkMGJfNy03LTEtMS0w_ff315bb4-a20a-4f7c-9116-a53a6613a9ba"
      unitRef="usd">183464000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwOTE_4464bb93-a1d6-403c-a648-3d598b837e14">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_3f99c666-45df-4335-b64c-6a20badce5a0"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_a1b828d5-09d7-466d-b93c-d9410295b3db"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_b9f6a409-d6c9-4295-a240-0f21c595ec32"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5MzkzNw_efad7904-5b4e-44db-bbb4-29abf2369cba"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNjE_8e6c16e8-ff64-4e80-bbbb-01627503dae2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTc2NjU_5663b87a-0aa1-4f37-9c0a-eec9c92375e6"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_16a70ed7-5cfb-4f7c-a821-1b9e1a60314a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_38bdd138-4559-4031-b5f7-981c7ec0f29b"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_6ac1c92c-eb16-428f-bc8f-4762da010d74"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjc2NA_f6e91783-2f75-43ce-b18f-23fef4b8a1d1"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMjE3NQ_90a26465-e5e0-4af0-9015-8ea55015c631"
      unitRef="usd">239100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzMjE3NQ_e2cd088e-8cb7-497a-b208-aa5020daccf5"
      unitRef="usd">239100000</us-gaap:Goodwill>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTM_75ae68b7-f572-4478-9a62-fd94ba8f87a5">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Cost Method &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDY_3a64d746-2461-4ce8-8790-314c2c1955c3">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <ameh:FiduciaryCashAndPayablePolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwODM_d0dd61c2-ca6d-443f-be99-751e74f555b1">Fiduciary Cash and PayableAPC, Alpha Care, and Accountable Health Care collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of</ameh:FiduciaryCashAndPayablePolicyTextBlock>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjg4NA_f94bc676-9578-4494-80e8-b74a0059a98f"
      unitRef="usd">9100000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjg4OA_527aeb42-f05e-40fd-9261-4a1efa7730bc"
      unitRef="usd">9600000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNjU5NzA2OTgzNDAzOQ_2a3ba9fd-91e3-4b37-9bcd-e6dd4fed940a">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 8 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;The estimated fair value of the derivative instrument was determined using Level 2 inputs. The fair value of the derivative instrument as of June&#160;30, 2021 and December&#160;31, 2020 was $1.2 million and $0, respectively, and is presented within other long-term liabilities in the accompanying consolidated balance sheets.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9b7eb2683f4c475faeaec9c8b1f67839_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNjgyNw_43c5a994-d30b-4550-a7d2-9193beb2650a"
      unitRef="usd">1200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5f03ca66055944a6b0fb9d49c0ba7b81_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNjYzMg_62485515-11d9-4e78-a42a-1aff8665bb86"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNTk_05170899-8ee5-4f11-aa58-b52aa275e6ad">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like payments, called All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 7), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#x201c;Participation Agreement&#x201d;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $24.3 million and $48.1 million in total AIPBP payments for the three and six months ended June&#160;30, 2021, respectively, of which $14.1 million and $31.2 million has been recognized as revenue for the three months and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system, and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i73ebc5992e5544fa9612e04b047d6eb0_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMDI_f17818f6-ae42-42cb-9967-f2e487dfd516">one year</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzQwNTM_dc97f467-9417-44c6-ae9b-b79f48857b74">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzQzMTM_3838e485-4381-420e-a1be-4d0cb8bd7c6a">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i6d0f6e94a090483b93aaa2aa9c5be1ba_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMzQ0MzY_3838e485-4381-420e-a1be-4d0cb8bd7c6a">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:PaymentOfRevenueMonthlyAmount
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjY5Mw_b9054372-bb41-427c-9fa3-07d1f46f2eee"
      unitRef="usd">8000000.0</ameh:PaymentOfRevenueMonthlyAmount>
    <ameh:PaymentOfRevenue
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjY5OA_bf8b1959-dda7-46ba-968b-a8f1ed27511d"
      unitRef="usd">24300000</ameh:PaymentOfRevenue>
    <ameh:PaymentOfRevenue
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjcwMg_9ae0f0dd-c398-4ce3-8654-bddb6a03db92"
      unitRef="usd">48100000</ameh:PaymentOfRevenue>
    <ameh:PaymentOfRevenueRevenueRecognized
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjcwNg_1f7e584c-5be8-47ae-a04e-ffb8c16e8094"
      unitRef="usd">14100000</ameh:PaymentOfRevenueRevenueRecognized>
    <ameh:PaymentOfRevenueRevenueRecognized
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTY0OTI2NzQ5NjcxMA_30cce759-7b86-4e36-9f76-c25638d43dd7"
      unitRef="usd">31200000</ameh:PaymentOfRevenueRevenueRecognized>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i2445932d5cee413a82029f7fb82d054a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTU_f6f72bd8-2694-4f8c-bed4-275f6d476bbd">10 years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5Mzk0OQ_fadddf52-44e6-4f02-a7d7-f6b641e9d708"
      unitRef="usd">29600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTQ5NzU1ODE5Mzk1Nw_12127c86-5e52-4d50-bdd9-96ac3bc999e5"
      unitRef="usd">13000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if30af78cdea54cdbafd288daa6d2c6fe_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMTA5OTUxMTY4Mjg3OQ_bf3a45df-85f2-4d2f-8b1f-ec9655cafe61"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzA_f6543227-9de7-4d52-8418-c7db7747b117">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNzA_5de2cb26-219f-493c-876c-ff930ee5fdc8">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDc_c58f6ca4-a502-40e7-9ec8-93d3636c7463">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities &lt;/span&gt;&lt;/div&gt;outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</us-gaap:EarningsPerSharePolicyTextBlock>
    <ameh:MinorityInterestPolicyPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzY_b81921ba-77c5-4cf6-9a01-eb39a4cfa0a5">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</ameh:MinorityInterestPolicyPolicyTextBlock>
    <ameh:TemporaryEquityPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTY_57e28bd1-0cfc-4de0-9166-d14709507d93">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2021 and December&#160;31, 2020, APC&#x2019;s shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;</ameh:TemporaryEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwNDE_0e32f905-9597-4a45-ab30-7eccfba95ccb">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12 month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ameh:BeneficialInterestPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMwMzE_8a63d483-260e-4667-8890-e799e607c4bd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Beneficial Interest&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI pursuant to the terms of the stock purchase agreement, APC received a beneficial interest in the equity method investment sold. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free Treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#x2019;s gross margin for the year ended December 31, 2020 was assessed and beneficial interest was concluded to not be collectible. For the three and six months ended June&#160;30, 2021, the $15.7 million was written off and expensed in other income in the accompanying consolidated statements of income.&lt;/span&gt;</ameh:BeneficialInterestPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i130bee7db4b74cfdac137ec49a5678ab_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNDk4ODE_b48ff815-ea25-41f8-8c98-bb50c12921a0"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="if5ce879e744f44499873676c0b759e61_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNTU1NA_d18ef0c7-cb43-4928-b8c0-eee330e9c73a"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="ib82f85b4c8b24e3eb8d0b090521fffd3_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTAxNDI_1f76b63d-df65-4d1a-af06-7a90b20a336c"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationCash
      contextRef="if5ce879e744f44499873676c0b759e61_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTA0NTQ_242a10bc-2feb-47cc-a772-ea688499d7f5"
      unitRef="usd">15600000</ameh:EquityMethodInvestmentSaleContingentConsiderationCash>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares
      contextRef="if5ce879e744f44499873676c0b759e61_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTA1MTA_55c6bcff-1757-4728-a77f-8ff55f45bdc2"
      unitRef="usd">6400000</ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue
      contextRef="if5ce879e744f44499873676c0b759e61_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTA1NDQ_3777c347-550f-4c31-ad11-a0b2bfdc5ef9"
      unitRef="usd">22000000.0</ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue>
    <ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds
      contextRef="i31665be81e024f77a8eb0c64fdd329d5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNzczNw_8c116896-594c-4a95-b0c0-5d265edcddb7"
      unitRef="usd">15700000</ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds>
    <ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds
      contextRef="i9e33fda836264739aa7bb8163bc33a5e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfMjc0ODc3OTEzNzczNw_c8f116a2-e747-4330-bb93-8b53326985f6"
      unitRef="usd">15700000</ameh:EquityMethodInvestmentWriteOffOfAdditionalProceeds>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80My9mcmFnOjRhZjgwMDdmNmFhNzQxYzBiNjlhMTAxYzU5MGM3MjY5L3RleHRyZWdpb246NGFmODAwN2Y2YWE3NDFjMGI2OWExMDFjNTkwYzcyNjlfNTMxMTc_121aee19-6820-4b4b-9be9-6ffb651f90bd">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related to the approach for intraperiod tax allocation, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfNDk1_02481a69-a114-41b5-92b6-8ef2170c7e02">Intangible Assets, Net&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $3.7 million and $4.1 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $7.5 million and $8.2&#160;million for the six months ended June&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfNDk3_6bb0b80d-4a99-41dd-8173-d7bc203c29cc">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June&#160;30, 2021, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(89,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i82dd99b346d847f6afecef6b4ffe3d89_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi0xLTEtMS0wL3RleHRyZWdpb246ZjRlYWFhNjM1Mjg0NDBkMDgwZWQxZTQ4OGVhZmNjOGFfNA_221aab28-2d71-4459-adf7-ca5ffc834895">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8330c3700a474f29947f7fde24cb31d0_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi0xLTEtMS0wL3RleHRyZWdpb246ZjRlYWFhNjM1Mjg0NDBkMDgwZWQxZTQ4OGVhZmNjOGFfNw_39ed9166-452d-4017-8f9c-1452c2c32a58">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id890472ab2d0424986384ec74225309a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi0zLTEtMS0w_bd2f8914-231c-428d-9e2a-9435a4f40e14"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id890472ab2d0424986384ec74225309a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi01LTEtMS0w_25d7f74e-fb19-4935-bf03-428f40907f33"
      unitRef="usd">79057000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id890472ab2d0424986384ec74225309a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMi03LTEtMS0w_42759973-5004-4b94-b34d-9d370b704fe7"
      unitRef="usd">64873000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iab2ae2abe941465e94134f35120b632f_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy0xLTEtMS0w_0cbaed3b-a05f-4951-80e0-31eb18dbc952">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i709e028ffa954eac8fe9f174ae35a812_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy0zLTEtMS0w_349feed7-7769-4bdf-91d3-45903b8b2af8"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i709e028ffa954eac8fe9f174ae35a812_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy01LTEtMS0w_5f157d7f-8db1-4ef1-9144-d31327c33ad1"
      unitRef="usd">12693000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i709e028ffa954eac8fe9f174ae35a812_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfMy03LTEtMS0w_1b83480f-4650-4ebc-a93f-ef056c6adf22"
      unitRef="usd">10139000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia462a1dff6eb49f0a14538bf7d4535a8_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC0xLTEtMS0w_5e260a17-1dbb-4e6b-be5b-bc6066e075e2">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC0zLTEtMS0w_2e5954a7-1d24-4d95-b564-916e0a57d20e"
      unitRef="usd">7396000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC01LTEtMS0w_63ca57ed-ee2b-4562-a120-e0f971293973"
      unitRef="usd">3595000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i38a9a0f7f9b644c5bd84f3b6d2fb31ed_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNC03LTEtMS0w_ee925d04-143d-455e-9789-7b5ff13cf223"
      unitRef="usd">3801000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia873358d93f341de98ab17edbffcde50_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS0xLTEtMS0w_0aeb7585-a518-4c7e-947f-e5c517693d15">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS0zLTEtMS0w_00b64e2c-4759-41b9-b486-6cdceaba9575"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS01LTEtMS0w_68377c2b-9dfc-4386-8c91-8c2512f83fa4"
      unitRef="usd">1476000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0c57c2a86ad8458c9b2b0bdd03b3b7e4_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNS03LTEtMS0w_fd5c0867-5827-4ee3-80f8-226560afe9ba"
      unitRef="usd">584000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i54b9d769c77c4104928dc588fb0c91ca_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi0xLTEtMS0w_32139b8b-325f-4990-bdea-50274bee625b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi0zLTEtMS0w_b83ebd0c-7559-477c-b899-d7a0ec05080a"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi01LTEtMS0w_621e6716-983b-4c39-84e8-9d6ee23e375a"
      unitRef="usd">181000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5f03b16725e94b2e89ffafc7bbe809ef_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNi03LTEtMS0w_be15b9a4-a4b5-4ea4-a75f-42aa4f0f0520"
      unitRef="usd">830000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNy0zLTEtMS0w_382ad1e6-ffd7-4096-add3-9883420104b3"
      unitRef="usd">177229000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNy01LTEtMS0w_5653ab70-a862-4b70-8eb4-8602b5eaab47"
      unitRef="usd">97002000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmMyMWMxYzI5YmQ3ZjQ3Mjg4NDVmN2I4NjYxZjZjN2Y0L3RhYmxlcmFuZ2U6YzIxYzFjMjliZDdmNDcyODg0NWY3Yjg2NjFmNmM3ZjRfNy03LTEtMS0w_473605cd-2f6b-48b3-b3c3-667593ab98f0"
      unitRef="usd">80227000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i044041f8aebc43dea7c8afc0da3d2cae_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi0xLTEtMS0wL3RleHRyZWdpb246YTYxOTc1ODk5YjdjNDFlNGFkYWZjYzhmNGE1NDExMzNfNA_82ac0614-305f-4b46-8ea4-2153434dc75b">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id2589d5bf11b47ddb890e3feeb7d0e43_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi0xLTEtMS0wL3RleHRyZWdpb246YTYxOTc1ODk5YjdjNDFlNGFkYWZjYzhmNGE1NDExMzNfNw_38580672-a52d-45f5-acd4-22a01fd56874">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i42823b74ab154e4cb57ada3938ebe79a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi0zLTEtMS0w_ad31f0c5-641d-4a50-bb98-2c8c9ef548c6"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i42823b74ab154e4cb57ada3938ebe79a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi01LTEtMS0w_8976d71b-7dc5-4017-8c94-abfe88dec73c"
      unitRef="usd">73169000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i42823b74ab154e4cb57ada3938ebe79a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMi03LTEtMS0w_a4e7b5f9-2c53-47a8-b98f-b84d8c711dba"
      unitRef="usd">70761000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3e5c9b3bb5cf4c068e18e1fbe99c4bcf_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy0xLTEtMS0w_2f9eda15-ed49-4d91-9bba-3018b6b28506">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy0zLTEtMS0w_62181fec-6c16-457a-a612-4c9050fa6f6e"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy01LTEtMS0w_3268d44c-1413-4bad-b2a6-71bb5c372620"
      unitRef="usd">11715000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iee76fc8ae25d4d7c9f8cafea96482db4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfMy03LTEtMS0w_10aa0e8b-ad09-4d88-a3a2-50f2fb317cc0"
      unitRef="usd">11117000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if0fbf27e2a7647899d67e3bd220dbeda_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC0xLTEtMS0w_632d9016-6cb2-4b71-a332-cc400c2b88ad">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i73f982d527bd42e7b4fab85539b28ffc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC0zLTEtMS0w_ea41725f-e72e-429f-bafc-2fea261c85ff"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i73f982d527bd42e7b4fab85539b28ffc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC01LTEtMS0w_fccb1d01-e57a-4eb8-a7a0-515c2afc8f30"
      unitRef="usd">3234000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i73f982d527bd42e7b4fab85539b28ffc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNC03LTEtMS0w_9de0eb3f-efd3-4da4-aeef-fab759c4dd6f"
      unitRef="usd">3462000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1b898d0feaa140ab9e92e780e9feb0ba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS0xLTEtMS0w_27eb454c-5522-4ca5-9598-87b573e56c8e">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib101f9ba2e1e4330b0065d49f9aed221_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS0zLTEtMS0w_a7f120ea-1048-4528-a1f0-2973c15e21a9"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib101f9ba2e1e4330b0065d49f9aed221_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS01LTEtMS0w_86bf53a2-393e-4a72-8cb8-40a35e8f40e6"
      unitRef="usd">1270000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib101f9ba2e1e4330b0065d49f9aed221_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNS03LTEtMS0w_1c2668f2-d6d2-498e-8ff6-7dffb799a51a"
      unitRef="usd">790000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0341cbb996e048a6854636392a8e25d5_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi0xLTEtMS0w_ebc57e58-dcfa-4837-8f58-ff0d756d12ef">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8bec418630414a69a769bf4b40f4e7e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi0zLTEtMS0w_08853971-a3c4-4b09-b351-3ec1af82a584"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8bec418630414a69a769bf4b40f4e7e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi01LTEtMS0w_35463434-84d3-4baf-9376-6b2583f1ec42"
      unitRef="usd">156000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8bec418630414a69a769bf4b40f4e7e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNi03LTEtMS0w_425db7bd-56f6-44a8-82e6-fb74572ae0ef"
      unitRef="usd">855000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNy0zLTEtMS0w_613b93d9-e722-4841-b68c-51e5231d7147"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNy01LTEtMS0w_cb17002d-de63-4f3c-942f-af2b5328f632"
      unitRef="usd">89544000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmUyOGExMjUwZDkyMTRhODdiNDcwMDQ2MTgyNDM2MGIzL3RhYmxlcmFuZ2U6ZTI4YTEyNTBkOTIxNGE4N2I0NzAwNDYxODI0MzYwYjNfNy03LTEtMS0w_d4961326-feb9-40f9-9d10-78864eef6446"
      unitRef="usd">86985000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMzM2_484a77c4-26e4-459c-aeb1-8602888ed603"
      unitRef="usd">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMzQz_8a5414bb-5cd9-42c4-9dbb-605f046328f6"
      unitRef="usd">4100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMTA5OTUxMTYyODM4MQ_6cf743d7-5151-4cf7-b750-69baa701b931"
      unitRef="usd">7500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfMTA5OTUxMTYyODM4NQ_c4c96d78-3849-46fb-8166-b9d533afa718"
      unitRef="usd">8200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RleHRyZWdpb246Yzg3ZDNlOThjZmJjNDg0NGI0YzNkOWZjMDYxMGIyMDRfNDk5_6526b45e-fba3-4220-96b5-7c0b37b5a2d5">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021) &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfMi0xLTEtMS0w_d38fe9e5-2a73-4cbd-8114-8f3730920edd"
      unitRef="usd">7533000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfMy0xLTEtMS0w_51e243d7-d377-47b9-97ab-19319165fd43"
      unitRef="usd">12906000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNC0xLTEtMS0w_b6aa85a2-f25b-49c2-8991-f7cec3b60c64"
      unitRef="usd">10842000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNS0xLTEtMS0w_71542780-8674-4130-bada-846b92692d08"
      unitRef="usd">9830000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNi0xLTEtMS0w_3029e876-e514-4535-9b39-476e2a9b155b"
      unitRef="usd">8758000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfNy0xLTEtMS0w_c21862ec-cdbd-4380-8dca-5ac8de783dd1"
      unitRef="usd">30358000</ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF80OS9mcmFnOmM4N2QzZTk4Y2ZiYzQ4NDRiNGMzZDlmYzA2MTBiMjA0L3RhYmxlOmU1N2IzOTU3OWNiZDRjOGRhZjBiNjViZmVjOWU0NjA3L3RhYmxlcmFuZ2U6ZTU3YjM5NTc5Y2JkNGM4ZGFmMGI2NWJmZWM5ZTQ2MDdfOS0xLTEtMS0w_e3540a3a-c8c7-485d-8750-552f16ef0a83"
      unitRef="usd">80227000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ameh:EquityMethodAndOtherEquityInvestmentsTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI4OQ_4408244d-8a55-4305-b417-8eb78cdc8dc1">Investments in Other Entities &#x2014; Equity Method&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Entity Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-8 Medical Investment Group, LLC - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties through its network of approximately 2,400 independently contracted primary care physicians and specialist providers. LMA&#x2019;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#x2019;s IPA line of business. On December 18, 2020, the Company exercised its option to convert the promissory note totaling $6.4&#160;million due from Dr. Arteaga into an additional 21.25% interest in LMA&#x2019;s IPA line of business. As a result, APC-LSMA&#x2019;s interest in LMA&#x2019;s IPA line of business increased to 46.25%. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#x2019;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of $3.6 million and income of $0.2 million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and June&#160;30, 2020, APC recognized a loss from this investment of $4.3 million and a $0.4 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $8.7 million and $13.0 million at June&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the six months ended June&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at its facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.6 million and $0.4 million, for the three months ended June&#160;30, 2021 and 2020, respectively, and fees of approximately $1.0 million and $1.0 million for the six months ended June&#160;30, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#x2019;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of approximately $16,000 and $10,200, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recognized a loss of $30,000 and income of $0.1 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $1.4 million and $1.4 million at June&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, David C.P. Chen M.D., individually, and APC-LSMA entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#x2019;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized income from this investment of $0.2&#160;million and a loss of $0.1 million, respectively, in the consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recognized income from investment of $0.2 million and a loss of $0.1 million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.6 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;531 W. College LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, College Street Investment LP, a California limited partnership (&#x201c;CSI&#x201d;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC, and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owned 50%, 25%, and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#x2019;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $16.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of $9,000 and $0.1 million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recorded a loss from this investment of $0.1 million and $0.2 million in the accompanying consolidated statements of income, respectively. The accompanying consolidated balance sheets include the related investment balances of $17.1 million and $17.2 million at June&#160;30, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College LLC&#x2019;s balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the six months ended June&#160;30, 2021 and 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;br/&gt;One MSO LLC - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in One MSO LLC (&#x201c;One MSO&#x201d;) for $2.4 million. One MSO owns an office building in Monterey Park, California that is currently being leased to tenants, including NMM. For the three months ended June&#160;30, 2021, One MSO recognized income of $0.1 million in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021, One MSO recognized income of $0.2&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.6 million and $2.4 million at June&#160;30, 2021 and December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in Tag 6 for $4.5 million and a 50% membership interest in Tag 8 for $2.1 million. The Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. For the three and six months ended June&#160;30, 2021, Tag 6 recognized a loss of $0.2 million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the Tag 6 investment of $4.7 million and $4.5&#160;million at June&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in privately held entities that do not report net asset value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MediPortal, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AchievaMed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, NMM and AchievaMed, Inc., a California corporation (&#x201c;AchievaMed&#x201d;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investment in privately held entities in the accompanying consolidated balance sheets as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</ameh:EquityMethodAndOtherEquityInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI5NA_7409cf09-5d20-4cc5-b65a-7c5d63166648">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Entity Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One MSO, LLC - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tag-8 Medical Investment Group, LLC - related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,812)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the six months ended June&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,857)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College LLC&#x2019;s balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the six months ended June&#160;30, 2021 and 2020, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i126879ce11594831961b89ab705a48f0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS0xLTEtMS0w_0a2651f3-8148-4f59-a993-51efcaba40b8"
      unitRef="usd">13047000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS01LTEtMS0w_2fcc530d-012e-46c3-b355-336b09ac5fd5"
      unitRef="usd">-4328000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS03LTEtMS0w_b177c304-9217-49ce-9cf4-45ed64a34354"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i9cf5c8ca87614f10b4c2479aa1710ecb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS04LTEtMS0xMDk0MQ_5660ae44-1b92-4ccf-a616-02662ef538a3"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i93a51086c7d546adab3f7e56b087b382_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMS0xMS0xLTEtMA_0cfa5d33-6364-46dd-8ee3-5eb987187717"
      unitRef="usd">8719000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ib9329af8296b449084545734af6bd691_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xLTEtMS0yOTM5_1b58ee81-6be5-4d9a-8590-23043fd91d35"
      unitRef="usd">1413000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi01LTEtMS0yOTM5_52397d9f-5bfb-4f14-9a1a-beebe6c0e7ab"
      unitRef="usd">-30000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi03LTEtMS0yOTM5_5f03bce6-ce9e-4acb-83b0-23985cc43952"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi04LTEtMS0xMDk0MQ_d19edfbb-7197-4403-9843-4efb9697ca2a"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="ife67641ec17b442283895740613c5731_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xMS0xLTEtMjkzOQ_a973d93d-6d27-491a-82d7-84f66918b870"
      unitRef="usd">1383000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1f711e268b9d414f8665d1f912ae7f03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xLTEtMS0w_d2aed3d3-fdfc-4a85-b312-8c502ad877f2"
      unitRef="usd">2613000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ieb25a59000ec47a68ab4d4b9b24dacb3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi01LTEtMS0w_21351e9c-4200-45b4-869c-dab3b4498886"
      unitRef="usd">220000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi03LTEtMS0w_b84ba69d-0d7b-4c4b-bd69-2adbe82030f3"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ic962f439bc2f435e8fbdbc643668ab36_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMy04LTEtMS0xMDk0MQ_87938fb5-39e4-41d1-a0cc-bfbf27aa44d2"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i4181eb02bb2f4393a3250731eddb20f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMi0xMS0xLTEtMA_45bd9979-7c81-4f14-8dca-8d9526ac671e"
      unitRef="usd">2833000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9343b3aac1264fccba1bf8a8c124302f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS0xLTEtMS0w_6ac9f71e-9b22-4e46-8935-287f7f640b6a"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS01LTEtMS0w_56ae6ff9-ceac-4cc8-bb65-3d05602b269a"
      unitRef="usd">-115000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS03LTEtMS0w_77eb73cc-9baf-49a2-ba0f-b31de3a16296"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNC04LTEtMS0xMDk0MQ_367de8ed-72d5-46b8-a564-e8f189461181"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i009c403c4ff240a19cc16cdbe7834056_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS0xMS0xLTEtMA_5cc10bbf-5f6e-4946-8b78-c07dda92baf2"
      unitRef="usd">17085000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0eddafd4ca9e4212901159b5340a98fe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy0xLTEtMS0w_121551ad-600f-48b1-becb-d8cd168c0d02"
      unitRef="usd">2395000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia8c75381253b47bd8691ab6ed609fbda_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy01LTEtMS0w_b1dc5345-f664-467a-806f-8ada6da6db61"
      unitRef="usd">246000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy03LTEtMS0w_319791a8-8cf4-42a3-8aa3-7c98340e9d07"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i8b482750d838451c9690b24453bd04a7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNS04LTEtMS0xMDk0MQ_21c3ad4a-cfb6-454f-a1e1-daddb04def82"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="ib7bc039d7edc42b1b767425117d101c9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy0xMS0xLTEtMA_78953149-73cc-43df-830d-785f0d21231b"
      unitRef="usd">2641000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8c39d18aa59f4fdab441e373be437999_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC0xLTEtMS0w_a3d000bd-5747-4a0c-a4b7-f2ce47828f73"
      unitRef="usd">4516000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC01LTEtMS0w_176df6d0-f634-40c8-b9ef-20174d35d470"
      unitRef="usd">195000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC03LTEtMS0w_9031b4da-8875-4235-bed9-59dbd59e345e"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="idfdc889b53c94180bff3d59a025099fa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNi04LTEtMS0xMDk0MQ_e28a4e38-3ec9-41c0-986a-0e9894c6da59"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i302d2d42eb894edfa8abcbb27511f099_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC0xMS0xLTEtMA_18de79d9-051a-4709-af27-e7a091b11860"
      unitRef="usd">4711000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if978e802ab374bcb978febf6e68a5f0a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS0xLTEtMS0w_f724add6-bf6d-4529-981d-78ece5883f22"
      unitRef="usd">2108000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS01LTEtMS0w_cf1ad796-6c7f-4900-b2b0-0cca56adb90a"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS03LTEtMS0w_590cf21e-aaa8-4ae4-8e89-b418261815ec"
      unitRef="usd">1660000</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i9dc53ff3c4364a66862590173dceb21a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfNy04LTEtMS0xMDk0MQ_cd4579de-c3aa-4468-99be-ad7bb8818ba3"
      unitRef="usd">3768000</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i62d380a7b57e4077a43fd2ca0fe6d807_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOS0xMS0xLTEtMA_2d70a510-54ef-4c8f-b1e7-cc8745c982df"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtMS0xLTEtMA_29177d7e-c4ec-41a1-a301-b341535a0110"
      unitRef="usd">43292000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtNS0xLTEtMA_42b2b42e-5ee6-4835-92c9-90bd4f16c6ab"
      unitRef="usd">-3812000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtNy0xLTEtMA_1cd14739-816d-4b13-837c-30d6b350892d"
      unitRef="usd">1660000</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfOC04LTEtMS0xMDk1OQ_14972e3b-46c8-49a6-9dbe-5d7b0e50b553"
      unitRef="usd">3768000</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmMwZjRkYzI3NzJjNzRlZGNiZmZkNDFhZGUxMjgwYWUxL3RhYmxlcmFuZ2U6YzBmNGRjMjc3MmM3NGVkY2JmZmQ0MWFkZTEyODBhZTFfMTAtMTEtMS0xLTA_94ffe4b7-da31-481a-a02d-a0b5662bcb67"
      unitRef="usd">37372000</us-gaap:EquityMethodInvestments>
    <ameh:NumberOfEmployees
      contextRef="i93a51086c7d546adab3f7e56b087b382_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzk0_b85aa28e-8260-4a19-95f4-eb1a88d8bfeb"
      unitRef="provider">2400</ameh:NumberOfEmployees>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i1e1b0a8248204e63bc412a37ae8ab329_I20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzEx_504f6788-fa58-4541-9f6b-adf51781f605"
      unitRef="usd">5000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1e1b0a8248204e63bc412a37ae8ab329_I20121231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzIw_51aae810-5fa0-4aa5-992b-60b2c64034bc"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NotesReceivableNet
      contextRef="i2699be005bc448cf854162e6c83dcef3_I20201218"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODU4_802a118f-488c-4b78-84bf-10c6d5031ec7"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease
      contextRef="i2699be005bc448cf854162e6c83dcef3_I20201218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTAx_1a692d52-7ba7-4173-b7f1-be3d6e596d73"
      unitRef="number">0.2125</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion
      contextRef="i4301c2756dfb415abb72c0f8eb734638_I20201218"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTAyMA_096c6739-08b3-46dd-aa6f-e18872c6026c"
      unitRef="number">0.4625</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i54987c743be74a588a51746074a0a1be_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTI2NQ_0d645c07-23b2-41b7-860b-de76efff1e57"
      unitRef="usd">-3600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7b874970f5404290acf4e877e53cc4d3_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTI3Mg_b7134f3c-7165-4667-8de8-60d3853e0611"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i85e16b9f030248348c4c2fa5de4c74e2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTI1OQ_524199e5-c368-4510-97b3-3f2671da834b"
      unitRef="usd">-4300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3273b2373fda4cdcb3db5f9523c73062_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTI4MQ_8830ea42-c28b-4223-9d78-dfa585468924"
      unitRef="usd">-400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i93a51086c7d546adab3f7e56b087b382_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTQzMw_16045acf-34b5-462a-9c10-8dece09a32d7"
      unitRef="usd">8700000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i126879ce11594831961b89ab705a48f0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTQ0MA_c3aff98f-297d-41ad-aee7-d24a5650e8d5"
      unitRef="usd">13000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMy0xLTEtMS0w_60c82293-8157-4d52-822d-3b68ff66c821"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMy0zLTEtMS0w_48af263c-01a2-41e0-ae74-cf5cbd11c430"
      unitRef="usd">9350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNC0xLTEtMS0w_8d96a73e-e385-400c-9231-58e4cec0325b"
      unitRef="usd">694000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNC0zLTEtMS0w_d429fb5e-34ff-40d1-a79d-af5f90dfa8ee"
      unitRef="usd">691000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNS0xLTEtMS0w_1a8b2a05-4619-422f-bdb4-9078652db32b"
      unitRef="usd">6300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNS0zLTEtMS0w_7ffe05da-e8cb-4c9d-b835-e63399513945"
      unitRef="usd">3918000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNi0xLTEtMS0w_48193a4a-4933-4413-b01a-0013f647ada6"
      unitRef="usd">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNi0zLTEtMS0w_dd542fdd-30e9-4cb2-ace9-ff0278a77691"
      unitRef="usd">881000</us-gaap:OtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNy0xLTEtMS0w_b74a22a9-02b9-4e4e-9ea1-5cb0dc6eaba3"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfNy0zLTEtMS0w_9b5cf51f-77ff-4976-9e95-cb4cf3937700"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:Assets
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfOS0xLTEtMS0w_76c01268-7ebe-4830-8110-7fea8b22dbb5"
      unitRef="usd">9244000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfOS0zLTEtMS0w_72fc3100-e1dc-486b-acc1-018daaa88a8f"
      unitRef="usd">17090000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTItMS0xLTEtMA_dd034919-bc3f-4f45-8a5a-dcc912497dee"
      unitRef="usd">23101000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTItMy0xLTEtMA_733855ec-2118-4c90-a9c4-52dbe79af2d9"
      unitRef="usd">21589000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTMtMS0xLTEtMA_ea7318e3-2167-4a02-bcdc-2150ee587f95"
      unitRef="usd">-13857000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTMtMy0xLTEtMA_2088cec2-a04a-4e75-8904-75b0649179a6"
      unitRef="usd">-4499000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifd05517d558847b49c015f173be8b91d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTUtMS0xLTEtMA_4eb9c32c-f4e6-4bc7-8c36-e1654fe3ae6d"
      unitRef="usd">9244000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id7db85519bc746c39bb248797feb58c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOmJmZjAwY2Y3NTk2NTRhOGFhZDZhODA5ZjllNTY0ZjY2L3RhYmxlcmFuZ2U6YmZmMDBjZjc1OTY1NGE4YWFkNmE4MDlmOWU1NjRmNjZfMTUtMy0xLTEtMA_d482b597-acd3-4120-8a1b-7155a451b67c"
      unitRef="usd">17090000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfMy0xLTEtMS0w_dda287b3-c70d-41fb-8c18-2f52edb4831a"
      unitRef="usd">95212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfMy0zLTEtMS0w_ec8e77d1-2a0f-448c-9777-9dcf4dd42f4f"
      unitRef="usd">92113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNC0xLTEtMS0w_c2ca2241-a135-43c0-8f1e-df037f797d07"
      unitRef="usd">104570000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNC0zLTEtMS0w_550465fd-fc0b-43a9-b513-71926a537de1"
      unitRef="usd">93680000</us-gaap:CostsAndExpenses>
    <us-gaap:ProfitLoss
      contextRef="i39f330eaca3043d8bd9bce293792b4aa_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNi0xLTEtMS0w_d191a2ae-ca9f-4f3f-b46f-6d40fb2ed6ae"
      unitRef="usd">-9358000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0dbc24287c3f4456a9e1a17e45a4b07c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjUzNWU4ZDY5MTU5NzRjZWI4ZmVjNDljNjUwMDhjMzkxL3RhYmxlcmFuZ2U6NTM1ZThkNjkxNTk3NGNlYjhmZWM0OWM2NTAwOGMzOTFfNi0zLTEtMS0w_2af86831-28bd-4093-9358-d78e6b7963d2"
      unitRef="usd">-1567000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i739839922e4c4c609f191b0dcbabc14c_I20150731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjE3Mg_7cad56ef-1cd2-471d-9c9a-234f6cde07dd"
      unitRef="usd">1200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i739839922e4c4c609f191b0dcbabc14c_I20150731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjE4MQ_291edf46-14a3-4ad3-ac1c-70ac23ebf9ce"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsForFees
      contextRef="i1303e2069e6247dbb7f793e04ef343c5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjQzOA_2383fd02-8595-4c4f-8a90-874cf8c5a0c5"
      unitRef="usd">600000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i17796dfb151e489dab379fce67d4e1b8_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjQ0NQ_270a0307-6a93-4276-b872-e3c1c43f4e1c"
      unitRef="usd">400000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i6bca3a4a2ef740ff94ca5e1a3a2ad63e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTc0NA_a9b23bcf-7ed0-4bc2-a01b-45269a0a6841"
      unitRef="usd">1000000.0</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i0899c47275134483b8d984adf3740b3e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MTc0OA_22e1dc61-189b-4330-99eb-753f74e0499b"
      unitRef="usd">1000000.0</us-gaap:PaymentsForFees>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i32cbe872dd774db5b7d4800706c08caf_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc3MQ_6ca0ea01-64b5-415e-9b61-1fbeda2be93d"
      unitRef="usd">-16000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2887d4b59c254ece9c755540893a51fb_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc3OA_bdb431ab-832d-40de-8a7a-8ace87d617ec"
      unitRef="usd">10200</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i29508ad62c9a4ffa96ab856825835cc0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjA0Mg_87475955-6d42-4248-887f-f4683db3740b"
      unitRef="usd">-30000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i971d5df0b77740f8906d90e5210fbc87_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjA0Ng_601d0306-c5e0-42be-8f6e-814bfee2301f"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if37ba02674fc4f47a192436d297aff26_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjg4Mg_02cc362c-3442-4830-ba98-3ab5cf501ad7"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iefe421e759914ed0b7a4b1765437668b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjg4OQ_9b9d0861-2f1e-4bf3-aaad-60d8cfce1111"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0a037a875d3544e78944fdfbdef2af99_I20160531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzA3NQ_6de2aa58-3bd6-4e0b-bbd1-42cf61c5f9ad"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idbffb487ac384d7b9e97a9a77c64595e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzM2MA_fd79e39e-a70a-4f17-8933-de8a454a432f"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3cd84561b1874a4b9c02a9c4d5aea63c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzM2Nw_a9a2ed92-47ee-4b40-9085-f5feefcb8111"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8abff36813164c6c84417bf95217cc72_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjIwOQ_4c9338d1-dd37-4684-a71a-2c99c2650eff"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i94b60c63c1bc4a058e9a3b6b3cbe98e0_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ1MjIxMw_da6ba07d-647b-4e0d-b8b8-eb3bba9841e7"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i4181eb02bb2f4393a3250731eddb20f1_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzUxNQ_717babc9-0ba8-408a-8ace-1f6060558e39"
      unitRef="usd">2800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1f711e268b9d414f8665d1f912ae7f03_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzUyMg_32331f35-df6c-472d-8755-e616980398fe"
      unitRef="usd">2600000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1d9d1b124a0e459ca79a0ece66636348_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzkwNA_8e8a4ae0-fa06-4338-980a-a14e7b4bb720"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3b4a44d05fbf46488b4af77f35c9567d_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzkwOA_61cd0bfe-624c-4e2d-8287-0d7c27204b83"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i8eeb59c450004d3e92ae1911c1e1cbeb_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzkxNg_cda63c6d-6e68-4b9c-ad4d-cf835a05bf0a"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MembersCapital
      contextRef="i1d9d1b124a0e459ca79a0ece66636348_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzk5Mg_8ce50ad9-9538-4b9c-97b1-4c4d2695c151"
      unitRef="usd">16700000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i3b4a44d05fbf46488b4af77f35c9567d_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMzk5Ng_54a6fdf7-00a8-434f-9f20-c7b76000449a"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i8eeb59c450004d3e92ae1911c1e1cbeb_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDAwNA_905b78e7-b74b-4d1c-97e1-ce95f666450f"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:PaymentsToAcquireRealEstate
      contextRef="i75b545869a11420f9ea79a9c44e04340_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDI1OQ_2a5b1afe-2de4-4eb2-bcb2-86c32eec648b"
      unitRef="usd">33300000</us-gaap:PaymentsToAcquireRealEstate>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i70ff4fbd4b12465585f409d00f3b5b5e_I20190423"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDM2Mw_a60be28c-3fcd-4633-930d-30b8093d4c81"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i70ff4fbd4b12465585f409d00f3b5b5e_I20190423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDQyNw_a35aca8c-29bd-454c-8af6-a2ed64ecda82"
      unitRef="usd">8300000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib451b96ba18f4df7a702b76736baf9a3_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDQ1NQ_851a294b-e8cc-455a-af0a-3ea0cd209fbb"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i0597b46866404e3c9244a5206a042d40_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDUzOQ_d49836f8-35af-49ce-aa99-f8f313767348"
      unitRef="usd">16100000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i06dcdcd971e4410ba873f348e8e7adc2_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDgxNA_6e8438ce-f166-44b8-8af8-1f1e6b5c1b4c"
      unitRef="usd">-9000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icc7595906102441585b7663ded30146e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDgyMQ_b5ea93e0-5981-42f7-8bb1-30e68b132bdf"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibf5836787810470aa58c74049921dc6e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTA5OTUxMTYzODYyOA_44fa09c2-2fb8-4355-b68b-26d92d59f6b3"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib64a97044a35489c8feb4989784095cf_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTA5OTUxMTYzODYzMg_928ab686-6c88-4c66-8da4-96c1125a17ea"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i009c403c4ff240a19cc16cdbe7834056_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNDk4Mg_fdd81ba3-ad40-4e3d-90d8-8c9eab274cd4"
      unitRef="usd">17100000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9343b3aac1264fccba1bf8a8c124302f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc0ODc3OTA4MDc1Mw_6cd09e92-232a-4038-a15e-70ea72a0c282"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMy0xLTEtMS0w_554995f7-23a8-41bb-a71c-b3be0406d32a"
      unitRef="usd">305000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMy0zLTEtMS0w_dd1e9a76-20c6-40d9-8173-b127e5a6b764"
      unitRef="usd">648000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNC0xLTEtMS0w_7638a922-1c0b-4666-b402-6407d5043b8c"
      unitRef="usd">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNC0zLTEtMS0w_15d5ea9d-0b0c-458b-9d6d-ed279ede636d"
      unitRef="usd">17000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssets
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNS0xLTEtMS0w_e0d0186c-157b-44f6-9ec3-e8d7ea206698"
      unitRef="usd">172000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNS0zLTEtMS0w_d13144b8-3922-4fa9-889e-2a58f14ddb80"
      unitRef="usd">70000</us-gaap:OtherAssets>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNi0xLTEtMS0w_75c534f8-f48f-4cf5-98f9-7d09da16663c"
      unitRef="usd">33693000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfNi0zLTEtMS0w_8bfc2bb2-3fce-403b-bdf2-c0f2b18725c0"
      unitRef="usd">33697000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfOC0xLTEtMS0w_02b105e9-33b7-4f8a-9b5d-f9d21867f9c6"
      unitRef="usd">34170000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfOC0zLTEtMS0w_3a9636a4-c3bc-492b-b1b7-fcac6d18eaea"
      unitRef="usd">34432000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTItMS0xLTEtMA_9c0f9523-04e4-4947-ae97-8f99985297b3"
      unitRef="usd">0</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTItMy0xLTEtMA_c75982ca-2e5c-48c4-b81d-81c788ce3842"
      unitRef="usd">32000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTMtMS0xLTEtMA_fccc57b1-eb23-4ac0-956b-1d474740b28c"
      unitRef="usd">34170000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTMtMy0xLTEtMA_789ee816-35e7-4742-94b1-7cf49917231a"
      unitRef="usd">34400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic1a19122d99d474881d161ebb0dbea6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTUtMS0xLTEtMA_e5d9c235-7677-4ee2-a4b0-18c770dc465d"
      unitRef="usd">34170000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i12a87e3f2b914663a5c4b08bb19b93a9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjE2ZTIwNDVmY2E0ZTRiNjJhNGIxZmY2NjE3ODQ4MTNjL3RhYmxlcmFuZ2U6MTZlMjA0NWZjYTRlNGI2MmE0YjFmZjY2MTc4NDgxM2NfMTUtMy0xLTEtMA_4e99ac65-36b4-40c3-affe-c1fdd69a4e4b"
      unitRef="usd">34432000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMi0xLTEtMS0w_09640d07-4fb8-4ce1-9d27-1674c9297c99"
      unitRef="usd">116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMi0zLTEtMS0w_d576de28-2a73-4bf8-926c-1d212eb7a86d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMy0xLTEtMS0w_c36bb3bc-23b0-43a6-9983-e7aed69a51b8"
      unitRef="usd">344000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMy0zLTEtMS0w_ec3c9c4f-14d3-41ed-9e02-f3d3b614431d"
      unitRef="usd">579000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNC0xLTEtMS0w_12627633-f8e4-42db-8392-20a0c1d953af"
      unitRef="usd">-228000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNC0zLTEtMS0w_3fbd5c91-0a62-4fdd-9b8a-a5ed6667cbe1"
      unitRef="usd">-579000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNi0xLTEtMS0w_0d901955-a8cb-45dd-aaf9-e71b085761a5"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfNi0zLTEtMS0w_4dc7a921-c185-4684-866b-edc03ce2d8fe"
      unitRef="usd">21000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfOC0xLTEtMS0w_ecb86fe4-675f-40eb-b8e3-9946a0c77449"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfOC0zLTEtMS0w_8e4201fa-36d9-4ba2-bff5-9efa3b8c81e6"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i44baa77fd69440eaa05fa6296135caf7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMTAtMS0xLTEtMA_8f88c604-01d0-4066-b117-3af55e4e55d9"
      unitRef="usd">-230000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8672f34024834923868d11e08668c214_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RhYmxlOjIxNWVjYjI3OGJkYTQzOGJhOGQ0MGFiYzgwN2JmN2MzL3RhYmxlcmFuZ2U6MjE1ZWNiMjc4YmRhNDM4YmE4ZDQwYWJjODA3YmY3YzNfMTAtMy0xLTEtMA_71154277-ddc3-4299-b60d-ae7c94d5d98c"
      unitRef="usd">-558000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia760a8cfd561490c90a49b778a9afee7_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNTMyNQ_10693254-b525-4825-a9cb-7f4a5b1f3429"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i0eddafd4ca9e4212901159b5340a98fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNTM3OQ_854f09d4-765e-4ed8-a00c-2b4ae9850453"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i554fe9dff9674725962bb4cb2f88b9b2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNTkzMQ_eb0c0b04-1d96-4dc0-917a-6f033bedf678"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia8c75381253b47bd8691ab6ed609fbda_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTA5OTUxMTYzOTAwOQ_f7551e32-9cb4-444c-9e88-7312fc9bdb44"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ib7bc039d7edc42b1b767425117d101c9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjA3Nw_491a4791-43bb-4872-9773-b796cd7fec4f"
      unitRef="usd">2600000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0eddafd4ca9e4212901159b5340a98fe_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjA4NA_854f09d4-765e-4ed8-a00c-2b4ae9850453"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9c5d3001970541c9b1b6bb12adceff18_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjI5Ng_20ab9cd6-0243-488e-a45b-616873f7d795"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i0536df6fbb684da2b13045d260e8302a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjM3Mg_e697380a-8122-40e7-99ae-c6dc27229538"
      unitRef="usd">4500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5120ab4996b447e5a3530a8dcd7ceec9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjU5NzA2OTc4OTcwOQ_7355cb3d-76a4-4ed0-a0fe-ade0b1bce098"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="if5a95fe077074fdeb9c94b5a02ce35b2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNjQ1Nw_c0228109-121e-4724-a55f-606d48252b2c"
      unitRef="usd">2100000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibb19e6a0df8745acaa9ce709c7fe83bd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ0Mzk3ODg_02242d94-668f-40c1-80c7-7fcb127ca0f3"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6917df2647d94638b04a3554df231459_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMTY0OTI2NzQ0Mzk3ODg_35eb8380-6f2a-42cd-a145-40f4c579ccff"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie9a4d75c299c4d8890a93379fee46e7d_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzI3Nw_4ca9a415-ce26-45ad-9e70-c37ce9bc90ec"
      unitRef="usd">4700000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0536df6fbb684da2b13045d260e8302a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfMjc0ODc3OTA5MzcyNQ_63c80b8c-d56d-4cc3-a8ef-3081832ee3dc"
      unitRef="usd">4500000</us-gaap:EquityMethodInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares
      contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzQ1MQ_f5904b75-ff0d-4ec3-8707-96c936f87143"
      unitRef="shares">270000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares>
    <ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzUzNg_d36911fe-0b47-4b58-bea9-f15dd11f8766"
      unitRef="usd">400000</ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest
      contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzU0Mg_94a6a18f-053c-4c64-961e-fb9c62341391"
      unitRef="usdPerShare">1.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzYwNQ_3d237356-b7e1-44b0-bdbf-0a7fa13eeb8f"
      unitRef="number">0.028</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI5Ng_ea30cb0b-e501-4d66-aaea-1e2294f39881">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzcyNg_987447d7-e3f8-48a5-91af-fd4884f57786"
      unitRef="shares">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption
      contextRef="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI4Ng_f93840b6-eb52-4d4d-90e7-738e7415815b">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests
      contextRef="i53b4bd022ea747869c32d967360df0b1_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzc5NA_53609916-2a85-4011-b0e7-2e012630b57a"
      unitRef="shares">380000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfOTI5Mw_d5490eec-0b7a-4096-a3a3-2f097f6db5de">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet
      contextRef="iac14ba3f77974628a3f15fb0add7d76e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfNzg1Mg_5c96bca3-f169-464a-942a-db065a9138b7"
      unitRef="shares">480000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears
      contextRef="i536e73d35938450abf342effa9713c79_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODQ2MQ_85ec3b57-7ed0-4891-8082-df3d09799df7"
      unitRef="number">0.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment
      contextRef="i8e2323bab9c3467682e9da242c1cd16f_D20190701-20190701"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODU1NQ_ee28a208-6924-4316-bd94-449f20e12b50">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="i536e73d35938450abf342effa9713c79_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODYwNA_b7d6925c-2f7b-4219-858a-ba996197cbe4"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i536e73d35938450abf342effa9713c79_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODYxMw_38d41c2d-f538-45cf-84e8-635953a0b0e0"
      unitRef="number">0.10</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i5691cb4056714c69a234024bd01402c0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF81NS9mcmFnOjcyNWU4NjhkMzI3MTRlNjViMzViNzE0MmY0MjUzY2E0L3RleHRyZWdpb246NzI1ZTg2OGQzMjcxNGU2NWIzNWI3MTQyZjQyNTNjYTRfODY2MA_46197a88-d154-4145-b794-29b7259e6805"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:LoanReceivableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfMTI3NQ_d27527e9-a444-4697-9417-6a6b245206a7">Loan Receivable and Loan Receivable &#x2013; Related Parties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pacific6&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, NMM received a promissory note from Pacific6 totaling $0.5&#160;million as a result of the sale of the Company&#x2019;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AHMC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, APC entered into a promissory note with AHMC (the &#x201c;AHMC Note&#x201d;) for a principal amount of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of June&#160;30, 2021, the total principal of $4.0&#160;million remains outstanding. One of the Company&#x2019;s board members is an officer of AHMC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#x2019;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.&lt;/span&gt;&lt;/div&gt;</ameh:LoanReceivableTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfMTU5_d0bfce48-9c23-4070-8723-dc5311ee3ef1"
      unitRef="usd">500000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfMjUw_c9527381-381e-4ad0-9294-ab5e15d15a24"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="ie243ca1688274f6687245974580a1e3c_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfNDc4_23f6076f-89ee-4c38-8f77-4273559d33a1"
      unitRef="usd">4000000.0</us-gaap:NotesReceivableGross>
    <ameh:FinanceReceivableInterestRateStatedPercentage
      contextRef="ie243ca1688274f6687245974580a1e3c_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfNTkw_56621a22-a30a-4210-b8d0-a890a31f09c8"
      unitRef="number">0.0375</ameh:FinanceReceivableInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="i212b0ef9733140d5b7611df1f124ec26_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82MS9mcmFnOjQzMTI4NTc1MmM2NjRlZjZhYzM3NjVlOTc2NzU3MTEyL3RleHRyZWdpb246NDMxMjg1NzUyYzY2NGVmNmFjMzc2NWU5NzY3NTcxMTJfNzg0_e5289296-669c-4aa9-b458-621dc04697ec"
      unitRef="usd">4000000.0</us-gaap:NotesReceivableGross>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RleHRyZWdpb246MThiMmVmZjQ4NWExNDNkNDlmNjhmODE1YzQzNThjMGVfMTQz_55422a86-2997-4259-90e2-6154becdc89d">Accounts Payable and Accrued Expenses&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RleHRyZWdpb246MThiMmVmZjQ4NWExNDNkNDlmNjhmODE1YzQzNThjMGVfMTQ2_cd574581-2536-4b69-8b84-8fce01ea53e1">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMS0xLTEtMS0w_f4ef969d-ade8-4134-9e3b-775c75491d1e"
      unitRef="usd">11192000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMS0zLTEtMS0w_6aef4056-8557-4381-bb5a-f880873386e6"
      unitRef="usd">9554000</us-gaap:AccountsPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMi0xLTEtMS0w_09de157c-2b51-4785-bfdb-e9674278fe69"
      unitRef="usd">2600000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMi0zLTEtMS0w_b2980a9c-1088-4c9f-b93e-086ff5fea75e"
      unitRef="usd">3541000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SubcontractorIPAPayable
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMy0xLTEtMS0w_356140eb-f5d9-465a-ac37-5e26e94d1fd4"
      unitRef="usd">2356000</ameh:SubcontractorIPAPayable>
    <ameh:SubcontractorIPAPayable
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfMy0zLTEtMS0w_66d3e272-54f6-43bd-9571-7938b732778b"
      unitRef="usd">1662000</ameh:SubcontractorIPAPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNC0xLTEtMS0w_e3289567-4ecf-4fb4-8351-2aadada098cf"
      unitRef="usd">962000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNC0zLTEtMS0w_baa0705c-8f53-417a-8364-bd7cc2664f84"
      unitRef="usd">1378000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNS0xLTEtMS0w_f11e4739-12c6-41f5-9729-d93dc54aea06"
      unitRef="usd">188000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNS0zLTEtMS0w_08ec3810-193b-4eb6-a58d-1e14308d0b8c"
      unitRef="usd">50000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNi0xLTEtMS0w_55041409-9bd9-4140-910c-e5df0487caf6"
      unitRef="usd">29594000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNi0zLTEtMS0w_5e0ff64e-b6e9-4d5d-b1f0-859369802af6"
      unitRef="usd">12988000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNy0xLTEtMS0w_dc98052f-4137-4cf6-bf64-7c42f1beb79e"
      unitRef="usd">6900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfNy0zLTEtMS0w_524b46fb-67ba-455e-a618-bede00501b29"
      unitRef="usd">6970000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfOC0xLTEtMS0w_72cfade9-69cb-4fa7-a291-c199eb26c344"
      unitRef="usd">53792000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF82Ny9mcmFnOjE4YjJlZmY0ODVhMTQzZDQ5ZjY4ZjgxNWM0MzU4YzBlL3RhYmxlOmFlNTYzOTYyMGJlNzRiOTk4NTk5YzUyMzk0ZDMzMzQ5L3RhYmxlcmFuZ2U6YWU1NjM5NjIwYmU3NGI5OTg1OTljNTIzOTRkMzMzNDlfOC0zLTEtMS0w_08316ff9-8d77-49cc-893c-d00848aab0cb"
      unitRef="usd">36143000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RleHRyZWdpb246ZmM5YzEwYzlmNDY0NDFlNzhjZDJjOWM0MmUwYzY0ODJfMTA4_3bc9432a-8630-4703-ae68-b65ac7286739">Medical LiabilitiesThe Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RleHRyZWdpb246ZmM5YzEwYzlmNDY0NDFlNzhjZDJjOWM0MmUwYzY0ODJfMTEx_10c1ccad-9bef-4d8c-8808-e751fac147b3">The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(97,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMS0xLTEtMS0w_342bfe4e-8413-43b4-9390-d32863d1e567"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2980472eb7b9414ba636a7c0026908e7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMS0zLTEtMS0w_ca586009-e08c-4de6-b5d9-72da0cc03c94"
      unitRef="usd">58725000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMy0xLTEtMS0w_571e2112-6ca3-408c-b075-1f87fb1a9ab1"
      unitRef="usd">158739000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMy0zLTEtMS0w_f419b2b2-bc6a-419e-92d7-a41a51e45b8e"
      unitRef="usd">165571000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNC0xLTEtMS0w_3d536833-5b5e-4c9d-896a-49c94e0b2967"
      unitRef="usd">-1293000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNC0zLTEtMS0w_7378b602-c7cd-4bad-9dc6-7016b9923792"
      unitRef="usd">233000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNS0xLTEtMS0w_499b05e0-b1aa-414c-931b-57e8c05f2768"
      unitRef="usd">157446000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNS0zLTEtMS0w_ae8a5124-8a19-4562-a64b-740fb93cb23a"
      unitRef="usd">165804000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNy0xLTEtMS0w_0ccb6d2a-41c5-4f8d-b5b0-f91554adaf52"
      unitRef="usd">103302000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfNy0zLTEtMS0w_0326d7df-3859-40b1-9989-d16600fd9635"
      unitRef="usd">97112000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOC0xLTEtMS0w_37db14e7-166e-470e-8e4e-a77ef1405859"
      unitRef="usd">45130000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOC0zLTEtMS0w_9fd48fac-d424-4a77-aa1d-f673f6fc7c16"
      unitRef="usd">57470000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOS0xLTEtMS0w_16c54efb-03c5-40be-88b8-0862f1cf0e31"
      unitRef="usd">148432000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfOS0zLTEtMS0w_8438ebaa-9c28-4849-885a-45eb4bbe8283"
      unitRef="usd">154582000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTAtMS0xLTEtMA_1195844d-62c9-43e1-8878-54567c650955"
      unitRef="usd">-37000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTAtMy0xLTEtMA_77dc34a7-a435-4b7d-96b9-f3dc1bd3a925"
      unitRef="usd">326000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTItMS0xLTEtMA_e35d1838-347b-496d-b092-e00ad8c500d1"
      unitRef="usd">59307000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83MC9mcmFnOmZjOWMxMGM5ZjQ2NDQxZTc4Y2QyYzljNDJlMGM2NDgyL3RhYmxlOjM0NTFhNzVkY2UyZDQ4NDQ5NWI2MTA3MjgxZDBlNWI2L3RhYmxlcmFuZ2U6MzQ1MWE3NWRjZTJkNDg0NDk1YjYxMDcyODFkMGU1YjZfMTItMy0xLTEtMA_59eea286-c5de-4e63-87d9-158d74480c5d"
      unitRef="usd">70273000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDM_f454b9ab-48f0-4ddb-9d2c-c19da402d062">Credit Facility, Bank Loan and Lines of Credit&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a secured credit agreement (the &#x201c;Credit Agreement,&#x201d; and the credit facility thereunder, the &#x201c;Credit Facility&#x201d;) with Truist Bank (f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders. The Credit Agreement provided a five-year revolving credit facility to the Company of $100.0 million, which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provided a term loan of $190.0 million. Amounts borrowed under the Credit Agreement bore interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#x201c;LIBOR&#x201d;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement and, together with the Company, granted the Lenders a security interest in all of its assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#x201c;Amended Credit Agreement&#x201d; and the credit facility thereunder, the &#x201c;Amended Credit Facility&#x201d;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#x201c;Agent&#x201d;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#x201c;Lenders&#x201d;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Wells Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement provides for a five-year revolving credit facility (&#x201c;Revolver Loan&#x201d;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts borrowed under the Amended Credit Agreement will bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters LIBOR01screen page, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.5%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio. As of June&#160;30, 2021, the interest rate on Amended Credit Facility was 1.65%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.35% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#x2019;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter.  The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At June&#160;30, 2021 and December&#160;31, 2020, the unamortized deferred financing cost was $4.7&#160;million and $4.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Real Estate Loans&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MPP&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $6.4&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $6.2 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AMG Properties&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ZLL&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Construction Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#x201c;Construction Loan&#x201d;). Tag 8 is a VIE consolidated by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#x201c;Construction Loan Term&#x201d;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#x201c;Permanent Loan Term&#x201d;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of June&#160;30, 2021, the balance outstanding was $0.1&#160;million. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#x2019;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s average effective interest rate on its total debt during the six months ended June&#160;30, 2021 and 2020, was 2.31% and 3.93%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2021 and 2020, of $0.4 million and $0.3 million, respectively, and $0.7 million and $0.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#x201c;APC Business Loan Agreement&#x201d;) was amended to decrease loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#x2019;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. One of the Company&#x2019;s board members is the chairman and CEO of Preferred Bank. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#x2019;s board members, totaling $14.8&#160;million for the benefit of CMS. In August 2020, the irrevocable standby letter of credit was  released by CMS. As of June&#160;30, 2021, there were no outstanding letters of credit and the Company had $25.0&#160;million available under the Amended Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA4OTk_538edce9-13bb-488f-ba6a-f8644742838d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real Estate Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i87f01cf6f2e04623bfa74a1b1dc2f34b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMi0xLTEtMS0w_78c6ead2-85ce-439a-b4af-cbbc73e9404d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1b65d59e8cee4de190ada04f5c5338aa_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMi0zLTEtMS0w_e3f2eda3-dd08-4c1b-aa38-47e98f74f100"
      unitRef="usd">178125000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i98420e28f93c487e9091b0de8ef73848_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMy0xLTEtMS0w_23116e57-a3d9-475b-9686-2bfe3ac0d209"
      unitRef="usd">180000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i25dc88dcb88941818003f295e6eaf494_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMy0zLTEtMS0w_01486cc3-1767-413c-b1f4-8297e8798899"
      unitRef="usd">60000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie19976568f554a309dc818b6740971de_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNC0xLTEtMS0w_216a7ff9-5066-4844-b1a9-6ccbe031115e"
      unitRef="usd">7498000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaa899988e7284ac8a1326212ba5333ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNC0zLTEtMS0w_1981d838-4e71-460a-b2ae-890bd801a4e7"
      unitRef="usd">7580000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id92d7c50296e4adb9c6f07c18bd63da6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0xLTEtMS03OTAy_ce81ea9b-b289-44f1-9e49-f350a66ef053"
      unitRef="usd">77000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibeafd2d681174371ab57d8e8d2bd170b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0zLTEtMS03Nzky_babc427c-7c78-4936-a84a-077595613ae2"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0xLTEtMS0w_794c82c8-be50-4e76-bb0a-6a10b3f42519"
      unitRef="usd">187575000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNS0zLTEtMS0w_c81e22c9-981c-4438-9804-2c5544ac2922"
      unitRef="usd">245705000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNy0xLTEtMS0w_90d2e029-1e56-45dc-b66b-80e17615dd3b"
      unitRef="usd">205000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfNy0zLTEtMS0w_c9cc1bde-bf69-4ccb-b424-c689b873aef9"
      unitRef="usd">10889000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfOC0xLTEtMS0w_e251f3c3-576b-4dbe-9d04-b5afe535cbc3"
      unitRef="usd">4665000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfOC0zLTEtMS0w_83f13b56-60cb-4f0a-8d35-bba62cdff075"
      unitRef="usd">4605000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMTAtMS0xLTEtMA_e093f289-69a4-4156-b6da-b5a5414ec124"
      unitRef="usd">182705000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOjYyNTNkZGE5ZGIwZjRiN2JiM2MwNDRjY2MwOGJmZWYyL3RhYmxlcmFuZ2U6NjI1M2RkYTlkYjBmNGI3YmIzYzA0NGNjYzA4YmZlZjJfMTAtMy0xLTEtMA_0d81fdb6-b352-4e31-ae63-7cbf4da04bc4"
      unitRef="usd">230211000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDU_486d2ded-c438-483c-b5d6-5f8dfddf3de6">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfMS0xLTEtMS0w_46fedbe8-6c7f-42a8-8f04-4650abf5fdfa"
      unitRef="usd">106000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfMi0xLTEtMS0w_189469f8-f14f-469e-be22-af3b7b3751f1"
      unitRef="usd">285000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfMy0xLTEtMS0w_5e9faa3c-6e76-47cf-8fb8-02a6d701902d"
      unitRef="usd">215000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfNC0xLTEtMS0w_5dbc214a-af36-41ff-9073-27cbc9413cdc"
      unitRef="usd">222000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfNS0xLTEtMS0w_86974d73-3610-4ff3-842f-2d306a7aef52"
      unitRef="usd">186747000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LineOfCredit
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RhYmxlOmFjMzFmMzc2ODE2ZjQ2MGM5OWJmMjNlMzAwY2NkYWFmL3RhYmxlcmFuZ2U6YWMzMWYzNzY4MTZmNDYwYzk5YmYyM2UzMDBjY2RhYWZfNy0xLTEtMS0w_44094640-35c6-479b-ab12-74a5ee20ced6"
      unitRef="usd">187575000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="ifd17107a4e4f4d0db7e8fffc934a9f43_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDY_0d1c2006-86e3-4e3a-a605-1c313579ae85">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id5fb36211de84d458695b36c94e44b09_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTU1MA_1999af79-890e-4e0e-9a42-4037120068c9"
      unitRef="usd">100000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iaaa02904edf64fd19eb45f52d4bfd62e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTYyNw_e72a3414-f28e-491c-af38-360c4315d00d"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="idf95943f3b45491bb70c64e65514db5b_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY4NQ_3ea4a04a-5220-49d9-a4a5-1784ef948039"
      unitRef="usd">190000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i99dcab7c36f94052a58f43fb2416b256_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5MTM_4e9ea5a6-562d-44f3-94de-5125c9ffae06"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia9b7755ce16d436fb858171518d6db85_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5MjY_2f17548f-eaf2-4297-9246-8937a8ff1f6a"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9928b035437a466c8063602b61157c72_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5NjU_74929f38-2185-41bb-9c36-c475d9544fec"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie3689d97acee409f811f71e5d018b255_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTY0OTI2NzQ0NzM5Nzg_b5e96d2d-90a1-4376-bb28-4eeda38e934b"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm
      contextRef="i37ce176ad8164bbda4a85cdb5c1abe96_D20210616-20210616"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjU5NzA2OTgyMjE2Mw_f1a262f7-f86e-44fb-9e45-e7be20f89860">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iaecc589e663140efa9bdde31ca9fc76e_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjIzNQ_029e6bf4-443d-4a57-a104-0a5e80bc38aa"
      unitRef="usd">400000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic3fe84306a564af99059a846dc55527f_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjI3Mw_17a8c2a3-dce3-4bee-b746-ebc7925fec93"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i61695e4f773245978fcdb79b78a5f4e1_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjI4Ng_40e5e136-3ccd-4888-94cf-8a5367f76dd4"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4ad3cbb03fee4c6d849f2b2c7097f926_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMwNg_fa95f176-36bb-4b0a-acb0-c5eba2ee9eb0"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i30999fd4c670468fa0ac9bc1446026a9_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMxMw_61d0ea5f-0636-4c74-8de6-b1d2f8de57e3"
      unitRef="number">0.025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ife4010452d164857b9e426a42b03e2fa_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMxOQ_e91f66c7-819e-40b3-a3bd-1696f135e3ae"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ief20ee6c5c2c4b5f9ca95cdf09203cf9_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMyNg_ed8bc075-35be-480d-9700-bd748aa945ea"
      unitRef="number">0.015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i25174623ac76453388419ec64c9378b3_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfOTg5NTYwNDcwNTUwNw_4e47a3b1-cde8-4356-8b23-3d2fc9d42475"
      unitRef="number">0.0165</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i7ba990e321754287bccd67c80d254cf2_D20210616-20210616"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjMzMg_db86506d-c6f0-4e64-9306-6b53be42cea1"
      unitRef="usd">50000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ife4010452d164857b9e426a42b03e2fa_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM0MQ_8e420527-b10d-4419-87de-9c20cd9f22d5"
      unitRef="number">0.00175</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ief20ee6c5c2c4b5f9ca95cdf09203cf9_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM0OQ_b4135bfa-385a-4a76-ac0d-2183ae62aa91"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i2864d7724e914818863fb152ae703113_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM1Ng_c9987859-4f04-4bf3-8f11-aa67230a0357"
      unitRef="number">0.0125</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i75bb15e4135844e0b0a19cffc0d0a363_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyMjM2Mw_f7ca4477-9e1d-4617-93a5-bd5ea381d56d"
      unitRef="number">0.025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ameh:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="if75078b89e36407a8a184d96312607c7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNDkxMQ_e86e00bc-a46b-44c5-8757-2853863b998b"
      unitRef="financial_ratio">2</ameh:DebtInstrumentNumberOfKeyFinancialRatios>
    <ameh:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="if75078b89e36407a8a184d96312607c7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTA2MQ_f4e04dcc-3c89-4adf-9c33-799e03c01f98"
      unitRef="number">0.0375</ameh:DebtInstrumentCovenantLeverageRatioMaximum>
    <ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i5e7f468af62c460593057d3940ee2131_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTM0Nw_9031d6e7-e57a-4d14-86c3-e21d543f12d9"
      unitRef="number">0.0325</ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i00a33c8eaad843f0bed2823a082ba35f_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTYxNg_043fe7d6-f1e7-4dc5-ba3f-2dedbd0825f1"
      unitRef="usd">6500000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i25174623ac76453388419ec64c9378b3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyNTI5Nw_e3a3e5de-69fb-4a33-9191-d816e9ea0f09"
      unitRef="usd">700000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTk0OA_91d15889-659c-44ce-861d-27eedda53856"
      unitRef="usd">4700000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNTk1NQ_f51d90e3-d27f-4e3a-a703-045fde68a4e1"
      unitRef="usd">4600000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i65ada19782cc4566a752ee378270990e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjA3OA_6775acb7-08b2-4b64-9a2b-0a555a38fe2f"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i982a35d5c552427f8707f6f7c52c8456_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjA3OA_680543cc-c7df-4e4b-b320-1993e2eaa6ec"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i3fbd15394d2c4d85868b44d4b1890872_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjA3OA_b4e58102-0d9f-41fb-a657-df47ad639acc"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1423c5795a1b4d749457b1fe689f6082_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjM3OQ_e7968fac-118f-4e2b-b7d4-101c428bada7"
      unitRef="usd">6400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5dac28efd63c445d90c56c1473b525a9_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjQxNQ_5a184d45-7f7f-420a-93ad-9df0eba134ab"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i7340fb66912c49d688f6edcdd3993379_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjc0NA_2ed946de-c102-4566-9b87-5c0e73c0a7b5"
      unitRef="usd">6200000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i89b4dbef7f2e489f89f33ea163fc5c46_D20200703-20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjkwNw_757c3179-9682-434a-8dce-44142012efab"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ife40aedab12e4720ba1ac1505ee27d57_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzA5OQ_36ac2dff-aa56-4467-8dfa-480527c262f6"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6d1b698d8e0c455ba42b48cbac36f252_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzEzNQ_a8c85ac9-2f0c-4f70-b3cb-2ba2ef7ab2c0"
      unitRef="number">-0.0030</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="id7fb86722c074f2eafdd868708d994e2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzQ3NA_5a658109-a771-4496-8ae9-a0876f503ba1"
      unitRef="usd">700000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i7f73410dbab04d0b9949a4de8859b032_D20200805-20200805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzY0OA_1be08bb8-b0e2-4e3d-a562-1aae730cd21e"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id96f1aad698b48e38639c8ec1d301f92_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzgxNg_e64d085d-a784-4f79-8080-9dda8c18a347"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i63d7d91e880042f0a4f362f355b812b5_D20200727-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNzg1Mg_f5ddbb7c-ac2f-4d15-a967-f95cda721851"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i7cd4cea3e6d54191b5d35c584c4abfc5_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODE4MQ_a44386ee-b0a0-4046-a6e4-a9ae6eee3fdc"
      unitRef="usd">600000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="ib3215aa218c043138dfbec866e107ea5_D20200727-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODM0NA_4fb41228-0007-41e9-9538-d7fc824b9cd6"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie5a28537ca584fb4b0ee10b7408d0fbf_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTA5Njg1OA_d9214a3b-e8ed-469e-85d5-a49a308ff657"
      unitRef="usd">10700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iaa84fde67bb645cd91b5367196c1f03a_D20230101-20231231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjU5NzA2OTgyMjEzOQ_623d357a-0189-4d0f-9944-c9ab40555ad4"
      unitRef="number">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebt
      contextRef="i63fd321ddf634615addc134b27259f9f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEyNTEwOA_412a39ae-27da-426b-bc94-2ec73a1e7a78"
      unitRef="usd">100000</us-gaap:LongTermDebt>
    <ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum
      contextRef="i63fd321ddf634615addc134b27259f9f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfNjU5NzA2OTgyMjE0NQ_644e6f2e-af90-4bf5-b66b-7a77c96312fa"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i5e7f468af62c460593057d3940ee2131_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODQ4Nw_d44221f2-b306-411a-8a9d-dd43431678a8"
      unitRef="number">0.0231</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i625945a27da84fc6aa443add380d4c00_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODQ5NA_b64cf31b-b1a0-4f42-a8e7-82a14a570e31"
      unitRef="number">0.0393</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="i144a76c21edf4613a46ce3728e38457d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODgxNQ_e068b819-7f62-4b3a-8148-a55a21678c50"
      unitRef="usd">400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5e7f468af62c460593057d3940ee2131_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODkyNA_fe77fba9-31b0-4046-929d-a09eba27ae46"
      unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib533cc59686046eeae2f5f232fac7f9a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODkyMA_1f6b1b52-e45f-4d20-bfe2-a03215706ee9"
      unitRef="usd">700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i625945a27da84fc6aa443add380d4c00_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5OTUxMTYzODkzMg_d7c6dfc0-5119-419b-9450-133370ff67b9"
      unitRef="usd">700000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i737b37c63ad94a628ff69100f7a2c406_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfODg3NA_89ffb8f4-9691-4ccd-8e4d-d387cb924d85"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i192b7b8b3d8049bf9d6f9d1c1dc9c763_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfOTg1OQ_ea5da6aa-037f-48ea-8bb9-9255644bdb1d"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib146802ffc804944934f116ce84a41c6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEzMDQzNQ_981d320f-3e56-411e-9f10-19f405ce5321"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i94b5a906722e4e3d8e26a50cae38e0e7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMjc0ODc3OTEzMDQ1MQ_6e6d5f75-125d-4fd1-a6ae-dc0116055997"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i8a509d20ed71452e9deba1a12c4e6e19_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTAxNjA_564a7e3a-d29c-429c-a881-3f0a7cf499b7"
      unitRef="usd">300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i750613cd3f5f46ae8a081a28e372e80b_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MDc_c52cc0e9-1c7f-4402-a030-694afa8e77ab">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2155db54a6e94fb3ba14b735aaf78990_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA1OTc_f32fa53e-49ad-4cb2-b19d-9918ec830e42"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i4ae2fb1304c141cd8ca7616ff44b486d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83My9mcmFnOmIxYmYzMzUxZDY1ZDRlYjdhYzI3NzhjMmE4OGMzYzVkL3RleHRyZWdpb246YjFiZjMzNTFkNjVkNGViN2FjMjc3OGMyYTg4YzNjNWRfMTA5MTE_321ffc6f-c552-4f92-a2da-1048d6838fff">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTc4OQ_aeb12d88-ea12-4b31-8ce1-dc84f5d40a94">Mezzanine and Stockholders&#x2019; Equity&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#x2019;s shares are not redeemable, and it is not probable that the shares will become redeemable as of June&#160;30, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, 143,052 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;br/&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC owned 10,885,732 and 12,323,164 shares of ApolloMed&#x2019;s common stock as of June&#160;30, 2021 and December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. During the six months ended June&#160;30, 2021, the Company issued 34,158 shares of common stock to APC as a result of APC exercising its warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2021 and 2020, APC paid dividends of $19.9&#160;million and $19.6&#160;million, respectively. During the six months ended June&#160;30, 2021 and 2020, APC paid dividends of $19.9 million and $29.6 million, respectively.&lt;/span&gt;&lt;/div&gt;During the three months ended June&#160;30, 2021 and 2020, CDSC paid dividends of $1.5&#160;million and $0.6&#160;million, respectively. During the six months ended June&#160;30, 2021 and 2020, CDSC paid dividends of $1.5 million and $0.6 million, respectively.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ameh:StockIssuedDuringPeriodSharesMerger
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY4Mw_43658e34-d836-4b34-beb7-6a81652297c0"
      unitRef="shares">143052</ameh:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i3bebc359d95142548ffc5a9df83139c8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY5MQ_73848690-c100-4a04-b097-38842a3613e1"
      unitRef="shares">10885732</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if4e562e2f0f644e696c375ad1dea58ee_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY4Nw_8aecc3be-ee1a-4d39-9920-376a65c081ff"
      unitRef="shares">12323164</us-gaap:TreasuryStockCommonShares>
    <ameh:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTYxMg_675bd86a-3590-42fd-9107-dfad589ea977"
      unitRef="shares">34158</ameh:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:Dividends
      contextRef="ia10f8b79fb1344b7a87ded9035353132_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTg5ODU_232a8de4-7231-4cde-8828-dfd5a5cfe8dd"
      unitRef="usd">19900000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i320308565cd449e19c679138f90e503b_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTg5OTQ_03896de5-5c50-41a8-96c9-b556ab6f6b1d"
      unitRef="usd">19600000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i0408c582d1c8484f98671f80a6529d71_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTY5Ng_63c233e2-8769-453d-a37e-604e9adc0f62"
      unitRef="usd">19900000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="id3bc4e2285e0444884aee89b77334ea4_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTcwMQ_c588a0fc-9e37-4b81-923d-b256a551401c"
      unitRef="usd">29600000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i5b0212d54ced47e0b843d969230e7056_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTkwMTI_1b904a13-41a1-4262-badd-520af5d90a45"
      unitRef="usd">1500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i6196e45da98644ffb45f1e5043cc3bb4_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTY0OTI2NzQ0MTkwMjg_01fb767d-589e-42a3-b815-e33f7522402d"
      unitRef="usd">600000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i8a82fbc742c24e8287ecd7cb5cc7cbbb_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTcwOA_97498ea5-e679-4863-b78b-9a41591ccf6a"
      unitRef="usd">1500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i5baedd233dd54d5f839fd76b1cae7d1c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF83OS9mcmFnOjhlZjYyZDNiYTE1YjQxYzBiNGQ1NGI5MGUzZGZiOTc2L3RleHRyZWdpb246OGVmNjJkM2JhMTViNDFjMGI0ZDU0YjkwZTNkZmI5NzZfMTA5OTUxMTYyOTcxMg_ebbbc221-1416-4aeb-8862-e094165063e8"
      unitRef="usd">600000</us-gaap:Dividends>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzU_a577a821-507d-44a7-98a7-f39ca02ad93a">Stock-Based Compensation&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three and six months ended June&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2021, was $8.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021, no stock options were exercised. During the six months ended June&#160;30, 2020, options were exercised for 120,000 shares of the Company's common stock, resulting in proceeds of approximately $0.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Executives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock awards to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#x2019;s closing market price of the Company&#x2019;s common stock. During the six months ended June&#160;30, 2021, the Company granted restricted stock awards totaling 150,130 shares with a weighted average grant date fair value of $24.16. The grant date fair value of the restricted stock was $3.6&#160;million and will be recognized on a straight-line basis over the awards&#x2019; vesting period of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzExNTQ0ODcyMDk0NDMx_f69dfb9e-740f-4b1d-890a-b5aa38e16317"&gt;one&lt;/span&gt; to three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710,756&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the six months ended June&#160;30, 2021 and 2020, common stock warrants were exercised for 474,506 and 273,900 shares of the Company&#x2019;s common stock, respectively, which resulted in proceeds of approximately $4.8&#160;million and $2.6 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2021 and 2020, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzY_0cfc0bc4-7783-4579-936a-d137bac2812e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans for the three and six months ended June&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2a3ac3a0d777469a946e0a10c6595964_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzEtMS0xLTEtMA_4df1b13e-1fc6-4ca1-b1b3-e3e898c5ae50"
      unitRef="usd">602000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9a1a8b237d3a4bf0bf360bf0964d3f6d_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzEtMy0xLTEtMA_e4a0f9a2-fb94-456d-98a2-7230552fd8fa"
      unitRef="usd">298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1008be7007d14a7f8231a7aa65e1e551_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItNS0xLTEtMzI3OA_04376fd3-4fdd-48bd-a1b8-20328b9777c1"
      unitRef="usd">1191000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5adbba48d4f44cf399a195dcbb2b1cce_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItNy0xLTEtMzI5MA_bd9a4054-edfc-4906-8560-5201ae3e4be0"
      unitRef="usd">972000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2d6dddcc345e4f90952f2a96948a910b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItMS0xLTEtMA_634262b6-f707-417b-8c8b-a67e620b58ca"
      unitRef="usd">954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i71a70b05372d474ebacf388a6848532b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzItMy0xLTEtMA_e6a3b747-e00f-4a62-a00f-5317404c6f7a"
      unitRef="usd">554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3cb49c95ec604beba965acb646442a78_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzMtNS0xLTEtMzI4Mg_1163750e-9a05-41f0-88e5-2ff8e87333ab"
      unitRef="usd">1711000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92a3b4c371be499a9e024cfd590d0e4a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzMtNy0xLTEtMzI5NA_d5e80398-fc16-454d-85a7-ddcc78eb911f"
      unitRef="usd">938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzQtMS0xLTEtMA_ef98fbc2-dba9-4a91-89ba-c838a5bea9ca"
      unitRef="usd">1556000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzQtMy0xLTEtMA_4454b3ee-b756-49f7-a671-89892cb9e005"
      unitRef="usd">852000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzUtNS0xLTEtMzI4Ng_4197684a-7e70-4b2c-afbf-892ef4917f60"
      unitRef="usd">2902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTphN2NmNDcyYmY4N2M0MjQzYTgxMjdhMDg3NjMzNGJlYy90YWJsZXJhbmdlOmE3Y2Y0NzJiZjg3YzQyNDNhODEyN2EwODc2MzM0YmVjXzUtNy0xLTEtMzI5OA_3c378dc5-6732-4950-b2ec-9997ed55982d"
      unitRef="usd">1910000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NjI_1ee8859d-6313-401f-a958-363978f600f5"
      unitRef="usd">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzc_386f30c8-f98c-4ea9-a178-afa4f68b33f2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtMS0xLTEtMA_4f17f1dd-48bb-4bd3-afd2-5fffc3a38038"
      unitRef="shares">725864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtMy0xLTEtMA_87aa4ad3-39f1-45ab-b7d9-cf8a3eaf6746"
      unitRef="usdPerShare">13.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i77783b1764504ea0907a1d3ac4b0ada2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtNS0xLTEtMA_68c3b0c8-6cb1-4450-bb81-82a44ad33e5e">P3Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzEtNy0xLTEtMA_f76b1ad6-df46-4600-8f2a-628be9f0ab16"
      unitRef="usd">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzItMS0xLTEtMA_70dca5ea-84f0-496c-b379-83cc71f125e1"
      unitRef="shares">24437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzItMy0xLTEtMA_76ad2d26-de66-4c26-843f-d9136aa68032"
      unitRef="usdPerShare">23.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzMtMS0xLTEtMA_12a59199-46e5-406f-bcc8-325b5996a2d5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzMtMy0xLTEtMA_2732eab0-eb1d-43ac-9e9c-bf60405bc42a"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzQtMS0xLTEtMA_c3ca51a5-4bfe-4b16-963c-1a300049c2e5"
      unitRef="shares">9826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzQtMy0xLTEtMA_b0cabd8e-e742-4b45-8c38-bad880c19deb"
      unitRef="usdPerShare">3.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtMS0xLTEtMA_1cc7fbb4-69ef-492b-88e7-05e2deb721b9"
      unitRef="shares">740475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtMy0xLTEtMA_a77b61c8-37b0-4bf5-8ba8-9582be88a13c"
      unitRef="usdPerShare">13.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtNS0xLTEtMA_655faac2-c169-4ded-8590-489b4d9fbc14">P3Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzYtNy0xLTEtMA_9be8dde8-a829-432b-9bfb-d11ff3fed0fa"
      unitRef="usd">36400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtMS0xLTEtMA_f911cd72-3d76-4a68-927c-61c6d71d87df"
      unitRef="shares">529638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtMy0xLTEtMA_9fd5559b-05c3-4e23-9534-3d56803618d6"
      unitRef="usdPerShare">8.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtNS0xLTEtMA_23d12d55-9b07-470f-a7c3-fa7cdc11f42d">P2Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo2M2Q5MjZkMzQ3Zjg0YjczYjZmMDc1Yjg2NmZjMWZjNy90YWJsZXJhbmdlOjYzZDkyNmQzNDdmODRiNzNiNmYwNzViODY2ZmMxZmM3XzgtNy0xLTEtMA_1d6ffa9a-9622-4ebd-8874-66286c9de2bb"
      unitRef="usd">27100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzYzMg_12a59199-46e5-406f-bcc8-325b5996a2d5"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzcyNg_bd648b63-f22a-42ca-9a3f-e0d2d3f64df8"
      unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic9e1ac26256349d8a8b6660fb3b0cf14_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzgwNg_d6c92065-c348-476a-af7e-7c01f1bc0de7"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwNzg_f4fccfaf-5309-4ae3-b1b8-2aaadc9d73d8">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Executives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzg2MQ_4956ec50-6d85-4410-83bf-c3d36ba7974d"
      unitRef="shares">24437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic54f87af0d7b41e38ac47a6d994ecf51_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzkwMw_cc211d95-271b-4238-bc0b-de3bc0387d12">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic3f89ff410504d43a409f8a0a4d4dc9b_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NTQ_16d26415-d375-4e4d-b0f2-6cba49994590"
      unitRef="usdPerShare">23.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzEtMS0xLTEtMA_0e3e1bec-e675-4d1f-ac01-c5f63642331a">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzItMS0xLTEtMA_ef11b862-5af7-4b3e-87d9-e1ab5d3c80b0"
      unitRef="number">0.8110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzMtMS0xLTEtMA_57b4fce6-cf01-4cb4-847b-e37b07a9d0a3"
      unitRef="number">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="ic3f89ff410504d43a409f8a0a4d4dc9b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzQtMS0xLTEtMA_f9149c83-d06b-4189-83c3-aa4cfd6621b6"
      unitRef="usdPerShare">12.86</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzUtMS0xLTEtMA_7bac343b-6549-4313-af38-98eb6a16f9d0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="ie69084b20d984611b151ed5ed8994475_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTowYjY4NWNkZTA3NzU0ZTNjYjkwOTA3YTY2YzYzNTE4Yy90YWJsZXJhbmdlOjBiNjg1Y2RlMDc3NTRlM2NiOTA5MDdhNjZjNjM1MThjXzYtMS0xLTEtMA_dd16f7c5-dafb-43b9-aed8-a440f0df33d6"
      unitRef="number">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i05b5e17ec6f54ce9b949906a91fbc7d6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzk4OTU2MDQ2NTI3Nzg_d8b2c4e9-30ae-444c-a029-16eb57ad3a4e"
      unitRef="shares">150130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i05b5e17ec6f54ce9b949906a91fbc7d6_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzk4OTU2MDQ2NTI3ODU_42929246-131e-4bff-a959-4e33b23e8117"
      unitRef="usdPerShare">24.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="i12dc265133f44d93bfbea364c99e892e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzk4OTU2MDQ2NTI3OTI_02976472-1ab5-4646-867a-3e77cdc2de35"
      unitRef="usd">3600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5d70de54c6ef4853af97ba0be0d711b6_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwODI_9b8bf42f-2c70-4766-9237-2a204f1ae4d7">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzIwODM_f69cd960-987d-490b-992c-41dea5ce3b27">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474,506)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710,756&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;710,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675,061&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                  10.00 &#x2013; 11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtMS0xLTEtMA_61321177-2fda-4ccb-b439-b47f47ec74bd"
      unitRef="shares">1878126</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtMy0xLTEtMA_c320f09f-b521-4a50-9f80-99e96ebec2dc"
      unitRef="usdPerShare">10.39</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i77783b1764504ea0907a1d3ac4b0ada2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtNS0xLTEtMA_3d5392d8-2bb2-481c-83cb-45a4b1857ebe">P1Y7M17D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzEtNy0xLTEtMA_ab5f26ab-60a7-4017-9c64-34993a70f872"
      unitRef="usd">14800000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsGranted
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzItMS0xLTEtMA_7813d389-e684-4cb9-b8e6-706ff1ba2f86"
      unitRef="shares">0</ameh:NumberOfWarrantsGranted>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzItMy0xLTEtMA_0edc28e7-08f4-4542-bf84-c500f56e338b"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod>
    <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzItNy0xLTEtMA_e17d9ad7-148e-4637-80c3-e12522b42c60"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsExercised
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzMtMS0xLTEtMA_13fa9510-d1c2-4f31-9646-dcf5ca0fbc0b"
      unitRef="shares">474506</ameh:NumberOfWarrantsExercised>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzMtMy0xLTEtMA_3413229a-491e-4d07-9406-de15109d1066"
      unitRef="usdPerShare">10.15</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod>
    <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzMtNy0xLTEtMA_f7be38c0-9d02-49da-acd0-e005dbe52f52"
      unitRef="usd">8100000</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>
    <ameh:ClassOfWarrantOrRightCancelledInPeriod
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzQtMS0xLTEtMA_e5afccd9-cee0-47a5-8643-d6aa88859055"
      unitRef="shares">17803</ameh:ClassOfWarrantOrRightCancelledInPeriod>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzQtMy0xLTEtMA_2c5860d8-b2d9-4877-a9df-8d398f22d752"
      unitRef="usdPerShare">9.72</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod>
    <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzQtNy0xLTEtMA_ef8c3042-9156-4c30-b922-d94b6c4a3b75"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtMS0xLTEtMA_81103bdf-de1b-4fe2-b02b-1743169f9f06"
      unitRef="shares">1385817</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtMy0xLTEtMA_ff01143a-d664-4191-8970-471de6d25109"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtNS0xLTEtMA_5bc226a4-44db-4dc2-842b-97a919c33065">P1Y5M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo4MjUyNjA0MWZiMzE0NjRkODFmMjFhOWIxMTQ3NTQ5Ni90YWJsZXJhbmdlOjgyNTI2MDQxZmIzMTQ2NGQ4MWYyMWE5YjExNDc1NDk2XzYtNy0xLTEtMA_765944c5-6e86-4247-88ae-d045c9cc4f22"
      unitRef="usd">72500000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i434a1fa4730047f5ba3436f45a45cd10_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtMC0xLTEtMA_72af1f0e-0d56-4f3d-a104-759b13915086"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i89c8731f72584484a875a2c7da57e7d4_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtMi0xLTEtMA_9fb0c4fe-4282-48d9-9a5b-9a612ebb7998"
      unitRef="shares">710756</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i89c8731f72584484a875a2c7da57e7d4_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtNC0xLTEtMA_b86edbb8-45a5-4dd0-82ca-ed6cffbee69f">P1Y5M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i434a1fa4730047f5ba3436f45a45cd10_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtNi0xLTEtMA_e19184b7-cd6e-4dbc-92cc-754add327a07"
      unitRef="shares">710756</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i434a1fa4730047f5ba3436f45a45cd10_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzEtOC0xLTEtMA_cbd590e9-3334-454e-98af-181f24eebad5"
      unitRef="usdPerShare">10.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i155643ff74b34c9b8cc8ec0293852ad6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItMC0xLTEtMA_6c7b8ae6-5cab-48ad-b8f9-cc4a8c921299"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i4833707bf8a34d11992ba230abca2c89_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItMi0xLTEtMA_83adc71c-4a90-4a1c-9b07-6329ea918c83"
      unitRef="shares">675061</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i4833707bf8a34d11992ba230abca2c89_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItNC0xLTEtMA_515a5819-6bc6-46f8-99a3-40ab45465bc7">P1Y5M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i155643ff74b34c9b8cc8ec0293852ad6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItNi0xLTEtMA_8becc912-ce66-4b06-8090-f1d9e32ee534"
      unitRef="shares">675061</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i155643ff74b34c9b8cc8ec0293852ad6_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzItOC0xLTEtMA_a7697400-4914-41df-91e4-25eb5c666309"
      unitRef="usdPerShare">11.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2a6a7f97a8e146cd980c88fca3b2ab01_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM1MTVmMDIzNTIyYjRhNjRiNGJhMDhlYzFlMTBlNmY0XzEwOTk1MTE2Mjc4NDY_97a02b5d-19ad-4be9-b32a-9f3aa15ddc52"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia1f5a0f1507848fe8995404c6c8e603f_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtMC0xLTEtMC90ZXh0cmVnaW9uOjM1MTVmMDIzNTIyYjRhNjRiNGJhMDhlYzFlMTBlNmY0XzEwOTk1MTE2Mjc4Mzc_cf2978d7-5125-4900-bb35-a29fc83f9b33"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="if811abb97e1d4b6aac19545793d3feba_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtMi0xLTEtMA_e6de2ba5-dc0b-4d04-9aa6-27f142b54fb8"
      unitRef="shares">1385817</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="if811abb97e1d4b6aac19545793d3feba_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtNC0xLTEtMA_f268e74f-328a-4eb9-80ea-ee3d8aa1cfee">P1Y5M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="ie1f67bbbdb42498ca966599acb11dff3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtNi0xLTEtMA_1afa6390-f201-4b84-8cda-9cb6b7fbb946"
      unitRef="shares">1385817</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="ie1f67bbbdb42498ca966599acb11dff3_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90YWJsZTo1MzlhMWE5MGQwODg0MTZiOGNkNzk4MDZhNjc2YjRmMi90YWJsZXJhbmdlOjUzOWExYTkwZDA4ODQxNmI4Y2Q3OTgwNmE2NzZiNGYyXzQtOC0xLTEtMA_fb033c87-d629-410e-b095-852eaf72cd62"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MjI_0e42bdfa-6ee3-44fc-898b-88c579fafbb9"
      unitRef="shares">474506</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MjY_27f5b116-ee39-469a-82a7-e58f2126e8c8"
      unitRef="shares">273900</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MzA_18163a09-b6ad-4959-af17-8037ffe3de94"
      unitRef="usd">4800000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5MzQ_a15ffc45-66b6-420f-b9e5-8b2389a16662"
      unitRef="usd">2600000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i446e0195307d4b82b3e9a4cb39c02c68_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NDY_703e082c-0eec-42c0-870b-df7ba1b92055"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="ib3235fb88c784a87a0e286f32316d340_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NDY_cc7a82a8-0379-4ae8-b981-ed6931bde682"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="icec95d5e3a26463e80da6e3b8af4d420_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NTA_c4dfc018-5080-4509-86d8-04b121eda52c"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i408bcca588524bb39b519aeebdc4cac2_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzEwOTk1MTE2Mjk5NTA_f6f5576d-d296-49a7-a457-5faa792e191b"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMzgzMw_3d5b63d5-2d64-441e-8a11-c4f9868380eb">Commitments and Contingencies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#x201c;DMHC&#x201d;) regulations, including maintenance of minimum working capital, tangible net equity (&#x201c;TNE&#x201d;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the payor and provider contracts with the Company&#x2019;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS. The guarantee generally must be in an amount equal to 2% of the Company&#x2019;s benchmark Medicare Part A and Part B expenditures. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS and $0 million remains outstanding as of June&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8 million, respectively, for the benefit of certain health plans (see Note 8). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ameh:PercentageOfFinancialGuaranteeBenchmarkAmount
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMTc2NQ_b3d697e3-7c15-4b10-93d9-495b10b7d9ba"
      unitRef="number">0.02</ameh:PercentageOfFinancialGuaranteeBenchmarkAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="id9eeadfa628b409395cec8d188e856a9_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMTg1Mg_e10004af-a72b-433a-8aef-d71d7532d2c8"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="ia8ce5a693324465ebfe2a470a3639175_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMTkyNQ_eb4c0dc1-ac13-4b44-b36f-9ce8eef86baa"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ie0a4be6b433c49f6bd902b1cf0e83be9_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMjA2NQ_25baeb61-7064-435a-b94d-d9d289ca875f"
      unitRef="usd">300000</us-gaap:LineOfCredit>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities
      contextRef="i5fab8a89ec0e445ea9f230be250f041a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84NS9mcmFnOmNmMDJjODdhNGRlZDQ5ZWQ5YzdjODU4Yzg2OGI2MTNiL3RleHRyZWdpb246Y2YwMmM4N2E0ZGVkNDllZDljN2M4NThjODY4YjYxM2JfMjA3Mg_877af320-7f70-418f-9c08-63a59ef79ac2"
      unitRef="usd">3800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzkxMg_41b8b311-3085-4bfa-b9ea-ea59add0a1e6">Related-Party TransactionsDuring the three and six months ended June&#160;30, 2021 and 2020, NMM earned approximately $4.2 million and $4.2 million, respectively, and $8.7 million and $8.4 million, respectively, in management fees from LMA, which is accounted for under the equity method based on 46.25% equity ownership interest held by APC in LMA&#x2019;s IPA line of business (see Note 4).&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $0.6 million and $0.4 million, respectively, and $1.0 million and $1.0 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $1.7 million and $0.9 million, respectively, and $3.2 million and $2.6 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $30,000 and $0.1 million, respectively, and $51,000 and $0.1 million to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $19,000 and $25,000, respectively, and $52,000 and $76,000, respectively, to Fresenius Medical Care (&#x201c;Fresenius&#x201d;) and their subsidiaries for services as a provider. During the three and six months ended June&#160;30, 2021 and 2020, APAACO paid approximately $0.2 million and $0.2 million, respectively, and $0.3 million and $0.3 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#x2019;s board members is an officer of Fresenius.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $0.3 million and $0, respectively, and $0.4 million and $0, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shared a common board member with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June&#160;30, 2021 and 2020, APC paid an aggregate of approximately $8.2 million and $9.0 million to shareholders, respectively, which included approximately $2.2 million and $3.0 million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2021 and 2020, APC paid an aggregate of approximately $15.6 million and $16.3 million to shareholders, respectively, and $3.8 million and $4.8 million, respectively, to shareholders who are also officers of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 and 2020, the Company paid approximately $0 and $0.1 million, respectively, and $0 and $0.2 million, respectively, to Critical Quality Management Corporation (&#x201c;CQMC&#x201d;) for an office lease. CQMC shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and six months ended June&#160;30, 2021 and 2020, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.2 million and $0.2 million, respectively, to Numen, LLC (&#x201c;Numen&#x201d;) for an office lease. Numen is owned by a shareholder of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six ended June&#160;30, 2021 and 2020, APC paid approximately $0.4 million and $0.4 million, respectively, and $0.7 million and $0.7 million, respectively, to One MSO, Inc. (&#x201c;One MSO&#x201d;) for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;), Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC Healthcare Inc. (&#x201c;AHMC&#x201d;) for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended &lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $14.2 million and $10.2 million, respectively, and $31.2&#160;million and $21.0&#160;million. $63.8 million and $45.3 million remained outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021 and 2020, NMM paid approximately $44,000 and $0, respectively, and $44,000 and $27,000, respectively, to an ApolloMed board member for consulting services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, affiliates wholly owned by the Company&#x2019;s officers, including the Company&#x2019;s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#x2019;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments, loans receivable and line of credits from related parties, see Notes 4, 5, and 8, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i6655222595b8466db9fa7f8f6e28d701_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTAw_3107723b-e773-434b-9e6f-b9fff32cd21c"
      unitRef="usd">4200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i92e9a46fd55843e19b666e23a93b8077_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA3_203dbdcf-851e-432e-8ed1-af13a08e2ef0"
      unitRef="usd">4200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i874d478f73294316ad576a40bb59e1ba_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTcyOQ_5fc4f93c-af64-46a7-be35-3bfd448a48f5"
      unitRef="usd">8700000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i25a8271afdf84b0ba8fed37136cb3814_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTczNw_1daa0923-dff3-48da-b2d2-8e1cc3ec7e53"
      unitRef="usd">8400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id89e4b9b73134459ace8ce5c0489bead_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjEw_8165251b-315b-4078-b0fa-bcdafedfb6b6"
      unitRef="number">0.4625</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5e548a742a8e402cac322c329bba3e8e_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjEw_e6ac47cf-5d29-4933-9b66-62e2baed0e90"
      unitRef="number">0.4625</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic24b4e50300a456398b12c3d4e9c5ad6_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzU2_341da55f-9a8f-407a-b695-f4de77b52fcc"
      unitRef="usd">600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i49a2d42d5c87493e92c0eb8c7fd269db_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzYz_748891d6-96de-4032-8e76-ac2e9b31c964"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6ea5c3d23fde4210b75ead61697da1df_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc1NA_ad786499-c9ca-4a7d-90d7-f586e7534ac4"
      unitRef="usd">1000000.0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7a3adda3f7674cf188378375d6706703_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc2Mg_53f81f26-8f8c-4009-a957-e81e62a6b894"
      unitRef="usd">1000000.0</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie006af53fd884424a259b9fa982a4348_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNDY5_6ac63e97-cb4f-4c4e-9b69-d4ba9eb4cf6d"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7f54f9743af8462db5f026514b1e7f21_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNDY5_b54ccbe6-f5e2-4015-bbd1-9ef7577a54bb"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ieec217ded7454689910a87b9c2fbed59_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNTg1_0fe38f4c-1983-4765-9a7e-d17efbc8d1cc"
      unitRef="usd">1700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i53ddd200d6094338a149fcbc196b306b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNTky_f1b7eff7-19a0-4546-be6f-0f97b9ff3a5b"
      unitRef="usd">900000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i22b8a06109754f1285d0b76fad17c51e_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgwNw_cfc19127-99bc-4768-b984-0dfa3399d041"
      unitRef="usd">3200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic98de02634744e4eb83e5a16fad56985_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgxNQ_34079042-34c0-4695-abf0-56b140c0dfe3"
      unitRef="usd">2600000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="idef15142ee464a63a23eb8e6756f0416_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNjk2_9fb3374c-abea-4161-a31b-81168fb8885c"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id9c0a7c27eb7463185729d7662e9b27f_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfNjk2_bec2d7df-b8b8-409a-9965-41cd4479b497"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i66379f58d2d94f269eab8ba02e886336_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfODEy_bba3e899-c839-493d-a1b9-fad0d5946e79"
      unitRef="usd">30000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i24dca2e9c9d84a809178fcf0be16e039_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfODE5_7eeab4a5-7b74-4008-9c1b-d8fba7941c5e"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i07d33951a6dc47ab94b24b9ea268e74c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc4MA_d1ca2572-9a36-4974-b8c8-c287d6848511"
      unitRef="usd">51000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8bba769854d545f5b616e3e0f528bbb8_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTc4OA_f8758e23-8414-4209-ae29-a4adfa759402"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i4d16dbc5ae1849d0ac736d665bd1ea4f_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA2MQ_4bb954bc-597a-4410-b1a4-0a97f667f8cc"
      unitRef="usd">19000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6eea3af5cbd2450785901edf939f6913_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA2OA_a890186c-985b-421f-86eb-03c892447005"
      unitRef="usd">25000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i47874f0012974d65ab80752547b88e0a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgzNA_bc084923-ade2-47d8-ade8-bcebf8592671"
      unitRef="usd">52000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iecc948505e8f40a58d9ef50d08c16138_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTgzNw_dd88f478-983f-436d-ad0d-2fc9f01e09ab"
      unitRef="usd">76000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3e531b4a2b3848308af8e4c062dc3ae9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTI0MQ_65abe391-2f1c-4ba6-87ad-620ebb918876"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if1a2f4f2d93b403298227a14e3ea027f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTI0OA_bfff0dc3-fe63-4af6-ba9c-3a0b061030ab"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie7b855636fc848dbb30121df166e6660_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg3MQ_17671918-29b6-44a3-afa0-359eefafc1c2"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i561f53dbd6ec40abbfe2adb13955f8b5_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg3OQ_f90aca69-d2e1-4958-9379-c2a7e973fd6f"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7235acd9aa184415ae42f56c42c67220_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTQ1Mw_45c736bf-5a1e-47fa-9bc0-78697bc41a46"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib88f4defee8d42ec9fb95d874467a531_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTQ2MA_9029e6e0-bcf3-4eb6-b3dc-a8218460d41e"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i48119f8925ce4b7fa46fa0bc444edaf0_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg5MQ_0aa5bdaf-dd6c-441c-8086-bea54b04c3c3"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3340686a998b49ce95642072d397de0e_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTg5OQ_75ead3c9-d94d-4f3e-808b-3c0d5537d12c"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i64f0216262ee437f994ada0f2b06c020_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY3OQ_495ba60a-2f6b-4ac1-823e-1adaf9f9666f"
      unitRef="usd">8200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6e93a59c26d54a048d85bd6ba5ea6cab_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY4Ng_875eeda5-d725-466b-8c52-162ff6931a32"
      unitRef="usd">9000000.0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i002d7abe90a74c1f87d36f02f9911e16_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjQyMA_ea943ecf-c212-4431-8cb5-d557b546220b"
      unitRef="usd">2200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib518c264f77248c2961f26353ebe9258_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjQyNQ_a10e75ae-cfe3-4795-956d-95cbd8413b4f"
      unitRef="usd">3000000.0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3b03e8cafdca4ef3b5ae3b6f88c8d2ef_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTkzNw_ae7562fb-4fa5-46f6-98f8-fdb57197d4a9"
      unitRef="usd">15600000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ied858eeea01d43f0ab1bd6a8e9d390cf_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTk0NA_fa4e7b53-5bdb-4e22-84bd-73bd9c3742c2"
      unitRef="usd">16300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i5093b44a796548d5a32e7a485043d5ca_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMTk5NA_6808228f-85de-40af-865b-a55631c402cb"
      unitRef="usd">3800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic7f32e9378184e58bc262fb167c76e2b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjAwMg_a6376c5a-8f95-472d-8870-100aa5d7edd0"
      unitRef="usd">4800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if9c44ce4c45c45128c3cb4190f57ff3e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTg5Nw_0097e9bf-fa6b-4dc2-8f67-30f2e4c3cb45"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i646e9e6069754dd7973d990412c1ad05_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTkwNA_a8729672-c368-473b-bdf1-b9c125c870f3"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia6396fb99dba4c38bbcd4ff6c21c04cb_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjAxMw_ad79ce40-35a2-42fc-b469-2e78035262dd"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i55e1d1a632d943cd8f9bc6caab027705_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjAyMQ_c2cf0ff3-b434-4c82-a4bb-176cfc6d1d04"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if186b20296204ef3ad7eef32555753af_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjExOA_aa0fac5e-391f-437b-90b2-779d0a979112"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib0163830e210412f9315ea00b043a5fd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjEyNQ_6d8d99c2-0141-43e8-9b9c-b5e0c041c2bc"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iae403e37990e47ed849d50e7b275152a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE1NA_6ae013fe-386e-4ae9-9739-d1c1f7438510"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id613d04fbab14d078323ed4a8af18081_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE2Mg_9033d8ee-2157-450f-ade9-36f8010df2fd"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie09d5b85850142b5ba448c3c23a85993_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjI4Ng_3da9a6bb-1db8-4c22-a23c-1c832575110b"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0b4bfb2672b04d938b81043fab621f6f_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjI5Mw_9ce6f186-c4d2-4317-8962-7bd60f2c2061"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia6eb80252b8d41968ceed50dd21e9d24_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE4Ng_ffff1094-efbd-4648-a623-d7712c742c77"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i6017f3dab4824927a649da5bf8db28a2_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjE5NA_6f4767e6-0ad5-478f-a43b-cb10031e8fe1"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib6670c16ced04552b621f7bdec168bce_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjQxNw_b19f06f8-6588-4042-951a-564a939af652"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i7cf2fcb06956482fa26b7e68b4e24699_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMjQxNw_d920f039-8905-4fed-916b-48383e2f7350"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzkxNQ_112e9bb8-fc89-4eda-830b-b9653d29e9c2">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended &lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(152)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i3629ab6d4d2d4265be7f841a30358d25_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi0xLTEtMS0w_bed17f58-780e-4ddd-a0cb-c93ec7d709dc"
      unitRef="usd">12696000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i481dd6af2bdd4cf09e6db33df73fe757_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi0zLTEtMS0w_8f6d6b04-e134-4117-a3c9-a75865ee9dff"
      unitRef="usd">6057000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="ic07412c61c634f9ab38ea2cc8e9bb8d9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi01LTEtMS0w_e779954e-20e5-443a-bfaf-9fec3a97ff27"
      unitRef="usd">25793000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i785190d436454824afe1c0c04e317050_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMi03LTEtMS0w_5494164e-4880-4503-899e-82635f81d8e1"
      unitRef="usd">18056000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <us-gaap:ManagementFeeExpense
      contextRef="ie215578f33b740438664f8f4e662aaf5_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy0xLTEtMS0w_5b9b8010-6e3c-4e35-8fed-b05db5c3745c"
      unitRef="usd">31000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i95fb39ce145c4439b0424fb05b3ed94e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy0zLTEtMS0w_31f8e8b1-b27e-4772-84a0-970967876d33"
      unitRef="usd">189000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="if63a149dde3b4d70ac4a2c1ebf3233dd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy01LTEtMS0w_693b8f43-1d96-44de-a50b-185382cb51f7"
      unitRef="usd">108000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i9654cd90ba324591bbfdc696ed176e15_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfMy03LTEtMS0w_51221f99-ceb1-4647-bb8c-30c6c24a758a"
      unitRef="usd">321000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i605e900922024071b01391ab39f722ff_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC0xLTEtMS0w_506d670f-83a2-4a1f-a97f-9d0684001dd0"
      unitRef="usd">77000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i55490cf44eb04081807b779af67ab181_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC0zLTEtMS0w_c5f3c6c3-b152-4f01-b7d4-44f71b860693"
      unitRef="usd">53000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ie1a89c6eeac245a88286608dbe3adbcb_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC01LTEtMS0w_21fc2d72-b140-4191-8117-8e60d2771766"
      unitRef="usd">152000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i5a76c5ebb0ec466fb2566e77ead1ee3f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNC03LTEtMS0w_3f21a529-00d4-4e16-a9bf-f672401a5571"
      unitRef="usd">128000</us-gaap:ManagementFeeExpense>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi0xLTEtMS0w_5ace83f0-d29a-4220-b2a5-0ffc22458145"
      unitRef="usd">12588000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi0zLTEtMS0w_5ce19922-cda3-4e34-bf2f-e6df90d230ce"
      unitRef="usd">5815000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi01LTEtMS0w_f2b08c95-3dd1-4ecc-9954-33eb73f057cb"
      unitRef="usd">25533000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RhYmxlOjI2MGNjODU2NGM2YTQxYWE5ZjAyMGNiYTU0MDU4M2ZjL3RhYmxlcmFuZ2U6MjYwY2M4NTY0YzZhNDFhYTlmMDIwY2JhNTQwNTgzZmNfNi03LTEtMS0w_76d6222a-468d-4d45-8d34-0f752b030121"
      unitRef="usd">17607000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i3629ab6d4d2d4265be7f841a30358d25_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzEyNA_abc35f77-066a-4946-97b2-5eb38d33bad2"
      unitRef="usd">14200000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="ic07412c61c634f9ab38ea2cc8e9bb8d9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzEzMQ_ab62ea5e-ef91-4c2f-8181-7067cb09dad7"
      unitRef="usd">10200000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i481dd6af2bdd4cf09e6db33df73fe757_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY0OTI2NzQ0NjI1Mw_7f0dba28-9721-4ab2-85fa-5a8c127bcef5"
      unitRef="usd">31200000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i785190d436454824afe1c0c04e317050_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTY0OTI2NzQ0NjI1Nw_0bf6a6b0-432b-48c1-a53d-8166577fcb9d"
      unitRef="usd">21000000.0</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="ib46d8ce11bc946359432bb84ee798ea2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzE1OQ_8a0ad7bb-c225-4926-8bf4-6047b0802f77"
      unitRef="usd">63800000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i4196d26cb6024d61bcd2b84921ae5be6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzE2Ng_74dd7e76-86b4-4659-a939-39cf75d65ef2"
      unitRef="usd">45300000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <ameh:PaymentConsultingFees
      contextRef="if70bdfc17f4843378fe0e472c8f0af69_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzI4Mw_831192bf-858d-4316-8500-4a0f88bba582"
      unitRef="usd">44000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="ifc0c32e700994ca0b101674055e539a9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMzI5MA_302e6a7f-4350-4bb1-a091-deb607804c0c"
      unitRef="usd">0</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i9955d34b683e4071859b13221b7991a2_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjMwMQ_31237967-0ebd-4487-a655-451f16f150e9"
      unitRef="usd">44000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="if2f45e79358241e4bc75610a691f200c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF84OC9mcmFnOjQ2NzQ5NWM4YWIzYjQ2OTg4NTc2MjAxNmZhMzYxYmE0L3RleHRyZWdpb246NDY3NDk1YzhhYjNiNDY5ODg1NzYyMDE2ZmEzNjFiYTRfMTA5OTUxMTYzMjMwOQ_4b399fa0-9388-4418-916c-de921d83bb71"
      unitRef="usd">27000</ameh:PaymentConsultingFees>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85NC9mcmFnOjE3MWU1OTUyNDM3MjQxZmRhZjBmY2JhZTQ3NTBkZjYxL3RleHRyZWdpb246MTcxZTU5NTI0MzcyNDFmZGFmMGZjYmFlNDc1MGRmNjFfMjQ4Ng_da46f367-d46f-481e-a1ab-aeda48f2de7b">Income Taxes&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#x2019;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#x2019;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for the six months ended June&#160;30, 2021 and June&#160;30, 2020, was 30.0% and 28.5%, respectively. The tax rate for the six months ended June&#160;30, 2021 differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#x2019; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2016 through December&#160;31, 2020, and for the years ended December 31, 2017 through December&#160;31, 2020, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85NC9mcmFnOjE3MWU1OTUyNDM3MjQxZmRhZjBmY2JhZTQ3NTBkZjYxL3RleHRyZWdpb246MTcxZTU5NTI0MzcyNDFmZGFmMGZjYmFlNDc1MGRmNjFfMTY0OTI2NzQ0MTkxOTg_a0352966-0761-48d3-b0eb-2ffff598d9ff"
      unitRef="number">0.300</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85NC9mcmFnOjE3MWU1OTUyNDM3MjQxZmRhZjBmY2JhZTQ3NTBkZjYxL3RleHRyZWdpb246MTcxZTU5NTI0MzcyNDFmZGFmMGZjYmFlNDc1MGRmNjFfMTY0OTI2NzQ0MTkyMDI_1414f947-515a-4725-9e1e-13488494e938"
      unitRef="number">0.285</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfMTEyNw_aa372ed2-cb05-4ed7-aef8-693f644793ba">Earnings Per Share&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021 and December&#160;31, 2020, APC held 10,885,732 and 12,323,164 shares of ApolloMed&#x2019;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0408c582d1c8484f98671f80a6529d71_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfNzI3_8cb735ae-0fc7-461e-aeca-9ebaa6c68d0f"
      unitRef="shares">10885732</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iab736275bf9d4781ab26f264e447d2b9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfNzM0_e4c2ce10-761f-4aa9-aae8-b59ffe90ab54"
      unitRef="shares">12323164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfMTEyMg_673e74ce-07c8-47f7-a08e-88d8289c888b">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMS0yLTEtMS0w_bfe1fda5-6529-4eaf-b951-3d6120db2594"
      unitRef="usdPerShare">0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMS00LTEtMS0w_674f79d8-3ae8-4be2-a58b-89c8a15166ef"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMi0yLTEtMS0w_8ab70872-57a6-4e20-8136-9db504f350d6"
      unitRef="usdPerShare">0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMi00LTEtMS0w_a6581ae8-5c8c-42f3-9f0d-890afcd9a2cf"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMy0yLTEtMS0w_548c67e4-79cb-459c-b7f1-6284ca300543"
      unitRef="shares">44165264</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfMy00LTEtMS0w_5eaef521-e1ec-48e1-a446-f56f10012f32"
      unitRef="shares">36071604</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfNC0yLTEtMS0w_147215dd-1146-4031-8ecc-4a3957043be6"
      unitRef="shares">45828802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmI1OWI5OWI2NzQ0ZTQ2Y2ZhODMzNWU5MGViNjQ1ZDY0L3RhYmxlcmFuZ2U6YjU5Yjk5YjY3NDRlNDZjZmE4MzM1ZTkwZWI2NDVkNjRfNC00LTEtMS0w_48309598-6a79-4886-be48-d63981f00d2d"
      unitRef="shares">37285585</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMi0yLTEtMS0w_3c490f4c-127e-4b8d-87a2-009a7764e267"
      unitRef="usdPerShare">0.60</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMi00LTEtMS0w_9238accd-b3b6-4e24-939b-dd25ee1ef101"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMy0yLTEtMS0w_dfa2b83c-1f00-4f83-9e85-08ce492aeb38"
      unitRef="usdPerShare">0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfMy00LTEtMS0w_dfc0299e-acab-4993-a2f7-dadcaebfec2c"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNC0yLTEtMS0w_b862a31f-2fc1-4c72-97bd-7811dfc43bee"
      unitRef="shares">43255901</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNC00LTEtMS0w_471810b4-319a-4a96-acd5-ae34dd1cf841"
      unitRef="shares">36040936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNS0yLTEtMS0w_fc05a589-e2b9-46a6-a3d0-209f30ff06b9"
      unitRef="shares">44746761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmExOTE4MTU1ZmUzNjRjZWU5YmE2N2EyZTY1MmU3MmQxL3RhYmxlcmFuZ2U6YTE5MTgxNTVmZTM2NGNlZTliYTY3YTJlNjUyZTcyZDFfNS00LTEtMS0w_48481688-8dcc-4853-8659-969c546dda1a"
      unitRef="shares">37296913</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RleHRyZWdpb246MDM5MDU5ZDAwMjM1NDU1M2FkZTExY2NmMTk1MzdhZTNfMTEyNA_c564d3d4-0f76-4ca4-a5e7-e9f02214e8b1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,165,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,071,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,041,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,828,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,285,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,255,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,040,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,076,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,746,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,296,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMS0yLTEtMS0w_c41fe26f-abe3-409a-bb7d-149ba06bfb8e"
      unitRef="shares">44165264</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMS00LTEtMS0w_d976ba20-7be5-45ff-83d5-2bc2b5a1c199"
      unitRef="shares">36071604</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic3ad5bba1b2945d5aca93409af485c52_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMy0yLTEtMS0w_2b52a4b4-66c7-4136-8969-8c70eb29c232"
      unitRef="shares">466104</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic7d0522994fa4c0e8e71d2a65df6059b_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfMy00LTEtMS0w_283a25e0-7ff3-4934-a044-7a43ac32208b"
      unitRef="shares">169402</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0014be1c64d54d3b9a57ae96f20be2db_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNC0yLTEtMS0w_d0f3c0f3-f606-4d09-aabe-a4aa497f8dff"
      unitRef="shares">992723</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i81cd6e624ce543c1b130425e84f9df76_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNC00LTEtMS0w_9f8ff432-6c8a-4654-88f8-14348efd716b"
      unitRef="shares">1041784</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="icb713daf92854f7dbdd3bde3a5d23576_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNS0yLTEtMS0w_5c9bd39e-16fb-4a8a-afc6-abe1174c9a74"
      unitRef="shares">204711</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i8efdd516ad464b9cae1cee095ce35994_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNS00LTEtMS0w_8788980c-eca3-4a84-938f-729fb01eac57"
      unitRef="shares">2795</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNi0yLTEtMS0w_824a63e6-2a33-47db-a4e3-c6c381c6d2eb"
      unitRef="shares">45828802</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOjUyN2QzMjljM2I2YzQwYTc4ZGQwMDE3OTZmMzNjYjY0L3RhYmxlcmFuZ2U6NTI3ZDMyOWMzYjZjNDBhNzhkZDAwMTc5NmYzM2NiNjRfNi00LTEtMS0w_27696a75-dfc6-457e-96f0-c7190d1471b8"
      unitRef="shares">37285585</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfMi0yLTEtMS0w_2d91ee07-2368-4088-ab52-469e24f9fdb5"
      unitRef="shares">43255901</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfMi00LTEtMS0w_17e10ade-7df2-4a7c-87d4-43ec70243b7c"
      unitRef="shares">36040936</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ife0aa2938ef848b2a9705be0c7e31425_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNC0yLTEtMS0w_e8f0cbee-ccb5-4856-aec3-6a02d5129f05"
      unitRef="shares">409154</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib82e7ef87abf4a5ca9af04095e4d8100_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNC00LTEtMS0w_58543671-50c0-4e4b-9669-6110161df897"
      unitRef="shares">173299</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4c51e142647147e3a11ac050a6f7d7f0_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNS0yLTEtMS0w_8647f6d0-bd0f-4b5f-a025-520efbffca07"
      unitRef="shares">911131</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4e3ea018e65d4409898ec845c882ed39_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNS00LTEtMS0w_9787975a-4c69-4911-b74a-f7360bc6406b"
      unitRef="shares">1076802</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4c8b5b78dbb848798300feff662c4c35_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNi0yLTEtMS0w_4b10c7f4-b45e-4233-8983-9cb85430d77e"
      unitRef="shares">170575</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i89350f0ae8aa4d629dde6b21abd22cb6_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNi00LTEtMS0w_0ca3bf3f-8a5c-4f33-83ea-3580d647a68d"
      unitRef="shares">5876</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNy0yLTEtMS0w_2f695886-223e-41c2-9b47-555a656edd6f"
      unitRef="shares">44746761</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF85Ny9mcmFnOjAzOTA1OWQwMDIzNTQ1NTNhZGUxMWNjZjE5NTM3YWUzL3RhYmxlOmZmYWY3YjA3NGM2ODQ4OGZhYmRjNmQyNzMxOWM4MDI0L3RhYmxlcmFuZ2U6ZmZhZjdiMDc0YzY4NDg4ZmFiZGM2ZDI3MzE5YzgwMjRfNy00LTEtMS0w_8f1a4d39-56df-40a5-8629-6fb83811e719"
      unitRef="shares">37296913</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90ZXh0cmVnaW9uOjQxOGEyMWRhYjQ2NTRmOTM5YzhiY2RmNmUwYTc0OTRiXzE5MTU_b0f1f90c-fbe7-4231-b53e-a40a47bc98aa">Variable Interest Entities (VIEs)&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#x2013; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#x201d; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets of the Company&#x2019;s other consolidated VIEs were not considered significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90ZXh0cmVnaW9uOjQxOGEyMWRhYjQ2NTRmOTM5YzhiY2RmNmUwYTc0OTRiXzE5MTI_e69f2e01-f163-4fe9-b0c4-fe5ca46b2096">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due from affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion and deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQtMS0xLTEtMA_7d7b0579-813b-4e67-9941-a05ccdaa921d"
      unitRef="usd">105108000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQtMy0xLTEtMA_27771166-fc08-4b5f-b801-5fa16e57e3bc"
      unitRef="usd">126158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzYtMS0xLTEtMA_21258628-c04b-419f-832d-7fd97be0b8ab"
      unitRef="usd">187130000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzYtMy0xLTEtMA_0843247d-2ca8-4959-9b80-8833660ff50e"
      unitRef="usd">67637000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzctMS0xLTEtMA_091c2fde-33c2-497f-bf94-58cddc023b51"
      unitRef="usd">14796000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzctMy0xLTEtMA_fdc92cba-d30c-4c37-ad10-135b35b2df6f"
      unitRef="usd">5155000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzgtMS0xLTEtMA_e3269307-5514-4341-b1a7-037cf5b7670a"
      unitRef="usd">66670000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzgtMy0xLTEtMA_6b82882c-52e8-458c-bf96-ea8f4f141291"
      unitRef="usd">46718000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzktMS0xLTEtMA_9c5ebdb1-1ccc-49ba-90a4-f82aaa11fb46"
      unitRef="usd">1814000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzktMy0xLTEtMA_601812b9-edfe-4a24-9043-36d8c252c336"
      unitRef="usd">1084000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEwLTEtMS0xLTA_eedb4351-17ae-4047-80c7-d2a796555539"
      unitRef="usd">10262000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEwLTMtMS0xLTA_ceda0a1f-cc54-4017-8f28-b943f5cd4d77"
      unitRef="usd">14863000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTEtMS0xLTEwODY0_ba41db3d-86e6-4f3a-b2c5-73ea86c1a6d6"
      unitRef="usd">4000000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTMtMS0xLTEwODY3_279dd922-9998-4248-9038-2a522da224c8"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE0LTEtMS0xLTEyNjA5_b7a0e06f-a79b-45e8-b5ab-f69f03919bbf"
      unitRef="usd">16286000</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:DueFromAffiliateCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE0LTMtMS0xLTEyNjA5_fd4d24b7-1b77-48d2-97bc-da6fd34df474"
      unitRef="usd">0</us-gaap:DueFromAffiliateCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTEtMS0xLTA_d81d2539-887f-4b37-99ac-e211767d4c1d"
      unitRef="usd">406066000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzEzLTMtMS0xLTA_a0a314ca-93e3-4ba1-ab37-a1ec79dfaf68"
      unitRef="usd">261615000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE2LTEtMS0xLTA_25944d36-fa4d-499a-ad2e-b822294eba6d"
      unitRef="usd">38770000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE2LTMtMS0xLTA_fc8f26b3-ead0-4b3b-8ce7-7fe36878e8a5"
      unitRef="usd">27599000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE3LTEtMS0xLTA_de47c03d-4e04-4464-a9d2-87709eef2a3b"
      unitRef="usd">64246000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE3LTMtMS0xLTA_ad8f0c81-14bc-4c09-b79d-c3cfd54a293d"
      unitRef="usd">69250000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE4LTEtMS0xLTA_a9ad470b-2ecf-46c9-880a-16cda05d5d6a"
      unitRef="usd">109460000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE4LTMtMS0xLTA_c8b1ec6e-f643-48b1-b143-78d1bbe321c7"
      unitRef="usd">109460000</us-gaap:Goodwill>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE5LTEtMS0xLTA_6d341bae-5951-43a6-8d15-517b74c4bf1f"
      unitRef="usd">114000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzE5LTMtMS0xLTA_bc83cf42-341d-427e-9e6c-a37a330ef1da"
      unitRef="usd">4145000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:OtherLongTermInvestments
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIwLTEtMS0xLTA_ca6f07c0-38a9-4340-9278-ebed20ecd5d4"
      unitRef="usd">683733000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIwLTMtMS0xLTA_992f6478-57ae-4126-93e7-56c392bb54bb"
      unitRef="usd">225144000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIxLTEtMS0xLTA_92d2a9d0-c305-4455-8260-52deb5f0f634"
      unitRef="usd">37372000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIxLTMtMS0xLTA_2f47a2b6-01e9-4e36-b9cc-39cd1b2608c6"
      unitRef="usd">43516000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIyLTEtMS0xLTA_e1c1d978-5dfc-46d8-835b-3a716412e740"
      unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIyLTMtMS0xLTA_91091314-67c4-44a1-aaf6-5ac8ca8fcee4"
      unitRef="usd">36584000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIzLTEtMS0xLTA_c005b688-cb76-4c18-aeca-b6ab8a53c5ea"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzIzLTMtMS0xLTA_a4149ac9-6711-4cf7-9b78-bbc46358d8d9"
      unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI0LTEtMS0xLTA_86a544a9-69b1-4755-a89a-409b7d4b1e5e"
      unitRef="usd">5597000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI0LTMtMS0xLTA_6f68f411-c64b-4240-8515-15b51aed03ba"
      unitRef="usd">6298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI1LTEtMS0xLTA_0408debb-d9b5-49b7-b873-cb0c20122106"
      unitRef="usd">1812000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI1LTMtMS0xLTA_fce35c94-2d5b-4e8c-963c-2ab1a2cc7d0f"
      unitRef="usd">17177000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI3LTEtMS0xLTA_4b3e1918-ea30-4502-a39e-303b3f2a473b"
      unitRef="usd">941509000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI3LTMtMS0xLTA_4a7b7af8-9b8b-4f90-9f10-00a4cdb4962a"
      unitRef="usd">539673000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI5LTEtMS0xLTA_f4762602-91f9-487a-a241-bccf46714652"
      unitRef="usd">1347575000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzI5LTMtMS0xLTA_a2070f10-3468-4151-aad6-e5e5981e5296"
      unitRef="usd">801288000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMyLTEtMS0xLTA_429e39f7-38f7-40fa-a015-c5a0757e5d5d"
      unitRef="usd">14310000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMyLTMtMS0xLTA_cc1c5549-bc0b-48f4-8d97-fcdc746d5b7f"
      unitRef="usd">12963000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMzLTEtMS0xLTA_c8d76729-b60f-4920-954e-1f65411034cc"
      unitRef="usd">9092000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzMzLTMtMS0xLTA_93c4cf8e-ff12-4a5e-b7a4-1cfa2339fa0f"
      unitRef="usd">9642000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM0LTEtMS0xLTA_0b77dddf-2ab9-4152-ae94-ebff87fa3de6"
      unitRef="usd">46256000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM0LTMtMS0xLTA_cc6eca3b-b480-4464-953e-8770c360b153"
      unitRef="usd">37684000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:TaxesPayableCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM1LTEtMS0xLTA_fb4919b8-d6d5-469d-8936-a8d224f58811"
      unitRef="usd">1784000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM1LTMtMS0xLTA_45e8bf04-f9cd-4c68-ba60-b195543d09a1"
      unitRef="usd">4225000</us-gaap:TaxesPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM2LTEtMS0xLTA_ef74a73b-0874-4161-8086-42b60b5d16bf"
      unitRef="usd">536000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM2LTMtMS0xLTA_c89d214f-5887-42f4-8352-1816cdc9b6b9"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM3LTEtMS0xLTA_abdcc33d-aa15-497e-ae62-88b6f55d2adb"
      unitRef="usd">0</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM3LTMtMS0xLTA_5c617867-3f76-4d75-84e7-3ad728cc7347"
      unitRef="usd">22698000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM4LTEtMS0xLTA_682a92e7-0005-48bf-b70d-a38f24dffc8a"
      unitRef="usd">205000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM4LTMtMS0xLTA_90dcda14-f764-457f-bc86-9bdc13b58435"
      unitRef="usd">201000</us-gaap:LongTermDebtCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM5LTEtMS0xLTA_fd60f228-90d4-4802-9cc4-75ce413f7e85"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzM5LTMtMS0xLTA_e3a54bc6-102d-4d0f-92de-c19b79506139"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQwLTEtMS0xLTA_cbd1a820-d368-4307-a0d2-3e35a532fa7a"
      unitRef="usd">1245000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQwLTMtMS0xLTA_4ebb5deb-1df9-4128-a729-6995ccb438ea"
      unitRef="usd">1242000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQyLTEtMS0xLTA_74fbd93e-e57e-423b-aed6-5bb805353167"
      unitRef="usd">73538000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQyLTMtMS0xLTA_777af49a-6118-4a5a-a38f-50b0a3f49579"
      unitRef="usd">89242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ1LTEtMS0xLTA_33615a36-142d-408c-b811-1713e2ab3803"
      unitRef="usd">7390000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ1LTMtMS0xLTA_f90118a1-787a-40d1-86d0-18f9ba169e70"
      unitRef="usd">7379000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ2LTEtMS0xLTA_a91765bf-2ce6-4f6a-afaa-e7357a5af002"
      unitRef="usd">20190000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ2LTMtMS0xLTA_278325ee-eb8a-4783-a878-025fb3708673"
      unitRef="usd">9144000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ3LTEtMS0xLTA_a1955e70-ab89-4181-8b5f-d338763953d0"
      unitRef="usd">249000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ3LTMtMS0xLTA_8c51cab9-3038-4d6d-aa04-53e7c47bad86"
      unitRef="usd">311000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ4LTEtMS0xLTA_0e05c0b1-26c4-4605-9564-f487143c281f"
      unitRef="usd">4575000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzQ4LTMtMS0xLTA_6d36e539-46f6-4673-946a-41f50f328cc8"
      unitRef="usd">5242000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTEtMS0xLTEwODgx_68b9588b-8e65-41ed-a364-c28995076dbf"
      unitRef="usd">1195000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTMtMS0xLTEwODkw_1b091ea6-a025-4145-96c4-68e601a30361"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTEtMS0xLTA_efad1489-9b34-4353-9a69-45fd35b65f10"
      unitRef="usd">33599000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUwLTMtMS0xLTA_2776a8d6-2a60-419c-b60b-9ccf01de587a"
      unitRef="usd">22076000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUyLTEtMS0xLTA_4b663f1b-97b7-4131-86b4-ac0362d52d75"
      unitRef="usd">107137000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i34bf991f15464550976d811de0d62e73_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDAvZnJhZzo0MThhMjFkYWI0NjU0ZjkzOWM4YmNkZjZlMGE3NDk0Yi90YWJsZTo5ZGM2M2MyZmE0ZmM0YmI4ODBiMjExMDZiMzhmMjdkNy90YWJsZXJhbmdlOjlkYzYzYzJmYTRmYzRiYjg4MGIyMTEwNmIzOGYyN2Q3XzUyLTMtMS0xLTA_183bda3d-1461-45fa-b892-86efcd0e89bc"
      unitRef="usd">111318000</us-gaap:Liabilities>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNjM_e6946198-ee22-4c1d-a063-2ddd5f0ce85e">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.4 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNzQ_ad97f98b-52b7-4edf-897f-a63aa4a1e23a">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.4 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i64c51ebc726a488fbd985b493d51b309_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTc_2d57f2a0-4522-44f4-aa51-d5dd74152f9e">P1M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i64c51ebc726a488fbd985b493d51b309_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTc_b55c7a28-f093-4cd4-8117-62caafaffb43">P1M</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ib4db1a9674a54a7ebe6ebf2c416564b2_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTM_8e8f39cd-fc5c-4021-8ac9-416d4894bfad">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="ib4db1a9674a54a7ebe6ebf2c416564b2_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4OTM_c44fe732-aac7-46e4-b2fc-1ba1ccd0ac22">P5Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzI0OA_022737a9-f368-409e-bb0f-d4bdb96b3260">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzI0OA_c173aa78-3aa6-4ad6-af79-2ba93393854b">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzMyNw_6902406d-a152-44cb-8298-563308e233d9">P1Y</ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzMyNw_b72922d5-5e07-4435-aa11-4cea95fbc69b">P1Y</ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4ODM_1c472579-67fa-42e7-893d-c99370917c1f"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4NzU_996ab2b6-21a6-49b5-92ef-a7b37dc0c695"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4ODg_c12c8e8b-c5f4-4d48-b1f2-83536cd3c027"
      unitRef="usd">500000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i5c98b023802344859e6d11a8234f1cf2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwOTk1MTE2Mjg4Nzk_7689223e-f4ba-4b69-8da1-1f4babac8812"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNTg_fe69591a-9e53-4a16-a9f9-4dd6187bc915">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(360)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.56 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.06 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzMtMS0xLTEtMA_eb28a7ca-e506-44a0-a6b3-b3176cee842b"
      unitRef="usd">1263000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzMtMy0xLTEtMA_076b1a6d-9795-46ce-847b-b23664c4290e"
      unitRef="usd">1446000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzYtMS0xLTEtMA_caa0a5e6-e668-4caa-b86e-dff958dba2af"
      unitRef="usd">27000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzYtMy0xLTEtMA_cceac0f5-7bbd-4a04-bcaa-3148ba978d72"
      unitRef="usd">35000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzctMS0xLTEtMA_a92592d9-c303-4603-b93e-b176f3f96faa"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzctMy0xLTEtMA_7ae3d8e7-1602-44c2-968c-7def4af312b2"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzktMS0xLTEtMA_97199767-8ea9-4686-ab71-22247dd6d1f8"
      unitRef="usd">280000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzktMy0xLTEtMA_9f64c6b5-5ecf-43b3-89fb-d21be0e6f1d8"
      unitRef="usd">226000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzExLTEtMS0xLTA_32767a93-4c30-466c-980c-e8899e02db38"
      unitRef="usd">1013000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTowNzBjMTM4OGY3OWQ0Mzg2OWFhYjU5NjQxZDA3NzJiZi90YWJsZXJhbmdlOjA3MGMxMzg4Zjc5ZDQzODY5YWFiNTk2NDFkMDc3MmJmXzExLTMtMS0xLTA_0edc8c54-7a50-4cdc-993e-7b9806e0ef00"
      unitRef="usd">1259000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzQtMS0xLTEtMA_8447755f-9da5-4a8f-926e-63b7072fce64"
      unitRef="usd">2515000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzQtMy0xLTEtMA_eb71a0cc-ff5b-4b70-b7e3-7de8c572dd14"
      unitRef="usd">3388000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzctMS0xLTEtMA_7b44c892-7ef8-4843-8be2-0c19a43efc51"
      unitRef="usd">54000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzctMy0xLTEtMA_fb8c99d5-f16f-4229-aa85-ab055c7b4fc8"
      unitRef="usd">61000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzgtMS0xLTEtMA_1ded3ad8-3d04-4c11-a9b3-79da6ded5a50"
      unitRef="usd">6000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzgtMy0xLTEtMA_fd32fa91-b4cb-4a3b-8e3c-04a19ee8b288"
      unitRef="usd">7000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEwLTEtMS0xLTA_d7b080d5-b669-493b-83b9-2783aa9b1784"
      unitRef="usd">473000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEwLTMtMS0xLTA_1009f6ec-7c92-4a0d-bc0c-5fb596084d16"
      unitRef="usd">360000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEyLTEtMS0xLTA_d824380e-2697-4e3f-b214-a50518af96bd"
      unitRef="usd">2102000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTplNTBkOWNkZjBhODM0YjQ0OTFjNmZiN2M4ZWYyYjM3MC90YWJsZXJhbmdlOmU1MGQ5Y2RmMGE4MzRiNDQ5MWM2ZmI3YzhlZjJiMzcwXzEyLTMtMS0xLTA_24c41176-d80e-44f4-8a84-2161bc9a0141"
      unitRef="usd">3096000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzYtMS0xLTEtMA_080449ca-1799-4e72-bb36-044fdd31869f"
      unitRef="usd">1293000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzYtMy0xLTEtMA_0eb4f2a7-594c-4c14-91d2-51b8065d43c1"
      unitRef="usd">1333000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzctMS0xLTEtMA_001497c8-93f3-4678-b8a4-31b458fbf9fd"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzctMy0xLTEtMA_abfd6a10-e056-4b67-b8f5-6945fa22dc67"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzgtMS0xLTEtMA_eccbc902-c7ff-4249-8c25-b9ab3244ac17"
      unitRef="usd">27000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzgtMy0xLTEtMA_12935600-e854-4b68-b576-1fac36d780ec"
      unitRef="usd">35000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib8d088f0b5154bc889a9986965e09753_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzExLTEtMS0xLTA_b39ebbcd-10dd-40b6-abed-371e2604d590"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i8fe40f09b0374a11b9d8220b99651642_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzExLTMtMS0xLTA_521a57f0-fc7b-4625-9432-91e6df44e1f4"
      unitRef="usd">2907000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIwLTEtMS0xLTA_5436b99c-f492-4be6-8b88-4491fe0218e9"
      unitRef="usd">3149000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIwLTMtMS0xLTA_b946f3b7-2b9a-4df4-9a5f-d23855fdef14"
      unitRef="usd">2880000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIxLTEtMS0xLTA_01757519-0055-4d31-934d-8e68260756ff"
      unitRef="usd">6000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIxLTMtMS0xLTA_cfd53e5d-4d5a-4e2f-acb3-a90994488f3f"
      unitRef="usd">7000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIyLTEtMS0xLTA_4f8454da-a1c2-44c0-9217-74a717628106"
      unitRef="usd">54000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzIyLTMtMS0xLTA_519abb0e-b0b2-4da7-ba2e-ef3056f819a3"
      unitRef="usd">61000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzI1LTEtMS0xLTA_79740da6-2588-49bf-976c-18ff1d6dc7f0"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i98a75e06566646bc834f3f5cf2923f3c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzI1LTMtMS0xLTA_be27a734-838e-4c87-a5d5-50b0648fd65a"
      unitRef="usd">7652000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMyLTEtMS0xLTA_1007e807-61b8-49d6-b5e5-253bae5f6b1a">P6Y6M21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMyLTMtMS0xLTA_9a0d58dd-6d7a-428f-b369-b448f0e93f45">P7Y21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMzLTEtMS0xLTA_993e1a95-6274-4282-a52e-de0607b6d98e">P3Y2M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzMzLTMtMS0xLTA_e2e07c56-a751-4604-937e-a5ef2933d697">P4Y2M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM3LTEtMS0xLTA_a9fc02e3-625c-45a8-896c-9bf299b68dbc"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM3LTMtMS0xLTA_046e00c2-f994-4b37-b48f-7fcc68302f5a"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM4LTEtMS0xLTA_428b66bf-c10e-4c15-b342-71bb2e205cdb"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i763c2ef5c52c4947b684f5eeda8ff491_I20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTphYTI1N2Y1MTdjMzc0MzAzODJhNTVmNTUzNjAwMWRiNy90YWJsZXJhbmdlOmFhMjU3ZjUxN2MzNzQzMDM4MmE1NWY1NTM2MDAxZGI3XzM4LTMtMS0xLTA_6198a85f-9cad-4034-9386-a9e9bc6dd452"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNjE_4a6021a8-a84e-4dc8-b49c-b81edb7b8d43">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90ZXh0cmVnaW9uOmE4ZjY1YzMzM2E4YTRmZTg4OTk1MGIzZWYwYmJjMTRiXzEwNjI_64b9ac54-a947-4c2e-ab4d-8bfd3f6e9f20">&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEtMS0xLTEtMA_5bd7a93f-8281-42be-8e93-17765bcf6aa8"
      unitRef="usd">2042000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEtMy0xLTEtMA_5b43ce0b-360c-4f6b-abf1-7deba2c8bee8"
      unitRef="usd">60000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzItMS0xLTEtMA_46e09581-d661-4f07-b121-c1b890f53d86"
      unitRef="usd">3529000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzItMy0xLTEtMA_9b05e6ed-0b39-4e5e-9b8b-b8de528120b5"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzMtMS0xLTEtMA_0e0e34e0-1088-408c-83fb-44987a0fc1d9"
      unitRef="usd">3303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzMtMy0xLTEtMA_0b192a4d-7009-4b28-8596-cf9f7485a942"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzQtMS0xLTEtMA_f3c963b5-af94-45c1-9af4-c0ec41f5c9d5"
      unitRef="usd">2940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzQtMy0xLTEtMA_a966c0ba-c404-45f5-800c-06d9cbfa87df"
      unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzUtMS0xLTEtMA_74870707-216d-4a8e-9200-9b0648f2a6e7"
      unitRef="usd">2648000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzUtMy0xLTEtMA_3058422f-bc36-4793-9093-6c58add67f0e"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzYtMS0xLTEtMA_5d288292-6ef1-44c5-8013-8b70c1feb159"
      unitRef="usd">6811000</ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <ameh:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzYtMy0xLTEtMA_e89d0ced-1ce1-4937-b1c1-63b0d1ad3dad"
      unitRef="usd">0</ameh:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzgtMS0xLTEtMA_869b2c5a-bd60-4314-bff7-59ad43de3429"
      unitRef="usd">21273000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzgtMy0xLTEtMA_f79681a3-b74e-4012-93fc-6fb7f9550652"
      unitRef="usd">377000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzktMS0xLTEtMA_922cb837-5ee9-454b-8b9a-e8bb7463e0f2"
      unitRef="usd">3929000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzktMy0xLTEtMA_03914fbd-bcce-41d6-8f5f-d5670a5f5ce8"
      unitRef="usd">18000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEwLTEtMS0xLTA_8e4592e3-b0ff-4009-8176-f6e49479f987"
      unitRef="usd">17344000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEwLTMtMS0xLTA_daa21059-e8fb-4998-84b1-0d888d885bad"
      unitRef="usd">359000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzExLTEtMS0xLTA_1e9507f2-f286-4b95-b78e-40314611b06e"
      unitRef="usd">2831000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzExLTMtMS0xLTA_8864100a-65c5-4b6c-aa43-c57af0abe3e7"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEyLTEtMS0xLTA_d8d65091-703f-4180-b849-ce02488bb21c"
      unitRef="usd">14513000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDMvZnJhZzphOGY2NWMzMzNhOGE0ZmU4ODk5NTBiM2VmMGJiYzE0Yi90YWJsZTpkZjNiOGJkZjliYmI0YTIzYTQwNDU0ZjNkZjVmYjlmNy90YWJsZXJhbmdlOmRmM2I4YmRmOWJiYjRhMjNhNDA0NTRmM2RmNWZiOWY3XzEyLTMtMS0xLTA_647e023d-27b2-4952-8d3d-1f742434e48f"
      unitRef="usd">249000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2Xzc3Mg_f2ee8cc9-a6da-4788-aaa4-2f9ba88159fa">Subsequent Events&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Access Primary Care Medical Group&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 15, 2021, a physician-owned designated shareholder professional corporation affiliated with the Company entered into a definitive agreement to acquire 80% of the fully diluted capitalization of Access Primary Care Medical Group (&#x201c;APCMG&#x201d;). 50% will be paid out in cash to APCMG within 10 business days of the transaction and the remaining 50% will be paid out in cash upon APCMG&#x2019;s achievement of certain financial milestones related to fiscal year 2022. APCMG is a primary care physicians' group focused on providing high-quality care to senior patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Sun Clinical Laboratories &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 1, 2021,  the Company entered into a definitive agreement with Sun Clinical Laboratories ("Sun Labs"), under which the Company will purchase a 49% interest in Sun Labs for $4.0&#160;million. Sun Labs is a CLIA-certified full-service lab that operates 19 locations across the San Gabriel Valley in southern California.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The transaction is expected to close by the end of the third quarter of 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i88ec600700d74563b50882f619542a97_I20210715"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3NzAwMDI_99d18650-a29a-4372-9da2-6455a33db1ec"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ameh:BusinessCombinationPercentagePaidInCashWithinTenBusinessDays
      contextRef="i84b60bfd8fde493d8a88c8fd34276c56_D20210715-20210715"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3NzAwMTk_dfb11725-37d4-4c28-8245-b312f539b965"
      unitRef="number">0.50</ameh:BusinessCombinationPercentagePaidInCashWithinTenBusinessDays>
    <ameh:BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones
      contextRef="i84b60bfd8fde493d8a88c8fd34276c56_D20210715-20210715"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3NzAwMjY_5f871d61-d83d-4163-b598-cdf716ad92fa"
      unitRef="number">0.50</ameh:BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="id1d3f4fbb7de478bbc51935ca41ab818_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3ODc5MDI_850485f9-be14-43c4-a901-d4acd13cfb1d"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i57b89d29a2264160815b2599c489d073_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3ODYyMDk_53048dbb-0954-4e96-a3a0-0a11dc471841"
      unitRef="usd">4000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfLocations
      contextRef="id1d3f4fbb7de478bbc51935ca41ab818_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMTIvZnJhZzo2OGM3Mzc4NzkyNmM0YzY0YjZmZTFlMGIyMzdhNzllNi90ZXh0cmVnaW9uOjY4YzczNzg3OTI2YzRjNjRiNmZlMWUwYjIzN2E3OWU2XzY1OTcwNjk3ODYyMjM_f60a238a-df92-42d6-9e50-c6a4d34d5a39"
      unitRef="location">19</ameh:NumberOfLocations>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMS0xLTEtMA_bdc9231e-d10b-4879-961f-7bf270c932ce"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMS0xLTEtMA_bdc9231e-d10b-4879-961f-7bf270c932ce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMy0xLTEtMA_6366d7b1-1d44-47df-9924-2597b54deede"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMy0xLTEtMA_6366d7b1-1d44-47df-9924-2597b54deede"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMy0xLTEtMA_f03eecc3-ad45-423f-ae4b-83573a07eaf6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMy0xLTEtMA_f03eecc3-ad45-423f-ae4b-83573a07eaf6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMS0xLTEtMA_6fb4196b-8ede-4315-ad4b-455a523a32b8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMS0xLTEtMA_6fb4196b-8ede-4315-ad4b-455a523a32b8"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#x2019;s consolidated VIEs totaling $1,347.6&#160;million and $801.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#x2019;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $107.1&#160;million and $111.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. See Note 15 &#x2013; Variable Interest Entities (VIEs) for further detail.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMS0xLTEtMA_bdc9231e-d10b-4879-961f-7bf270c932ce"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMy0xLTEtMA_6366d7b1-1d44-47df-9924-2597b54deede"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfNTUtMy0xLTEtMA_f03eecc3-ad45-423f-ae4b-83573a07eaf6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RhYmxlOmMwZWMyMWY1ZGEzYTQ3ODdiZjAzNjBmZGQ1N2RhMDY3L3RhYmxlcmFuZ2U6YzBlYzIxZjVkYTNhNDc4N2JmMDM2MGZkZDU3ZGEwNjdfMzEtMS0xLTEtMA_6fb4196b-8ede-4315-ad4b-455a523a32b8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8yMi9mcmFnOjgzMzExODYwZDFkZjQxMTZiZThjNDMyZjA5OTVkMzAyL3RleHRyZWdpb246ODMzMTE4NjBkMWRmNDExNmJlOGM0MzJmMDk5NWQzMDJfNzcw_aa14d485-1ac5-418c-b955-ab3023423b95"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923510647912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jul. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,340,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504708712">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 177,287<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187,206<span></span>
</td>
<td class="nump">67,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,540<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,767<span></span>
</td>
<td class="nump">49,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,562<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,188<span></span>
</td>
<td class="nump">16,797<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">470,550<span></span>
</td>
<td class="nump">338,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,738<span></span>
</td>
<td class="nump">29,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,227<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239,053<span></span>
</td>
<td class="nump">239,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">594<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,372<span></span>
</td>
<td class="nump">43,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">896<span></span>
</td>
<td class="nump">37,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,928<span></span>
</td>
<td class="nump">18,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,072<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">423,880<span></span>
</td>
<td class="nump">478,909<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">894,430<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,792<span></span>
</td>
<td class="nump">36,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,092<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,307<span></span>
</td>
<td class="nump">50,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,215<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">536<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">205<span></span>
</td>
<td class="nump">10,889<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,088<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,242<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">249<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,513<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,705<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219,904<span></span>
</td>
<td class="nump">257,346<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">347,992<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">141,856<span></span>
</td>
<td class="nump">114,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,246,796 and 42,249,137 shares outstanding, excluding 10,885,732 and 12,323,164 treasury shares, as of June&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305,736<span></span>
</td>
<td class="nump">261,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,580<span></span>
</td>
<td class="nump">69,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity, parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">401,360<span></span>
</td>
<td class="nump">330,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">404,582<span></span>
</td>
<td class="nump">330,911<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">894,430<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $1,347.6&#160;million and $801.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $107.1&#160;million and $111.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923512456984">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,246,796<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,885,732<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 894,430<span></span>
</td>
<td class="nump">$ 817,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">347,992<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,347,575<span></span>
</td>
<td class="nump">801,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 107,137<span></span>
</td>
<td class="nump">$ 111,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $1,347.6&#160;million and $801.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $107.1&#160;million and $111.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504367784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 175,638<span></span>
</td>
<td class="nump">$ 165,169<span></span>
</td>
<td class="nump">$ 351,696<span></span>
</td>
<td class="nump">$ 330,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of services, excluding depreciation and amortization</a></td>
<td class="nump">136,214<span></span>
</td>
<td class="nump">136,079<span></span>
</td>
<td class="nump">276,829<span></span>
</td>
<td class="nump">280,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">14,199<span></span>
</td>
<td class="nump">11,556<span></span>
</td>
<td class="nump">23,663<span></span>
</td>
<td class="nump">23,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">4,628<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">9,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">154,650<span></span>
</td>
<td class="nump">152,263<span></span>
</td>
<td class="nump">308,926<span></span>
</td>
<td class="nump">313,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">20,988<span></span>
</td>
<td class="nump">12,906<span></span>
</td>
<td class="nump">42,770<span></span>
</td>
<td class="nump">17,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="num">(3,134)<span></span>
</td>
<td class="nump">834<span></span>
</td>
<td class="num">(3,812)<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain on sale of equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,647<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(2,673)<span></span>
</td>
<td class="num">(3,376)<span></span>
</td>
<td class="num">(5,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">563<span></span>
</td>
<td class="nump">863<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">67,886<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">69,190<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">63,462<span></span>
</td>
<td class="nump">99,953<span></span>
</td>
<td class="nump">62,914<span></span>
</td>
<td class="nump">100,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before provision for income taxes</a></td>
<td class="nump">84,450<span></span>
</td>
<td class="nump">112,859<span></span>
</td>
<td class="nump">105,684<span></span>
</td>
<td class="nump">117,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">24,920<span></span>
</td>
<td class="nump">31,858<span></span>
</td>
<td class="nump">31,696<span></span>
</td>
<td class="nump">33,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">59,530<span></span>
</td>
<td class="nump">81,001<span></span>
</td>
<td class="nump">73,988<span></span>
</td>
<td class="nump">83,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="nump">46,872<span></span>
</td>
<td class="nump">73,957<span></span>
</td>
<td class="nump">48,179<span></span>
</td>
<td class="nump">72,892<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 12,658<span></span>
</td>
<td class="nump">$ 7,044<span></span>
</td>
<td class="nump">$ 25,809<span></span>
</td>
<td class="nump">$ 11,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 144,550<span></span>
</td>
<td class="nump">$ 140,949<span></span>
</td>
<td class="nump">$ 289,290<span></span>
</td>
<td class="nump">$ 281,370<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">16,214<span></span>
</td>
<td class="nump">12,003<span></span>
</td>
<td class="nump">34,224<span></span>
</td>
<td class="nump">23,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,143<span></span>
</td>
<td class="nump">8,690<span></span>
</td>
<td class="nump">16,693<span></span>
</td>
<td class="nump">17,505<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">4,621<span></span>
</td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">7,707<span></span>
</td>
<td class="nump">5,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 2,110<span></span>
</td>
<td class="nump">$ 1,257<span></span>
</td>
<td class="nump">$ 3,782<span></span>
</td>
<td class="nump">$ 2,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923590986664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Mezzanine</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 192,335<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 159,608<span></span>
</td>
<td class="nump">$ 31,905<span></span>
</td>
<td class="nump">$ 786<span></span>
</td>
<td class="nump">$ 168,725<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(1,160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2020</a></td>
<td class="nump">197,961<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">161,087<span></span>
</td>
<td class="nump">35,957<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="nump">157,439<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,042,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">7,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,044<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">73,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2020</a></td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">163,986<span></span>
</td>
<td class="nump">43,001<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">210,980<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,309,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2020</a></td>
<td class="nump">330,911<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">261,011<span></span>
</td>
<td class="nump">69,771<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="nump">114,237<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">13,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,151<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sales of noncontrolling interest</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">4,256<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2021</a></td>
<td class="nump">349,687<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">266,126<span></span>
</td>
<td class="nump">82,922<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">114,847<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,638,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">12,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,658<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">46,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(2,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,450)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Sales of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Sale of Sales by NCI (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Sale of shares by noncontrolling interest</a></td>
<td class="nump">40,133<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">40,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Investment in noncontrolling interest</a></td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(1,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,156)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 404,582<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 305,736<span></span>
</td>
<td class="nump">$ 95,580<span></span>
</td>
<td class="nump">$ 3,222<span></span>
</td>
<td class="nump">$ 141,856<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,246,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923503485928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 73,988<span></span>
</td>
<td class="nump">$ 83,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">9,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">741<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="nump">1,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized (gain) loss from investment in equity securities</a></td>
<td class="num">(83,769)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss (income) from equity method investments</a></td>
<td class="nump">3,812<span></span>
</td>
<td class="num">(2,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(99,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of beneficial interest</a></td>
<td class="nump">15,723<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Loss on interest rate swaps</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="nump">10,283<span></span>
</td>
<td class="num">(4,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherOperatingActivities', window );">Other</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables, net</a></td>
<td class="num">(9,975)<span></span>
</td>
<td class="num">(6,284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables, net &#8211; related parties</a></td>
<td class="num">(19,508)<span></span>
</td>
<td class="num">(11,191)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(266)<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,613<span></span>
</td>
<td class="num">(873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOperatingLeaseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,646<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(426)<span></span>
</td>
<td class="num">(5,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">16,984<span></span>
</td>
<td class="num">(3,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="num">(550)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">8,977<span></span>
</td>
<td class="nump">11,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(2,009)<span></span>
</td>
<td class="nump">37,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,698)<span></span>
</td>
<td class="num">(1,247)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">31,286<span></span>
</td>
<td class="nump">12,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Proceeds from repayment of loans receivable &#8211; related parties</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired</a></td>
<td class="num">(117)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PrepaymentForInvestmentPurchase', window );">Purchases of marketable securities</a></td>
<td class="num">(4,450)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(670)<span></span>
</td>
<td class="num">(1,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of investment &#8211; equity method</a></td>
<td class="num">(1,660)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,364)<span></span>
</td>
<td class="num">(451)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity', window );">Cash received from consolidation of VIE</a></td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">1,106<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(9,802)<span></span>
</td>
<td class="nump">67,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(21,110)<span></span>
</td>
<td class="num">(30,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(238,208)<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of stock options and warrants</a></td>
<td class="nump">4,816<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares</a></td>
<td class="num">(2,981)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Purchase of noncontrolling interest</a></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromSaleOfNoncontrollingInterest', window );">Proceeds from sale of noncontrolling interest</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings on revolver</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of shares</a></td>
<td class="nump">40,134<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(727)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(38,167)<span></span>
</td>
<td class="num">(30,548)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(16,683)<span></span>
</td>
<td class="nump">49,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">193,970<span></span>
</td>
<td class="nump">104,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">177,287<span></span>
</td>
<td class="nump">153,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">23,324<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">2,507<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend declared included in dividend payable</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Preferred shares received from sale of equity investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CancellationOfRestrictedStockAwards', window );">Cancellation of Restricted Stock Awards</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">177,287<span></span>
</td>
<td class="nump">152,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash - noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash total</a></td>
<td class="nump">$ 177,287<span></span>
</td>
<td class="nump">$ 153,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CancellationOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CancellationOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PrepaymentForInvestmentPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment for Investment Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PrepaymentForInvestmentPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Cash Received from Consolidation of Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromSaleOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromSaleOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from operating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500543816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) on December 8, 2017 (&#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;), and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the following brands: (i) Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), (ii) Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), and (iii) Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;). These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MSOs and Affiliates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPAs and Affiliates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC is owned by California-licensed physicians and professional medical corporations, and contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans, as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is subject to stop-loss provisions in contracts with HMOs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. Under this management arrangement, NMM performs only non-medical administrative services, does not represent that it offers medical services, and does not exercise influence or control over the practice of medicine by APC or its physicians. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company and is consolidated by NMM.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. In accordance with relevant accounting guidance, AP-AMH is determined to be a VIE of ApolloMed and is consolidated by ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends (&#8220;Series A Dividends&#8221;) that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased 15,015,015 shares of ApolloMed&#8217;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transactions described above, APC and AP-AMH entered into a Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term &#8220;Excluded Assets.&#8221; Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred Stock equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC&#8217;s ownership in ApolloMed was 19.77% at June&#160;30, 2021 and 22.58% at December&#160;31, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare. As of June&#160;30, 2021, APC owned 45.01% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. In accordance with relevant accounting guidance, CDSC is determined to be a VIE of APC and is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care, Accountable Health Care, and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, and Medicare. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a 50% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants or vacant land with plans to lease the building in the future. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A with APC as their guarantor, causing the Company to reevaluate their consolidation of Tag 8. Based on the reevaluation, it was concluded that Tag 8 is a VIE and is consolidated by APC because APC has the ability to direct the activities that most significantly affect Tag 8&#8217;s economic performance. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the definitive proxy statement that ApolloMed filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 31, 2019 (the &#8220;2019 Proxy Statement&#8221;), and consequently will not affect net income attributable to ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO</span></div>APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model of CMS in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500515624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2021, and for the three and six months ended June&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01. Operating results for the three and six months ended June&#160;30, 2021, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021, or any future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of June&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of income for the three and six months ended June&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIE, AP-AMH; AMM&#8217;s consolidated VIE, SCHC; NMM&#8217;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#8217;s consolidated VIE, APC; APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties and ZLL, APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 15 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of June&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $268.2 million and $294.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consisted of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.2 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy where quoted market prices from reputable third-party brokers are available in an active market. Equity securities held by the Company are primarily comprised of common stock of a payer partner that completed its initial public offering in June 2021. The shares were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. As of June&#160;30, 2021, equity securities amounted to $119.9 million. As of December&#160;31, 2020, prior to our payer partner&#8217;s IPO, the related investment balance was included in investment in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. For the three and six months ended June&#160;30, 2021, the Company recognized unrealized gains of $83.8 million in other income in the accompanying consolidated income statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivables</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivables and loan receivables &#8211; related parties consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the six months ended June&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the six months ended June&#160;30, 2021 and 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no impairment of its goodwill or indefinite-lived intangible assets during the six months ended June&#160;30, 2021 and 2020. Goodwill as of June&#160;30, 2021 and December&#160;31, 2020 was $239.1&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Cost Method </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiduciary Cash and Payable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, and Accountable Health Care collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $9.1 million and $9.6 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 8 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the derivative instrument was determined using Level 2 inputs. The fair value of the derivative instrument as of June&#160;30, 2021 and December&#160;31, 2020 was $1.2 million and $0, respectively, and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like payments, called All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 7), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $24.3 million and $48.1 million in total AIPBP payments for the three and six months ended June&#160;30, 2021, respectively, of which $14.1 million and $31.2 million has been recognized as revenue for the three months and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#8217;s contract liability balance was $29.6 million and $13.0 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is presented within accounts payable and accrued expenses in the accompanying consolidated balance sheets. During the six months ended June&#160;30, 2021, $0.4 million of the Company&#8217;s contract liability accrued in 2020 has been recognized as revenue.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2021 and December&#160;31, 2020, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12 month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI pursuant to the terms of the stock purchase agreement, APC received a beneficial interest in the equity method investment sold. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free Treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020 was assessed and beneficial interest was concluded to not be collectible. For the three and six months ended June&#160;30, 2021, the $15.7 million was written off and expensed in other income in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501660904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,002)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,544)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $3.7 million and $4.1 million for the three months ended June&#160;30, 2021 and 2020, respectively, and $7.5 million and $8.2&#160;million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500454648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock', window );">Investments in Other Entities &#8212; Equity Method</a></td>
<td class="text">Investments in Other Entities &#8212; Equity Method<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contribution</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity Consolidated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties through its network of approximately 2,400 independently contracted primary care physicians and specialist providers. LMA&#8217;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#8217;s IPA line of business. On December 18, 2020, the Company exercised its option to convert the promissory note totaling $6.4&#160;million due from Dr. Arteaga into an additional 21.25% interest in LMA&#8217;s IPA line of business. As a result, APC-LSMA&#8217;s interest in LMA&#8217;s IPA line of business increased to 46.25%. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of $3.6 million and income of $0.2 million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and June&#160;30, 2020, APC recognized a loss from this investment of $4.3 million and a $0.4 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $8.7 million and $13.0 million at June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the six months ended June&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,358)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,567)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at its facilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.6 million and $0.4 million, for the three months ended June&#160;30, 2021 and 2020, respectively, and fees of approximately $1.0 million and $1.0 million for the six months ended June&#160;30, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of approximately $16,000 and $10,200, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recognized a loss of $30,000 and income of $0.1 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets had investment balances of $1.4 million and $1.4 million at June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#8217;s operations. For the three months ended June&#160;30, 2021 and 2020, APC recognized income from this investment of $0.2&#160;million and a loss of $0.1 million, respectively, in the consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recognized income from investment of $0.2 million and a loss of $0.1 million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.8 million and $2.6 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC, and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owned 50%, 25%, and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $16.1&#160;million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended June&#160;30, 2021 and 2020, APC recognized a loss from this investment of $9,000 and $0.1 million, respectively, in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021 and 2020, APC recorded a loss from this investment of $0.1 million and $0.2 million in the accompanying consolidated statements of income, respectively. The accompanying consolidated balance sheets include the related investment balances of $17.1 million and $17.2 million at June&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the six months ended June&#160;30, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><br/>One MSO LLC - Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in One MSO LLC (&#8220;One MSO&#8221;) for $2.4 million. One MSO owns an office building in Monterey Park, California that is currently being leased to tenants, including NMM. For the three months ended June&#160;30, 2021, One MSO recognized income of $0.1 million in the accompanying consolidated statements of income. For the six months ended June&#160;30, 2021, One MSO recognized income of $0.2&#160;million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.6 million and $2.4 million at June&#160;30, 2021 and December&#160;31, 2020, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC - Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in Tag 6 for $4.5 million and a 50% membership interest in Tag 8 for $2.1 million. The Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. For the three and six months ended June&#160;30, 2021, Tag 6 recognized a loss of $0.2 million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the Tag 6 investment of $4.7 million and $4.5&#160;million at June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. A five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date. However, APC did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in investment in privately held entities in the accompanying consolidated balance sheets as of June&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method And Other Equity Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodAndOtherEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923502046520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loan Receivable and Loan Receivable &#8211; Related Parties</a></td>
<td class="text">Loan Receivable and Loan Receivable &#8211; Related Parties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 totaling $0.5&#160;million as a result of the sale of the Company&#8217;s interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC (the &#8220;AHMC Note&#8221;) for a principal amount of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of June&#160;30, 2021, the total principal of $4.0&#160;million remains outstanding. One of the Company&#8217;s board members is an officer of AHMC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500563960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500579832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical LiabilitiesThe Company&#8217;s medical liabilities consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500571464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loan and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loan and Lines of Credit<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the &#8220;Credit Facility&#8221;) with Truist Bank (f.k.a. SunTrust Bank), in its capacity as administrative agent for the lenders, as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders. The Credit Agreement provided a five-year revolving credit facility to the Company of $100.0 million, which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provided a term loan of $190.0 million. Amounts borrowed under the Credit Agreement bore interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement and, together with the Company, granted the Lenders a security interest in all of its assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacities as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders (the &#8220;Lenders&#8221;), and Bank of the West, The Toronto-Dominion Bank, New York Branch, Wells Fargo, National Association, and City National Bank in their capacities as Lenders, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, certain Lenders and the Agent, in its entirety.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement provides for a five-year revolving credit facility (&#8220;Revolver Loan&#8221;) to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement remain in effect. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts borrowed under the Amended Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters LIBOR01screen page, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of June&#160;30, 2021, the interest rate on Amended Credit Facility was 1.65%.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.35% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.5%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter.  The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7&#160;million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility. At June&#160;30, 2021 and December&#160;31, 2020, the unamortized deferred financing cost was $4.7&#160;million and $4.6&#160;million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of this purchase, APC assumed the existing loans held by MPP, AMG Properties, and ZLL. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $6.4&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $6.2 million. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1. <br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $0.7 million. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2020, the principal on the loan was $0.7&#160;million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying ZLL. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. As of June&#160;30, 2021, the balance outstanding was $0.6 million. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $10.7 million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of June&#160;30, 2021, the balance outstanding was $0.1&#160;million. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the six months ended June&#160;30, 2021 and 2020, was 2.31% and 3.93%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and six months ended June&#160;30, 2021 and 2020, of $0.4 million and $0.3 million, respectively, and $0.7 million and $0.7 million, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, the APC Business Loan Agreement with Preferred Bank (the &#8220;APC Business Loan Agreement&#8221;) was amended to decrease loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#8217;s board members, totaling $14.8&#160;million for the benefit of CMS. In August 2020, the irrevocable standby letter of credit was  released by CMS. As of June&#160;30, 2021, there were no outstanding letters of credit and the Company had $25.0&#160;million available under the Amended Credit Facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500579832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders' Equity</a></td>
<td class="text">Mezzanine and Stockholders&#8217; Equity<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature of the APC shares (see Note 2) is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares are not redeemable, and it is not probable that the shares will become redeemable as of June&#160;30, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, 143,052 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the 2017 merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned 10,885,732 and 12,323,164 shares of ApolloMed&#8217;s common stock as of June&#160;30, 2021 and December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. During the six months ended June&#160;30, 2021, the Company issued 34,158 shares of common stock to APC as a result of APC exercising its warrants. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2021 and 2020, APC paid dividends of $19.9&#160;million and $19.6&#160;million, respectively. During the six months ended June&#160;30, 2021 and 2020, APC paid dividends of $19.9 million and $29.6 million, respectively.</span></div>During the three months ended June&#160;30, 2021 and 2020, CDSC paid dividends of $1.5&#160;million and $0.6&#160;million, respectively. During the six months ended June&#160;30, 2021 and 2020, CDSC paid dividends of $1.5 million and $0.6 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500552632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care, and Accountable Health Care are required to comply with the California Department of Managed Healthcare (&#8220;DMHC&#8221;) regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the payor and provider contracts with the Company&#8217;s affiliated physician-owned medical groups are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS. The guarantee generally must be in an amount equal to 2% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS and $0 million remains outstanding as of June&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8 million, respectively, for the benefit of certain health plans (see Note 8). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501937080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party TransactionsDuring the three and six months ended June&#160;30, 2021 and 2020, NMM earned approximately $4.2 million and $4.2 million, respectively, and $8.7 million and $8.4 million, respectively, in management fees from LMA, which is accounted for under the equity method based on 46.25% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 4).<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $0.6 million and $0.4 million, respectively, and $1.0 million and $1.0 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $1.7 million and $0.9 million, respectively, and $3.2 million and $2.6 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $30,000 and $0.1 million, respectively, and $51,000 and $0.1 million to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $19,000 and $25,000, respectively, and $52,000 and $76,000, respectively, to Fresenius Medical Care (&#8220;Fresenius&#8221;) and their subsidiaries for services as a provider. During the three and six months ended June&#160;30, 2021 and 2020, APAACO paid approximately $0.2 million and $0.2 million, respectively, and $0.3 million and $0.3 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, APC paid approximately $0.3 million and $0, respectively, and $0.4 million and $0, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shared a common board member with the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2021 and 2020, APC paid an aggregate of approximately $8.2 million and $9.0 million to shareholders, respectively, which included approximately $2.2 million and $3.0 million, respectively, to shareholders who are also officers of APC. During the six months ended June&#160;30, 2021 and 2020, APC paid an aggregate of approximately $15.6 million and $16.3 million to shareholders, respectively, and $3.8 million and $4.8 million, respectively, to shareholders who are also officers of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, the Company paid approximately $0 and $0.1 million, respectively, and $0 and $0.2 million, respectively, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and six months ended June&#160;30, 2021 and 2020, SCHC paid approximately $0.1 million and $0.1 million, respectively, and $0.2 million and $0.2 million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six ended June&#160;30, 2021 and 2020, APC paid approximately $0.4 million and $0.4 million, respectively, and $0.7 million and $0.7 million, respectively, to One MSO, Inc. (&#8220;One MSO&#8221;) for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 4).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare Inc. (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and six months ended June&#160;30, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $14.2 million and $10.2 million, respectively, and $31.2&#160;million and $21.0&#160;million. $63.8 million and $45.3 million remained outstanding as of June&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021 and 2020, NMM paid approximately $44,000 and $0, respectively, and $44,000 and $27,000, respectively, to an ApolloMed board member for consulting services. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company&#8217;s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable and line of credits from related parties, see Notes 4, 5, and 8, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500552632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the six months ended June&#160;30, 2021 and June&#160;30, 2020, was 30.0% and 28.5%, respectively. The tax rate for the six months ended June&#160;30, 2021 differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2016 through December&#160;31, 2020, and for the years ended December 31, 2017 through December&#160;31, 2020, respectively. The Company does not anticipate material changes to the unrecognized tax benefits within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923499444840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021 and December&#160;31, 2020, APC held 10,885,732 and 12,323,164 shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,071,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,285,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,040,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,296,913&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,071,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,285,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,040,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,296,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500300552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and their treatment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of the Company&#8217;s other consolidated VIEs were not considered significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501957336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.4 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms of one month to five years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of June&#160;30, 2021 and December&#160;31, 2020, assets recorded under finance leases were $0.4 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases were $0.5 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501942648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and six months ended June&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of June&#160;30, 2021, was $8.0 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, no stock options were exercised. During the six months ended June&#160;30, 2020, options were exercised for 120,000 shares of the Company's common stock, resulting in proceeds of approximately $0.3 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the six months ended June&#160;30, 2021, the Company granted restricted stock awards totaling 150,130 shares with a weighted average grant date fair value of $24.16. The grant date fair value of the restricted stock was $3.6&#160;million and will be recognized on a straight-line basis over the awards&#8217; vesting period of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjExMjNjNDdkZWMwNzQyNjliMzgyNTQwYWU2MjA2YzI4L3NlYzoxMTIzYzQ3ZGVjMDc0MjY5YjM4MjU0MGFlNjIwNmMyOF8xMDYvZnJhZzo0OWUyOTlkYzI1MGY0NzgxYTNiNzAzMGE2OTM4OGY3MS90ZXh0cmVnaW9uOjQ5ZTI5OWRjMjUwZjQ3ODFhM2I3MDMwYTY5Mzg4ZjcxXzExNTQ0ODcyMDk0NDMx_f69dfb9e-740f-4b1d-890a-b5aa38e16317">one</span> to three years. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710,756</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the six months ended June&#160;30, 2021 and 2020, common stock warrants were exercised for 474,506 and 273,900 shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $4.8&#160;million and $2.6 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the six months ended June&#160;30, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501684408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Access Primary Care Medical Group</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 15, 2021, a physician-owned designated shareholder professional corporation affiliated with the Company entered into a definitive agreement to acquire 80% of the fully diluted capitalization of Access Primary Care Medical Group (&#8220;APCMG&#8221;). 50% will be paid out in cash to APCMG within 10 business days of the transaction and the remaining 50% will be paid out in cash upon APCMG&#8217;s achievement of certain financial milestones related to fiscal year 2022. APCMG is a primary care physicians' group focused on providing high-quality care to senior patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Sun Clinical Laboratories <br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 1, 2021,  the Company entered into a definitive agreement with Sun Clinical Laboratories ("Sun Labs"), under which the Company will purchase a 49% interest in Sun Labs for $4.0&#160;million. Sun Labs is a CLIA-certified full-service lab that operates 19 locations across the San Gabriel Valley in southern California.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The transaction is expected to close by the end of the third quarter of 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923510686360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying consolidated balance sheets at December&#160;31, 2020, have been derived from the Company&#8217;s audited consolidated financial statements, but do not include all annual disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of June&#160;30, 2021, and for the three and six months ended June&#160;30, 2021 and 2020, have been prepared in accordance with U.S. GAAP for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the SEC on March&#160;15, 2021. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as required by Regulation S-X, Rule 10-01.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div>The consolidated balance sheets as of June&#160;30, 2021 and December&#160;31, 2020, and the consolidated statements of income for the three and six months ended June&#160;30, 2021 and 2020, include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIE, AP-AMH; AMM&#8217;s consolidated VIE, SCHC; NMM&#8217;s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM&#8217;s consolidated VIE, APC; APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties and ZLL, APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax-valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by the Company in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements. To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:10pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:10pt;padding-left:108pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company determines that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div>If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 15 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIEs. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Business CombinationsThe Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashRestricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consisted of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to 24 months. As of June&#160;30, 2021 and December&#160;31, 2020, certificates of deposit amounted to approximately $67.2 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.</span></div>Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy where quoted market prices from reputable third-party brokers are available in an active market. Equity securities held by the Company are primarily comprised of common stock of a payer partner that completed its initial public offering in June 2021. The shares were acquired as a result of UCAP selling its<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock', window );">Receivables, Receivables &#8211; Related Parties, and Loan Receivables</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables,  Receivables &#8211; Related Parties, and Loan Receivables</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loan receivables and loan receivables &#8211; related parties consist of promissory notes from payees that are expected to be collected between two to four years and accrue interest per annum. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div>Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risks</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. </span></div>The consolidated statements of income present disaggregated revenue by service type.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div>Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) management services, (2) IPAs, and (3) accountable care organizations. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities - Equity Method and Investments in Other Entities - Cost Method</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under income (loss) from equity method investments and also is adjusted by contributions to, and distributions from, the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Cost Method </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div>An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryCashAndPayablePolicyTextBlock', window );">Fiduciary Cash and Payable</a></td>
<td class="text">Fiduciary Cash and PayableAPC, Alpha Care, and Accountable Health Care collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 8 for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.</span></div>The estimated fair value of the derivative instrument was determined using Level 2 inputs. The fair value of the derivative instrument as of June&#160;30, 2021 and December&#160;31, 2020 was $1.2 million and $0, respectively, and is presented within other long-term liabilities in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Final settlement of risk pools for prior contract years generally occur in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement, the amount of the profit/loss cap, alternative payment mechanism, benefits enhancements, if any, and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like payments, called All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 7), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess AIPBPs for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company, the risk arrangement for which the Company has been approved by CMS, and as otherwise provided in an NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;). Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2021, the Company receives monthly AIPBP payments at a rate of approximately $8.0 million per month from CMS, and must comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $24.3 million and $48.1 million in total AIPBP payments for the three and six months ended June&#160;30, 2021, respectively, of which $14.1 million and $31.2 million has been recognized as revenue for the three months and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of gross revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s affiliated physician-owned medical groups are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system, and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div>Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities </span></div>outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of June&#160;30, 2021 and December&#160;31, 2020, APC&#8217;s shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under a 12 month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BeneficialInterestPolicyTextBlock', window );">Beneficial Interest</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI pursuant to the terms of the stock purchase agreement, APC received a beneficial interest in the equity method investment sold. The estimated fair value of such interest in April 2020, was&#160;$15.7 million and is included in other assets in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free Treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020 was assessed and beneficial interest was concluded to not be collectible. For the three and six months ended June&#160;30, 2021, the $15.7 million was written off and expensed in other income in the accompanying consolidated statements of income.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BeneficialInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BeneficialInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryCashAndPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiduciary Cash and Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryCashAndPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49178521&amp;loc=d3e9162-115647<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501903576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Each Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by payor type for the three and six months ended June&#160;30, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,638&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.643%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of June&#160;30, 2021, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020, are presented below (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500554312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June&#160;30, 2021, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,057)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,229&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,002)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,544)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021) </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,227&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501758312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contribution</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity Consolidated</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,719&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One MSO, LLC - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC - related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC - related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,292&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,812)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and summarized statements of operations for the six months ended June&#160;30, 2021 and 2020, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,244&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,358)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,567)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at June&#160;30, 2021 and December&#160;31, 2020, and statements of operations for the six months ended June&#160;30, 2021 and 2020, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,170&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,432&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(579)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(558)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500507048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500621864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text">The Company&#8217;s medical liabilities consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,293)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,446&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,432)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,582)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500663384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real Estate Loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction Loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,705&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Commitments of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500515624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</a></td>
<td class="text">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended <br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,056&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipts, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923502046520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,071,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,285,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,040,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,296,913&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,165,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,071,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,041,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,828,802&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,285,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,255,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,040,936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911,131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,746,761&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,296,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500598984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Assets and Liabilities, Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due from affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,137&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923510482088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Information Related to Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,096&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.56 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.06 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 %</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of June&#160;30, 2021, is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (excluding the six months ended June 30, 2021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,042&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923512087528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans for the three and six months ended June&#160;30, 2021 and 2020, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,638&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, the Company granted 24,437 stock options with a vesting period of two years to certain ApolloMed executives with an exercise price of $23.24, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474,506)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710,756</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,061</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                  10.00 &#8211; 11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504016520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 01, 1999</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>clinic </div>
<div>plan</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage', window );">Proxy votes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember', window );">AP-AMH Medical Corporation | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Term of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableStatedInterestRate', window );">Stated rate of note of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate', window );">Interest rate in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Fixed term of amended and restated management and administrative services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MPP, AMG Properties, and ZLL Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.77%<span></span>
</td>
<td class="nump">22.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Concourse Diagnostic Surgery Center, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AP-AMH Medical Corporation | Affiliated Entity | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Maverick Medical Group, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFederallyQualifiedHealthPlans', window );">Number federally qualified health plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Dr. Jay | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFamilyPracticeClinics', window );">Number of family practice clinics | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Modifications, Subsequent Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFamilyPracticeClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Family Practice Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFamilyPracticeClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Proxy Votes, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodProxyVotesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923505568760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,200,000<span></span>
</td>
<td class="nump">$ 268,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,200,000<span></span>
</td>
<td class="nump">67,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,637,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,900,000<span></span>
</td>
<td class="nump">119,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Equity securities, FV-NI, unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,800,000<span></span>
</td>
<td class="nump">$ 83,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after risk pool performance year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of main reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,053,000<span></span>
</td>
<td class="nump">239,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,053,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,092,000<span></span>
</td>
<td class="nump">9,092,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,642,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueMonthlyAmount', window );">Payments received, monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenue', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,300,000<span></span>
</td>
<td class="nump">48,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueRevenueRecognized', window );">Payments received, revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
<td class="nump">31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,594,000<span></span>
</td>
<td class="nump">29,594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,988,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,200,000<span></span>
</td>
<td class="nump">67,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | Universal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash', window );">Contingent consideration, cash held in escrow</a></td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares', window );">Contingent consideration, preferred shares</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue', window );">Contingent consideration, fair value</a></td>
<td class="nump">22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Universal Care Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash consideration entitled to be received</a></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds', window );">Write off of additional proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Interest rate swap | Cash flow hedges: | Derivatives designated as hedging instruments:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember', window );">PMPM Managed Care Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management Fee Income Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_CMSMember', window );">CMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport', window );">Expected period of payment upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Write-off of Additional Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueMonthlyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Monthly Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueMonthlyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_CMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_CMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923510949736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 175,638<span></span>
</td>
<td class="nump">$ 165,169<span></span>
</td>
<td class="nump">$ 351,696<span></span>
</td>
<td class="nump">$ 330,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">33,296<span></span>
</td>
<td class="nump">25,479<span></span>
</td>
<td class="nump">65,562<span></span>
</td>
<td class="nump">50,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">64,273<span></span>
</td>
<td class="nump">62,038<span></span>
</td>
<td class="nump">128,950<span></span>
</td>
<td class="nump">126,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">68,482<span></span>
</td>
<td class="nump">68,450<span></span>
</td>
<td class="nump">138,146<span></span>
</td>
<td class="nump">134,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 9,587<span></span>
</td>
<td class="nump">$ 9,202<span></span>
</td>
<td class="nump">$ 19,038<span></span>
</td>
<td class="nump">$ 18,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923506424520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="nump">11.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">16.70%<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504752856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 107,403<span></span>
</td>
<td class="nump">$ 115,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">67,200<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">120,006<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">294,609<span></span>
</td>
<td class="nump">183,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">107,403<span></span>
</td>
<td class="nump">115,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">67,200<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">120,006<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">294,609<span></span>
</td>
<td class="nump">183,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504684984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (97,002)<span></span>
</td>
<td class="num">$ (89,544)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">80,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">177,229<span></span>
</td>
<td class="nump">176,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">80,227<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">143,930<span></span>
</td>
<td class="nump">143,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(79,057)<span></span>
</td>
<td class="num">(73,169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 64,873<span></span>
</td>
<td class="nump">$ 70,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 22,832<span></span>
</td>
<td class="nump">$ 22,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(12,693)<span></span>
</td>
<td class="num">(11,715)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 10,139<span></span>
</td>
<td class="nump">$ 11,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 7,396<span></span>
</td>
<td class="nump">$ 6,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,595)<span></span>
</td>
<td class="num">(3,234)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,801<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,476)<span></span>
</td>
<td class="num">(1,270)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade names/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 830<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923510529736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923598270584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2021 (excluding the six months ended June 30, 2021)</a></td>
<td class="nump">$ 7,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">12,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">10,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">9,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">8,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">30,358<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 80,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504056744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="num">$ (3,134)<span></span>
</td>
<td class="nump">$ 834<span></span>
</td>
<td class="num">(3,812)<span></span>
</td>
<td class="nump">$ 2,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">37,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,328)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">8,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">2,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">17,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember', window );">Tag-6 Medical Investment Group, LLC - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">4,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember', window );">Tag-8 Medical Investment Group, LLC - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Entity Consolidated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Consolidated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923494341432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>provider</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>provider</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,134,000)<span></span>
</td>
<td class="nump">$ 834,000<span></span>
</td>
<td class="num">$ (3,812,000)<span></span>
</td>
<td class="nump">$ 2,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MediPortal LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares', window );">Membership interests purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Payments to purchase membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest', window );">Membership interests acquired (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption', window );">Term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests', window );">Options to purchase additional membership interests (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet', window );">Number of warrants available to purchase, contingent upon the portal completion date (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. | AchievaMed, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears', window );">Percentage of voting common stock, within five years</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment', window );">Duration of investment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost', window );">Investment amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Related investment balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees | provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,328,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,719,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,047,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC and APC-LSMA | Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion', window );">Ownership upon conversion of finance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,600,000)<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC | Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease', window );">Equity method investment, conversion of finance receivable, ownership percentage increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC | Ancillary Service Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRealEstate', window );">Purchase price of real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,000)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | College Street Investment LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | Network Medical Management, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC - related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember', window );">Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember', window );">Tag-8 Medical Investment Group, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MediPortalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MediPortalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_AchievaMedInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_AchievaMedInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923591408616">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 177,287<span></span>
</td>
<td class="nump">$ 152,441<span></span>
</td>
<td class="nump">$ 177,287<span></span>
</td>
<td class="nump">$ 152,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">894,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">894,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">404,582<span></span>
</td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">404,582<span></span>
</td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">$ 349,687<span></span>
</td>
<td class="nump">330,911<span></span>
</td>
<td class="nump">$ 197,961<span></span>
</td>
<td class="nump">$ 192,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">894,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">894,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">175,638<span></span>
</td>
<td class="nump">165,169<span></span>
</td>
<td class="nump">351,696<span></span>
</td>
<td class="nump">330,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">154,650<span></span>
</td>
<td class="nump">152,263<span></span>
</td>
<td class="nump">308,926<span></span>
</td>
<td class="nump">313,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,988<span></span>
</td>
<td class="nump">12,906<span></span>
</td>
<td class="nump">42,770<span></span>
</td>
<td class="nump">17,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,886<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">69,190<span></span>
</td>
<td class="nump">1,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,920<span></span>
</td>
<td class="nump">31,858<span></span>
</td>
<td class="nump">31,696<span></span>
</td>
<td class="nump">33,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,530<span></span>
</td>
<td class="nump">$ 81,001<span></span>
</td>
<td class="nump">73,988<span></span>
</td>
<td class="nump">83,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,212<span></span>
</td>
<td class="nump">92,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,570<span></span>
</td>
<td class="nump">93,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,358)<span></span>
</td>
<td class="num">(1,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (230)<span></span>
</td>
<td class="num">$ (558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $1,347.6&#160;million and $801.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $107.1&#160;million and $111.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923590688760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details) - Convertible Secured Promissory Note - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Pacific6 Enterprises | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">AHMC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Note receivable, amount</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableInterestRateStatedPercentage', window );">Note receivable, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923512191672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 11,192<span></span>
</td>
<td class="nump">$ 9,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIPAPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">2,356<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">962<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">29,594<span></span>
</td>
<td class="nump">12,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 53,792<span></span>
</td>
<td class="nump">$ 36,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIPAPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subcontractor IPA Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIPAPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923590452456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of period</a></td>
<td class="nump">$ 50,330<span></span>
</td>
<td class="nump">$ 58,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">158,739<span></span>
</td>
<td class="nump">165,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="num">(1,293)<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">157,446<span></span>
</td>
<td class="nump">165,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(103,302)<span></span>
</td>
<td class="num">(97,112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(45,130)<span></span>
</td>
<td class="num">(57,470)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(148,432)<span></span>
</td>
<td class="num">(154,582)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of period</a></td>
<td class="nump">$ 59,307<span></span>
</td>
<td class="nump">$ 70,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923503487624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 187,575<span></span>
</td>
<td class="nump">$ 245,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of debt</a></td>
<td class="num">(205)<span></span>
</td>
<td class="num">(10,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized financing costs</a></td>
<td class="num">(4,665)<span></span>
</td>
<td class="num">(4,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="nump">182,705<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember', window );">Real Estate Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">7,498<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember', window );">Construction Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923511976216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021 (excluding the six months ended June 30, 2021)</a></td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025 and thereafter</a></td>
<td class="nump">186,747<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 187,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923491870072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 05, 2020</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,605,000<span></span>
</td>
<td class="nump">4,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853,000<span></span>
</td>
<td class="nump">$ 2,673,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,376,000<span></span>
</td>
<td class="nump">$ 5,541,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">Medical Property Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Debt instrument, covenant, debt coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL Partners LLC | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Medical Property Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | ZLL Partners LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">3.93%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Annual agent fee</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.175%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt, principal sum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum', window );">Debt instrument, covenant, cash flow coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction Loan | Tag-8 Medical Investment Group, LLC | London Interbank Offered Rate (LIBOR) | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term Loan A | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Amended Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923510735128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">10,885,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,885,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Shares issued for exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">10,885,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,885,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="nump">$ 19.6<span></span>
</td>
<td class="nump">$ 19.9<span></span>
</td>
<td class="nump">$ 29.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923511569432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount', window );">General amount of guarantee (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">$ 187,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities', window );">Standby letters of credit assumed</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">14,800,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financial guarantee on benchmark Medicare expenditure amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PercentageOfFinancialGuaranteeBenchmarkAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923503746920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">$ 12,588<span></span>
</td>
<td class="nump">$ 5,815<span></span>
</td>
<td class="nump">$ 25,533<span></span>
</td>
<td class="nump">$ 17,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentConsultingFees', window );">Consulting services paid</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | PMIOC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember', window );">APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">8,200<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="nump">16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember', window );">Advance Diagnostic Surgery Center | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember', window );">Fresenius | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember', window );">Fresenius | APA ACO Inc | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember', window );">Fulgent Genetics, Inc. | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember', window );">APC Shareholders and Officers | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember', window );">Critical Quality Management Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC | SCHC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">$ 31,200<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Amount outstanding under agreement</a></td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember', window );">LMA | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">46.25%<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember', window );">PMIOC | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaAcoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaAcoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_SCHCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_SCHCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923601135128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Fees Incurred and Income Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">$ 12,588<span></span>
</td>
<td class="nump">$ 5,815<span></span>
</td>
<td class="nump">$ 25,533<span></span>
</td>
<td class="nump">$ 17,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet', window );">AHMC &#8211; Risk pool, capitation, claims payment</a></td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
<td class="nump">25,793<span></span>
</td>
<td class="nump">18,056<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">31,200<span></span>
</td>
<td class="nump">10,200<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember', window );">Aurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">$ (77)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (152)<span></span>
</td>
<td class="num">$ (128)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Services Revenue, Capitation, And Claims Payment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501978568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">28.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923501883112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Treasury shares not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">10,885,732<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923506822504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Earnings Per Share Computations (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.58<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,165,264<span></span>
</td>
<td class="nump">36,071,604<span></span>
</td>
<td class="nump">43,255,901<span></span>
</td>
<td class="nump">36,040,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">45,828,802<span></span>
</td>
<td class="nump">37,285,585<span></span>
</td>
<td class="nump">44,746,761<span></span>
</td>
<td class="nump">37,296,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923690797880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">44,165,264<span></span>
</td>
<td class="nump">36,071,604<span></span>
</td>
<td class="nump">43,255,901<span></span>
</td>
<td class="nump">36,040,936<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">45,828,802<span></span>
</td>
<td class="nump">37,285,585<span></span>
</td>
<td class="nump">44,746,761<span></span>
</td>
<td class="nump">37,296,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">466,104<span></span>
</td>
<td class="nump">169,402<span></span>
</td>
<td class="nump">409,154<span></span>
</td>
<td class="nump">173,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">204,711<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
<td class="nump">170,575<span></span>
</td>
<td class="nump">5,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">992,723<span></span>
</td>
<td class="nump">1,041,784<span></span>
</td>
<td class="nump">911,131<span></span>
</td>
<td class="nump">1,076,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504615704">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 177,287<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
<td class="nump">$ 152,441<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187,206<span></span>
</td>
<td class="nump">67,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,540<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,767<span></span>
</td>
<td class="nump">49,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,562<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,188<span></span>
</td>
<td class="nump">16,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">470,550<span></span>
</td>
<td class="nump">338,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,227<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239,053<span></span>
</td>
<td class="nump">239,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,372<span></span>
</td>
<td class="nump">43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,928<span></span>
</td>
<td class="nump">18,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,072<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">423,880<span></span>
</td>
<td class="nump">478,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">894,430<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,792<span></span>
</td>
<td class="nump">36,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,092<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,307<span></span>
</td>
<td class="nump">50,330<span></span>
</td>
<td class="nump">$ 70,273<span></span>
</td>
<td class="nump">$ 58,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">536<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">205<span></span>
</td>
<td class="nump">10,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128,088<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,705<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,242<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">249<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,513<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219,904<span></span>
</td>
<td class="nump">257,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">347,992<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105,108<span></span>
</td>
<td class="nump">126,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">187,130<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,796<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">66,670<span></span>
</td>
<td class="nump">46,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,814<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,262<span></span>
</td>
<td class="nump">14,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loan receivable &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateCurrent', window );">Amount due from affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,286<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">406,066<span></span>
</td>
<td class="nump">261,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,770<span></span>
</td>
<td class="nump">27,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">64,246<span></span>
</td>
<td class="nump">69,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,460<span></span>
</td>
<td class="nump">109,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivables &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">683,733<span></span>
</td>
<td class="nump">225,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,372<span></span>
</td>
<td class="nump">43,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">36,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,597<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,812<span></span>
</td>
<td class="nump">17,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">941,509<span></span>
</td>
<td class="nump">539,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,347,575<span></span>
</td>
<td class="nump">801,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,310<span></span>
</td>
<td class="nump">12,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,092<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,256<span></span>
</td>
<td class="nump">37,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,784<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">536<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Amount due to affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">205<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">73,538<span></span>
</td>
<td class="nump">89,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">7,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,190<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">249<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,575<span></span>
</td>
<td class="nump">5,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,599<span></span>
</td>
<td class="nump">22,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 107,137<span></span>
</td>
<td class="nump">$ 111,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $1,347.6&#160;million and $801.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $107.1&#160;million and $111.3&#160;million as of June&#160;30, 2021 and December&#160;31, 2020, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923502543384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923598667272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,263<span></span>
</td>
<td class="nump">$ 1,446<span></span>
</td>
<td class="nump">$ 2,515<span></span>
</td>
<td class="nump">$ 3,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease expense</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(280)<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost, net</a></td>
<td class="nump">$ 1,013<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">$ 2,102<span></span>
</td>
<td class="nump">$ 3,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923512258456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,293<span></span>
</td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">$ 3,149<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,907<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">7 years 21 days<span></span>
</td>
<td class="text">6 years 6 months 21 days<span></span>
</td>
<td class="text">7 years 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
<td class="text">4 years 2 months 1 day<span></span>
</td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
<td class="text">4 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923502118744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding the six months ended June 30, 2021)</a></td>
<td class="nump">$ 2,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">6,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">21,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">3,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">17,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">$ 3,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">14,513<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding the six months ended June 30, 2021)</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923511660680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,556<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">$ 2,902<span></span>
</td>
<td class="nump">$ 1,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
<td class="nump">972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 954<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">$ 1,711<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923591347912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 13.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="nump">474,506<span></span>
</td>
<td class="nump">273,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember', window );">APC Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Purchase price adjustment from Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period (in shares)</a></td>
<td class="nump">24,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 23.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="nump">150,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 24.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Grant date fair value of restricted stock to be recognized straight-line</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued During Period Value Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923512578664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">740,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">24,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(120,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(9,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">740,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">529,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">23.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">13.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 8.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">3 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">2 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 36,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 27,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500373816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details) - Board members<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 12.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923504677528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Warrant (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesWarrantsRollForward', window );"><strong>Shares, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,878,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(474,506)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Warrants expired/forfeited (in shares)</a></td>
<td class="num">(17,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">1,385,817<span></span>
</td>
<td class="nump">1,878,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageExercisePriceWarrantsRollForward', window );"><strong>Weighted Average Exercise Price, Warrants [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">10.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod', window );">Warrants expired/forfeited (in dollars per share)</a></td>
<td class="nump">9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term Years [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Warrants outstanding</a></td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">$ 14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Warrants expired/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageExercisePriceWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedAverageExercisePriceWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923511853432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">710,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">710,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">675,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">675,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">1,385,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">1,385,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923590721560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2021</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>location</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_SunClinicalLaboratoriesMember', window );">Sun Clinical Laboratories | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfLocations', window );">Number of locations | location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays', window );">Business combination, percentage paid In cash within ten business days</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones', window );">Business combination, percentage paid out in cash upon achievement of financial milestones</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Percentage Paid In Cash Within Ten Business Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Percentage Paid Out in Cash Upon Achievement of Financial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfLocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Locations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfLocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_SunClinicalLaboratoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_SunClinicalLaboratoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139923500602552">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash Equivalents, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash Equivalents, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &>!!E,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !G@093PU_3G>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G>R6%@G;7!1/"H(%Q5M(IFUPLPG)R&[?WFQLMX@^@,?,_/GF
M&YA.!Z%]Q.?H T:RF&XFUP])Z+!E1Z(@ )(^HE.ISHDA-_<^.D7Y&0\0E/Y0
M!X26\PTX)&44*9B!55B(3'9&"QU1D8]GO-$+/GS&OL",!NS1X4 )FKH!)N>)
MX33U'5P!,XPPNO1=0+,02_5/;.D .R>G9)?4.([UN"JYO$,#;T^/+V7=R@Z)
MU* Q_TI6T"G@EETFOZ[N[G</3+:\;2I^6_'-KN6BX6*]?I]=?_A=A9TW=F__
ML?%%4';PZR[D%U!+ P04    " !G@093F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M &>!!E.#$!=Q204  )D5   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9A=<]HX%(:ON[]"P^Q%.Q.P+0.!#F&&D*3-;M/2D-V=[LY>"%N )[+ERC(D
M_WZ/;+"3C#CV[ WXZ[Q^?"2]1])D+]5CMN5<DZ=8)-E%9ZMU^M%QLF#+8Y;U
M9,H3N+.6*F8:3M7&R5+%65@$Q<*AKCMT8A8EG>FDN+90TXG,M8@2OE DR^.8
MJ>=++N3^HN-UCA?NH\U6FPO.=)*R#5]R_4>Z4'#F5"IA%/,DBV1"%%]?=&;>
MQ[E/34#QQ)\1WV<OCHGYE)64C^;D-KSHN(:("QYH(\'@;\?G7 BC!!P_#Z*=
MZITF\.7Q4?VF^'CXF!7+^%R*OZ)0;R\ZHPX)^9KE0M_+_6=^^*"!T0NDR(I?
MLB^?'= ."?),R_@0# 1QE)3_[.F0B!<!?>]$ #T$T#<!7O]$@'\(\(L/+<F*
MS[IBFDTG2NZ),D^#FCDH<E-$P]=$B6G&I59P-X(X/;V200ZMH@E+0G*=Z$@_
MD]ND[!XFS5V2;9GBV<31\#83XP0'Y<M2F9Y0'I([F>AM!JHA#U_'.T!9H=(C
MZB5%!7_+DQ[QW3-"7>I9>.9-X:)'Z,@6_@K'KS+G%WK^";VYW'%%_IFM,JV@
M,_Z+2/8KR7XAV6]JC(?GE-LRCH=[;O<[0C&H* ;M*+[G3&FNQ#.YYZE4VD:$
M2VF5<X1H6!$-VQ$MN(JDZ:<A@=YN31&N=.Q#O[Q[U] -SBNV\Y9MIAB86S%H
M3J<+UUHSD6'Y&E5,(U3G,(YO(L')USQ><65CP35<U^OZY_Z8(CSCBF?<AN>>
M;R(S6"!97UEL;3U<9Y9*(22YXV$4,$$^2Q%&R28[ \<*>@BGY]9NZ+8A!3VI
MH T+#SPC2PV=C4A%YC)/M'J&_]"*WZ!^=8U!OK!LKPWD WLBMR%TO6@-Z2@Z
MWNG&;I <#[K]_CGU^V.,D-:$M WA+ RA=$#[' [(%WB.?$OLN<,EO>%P1)8]
M\HFI=<1%2&8[GJ#NXM5.[OG_'_=A+ZVXN"0%B[H14BH,L*X+'N[L;P'GY@SZ
MXX/<)U8X7&XFMBQ>*8:QU=7"PSW^+5LU6!9*[J(DL#<VKCF?86AUV?!PMW^+
MMI"9!M_X.TI/CV!<<>R-7*QJ>'79\'"O+YIP!C/OTRBXP) .,9"Z5GBXT7^1
MQDL76YE@Q:)!A(YHUZ6C$4945PL/M_F'2$/ADFOBT?>K#V3)@UQ!MJQ8N-)<
MQC'8XE++X/&,_.KVH*J1E"FR8R+G)(4)7#&]Q6:G=>V@N+O#!,"4([)\CE=2
MV&@;!&9WUY\QDKI T%8%8IXK968FY72D0(.QF5OG\@V*/]ZN %Z3U86!MBH,
MMPG,*\L5G)G(L2.JE0Q7;""K:P!M50/,G GJ/%C81BIKEVO0F04!K%%AYL##
M4@RCJPL ;54 EC$3@ESF&=S.[.V(ZS3-,&EM^[25[5_'7&U,U_H$"GH+9A:G
M++$G#A=L1*MMG[:R_>660[(P(%RF$:CV>HI;]7$\OG*C9;&N)M]R#44I*9SC
M?90<EML?K.O;\BV#XBUF?V8W'0S\ONN.!Q-G9R.LBP#%_7L&2YBP6,;<"+:Q
M)@L7:$Q6[?X4]^QJ07439:8R_>#@US=PT=[?<;&FM7YM[G[#U/T-U6$E>I*K
M0>X[MJSR:Z/WVQD]@"F NDU"_D1^Y];>WB#E0FET1WZ_C\TJ_-KH?=R6C[7G
M92-BR_8&N6[7HUW?VI3.B\TO8T;%GF!& K-4*_?!JJO5ON.LV&USZL?+3<L[
M9KPL(X*O(=3MG<-04^4^8'FB95ILI:VDUC(N#K><A5R9!^#^6DI]/#$OJ'9C
MI_\!4$L#!!0    ( &>!!E,'WQ@520H  .,K   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULM9I;;]LX%L>_"N$)9EO C<6+;FT2(+?.=-!+T'2Z#XM]
M8"0Z%BJ+'HI.FG[Z)27%M,6+W=W9AS:6=$C]>4B>'P^IDT<NOK4+QB3XOJR;
M]G2RD'+U>C9KBP5;TO:8KUBCGLRY6%*I+L7]K%T)1LNNT+*>H2A*9DM:-9.S
MD^[>C3@[X6M95PV[$:!=+Y=4/%VPFC^>3N#D^<;GZGXA]8W9V<F*WK-;)O]<
MW0AU-=O44E9+UK05;X!@\]/).7Q]%>>Z0&?QM6*/[=9OH)MRQ_DW??&N/)U$
M6A&K62%U%53]>6"7K*YU34K'7T.ED\T[=<'MW\^UO^T:KQIS1UMVR>M_5J5<
MG$ZR"2C9G*YK^9D__LZ&!L6ZOH+7;?<_>!QLHPDHUJWDRZ&P4K"LFOXO_3XX
MXI ":"B 1@4@\13 0P%\: $R%""=9_JF='ZXHI*>G0C^"(2V5K7I'YTSN]*J
M^56C^_U6"O6T4N7DV>6GC[>?WK^[.O]R?04NSM^??[R\!K>_7U]_N06OP)^W
M5^#%T4MP!*H&?%GP=4N;LCV92?5F77Y6#&^Y[-^"/&_Y8]T< QQ- 8H0=!2_
M"A>_8H4J#KOBT6[QF6KOIM%HTVC4U8=]C5X+P1H):-LRV08JQ)L*<5<A\55(
MVP50K@&%_L'^6E</M%9O<+JJKRKIJM+3\N$,IBG*TI/9P[9+'&8Y)FFT,=M1
M2C9*25#IN^:!M7*IM>D^57/]&Y/TKF:@9<5:5+)B3M%]K?&VFBQ%43(2;9LE
M:9+';LWQ1G,<U/R9%4PY5(ELIZ!ATJ4OMO4E,8E&\FRK-(HSM[IDHR[Y*77@
MUU\R!.$;%15K*ED)5E3XO)K8[LK29#P2;"N2H\0S$-*-[#0H^Y-<,*$T;L2[
M]*7VF^,$C>0YC%">NM5E&W594-V-8"M:E8!]5X!K6=M-+MY)+@*3MU>=V6,!
MP2P;R798):E/=[[1G0=U?^&2U@=(S&V?J9$8C\>K;89Q%J<>D3 R03\*!L"/
MO EIW*UU"R4PV/CWJI.F8"74HD3(IVG79SH6KG2X\<[<H=(=7T0I'G>7PPSE
M6>Z9!="@ *(] 5'2YK[2$;!WA5\HLA1D$4+CV>HR2_+,$P.A00P,,^8WSLO'
MJJZ=TK#M')Q',1YKVVNW*\Y0!8:Q\I[3IMT73:!-AS@G8XFV$<E\O6P( L,(
ML?3]3)2&-C;&$]5A0B#Q];E!"PRSQ=!:P[J/?^JBH_2F!7J*R2>P9'+!2Z=^
M&R XQ>DXCCO,"$8Y\C3"@ :&23-:<JR$Z@+)ZB>P8'6Y:8Y3N(V6+!\O.1Q&
M.(U2G^\-@6 809^5:%$5>FSH59U3G\T0:V#8)G'D&\Z&,C",F4\JPE)9-?>@
M9BKI 4)G-Z_X_-6Z90'J0)LG,,F1%6H=9HHZQ*T:&>J@Z( EAU_>4'PWP%K#
MU&$%LQQZ^AL9>J$PO7IT-V$R#D(=R$(XR\:=[[)+%;-RC]:M_"4,K5ZK5^#%
MGN+_@O]V-LM!KIP0;#7+80=3DB6>9AG$(7Q07E97]*ZJ'6%AMUY#)Q2FTWE1
M\+4./ROZU.4Z>F5"BT*LF5EB.CWB(!9.<VM(VF8X@<1#562HA<+4>EN5ZZ*B
MXDF+W6F!4ZS-(#74+*T.JX1X@CPRI$)A4GU@956H,>GMND&CS9@XQ]%X#>4R
MBS#VQ$UD4(3VH:C@2P8D_<["KK29@M!6B!E4NC(?Y N3!CPH#)ZKZJ$J65,&
M!3JP@L=D=!@1WSH4&?:@,'O>5@UM"C:09U]_.U "K7CB,(H\(Q(;VN ]M!DQ
M<H]2;&,%91B.-V5L*PQ]^1@V[,%A]CP'OA47W6XHGX.:-_>O)!-+4+([9SZ"
M'1E1-!ZC#B,899F'0-@0"!]"H&)?P!Z4VL" *(NLE-QE!TGN6X+BK>VY,%BV
M\MW#V((-6W"8+5=LSE3-I0XJF\J?G%ZP*8$@(N, [3"#41[[>LS !.^#B6?>
M]KM6:L@5NZ/0V0:;'HCDXQ;81AA"CWY#&!PF3& ^_U0+;+2H1 V.,V6769PE
MGNB)#8%PF$#O=Z:U3WBW0"F?1]:\ZSG=\H*WGCUE&T4P0ZD=#AQ@PQ'R]HZ!
M%@Y#JU_;FZ"U+R(X=M]@;JD-Y5>[0@V^\"$[=,T! 6%0:L,)P3R/QOL6+KLX
MQ<2S*":&8R3,L5YP6.7%GCH\"W[BH!E)<VO-Z+)+$<:>G7-BN$?V<(\OE]6P
M-= =G_!&SW"F1KM:H+WXR"4#$+YT:@_6K(]+7[<K6K#3R4JPEHD'-CD#KJ.G
MOZ&BW=8;AI+P,=0']N,';=3-80LG5*E!'0EO$VK4*2\*7M<Z8E2-FHZL[?:/
MSM4M%4YN%D]MI=**IM61YY+6U9R+IJ)30,&-X'/6ZD-=->:>U_277*BX1'T1
ME=B;BI# ++;.AAQV4.7-GM43V3K2(D$_WDI>?%OPNF2B[3;%TC<'>-2 DX3!
MJ0>I"LFM?LL4'$7'403U=B%XH/6: 84ET"ZH8&\ C*)IU/_K;ZE1O98++JH?
MK)P"0J:()-,T3[K!3I"ZS*<0I\_&?"U;J1ZICINJO+2HU_JGJG::9?$TQ:@K
M!]$4(SR%"0%2*!2N57[85Z!ZL.O3/]8-^_47F$1OGL]<NX)7K&#+.R:&1\-Y
MZA2HDBO6G;_7SH4+<6QNCL.?R\:S;",&^22,_/.RK&0_%O5IT"LUA@NZJE0\
M=,IT;'-&*@1;X]"V0PF,? PDANTDS/;/3%)UJP2,JOG4W+L/4FT"YW%L;1TY
MS)(\37T:#:=)F-,]3=JM&?./8:Y,]9A6D=@IVI%)1A GEFK;3F7MF2\G)H;:
M)$QM3U1S:G4<FB%D(<VVRCR!*#:HC@]!=7M@.!H.KFVVDHC$V5BPPTZY-O>-
MVM@P.#YDWW-G-;T<@:D_ROO)=MF)IW,ST647V$R,#5WC<(9ZRX1>1)PKICTO
MI#M0!)@0&\K&X83ROT).;(@6AY-*([FU)0_^M=-$R[4ADUUE6Y]BA&$X>/7B
M9[QJXGV<_!^\:N)S'([/AWBUKR$)>35DLJM,1^7=.R;@Q>& YUZQ7^PI]67!
MU&IMN:+-T^"_5J^I6UY797?*>4?K;A.@^V!,'\?I-08#*GD;3A.ZF;X5#/1R
MHI*C6KZ^NVZ/@7[9095O'5:H-U&I(-Z .P;6K2K$F_I)F0#U5-8,\+NZNN^6
MFMVKY;X&:2G]&S07CN!4)3#'2;_"65:*%D,R?91%\!B/[O^OBZ4^+LIQ #U<
MN%IX@\=%52Q H89E);EH0<E5=BK!@CXP?6#-UZ+5/NQJ5)D1$WK?K;-^?L]*
M5/J;3>72ALVK_L! /3J"47H,':Z \.]WQ3&X90ST"5N\.9K^2D75';B\>TY#
MKI]/KU]H![SL/#!?BV[WH-3KI_K8-==G6U\X+IFX[[X4U1Y=-[+_3&]S=_,U
MZD7WT>;X?IR]OE03TWZBYI9ZTGW .C.OZ#]__4#%?:5&9,WFZG71<:J"I.B_
M*.TO)%]UWUC><2GYLONY8%3%,6V@GL^Y\LQPH5^P^:[W[#]02P,$%     @
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M;\H"&[^DP&K=P.W?_M<IL."T CMFMLVAE@K<KA6O4&#AJ05VW'";1*T_N%V
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M;[W ?^-1GQ)$S]7IPWV'G& _GT%[O< VGVF]\I:P.&IO*<7:@_4FTZ:H'KJ
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MO% R:1R+C5.7I+GKSL@J*8? NCSB<D%C*1S::QFS/=",$39B09Y_PXSG>I*
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M,#0K][*O6>UTML8\(J;BSDS[L^GY+NT9A:].IT_B"Q]WYI56QB<FBI0D3M3
M?&40GL\4,R.LJCCNV*F;3'8*U=Y/YMZ1QRRQ,[@M^#)P&MJW0'[5\*Q=GG/.
M%XO,3^*&?CV7VO.%XW?C4>7_^OCQ 'B\&44.6CT]@.\GI%3SJT_C[?YA.NT?
M>GW\+$4\*>;V,4"^&6O5LS&BM/W%G]C^8G<^.G[%0)JY'*R4:U+=J!@ZZNZ
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MM.JV<_D(#/Z("":NXSSVM%>TI;!PU!W<-A #^!AOBQYF?V)6AIQJ%/% WRY
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MTK<D6RO4PH/5-U^+U>IIQ/89]S,LOU=]G]2 ?\FA:$K8^$XNO$].I[3FTY,
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M7?UL')@#ZY$&MX37&OG6<4[11%&Y,Z@YU]," )'K8@MG_B3.G%S75JYFN2X
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M$_00A/&"XN#R[<7)Y=M3\/;JW<GY.T_0OZR*4R5SU"Q@5X2-)U!-<UD0)/5
M;Z[)=K?'N;P#J:F!<A.2HD1Z*_,[&^;UL*5<+LT\EP!QE"8H,&?8#EFC]Z W
M6(?PH!\,MN"1%>D+ *1@4Y <0.K[/PBSSJ"KA5YU4 $OZLI\P\-"PD (M-,,
MC*>$2Z^M)NU^4W+.F2L.UIJ/>\:^83$:FX*7J5K(=$;.2\L1!LARVI39=,Z
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MNZWX/>/1\G7OS'GKU+;C:I\4A%LW\Q 3-W8WLE!I0CLS[2[J@'QB&/GG"MO
MDH$%@PA![F&O+UWA!5V5H9#<]!W'VY$4CFS#=D=,L/8VI%PC 25R+?Y%MX,>
MZ$%P$+7.)@3]#GH#7Z!B[UK+P_Y2QW08O,)/VH4FO/WLWC[JC7=U+WE##V-F
M[G(ONS$9KNXBU-(VVP"E;]B]9O@\OJ-#L[7,*5KYFE734>W>:WE 4=@AMFAM
M;MGL(16-']"Y35,/<]9_B, :G[PEA(^3MU8KESU6UHQDI%0QB^3Z/?&K60-[
MY58[B4[8LYJ]I]U/VEO3LY*P\&9^?=[%A/D6#Y,P\%*BP0=P'[FG)?%3&;\O
M[N]JW=&@\NYMVB@'V@TUS$J^9ZN+A()D@?TN#Y)I23?@*-IJ;Y-VP[ A7G?:
MIJJ>FE PQX8\5";_K8IZ!3.E,T$^O;>M%E@&^K;VTP@#G7,DNTL.]=L.VN"X
MK=/3:;S0R.Z(M_;I:KL]TPRP=TVWFD.MEE"#%S=3-GW'_1T>,&350BNN386D
MTW@<=UFLM>4<,^;PG+J.X'G=I^.; %PL-M*P_20%OK:]CU(#9)%_L#O$BC1*
M349R]^Y=L*9[42($"FG#F[C;G!+[K;1K&V&!_T,K-;Q[$%"YVK(AH9O4SP;J
M]GCV9>0/%J3M7?+]]G5OU_7QD]95_J7*Y_P'"Q08<'1[J[]YVOQ-Q*G]4X#-
M</L'%9<RGVML"5(UPU2_-QH<V*9N_:,T*_[#@*DI2[/DKPM%%TEI -[/C"GK
M'[1 \Y<B+_X/4$L#!!0    ( &>!!E,G/6UP/P0  +T)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;+U6VVX;-Q#]%4)-BQ9P=;=CQ+( 67'A%)$C
M.&WS4/2!VIW5$N:2&Y)K67_?,]R+%#OV6PL8UI*<.3-S>,CA;&?=O<^)@G@L
MM/&7O3R$\MU@X).<"NG[MB2#E<RZ0@8,W7;@2T<RC4Z%'HR'P[-!(97IS6=Q
M;NWF,UL%K0RMG?!544BWOR)M=Y>]4:^=N%/;//#$8#XKY98^4_BS7#N,!AU*
MJ@HR7EDC'&67O<7HW=64[:/!7XIV_NA;<"4;:^]Y\"&][ TY(=*4!$:0^'F@
M)6G-0$CC:X/9ZT*RX_%WB_Y;K!VU;*2GI=5?5!KRR]YY3Z24R4J'.[N[H::>
M4\9+K/;QO]C5MJ?3GD@J'VS1.".#0IGZ5SXV/!PYG ]?<!@W#N.8=QTH9OE>
M!CF?.;L3CJV!QA^QU.B-Y)3A3?D<'%85_,+\HY5&W%%"ZD%N- EI4O%T[J<?
MSL>CT06FM R4BK5T09&?#0(28)A!T@2[JH.-7PAV)E;6A-R+:Y-2^JW_ (EW
MV8_;[*_&KP+^7IF^F Q/Q'@X'KV"-^G8F$2\R0MXAZ*]^'NQ\<%!-?^\ CSM
M@*<1>/K_T/R?!:OMW,%N+1.5J>1,?##B4Q+LAAR3#<IO5ZO&$.Y2E,X6RGOK
M]L+80"+#^. =;)!(<RO>#/NGT+'6\4AZ.#KR.$'"9B+D)+Q$T.9[:8M2FGU,
M]>V%%\H$@G7 AUA]N>TCIV9")HFKD+T,#(B"&.+T1U$B6VE,540.E!>EW,>R
M"M:AWB.,L]4VC^%PQ"NGPEZD#<![5%=PP:,HL$G_&3LMBZYAL6Q87-RLEL\9
M6ZR7@F+**==BO\/:3H6\]OZ94V+\\? B3MQB/8Y'%[\(W,;16YE$E5(+6=C*
M1!+?3/O#CN ()Y]7MH"GYJS&??$'XB2@@Z5> :ICN>;11&ZZ#)C$2?_M,;<U
MQ,%BAVW]ILS*\\XGTN<")THE <2WC&&9\:\?$UWA3A +[REXS&$K=X 06S+D
MHFE45-0(.2:95>*D\3+>[[[A;OWK8G73!PZOXWZ@[GXXB<Y1B4?,/:7,$;<R
M>%?!!Z@&J??%)_.B*#=6NE0442B>V8%"; ;1@QYF&K34!#6.$+TG_*41[2B*
MT$_$5>&2='7,Z^5'2#8E+38M 'OP&DOND(W<*,T;#5HA=;9V](!.UE@K=]A>
MK*.Y!I$K-!GH[VL%)')Z?R(R923H 3OM(F^TU+S&!PG=O\N!2P)?5C^021!.
M^?MZ]T"%2A$ %P"E.*L9A)A)I2M';7HV22KG3XYY;>GQ]6:1*WS+/!\0'^,C
M?05-QY&@QQ(='GPF$)P*H-'[V*C35KS84A7 <@+IX%&35H<KAC'[W[O?!T<M
MM2"WC0\'CX."8U9WUVZV>YLLZI9\,*\?-BOIMJPH31E<AS@\/= 4'POU(-@R
M-NB-#6CW\3/'^XH<&V ]L\BR&7" [L4V_Q=02P,$%     @ 9X$&4U@4Q8/7
M @  1 8  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK57;;MLP#/T5
MPBN&#3#J6YS;D@!)NV$=4"!HN^UAV(-BTXE06?(DN6G_?I2<I-FP!GW8BRU1
M/(>'E$E/MDK?FPVBA<=:2#,--M8VXR@RQ09K9LY5@Y).*J5K9FFKUY%I-++2
M@VH1I7'<CVK&93";>-M2SR:JM8)+7&HP;5TS_;1 H;;3( GVAAN^WEAGB&:3
MAJWQ%NW79JEI%QU82EZC-%Q)T%A-@WDR7O2<OW?XQG%KCM;@,EDI=>\V5^4T
MB)T@%%A8Q\#H]8 7*(0C(AF_=IS!(:0#'J_W[)]\[I3+BAF\4.([+^UF&@P#
M*+%BK; W:OL9=_GDCJ]0PO@G;#O?C)R+UEA5[\"DH.:R>[/'71V. ,/X!4"Z
M Z1>=Q?(J[QDELTF6FU!.V]B<PN?JD>3."[=I=Q:3:><<'8V+PK52FM@R9[8
M2B P60(9=8LE?'RDNS=H)I&E4 X0%3O:14>;OD#;AVLE[<; 1UEB^2<^(HD'
MG>E>YR(]2?BEE>>0Q2&D<9J<X,L.>6>>+WN!;Y>N><Z7"0,_YBMC-7TI/T^$
MZ!U"]'R(WO\N[4E:UZ5CT[ "IP&UH4']@,'K8L'=!N%"U0V33V_?#--D\('R
MWR.;(R3;(7&/+!2UH;%D4A58HJF4H'[F<@WON"2+:@T!S?LQT$VAOZE+++!>
MH88L"6'^=Y@S2)(P&:6T&(5YWH,+UG#+?*ON?=*P'\>0A7DO@=MV12+\Y2@-
M5\OYD5>6]R$)^_T4EEI5:-S$8 (J).4CLB9A-AC"98M@%4T2P5PB#=.6DT,R
M'$(>4UTZ<A"<K;C@_BPE::,>)&DX(J]]/0LJ(96ET]H/1Z21GH,8[I2EL*^K
MZ!GD63CP^6?],.EE\*]/+CKJ[!KUVL\O=QT4H&OR@_4P(N?=9'AV[^;K-=-K
M+@T(K @:GP_R '0WL[J-58V?$RME:>KXY8;&/&KG0.>54G:_<0$./X[9;U!+
M P04    " !G@093N05P@@T#  #0!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6RE5=MNVS@0_96!NB@<0(@NE"S'M0TX;HMVL0&,WO9AT0=:&EML
M)5(EZ3KY^QU2LI+NID&!OHA#<L[A&<YPM#@I_=74B!9NVT::95!;V\VCR)0U
MMMQ<J@XE[>R5;KFEJ3Y$IM/(*P]JFRB-XVG4<B&#U<*O;?5JH8ZV$1*W&LRQ
M;;F^N\9&G99!$IP7WHE#;=U"M%IT_(#OT7[LMIIFT<A2B1:E$4J"QOTR6"?S
MZ\SY>X=/ D_F@0TNDIU27]WD;;4,8B<(&RRM8^ T?,<--HTC(AG?!LY@/-(!
M']IG]M<^=HIEQPUN5/.WJ&R]#&8!5+CGQ\:^4Z<W.,23.[Y2-<9_X33XQ@&4
M1V-5.X!)02MD/_+;X1Y^!9 .@-3K[@_R*E]RRU<+K4Z@G3>Q.<.'ZM$D3DB7
ME/=6TZX@G%W=8"5*WL!?@N]$(ZQ LX@L$;OMJ!Q(KGN2]"<D4[A1TM8&7LD*
MJQ_Q$0D:5:5G5=?IDX1_'N4EL#B$-$Z3)_C8&"7S?.PG?.?H[H#*&#[*CHL*
M-@T7K0$N1W-=?:$;IY*S\.J6RMY@"&M7-@XI)-S3_+/>&:NII#X_H2X;U65>
M7?9[.7B2Q#W>N>EXB<N 7J=!_1V#QY@_U @;U79<WCU_-DN3XH6!=G!K[MV@
M5/3PC,4*U!XL@?:JH1<LY $F=!6V5D=#5V<NYD#90I^MT;CY/V$(.SP(*1T!
M,7:HA:K@#\CCD+'8&;.P2'.O34E*@7%N9V4EUTB2#*UJ;+B39164?=J$+(]:
M8S6'C1LI>P-[XCC9%233/,R+!+:TJH=- Y,D3*_8!:2,P0=EZ91'3DOR(LRR
MJ:>8Q1EL^5WKQ;E"^CUUDR1F(8O3"YA<%6&2D/$?@5D>)BRF?2>B(*.7Z:MW
MDF2S,&,.G>19F,_(NJ]? K/B E@Z?3P7**L?LW!%2@HRBCA,"P:/577TH,NT
MJ ^^E[I".4K;-YQQ=6S7Z[Y+W;OWO?Z&:ZH% PWN"1I?%GD NN^?_<2JSO>L
MG;+4 ;U9TR\'M7.@_;U2]CQQ!XP_L=6_4$L#!!0    ( &>!!E/!/H%]J!
M !,Y   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;.U;;6_;R!'^*PO7
M5]@ (TN493MW20#9<:XYV!?#3N[0%OVP(E?2-A17Y9)^Z:_O,[/+%4F]Q @N
MZ%U1X'"1*.[L[,PS[^M7#Z;X;.=*E>)QD>7V]=Z\+)??'QW99*X6TO;,4N7X
M96J*A2SQM9@=V66A9,J+%ME1W.^?'"VDSO?>O.)G-\6;5Z8J,YVKFT+8:K&0
MQ=.YRLS#Z[W!7OW@5L_F)3TX>O-J*6?J3I6?EC<%OAT%*JE>J-QJDXM"35_O
MC0??GQ_3^_S"+UH]V,9G02>9&/.9OKQ/7^_UB2&5J:0D"A+_W*L+E65$"&S\
MR]/<"UO2PN;GFOH[/CO.,I%679CL5YV6\]=[9WLB55-99>6M>?B+\N<9$;W$
M9);_+Q[<N\>G>R*I;&D6?C$X6.C<_2L?O1P:"\[Z6Q;$?D',?+N-F,NWLI1O
M7A7F013T-JC1!SXJKP9S.B>EW)4%?M585[ZY*%2J2_%.)CK3Y5,DSF7^65P9
M"8'EJ;C"ZU:8J7#OO3HJL2>M/$H\_7-'/]Y"_T1<F[R<6W&9IRIMKS\"KX'A
MN&;X/-Y)\*<J[XEA/Q)Q/Q[LH#<, A@RO>$6>F_5I!1OM4TR8ZM"B;^/)[8L
M )9_["!^'(@?,_'C;R;=WY*^Z+PN/LZ5N#"+I<R?_ORGLWAP^H,%HB&/B<QD
MGBB1&%B?+9E&B9>G)H,5ZWPF#G2.)Z:RV,<>?B^@%A74(MZJ1"TFJA## 3_I
MBX^J6#C&QF)?\&[Q#_@T.#V+!O%(W*I[D]UC!;\S..M'_7Y?G+A_;I7,Q*4M
M9:G<[Z?1\<LS_']TUL<!<BBL<D;N?CT-&WPT)9;RF09G>/]T).+C473:'XDK
M9>WWXJ(J"I678FD*)H"#\ML'<7]T* X&_>CL[.6A?_E3+A?TWK]5*J8ZAXA(
M%(DA"1T<1R<GM 3_TM(KD\]>E'1JIH>3GL6\[[Z((:=X,&#Q*UMJ^!8B*'4A
M[F56*6+"5(7(VB0>)&F'OD.MJ:@L;7ZE[E4F8J'S904NE@6H%3I[@L/,F&QI
MP"!47,A)IN YBL_P]'@M4;;''*QT*@%_UG)5DB5@V4*7<, K_6\$"R(#__BD
M9&&%RE.BU4# &E;&"U-!Y(R4 _689!4O(1I6/XJ%<QB*'$8;5X<DQOX)?8Y%
M?#:B#T,1#_C#L8CI:1]@(NR#&H+4%.*"Y$^BT^-3#X;]@ 1O#N-9H10=4[S/
MQ9U:EH[QN#]X&35/#8Y #3SI'$*5PJJDHJ^)(R,#F0-:1#**^S]T]XCX^>"'
MFL=Z];2V2>:[PMD+MWF;3FVZGLHAHD4Y%Q^+"E;JC/]@VOO<DSUQ5^5X[)\>
M1F!::"@RD4N0P#X DTR!)$W>CB(C#D#,U]K,2/Z%C?A%_PU?0,7:"N(!(C)5
M0B ,CEH&.!3>MP0G\E6-=:FX0;Q5!4F,6(K$3S?72"9 \6*.L.H?_MP;]R)Q
M_>G=C[ V,LCFXUOS! 7R,<FIR5RF,A+O])1D,->%H\R;7= 9?Y9DTWX)G\2?
MRB%_3?_+PMQK0IV$>=^K%X1H&!)Y)C;TKJI,"QY@:7_0[_?ZB--9AHTC\3#7
MR1RB)X@K)T<264-BMIH$>GA:+8GJ?CQ:4=G"J\RL:3+,?B(C]\=\O.PW*3B+
MLV)B"D0P<AXD!L=]ES#>401QP!#HD:14_)=7$&-!#EC]BSZ"2Z4)JQ&]LLDW
MF&7),CB0A_P[+R9T75:%2=CM)D_P($MC"9@U[A*PJ.S2.#<2?L:A/O7N>B*%
MMR(W(Y=+*(=> 49N5<5 O(-0%8+ ^_,/M_V!N &BQ8$W('Y8FPV83O\)XR"W
MBWU)>]A4%;"" N?3A1,%;$9-I\@?([',*M*?RWR)FXDJ'VBSN-?O?\>0&](G
M1EG#2U/B*2"Q D_@E9% :LMI)/^T26X9/'I!G)-9FDB OX/)(:C0*I9BEYN:
ME4%@)?X6K/3(/R(CR'U"S:Z'58;4B34QW8BHEA.-V L!]5:G&E4 3/OZ.@K>
M<,P^J.-H?P3/,B>?A;?NR.N2M8PW^MLOO+L"P+(J;(4W"<ELIF "D0>G(%2#
M&9S(,G=BYF@JY7@TDTS/V+-TX^(NLP(_$(29*28?9!?$,N,MW Y7SDO5,89.
M$ P2F)191AN3(*6UJK21=S%@.6+2J+Y$IA&]I;-!6H%2(G&^T9V0<$Z$R9T#
M0QQY=+%2C8;#.@AT21"'SK^#5D&UCG6G(&L%(FIO.+YY,;[^"R=B/?$A=P%\
M<.("^*YXBG,M7,RG7>BLG+_LC*YCOZ(K[:\,LAUR7PRVW:A*(GMF7.6DR%:(
M#G5$;G,R:X&5E$1*F/"FW?#JU!)BK6?0@Q\\13#<I/<U ;<;LC<'8-J^&X2C
M5? =6VL2[9'(J2#AK"VR?QJ  "> -Y,%+&'&\,_3(T@M2*PA'V\A#7^>IX$O
M>N]7X"?BR/G1%$@HS8NWAK2R.J!Z$'\UQ6=QCNW(^G]566:A\V)FMC&_.;'8
M=J:K.H,JS6;?PGAOHAV_()@FJB@E:':1'XF4+6*5H@ZXNJ(T=>(<GMNEY5=J
M:L&G-#UM # ^(^B53R[9V&96=;[AHO7SDJ0Z_K8*O&!1&U*HXZ](H5Y\(8?R
M%M(P'$J4N@LWI%W;S_6 UQ!Y489QD;59PS ?+A-54(-ZA&T2/9U3\:125.AK
M882XK1<T_7$DNN1\J283.'/D21R3:+7.[P$IKMT<;+WF6''4)^,CR:6FBBA'
M9+.-R !D(.QGE(JA+"9<(E@B#Z.*\5.(<-M XOP891V.9D*I7"M:?BF>(_NB
MLX7L:V?^NA6K7D$ YQ\SF?59K'4Y+75(?X.L=5J8!?+$>/0='3KNC?XK"2L8
MZ=<\#+X!#P ,"[G5/'"X#%A@#8+:EIC/W99![V3T7:_9)D,DKF7-K96E?&I
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MA*3Y(W0$!- +^'UJ3%E_H0W"WT&^^0]02P,$%     @ 9X$&4[&?@X 4!0
M=0P  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULK5?9;N,V%/T5PBVZ
M ((7V5EFF@1PDAFT!3(()ET>BC[0TI5%A"(5DHKC^?J>2RUQ%@?MH"^.='6W
M<^Y"YF1CW:TOB8)XJ+3QIZ,RA/K]9.*SDBKIQ[8F@R^%=94,>'7KB:\=R3P:
M57J23J>'DTHJ,SH[B;)K=W9BFZ"5H6LG?%-5TFW/2=O-Z6@VZ@6?U;H,+)B<
MG=1R33<4?J^O'=XF@Y=<562\LD8X*DY'R]G[\P7K1X4_%&W\SK-@)"MK;_GE
ME_QT-.6$2%,6V(/$GWNZ(*W9$=*XZWR.AI!LN/O<>_\8L0/+2GJZL/I/E8?R
M='0\$CD5LM'AL]W\3!V> _:76>WCK]BTNO.CD<@:'VS5&2.#2IGVKWSH>-@Q
M.)[N,4@[@S3FW0:*65[*(,].G-T(Q]KPQ@\1:K1&<LIP46Z"PU<%NW!V15^^
M2 .AD"87-\%FMZ75.3G_O?APUZBP/9D$Q&'M2=;Y/&]]IGM\'HHK:T+IQ0>3
M4_[4?H+\AB33/LGS]$V'OS9F+.;31*33=/:&O_D >A[]S??X>PVF^&0#B;^6
M*Q\<6N7O-\(LAC"+&&;QOW+[M3Z_^^8XG1W]U,-Y5%QZ$4K"!.54U7$4"I*A
M<21L$;\LKR^$+Z4C+W[P1"T3Z8]">6%L$-YJTEOT92B5B089RNO0JK"';1)E
MU(9M12*WU!K?-5*K8BND%S5AB@R9T.LR@A(?5D1&9%IZKPI%.>L::[H@(& M
ME F$] (>HGMH5 ,^ZT0 ,NNP5#K78];J"/$]-OS$E)@(;+:5IB2FH$*/M'9V
MQ7( DB&BZDPW2FNDF=F*=LPY#>!%=]+0G='C)654K<B)^2Q*I^.W*K5\Z241
ML\4\F1ZD@DU6,KOM,RGE?8LBDJ:\;T!8L"(C%[""!:]I!/YT==5:="'%IK1B
M PY??NF0!JQ:SB/3UC/E76^DT]D1>LFMR26,%[)MF\06)P8"^V95J4@=ZHLV
M 4>UIH"L\!LX 'MRTGBH!:G99EFCKO8*.LC8.J3!4@?6L*$YA'+L4#AL-('"
MQJ;ESAKL$*6"S#.KD?*-=(@1/.?(G8.&T)*S:$QTWT.I(A0AUPY%1"^.Q369
MG '[)BO;'.J0M&_[R(SXXTSQSM_)/8E3@K-OZ-CD.9SHB,'DZE[EB.VY@7.%
MM:-6#2/UT8F0[!3DB!PXA"Q"!X.*@N)19LC[5\HT%K^U(XJY57GDH%!&FDR!
M?!\@8-P]"!SDK!'A=BW&3?"$7HB: ,O(4R+6'+M;*9&M/HFVX,_KK6)!/+!B
M<G@)%(W)@G7M_+/=!5I&FBUK:EI+C2ZR*ZW6,3.0&[N<-?TPD.@;.#7=T1[Y
M>D$#+PJ[,? QFR;'QP?)T3R-,6=I,D_GR>QPL0-YZ*UA;;P@X5^->@)6?-U6
M2&_1$*4"M5SS'ELWM&R]PZM \04]9+K)N6+.5OOJL6OTN)#?KG:<W=TB<T)]
M\7FL\>@;U*3[C,['A2FSC0D<IFY<;3WYL;AL' OB;E0/HFH/>N*#_OD*>UK:
MB'F^2&8'Q_N \69HESOWOL>]JC].Z(%<IN)>4FC=?MB1SC!$.XF%$L/]1FJ1
M^K96[+R6*M^=QD)\.WLW?H?;%@X?OCA"FR6'O>1IB?\#)U\3.-T?^+4KRF3G
M*AAW'5]XN9=1R?96.$B'._6RO4H^JK<7\BOIULKP3!8PG8Z/#D;MPNM?@JWC
MQ7)E ZZI\;'$_P7D6 '?"XN+1/?" 8;_-,[^ 5!+ P04    " !G@093&?U<
M:7 (   Q%   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RM6.]OVS@2
M_5<(7_?0!1S;<=+=8)L$<-PNNH>F%S1[MQ\6^X&6*(D;BM22E%7?7W]OAI)L
MMTGN]@=0-)9$#F?>O'DSTF7G_$.HE(KB4VULN)I4,3;?S><AJU0MP\PURN))
MX7PM(RY].0^-5S+G3;69+Q>+;^:UU'9R?<GW[OSUI6NCT5;=>1':NI9^=Z.,
MZZXFIY/AQD==5I%NS*\O&UFJ>Q7_U=QY7,U'*[FNE0W:6>%5<359G7YW<T[K
M><&_M>K"P6]!D6R<>Z"+'_*KR8(<4D9ED2Q(_-FJM3*&#,&-WWJ;D_%(VGCX
M>[#^/<>.6#8RJ+4S/^D\5E>3BXG(52%;$S^Z[IWJXWE%]C)G O\ONK3VU7(B
MLC9$5_>;X4&M;?HK/_4X'&RX6#RQ8=EO6++?Z2#V\HV,\OK2NTYX6@UK](-#
MY=UP3EM*RGWT>*JQ+UZO75WK")1C$-+F8NULU+94-M,J7,XCCJ"%\ZPW=Y/,
M+9\P]XVXA8$JB+<V5_GQ_CE<&_U;#O[=+)\U^(_6SL398BJ6B^7I,_;.QGC/
MV-[9'XE7O-$A,RZT7HF?5YL0/4CSRS.GGH^GGO.IYW\5RG_"G/BHRM;(Z/Q.
MW,H8E0_BO>S22I^>H1Z"*-U6>8M](E9*W*I<9Q*!-]Z57M:\O%+2Q(IOP[KR
MTIB=H*O,U8U1GWA1:#>_HL9$=$);' =QB'S$3/P(PW"VD78G-LIHM85_L9)1
M:/P+6)\L:6DS!>;'2N ((1O<RN3&*&$>\YRNL=NZ*&1'[KA"T!%0JISB<1Z'
M0*(B?,9*BU.C+OO-N'1F2\MPE!KNPD+CL#YJB1+TSI:YPYJ9^*G2<,.ZP0&"
M5=O?6NT)ZTIN%2)3%C69J^D7T80VJQZ/(9,6&P_!*]I(Q$MIH>1B_99TC<,]
M0G8J9!"=(JB""+JTN@!>O&-T4F9II;:9:1F6 C0*4T()6=7TDRRK3WC.&EMX
M5Q]S@9[3Q<D:J/3$"#.Q"L+K\'"R4=(GO$MI]7]29%.QNEOC/]-44JQA)1VS
MRC+7VLA)?<>TXH?,)J\(3Z0**#""NX0>^8*3-7J/U5*\48WT3'M*UZVTZ!IY
M;XS=??GWOUTLEXO7;V[?K?GGZ>NO#T$_!(,:%O+-J8(U2*NNVYI["#W.9*.C
M-%,1I2TU.6W1(<G/N!O/^?'#V^$8I%Z&ZB2ZD\Q(70,@.C*%WM]IY*[/*D>;
MRA<I#9G7&P2RV7' Y#PJY\-;HCCZBR8.(\T'YQL5B,>#:XB+[UAG3\!IUS'(
M,@2% UYVE08'4^!*M#:HK"6L94WYP!&M2IF71:'!W:@"HFG "2*G\T +]W+A
M-F:HH1F!OR/8R&'$A8*C0,&0K<Z51Q(M:V<XR&.2 <+K]-O787\:ME6[H#-4
MS8GK*-B:Z6=$Z5W;A".]@6# F[:G9BUWG]50KHM",2>/"R80#:3GS!\%SE*A
MDN=<!,2%_OR@_%9G"N'>4QD_;9O\(#&"EXJ\,#0* .JH4:#D7D"J6%D:&' Y
M(X?1!O)!M$"B<GA"F6/J]> )33$337HU?:_E!IA1Z;+C/:]R'9H66>M+*4/*
M8*^K($H4&OI9("HAQ$TB!E$RJ0_I8DTY0$TCH3+_%1-'(F8DQ2,$1L,%35*L
MIQA,O.<R1#P#)>X18PX.OU>IYR#&-7@&H5]1D#X.?%G=K5;K?_(M9+WA_8DG
MZ]O[Z2%91 UW!E8!2=0"ZI5P+%OI :EBN+$MM9K]W7VW8A,(%5XCYI1[JB,8
MP=;E5X-7G_-S@VY:84Y]V*OA'06Q8OSXYPVTDUL.$1((_&#%JBWI/ PK&%E>
MG)[/+J LQO3$HG,TD-NZU-Q"#YG90Y8ER#K%D!LE0U(&Q,@'OUB,!B$AT##L
M:B,;8FZS$0Q-:AR:9J3'28)'2:;$PP.-N3'_?SWBYBSNP /E23]NI'U@&DH
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M5Q/(*'^@2A?1-?Q1:.-B=#7_1-/%[$X+\+QP:+C]!1TP?B6\_B]02P,$%
M  @ 9X$&4VHH&H+'!P  L!H  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&ULW5E;<]NV$OXK&#6GX\PH$DE=G=B>4>2T3D\4NW9/^]#I T2N1$Q @@5
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M&"^WQF*_@]RAM6OK)6ZR*U1[?KLTO*G22T&D^[)]R:7?;QR+]Z+0E A&!\Z
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MS*3X"O$@7GS+F7&]%*B_A 4.Q>IIT$*J<=]'BA>K,O=-8JZL58E[C($C\Y
M]B\4&E"^T +U1ZJ+_P-02P,$%     @ 9X$&4[RB&T2S!0  5 X  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&ULG5==<]LV$/PK&'72)T6?3NQ);<_8
M3CM-9C+-Q$GST.D#1)Y$)""@X$.R\NN[!Y 49<MNVA=;!'%[B[W%@3C?6O?5
M5T1!W-7:^(M!%<+ZU7CLBXIJZ4=V309OEM;5,N#1K<9^[4B6*:C6X]ED\G)<
M2V4&E^=I[+V[/+<Q:&7HO1,^UK5TNVO2=GLQF [:@0]J504>&%^>K^6*;BE\
M6K]W>!IW**6JR7AEC7"TO!A<35]=G_#\-.%/15O?^RUX)0MKO_+#F_)B,&%"
MI*D(C"#Q;T,WI#4#@<:W!G/0I>3 _N\6_;>T=JQE(3W=6/U9E:&Z&)P-1$E+
M&77X8+>_4[.>%XQ76.W37['-<^?S@2BB#[9N@L&@5B;_EW>-#KV L\DC ;,F
M8)9XYT2)Y6L9Y.6YLUOA>#;0^$=::HH&.66X*+?!X:U"7+A\8PI;D_@H[\B?
MCP,0>7Q<--'7.7KV2/1+\<Z:4'GQJRFI/(P?@TE'9];2N9X]"?@VFI&83X9B
M-IE-G\";=\N;)[SYORY/O%:^T-9'1^*OJX4/#H;X^XD4)UV*DY3BY'\J^./1
MXF-%XL;6:VEV(GH,! QH)1=*J[ 3-87*EL(NX>7"1A.460GL2Z$R2$@@T@N/
MS8SQ4.&-N+J]$:<G$W&0:20^H6+N:((ANYJ<H[)%A&0E!7+P'P9Y$X"%$:5:
M8AZ9 G,6%+9$)@$NE9&F4%(+'V0@;.$@I$EH*=BG)7BP]&F\):#P)GI>%!D4
M)^<7#A!^)/[ #C98#VBHFF&4'Z9LK6#D@ZIYKMA6,@B5P(,JU%HRE#0F@A&!
M<FH$'38VG-;@GZ@X*JPK$2F^1>F02^]ZZHJULQN5^I$RJ0BNQ$H9 EHSF99$
MEX\S#,5:QUQ,!LD46(."7$#?A)"^<! 8I*GFB> OG?*0/3K6@T,;0B-QY1N5
M?8$$.Y*.>:T<0=%[FJ##H60^B;'7IRL@1$Z:;%"A7(I]Z0"'QN:/,OA8*<\Y
M47@O"FF:R2R*5RNCE@J#0125-"MVL>V3^OFGL]GT]!??T^IA44;B<Y7<A$2V
M**)K%G:\%N!>?D&O!-1#NLQJ6ZGBL$#9U5F?4GB;1><9+.CS8)^7[(U]$DSE
MD\0?+_.Q%6 WHX*-"$,AM06QY)3,MDZJ/R+._2V8O*E3RHW44>8C3>-,90,.
M<23L!#S$G)<Z<EUYAN?%,[S=D,/L8_9?.EMW6H%-WV?P*#HR=1T9K2%22[G%
M+&(=P8Q!T5]Y>Z-*,9%7K%O!^Y]5O6=._F1@^[.*8AF!=&1E0JXPQ>?]W!>E
M;2"M*B#%V=$Z0NXD_52PH[$P)!2Q6J7*QJ[_+:GDA230_8Q4\ZA3Y3B+U.I[
M'H4H(96V80#[1=-LY5&_A^^=WJG>\V\6WV8.7MV).A^EQ$?IH>RI_/T1_-V"
MU7PRFCQ++V=GHQ?/AKP/USF3WF4J_S53T]/+; L.^#2Z'74:<4./P;I=!EVC
M%Z-1H4DVOD@-_^ \&K9/"7")L@+5V;BJNE(-A;%,!;95"PU4G#32L&M2/QRF
M%>9]Q(XZXI)'S-JW0&GA"39!)3?<ZW'"&N[V:%??&T<MR* ?''IJ@^59-.]6
M *9R?Y%P<L".\0?%S\=*EX%/"Q?3EL!4](^$A$]KJ9-;>RD?YZ5,/RO=(=S3
M85:8T<?%%SY@ '50NUXHO+/%AS#_[XT"_@8VAU.,DH>P3)89 -NK4D$4\HV]
M&SG2Z?$P$XZUZ$SNMGR38%8REBKT-F V%7$!M:I5:%I7Z]C4.AJSOD8WJ1>(
MFT^YR-.7G9GNO>$MDBC] ,CI4R /M]0#1^T_,]@)^#Z!!/?.OL=KR@="TZ0-
MW04QG37;<W3LVW3<^]*OR:W2?09G,'\-YH_^;K2[,EWEF\)^>KYOO9-NA<XJ
M-"T1.AF=OA@(E^\P^2'8=;HW+&S +23]K'#M(\<3\'YI;6@?.$%WD;S\!U!+
M P04    " !G@093?AH"Y7,$  "S#0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6S%5UU/[#80_2NCM.J3R\;YW'!WD?BX55L)"4%;'JH^>)-98I'$
MJ>VP\.\[=K)[%PH4]4+[DCCVS/&9X_'866R4OC4UHH7[MNG,,JBM[0]G,U/6
MV ISH'KL:&2M="LL?>J;F>DUBLH[M<TL"L-LU@K9!4<+WW>ACQ9JL(WL\$*#
M&=I6Z(<3;-1F&?!@VW$I;VKK.F9'BU[<X!7:7_L+35^S'4HE6^R,5!UH7"^#
M8WYXDCA[;_";Q(W9:X.+9*74K?OXJ5H&H2.$#9;6(0AZW>$I-HT#(AI_3IC!
M;DKGN-_>HO_@8Z=85L+@J6JN967K93 /H,*U&!I[J38_XA1/ZO!*U1C_A,UH
M&X<!E(.QJIV<B4$KN_$M[B<=]ASF+SE$DT/D>8\3>99GPHJCA58;T,Z:T%S#
MA^J]B9SLW*)<64VCDOSLT6>A.]G=&+A #5>UT+B86<)UH[-RPC@9,:(7,#(X
M5YVM#7SN*JP>^\^(SXY4M"5U$KT*^//0'4 <,HC"B+^"%^^"C#U>_.8@X??C
ME;&:<N*/5_"3'7[B\9.O$O%5#+?Y#DTO2EP&M+L,ZCL,GB-^(HPL ;<#/0T8
M/R -E*(IAT98K& P- RV1MCXQ*0N<8>:]AET0[LB+[4>'8UK.<-3U?:B>_CN
MFWG$\T^$IMJ6]@VE8'E+Z&9P&%T%M+6-I8:;H!JT>PDH45LJ 8Z/5!7SAH\9
MK1Z@DG?2NW54;61'$R (:[5<#5:L&@2KX+A73:/.1X?_BK\9RGJB?@!GLAG<
M?.^M\2,^CDBO+'96BJ9QTM"D5)]>LG^&M)MX*_<7*L)\+YUO1TP<HQ9MK2J@
M\@T&RT%3US0HG>(=<3 ,*.76J-V@GVY</P=GJ=*;03],-/;05._*JO&6CZAN
MA-:BHZ,"CGT<M)MQMYN]^1F6Z/6)N>^EL>.+4ZBQJ8"';#Y/61Y'WI1'+(YB
MQK-D3YE=CCR[UHP."].C+_?- X--+6EUW?*Y8/PJF;VX1E07D2A+-=""D)+]
MH'ME<(R.-'+9V@Q4W:CA=?G'!=Y?L,&0(^7V+G>>R:T#\">D2S&Q/2*WF?U,
M)M)</6T:OP2'\$NM$1]5X2>J.Y'A\]]AO(#\DSO8J*I\"^%!5(RO5\VK:8MX
MR[E_\0*NG^Z"-TCSF$"2T$JG+*+5CC,6YIQE8?)5N%NF2<KFT9S-PPCBG$64
M8>D\A2MY_SZJ9:%_Q?RMJJ6C:G'X'JK%+$I35H3<JY:$K(BS]U$M87F2L3SC
M7K4B8P6/7TG4:8JGFZ5ZN:+^FSS^J#R[&KVFNI9D&>/4R[.")90VUU-9@Z*(
M6![%P$EJSO)Y I=(=PE9VFWY!$$UL#+$EO3CQ)KE1?H_I_%'I=D3T<*"\91$
MR\FX*/9$XYQQVAXD6IYY_B^)QO.0I7D*%&G^D5G\W+UOMG>1;E'?^-\%=[K0
ML3#>J7>]NS^2X_$B_L5\_)TY%_I&DB(-KLDU/,C3 /3XBS!^6-7[:_E*6;KD
M^V9-?U6HG0&-KQ4=S=.'FV#WGW;T%U!+ P04    " !G@093RW!?\/$'  #[
M$@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6RM6.]SV[@1_5<PZDVG
M-P-;_$TI<3SC.)=>.O'%$Z?IATX_0"0D84P1# !:\?WU?0M0%.U$:>?:#Y9)
M8K'8?>_M N3%7IM[NY72L:^[IK6O9EOGNA?SN:VV<B?LN>YDBY&U-COA<&LV
M<]L9*6H_:=?,DR@JYCNAVMGEA7]V:RXO=.\:U<I;PVR_VPGS^%HV>O]J%L\.
M#SZJS=;1@_GE12<V\DZZOW>W!G?ST4NM=K*U2K?,R/6KV57\XG5&]M[@LY)[
M.[EFE,E*ZWNZ>5>_FD44D&QDY<B#P+\'>2V;AAPAC"^#S]FX)$V<7A^\O_6Y
M(Y>5L/):-_]0M=N^FBUFK)9KT3?NH][_*H=\<O)7Z<;Z7[8?;*,9JWKK]&Z8
MC AVJ@W_Q=<!A_]F0C),2'S<82$?Y1OAQ.6%T7MFR!K>Z,*GZF<C.-42*7?.
M8%1AGKO\+(P2JT:R=ZV31EK'?FF=<DI:]I?/[WZQ/U_,'98AXWDUN'P=7"8G
M7!;L1K=N:^&IEO73^7.$-\:8'&)\G?S0X=_Z]IRE$6=)E,0_\)>..:?>7WK"
MWP>S$:WZ79 L.+O6K=6-JD5025NS6^ @6Q<>Z#5[JUK15DHT[ X/)23I+/OG
MU<HZ U']ZP<196-$F8\H^W^R\#^Z9%<,_YFR)&),KIFP3+!&;I"H)-M'MM]J
M*YG\TM.-WK?2P%JS5CNV%0\2I;Q>JTK!^F D'#/*WG.F#0\.-T;W'6=N*]E6
M-S6Y *9T.TQ1[0/"(U0/LUDCJGM0\7BP7.L&W4.U&]P9*5FU%02]A+%3E7V!
M%"I%?>)L)^[)S% QVK"J7C5J$\ATFHF5U6;%&FVMM!2FM_'V-&QD)=$F0GQ?
M._0.  /X5-T#%B-=;]IC AZE<_8)UYU1U-782K:2,*%K8*MJ,EJK "]->C@0
MHP[$!%@P* A6RU;:;;UII_?T7+-:(2[GG_DV%G@<HB 6_=R=AC.K-BW6JT3K
M&M"Q7A\FAF#__*=%$I<O+9.5;O5.5:R3QO?VMI)>_2<A&^$(V)V$+B" $ED;
MO9LL'8*L=-_4R,S10]$TA-@T:/(T9!6 O=:[CJ00-&#9ID>M4K 4',:K)_4+
M3$C=82U#"@/$L"$?A!F\]TXUZG<DR[Z 4T5UCJA%UQDMJJV'6X(9-%N) I!8
MPS#EB$QW@F<L*D+ =Q#G;\B-)<PC';_T_Y/HY6MAE:?L27<AP._"?DAC=Q,<
MKBI !8R@YEOD5U'T9^QT6?MUL-Z GZA"TH_DX(@1Z%N/[<P>VQDD $&&3=[C
MV$*6>^_I0,"(B@T0#V)1D &. [Z  V.3:AV$7C5]C6D"NG$#-\@1BP3Z>XNP
M$#=&71-JKT&6H.F@\ZO;:[\>R8H6YX-36N2JZ;:"70L3]#O@YE?^58H&M41C
M/,2K0:FJ0GE51M;*:7-8X8\X]6VP]>+7O4&S'. ?0.,8,]0RGZPU1=4[&&>+
M#<Y1=JCT@-8?C<US84<W9#D!E>.<,709^;62W:%XZ,&D(2M(E"3_ *& JZU$
M[4ZKN=;@A[8#(SMM'&MQC/0+HLTUO:3FPNSV$*G84:#80GJ/$YH3HH%GBL:S
M0H:R41"95VK?(:BG]>VC_NWFAGO;05DUQ?ECT:]$XYN&/REA"_03=&\1EOWY
MG.&((?T1XPV:V&Z%J-.8LZL W75OC-^=AEMAMSZ=BBZHQ2!77T0_L3C*>1PM
MZ"HI>)PO4*=3,%'H]S)09675FR#P>%'R.(U84?(B+=E'WTC)", 0HG'&RV7!
MX#K/OQT]-!HC&Y]J)PSH*0I>E!'+"E[&"_;!=S%SG,IBOH@S_$:+C%I2)U3M
M.WQ+K9VRTWY*]33W..))D5! BR)E[[5H)TY/1)+Q*(K"6/*277D-> GX_6$4
M 8L+GBR*T?"3=FA1S];/HH)'1<&2(N9%G*/7ML\LWB-V#LGBM846ITR(HHX8
M"'BE"UX"F:3D^7))?52T&T7A!P_!J,AXDA6L6/(DC]A?M:[WJFF0_Y)G133^
M)P3L?X+ 4PRP,QYG^3-!'&N %8N4EVG*D@1$9]G$T))EX$,>#G&'A89#U [[
ME*Y96O*T3%B6\CPNGBWUO3(F3UF4L[3@.83P$>9&^4W>B_O 10X"/P!0X;>C
M1N(U*.S[9WI]UA^;3 Y(2P8>EP?)'70#M4$VD'E9#LRVWU"WS&*>1TN6ITMH
M-QWLAD%4%$\S<%;FN%Y$,<2R&$MSNET,_= "^T?/B6\]565Z.9'X3R3B-(Y\
MJ?(EU/P69[RPGXOG'I8\6B;X+;+D1*NX07NO$.TT$-1>DA?$2;$@.M&;T/?$
M5WET'/-R0<( Y^P-SG4X+=;'T3PM6+;(IS4S;9LC/4G"B^41#.K$0SMO=+LY
MHVT;N_?*X04JQU\\O-'(@<EIS'%,XDZ^8?N)#4HC][_)LRJ=6I708+I@BZ6W
MFQ3JU.C]D_A"Z2'LZEDFQ"#>4B2>CN<7W^$M2(+DEQ']EDMP,A@!YG&A1^3,
M8]@L?5V=3/[D\DFV!,GQCT Y.3?SBLT]"*$DCIP\!35>YL^:7_M]T-+4=RZP
M'I7%8#H=IVV(-I22KF*4#3: 3T\.%),#R/A",/3[Z:;ICWEX!9%^BZ<A")30
MG9S7S[_W^CN??)#82;/QGUWH& X9AV\3X]/QR\Y5^*!Q- ^?A6Z$V>!(!,37
MF!J=E_DLM)[#C=.=_[R!MR:G=_YR*P7B) .,KS7.X\,-+3!^[[K\-U!+ P04
M    " !G@093RS'MYPP&   ?'   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6SM6=UOVS80_U<.7C<T@&+KR[*=)@&2M,$ZM&B1=.O#L =:HBVBDJB2
M5!WOK]\=*?DC;CRWPX ^^$42*=[=[[Y)\'PAU2>=<V[@H2PJ?='+C:G/!@.=
MYKQDNB]K7N&?F50E,SA4\X&N%6>9)2J+0>C[R:!DHNI=GMNY]^KR7#:F$!5_
MKT W9<G4\IH7<G'1"WK=Q)V8YX8F!I?G-9OS>VY^K]\K' U67#)1\DH+68'B
MLXO>57!V/:3U=L$?@B_TQC>0)E,I/]'@=7;1\PD0+WAJB /#UQ=^PXN"&"&,
MSRW/WDHD$6Y^=]QOK>ZHRY1I?B.+CR(S^45OW(.,SUA3F#NY^)6W^EB J2RT
M?<+"K0UP<=IH(\N6&!&4HG)O]M#:88-@[#]!$+8$H<7M!%F4+YEAE^=*+D#1
M:N1&'U952XW@1$5.N3<*_PJD,Y=O.*JDSP<&>=',(&WIKAU=^ 1= F]E97(-
MKZJ,9]OT \2P A)V0*[#O0Q_:ZH^1+X'H1\&>_A%*\4BRR_:JQC\>3751J'O
M_]K#,U[QC"W/^)N-=0@=?,@YW,BR9M42<J8!,TLQ(ZHYL"J#F:A8E7(HW&+,
M-TBEJB4NX2!G,Y%R[4&=+[5(!:OT+S^-PV#T8OV+F*1<&<Q$X)\;46/NF#Y)
MU2NN.?O",9<H6TFNG07#58EH9B K#B6Y%8Q$/+ATR9E"UEJ6A $6N4AS#+\E
MB"HMF@PG:THN303\P7"$8/(M'9J:_@5^QXI0'L2.4*%)4/D-C@MA<E2/@!*_
M/EQ9X!@\?!4\5L1+GO)RRA5$@9W%?TQK;C1JCV;%F(4&(U<]-ON"*P[/_'Z,
MR584MFX@M\T)#SGHFMMJ4BR=0BQ-F[(I$&R&)0&K(WK(%1VM)7WC/$%_2MKP
M0&FH;Z&E9RW219)"+Z,1J-!.6[9=%&"5+H!K8XV(%LV%RJ!FR@B*%V=]A@@0
MOFPJ DD>VXI,Q[$/;];V1XSH+V$$,B<GD0."T 6.!5)PK2W?2IJUN5$Y@CUE
MA;6 +5DV.C',RQH]:M68M3')'[#MX-M:B%$H%=@_-#P7Q$8V&@VE3\Z07G&^
M58L>!0/Y'MYMZX,2M8%G$'AA$MEW'"=PN^D;M^2JE&BLOYTO=["%(XB&\!H-
MASXRI*#[7P@V%84@*T,$,=RWCJ$HI\A_'H[]$WR&R0E\D ;-N!;I0<4=-#]P
MT,+A!.[%P_?J&'K#8(COR(O&XV_7<1A#$OR+C@F,=G6,1Q'J&"7^TSJ&7N"'
M%IH_2> =1H="<K?1<#W?912&;I<O& G_.1CNF[HN.!5'1'7#= ZWEMOK#=%V
MNF:BS8B2TD-W52H#X6*Y1%2-LJS6EMNPS-F&4U+B.+."9DJ6.RGF?#UQ/H^B
M: _IHR)"(>;\>L!B%[-V[W4J9Z>-YEU=E%.J&4XY_I#FK)ISJ_U>M5;@;3L*
M7UBW3OS102'[PWHB\H)X8E49C_W#/4&)<+ G7&;]KYX8><DP_)KA/]K-*DJX
M^H+DR/UNM26PA1X^4%W?X9WTAXGKXS#J^]WG[:-P[ >C]D^\_MR1^%)HVW3@
MCKK35T3AEN'G[K4CPJ?9]G7;&'0];8Y%V92MD6JV+&U'<5V^DM5I2BR*@F&A
MZABQW=V#!V)OC=FVYAIWVR [I.W0+GJ.3L1HI544JQHSHVV6?#<S3FS8^3$5
MQL2GJ1##<1A.( @F-(RHE/M1-XPIWV(?1G8TQ%$2CU<Q@.T5-P$SK-Z0>.,@
M6/^P-7FVUW1HC'"$XD8C5$=CL(FR;HR-R[8=1-Z$@(VW2OQF:PA&7A3'6'(F
M+8NT4;1A@9J:#J8W9E@4H"X^O)'5_-3N)W;98$V,L8]1<0PQ,;^RZ=O>$V42
MB6CW8?>[+,L$"4.$>[?<)F<M!9$NL4=A*T-3I#SK[SD]#%>GA^%WGAX.H3N>
M'HZGA^/IX7AZ.)X>CJ>'X^GAA_;$\?1P/#T<3P_'T\/^T\-@X]*FY&INKZ9P
M]T5A[>YO5K.KVZ\K=^FS7NZNSMXR-1>X[RWX#$G]_@@/%,I=1[F!D;6] II*
M8V1I/W/.,+1I ?Z?26FZ 0E8W0E>_@-02P,$%     @ 9X$&4U5<Z#7*!@
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MJ1$![B^5LMT-*>@_\5S\"5!+ P04    " !G@093LJX%'.0#  !>"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RE5N]OVS80_5<.VKJU0&+)BM,F
MC6W \;JL18,9S=9]&/:!DDX648I42"J.]]?OD;+==%BR%?MB\]>]>W?W>-1T
M8^PGUS![NF^5=K.D\;Y[G::N;+@5;F0ZUMBIC6V%Q]2N4]=9%E4T:E6:9]G+
MM!52)_-I7%O9^=3T7DG-*TNN;UMAMY>LS&:6C)/]P@>Y;GQ82.?33JSYAOVO
MW<IBEAY0*MFR=M)HLES/DL7X]>4DG(\'/DK>N =C"I$4QGP*D[?5+,D"(59<
M^H @\'?'2U8J ('&[0XS.;@,A@_'>_0?8^R(I1".ET;])BO?S)*SA"JN1:_\
M![/YB7?QG :\TB@7?VDSG,W/$RI[YTV[,P:#5NKA7]SO\O# X"Q[Q"#?&>21
M]^ HLOQ!>#&?6K,A&TX#+0QBJ-$:Y*0.1;GQ%KL2=GY^TQ>.;WO6GM[<X==-
M4P_8L)F6.XC+ 2)_!.(E71OM&T=O=,75E_8IZ!PXY7M.E_F3@.]Z/:*3[(CR
M+!\_@7=RB/$DXIW\UQCI]T7AO(4B_G@"?G* GT3XR?])X5="T*(LV3E:61GN
M"BV%9;KF2I9"T94U?4<_:WK7JRV-3X=$'9&@KMDZ64JAC\U&<P5Y.KG6PF/H
M&D T1E5LJ;.F!CIN!=!*8SMCQ7!'ZEHJ&<]OI&_(-TQ+TW9";PFTV&)#:F_@
M"LJ76H8K16)MF=M /NR4M[T$V;/L&9DZ(M2] L]*JCX EZ*37BCYY^ 29_X]
MUN???7.6Y]G%8K6\OHKC\<6+$9W"QT8J1053)V1%Z#K@!Q>N"5SB\1@)%L<9
M%;U#XN&J$ENW9P<=:"=V/4)7<<URZ&=2KY]VT7>P.7 :O[IP"+^1?#=D PY*
MMAY(A%P)C<(HW&'%N-6@ 2\JIAI,:^E"M%L6-A0S'^VX2Q>JNDM,&1)S*+'[
MGM8Q.;5!GP ,N*"P=[(*O!MTH^/;'GGV.T-X<:RE0?F1^2"R$=WTFI808TSU
M>U$$'1@KP2VJ2S.-]^+Z6BE$_3R._SP)>UARR8LCZG60Y::1Y9>:BYGO>ELV
M:+SP-#E_%IS"N8M5V&,@!Y:^G8RRD%Z%2HX^;\44+M^_71R'8LA:@GA0Y+%C
M>R=+)B4*.!6H5\?@!W+C<U*FC/H,%;4&D@FT;H2F*U$@ $4?A5*\#20<)-&P
M1:3(-HAH*4;TR]^4!19\W^$I&NI=*H. BFV$9:AN+\9&VHI0-XL@PV)(_NB?
MFE3ZH.>W;-?Q97.XS;WV0_L_K!X>S\7P9GP^/KR\U\*N)2)57,,T&[TZ3<@.
MK]DP\::++TAA/-ZC.&SP < V',!^;8S?3X*#PR?%_"]02P,$%     @ 9X$&
M4RC^Y!JA/   *-$  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULS7UK
M<QM'DN!?Z=#.;) 138BD)-LC/R(HVIKAGN7ABK;W(B[N0P-= -IJ=,/]((7Y
M]9?/JJQ^@)3LN]L(AT4 W55965GYSJQO'NKF0[MUKDL^[LJJ_?;9MNOVKY\_
M;U=;M\O:1;UW%?RRKIM=UL''9O.\W3<NR^FE7?G\\OS\B^>[K*B>??<-?7?;
M?/=-W7=E4;G;)FG[W2YK#F]<63]\^^SBF7[QOMAL._SB^7??[+.-NW/=+_O;
M!CX]]Z/DQ<Y5;5%72>/6WSZ[NGC]YL4YOD!/_%JXA];\G>!2EG7] 3_<Y-\^
M.T>(7.E6'0Z1P3_W[MJ5)8X$</PN@S[S<^*+]F\=_2TM'A:SS%IW79?_5>3=
M]MMG7SU+<K?.^K)[7S_\P\F"7N%XJ[ILZ?_)@SQ[_BQ9]6U7[^1E@&!75/QO
M]E$0\907+N6%2X*;)R(HO\^Z[+MOFOHA:?!I& W_H*72VP!<4>&NW'4-_%K
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MTZ]Q U\(?+QT?IH%6Y9LFKI'7I2M/C#%#XB"V!:Q -@ ''A\O!?)#]'(3/[
MYELE?R!BILT#3S2UKZ^3C,'<UP^NP9,"D&VV U3!:EI@FV76R#<I;F4.)I&8
M-F8G(T["%+G#\]P&TZ!$L;H&MH.$,,%V/*Y!LR/?/<LD^.$>A"E\0"G]&IAH
M<F=V%[D\D-L^LY #I\NSPUE7G\$_5EQ.,[RP#MK"8C#%AV+UX0S)5/%R+T<4
MYSZ@UK9'@8],8DTX"]90+BH>#%S@L(CS&JAUP]P&T)DMV[I93N(#5-P5R:P:
MF+& =L]C$"3X.AL&T_C4]P' (F?]$B1QQ5S=,D?/&Y27!)*99 !,J,@^D.L
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M1W?B.FNWA"[Z X4MT/O<IG[N6!93GE^O]&GZPYFG03/9 9\K#XFXR<DM!5A
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MU:ZO*"B:#S8>C$7?/ 8C!D&^8*6Q8;":3"ZLD&IKKCS"A"ER%;SV4O"=[]R
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M:LGL'SE>[633>/PZA)UM^B+GZ]N'OE&^&('MY'HO6:?NH^,\:^XDQYK(^((
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M@K(/8@E$5%)+\(:NP'/*N;V*:I^-^.!:RRPKMZD[,1-$1#8VXKK*6A'T8S.
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M&7O#]$-7[W%(3!KJZAW]N749:!+X /R^K@$1\@$GP-Y1!-YW_P=02P,$%
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MKF2)Y?_Q$6G="TY[P>?INX#?6WD*61Q"&J?).WC9O@"9Q\O>P-OE;5X29\+
M[\7*6$T_F3_O4 SV% -/,7B#XHXFJ6RIMJJ"#]7[M3*_2^%&]\PTK,!90+-I
M4#]B,+_?(%RHNF'R^?.G<9J,OE"6/7]SP,]V_-CWNU T=<:2B21;@JF4H/'E
M<@W'7))%M88"S<D94#_0]^,2"ZQ7J"%+PI<T>YHC2)(PF:1TF(1Y/H +UG#+
M_&3V/FDXC&/(PGR0P%V[(A&^!4K#]7)QX)7E0TC"X3"%I585&K<@F( *2?F$
MK$F8C<9PV2)818M#,)=(P[3EY)",QY#'5)<.' 1G*RZX?TM)VF0 21I.R*OO
M2D$EI+)T6H?AA#32YRB&>V6)]F,5/8(\"T<^_VP8)H,,7OMA10>#7*->^W7E
MVD$$W4SOK?N-N.@6P8M[MTYOF%YS:4!@1:'QZ2@/0'<KJKM8U?BUL%*6EHP_
M;FBKHW8.]%XI9?N+(]C_3\S_ 5!+ P04    " !G@093O 80&A\#  #2!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6RE56UOVS80_BL'K1AL0(C>
M+<>S#3A>AVY8 *-)UP_%/M#2V>9*D1I)U\F_WY&2E;1S@@+]8AW)N^>>XST\
MST]*?S8'1 L/C9!F$1RL;6=19*H#-LQ<J18EG>R4;IBEI=Y'IM7(:A_4B"B-
MXTG4,"Z#Y=SO;?1RKHY6<(D;#>;8-$P_WJ!0IT60!.>-]WQ_L&XC6LY;ML<[
MM!_:C:95-*#4O$%IN)*@<;<(5LGL)G?^WN$OCB?SS 97R5:ISV[Q>[T(8D<(
M!5;6(3#Z?,$U"N& B,:_/68PI'2!S^TS^F^^=JIERPRNE?C(:WM8!-, :MRQ
MH[#OU>D=]O44#J]2POA?./6^<0#5T5C5],'$H.&R^[*'_AZ^)R#M U+/NTOD
M6?[*+%O.M3J!=MZ$Y@Q?JH\F<ERZIMQ93:><XNSR%FM>,0%_<K;E@EN.!D;W
M;"O0C.>1I0S.+ZIZM)L.+7T!;0*W2MJ#@;>RQOKK^(B8#?32,[V;]%7 /X[R
M"K(XA#1.DU?PLJ'<S.-E+^"=RWP$TC-\D"WC-:P%XXT!)@=S5?]#5T_:L_#V
M@?1O,(25TX^+Y!*>8#ZMML9JTM;?K[#+!W:Y9Y>_P.Z.GEQ]% AJ!Q<:<ZD?
MKP*Z%STS+:MP$="3-:B_8+"\/R"L5=,R^?CS3],T*7\QT/39Q#,95(J>GK%8
M.SJ6@G9*T!OF<@\CN@-[4$=#=V;&,Z VH6_38-S^'S"$+>ZYE Z $%O47-7P
M!HHXS++8&=.P3 O/34FZ>^/<SLPJII$H&=K5*)BC91547;^XK(Y:8SV#M?M2
MVWKTQ&%FUY!,BK H$]C0KNX/2>A)F%YG8TBS#.Z5I2P7LB5%&>;YQ$-,XQPV
M[+'QY)R"?HS=*(FS,(O3,8RNRS!)R/B&8%Z$21;3N2-1DM'1]+(=)?DTS#,7
MG11Y6$S)>A(N!6?E&+)T<KD7*.NONW!-3$HRRCA,RPPNR3EZ-F<:U'L_39U0
MCM)V(V?8'0;VJIM33^[=M+]EFK1@0.".0N.KL@A =Q.T6UC5^JFU599FH#</
M]*>#VCG0^4XI>UZX!,/?V/(_4$L#!!0    ( &>!!E.QDB^4@ ,  +H'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;(U5;6_B.!#^*Z-<=0*);1)#
M(,L"$M"M[DY=J6J[=Q].]\$D UAU;,YV2GN_?L<.9*EN0?LE\<O,,V^/9R9[
M;9[M%M'!:R65G49;YW;C.+;%%BMNK_4.%=VLM:FXHZW9Q'9GD)=!J9(Q2Y)A
M7'&AHMDDG-V;V4373@J%]P9L757<O"U0ZOTT2J/CP8/8;)T_B&>3'=_@([JO
MNWM#N[A%*46%R@JMP.!Z&LW3\2+S\D'@3X%[>[(&'\E*ZV>_^;V<1HEW""46
MSB-P^KW@$J7T0.3&OP?,J#7I%4_71_3;$#O%LN(6EUK^)4JWG49Y!"6N>2W=
M@][_AH=X@H.%EC9\8=_(9L,(BMHZ71V4R8-*J.;/7P]Y.%'(DS,*[*# @M^-
MH>#E#7=\-C%Z#\9+$YI?A%"#-CDGE"_*HS-T*TC/S98&2^'@EA=""O?6@P57
MSW"G.25,E7!'XA;T&@YRG2>^DFB[D]B1<0\1%P=#B\80.V-H"%^T<EL+GU6)
MY7O]F)QN/6='SQ?L(N ?M;J&?M(#EK#T EZ_S40_X/7/X-W@RL&-L(74MC8(
M?\]7UAEBS3\7P <M^"" #\Z /])C*FN))ZD\IOQ'J;P(YM_IV.YX@=.('J)%
M\X+1[&F+L-35CJNW7W_)63KZ9(F=%-**2ZX*A$+32[(N5-.1\%I+>I%";: C
M%)WHVE+%;7<,E%EL,PLW6&"U0@/]-)PD\(2F:B@RARL(UM@G6J6CO)>R#![P
M1<L7T@@R:9[TDB2!8?-[0"[ALW7<87,_Z@T^YO3-\H0"4)3SNGFPS>VH-?"D
M':F&F-*<Y$<9L$'6&R49W*&U8UC6QJ!RL-,F %"@0;K#DJP+G33IY?G'[D'X
MJ^*5E_L/2U@+12GRJ2BTSU!GT!L.O0K]O>J=5IL/SD<=\"C2G 6[5\ H3RQ-
MX0)'LI8CV4]SY+9VGH-4T$HXZH'._B1S+IHXSYSO9.!D-M"C\:!X[X$[QS(:
M#^'R#;FQ@*KT6"?4^1_)YI6NJ5:!8AU\+60=5#R&%:]0-<T"?;-X3\BNSW\R
M]&L&+,_\H@\L#8L!,'^:$ M]^R(TFE1K*AV5;-@;#48'%EVU%/I1X>*3?EJA
MV82I82D7Y''36MO3=C#-FW[\7;R9:E^XV0AE0>*:5)/K$17(-).BV3B]"]UY
MI1WU^K#<TG!%XP7H?JVU.VZ\@79<S[X!4$L#!!0    ( &>!!E,D/8S8]0(
M $L&   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;'U5;6^C.!#^*R/N
MM$HEKKRD!-I-(J7=775/BK9*>G<?3OO!@2%8!9NS3=/^^QL;RJ92DR]F/)[G
MF6<P,\P/4CWI"M' 2U,+O? J8]J;(-!YA0W3E[)%02>E5 TSM%7[0+<*6>%
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M<):GB[%![%^LZOU%8J4LKB5^V. >*+03P/Q:*;M_<08.-\O+_P%02P,$%
M  @ 9X$&4_J"6C_?!   #1   !D   !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL[5A9;^,V$/XK _? !G!B79;L-#'@9!LTQ2XV2-+N0]$'6AY9PDJD2E)Q
MTE_?(2G+]CI1TRT*]&%?3/&8;^X9TF=K(3^I'%'#8U5R=3[(M:Y/1R.5YE@Q
M=2)JY+23"5DQ35.Y&JE:(EM:HJH<!9X7CRI6\,'LS*[=R-F9:'19<+R1H)JJ
M8O+I DNQ/A_X@\W";;'*M5D8S<YJML([U+_4-Y)FHPYE653(52$X2,S.!W/_
M]"(VY^V!7PM<JYUO,)HLA/AD)M?+\X%G!,(24VT0& T/>(EE:8!(C#]:S$''
MTA#N?F_0KZSNI,N"*;P4Y<=BJ?/SP60 2\Q84^I;L?X)6WW&!B\5I;*_L'9G
MDV@ ::.TJ%IBDJ JN!O98VN''8*)]P)!T!($5F['R$KYEFDV.Y-B#=*<)C3S
M856UU"1<P8U3[K2DW8+H].P=DDH*WMRS18GJZ&RD"=1LC=(6X,(!!"\ Q/!>
M<)TK^)$O<;E//R)A.HF"C40702_@SPT_@= ;0N %?@]>V&D86KRP7\/?Y@NE
M)07![SV848<96<SH!<QK[M+!Q-4MEDSC$K0 RPHNA=+J.4/V8][G"*FH:L&1
M:P4B@]+"X2,E((UKE A,029*RB1R6<%!YZ)1C"_5T2G<YQ)QSQE IL3.E.;'
M@P\U2I*;KUKTE(2%;\$?!G%HQRB*X:K@C*>X>V1>":F+/YW*![(%"81CN.::
M9*3#=,3MEP5;%&6A"W) "!'<-0NW47!2%>%-,/&.Z#>(C^!>:%;NL!P"1R>:
MYSO1@O$4[HK'+]4Q&([],8WA,)Q,_KF.XPAB_V]TC"$YU#%*0M(QC+V7=0R&
MOA=8T;QI#!]TCI+(MS$FMS%6NG!>4R3\ZV"X:^JZ1"JQ1JI+IG*XLFB[X6V7
M:U8LB9<$5HG&1"?I5C8&U?)%J$BJ1EJHK>5V+'.ZXY34(&:6429%!6+?7<KY
M>NI\'H9A#VFVZT078LZOKSCL8M9VH6.1'3?*9)="DWH+3=W,*8>/:<[X"JWV
MO6IUPG__S23P@Q^L6Z=>\JJ0_=]Z(ASZT=2J,IEXK_>$2817>\)EUG_JB608
MCX/G#/_1MFWB,'\@<D*_17.5,3"NFM^CK ZQXY-Q#$_(I(+DQ-M\7GT6CB=^
MTNY$V\\#CF\+E1I?PBWE^'.L? ^^VPP'+#RSZH:>QC;N&MNXMPG=T:5OV91H
M0N>JT11(\)ZL436[-G"&N6%/E>U4\XQ*(LR7HMX4SDD4/-?_>EF;V^>IJEF*
MYP.Z7BJ4#SB8M3)4K0S.[?6&<T/I)($+?IP:HY2EN<1L3,-L#]US^1"*WJJY
M'Q^?*;QU;SNUA]Y06%+^F5,F^Q3E>N5R'0]S_<@FDA>94A][9BF@!!L'4_#]
MJ9F&ICEYX68:F0H2>9#8V9AF<33IHIHN#'0-M\:/AQ/?WV[8+I/UFHZ,$23$
M+DE('47I4U1UHVVFM0TN'$Z-8).]IK7;[/QD&$81%=%I"Y$V4IJR4YLV2I%
M-2/T21</W@F^.M8FDPYAJ,I'U)E-N0^HU/0$<=P%<?RE0;SGPB\(X5[&7T/X
M:PB_%,*CG2=:A7)E'Z(*;.%WK[5NM7OKSMT3;WO</93?,[DJN"(Y,B+U3A*J
MJ](]/MU$B]H^^!9"T_/1?N;T7D=I#M!^)H3>3 R#[A^ V5]02P,$%     @
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MBJ84H.;0*GXAV.?WM!8OQ7JO="K9([/BN3@984T:H>_$Z/1Z*6"N2JPW62_
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M8$\^D_?#_7WE_%_TZ3]'WVI&U ](9/FB WR?."\:?;<(LP+M3 O*B,PIE[4
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M.+]<,!JP-!N@/I]Q+E]OL@#5_P$8_0=02P,$%     @ 9X$&4P?EB_7T"@
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M_4(U2\5FH:9)V?5:HMMF=W;B=D_*I>'E\\6L.4)M8Z.<[T@5U5(FE;POT;5
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MY--Q?(D2QO_"MK"- DC6QJJL %,$&9?YR)Z*.NP FNT]@+@ Q*\%M I Z[6
M=@%H^\KDJ?@ZC)EE@YY66]#.FMC<Q!?3HRE]+IWL,ZOI*R><'=PH)N$.$^0;
M]B 0F$SA[[UW;T[C9O,#;0EF,84ITY:C@?<P3%/NY&,"KF5^!IV8AV.TC MS
M1"8C)3=(]HYHALE:.P*M,FZ,TL]PJRR2U?UL#(<'1W  7,*$"T$TIA=:RM#%
M&29%-A=Y-O&>;#ZM90-:T3'$4=RL@(_JX9\32_"FAT<5\/%KX%$5/"192FWB
M4IO8\[7W\$U9PN<\Z<)':5&O-#=4])]P.YG4D+=*\I8G;^TA'R:)6DMKCKT$
M-#C5C=?_DDLF$RX7NX?@VPT1P+7%S'RO<=\NW;=K<QMFSCNH.0CR6U7K''_F
M\:YY;091H],+-Q5..Z733JW3:U='-!8TG6.@@^I\4_-Z2;(JC'K&3B.*WM:4
MHUM&UJTOQ]5D1-(.IZ,:LI.2[.1_2'M:NC^MS<5?Z=]%/0;FM:ZZS3E1=T?C
M=JEP?F'K+/Z([JR,[NS?HN.[AZ*J9]3SM1HGG<H3$.XT9?>"3IA><))!X)R(
M(H(%H/-7*5]8M?)]^D%9ZOI^NJ2''+4SH.]S1:$7"]?ZR[\&@U]02P,$%
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M#7!MH-[GC,F7@;XSNV^D^7]02P,$%     @ 9X$&4^S%:-%O P  6PL  !D
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M,B*,%-I"8//W2):$,8MD>/S=@09]3.MX/'Y"_\,E;Y)98T66@GVFI=[-@TD
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MGZ)H0'EHED<P/[U<PJ,VI2)RZ[HW94Y@PW7[K/>K?8=X[?JBD_4;VSFZ]N<
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M 7I^RKEZ[YB;8?%/8/ ?4$L#!!0    ( &>!!E.)5*>O@0(  $@&   9
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MYN82Z-%.)=\98\"XE7@75%^(/R7;). =<,O-X/%Z&]?=AI-M4],ZG>=53_?
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MFVNA[^R:)2$9,$DX0P)6(^O"/5^XO@$4$=\);.7!-3*EW')^9VXNDY'E&$5
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M<'^3GV0VCST%#IL(PY?O^*@)-GH&-BN,_@Z;W2@Z2.5I$_OTZ51FFS4G,==
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MBT$Y7./=#;0SP/=+I>S]Q 5H;H/3_P%02P,$%     @ 9X$&4W4:FO;1!@
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M0NIIU*"06N/H4$/E/&I0>+CK0"*I(LBL(BX/Q#FD(?@]IV$@HCRE,5VP(A;
M3?C*%%R9NE''31@D\S<RU]Z'\KBWB>+NAW@:B%K.:$!P)W]21-">ADPNE@MN
M;LKLZ7XVGCN9I5''G1DLLS0V5]@'\H75-HD2:5<#4G\@MO$TV>.IN68I%]@L
M%[<BA-/[VTWM,\52IF7<<4L&R\R,W[0E@UOT45P-2/GU[[7Q--GCJ;GFC:[\
MGH;,YZF1)YES<<<=&"PS+S87S0<_2M"T8#2=SQJV^00 V9HSIO%FJ:6FQAO<
MW4'#4@OPGCY,E.1"QI(\2S-1H12M^3P6]0J@"\Y*B=.&8*#,QE'UV&L'N]+
M,-E92&.9][$Y[]],QR)S?)E.3=M$)GS<<<(G,N$3<\*_?8I%D;@,5B H&B@L
MU9*PQPEV3B#Y1?<\\UA#[UC#R1&&S=!)W2![?F;4;?Q7]!>)%!/2L9@0*2;$
M+"8MMX39";9.+$N_)8XT](XUG!QAV R=U"1BUJ3J\<!K-L3&X]F.58M(U2)F
MU6JY(<Q.#!OB2$/O6,/)$8;-T$G-(V;-.ZRV)%)O2,>/&X@4(V+N$;5DW^R$
M[&;_2$/O6,/)$895Z/H;;T1%C"_*=]=2,"O*FNJ]E?7=]?MQX_*ML*W[E_:I
M:VON>_;II'K[3;JO7L:;4KX(XA2$;"Z&LDX&(CGPZOVVZB)+5N7[6 ])EB51
M^77)J,@^!4#\?YXDV<M%,<#Z+<.+_P%02P,$%     @ 9X$&4ZC&N$J$ P
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M1R7D [I%1+Y94U9"(:=L8_,M0S#3I+*P/<>)[!)B8DU&>FW))B-:B0(3M&2
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M9XSO0S<CEVIGY-#/R'A#NU!.3WM)EM&$!L.<GLK!T29).FQB+D!"2#"LQD[
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MFJO&".C?Y[5>F>T?9H#=K=J+_P)02P,$%     @ 9X$&4RA3!119 P  6@P
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M92RGA=6'E+HAZ%;_A9=4R'^Z?LSEN0XQ)9#OUY2*?4,E:$^*DS]02P,$%
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M"BPSR#$I?^%C9<0!P/%. )P*X#0![@F 6P'<<T<85H#AN2-X%4!+-TOMVK@
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M$5,!\GU"J=@UU #UOP_F_P-02P,$%     @ 9X$&4^+W!F[D P  <@\  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULK9==;Z,X%(;_BH7FHI6V!1O(
M1Y5$VFE5[:XZN]5TNGOM@!.L 9NU3=/Y]VL#A4QMDU3:FX0/G_.^YQ@>[-6!
MB^^R($2!UZID<AT42M4W82BS@E187O.:,'UGQT6%E3X5^U#6@N"\#:K*$$71
M+*PP9<%FU5Y[%)L5;U1)&7D40#95A<6/SZ3DAW4 @[<+7^F^4.9"N%G5>$^>
MB'JN'X4^"X<L.:T(DY0S(,AN'?P*;VY1:@+:$7]3<I!'Q\"4LN7\NSGY/5\'
MD7%$2I(IDP+KOQ=R2\K29-(^_NV3!H.F"3P^?LM^WQ:OB]EB26YY^0_-5;$.
M%@'(R0XWI?K*#[^1OJ#68,9+V?Z"0S\V"D#62,6K/E@[J"CK_O%KWXBC )AX
M E ?@,X-B/N N"VT<]:6=8<5WJP$/P!A1NMLYJ#M31NMJZ',3..3$OHNU7%J
M\T!T#R2X O>-:@0!7RBC55.!1_Q#3Y:2X)GE1( _.;O*,,M(B;<E 7W4Q1U1
MF);R4L<_/]V!BT^7X!.@#'PK>",QR^4J5-JDD0JSWM#GSA#R&/JC8=<@CGX!
M*$+0$7X['7Y',AT.V_#HY_!0MV;H#QKZ@]I\L2??7S416%&V[VN>2!D/*>,V
M9>)):0H#%^0U*YO<)%8% 9*^@HHS54A =,-SH-M AC9<NMK8B<Q:$?.RONC$
M"5J%+PYKR6 M.64-N;2ZJ/1(*T[1TJV5#EKI*:W8I97:6G$4N[5F@];LE%;B
MTII96FB91&ZM^: U/Z65NK3FMM8L6;BU%H/68E+K6T$TNW>*")?BPE*<+2!T
M*RX'Q>6T(E>X!+L.%E4/B]*\&J#ND>&RLK2+AVCNF548C?"*)MT\$"EO *WJ
M1NEWAC+=""*5$SJ1_5@M?8\P/*(G/*,=7?TEQ5M:4D7?4Z)W "T'<!XGB<?"
M""B(SNA!U@BAFP]J+LSGT6D V9.PB,?GH<<KLK@2P_G<XW)D'IR&W@-G^RL]
M/=69S8KM9B4IC-^;=0Q+%[/4XW;$($PFJ7]/F?G8G68^'&D'3^+N_Z ^M/$X
M\P +CG2$)_'HQ#ZT^0BA[YT9^0A/ M()?F@3TJ\V$A).(]*'?FC3<>X3&^$(
MI^GH8S^T^>>9-#2R#TVS;YK]R.:=3W&$'3H'=A]F/[+!%_N @H[69>=@[QST
M(YM[T//=12//T#3//@!^9$,J3CV/&AH1A::7:F=C']F+-PBC=R!U#8H\BTDT
M,@]-,^^#T.^S_;2D39;OG=J#8FM1$QYMB,QN] L6>\JDMK'34='U7"<1W0:O
M.U&\;O=(6Z[TCJL]+/2FF @S0-_?<:[>3LRV:]AF;_X#4$L#!!0    ( &>!
M!E.<]LL9!0,  *D*   9    >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;,U6
M6V^;,!C]*Q;J0RNMY9Y+E43*;5JG58J:=7N8]N# EX *=F:;TO[[V8902BB*
MMC[T);'-.>>[@K]13MD#CP $>DH3PL=&),3^VC1Y$$&*^17= Y%/MI2E6,@M
MVYE\SP"'FI0FIF-9/3/%,3$F(WVV8I,1S402$U@QQ+,TQ>QY!@G-QX9M' [N
MXETDU($Y&>WQ#M8@[O<K)G=FI1+&*1 >4X(8;,?&U+Y>VI8B:,2/&')>6R,5
MRH;2![6Y"<>&I3R"! *A)+#\>X0Y)(E2DG[\*46-RJ8BUM<']<\Z>!G,!G.8
MT^1G'(IH; P,%,(69XFXH_D7* /RE5Y $ZY_45YB+0,%&1<T+<G2@S0FQ3]^
M*A-1(TB==H)3$IPFP7N#X)8$]U0+7DGP3K7@EP0=NEG$KA.WP )/1HSFB"FT
M5%,+G7W-EOF*B6J4M6#R:2QY8K(6-'A ,YGJ$,UI*ON/8UW!2[2.,(/+ED?+
M)[4&=+X @>.$7TCP_7J!SL\NT!F*"?H>T8QC$O*1*:2/RI(9E/[,"G^<-_QQ
MT2TE(N)H24((6_B+;GZO@V_*W%0)<@X)FCF=@E\S<H5<ZQ-R+,=N\6=^.MUJ
M"^?_K"__V?JK9+A5M[A:SWVK6W1+;(Y;8LH8)CN07Q"!-L^HCEOA9WT\S3$+
MT:]O4A+="$CY[PZ'O,HA3SODG>!04'<(BAYM:\!"L:<5U7?T<6+[?F]D/M:K
M>@P:^,YKS.(8XPRM!FC98FUH6Q7H5=1^%;7?';5^:>E>1<H[LMBK]'H?HZS]
MRJ'^NY>U4/1KB>XUBS$_QCC#0:.JQQA;5JQ1U6/0L.^T%W50Q3SHC/D.N&!Q
M(&3(7-<7J\QVE7=8*0\_1GEMZ^76L=Z]P*5D_54:^EZCPBT@OPE:M(#LOMVL
M<9L]=] HLEF[>E-@.SWS<!E31D3Q7:U.J[EJJJ>)QOG,OI[;+><+-8?IJ_Y%
MOACB;C';Q82C!+;2E'75E^W(BKFHV BZUQ?_A@HY1NAE)&=)8 H@GV\I%8>-
M,E!-IY._4$L#!!0    ( &>!!E.<[0^%"04  /$6   9    >&PO=V]R:W-H
M965T<R]S:&5E=#8W+GAM;,U836_C-A#]*X2QAP386!(I?P6. 7]LVRP:U$B0
MW4/1 RW1-KN2Z))TG!3[XTM2LBC;$ITM]N!++%&<X7LSP\<)ASO&OXDU(1*\
MIDDF[EIK*3>WGB>B-4FQ:+,-R=27)>,IENJ5KSRQX03'QBA-/.C[72_%-&N-
MAF9LSD=#MI4)S<B< [%-4\S?)B1AN[M6T-H//-+56NH!;S3<X!5Y(O)Y,^?J
MS2N]Q#0EF: L YPL[UKCX':&.MK S/A"R4Y4GH&FLF#LFWZYC^]:OD9$$A))
M[0*KGQ<R)4FB/2D<_Q1.6^6:VK#ZO/?^BR&OR"RP(%.6?*6Q7-^U^BT0DR7>
M)O*1[7XC!2$#,&*),'_!KICKMT"T%9*EA;%"D-(L_\6O12 J!LI/O0$L#."Q
M0=A@@ H#]%Z#L# (361R*B8.,RSQ:,C9#G ]6WG3#R:8QEK1IYG.^Y/DZBM5
M=G+T)%GT[6:B(A>#*4M5.0EL$G(#QG%,]2-.P'V65YC^<#4C$M-$7*LIST\S
M</7A&GP 'A!KS(D - //&97BHQI4SP\T2925&'I2H=5K>E&!;)(C@PW(NN"!
M97(MP*<L)O&AO:=8EE3AGNH$.AU^WF9M@/R/ /HPJ,$S?;^Y7V,^<YO/2*3,
M@SKS S:H3!PR_E!3XG2X;Q:GB1MSCK,547M3@L4;J,Z;XS<S/-YA'H,_?U<N
MP;TDJ?C+ 2@L 84&4-@ Z#GC)&*KC/ZK5HJJB,BK?B9U)9"[[!J76J)>1OVA
M]U*#HE.BZ#A1/!55*,16P5!5JU8G/**" +8$;*,!"8"S&*@8J$!) :Y4F>;%
M>UT',5^O4X'HEQ#SNCF=$2C9]?UZ)MV22=?)Y*N1+$4"OQ"N)-@2V7 :$0,[
M9DF"N0 ;PG,*M0SR=?I5?*C=.R0QJYT$._4<>B6'GIO#/L9[[/&Y:/=.8AGV
MPH[?/0KYZ3380X.FD/=+N'TGW#EG$2&Q $O.4EL@)?@ZP+G'015PNW^$]G0.
M;'?KH0Y*J ,GU >:T72;.O9MX-LCP+\,*0DJIU+@I/?IL-;5UCW-Q@_L@&*U
MJLX,CG+DG'+( EH6T)TD_'HN25;N@PO1^\ *?N!6_)^=I-/#( B.L^2<<\C#
M'AF!^\P8SZ? ]$'@#W,^N()CU3OH7DB^K!@';C6>;WFTQF6^</RWZB_-@D;O
M'@A?$5[7&!5^JP+FMU%#V*W8!FZUG3#-,B7I@G#A(F@U,1A<1LRAU5;H.TGF
M%:6ZX56^,=1N4+N LK,'8>'WX(@+0]2KCSJTR@K=ROKSVHIBH6K+ %7+$#8@
MM*H)W:J9;\5]J_8=O+=.H-52>"%:"JV60K>6?B%"TFQ5%$=MN-T.('@CV!T?
M*XC0+8B/"HPJ!ETEPB0#:]).WU87X87H(K2Z"-VZV$ WW[+G6U9XVHP&'3]
M#<THM ()W0)YLE4-(!!C2< 24PY><++]H1W;/]VQ83MH:$6AU5WH;D9_K<6E
M^@%^'%G)P(* RC^*ZCO6+&^TSUK,@Y.S!S4US\C*,G++<E/*OX/SC36R6HN"
MRZAU9,45N<7UO,Z<<1 8G7%AJ=Q@H/^;A+.-,[+*BL(+28+55^36UW<DP>T
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M14GB1P#S*X@B#(&W$4<P!: !0Z*HV@?W]J-PLT^%[:]@X]]02P,$%     @
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M #)$(,-/A)POW,?%>.H 9V=L,CV9 <@(@8QV!GDQ_O$#0,8(9+PSR)/1_#N
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MX:U8+""X[JN25IQ13S*-L@'DE!^*;1#02K+[MIR!?5 />A)Q1JA 7/X!^H2
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ML^QM.[SDL^E_I.L_4$L! A0#%     @ 9X$&4P=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !G@093
MPU_3G>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !G@093F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &>!!E.#$!=Q204
M )D5   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !G@093!]\8%4D*  #C*P  &               @(&,
M#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 9X$&4PQZ
M[SU2!0  610  !@              ("!"Q@  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( &>!!E,;$CC_3@<  /8@   8
M  " @9,=  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !G
M@093*>;F<@<)  #C,@  &               @($7)0  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ 9X$&4PQ&*,9'"@  JRX  !@
M         ("!5"X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( &>!!E,?,)\, !8  !D_   8              " @=$X  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !G@093PNM0MT4I  !MAP
M&               @($'3P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ 9X$&4Y7B!HY5!   ?@H  !@              ("!@G@  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &>!!E.K%^T\"P\
M #4R   9              " @0U]  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ 9X$&4R<];7 _!   O0D  !D              ("!
M3XP  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !G@093
M6!3%@]<"  !$!@  &0              @('%D   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( &>!!E.Y!7""#0,  - &   9
M      " @=.3  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ 9X$&4\$^@7VH$   $SD  !D              ("!%Y<  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !G@093L9^#@!0%  !U#
M&0              @('VIP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( &>!!E,9_5QI< @  #$4   9              " @4&M  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 9X$&4VHH&H+'
M!P  L!H  !D              ("!Z+4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !G@093O*(;1+,%  !4#@  &0
M@('FO0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &>!
M!E-^&@+E<P0  +,-   9              " @=##  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ 9X$&4\MP7_#Q!P  ^Q(  !D
M         ("!>L@  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !G@093RS'MYPP&   ?'   &0              @(&BT   >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &>!!E-57.@UR@8  .X1
M   9              " @>76  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ 9X$&4[*N!1SD P  7@@  !D              ("!YMT
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !G@093*/[D
M&J$\   HT0  &0              @($!X@  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( &>!!E/),*&U804  ,@.   9
M  " @=D> 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M9X$&4_='A0D<!   \@D  !D              ("!<20! 'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !G@093EHVL['L%  "A#0  &0
M            @('$* $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( &>!!E.:B!$>Z (  #,&   9              " @78N 0!X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 9X$&4[P&$!H? P
MT@8  !D              ("!E3$! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !G@093L9(OE( #  "Z!P  &0              @('K
M- $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &>!!E,D
M/8S8]0(  $L&   9              " @:(X 0!X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ 9X$&4Y<FH*UA P  O H  !D
M     ("!SCL! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &>!!E/=).B/) @  * G   9              "
M@>U7 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 9X$&
M4XONKS24 P  < T  !D              ("!2& ! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !G@093JGD^*N\#  ""%   &0
M        @($39 $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( &>!!E-S,(PX<00  -\5   9              " @3EH 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 9X$&4PT&O7U%!0  ,!L
M !D              ("!X6P! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " !G@093")'UYXD"  #&!@  &0              @(%=<@$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &>!!E/"K]A7
MD (  +8&   9              " @1UU 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ 9X$&4X4[&?#U!0  #R   !D
M ("!Y'<! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !G
M@093!^6+]?0*  #510  &0              @($0?@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &>!!E/**$ =?PD  .TO   9
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M970U,"YX;6Q02P$"% ,4    " !G@093B52GKX$"  !(!@  &0
M    @(%\H $ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M &>!!E-=M;.^JPL  +)/   9              " @32C 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ 9X$&4^ EMGUJ P  2 P  !D
M             ("!%J\! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " !G@093GRTM2(\#   9#@  &0              @(&WL@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &>!!E-U&IKVT08
M '$H   9              " @7VV 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ 9X$&4ZC&N$J$ P  G0P  !D              ("!
MA;T! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !G@093
MZ,UO,2D"   O!0  &0              @(% P0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( &>!!E-("6^!8@(  ,8%   9
M      " @:## 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ 9X$&4W9%$Z\= P  .0H  !D              ("!.<8! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !G@093@7DYF+$#  #&#0
M&0              @(&-R0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( &>!!E-8E@WI;PL  &$[   9              " @77- 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ 9X$&4RA3!119
M P  6@P  !D              ("!&]D! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " !G@093RN4<("8#   U"@  &0
M@(&KW $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( &>!
M!E.TV8[=[ ,  $H0   9              " @0C@ 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ 9X$&4^+W!F[D P  <@\  !D
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M=#8Y+GAM;%!+ 0(4 Q0    ( &>!!E/)Z">>) 0  !80   9
M  " @5SX 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @
M9X$&4V@:%9\$!   7A,  !D              ("!M_P! 'AL+W=O<FMS:&5E
M=',O<VAE970W,2YX;6Q02P$"% ,4    " !G@093'YI)*!$#  #7"   &0
M            @('R  ( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4
M Q0    ( &>!!E._^5N[% (  ,H&   9              " @3H$ @!X;"]W
M;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ 9X$&4^?=#O\K P
M$A,   T              ( !A08" 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !G@093EXJ[',     3 @  "P              @ ';"0( 7W)E;',O+G)E
M;'-02P$"% ,4    " !G@093]Z58LKP%  "7,   #P              @ '$
M"@( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 9X$&4[?' S!" @  0BL
M !H              ( !K1 " 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 9X$&4_C# AT& @  3RH  !,              ( !)Q,"
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %$ 40 N%@  7A4"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>462</ContextCount>
  <ElementCount>545</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>147</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Investments in Other Entities ??? Equity Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</Role>
      <ShortName>Investments in Other Entities ??? Equity Method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2122106 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Credit Facility, Bank Loan and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2137111 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2141112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2143113 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2148114 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2151115 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2157116 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2165117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Investments in Other Entities ??? Equity Method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables</Role>
      <ShortName>Investments in Other Entities ??? Equity Method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2338307 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2344308 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2349309 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2352310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2358311 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/StockBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Investments in Other Entities ??? Equity Method - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities - Schedule of Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails</Role>
      <ShortName>Related-Party Transactions - Fees Incurred and Income Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442422 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2447425 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Variable Interest Entities (VIEs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2453427 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2454428 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2455429 - Disclosure - Leases - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2456430 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2459431 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2460432 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2461433 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2462434 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails</Role>
      <ShortName>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2463435 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2464436 - Disclosure - Stock-Based Compensation - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ameh-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ameh-20210630.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ameh-20210630.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ameh-20210630.htm">ameh-20210630.htm</File>
    <File>ameh-20210630.xsd</File>
    <File>ameh-20210630_cal.xml</File>
    <File>ameh-20210630_def.xml</File>
    <File>ameh-20210630_lab.xml</File>
    <File>ameh-20210630_pre.xml</File>
    <File>ex102021063010-q.htm</File>
    <File>ex31120210630110-q.htm</File>
    <File>ex3122021063010-q.htm</File>
    <File>ex3132021063010-q.htm</File>
    <File>ex322021063010-q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>92
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ameh-20210630.htm": {
   "axisCustom": 1,
   "axisStandard": 37,
   "contextCount": 462,
   "dts": {
    "calculationLink": {
     "local": [
      "ameh-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ameh-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ameh-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ameh-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 783,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 96,
   "keyStandard": 449,
   "memberCustom": 86,
   "memberStandard": 42,
   "nsprefix": "ameh",
   "nsuri": "http://www.apollomed.net/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.apollomed.net/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Investments in Other Entities \u2014 Equity Method",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod",
     "shortName": "Investments in Other Entities \u2014 Equity Method",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122106 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - Medical Liabilities",
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "shortName": "Medical Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Credit Facility, Bank Loan and Lines of Credit",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Mezzanine and Stockholders' Equity",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137111 - Disclosure - Related-Party Transactions",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141112 - Disclosure - Income Taxes",
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143113 - Disclosure - Earnings Per Share",
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsAtCarryingValue",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NotesAndLoansReceivableNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148114 - Disclosure - Variable Interest Entities (VIEs)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "shortName": "Variable Interest Entities (VIEs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151115 - Disclosure - Leases",
     "role": "http://www.apollomed.net/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2157116 - Disclosure - Stock Based Compensation",
     "role": "http://www.apollomed.net/role/StockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165117 - Disclosure - Subsequent Events",
     "role": "http://www.apollomed.net/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Investments in Other Entities \u2014 Equity Method (Tables)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables",
     "shortName": "Investments in Other Entities \u2014 Equity Method (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Medical Liabilities (Tables)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "shortName": "Medical Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338307 - Disclosure - Related-Party Transactions (Tables)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "shortName": "Related-Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344308 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349309 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2352310 - Disclosure - Leases (Tables)",
     "role": "http://www.apollomed.net/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2358311 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i7b5c9bd04c8c416990298e211b5fad7f_D20190901-20190930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i185f42a9a8b54e0ca62108c41bd664d8_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ia75080dfd6264d258c11212217c8b10f_D20210401-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ia75080dfd6264d258c11212217c8b10f_D20210401-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i5c98b023802344859e6d11a8234f1cf2_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentsContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "iac14ba3f77974628a3f15fb0add7d76e_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsAtCarryingValue",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i5c98b023802344859e6d11a8234f1cf2_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "idaaa7f5ccac14b0bbe403036ddcc6e72_I20201030",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i5c98b023802344859e6d11a8234f1cf2_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
     "shortName": "Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i2980472eb7b9414ba636a7c0026908e7_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "id3da79ae9a6b41debf540b695fc08b49_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i1423c5795a1b4d749457b1fe689f6082_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Related-Party Transactions - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "if70bdfc17f4843378fe0e472c8f0af69_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:PaymentConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
     "shortName": "Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i3629ab6d4d2d4265be7f841a30358d25_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442422 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i0408c582d1c8484f98671f80a6529d71_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i0408c582d1c8484f98671f80a6529d71_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447425 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ic3ad5bba1b2945d5aca93409af485c52_D20210401-20210630",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsAtCarryingValue",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Variable Interest Entities (VIEs) (Details)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails",
     "shortName": "Variable Interest Entities (VIEs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ibfca9028bfa64d778f68d8aa4ffdd6f1_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453427 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454428 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455429 - Disclosure - Leases - Other Information Related to Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456430 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459431 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ib8d088f0b5154bc889a9986965e09753_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460432 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461433 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie69084b20d984611b151ed5ed8994475_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462434 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
     "shortName": "Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie69084b20d984611b151ed5ed8994475_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i5c98b023802344859e6d11a8234f1cf2_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463435 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
     "shortName": "Stock-Based Compensation - Summary of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "ie0ce2c5b21ad4a46b6c04d08b22868ec_I20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464436 - Disclosure - Stock-Based Compensation - Warrants (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails",
     "shortName": "Stock-Based Compensation - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i434a1fa4730047f5ba3436f45a45cd10_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "id1d3f4fbb7de478bbc51935ca41ab818_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "id1d3f4fbb7de478bbc51935ca41ab818_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Intangible Assets, Net",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i4e91f3a922854a3caa8d484d9bf441e3_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i5c98b023802344859e6d11a8234f1cf2_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ameh-20210630.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ameh-20210630.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20210630.htm",
      "contextRef": "i5c98b023802344859e6d11a8234f1cf2_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 147,
   "tag": {
    "ameh_AHMCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AHMC [Member]",
        "terseLabel": "AHMC",
        "verboseLabel": "AHMC"
       }
      }
     },
     "localname": "AHMCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AMGPropertiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG Properties LLC",
        "label": "AMG Properties LLC [Member]",
        "terseLabel": "AMG Properties LLC"
       }
      }
     },
     "localname": "AMGPropertiesLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APAMHMedicalCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AP-AMH Medical Corporation [Member]",
        "label": "AP-AMH Medical Corporation [Member]",
        "terseLabel": "AP-AMH Medical Corporation"
       }
      }
     },
     "localname": "APAMHMedicalCorporationMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APCAndAPCLSMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APC And APC-LSMA [Member]",
        "label": "APC And APC-LSMA [Member]",
        "terseLabel": "APC and APC-LSMA"
       }
      }
     },
     "localname": "APCAndAPCLSMAMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccessPrimaryCareMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access Primary Care Medical Group",
        "label": "Access Primary Care Medical Group [Member]",
        "terseLabel": "Access Primary Care Medical Group"
       }
      }
     },
     "localname": "AccessPrimaryCareMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountableHealthCareIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accountable Health Care IPA [Member]",
        "verboseLabel": "Accountable Health Care"
       }
      }
     },
     "localname": "AccountableHealthCareIPAMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsPayableAndAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Expenses [Member]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Line Items]",
        "terseLabel": "Accounts Receivable And Net Revenue [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueLineItems",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Table]",
        "terseLabel": "Accounts Receivable And Net Revenue [Table]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueTable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AchievaMedInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AchievaMed, Inc. [Member]",
        "label": "AchievaMed, Inc. [Member]",
        "terseLabel": "AchievaMed, Inc."
       }
      }
     },
     "localname": "AchievaMedInc.Member",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "label": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "terseLabel": "Additional cash consideration entitled to be received"
       }
      }
     },
     "localname": "AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_AdvanceDiagnosticSurgeryCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Diagnostic Surgery Center [Member]",
        "terseLabel": "Advance Diagnostic Surgery Center"
       }
      }
     },
     "localname": "AdvanceDiagnosticSurgeryCenterMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AggregateintrinsicvalueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "localname": "AggregateintrinsicvalueAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AlliedPacificOfCaliforniaIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allied Pacific Of California IPA",
        "label": "Allied Pacific Of California IPA [Member]",
        "terseLabel": "APC",
        "verboseLabel": "APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlphaCareMedicalGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Care Medical Group, Inc. [Member]",
        "label": "Alpha Care Medical Group, Inc. [Member]",
        "terseLabel": "Alpha Care Medical Group, Inc."
       }
      }
     },
     "localname": "AlphaCareMedicalGroupInc.Member",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmgIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMG, Inc [Member]",
        "terseLabel": "AMG, Inc"
       }
      }
     },
     "localname": "AmgIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AncillaryServiceContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ancillary Service Contract [Member]",
        "terseLabel": "Ancillary Service Contract"
       }
      }
     },
     "localname": "AncillaryServiceContractMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaAcoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APA ACO Inc [Member]",
        "terseLabel": "APA ACO Inc"
       }
      }
     },
     "localname": "ApaAcoIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaacoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APAACO [Member]",
        "terseLabel": "APAACO"
       }
      }
     },
     "localname": "ApaacoMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Business Loan Agreement [Member]",
        "terseLabel": "APC Business Loan Agreement"
       }
      }
     },
     "localname": "ApcBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcLsmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC LSMA [Member]",
        "terseLabel": "APC LSMA"
       }
      }
     },
     "localname": "ApcLsmaMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Shareholders [Member]",
        "terseLabel": "APC Shareholders"
       }
      }
     },
     "localname": "ApcShareholdersMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Stock Option [Member]",
        "terseLabel": "APC Stock Option"
       }
      }
     },
     "localname": "ApcStockOptionMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloMedicalHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Medical Holdings, Inc [Member]",
        "terseLabel": "Apollo Medical Holdings, Inc"
       }
      }
     },
     "localname": "ApolloMedicalHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AssetAcquisitionPercentageOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Percentage Of Shares Acquired",
        "label": "Asset Acquisition, Percentage Of Shares Acquired",
        "terseLabel": "Asset acquisition, percentage of shares acquired"
       }
      }
     },
     "localname": "AssetAcquisitionPercentageOfSharesAcquired",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_AurionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Aurion Member",
        "label": "Aurion [Member]",
        "verboseLabel": "Aurion"
       }
      }
     },
     "localname": "AurionMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BeneficialInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Interest",
        "label": "Beneficial Interest [Policy Text Block]",
        "terseLabel": "Beneficial Interest"
       }
      }
     },
     "localname": "BeneficialInterestPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_BusinessCombinationPercentagePaidInCashWithinTenBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Percentage Paid In Cash Within Ten Business Days",
        "label": "Business Combination, Percentage Paid In Cash Within Ten Business Days",
        "terseLabel": "Business combination, percentage paid In cash within ten business days"
       }
      }
     },
     "localname": "BusinessCombinationPercentagePaidInCashWithinTenBusinessDays",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Percentage Paid Out in Cash Upon Achievement of Financial Milestones",
        "label": "Business Combination, Percentage Paid Out in Cash Upon Achievement of Financial Milestones",
        "terseLabel": "Business combination, percentage paid out in cash upon achievement of financial milestones"
       }
      }
     },
     "localname": "BusinessCombinationPercentagePaidOutInCashUponAchievementOfFinancialMilestones",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_CDSCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CDSC",
        "label": "CDSC [Member]",
        "terseLabel": "CDSC"
       }
      }
     },
     "localname": "CDSCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMS [Member]",
        "label": "CMS [Member]",
        "terseLabel": "CMS"
       }
      }
     },
     "localname": "CMSMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CancellationOfRestrictedStockAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation of Restricted Stock Awards",
        "label": "Cancellation of Restricted Stock Awards",
        "terseLabel": "Cancellation of Restricted Stock Awards"
       }
      }
     },
     "localname": "CancellationOfRestrictedStockAwards",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Lease Liabilities [Abstract]",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ClassOfWarrantOrRightCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, cancelled in period",
        "label": "Class Of Warrant Or Right Cancelled In Period",
        "negatedLabel": "Warrants expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledInPeriod",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Warrants Exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued in Period",
        "label": "Class Of Warrant Or Right Issued In Period",
        "verboseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights exercised in period.",
        "label": "Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights forfeited in period.",
        "label": "Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants expired/forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights granted in period.",
        "label": "Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights outstanding.",
        "label": "Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted Average Exercise\u00a0Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period",
        "verboseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights forfeited during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period",
        "verboseLabel": "Warrants expired/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights granted during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period",
        "verboseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_CollegeStreetInvestmentLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "College Street Investment LP [Member].",
        "label": "College Street Investment LP [Member]",
        "terseLabel": "College Street Investment LP"
       }
      }
     },
     "localname": "CollegeStreetInvestmentLpMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:CommercialMember",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ConcourseDiagnosticSurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concourse Diagnostic Surgery Center, LLC [Member]",
        "terseLabel": "Concourse Diagnostic Surgery Center, LLC"
       }
      }
     },
     "localname": "ConcourseDiagnosticSurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ConstructionLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction Loan",
        "label": "Construction Loan [Member]",
        "terseLabel": "Construction Loan"
       }
      }
     },
     "localname": "ConstructionLoanMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Axis]",
        "terseLabel": "Contract Type [Axis]"
       }
      }
     },
     "localname": "ContractTypeAxis",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Domain]",
        "terseLabel": "Contract Type [Domain]"
       }
      }
     },
     "localname": "ContractTypeDomain",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CriticalQualityManagementCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Critical Quality Management Corp Member",
        "label": "Critical Quality Management Corp [Member]",
        "terseLabel": "Critical Quality Management Corp"
       }
      }
     },
     "localname": "CriticalQualityManagementCorpMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, cash flow coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashFlowCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, debt coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Minimum consolidated interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Maximum consolidated leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentNumberOfKeyFinancialRatios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Key Financial Ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "terseLabel": "Number of key financial ratios"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DiagnosticMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diagnostic Medical Group [Member]",
        "terseLabel": "Diagnostic Medical Group"
       }
      }
     },
     "localname": "DiagnosticMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DmgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DMG [Member]",
        "terseLabel": "DMG"
       }
      }
     },
     "localname": "DmgMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.ArteagaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Arteaga [Member]",
        "label": "Dr. Arteaga [Member]",
        "verboseLabel": "Dr. Arteaga"
       }
      }
     },
     "localname": "Dr.ArteagaMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.JayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Jay [Member]",
        "label": "Dr. Jay [Member]",
        "terseLabel": "Dr. Jay"
       }
      }
     },
     "localname": "Dr.JayMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Earnings Per Share [Table]",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share [Table]",
        "label": "Earnings Per Share [Table]",
        "terseLabel": "Earnings Per Share [Table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquityMethodAndOtherEquityInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method And Other Equity Investments [Text Block]",
        "label": "Equity Method And Other Equity Investments [Text Block]",
        "verboseLabel": "Investments in Other Entities \u2014 Equity Method"
       }
      }
     },
     "localname": "EquityMethodAndOtherEquityInvestmentsTextBlock",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase",
        "terseLabel": "Equity method investment, conversion of finance receivable, ownership percentage increase"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "terseLabel": "Ownership upon conversion of finance receivable"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Disposed",
        "label": "Equity Method Investment, Ownership Percentage Disposed",
        "terseLabel": "Ownership interest disposed"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageDisposed",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "terseLabel": "Contingent consideration, cash held in escrow"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationCash",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "terseLabel": "Contingent consideration, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationFairValue",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "terseLabel": "Contingent consideration, preferred shares"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationPreferredShares",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentWriteOffOfAdditionalProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Write-off of Additional Proceeds",
        "label": "Equity Method Investment, Write-off of Additional Proceeds",
        "terseLabel": "Write off of additional proceeds"
       }
      }
     },
     "localname": "EquityMethodInvestmentWriteOffOfAdditionalProceeds",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsConsolidated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Consolidated",
        "label": "Equity Method Investments, Consolidated",
        "negatedTerseLabel": "Entity Consolidated"
       }
      }
     },
     "localname": "EquityMethodInvestmentsConsolidated",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Contribution",
        "label": "Equity Method Investments, Contribution",
        "terseLabel": "Contribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentsContribution",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option",
        "label": "Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option",
        "terseLabel": "Term of option"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Related investment balance"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "terseLabel": "Duration of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "terseLabel": "Membership interests acquired (in dollars per share)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "terseLabel": "Options to purchase additional membership interests (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "terseLabel": "Number of warrants available to purchase, contingent upon the portal completion date (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "terseLabel": "Percentage of voting common stock, within five years"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "terseLabel": "Membership interests purchased (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiduciaryAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Fiduciary Accounts Payable Current",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "FiduciaryAccountsPayableCurrent",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiduciaryCashAndPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiduciary Cash and Payable",
        "label": "Fiduciary Cash and Payable [Policy Text Block]",
        "terseLabel": "Fiduciary Cash and Payable"
       }
      }
     },
     "localname": "FiduciaryCashAndPayablePolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceReceivableInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Interest Rate, Stated Percentage",
        "label": "Finance Receivable, Interest Rate, Stated Percentage",
        "terseLabel": "Note receivable, interest rate"
       }
      }
     },
     "localname": "FinanceReceivableInterestRateStatedPercentage",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "label": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "FinanceReceivableModificationsSubsequentDefaultInterestRate",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Stated Interest Rate",
        "label": "Finance Receivable, Stated Interest Rate",
        "terseLabel": "Stated rate of note of loan receivable"
       }
      }
     },
     "localname": "FinanceReceivableStatedInterestRate",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableTermOfReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Term Of Receivable",
        "label": "Finance Receivable, Term Of Receivable",
        "terseLabel": "Term of receivable"
       }
      }
     },
     "localname": "FinanceReceivableTermOfReceivable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiveThreeOneW.CollegeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Three One W. College LLC [Member]",
        "terseLabel": "531 W. College LLC",
        "verboseLabel": "531 W. College, LLC \u2013 related party"
       }
      }
     },
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FreseniusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fresenius",
        "label": "Fresenius [Member]",
        "terseLabel": "Fresenius"
       }
      }
     },
     "localname": "FreseniusMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FulgentGeneticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fulgent Genetics, Inc.",
        "label": "Fulgent Genetics, Inc. [Member]",
        "terseLabel": "Fulgent Genetics, Inc."
       }
      }
     },
     "localname": "FulgentGeneticsIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HSMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_HSMSO Member",
        "label": "HSMSO [Member]",
        "verboseLabel": "HSMSO"
       }
      }
     },
     "localname": "HSMSOMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthCareCapitationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_HealthCareCapitationRevenueMember",
        "label": "Health Care Capitation Revenue [Member]",
        "verboseLabel": "Capitation, net"
       }
      }
     },
     "localname": "HealthCareCapitationRevenueMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_IncreaseDecreaseInMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.",
        "label": "Increase (Decrease) In Medical Liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase in operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial fixed term of amended and restated management and administrative services agreement.",
        "label": "Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement",
        "terseLabel": "Fixed term of amended and restated management and administrative services agreement"
       }
      }
     },
     "localname": "InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "label": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "terseLabel": "AHMC \u2013 Risk pool, capitation, claims payment"
       }
      }
     },
     "localname": "InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share .",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "verboseLabel": "Investments in privately held entities"
       }
      }
     },
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LasalleMedicalAssociatesIpaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LaSalle Medical Associates IPA [Member]",
        "terseLabel": "LaSalle Medical Associates \u2013 IPA Line of Business",
        "verboseLabel": "LaSalle Medical Associates"
       }
      }
     },
     "localname": "LasalleMedicalAssociatesIpaMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease liabilities:"
       }
      }
     },
     "localname": "LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Discount Rate [Abstract]",
        "verboseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]",
        "verboseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "terseLabel": "Finance lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "terseLabel": "Operating lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LMA [Member]",
        "terseLabel": "LMA"
       }
      }
     },
     "localname": "LmaMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LoanReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Receivable",
        "label": "Loan Receivable [Text Block]",
        "verboseLabel": "Loan Receivable and Loan Receivable \u2013 Related Parties"
       }
      }
     },
     "localname": "LoanReceivableTextBlock",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MPP, AMG Properties, and ZLL Asset Acquisition",
        "label": "MPP, AMG Properties, and ZLL Asset Acquisition [Member]",
        "terseLabel": "MPP, AMG Properties, and ZLL Asset Acquisition"
       }
      }
     },
     "localname": "MPPAMGPropertiesAndZLLAssetAcquisitionMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ManagementContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Contracts",
        "label": "Management Contracts [Member]",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementContractsMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MarketableSecuritiesCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current, Maturity Period",
        "label": "Marketable Securities, Current, Maturity Period",
        "terseLabel": "Short-term marketable securities, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_MaverickMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maverick Medical Group, Inc [Member]",
        "terseLabel": "Maverick Medical Group, Inc"
       }
      }
     },
     "localname": "MaverickMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MediPortalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MediPortal LLC [Member]",
        "terseLabel": "MediPortal LLC"
       }
      }
     },
     "localname": "MediPortalLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicaidMember",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Care Costs [Abstract]",
        "label": "Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "MedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MedicalPropertyPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Property Partners LLC",
        "label": "Medical Property Partners LLC [Member]",
        "terseLabel": "Medical Property Partners LLC"
       }
      }
     },
     "localname": "MedicalPropertyPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicareMember",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MemberRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Relationships",
        "label": "Member Relationships [Member]",
        "terseLabel": "Member relationships"
       }
      }
     },
     "localname": "MemberRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MezzanineEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEZZANINE EQUITY [Abstract]",
        "verboseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "MezzanineEquityAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine [Member]",
        "terseLabel": "Mezzanine"
       }
      }
     },
     "localname": "MezzanineMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MinorityInterestPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minority Interest Policy.",
        "label": "Minority Interest Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestPolicyPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NetworkMedicalManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management, Inc. [Member]",
        "terseLabel": "Network Medical Management, Inc."
       }
      }
     },
     "localname": "NetworkMedicalManagementIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management [Member]",
        "terseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Network Relationships",
        "label": "Network Relationships [Member]",
        "terseLabel": "Network relationships"
       }
      }
     },
     "localname": "NetworkRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employees",
        "label": "Number Of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFamilyPracticeClinics": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Family Practice Clinics",
        "label": "Number Of Family Practice Clinics",
        "terseLabel": "Number of family practice clinics"
       }
      }
     },
     "localname": "NumberOfFamilyPracticeClinics",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Federally Qualified Health Plans",
        "label": "Number Of Federally Qualified Health Plans",
        "terseLabel": "Number federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfLocations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Locations",
        "label": "Number of Locations",
        "terseLabel": "Number of locations"
       }
      }
     },
     "localname": "NumberOfLocations",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Granted",
        "label": "Number Of Warrants Granted",
        "verboseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numen LLC [Member]",
        "terseLabel": "Numen LLC"
       }
      }
     },
     "localname": "NumenLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, Inc. [Member]",
        "label": "One MSO, Inc. [Member]",
        "terseLabel": "One MSO, Inc."
       }
      }
     },
     "localname": "OneMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC",
        "label": "One MSO, LLC [Member]",
        "terseLabel": "One MSO, LLC - related party"
       }
      }
     },
     "localname": "OneMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC",
        "label": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:OtherThirdPartiesMember",
        "label": "Other Third Parties [Member]",
        "terseLabel": "Other third parties"
       }
      }
     },
     "localname": "OtherThirdPartiesMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Pacific6EnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific6 Enterprises [Member]",
        "label": "Pacific6 Enterprises [Member]",
        "terseLabel": "Pacific6 Enterprises"
       }
      }
     },
     "localname": "Pacific6EnterprisesMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificMedicalImagingAndOncologyCenterIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]",
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc."
       }
      }
     },
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PatientManagementPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Management Platform",
        "label": "Patient Management Platform [Member]",
        "terseLabel": "Patient management platform"
       }
      }
     },
     "localname": "PatientManagementPlatformMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentConsultingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Consulting Fees",
        "label": "Payment Consulting Fees",
        "terseLabel": "Consulting services paid"
       }
      }
     },
     "localname": "PaymentConsultingFees",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentMadeToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit/Duration (Amount paid to related party in relation to providing services",
        "label": "Payment Made To Related Party",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentMadeToRelatedParty",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue",
        "label": "Payment Of Revenue",
        "terseLabel": "Payments received"
       }
      }
     },
     "localname": "PaymentOfRevenue",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueMonthlyAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue, Monthly Amount",
        "label": "Payment Of Revenue, Monthly Amount",
        "terseLabel": "Payments received, monthly"
       }
      }
     },
     "localname": "PaymentOfRevenueMonthlyAmount",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue, Revenue Recognized",
        "label": "Payment Of Revenue, Revenue Recognized",
        "terseLabel": "Payments received, revenue"
       }
      }
     },
     "localname": "PaymentOfRevenueRevenueRecognized",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Medical Care Costs [Abstract]",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Payments to purchase membership interests"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PayorAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor A [Member]",
        "label": "Payor A [Member]",
        "terseLabel": "Payor A"
       }
      }
     },
     "localname": "PayorAMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor B [Member]",
        "label": "Payor B [Member]",
        "terseLabel": "Payor B"
       }
      }
     },
     "localname": "PayorBMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor C [Member]",
        "label": "Payor C [Member]",
        "terseLabel": "Payor C"
       }
      }
     },
     "localname": "PayorCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payor D [Member]",
        "terseLabel": "Payor D"
       }
      }
     },
     "localname": "PayorDMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payor E [Member]",
        "terseLabel": "Payor E"
       }
      }
     },
     "localname": "PayorEMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor F [Member]",
        "label": "Payor F [Member]",
        "terseLabel": "Payor F"
       }
      }
     },
     "localname": "PayorFMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor G",
        "label": "Payor G [Member]",
        "terseLabel": "Payor G"
       }
      }
     },
     "localname": "PayorGMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PerMemberPerMonthManagedCareContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per-Member-Per-Month Managed Care Contract [Member]",
        "label": "Per-Member-Per-Month Managed Care Contract [Member]",
        "terseLabel": "PMPM Managed Care Contract"
       }
      }
     },
     "localname": "PerMemberPerMonthManagedCareContractMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PercentageOfFinancialGuaranteeBenchmarkAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financial guarantee on benchmark Medicare expenditure amount.",
        "label": "Percentage Of Financial Guarantee Benchmark Amount",
        "terseLabel": "General amount of guarantee (as a percent)"
       }
      }
     },
     "localname": "PercentageOfFinancialGuaranteeBenchmarkAmount",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_PmiocMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PMIOC [Member]",
        "terseLabel": "PMIOC"
       }
      }
     },
     "localname": "PmiocMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PreferredBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Bank [Member]",
        "terseLabel": "Preferred Bank"
       }
      }
     },
     "localname": "PreferredBankMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PrepaymentForInvestmentPurchase": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment for Investment Purchase",
        "label": "Prepayment for Investment Purchase",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PrepaymentForInvestmentPurchase",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "label": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "terseLabel": "Cash received from consolidation of VIE"
       }
      }
     },
     "localname": "ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ProceedsFromSaleOfNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Sale of Noncontrolling Interest",
        "label": "Proceeds from Sale of Noncontrolling Interest",
        "terseLabel": "Proceeds from sale of noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Receivables and receivables from related parties.",
        "label": "Receivables And Related parties Receivables Policy Text Block [Policy Text Block]",
        "verboseLabel": "Receivables, Receivables \u2013 Related Parties, and Loan Receivables"
       }
      }
     },
     "localname": "ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "terseLabel": "Expected period of payment upon termination of agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "terseLabel": "Risk pool surplus or deficits, settlement period after risk pool performance year"
       }
      }
     },
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_SCHCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCHC [Member]",
        "label": "SCHC [Member]",
        "terseLabel": "SCHC"
       }
      }
     },
     "localname": "SCHCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "terseLabel": "Exercise price of warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ShareholdersAndOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders And Officers [Member]",
        "terseLabel": "APC Shareholders and Officers"
       }
      }
     },
     "localname": "ShareholdersAndOfficersMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_SharesWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Warrants [Roll Forward]",
        "label": "Shares, Warrants [Roll Forward]",
        "terseLabel": "Shares, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "SharesWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SpecialtyCapitationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of specialty capitation payable current.",
        "label": "Specialty Capitation Payable Current",
        "verboseLabel": "Capitation payable"
       }
      }
     },
     "localname": "SpecialtyCapitationPayableCurrent",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockAwardsAndUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Awards And Units",
        "label": "Stock Awards And Units [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "StockAwardsAndUnitsMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_StockIssuedDuringPeriodProxyVotesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Proxy Votes, Percentage",
        "label": "Stock Issued During Period, Proxy Votes, Percentage",
        "terseLabel": "Proxy votes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodProxyVotesPercentage",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to merger.",
        "label": "Stock Issued During Period, Shares, Merger",
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Shares issued for exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of share issued exercise of option and warrants during the period",
        "label": "Stock issued during the period shares of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents value of stock issued during the period",
        "label": "Stock issued during the period value of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SubcontractorIPAPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subcontractor IPA Payable",
        "label": "Subcontractor IPA Payable",
        "verboseLabel": "Subcontractor IPA payable"
       }
      }
     },
     "localname": "SubcontractorIPAPayable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SunClinicalLaboratoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sun Clinical Laboratories",
        "label": "Sun Clinical Laboratories [Member]",
        "terseLabel": "Sun Clinical Laboratories"
       }
      }
     },
     "localname": "SunClinicalLaboratoriesMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC",
        "label": "Tag-6 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC - Related Party",
        "label": "Tag-6 Medical Investment Group, LLC - Related Party [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC - related party"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCRelatedPartyMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-8 Medical Investment Group, LLC",
        "label": "Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "Tag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag8MedicalInvestmentGroupLLCRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-8 Medical Investment Group, LLC - Related Party",
        "label": "Tag-8 Medical Investment Group, LLC - Related Party [Member]",
        "terseLabel": "Tag-8 Medical Investment Group, LLC - related party"
       }
      }
     },
     "localname": "Tag8MedicalInvestmentGroupLLCRelatedPartyMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity [Policy Text Block]",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A [Member]",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareAcquisitionPartnersLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Acquisition Partners, LLC [Member]",
        "terseLabel": "Universal Care Acquisition Partners, LLC"
       }
      }
     },
     "localname": "UniversalCareAcquisitionPartnersLlcMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Inc [Member]",
        "terseLabel": "Universal Care Inc"
       }
      }
     },
     "localname": "UniversalCareIncMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range One [Member]",
        "verboseLabel": "Warrant Exercise Price Range One"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeOneMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Three [Member]",
        "verboseLabel": "Warrant Exercise Price Range Three"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeThreeMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Two [Member]",
        "verboseLabel": "Warrant Exercise Price Range Two"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeTwoMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued During Period Value Stock Options Exercised",
        "label": "Warrant Issued During Period Value Stock Options Exercised",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "WarrantIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WeightedAverageExercisePriceWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "label": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price, Warrants [Roll Forward]"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WeightedaverageremainingcontractualtermyearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term Years [Abstract]"
       }
      }
     },
     "localname": "WeightedaverageremainingcontractualtermyearsAbstract",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ZLLPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZLL Partners LLC",
        "label": "ZLL Partners LLC [Member]",
        "terseLabel": "ZLL Partners LLC"
       }
      }
     },
     "localname": "ZLLPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20210630",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r397",
      "r575",
      "r576",
      "r579",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r139",
      "r286",
      "r291",
      "r297",
      "r483",
      "r484",
      "r491",
      "r492",
      "r582",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r139",
      "r286",
      "r291",
      "r297",
      "r483",
      "r484",
      "r491",
      "r492",
      "r582",
      "r705"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r71",
      "r73",
      "r136",
      "r137",
      "r303",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board members"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r216",
      "r378",
      "r383",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r302",
      "r340",
      "r400",
      "r403",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r622",
      "r684",
      "r687",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r302",
      "r340",
      "r400",
      "r403",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r622",
      "r684",
      "r687",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r216",
      "r378",
      "r383",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r214",
      "r378",
      "r381",
      "r623",
      "r683",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r214",
      "r378",
      "r381",
      "r623",
      "r683",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r302",
      "r340",
      "r389",
      "r400",
      "r403",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r622",
      "r684",
      "r687",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r302",
      "r340",
      "r389",
      "r400",
      "r403",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r622",
      "r684",
      "r687",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r72",
      "r73",
      "r136",
      "r137",
      "r303",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r149",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r149",
      "r154",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r149",
      "r154",
      "r280",
      "r401",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r217",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r47",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "verboseLabel": "Receivables and Receivables-Related Parties"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r36",
      "r218",
      "r219"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r62",
      "r135",
      "r576",
      "r579"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Receivables, net \u2013 related parties",
        "verboseLabel": "Receivables, net \u2013 related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r27",
      "r643",
      "r666"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r53"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r37",
      "r438",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r435",
      "r436",
      "r437",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r405",
      "r432",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r87",
      "r117",
      "r322",
      "r548"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r117",
      "r259",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Treasury shares not included in the calculation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r117",
      "r272"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of beneficial interest"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r132",
      "r196",
      "r206",
      "r212",
      "r235",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r483",
      "r491",
      "r536",
      "r584",
      "r586",
      "r641",
      "r664"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r66",
      "r132",
      "r235",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r483",
      "r491",
      "r536",
      "r584",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r132",
      "r235",
      "r286",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r483",
      "r491",
      "r536",
      "r584"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent assets",
        "verboseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r222",
      "r225",
      "r247",
      "r648"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities \u2013 certificates of deposit"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r407",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r509",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Bridge Loan"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r399",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r399",
      "r402",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r471",
      "r472",
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r471",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of shares transferred in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities": {
     "auth_ref": [
      "r467",
      "r468"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities",
        "terseLabel": "Standby letters of credit assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r140",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r44",
      "r119"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r120",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r110",
      "r119",
      "r125"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "terseLabel": "Cash, cash equivalents, restricted cash total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r110",
      "r537"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r129",
      "r132",
      "r157",
      "r158",
      "r159",
      "r161",
      "r163",
      "r172",
      "r173",
      "r174",
      "r235",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r338",
      "r339",
      "r343",
      "r347",
      "r536",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise\u00a0Price\u00a0Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants received (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r364",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r279",
      "r650",
      "r672"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r281",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r33",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r33",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 100,000,000 shares authorized, 44,246,796 and 42,249,137 shares outstanding, excluding 10,885,732 and 12,323,164 treasury shares, as of June\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r216",
      "r534",
      "r535",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r216",
      "r534",
      "r535",
      "r694",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r216",
      "r534",
      "r535",
      "r694",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r178",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r182",
      "r183",
      "r216",
      "r534",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r216",
      "r534",
      "r535",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Other Entities - Equity Method and Investments in Other Entities - Cost Method"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r490",
      "r494",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entity"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r366",
      "r367",
      "r379"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Accrued contract liability recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r122",
      "r123",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Preferred shares received from sale of equity investment"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of services, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r181",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r128",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r316",
      "r323",
      "r324",
      "r326",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility, Bank Loan and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r131",
      "r139",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r330",
      "r331",
      "r332",
      "r333",
      "r549",
      "r642",
      "r645",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r28",
      "r327",
      "r645",
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r299",
      "r330",
      "r331",
      "r547",
      "r549",
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt, principal sum"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r55",
      "r319",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Average effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on loan receivable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r56",
      "r131",
      "r139",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r330",
      "r331",
      "r332",
      "r333",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r56",
      "r131",
      "r139",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r306",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r325",
      "r330",
      "r331",
      "r332",
      "r333",
      "r355",
      "r358",
      "r359",
      "r360",
      "r546",
      "r547",
      "r549",
      "r550",
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Revolving credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r312",
      "r328",
      "r330",
      "r331",
      "r548"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Unamortized financing costs",
        "terseLabel": "Unamortized financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Amount outstanding under agreement"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r117",
      "r193"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r68",
      "r73",
      "r74",
      "r512",
      "r604"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r73",
      "r510",
      "r513",
      "r515",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r507",
      "r510",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73",
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r511"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Loss on interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r504",
      "r505",
      "r507",
      "r508",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated as hedging instruments:"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Disaggregated Revenue by Each Payor Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r361",
      "r658"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "verboseLabel": "Dividends paid"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r53"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable",
        "verboseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r27",
      "r30",
      "r644",
      "r665"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividend declared included in dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromAffiliateCurrent": {
     "auth_ref": [
      "r62",
      "r576",
      "r578",
      "r583"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due within 1 year (or 1 business cycle).",
        "label": "Due from Affiliate, Current",
        "terseLabel": "Amount due from affiliate"
       }
      }
     },
     "localname": "DueFromAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r25",
      "r135",
      "r576",
      "r696"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Amount due to affiliate"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r47",
      "r135",
      "r289",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298",
      "r576"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r86",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r155",
      "r157",
      "r161",
      "r162",
      "r163",
      "r168",
      "r169",
      "r522",
      "r523",
      "r653",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r86",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r161",
      "r162",
      "r163",
      "r168",
      "r169",
      "r522",
      "r523",
      "r653",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r164",
      "r166",
      "r167",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r433"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r78",
      "r79",
      "r80",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r171",
      "r237",
      "r354",
      "r361",
      "r435",
      "r436",
      "r437",
      "r454",
      "r455",
      "r521",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r688",
      "r689",
      "r690",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Amount invested for interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r2",
      "r132",
      "r235",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r2",
      "r132",
      "r235",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest",
        "verboseLabel": "Investment, ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r89",
      "r90",
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedLabel": "Gain on sale of equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r45",
      "r197",
      "r232"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "verboseLabel": "Investment in other entities \u2013 equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "verboseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "verboseLabel": "Investment in privately held entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable securities \u2013 equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Equity securities, FV-NI, unrealized gain"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r525",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r314",
      "r390",
      "r391",
      "r396",
      "r398",
      "r525",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r396",
      "r398",
      "r525",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r525",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r314",
      "r330",
      "r331",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r554",
      "r562",
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "verboseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r556",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "verboseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r553",
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "netLabel": "Less: current portion",
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Finance Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r555",
      "r565"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease obligations",
        "verboseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets recorded under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r554",
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r554",
      "r562",
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "verboseLabel": "Amortization of lease expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r568",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r567",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r248",
      "r249",
      "r250",
      "r251",
      "r325",
      "r352",
      "r520",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r476",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r476",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r260",
      "r261",
      "r265",
      "r268",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r265",
      "r625"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Amortized intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r260",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r265",
      "r624"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r95",
      "r117",
      "r224"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain on sale of equity method investment"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r252",
      "r254",
      "r586",
      "r639"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r256",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r117",
      "r253",
      "r255",
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "verboseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOtherMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.",
        "label": "Health Care, Other [Member]",
        "terseLabel": "Risk pool settlements and incentives"
       }
      }
     },
     "localname": "HealthCareOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Fee-for-service, net"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r507",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r117",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of finite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r117",
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r117",
      "r272",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets and Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r196",
      "r205",
      "r208",
      "r211",
      "r213"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r82",
      "r117",
      "r194",
      "r232",
      "r651",
      "r674"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss (income) from equity method investments",
        "netLabel": "Income (loss) from equity method investments",
        "terseLabel": "(Loss) income from equity method investments",
        "verboseLabel": "Allocation of Income (Loss)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]",
        "verboseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r448",
      "r449",
      "r452",
      "r456",
      "r458",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r134",
      "r152",
      "r153",
      "r195",
      "r446",
      "r457",
      "r459",
      "r677"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Provision for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r77",
      "r442",
      "r443",
      "r449",
      "r450",
      "r451",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r113",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivables, net \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of business combinations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r116",
      "r565"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r258",
      "r263"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r81",
      "r192",
      "r545",
      "r548",
      "r654"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r108",
      "r112",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r94",
      "r191"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r569",
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost, net"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Information Related to Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, finance"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r51",
      "r132",
      "r207",
      "r235",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r484",
      "r491",
      "r492",
      "r536",
      "r584",
      "r585"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r132",
      "r235",
      "r536",
      "r586",
      "r647",
      "r670"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities, mezzanine equity, and stockholders\u2019 equity",
        "totalLabel": "Total liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Deficit",
        "verboseLabel": "Liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r132",
      "r235",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r484",
      "r491",
      "r492",
      "r536",
      "r584",
      "r585",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r28",
      "r29",
      "r132",
      "r235",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r484",
      "r491",
      "r492",
      "r536",
      "r584",
      "r585"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities",
        "verboseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r678",
      "r681"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical liabilities, end of period",
        "periodStartLabel": "Medical liabilities, beginning of period",
        "terseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r680"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedLabel": "Current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r680"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedLabel": "Prior periods"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r679"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Medical Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r28",
      "r645",
      "r662"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "totalLabel": "Total",
        "verboseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r49",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Annual agent fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Required annual facility fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Term of facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r49",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Amount available"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r49",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r28",
      "r313",
      "r329",
      "r330",
      "r331",
      "r645",
      "r667"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Less: Current portion of debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r139",
      "r284",
      "r318"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r139",
      "r284",
      "r318"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r139",
      "r284",
      "r318"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r139",
      "r284",
      "r318"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs",
        "verboseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r56",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "negatedLabel": "Management fees"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementServiceMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business.",
        "label": "Management Service [Member]",
        "terseLabel": "Management fee income",
        "verboseLabel": "Management Fee Income Contract"
       }
      }
     },
     "localname": "ManagementServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r52"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "verboseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "terseLabel": "Initial capital contributions"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r64",
      "r132",
      "r235",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r536",
      "r646",
      "r669"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Dividends"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r361",
      "r481",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r175",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r110",
      "r115",
      "r118"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r75",
      "r76",
      "r80",
      "r85",
      "r118",
      "r132",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r160",
      "r196",
      "r205",
      "r208",
      "r211",
      "r213",
      "r235",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r523",
      "r536",
      "r652",
      "r675"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Apollo Medical Holdings, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r75",
      "r76",
      "r80",
      "r152",
      "r153",
      "r487",
      "r501"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r362",
      "r469",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Investment in noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r362",
      "r481",
      "r489"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "terseLabel": "Sales of noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r361",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r34",
      "r218",
      "r219",
      "r649"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Loan receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Loans receivables"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r220",
      "r238",
      "r241",
      "r243",
      "r245",
      "r246",
      "r719",
      "r720",
      "r721"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of financing receivable.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Note receivable, amount"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Convertible Secured Promissory Note"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r36",
      "r218",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Amount of loan"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r62",
      "r135",
      "r576"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "terseLabel": "Loan receivable \u2013 related party"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r18",
      "r35",
      "r135",
      "r576"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Noncurrent",
        "terseLabel": "Loans receivables \u2013 related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of main reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r196",
      "r205",
      "r208",
      "r211",
      "r213"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r563",
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r557",
      "r565"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r568",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r567",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r24",
      "r640",
      "r663"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r65",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r45",
      "r673"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Investment in affiliates"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Fees paid"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r114",
      "r680"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r100",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payments for business acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchase of investment \u2013 equity method"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRealEstate": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.",
        "label": "Payments to Acquire Real Estate",
        "terseLabel": "Purchase price of real estate"
       }
      }
     },
     "localname": "PaymentsToAcquireRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r32",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r32",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r42",
      "r43"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r98",
      "r575"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.",
        "label": "Proceeds from Collection of Long-term Loans to Related Parties",
        "terseLabel": "Proceeds from repayment of loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r103",
      "r131"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings on revolver"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherOperatingActivities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from operating activities classified as other.",
        "label": "Proceeds from Other Operating Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromOtherOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r75",
      "r76",
      "r80",
      "r109",
      "r132",
      "r144",
      "r152",
      "r153",
      "r196",
      "r205",
      "r208",
      "r211",
      "r213",
      "r235",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r480",
      "r486",
      "r488",
      "r501",
      "r502",
      "r523",
      "r536",
      "r655"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r67",
      "r273",
      "r562"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r273",
      "r586",
      "r657",
      "r671"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Land, property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstateLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan to finance the purchase of real estate, including but not limited to, land or building.",
        "label": "Real Estate Loan [Member]",
        "terseLabel": "Real Estate Loan"
       }
      }
     },
     "localname": "RealEstateLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r397",
      "r575",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r397",
      "r575",
      "r576",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "totalLabel": "Receipts, net",
        "verboseLabel": "Recognized risk pool revenue"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r397",
      "r575",
      "r579",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r573",
      "r574",
      "r576",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r125"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r125",
      "r698",
      "r700"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash - current"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r10",
      "r24",
      "r125",
      "r698",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash - noncurrent"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r24",
      "r125",
      "r699"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r361",
      "r438",
      "r586",
      "r668",
      "r691",
      "r692"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r237",
      "r435",
      "r436",
      "r437",
      "r454",
      "r455",
      "r521",
      "r688",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r189",
      "r190",
      "r204",
      "r209",
      "r210",
      "r214",
      "r215",
      "r216",
      "r377",
      "r378",
      "r623"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r92",
      "r289",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298",
      "r697"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolver Loan",
        "verboseLabel": "Revolver Loan"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r566",
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r182",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "verboseLabel": "Net Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r405",
      "r431",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r2",
      "r132",
      "r234",
      "r235",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r260",
      "r264",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r260",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Medical Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Schedule of Fees Incurred and Revenue Earned from Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r407",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r411",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r60",
      "r129",
      "r172",
      "r173",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r347",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r364",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r483",
      "r484",
      "r491",
      "r492",
      "r493",
      "r495",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r493",
      "r495",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "verboseLabel": "Schedule of Assets and Liabilities, Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Reportable Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r413",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "verboseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r404",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Market value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Grant date fair value of restricted stock to be recognized straight-line"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r426",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r282",
      "r283",
      "r477",
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r129",
      "r132",
      "r157",
      "r158",
      "r159",
      "r161",
      "r163",
      "r172",
      "r173",
      "r174",
      "r235",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r298",
      "r338",
      "r339",
      "r343",
      "r347",
      "r354",
      "r536",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r61",
      "r78",
      "r79",
      "r80",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r153",
      "r171",
      "r237",
      "r354",
      "r361",
      "r435",
      "r436",
      "r437",
      "r454",
      "r455",
      "r521",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r688",
      "r689",
      "r690",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r171",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r32",
      "r33",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Sale of Sales by NCI (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r32",
      "r33",
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares purchased by related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r32",
      "r33",
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedTerseLabel": "Cancellation of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r33",
      "r354",
      "r361",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r61",
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Sale of shares by noncontrolling interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r32",
      "r33",
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock subscriptions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r32",
      "r33",
      "r354",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedTerseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r32",
      "r33",
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r32",
      "r33",
      "r361",
      "r406",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r354",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Purchase price adjustment from Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r33",
      "r39",
      "r40",
      "r132",
      "r221",
      "r235",
      "r536",
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity, parent"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r79",
      "r132",
      "r141",
      "r142",
      "r143",
      "r145",
      "r151",
      "r235",
      "r237",
      "r361",
      "r435",
      "r436",
      "r437",
      "r454",
      "r455",
      "r478",
      "r479",
      "r500",
      "r521",
      "r536",
      "r538",
      "r539",
      "r543",
      "r689",
      "r690",
      "r723"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "terseLabel": "Stockholders\u2019 deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r130",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r353",
      "r361",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Mezzanine and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r564",
      "r571"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r544",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r544",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r544",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r544",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r587",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r679"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r679"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r59",
      "r132",
      "r235",
      "r536"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "terseLabel": "Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trade names/trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r325",
      "r352",
      "r520",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r33",
      "r354",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r354",
      "r361",
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized (gain) loss from investment in equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r176",
      "r177",
      "r179",
      "r180",
      "r184",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Variable Interest Entities (VIEs)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r483",
      "r484",
      "r491",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r156",
      "r163"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r155",
      "r163"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r708": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r709": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r710": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r711": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r712": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r713": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r714": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r715": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r716": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r722": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>93
<FILENAME>0001628280-21-016083-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-016083-xbrl.zip
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M24.J0.)5KKE2&"2U^MYDLA\?7-=7F7S&,()_@SZ?LQ:AQ;X;4HSKZV=M1&<
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M5YM]QN;7#2W*LX6R]$2X]5JPUF)B5Y+*!=.<0X$)T&=T\6AX5-7Z&7V1Z@V
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M_N-';GB_RHF+\5B3U *.+:>8P 5K4U5HRX@K_HX?W2MQI+DH6C83!6S0*C&
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MF'GK]H.K7FXW2&R,%J- J*1^%*"UWJG8:E0$7XIGADG'QBV -D@,S)1=XY+
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M6-!0@F);3M5'==+JFJT5.X7='J,D\A^3ZDU&W9C7HZ;WMJ->DH/-ZB*AI>1
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MFS6#R)$:K:\&&A-;J"9E[[Q4H$P:NTRV$Y CUYXU0_0D4M_".>1@+#@.FK=
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M].QXL_MCGHU>H([N5=Z($!'/P1M<AU@G-DZL\WHP5KXI4F(9ISY+>1(E!=Y
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M.^VX@W3@I73H&_J\/98BWR,612+A"E%@)\25=>#T<HV,#JT5F"9.Q2MK]6/
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MW'DJIQ;TW=#O*)JKFXQ52NY,3NM4#6P?J9&N%!(#LR&<23C2V!\2%#1$*G'
MIIIH1K5VTA# %7R>FM=6:;=S RHJ.7U1.9VJ#@;Z$B<A08X3XSLP8*1C19%0
MU$AC*%#-KJPQ,D_I\6\J'/&3,SO/"AS>A)<SN[,\E;9ZG+9J7ZD@QI5TD8T=
M8H;X?C&.(!TE"2*4.$$CE\0) S^'UP1Y<CN&*EHQOW(\N_,\E1P_7HZG=@N)
M(:$4$9(XBL$[P +%5C/$>$Q"9E3(!7@'1-3B<)[R#]]4O&+K2G[S75BCZ,1G
M)ULF20'4/5@QV6!8'2J>:4[35.)EI;6>CC[:==$Z;WZGVDK,N4;4"HIX'(5(
M26X1MTX0&B=<&E^))*:UZ.FYTU5P8WY%^)5SIRL1?CKP&(MP:*0(E9,H-%&"
MN!$.*<,IPAQ'G&FK(\U7UBC#-5K%/686]QAV7#YUR*HJ8S8?L**@R_3.;:67
MG@%:D.;AE^]1R%FH"4-A& D %"%!FDB)#&'6QHF@H30 +6I$SI-35 4WYA)8
MG+L\LVK0J>3W-7 %R&_]NXI#BD62(.T,X H2.J234""0:8$MY<:J> 4D-::$
MOI\C"7Z6-.=GS$%]KN/OLQGDBZ;0SDUV],\.P/4?DR/]YM7^ZQYSJ]3^(]5^
M\VI96H.EP@K9,-&("V:0C#!&P,*.Q;&DPODL%R)K$L]34XP*L\TE9JN$]^6%
M]W(3RAG))68629: NT4$P#7C"V)@4,/@<CF:2!!>$=48?W*OB0JNS2E<>S.(
M[?925R5BFX)IP82EGW4TX:JXQW!N*87H"8;8ZBWU\;0:./^ E;7?R.\5N)PG
M<%E9I0=9I2O%$[0U$F""0Y9@[?<7)9(A25"D$QIA(QDUP/*,1\]QD+J"E/,K
MLJ\+*2N1?:C(7@+)!#/GC&$(="L 2<H2I!S7*&8B8@I'3B4AB&Q$:XP]N=[)
M$@/)N7[&J\+!650V6,]ZO;1HNCXHDKJ\,H*!N[[QJ/"W5C9T 9E"6L^@]%\&
MOYP.TG?]M/N?E6$^<M=5WM0L?;OYZ3E6*O!!*M!,HQ;#G0-,8I",!4-<686D
M(A8I'B7,D,1@$7I)NJ;[YJ:"R>UUO@L=^K,:X946G6<M.K,B,2^$\AZOV"IU
M=A]U-M7)*E+:&&40#PDX89&D2(4N1H0Y%BHA-8MO4V=-=WZN^L .@?O?:+IH
MS,/+ KVABD^+D8_F8^YP4YYUNSZ_/?45Z]U@"+\$=?C(V>!SYVR0FA3>X?/D
MUV' X(CU4U4+5/ YSQ(W& "3J&[0=-9/*5C/\N/,'S*ISOK/-'+5=CU/A_QL
MHY#:=97G9["@]1XL]G"S;[HCO[Z?RP,/]>$P3_6H:.+1SJYRQ>:8*2HH^2#=
M>WCEC)_4B3/"2:25C1 '6B/)<(B4"@77D;'8^%HFG-1B4;4 7V+)?X4 6"7Y
MLY?\J3B:Y%:82"+&I4==_GR@<P3A)&9*"2Z5MF4-4<KFKM77')4)?;D-V9D.
M\FT4&-T=9N:HDW5A<09%JFCT_NG>1!4:N$G>R8/'WT?^YG>$%&[(C(SC+GP-
MGE8'=V%RHG;@V:$6_/-G=O.SRW<[*G?7["=HS2BF(F1.8:X%4<Q8*CQNEIQ*
M[&ZWGYNM#]>MY,5H"M[\K/+M?'>HAL[^K;HC=_GVL>7#E>6[A^5K#IOK8\NW
M+O'^?SO8]/[NJV]RM W?;WZ$V?2^$!@+;[9WCEJ''SHP9PKCP*U>"W[O=IKT
MK^Y_SYLGWYE6+-::HT3&''%I'=A-$P*/*B8)CD+JU,^1UQT<)$P(4(N[!#O*
M 7''EC%-+4F$A"N6W.Y[51RT<!QD0V.5L@(9SA/$<6B0% HCXDCH<*AI1.C*
MFN\^>?,\Y(T/@F.5!S\\88-C!ZC(D_9]<"?[%=<'SZ>[[@W^KS)EP8&#^FC8
MR7)0V;9BQIDPXU?\G>K( O8'.^]\*X$DI$B)"",+_H&)A1.:L9^HLUOYZ0F:
MK.*G!>>G.,02)Q:<R82#>0P=1\K_*;1VF"91:(5;61,UP';^OWLHN)+% G5!
MW."WU <+!ND/YV._JML-CJ]#N'023@C&,._/ZS#O]X=JR5EQ]>9@,*HX>D8<
MO8%;)]_CB$32,85TI#Q/,XFDQ R)V)<S"(W3UCY41\[*YE;<-&MN2F0D"342
M&19+Q(UW("+XH0307\:AHY(6!\])\=\]-&1:T+3((YH%$X(#;CPCGF2Y';C^
M?;AP>S0<#&&\H* K5IP-*]+FE^_@O6J1)!@QZG,I8^>0QB1!\%F46$.ECF8$
M_BJ>6E2>TMB&C#B)E-7@4&"BD6;2(8,-HTP#+YAX9<T73+B'9LLN:5H=.OG5
M!MYCY.Z^A2RN"EP12*HVWQXJ9)?;[C9.%.=2(B%\'Q$I.8IC"[!2A(0PCC7&
M8AZ+5U3G3IY9:A^'P"JI?46IO=PR!TU*#>81BD7DR_>;$"DG,0+"6,EC8%B<
MS*/4OO9>[OQN]MV( CUNLR\BD>,&QTHDF NKE:5)A"/B2,2H2'2U53-+F?UR
M-YSM-7&K[=?EB,)WSIKG.[W6^:9H-C99"^:Z?[@'S]E)]P[W3HJMFBC15A-I
M$*4"))Y% BF:$&2H *6L,,-:/VJSCS.6: ?^OM8)QXG2#(<N,5(Y)ZD34;5=
MO"0<9$P2)YR'* P=N$,1)V ]:(C RD<^HQ93*UYUL^\)NJO:G%ED9OR*OV-P
M!U4<2N1U"^+"&*2P9?!;&&%)$XF->&B\YPF:K.*G!><G!UHB ?B(1!(FB(>4
M(,EM@ES"8P>J16J.9['9=R.GZ\&;?;/BZFI[9H8<76S/8!.YD!B)$I. 9F0$
M>!I3AP@W_AB,@H^3A^K(6=G<BIMFS4TVCH@!3P$)Z3M^QUC[WCL4)3JB7"DJ
MJ)2@(86HP7\ON=7W/ JMVI991$;TVS)8,<9B[)")I/3U]Q*DK*/(N,A$O@1?
MC!\,_9Y'K54\M:@\I0F.C!$18LKG#A)!D70*HRAV$;<A$)ZI5][J>Q-G]1XG
M=]6FP2L*V52).2Y4HBTH7N)+'! 0EUA%&H4AC^(8Z*B)>[9-@^J$[?Q*[>,0
M6"6UKRBUEUM]C&),G#-(,<D1-SQ"FMH0)508SKD17)EYE-KJ7%]16BWK/V5[
M[W%5,&[9G"F'4NW,/)^0?OU)JMKFR?[A5[KM,>PWP*GM+W3_VP;?;QS ?WN\
MU3@0K=[F*3Q5 '[EWPGA/%8^C5O&(>(ZEBAVOA^4BK"06K(P>=S>WN-**53L
MLUCL$Y&8.>G/N$3>^0E#@F2B"<)$@_80%ECH=4_Q/4%KW3O(.,61U2[,7'#B
ME[/OC"@N,&/(\1@\#"T8DAQ;9!,A!%'8@MIY>!;WHW58Q4R+S$Q11*PQ'/28
MU*%OLA,C*0B%'^"N)$[JN"@(56[H/793K[8(JJT*,LZ:'??P]U!JDWB0QC%5
M8&HU1TI1B12-;>)3:AP&=N2\1GE8B^3-$F6/V"J9B>ZKN&W6W&9.OYO$AI12
M\/IE4O24C) DW*(P5H1(IL U $O**7";K)%;RF)-5-U4,+L6N--)>L+\:;UV
M[M1@E)\5G#AFRO%8*B:<A6-QTJI_UT9+94F""-42<6 V!#X%\4>HE (-A WV
MI=EP+8Y%+6(W&Y/,J=*KF&W.F.VT^>6[Y-*&H=*@[KPSRY(0 2=0%'-+69(8
M34)_')G6&&4U$MYLK!@,QV0=*[]:H(J:O'^-^JX,A#)<"[RJ*MBRX8SK:9>/
M+Y'B$MP WSQVQK>AZOZJ^-J;/S7T^#*]=Z*0:L?@47)XN<^'M>%,@P@EB0/L
MP# H;3P&$#9T@%^I\$AUCLX%5:?YYJ:(;B67SRN74W5N-9 UC W"S#K$9>R+
MMP"L JO')0F)IHIZ3#]'<OFVS^L5A5GK,))A6<#_6*46I?W J.-TJ+I5<M#,
M2_A?$N<ST&:SOUY2IM)2#])2>U?J\%NL" :U9*4)$8^B!,4D"A%E+E$AY@+^
M6%ECV/M[51W^)1;?5ZC#7XGO,XGO)<C0(7C+FBN$,8V1/RF"M!8^7<A$EL11
M" *]LD9#4L.W5/2JTH5FB#1VW%#!AS9P*N_#F 95\&'F &-"DXTQ2>K&C'JC
MKL]^:;@D->FP4E8/4E97VD>Z& P*LQ1I(!?BX!\A*31'@H:,"&UC2]7*FA0U
M$=_<W:VB%4LCR*\ -2I!?GY!GFJ<*$1$3.10## #<9[XWYSV!2:(H[$6B94K
M:Z&L1=&30<<<A3>>XCS<JQ'.<HK[*]CMZ78Z99.O2KP?)-X'TW9:)$88$EH4
MD40A+AU#FD48:1%+)4T<*<-7UC@F-18^V5 _5#X6*&#PAF7^%4Q\)?-/E_E+
MDZX46%F"8X#EUH#,<XV4D0I9&87<L3@T)%E98PS78OKDK<37DOEY:]DWU\^H
M-G_NZOY<[?S,'. UTWZ6@XJ?=&"M5/U#5/WYE=;+B0W#B%.%I %DQY7U.5=1
M@BC7)E0JD1C'H.IKE#YY;[K:\)E?J7VNG)%*-)\JFI<HC+C(42$P(LQJQ*UO
M_1,R@JR24C+%HXC*E;6X:HM<M45^270V"\W5SH:J6QZ>_WE?Y$J1ST-\;7-2
M^O)SEOL!UH?#/-6CH=)=U\ZN NG*,CS*,FQ>J>831]0R0Y&+F$1<2()T#.8A
M$;$UBF/.1.)C<KPFX@JV+;&TSR2R5DG[:TC[% Y,L(U9XI PF/KS@ HIQT/D
ME""46\TB(<IHG)S'M)X*#%9@\)[Z,+HU$%>"P6ZJ=-I-AZD_V]5SY^>J#W>.
M\6"M.-1U?[QXSV!TR<_O&!#"9B-0;_??L+EM"6=J5?[YLFNP-";U%0#TUB4K
MU_NVVKIZHK&\5NA261WZ/#+M2UV;D*/8686PE%@)(8R*S<I:+'F-LV?>KKZ?
MI,P8.U>:K])\LW,F*LWWW)KOTDV((VZ<Q. F$",0UPE'.@0=R!(N0QHK'3H-
MFH]$-1X_U^&=5]%\!<#]HW O)]NN4SO&/94?I/T",(NKBL@X[WS.:/>XW7&!
M,B;KP;O/_/YQ/QOZZE,Y?-PO-I,/\N)883[T90J&'3=P()P*'.NA\ZJ^7T!_
MGZ,:)&E?]4U:1$3A@Q[,:[!Z=1]Z:D'&P^!^-8ZS07'(YEWNNLI7-7A_DMIA
M9Z(;IKXU)B&^_(K2,(+1\.ZOW%CJ<O'3OH6_WK%P9COWX;4]^JF?G0MW]%@=
M.*1SIXZ02F#P[U3W1)T-5OZXREW 6N-GQ][.W;468RX<KR*-+N:^]F^=PR-O
M&=#M/%Q,<6IE#T>#89J</?=*AJOB'DMY"__X,2)6?/NZT*J!\P]86?N-_#Z9
M\"S(7]2<2;)LZ$5N(<U(UWW:.=O_9H\UY>%VHWG>;&]P,!U'S6\[O59CX[35
M^ZN[_;&)F^?>-!R)UK<OY\W&7V 2S,EWI0BW8+\14=X0D-@@+85 OM8WV'+*
MX"]OL\L%VLD*I3$<'K_[XX^3DY/54YUW5[/\X ^*,?LCA\M_3.XMU=IZJ=3&
M'O;@JJ[2J@NZR@6#CG/#P;@IEO/Z+5"#@?_(>^I3SKS7?NGPVE/^WMP8K ;^
M9?=Z>!$@&#]^V%'#P #7:="G _A2UN^>P2T!7!V"9<HT<*OR3#T8*]Z?3\@/
MI7R#U^(_+>1\#4_IQ"B)::P3%7(;17$2QC96BB>)M6%R5R]T\9!#E,6<+U!3
MN)BHZ?'LWC!GWZV)$J ;09(IAWBD0J1QS% <46J8T:$4ODY5C?%H]2[< UJH
MZZGI>?,A)&8 LZ0D"1$\Y$)@&84V)L0Z;$/J(G8'9*Y(_! 2B^\B8;#"6B(:
M\0AQFC#?_%HBSGD$:Z]!OCRTQ625_8K 3RT*548:A]=#DO=7)4#XX*23FDY@
M<@=@+\L' )H]/ PZZH>#EYELE ^\5BN>>.#ZSB/%\N[)>XYSX)7\#)1<OSC!
MY'^'2W.FGJ;<O;?+P(=[Y]\%)3JFD4$J3H@WR0+%5!(4F=!8AJTV)O2U]*+5
MNS9PYEA#553V5 ;@96GBPI H%!,,RBFTUE<M%L@)1A/A(RN1!"J35U!3J\&N
M<T'+ V B@D(=D??!WRI/O1L=3+9E@XW^L-1?OWGE]'NAG9)1#BHF!W88JK2[
M6@QU@@#7*K?S3K\CNMOM],,OY(& I!D>@23AB--0:A93P;%R(<6AH?%W7Y[M
MZ;XJIZN1F(6[.BN*W+YS6/^\O;6U'30W&IOK]:W@T_968[/U<;<6;+;6[PZ@
MO'X(Z?;1KV^W=K>W-AOU]D8CV&W#/\V-5GLWV/[@Q[_=W)BC&=PN$;]MMH+V
MI^VON_56 U9]X[_K&Y_;P>>-G6#W4WUG(Z@WM[_"C'Z?_XE\;=6_-C:!$'>/
M]6H@TJ<X%*KV0M$5D5(8<%<=#]R[R2_O;3HX[JJS=VF_>&WQI?=7Y?.68$NQ
M,.7E2R%?Q:6@CY,!QF\>7UXM+ET+[);7> S:@MUY&:^2.Z_][+'>SM'P48_]
M^346\S<^6+PJI%B<P48\OM=C?Y'*\LO\&GGCUEOV)\<F:C:;=#<T?9GNW,D!
MK37AOLX ()EUMC##'O\% /WNS'9^ TNSFY[><V&>RCQ3F^H/.(HZY\OGG89[
ML,^SI<8MU<KAYQ"\95V<BJV>AZU>J?C=3">]XWZX_LC=AV/>6/)N-<@Y2X,N
M,E2B,GHR'R)U1W_9HERJCYC5@KX;/B6__]Y9?+,[#_C@%+Z'9>C-;F(/B.3[
M=CPT#HDBQG(J#,Q=Z##6"DME(BN_-XK]&HX)>H;2EX7"_I!GO75_F =&]RT=
M=M9' ^!XEV],>DGYS4GXOVVKT[E)W6OM3D+_1ZSU\0O9;A_ ^[[09F/G:.^\
MF[;HAZ/]QH=NL[<IFA^_,I^*=Y&Z=_CEK/GM"]YN'_'FQPVV?PB?'WX1S3:\
ML_$AW6]LXF:[2?<;?Q]=3]UK-39/]QM?!+SO9*]M>ZV/'])6X^@4YG?2_/;7
M4=-O/9SO'[6^[207:7N[^.1[PI(X"IE#G/L-[%!HI!V)4<B5-#@VU$5\98UP
M7A/BN5*6'Y>75\K):Z8C5WIJ/B;V$#U%$A:YY/]G[^V;VCJ2MO&OHN*YZU>[
M56KOO/2\)7=116PGZWT".+&S^R3_N'K>@A*0O!+$L3_];T8"(VQP$!+B2$SM
M!@,Z$N=,SW5USS4]W9AM0N2HK34F"K0< [>*^)2GV 5/L<93W>:I#Q]Y*@@7
MG!6JMIGVA:RX!.^-ARQ1!(S.>#7E*=9WZ!I/-9[J-D\YK0-+,N1H/'+!*4DK
MB!&1*Z24U'D\Q5L\M1$\Q<]Y"O??O7',*JV, ID3!Z20P6<E05F-DEFCJ"9B
M".OZPK6(JC%5QYDJ):ZM3IYT3J@264I*N8#2%8\L%)U'5+Q%5!O!5'*.J21/
MS!L>@24?H03)&CR/#K0DA<S9$C7'RE2\+TUGF&I%DO6F2&T_#B:_]]Z.1L?G
M1PBFYZ^FF7B#8=UA&/R1)C=*V_?6WV$CF$M[SH(E*J0ET!$2\AB]=R%@2B76
M:IK5YC#7P=,YS<KD+))-"2(3&I A@N.UF8MP:&3@3 96UH*Z+_C#]IJ]0X#U
MX*U;-@+:3&(Q>]0QL83,(YED?#&^$U(%+E63>38*VG,R#Y>!;'+ LZAG%7A!
M-;<&F/=>**NBPC1MQ<[836GL#=H;#6V!(7D;4"1"Y$Y883AA3DX'8T0P31G9
M*&C/*R.962F"C""]SX Z"+#6I0+S3-*@-Y[5#J_8%\LW=FC@[B*XE<[.H!-<
M)U>B<>V,*-]HP;A'R8QM8L)&@7M>3*#$42:2@'9V$KJ>,B0$L@JCY*' W>[L
M"MD7<NG]F56!^Y&E[>S3D'Z=*@B]G%(5$ H0UE_->B.8BGFC#,,LO/*H??1,
MN5J;2J:  643#S:)J5[-B0>I+!!%) (?8UEA)%N^<SI!-BJD:(.*H@0AME_8
MK"N2Y\94KMX(9'-.+O.HDDL*2]A)G"M%7B74SBOCFG:P4<B>TPXBD[8N+Y L
M @HCP ?O09>YK!,:RQ-69.NMVW9MR#Z7#E Y*6(A\H1<DBWX==ED;T5D"JE)
M!QN%['GI0)&+'$E SE$ RLS &FE!2VE16J&U<U/)7[OFMK<2W#S$[,@(YIQ
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M0BT==S1D=Q+9PBC'I&=<922;G361*6YBXE%[(9M>L%'(GM<+C(Z:\TB@- G
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M3.6^QGF-\QX[YX42&B07A(\8L#RB0Y&#B4PQGPP)U1: &TJ'\B,=>G)1B"C
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MTVW!<L/']':2OKKXYNL+[S083O_L]$U?7P5>A>BGAU[KP,Q>OD3O$S9#\'D
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M@A.K,F9 =$NJL8]WGXNK1LY-#.%P@^GY4%_B//WU\N"QKGP@^\VF0J90#/7
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M"6AG/IF [-D>.>S9$#]TB.96B.;#0E@,YZ P:DT<TSD1AF7$&,^),RJW*F,
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M8^U<7/0MKMN="$9+3]]2N8>7H<T^Q H\&TG=-8)X3N+]70N,298D+.>")*+
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M$B(<Z(NI$)ET++K.U*U=9UVT;B?UGK+4>R2'62?U'DGJM:)U4VM=806A+&&
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M<#3!X3!JKR-,:#+K[00E]XL#OMOY=6=AVKWR@*A%0N">!O,TU+(-^P4_+6_
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MP P R(U.^N@C'/H04M,/_K0YVN'@^S8^QM\J(P0>Q!-LHXH4/OGH9^4H9^=
MY.%KG(YW<QMNW.K]W/1[O;<E8$.IX):R$/?JIK)P$XB9\>!^V@G$# 14BI":
MI/DR(>.>13O7DAFO)LC( [ 0(&^.@IB(^PZPNI%B!)83!$Y;T8KKMJ!G-?S0
MZ%N1""M]:QH5+C0NC.?3ZD /AAX_"AV!5ZO O^XW*G"T(LT"^*QF=?7%(DH(
M)@_G 9K&)0HXN9'-_W<T_H?\7P\Z\((&4Z+DWA$, 6I. $Q,Y>E6[PT"*I@,
MP(N3\:S41@#Y_H-VF="NN'<>U,5@HPM_PIN?UN]QM'_4Z+]!]@Z")#$P7\3G
M:.@YVMD"+0#@\6P^ 6['32DME8WF6^,UF-FJ387-JY8<]STL>FOG8)0O;EQX
MU@)B"F:JY@!I/S#23M0,IDNVLZ -E) 3+:3!<A?GOXXF8:?\/VC(K>YKK_ 4
MFU-[N!UDT+OQF:^N"<_!Y82UFA9^@M::TI!7K<4B_2ZO0OOMHP"OA@09^#=(
MYF!A!K%&AN-IJ1I-PU)5-LJ&PI%@GZ<NPE*4FZ/>O^=P1(#(49%$ [X)3(8J
M(L"0,S2HN#H3)Z*NYD ,FNRBX:<122<3'Z^*5G(XF[X+5N31 )7)E>=JZQY@
M^8791-&8?Q\H.K@9XC"1J.#",R2AZ]RET@HK"Z>RPAF1,6L4]UF29+3@QBMM
MCG=Q(6A.&:G^6 AZAF6V/[CYY!*P8.5'A7].?]B+4_D99_(>)G)8;,=U*^.<
M<=4:6QI\N;VP9)4ZOUV]_ MSP1[LOKDX_/W8)XDPU!F2JI01D4A#C./P,><J
MS846#/V4"5UVE_9P/Z;H+XAF&.#T-H4V[J&(CT"<XYXB3@;2AW%()3?7$'*_
MY\9 FJ/Q#%C@'+@ AXU2'Z5@@=::9<MB/"_K^_P_?F('4Z3]8CCW\81L'"*?
M2O-1;?T%0@XC L<&PQAP)EP?_'.UX O'"P+,B0M';F"RB1_Z3QI?NT:>O9/Y
MP$4@62(#YY%;PF$:#RV--NU* %?&B>"@6'(GP%Q@";=Z2ZCQ7TL^ZBZZZTI\
M1[(^NFNS K56AAM\,7Q@*=P@R6UA'5?>6"-4FFJXTKJBR%(MI?7ZVG"#S=$W
MMX\(*N^+*N>^OD2E2T4_'##3%"8:O7>-!W4M)-GJ[4X0E<#DIKW?]!F:$MKW
M58[9G=.!+WIO_O%V'H3187!3Q-_C;S_7T*SZ#14[Q&]XR9BL&V'1J#*(. _X
MRB_,(XR%;W\G,1.6[5I)L^0(O2IG&A5U(S74Z_71$2@?Y[.H/D1::=XW:/8>
MWW+1OX3/BA:+ 'UC5DZ)0U'R-YZ3>H6#RGNT\\.-5V@A  [%X8HU^P8Q<6MD
M9KWSC__TI5!!NI7B,C2;.!QK).IR'_[/;9IE6&HUIS)/E!:)MSHSSM$4%%.M
M<\W*]#NJEIIEI+=(OSO Z(>W0;M"=]R!;^I$9"\-6KZ'>6P?9XE/O,L5R:Q2
M6.VA($KSG+!$FU2*PJ8R>?4Z%>G6U;RXWAE:]F!3S^>3Z1R%'JI&URH:RL \
MO:=)ZG.1&RY9DF:"6J4U3U).,2X3]SC$95:;?1-%(\I\W^QMU#::SR]O>].#
MBV.>:I-D/B68VTH$S0O0' KXQSJ6 #O;K+"8^+BL.1!<8!"\=CXI>;JE@'[7
MBA J^?PWN&+1,QSNP?"Z:1-A@V[7'IKS6OKH5<D ' RGPX,(!WX]C;P+^N=>
M.;VW\*$6!X2_.(+Y71R<'%N6&ENDCH"FB7UM"D9DP2BQW'K/G=(N,6V"J87!
M_P1KH![![F&LUWDKLBI@*53V0$4\UY<A$.([M'^=SX)ER4]"%-QP<!;S9083
M.S_#&#I0%[_',+;_S@<P3J\,4@J1CY<A6"VZ5DOJ"EHKQBE.)DAV_0H_550,
MT E-F1-T@DX&,7PO_(9_U*/@ ,-A@_(>YZ1='=5;NGV_W6'_ZC7:SZ<>/86-
MQSS 8D3$TPI8OXL(;;MW%(+Z<+7?A9A'.!GL:0AE",HZ+FAILL9X;X/?>T!Y
M(#*B(1/XO;8A-&!Y'D)A@T=*?T0[;6N_2E+H79SZ4<_-??#RS-&@,.O!DVM;
M:@_ WP"0FPMNP!B2<LW$!Z/I'-6"X+,/@;"!MC#P%H-P3Z],(,1-QH';$:!
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MA3AB3!QN-:H/P?Q8#[1?UDL-9:S.8ZYPH)_Q0D6IA63'V"O^O):-865&X]X
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M!YJH ^?*QHF;SI3J<,,5J:X&YG"Y$T00R3UO(&#</[GO C4!E\XE]'3.ZFD
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M)G\2RSB4O@+HO&'QD H8JC>B,+N9N$39T#_PSB^P^FNUCX/X7BU*4]=S4Y_
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M:GZ.L;8:_%U01-B6"X9PZRO1F/"#M1@/E)9%OPZ>:XEKWA+BC6(K@EO=7"@
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M*H#MCVSWZB'0^F%_FXW^E&.DU]J#1MHT8Q@>0*9LSAK=D8G<M=4BK[U"7(N
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M!P8R!PR",J."24BXY! 8ZQP92RQR,;HH/8[*NER+W PX?SS,NTC%IZ/"@B#
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M/C.&@6O]VA&8)ZFT!JD@=&[K1Y!)TB$;DB!*DR2Q>/%*K)S#+B!%NOF$X3"
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M@WQ<\*2MXJ@[&MAAYHX67&\WGW[Q"PWL,5S*]7NP^OP4.40R&ARWRG,=?^S
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M%CUNC 22K:*P3#!L=0#JXV/TUU3[KC3]/NO\333.-^CVCN?P)QL^B@GA'0M
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MV)T%3*NUTX.F/\@L!'[-C9I"#GFT)R?=SB]8Z8*\S!D3?2]Q8@\5INH\XY+
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M0ZD6W#)O+>PJF@?C$N<DLIFY/A.(_$_'MK\41_@9=7?@OG^UP*QY7H"E]3'
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MBJT*?K6QU/-I\)OQ9GT=N%'H5Z=;V_JTL0!2,6,N7A\D/3JIF%P86)<A'E5
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M^[NPJK_+S%+X^KGZNVQ&UU_"IBVC-E#'6[]VCW?/Z^??0(]WR8_-+ZW=PW
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MJFR+I![L<)>+HHG:R#03=ZIDS=DO[^Q/]U*R< P&C#(K"I$@= F:X827Z I
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MO[^??#O^L4@*&D?^Q\G1)W%P]!XW+CU\_UW[Y+=W[<9O\.DVW&_/D\9O']M
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M%4Y?R1(&E>\."#T8 ?;LK4")LC$[8S1/8A]!;#'D!RDN.OU$L5*'K6*]Y;N
M6"Y'KXZ"-V%!CD< 2C/LC %H#65]=!.@3!;W#$R,UGAW-&GW/4>Z]C+\/(<)
MO=4%V1EF']1JTXJNU:W9OWJ^B77Q$1[N[8C' NH=GL&**-1^XH%$=-.LC9D8
MG<;1]Q^'1U^_6,P$-5(BK"0!TR,PY'!TB.:*',+H8'*C/89O"-+Y[V(Y/$SL
M2V9*5&)?7NP7C;WW7P@G/!FND"#"(JZH0":"V4D8UYH;T$ZFMW:HWKZ>#?O?
M"SZJO)<_#DW&I#Z,MMG\K4_;?VU/T#LS^N&@V[L87?D,N"T0O^RV'.U8!>.?
ML\SJ5W\5%TRPX>1S\N[PZ^ED$ZG7X%E@/$ #FME?!^L#\#;O9P6_'+GA1KPD
M[W4W[%]KN"'<OOG?Z"$>Y4MD"[DSDVQ0F%2Q ZQP?H_^!X32!0I_);8B)F%!
M-, ,!L";^J/%<G7#PKB8W"';#+UA03'@H\ BBRN=@7W6*G;_F5O>/JYF9_:N
M<52_; TE-CM-S<+%_BW;1?#L<RHR\ZRP Y]'F$_;GWT5YN,M/ ]H9:=IYV<_
MSVZ>LEGW_9@NC.57&#W7[P36V+#7&1D)W;-LB71K=AB:@QD&-M+=P@O>:K;'
M;='Z$W0HN.,8&*Z"MVJCN"TB)SI[6UA7,:Y[7$G=>:7K0'9-&:9V<E[$($V8
MC 7C[?;EF"V:L971@:55(W0,BJOT[*O*LW^S9Y]OW^I=?UH/][X%=>M\[?\9
M>W_E]+'2N+<OKIC'[N7AT2XY_/SA'-C )5R;'!P=G)[\]NE'X_/!MY-O^\ L
M&@SN=WF->>PU1&/ODSC9VSUO?&N0@[U/I$'??3\YVO]Q3.%.1]])XS( >SD
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M%T776O]J*^=QF6=384=@B&#B#/EY2 +F=B5YJJRWE\E]X"^%K[@&G&']U?;
M8N)K9.]<TRR/QNP54:"$(KT.+UQS-P8!$LW9]3^9O8@ 9PXKB"?XZ /U*2I=
MD9[DGHZFPB:C>B#YYNP4A[H@X(3P5XO0]1QW=$699>C/DEG;EC57]V@MT8=G
M2(&)9(SI[*R.\S>J H7?4215CF-&[%4"83H7,1017A:ZX,0^P1*P'U8%JBH8
MLR"8H6;QC&H<=!33T(=YJ3^(89]WCRT:8[8_4 :41.,!"W<,2T;!9#9ZOVWE
M,P7(DSL<#Y<Y2I,1&"UCC*V,DE$>\=@T'Z0^ *ZR-G1 (_#-\2/X MT857F@
MA<4++S,7ZP[_"%3EGD0Y;?5(-K6\!$9I*[_!^^$0A00=CI('RKFJ]AZ/Z- T
M*Y@RIN.')/V&GXAU\$\ *>C4%2$?C#V)J _;J@CYX"@$ )*-6[3?!VL#@PRP
MTYBFBZ-!FRI[02F6P8Y>OQ\EW-E_QV093/S^(0S&@Z+@J/:A*!O1JD_ ^4@P
MD;#PD]H:?19.:0J'H \^89S5_CLH;UD< :FU>J /O[78E<?O2/2 .8.WDW(!
MA,(44!?!0X@0 4FCL[1$8@6,-P6<OX(\$-8O5U3=:$"&O92H-3]#932?Y;TL
M#$+"XF/(PO\^/RN57)V]A?,*ZC"]([%(465E^NGBYJJP"=ZH==F&T!A1!A+@
M4[3C0>^3+$M 3DT.<?ZE6Q\"UD(4;%*K?**Q4+^8#\/K,5"0\63856TUY4B7
MG[JG5U4N[%)(@R)Q5ID'8.K$?KOZ[N*B^(I;"2,TW9[^KEO_#N7) ,N*\*K&
M;)P2'J.$X3@T4V;*%-#D8A>!7U@+2_3"HF2T*$Y"=P8AS'7,!.#+>'A=)!9J
MIEP,\$("L_M\N?=A.@9!"28=CY0"_<1!01NH'D["-T!9$<8WOE03@%"M$QE1
MOM177<#RM)9*#]J]-FF70Q$_A#5,CJ, <=13G16=G(1L%:,!F9,=Y7CBQ 0O
MXILU OJ5ZS#V&8S?5L!:SVH(R!@RLWR$IAVL#!Q-3A$PA_)KDO%D;39&/3QW
M8Q5]_#I)V#>S;C^N!@S(4R:7GQSQYO37TXK KX"1&<U7$26.,J2G+D .'DV3
M[)=NC4<X;MG21@2K!L,1&P5$!XN,\T4Q$N6K KC\/S(<O1=_AK"E@HB 2$&M
MH[IGD76"SD]6JNC"ID&+/<ORH5#**=@P]S1BU%,9_&F8?>.+ E,?;!Y&C")Y
M!  27Z;T@8"[SW<,PI:,P?3IY0@O85+@."VLZD"JY4;%&GI\D51?N_JE*>KA
M%>U1@69XG*1!R,MI@-9!RM%,(*,83%ANF+6#+7(AA#9LS0BK!<60-T& _IFD
MPG";,-AP*#^Y9^H.N!1&O4<K$]-X>0\\=1@LRU-6S2E6B*XP[.9N4!*T6M*R
M6K-E%<QX _&Q;^>KOE\O*M77!KGP@ 8T,G V))A)XH?!BS6G\#3.<;F(T7Z:
M#,&1C5ML@0CZ(NV(5F\)3;X_ 5(<K!39:!0#1W#0,*P *G*16)TRDTN3/'O,
MP)%6:Z*\F!8\4:0X@<NY&555R484V5-(/A\L3O[.0(A$_#4"@1%SU0?6*66,
M'<9B&H7#NQRS3E@"[. UQ!F7;-5KA5F/V\39<= 55EE7?VR*FNAF<"Z\DHH:
M"^*8L@!^32($5S8M3 NM,&$]C"=B/W5#ZYT"EH:J=/$_S,Y@PKCX*$P7<5>%
MKXD7T&0[:H'VF;,]J=NK8TJ&7+AES*&-,!%" DZ)&$0&1 !/,Z\42:=>(%"1
MRX):@;H,4Y>ZQ1S!LPS<KY<8*%U,&:4LWE0NZ($RX<%].Q[O'I-O:%C>$Y8%
M+C@\&X3]<:&JO[9OVG6>!^0 KH _Q@G3DM6&ZCXW#YZQ<%<+4^5X'5U]% 9'
MPF'$("3X.(/_S?H\.*_.EE.(S8,CK5"T*Q'BC\\IJ&@*P=T*\9"4AA>S*H33
M4H@IP _Z-!QZPX0Y!K!60X7%+99;'?9XKO12L5HKP'!C_3><U,(12SF)O]0&
M )BA'X!6I: M<5H(!!U@?832%.WA/M,@!9&BE.&, ;;!".CF.RQX3+&,MJTK
M(NVY2%UO'J6TCC*S<DW](H9VQ<RR#V@.)Z,YM_O+"O77K%!OBH29+5E_1H&Y
MJ[U^P;&MO7K1Z=(I9)GA[AEX29GA7NO\)E<G6MZR:C6KK;U@F9+NR=J6?:AM
MV4_I<9J@A"ST4(;AIRX[V@>+ SMZST4([O <1 B)<]0?3^GT>%*3UQC>U&H,
M?]K%P/C%S56[^F<1-LHFW%",&(!_!_I(G<I-< \B86:G"'9/Q)<FL@XUI["0
M$V7VM1Z@@.].!ZC@J5)'HA*\[;T%L;,<U2 *V6Y0#E;9[:<R236-.Y/90)!.
M^#!:VYX0C/ )UF64(6\ /D$&0\S_CL[<*2IOV+8(1;XBYZ[J*76.TE/Z)RB7
MJF+G@A*,F_*XWGF,6 =MNKK'U$QQR#V \C*":QXR7KPK64/P$S^5M'<U!'NA
MNS@YUG(759R\'HGGSB23B.)%E6?P1DF"HG@\CFK5>Z J,+!]CW%M'D(#B?_+
ME^K36BRW3S&0B1D3KJL^?KPIWN/2&.N+< D]%.;B^H["HV-+P.4E8)CZ9? U
MR_U!I1^&Y)&K@WM4SBB['T<LP%ILN?!&P;T#/"\K!-I+$7,&^BO.EHB8_2+4
M"%9+6>23;ZNLRJ@GH'A@F@424&N+XHEZ^K.JF66OLFQ3:6),5KY-E7O,LZ,6
M)5E%]JLH/YA7<U/4X^3CL S6\+S"Q ?UE%II(0F>4*O,XZ,?E=9;-O>;B?S%
MY,XPRYHAN-&D9)"H1JKLR,K:+!]O;NF8V@J6CJRV6UU3ZONO*7<6IY]3$[Z)
MT.04L:-=+,UJKQ(LW^GJ3^NY[^I$ DNW,2.A03N8SX GY^AD)GF&!75OFK_<
MK\4ID\5KG;P1#IN@LQ*[4GJRN^S0!".CC+XK_O$^"+-11![?A3&;EGWT?E)0
MH$B9NLJ. 88_KJ1-6^,21UP;+686C]OLT=3%?/R9Y8+8,A<^UMKZPF?+AM6U
MMNNZ&PV[_)EM+IY4+K:)B_56HZXG+CU_LA6!-_/JG'MEA24RQ5##, @BNGUY
MKHEB"O#O+N"]0::<L6-2+-%B:NKTC9J;@&4GKSX7E[4KBU>]!O1I+&_IKMSY
M6,9@YPKH?'J[QP4S[758X&5Z+NW4#/Q1.1V0^&[*VGMU,#6+3!@D?IJ&Q(ZZ
M<NW*)6-AC97)8.'.5[J3?A7ILW$S(;G(1B_RA;K2\.O^#=99IM%7_I^6 7T5
M:UK7O=Y\HQX'@(Y]:7"P7J."W6U,MRS5MK7-[JC?[*YYOMEM-N*0Q-:,C>F6
MIGJ6)XFM6:+\E>EMIWLS54?3MTEP.^]KO8<=)<V=(&@7._WI-=RPO;$9KU<H
M^%@8TGBU9JH[U(>.:NC6-CMI;J .=][L=H?XP=-XZPJGH\//3D6*!1RTKGZ7
M':.WK=_MG6!H#Q7\G@>%+N:596ZDT9]ES.Y.8[BJ;FW5FGUY__:PT>-X>Q[K
M.G!7\,2V.F^DI]Y8]#C;1LX>*O$]]](_4MKJ)VEQU#>;F]\Y9+?/4AUCJS[%
M/GI]NT./H1J==97XT:%GIQ+$4$U;.N4-1Y*N;37RN,\*?<^]<GYIU/$YXX:J
MZ]+;:RQZ=-6P.Q(]#1:;KKV;S*Q$T<HH<ER9.]]6"?-4 3B_2=&PV,'6'9V^
MNTW&>!7Z2E7.*YBQJYV-V OETK%5QUR7.=8"P[XXD >$5,=6=6?=^D&)U&8C
M55,MB=/7P.EN#9-F8+1Y%DNQB.)-BY^(?V%K=X4Q7N8TI5SA0:WP:$X&5M=;
MT;G76^WJY)D<8TMC'%$46-R,PV\IJ]*Z]'MQ(6M 1RDM;DIE-Y8-L3$1OTSL
MF$+&NKE)2?;1125WBR"ML^='R X\)JFO7>\KP\9;1A%K@V&\E['CG<:.=9V9
M#3LR"'CGW&C>#:4KFL0'6%RD6ZKN;1B-VL>8T][A1U=M>\/8TO'@9\?57\[:
M9R!D]=>VD;0;#.VA[I]O].RY[O^PDL._OM;?4Z_24@U3EB(U&#V.L=4ZEWU$
MSV[/!9F>+H]M-1<]KCRV-44BQ>7B<1+3Y<0DWYQ\LRG1DR94WKU<H.2 "GIL
MT-=K7RDH*WH:CE1#-9P-G4:)U,;J3$,UW74]G]<NU9*(?0G$-@RIC3$(9?V=
M7&%S5[AMXWH7I7>\$9?23Y.A:!\_T2CM"+)8AJ9Z[H:'4_;19-I#_:D;JJ=M
M-=&X<_MG#['DJIJ[H:4CD;0M)&WJ-DJ+<UNVR%X83'NQR'U=X3'8G2O=@[+O
MQQKD&,=]S./D<Y)E;P25<Q^+_I6'XT=E2,>#!*_:OZ?9F%V]?TPG.TY,53>M
M+:5!][%^8(>W\IKRP$V3C5I@'<_9>@6!1-#J"+(Z\E[>34W6?=#L;/>?2!@K
M"4Q+(HH'.1>I]6,*I&YVCNGH(JF[0Y#GJ8ZU88+Y>/"SKESIIB&)%B#&6TUE
M<,2LKC5DU'0K:('_V39.MK8Y>1!C7BYT3%-0W$4EX?&=O3C15=<VI6/>1-08
MJM.1J&FH-^0:6[W<6CKFFT1.MGXJYF#\\D-1[%/YIJ.Y2<'>;MI_']V^'8;<
M)7(:+5%/S.W[@1(]:Z#';JB7WB2]?I .^]PBDJ-QUIV.ZKKK5L4>G5NXTYXZ
M:]?#'AUZ=EL,ZZC.VIW7&NRX/T\!- \___UJ.6;#9N?5FYICKIUJ3VHZ[MG=
M7P_G#+1CJI;3D'.5AW4$>J?Y:6_M+F<2ITV7XB>FHUKK7$DDS[3O!5;7+UB0
M!]JW;N?),?9@C&,X\",.FO=H/TFI,DJ3^S##"R_AS^* Q)A\IT=U]-RU5&O3
MRYGVT:S9-_SHNJ&ZMKR!O,EJ^,1P54OS9(*FP1@ZW@2-M ?E&#NS!_?A- VS
M#;](:Q O(K)4;^TRPJ,S-G:''Q.+H^5%44W6P2>.ZIEKG(Z5MN#6;4%#VH+2
M%I1CR-A@S?Z[I#.EV0U(K^RP7-M3;5->VGY0.'5U5=-TB=-#2X,:NFIU9'+[
MT+ JD]O2@)5C2 -VM0!F9< J9#Q.PUX^)KV(*N-$B1/X/1ZG202?W<%;_"CB
M]@.;.Y4GEJ.Z'7DY=,.QU#%5S][J!4$22QL9)ZKF;CVG*C'TJK61TDC<%X-&
MCB&-Q.=%.6>,Q.X(S,-$N: !+E;Y-8EP5YFJG,=^>T-'E._UG0FR)$ARG(@Y
MH\_PTYMD=C,!].-.0--LH:P;JK-IEOHEP+-CRT(RAV2.)0Z.JEGKGO>5O"%Y
MXQAXPU8=_7AY8X-4Q\OS2?.(PGU>%GK;%-$0+_@M,^Q_%G?1U.[.J6W$IQ@)
M%FO^^7]ZZ=N?)Z^PJ7TV).E=&'-XX:(FK^!Q"R(*XP &?=?"7W84"/]O3BZS
M__U"4]PQN:.*/R#Q';LU/P$\*C9 <>'.Q>"6P:]K&"59B U*WZ4T(N/PGKY_
M"(/Q0&"B_J&@/*WZA/2 SO+QXD]FD#,!5=/9&5!M8^IRH]I_!V7 902P;?52
M2KZU2!]6_XY$#^0Q^^'M)"D!'4T!=1$\!-4)2!J=<O_SJ/6%:)9[Q"4.F9@
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M?=Q<MB]:[@DZ!$*\#K-ORBA)(M#^XW%$L2\:@PT "OX)&)A/H#]:-6%1,:_
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M/=LFS'E*8A(05?D8]A$&@S#E(_,N]KC'2]8)4WS"=B)VQ1O/3>.FZE])E#Y
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MVQ2)RIQ=7P3SYOLS^R=ISK"4#TGZXE=5N;CX!+;\/R^4"^ >'[3IIS3)1_S
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M>V-BLQG6DN9K^Z:M?.IVOQ3=XC+6I;/6PZ9H"_1G'MRQX57>3'C$.\_A7+0
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M&"@# Z8>32X>8\(DG*C>@%GNPX";E*P4%8R?B(?#!DG&BC["# L\+S!X*)R
MZ?C8B#RRG$Q0#)?6(G:$F=K#483QTEB)":^M@I>'Y!'-VEH0FA=B\I(M8-]1
M2L>BK*"RL(H:X2"O(DQLVDRX(M.;+0+3.!UF.AA*8+((L:Q@$5B$.9J\A_$S
M+!\5EBS;+6(10Z8C+)E&ZQ0-0%&NQC:(8;^(&9^BO/<WRF9B99D"_[4=8F O
MQ:ALEF.,E*^,ESL76*T7DPH, [3>HAU?>P(&!PNR^4 9L,4>>I25E\9"H_T5
MW .L#O?IB'U<^A>,F@FSBN !\SL?><;DL5@Z&AP5A980+NN2,0;HL_@PVN3
MZ&&0,PLD20NW@-S=(5;1LA:U4&4I$0G %,GJI5 YJV6JLQP/&V-!$FA<@7I<
M( ,9OHPU[7?<D9I,=83Q@%?[5C7$C\*Y*..<2Q<S-T8\MTZKC.NJ/%(]IP!K
M\SAGQVW$:93=Z)ENFU6\*!^[I[=7UWNH6*XFU,=<\JE%69AK*8Y2H/@4AC_+
M]BAQCE72['0*2*0D92*/,DDCR@N!\;[%R4.,5)C'[)]U7QG+%TK'W6=U_XS?
MD- 'E$3C@4]8WB( D*6/S#5^H!'P1L85/1^@?ABEV!IWJ.Y R:4DFD@I%U7
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M'YJ $\+S?IZ(\.O(=T&?\X-U"/XZ]FX^L#N>4,E9"=F9)+QIJ,YL, >J>^&
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M@]D='J/8I8.+O7_'R"5C@AW*""X&4J\TR/P<H6""HV>Z#.$<V5AG*7[]R;*
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M*.62+;'N:5$2(.T]-<"V*)STE5"&CZ,7C!SB@J>+$I'R.1WC\E'7S(,"7#H
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M@C6!"]I]"/RD_^T.GE25O8J:FC"'!WC,"W?)*TL\0-Z$0(@^\%?B &G/(#B
M>S;TJLUNA=-0Z;VM,[7DM-JW#U?9[:'=MVF=NS0G3/CGY#M* ]"$_=4/?!MC
M)WP(_!G4#NN-B\-JRA5?;01;G 9[W3IKX4*Z+PJHP PIS@"%!^@ F%\8]!6E
MLZVPM0FL*LU@J!2W60V-"7-?IANB&;4>^S K8F-^NZB1I%@,=>B(R.U,Y.71
M :4M]Q13OM:'H6?_([QWBMP'\I:4,V_S&CA4I0-_#7!T&CL$>IY#YTQ@O2*J
M! UP\$K9(EQ:,A([8-<='?Y^HNCQ/'@B%Y)*(,55I0'IPQ]:E2E+]%.Z/#4
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M2]:I$</MH!Y#0+2C1CE(1EW<I-_"?!ZFRQ=_XCR-:_EJ3#'06BTMK9:OVAB
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MH>U.\T.EU2Y.])G>R1I ?SF;UYY!7[L3UPXP5WH5:YN4$=8!\D3H0LWNU2:
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MZ&1EGZRZ'8$.R[8?$.WV$>3#L&TU^,,;$0MZ!EE*M6Y<&6.*])5D.DBMBW_
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M<;)%>0Z\(F"2-8RJ9%RCO>305']_N=Y4LJFCY+>3<;PVPX 3]#DRPCQ:-U(
M(R$S(-D(S1TUCHJ6T:>;B X@*+&CF!OX%B?3R1>8SG^<C#R"&J?B%'\IH3?\
M^N5P7$Z[7H.?P?MR]/<N_XE+59G)49[C8A7CV>E99^L\AR]3B,/N> O_Y='I
M!&V??W7?#HP$"-T6YTTD$F+9]B@09@!<U)HG:1KM)*WG]E"4W)5'-_:B1T6"
M!A&55^.Y'W\:HAFV%"#,7WR/H[-R//['9)*^#4>C@58\&J4="4)((M&/(R%R
M2SRS3(2D0J)M[. ^Z Z$:M45T6!-/,=A/ 45G2&^RVGPN"N[G!GN^=YJ3XU'
MXZP)(0Y,Z?<2:(.PR=O)'&:X,KV>^/'5N,[%A >XB9>('OKI-J%O%D$3_"X2
M;P-0)1RSL4T,O@^Z R%$=44T")AT&#<%=2[!C*"XD!)=,V%0#DY+@C0&0E.P
MU'K'E&^S:_0$>$B4J:R.!J&58CK-?[R!^>=)>C7^"K-YL:-F \:,ECI&DK4J
M 6/N24"OD<3,8HI* _5MSG<W #H05M00=\7(2<G>&5S@>#4^F2)=YS#Z\3<8
MI1?C.8+]^-G/GT\*9^?OX0N:R+CJ=;)9'#TJ&H )7PBK!$&G$IW,E ,B!Y#
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MVNY3/RJHTBEJH0AE/OP*J_;>PGI6>K,2#P&]3"V!H+0D2<" T4!=AC9.UAW
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MB$)#-7').+=MFE+? NJP25-+&PU2FJ] ZWI;KI"=^&GW_2(+?P#!156:9F<
M2Z1$:\X;DTG0V@0=J8+0)M;5%^%/1*%:>FJ02=WA6S16?GXV+7LR3(>3M"#]
M>UPPI\,X7Y;0/RI20>%D&);,+NX<C['$=]$?(#(J2P)^5M9-@;"9H[[-NG1_
MS(?-N3WILD$&]@;DW7MR"_"STK%10^*&,TV<E:J$ESWQW$A"P1IG@J=1M<GB
MW0'T3\G#ZMILD"B^]2OTQ[2DMVN>N7:E2 #:B^B*^$!L3):45J):  3O6Y6
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MPFO '# I=A5][<J/;_STG[ D9SR;#HOG<GPV+7V@WOAY^>#'HM\8+FLB>9X
MK4AOB?3,DT#1H'4THFE C3:T7W/AWD,>( T:RKQ!.8JCKVB4%9PO)],/_C+<
MYQ#F%]\- L.52R-EN:3(8$;1G76IG'-(9X&#IXXV63SZ(CQ *C554NW>Y>LO
M.*QI0O=\./M2VC0,$N5996 DLD!+O0:/ZR$ZT3%;&6VFB?-^9\=;#WV 7-F#
M#BK>.%LQ>P'X@L$OO[X=#FRP7G+G"4^B%&3+JEC7G%BM*;JF3!MH8\.N0W.
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M]<=DDKX-1Z,+%K_NVOM&:@)%1"D92Z0M(<?2\3TQ;:U0G(O0J_S+UKQ8C^>
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MP%*J2 J/;U$N#H4L =9 E0ZT%^WN-?RA4JN]+M;0Y][1[OM!ONA5]!D7Y-F
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MEH1AX7IWT%IY!G=!V_^V\G ,O)&=4%5O#?)62FU%G'[YJW0X^^I'92%8 W@
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M=6DLSO#=L,D2 )$L%])DV2P_JR_(A\HR:$63_J;33NK:KT=W ;345EF%AGO
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M1$*U.J^%3JROUI]ZV-EHO:I4*W(F)!B/WL&%O^QH)[\OA[@GW'=R$L0X:O#
MD)*$THIIF \B&&'SHW7$<XA_NYA^^SM^]#(BQS]TVN\TO^6!9YCK&RK6BNY6
M@;)$L3+C/CAZ).N>5O/=IQXW'3=8_-.*LJL8&SW 8PJ9;* 9@S)F,48K@ZX*
MP0+Z[\EH+;EV[)GK<$=^K)D*]Q%9[;#VU8?7&'#CUW>??GVUVO@U6!XDKH<+
MY0K+)2->83R&$;9R*G":9;]H=LN''^_X'";F:449U4Y2O?H:W\VOUNDR&Q)H
MXSD1 L\!R3P0JSW%P#DI*CQ3R?1CW+OWL4<>>SI8Q-,J\JG^=EU>C@O;>I?F
M>I]?^\MQGLXF8__VPZN;B(H;HP0ZTXSG8I7H92GOB$N"\2A9<J)?_OCI9[UH
MG=:59.WDT2K%\6DQ UC<^FOOUHDM2KFQ'&PIM40C%!)PW4X0A=&ST#E1U3-/
M_,2#7N+V6E-VM5_@WV#QQW3V^RI4^M5/_$57-W&;D^:96P@*%^M*_6)RC@2=
M7)GNB0:M4\Z^W_O[Y*->HF[KRJ_^6SM9S'Q<?,:_W+ES>%107 L0FA.:&CB&
M[ASN5EIZK;40"4.KGJ_I_4\^PX!RN 1KIW;O@ED9;A\XVR/+'HH]11Q90>J[
M]#= 9+6WW2VPJ*1@;>'@ ND+15LD@4I!$%^4SH 0O%]Y];$TN".*;*_ ?215
MW>&=Q/'EI9]]_P2S;^,(:WCKS5[1C&<V>GX9_31IK2(^=NR;U#BO??2B9ZSR
MZ'..[.@.U<&TC0 KAITE%?UZ>EUNX[^6T5$W)3]<2Q>2DGAP9%QG4)Q8$Q+Q
MZ.?'S(2W;L.O'5 KM0W!&1ZL581=\?*MX/D(7]?MEQ?HIB\YO>]#7%E^'Y#5
M"R][PSM^#>9P34Z/I8;*99;]P9:7Q.1HB&41P5(=2HK&D=*J*Y,2RFRFL%ZN
MK3Q2?'DB4]E'^B=(D'D=(.L2[W.A,/S7B;A,@63&O/$B:"[Z<9P]IP190PWM
MF37;1[R5/8J;%N;.T#4H9JU4Q$7!B?00T&4*Y;Q,2D<)WEM9;1.X]^@S]2$.
M%V_%&HY[0%;FW =*=1=A \3Q'8$!ZMBFU &RK'S.;T)BRF>:4?JA$!1+&2/Q
M"J-:%JS2FN*6DNN=YD=1ZR-G=ANM[B/"VD=RR=5^F,X6_O). 9A)>-881K2G
MD<BH@824'1'@G:("HG&AUQF\Y<./>^@.DO2THIBJ7PK'+V/XYA'6VTG\VPI0
MCDIYE3,QF9E5%[(PB$H"F)@2R-CS<G'+I[]0Q0T65(/!GJ]B+)[?O)L-^&[J
M)X42=#DH:SRYN!V5]=/WVS_?Y Y- MQ<6)F)94MB"'TYW'0TX9E:':TU0O9R
MG/;NX1Z"^@Q]KJ,KL\&@JON(UK=_/3#MXZ_M;6C;4!W7@3N^;J>-%--@]]J*
MC6N>8F")<%<XKT$[XICT)&HF<X;2*]HK,_R,C66'6_@\;64??32PD8VIM^MR
M(.I-"'AJ&U'H6D6YSM!1$(H_%,9&Y6-N8B1;X1R?R&:XIAX?+GR F"OZI;>K
MO/2+DH::+;Y_GN%[X&/'Z5@,__8WRP!*AF3*/:CD9<P-%Z7W%P,H8VUD6H7$
M<ZM=HR_&,_9<&BGJH4D-'IQX%\\Z$](#46,O91/3:7R45EI\Q%@&J*")/_(
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MQ1R7@6@6"S[J<.V(E&>?-4U!)=?F O\E<9\?SY5II+DFO5P/J(#[(/I!ACY
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MQM=7&$IW?W4^OR[U:1TQ5*E^9Z6^7:I<' -#9'+H'5@NB*&&.IN#M*;-/=)
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M#96,Q1A:]3$\1'."'&$%33UP#@:*N78EQNMIE]ONRJ;O0-)>!D>E(QDR.D#
M$_%<EY%* 8*-6IK<CQMN^^>_:%W6DMNSJKFHS?-6X:G'J\ XF-DM6)T@@.3
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MZF3WS77 P]9/9S&<I5029J0BDC%&K/6EA"D&JXP"DQL5>YR\Q;Z!GJ=5Y=W
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MJZTH;'N!*\NS:$0DO!W/23>(H4I[Q*,\4.(-[C+>0 8$DMY.XO0*/OL_[PH
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M@#C;4'0OZ39P%3[%+Y"N+^%]WL4'O9RY$F5.!LV.<+!HCY[AID2Y)18M4XK
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MU6X443-P&EEP+GCP!7DP1Z+EX6T_\-+6(8TY Q^69[!%&5UJBE\&II6B_9D
MPVK2(BGDF%2[&KUSVZ@>;LHA_+F&50<QSI7#IY<+=K"_'&*_ 3E\K!/1&)\(
MDIGF(.D*@\"!$2HQJ-J<4./+<6,G#I\67NQCMD$Y?*S4SJ !)@*OM5#*,>_(
M\!%HZZ.#DL:T*T!\)AP^O8R_D\.GC^4&Y?!Q4#(4 4S:8)BV&1E%>VI%RJA)
M+RVZ'1&_) Z?@UUXL.7&XO"YB0O\^P8I.ONGEM^_R7GU4+C^=5IF\[]68>,Q
M]8!]GM^D+/!@A3:K WFTW #7.H;:P@F<5T&!5$*D*'FYZO6F(X\''[_J(1O&
MDRI"1\6DK#=U0?/*J>N9*^A*"<KQ;LMA_S.^'1(=M7'[Z69!SUDL:,L2)].5
M_=Y1-$O/AT_X#B;YU^D%+#[7JMW)]"-.U[__&;XNK@(: UE9EK*L)VL*:F*0
MYD<=LTI2\V*[-2(]1HH3;/1:0./1;FTT+[0^(]HK^.7-\E;V/[Z02]+G"?ZS
MRLA>EK?T^VF:P/7ODVM<+&?TF"NLX95QDG'I*?@R13':_TKF1,D""NU(Q=[I
M;P"Y7@7$AO/4 ,F;M39OTM\WD\7DL3:7Y<_9<C+]M&;:N/W5'/,5.*W!A\"*
M7]TKMX8%I-#.&$MAGD/GPC#=& ^3]X7C;D1G#<"-LF7 7,QH$TE/7_WQ<0[3
M1<$YB2JNE"X8%2IR?=9,(TW$8.K-W5),BJXVM1H66%VD/#,X-7=,ZZ+%_]Q4
MZUR6W^K/ZG6GJQQ!*5&G254/7%4V+!836)!%!T(TS:C= J;O'OW"?=O 7@-4
M"VZH>'M,6Z0(UNG"#-3+BJ[V8A+6,0[*2/)4@J$:_FV19C1>@R$&\M'F?395
M@1N*K'L9TCH50&3'G.58K\[+.N\ RU$'"UP4#@-Q:FT7Z&1D!$<[>@]R#C'X
M$"5%WXMUE\?K(MBP%7*[1#M1G5L+!^X'Q1'6'Q4>)2KAQ6HLU/8=7@465_>W
M:$*U6D9=W&@3Q2FKOT9%11^C#X^&^U-O+J6A+740IL:KPC&P,C&K<W1!9I5\
MIV3-L4@X61%%&W<]#8(#;#T /?.6;?$*[=$D[J!8YC1ZIHUSS/-".Q@552FZ
M:,T[%42T.*0XJZBAA<$'/&CX5JS;,Y U]+L(.&CTL%?$TT0131S: 23'>V.<
M(] -06EM3 4,9PHT"9K0LA!%9 !%V8*1BSS>1#("7/9$%Z=!2Q\G-&^-F1+)
M]FX^^0OF7R]@CK]CGB2X_F4^N_ERMPAFG9R1OC+EU%/6H#,+(7(RAA59&H3H
MNZ5<.KQL_'"BL7]F QJW=6KNP\WT@KZH(OT&<3:OOYW@8BU9#,$J":QH1=%4
M](9YBGI(;40?4^1ND^Y[%Q/M4Z\Y*X>W,VCC<J\/2UBN#K0^))S"?#*[(U7+
MR@J?F4OUDKY7I"<OD96@O8PI22CM:H:VBO#B \<VQFW<+7,MQQ_3Q1=,DS+!
M?$^.N%^HYG6W.\49OPJW@:MF0]FY]9#?*9P+6JF<(W/"%*95J2P=A3:U-D-)
MSO&0VW7<'-GY3]3NCN7[/N8=R.=O9W-,L%B?8I@L'<6OD8E<KXB9;!F@CDR"
M(B4#5Z@Z\5;T<OAC&<8M$FWDG"WN/L*R?4DD[_Y=/VICL7__Z_]02P,$%
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MESO8+/R\%9(\+U9MX%=5+H4$,DI]GD AB \1P0RF+/9@R#"A/I%$IN;QL1<
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M#F-&[&(PCEG=&7JQ<\-X$1?'<.X$6AR]P/[ XI64V2);GX%\:=ZC4&+EEO
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MT2@WF/-,YCVPF&I.MW?'F,S"RC:P;3_8(D!'R6Y?U^8:;!S*AH>="?$,M%R
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M:FWDTF=GC#XL;W;NAA[+UN^?%_?JD;IB[RICY<V2-5LJ,4YDH-,R24%BB(*
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MT[X[H1ZT7.E@$N5J?JO0 U;!!Z7&/ZM*$65+()4)X$7;8!$O]+JO3;?^OC[
M"6E[LQ&SM4+8, $:*L V%V KM?D6'3.P(42_3FM*UBFO=*J)FA50TU(GGIB!
MFAF@J0'_\=_J);.(8_MO\[*-%/KVW^>ELXN:FT0_=P;:O2["\6+S)M$3.^%\
MTT#4PP.\62J\9/$^^U$EKGR\E5<*$J\*7']6K>N-V_HXD$:J?GG%E2%9N=*>
MZ#?Q113?,B;*J_M"5%?,XR24<90@2#S$(>(R@!3[#$H_";V$RS1)S)TZU^BF
MYJ=5AH'J;(O2.%+;5D6D%8UUX'%M7O5[LF,@*!L+ 6E-M!AAG?>]@6?VFCTZ
ML+/5F ;J3M7&Z?COQKSJM'IK(-A86/U^UT;0&@FNIM"I%I[0:W;N2,[-UP>A
M'(^ZHZ7[K_<71[[*4#W1Z7XX;W0\CV(HOG:<A,$:Z3'N?Q*K[WGQ>U6&7N>\
M50Y'V9Q)3YE@ 4TY#$3"($HQAVG",$S3!$<$A]3SI/$(?KJ=J8W%#5+U[6Y!
MM1#>#D8-QD4W/ T\PK44[:#LDR&A@RN+X<8-9R,-'$>Y<Z3VYXGHU.V.V\=3
MX/,V[&BIP>5VJE@6J_E'\B-[?'YLWT2.0D("!BG1=9,H$C#5=20ICD0H S7-
M28U*:1\\>6K*UX S^WX/>>I6MXNL'UC/&EP.4XZ<M+9K2TO=M+6=I?ZUOY5U
M^-11OLN3QK1?XND+^H4*;,[1W,KK_%%O;U5?=_65"WZ=EZNR*OE;5?QM$W]?
MT;(Z#VFX,7M9(Q-Z>\\4/P:_M9@='JMP0Y[3_=T+(8VZ_^N&OOW]84=/[3&+
M^#\?/MR18J57+#]\N&Y3QGI,();X, EY#%',/$@]$<(HH-PC7JBW?8WG#\=:
MF-KXJ3""%J1EM=*C!!I,%RZE96!IVF>DSQSA*#46LX-+*1II7F#\\MA-";JL
M[YP,'+UQO&E %^Z="4#GA3VDK#FBK[=B1+%Z.7SU4BH%\@B&24P91,R/(2&<
M0QPG,B*2AQ'WC&7M7&M3D[@V@4$+N*_>G6790/M<<C?T!*.+MCZB>)8_"X%T
MR>-(8MGO-;133E-:.E7T[$/&4U13>W;4U?BFWD&'^X>%OY"%6*<77JF?RHQ7
MX8[Y\DXQ+8I"\,J)+>=IP@B35,*$(J1K+H4P]:52XLCG"641([[1PHP3-%-3
MZ@UJP+9AS\!3"[PYNVL=BW5!EQG(^I@=,;#LG\Y_H,V9@:T^NM[MH[5-X,OH
M?60=\C9.7XT;M39DG_4)-[N<8X.(L0L:&3OHZW(^CL1M.7BHW3C(13;_(.[)
MXIUJ9/52I84)O(@DL620BS2 *)$>Q+Z/(/<E37CHI908;;L>>?;4QJ@*'JCQ
M627=.<9;]]!R(1L##Q0V1!BK1X?)1Q9>2\%^N<^__:KNJM=<U0^54%0B<>Q9
MHWSR'4:T'W#7)3U+8>EZ>3J]<?U!(IX&* Y@S$0(48PBF&)"(<(1B?R$<1I;
M9=3:>?K4/LD*7)-:NT<6K%WFS#9B>O,Q\$=I3H5]F:IC)KLM2[73PKAEJ(X9
M=U!VZNA%/3,*B-4U*1_4)/6;&I_YFY>_ECK+U/I$^15;9=^J<.SU%F$2492F
M7$(2IVKJF"@.TR3V8, $IS1B023M,@Y80YC:AZ_A [G(OS?9-^3Z/#Y98[?,
M4V#?+6:",2S9 ZN* @\JKEOX.DO3S]H"D"W_ #9I$#96#+*#VY]$MPD1[&&,
MFS"A-TT'"17Z/\E5685KG4-#)WUJ4TO//2)\SCT.8Z+3K_BQ@,0+$BAC)IF:
M(<8\C.9+Y5RM!#=81#-KU>AK3.NO<;OMX3[*=98T\>,I4Y.Z7V5>2)&M^N2X
MLZ'?8#G,(:6O7,4 K%%ODMZ[I_32P@,743MJ48%-2D:=W*^HTP&R-<?JO7WJ
MYMA!L8"3;-D7 CA\U"LG^3]IV_D$_J=O[9F<7Y2E$+=MWH</NMS[.C?U1[+2
MIPU?JCJ,FSSO7.HB[)Q#B@.L$T%[$,LH@;J,<Q Q+^ RMLK&;X]A:C[N%_8@
M^/.B2H;09('_F"VKT,^U7: RK VD*\%5G8&*YT_M$62, LND_3UZS\P3'KA/
M!E_UTNAG^]S/UN417F:@-:*IZ0J&R</?GT:WB?=[X!@WTWY_H@Y2ZU_PJ'XB
MVG[]M_*S^":6S^*-:N<_\^+ZN5SECTI^WKQ\%M7YZ^7]%W%???Y[7R65/)(>
M1Y!2PB *L =I',50Q#*BB<"^GQ"[)&67@[+YH,=)9+8MLU61FHP^5X<SP"H'
MC9G5,<A->KE2SX*5YN:665$=]*F9TH[;3P,+[W8'M?VA^*\, FN+]*_6-H'6
MJ$&%V!W+3G79 :Q19=H=C?NJ[?#)/45<Y[UXR!?JCK+>M)V'01"@!#&8RCB&
M2/(4IG$0P(1)@6*9<L+I?)6OR,)0D@^:L/)CUPT-]_U^U6W4";P:G/\3B KI
M##R1PCA10 >IAJIX$55#J]P./TU<Q]6J'HXJ#5/#T5TW7?8*=I(1MXITV,RX
M"G/2S /%.'UE/P6X6;)".XMO1?W?F^458SJ;<JG\!]VM^L \8\6SX%MEUN:(
M>R0)_  &0A>GPPQ!':P- Q^E/.%)PH116,5E,*8V(VXQ*]FH0-?9*6K8>C%4
M)Y:TW/;IV3]F@C,\ZP.+4FL ^+DUX0]ZI6[=#W=;_= 88E0MT%JH+F/2J9CU
MA#*JX%U&U[XH7OBTGJ[3^NC?]N' K9.B;UX.3@=6V_2WU=)7^>Z'*%A6:G@W
M>E*W+#-693#SYQA[8<@9ASRA 42,(HAU/O]4!BA(A9]BPBSGQ8.!G=Y\N8&L
M]':-V=)_&ZYG#?W 2?36T/[DUCGK;3-W#ENK.?/1\]C:6+W269D[ UL&S\#:
MY#K]I4-G=/!N<>O4#@=W7.=X<-H/G.SA6W1VP.<Z5S\6I6KV5M;!#V*S#KC.
M>KG)7/W7IWRYN6?.98Q%@%+MPD<0>1Z#.*8$,L(X$9Z(8F9^JGP(A%-S\3<9
M<Y\53GT8J &J5__J*"_1E/0S'WF&ZU^#D(C7[K6!QYG3)U V<'5\16/D3KV<
M36=OI7[7EF[=^]H]?/'YHO%Z^M7/' W<XRY.(KGIC1ZGDRYL^+5/++GAS> 4
MDZ.&>J9R$F5VO]0A?%?E7P2_KZJ6E*NB^JR:L^HR"2/DJ]%<>#JC0L #2'WJ
M0<:C!/LRBA.&;9;F#-J<VB#]5A2J/W1VSQ+P-7Q 2O!0&P"RM07E'^UFAR9=
M8#;-<TSLP./HVQT>&[Q@ ]AANK<>!+G-?670[K@)KLR).,AB97%K/TWZ<Y[S
M[]EB<;54*KE2KTRF5]S*4JS*30JM]9D$$:,8^Z$/?9:H60=)?36W#QF,B4Q3
M[B,>B<1&G:Q:GYI.M>"K]>D-?%#C!QL#3,XL..@<,]T:C/*!%<PIV]9BUHLU
MI[)FAV!4@>M%SK[4]7M(WVW34PUL0J%(XC$L4@R9Y!%$- HA3A-?25V4^!R'
M84A"NSW2LVU.3> .OK(9^"0LPRE,J#;=[G1*X.![FUT*-4C F 5!CK<LS[<[
M\OZD,1&'FY'FM_;3GC:8_GU>?!9/ZG5[(&6=H[2M9#0G,5.OEV"0"4]"-1N,
M(<:AF@B&/DH\HGHA2,P.HIDW:O3IC'H.;0-4+\[:I&>RH-I,>AS1-X[RK$]K
MZ/K@NR1NUX1SISOF[#B5'8-F1U4=<QKV1<?BSKX+3W5^GKI:?*E<K*I\[G;(
M$9.12$,A84A]7[D[:01QD##H>PD*TH#'B'"[=:=S34[-V[EZU$$G(']>E6H,
MX'I]Y'FI.+8M(V9!NNE*DTLJ!U]H:O)^-6BKZ5I=3GN0T"US<APO,IUM=N0U
M)E,:#I>8C._L)S[7VH+EJDX5]CDK?Z];TC_-4\X3AN, $AHSY>D0#U*6QC!0
M,RPB$(I]9I0_V*"MJ<G-#M3J '.-%6BPEHY.%\5F&N.(N('%90=E1=1LF[49
MN,L7&7L!OS7_'62:94"54ZGI:F]4C3$P?%]<3&[IIRHG#DM^4@T^%_H8PQRG
MWO_/WMOVQHVC::-_A< ">WH <U82*8G<_>2X.[-YD,1!DI[!GOY0X*NCI\M5
MWE(YW9E??TA)]>:J4I$L2M8 9P>;MA-)O.^+TL6;O-^P)#JW4>T%Q(()2'.1
M04,J12*T)D)ROSC,BV-.,9QRDTX\;R*MYSM:OP$+M;:\TPD/NG:[?M1S>1YP
M3GA18&P;YAGTJ=G7LI0K2,V65A:Y4!)[)1M$G851*CLN%P^PZ8AY- >QL78C
M^Z@(#DSY??GP.X'CL;LS-E$Y_O*HHS*],P@O^=[]QC#6[T(V#I^^V3[__*QF
M0J24*\QLR+TQ*#7CAFQ$#@5"!4JQ)KDH?/(?+PWHQ36C94/JMI['8U?/HZ6=
MITYJ/\ZYB+@;Y<3$<6#&V026'?--)^\-^#EF8+HK-%$)Y^*@H_*-*P0OZ<;Y
MOM!C,[[>A5N\-:]+>T8TTQQI3#F!9<8TQ+G!EU*40HP956E*,H6]PB#.#30U
M2\;*:7LF5 M1/=FL:]<&F1<1=3T)NQZGP<^_^'HOKNH&6"E!*V;,4Z]^("*?
M=9T9;.03KGZ5C\^U+EP?D,2QH9:ORUOQO\_52K5!IE^4L!5ZC#W_CVK];?F\
M_JR8K.8_?E;6ZC<<Q>?J+:M631;)+A:UGG%9<BH$@FEBV2,G!62<&3))),Y5
MJG..N'/^1F3AIL8]6[?6>@FV/JW')@2NB?BN%D8*([Q/>Y#8\]G/8J\]2V/Y
M';\N0:?;IM#$3CO0J0<Z_<"^@L!JV.;][07^O^:$>J1GO.+$CI29,?X$^Z5D
M##0#O=D8L<<<+Q%C(+0.<C"&&B.PDT43T;,[B]@&SFK)2,J2'"84%1!+C2#E
MTJS*)2IIEA::L\+OI/C<4-,[(-[)"%@CM&>/BW.8HK3,2RX%)$*5QK3)&*28
MFAV34@3E F5:>E5<C8'H&&;*4'BZ;9!BH#2PF;"-)-T!-43 ]B4DXC88.3?8
MN+U&+JA\U';DTO4!.Z1;^=V>R/Q<L8?%LEY7XLOSZD&M?MPI:YYW"59900P5
MR QFJ=809[F&M)0E9#@E5&)-5>[41,AYQ*F11"<SV D-.JE!*[:'R>N$N,/&
M)#:.0]/()0@C9K1YX]-K,CH]:#P[T$>O ^/.Z\8 *KE?J ]?[M\MQ%^[EYC+
ME B4*HAI;DM>E!)R*BDTA@;+"BIR4KB?EKQ\^M0HPL@'C("V(([XJP<='*'F
M\.E?@\70[M]]&$*:@Q_AX;&EOP:7D?;DGOCX4=XY_7OI[>BF\:CLG+P'M'7V
MHBL*R7U:54+-5)X46I09S).4F&VDV?*P$I=0Y3256)9IPJC/EF?WZ*F1TP>V
M^EVMP??F(,=&$+5Y!4T1WJ9)D%S.YVQ5VZ8K;>:&8[^@$ZBZ;7S"L!J8O!JA
M0"-5Y#IF!YK&KSO6/G[\.F$':IVLZW5X1<0@DIGY=BG*&8'2?,,0"U1 7EAC
M(Y5(Y7DF2$JNCAR99KC(E6%II_%T^VZO1FG@3_A<,,C X1_CQ7Q,(-##*[KC
MRF__5*>5S^J158O-;U_5ZG$FRA(E9L6&&&6Y#2/+(4,E@80QG!=%*77BU1+5
M;=BI+?-;"3N&L*?S-V"YT>+ZQD\GD'>CC?AX#LPC9]L[[3!N>VU9N8=MYG0>
MI\'[-YT8^M5;-IV'PZ5+4\_=P17]EX_JB]DW-BF'V_-_*7"*REQ *1(&L<(9
MY Q+6#*%2YWQ-.5>FXLSXTR-@EHQP5;.X%(ZYW#-$LH3LS.#!;)YKQ@GD&0:
M0:ZXT52JA"?8S_<7 =F16E-M1&RRS[KW>KGP;W%P$E@W(H\ UL#,'?(&AC0@
MZ(,A=H>!DV.-W4*@3^$3/0)Z+P_CVM,E(NM9*0R=YEA!16T2 4X*8_C9 LME
MR2E*F$ D\^.$,R--CQ-VPME.',LF;]O\TH;V_/N_D2Q-_ZMKKP0>&W7\V.(<
MY#H56:Y4"E6I[0&_S P-*P2U5$IA23.6TEG;PM>\!:OU:+"_'',XZ-^HAVK1
M6()OV-QN?.(@FZ)$I"PO[=M+#;(9:>K(0%1P+!G3&<*H0_:7A6,YF6BX;D8<
M#M5?VDH.42'E+)4D%1SJC!###YGA!ZP8)#DI\[PD.LV]=H<1X!S'%MN*-BXY
MN)D2$5 <V)0X5]HZ8CF,"R!$-23.C36J(7%!X9>&Q*7+ _S4/ZM:K*JF=\2]
M?O-<5PNS3VSZ/,YD0E3)B8:E3K79M&72<*_2D*D,HQQG#"&GHCH7QID:4>Q)
M:BNU;V3MNJ7Z>&][L.TGA8B(#4P*H6#YN7(O0]'KU.VY?3SW[F4=#AR]#I<'
M?.V-%^I-0'>9?S![S;KK+J/DYH?6RYDBQ)4P9IEDG$&<*6.E"4YAAG+"*">D
M1$[51@>4<6HLLQ'.YB.*Q@W]1RO^MGF8DE<YHX><;P?V>OU9')CYVMY@;_I[
MB+WI>HB!DSW$.E7!5M=M-[%+?O?19MHCWNCU9WRDJ*57G7F_A7/8.>E== <:
M>KP%>UCL#A;[@8<:IEK)_RBV^FI> 37+2*$9HP(B*1.(L6;0[!P45%F"L$0<
M%<C+N^,\\M06=?,5X+@%2G8@NQTC# +=P"OI^9(EZR7@AA!99?C12@X:T<<K
M7G*$UJA53':COWZ42Q\HOG5-CA\P'$&]-6_IC* <Z8(22,M40*P(A@P)!"G+
M\IRK)-6IBLU/=N )TE,>GYX:B..QDR]PTR$G*_FXW+2/U>C4U P^.6;:AR2$
MF [N#SAA>;>HGU=VE"]J]=T88?5G]5TMGM4=>ZK:C<GM0M[-6?58=R-_5.L9
M(3G7N-0PE\A84$6.(4%E"JFQG(JRI)Q0]U:X02),C:MN__O#W=8K8RNN@J?E
M<GX#Q%8)\W.CPZ8TG,=F.6R2'$X]!H=^8+;;R@\V"H!.@QMPMX>\T0*T:NS*
MRCDWU[EB"CR.(P:?BI%.&X::$K^#A*O0[#TG"'OR>,< 5VE^L,N_[DEA-O)G
M-;?-;CZQU?K'5S-XS40ST)]5/5,I$EF.*4PTEQ#KLH 4:0$35 @N69$6?D4N
M>L::VNK2B0H:6<&>L. W*ZYG=&8?R&Z&<23H!EX=@E'S-GX=\(AJ[_:--ZJ)
MZZ#X2ZO6Y98KLD/[CB7K[ESRS<MSR?O&<6E; FE5V6J^];O%IR9FZA^J>OAF
M.\)^5ROVH Z]#0DM$UU2V[!0&D:BQA9F@F=FMK*4:9HJ*KU"D\968&HTUVEA
M>VE9-:[T*+[::^'&H5.>[%%\D;S7(U4#WKFDX$F75 ?"#=B#P0;*M4#<@ T4
MH,,BNL/JM><Q?B+RF$J,G^[\"E-T,JGZ->2X)COJ*_OSES^ML.J-6BA=K6<Y
M+1%!RACB9<'-VI=ED!5%"6E2:(003O+4:]D[,\[45J=/J^7WJK8T97L]5FVF
MRIK]Z9O!?0Y6KO,\I[*$N4A+B!%CD.G"[&]RJD1&&$5,AR1'707L.(D0YZ"-
M ZS;>AP!K,%/NQI<C(B@DQ'\U$EYWB0*S(XZB\, V5''8[U"=M19A4]G1YV_
M/+!<JA"V7GK]60E5?;=QDQ_5^JYK-(0TS7!2VE0=RPS*8,ES@F&>ZU0CI42)
M4L^2J3W#38\>=E*V?;0\JWSV0>O&#;'@&I@@-F*"G9PW@&E;G^]V/E_^T1S+
M6H;MVOB]7]8&T+O879U<T(I;$;1OP'&K@CJH?E09U.6>H%2)_9X,=\OO:L$6
M:_NW]F=K+'ZV]N>'MF_13.0$E4DNH4PHACCG'#(B&40*EQA3S0N=>:1/^(P]
M-4NO:2M2[;45$9T"-T#:?Q*=#J#)X;[9M'[R2K7PFAL'5]YPB ],6D<]7.ZV
M8#?_M!$??&[!_C TV!Y.N^% '\E;%QM\WSR9$/@NY,YX/7+,?)H075_DV 0]
M(LP@_6_%YNMO=VREF@[573U/JKA9$T0.)6>9K=8F("540BW,+/""*"V]6DB?
M'&5JR\$VG /4:KV>=\>3MM5ZU33<K;[['@&<!M?-%KT:LH'YO)4/6 %ONE[T
M\2JE.H$0U;8\/=*H1F6OLB^MR?Z+P]MPW2T7]?/<EF)ZJU0]*ZBB2"495$)2
M8RT6":0%*Z V#$$E%UJ73L[X\T-,C05VTAD:Z");GECEF'7? Z6#<7<U0 -_
M\QO?S!Y&5L*KH?'O"!4.T;A]G9RA"NK*=!H%E]Y*+^X<O4/2:<E/]3DZ<^4U
MW8HVAT+$<%B1EA0*EIJM<(D4)"+-("HT(PEGFN5>U6D/GN[%:Z-5I;V^C8[G
MB5HH)$,?H74-<^(?BIU2>("^.*]S['5*N=,=<*X[V.JK#GFR87;!2TEUKJ#6
MTGS*&B/(B?6LD3+1"<MT0DN?3]EUX&E^Y1%;E3O/@!L?#('KP%1QMLKLR:2;
M8<O,CM;*W'GP5R\UZ]/:W/O^6$Z^;N>/>8JI3#5DC*409Z4A*,$0%&8WE2K*
MTQRC:QU\_@<%HSOWFC.5O=_A?@2O=Z7\LVB'^OPF=]1RPM\WP%G+)2 &=N6]
MQHG+)94ON_#BM+L1WY1\GJM[_<4V>WGSXV[.-A6Y,.>HH&4.4:(R8]@D"C*I
M*4QQ7F0%*;G 3OVY',::VDG,1E1;A:@1UH:*-N+Z%3US@=F-*R*!-S!=7(&;
M?U3L943B!K#VC#=NK.EEQ8_"0AUNB9D1T0:3WB[DNXW[XI-Y3^I/RWDE?LPT
M+:165$-<V-S>1&2&6!"%4F$AB"ARP:F?+1(@Q?3,E'-5E&+D(O1/B",%#0OR
MT-1T*M!_KSS5;ZW$X*OZ<PW>F._M]YA<%0[="$'X_7),(([>"2BW4'BW1UUK
M3/V=K2I+KN]LZU15KW_IJBJW*WY)A":,2U@BBB#.)37OI<IA@A*>:)6C$NLP
MPZIWW"D;61O!P49RL!']6H.K?RI\C:]H (]HB%V![15&F1-2 QEH_6._DK'F
M!,AYP\WM]D#BVC3BN-=M19B*S3\MZZJARDT#&$'+DI",05+8./&4*4BEV1@2
M11C6)3.$YM3EW6?0R5'6MFN,^:ZV4H.-V,'=C)PFP)&K(L,Z-%%=CZ@_27E
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M7=-'&X/UW%HKGDD68=/HZ"P?>FJ&]I[OS<E1.>)6A[WI:J-]!HIPO ;)@<*
M?"1YI:"@ +#.APB%/"S4<OORR.;SS1'R#&N>LTQ3,R=:&]+$ G(E)21%IB1#
M>9X73J>\9YX_4<NLD7'K0?&UP0X1=+6Y@G$9Q\9RA"3 FCJI^!76T^'S1K:6
M3BIS;!V=OBPPE.;Q:;[\H3:M=DY'1W]<=B$D34GPNDGIWO]WZU'_N%S_CUI_
M5F+YL*C^J>3N2>U-35&@K]]8%VI=S_($ET(*0PXD*2!F'$.:J12F%&<%2;!A
M#J]BWJ^FR=1HZ-?%:BL[$/M=#E1;.-@S]N?5WA W8^U?8MZ'-OCZLUANP%;_
M31>+7_ZT-KH- 6BUN6GBF,QU:_!#K<$.A1O0AI%%#'%Z[0F+&SCU:MJ,&X[U
MVI-V%.3UZ@(%'C^P^;:AW4>U[BH#Y)H0IDL,DR)+(-::0X9E"BGFC.>(4Z0S
MS^.%4^-,[_C@8T,VC92>^_^3.#KN[Z_%9F Z[T0#;]1"?'MDJ]\'**[0BT'<
MG??)D<;=6?<I>[1S[KWXFHAU2SW+A5F0?UX^LFHQHZ+4.C=?O=DD,YOQEQL3
M.$TAEX642&,N0F+47XPR-?.TBZG>2@E^:^7TS(TYC:BCR7@M3D/OFKTA"HPS
M/P/! )'E+T=ZA5CR,\J>CAX_=_&P5>,^JC_77_]0\^_JPW*Q_E;/"*$90C@W
MNV(J("YP!HFDQDR@"!O[H#![9*]B*Z&"3(U$S+N6#5,V[F@*W"AE#& '9AV_
MLG(WX'\46X'[1<2.AM>"^"H%YXZ$F60!NG.0A1:D._N\:YVRFXI69ENFZO=+
MMJAO%[)+)%P\[.I<M8GZM#"[(\0TU$Q1B(5M!L@1ABDV)A7F4A/FE5(3*,?4
MZ''? ;A1Q!X"K6T?JT:9IN+=5IV#.F[7%5;PFS]??^Q@LS*B1S;VA%SAE V"
M<R"WK)\LK^28#0+LO&LV['%A%'NR4L2/]]5"O5NKQWK&TU1ETK833Z0Q-56"
M($L,J:HB3106N2Y$Z4.E%\:;&F6>*8?R _QF10:-S)ZD> EQ-_*+B./ )'<=
MA-XTY@A,5+JZ-.:HM.0(P$OZ<;WM6DON=!IV5V$IHR5/N5*P4!Q#G(H2,IUF
M,$6\D(E*RU*P,,.M;]BID<Z^67"NUL#5I:YZY\'7 (N%[HCV5CBP5UA6+C@-
M9$CU#OU*=I,+'.?-)*>[ Y+G6DM+'6YROR[?*'O <6O;U]HSCK?FK9PA+4N&
M#5\I)(QUA&SK^2Q%4!9"9451Z@(IY[93[N-.C;"^?C-+1M/8UR/1R@/F?CH:
M$+R!^:@3^L2)VM<E>+,Y46ND;\_5K/S#0.R1MS8,U"/EJ,6%W"\]S1^XWE0T
MC\>-EW;FK^-!BEG [6$&Z8F"%K:#5R55FU[R=66VW5JM5DJVZ\S&+J[?U?6S
MDK8HK/FAL99DR3,A=0(+E)?0;(H32+DD4)59RLN"%5QZQ2Q&E&UJ*\7?-XFA
M=9MEL-ZI8O-"F##ZM$7A_.S:F-/I9OR^TB0-O"*=JO!S PX4 WN:W6S,Z*UR
MH-6N.;?<Z!?/DAX ]*CF=DSY1K7)!P#VI>$^Q!!AW/]IM7Q2J_4/6\Q[;1YK
MAWMJBL%MCEG;!:A);[[7O]:JZ177+#^WPI@ISTT;H)_5TTJ)BG4UPF\?;6&9
M?[8&5)ZF.J>T@*5&*<24:D@E8E!I1E-6I$66><7P#"_RU%:*]X9!;L!3I_=-
M0RAJH_4-6"C/RCTC3+K;PC&MJ1QX/?FTG;]&W78:MQKO>;<ZB[PM[P&7&AJ]
M0:.XN:>QQO=T!_O*-P_95S_><C/>5$5=A480>]3%:;QI>+EFC3AR:#'VI?B]
M71]_?EY5BX>V!$>;Q7F[LZ;K62J%2',E8))D$N*"Y9 7J8 E)8JSA**")GX5
MV1U'GMK"8@-YFSQG&]!K6TY]O'L'?C*;CW9+\A??8NRN$^!XICX$K$,?JS?-
MNSK#OY5Z6Y*I%?P&[(L>LSB[)UJ1*[2[CCYRF79/4(YKM?L^((R\WCT^L6K5
M%H4WQKYYI2ICW+=]F0V[5FLUK[XK.2.X$(6@)<R0+"$FY@^*.3;\I0DA@B0)
M=CIE]QQW:L2U$]O2EVX$A8VDMB)RIT50QW37B7"CL '@'9C #I'=R0PV[=??
M[H$=C[T\@8K*7:YCC\I<GH"\Y"W?V\-8Z[.JUZM*&+/NCM7?;.GDK@YLJDH#
M-K$];PSDF' $65E@6.9(J0R)O%2I7[;>N:%\/IVQNB9O) 7"B.I'/^<1Y6E*
M4DE@JK.B#0>AM&!0$T602C.L$J]3E!AXCL'TPZ#IQMXQ,!J8KO?@L3(V>>R=
ME/'(^1(.4=GX[&"CTN\EE5_R[<7K X(O=H$<[Q:?5M5WLWV>__AO-9=M/-K7
M;VS]\U+9T-C/RE;R_FAVVY;@V^JK99KQ0@H&14$,80B:0):D"10D4SE-N9"Z
M]"A<?)4PTR/I_2 G6WMUHQ'X9E0"JNL1YQ%?<-UD.41UC#8!0QN8NW8FMESQ
M%GBKRB8<UBH#K#9-N8U6'V 3X1N-O.L87S<W'N$@H\W12!$B33F(=A^PWX/F
MU-?R ZSMI$D[:0LS::MVTA9FNIIM6%<'^4FMVL,E$*O0<13,>X-+KAMAO'B3
M*$@<A*#$>6+@<:Y:&09^\\G,3.,(;4YBNB(6DNFF1QW,%+/=T(F&G"H%RRQ%
M*2T53T3F=8![?JRIV<.MJ. -V H+&FD]CVI[P'4\G(T#V=#'L6?0&J)<R&5
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MANLX6X/!D'5;>J*A-?"JLI6SJV8#-I(.T.7<"9.HBT#_B*/RNY/R+ZG;[:8
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MXL+@2/($09Q@1%+S*\)> 5SG!IK:N<-&3EO IDUE<_'E^V'KQ@XQ$!N8'<+
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MZ[%]/%$'\S3:W/@$P8TU1R.%N;U;F]5Y&^FVV';<;B9I,X<7YNEXCF-%Q\4
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M/1QN;SS1(WGHWF["_5Q[ \Y&IR]PB'''<QX.B-J>MW'(<7HV;"R70BE9?3"
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MY9A4ZPNVHT,_/(1#^^UM7;WC&CHW.S5V@)$;-((']-G[(176->\X]K@>>#]
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M<X(PXYJX;" ZQIC:OJ$1$[1RW@ KJ<$16%G=N+H+T&ZV#033P'S9"R%GLG/
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M1DQR]-1O/P'2]^:>J1W66<E?/ZJ5Y<@'?5<J6:S:<_!<)BI)(@2S6*40<9)
MSG0$:2(YU81AE'NU&^P:;&ITWLH*6F'MU]"(ZYD*TH6OF[49"K6!B?HL8$.D
MCCA $C:3I&O <1-+'%0_RC-QN<>//ZIR-6O+T:S)0B<D2K"&+,'6N2@22)#"
MAC8,5T2)UJETVJT>/7EJS.!5PNH8)VE8-:<1A;G&'"*M%>1Q@@Q.2C+$$JXX
M=W.L7(742/U3KL.JFR"OTG]@-EQ7I0O'?6>U[2(Z<],.R9E_'1+<\5-'8;.S
MRJRIZ_P%?:(D__[+NH)(*F,2"T-+>9X:;A(IA2S-N2W1(/-848W=?&H'SYT:
M1UG)?*(@MP#)3-&81PPRP<U>/HFX(?280"EE)'+*(D(CCTY/_2 :AYSZ@^2P
MU>ZG^,"L9(4*'@IZI&AW .CV\A'#/H]DW _V//[U-4EPF\.;.DUF4S:K3>*O
MWKVH_U&L_/;'<A8)2E3&!!0QR@P;:02IIC$4&4-9GN4Y)\P_,<YY_*FQEGE;
MTC[I<.Z N^VX!H1QX ]\G3:W/<QM$^AV:NZMEH K\)D5\@98#8!1(70RG3=V
M R38N<OP!DEWW@"=3L3S?TS?G@4+M=XWSE"$%:5(PER9/U#.S4XOIA)BE&M-
M$!7:%J#VZ4^P?;@7)8W5B\"W=OT.5EF*2,PR"I.,&GLS3CDT!I2&>2I%G)*,
MIL0S**\O6B/95&V'LVT8Y!7@.;)U3T"&IN+EXA&:5?,)6 $=_(<]2OH?*QZX
M?/_. ".7ZC]6[;@L_XEK>NP.:^IL@G?UKY5JFF<_\!4SSY?WB_=_BN^V*-.'
M95E?^<#GQ6-]&K.- E,9H5FL)*1,"XATPB!)\P3JE"JF,$E1C#PV3==+-#UB
MJ-6!2PU?*@58K1%8MBK9,FVJ50KH90GF5JW=DLO_Y;%/"S"?#ON[<>=H<+/1
MXEUK8W-&C#Z@40BL-0+W"[#6"1BE&KL2[*@5O@5P.(@[=Z0!AAEO)QL.D[T=
M<,#']F#@=<[TW?*)%XOZN=L(%KM1N5_<L>J[+49=++ZIQ2;'FKU6LY3C)!>8
MPD@)P[U9+B%'.8.6<S'A5"3<W:-WC213VTUOZ@^(K3(WMEQJJPYX-OK8[UH8
MC>H:[8:&5VH!^/I&:;3R(-ZKIM&!<L>:G(')=C,O=[OSLM6DWIK;>;'*@$8;
M8-0!VX(2(\Z+1_C+6/,S4DC,P//DMQ:&P+9S%;QJ@/'6OQ X[*U\01[8SZER
MOS#,K#XNJSK(Q[9<*!8O9L?<.G7,XOJS,M:P:J[[QOY4U2_%8ED6J]=U],_M
M0NX_Y71@:#5C>9*H2*509SR%".<QY#FG,$UCI0@1B$9>/IL199^:2Z@1&O!:
M/_!<+G\4E2VQ83<N1?.[E=77S_$QYLO@YE>9Z!0/O#JWL_N3E?@O333D5G6P
MU7T]_^?BZJNZ)Z]]5(W,S7"QE&\X7T&]36/*/ZHSZPTFYM!7]A8B]%L4/YM7
M2I6E:OILUHFQU>V+&:,L_J7D+(N90B+.H(IL3I0-,&,9$C!+(A&+7"**I<^)
M:?=P4]O2;:1M&NW>-(TO*L V$M>M,9J?>O;#N "\VYH1#LZ!:7Z+Y-<&R496
ML!4V'#&[@1*42R\,.2K]N:E_R%B.=_7P-GTP9KX1?%L/^9LJGQ[T]M^S)"4I
MB5,"LT@D$"G*(%<1@7F2*X9)8LA&.;N4+@XW-9*Q\MGCJG(CH8>OX3*X#HZ>
MH) -3"2MK#L5SV] C>"#WOE94 0]7#)!D1S)[W(EHGY^%6> .ITGEY\RGH?$
M6:,]-XC[7==5=[X5QFJLBGTWRX/^QW*UD]/47&6X?R:C1 H:2YARK6P;6@YI
M9FP^2CA-S;]D&CN5,KU.C*DQ]*:I,VL%[%>NV7,NW"S X1$>RSV_H\&>V]<L
MC8T6FSU\>VW71/0NW-P/QT&*-WN*\B8%G/O!=:Z(<\^G]3%*Z\K0Q4O51I@C
MDAO&$S'$L>(0$8T@(RF"1$J>JTR3.'*OX7SP\*G1V48\'ROI "\7J[(_"D/;
MD&O)^C3(/43"QSKLC\A8MN#%5\/3W#NM<;=Q=W#/B*;<:6GW#;<SU_3@H&_L
MD?RB9"'8?.O/^UNY?'G^^/'NBYJSE>U$6%J?7_.FH2SE<41A2B,,D68*TDBF
M,(YP%J,DQRK'SASE.?C4.,R(#PEH%=@Y!@"U"C? * &@V5+7>H!GJXC'-^X[
M,PYL."#> [.E&]2M"J#6H0^O>G\-[KP[(/8C\7*/.0C$X#VQZV1XWV>.MP+T
MU'9OA>C[C'X;_?VRR&U5Y*8_F<(Q(L@L$!+9=DT"IY"DB5D^%%=)EJ$H287/
M9O[\4%-;'9IJ[,M--79;YKN)MNW5!*X#8[=->ACD!N;Y_J!Y;[8OXQ%T0]TQ
MW*B;YLMJ'VZ,'>[HF6"V7#Q:E^,[Q5>_L-5+68?]?U'/;2:;[9U4+$3Q;$G,
MYK1],._9+-.8DXPRJ/,\@B@U^V5*-:O;'6&N2&0FP"M_MH\44R,;HW-6]QE;
M?5>E8MJ,Z9F#U6LNW)AG<(0')J4ZJZL^C; :W(!6A]<VE=9*&S#!ZQJPPF:"
M]9)DW)2Q:\ ZRBV[ZF%]2[$MQ3_OJ^I%R7=FP,7CY[HS3]TTXI/ZH_Y--8M2
M8RL1DL*<&:)#*=:08+O]5BQ*&(T2$E._FFP.HTZ-XIK69M4+W_38\XRV=,/:
MC=*"(S@PA37@-0*#1F+0B'S3=/ZY 4;LYH( ?K=>, 4NWN8R\LA5W#S ."[G
MYG-SSS"\ENB^+=O3C?61B*H^J=6#MC'Q.Z>T6N!,8IBER# 18A$D/,YAI'22
M29)'C-+9HNZ%<Z'K69_AG3XMVGQ:NT(,]X6MI:]#PC?95&SW/'&A5G9K4Z=>
M]3O%]9HA-R8+COI(L7QKN%?+]4$LV$INV:S&ND[3"7]0VP>TL+%^/@*,&_G7
M YJC., ^S^C'>=;8>U=48KZL7G8[0 FSQ40:"T-JAN,01CFD"4*0QC3%/&-"
M:R^_U9EQIF9DM=5;/S#1%@[ZF2W^"3XN6=/%^J.=A;YE<<]![<93 0 <F)*L
MA& KXD!]MB[@$)1ESHTU*J%<4/B0.RY=?GTMI/;L)TYDKJ0F4*8:F4U9K"#7
MFL-<$)&DDJ4)]0I3.QYB:N3PT:VFC2N CLZCJV 9VC.TA\@ 1:_/:S]8T9^W
M*'!]7LVN D!!SJZV7&$>NWRRG;?J<]3VD.QN6:VJ.A/A9U;9,[/6,MFL7CHA
M6FL409$1#9%(,*1IFD).-,UYE""LB9>A<)T\4^.,QO%0RPIVU?$T':Z<)$<3
M8SSHAW;W6"DAKU%OY02W]OCF4=5_'\@T"8-?6!/F2IG&-77" 'AD$@5Z;#^"
M_<"*LG93W2^>7U;51_5#S=/6!& (Y;%(8YAA;2MSVV8C.1$P3IA,8ASSB'HU
M)^T8:VK$6,L&/$O?=F'IQG&!$!J8OZR4:[]T(^@-: $;P,ARP"0H)W6--RK?
M."A^R"4NM_3DB3H;J6#SKR_/S\MR]6W95$^HEO-"U@Y<]<CF[Q>K8O5Z^V=1
MS92*E:VF"JDA#HARB2!#/(%Y(C,4<Y*C7'N1AZ< 4V.4C?R@5<#Z1@]4 +4.
MH%$"_&[5\(Q#\IXF1UX:$/RAR2HT[OX$UA.\L*SF*\2X5-<3HB/^Z_N<:YH+
MU/47J\]F"/&ZXZ*.*4Z3V/!?DDB(J)*0D(@86PI'N?E1AGF/1@(GQYH:U35"
M]FD;<!I*1U=4&("&]DFU[0 :.<'OC:1@D!V? R(#%/D_/=X;%/3O5/QT\?[N
M6X(&$37U,W:BB!*>XYA0**/(AF+7)?S-'XP3%9$H1S3V*J/C-NS4J./3B[55
MK=.VK:/S;)[\O?:4\-<^R3J>L^!&->&Q'=KCU!%@U$@]:H31&:#&"#$Z''H*
M,49GX' ,,CIW=S^V:CY 6V;"VD\VC/RK>FQJ%!(AI8@(AHG,.41*V[+..H,X
M2A'.$<](['7H?GZHZ;)2N9$55*VP?CS4@:\;]X1!;6"^V0*V%1-\O028-[U<
MQB(HI70,-RJ-7%;[D#H<[NC3Q''^_)W=&?9I<]GJ#+;[A?AKZ_/4*,Z58 Q*
MP7*(I$*0I)A!HA5.,RX1II%[9\?NP:9&&;6XP,J[R<EL$S&MS#X]#B^ W,T:
MH:$;F#>Z4>N3,WP)/H\<X8 PCI03?"V<GFTGW?#I[D5YX1DC-JATTV:_:Z7C
M/?U,LULA2F/[?2Z7VFQ6S8O#YA^4JNY>RM*\2K-<9X)R*F'$,\.V(DLAPWD$
M#0-+G(@X%B+WZVO6/:#/^SY.0Z-=08%6OBZH"_BZF6?A,!N::AM!P1YH5M0;
MT H;SDYS R6HK79AR%'M-3?U#VTVQ[OZ>JY7U@I:QVH];)L#-NT"9SIGC,5Y
M A.A4XA0E$#[;YA&0B:8T)AQKZ2V2P-.SGZ[MFOB)8!=G=KA8!O<LUV+NA-P
MN2/M#6CD#>G<=D,FL(?[PJ CN[G=(#CV=3O>UV-/>+><S]6C^KHJE5IMBYM\
M?&[M;9[$&<U3 5FLJ2T?JB%+)(<YCB7+I=2I6^:&RV!3XY167-#(NUNCY^-G
MCRW-)8@==H0!@1N85;HPZ[,?O 2>QWXP((@C[0>=P#SOG/#;#CK"T[D=O/2,
M\;:#CMKL;0==[^D=&L\>'TO5='VTOKT?:O&B/A8+=;]23]6,ZA0AE410YUA!
ME.L$DIS%4,18B4A%)#$;0K_8]\X!IT:W^_(VSNA:8O"[E1G40GO&5UT$W<VL
M"PGEP 1\)8I]PM2=H D=A]X]Z-B!YDX0G(@D=[NOY]'@<K%LFA/92LNV[]#[
M/VVTNIH)R5,5,PUCH3*(8AY#@F@*M=($R4AHDC"?5G9G1_*BF!$:SWVS8X"E
M+>O4-IJKZPAX'@F>Q=7Q1# $6D,?".[(N.["]E,KYOFN2/X'@I>@"'L>>':T
M<8\#+RE]=!IX\8:>'25859A=Y:T0=A=I Q3J0*K#<+X$\S2/50IC9JP1Q'$&
MJ;"E2K Q5*(TYSGVLDO<AIV:=5)+;9?3SW6YZ%6/O#M'O-U8)#R* U/*!L"M
MR#>@#:<<-*S2#ZFP?1_<AAZWSX,7'$=]'?SN[ED!=_GT5#2]$&\7LNFU^*@6
MHE#5+,DY2S.90"F3%"*51Y!+DD)"4&*H28F$*K]CLX[1IG=FMB-L74-$[(H+
M?OJT7"D0QYZ-"[OP=F.C0!@.[IS:!V]/SH"U<"^#$;88;L=XXU;#O:SX43E<
MAUOZD<BW4K'JI7RMPS#K)+MUD://K$FZ:QJOSG0<Y2+&*4P2G4!$40PYRPDD
M6:*Q^1?-$?*KO>8ZM-.G,6[=M39\VZ[3JU:+-K3;CU*<T7?CEZ"(CM1D80U?
MVQZU3<!=RWUC:_HW/VQ;7X<C(%^T@K*1\^"C4I,O)(<\Y7U_SYBAJE*KRB;!
MM5$L:<JH9"F'*;*5TRCEAIQT#&6<\C25G"N%?5PUAP-,TT.SV,@'6"VP9V30
M(8IN)',--@.322/:#=@*%S#:YXS:8>-[#@<9-Z+GC(I',3SGKNN92O;"*_5_
M7\R#WO\P?S3])1")TDP9(T-Q6^F,* 59RB1,\DRI2*2I2KT2[4\-,C7GR59&
M4 O9KVG'23C=/NUK01KX\_;&QS^SJP. L'E<IP8:-VNK0]6C'*VN:_M]]%]4
MM2H+84L!L>K[>V,D_&!SN[]9!Z9&2DG!;)0>X3%$29Y FMBJ/5%,-=<JYLJK
MU.&E :=&!EMYF^+-$%Q:TOKA[,8,(=$;F"5V@*LK,>\(.T 0L"LP0=GCXJ"C
M,HDK!(>LXGQ?CX ]^[35ZU<EVHX:OQ5FV_&R^J*8+.:O[Y3Y@I^*A>6QG>)"
MZU"6:B;CC&%&,20*)Y:!(DC3)((X4DF,=1+1-'6.Y[M.ENGQ4I.M7FS#K#B;
MVY[N'O%J5TY/-V>-#/K =-8H K::@%85T.H"=I4!VRIF.X%P/@V/K_URW",-
MQYNBD0(1AYTJOSC%,.!VAC%>.<1X48YAL-@+@@STR!XKV\-"_?+UX>/'NS:T
M%\<T8JE",!,1,4M53B#CJ5FT,,.*"YHGD7)>J@X>/K6UQX@'C'S7=CD^A-!A
M.;D"F('7ASU,>H2.'X+A0>!7@#(2(^^"$XA8SRC=R92']XQ'?6>DW>.R<]=<
MN[&O#P'6"3*$QK%"$<PIHA!1DD"69 I2'-&,B02CI.=N?F>4J='5SDZTJDL5
ML3]8*3V]]*?Q]-VU]T1IO*UZ4\LI?)W=3@@&VI3OCO1&._$3RI[??I^Z>/0]
M]_I,_4$WI9]F<4J)N55 E2L-41Y)R"3C,$$Y4YQC+6.G@,H!9)L:T31S5WTO
MGLVVW QHY-ZM,?=3L6BC$QPCGH:8SL'W[-=,TK_#'OX&;,).'G1;W^[MIG.T
M??XUT_KOM._WFMXQ?0'G)F! W\#1D/\NOH)S6 7T'9P=XKK^JP_:-C&SQ1:M
M*[=NSS$CF8@1YP0*FF<0I9)!*G *)2=18A9GG6#9K]WJB=&<ONNWZ*YJ@_RD
M;;-7M.("8>7MUT3U%,QNMORUT(W<(M6 5O<F7 L*[CI!Z]T-M0..09J?GAKO
M37J==BA^KK5IURT][/W[A;#A?NJ=:OY[OWA8YU_5%:>;,*$9SN,XQQF%*J$2
M(D8)Y$DD(-,\T:F,D$Y3MU0$CU%]/HEQ4A*^%(_?5W"IX8M9X7W"]7RP=C"R
MP^,W,*6L!08_K47^B[&;P$;JIN@\N!T(4@]#-SRT(QFP7]1SDZY7V7S?!FVS
M9]SFML[K'S5O;:A*&GYH=5J;CH\:SXKTTVW/.O2\M:^35JCBAS4QJUM>K4HF
M5C.MI8II3B!6$376'D%MP%7&A=0BQ0GW*M5_8HRI^4UV1 2_KX7T#+<\!:6K
M=_8J@ ;WS7IAT\,Q>U;[P&[9XW%&=LJ>5?38)7O^4K\/7:IB]JY=/)J"^N\7
M\IW9-,VH2B7)$@)I'!ES+",<L@@)F#&6ZIPG-L?+Y3,_.\+4/O*UD&UK"&#$
M!%9.M\_\/)#='WD0> ;^Q+V1<?[(+VI_XA.OE/CKX_+'?YI[FZ_;_*7^J.O/
M^?P31_F8+RJT_I0O7]AOQ3YT&GWX\:GX=6$LA'GQ+R7_QHK%C" A99YC2! 7
M$,5)!DG*8BC3A&/.\IPPKS/6RT-.[5-O';'51N0;\.$?\-/]#7C9R T>C>!^
M2[P#]FXK?EA$QSZTV("Y%1G\K0M,;YO '9^@)H+#L*-:#.XP'!H0'G?VK3E1
MU2GH;6F=:B8RG3-K26 9$X@4HI!&*(*:99K@C,5IAGPR+P\'\**8T3(O52N=
M;P&) _"R!.590ADT^]G8IJTFD*5Q HGF698AAB.W5B)!P!N#G\/ YD:VUX Q
M,+76HM6U-2XBTJ.LQFFU ]?2.!ADY (:IU4\KIIQYCK_O=3[NKGJ%_58V&W9
M8O7)S.X,:9IE.28P(0I#%"D-B:0YC)#,TYRJ.&%.59_/#3"YS[?I)+P5$E@I
MW?=1)T&\O(VZ%IJA[20_5+SV4%VJ]]I"G7S@:#NH+G5V-U"=U_6.3&M*3VR/
MTK^RN=J4TEF9OU6%K#VMR\7FX'T68<(I(ABJU';[4DQ 1G($DSC'"O-,$.34
M\/A*.:9&!5MY;6VMK< W0-OHEA]69N_@I%X3Y'#D-0[LXVS'&BUV H=N@%7D
M!NS,R-W^C&SCC<:9$>_0L*%G9MPPL&%FJ$_$US6X.D1W]7K\V)%<UV!P(FKK
MJL?UW'*SZKLM^K:?(WU8#A4AP=,4"ZA1GD#$= XY0@IJ151L=I9,22_GG].H
MDUN5;+Y_7;+P(/'?<\/IA+CC+C0TCD-O3<]!.$X56B^XPFYIG48>=Y_K \;1
MYM?KYCX]D>:LJA[T;ZRT)GKU4-813K\I^Z>2MS\,#3ZJ]W^J4A25^EP60FTO
M_IO]\W[1')#,%(Z%5+F":4)2B*@P-K;904/,%<F3*$<991X18L$$\_DLQPDB
M6XL)'NU_VM0.N9S/65F!9U4V:1X^61[A9M'!$'^3F1F:,*U.-F1_,S</):CU
MN@%KS4"K&ECK!FKE=N^Z ;6"-K*M4?%-YM"G3]1;S.58EOQZFI[K:=I\6#:J
M^8_U-"]+4%IEMQ^C?"EML-SJ>WV+42U8TZG06'>WIPHVVHB-K$(CM-_R*OC3
M>VX%]N1HQ=AI=#C3&"/%$8%1E#.S"T@$Y(FT_4V9F6*:XDBA6?-N?EVQ<N6X
M%[@PK,\7?#CX"&OE<K=A)U>/Q6)A/].V:I%_=J3S;"BB4ZXPAHF4&J(D2R'/
M%(<QICF/421YGK>S\7[AF$$3?B[60X\]$ZK^[PC3X+A1"PCL*";'<F,\V*6H
MM3@>'#K[^F_*'*$)NQ^[-.BX6S%'"(YV8:[W]=B ?5RRQ39B=.N8H"R.J,P)
MU,16ZE<80:)LA&<FL"+F_W*9>6RGS@PSO<V1%11L):V]&(<_^U__09(X_F^P
MKF+WV:Q#75TMW%%WV/X$0')@9CF$ZW<7)X\[1A[;BP!8C;19., LD,E_0?].
M _[<O>.9XQ>DWS.N+UW;SU3^J*I*J?W4F8\%X\6\6+W^:KBWJELS*?G^3V$N
M;=O7\YA)+;$TBU&60X2R"!*>$AC3F+(((90HI^#XJZ28FE?=*O%?H'AZ?FGJ
M?C8%1OR,M'[3X6:Y#0[RT*1;RW]SF-%X S9*V)#;K1J@T0,TBH0S\Z[",:CM
MUT^240W"J\ ZM!*O>UC/'BI-;[IJ2[VM3=2:1.OZX"S2FA(M(4V%@"AB.222
M"(B5($JJG"K)?2C1<=RID>!.:E;=#'=C2>X6H72V)'TG(:8$,4()I-)&(45<
M0!8+#A.I%2$HQ8(3OW9^ TS#2'GT+A/A6 W4=QK<UJ,!H!UX!5I+O&/&WAQN
MD0:HG>\)5-A..XYCC]N QP^0H[X\GK?W\#E\LCNJG>+#&-,\5I$!6"*(T@A!
MCFVG#IJEG* $:4&=HR/WGSVU!:"6KK..[$6T'%P$_3$8F"(VZ@>LT=FA<>?^
M]N"6\;:UIV7=V\V>N:2?C?:A6+"%*-C\?E&MRMJ9<?MG4<T$E6FJ8@6EI!%$
MN8X@2W0*::2P9!S'@B4^-MF9<:;V"6[$!%LYP>]64L^:#>=P=5O? Z U\,?:
M!RCOU?L"#$%7ZW-CC;HZ7U#X<#6^='F?D*OS;8 _%@MUOU)/U8P@S!G.8L@P
M-6NR4BGD2$20*TXCLY5#BCDE%3J/.#6:V.U??7O8OQK\;N4&M> ^+FTGZ!T6
M^-" #GW4>#V6GJ$N'OAT1[&X/&C$ !4/O?9C3WQNO,;,4(Y.6<ES'%.!(4DX
MAXAF">2IQ%!(06.4THP@KZ1EK]&GQC4A?.-^\/O8* . .HKEHM[( ]X+M0$,
M'5<)WL#\\03GM%'D^Y >IM+7N[]OG!013WF6YC#3MD-2@H@A+,Y@BJ)82,)P
M*IT*VQT\=VI49"7S,&AV '(P6_JI/3!96*'ZM#S:4=TC(J$?!",%(;A!X6>*
M'2O<:7#M7#Z>674LXY[Q=.+75Y=)+WX44BUD97B%J9BS#";"L G"DD.:2P8C
MSC/.)2,XHNORZ-_<[:$30SF]</NUT;^-45EO+1]X9H5CPD(7H&ZF35]\WJ
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MW4R:*\ 9F*/:6-!:-/"Y*X6T1S3X2:4#!X'OCS%R[/=)!8]#OD]?UK-FL#T
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M.?&AG@%EG1IQ[4H*MJ+VHJ\AA]B-_"8R< -39\\Q\R;0$= ,2K]#RCLJ>8\
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M,I;',!<ZSXF6FL3(BP=.]3(U&KA]JG+<R!<%UDO 6FD].> DGHX4<"U*0S-
MC<Q&PAO0R!B0 +H@"#O_3_8T[O3O4O9H]G<^W+<:YZV4Y@M955XM]^5#N?Q>
M&-%G2#$I>,R@V9\0B/,H@MQP E2(:<53FFE&_2ISGNYH:A10RPH:86_J+ @V
M'4(KL&_1SC/X=O-!2-0&IH3^@/6H[=F-QA5U/L\T/'+-SV[UCNM_7GB^MSU@
M([J/5K LI;EF:0139A,[\ Q#FD<,$J)2K3.M<N:48?Y"/U,CA!V;H$I0T-\J
M.(FJLUUP+58C6 85/@/;!ETPA+8.3O8UMGW0I? )"Z'S\;XV0EOQ-TNUBLR>
M((NMCRF2 AHC04"52"4SP8B43MY/APU/;<HW2YI?:=XCM%Q7^.D5T754O\?Z
M?;':K>MZ/6:YVG/B'Z_'5Q66K4,(3Q9NM,> ]C:P6#R:W\Q/JT)6WBW+Q1U;
M?9L)E;%4Q@E$228@UAI!GD@,[65JK#/)2.1T:-=?A*E-X:VH0.S*>@.$D19\
M4W-IDV_;*Z'E;SY1P[W&IYL*QD%]:-(X6WG;ZF!L@>V W.T/B%5D\!'PB>D>
M>B1&\F,<:$0\0\"O ;,[/+Q7RR.&CE^C^7Y8^54M^=<7^\3^>UG>O:S6RR?#
MU%51K"A'(A,JA@EA%&*52TB1L9DICP7AE,B(.UU@GVY^<HM'(YQW0;$3R'53
M__5X#$SKKE!X51 [K_'5]<-.-#U:];#S:NW6#NMXJJ?W\4G7O1TGSC<_MH\T
M/IY5$,U]Y0NS^KDJN_-A47L#_EPN5ZL92P7'F<BARJ((8D(XY(H+2',I<8:9
M0$)X!1B'EW%JI-%(>@,>Z]I6QKI\KJ2](JAP@)%U.V]ZY?$:F-1VG9YW]=OU
M? ;\QVGGZ#H:<3/:/V]&NPUDK+0-Z"8]W%"$]:,>0,YQ':V' _K($WO KOJ>
M\7TQ>^*Y%8<M?LQD3GA$,P;S""F(I5"0Q9)!(2.&I58Z5DYYV$XW/S7J;@Z\
M*A%!(Z/OH=\>?*Y'?WU!&>< T V/'J> I]2^XBQPK[F13P1/J7)\+GCR*?^)
M^M%@.W_XMERH7UZJ)*@ZRT0D-((81=B8:11#LQ=CD"><IHPAE&&G*[E3C4]M
MDE;R@4I 4$OH/D6/@+L\0:^!8^#IZ8&$U^0\IW*OJ7G4V&@3\YP:N]/R[#/7
M%F]^]_0\7_Y0JBD,?6:AGU<#404B?%9B^;@H_F76^6HQOUNN=FL'9Y$0,4,:
MZ@@G$"N>0(X2!E,2"2D1SC5VNG(;7-*IT<5>*>+*CG]S;.^_^]W^['F3/]Q@
M.^[-IC"$(^[03H:E-B,GJU36=^RY6+.YU>L&-/X:XQ24'F@$!BHX'5K:5RI(
M/1#HYPM6#]6A_]'\%Z$6S+3X?EDJP5;K)AF^2*4B*4(PT=*L$I1S2.),P#S'
M,9&:JTP[.6N?[V)J]-Y*YWXV?P:ZR^?SUP,R,%FV@EVNR>!U2M^M]]4G]6>:
M'^VTOEN]W1/["T\&*N_\65G?D39?R5=5/FW"A[ FL6 "0ZXPA3C)!:38V(01
ME2J2">,B)E<6>3[?N\^'_DJEGC?"UYEZP%?G>/D^H]'-& ,C//36\G3UYU,
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MTBQ*("%QEBF4,.Q6RN%B3U,CB2:+M9$6[(OKG3ZX&^!N<@@*V\ 4T1NQ'CG
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M[ZT#"9=;3< ?_T"2./XKX%:E_E52_4;.S5(<;#0&7@*.,K=O0X*:8.@=X6]
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M&L&(HPSBA"C(5<QA%F41$5&68^ZTH_?N>6J+FI']!ACIP5;\FRK0R&@ *A7
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M2MTM5^L9TQG6&L<P0YA C F#7.09U&:E("*5.J.93T+[3<M>J\ (6>N_VC[
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MOG1:?^F[?8YPW&W6QW4C>&N ] [!Z<+;C2JNQ7 <MFBE/ S!:44-Z7Y^$8_
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M#MF*U_@K>]@PAX@YF(A7X##P;-Z!H(^'Q"$6'H;:%9B,98'Y8.-G)YU1OM,
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ME",8R3R'6*8*4F:8G>&(4,U3I')W*M]K>FID;2M#?/SRR2>\:A\J!R[N#<#
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M<\@DBB!'B<I(+(36S-G<?W5UIK:8_/)B#0-[G;BY0F3?63%O*Y\]-\K= %L
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MFNPG_W=ZH^<=M'7R5;N.=9^5/60N%H_5;U]5^32CFBJ6J0QJB6WE'2$@IYC
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M]8__]3_:OS%_<+92_^M__/]02P,$%     @ 9X$&4UNZMVUAZP  G7(* !4
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M@5[,;W"0 XWEUB?)L?0GCL$0;SP0L JHEY[?:S8S8"!SDY*Q[S4V@[.]5-3
M3GZ04C?&VL^._32]FQ_ZLRF&Y!,AG68ZHW_D-,J$E?Z&*DA"(4;N@_9)U#GY
M?(2@<9,O#0%N"(4U@+M/L/;HE:>W?HG>^<GJ5MO?/(W3]20E[QQ#=]C2E%%*
M5*. HB;<NA#0=\G&U9EY\#QMXR9O&D+CP&IL )CWA3LQE*$\G"51(UZD"H'X
M!(E$3SUE3N7,:XURO4O+N FAAH"WIYH:2%A_F,X7RTZ$&[%,P#N;#%7$,UP>
MTJ$/X6,N%XR3XI;:['V=GB=W*1DWCFT(9'NIJ$E;MHLH)XRE $HJ4D8GX9?"
MM:6> -<@6+;1YSI-"(>A?]S;*PW!>00X-&!GG\N+3;PV/%%01&0?RK%X)EX(
M(!H2Q[5N>%!U^B(^1UDSUZY>Y<!Y?^4,!K9_^_6>Q-_C&]VONM^4?_4)\D_E
M^U\^O;OU^?X,U\OB%-(O<UAO/O_PZ./GH_?OWAQ\>?OFMX/W!Q\/WW[^\]NW
M7SX?=YKX"NMIQ!#W%ANKZ>G9[,ZE]ON'AST_^==KTN\RM7W />@,Q 9\7\,<
MO;"?]]W)MIVLCO*F1GB*\>]BU47"U[;191>U=\1R$=$P45&&1T9"C5,Z9\E]
M-3_]>>KVW\NWS_A2C/,$<K2B] CL3HTDK@/BI<4@RP7.P)<IAW6N:-VF8^Q\
M\\"HN+]C[BST)MR_+?6',[]:'>7.O!Y\GZXFQH3.5R4V1(DF.Y?&((R2:"FW
M-EL>0RV/[A&2&@'2#GI^##)[";T!]-RD_\WBU$_G$UJZ ^9$2=:Y=*(,E'CG
M!1'X"^1):\7J1*CW:6D$+_LI^>Y9PGX2;P SGV%9/+G;AV\?X#3 <L*UC)IS
MCA%S2*5\V1*?7"(10#C/DZV5WGB"J'%1M*^^[UJ>@83?#(Y^>Y 5#<HQAER@
M)6:;Q@Q.FDR2L3:X9)7+E;R\QXD:]SBT"H[V%_Z(.%HMUY/#Q7RUF$U3.8MX
M6Z:&E,513#30F*71)852VC=R98B+BA.M/0CJ7$0#W@= ^) ;X,&?[@+G*2K&
M/D#?V]\93,0-PF2[B 1HZDL%O*;"$^F#*H>KEC!EA':.><][><D[ V5,5V<X
M_3X#F!V$W< .]5>_G):U<YD5[;BY.%Y.3_WRXC>8=X>?^')K-YE5"=T_@T%H
ML*4GC$%[;!TQR7)>ZD60]2J;ULOH; MJNR!C\6IJ:@"$#_1W!X>>G $@43)%
M9)EZ99F,^,5G(Z3.SM4JI;U+R]@E.\.']+N)N0&@W/;ECOWR:-DQE;J:M6-8
M?OZ*0IT(Z2TP*PGU*A"I-#*4LR966?3KN @NO$8EZV/T-1+S[XB")PM4!U%)
M$S6KM_GJF%@=G*^_+I;3?T":R&"RIQ"(ML:AA762H N1B?+:)<43^$JMQ9ZF
MJQ%WO :T]E)!<[9KP\V[U>H<.5$J:Q^I(%19-.KEBT=O@41OC11.AICJE$,_
M3E,CFUX](.T@^F;MTM'Y>K7V\U( ,3'!)LFD(TJ6GB^> ;&4&T)EX$IK[B2M
M4P7P#&%CEYI6!]2N2FC --TH_G]T W?.R,BD(<F7'OR<EY(QYHF5H!UC&#;'
M2F<FSQ,W=C7IH-@:6AEMX>O>+NZBR*Y<$8W4)")9TB0D@4&KR4X)DP&746U<
M[>1%52P<K86GO83?(HYNV5S%0J3>$9>!HLU%&3GA#/Z8>5**.W067P=(+]WU
M*M9LUD72KN)OPI'ZL@2_.E]>=/QL6>NXFE MP:A,"4VYM,WCEKA0!$4SAAO(
M%,UU8KM'21JWY_C ,!I&\ V8H^U04@I26&H58<EUI1*>!(K*E1DCT1*(,EW'
M\+Q@QFNUSN(#8V,'D38 A)OMIA+R&[GS)%G(1 */Q)4I,1I)=E)(COS7KL(>
M>8KXP)C85;J# :-F&?7G+_CUP]N/7SX?_?[NX^'1A[?[ED\_\(G#ETT_1_9
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M[@-'*30;$Z50Q)5J7QFL((%Z2DKN44LFI%>5\VSO7]1G[K4&8P^27-M-S T
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MYW#)R[%?=C]O+@].(+BH<M8D U@B);K WIA,@M8FZ$@5A#I3)_I2..[=N]$
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M4ECC7,ZATD6HYVEK\BBOMNLVD*H:*W&X' O;M;K?#D.<T,"\,#81K@$]TY
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MY(US1: RQ(973!O;IE]]/9BG\JT<A'SSLW+:=\]MM-8'*B-A/";T!B):Y&2
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MJ(O3$&A(WLE,ZW2)WP]=YW\'<9#$^\Z8O!^GVSA&$6UU+5]?XXVT$)XG8TB
M6!I]V4"<R)PDZ9(094QNV*JL?28G\LI"[4!RYA<(70I[ ";F_EW->S2K__"3
M6RB/WS<_W+0D_S'**0IOO23@RL15'@'YXI((I;.3S&266TV:/N*-W,L4MD/?
M^=\K5-'8 )#X&;[#]!8>) H_A<GX:E6A#(LX']^4+S_EK^-K%.I(>QM8S)J
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MA-PS1,I,QT_Y$0_KSJ?9"..2\4304B6AT*>PD4?"A)19)*:1K\Z0\BP9_4W
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M:F$(@%K;ZB<LK<VNE8;;C%N.Q5+3%0,E)1XF0#7-/ D?9*4+^Y<)&QBP#@7
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M_FZZ;/H!KV8\_ ++;[.M0OZV>=16G]Q5ZG1_-CK*ECY<X $9",__-1M/E__
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MF =@<1YP,'(429;1DIC!EX'ICH1@(@G<B!BIB"+6F;7V@(A^&VO6@<9>@AT
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M#0BNOIF+/%ECD\$\7M^!'8F;+H@> 0;/@6I$G4P,MS>S)2;Z[9M[Q5@\.JY
MDZ H-DEU\JG6]%/'5$".1N%H:'JX=D=@&5.]BU%DW8$+M,5Z_WK;PY=;P>A
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M-OC*1R:G/5E!9Z7R+)K$PV8F<*"#\.NTM8TCGPDC2K&#T/@5[9)<8_S9-_R
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MS,YG=>3I#1N::XUUTF&0"E2.&;S5ABPRXU$S*5&W*3[>0M @++G3P=(8<N\
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MK@,,_H'D!,U2C28K*]=,,*$5T1J 8>WCE*.HHR_((RHY<8[6)-ZFW]&3Y/R
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M&R<M]5 @9T(+$2QR<)J1!\ 5!Q^2@:A#B#Z9',-$MX'[LG3"[N:HJ&V7V3P
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MD9IZR0SVVM29#T#;-7WH?SJ5\.M+&<$?;S[=A[V>G>/TWCM.MV$;'XHVW31
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M#\[AC[W3X?[!>3#X[70XA._/EQ+EW4AY-4_\4>; GO-E>$2/[GE,E/4VGN*
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MWVKAN<;-3#-=CA^4N9XV9=[/,$DLDXMBHBMK#LS#60 TI@76&IH:"$6T4ZA
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MLTRR$IW1 T7L,+\N5)J.3,6[SA2;VB%WW<C+5O$S5&F(=K,:*\F(WWI*N&1
M-RP9T@<6<U,S<;R9LYY/I"R:F\'OBSQ;#4K@O;!7NDNRHPO8"*>'D8VB?Z/?
MQL6K7B(B//L^'ON>%6G8B1&=#2:%/S,$_V&L&&PV(B9#P)4+F5 )(Y!UK*8*
M21PT3F'BWL8\I?GSTU'STXJOD7TN14Q5Z&N<]Z Q$T"CD_0*Z#0'HD)=N&X-
M6V+0;*;WL^<^MV<7$RM3+8#%(&2^N@^S]8<32<NX3 W,8@*B@_[H.1-QT55
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M8TRKV!:;X5_F6U-D[::A-85U*B+WP;4[!M=NX 1<"(7%OR]V<Y;'V:STTUL
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M$IN("#D8@=6P"@4?CA+"!'EZ00B&?AHI40\MX1@B^ +QJ9S(-DU0Y/HTN3+
MY(:&=/T]S[>U +]N)(DP&JL8E]%H-KMCA_BX]4#XZ"\@M#(1P\N3O 0/,B]Y
M=OU>FLW2"BFL4K<D?O"CL?ZM1M;"RF91%A-N=$$H -:R//41\<9%J!B CD#V
MEI[.9Q!;X# %@] /^KXI5XLZ2VNET,;-..\81"NPXZ7*BM*&4GF(WD3-Z+2=
M05RZ=02M*P<PD.LI1=$PT6["H=Q$3@5SM23FP!)/G@8Q5?IK^Z%:FWV\M6>T
M=:T8SXX/I";D6(E,IV6"M^;@Z*0>,R7.2\NLJ/R-MKBK_:U,@'5#::#S#"(=
M783"C[MRBP),<[Z&<TP5.B>#XM66N6;0A]OW!.<&P+LBEV 8>5927VT/DU7B
M,KW2 [FXO,X$^ZBWB9G?E-II^XWVQ'GZ9C# PZM90JL$=IWF$!6RA=)8M-J^
M.K%N\ RSM+R8D'CG!KMJH%F*PBG'YZ!*&"G6]&*4<RHO46,:F0!:(NOI#HNF
M-JM-:5O" VO/RYT?K3_MW'M2\KKGFGJ\C((W06+315ZWI-.&D4B>:MW;HX\6
MW!<\6/K&$*>/P/W\"%P:@ZFQEC\II9G(F[$'T4X*.KUM?^["=CEIGEA<C4OX
M=YK(>6O^T$>S'X.7X#$@&5L01CM")BQW&S"^"\XXF@[D8SA &Y@+7)&:IOH>
MXR P>G!8&)O/E]-4Y32[W2^GL7.M/;NO9/>AR,"A.I[A1@5#C071+8;OF0H]
M+);;H.'"L*S/,@$'163?3:9B0#T).%3IX/,Q(AYI2"$]CYC1_WA$QIW'UG_8
MNEZQ;/3?/QTV=G\Y-K8.V(<W<)!2<N@X_5,+J%8R=D5T%+ZC1X';9_([= X4
M@)EQ:Q<%/4W4W6*-C/$F^H"!*M.RP YT<J.^;9YM@M^,=AY0L@8J09CB.7P?
MTC\Y_!2,1:AB[I W$4,J_$"?4@"1KU$TKLIK44.8@9) 6"G=8A;/;8/<.B*"
M'W\YW>!8/-=:5[$HKL\6W*J)?]1C3G0Y_Y*<$;R"VF8$!L\T$?,]K5>X^K4P
M/;<8;-<.#16/P14<<(>W$+8Q9TPU6I=*7JV3!_IR^6![Y40"'C1AD6]N$]TE
MR@<*N: .K#&0"9;65]&512ED;U$AGZQ,3RSU4.UZ-?/I ?+>*'X$+3D<!%\L
MS-N!@53JFJ:D6@6*G[',4-5".:IY*;EK+Z!(F]L&HKC*#E_T*T&(!7N8F,XL
M3$[NEI%PV'LF,Q?*AWY\*LF(I199$_[CG#'%84%F%?/%!Z]\KC!16'Z*^U(U
M#%"3V1$:_E/E#OXG)V5"7D:%V.?>[+:KRFLNR$U7EM%F+"Z0X8YKNUQ#-W:W
MNTHMTL9X"? X$J!."AUC?0?!BC$ 356!_G!8(JX57 AN+[+#00@>:A+U@D,E
MPPFH&]!:BJGP*,W 4_-4]3A4U28Q.TA;NGZCWNCDY$RUR:O3O7#H&=M!)*NN
M_?%XF?9QS&Q*T8$1="'ENNE@Y_;^7(W0-I[;I'16[:ESZU8-[LG\$<@<=HR:
MX0:Z>J"#]*T)EQS2J<14I_%_5::SCSHGEU1%$!Q8[.:FV_$ 6YMOGQ99W#%I
M3/LDYD1S"NS WA/"!?8ZCIS*5[^U-W!S1^M4C>++_!]#B"67*DM-;0-.M)@F
MW5/5%'&3M:4JLU0NGQC-=7ZZPGLB'7V* ]:'G/]HEB/',KK@65][&((KJ'3J
M@9&>/ SELV6&KK3<NBH=_N&4+F/>CV=KXO_8:9HY5CU&DLHT([(.];\E=LGR
MB,Z\FMI)=/I'F83ZMQR@H]RA+?>IBI48S[B'<;]I&5OD8<K<F5&2(S*<;;'U
MDI(R3B9R12)>=E6U)CBLCD^27,&I SX9#DR=VJK*1!0EUSSF:9G1JY*[*!)A
MNG\1H0,YD+B6)OPA%J']E&WIW\6_11:E91Y\15& !C5/1YB "*$WP?&!8TD2
MA[L0L#A*XX/+'[,41SCA#Q;OY,.9C\^]2K#[U#46!E*+S=JH/!EY0"=J*HR]
MAH=H?\&0,D#^%Y+8/.?*QJ9NQ)"H:=) PD5C'\L3=;>]_E7#<T4VS7'U/8PE
MXOV;O%4]>283X K%8L+H8O@3Z\2;<Q:6#Y[F>M1X[E:GQG.=QL)WIPP$"J(J
MT413UI*YGGI-=X_1?8Z"2Y7&HN8>-^5YKQH(!%NN!Q_W@C*7/?"]DRBF 6NP
M'TF.K6_ZZQQT,[QUCZ>#FJ1:I.":'%>P3'Y0R;M:NEQ79*RXP>6Z11FZ@PRC
M\UF[7*\5H/8<'&\+7L#^2XZ+=* 3:JT&'":N:%%1 6TY916@IC@D-6H% C1C
M*5/04BELLJ\[J>I.WG>_[L1KI;MKI=.#LT''=!!%SJ>S.)U+%"R%C@7I\<4.
MJ"[W?_0_[+[M.2BSG-0Q ":+X"8:ZH5QI< @RU,.VY>%!K$EH1#I4)2U6FLF
M)2FM,J9AS7J$1F%;RKPU]4AT&PS&8Q#U<"(=HV ].<K&-IM3NL]5 ?[1 :HE
M_<]_X,?\4MB?JV-=;_O;1C<1B!'#IU0-"QH?+3,0?X;,J8M!GQ\B-L,3)#-4
M9N?%N.:<N+A T%F;.KBI@<3QPFJU;]=&W$T*_YERWC5=K[V!^W);6WW[UIYG
M'HMG"&ZG8_QBC&:]?9DD\Q9C" 0Z9*O\=>Z>$_P5';U]4W'/@GD7G,3X!+8B
M@1NIR("QC$1>F8U(H2>??]NCQM$KH2YM.-P9<[JYO=V#_[S!_^S@?W:1H#>W
MW^/SZ=>G5F'4U]?(:^#U[O>Z?H)?P30V Q?;?G];CX0+7^<6QS5CO!OX"'B9
MJ?@NJ=).QQ+)IE:CTM0P4=8E%EHNL3RI&N)PE60G5XU\8$_+Q)F<EH3E=,0-
MGSK*6!LN90=+-43#FZUE8N#-UAO\\^W6N_=V"WKFWB!F<HTOI;M"S7*<A?18
M]VJ<5117^E<.294)P3N@0SDMI^W[XXA&_2L1PD/P/+&/5W>1(P6&"M'9S/5K
M#EW6Q&H-NLANQ8?=?G,O,"(;$!&#>"U((WRN]$0E)4&N7DT8*X FQQ6:4GM&
M2*,ZY.UBO<"%I*A^.#)ENJZ%W0GS6G2C;$&B;R\_MNT53&>H#'[P%7UEHWWH
M4WVZ%OR$UZQS41@NMZ_3AK1@;JVXSQN<//!4&0"7-!^%M46Q 33PG>TZHZ<6
M5*UE(\U'*K%5RXW:V]Y2%5B;8Z8RLPL8L&C8*';R:N6A+EG7+?>S)MS(U  A
MH\IICM@A9*HBI6 [7@+T ,*G<<A;6[L5A9D]N31;XE2SC9T^^-SR:*W6NQ*N
M:>:@76B,9"UN-' JG;=[> XNW$6&D]YRF\I8O@YS5"A^>PNO]M:A4G,OEZ;2
M<25KN&7?B&=AVO'I '0HRE ";KO>J<LGHITFC> C\;,H$U<<R:&R;_BG\RDY
M0S?B3FG%Q<]\'5UMJ[N#6TA;T7 3\.LPXI.Q@ T1+234HW_+IA7Z9FNGR>"7
MFK\?[XVL!',>B7^VO*&M8OZIRW%R 8M*_I\5@=BX-#VL'>JF]9B6"V,&,]4M
M_@N ID[[O$'\JQRD!5%]B:):)A?BPF1FX V3#?D#EE.@5)BH$36849!4,$6T
M/\+1QSO+791WC150N-(J#$?=.H7C!)C$/*DW3SIJ:UR-F#+[:N0BV228ON'\
M#A;_X_<BKIDI.4,71%P7STWP0"/$'2*@Y@T<%5M[P.H=V'K;U_6QVOIRWFU!
MH/:QH+=R5F_^ZE:PU.5OM36K'^4]Q$?P$$$")1(#]"<\NZ8+?B(Z9"[ENM/:
MJ-Z^XP5+'S;[.^#?^?$FKXQW$$9$>XJZ!M-SU -R5.0YZM5QU,%T)LBXW(N!
M9CTK>5;RK'1'5CJ519DECH[RW.2YR7/3';GIK!QEJ2YH.\5[>.7TTMGI]56"
M??"58"]9J'UC'-T#A+&_4+G)8H<3&95Q)RILJNE>URR6>U_=49O4>/-59-]E
M@<YX&G*U,6'NU$O!N"=QG2K*5E21>3W[""199BG##W6 ^GH\CJ',N?HDDV/)
MZ3Z=GR4* _KA- Y5:M,UNL:$L_9VYH@-AO, $L0ZUD4+=(ESDY$465[!&%,&
MAH"+3&Z&B;RVGG90'$^RCT"RC6%F'2#<%S!8Z[V?#O[B&>='.,$</U9U=X=I
M;#VZ+CK'++R[4JX_?W.K^G-/38]"33B(/8(S"A'4I!/NN(NN"<^.N70C1J@N
M#2'V;YFE&R,14WFET$NOD+QF8I[![[AH8I+&/)1#_""*XQJPL8K*D.&QL@#A
ML-(KYT:UAF\]U\'TM/Z@S#U76>H?6/C&-$%(PRE_&$F,(@@SVV2F0R!8E76W
M]9F:)NI)QY0_V#(TMLFN^Q9+7;)*OB798CBNB_N*6SM_=:'-^41ED6[5/Q'S
M--.S[G$(04'?S>B[VJB6^RV9!UM%YC=N^Z.N>M-;C=MI"(CF]^(Q3.:Y@IV%
M/]URP*K/.!A+F5==S087I/X44_XGUQ>6B3_2"] 3@_>^GIGQ.9=4JAS,I1[M
M1EW@NJ@O%FIJ-F]LN@WUO7%.![8:ZB$./&;$,J];_,0WP#=?NUAW9[F96X$
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MV,W(?SNZ. J6:4)NJ]O,UUM8[5T#:5"M!D/0*+4T3)G)Y_L/&*ON/+DIP\C
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M<A.Y%]4="R)$2!3@3(V"%<C+#*.8;FS=15G F[V7JSH4!;.0+3KZ@X\1RTC
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M3M_<@.F.>,8=SJ)=B("5.8VX5&L%AYY%,A;K!1R,' X7I@FPU#-_-<W"VG7
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M;9^7\[.1&3V4U,#4UW-L4F[T$*7.3<0N:"O;A/-NN10'Z"7L85A\;#M/X23
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M@NF4@Z=Z0(3VIO5 OZV]M5 <*G=::,MX0P4&BY"0FC)6H6+:IPR4WT.P#Q7
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M5T'Z[Q94GQCBM6PB[J^&^VO$!N21?]<N\JR^$HP"BO A2]PV[*P>)I>T>GM
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M/-,FTMZ*T"N #76-[C.F+7@K8=],+9S>U*YD[_ ^7>=1S 4F [D)FP4X^<%
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M*XO!1(S'Q4>U>\L%P4[65^#6'Q+8Y\)65]-F+"E:R@9?IABUG<$RM-11\*X
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M*UV"[6QR+B&":IIR<U<R(>1^2;6NR;9WU#055.SLD6?7:3\1]Z<(=HB+L[$
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MQ1-(,+I:38:/-OYE 3S%T=,9H%UC#PSDYIT91%L3;X(--SA>*,S$*91IL>H
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M*SAV]FRUN ^8R9FN/$50KBE!9L:6YR#%Q:UY5#&I%F#<DY=P=C@%;0[) 0^
M,0+ TF=##18-"J6V&UDK7R[E:2\J$,%A5S#<)Q;IC"T2[JIHEP,7 WIS:;%
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M)@ATLS1'9FZ&?Q,TEM1G3.?E49(7?]@=H)D')*.S1#P_\M:V6)91R)HH /Q
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M7X^9*M/56_7,T4(V5)8+LJN+>T<R1X35TD9HF,=<PF_G3\Z^-Q;-05LY4S[
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M*O^;>KHWP##W&T]4D9<Y*0$F0*)!$W%HUI(U/-G/AO6-A6P,U+N!==/=6H(
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M8I@R\AGO"^YWE8A#=L]'+*K=V]6"U2FDQ]:4H4*A:8E1;)<C-Q='/>QI0)
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M'OA8QZ4BRZ%*J]GCUZU I+J>6O@-\X0=O+AW]&*< ?60CX.!I?]U_9TJ\GW
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M:;&J&XY7Z-ING+S@Q[Z88DJ.D+08O'\0MXA"1<[P6:X8%16DU&IQM1*:C8K
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M^>309H;;=+9R%D!]#.7DM&GK,YAD>J&JYA9"*B.,[2$1W"9QSB>^CLMIYRS
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M7FVH5<Y!*3^K>["M:!@B,AC$0XEE=-"N8%SAX7D$/5^[5G&HM\_BX]#I\'B
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M6MWU#]0"&NCJ91 +$S$M>1%BI@E.2CC[1-W;9"+SZ9251"O-TPF+4T]FWRP
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M>B&,4X?%S['<0U)OLX*E+*_\]2JZGFUK18;\%%%T9Q,!"C/LN=7#3-7O;7M
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MX5S.67Z-'4#I/$^T[;OOHUQ*:E.-L7R#YQE;S-))$%OH"4R.N-.[H98BQJ5
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MJ&/@V.S97P_+GOW(ZP:6W5O.C1^P*?O"_N&'/%^(MZ85A:E4%,3=X.8L5X/
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M_B^0RC_E[ \A9V^\W[X,]1;!@INWDS-[5,[LJ4GF0$F0T'SOF $IH&)H [C
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MG,N-66TFS\:/1^@%]7,)P;-F5)E-B9.,N<J8M55].QAXV,R,/,/X=I'>TQG
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M,^4L/[HQ"W!S)E0WG:5WX\UJQ]\@K._I4<#Z]K.$K]@N9Z#$.#'1 [HRT[3
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M)8RE8J\. 4JSA$5)*Z+HG*YFQ/N#HB^2(!GPY(JR[<NEK,VH3EXM1QS7LT*
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MX\UH30E EGZ\XC[+$F8#1GFZ)7469^"ZC4@;+@^;;Z(N=R%90VJ_98H_C+@
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M)3051\76BWQ?!*-I'.73>P4AFW!;-86II+RG+?2#DYZX#>E7/M*F<$&2!X1
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MP7:)_[L(@[/#WF% 9;?!B]=@A?N)W_T$/\J.C+/\.HG0F%2Q_/U</MZ4+0D
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M.(,G68Z<G[4,A/^]C L4(6F$;$N&VJE$AS5"!#FB5!!:+L)34S04:[@ZCV2
M]D(GKYX?OO8G?L,\+AZ:W2(C4H71391>QTQ))(N G)Y6GJ0D3PCS>25BGF-D
M&MXK>DA<([[>QZ1_PO"&S?B&N B.VFTEO'&994(QCSA(0L'Y)LA 9!@Q"Z5!
M#_U5)39Y@LPW6.*C++V-TX2(XXB>>R'HOO^+1\X,U&"Y-?/P""])A1,E=C3C
M#AT1[8'%E*$:<QR-\(X*PSCL5 $EOXCSPC08YH2R:,C"Y!O+25[E'8 KKPFK
M$06 [,HVKINP6BAAK^<7*!1; K.3PA"G231,ICCF&@8ZWOXRUHQI7X25@$D.
M&0(Y^A83<#+>F/]H@8%?N4$2)"F"8>&2.I8YLR.24>F@T\SPPCKX[/+"\TK-
MHWM%Y638W/DE-<:S$PANPG#5"#\3R5Q3&N\=W"[+#>"F< $,F59B$B7391[_
MT$E11^1.T%UANT\2T[<JJ] ^,PY#G'F??F1E\('^$)CW#8XEG+O;*$_J&(%H
M)HM%EK72482\S/6D1&Y"A!0'Q(5;AW7VQQ-!)1[N&"IQ#XG6<EJ58T_I[O&)
M_UQ\XK,U8(.UIC":P]<G3C *L97#"<9#M\SA5-^P+HO=RGM/"@X<J4?\C%"!
M\5E]#),C#1SUYB,[ OS[+AX6R2(N.AYI%Q'%C4&X$AMEGJW@N0%WY?TO6TIN
M092;XWBSQ2^67 ULJO@ZPX5Q:@_9;,@T,,:9:#O%XUG6&<FDS)U7D>Q54M2(
MB=D).+J10(8ICY#U")EAHCDE#9! @[1D@E2HN'U0Y2 3GMA;HD-#;5\V[<X6
MHD;1H]:B:")N%,8J)-<E2/!U +OAG3PGI&EXQ3H'(=EO^;6V/,]9-+4<6VH^
M1;P1VQ#;^4PBO42B(+.B67DIG[!B:=8L7U)DMV\^M(YV#:'N1WDRQ,J.@VYG
M]<D@K'BFPC*JP@1<2ES6EO",' :B#Y58E7 A*=I3)"D??4NS._#@KMF?M51H
MR* (OQLK)L\#83 V.D9XI83$RMQ7',YX;,BE)LMT) *A<-R9H2&_DO>Q/I8Q
M\$LCZS =\H=.\Z8+YEEA*"'35CVZQJSI+YRS4#,K)(B+\K)$2$/&:SPVH3"G
M54;3: G; )=>N!$L]S0=2.WIEE^3? S+0$J49W@HX(R0E(?GF)<T8R%B'GCX
M7ABN(0S#,G,%KU5!BV6V8#3,4(T:_>Y6BK?PGJM;]8YM?=W%VCIH0RJG<OK1
M&B6% !K:G/D4,;Q HBT+^#V<^9L,S",3<['"*FR7+&6I"(*4HF/#&.1Q(<*.
M@L'SF/CJX?[VB2(W4YBVX(/Y\"2Z5V2',HJG;!PT6P=7VF161,^ME,DAS._"
MC[U):(^6!^EFOL6E@$)P0,IG0H&A83S-[CI*82QJVLBLCZN36Z3F4:.:+59Z
M2H;DQL-%<)(A*3926L#H84Z^@4US>9^.X2_P;HZG<91?1.P?(6]SL0";/6$6
M9Z&;5#9^<0\:?/:$-\AM\_[XU LN3KM7'\\'GX/^97 Q./^M?]([,696]Q(^
M-395]TQ_WOVMVS_M?CCM'9KOSWI]N-\@P)MV3S[WS_J75X/N5?\W^//7WME5
M<'8^@)O\'IQ_#/I7E\&@!T^&9UUT!U?]WF7PM3L8=.$R^OWQ\9=!]QBN'03'
MYY\O3GM7O;/>Y27^%K__<#X8G'^%AWV&6PSZW=-+O)*?W/OO+_1+OM*\7DCC
M[_W/Q0!N<_I[<-*_/#[M]C\'I_WNA_YI_^KW "X+>G#? ;SU&=[O_'/_\K)_
M?D9_X\U@*)^_G/6/X:WPTP.8AY/>Q_X9O,6'WNGYUPX]Y./@_'/#* ]A$LR+
MTA!Q/O[9/SL)S=!@4\/K]N&.,(#+J^[5EZOSP>_PZ=GQZ9>3_MFO]!-]B\^]
MP?$G^$->(PP^]J]HKO!]NCR]QU].NX/@XLO@XORR%\(@SOIG'P=PM]YG7!F:
MJ_Z U^+W8-#_]=,5S>C'0:]W F]#K_1;?_#ELD>?G]-*'Y^?]' ">L=7..Y+
M>$_XX,/OS5N@?0? +!^?GYW![6!Z@Z^PG58LMEG<0R2Y3[,@OG7TOLTND? L
M3\B&'J E) SLE&6L3<U88DFF9':W@*<D>:!XZ2]!W"3C),H39@>^M]SO3>%]
M/\V3<WZ+5=@T*PJ\#;'[PG_'T0RL%OB'&5S"/DG\?8[TNX5)2GQ+4LW?&]80
M^"(]=X[$PN2J\+]!5<-K@*"DWY*)'TU99</=P<4B*:I&0</3 X GW<3T/I*0
MLH3 L C):*%F]<!<2>G(?!%2:B&/>$C6;^W Q.5)09I_:7-?;BT<WV[>$H24
M:XCW=984A21PK&[\#'L@AW=#]9AGRVO.H!AWSK"-E^C%G=OTX'6*<C1XF#-5
MB*L#I'6C%T1*\9B>\"\PMHIQPHD^N@@T;,0QVS1+GT7S>1RQCOW7<GP]$X^=
M]C#LR>44=[9UKZ]S&"882]>@IBAE"R/"2-UD.0U@4F#ZQ\M1:WK9AA/UJ;G?
M^W@K?+QP2R?G!O;^K:MLV<3<A!)6?K#X]G;@IJ7V9)40#4LB%*Z?@UU+SQ9A
M029T-D<L9/*"G'@&D;AT8K?S!\I#W]P^-.;>=N[>[4EI&@MX%D=(]HX=$[RO
MIO>\@=CY!;T0P[/&H>\"AQH.&ZX1ZFH7VIF)<@J,,$-5@-^"3HCAL$RJN\#+
M5%18L<W>H.7G,I*"M&\\F_.I6DB=D*TP&.,62H:F+JZ]B*$E/06_I5G"(:^7
M9UG<P..%F%G9-)ZBOH!1XQ0^E4*#T8X5&ERY\H]M8$ .)"OBDA^*Z=><(=[A
M:]+ZVE^AI)>SL4TTOF1<NN/$:0%+[!O::JM'42*[Y&@3.;)[YUDTMO$>EV)6
M5W)IZ&-IAW<P^M)XE)-)N>@O7&'UE++X9IHYY1)6ZF_#ZI9PQ;KE%6&KA?;<
MQ%CY8MW _MY.L2-:(3AZ?GAT$'4V:N-S*2)-&Q^L'UV6?4+')73*'*_[A,Y#
M]Z<<\LA+WF,'1*0[';C0'PL[UZC$)QEN%>-N"(GQ1H4$!THT5.N3TW:KU%VY
MG>F/TV)2'-;6"_14W(5Q<^,(''65?EVKVJ?4[Y-PXT$^]JO+Z> 7G)6;L)/6
MM1TJ&-XD2]"6ML01'$>V(+/1:$G5[& ;F=A&J>0%M%E\B_Z?-Q*JA( =1F41
ML)UJ[6NTGMFPIE@TF.FP8F+4U+C-C4_CLXJ%%^4GX1Z$;0H/"0Y>=;R\,\PO
M:AZXGK2L*>O 7\#.QL0FZ"BLQ)I'R5B><%Q]@CT"YA5,EYJ9)BS8I 2YM .(
M4Z[PIUC.! <GU;N7CE-8BFIKB6YJAH92?L)-.=2(@8<)1K&=,G\KHKZ)],[P
M)/*:V,FEJ.<ZQ:F-'@&Y=+Y+X,5-NE@Q"5*TW_=S^6[YEND"I2F=0'#X;#V:
ML0;8_*_+K47!;8;6 8ECF+,"M[5W;RR[LV$OO^*#\TFNB\6ZET]%',>-XMB+
MPMDZ5XG"DJ\-JTH@#.B"L> JN_F\4=I+J.TZ<)7,Q#7JC.W#*51!!B#5W-+"
M8JW.\%\8=D9QZ]SWT^@NY!@[%7=&,RHL'&EY@"L.4[>4*@L:>I8GUYBO*ORX
MR!!#Y1B_3BDF8:.6%'NG_7YM1ZBZ(G[F]GCYYD_8'F]KMX>R1U]L-LI7-[XV
MJ?HU0B7"@JP+FVA,&^FIG-JHI7O'-12B;I_BL?VQ%LOX>YR/.(N#7Q! 'B6%
M*!OM F[P$?]#V<U:AH22"B:;AVM'QW%$O1?#>'&')H+7-M'6PNJ/,I3SFLUC
MN$@$^AWM ,X.9!/LZ3!-FB1@$"V-YH@<13#KY#5C3P3Y+QN:QT9#&%R6FOS$
MF!+2BP0D"J6J)[ AXCFIQ#AEX5-[-S"N,$,0JQGCYB@6FV9 \@HF$U(>*/^P
M;5D63FV1R*5K"['2P"!+XJ*]_71UO[!['GXC$5A7,>?K$C2YX=]+#@.Q=9!3
M R86+TS!2+VU;R=CI=BR#%6GEJ;1W6$ FUY66WYD#?X:>S_+_8FK9)LH^^D<
M#+"/88?@@:KT75/=.%8L\+Z2)E,V/DK6B^U\((5DU8L+7),A,RQ$X*(5:X9N
M\TDRYV*JF3=V W9=Y_;!R%-K+'MQ-T?P=\'H$7A#4WTJU+;T-V?2*'1^&'S5
MY3BFUA&V18S5C N3HG;%^Z&X$=^D #;B&9;')$5A#TE415'WK#]\KT6^1$M#
M'6A9O)-X$BVGM&"]6T$:D,^P=>(ZRL=3,2A,\<ZC$X%H^Y!%<1.-57&P[;^P
M?4$M@S*EP0M0!$]%#37W&/>X!BDJO*8>YZSY9W)E^==.!>]>'!Z]V:@S1W$/
M*1@Q;EDRFT]IKAT@0/ A3D<WL..^!8-X/HU&+!\'J$%A [MOCS/*^>-Q."8P
M%:[_<% VDH'OH)(-(F-M4<G6 \5RH\HXR.0(1RS,/L:Q2(\.J_:'2^WP\6*[
MG$6UWD^M 3.(_W>98$!#E&58Z1!M-75L&,N\HLQ3];:^@K +$?YL76&_;5 :
M-?$#SUO3)P6$"+448>28&[RR]5Y6;[7&-VS/U_X%LU,OGDYV:FO48$L>(1W!
M++()3P5KR<*@(BF3PV@\ZDUT\"UF^ZL6>3I8?\6$#)S\Y2B68#Z6*LZQLGBF
M(8:,E7EZ')PDQ1!=3*-8U*_)/\1R>CR%B/O$SA6"3:#P)XF..FGL>H^<#L._
MC#G7-S>@.QX8\W9FA(+QVCK&-TTI;$E2;!T!UPG5R DG*.:Z;,G8T[N#613=
M4]3+^E_AJNVD<:HL3A$-=GC_U/=7\P;#?,<<<W,X:V-<TDGR75(QG&:ZI]VD
M[1#\'&LDHT66WW.FY)Y;L:V]8[8J!B"XSYHW#;MSK9NV><T]WU[M;7L>1!UR
M%?\(LR(VH"%###E2H-ZY&-W G;"FB]_>E%U2V;\-AM/3-*24$VK[C?>8KK9H
MNL S*R"%6+!G(M<2JL8>"_S2>-ZPIP0X+D<+"\5/%"Q RRQTM2SAHM,:<6!<
M+YEL@4+AZS1X71A^B>WE]$#[9\<&>3PS?M4]==9GV]VX%T=@G&ZZ4&L[)VFT
MGY:VO?/N\,4F)ZBS,A8/_M-I$F,# $'9Q.."6RJF6%*?<].'E?6(H:0$O18<
M')GC]BWRBF\RCJK#O]$!)YF#E;-&?+GX'UXS6N8Y=G>%U2IZ/S)@@D@AX8'
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M+7E[N<QO$S 8-BM:NX0N=HNI;9(H]OS@V< P&0*\.0SMNRC',".>;6-P>48
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MQ/U,=\\$3WA$9DBTA/<DG"6"],S-[J8PI-^S3F57/I$I)32GDV?ZUO:&7+;
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M 6:ZY^5.N6VKGTKE-+B[L(XY!8FT\Z)+K=#Z)80'>"]X(BP8[*G[.>X$(8Y
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M.,0]N1?N/UNX>][^-LCV&XE[F?I,8><3_@Z[ITS=E&.J>-B.4L+N* S@J+Y
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M:_)'1A4L #&%]ZE4ALB$O)<J)GZE]&\B(]).I1"2?&(A#Z@@'Z3 GG61])+
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MG6/VY:3\AO/L3U!+ 0(4 Q0    ( &>!!E.5GY+\+3P# *AT)0 1
M      "  0    !A;65H+3(P,C$P-C,P+FAT;5!+ 0(4 Q0    ( &>!!E,P
M M#DX1T  #9; 0 1              "  5P\ P!A;65H+3(P,C$P-C,P+GAS
M9%!+ 0(4 Q0    ( &>!!E,XT  "3#$  !/] 0 5              "  6Q:
M P!A;65H+3(P,C$P-C,P7V-A;"YX;6Q02P$"% ,4    " !G@093T]T)6?VG
M  #^$0< %0              @ 'KBP, 86UE:"TR,#(Q,#8S,%]D968N>&UL
M4$L! A0#%     @ 9X$&4PHXLD1Q<@$ @%0/ !4              ( !&S0$
M &%M96@M,C R,3 V,S!?;&%B+GAM;%!+ 0(4 Q0    ( &>!!E-;NK=M8>L
M )UR"@ 5              "  ;^F!0!A;65H+3(P,C$P-C,P7W!R92YX;6Q0
M2P$"% ,4    " !G@093$/H:BW)> @!\7A, %               @ %3D@8
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H,S(R,#(Q,#8S,#$P+7$N:'1M4$L%!@     +  L V (  +00"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
